PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	DANTZKER, DR; STEINBERG, H				DANTZKER, DR; STEINBERG, H			PULMONARY AND CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE SLEEP-APNEA; MONOCLONAL-ANTIBODY; TISSUE OXYGENATION; SEPTIC SHOCK; ENDOTOXIN; FAILURE; PH		LONG ISL JEWISH MED CTR,NEW HYDE PK,NY 11042	Northwell Health	DANTZKER, DR (corresponding author), ALBERT EINSTEIN COLL MED,BRONX,NY 10467, USA.							BENNETT WP, 1993, CANCER RES, V53, P4817; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; DANTZKER DR, 1991, AM REV RESPIR DIS, V143, P675, DOI 10.1164/ajrccm/143.3.675; FISHER CJ, 1993, CRIT CARE MED, V21, P318, DOI 10.1097/00003246-199303000-00006; GRUM CM, 1984, J APPL PHYSIOL, V56, P1065, DOI 10.1152/jappl.1984.56.4.1065; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; KIM JS, 1992, J NCI MONOGR, V13, P101; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; KRYGER MH, 1993, CHEST, V104, P2, DOI 10.1378/chest.104.1.2; MAYNARD N, 1993, JAMA-J AM MED ASSOC, V270, P1203, DOI 10.1001/jama.270.10.1203; MOHSENIFAR Z, 1993, ANN INTERN MED, V119, P794, DOI 10.7326/0003-4819-119-8-199310150-00004; RICHARDSON GE, 1993, SEMIN ONCOL, V20, P105; RONCO JJ, 1991, AM REV RESPIR DIS, V143, P1267, DOI 10.1164/ajrccm/143.6.1267; Sabichi A L, 1993, Oncology (Williston Park), V7, P19; Shapiro L, 1993, New Horiz, V1, P13; SHEPARD JW, 1990, MAYO CLIN PROC, V65, P1260, DOI 10.1016/S0025-6196(12)62750-5; VINCENT JL, 1992, CHEST, V101, P810, DOI 10.1378/chest.101.3.810; WARREN HS, 1993, J EXP MED, V177, P89, DOI 10.1084/jem.177.1.89; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	22	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	1994	271	21					1709	1710						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN117	8182865				2022-12-01	WOS:A1994NN11700044
J	STEHLE, T; YAN, YW; BENJAMIN, TL; HARRISON, SC				STEHLE, T; YAN, YW; BENJAMIN, TL; HARRISON, SC			STRUCTURE OF MURINE POLYOMAVIRUS COMPLEXED WITH AN OLIGOSACCHARIDE RECEPTOR FRAGMENT	NATURE			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; SIALYLOLIGOSACCHARIDE RECEPTORS; SIALIC-ACID; RESOLUTION; BINDING; VP1	THE polyomaviruses are non-enveloped, icosahedrally symmetrical particles with circular double-stranded DNA genomes(1,2). The outer shell of the virion contains 360 copies of viral protein VP1 (M(r) similar to 42K) arranged in pentamers(3). We report here the structure at 3.65 Angstrom resolution of murine polyomavirus ('polyoma') complexed with an oligosaccharide receptor fragment. This structure has been determined using the previously described model of simian virus 40 (SV40)(4). Although very similar in structure to SV40, polyoma has interesting biological differences. Cell-surface N-acetyl neuraminic acid (sialic acid) is required for polyoma infectivity, but not for SV40. Polyoma attaches to the surface of susceptible cells by stereospecific recognition of oligosaccharides terminating in (alpha 2,3)-linked sialic acid(5,6). Studies of pathogenicity show that the specificity of viral binding to such oligosaccharides is an important determinant of the virus' ability to establish a disseminated infection and to induce tumours in the natural host. The complex described here shows how polyoma recognizes the receptor fragment and how strains with different receptor specificities can distinguish between alternative ligands. The results also suggest an explanation for the large disparity in pathogenicity exhibited by strains differing in only one amino-acid residue of Vp1(7,8).	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	STEHLE, T (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CAHAN LD, 1983, VIROLOGY, V130, P281, DOI 10.1016/0042-6822(83)90083-1; CRAWFORD LV, 1969, FUNDAMENTAL TECHNIQU, P75; Eckhart W., 1990, VIROLOGY, P1593; Flint S. J, 1981, DNA TUMOR VIRUSES; FREUND R, 1991, J VIROL, V65, P335, DOI 10.1128/JVI.65.1.335-341.1991; FREUND R, 1991, J VIROL, V65, P350, DOI 10.1128/JVI.65.1.350-355.1991; FRIED H, 1981, VIROLOGY, V109, P188, DOI 10.1016/0042-6822(81)90485-2; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; POPPE L, 1989, EUR J BIOCHEM, V180, P337, DOI 10.1111/j.1432-1033.1989.tb14653.x; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; RAYMENT I, 1982, NATURE, V295, P110, DOI 10.1038/295110a0; SABESAN S, 1991, CARBOHYD RES, V218, P27, DOI 10.1016/0008-6215(91)84084-R; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3; 1979, CCP4 SERC COLL COMP	22	267	276	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 12	1994	369	6476					160	163		10.1038/369160a0	http://dx.doi.org/10.1038/369160a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK971	8177322				2022-12-01	WOS:A1994NK97100053
J	GOSTIN, LO; LAZZARINI, Z; ALEXANDER, D; BRANDT, AM; MAYER, KH; SILVERMAN, DC				GOSTIN, LO; LAZZARINI, Z; ALEXANDER, D; BRANDT, AM; MAYER, KH; SILVERMAN, DC			HIV TESTING, COUNSELING, AND PROPHYLAXIS AFTER SEXUAL ASSAULT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; POSTEXPOSURE CHEMOPROPHYLAXIS; ZIDOVUDINE THERAPY; INFECTION; AIDS; RAPE; RISK; TRANSMISSION; ANTIBODY; VICTIMS		AMER SOC LAW MED & ETH, BOSTON, MA USA; GEORGETOWN JOHNS HOPKINS PROGRAM LAW & PUBL HLTH, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BETH ISRAEL HOSP, BOSTON, MA USA; NATL VICTIM CTR, ARLINGTON, VA USA; MEM HOSP RHODE ISL, PROVIDENCE, RI USA; BROWN UNIV, PROVIDENCE, RI USA	Johns Hopkins University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Brown University								ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; BAYER R, 1986, JAMA-J AM MED ASSOC, V256, P1768, DOI 10.1001/jama.256.13.1768; BRANDT A, 1987, NO MAGIC BULLET; BRANDT AM, 1993, AIDS LAW TODAY GUIDE, P46; BRANDT AM, 1990, AIDS HLTH CARE SYSTE, P125; Brownmiller, 1975, AGAINST OUR WILL; BURGESS AW, 1974, AM J PSYCHIAT, V131, P981; CAMERON DW, 1988, 4TH INT C AIDS STOCK; Centers for Disease Control (CDC), 1987, MMWR Morb Mortal Wkly Rep, V36, P509; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; EISENSTAT S, 1991, U PITT LAW REV, V52, P327; ESTREICH S, 1990, NEW ENGL J MED, V323, P1141; Estrich, 1987, REAL RAPE LEGAL SYST; EYSTER EE, 1987, AIDS, V11, P131; FAZELY F, 1991, J ACQ IMMUN DEF SYND, V4, P1093; Fee Elizabeth, 1988, AIDS BURDEN HIST; FISCHL M, 1989, Journal of the American Medical Association, V262, P2405, DOI 10.1001/jama.262.17.2405; FRANZEN C, 1988, 4TH INT C AIDS STOCK; GAINES H, 1987, LANCET, V1, P1249; GELLERT GA, 1989, PEDIATRICS, V83, P644; GELLERT GA, 1989, NEW ENGL J MED, V321, P685; GERBERDING JL, 1992, CLIN INFECT DIS, V14, P1179, DOI 10.1093/clinids/14.6.1179; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; GOSTIN L, 1991, ARCH INTERN MED, V151, P663, DOI 10.1001/archinte.151.4.663; Gostin Larry, 1989, MD Law Rev, V48, P12; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1961, DOI 10.1001/jama.263.14.1961; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; HAMMETT TM, 1990, NCJ124549 AIDS B PUB, P1; HENDERSON DK, 1991, AM J MED, V91, pS312, DOI 10.1016/0002-9343(91)90388-E; HOLMBERG SD, 1989, J INFECT DIS, V160, P116, DOI 10.1093/infdis/160.1.116; HOLMES KK, 1970, AM J EPIDEMIOL, V91, P170, DOI 10.1093/oxfordjournals.aje.a121125; HOLMSTROM LL, 1979, FAM COORD, V28, P321, DOI 10.2307/581944; HOOPER RR, 1978, AM J EPIDEMIOL, V108, P136, DOI 10.1093/oxfordjournals.aje.a112597; HORSBURGH CR, 1989, LANCET, V2, P637; JACKSON MH, 1992, AIDS AGENDA EMERGING, P239; JENNY C, 1990, NEW ENGL J MED, V322, P713, DOI 10.1056/NEJM199003153221101; JUDSON FN, 1981, SEX TRANSM DIS, V8, P336; KELEN GD, 1989, JAMA-J AM MED ASSOC, V262, P516, DOI 10.1001/jama.262.4.516; KELEN GD, 1988, NEW ENGL J MED, V318, P1645, DOI 10.1056/NEJM198806233182503; KILPATRICK DG, 1987, 84IJCX0039 NAT I JUS; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; LAFON SW, 1990, 30TH INT C ANT AG CH; LEWANDOWSKI C, 1989, 5TH INT C AIDS MONTR; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; LIPSCOMB GH, 1992, JAMA-J AM MED ASSOC, V267, P3064, DOI 10.1001/jama.267.22.3064; MCCUUNE JM, 1991, SCIENCE, V247, P564; MORGAN M, 1990, JUDGES J, V29, P22; NACCI PL, 1982, SEX SEXUAL AGGRESSIO; OSTERHOLM MT, 1987, NEW ENGL J MED, V316, P1024; PADIAN N, 1990, CONRAD W S, P25; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PADIAN N, 1988, 28TH INT C ANT AG CH; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P113; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1002/jts.2490050309; SEAGE GR, 1989, AM J PUBLIC HEALTH, V79, P1638, DOI 10.2105/AJPH.79.12.1638; SHERMAN R, 1993, NATIONAL LAW J, V15, P28; SHERMAN R, 1993, NATIONAL LAW J, V16, P33; SHIH CC, 1991, J INFECT DIS, V163, P625, DOI 10.1093/infdis/163.3.625; SILVERMAN DC, 1978, AM J ORTHOPSYCHIAT, V48, P166, DOI 10.1111/j.1939-0025.1978.tb01298.x; SILVERMAN DC, 1992, MALE VICTIMS SEXUAL, P87; SIMOTAS L, 1991, NEW YORK U LAW REV, V66, P1881; STEIGBIGEL NHJ, 1988, 4TH INT C AIDS STOCK; WEBER JN, 1986, GENITOURIN MED, V62, P177; WHITE PN, 1981, FAM RELAT, V30, P103, DOI 10.2307/584243; ZIERLER S, 1991, AM J PUBLIC HEALTH, V81, P572, DOI 10.2105/AJPH.81.5.572; 1991, MMWR MORB MORTAL WKL, V40, P1; 1993, BUREAU JUSTICE S MAR; 1993, CURRENT TRENDS CHILD; 1987, DIAGNOSTIC STATISTIC; 1988, MMWR MORB MORTAL WKL, V37, P377; 1992, CRIME US 1991; 1994, ACTG076 NIH NAT I AL; 1993, RAPE AM REPORT NATIO; 1979, CDC798195 CTR DIS CO; 1988, PEDIATRICS, V81, P595; 1992, WHOGPAINF932 GLOB PR; 1989, MMWR MORB MORTAL WKL, V38, P1; 1988, MMWR MORB MORTAL WKL, V37, P387; 1993, MMWR MORB MORTAL WKL, V42, P1; 1992, TESTING OFFENDERS HU, P1	82	70	70	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	1994	271	18					1436	1444		10.1001/jama.271.18.1436	http://dx.doi.org/10.1001/jama.271.18.1436			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ693	8176804				2022-12-01	WOS:A1994NJ69300032
J	GELPERIN, A				GELPERIN, A			NITRIC-OXIDE MEDIATES NETWORK OSCILLATIONS OF OLFACTORY INTERNEURONS IN A TERRESTRIAL MOLLUSK	NATURE			English	Article							ACTIVATION; MESSENGER; SYNTHASE; RELEASE; BRAIN; RAT	THE interneuronal messenger nitric oxide(1,2) (NO) may play a central role in the processing of olfactory information(3). Several circuit elements in the mammalian olfactory bulb contain NO synthase(4) or its functional equivalent, NADPH diaphorase(5-7). The effects of NO on cellular,excitability or circuit dynamics in the olfactory bulb are unknown, although NO effects on other rhythmic cells(8) and circuits(9) have been described. T have studied the role of NO in central olfactory processing using the procerebral (PC) lobe, the major central site of odour processing in terrestrial molluscs(10,11). As in the mammalian olfactory bulb during odour stimulation, the basic dynamics of electrical activity in the molluscan PC lobe is an oscillation(12-14). Here I report an obligatory role for NO is the oscillatory dynamics of the PC lobe of Limax maximus. Nitric oxide mediation of the olfactory oscillation may relate to the highly developed odour sensitivity and odour-learning ability of Limax(15,16).			GELPERIN, A (corresponding author), AT&T BELL LABS,BIOL COMPUTAT RES DEPT,600 MT AVE,MURRAY HILL,NJ 07974, USA.							ACHE BW, 1991, SMELL TASTE HLTH DIS, P3; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BREER H, 1993, TRENDS NEUROSCI, V16, P5, DOI 10.1016/0166-2236(93)90040-S; BUXTON ILO, 1993, CIRC RES, V72, P387, DOI 10.1161/01.RES.72.2.387; CARTER TD, 1993, J PHYSIOL-LONDON, V467, pP165; CHASE R, 1989, J COMP NEUROL, V283, P143, DOI 10.1002/cne.902830112; CHASE R, 1993, J ELECTRON MICR TECH, V24, P214; COOKE IRC, IN PRESS CELL TISS R; CROULOTTMAN CE, 1988, BRAIN RES, V460, P323, DOI 10.1016/0006-8993(88)90376-9; DAVIS BJ, 1991, J COMP NEUROL, V314, P493, DOI 10.1002/cne.903140307; DELANEY KR, 1994, P NATL ACAD SCI USA, V91, P669, DOI 10.1073/pnas.91.2.669; ELOFSSON R, 1993, NEUROREPORT, V4, P279, DOI 10.1097/00001756-199303000-00013; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GELPERIN A, 1990, NATURE, V345, P437, DOI 10.1038/345437a0; GELPERIN A, 1993, J NEUROPHYSIOL, V69, P1930, DOI 10.1152/jn.1993.69.6.1930; GELPERIN A, 1989, PERSPECTIVES NEURAL, P121; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MOROZ LL, 1993, NEUROREPORT, V4, P643, DOI 10.1097/00001756-199306000-00010; NIKOLSKII AB, 1976, SOVIET J COORD CHEM, V2, P508; PAPE HC, 1992, NEURON, V9, P441, DOI 10.1016/0896-6273(92)90182-D; RHINES LD, 1993, J NEUROPHYSIOL, V69, P1940, DOI 10.1152/jn.1993.69.6.1940; SAHLEY CL, 1990, CONNECTIONIST MODELI, P36; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813	28	202	203	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					61	63		10.1038/369061a0	http://dx.doi.org/10.1038/369061a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164740				2022-12-01	WOS:A1994NJ86000053
J	KAGI, D; LEDERMANN, B; BURKI, K; SEILER, P; ODERMATT, B; OLSEN, KJ; PODACK, ER; ZINKERNAGEL, RM; HENGARTNER, H				KAGI, D; LEDERMANN, B; BURKI, K; SEILER, P; ODERMATT, B; OLSEN, KJ; PODACK, ER; ZINKERNAGEL, RM; HENGARTNER, H			CYTOTOXICITY MEDIATED BY T-CELLS AND NATURAL-KILLER-CELLS IS GREATLY IMPAIRED IN PERFORIN DEFICIENT MICE	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; PORE-FORMING PROTEIN; SERINE PROTEASES; CYTO-TOXICITY; TARGET-CELLS; STEM-CELLS; INVIVO; EXPRESSION; INFECTION; GRANULES	Perforin-deficient mice have been generated by homologous recombination to determine whether the effects of CD8(+) cytolytic T cells and natural killer cells are mediated by pore formation involving perforin. These mice are viable and fertile and have normal numbers of CD8(+) T cells and natural killer cells which do not lyse virus-infected or allogeneic fibroblasts or natural killer target cells in vitro. The mice fail to clear lymphocytic choriomeningitis virus and they eliminate fibrosarcoma tumour cells with reduced efficiency. Perforin is therefore a key effector molecule for T-cell- and natural killer-cell-mediated cytolysis.	SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND; UNIV MIAMI, DEPT MICROBIOL & IMMUNOL, MIAMI, FL 33101 USA	Novartis; Sandoz; University of Miami	KAGI, D (corresponding author), UNIV ZURICH, INST EXPTL IMMUNOL, DEPT PATHOL, CH-8091 ZURICH, SWITZERLAND.							ACHAORBEA H, 1990, EMBO J, V9, P3815, DOI 10.1002/j.1460-2075.1990.tb07599.x; BAENZIGER J, 1988, SCAND J IMMUNOL, V28, P411, DOI 10.1111/j.1365-3083.1988.tb01470.x; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; BERKE G, 1987, TRANSPLANT P, V19, P412; BINDER D, 1991, J IMMUNOL, V146, P4301; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; Cerottini J C, 1974, Adv Immunol, V18, P67, DOI 10.1016/S0065-2776(08)60308-9; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; DENNERT G, 1983, J EXP MED, V157, P1483, DOI 10.1084/jem.157.5.1483; DOURMASHKIN RR, 1980, CLIN EXP IMMUNOL, V42, P554; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; GARCIASANZ JA, 1987, EMBO J, V6, P933, DOI 10.1002/j.1460-2075.1987.tb04841.x; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HOWELL DM, 1987, J IMMUNOL, V138, P3695; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; KAWASAKI A, 1992, EUR J IMMUNOL, V22, P1215, DOI 10.1002/eji.1830220516; KAWASAKI A, 1990, INT IMMUNOL, V2, P677, DOI 10.1093/intimm/2.7.677; KOHLER M, 1990, CANCER IMMUNOL IMMUN, V32, P117, DOI 10.1007/BF01754208; LEDERMANN B, 1991, EXP CELL RES, V197, P254, DOI 10.1016/0014-4827(91)90430-3; LEHMANNGRUBE F, 1988, ANN NY ACAD SCI, V532, P238, DOI 10.1111/j.1749-6632.1988.tb36343.x; LEHMANNGRUBE F, 1993, J VIROL, V67, P332, DOI 10.1128/JVI.67.1.332-339.1993; LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTZ E, 1989, IMMUNOL TODAY, V10, P79, DOI 10.1016/0167-5699(89)90231-4; MELIEF CJM, 1992, ADV CANCER RES, V58, P143, DOI 10.1016/S0065-230X(08)60294-8; MOSKOPHIDIS D, 1989, P NATL ACAD SCI USA, V86, P3291, DOI 10.1073/pnas.86.9.3291; MUELLER C, 1988, J EXP MED, V167, P1124, DOI 10.1084/jem.167.3.1124; MULLER C, 1989, EUR J IMMUNOL, V19, P1253, DOI 10.1002/eji.1830190716; MULLER D, 1992, SCIENCE, V255, P1576, DOI 10.1126/science.1347959; PARR EL, 1990, J IMMUNOL, V145, P2365; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PODACK ER, 1985, IMMUNOL TODAY, V6, P21, DOI 10.1016/0167-5699(85)90164-1; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; PODACK ER, 1988, IMMUNOL REV, V103, P203, DOI 10.1111/j.1600-065X.1988.tb00756.x; RAMSHAW I, 1992, IMMUNOL REV, V127, P157, DOI 10.1111/j.1600-065X.1992.tb01413.x; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1983, IMMUNOL REV, V72, P97, DOI 10.1111/j.1600-065X.1983.tb01074.x; SELLINS KS, 1991, J IMMUNOL, V147, P795; SHINKAI Y, 1988, NATURE, V334, P525, DOI 10.1038/334525a0; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; STEWART CL, 1987, EMBO J, V6, P383, DOI 10.1002/j.1460-2075.1987.tb04766.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TRAPANI JA, 1990, J EXP MED, V171, P545, DOI 10.1084/jem.171.2.545; YOUN BS, 1991, J EXP MED, V173, P813, DOI 10.1084/jem.173.4.813; YOUNG JDE, 1986, CELL, V44, P849, DOI 10.1016/0092-8674(86)90007-3; YOUNG LHY, 1990, LANCET, V336, P1019, DOI 10.1016/0140-6736(90)92486-2; ZINKERNAGEL RM, 1986, J EXP MED, V164, P1075, DOI 10.1084/jem.164.4.1075	49	1510	1535	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 5	1994	369	6475					31	37		10.1038/369031a0	http://dx.doi.org/10.1038/369031a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164737				2022-12-01	WOS:A1994NJ86000043
J	MURPHY, S; KHAW, KT; MAY, H; COMPSTON, JE				MURPHY, S; KHAW, KT; MAY, H; COMPSTON, JE			MILK CONSUMPTION AND BONE-MINERAL DENSITY IN MIDDLE-AGED AND ELDERLY WOMEN	BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-ACTIVITY; HIP FRACTURE; DIETARY CALCIUM; RISK; OSTEOPOROSIS; EPIDEMIOLOGY	Objectives-To study the effects of historical milk consumption on current bone mineral density at the hip and spine. Design-Cross sectional study. Subjects-284 community based women aged 4474 years recruited from four general practice age-sex registers in Cambridge. Subjects categorised their average milk consumption up to age 25, from age 2544, and from age 44 to the present time as greater-than-or-equal-to 1 glass/day, < 1 glass/day but > 1 glass/week, or < 1 glass/week. Main outcome measures-Bone mineral density at the hip and spine measured by dual energy x ray absorptiometry. Results-Data on milk consumption up to age 25 years were available for 252 women. There was a consistent upward trend in bone mineral density at all sites with increasing historical milk consumption (total hip, femoral neck, trochanter, intertrochanter, P<0.05: Ward's triangle, P=0.005). Adjustment for age and body size did not alter these trends. Milk consumption up to age 25 was a significant independent predictor of bone mineral density at all sites in multiple linear regression analyses controlling for age, body mass index, menopausal status, smoking, ever use of hormone replacement therapy or oral contraceptives, physical activity, and alcohol intake. The effects of milk consumption from age 25-44 and from age 44 to the present were similar in direction though not statistically significant. Conclusion-Frequent milk consumption before age 25 favourably influences hip bone mass in middle aged and older women.	ADDENBROOKES HOSP,CLIN GERONTOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND; ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARAN D, 1990, J CLIN ENDOCR METAB, V70, P264, DOI 10.1210/jcem-70-1-264; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; GARTON MJ, 1992, BMJ-BRIT MED J, V305, P82, DOI 10.1136/bmj.305.6845.82; HOFFENBERG R, 1989, FRACTURED NCK FEMUR; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; KANIS JA, 1992, BONE, V13, pS7, DOI 10.1016/S8756-3282(09)80004-5; KELSEY JL, 1992, AM J EPIDEMIOL, V135, P477, DOI 10.1093/oxfordjournals.aje.a116314; LASKEY MA, 1991, BRIT J RADIOL, V64, P1023, DOI 10.1259/0007-1285-64-767-1023; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; MATKOVIC V, 1979, AM J CLIN NUTR, V32, P540, DOI 10.1093/ajcn/32.3.540; NIEVES JW, 1992, OSTEOPOROSIS INT, V2, P122, DOI 10.1007/BF01623818; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; RECKER RR, 1992, JAMA-J AM MED ASSOC, V268, P2403, DOI 10.1001/jama.268.17.2403; RECKER RR, 1985, AM J CLIN NUTR, V41, P254, DOI 10.1093/ajcn/41.2.254; ROBERTS DJ, 1988, P NUTR SOC, V47, P323, DOI 10.1079/PNS19880050; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; SANDLER RB, 1985, AM J CLIN NUTR, V42, P270, DOI 10.1093/ajcn/42.2.270; SENTIPAL JM, 1991, AM J CLIN NUTR, V54, P425, DOI 10.1093/ajcn/54.2.425; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; 1990, HOUSEHOLD FOOD CONSU; 1975, 10 DEP HLTH HLTH SOC; 1992, EPIDEMIOLOGICAL OVER, V1; 1987, HLTH LIFESTYLE SURVE	26	129	130	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					939	941		10.1136/bmj.308.6934.939	http://dx.doi.org/10.1136/bmj.308.6934.939			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173399	Green Published			2022-12-01	WOS:A1994NF48500014
J	ROSS, AM; FLEMING, DM				ROSS, AM; FLEMING, DM			INCIDENCE OF ALLERGIC RHINITIS IN GENERAL-PRACTICE, 1981-92	BRITISH MEDICAL JOURNAL			English	Article							HAY-FEVER; PREVALENCE; ASTHMA	Objectives-To determine the epidemiology of hay fever and to consider the role of pollution. Design-Examination of data on weekly incidence of allergic rhinitis and hay fever by age, sex, region, and location. Setting-Royal College of General Practitioners Weekly Returns Service. Practice data were based on registered populations of 220 000 in 1991, rising to 700 000 in 1992 from England and Wales. Main outcome measures-Numbers of new cases of hay fever and allergic rhinitis. Data on pollen counts for Darlington, Derby, and London. Results-The incidence of allergic rhinitis fluctuated greatly from year to year but showed no trend. Peaks in hay fever coincided with peak pollen counts. No important differences were found between urban and rural locations or different parts of the country with respect to both size and timing of the peaks. Incidence was highest in children (5-14 years). Conclusions-The similarity of the results throughout England and Wales does not support an important role for local pollutants in hay fever. However, the possibility that levels of pollutants are high enough to act as an adjuvant in hay fever across the whole study area has not been excluded.			ROSS, AM (corresponding author), ROYAL COLL GEN PRACTITIONERS,BIRMINGHAM RES UNIT,BIRMINGHAM B17 9DB,ENGLAND.							ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; CHARPIN D, 1988, REV MAL RESPIR, V5, P109; CROMBIE DL, 1984, 25 ROYAL COLL GEN PR; EWAN PW, 1989, J ROY COLL PHYS LOND, V23, P68; FELL PJ, 1992, CLIN EXP ALLERGY, V22, P501, DOI 10.1111/j.1365-2222.1992.tb00154.x; FINN R, 1992, LANCET, V340, P1453; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MOLFINO NA, 1992, CLIN EXP ALLERGY, V22, P667, DOI 10.1111/j.1365-2222.1992.tb00189.x; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; PEDERSEN PA, 1981, ALLERGY, V36, P375, DOI 10.1111/j.1398-9995.1981.tb01841.x; RICHARDS S, 1992, BRIT J GEN PRACT, V42, P284; SIBBALD B, 1991, THORAX, V46, P378, DOI 10.1136/thx.46.5.378; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; THOMAS E, 1993, AM REV RESPIR DIS, V147, pA643; VARNEY V, 1991, CLIN EXP ALLERGY, V21, P757, DOI 10.1111/j.1365-2222.1991.tb03210.x; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; 1990, MB52 DEP HLTH OFF PO; 1974, STUDIES MED POPULATI, V26; 1986, MORBIDITY STATISTICS; 1993, 934 DEP PHS LUNG AST; 1958, STUDIES MED POPULATI, V14	24	31	32	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					897	900		10.1136/bmj.308.6933.897	http://dx.doi.org/10.1136/bmj.308.6933.897			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173372	Green Published			2022-12-01	WOS:A1994NE60000025
J	MORSE, RH				MORSE, RH			NUCLEOSOME DISRUPTION BY TRANSCRIPTION FACTOR-BINDING IN YEAST	SCIENCE			English	Article							RNA POLYMERASE-II; TUMOR VIRUS PROMOTER; DNA-BINDING; POSITIONED NUCLEOSOMES; SACCHAROMYCES-CEREVISIAE; REGULATORY PROTEINS; CHROMATIN STRUCTURE; PHO5 PROMOTER; MAJOR LATE; GENE	Studies in vivo and in vitro have shown that the packaging of DNA into chromatin can affect gene expression. Here, binding of the yeast transcriptional activator GAL4 to DNA in chromatin has been investigated in vivo with a yeast episome. A positioned nucleosome that is present in cells grown in glucose and contains a single GAL4 binding site is disrupted by GAL4 binding in galactose. GAL4 can also bind to DNA in chromatin when the carboxyl-terminal activation domain of GAL4 is either masked by GAL80 or is absent. These results show that a transcription factor can bind to its site in vivo in what would appear to be a repressive chromatin structure.	NIDDKD, CELLULAR & DEV BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Morse, Randall/0000-0003-0000-8718				ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BAJWA W, 1988, MOL CELL BIOL, V8, P3439, DOI 10.1128/MCB.8.8.3439; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; DOLLARD C, UNPUB; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1987, NATURE, V328, P353, DOI 10.1038/328353a0; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MADDEN SL, 1988, NUCLEIC ACIDS RES, V16, P2625, DOI 10.1093/nar/16.6.2625; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; MORSE RH, 1992, MOL CELL BIOL, V12, P4015, DOI 10.1128/MCB.12.9.4015; MORSE RH, UNPUB; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROSE MD, 1990, METHODS YEAST GENETI; ROTH SY, 1991, METHOD CELL BIOL, V35, P289; SAMBROOK I, 1989, MOL CLONING LABORATO; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	56	65	65	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1993	262	5139					1563	1566		10.1126/science.8248805	http://dx.doi.org/10.1126/science.8248805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248805				2022-12-01	WOS:A1993MK32900038
J	GADDE, J; SPENCE, M; WHEELER, B; ADKINSON, NF				GADDE, J; SPENCE, M; WHEELER, B; ADKINSON, NF			CLINICAL-EXPERIENCE WITH PENICILLIN SKIN TESTING IN A LARGE INNER-CITY STD CLINIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALLERGY; HYPERSENSITIVITY; DESENSITIZATION; ANTIBIOTICS	Objective.-To establish (1) the prevalence of positive penicillin skin tests among outpatients with well-defined but variable history of penicillin allergy and (2) the reproducibility, safety, and negative predictive value of skin testing with benzylpenicilloyl polylysine (PPL) and a minor-determinant mixture (MDM). Design.-Serial consenting outpatients with current indications for penicillin therapy were skin-tested in duplicate with PPL and MDM. Subjects with negative skin tests (93% of those positive by history and 95% of those negative by history) received therapeutic courses of benzylpenicillin (81%) or ampicillin (19%). Negative predictive value of skin testing was established by 72-hour follow-up for adverse reactions to drug. Setting/Patients.-A total of 5063 consecutive, qualifying outpatients in a Baltimore, Md, sexually transmitted disease (STD) clinic. The study group was young (73% between 20 and 40 years old), 66% male, and 90% black; 25% had history of atopy. Follow-up was 94% complete. Results.-Positive skin tests were observed in 7.1% of 776 individuals with previous history of penicillin allergy and in 1.7% of 4287 subjects negative by history (P<<.001). Previous history of anaphylaxis or urticaria was associated with significantly higher rates of positive skin tests of 17.3% and 12.4%, respectively (P<<.001). Only 4% with history of exanthem had positive skin tests (P=.03). The coefficient of variation for duplicate skin tests was 11%. Time intervals since last penicillin treatment did not influence the rate of positive skin tests. Adverse reactions to skin tests occurred in 13 (1.2% of patients positive by history; 9.4% of those with positive skin tests). A mild anaphylactic reaction occurred in one individual whose preliminary scratch testing was inadvertently omitted; systemic pruritus or urticaria occurred in 11 subjects; one had a large local reaction. After penicillin administration to individuals with negative skin tests, acute allergic reactions occurred in 0.5% of subjects negative by history compared with 2.9% of subjects positive by history (chi2=33.3; P=.0001). Reactions were generally mild and self-limited; only two cases of mild anaphylactic reaction occurred, both in patients with history of severe IgE-mediated reaction. Conclusions.-Skin testing with both major and minor penicillin determinants is safe using current recommendations, and both reagents are necessary for maximizing the identification of sensitized subjects. Routine penicillin skin testing can facilitate the safe use of penicillin in 90% of individuals with a previous history of penicillin allergy.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV ALLERGY & CLIN IMMUNOL, BALTIMORE, MD 21205 USA; BALTIMORE CITY EASTERN HLTH DIST CLIN SEXUALLY TRA, BALTIMORE, MD USA	Johns Hopkins University					NIAID NIH HHS [AI 11936] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; BOGER WP, 1953, J ALLERGY, V24, P383, DOI 10.1016/0021-8707(53)90038-0; BROWN BC, 1964, JAMA-J AM MED ASSOC, V189, P599; BROWN LA, 1982, J ALLERGY CLIN IMMUN, V69, P51, DOI 10.1016/0091-6749(82)90087-2; BUDD MA, 1964, JAMA-J AM MED ASSOC, V190, P115; CHANDRA RK, 1980, ARCH DIS CHILD, V55, P857, DOI 10.1136/adc.55.11.857; DOGLIOTTI M, 1968, DERMATOLOGICA, V136, P489, DOI 10.1159/000254145; FINKE SR, 1965, AM J MED, V38, P71, DOI 10.1016/0002-9343(65)90161-0; GOREVIC PD, 1981, J ALLERGY CLIN IMMUN, V68, P267, DOI 10.1016/0091-6749(81)90150-0; GRAYBILL JR, 1974, SOUTH MED J, V67, P62, DOI 10.1097/00007611-197401000-00017; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; LENTZ J W, 1970, British Journal of Venereal Diseases, V46, P457; LEVINE BB, 1966, J CLIN INVEST, V45, P1895, DOI 10.1172/JCI105494; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; NACLERIO R, 1982, Journal of Allergy and Clinical Immunology, V69, P139; PARKER CW, 1962, J EXP MED, V115, P821, DOI 10.1084/jem.115.4.821; REDELMEIER DA, 1990, ARCH INTERN MED, V150, P1939, DOI 10.1001/archinte.150.9.1939; RYTEL MW, 1963, JAMA-J AM MED ASSOC, V186, P894; SHEPHERD G, 1992, ARCH INTERN MED, V152, P2505; SIEGEL BB, 1964, J ALLERGY, V35, P488, DOI 10.1016/0021-8707(64)90080-2; SOGN DD, 1983, J ALLERGY CLIN IMMUN, V71, P147, DOI 10.1016/0091-6749(83)90358-5; SOGN DD, 1984, J ALLERGY CLIN IMMUN, V74, P589, DOI 10.1016/0091-6749(84)90111-8; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; SOGN DD, 1986, J ALLERGY CLIN IMMUN, V78, P1051, DOI 10.1016/0091-6749(86)90303-9; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; SULLIVAN TJ, 1982, PEDIATR INFECT DIS J, V1, P344, DOI 10.1097/00006454-198209000-00015; TUCHINDA M, 1980, J MED ASSOC THAILAND, V63, P143; VOSS HE, 1966, J AMER MED ASSOC, V196, P679, DOI 10.1001/jama.1966.03100210049014; WARRINGTON RJ, 1978, CAN MED ASSOC J, V118, P787; WEISS ME, 1988, CLIN ALLERGY, V18, P515, DOI 10.1111/j.1365-2222.1988.tb02904.x	32	245	251	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1993	270	20					2456	2463		10.1001/jama.270.20.2456	http://dx.doi.org/10.1001/jama.270.20.2456			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG671	8230623				2022-12-01	WOS:A1993MG67100027
J	RONALD, PJM; ROBERTSON, JR; WYLD, R; WEIGHTMAN, R				RONALD, PJM; ROBERTSON, JR; WYLD, R; WEIGHTMAN, R			HETEROSEXUAL TRANSMISSION OF HIV IN INJECTING DRUG-USERS	BRITISH MEDICAL JOURNAL			English	Article							INFECTION		EDINBURGH DRUG ADDICT STUDY,EDINBURGH EH4 4PL,SCOTLAND; MRC,HETEROSEXUAL TRANSMISS STUDY,EDINBURGH EH4 4PL,SCOTLAND									DONOGHOE MC, 1992, SYRINGE EXCHANGE ENG; JOHNSON AM, 1992, BRIT MED J, V304, P1125, DOI 10.1136/bmj.304.6835.1125; ROBERTSON JR, 1986, BRIT MED J, V292, P527, DOI 10.1136/bmj.292.6519.527; ROBERTSON JR, 1990, AIDS DRUG MISUSE; RONALD PJM, 1992, BRIT J ADDICT, V87, P115	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1184	1185		10.1136/bmj.307.6913.1184	http://dx.doi.org/10.1136/bmj.307.6913.1184			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8251845	Green Published, Bronze			2022-12-01	WOS:A1993MF82400024
J	PALLADINO, F; LAROCHE, T; GILSON, E; AXELROD, A; PILLUS, L; GASSER, SM				PALLADINO, F; LAROCHE, T; GILSON, E; AXELROD, A; PILLUS, L; GASSER, SM			SIR3 AND SIR4 PROTEINS ARE REQUIRED FOR THE POSITIONING AND INTEGRITY OF YEAST TELOMERES	CELL			English	Article							SALIVARY-GLAND NUCLEI; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; CHROMATIN STRUCTURE; TOPOISOMERASE-II; BINDING-PROTEIN; DNA; RAP1; REPLICATION; CHROMOSOMES	Heritable inactivation of genes occurs in specific chromosomal domains located at the silent mating type loci and at telomeres of S. cerevisiae. The SIR genes (for silent information regulators) are trans-acting factors required for this repression mechanism. We show here that the SIR3 and SIR4 gene products have a sub-nuclear localization similar to the telomere-associated RAP1 protein, which is found primarily in foci at the nuclear periphery of fixed yeast spheroplasts. In strains defficient for either SIR3 or SIR4, telomeres lose their perinuclear localization, as monitored by RAP1 immunofluorescence. The length of the telomeric repeat shortens in sir3 and sir4 mutant strains, and the mitotic stability of chromosome V is reduced. These data suggest that SIR3 and SIR4 are required for both the integrity and subnuclear localization of yeast telomeres, the loss of which correlates with loss of telomere-associated gene repression.	UNIV CALIF BERKELEY,DEPT MOLEC & CELLULAR BIOL,BERKELEY,CA 94720; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	University of California System; University of California Berkeley; University of Colorado System; University of Colorado Boulder	PALLADINO, F (corresponding author), SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND.			Gasser, Susan/0000-0003-3610-9123	NIGMS NIH HHS [GM31105] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031105, R37GM031105] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOUTEILLE M, 1974, CELL NUCLEUS, V1, P5; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; DIFFLEY JFX, 1989, NATURE, V342, P24, DOI 10.1038/342024a0; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; Gilson Eric, 1993, Trends in Cell Biology, V3, P128, DOI 10.1016/0962-8924(93)90175-Z; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1985, GENETICS, V110, P381; HEGEMANN JH, 1988, MOL CELL BIOL, V8, P2523, DOI 10.1128/MCB.8.6.2523; HOCHSTRASSER M, 1986, J CELL BIOL, V102, P112, DOI 10.1083/jcb.102.1.112; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LIPPS HJ, 1982, P NATL ACAD SCI-BIOL, V79, P2495, DOI 10.1073/pnas.79.8.2495; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LONGTINE MS, 1992, MOL CELL BIOL, V12, P1997, DOI 10.1128/MCB.12.5.1997; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; MATHOG D, 1984, NATURE, V308, P414, DOI 10.1038/308414a0; MCCARROLL RM, 1988, CELL, V54, P5135; PALLADINO F, 1994, IN PRESS COLD SPRING, V58; Rabl C., 1885, MORPHOL JB, V10, P214; RINE J, 1987, GENETICS, V116, P9; ROSE MD, 1990, METHODS YEAST GENETI; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; Sandell L L, 1992, Trends Cell Biol, V2, P10, DOI 10.1016/0962-8924(92)90138-D; SHOEMAN RL, 1990, J BIOL CHEM, V265, P9055; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; VOURCH C, 1993, EXP CELL RES, V205, P142, DOI 10.1006/excr.1993.1068; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197	50	351	359	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 5	1993	75	3					543	555		10.1016/0092-8674(93)90388-7	http://dx.doi.org/10.1016/0092-8674(93)90388-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8221893				2022-12-01	WOS:A1993MF83000016
J	RABENECK, L; GYORKEY, F; GENTA, RM; GYORKEY, P; FOOTE, LW; RISSER, JMH				RABENECK, L; GYORKEY, F; GENTA, RM; GYORKEY, P; FOOTE, LW; RISSER, JMH			THE ROLE OF MICROSPORIDIA IN THE PATHOGENESIS OF HIV-RELATED CHRONIC DIARRHEA	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; DIARRHEA; ASTERISK-MICROSPORIDIA INFECTIONS; ENTEROCYTOZOON-BIENEUSI; ACQUIRED IMMUNODEFICIENCY SYNDROME	ACQUIRED IMMUNODEFICIENCY SYNDROME; SMALL-INTESTINAL MICROSPORIDIOSIS; AIDS PATIENTS; ENTEROCYTOZOON-BIENEUSI; PREVALENCE; MICROSCOPY	Objective: To determine whether infection with Microsporidia leads to diarrhea in patients with human immunodeficiency virus (HIV) infection. Design: Case-control study. Setting: Primary care outpatient HIV clinic at a Veterans Affairs medical center. Patients: One hundred six HIV-infected men, 55 with and 51 without chronic diarrhea. Measurements: Each patient underwent upper endoscopy and flexible sigmoidoscopy to obtain duodenal, rectal, and sigmoid colonic biopsy specimens. At the time of endoscopy, a fresh stool was obtained for culture, ova and parasite assessment, and Cryptosporidium examination. Biopsy tissue was examined using electron microscopy to detect Microsporidia. Results: The microsporidian parasite Enterocytozoon bieneusi was detected in the duodenal biopsy specimens of 31 of 106 men (29%); 24 of 106 men (23%) had other enteric pathogens. No significant difference was observed in the occurrence of microsporidiosis in patients with (18 of 55 [33%]) and without (13 of 51 [25%]) chronic diarrhea (odds ratio, 1.42; 95% CI, 0.61 to 3.31). A similar nonsignificant difference was observed after controlling for CD4 count and other enteric pathogens (odds ratio, 1.66; 95% CI, 0.68 to 4.06). Among patients with microsporidiosis, no difference was observed in the intensity of infection (defined by the presence of few, moderate, or abundant organisms) among cases and controls (P > 0.2). Conclusions: This is the first report to document the presence of E. bieneusi in HIV-positive patients without gastrointestinal symptoms. No significant difference was observed in the occurrence of E. bieneusi infection in HIV-infected patients with or without chronic diarrhea. Thus, the association between microsporidiosis and diarrhea, if one exists, may not be as strong as is currently believed.	BAYLOR COLL MED, HOUSTON, TX 77030 USA; VET AFFAIRS ELECTRON MICROSCOPY PROGRAM, HOUSTON, TX USA; VET AFFAIRS RES CTR AIDS & HIV INFECT, HOUSTON, TX USA	Baylor College of Medicine	RABENECK, L (corresponding author), VET AFFAIRS MED CTR, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.				NCRR NIH HHS [RR-05425] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bryan R T, 1991, Prog Clin Parasitol, V2, P1; CALI A, 1990, J PROTOZOOL, V37, P145, DOI 10.1111/j.1550-7408.1990.tb05885.x; CANNING EU, 1990, T ROY SOC TROP MED H, V84, P181, DOI 10.1016/0035-9203(90)90247-C; CHLEBOWSKI RT, 1989, AM J GASTROENTEROL, V84, P1288; Churukian CJ, 1982, J HISTOTECHNOL, V5, P127; DOBBINS WO, 1985, GASTROENTEROLOGY, V88, P738, DOI 10.1016/0016-5085(85)90145-3; GOODGAME RW, 1993, J INFECT DIS, V167, P704, DOI 10.1093/infdis/167.3.704; GREENSON JK, 1991, ANN INTERN MED, V114, P366, DOI 10.7326/0003-4819-114-5-366; KOTLER DP, 1990, ANN INTERN MED, V113, P444; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; MODIGLIANI R, 1985, GUT, V26, P179, DOI 10.1136/gut.26.2.179; NELSON JA, 1988, LANCET, V1, P259; ORENSTEIN JM, 1990, HUM PATHOL, V21, P475; ORENSTEIN JM, 1992, AIDS, V6, P195, DOI 10.1097/00002030-199202000-00009; POL S, 1993, NEW ENGL J MED, V328, P95, DOI 10.1056/NEJM199301143280204; RIJPSTRA AC, 1988, J INFECT DIS, V157, P827, DOI 10.1093/infdis/157.4.827; SCHATTENKERK JKME, 1991, LANCET, V337, P895, DOI 10.1016/0140-6736(91)90215-B; SHADDUCK JA, 1989, REV INFECT DIS, V11, P203; WEBER R, 1992, NEW ENGL J MED, V326, P161, DOI 10.1056/NEJM199201163260304; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; 1987, MMWR, V36	21	119	119	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1993	119	9					895	899		10.7326/0003-4819-119-9-199311010-00005	http://dx.doi.org/10.7326/0003-4819-119-9-199311010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD711	8215001				2022-12-01	WOS:A1993MD71100005
J	YE, BH; LISTA, F; LOCOCO, F; KNOWLES, DM; OFFIT, K; CHAGANTI, RSK; DALLAFAVERA, R				YE, BH; LISTA, F; LOCOCO, F; KNOWLES, DM; OFFIT, K; CHAGANTI, RSK; DALLAFAVERA, R			ALTERATIONS OF A ZINC-FINGER ENCODING GENE, BCL-6, IN DIFFUSE LARGE-CELL LYMPHOMA	SCIENCE			English	Article							NON-HODGKINS-LYMPHOMA; ACUTE LEUKEMIAS; CHROMOSOME-TRANSLOCATION; DROSOPHILA-TRITHORAX; FOLLICULAR LYMPHOMA; REGION; PROTEINS; REARRANGEMENT; BREAKPOINT; LOCUS	The molecular pathogenesis of diffuse large-cell lymphoma (DLCL), the most frequent and clinically relevant type of lymphoma, is unknown. A gene was cloned from chromosomal translocations affecting band 3q27, which are common in DLCL. This gene, BCL-6, codes for a 79-kilodalton protein that is homologous with zinc finger-transcription factors. In 33 percent (13 of 39) of DLCL samples, but not in other types of lymphoid malignancies, the BCL-6 gene is truncated within its 5' noncoding sequences, suggesting that its expression is deregulated. Thus, BCL-6 may be a proto-oncogene specifically involved in the pathogenesis of DLCL.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021; CTR STUDI & RIC SANITA ESERCITO,ROME,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO BIOPATOL UMANA,SEZ EMATOL,I-00185 ROME,ITALY	Columbia University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Sapienza University Rome				lista, florigio/0000-0001-5700-4772	NATIONAL CANCER INSTITUTE [R01CA048236, R01CA044029] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44029, CA 48236] Funding Source: Medline; NEI NIH HHS [EY 06337] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAKSHI A, 1985, CELL, V41, P899; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1992, BLOOD, V79, P2527; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; CHAGANTI RSK, 1989, MOL DIAGNOSTICS HUMA, P33; CHAGANTI RSK, UNPUB; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1991, CELL, V66, P663; DIBELLO PR, 1991, GENETICS, V129, P385; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FICHELSON S, 1992, LEUKEMIA, V6, P93; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KNOCHEL W, 1989, P NATL ACAD SCI USA, V86, P6097, DOI 10.1073/pnas.86.16.6097; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LADANYI M, 1991, BLOOD, V77, P1057; MAGRATH IT, 1990, NONHODGKINS LYMPHOMA, P1; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MEDEIROS LJ, 1992, NEOPLASTIC HEMATOPAT, P263; MEEKER TC, 1989, BLOOD, V74, P1801; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NATHWANI BN, 1992, NEOPLASTIC HEMATOPAT, P555; OFFIT K, 1989, BRIT J HAEMATOL, V72, P178, DOI 10.1111/j.1365-2141.1989.tb07680.x; OFFIT K, 1989, BLOOD, V74, P1876; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SUGAWARA MM, 1993, UNPUB; TAUB R, 1993, CAUSES CONSEQUENCES, P313; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WILLIAMS ME, 1991, BLOOD, V78, P493; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YE BH, UNPUB; YE BHH, 1993, CANCER RES, V53, P2732	48	597	624	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					747	750		10.1126/science.8235596	http://dx.doi.org/10.1126/science.8235596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235596				2022-12-01	WOS:A1993MD95200044
J	HOLLINGWORTH, W; TODD, C; PARKER, M; ROBERTS, JA; WILLIAMS, R				HOLLINGWORTH, W; TODD, C; PARKER, M; ROBERTS, JA; WILLIAMS, R			COST-ANALYSIS OF EARLY DISCHARGE AFTER HIP FRACTURE	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; FEMUR	Objective-To ascertain the economic impact of an early discharge scheme for hip fracture patients. Design-Population based study comparing costs of care for patients who had ''hospital at home'' as an option for rehabilitation and those who had no early discharge service available in their area of residence. Setting-District hospital orthopaedic and rehabilitation wards and community hospital at home scheme. Patients-1104 consecutively admitted patients with fractured neck of femur. 24 patients from outside the district were excluded. Main outcome measures-Cost per patient episode and number of bed days spent in hospital. Results-Patients with the hospital at home option spent significantly less time as inpatients (mean of 32.5 v 41.7 days; p<0.001). Those patients who were discharged early spent a mean of 11.5 days under hospital at home care. The total direct cost to the health service was significantly less for those patients with access to early discharge than those with no early discharge option (4884 Pounds v 5606 Pounds; p=0.048). Conclusions-About 40% of patients with fractured neck of femur are suitable for early discharge to a scheme such as hospital at home. The availability of such a scheme leads to lower direct costs of rehabilitative care despite higher readmission costs. These savings accrue largely from shorter stays in orthopaedic and geriatric wards.	PETERBOROUGH DIST GEN HOSP,PETERBOROUGH PE3 6DA,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	HOLLINGWORTH, W (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,HLTH SERV RES GRP,UNIV FORVIE SITE,ROBINSON WAY,CAMBRIDGE CB2 2SR,ENGLAND.		Todd, Chris/A-7904-2010; Todd, Chris/AAD-8661-2022	Todd, Chris/0000-0001-6645-4505; Todd, Chris/0000-0001-6645-4505; Hollingworth, William/0000-0002-0840-6254				BORGQUIST L, 1990, Scandinavian Journal of Primary Health Care, V8, P139, DOI 10.3109/02813439008994947; BOYCE WJ, 1985, LANCET, V1, P150; CAMPION EW, 1987, J GEN INTERN MED, V2, P78, DOI 10.1007/BF02596300; Drummond M.F., 1980, PRINCIPLES EC APPRAI; GREATOREX IF, 1988, J EPIDEMIOL COMMUN H, V42, P365, DOI 10.1136/jech.42.4.365; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; MOWAT IG, 1982, BRIT MED J, V284, P641, DOI 10.1136/bmj.284.6316.641; PARKER MJ, 1991, ACTA ORTHOP SCAND, V62, P563, DOI 10.3109/17453679108994497; PARKER MJ, 1992, J BONE JOINT SURG BR, V74, P261, DOI 10.1302/0301-620X.74B2.1544965; PRYOR GA, 1989, J BONE JOINT SURG BR, V71, P471, DOI 10.1302/0301-620X.71B3.2722942; PRYOR GA, 1988, LANCET, V1, P401; REID N, 1991, INT J NURS STUD, V28, P47, DOI 10.1016/0020-7489(91)90049-9; ROBBINS JA, 1984, LANCET, V2, P1028; RUSSELL EM, 1974, SCOTTISH HLTH SERVIC, V31; SOMMERS LS, 1990, CLIN ORTHOP RELAT R, V258, P168; TODD CJ, 1991, HLTH SERVICES RES PR, P185; Townsend P., 1962, LAST REFUGE; 1991, BRIT NATIONAL FORMUL, V22; 1982, LANCET, V2, P419; 1987, HOSPITAL IN PATIENT; 1992, SOCIAL TRENDS, V22, P27	21	90	90	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					903	906		10.1136/bmj.307.6909.903	http://dx.doi.org/10.1136/bmj.307.6909.903			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241853	Green Published, Bronze			2022-12-01	WOS:A1993MB84700017
J	KANAGAWA, O; VAUPEL, BA; GAYAMA, S; KOEHLER, G; KOPF, M				KANAGAWA, O; VAUPEL, BA; GAYAMA, S; KOEHLER, G; KOPF, M			RESISTANCE OF MICE DEFICIENT IN IL-4 TO RETROVIRUS-INDUCED IMMUNODEFICIENCY SYNDROME (MAIDS)	SCIENCE			English	Article							T-CELLS; LYMPHOCYTES-T; VIRUS; AIDS; INFECTION; SUSCEPTIBILITY; PATHOGENESIS; SUPERANTIGEN; PROGRESSION; DISEASE	The murine acquired immunodeficiency syndrome (MAIDS) is induced by a defective murine leukemia virus and has many symptoms similar to those found in patients infected with the human immunodeficiency virus. The presence of both B cells and CD4+ T cells is critical for the development of the disease. Furthermore, a Th2 cytokine response dominates during the progression of the disease. When interleukin-4 (IL-4)-deficient mice that are defective in Th2 cytokine responses were infected, there was no lethality, and the development of the T cell abnormalities associated with MAIDS was delayed. These data suggest that IL-4 or a Th2 response is involved in the development of retrovirus-induced immunodeficiency in mice.	MAX PLANCK INST IMMUNBIOL,W-7800 FREIBURG,GERMANY	Max Planck Society	KANAGAWA, O (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL & MED,ST LOUIS,MO 63110, USA.		Kopf, Manfred/B-6907-2009	Kopf, Manfred/0000-0002-0628-7140	PHS HHS [A130803] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BRADLEY LM, 1991, J EXP MED, V174, P547, DOI 10.1084/jem.174.3.547; BUDD RC, 1987, J IMMUNOL, V138, P3120; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GAZZINELLI RT, 1992, J IMMUNOL, V148, P182; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HARTLEY JW, 1989, J VIROL, V63, P1223, DOI 10.1128/JVI.63.3.1223-1231.1989; HUANG M, 1992, J VIROL, V66, P2398, DOI 10.1128/JVI.66.4.2398-2406.1992; HUGIN AW, 1991, SCIENCE, V252, P424, DOI 10.1126/science.1850169; JOLICOEUR P, 1991, FASEB J, V5, P2398, DOI 10.1096/fasebj.5.10.2065888; KANAGAWA O, 1992, J IMMUNOL, V149, P9; KANAGAWA O, UNPUB; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Kopf M.H., UNPUB; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LUCEY DR, 1990, AIDS RES HUM RETROV, V6, P427, DOI 10.1089/aid.1990.6.427; MAKINO M, 1991, IMMUNOGENETICS, V33, P345, DOI 10.1007/BF00216693; MORSE HC, 1992, AIDS, V6, P607, DOI 10.1097/00002030-199207000-00001; MOSIER DE, 1987, J EXP MED, V165, P1737, DOI 10.1084/jem.165.6.1737; MURALIDHAR G, 1992, J EXP MED, V175, P1589, DOI 10.1084/jem.175.6.1589; SWAIN SL, 1990, J IMMUNOL, V145, P3796; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3	23	111	120	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 8	1993	262	5131					240	242		10.1126/science.8211142	http://dx.doi.org/10.1126/science.8211142			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA665	8211142				2022-12-01	WOS:A1993MA66500034
J	SCHWARTZ, DC; LI, XJ; HERNANDEZ, LI; RAMNARAIN, SP; HUFF, EJ; WANG, YK				SCHWARTZ, DC; LI, XJ; HERNANDEZ, LI; RAMNARAIN, SP; HUFF, EJ; WANG, YK			ORDERED RESTRICTION MAPS OF SACCHAROMYCES-CEREVISIAE CHROMOSOMES CONSTRUCTED BY OPTICAL MAPPING	SCIENCE			English	Article							INDIVIDUAL DNA-MOLECULES; GEL-ELECTROPHORESIS; RESOLUTION; ORIENTATION; GENOME; YEAST; MODEL; CHROMATIN; INSITU	A light microscope-based technique for rapidly constructing ordered physical maps of chromosomes has been developed. Restriction enzyme digestion of elongated individual DNA molecules (about 0.2 to 1.0 megabases in size) was imaged by fluorescence microscopy after fixation in agarose gel. The size of the resulting individual restriction fragments was determined by relative fluorescence intensity and apparent molecular contour length. Ordered restriction maps were then created from genomic DNA without reliance on cloned or amplified sequences for hybridization or analytical gel electrophoresis. Initial application of optical mapping is described for Saccharomyces cerevisiae chromosomes.			SCHWARTZ, DC (corresponding author), NYU,DEPT CHEM,WM KECK LAB BIOMOLEC IMAGING,NEW YORK,NY 10003, USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000225] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00225-01] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ATKINS EDT, 1992, BIOPOLYMERS, V32, P911, DOI 10.1002/bip.360320803; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CAVALLISFORZA LL, 1990, AM J HUM GENET, V46, P649; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; De Gennes P-G., 1979, SCALING CONCEPTS POL; Doi M., 1986, THEORY POLYM DYNAMIC; GURRIERI S, 1990, BIOCHEMISTRY-US, V29, P3401; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HOLZWARTH G, 1987, NUCLEIC ACIDS RES, V15, P10031, DOI 10.1093/nar/15.23.10031; LAWRENCE JB, 1988, CELL, V52, P51; LINK AJ, 1991, GENETICS, V127, P681; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MANUELIDIS L, 1982, J CELL BIOL, V95, P619, DOI 10.1083/jcb.95.2.619; NOOLANDI J, 1989, SCIENCE, V243, P1456, DOI 10.1126/science.2928779; Roberts T M, 1975, CRC Crit Rev Biochem, V3, P349; SCHWARTZ D, 1985, THESIS COLUMBIA U; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; STELLWAGEN J, 1989, NUCLEIC ACIDS RES, V17, P1537, DOI 10.1093/nar/17.4.1537; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; YANAGIDA M, 1986, APPLICATIONS FLUORES, P321; ZIMM BH, 1991, J CHEM PHYS, V94, P2187, DOI 10.1063/1.459890	23	285	315	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 1	1993	262	5130					110	114		10.1126/science.8211116	http://dx.doi.org/10.1126/science.8211116			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ635	8211116				2022-12-01	WOS:A1993LZ63500035
J	GILES, WH; ANDA, RF; JONES, DH; SERDULA, MK; MERRITT, RK; DESTEFANO, F				GILES, WH; ANDA, RF; JONES, DH; SERDULA, MK; MERRITT, RK; DESTEFANO, F			RECENT TRENDS IN THE IDENTIFICATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL BY PHYSICIANS - PROGRESS AND MISSED OPPORTUNITIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; UNITED-STATES; PRESSURE; TRIAL; RISK; ATHEROSCLEROSIS; MORTALITY; REMINDERS; PROJECT	Objective.-To investigate recent trends in the percentage and characteristics of patients being treated by a physician for high blood cholesterol (HBC) and to assess missed clinical opportunities to screen for HBC. Design, Setting, Participants.-Telephone interviews of 154 735 adults in 37 states that participated in the Behavioral Risk Factor Surveillance System during 1988-1990 to assess trends in the percentage of patients treated for HBC by a physician. An opportunity was considered missed if a person did not report being screened for HBC despite seeing a physician for preventive care in the last 2 years. Results.-Between the first quarter of 1988 and the last quarter of 1990, the percentage of persons treated by a physician for HBC increased from 7.6% to 11.7% (P<.001). However, since an estimated 36% of US adults need treatment for HBC, fewer than one third of persons who need treatment are receiving it. Persons with two or more cardiac risk factors were more likely to be treated, while men, blacks, persons in lower socioeconomic groups, and persons between 20 and 34 years of age were less likely to be treated. Among the 126 571 persons who had seen a physician for preventive care within the last 2 years, missed opportunities to screen for HBC were most common among persons aged 20 through 34 years (59%) and among women who had seen obstetricians/gynecologists for preventive care (43%). Conclusions.-Fewer than one third of persons who need treatment for HBC as estimated by data from the second National Health and Nutrition and Nutrition Examination Survey are receiving treatment. Better use of clinical opportunities to screen for HBC could substantially accelerate the progress in identifying persons, young adults in particular, who are likely to benefit from cholesterol reduction.	CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV NUTR,EPIDEMIOL BRANCH,ATLANTA,GA; CTR DIS CONTROL & PREVENT,DIV CHRON DIS CONTROL & COMMUNITY INTERVENT,ATLANTA,GA; UNIV MARYLAND,DEPT EPIDEMIOL & PREVENT MED,BALTIMORE,MD 21201	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University System of Maryland; University of Maryland Baltimore								BERENSON GS, 1987, AM J MED SCI, V294, P429, DOI 10.1097/00000441-198712000-00008; BLOCK L, 1988, AM J PREV MED, V4, P255, DOI 10.1016/S0749-3797(18)31158-9; BOSTICK RM, 1991, ARCH INTERN MED, V151, P478; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; COLLINS JG, 1983, PHS831572 US DEP 10; DAVIDSON RA, 1984, ARCH INTERN MED, V144, P2167, DOI 10.1001/archinte.144.11.2167; FLETCHER GF, 1992, CIRCULATION, V86, P340, DOI 10.1161/01.CIR.86.1.340; FORTMANN SP, 1990, AM J EPIDEMIOL, V132, P629, DOI 10.1093/oxfordjournals.aje.a115705; Foster J D, 1988, J Cancer Educ, V3, P121; Gregorio D I, 1990, Conn Med, V54, P370; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849; HEADRICK LA, 1992, ARCH INTERN MED, V152, P2490, DOI 10.1001/archinte.152.12.2490; HULLEY SB, 1982, METABOLISM, V31, P773, DOI 10.1016/0026-0495(82)90074-9; MARTIN MJ, 1986, LANCET, V2, P933; MCDOWELL I, 1989, MED CARE, V27, P297, DOI 10.1097/00005650-198903000-00008; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; PYE G, 1988, J EPIDEMIOL COMMUN H, V42, P66, DOI 10.1136/jech.42.1.66; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; SCHUCKER B, 1991, ARCH INTERN MED, V151, P666, DOI 10.1001/archinte.151.4.666; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3521, DOI 10.1001/jama.258.24.3521; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SHAH BV, 1981, SESUDAAN STANDARD ER; SHAH BV, 1984, RTI LOGIT PROCEDURE; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STEWART AL, 1982, J CHRON DIS, V35, P295, DOI 10.1016/0021-9681(82)90085-6; TURNER BJ, 1989, J GEN INTERN MED, V4, P403, DOI 10.1007/BF02599691; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WETZER HP, 1985, AM J PUBLIC HEALTH, V75, P129; WYSOWSKI DK, 1990, JAMA-J AM MED ASSOC, V263, P2185, DOI 10.1001/jama.263.16.2185; 1985, JAMA-J AM MED ASSOC, V253, P2080; 1988, ARCH INTERN MED, V148, P36; 1990, MMWR, V39, P633; 1993, JAMA-J AM MED ASSOC, V269, P505; 1987, JAMA-J AM MED ASSOC, V257, P937; 1984, JAMA-J AM MED ASSOC, V251, P351; 1990, MMWR, V39, P304; 1990, MMWR, V39, P311; 1984, CIRCULATION, V70, pA157	38	102	103	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1993	269	9					1133	1138		10.1001/jama.269.9.1133	http://dx.doi.org/10.1001/jama.269.9.1133			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN611	8240474				2022-12-01	WOS:A1993KN61100030
J	TROSHINSKY, MB; KANE, GC; VARGA, J; CATER, JR; FISH, JE; JIMENEZ, SA; CASTELL, DO				TROSHINSKY, MB; KANE, GC; VARGA, J; CATER, JR; FISH, JE; JIMENEZ, SA; CASTELL, DO			PULMONARY-FUNCTION AND GASTROESOPHAGEAL REFLUX IN SYSTEMIC-SCLEROSIS	ANNALS OF INTERNAL MEDICINE			English	Article						GASTROESOPHAGEAL REFLUX; SCLERODERMA, SYSTEMIC; RESPIRATORY FUNCTION TESTS; ESOPHAGEAL MOTILITY DISORDERS; SMOKING	INTERSTITIAL LUNG-DISEASE; GASTROINTESTINAL MANIFESTATIONS; DIFFUSING-CAPACITY; SURGICAL-TREATMENT; D-PENICILLAMINE; SCLERODERMA; ACID; PATHOGENESIS; SURVIVAL; THERAPY	Objective: To determine the relations among esophageal dysfunction, gastroesophageal reflux, and lung involvement in patients with systemic sclerosis. Design: Retrospective review of esophageal motility, esophageal pH, and pulmonary function data. Setting: University hospital outpatient clinic and community. Patients: 39 consecutively referred patients who were grouped according to the presence or absence of abnormal distal (pH <4.0 for >5% of the 24-hour monitoring period) or proximal (pH <4.0 for >1% of the 24-hour period) gastroesophageal acid reflux. Patients were also grouped according to the presence or absence of distal esophageal peristalsis. Measurements: Esophageal manometry, dual-probe (distal and proximal) esophageal 24-hour pH measurements, and pulmonary function studies (forced vital capacity, forced expiratory volume at 1 second, total lung capacity, and single-breath carbon monoxide diffusing capacity [DL(CO)]). Results: The mean total lung capacity (values as percentage predicted) was 87.1% +/- 11.2% (SD) for patients with abnormal proximal reflux and 77.8% +/- 21.6% for patients with normal proximal reflux (difference, 9.3%; 95% CI, -1.4% to 20.0%). The mean forced vital capacity for these patients was 91.1% +/- 12.4% and 85.4% +/- 25.6%, respectively (difference, 5.7%; CI, -6.9% to 18.1%). The mean total lung capacity was 83.8% +/- 15.4% for patients with abnormal distal reflux and 77.9% +/- 22.7% for patients with normal distal reflux (difference, 5.9%; CI, -7.6% to 19.4%). Among potential confounders of pulmonary measures, only smoking was related to decreased pulmonary function (smoking related to decreased DL(CO) P < 0.01). Smoking was more common in patients with abnormal distal reflux than in those with normal distal reflux (65% compared with 25%, P = 0.03). After adjusting for smoking, the difference in mean DL(CO) between patients with abnormal compared with normal distal reflux was 7.19% (CI, -8.5% to 22.9%). Conclusion: Important measures of lung volume indicative of interstitial lung disease (total lung capacity, forced vital capacity) do not appear to be related to abnormal gastroesophageal acid reflux in patients with systemic sclerosis.	GRAD HOSP PHILADELPHIA, DEPT MED, PHILADELPHIA, PA 19146 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DIV PULM MED, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DIV RHEUMATOL, PHILADELPHIA, PA 19107 USA	University of Pennsylvania; Jefferson University; Jefferson University				Jimenez, Sergio/0000-0001-5213-1203	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042309] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42309, AR19106] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTMAN RD, 1991, ARTHRITIS RHEUM, V34, P403, DOI 10.1002/art.1780340405; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1299; BAGG LR, 1979, THORAX, V34, P224, DOI 10.1136/thx.34.2.224; BRAITMAN LE, 1991, ANN INTERN MED, V114, P515, DOI 10.7326/0003-4819-114-6-515; CASTELL JA, 1990, AM J PHYSIOL, V258, pG173, DOI 10.1152/ajpgi.1990.258.2.G173; CHERNOW B, 1979, DIGEST DIS SCI, V24, P839, DOI 10.1007/BF01324899; COHEN S, 1980, GASTROENTEROLOGY, V79, P155; CONRAD SA, 1984, PULMONARY FUNCTION T, P112; DANGELO WA, 1969, AM J MED, V46, P428, DOI 10.1016/0002-9343(69)90044-8; DECLERCK LS, 1987, ARTHRITIS RHEUM, V30, P643; DOBHAN R, 1993, AM J GASTROENTEROL, V88, P25; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; HARRISON NK, 1991, AM REV RESPIR DIS, V144, P706, DOI 10.1164/ajrccm/144.3_Pt_1.706; Hosmer D, 2013, APPL LOGISTIC REGRES; JOHNSON DA, 1989, ARCH INTERN MED, V149, P589, DOI 10.1001/archinte.149.3.589; JOHNSON LF, 1974, AM J GASTROENTEROL, V62, P325; KEOGH BA, 1980, CHEST, V78, P856, DOI 10.1378/chest.78.6.856; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; LARRAIN A, 1991, CHEST, V99, P1330, DOI 10.1378/chest.99.6.1330; LEROY EC, 1988, J RHEUMATOL, V15, P202; MANSFIELD LE, 1981, ANN ALLERGY, V47, P431; MANSFIELD LE, 1978, ANN ALLERGY, V41, P224; MANSFIELD LE, 1989, J ASTHMA, V26, P271, DOI 10.3109/02770908909073263; MCCARTHY DS, 1988, SEMIN ARTHRITIS RHEU, V17, P271, DOI 10.1016/0049-0172(88)90012-1; MILLER A, 1983, AM REV RESPIR DIS, V127, P270; MORAN TJ, 1955, ARCH PATHOL, V60, P122; OGILVIE CM, 1957, J CLIN INVEST, V36, P1, DOI 10.1172/JCI103402; PACK AI, 1990, AM REV RESPIR DIS, V141, P1391, DOI 10.1164/ajrccm/141.6.1391; PERRINFAYOLLE M, 1989, CHEST, V96, P40, DOI 10.1378/chest.96.1.40; PETERSGOLDEN M, 1984, AM J MED, V77, P1027, DOI 10.1016/0002-9343(84)90183-9; POIRIER TJ, 1972, AM J GASTROENTEROL, V58, P30; ROOK AH, 1992, ARCH DERMATOL, V128, P337, DOI 10.1001/archderm.128.3.337; SEIBOLD JR, 1989, TXB RHEUMATOLOGY, P1215; SILMAN AJ, 1991, ANN RHEUM DIS, V50, P267, DOI 10.1136/ard.50.4.267; SILVER RM, 1990, RHEUM DIS CLIN N AM, V16, P199; Snedecor G. W, 1989, STAT METHODS, V8th; SONTAG SJ, 1990, GASTROENTEROLOGY, V99, P613, DOI 10.1016/0016-5085(90)90945-W; STEEN VD, 1985, ARTHRITIS RHEUM, V28, P882, DOI 10.1002/art.1780280807; TEABEAUT JR, 1952, AM J PATHOL, V28, P51; TUCHMAN DN, 1984, GASTROENTEROLOGY, V87, P872; YARZE JC, 1993, AM J GASTROENTEROL, V88, P870; YOUSEM SA, 1990, HUM PATHOL, V21, P467, DOI 10.1016/0046-8177(90)90002-M	43	48	48	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1994	121	1					6	10		10.7326/0003-4819-121-1-199407010-00002	http://dx.doi.org/10.7326/0003-4819-121-1-199407010-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN271	8198350				2022-12-01	WOS:A1994PN27100002
J	JANIN, A; SOCIE, G; DEVERGIE, A; ARACTINGI, S; ESPEROU, H; VEROLA, MO; GLUCKMAN, E				JANIN, A; SOCIE, G; DEVERGIE, A; ARACTINGI, S; ESPEROU, H; VEROLA, MO; GLUCKMAN, E			FASCIITIS IN CHRONIC GRAFT-VERSUS-HOST DISEASE - A CLINICOPATHOLOGICAL STUDY OF 14 CASES	ANNALS OF INTERNAL MEDICINE			English	Article						GRAFT VS HOST DISEASE; FASCIITIS; BONE MARROW TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; EDEMA	EOSINOPHILIA-MYALGIA-SYNDROME; BONE-MARROW TRANSPLANTATION; TOXIC OIL SYNDROME; DIFFUSE FASCIITIS; PERIPHERAL NEUROPATHY; SYSTEMIC SCLERODERMA; MANIFESTATIONS; TISSUE; SKIN; POLYMYOSITIS	Objective: To describe the clinicopathologic features of fasciitis in patients with chronic graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation from human leukocyte antigen (HLA)identical donors. Design: A retrospective cohort study. Setting: Tertiary care center. Patients: Patients who had allogeneic bone marrow transplantation and developed chronic GVHD with clinical and pathologic signs of fasciitis. Main Outcome Measure: Analysis of clinical presentations and of deep cutaneo-muscular biopsy specimens. Results: Between January 1974 and January 1991, 14 of 475 patients who had allogeneic bone marrow transplantation developed chronic GVHD that began with the sicca syndrome and liver or digestive tract involvement, or both, 60 to 170 days after the graft was received. Sudden and painful skin swelling was reported 350 to 3745 days after the graft was received. Follow-up over 2 to 7 years showed failure of the fasciitis to respond to steroid therapy or to any conventional treatment of chronic GVHD. Although 7 patients showed moderate improvement, the others remained functionally disabled because of skin tightness, joint stiffness, contractures, and sores. Patients with fasciitis in chronic GVHD had no specific immunogenetic profile and no history of L-tryptophan intake or phytonadione injections. Conclusion: Among alloimmune syndromes, fasciitis is a distinct entity that leads to functional disability. This rare form of chronic GVHD may provide clues to understanding the mechanisms involved in fasciitis from other causes.	HOP ST LOUIS, UNITE GREFFE MOELLE OSSEUSE TREFLE 3, F-75010 PARIS, FRANCE; HOP ST LOUIS, DERMATOL SERV, F-75010 PARIS, FRANCE; HOP ST LOUIS, CENT ANAT PATHOL LAB, F-75010 PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	JANIN, A (corresponding author), HOP CALMETTE, DEPT PATHOL C, BD J LECLERCQ, F-59800 LILLE, FRANCE.			Aractingi, Selim/0000-0002-7766-2673				ALONSORUIZ A, 1986, SEMIN ARTHRITIS RHEU, V15, P200, DOI 10.1016/0049-0172(86)90017-X; ANDERSON BA, 1982, ARCH NEUROL-CHICAGO, V39, P188, DOI 10.1001/archneur.1982.00510150058015; BARNES L, 1979, AM J PATHOL, V96, P493; BOTET MVV, 1980, J AM ACAD DERMATOL, V2, P36; CAPERTON EM, 1976, ARTHRITIS RHEUM, V19, P792; CHOSIDOW O, 1992, J AM ACAD DERMATOL, V26, P49, DOI 10.1016/0190-9622(92)70005-Z; CRAMER SF, 1982, ARCH PATHOL LAB MED, V106, P85; DEEG HJ, 1984, BRIT J HAEMATOL, V57, P185, DOI 10.1111/j.1365-2141.1984.tb08521.x; FELDMAN SR, 1992, J AM ACAD DERMATOL, V26, P95, DOI 10.1016/0190-9622(92)70014-7; FERRIER MC, 1988, DERMATOLOGICA, V176, P299, DOI 10.1159/000248740; FLEISCHMAJER R, 1977, ARTHRITIS RHEUM, V20, P975, DOI 10.1002/art.1780200410; FLEISCHMAJER R, 1972, ARCH DERMATOL, V105, P59, DOI 10.1001/archderm.105.1.59; FLEISCHMAJER R, 1978, ARCH DERMATOL, V114, P1320, DOI 10.1001/archderm.114.9.1320; GODEAU P, 1977, NOUV PRESSE MED, V6, P4039; GRAHAMBROWN RAC, 1983, CLIN EXP DERMATOL, V8, P531, DOI 10.1111/j.1365-2230.1983.tb01820.x; GRAZE PR, 1979, AM J MED, V66, P611, DOI 10.1016/0002-9343(79)91171-9; GUSTAFSSON R, 1991, ARTHRITIS RHEUM-US, V34, P414, DOI 10.1002/art.1780340406; HERRICK MK, 1991, HUM PATHOL, V22, P12, DOI 10.1016/0046-8177(91)90055-T; JANIN A, 1993, THORAX, V48, P57, DOI 10.1136/thx.48.1.57; JANINMERCIER A, 1981, VIRCHOWS ARCH A, V394, P177, DOI 10.1007/BF00431676; JANINMERCIER A, 1981, ACTA DERM-VENEREOL, V61, P187; JANINMERCIER A, 1984, AM J PATHOL, V115, P296; KAHN MF, 1991, MALADIES SYSTEMIQUES, P465; KERR LD, 1992, J RHEUMATOL, V19, P294; KRIEG T, 1988, J AM ACAD DERMATOL, V18, P457, DOI 10.1016/S0190-9622(88)70070-5; LAWLEY TJ, 1977, ANN INTERN MED, V87, P707, DOI 10.7326/0003-4819-87-6-707; LIN JD, 1992, HUM PATHOL, V23, P429, DOI 10.1016/0046-8177(92)90091-G; MADDISON PJ, 1991, ANN RHEUM DIS, V50, P887, DOI 10.1136/ard.50.Suppl_4.887; MARKUSSE HM, 1990, J RHEUMATOL, V17, P692; MARTINEZTELLO FJ, 1982, VIRCHOWS ARCH A, V397, P261, DOI 10.1007/BF00496569; NOGUCHI H, 1992, AM J PATHOL, V140, P521; NOGUCHI H, 1990, FASEB J, V4, pA1943; NORIEGA AR, 1982, LANCET, V2, P697; OWEN WF, 1990, P NATL ACAD SCI USA, V87, P8647, DOI 10.1073/pnas.87.21.8647; PHELPS RG, 1988, J AM ACAD DERMATOL, V18, P313, DOI 10.1016/S0190-9622(88)70046-8; PIER N, 1983, BRIT MED J, V286, P2024, DOI 10.1136/bmj.286.6383.2024; PINCUS SH, 1987, BLOOD, V70, P572; RODNAN GP, 1975, ARTHRITIS RHEUM, V18, P422; SATSANGI J, 1992, J NEUROL, V239, P91, DOI 10.1007/BF00862980; SAURAT JH, 1981, INT J DERMATOL, V20, P249, DOI 10.1111/j.1365-4362.1981.tb04329.x; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; SHULMAN HM, 1978, AM J PATHOL, V91, P545; Shulman L E, 1975, Trans Assoc Am Physicians, V88, P70; SMITH BE, 1990, NEUROLOGY, V40, P1035, DOI 10.1212/WNL.40.7.1035; SPIELVOGEL RL, 1977, ARCH DERMATOL, V113, P1424, DOI 10.1001/archderm.113.10.1424; STORB R, 1989, BRIT J HAEMATOL, V72, P567, DOI 10.1111/j.1365-2141.1989.tb04325.x; SULLIVAN KM, 1981, BLOOD, V57, P267, DOI 10.1182/blood.V57.2.267.267; TEN RM, 1990, CLIN EXP IMMUNOL, V82, P313; TUTSCHKA PJ, 1987, PROGR BONE MARROW TR, P457; URBANOMARQUEZ A, 1986, NEUROLOGY, V36, P1091, DOI 10.1212/WNL.36.8.1091; VANDENBERGH V, 1987, AM J MED, V83, P139, DOI 10.1016/0002-9343(87)90509-2; VERITY MA, 1991, HUM PATHOL, V22, P3, DOI 10.1016/0046-8177(91)90054-S; ZWAAN FE, 1980, LANCET, V1, P1081; 1989, MMWR-MORBID MORTAL W, V38, P785; 1990, MMWR-MORBID MORTAL W, V39, P789	55	91	93	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1994	120	12					993	998		10.7326/0003-4819-120-12-199406150-00004	http://dx.doi.org/10.7326/0003-4819-120-12-199406150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ964	8185148				2022-12-01	WOS:A1994NQ96400004
J	TAME, JRH; MURSHUDOV, GN; DODSON, EJ; NEIL, TK; DODSON, GG; HIGGINS, CF; WILKINSON, AJ				TAME, JRH; MURSHUDOV, GN; DODSON, EJ; NEIL, TK; DODSON, GG; HIGGINS, CF; WILKINSON, AJ			THE STRUCTURAL BASIS OF SEQUENCE-INDEPENDENT PEPTIDE BINDING BY OPPA PROTEIN	SCIENCE			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; OLIGOPEPTIDE PERMEASE; TRANSPORT; RECOGNITION; ENCODES; GENE; MAPS	Specific protein-ligand interactions are critical for cellular function, and most proteins select their partners with sharp discrimination. However, the oligopeptide-binding protein of Salmonella typhimurium (OppA) binds peptides of two to five amino acid residues without regard to sequence. The crystal structure of OppA reveals a three-domain organization, unlike other periplasmic binding proteins. In OppA-peptide complexes, the ligands are completely enclosed in the protein interior, a mode of binding that normally imposes tight specificity. The protein fulfills the hydrogen bonding and electrostatic potential of the ligand main chain and accommodates the peptide side chains in voluminous hydrated cavities.	UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN BIOCHEM,OXFORD OX3 9DU,ENGLAND	University of York - UK; Cancer Research UK; University of Oxford; University of Oxford				Wilkinson, Anthony/0000-0003-4577-9479				ABOUHAMAD WN, 1991, MOL MICROBIOL, V5, P1035, DOI 10.1111/j.1365-2958.1991.tb01876.x; AMES BN, 1973, P NATL ACAD SCI USA, V70, P456, DOI 10.1073/pnas.70.2.456; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; Brtinger A. T., 1990, X PLOR VERSION 2 1; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; FICKEL TE, 1973, NATURE-NEW BIOL, V241, P161, DOI 10.1038/newbio241161a0; GLOVER ID, UNPUB; GOODELL EW, 1987, J BACTERIOL, V169, P3861, DOI 10.1128/jb.169.8.3861-3865.1987; GUYER CA, 1986, J BACTERIOL, V168, P775, DOI 10.1128/jb.168.2.775-779.1986; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HANSON MS, 1992, INFECT IMMUN, V60, P2257, DOI 10.1128/IAI.60.6.2257-2266.1992; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HIGGINS C, 1987, NATURE, V327, P655, DOI 10.1038/327655a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HILES ID, 1986, EUR J BIOCHEM, V158, P561, DOI 10.1111/j.1432-1033.1986.tb09791.x; JONES TA, 1991, O MANUAL; Kleywegt G. J., UNPUB; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUEHN MJ, 1993, SCIENCE, V262, P1234, DOI 10.1126/science.7901913; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; NAVARRO C, 1993, MOL MICROBIOL, V9, P1181, DOI 10.1111/j.1365-2958.1993.tb01247.x; OH BH, 1993, J BIOL CHEM, V268, P11348; OLSON ER, 1991, J BACTERIOL, V173, P234, DOI 10.1128/jb.173.1.234-244.1991; PAYNE JW, 1971, ADV ENZYMOL RAMB, V35, P187; PAYNE JW, 1968, J BIOL CHEM, V243, P6292; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; TAN R, 1993, MICROBIOL REV, V57, P320; TOLLEY SP, 1988, J MOL BIOL, V204, P493, DOI 10.1016/0022-2836(88)90591-8; 1986, CCP4 SUITE PROGRAMS	32	210	214	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 10	1994	264	5165					1578	1581						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ285	8202710				2022-12-01	WOS:A1994NQ28500032
J	CAMPANELLI, JT; ROBERDS, SL; CAMPBELL, KP; SCHELLER, RH				CAMPANELLI, JT; ROBERDS, SL; CAMPBELL, KP; SCHELLER, RH			ROLE FOR DYSTROPHIN-ASSOCIATED GLYCOPROTEINS AND UTROPHIN IN AGRIN-INDUCED ACHR CLUSTERING	CELL			English	Article							ACETYLCHOLINE-RECEPTOR AGGREGATION; DUCHENNE MUSCULAR-DYSTROPHY; TORPEDO ELECTRIC ORGAN; NEUROMUSCULAR-JUNCTIONS; SKELETAL-MUSCLE; MOTOR NEURONS; CELL-SURFACE; EXTRACELLULAR-MATRIX; TISSUE DISTRIBUTION; CULTURED MYOTUBES	Synapse formation is characterized by the accumulation of molecules at the site of contact between pre- and postsynaptic cells. Agrin, a protein implicated in the regulation of this process, causes the clustering of acetylcholine receptors (AChRs). Here we characterize an agrin-binding site on the surface of muscle cells, show that this site corresponds to alpha-dystroglycan, and present evidence that alpha-dystroglycan is functionally related to agrin activity. Furthermore, we demonstrate that alpha-dystroglycan and adhalin, components of the dystrophin-associated glycoprotein complex, as well as utrophin, colocalize with agrin-induced AChR clusters. Thus, agrin may function by initiating or stabilizing a synapse-specific membrane cytoskeleton that in turn serves as a scaffold upon which synaptic molecules are concentrated.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa	CAMPANELLI, JT (corresponding author), STANFORD UNIV,HOWARD HUGHES MED INST,DEPT CELLULAR & MOLEC PHYSIOL,STANFORD,CA 94305, USA.		Roberds, Steven L/AAP-4985-2020	Roberds, Steven L/0000-0003-0676-272X; Campbell, Kevin/0000-0003-2066-5889				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BEVAN S, 1977, J PHYSIOL-LONDON, V267, P195, DOI 10.1113/jphysiol.1977.sp011808; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; BUONANNO A, 1986, J BIOL CHEM, V261, P1452; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; BYERS TJ, 1991, J CELL BIOL, V115, P411, DOI 10.1083/jcb.115.2.411; CAMPANELLI JT, 1991, CELL, V67, P909, DOI 10.1016/0092-8674(91)90364-5; CAMPANELLI JT, 1993, THESIS STANFORD U ST; COHEN MW, 1992, J NEUROSCI, V12, P2982, DOI 10.1523/JNEUROSCI.12-08-02982.1992; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FERTUCK H C, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1376, DOI 10.1073/pnas.71.4.1376; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GAARN EEZ, 1988, NATURE, V333, P466; GEE SH, 1993, J BIOL CHEM, V268, P14972; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GORDON H, 1989, DEV BIOL, V135, P1, DOI 10.1016/0012-1606(89)90152-8; HIRANO Y, 1989, J NEUROSCI, V9, P1551; HOCH W, 1994, IN PRESS EMBO J; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MAGILLSOLC C, 1990, J EXP BIOL, V153, P1; MAGILLSOLC C, 1988, J CELL BIOL, V107, P1825, DOI 10.1083/jcb.107.5.1825; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; NASTUK MA, 1991, NEURON, V7, P807, DOI 10.1016/0896-6273(91)90283-6; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; PODLESKI TR, 1988, J NEUROBIOL, V19, P167, DOI 10.1002/neu.480190206; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1992, J NEUROSCI, V12, P3535; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; STEINBACH JH, 1981, DEV BIOL, V84, P267, DOI 10.1016/0012-1606(81)90394-8; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WALLACE BG, 1990, J NEUROSCI, V10, P3576; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WALLACE BG, 1992, J NEUROBIOL, V23, P592, DOI 10.1002/neu.480230512; WALLACE BG, 1988, J CELL BIOL, V107, P267, DOI 10.1083/jcb.107.1.267; WALLACE BG, 1986, J CELL BIOL, V102, P783, DOI 10.1083/jcb.102.3.783; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; YEADON JE, 1991, J CELL BIOL, V115, P1069, DOI 10.1083/jcb.115.4.1069	59	345	349	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 3	1994	77	5					663	674		10.1016/0092-8674(94)90051-5	http://dx.doi.org/10.1016/0092-8674(94)90051-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NQ123	8205616				2022-12-01	WOS:A1994NQ12300007
J	GINTY, DD; BONNI, A; GREENBERG, ME				GINTY, DD; BONNI, A; GREENBERG, ME			NERVE GROWTH-FACTOR ACTIVATES A RAS-DEPENDENT PROTEIN-KINASE THAT STIMULATES C-FOS TRANSCRIPTION PHOSPHORYLATION OF CREB	CELL			English	Article							MULTIPLE SEQUENCE ELEMENTS; CAMP RESPONSE ELEMENT; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PC12 CELLS; MEMBRANE DEPOLARIZATION; SOMATOSTATIN GENE; NUCLEAR-PROTEIN; MAP KINASES; RECEPTOR	A mechanism by which the nerve growth factor (NGF) signal is transduced to the nucleus to induce gene expression has been characterized. An NGF-inducible, Ras-dependent protein kinase has been identified that catalyzes the phosphorylation of the cyclic AMP response element-binding protein (CREB) at Ser-133. Phosphorylation of Ser-133 stimulates the ability of CREB to activate transcription in NGF-treated cells. These findings suggest that CREB has a more widespread function than previously believed and functions in the nucleus as a general mediator of growth factor responses.	HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	GINTY, DD (corresponding author), HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA.				NCI NIH HHS [R01 CA43855] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DEFRANCO C, 1993, MOL ENDOCRINOL, V7, P365, DOI 10.1210/me.7.3.365; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HAWLEY RJ, 1992, J NEUROSCI, V12, P2573; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KIM KS, 1993, J BIOL CHEM, V268, P15689; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KRIEG J, 1988, J BIOL CHEM, V263, P11473; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; Lo D C, 1992, Curr Opin Neurobiol, V2, P336, DOI 10.1016/0959-4388(92)90125-5; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; TAYLOR LK, 1994, J BIOL CHEM, V269, P308; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; VOLONTE C, 1992, J BIOL CHEM, V267, P21663; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YOON JK, 1993, J BIOL CHEM, V268, P9148	53	691	705	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	1994	77	5					713	725		10.1016/0092-8674(94)90055-8	http://dx.doi.org/10.1016/0092-8674(94)90055-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NQ123	8205620				2022-12-01	WOS:A1994NQ12300011
J	BRANDSPIGEL, K; BRAWER, MK				BRANDSPIGEL, K; BRAWER, MK			STAGING FOR PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ANTIGEN		UNIV WASHINGTON,SEATTLE,WA	University of Washington; University of Washington Seattle								BRAWER MK, 1993, J UROLOGY, V150, P106, DOI 10.1016/S0022-5347(17)35409-5; BRAWER MK, 1991, ACTA ONCOL, V30, P161, DOI 10.3109/02841869109092342; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHYBOWSKI FM, 1991, J UROLOGY, V145, P313, DOI 10.1016/S0022-5347(17)38325-8	5	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	1994	271	20					1628	1629						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL758	8182820				2022-12-01	WOS:A1994NL75800039
J	MAEDA, T; WURGLERMURPHY, SM; SAITO, H				MAEDA, T; WURGLERMURPHY, SM; SAITO, H			A 2-COMPONENT SYSTEM THAT REGULATES AN OSMOSENSING MAP KINASE CASCADE IN YEAST	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; SHUTTLE VECTORS; PROTEIN; GENE; CHEMOTAXIS; HOMOLOGIES; STRAINS	IN the prokaryotic two-component signal transduction systems, recognition of an environmental stimulus by a sensor molecule results in the activation of its histidine kinase domain and phosphorylation of a histidine residue within that domain(1-3). This phosphate group is then transferred to an aspartate residue in the receiver domain of a cognate response regulator molecule, resulting in the activation of its output function. Although a few eukaryotic proteins were identified recently that show sequence similarity to the prokaryotic sensors or response regulators, it has not been clear whether they constituted a part of a 'two-component' system(4-7). Here we describe a two-component system in Saccharomyces cerevisiae that regulates an osmosensing MAP kinase cascade(8,9).	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Maeda, Tatsuya/L-5540-2019; Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BOGUSLAWSKI G, 1992, J GEN MICROBIOL, V138, P2425, DOI 10.1099/00221287-138-11-2425; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; GUAN KL, 1992, J BIOL CHEM, V267, P10024; JAMES P, 1992, GENE, V122, P101, DOI 10.1016/0378-1119(92)90037-P; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MAGER WH, 1993, MOL MICROBIOL, V10, P253, DOI 10.1111/j.1365-2958.1993.tb01951.x; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; NAGASAWA S, 1992, MOL MICROBIOL, V6, P799, DOI 10.1111/j.1365-2958.1992.tb01530.x; OTA IM, 1992, P NATL ACAD SCI USA, V89, P2355, DOI 10.1073/pnas.89.6.2355; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; SCHNEIDERPOETSCH HAW, 1991, FEBS LETT, V281, P245, DOI 10.1016/0014-5793(91)80403-P; SIKORSKI RS, 1989, GENETICS, V122, P19; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0	25	929	970	3	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					242	245		10.1038/369242a0	http://dx.doi.org/10.1038/369242a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	8183345				2022-12-01	WOS:A1994NM06700059
J	FATH, I; SCHWEIGHOFFER, F; REY, I; MULTON, MC; BOIZIAU, J; DUCHESNE, M; TOCQUE, B				FATH, I; SCHWEIGHOFFER, F; REY, I; MULTON, MC; BOIZIAU, J; DUCHESNE, M; TOCQUE, B			CLONING OF A GRB2 ISOFORM WITH APOPTOTIC PROPERTIES	SCIENCE			English	Article							SH3 DOMAINS; PROTEIN; AFFINITY	Growth factor receptor-bound protein 2 (Grb2) links tyrosine-phosphorylated proteins to a guanine nucleotide releasing factor of the son of sevenless (Sos) class by attaching to the former by its Src homology 2 (SH2) moiety and to the latter by its SH3 domains. An isoform of grb2 complementary DNA (cDNA) was cloned that has a deletion in the SH2 domain. The protein encoded by this cDNA, Grb3-3, did not bind to phosphorylated epidermal growth factor receptor (EGFR) but retained functional SH3 domains and inhibited EGF-induced transactivation of a Ras-responsive element. The messenger RNA encoding Grb3-3 was expressed in high amounts in the thymus of rats at an age when massive negative selection of thymocytes occurs. Microinjection of Grb3-3 into Swiss 3T3 fibroblasts induced apoptosis. These findings indicate that Grb3-3, by acting as a dominant negative protein over Grb2 and by suppressing proliferative signals, may trigger active programmed cell death.	RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,F-94403 VITRY,FRANCE	Sanofi-Aventis								BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; L'allemain G, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000255; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELLICI G, 1992, CELL, V70, P93; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REY I, UNPUB; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WASYLYK C, 1988, EMBO J, V7, P7952	31	98	102	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 13	1994	264	5161					971	974		10.1126/science.8178156	http://dx.doi.org/10.1126/science.8178156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK974	8178156				2022-12-01	WOS:A1994NK97400037
J	FELDMAN, S; ANDREW, M; GILBERT, J; BRACKEN, B; THOMPSON, FE				FELDMAN, S; ANDREW, M; GILBERT, J; BRACKEN, B; THOMPSON, FE			MEASLES IMMUNIZATION OF 2-YEAR-OLDS IN A RURAL SOUTHERN STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; HERD-IMMUNITY	Objective.-To assess the measles vaccine coverage of 2-year-old children livin Design.-Survey of 2-year-olds randomly selected from the 1987 birth cohort. The status of measles-mumps-rubella (MMR) vaccination was determined by medical record reviews and family contacts. Setting.-A predominantly rural state in the southeastern United States with a large black minority population (35%) and; a low per capita income ($9827 to $12 899). Approximately 80% of MMR immunizations are given by public health service nurses working in nine health districts. Subjects.-A total of 2450 preschool-aged children representing 6% of the 1987 birth cohort (n=41 279). Three hundred forty-one children were considered ineligible, leaving 2109 in the final sample. Main Outcome M easures.-Confirmed vaccination by the age of 2 years. Rates of immunization were calculated for the entire state, its health districts, and subgroups based on population density, per capita income, type of clin ic visited, and race. Results.-The statewide immunization rate was 87% (95% confidence interval, 86% to 88%). Among the nine health districts, rates varied from 79% to 97% (median, 88%). They were similar for white and black children in each health district and within the state as a whole. The lever of vaccine coverage was significantly higher in districts with lower population densities (89% vs 85%, P=.02) and in those with higher per capita incomes (89% vs 86%, P=.03). There were four minor outbreaks of measles during 1989 and 1990; half of the cases occurred in unimmunized children too young to receive the MMR Vaccine. Conclusion.-A high rate of measles immunization is attainable among 2-year-olds living in a rural state with a large black minority population and limited economic resources.	UNIV MISSISSIPPI, MED CTR, DEPT PREVENT MED, JACKSON, MS 39216 USA; MISSISSIPPI DEPT HLTH, JACKSON, MS USA	University of Mississippi; University of Mississippi Medical Center	FELDMAN, S (corresponding author), UNIV MISSISSIPPI, MED CTR, DEPT PEDIAT, 2500 N STATE ST, JACKSON, MS 39216 USA.							[Anonymous], 2017, RE DANIEL; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; FARIZO KM, 1992, PEDIATRICS, V89, P589; FOX JP, 1971, AM J EPIDEMIOL, V94, P179, DOI 10.1093/oxfordjournals.aje.a121310; FREED GL, 1993, NEW ENGL J MED, V329, P1957, DOI 10.1056/NEJM199312233292611; GINDLER JS, 1992, PEDIATR INFECT DIS J, V11, P841, DOI 10.1097/00006454-199210000-00007; GUENTHER W, 1973, CONCEPTS STATISTICAL, P517; JONES VF, 1992, CLIN RES, V40, pA809; KATZ SL, 1991, REP PEDIAT INFECT DI, V1, P1; LANGBEIN LI, 1978, ECOLOGICAL INFERENCE, P9; SCHLENKER TL, 1992, JAMA-J AM MED ASSOC, V267, P823, DOI 10.1001/jama.267.6.823; WOJCIECHOWSKI B, 1992, CLIN RES, V40, pA809; YOUNG SA, 1980, AM J PUBLIC HEALTH, V70, P422, DOI 10.2105/AJPH.70.4.422; 1991, MMWR MORB MORTAL WKL, V40, P369; 1991, RANKINGS STATES 1991, P54; 1994, MMWR MORB MORTAL WKL, V42, P985; 1992, REPORT BUREAU EC ANA, P8; 1991, MMWR MORB MORTAL WKL, V40, P36; 1992, 1991 MISS STAT DEP H, P43; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1992, STATE HLTH AGENCY OR; 1992, STATISTICAL ABSTRACT, P22	22	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	1994	271	18					1417	1420						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ693	8176803				2022-12-01	WOS:A1994NJ69300029
J	STEVENSON, RN; UMACHANDRAN, V; RANJADAYALAN, K; ROBERTS, RH; TIMMIS, AD				STEVENSON, RN; UMACHANDRAN, V; RANJADAYALAN, K; ROBERTS, RH; TIMMIS, AD			EARLY EXERCISE TESTING AFTER TREATMENT WITH THROMBOLYTIC DRUGS FOR ACUTE MYOCARDIAL-INFARCTION - IMPORTANCE OF RECIPROCAL ST SEGMENT DEPRESSION	BRITISH MEDICAL JOURNAL			English	Article							MULTIVESSEL CORONARY-DISEASE; PROGNOSTIC VALUE; PREDICTIVE VALUE; ARTERY DISEASE; STRESS TEST; ELEVATION; ANGIOGRAPHY; LEADS; ECG	Objective-To investigate the clinical importance of reciprocal ST depression induced by exercise testing early after acute myocardial infarction in patients treated with thrombolysis. Design-Prospective observational study. Setting-District general hospital in London. Subjects-202 patients (170 men) aged 33-69 with acute myocardial infarction treated with thrombolysis. Main outcome measures-All patients underwent exercise testing and coronary arteriography. ST depression induced by exercise was classified as either reciprocal (associated with ST elevation) or isolated (occurring on its own). The relation between reciprocal ST depression and the following end points was studied: characteristics of the infarct, left ventricular ejection fraction, extent of coronary artery disease on arteriography, and presence of angina induced by exercise. Results-Reciprocal ST depression occurred almost exclusively in Q wave infarctions and was associated with a lower overall ejection fi action than isolated ST depression. It tended to be associated with persistent occlusion of the coronary artery related to the infarct and did not indicate remote ischaemia due to multivessel coronary disease. Unlike isolated ST depression, reciprocal ST depression was not associated with angina induced by exercise. Conclusions-Reciprocal ST depression induced by exercise is usually associated with extensive Q wave infarctions and persistent occlusion of the artery related to the infarct. It does not seem to indicate reversible ischaemia and should not be used as a non-invasive marker of multivessel disease in the assessment of requirements for further investigation soon after acute myocardial infarction.	LONDON CHEST HOSP,DEPT CARDIOL,LONDON E2 9JX,ENGLAND; NEWHAM DIST GEN HOSP,DEPT CARDIOL,LONDON E13 8SL,ENGLAND	University of London; Queen Mary University London								AKHRAS F, 1985, BRIT MED J, V290, P1931, DOI 10.1136/bmj.290.6486.1931; COMACANELLA I, 1991, EUR HEART J, V12, P909, DOI 10.1093/eurheartj/12.8.909; DEFEYTER PJ, 1982, CIRCULATION, V66, P527, DOI 10.1161/01.CIR.66.3.527; DILLAHUNT PH, 1979, CHEST, V76, P150, DOI 10.1378/chest.76.2.150; DUNN RF, 1980, CIRCULATION, V62, P726, DOI 10.1161/01.CIR.62.4.726; FORTUIN NJ, 1970, AM J MED, V49, P459, DOI 10.1016/S0002-9343(70)80039-0; FUBINI A, 1986, BRIT HEART J, V55, P535; FULLER CM, 1981, ANN INTERN MED, V94, P734, DOI 10.7326/0003-4819-94-6-734; HERBERT WG, 1991, AM HEART J, V122, P993, DOI 10.1016/0002-8703(91)90463-R; JENNINGS K, 1983, BRIT MED J, V287, P634, DOI 10.1136/bmj.287.6393.634; KOTLER TS, 1990, ANN INTERN MED, V113, P684, DOI 10.7326/0003-4819-113-9-684; LAHIRI A, 1980, BRIT HEART J, V43, P582; MIRVIS DM, 1988, AM HEART J, V116, P1308, DOI 10.1016/0002-8703(88)90456-5; NORRELL MS, 1989, J AM COLL CARDIOL, V13, P1270; PATTERSON RE, 1983, AM J CARDIOL, V51, P361, DOI 10.1016/S0002-9149(83)80066-6; QUYYUMI AA, 1986, LANCET, V1, P347; SALCEDO JR, 1981, AM J CARDIOL, V48, P1003, DOI 10.1016/0002-9149(81)90312-X; SANDLER H, 1968, AM HEART J, V75, P325, DOI 10.1016/0002-8703(68)90089-6; SCHARTZ KM, 1981, ANN INTERN MED, V94, P727; STARLING MR, 1980, AM J CARDIOL, V46, P909, DOI 10.1016/0002-9149(80)90344-6; SULLIVAN ID, 1984, BRIT HEART J, V52, P147; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; WATERS DD, 1980, CIRCULATION, V61, P286, DOI 10.1161/01.CIR.61.2.286; WEINER DA, 1978, CIRCULATION, V58, P887, DOI 10.1161/01.CIR.58.5.887; 1985, NEW ENGL J MED, V53, P457	25	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 7	1994	308	6938					1189	1192		10.1136/bmj.308.6938.1189	http://dx.doi.org/10.1136/bmj.308.6938.1189			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK956	8180533	Green Published			2022-12-01	WOS:A1994NK95600014
J	BERTINA, RM; KOELEMAN, BPC; KOSTER, T; ROSENDAAL, FR; DIRVEN, RJ; DERONDE, H; VANDERVELDEN, PA; REITSMA, PH				BERTINA, RM; KOELEMAN, BPC; KOSTER, T; ROSENDAAL, FR; DIRVEN, RJ; DERONDE, H; VANDERVELDEN, PA; REITSMA, PH			MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C	NATURE			English	Article							FACTOR-XA; COMPLETE CDNA; FACTOR-VIII; CERULOPLASMIN; DEFICIENCY; INHIBITION; SEQUENCE; THROMBIN; CLONING; HEPARIN	ACTIVATED protein C (APC) is a serine protease with potent anticoagulant properties, which is formed in blood on the endothelium from an inactive precursor(1). During normal haemostasis, APC limits clot formation by proteolytic inactivation of factors Va and VIIIa (ref. 2). To do this efficiently the enzyme needs a nonenzymatic cofactor, protein S (ref. 3). Recently it was found that the anticoagulant response to APC (APC resistance)(4) was very weak in the plasma of 21% of unselected consecutive patients with thrombosis(5) and about 50% of selected patients with a personal or family history of thrombosis(6,7); moreover, 5% of healthy individuals show APC resistance, which is associated with a sevenfold increase in the risk for deep vein thrombosis(5). Here we demonstrate that the phenotype of APC resistance is associated with heterozygosity or homozygosity for a single point mutation in the factor V gene (at nucleotide position 1,691, G --> A substitution) which predicts the synthesis of a factor V molecule (FV Q506, or FV Leiden) that is not properly inactivated by APC. The allelic frequency of the mutation in the Dutch population is similar to 2% and is at least tenfold higher than that of all other known genetic risk factors for thrombosis (protein C (ref. 8), protein S (ref. 9), antithrombin(10) deficiency) together.	UNIV LEIDEN HOSP,DEPT CLIN EPIDEMIOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	BERTINA, RM (corresponding author), UNIV LEIDEN HOSP,CTR HEMOSTASIS & THROMBOSIS RES,BLDG 1-C2R,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Bertina, Rogier/AGQ-5246-2022; Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496; van der Velden, Pieter/0000-0002-5710-9256; Dirven, Richard/0000-0001-9626-9925				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; Chromczynski P, 1987, ANAL BIOCHEM, V162, P156; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; ENGESSER L, 1987, ANN INTERN MED, V106, P677, DOI 10.7326/0003-4819-106-5-677; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; GRIFFIN JH, 1993, BLOOD, V82, P1989; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HIRSH J, 1989, AM J MED S3B, V87, P345; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KANE WH, 1987, BIOCHEMISTRY-US, V26, P6508, DOI 10.1021/bi00394a033; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; PIETERS J, 1988, BLOOD, V72, P2048; REITSMA PH, 1991, BLOOD, V78, P890, DOI 10.1182/blood.V78.4.890.bloodjournal784890; SHEN NLL, 1993, J IMMUNOL, V150, P2992; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; VERDUYN W, 1993, HUM IMMUNOL, V37, P59, DOI 10.1016/0198-8859(93)90143-O; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WALKER FJ, 1990, J BIOL CHEM, V265, P1834; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; Wang H, 1988, GENOMICS, V2, P324, DOI 10.1016/0888-7543(88)90021-3; YANG XJ, 1990, BIOCHEM J, V272, P399, DOI 10.1042/bj2720399	30	3608	3741	3	143	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					64	67		10.1038/369064a0	http://dx.doi.org/10.1038/369064a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164741				2022-12-01	WOS:A1994NJ86000054
J	MCCANCE, DR; PETTITT, DJ; HANSON, RL; JACOBSSON, LTH; KNOWLER, WC; BENNETT, PH				MCCANCE, DR; PETTITT, DJ; HANSON, RL; JACOBSSON, LTH; KNOWLER, WC; BENNETT, PH			BIRTH-WEIGHT AND NON-INSULIN-DEPENDENT DIABETES - THRIFTY GENOTYPE, THRIFTY PHENOTYPE, OR SURVIVING SMALL BABY GENOTYPE	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; PIMA INDIAN WOMEN; MELLITUS; PREGNANCY; GROWTH; FETAL	Objective-To determine the prevalence of diabetes in relation to birth weight in Pima Indians. Design-Follow up study of infants born during 1940-72 who had undergone a glucose tolerance test at ages 20-39 years. Setting-Gila River Indian community, Arizona. Subjects-1179 American Indians. Main outcome measure-Prevalence of non-insulin dependent diabetes mellitus (plasma glucose concentration greater-than-or-equal-to 11.1 mmol/l two hours after ingestion of carbohydrate). Results-The prevalence was greatest in those with the lowest and highest birth weights. The age adjusted prevalences for birth weights <2500 g, 2500-4499 g, and greater-than-or-equal-to 4500 g were 30%, 17%, and 32%, respectively. When age, sex, body mass index, maternal diabetes during pregnancy, and birth year were controlled for, subjects with birth weights < 2500 g had a higher rate than those with weights 2500-4499 g (odds ratio 3.81; 95% confidence interval 1.70 to 8.52). The risk for subsequent diabetes among higher birthweight infants (greater-than-or-equal-to 4500 g) was associated with maternal diabetes during pregnancy. Most diabetes, however, occurred in subjects with intermediate birth weights (2500-4500 g). Conclusions-The relation of the prevalence of diabetes to birth weight in the Pima Indians is U shaped and is related to parental diabetes. Low birth weight is associated with non-insulin dependent diabetes. Given the high mortality of low birthweight infants selective survival in infancy of those genetically predisposed to insulin resistance and diabetes provides an explanation for the observed relation between low birth weight and diabetes and the high prevalence of diabetes in many populations.	NIDDKD,PHOENIX EPIDEMIOL & CLIN RES BRANCH,DIABET & ARTHRIT EPIDEMIOL SECT,PHOENIX,AZ 85014	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Bennett, Peter/AAH-9605-2021; Hanson, Robert L/O-3238-2015	Hanson, Robert L/0000-0002-4252-7068				[Anonymous], 1989, LANCET, V2, P839; ATHENS M, 1993, DIABETES, V42, pA61; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BENNETT PH, 1971, LANCET, V2, P125; COMESS LJ, 1969, DIABETES, V18, P471, DOI 10.2337/diab.18.7.471; FRIENKEL N, 1980, DIABETES, V29, P1023; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MCCANCE RA, 1974, PROC R SOC SER B-BIO, V185, P1, DOI 10.1098/rspb.1974.0001; NEEL JV, 1962, AM J HUM GENET, V14, P353; NEEL JV, 1982, P SERONO S, P283; PETITT DJ, 1980, DIABETES CARE, V4, P458; PETTITT DJ, 1991, DIABETES, V40, P126, DOI 10.2337/diab.40.2.S126; PETTITT DJ, 1983, NEW ENGL J MED, V308, P242, DOI 10.1056/NEJM198302033080502; PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; SAVAGE PJ, 1979, DIABETES, V28, P939; SWEENE I, 1981, DIABETES, V29, P686; SWEENE I, 1987, DIABETES, V36, P454; van Assche F A, 1979, Contrib Gynecol Obstet, V5, P44; WILKIN TJ, 1993, BRIT MED J, V306, P283, DOI 10.1136/bmj.306.6873.283; 1985, WHO TECH REP SER, V727, P9	28	534	542	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					942	945		10.1136/bmj.308.6934.942	http://dx.doi.org/10.1136/bmj.308.6934.942			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173400	Green Published			2022-12-01	WOS:A1994NF48500015
J	ROOME, AJ; WALSH, SJ; CARTTER, ML; HADLER, JL				ROOME, AJ; WALSH, SJ; CARTTER, ML; HADLER, JL			HEPATITIS-B VACCINE RESPONSIVENESS IN CONNECTICUT PUBLIC SAFETY PERSONNEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EFFICACY; IMMUNOGENICITY; EPIDEMIOLOGY; PREVENTION; SMOKING; VIRUS	Objective.-To determine the level and determinants of vaccine response in recently inoculated public safety personnel. Design.-Prevalence survey. Participants.-Public safety personnel who had completed vaccination 1 to 6 months prior to testing and had no serological evidence of previous exposure to hepatitis B virus. Main Outcome Measure.-An inadequate level of antibody to hepatitis B surface antigen was defined as less than 10 mIU/mL. Results.-All subjects in the study had been vaccinated using Recombivax HB, a recombinant hepatitis B vaccine. Of 528 individuals, 11.9% were found to have no or inadequate levels of antibody. The frequency of inadequate level of antibody increased significantly relative to age, from 2.8% among those younger than 30 years to 42.1% among those older than 60 years (P<.0001). Smoking (odds ratio [OR], 3.6; 95% confidence interval [CI], 2.0 to 6.4), extreme obesity (OR, 13.3; 95% CI, 3.8 to 49.1), and increasing time interval since completing the vaccine series (P<.01) were also associated with inadequate levels of antibody. These findings were confirmed by multivariate analysis using logistic regression. Conclusions.-Routine immunization of public safety personnel should include selective use of postvaccine testing. Postvaccination testing optimally should be performed in the 30- to 90-day interval after the last vaccine dose. New vaccination strategies are needed to improve response rates in persons with predictably poor response to hepatitis B vaccine.	CONNECTICUT DEPT HLTH & ADDICT SERV,EPIDEMIOL SECT,150 WASHINGTON ST,HARTFORD,CT 06106; UNIV CONNECTICUT,CTR HLTH,DEPT COMMUNITY MED,FARMINGTON,CT 06032	University of Connecticut								ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDRE FE, 1989, AM J MED, V87, pS14, DOI 10.1016/0002-9343(89)90525-1; BLUMBERG BS, 1989, AM J MED, V87, pS2, DOI 10.1016/0002-9343(89)90522-6; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; HOROWITZ MM, 1988, ANN INTERN MED, V108, P185, DOI 10.7326/0003-4819-108-2-185; JILG W, 1986, J HEPATOL, V3, P190, DOI 10.1016/S0168-8278(86)80025-3; MACKENZIE JS, 1976, J HYG-CAMBRIDGE, V77, P409, DOI 10.1017/S0022172400055790; MARGOLIS HS, 1991, SEMIN LIVER DIS, V11, P84, DOI 10.1055/s-2008-1040427; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; STEVENS CE, 1987, JAMA-J AM MED ASSOC, V257, P2612, DOI 10.1001/jama.257.19.2612; WEBER DJ, 1985, JAMA-J AM MED ASSOC, V254, P3187, DOI 10.1001/jama.254.22.3187; WONG VCW, 1984, LANCET, V1, P921; 1991, MMWR MORB MORTAL WKL, V40, P1; 1991, JAMA-J AM MED ASSOC, V266, P1338; 1991, FED REGISTER, V56, P64004	15	155	165	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2931	2934		10.1001/jama.270.24.2931	http://dx.doi.org/10.1001/jama.270.24.2931			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM119	8254852				2022-12-01	WOS:A1993MM11900026
J	MOLINA, CA; FOULKES, NS; LALLI, E; SASSONECORSI, P				MOLINA, CA; FOULKES, NS; LALLI, E; SASSONECORSI, P			INDUCIBILITY AND NEGATIVE AUTOREGULATION OF CREM - AN ALTERNATIVE PROMOTER DIRECTS THE EXPRESSION OF ICER, AN EARLY RESPONSE REPRESSOR	CELL			English	Article							CORTICOTROPIN-RELEASING FACTOR; DEPENDENT PROTEIN-KINASE; DNA-BINDING PROTEINS; NUCLEAR FACTOR CREB; CYCLIC-AMP; LEUCINE-ZIPPER; TRANSCRIPTION FACTORS; C-FOS; ELEMENT; GENE	cAMP-responsive element modulator (CREM) expression is tissue specific and developmentally regulated. Here we report that CREM is unique within the family of cAMP-responsive promoter element (CRE)-binding factors since it is inducible by activation of the cAMP signaling pathway. The kinetic of expression is characteristic of an early response gene. The induction is transient and cell specific, does not involve increased transcript stability, and does not require protein synthesis. Significantly, the subsequent decline in CREM expression requires de novo protein synthesis. The induced transcript encodes a novel repressor, inducible cAMP early repressor (ICER), and is generated from an alternative intronic promoter. A cluster of four CREs in this promoter directs cAMP inducibility. ICER binds to these elements and thereby represses the activity of its own promoter, thus constituting a negative autoregulatory loop.			MOLINA, CA (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE.		Lalli, Enzo/F-7052-2013; Foulkes, Nicholas S/K-7003-2013	Lalli, Enzo/0000-0002-0584-5681; Foulkes, Nicholas S/0000-0002-1794-9891				AIBA H, 1983, CELL, V32, P141, DOI 10.1016/0092-8674(83)90504-4; AKERBLOM IE, 1990, MOL ENDOCRINOL, V4, P589, DOI 10.1210/mend-4-4-589; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DELMAS V, 1993, MOL ENDOCRINOL, V10, P1502; DRUST DS, 1991, MOL ENDOCRINOL, V5, P1541, DOI 10.1210/mend-5-10-1541; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FLINT KJ, 1991, ONCOGENE, V6, P2019; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; Frohman MA, 1990, PCR PROTOCOLS GUIDE, P28; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Maniatis T, 1989, DECONTAMINATION DILU; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MELLSTROM B, 1993, NEURON, V10, P655, DOI 10.1016/0896-6273(93)90167-P; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; NATT E, 1986, NUCLEIC ACIDS RES, V14, P7128; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RIVIER C, 1983, ENDOCRINOLOGY, V113, P939, DOI 10.1210/endo-113-3-939; RIVIER J, 1984, SCIENCE, V224, P889, DOI 10.1126/science.6326264; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SASSONECORSI P, 1990, PCR PROTOCOLS GUIDE, P84; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TEGTMEYER P, 1975, J VIROL, V16, P168, DOI 10.1128/JVI.16.1.168-178.1975; Treisman R, 1990, Semin Cancer Biol, V1, P47; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WILLIAMS JG, 1987, NUCL ACID HYBRIDISAT, P139; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	59	514	519	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					875	886		10.1016/0092-8674(93)90532-U	http://dx.doi.org/10.1016/0092-8674(93)90532-U			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252624	Bronze			2022-12-01	WOS:A1993MK96600008
J	PORTER, JA; YU, MJ; DOBERSTEIN, SK; POLLARD, TD; MONTELL, C				PORTER, JA; YU, MJ; DOBERSTEIN, SK; POLLARD, TD; MONTELL, C			DEPENDENCE OF CALMODULIN LOCALIZATION IN THE RETINA ON THE NINAC UNCONVENTIONAL MYOSIN	SCIENCE			English	Article							ROD OUTER SEGMENTS; CA2+-DEPENDENT REGULATOR PROTEIN; INTEGRAL MEMBRANE-PROTEIN; INTESTINAL BRUSH-BORDER; BINDING-PROTEIN; DROSOPHILA-MELANOGASTER; GUANYLATE-CYCLASE; SACCHAROMYCES-CEREVISIAE; DICTYOSTELIUM-DISCOIDEUM; PHOTORECEPTOR CELLS	Calmodulin is a highly conserved regulatory protein found in all eukaryotic organisms which mediates a variety of calcium ion-dependent signaling pathways. In the Drosophila retina, calmodulin was concentrated in the photoreceptor cell microvillar structure, the rhabdomere, and was found in lower amounts in the sub-rhabdomeral cytoplasm. This calmodulin localization was dependent on the NINAC (neither inactivation nor afterpotential C) unconventional myosins. Mutant flies lacking the rhabdomere-specific p174 NINAC protein did not concentrate calmodulin in the rhabdomere, whereas flies lacking the sub-rhabdomeral p132 isoform had np detectable cytoplasmic calmodulin. Furthermore, a defect in vision resulted when calmodulin was not concentrated in the rhabdomeres, suggesting a role for calmodulin in the regulation of fly phototransduction. A general function of unconventional myosins may be to control the subcellular distribution of calmodulin.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University	PORTER, JA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.		Montell, Craig/AAH-3357-2021	Montell, Craig/0000-0001-5637-1482	NATIONAL EYE INSTITUTE [R01EY008117] Funding Source: NIH RePORTER; NEI NIH HHS [EY08117] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ARIKAWA K, 1990, J CELL BIOL, V110, P1993, DOI 10.1083/jcb.110.6.1993; Blest A., 1988, ADV INSECT PHYSL, P1, DOI 10.1016/s0065-2806(08)60021-1; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BROCKERHOFF SE, 1992, J CELL BIOL, V118, P619, DOI 10.1083/jcb.118.3.619; BUCHNER E, 1991, J NEUROGENET, V7, P153, DOI 10.3109/01677069109167432; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; COLLINS JH, 1984, J BIOL CHEM, V259, P4128; DECOUET HG, 1989, CELL TISSUE RES, V244, P315; DEDMAN JR, 1977, J BIOL CHEM, V252, P8415; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; GLENNEY JR, 1984, CELL, V37, P743, DOI 10.1016/0092-8674(84)90410-0; GLENNEY JR, 1980, P NATL ACAD SCI-BIOL, V77, P6458, DOI 10.1073/pnas.77.11.6458; GLENNEY JR, 1980, J BIOL CHEM, V255, P551; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HARDIE RC, 1983, PROGR SENSORY PHYSL, V5, P1; HEIZMANN CW, 1992, TRENDS NEUROSCI, V15, P259, DOI 10.1016/0166-2236(92)90067-I; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOHNKEN RE, 1981, J BIOL CHEM, V256, P2517; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; MATSUMOTO H, 1982, SCIENCE, V217, P839, DOI 10.1126/science.7100927; MATSUMOTO H, 1987, P NATL ACAD SCI USA, V84, P985, DOI 10.1073/pnas.84.4.985; MINKE B, 1992, NEUROMETHODS, P517; MISMER D, 1987, GENETICS, V116, P565; MONTELL C, 1987, J NEUROSCI, V7, P1558; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; NAGAO S, 1987, BIOCHEMISTRY-US, V26, P1659, DOI 10.1021/bi00380a026; NAGY K, 1991, Q REV BIOPHYS, V24, P165, DOI 10.1017/S0033583500003401; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PORTER JA, 1992, J CELL BIOL, V116, P683, DOI 10.1083/jcb.116.3.683; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; PORTER JW, UNPUB; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SEAMON KB, 1980, BIOCHEMISTRY-US, V19, P207, DOI 10.1021/bi00542a031; SMITH DP, 1991, ANNU REV CELL BIOL, V7, P161; SMITH VL, 1987, J MOL BIOL, V196, P471, DOI 10.1016/0022-2836(87)90025-8; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STEELE F, 1990, NEURON, V4, P883, DOI 10.1016/0896-6273(90)90141-2; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; SUN GH, 1992, PROTOPLASMA, V166, P110, DOI 10.1007/BF01320150; SWANLJUNGCOLLINS H, 1992, J BIOL CHEM, V267, P3445; VANELDIK LJ, 1981, J BIOL CHEM, V256, P4205; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WOLFF DJ, 1977, J BIOL CHEM, V252, P4108; WONG F, 1989, NEURON, V3, P81, DOI 10.1016/0896-6273(89)90117-7; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; YAMANAKA MK, 1987, NUCLEIC ACIDS RES, V15, P3335, DOI 10.1093/nar/15.8.3335; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347; [No title captured]	62	124	125	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1038	1042		10.1126/science.8235618	http://dx.doi.org/10.1126/science.8235618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235618				2022-12-01	WOS:A1993MG18700030
J	MULLER, M; BRISCOE, J; LAXTON, C; GUSCHIN, D; ZIEMIECKI, A; SILVENNOINEN, O; HARPUR, AG; BARBIERI, G; WITTHUHN, BA; SCHINDLER, C; PELLEGRINI, S; WILKS, AF; IHLE, JN; STARK, GR; KERR, IM				MULLER, M; BRISCOE, J; LAXTON, C; GUSCHIN, D; ZIEMIECKI, A; SILVENNOINEN, O; HARPUR, AG; BARBIERI, G; WITTHUHN, BA; SCHINDLER, C; PELLEGRINI, S; WILKS, AF; IHLE, JN; STARK, GR; KERR, IM			THE PROTEIN-TYROSINE KINASE JAK1 COMPLEMENTS DEFECTS IN INTERFERON-ALPHA/BETA AND INTERFERON-GAMMA SIGNAL-TRANSDUCTION	NATURE			English	Article							DNA-BINDING PROTEIN; TRANSCRIPTION FACTOR; STIMULATED TRANSCRIPTION; CYTOPLASMIC ACTIVATION; IFN-GAMMA; RECEPTOR; PHOSPHORYLATION; CLONING; CELLS; CDNA	We have produced a cell line which lacks the protein tyrosine kinase JAK1. and is completely, defective in interferon response. Complementation of this mutant with JAK1 restored the response, establishing the requirement for JAK1 in both the interferon-alpha/beta and -gamma signal transduction pathways. The reciprocal interdependence between JAK1 and Tyk2 activities in the interferon-alpha pathway, and between JAK1 and JAK2 in the interferon-gamma pathway, may reflect a requirement for these kinases in the correct assembly of interferon receptor complexes.	IMPERIAL CANC RES FUND, POB 124, 44 LINCOLNS FIELDS, LONDON WC2A 3PX, ENGLAND; UNIV BERN, INST CLIN & EXPTL CANC RES, CH-3004 BERN, SWITZERLAND; NYU MED CTR, NEW YORK, NY 10016 USA; LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, MELBOURNE, VIC 3050, AUSTRALIA; INST PASTEUR, INSERM, U276, F-75724 PARIS 15, FRANCE; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA; COLUMBIA UNIV, MED CTR, DEPT MED, NEW YORK, NY 10032 USA; CLEVELAND CLIN FDN, RES INST, CLEVELAND, OH 44195 USA	Cancer Research UK; University of Bern; New York University; Ludwig Institute for Cancer Research; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; St Jude Children's Research Hospital; Columbia University; Cleveland Clinic Foundation			Guschin, Dmitry/U-3731-2019; Pellegrini, Sandra -/G-5546-2015; Pellegrini, Sandra/Y-6351-2019; Wilks, Andrew F/R-5542-2019; Barbieri, Giovanna/AAH-3645-2019; witthuhn, bruce/GSE-3193-2022; Guschin, Dmitry/O-7594-2018	Guschin, Dmitry/0000-0002-4184-0001; Pellegrini, Sandra -/0000-0001-5837-7589; Pellegrini, Sandra/0000-0001-5837-7589; Guschin, Dmitry/0000-0002-4184-0001; Briscoe, James/0000-0002-1020-5240; BARBIERI, GIOVANNA/0000-0002-5895-1795; Muller, Mathias/0000-0002-7879-3552				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BEYERS A D, 1992, Trends in Cell Biology, V2, P253, DOI 10.1016/0962-8924(92)90190-X; BOLEN JB, 1993, ONCOGENE, V8, P2025; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, 1993, J BIOL CHEM, V268, P6593; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; Demaeyer E., 1988, INTERFERONS OTHER RE; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HARPUR AG, 1992, ONCOGENE, V7, P1347; HOWARD OMZ, 1992, ONCOGENE, V7, P895; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	51	720	736	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					129	135		10.1038/366129a0	http://dx.doi.org/10.1038/366129a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232552				2022-12-01	WOS:A1993MG21600048
J	GUI, JF; LANE, WS; FU, XD				GUI, JF; LANE, WS; FU, XD			A SERINE KINASE REGULATES INTRACELLULAR-LOCALIZATION OF SPLICING FACTORS IN THE CELL CYCLE	NATURE			English	Article							RICH DOMAINS; SR PROTEINS; PHOSPHORYLATION; IDENTIFICATION; NUCLEUS; COMPARTMENT; INVITRO; FAMILY; SITES	Small nuclear ribonucleoprotein particles (snRNPs) and non-snRNP splicing factors containing a serine/arginine-rich domain (SR proteins) concentrate in 'speckles' in the nucleus of interphase cells(1). It is believed that nuclear speckles act as storage sites for splicing factors while splicing occurs on nascent transcripts(2). Splicing factors redistribute in response to transcription inhibition(3,4) or viral infection(5), and nuclear speckles break down and reform as cells progress through mitosis(6). We have now identified and cloned a kinase, SRPK1, which is regulated by the cell cycle and is specific for SR proteins; this kinase is related to a Caenorhabditis elegans kinase and to the fission yeast kinase Dsk1 (ref. 7). SRPK1 specifically induces the disassembly of nuclear speckles, and a high level of SRPK1 inhibits splicing in vitro. Our results indicate that SRPK1 mag have a central role in the regulatory network for splicing, controlling the intranuclear distribution of splicing factors in interphase cells, and the reorganization of nuclear speckles during mitosis.	UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; HARVARD UNIV, CAMBRIDGE, MA 02138 USA; CHINESE ACAD SCI, INST HYDROBIOL, WUHAN 430072, PEOPLES R CHINA	University of California System; University of California San Diego; Harvard University; Chinese Academy of Sciences; Institute of Hydrobiology, CAS								AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; ANDRADE LEC, 1993, P NATL ACAD SCI USA, V90, P1947, DOI 10.1073/pnas.90.5.1947; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P111; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOGNER D, 1988, EXP CELL RES, V176, P281, DOI 10.1016/0014-4827(88)90331-X; JIMINEZGARCIA LF, 1993, CELL, V73, P47; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRANIER AR, 1990, GENE DEV, V4, P1158; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NAKAGAWA J, 1989, J CELL SCI, V94, P449; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; TAKEUCHI M, 1993, MOL BIOL CELL, V4, P247, DOI 10.1091/mbc.4.3.247; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	30	451	475	2	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	1994	369	6482					678	682		10.1038/369678a0	http://dx.doi.org/10.1038/369678a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	8208298				2022-12-01	WOS:A1994NT45900064
J	NAYLOR, CD				NAYLOR, CD			PHYSICAL-EXAMINATION OF THE LIVER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SIZE; ULTRASOUND; DIAGNOSIS; DISEASE		SUNNYBROOK HLTH SCI CTR, DIV GEN INTERNAL MED, TORONTO, ON, CANADA; UNIV TORONTO, GRAD DEPT COMMUNITY HLTH, TORONTO, ON, CANADA; UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA; UNIV TORONTO, DEPT SURG, TORONTO, ON, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto	NAYLOR, CD (corresponding author), SUNNYBROOK HLTH SCI CTR, CLIN EPIDEMIOL UNIT, TORONTO M4N 3M5, ON, CANADA.							ARIEL I M, 1976, Medical and Pediatric Oncology, V2, P69, DOI 10.1002/mpo.2950020108; Bhatia M. L., 1974, INDIAN HEART J, V26, P165; BLENDIS LM, 1970, BMJ-BRIT MED J, V1, P727, DOI 10.1136/bmj.1.5698.727; BOKHARI SI, 1979, CHEST, V76, P89, DOI 10.1378/chest.76.1.89; CASTELL DO, 1969, ANN INTERN MED, V70, P1183, DOI 10.7326/0003-4819-70-6-1183; CLAIN D, 1966, LANCET, V2, P516; DACOSTA JC, 1915, PRINCIPLES PRACTICE, P542; ESPINOZA P, 1987, DIGEST DIS SCI, V32, P244, DOI 10.1007/BF01297048; FENSTER LF, 1961, AM J MED, V31, P238, DOI 10.1016/0002-9343(61)90112-7; FULLER GN, 1988, LANCET, V1, P181; GEORGE DS, 1988, CLIN CARDIOL, V11, P349, DOI 10.1002/clc.4960110515; HALPERN S, 1974, ARCH INTERN MED, V134, P123, DOI 10.1001/archinte.134.1.123; HARDING SMR, 1987, CAN MED ASSOC J, V136, P921; HARDISON JE, 1977, ARCH INTERN MED, V137, P1623, DOI 10.1001/archinte.137.11.1623; KINGSTON M, 1985, CANCER, V55, P1579, DOI 10.1002/1097-0142(19850401)55:7<1579::AID-CNCR2820550728>3.0.CO;2-D; MALCHOWMOLLER A, 1984, DAN MED BULL, V31, P63; MANGA P, 1984, BRIT HEART J, V52, P465; MEYHOFF HH, 1979, ACTA CHIR SCAND, V145, P479; MOTOKI T, 1978, LANCET, V2, P259; MOTOKI T, 1979, AM J GASTROENTEROL, V71, P582; MULLER O, 1954, BRIT HEART J, V16, P195; NAFFALIS J, 1963, AM J DIG DIS, V8, P236; NAYLOR C D, 1988, Clinical and Investigative Medicine, V11, pC90; NAYLOR CD, 1987, CAN MED ASSOC J, V136, P48; OSLER W, 1893, PRINCIPLES PRACTICE, P428; PALMER E D, 1958, U S Armed Forces Med J, V9, P1685; PELTERET RM, 1988, S AFR MED J, V74, P74; PETERNEL WW, 1966, AM J DIG DIS, V11, P346, DOI 10.1007/BF02233628; RALPHS DNL, 1983, ANN ROY COLL SURG, V65, P159; RAMAKRISHNAN T, 1978, ARCH INTERN MED, V138, P826, DOI 10.1001/archinte.1978.03630290106043; ROSENFIELD AT, 1974, AM J ROENTGENOL, V122, P313, DOI 10.2214/ajr.122.2.313; SAPIRA JD, 1989, SOUTHERN MED J, V82, P364, DOI 10.1097/00007611-198903000-00020; SAPIRA JD, 1979, ARCH INTERN MED, V139, P971, DOI 10.1001/archinte.139.9.971; SAPIRA JD, 1989, ART SCI BEDSIDE DIAG, P377; SHERMAN HI, 1979, JAMA-J AM MED ASSOC, V241, P1495, DOI 10.1001/jama.241.14.1495; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; SKRAINKA B, 1986, J CLIN GASTROENTEROL, V8, P267, DOI 10.1097/00004836-198606000-00013; SULLIVAN S, 1976, BMJ-BRIT MED J, V2, P1042, DOI 10.1136/bmj.2.6043.1042; THEODOSSI A, 1981, Liver, V1, P21; THEODOSSI A, 1983, LIVER, V3, P315; THEODOSSI A, 1985, CLIN GASTROENTEROL, V14, P545; WALK L, 1983, RADIOLOGE, V23, P189; ZONERAICH S, 1971, ANGIOLOGY, V22, P197, DOI 10.1177/000331977102200405; ZUIDEMA PJ, 1966, TROP GEOGR MED, V18, P265	44	28	28	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1859	1865		10.1001/jama.271.23.1859	http://dx.doi.org/10.1001/jama.271.23.1859			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	8196144				2022-12-01	WOS:A1994NP95900031
J	CRESPO, P; XU, NZ; SIMONDS, WF; GUTKIND, JS				CRESPO, P; XU, NZ; SIMONDS, WF; GUTKIND, JS			RAS-DEPENDENT ACTIVATION OF MAP KINASE PATHWAY MEDIATED BY G-PROTEIN BETA-GAMMA-SUBUNITS	NATURE			English	Article							NIH 3T3 CELLS; ALPHA-SUBUNITS; RECEPTOR; EXPRESSION; TRANSFORMATION; PROLIFERATION; STIMULATION; FIBROBLASTS; INHIBITION; SIGNALS	MITOGEN-ACTIVATED protein kinases, MAP kinases or ERKs (extracellular signal-regulated kinases) are rapidly stimulated by growth-promoting factors acting on a variety of cell-surface receptors (1,2). In turn, ERKs phosphorylate and regulate key intracellular enzymes and transcription factors involved in the control of cellular proliferation(3,4). The tyrosine-kinase class of growth-factor receptors transmits signals to ERKs in a multistep process that involves Ras and a limited number of defined molecules(5). In contrast, ERK activation by G-protein-coupled receptors is poorly understood(3,6), as is the role of ras in this signalling pathway(7,8). We have explored in COS-7 cells the mechanism of ERKs activation by m1 and m2 muscarinic receptors, typical examples of receptors coupled through Gq proteins to induce phosphatidylinositol hydrolysis and to G(i) proteins to inhibit adenylyl cyclase, respectively(9). Here we present evidence that ERK activation is mediated by beta gamma subunits of heterotrimeric G proteins acting on a ras-dependent pathway.	NIDR, CELLULAR DEV & ONCOL LAB, MOLEC SIGNALLING UNIT, BETHESDA, MD 20892 USA; NIDDKD, METAB DIS BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MUSSACHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343; PELECH SL, 1993, CURR BIOL, V3, P513, DOI 10.1016/0960-9822(93)90043-N; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; UI M, 1990, ADV SEC MESS PHOSPH, V24, P63	30	783	791	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	1994	369	6479					418	420		10.1038/369418a0	http://dx.doi.org/10.1038/369418a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	8196770				2022-12-01	WOS:A1994NP17400062
J	OBRIEN, SJ; PAN, WS; LU, Z				OBRIEN, SJ; PAN, WS; LU, Z			PANDAS, PEOPLE AND POLICY	NATURE			English	Editorial Material							POPULATIONS		BEIJING UNIV,DEPT BIOL,BEIJING 100871,PEOPLES R CHINA	Peking University	OBRIEN, SJ (corresponding author), NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702, USA.		OBRIEN, STEPHEN/ABD-1346-2020	OBRIEN, STEPHEN/0000-0001-7857-0757				BEAGLEY S, 1993, NEWSWEEK        0412, V121, P50; BLACK FL, 1992, SCIENCE, V258, P1739, DOI 10.1126/science.1465610; CHEN M, IN PRESS ZOO BIOL; DIAMOND J, 1988, CONS BIOL, V2, P121; Foose T.J., 1987, P304; Hu J., 1990, RES PROGR BIOL GIANT; JOHNSON KG, 1988, NATL GEOGR RES, V4, P161; LANDE R, 1988, SCIENCE, V241, P1455, DOI 10.1126/science.3420403; LU Z, 1992, THESIS PEKING U BEIJ; MAINKA SA, IN PRESS J WILD DIS; OBRIEN SJ, 1985, SCIENCE, V227, P1428, DOI 10.1126/science.2983425; OBRIEN SJ, 1987, NATURE, V325, P758, DOI 10.1038/325758a0; OBRIEN SJ, 1984, SCIENCE, V223, P1127, DOI 10.1126/science.6701515; OBRIEN SJ, 1988, TRENDS ECOL EVOL, V3, P254, DOI 10.1016/0169-5347(88)90058-4; Pan W., 1988, GIANT PANDAS NATURAL; RALLS K, 1979, SCIENCE, V206, P1101, DOI 10.1126/science.493997; ROBERTS L, 1988, SCIENCE, V241, P1594; ROBERTS L, 1988, SCIENCE, V241, P529, DOI 10.1126/science.241.4865.529; ROELKE ME, 1993, CURR BIOL, V3, P340, DOI 10.1016/0960-9822(93)90197-V; Schaller G.B., 1985, GIANT PANDAS WOLONG; Schaller G.B., 1993, LAST PANDA; Soule M.E, 1987, CONSERV BIOL, V1, P173, DOI [10.1111/j.1523-1739.1987.tb00027.x, DOI 10.1111/J.1523-1739.1987.TB00027.X]; ZHAO Q, 1993, GIANT PANDA STUDBOOK; 1993, IN PRESS SEP P INT G; 1989, NATIONAL CONSERVATIO	25	31	41	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					179	180		10.1038/369179a0	http://dx.doi.org/10.1038/369179a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	8183334				2022-12-01	WOS:A1994NM06700024
J	SIEVERS, D; VONKIEDROWSKI, G				SIEVERS, D; VONKIEDROWSKI, G			SELF REPLICATION OF COMPLEMENTARY NUCLEOTIDE-BASED OLIGOMERS	NATURE			English	Article							HEXADEOXYNUCLEOTIDE; SYSTEMS; LINKAGE; GROWTH	THE development of non-enzymatic self-replicating systems based on autocatalytic template-directed reactions is a current objective of bioorganic chemistry(1-6). Typically, a self-complementary template molecule AB is synthesized autocatalytically from two complementary template fragments A and B7-16. Natural replication of nucleic acids, however, utilizes complementary rather than self-complementary strands. Here we report on a minimal implementation of this type of replication(17) based on cross-catalytic template-directed syntheses of hexadeoxynucleotide derivatives from amino-trideoxynucleotides. In our experiments, two self-complementary and two complementary templates compete for their combinatorial synthesis from four common trimeric precursors. We provide kinetic evidence that cross-catalytic self-replication of complementary templates can proceed with an efficiency similar to that of autocatalytic self-replication of self-complementary templates. We observe selective stimulation of template synthesis, and thus information transfer, on seeding the reaction mixtures with one of four chemically labelled templates bearing the sequence of the reaction products. Our results bring a stage closer the development of schemes that might explain how replicating systems based on nucleic acids arose on the prebiotic Earth.	UNIV FREIBURG,DEPT ORGAN CHEM & BIOCHEM,D-79104 FREIBURG,GERMANY	University of Freiburg								ACHILLES T, 1993, ANGEW CHEM INT EDIT, V32, P1198, DOI 10.1002/anie.199311981; BACHMANN PA, 1992, NATURE, V357, P57, DOI 10.1038/357057a0; BOHLER C, 1993, HELV CHIM ACTA, V76, P2313, DOI 10.1002/hlca.19930760616; DOLINNAYA NG, 1991, NUCLEIC ACIDS RES, V19, P3073, DOI 10.1093/nar/19.11.3073; Eigen M., 1979, HYPERCYCLE PRINCIPLE; ESCHENMOSER A, 1992, CHEM SOC REV, V21, P1, DOI 10.1039/cs9922100001; FAMULOK M, 1992, ACTA CHEM SCAND, V46, P315, DOI 10.3891/acta.chem.scand.46-0315; FENG Q, 1992, SCIENCE, V256, P1179, DOI 10.1126/science.256.5060.1179; FERRIS JP, 1993, J AM CHEM SOC, V115, P12270, DOI 10.1021/ja00079a006; HOFFMANN S, 1992, ANGEW CHEM INT EDIT, V31, P1013, DOI 10.1002/anie.199210131; HONG JI, 1992, SCIENCE, V255, P848, DOI 10.1126/science.255.5046.848; INOUE T, 1983, SCIENCE, V219, P859, DOI 10.1126/science.6186026; KANAVARIOTI A, 1992, J THEOR BIOL, V158, P207, DOI 10.1016/S0022-5193(05)80719-2; Kauffman S.A., 1993, ORIGINS ORDER; LI T, 1994, NATURE, V369, P218, DOI 10.1038/369218a0; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; SZATHMARY E, 1991, TRENDS ECOL EVOL, V6, P366, DOI 10.1016/0169-5347(91)90228-P; TERFORT A, 1992, ANGEW CHEM INT EDIT, V31, P654, DOI 10.1002/anie.199206541; TJIVIKUA T, 1990, J AM CHEM SOC, V112, P1249, DOI 10.1021/ja00159a057; von Kiedrowski G., 1993, BIOORG CHEM FRONT, V3, P113; VONKIEDROWSKI G, 1991, ANGEW CHEM INT EDIT, V30, P423, DOI 10.1002/anie.199104231; VONKIEDROWSKI G, 1986, ANGEW CHEM INT EDIT, V25, P932, DOI 10.1002/anie.198609322; VONKIEDROWSKI G, 1989, ANGEW CHEM INT EDIT, V28, P1235, DOI 10.1002/anie.198912351; Wlotzka B., 1992, THESIS U GOTTINGEN; ZIELINSKI WS, 1987, NATURE, V327, P346, DOI 10.1038/327346a0	25	364	378	2	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					221	224		10.1038/369221a0	http://dx.doi.org/10.1038/369221a0			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	8183342				2022-12-01	WOS:A1994NM06700052
J	VITATERNA, MH; KING, DP; CHANG, AM; KORNHAUSER, JM; LOWREY, PL; MCDONALD, JD; DOVE, WF; PINTO, LH; TUREK, FW; TAKAHASHI, JS				VITATERNA, MH; KING, DP; CHANG, AM; KORNHAUSER, JM; LOWREY, PL; MCDONALD, JD; DOVE, WF; PINTO, LH; TUREK, FW; TAKAHASHI, JS			MUTAGENESIS AND MAPPING OF A MOUSE GENE CLOCK, ESSENTIAL FOR CIRCADIAN BEHAVIOR	SCIENCE			English	Article							MESSENGER-RNA LEVELS; SUPRACHIASMATIC NUCLEUS; FUNCTIONAL-ANALYSIS; RHYTHMS; DROSOPHILA; PERIOD; LESIONS; MUTATIONS; PACEMAKER; PRODUCT	In a search for genes that regulate circadian rhythms in mammals, the progeny of mice treated with N-ethyl-N-nitrosourea (ENU) were screened for circadian clock mutations. A semidominant mutation, Clock, that lengthens circadian period and abolishes persistence of rhythmicity was identified. Clock segregated as a single gene that mapped to the midportion of mouse chromosome 5, a region syntenic to human chromosome 4. The power of ENU mutagenesis combined with the ability to clone murine genes by map position provides a generally applicable approach to study complex behavior in mammals.	NORTHWESTERN UNIV, NATL SCI FDN, SCI & TECHNOL CTR BIOL TIMING, DEPT NEUROBIOL & PHYSIOL, EVANSTON, IL 60208 USA; UNIV WISCONSIN, MCARDLE LAB CANC RES, MADISON, WI 53706 USA; UNIV WISCONSIN, GENET LAB, MADISON, WI 53706 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019; Jansen, Heiko T./A-5770-2008	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878; Jansen, Heiko T./0000-0003-0178-396X	NATIONAL CANCER INSTITUTE [P30CA007175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [T32DC000015] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [P30-CA07175] Funding Source: Medline; NIDCD NIH HHS [T32 DC000015] Funding Source: Medline; NIDDK NIH HHS [R01-DK40493] Funding Source: Medline; NINDS NIH HHS [T32 NS071040] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; ASCHOFF J, 1960, COLD SPRING HARB SYM, V25, P11, DOI 10.1101/SQB.1960.025.01.004; Aschoff J, 1981, HDB BEHAVIORAL NEURO, P3, DOI DOI 10.1007/978-1-4615-6552-9_1; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; Bracewell R. N., 1986, HARTLEY TRANSFORM; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DAVIS FC, 1981, J COMP PHYSIOL, V143, P527, DOI 10.1007/BF00609919; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH W, 1993, GENETIC MAPS; Dowse H.B., 1987, Journal of Biological Rhythms, V2, P65, DOI 10.1177/074873048700200106; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; EBIHARA S, 1978, PHYSIOL BEHAV, V20, P795, DOI 10.1016/0031-9384(78)90308-6; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; Enright JT, 1981, HDB BEHAVIORAL NEURO, V4, P11; GAILEY DA, 1991, J COMP PHYSIOL A, V169, P685; GERKEMA MP, 1993, J BIOL RHYTHM, V8, P151, DOI 10.1177/074873049300800205; GERKEMA MP, 1990, J BIOL RHYTHM, V5, P81, DOI 10.1177/074873049000500201; HALL JC, 1990, ANNU REV GENET, V24, P659; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HITOTSUMACHI S, 1985, P NATL ACAD SCI USA, V82, P6619, DOI 10.1073/pnas.82.19.6619; IBUKA N, 1977, BRAIN RES, V122, P33, DOI 10.1016/0006-8993(77)90660-6; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KOZAK CA, 1993, MAMM GENOME, V4, pS72, DOI 10.1007/BF00360831; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LEHMANN U, 1976, INT J CHRONOBIOL, V4, P223; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MICHEL S, 1993, SCIENCE, V259, P239, DOI 10.1126/science.8421785; Ott J., 1991, ANAL HUMAN GENETIC L; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P291, DOI 10.1007/BF01417859; POSSIDENTE B, 1988, BEHAV GENET, V18, P109, DOI 10.1007/BF01067080; POSSIDENTE B, 1982, PHYSIOL BEHAV, V28, P199, DOI 10.1016/0031-9384(82)90126-3; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RINCHIK EM, 1991, TRENDS GENET, V7, P15, DOI 10.1016/0168-9525(91)90016-J; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; ROSBASH M, 1993, CURR OPIN GENE DEV, V3, P301; RUSAK B, 1977, J COMP PHYSIOL, V118, P145, DOI 10.1007/BF00611819; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; SCHEUCH GC, 1982, J COMP PHYSIOL, V149, P333, DOI 10.1007/BF00619149; SCHWARTZ WJ, 1990, J NEUROSCI, V10, P3685; SCHWARTZ WJ, 1991, PHYSIOL BEHAV, V49, P1283, DOI 10.1016/0031-9384(91)90364-T; SHEDLOVSKY A, 1986, GENET RES, V47, P135, DOI 10.1017/S0016672300022977; SILVER J, 1977, J COMP NEUROL, V176, P589, DOI 10.1002/cne.901760409; SMITH RF, 1982, MOL GEN GENET, V185, P30, DOI 10.1007/BF00333786; SOKOLOVE PG, 1978, J THEOR BIOL, V72, P131, DOI 10.1016/0022-5193(78)90022-X; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1992, SCIENCE, V258, P238, DOI 10.1126/science.1384127; TUREK FW, 1994, RECENT PROG HORM RES, V49, P43; VANDENPOL AN, 1979, BRAIN RES, V160, P307, DOI 10.1016/0006-8993(79)90427-X; YOUNG MW, 1993, MOL GENETICS BIOL RH	53	1212	1256	6	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 29	1994	264	5159					719	725		10.1126/science.8171325	http://dx.doi.org/10.1126/science.8171325			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171325	Green Accepted			2022-12-01	WOS:A1994NH71300037
J	ALPER, S; DUNCAN, L; LOSICK, R				ALPER, S; DUNCAN, L; LOSICK, R			AN ADENOSINE NUCLEOTIDE SWITCH CONTROLLING THE ACTIVITY OF A CELL-TYPE-SPECIFIC TRANSCRIPTION FACTOR IN BACILLUS-SUBTILIS	CELL			English	Article							POLYMERASE SIGMA-FACTOR; BACILLUS-SUBTILIS; RNA-POLYMERASE; GENE-EXPRESSION; SPORULATION; SPOIIA; LOCUS; TRANSFORMATION; ACTIVATION; PROMOTER	The sigma(F) factor establishes cell type-specific gene transcription during sporulation in B. subtilis. sigma(F) is negatively regulated by SpoIIAB, which forms complexes with of or SpoIIAA. ATP and its nonhydrolyzable analogs stimulate the formation of the SpoIIAB.sigma(F) complex, whereas ADP stimulates the formation of the SpoIIAB.SpoIIAA complex. Which protein SpoIIAB associates with is determined by the concentrations of the two nucleotides, on which basis we propose a partner-switching model for the regulation of sigma(F): [GRAPHICS] Consistent with this model, SpollAA reverses SpoIIAB-mediated inhibition of sigma(F)-directed transcription in a manner that depends on ADP. Cell-specific activation of of could be due to an alteration in adenosine nucleotide levels in one cell of the sporangium.			ALPER, S (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,BIOL LABS,CAMBRIDGE,MA 02138, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018568, R37GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON DE, 1969, ANNU REV MICROBIOL, V23, P47, DOI 10.1146/annurev.mi.23.100169.000403; BENSON AK, 1993, P NATL ACAD SCI USA, V90, P2330, DOI 10.1073/pnas.90.6.2330; BENSON AK, 1992, J BACTERIOL, V174, P749, DOI 10.1128/jb.174.3.749-757.1992; BINNIE C, 1986, P NATL ACAD SCI USA, V83, P5943, DOI 10.1073/pnas.83.16.5943; BOYLAN SA, 1992, J BACTERIOL, V174, P3695, DOI 10.1128/JB.174.11.3695-3706.1992; BOYLAN SA, 1994, IN PRESS J BACTERIOL; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; DELENCASTRE H, 1979, J GEN MICROBIOL, V114, P377, DOI 10.1099/00221287-114-2-377; DUFOUR A, 1994, J BACTERIOL, V176, P1813, DOI 10.1128/jb.176.7.1813-1820.1994; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; DUNCAN ML, 1987, J BACTERIOL, V169, P771, DOI 10.1128/jb.169.2.771-778.1987; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; GHOLAMHOSEINIAN A, 1989, J BACTERIOL, V171, P5747, DOI 10.1128/jb.171.10.5747-5749.1989; GUFFANTI AA, 1987, J BACTERIOL, V169, P4469, DOI 10.1128/jb.169.10.4469-4478.1987; HALDENWANG WG, 1980, P NATL ACAD SCI-BIOL, V77, P7000, DOI 10.1073/pnas.77.12.7000; HAROLD FM, 1972, BACTERIOL REV, V36, P172, DOI 10.1128/MMBR.36.2.172-230.1972; HECKER M, 1989, FEMS MICROBIOL LETT, V59, P125; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HUTCHISON KW, 1974, J BACTERIOL, V119, P70, DOI 10.1128/JB.119.1.70-75.1974; IGO MM, 1986, J MOL BIOL, V191, P615, DOI 10.1016/0022-2836(86)90449-3; JOLLIFFE LK, 1981, CELL, V25, P753, DOI 10.1016/0092-8674(81)90183-5; KALMAN S, 1990, J BACTERIOL, V172, P5575, DOI 10.1128/jb.172.10.5575-5585.1990; KARMAZYNCAMPELLI C, 1989, GENE DEV, V3, P150, DOI 10.1101/gad.3.2.150; KLOFAT W, 1969, J BIOL CHEM, V244, P3270; LIU HM, 1982, J GEN MICROBIOL, V128, P2805; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MARGOLIS P, 1993, THESIS HARVARD U CAM; Miller JH., 1972, EXPT MOL GENETICS; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PARTRIDGE SR, 1991, MOL MICROBIOL, V5, P757, DOI 10.1111/j.1365-2958.1991.tb00746.x; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHEN LC, 1968, BIOCHEMISTRY-US, V7, P4041, DOI 10.1021/bi00851a035; SINGH RP, 1977, J BACTERIOL, V130, P1130, DOI 10.1128/JB.130.3.1130-1138.1977; SOLS A, 1981, CURR TOP CELL REGUL, V19, P77; STADTMAN ER, 1970, ENZYMES, P397; STRAGIER P, 1993, REGULATION BACTERIAL, P139; SUN DX, 1991, J BACTERIOL, V173, P2977, DOI 10.1128/JB.173.9.2977-2984.1991; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VOLKER U, 1994, IN PRESS J GEN MICRO; YI F, 1991, J BIOL CHEM, V266, P3900; YOUNT RG, 1975, ADV ENZYMOL RAMB, V43, P1; YOUSTEN AA, 1972, J BACTERIOL, V109, P886, DOI 10.1128/JB.109.2.886-894.1972; YUDKIN MD, 1985, J GEN MICROBIOL, V131, P959; ZHENG LB, 1992, J MOL BIOL, V226, P1037, DOI 10.1016/0022-2836(92)91051-P	49	198	200	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					195	205		10.1016/0092-8674(94)90312-3	http://dx.doi.org/10.1016/0092-8674(94)90312-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168129				2022-12-01	WOS:A1994NH63400005
J	GOLUB, TR; BARKER, GF; LOVETT, M; GILLILAND, DG				GOLUB, TR; BARKER, GF; LOVETT, M; GILLILAND, DG			FUSION OF PDGF RECEPTOR-BETA TO A NOVEL ETS-LIKE GENE, TEL, IN CHRONIC MYELOMONOCYTIC LEUKEMIA WITH T(512) CHROMOSOMAL TRANSLOCATION	CELL			English	Article							TYROSINE KINASE RECEPTOR; GROWTH-FACTOR RECEPTORS; MYELODYSPLASTIC SYNDROMES; TRANSFORMING GENE; MYELOID-LEUKEMIA; C-FMS; DROSOPHILA; ACTIVATION; BINDING; FAMILY	Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome characterized by abnormal clonal myeloid proliferation and by progression to acute myelogenous leukemia (AML). CMML thus offers an opportunity to study early genetic events in the transition to AML. A recently recognized subgroup of CMML has a t(5;12)(q33;p13) balanced translocation. We report that the consequence of the t(5;12) translocation is expression of a fusion transcript in which the tyrosine kinase domain of the platelet-derived growth factor receptor beta (PDGFR beta) on chromosome 5 is coupled to a novel ets-like gene, tel, on chromosome 12. The tel-PDGFR beta fusion demonstrates the oncogenic potential of PDGFR beta and may provide a paradigm for early events in the pathogenesis of AML.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL & ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR,DALLAS,TX 75235	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	GOLUB, TR (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL & ONCOL,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R29CA057261] Funding Source: NIH RePORTER; NCI NIH HHS [CA-57261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BARKER GF, 1991, MOL CELL BIOL, V11, P60; BARTRAM CR, 1992, MYELODYSPLASTSIC SYN, P557; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BERKOWICZ M, 1991, CANCER GENET CYTOGEN, V51, P277, DOI 10.1016/0165-4608(91)90142-H; BIRREN BW, 1989, ANAL BIOCHEM, V177, P282, DOI 10.1016/0003-2697(89)90052-3; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BUSQUE L, 1993, BLOOD, V82, P337; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLARK RA, 1991, CURRENT PROTOCOLS IM; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; ERICKSON P, 1992, BLOOD, V80, P1825; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GANSER A, 1992, MYLEODYSPLASTIC SYND, P607; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; KEENE P, 1987, BRIT J HAEMATOL, V67, P25, DOI 10.1111/j.1365-2141.1987.tb02291.x; KNAPP RH, 1985, MAYO CLIN PROC, V60, P507, DOI 10.1016/S0025-6196(12)60566-7; KOEFFLER HP, 1992, MYELODYSPLASTIC SYND; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KOZU T, 1993, BLOOD, V82, P1270; LERZA R, 1992, BRIT J HAEMATOL, V82, P476, DOI 10.1111/j.1365-2141.1992.tb06450.x; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MECUCCI C, 1992, MYELODYSPLASTIC SYND, P523; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MORRIS SW, 1992, GENE CHROMOSOME CANC, V5, P385, DOI 10.1002/gcc.2870050414; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NUCIFORA G, 1993, BLOOD, V81, P883; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PANTAZIS P, 1991, P NATL ACAD SCI USA, V88, P2481, DOI 10.1073/pnas.88.6.2481; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RAO VN, 1993, ONCOGENE, V8, P2167; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROCHFORD R, 1990, MOL CELL BIOL, V10, P4996, DOI 10.1128/MCB.10.9.4996; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROSNET O, 1991, ONCOGENE, V6, P1641; ROWLEY JD, 1981, BLOOD, V58, P759; SALTMAN DL, 1993, GENOMICS, V16, P726, DOI 10.1006/geno.1993.1254; SAMBROOK J, 1989, MOL LABORATORY MANUA; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SETH A, 1990, ONCOGENE, V5, P1761; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SRIVASTAVA A, 1988, CANCER GENET CYTOGEN, V35, P61, DOI 10.1016/0165-4608(88)90123-9; THE SM, 1992, ONCOGENE, V7, P2471; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TIGHE JE, 1993, BLOOD, V81, P592; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VALIUS B, 1993, CELL, V73, P321; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WESSELS JW, 1993, CANCER GENET CYTOGEN, V65, P7, DOI 10.1016/0165-4608(93)90051-M; YAN XQ, 1994, ONCOGENE, V9, P163; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YUNIS JJ, 1986, BLOOD, V67, P1721	68	1036	1083	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					307	316		10.1016/0092-8674(94)90322-0	http://dx.doi.org/10.1016/0092-8674(94)90322-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168137				2022-12-01	WOS:A1994NH63400015
J	HEMMATIBRIVANLOU, A; KELLY, OG; MELTON, DA				HEMMATIBRIVANLOU, A; KELLY, OG; MELTON, DA			FOLLISTATIN, AN ANTAGONIST OF ACTIVIN, IS EXPRESSED IN THE SPEMANN ORGANIZER AND DISPLAYS DIRECT NEURALIZING ACTIVITY	CELL			English	Article							XENOPUS EMBRYOS; BINDING PROTEIN; AMPHIBIAN DEVELOPMENT; PORCINE FOLLISTATIN; MESODERM INDUCTION; MESSENGER-RNAS; EARLY RESPONSE; LAEVIS; GENE; DIFFERENTIATION	In the accompanying paper, we show that the expression of a dominant negative activin receptor can convert prospective ectoderm into neural tissue, which suggests that activin is an inhibitor of neuralization. Here we report the isolation and characterization of an activin antagonist, follistatin,that can induce neural tissue directly in vivo. Follistatin RNA is localized in the Spemann organizer and notochord, tissues known to be potent neural inducers. We demonstrate that follistatin RNA and protein are able to block the activity of activin in embryonic explants. Furthermore, we show that follistatin RNA directly neuralizes ectodermal explants in the absence of detectable mesoderm. Thus, follistatin is present at the correct time and location to play a role in neural induction in vivo.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BRADLEY LC, 1993, MECH DEVELOP, V40, P73, DOI 10.1016/0925-4773(93)90089-G; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CONDIE BG, 1987, DEVELOPMENT, V101, P93; FERREIRO B, 1993, MECH DEVELOP, V40, P25, DOI 10.1016/0925-4773(93)90085-C; FUKUI A, 1993, DEV BIOL, V159, P131, DOI 10.1006/dbio.1993.1227; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GIMLICH RL, 1983, NATURE, V306, P471, DOI 10.1038/306471a0; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HASHIMOTO M, 1992, J BIOL CHEM, V267, P7203; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1992, NEURON, V9, P417, DOI 10.1016/0896-6273(92)90180-L; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOGAWA K, 1991, ENDOCRINOLOGY, V128, P1434, DOI 10.1210/endo-128-3-1434; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; MALACINSKI G, 1975, DEV BIOL, V56, P24; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NIEUWKOOP PD, 1985, J EMBRYOL EXP MORPH, V89, P333; OTTE AP, 1992, CELL, V68, P1021, DOI 10.1016/0092-8674(92)90074-M; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; Ruiz i Altaba A., 1993, CURR OPIN GENE DEV, V3, P633; SAHA MS, 1993, MOL BRAIN RES, V17, P307, DOI 10.1016/0169-328X(93)90016-I; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXEN L, 1989, International Journal of Developmental Biology, V33, P21; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V152, P717, DOI 10.1016/S0006-291X(88)80097-4; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; Spemann H., 1938, EMBRYONIC DEV INDUCT; SPERMANN H, 1924, ROUXS ARCH ENTW MECH, V100, P599; Stern C D, 1993, EXS, V65, P369; SUGINO K, 1993, J BIOL CHEM, V268, P15579; TASHIRO K, 1991, BIOCHEM BIOPH RES CO, V174, P1022, DOI 10.1016/0006-291X(91)91521-D; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VANDENEIJNDENVANRAAIJ AJM, 1991, MECH DEVELOP, V33, P157, DOI 10.1016/0925-4773(91)90082-H; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	54	569	587	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					283	295		10.1016/0092-8674(94)90320-4	http://dx.doi.org/10.1016/0092-8674(94)90320-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168135				2022-12-01	WOS:A1994NH63400013
J	BROWN, DWG; RAMSAY, MEB; RICHARDS, AF; MILLER, E				BROWN, DWG; RAMSAY, MEB; RICHARDS, AF; MILLER, E			SALIVARY DIAGNOSIS OF MEASLES - A STUDY OF NOTIFIED CASES IN THE UNITED-KINGDOM, 1991-3	BRITISH MEDICAL JOURNAL			English	Article							VACCINE FAILURE; RISK-FACTORS; MUMPS	Objectives-To validate a method for salivary diagnosis of measles and to assess the diagnostic accuracy of notified cases of measles. Design-Blood and saliva samples were collected within 90 days of onset of symptoms from patients clinically diagnosed as having measles and tested for specific IgM by antibody capture radioimmunoassay. Setting-17 districts in England and one in southern Ireland during August 1991 to February 1993. Subjects-236 children and adults with measles notified by a general practitioner. Results-Specific IgM was detected in serum in only 85 (36%) of the 236 cases. In cases associated with outbreaks and tested within six weeks of onset, 53/57 (93%) of samples were IgM positive, thereby confirming the sensitivity of serum IgM detection as a marker of recent infection. The serological confirmation rate was lower in cases with a documented history of vaccination (13/87; 15%) than in those without (70/149; 47%) and varied with age, being lowest in patients under a year, of whom only 4/36 (11%) were confirmed. Measles specific IgM was detected in 71/77 (92%) of adequate saliva samples collected from patients with serum positive for IgM. In cases where measles was not confirmed, 6/101 had rubella specific IgM and 5/132 had human parvovirus B19 specific IgM detected in serum. Conclusions-The existing national surveillance system for measles, which relies on clinically diagnosed cases, lacks the precision required for effective disease control. Saliva is a valid alternative to serum for IgM detection, and salivary diagnosis could play a major role in achieving measles elimination. Rubella and parvovirus B19 seem to be responsible for a minority of incorrectly diagnosed cases of measles in the United Kingdom and other infectious causes of measles-like illness need to be sought.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON NW9 5EQ,ENGLAND; CENT PUBL HLTH LAB,PHLS,DIV VIRUS REFERENCE,DIV ENTER & RESP VIRUS,LONDON NW9 5HT,ENGLAND	Public Health England; Public Health England			Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				CARTER H, 1992, BRIT MED J, V304, P637, DOI 10.1136/bmj.304.6827.637; COHEN BJ, 1983, J HYG-CAMBRIDGE, V91, P113, DOI 10.1017/S0022172400060095; FARACLEGAN H, 1987, J INFECT DIS, V155, P1073; FARRINGTON CP, 1993, INT J EPIDEMIOL, V22, P742, DOI 10.1093/ije/22.4.742; HINMAN AR, 1983, REV INFECT DIS, V5, P538; HULL HF, 1985, PEDIATRICS, V76, P518; MILLER E, 1992, BMJ-BRIT MED J, V304, P1440, DOI 10.1136/bmj.304.6839.1440-b; MORTIMER PP, 1991, REV MED VIROL, V1, P73; PERRY KR, 1993, J MED VIROL, V40, P235, DOI 10.1002/jmv.1890400312; REYES MA, 1987, PEDIATR INFECT DIS J, V6, P848, DOI 10.1097/00006454-198709000-00012; ROBERTSON SE, 1992, PUBLIC HEALTH REP, V107, P24; White J M, 1993, Commun Dis Rep CDR Rev, V3, pR71; 1977, LANCET, V2, P571; 1966, SBL607 DEP HLTH STAT; 1990, KC51 DEP HLTH STAT D; 1988, IMMUNISATION INFECTI	16	106	108	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 16	1994	308	6935					1015	1017		10.1136/bmj.308.6935.1015	http://dx.doi.org/10.1136/bmj.308.6935.1015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167513	Green Published			2022-12-01	WOS:A1994NH08900020
J	SULTAN, AH; KAMM, MA; HUDSON, CN; BARTRAM, CI				SULTAN, AH; KAMM, MA; HUDSON, CN; BARTRAM, CI			3RD DEGREE OBSTETRIC ANAL-SPHINCTER TEARS - RISK-FACTORS AND OUTCOME OF PRIMARY REPAIR	BRITISH MEDICAL JOURNAL			English	Article							FECAL INCONTINENCE; VAGINAL DELIVERY; EPISIOTOMY; INJURY; ENDOSONOGRAPHY; LACERATIONS; INSTRUMENT	Objectives-To determine (i) risk factors in the development of third degree obstetric tears and (ii) the success of primary sphincter repair. Design-(i) Retrospective analysis of obstetric variables in 50 women who had sustained a third degree tear, compared with the remaining 8553 vaginal deliveries during the same period. (ii) Women who had sustained a third degree tear and had primary sphincter repair and control subjects were interviewed and investigated with anal endosonography, anal manometry, and pudendal nerve terminal motor latency measurements. Setting-Antenatal clinic in teaching hospital in inner London. Subjects-(i) All women (n = 6603) who delivered vaginally over a 31 month period. (ii) 34 women who sustained a third degree tear and 88 matched controls. Main outcome measures-Obstetric risk factors, defaecatory symptoms, sonographic sphincter defects, and pudendal nerve damage. Results-(i) Factors significantly associated with development of a third degree tear were: forceps delivery (50% v 7% in controls; P = 0.00001), primiparous delivery (85% v 43%; P = 0.00001), birth weight > 4 kg (P = 0.00002), and occipitoposterior position at delivery (P = 0.003). No third degree tear occurred during 351 vacuum extractions. Eleven of 25 (44%) women who were delivered without instruments and had a third degree tear did so despite a posterolateral episiotomy. (ii) Anal incontinence or faecal urgency was present in 16 women with tears and 11 controls (47% v 13%; P = 0.00001). Sonographic sphincter defects were identified in 29 with tears and 29 controls (85% v 33%; P = 0.00001). Every symptomatic patient had persistent combined internal and external sphincter defects, and these were associated with significantly lower anal pressures. Pudendal nerve terminal motor latency measurements were not significantly different. Conclusions-Vacuum extraction is associated with fewer third degree tears than forceps delivery. An episiotomy does not always prevent a third degree tear. Primary repair is inadequate in most women who sustain third degree tears, most having residual sphincter defects and about half experiencing anal incontinence, which is caused by persistent mechanical sphincter disruption rather than pudendal nerve damage. Attention should be directed towards preventive obstetric practice and surgical techniques of repair.	ST MARKS HOSP,LONDON EC1V 2PS,ENGLAND; ST BARTHOLOMEWS HOMERTON HOSP,LONDON E9 6SR,ENGLAND	Imperial College London; University of London; Queen Mary University London								BARTER RH, 1960, AM J OBSTET GYNECOL, V80, P654, DOI 10.1016/0002-9378(60)90573-1; BEK KM, 1992, BRIT J OBSTET GYNAEC, V99, P724, DOI 10.1111/j.1471-0528.1992.tb13870.x; BLAISDELL PC, 1940, SURG GYNECOL OBSTET, V70, P692; BROWNING GGP, 1983, BRIT MED J, V286, P1873, DOI 10.1136/bmj.286.6381.1873; BURNETT SJD, 1991, BRIT J RADIOL, V64, P225, DOI 10.1259/0007-1285-64-759-225; CHALMERS JA, 1989, BRIT J OBSTET GYNAEC, V96, P505, DOI 10.1111/j.1471-0528.1989.tb03246.x; COMBS CA, 1990, AM J OBSTET GYNECOL, V163, P100, DOI 10.1016/S0002-9378(11)90678-4; CORMAN ML, 1980, SURG CLIN N AM, V60, P457; Fischer S R, 1979, J Nurse Midwifery, V24, P18, DOI 10.1016/0091-2182(79)90189-7; FLEMING AR, 1960, OBSTET GYNECOL, V16, P172; FRENCKNER B, 1975, GUT, V16, P482, DOI 10.1136/gut.16.6.482; GASS MS, 1986, J REPROD MED, V31, P240; GREEN JR, 1989, OBSTET GYNECOL, V73, P732; HAADEM K, 1991, OBSTET GYNECOL, V78, P823; HENRIKSEN TB, 1992, BRIT J OBSTET GYNAEC, V99, P950, DOI 10.1111/j.1471-0528.1992.tb13695.x; INGRAHAM HA, 1949, AM J OBSTET GYNECOL, V57, P730, DOI 10.1016/0002-9378(49)90713-9; JOHANSON RB, 1993, BRIT J OBSTET GYNAEC, V100, P524, DOI 10.1111/j.1471-0528.1993.tb15301.x; LARSSON PG, 1991, GYNECOL OBSTET INVES, V31, P213, DOI 10.1159/000293161; LAW PJ, 1989, GASTROINTEST RADIOL, V14, P349, DOI 10.1007/BF01889235; NEILSON MB, 1992, BRIT J SURG, V79, P104; OLEARY JL, 1965, OBSTET GYNECOL, V25, P235; ORROM WJ, 1990, BRIT J SURG, V77, P876, DOI 10.1002/bjs.1800770810; PEZIM ME, 1987, DIS COLON RECTUM, V30, P521, DOI 10.1007/BF02554781; ROGERS J, 1988, GUT, V29, P1131, DOI 10.1136/gut.29.8.1131; SIEBER EH, 1962, OBSTET GYNECOL, V19, P677; SLEEP J, 1984, BRIT MED J, V289, P587, DOI 10.1136/bmj.289.6445.587; SORENSEN SM, 1988, ACTA OBSTET GYN SCAN, V67, P315, DOI 10.1111/j.1600-0412.1988.tb07806.x; SULTAN AH, 1993, INT J GYNECOL OBSTET, V43, P263, DOI 10.1016/0020-7292(93)90514-W; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SULTAN AH, 1993, BRIT J SURG, V80, P508, DOI 10.1002/bjs.1800800435; Sultan AH, 1994, CONT REV OBSTET GYNA, V6, P18; SULTAN AH, 1993, ATLAS GASTROINTESTIN, P115; SULTAN AH, IN PRESS DIS COLON R; SULTAN AH, IN PRESS BR J SURG; SWSH M, 1992, COLOPROCTOLOGY PELVI, P196; Thacker S B, 1983, Obstet Gynecol Surv, V38, P322, DOI 10.1097/00006254-198306000-00003; THORP JM, 1989, AM J OBSTET GYNECOL, V160, P1027, DOI 10.1016/0002-9378(89)90152-X	37	526	537	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					887	891		10.1136/bmj.308.6933.887	http://dx.doi.org/10.1136/bmj.308.6933.887			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173367	Green Published			2022-12-01	WOS:A1994NE60000020
J	CLARK, LR				CLARK, LR			JOSHUA KNEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2902	2902		10.1001/jama.270.24.2902	http://dx.doi.org/10.1001/jama.270.24.2902			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM119	8254837				2022-12-01	WOS:A1993MM11900002
J	TELZAK, EE; CHIASSON, MA; BEVIER, PJ; STONEBURNER, RL; CASTRO, KG; JAFFE, HW				TELZAK, EE; CHIASSON, MA; BEVIER, PJ; STONEBURNER, RL; CASTRO, KG; JAFFE, HW			HIV-1 SEROCONVERSION IN PATIENTS WITH AND WITHOUT GENITAL ULCER DISEASE - A PROSPECTIVE-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS SEROPOSITIVITY; CHANCROID; SYPHILIS; HERPES GENITALIS	HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED DISEASES; RISK-FACTORS; INFECTION; TRANSMISSION; TYPE-1; MEN; AFRICA; FEMALE; AIDS	Objective: To determine the relative risk for human immunodeficiency virus (HIV-1) seroconversion in patients with and without genital ulcers caused by chancroid, syphilis, and herpes. Design: A prospective cohort study Setting: An inner-city, sexually transmitted disease clinic. Patients: Patients seronegative for HIV-1 with and without genital ulcers who were followed for a minimum of 3 months. Interventions: Questionnaire to obtain data on demographics, sexual behavior, and illicit drug use; testing for HIV-1 at entry and at a minimum of 3 months after entry; medical examination for the presence or absence of genital ulcer disease. Results: Overall, 758 heterosexual men with no history of injection drug use completed the study; HIV-1 seroconversion occurred in 10 of 344 (2.9%; 95% CI, 1.4% to 5.3%) men with a genital ulcer and in 4 of 414 (1%; CI, 0.2% to 2.5%) without a genital ulcer (relative risk, 3.0; P = 0.05). In a multiple logistic regression analysis, those men with chancroid and a new sexually transmitted disease during follow-up each had about three times the risk for HIV-1 seroconversion (P less-than-or-equal-to 0.04). Conclusions: In this group of heterosexual men, chancroid and repeated acquisition of sexually transmitted diseases appeared to facilitate the sexual transmission of HIV-1.	NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA	TELZAK, EE (corresponding author), ALBERT EINSTEIN COLL MED, BRONX LEBANON HOSP CTR, DIV INFECT DIS, 1650 GRAND CONCOURSE, BRONX, NY 10457 USA.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354	PHS HHS [U64/CCU203312] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CAMERON DW, 1989, LANCET, V2, P403; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; CHIASSON MA, 1990, AM J EPIDEMIOL, V131, P208, DOI 10.1093/oxfordjournals.aje.a115491; GREENBLATT RM, 1988, AIDS, V2, P47, DOI 10.1097/00002030-198802000-00008; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; OBERHOFER TR, 1982, J CLIN MICROBIOL, V15, P625, DOI 10.1128/JCM.15.4.625-629.1982; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; QUINN TC, 1986, SCIENCE, V234, P955, DOI 10.1126/science.3022379; SCHMID GP, 1987, JAMA-J AM MED ASSOC, V258, P3265, DOI 10.1001/jama.258.22.3265; SHELDON WH, 1946, AM J PATHOL, V22, P415; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; STAMM WE, 1988, JAMA-J AM MED ASSOC, V260, P1429, DOI 10.1001/jama.260.10.1429; 1990, 5TH CONC C TEST HUM; 1991, MMWR MORBID MORTAL W, V40, P357; 1991, MMWR MORBID MORTAL W, V40, P369; 1989, MMWR MORBID MORTAL W, V38, P165	20	136	138	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1181	1186		10.7326/0003-4819-119-12-199312150-00005	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239249				2022-12-01	WOS:A1993MM12100005
J	SULLENGER, BA; CECH, TR				SULLENGER, BA; CECH, TR			TETHERING RIBOZYMES TO A RETROVIRAL PACKAGING SIGNAL FOR DESTRUCTION OF VIRAL-RNA	SCIENCE			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; CONSTRUCTION; SEQUENCES; SAFE; LINE	Cellular compartmentalization of RNAs is thought to influence their susceptibility to ribozyme cleavage. As a test of this idea, two retroviral vectors-one encoding a hammer-head ribozyme designed to cleave lacZ transcripts and another encoding the lacZ messenger RNA-were coexpressed inside retroviral packaging cells. Because of the retroviral packaging signal, the ribozyme would be expected to colocalize with the lacZ-containing viral genomic RNA but not with the lacZ messenger RNA. The ribozyme was found to reduce the titer of infectious virus containing lacZ by 90 percent, but had no effect on translation of lacZ messenger RNA. These results indicate that sorting gene inhibitors to appropriate intracellular sites may increase their effectiveness.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; CECH TR, 1992, J BIOL CHEM, V267, P17479; COFFIN JM, 1984, RNA TUMOR VIRUSES 1, P261; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; FERAMISCO JJ, 1982, P NATL ACAD SCI USA, V257, P11024; GOFF SP, 1989, RETROVIRUSES DISEASE, P1; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; LAWRENCE JB, 1990, P NATL ACAD SCI USA, V87, P5420, DOI 10.1073/pnas.87.14.5420; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; RAAP AK, 1991, EXP CELL RES, V197, P319, DOI 10.1016/0014-4827(91)90439-2; ROSSI J J, 1992, Current Opinion in Biotechnology, V3, P3, DOI 10.1016/0958-1669(92)90117-2; SANES J, 1985, EMBO J, V5, P3133; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SMITH C, 1993, LEUKEMIA, V7, P310; SULLENGER BA, UNPUB; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901	25	182	231	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1566	1569		10.1126/science.8248806	http://dx.doi.org/10.1126/science.8248806			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248806				2022-12-01	WOS:A1993MK32900039
J	MAHY, BWJ; ALMOND, JW; BERNS, KI; CHANOCK, RM; LVOV, DK; PETTERSSON, RF; SCHATZMAYR, HG; FENNER, F				MAHY, BWJ; ALMOND, JW; BERNS, KI; CHANOCK, RM; LVOV, DK; PETTERSSON, RF; SCHATZMAYR, HG; FENNER, F			THE REMAINING STOCKS OF SMALLPOX VIRUS SHOULD BE DESTROYED	SCIENCE			English	Article							DNA		DI IVANOVSKII INST VIROL,MOSCOW,RUSSIA; LUDWIG INST CANC RES,STOCKHOLM,SWEDEN; OSWALDO CRUZ FDN,DEPT VIROL,RIO JANEIRO,BRAZIL; UNIV READING,SCH ANIM & MICROBIAL SCI,READING RG6 2AH,BERKS,ENGLAND; CORNELL UNIV,MED CTR,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021; NIAID,INFECT DIS LAB,BETHESDA,MD 20892; KAROLINSKA INST,S-10401 STOCKHOLM 60,SWEDEN; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,CANBERRA,ACT 2601,AUSTRALIA	Russian Academy of Medical Sciences; Gamaleya National Research Center for Epidemiology & Microbiology, RAMS; Ludwig Institute for Cancer Research; Fundacao Oswaldo Cruz; University of Reading; Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Karolinska Institutet; Australian National University; John Curtin School of Medical Research	MAHY, BWJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333, USA.			Lvov, D.K./0000-0001-8176-6582				[Anonymous], 1980, REPORT INVESTIGATION; ARITA I, 1979, NATURE, V279, P293, DOI 10.1038/279293a0; DEQUADROS CA, 1992, ANNU REV PUBL HEALTH, V13, P239, DOI 10.1146/annurev.publhealth.13.1.239; DEQUADROS CA, 1988, GLOBAL ERADICATION P; ESPOSITO JJ, 1978, VIROLOGY, V89, P53, DOI 10.1016/0042-6822(78)90039-9; ESPOSITO JJ, 1985, VIROLOGY, V143, P230, DOI 10.1016/0042-6822(85)90111-4; Fenner F., 1988, SMALLPOX ITS ERADICA; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; Hopkins Donald R., 1993, P687, DOI 10.1017/CHOL9780521332866.100; HOPKINS DR, 1983, EPIDEMIOL REV, V5, P208, DOI 10.1093/oxfordjournals.epirev.a036259; HUGHES JM, IN PRESS SCIENCE; MACKETT M, 1979, J GEN VIROL, V45, P683, DOI 10.1099/0022-1317-45-3-683; MAHY BWJ, 1991, ASM NEWS, V57, P577; MASSUNG RF, IN PRESS NATURE; SCHCHELKUNOV SN, 1993, CONCEPTS VIROLOGY IV, P93; 1986, WEEKLY EPIDEMIOLOGIC, V61, P289	16	31	31	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1223	1224		10.1126/science.8235651	http://dx.doi.org/10.1126/science.8235651			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235651				2022-12-01	WOS:A1993MH32400026
J	YANG, J; ELLINOR, PT; SATHER, WA; ZHANG, JF; TSIEN, RW				YANG, J; ELLINOR, PT; SATHER, WA; ZHANG, JF; TSIEN, RW			MOLECULAR DETERMINANTS OF CA2+ SELECTIVITY AND ION PERMEATION IN L-TYPE CA2+ CHANNELS	NATURE			English	Article							SENSITIVE CALCIUM-CHANNEL; MONO-VALENT CATIONS; CONCENTRATION-DEPENDENCE; FUNCTIONAL EXPRESSION; K+ CHANNEL; PORE; MUTATIONS; BINDING; BLOCKADE; VOLTAGE	VOLTAGE-GATED Ca2+ channels link changes in membrane potential to the delivery of Ca2+, a key second messenger for many cellular responses1. Ca2+ channels show selectivity for Ca2+ over more plentiful ions such as Na+ or K+ by virtue of their high-affinity binding of Ca2+ within the pore2-6. It has been suggested that this binding involves four conserved glutamate residues7-10 in equivalent positions in the putative pore-lining regions of repeats I-IV in the Ca2+ channel alpha1 subunit. We have carried out a systematic series of single amino-acid substitutions in each of these positions and find that all four glutamates participate in high-affinity binding of Ca2+ or Cd2+. Each glutamate carboxylate makes a distinct contribution to ion binding, with the carboxylate in repeat III having the strongest effect. Some single glutamate-to-lysine mutations completely abolish micromolar Ca2+ block, indicating that the pore does not possess any high-affinity binding site that acts independently of the four glutamate residues. The prevailing model of Ca2+ permeation2,3 must thus be modified to allow binding of two Ca2+ ions in close proximity11,12, within the sphere of influence of the four glutamates. The functional inequality of the glutamates may be advantageous in allowing simultaneous interactions with multiple Ca2+ ions moving single-file within the pore. Competition among Ca2+ ions for individual glutamates11,12, together With repulsive ion-ion electrostatic interaction2,3, may help achieve rapid flux rates through the channel2-5.	STANFORD UNIV, MED CTR, BECKMAN CTR, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University				Ellinor, Patrick/0000-0002-2067-0533; Sather, William/0000-0003-1482-8055				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ARMSTRONG CM, 1991, ANN NY ACAD SCI, V635, P18, DOI 10.1111/j.1749-6632.1991.tb36477.x; CHOW RH, 1992, J GEN PHYSIOL, V98, P483; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FUKUSHIMA Y, 1985, J PHYSIOL-LONDON, V358, P255, DOI 10.1113/jphysiol.1985.sp015550; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HESS P, 1986, J GEN PHYSIOL, V88, P293, DOI 10.1085/jgp.88.3.293; Hille B., 1992, IONIC CHANNELS EXCIT; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KOSTYUK PG, 1983, J MEMBRANE BIOL, V76, P83, DOI 10.1007/BF01871455; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KUO CC, 1993, J PHYSIOL-LONDON, V466, P629; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Miller Christopher, 1992, Current Biology, V2, P573, DOI 10.1016/0960-9822(92)90146-2; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; ROSENBERG RL, 1991, J GEN PHYSIOL, V97, P1207, DOI 10.1085/jgp.97.6.1207; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TOMASELLI GF, 1993, CIRC RES, V72, P491, DOI 10.1161/01.RES.72.3.491; Williams R.J.P., 1991, BIOL CHEM ELEMENTS; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZHENG W, 1991, MOL PHARMACOL, V40, P734	30	513	524	0	18	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 11	1993	366	6451					158	161		10.1038/366158a0	http://dx.doi.org/10.1038/366158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232554				2022-12-01	WOS:A1993MG21600058
J	SCHEFFNER, M; HUIBREGTSE, JM; VIERSTRA, RD; HOWLEY, PM				SCHEFFNER, M; HUIBREGTSE, JM; VIERSTRA, RD; HOWLEY, PM			THE HPV-16 E6 AND E6-AP COMPLEX FUNCTIONS AS A UBIQUITIN-PROTEIN LIGASE IN THE UBIQUITINATION OF P53	CELL			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; N-END RULE; RETINOBLASTOMA GENE-PRODUCT; CELLULAR TUMOR-ANTIGEN; CARRIER PROTEIN; SV40-TRANSFORMED CELLS; INVITRO MUTAGENESIS; HUMAN KERATINOCYTES; CONJUGATING ENZYME; TRANSFORMED-CELLS	The ubiquitin-dependent proteolytic pathway plays a major role in selective protein degradation. Ubiquitination of proteins requires the sequential action of the ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzymes (E2), and in some cases ubiquitin-protein ligases (E3s). The oncogenic human papillomavirus (HPV) types 16 and 18 utilize this cellular proteolytic system to target the tumor suppressor protein p53. The HPV E6 oncoprotein binds to a cellular protein of 100 kd, termed E6-associated protein (E6-AP). The E6-E6-AP complex specifically interacts with p53, resulting in the rapid ubiquitin-dependent degradation of p53. Here we report the purification and identification of the factors necessary for the E6-E6-AP-mediated ubiquitination of p53. The ubiquitination of p53 requires the E1 enzyme and a novel E2 in mammalian cells, while E3 activity is conferred by the E6-E6-AP complex. Furthermore, E6-AP appears to have ubiquitin-protein ligase activity in the absence of E6.	UNIV WISCONSIN, DEPT HORT, MADISON, WI 53706 USA; NCI, TUMOR VIRUS BIOL LAB, BETHESDA, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128; Howley, Peter/0000-0002-8668-9579				BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CROOK T, 1991, ONCOGENE, V6, P873; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GIROD PA, 1993, J BIOL CHEM, V268, P955; GIROD PA, 1993, IN PRESS PLANT J, V3; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JABBEN M, 1989, J BIOL CHEM, V264, P4998; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1990, VIROLOGY, V176, P302, DOI 10.1016/0042-6822(90)90258-S; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MUNGER K, 1989, J VIROL, V63, P4417; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PICKART CM, 1988, J BIOL CHEM, V263, P12028; QIN S, 1991, J BIOL CHEM, V266, P15549; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REISS Y, 1990, J BIOL CHEM, V265, P3685; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; VIERSTRA RD, 1993, IN PRESS ANN REV PLA; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WING SS, 1992, J BIOL CHEM, V267, P6495; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	57	1896	1985	3	91	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 5	1993	75	3					495	505		10.1016/0092-8674(93)90384-3	http://dx.doi.org/10.1016/0092-8674(93)90384-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8221889				2022-12-01	WOS:A1993MF83000012
J	CHANG, C; KWOK, SF; BLEECKER, AB; MEYEROWITZ, EM				CHANG, C; KWOK, SF; BLEECKER, AB; MEYEROWITZ, EM			ARABIDOPSIS ETHYLENE-RESPONSE GENE ETR1 - SIMILARITY OF PRODUCT TO 2-COMPONENT REGULATORS	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PROTEINS; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; AGROBACTERIUM-TUMEFACIENS; PLANT TRANSFORMATION; ADAPTIVE RESPONSES; LINKAGE MAP; THALIANA; EXPRESSION; FAMILY	Ethylene behaves as a hormone in plants, regulating such aspects of growth and development as fruit ripening, flower senescence, and abscission. Ethylene insensitivity is conferred by dominant mutations in the ETR1 gene early in the ethylene signal transduction pathway of Arabidopsis thaliana. The ETR1 gene was cloned by the method of chromosome walking. Each of the four known etr1 mutant alleles contains a missense mutation near the amino terminus of the predicted protein. Although the sequence of the amino-terminal half of the deduced ETR1 protein appears to be novel, the carboxyl-terminal half is similar in sequence to both components of the prokaryotic family of signal transducers known as the two-component systems. Thus, an early step in ethylene signal transduction in plants may involve transfer of phosphate as in prokaryotic two-component systems. The dominant etr1-1 mutant gene conferred ethylene insensitivity to wild-type Arabidopsis plants when introduced by transformation.			CHANG, C (corresponding author), CALTECH, DIV BIOL 15629, PASADENA, CA 91125 USA.		Meyerowitz, Elliot M/A-7118-2009					Abeles F.B., 2012, ETHYLENE PLANT BIOL; ALEST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMASINO RM, 1984, MOL GEN GENET, V197, P437, DOI 10.1007/BF00329940; ARICO B, 1991, MOL MICROBIOL, V5, P2481, DOI 10.1111/j.1365-2958.1991.tb02093.x; ARTYMIUK PJ, 1990, PROTEIN ENG, V4, P39, DOI 10.1093/protein/4.1.39; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; Chang C. H., UNPUB; CHEN JM, 1990, INT J PEPT PROT RES, V36, P1; Dayhoff M., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; FRYXELL KJ, 1991, J MOL EVOL, V33, P367, DOI 10.1007/BF02102867; GOESCHL JD, 1966, PLANT PHYSIOL, V41, P877, DOI 10.1104/pp.41.5.877; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HARPHAM NVJ, 1991, ANN BOT-LONDON, V68, P55, DOI 10.1093/oxfordjournals.aob.a088218; HAUGE BM, 1993, PLANT J, V3, P745, DOI 10.1111/j.1365-313X.1993.00745.x; HERMAN L, 1990, MOL GEN GENET, V224, P248, DOI 10.1007/BF00271558; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOLSTERS M, 1978, MOL GEN GENET, V163, P181, DOI 10.1007/BF00267408; HRABAK EM, 1992, J BACTERIOL, V174, P3011, DOI 10.1128/JB.174.9.3011-3020.1992; HUA J, UNPUB; KENED H, ANN REV PLANT PHYSL, V44, P283; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; Koornneef M., 1987, ARABID INF SERV, V1987, P46; Kosambi D. D., 1944, ANN EUGENICS, V12, P172; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUCHI S, 1990, MOL MICROBIOL, V4, P715; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; MA H, 1992, GENE, V117, P161, DOI 10.1016/0378-1119(92)90725-5; MARX J, 1993, SCIENCE, V260, P1588, DOI 10.1126/science.8503004; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; MEYEROWITZ EM, 1993, METHODS ARABIDOPSIS, V3, P745; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAGASAWA S, 1992, MOL MICROBIOL, V6, P799, DOI 10.1111/j.1365-2958.1992.tb01530.x; NAGY F, 1985, EMBO J, V4, P3063, DOI 10.1002/j.1460-2075.1985.tb04046.x; OTA I, 1993, SCIENCE, V262, P124; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POPOV KM, 1992, J BIOL CHEM, V267, P13127; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEIDERPOETSCH HAW, 1992, PHOTOCHEM PHOTOBIOL, V56, P839, DOI 10.1111/j.1751-1097.1992.tb02241.x; SISLER E C, 1977, Tobacco Science, V21, P43; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; TANG JL, 1991, MOL GEN GENET, V226, P409, DOI 10.1007/BF00260653; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOLZ K, 1991, J BIOL CHEM, V266, P15511; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEINSTEIN JN, 1982, J MEMBRANE BIOL, V66, P203, DOI 10.1007/BF01868495; WOLFE AJ, 1993, P NATL ACAD SCI USA, V90, P1518, DOI 10.1073/pnas.90.4.1518; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	65	1180	1272	6	161	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1993	262	5133					539	544		10.1126/science.8211181	http://dx.doi.org/10.1126/science.8211181			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC935	8211181				2022-12-01	WOS:A1993MC93500031
J	BROWN, KE; ANDERSON, SM; YOUNG, NS				BROWN, KE; ANDERSON, SM; YOUNG, NS			ERYTHROCYTE-P ANTIGEN - CELLULAR RECEPTOR FOR B19 PARVOVIRUS	SCIENCE			English	Article							VIRUS; INFECTION; ANTIBODIES; GLOBOSIDE; SYSTEM; FETUS; CELLS	The pathogenic human parvovirus B19 replicates only in erythroid progenitor cells. This virus was shown to bind to blood-group P antigen, as measured by hemagglutination. Erythrocytes lacking P antigen were not agglutinated with B19. Purified P antigen (globoside) blocked the binding of the virus to erythroid cells and the infectivity of the virus in a hematopoietic colony assay. Target cells were protected from infection by preincubation with monoclonal antibody to globoside. Knowledge of a parvovirus receptor has implications for understanding the pathogenesis of parvovirus infections and for the use of parvoviruses in gene therapy.			BROWN, KE (corresponding author), NHLBI, HEMATOL BRANCH, BETHESDA, MD 20892 USA.			Brown, Kevin/0000-0002-1568-683X				ANDERSON MJ, 1983, LANCET, V1, P1378; BROWN KE, 1992, J GEN VIROL, V73, P2147, DOI 10.1099/0022-1317-73-8-2147; BROWN KE, 1989, BRIT J OBSTET GYNAEC, V96, P764, DOI 10.1111/j.1471-0528.1989.tb03313.x; BROWN KS, UNPUB; Christie W. W., 1987, HIGH PERFORMANCE LIQ; COCUZZA G, 1969, B I SIEROTER MILAN, V48, P204; COTMORE SF, 1987, ADV VIRUS RES, V33, P91, DOI 10.1016/S0065-3527(08)60317-6; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRICKHOFEN N, 1990, ANN INTERN MED, V113, P926, DOI 10.7326/0003-4819-113-12-926; KAJIGAYA S, 1991, P NATL ACAD SCI USA, V88, P4646, DOI 10.1073/pnas.88.11.4646; LENTZ TL, 1990, J GEN VIROL, V71, P751, DOI 10.1099/0022-1317-71-4-751; LEVINE P, 1963, TRANSFUSION, V3, P278, DOI 10.1111/j.1537-2995.1963.tb04643.x; LIU JM, 1992, J VIROL, V66, P4686, DOI 10.1128/JVI.66.8.4686-4692.1992; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; MOCHIZUKI M, 1978, JPN J VET SCI, V40, P375; MOREY AL, 1992, BRIT J OBSTET GYNAEC, V99, P566, DOI 10.1111/j.1471-0528.1992.tb13822.x; MORTIMER PP, 1983, NATURE, V302, P426, DOI 10.1038/302426a0; NAIDES SJ, 1989, PRENATAL DIAG, V9, P105, DOI 10.1002/pd.1970090205; ROSE HG, 1965, J LIPID RES, V6, P428; ROUGER P, 1987, REV FR TRANSFUS IMMU, V30, P699, DOI 10.1016/S0338-4535(87)80138-1; SHIMOMURA S, 1992, BLOOD, V79, P18; TONEGAWA Y, 1977, BIOCHEM BIOPH RES CO, V76, P9, DOI 10.1016/0006-291X(77)91661-8; VONDEMBORNE AEGK, 1986, BRIT J HAEMATOL, V63, P35; WALSH CE, 1992, P NATL ACAD SCI USA, V89, P7257, DOI 10.1073/pnas.89.15.7257; YOUNG N, 1988, SEMIN HEMATOL, V25, P159	26	613	656	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	1993	262	5130					114	117		10.1126/science.8211117	http://dx.doi.org/10.1126/science.8211117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ635	8211117				2022-12-01	WOS:A1993LZ63500036
J	PETRIDOU, E; KASSIMOS, D; KALMANTI, M; KOSMIDIS, H; HAIDAS, S; FLYTZANI, V; TONG, D; TRICHOPOULOS, D				PETRIDOU, E; KASSIMOS, D; KALMANTI, M; KOSMIDIS, H; HAIDAS, S; FLYTZANI, V; TONG, D; TRICHOPOULOS, D			AGE OF EXPOSURE TO INFECTIONS AND RISK OF CHILDHOOD LEUKEMIA	BRITISH MEDICAL JOURNAL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA		HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,677 HUNTINGTON AVE,BOSTON,MA 02115; AGLAIA KYRIAKOU CHILDRENS HOSP,DEPT PAEDIAT HAEMATOL ONCOL,ATHENS,GREECE; AGIA SOPHIA CHILDRENS HOSP,DEPT PAEDIAT HAEMATOL ONCOL,ATHENS,GREECE; UNIV ATHENS,SCH MED,DEPT HYG & EPIDEMIOL,ATHENS,GREECE; UNIV CRETE,DEPT PAEDIAT HAEMATOL ONCOL,IRAKLION,GREECE	Harvard University; Harvard T.H. Chan School of Public Health; The Aghia Sophia Children's Hospital; Athens Medical School; National & Kapodistrian University of Athens; University of Crete				Cassimos, Dimitrios/0000-0001-8738-0285; PETRIDOU, ELENI/0000-0003-3695-3439				DARBY SC, 1987, BMJ-BRIT MED J, V294, P603, DOI 10.1136/bmj.294.6572.603; GREAVES MF, 1988, LEUKEMIA, V2, P120; KASSIMOS D, 1992, THESIS ATHENS U MED; KINLEN L, 1988, LANCET, V2, P1323; MACMAHON B, 1992, AM J EPIDEMIOL, V136, P916, DOI 10.1093/oxfordjournals.aje.a116564	5	83	83	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1993	307	6907					774	774		10.1136/bmj.307.6907.774	http://dx.doi.org/10.1136/bmj.307.6907.774			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ478	8219951	Green Published, Bronze			2022-12-01	WOS:A1993LZ47800026
J	KAUSHANSKY, K; LOK, S; HOLLY, RD; BROUDY, VC; LIN, N; BAILEY, MC; FORSTROM, JW; BUDDLE, MM; OORT, PJ; HAGEN, FS; ROTH, GJ; PAPAYANNOPOULOU, T; FOSTER, DC				KAUSHANSKY, K; LOK, S; HOLLY, RD; BROUDY, VC; LIN, N; BAILEY, MC; FORSTROM, JW; BUDDLE, MM; OORT, PJ; HAGEN, FS; ROTH, GJ; PAPAYANNOPOULOU, T; FOSTER, DC			PROMOTION OF MEGAKARYOCYTE PROGENITOR EXPANSION AND DIFFERENTIATION BY THE C-MPL LIGAND THROMBOPOIETIN	NATURE			English	Article							STEM-CELL FACTOR; HUMAN INTERLEUKIN-6; GROWTH-FACTORS; KIT LIGAND; INVIVO; ERYTHROPOIETIN; INVITRO; PURIFICATION; SYNERGISM; MICE	THE development of blood cells including expansion of megakaryocyte progenitor cells requires the interplay of marrow stromal cells and polypeptide cytokines(1-10). Recently, characterization of c-Mpl, the receptor encoded by the proto-oncogene c-mpl, revealed structural homology with the haematopoietic cytokine receptor family(11), and its involvement in megakaryocyte development(12). We report here that the ligand for c-Mpl(13) is relatively lineage specific, works both alone and synergistically with early acting cytokines to support megakaryocyte colony formation, and acts at a late stage of development to increase megakaryocyte size, polyploidization and expression of differentiation markers. In vivo, c-Mpl ligand stimulates platelet production by greatly expanding marrow and splenic megakaryocytes and their progenitors, and by shifting the distribution of megakaryocyte ploidy to higher values. Thus, as c-Mpl ligand has the expected characteristics of the major regulator of megakaryocyte development, we propose that it be termed thrombopoietin.	ZYMOGENET INC,SEATTLE,WA 98105	Zymogenet Inc.	KAUSHANSKY, K (corresponding author), UNIV WASHINGTON,SCH MED,DIV HEMATOL,SEATTLE,WA 98195, USA.							AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; AVRAHAM H, 1992, BLOOD, V80, P1679; BROUDY VC, 1988, ARCH BIOCHEM BIOPHYS, V265, P329, DOI 10.1016/0003-9861(88)90135-X; BURSTEIN SA, 1992, EXP HEMATOL, V20, P1170; CANFIELD VA, 1987, BIOCHEM BIOPH RES CO, V147, P526, DOI 10.1016/0006-291X(87)90963-6; CARRINGTON PA, 1991, BLOOD, V77, P34; CHOW FPR, 1993, EXP HEMATOL, V21, P255; DEBILI N, 1993, BLOOD, V82, P84, DOI 10.1182/blood.V82.1.84.bloodjournal82184; FOSTER DC, 1991, BIOCHEMISTRY-US, V30, P367, DOI 10.1021/bi00216a009; GEISSLER K, 1992, BLOOD, V79, P1155, DOI 10.1182/blood.V79.5.1155.bloodjournal7951155; HAN ZC, 1992, BRIT J HAEMATOL, V81, P1, DOI 10.1111/j.1365-2141.1992.tb08161.x; HILL RJ, 1992, EXP HEMATOL, V20, P354; ISHIBASHI T, 1989, P NATL ACAD SCI USA, V86, P5953, DOI 10.1073/pnas.86.15.5953; ISHIBASHI T, 1989, BLOOD, V74, P1241; JACKSON CW, 1984, BLOOD, V63, P768; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; LEE M, 1979, BLOOD, V53, P619; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MAYANI H, 1992, EUR J HAEMATOL, V49, P225; METCALF D, 1992, TRENDS BIOCHEM SCI, V17, P286, DOI 10.1016/0968-0004(92)90436-D; METHIA N, 1993, BLOOD, V82, P1395; NEBEN TY, 1993, BLOOD, V81, P901; OGAWA M, 1993, BLOOD, V81, P2844; TERAMURA M, 1992, BLOOD, V79, P327; TSUKADA J, 1993, BLOOD, V81, P866; Vignon I, 1992, P NATL ACAD SCI USA, V89, P5640; Whetton AD, 1993, CURR OPIN CELL BIOL, V5, P1044, DOI 10.1016/0955-0674(93)90090-D	28	909	980	2	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 16	1994	369	6481					568	571		10.1038/369568a0	http://dx.doi.org/10.1038/369568a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	8202159				2022-12-01	WOS:A1994NR29400052
J	ELDER, ME; LIN, D; CLEVER, J; CHAN, AC; HOPE, TJ; WEISS, A; PARSLOW, TG				ELDER, ME; LIN, D; CLEVER, J; CHAN, AC; HOPE, TJ; WEISS, A; PARSLOW, TG			HUMAN SEVERE COMBINED IMMUNODEFICIENCY DUE TO A DEFECT IN ZAP-70, A T-CELL TYROSINE KINASE	SCIENCE			English	Article							RECEPTOR GAMMA-CHAIN; ANTIGEN RECEPTOR; MICE LACKING; ZETA-CHAIN; FUNCTIONAL COMPONENT; ACTIVATION; SELECTION	A homozygous mutation in the kinase domain of ZAP-70, a T cell receptor-associated protein tyrosine kinase, produced a distinctive form of human severe combined immunodeficiency. Manifestations of this disorder included profound immunodeficiency, absence of peripheral CD8(+) T cells, and abundant peripheral CD4(+) T cells that were refractory to T cell receptor-mediated activation. These findings demonstrate that ZAP-70 is essential for human T cell function and suggest that CD4(+) and CD8(+) T cells depend on different intracellular signaling pathways to support their development or survival.	UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; SALK INST, INFECT DIS LAB, SAN DIEGO, CA 92186 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Salk Institute	ELDER, ME (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029313] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01271] Funding Source: Medline; NIAID NIH HHS [AI29313] Funding Source: Medline; NIGMS NIH HHS [GM43574] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN IT, 1993, SCIENCE, V261, P1581, DOI 10.1126/science.8372352; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MONAFO WJ, 1992, CLIN EXP IMMUNOL, V90, P390; NAGAMINE CM, 1989, AM J HUM GENET, V45, P337; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; ROSEN FS, 1984, NEW ENGL J MED, V311, P300, DOI 10.1056/NEJM198408023110506; ROSEN FS, 1984, NEW ENGL J MED, V311, P235, DOI 10.1056/NEJM198407263110406; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Veillette A, 1991, Semin Immunol, V3, P143; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; VONBOEHMER H, 1993, CELL, V73, P207, DOI 10.1016/0092-8674(93)90220-K; WANGE RL, 1992, J BIOL CHEM, V267, P11685	30	423	427	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	1994	264	5165					1596	1599		10.1126/science.8202712	http://dx.doi.org/10.1126/science.8202712			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ285	8202712				2022-12-01	WOS:A1994NQ28500038
J	REICH, Z; WACHTEL, EJ; MINSKY, A				REICH, Z; WACHTEL, EJ; MINSKY, A			LIQUID-CRYSTALLINE MESOPHASES OF PLASMID DNA IN BACTERIA	SCIENCE			English	Article							DOUBLE-STRANDED DNA; CIRCULAR-DICHROISM; SUPERCOILED DNA; DEOXYRIBONUCLEIC-ACID; PHASES; ORGANIZATION; INVITRO; INVIVO; TEMPERATURE; MICROSCOPY	Bacterial plasmids may often reach a copy number larger than 1000 per cell, corresponding to a total amount of DNA that may exceed the amount of DNA within the bacterial chromosome. This observation highlights the problem of cellular accommodation of large amounts of closed-circular nucleic acids, whose interwound conformation offers negligible DNA compaction. As determined by x-ray scattering experiments conducted on intact bacteria, supercoiled plasmids segregate within the cells into dense clusters characterized by a long-range order. In vitro studies performed at physiological DNA concentrations indicated that interwound DNA spontaneously forms liquid crystalline phases whose macroscopic structural properties are determined by the features of the molecular supercoiling. Because these features respond to cellular factors, DNA supercoiling may provide a sensitive regulatory link between cellular parameters and the packaging modes of inter wound DNA in vivo.	WEIZMANN INST SCI, DEPT ORGAN CHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								BAUER WR, 1980, SCI AM, V243, P118; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; BOOY FP, 1991, CELL, V64, P1007, DOI 10.1016/0092-8674(91)90324-R; BOWATER R, 1991, BIOCHEMISTRY-US, V30, P11495, DOI 10.1021/bi00113a003; BRUGEROLLE G, 1979, BIOL CELLULAIRE, V35, P111; BUSTAMANTE C, 1991, BIOCHEMISTRY-US, V30, P5661, DOI 10.1021/bi00237a004; CHILAYA GS, 1986, MOL CRYST LIQ CRYST, V140, P243, DOI 10.1080/00268948608080157; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DURAND D, 1992, J PHYS II, V2, P1769, DOI 10.1051/jp2:1992233; HENRY NM, 1961, INTERPRETATION XRAY, P212; KANNAR R, 1992, CURR OPIN STRUC BIOL, V2, P369; KELLENBERGER E, 1992, FEMS MICROBIOL LETT, V100, P361, DOI 10.1016/0378-1097(92)90233-E; KELLENBERGER E, 1987, TRENDS BIOCHEM SCI, V12, P105, DOI 10.1016/0968-0004(87)90049-1; Kellenberger E., 1986, BACTERIAL CHROMATIN, P11; KELLER D, 1986, J CHEM PHYS, V84, P2972, DOI 10.1063/1.450278; KIM MH, 1986, J CHEM PHYS, V84, P2981, DOI 10.1063/1.450279; LEE FS, 1985, NUCLEIC ACIDS RES, V13, P1665, DOI 10.1093/nar/13.5.1665; LEFORESTIER A, 1991, BIOL CELL, V71, P115, DOI 10.1016/0248-4900(91)90058-U; LEPAULT J, 1987, EMBO J, V6, P1507, DOI 10.1002/j.1460-2075.1987.tb02393.x; LIVOLANT F, 1988, BIOCHEMISTRY-US, V27, P3056, DOI 10.1021/bi00408a058; LIVOLANT F, 1984, EUR J CELL BIOL, V33, P300; LIVOLANT F, 1987, J PHYS-PARIS, V48, P1051, DOI 10.1051/jphys:019870048060105100; LIVOLANT F, 1989, NATURE, V339, P724, DOI 10.1038/339724a0; LIVOLANT F, 1991, J MOL BIOL, V218, P165, DOI 10.1016/0022-2836(91)90882-7; MAESTRE MF, 1980, BIOCHEMISTRY-US, V19, P5214, DOI 10.1021/bi00564a010; MANIATIS TP, 1971, THESIS VANDERBILT U; MCCLELLAN JA, 1990, P NATL ACAD SCI USA, V87, P8373, DOI 10.1073/pnas.87.21.8373; Mitchell P, 1956, S SOC GEN MICROBIOL, V6, P150; REICH C, 1980, BIOCHEMISTRY-US, V19, P5208, DOI 10.1021/bi00564a009; REICH Z, UNPUB; RILL RL, 1986, P NATL ACAD SCI USA, V83, P342, DOI 10.1073/pnas.83.2.342; ROBINSON C, 1961, TETRAHEDRON, V13, P219, DOI 10.1016/S0040-4020(01)92215-X; RUDALL K M, 1955, Lect Sci Basis Med, V5, P217; SAMULSKI ET, 1974, LIQUID CRYSTALS PLAS, V1, P175; SAMULSKI TV, 1977, J CHEM PHYS, V67, P824, DOI 10.1063/1.434844; STRZELECKA TE, 1987, J AM CHEM SOC, V109, P4513, DOI 10.1021/ja00249a014; STRZELECKA TE, 1988, NATURE, V331, P457, DOI 10.1038/331457a0; TORBET J, 1989, EMBO J, V8, P4351, DOI 10.1002/j.1460-2075.1989.tb08622.x; VANWINKLE DH, 1990, MACROMOLECULES, V23, P4140, DOI 10.1021/ma00220a018; VINOGRAD J, 1968, J MOL BIOL, V33, P173, DOI 10.1016/0022-2836(68)90287-8; VOLOGODSKII AV, 1992, J MOL BIOL, V227, P1224, DOI 10.1016/0022-2836(92)90533-P; WANG JC, 1993, CURR OPIN GENET DEV, V3, P764, DOI 10.1016/S0959-437X(05)80096-6; WANG JC, 1969, J MOL BIOL, V43, P25, DOI 10.1016/0022-2836(69)90076-X; WANG JC, 1974, J MOL BIOL, V89, P783, DOI 10.1016/0022-2836(74)90053-9; WARING M, 1970, Journal of Molecular Biology, V54, P247, DOI 10.1016/0022-2836(70)90429-8; WHITE JH, 1969, AM J MATH, V91, P693, DOI 10.2307/2373348; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; YEVDOKIMOV YM, 1988, LIQ CRYST, V3, P1443, DOI 10.1080/02678298808086687	48	117	120	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	1994	264	5164					1460	1463		10.1126/science.8197460	http://dx.doi.org/10.1126/science.8197460			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	8197460				2022-12-01	WOS:A1994NP22100043
J	FRANKLIN, JE				FRANKLIN, JE			ADDICTION MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANABOLIC-STEROIDS; ALCOHOL-ABUSE; TRAUMA				FRANKLIN, JE (corresponding author), NORTHWESTERN UNIV, SCH MED, CHICAGO, IL USA.							AVINS AL, 1994, JAMA-J AM MED ASSOC, V271, P515, DOI 10.1001/jama.271.7.515; DURANT RH, 1993, NEW ENGL J MED, V328, P922, DOI 10.1056/NEJM199304013281304; EDWARDS RW, 1993, INT J ADDICT, V28, P1621, DOI 10.3109/10826089309062204; GRINSPOON L, 1994, NEW ENGL J MED, V330, P357, DOI 10.1056/NEJM199402033300513; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; JOHNSTON LD, 1993, NATIONAL SURVEY SECO; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KLEBER HD, 1994, NEW ENGL J MED, V330, P361, DOI 10.1056/NEJM199402033300514; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P184; SCHUCKIT MA, 1980, J STUD ALCOHOL, V1, P45; SU TP, 1993, JAMA-J AM MED ASSOC, V269, P2760, DOI 10.1001/jama.269.21.2760; WATTERS JK, 1994, JAMA-J AM MED ASSOC, V271, P115, DOI 10.1001/jama.271.2.115; YESALIS CE, 1993, JAMA-J AM MED ASSOC, V270, P1217, DOI 10.1001/jama.270.10.1217	14	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	1994	271	21					1650	1651						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN117	8182831				2022-12-01	WOS:A1994NN11700010
J	ROBERTS, MB; STRINGER, CB; PARFITT, SA				ROBERTS, MB; STRINGER, CB; PARFITT, SA			A HOMINID TIBIA FROM MIDDLE PLEISTOCENE SEDIMENTS AT BOXGROVE, UK	NATURE			English	Article							QUATERNARY	FOSSIL hominids from the earlier Middle Pleistocene of Europe are very rare and the Mauer mandible is generally accepted as the most ancient, with an estimated age of 500 kyr(1,2). We report here on the discovery of a human tibia, in association with stone tools, from calcareous silts at the Lower Palaeolithic site of Boxgrove, West Sussex, UK3,4 (Fig. 1). The silt units are correlated by mammalian biostratigraphy to an, as yet unnamed, major temperate stage or interglacial that immediately pre-dates the Anglian cold stage(5). Accordingly, the temperate sediments are equated with oxygen isotope stage 13 (ref. 6) and are therefore roughly coeval with the Mauer mandible. The massive tibia is the oldest hominid fragment from the British Isles and provides the first information about the manufacturers of the early Acheulian industries of Europe. It is assigned to Home cf. heidelbergensis.	NAT HIST MUSEUM, DEPT PALAEONTOL, LONDON SW7 5BD, ENGLAND	Natural History Museum London	ROBERTS, MB (corresponding author), UCL, INST ARCHAEOL, FIELD ARCHAEOL UNIT, LONDON WC1H 0PY, ENGLAND.							Andrews P., 1990, OWLS CAVES FOSSILS; [Anonymous], 1992, HIGH LODGE EXCAVATIO; ARSUAGA JL, 1991, J HUM EVOL, V20, P191, DOI 10.1016/0047-2484(91)90073-5; ASHTON NM, IN PRESS J GEOL SOC; BABA H, 1990, Bulletin of the National Science Museum Series D (Anthropology), V16, P9; Bergman CA, 1990, BIG PUZZLE, P265; Bishop M.J., 1982, SP PAP PALAEONTOL, V28, P1; BOSINSKI G, 1988, 2 AD BEITR; Bridgland D.R., 1988, P GEOLOGIST ASSOC, V99, P291, DOI [10.1016/S0016-7878(88)80055-5, DOI 10.1016/S0016-7878(88)80055-5]; BRIDGLAND DR, 1990, PHILOS T ROY SOC B, V328, P307, DOI 10.1098/rstb.1990.0115; BRIDGLAND DR, 1993, QUATERNARY THAMES; COOK J, 1982, Yearbook of Physical Anthropology, V25, P19; CURRANT A, 1989, BIOL J LINN SOC, V38, P23, DOI 10.1111/j.1095-8312.1989.tb01559.x; DAY MH, 1974, AM J PHYS ANTHROPOL, V41, P367, DOI 10.1002/ajpa.1330410304; Endo B., 1970, AMUD MAN HIS CAVE SI, P231; GIBBARD PL, 1991, QUATERNARY SCI REV, V10, P23, DOI 10.1016/0277-3791(91)90029-T; GOLDBERG P, 1990, SOIL MICROMORPHOLOGY, P441; HARTWIGSCHERER S, 1993, AM J PHYS ANTHROPOL, V92, P17, DOI 10.1002/ajpa.1330920103; Imbrie J., 1984, MILANKOVITCH CLIMA 1, P269; LUCA APS, 1980, NGANDONG FOSSIL HOMI; MACPHAIL RI, 1993, SOIL REPORT MICROMOR; Rightmire, 1990, EVOLUTION HOMO ERECT; Roberts M.B., 1986, Proceedings of the Prehistoric Society, V52, P215; ROBETS MB, 1990, SEQS, P62; SHACKLETON NJ, 1987, QUATERNARY SCI REV, V6, P183, DOI 10.1016/0277-3791(87)90003-5; Stuart A.J., 1982, PLEISTOCENE VERTEBRA; STUART AJ, 1976, GEOL MAG, V113, P469, DOI 10.1017/S0016756800050779; SUTCLIFFE A J, 1976, Bulletin of the British Museum (Natural History) Geology, V27, P31; Trinkaus E., 1983, SHANIDAR NEANDERTALS; van den Bogaard C., 1989, EISZEITALTER GEGENWA, V39, P62; van Kolfschoten T., 1990, Mededelingen Rijks Geologische Dienst, V43, P1; Von Koenigswald Wighart., 1992, SCHICHTEN MAUER 85 J, P101; West RG, 1980, PREGLACIAL PLEISTOCE; Whiteman C.A., 1992, P GEOLOGIST ASSOC, V103, P37, DOI [10.1016/S0016-7878(08)80197-6, DOI 10.1016/S0016-7878(08)80197-6]; WHITEMAN CA, 1992, QUATERNARY SCI REV, V11, P363, DOI 10.1016/0277-3791(92)90007-U; ZAGWIJN WH, 1985, GEOL MIJNBOUW, V64, P17; ZALASIEWICZ JA, 1988, PLIOCENE MIDDLE PLEI	37	98	100	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					311	313		10.1038/369311a0	http://dx.doi.org/10.1038/369311a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	8183368				2022-12-01	WOS:A1994NN10900046
J	LOIS, C; ALVAREZBUYLLA, A				LOIS, C; ALVAREZBUYLLA, A			LONG-DISTANCE NEURONAL MIGRATION IN THE ADULT MAMMALIAN BRAIN	SCIENCE			English	Article							SUBEPENDYMAL LAYER; CEREBRAL-CORTEX; AVIAN BRAIN; CELLS; RAT; NEUROGENESIS; ENOLASE; SYSTEM	During the development of the mammalian brain, neuronal precursors migrate to their final destination from their site of birth in the ventricular and subventricular zones (VZ and SVZ, respectively). SVZ cells in the walls of the lateral ventricle continue to proliferate in the brain of adult mice and can generate neurons in vitro, but their fate in vivo is unknown. Here SVZ cells from adult mice that carry a neuronal-specific transgene were grafted into the brain of adult recipients. In addition, the fate of endogenous SVZ cells was examined by microinjection of tritiated thymidine or a vital dye that labeled a discrete population of SVZ cells. Grafted and endogenous SVZ cells in the lateral ventricle of adult mice migrate long distances and differentiate into neurons in the olfactory bulb.			LOIS, C (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.			Alvarez-Buylla, Arturo/0000-0003-4426-8925	NINDS NIH HHS [NS 24478] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ALTMAN J, 1993, NEURONAL CELL DEATH, V6, P203; ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; ALVAREZBUYLLA A, 1990, SCIENCE, V249, P1444, DOI 10.1126/science.1698312; ALVAREZBUYLLA A, 1988, J NEUROSCI METH, V25, P165, DOI 10.1016/0165-0270(88)90155-0; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; BLAKEMORE WF, 1972, J NEUROCYTOL, V1, P69, DOI 10.1007/BF01098647; CLARCK SJ, 1989, J COMP NEUROL, V301, P114; COROTTO FS, 1993, NEUROSCI LETT, V149, P111, DOI 10.1016/0304-3940(93)90748-A; FARBMAN AI, 1992, CELL BIOL OLFACTION, P132; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; HATTEN ME, 1990, EXPERIENTIA, V46, P907, DOI 10.1007/BF01939383; Jacobson M., 1991, DEV NEUROBIOLOGY; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KAPLITT M G, 1991, Molecular and Cellular Neuroscience, V2, P320, DOI 10.1016/1044-7431(91)90062-S; KISHI K, 1987, J COMP NEUROL, V258, P112, DOI 10.1002/cne.902580109; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MCDERMOTT KW, 1991, J ANAT, V178, P45; MOORSHEAD C, 1992, J NEUROSCI, V12, P249; MOORSHEAD C, 1993, SOC NEUR ABSTR, V19, P870; NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834; OKANO HJ, 1993, J NEUROSCI, V13, P2930; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; Packard D S Jr, 1973, Differentiation, V1, P397, DOI 10.1111/j.1432-0436.1973.tb00137.x; PATON JA, 1984, SCIENCE, V225, P1046, DOI 10.1126/science.6474166; PRIVAT A, 1972, J COMP NEUROL, V146, P277, DOI 10.1002/cne.901460302; RAKIC P, 1985, SCIENCE, V227, P1054, DOI 10.1126/science.3975601; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SMART I, 1961, J COMP NEUROL, V116, P325, DOI 10.1002/cne.901160306; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520	36	1846	1905	1	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 20	1994	264	5162					1145	1148		10.1126/science.8178174	http://dx.doi.org/10.1126/science.8178174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM146	8178174				2022-12-01	WOS:A1994NM14600032
J	MARSH, DG; NEELY, JD; BREAZEALE, DR; GHOSH, B; FREIDHOFF, LR; EHRLICHKAUTZKY, E; SCHOU, C; KRISHNASWAMY, G; BEATY, TH				MARSH, DG; NEELY, JD; BREAZEALE, DR; GHOSH, B; FREIDHOFF, LR; EHRLICHKAUTZKY, E; SCHOU, C; KRISHNASWAMY, G; BEATY, TH			LINKAGE ANALYSIS OF IL4 AND OTHER CHROMOSOME 5Q31.1 MARKERS AND TOTAL SERUM IMMUNOGLOBULIN-E CONCENTRATIONS	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; IGE LEVELS; MAST-CELLS; GENE; INTERLEUKIN-4; EXPRESSION; ALLERGY; ASTHMA; IL-4; RESPONSIVENESS	Sib-pair analysis of 170 individuals from 11 Amish families revealed evidence for linkage of five markers in chromosome 5q31.1 with a gene controlling total serum immunoglobulin E (IgE) concentration. No linkage was found between these markers and specific IgE antibody concentrations. Analysis of total IgE within a subset of 128 IgE antibody-negative sib pairs confirmed evidence for linkage to 5q31.1, especially to the interleukin-4 gene (IL4). A combination of segregation and maximum likelihood analyses provided further evidence for this linkage. These analyses suggest that IL4 or a nearby gene in 5q31.1 regulates IgE production in a nonantigen-specific (noncognate) fashion.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA; ALLERGOL ALK LAB AS, DK-2970 HORSHOLM, DENMARK	Johns Hopkins University	MARSH, DG (corresponding author), JOHNS HOPKINS ASTHMA & ALLERGY CTR, SCH MED, 5501 HOPKINS BAYVIEW BLVD, BALTIMORE, MD 21224 USA.		Ghosh, Balaram/G-1248-2010; KRISHNASWAMY, GUHA/AAR-8844-2021; Krishnaswamy, Guha/R-9076-2019	KRISHNASWAMY, GUHA/0000-0002-9848-6197; 	NCRR NIH HHS [1 P41 RR03655] Funding Source: Medline; NIAID NIH HHS [AI20059] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020059] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; ARAI N, 1989, J IMMUNOL, V142, P274; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BLUMENTHAL MN, 1990, GENETIC ENV FACTORS, pCH9; BONNEY GE, 1986, BIOMETRICS, V42, P611, DOI 10.2307/2531211; BORECKI I B, 1985, Genetic Epidemiology, V2, P327, DOI 10.1002/gepi.1370020402; BORISH L, UNPUB; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; BRUNNER T, 1993, NATURE, V177, P605; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CASOLARO V, 1993, GENETICS ASTHMA, P291; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; COOKSON WOCM, 1989, LANCET, V1, P1292; EHRLICHKAUTZKY E, 1991, BIOTECHNIQUES, V10, P39; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FREIDHOFF LR, 1993, INT ARCH ALLERGY IMM, V100, P355, DOI 10.1159/000236438; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GERRARD JW, 1978, AM J HUM GENET, V30, P46; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; HENKEL G, 1992, J IMMUNOL, V149, P3239; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LOFTUS SK, 1993, HUM MOL GENET, V2, P1785, DOI 10.1093/hmg/2.11.1785; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MARSH DG, 1989, COLD SPRING HARB SYM, V54, P459; MARSH DG, 1992, NAT GENET, V2, P252, DOI 10.1038/ng1292-252; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1993, GENETICS ASTHMA; MARSH DG, 1994, SAMTERS IMMUNOLOGICA; MEYERS DA, 1987, AM J HUM GENET, V41, P51; MEYERS DA, 1991, GENET EPIDEMIOL, V8, P351, DOI 10.1002/gepi.1370080507; MIN LW, 1992, J IMMUNOL, V148, P1913; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MORTON NE, 1992, CLIN EXP ALLERGY, V22, P1041, DOI 10.1111/j.1365-2222.1992.tb00126.x; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MOUT R, 1991, NUCLEIC ACIDS RES, V19, P3763, DOI 10.1093/nar/19.13.3763; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; PURKERSON JM, 1992, J EXP MED, V175, P973, DOI 10.1084/jem.175.4.973; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; SALTMAN DL, 1993, GENOMICS, V16, P726, DOI 10.1006/geno.1993.1254; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; STOCK W, 1992, CYTOGENET CELL GENET, V61, P263, DOI 10.1159/000133417; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P335, DOI 10.1016/0167-5699(93)90230-I; VERCELLI D, 1991, J ALLERGY CLIN IMMUN, V88, P285, DOI 10.1016/0091-6749(91)90087-5; WARREN CPW, 1982, J ALLERGY CLIN IMMUN, V69, P370, DOI 10.1016/0091-6749(82)90148-8; WARRINGTON JA, 1992, GENOMICS, V13, P803, DOI 10.1016/0888-7543(92)90156-M; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEISSENBACH J, 1992, SCIENCE, V258, P67; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YOUNG RP, 1992, CLIN EXP ALLERGY, V22, P205, DOI 10.1111/j.1365-2222.1992.tb03074.x	63	874	911	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	1994	264	5162					1152	1156		10.1126/science.8178175	http://dx.doi.org/10.1126/science.8178175			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM146	8178175				2022-12-01	WOS:A1994NM14600034
J	KIM, TK; HASHIMOTO, S; KELLEHER, RJ; FLANAGAN, PM; KORNBERG, RD; HORIKOSHI, M; ROEDER, RG				KIM, TK; HASHIMOTO, S; KELLEHER, RJ; FLANAGAN, PM; KORNBERG, RD; HORIKOSHI, M; ROEDER, RG			EFFECTS OF ACTIVATION-DEFECTIVE TBP MUTATIONS ON TRANSCRIPTION INITIATION IN YEAST	NATURE			English	Article							POLYMERASE-II TRANSCRIPTION; PREINITIATION COMPLEX; BINDING-PROTEIN; BASIC REPEAT; DNA-BINDING; INVITRO; VP16	TRANSCRIPTION initiation by RNA polymerase II is effected by an ordered series of general factor interactions with core promoter elements (leading to basal activity) and further regulated by gene-specific factors acting from distal elements(1). Both the general factor TFIID (refs 2,3), including the constituent TBP (TATA-binding polypeptide)(4-7) and associated factors(8), and the interacting factor TFIIB (refs 9-11) have been implicated as targets for various activators. Towards an understanding of the basis for activator function, including the multiplicity of TBP interactions, we have now identified mutations in yeast TBP that selectively block activator (GAL4-VP16)-dependent but not basal transcription. We further show an effect of GAL4-VP16 on TFIIB recruitment to early preinitiation complexes, and that recruitment is disrupted by TBP mutations that impair its interactions with VP16 (L114K), TFIIB (L189K) or an unidentified component (K211L). Thus, GAL4-VP16 function seems to involve both direct interactions with TBP and a corresponding induction (or stabilization) of an activation-specific TBP-TFIIb-promoter complex.	STANFORD UNIV, SCH MED, DEPT CELL BIOL, STANFORD, CA 94305 USA	Stanford University	KIM, TK (corresponding author), ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA.							AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; FLANAGAN PM, 1992, P NATL ACAD SCI USA, V89, P7659, DOI 10.1073/pnas.89.16.7659; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAHN S, 1993, NATURE, V363, P672, DOI 10.1038/363672a0; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KEAVENEY M, 1993, NATURE, V365, P562, DOI 10.1038/365562a0; KIM K, 1994, J BIOL CHEM, V269, P4891; KIM TK, 1994, NUCLEIC ACIDS RES, V22, P251, DOI 10.1093/nar/22.2.251; KIM TK, 1993, J BIOL CHEM, V268, P20866; KIM TK, IN PRESS P NATN ACAD; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PTASHNE M, 1986, GENETIC SWITCH GENE, V1; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844	30	109	110	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	1994	369	6477					252	255		10.1038/369252a0	http://dx.doi.org/10.1038/369252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	8183347				2022-12-01	WOS:A1994NM06700062
J	ENGELBERG, D; KLEIN, C; MARTINETTO, H; STRUHL, K; KARIN, M				ENGELBERG, D; KLEIN, C; MARTINETTO, H; STRUHL, K; KARIN, M			THE UV RESPONSE INVOLVING THE RAS SIGNALING PATHWAY AND AP-1 TRANSCRIPTION FACTORS IS CONSERVED BETWEEN YEAST AND MAMMALS	CELL			English	Article							DEPENDENT PROTEIN-KINASE; ACID BIOSYNTHETIC GENES; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL CONTROL; ADENYLATE-CYCLASE; ACTIVATES TRANSCRIPTION; TRANSDUCTION PATHWAYS; RADIATION SENSITIVITY; NUCLEOTIDE-SEQUENCE; REGULATORY SUBUNIT	UV irradiation of mammalian cells activates AP-1 through a Ras-dependent pathway, independently of DNA damage. We show that the yeast S. cerevisiae has a remarkably similar UV response involving the AP-1 factor Gcn4, which is distinct from the DNA damage response. Transcriptional activation of HIS3 and HIS4 by Gcn4 is triggered by UV irradiation in a Ras-dependent fashion. Moreover, resistance of yeast to UV irradiation is correlated with the level of Ras activity and Gcn4 function. Like mammalian cells in which activated Ras leads to increased c-Jun synthesis and phosphorylation, the effects in yeast involve increased translation of GCN4 mRNA and a posttranslational event. However, this effect on GCN4 translation is different from the response to amino acid or purine starvation. Therefore, a UV signaling pathway involving Ras and AP-1 is an ancient and universal mechanism involved in protection against damage to cellular components other than DNA.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	ENGELBERG, D (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.				FIC NIH HHS [F05 TWO4865-01] Funding Source: Medline; NCI NIH HHS [CA50528] Funding Source: Medline; NIGMS NIH HHS [GM30186] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004865] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030186, R01GM030186] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; [Anonymous], 1985, DNA REPAIR; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS JL, 1989, CANCER RES, V49, P4682; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BUSCHER M, 1988, ONCOGENE, V3, P301; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P4618, DOI 10.1128/MCB.13.8.4618; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DONAHUE TF, 1983, CELL, V32, P89, DOI 10.1016/0092-8674(83)90499-3; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ERASO P, 1985, FEBS LETT, V191, P51, DOI 10.1016/0014-5793(85)80991-1; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KARIN M, 1989, GENES SIGNAL TRANSDU, P415; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; MATSUMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2355, DOI 10.1073/pnas.79.7.2355; MBONYI K, 1990, MOL CELL BIOL, V10, P4518, DOI 10.1128/MCB.10.9.4518; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MUNDER T, 1989, FEBS LETT, V242, P341, DOI 10.1016/0014-5793(89)80498-3; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; OLIVIERO S, 1991, P NATL ACAD SCI USA, V88, P224, DOI 10.1073/pnas.88.1.224; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; Romerdahl C A, 1989, Cancer Commun, V1, P209; SHIMM DS, 1992, RADIAT RES, V129, P149, DOI 10.2307/3578151; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; STRUHL K, 1985, COLD SPRING HARB SYM, V50, P489, DOI 10.1101/SQB.1985.050.01.061; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; STRUHL K, 1982, NATURE, V300, P284, DOI 10.1038/300284a0; THEVELEIN JM, 1991, MOL MICROBIOL, V5, P1301, DOI 10.1111/j.1365-2958.1991.tb00776.x; THIREOS G, 1984, P NATL ACAD SCI-BIOL, V81, P5096, DOI 10.1073/pnas.81.16.5096; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TZAMARIAS D, 1989, CELL, V57, P947, DOI 10.1016/0092-8674(89)90333-4; VANAELST L, 1991, J GEN MICROBIOL, V137, P341, DOI 10.1099/00221287-137-2-341; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAGLE K, 1990, MOL CELL BIOL, V10, P5553, DOI 10.1128/MCB.10.10.5553; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	72	199	202	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 6	1994	77	3					381	390		10.1016/0092-8674(94)90153-8	http://dx.doi.org/10.1016/0092-8674(94)90153-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	8181058				2022-12-01	WOS:A1994NK97000009
J	TAGLIALATELA, M; WIBLE, BA; CAPORASO, R; BROWN, AM				TAGLIALATELA, M; WIBLE, BA; CAPORASO, R; BROWN, AM			SPECIFICATION OF PORE PROPERTIES BY THE CARBOXYL-TERMINUS OF INWARDLY RECTIFYING K+ CHANNELS	SCIENCE			English	Article							POTASSIUM CHANNEL; SODIUM-CHANNEL; INTERNAL MG-2+; SHAKER; GENE; DROSOPHILA; REGION; CELLS; RECTIFICATION; INACTIVATION	Inwardly rectifying potassium (K+) channels (IRKs) maintain the resting membrane potential of cells and permit prolonged depolarization, such as during the cardiac action potential. Inward rectification may result from block of the ion conduction pore by intracellular magnesium (Mg-i(2+)). Two members of this family, IRK1 and ROMK1, which share 40 percent amino acid identity, differ markedly in single-channel K+ conductance and sensitivity to block by Mg-i(2+). The conserved H-5 regions were hypothesized to determine these pore properties because they have this function in voltage-dependent K+ channels and in cyclic nucleotide-gated channels. However, exchange of the H-5 region between IRK1 and ROMK1 had no effect on rectification and little or no effect on K+ conductance. By contrast, exchange of the amino- and carboxyl-terminal regions together transferred Mg2+ blockade and K+ conductance of IRK1 to ROMK1. Exchange of the carboxyl but not the amino terminus had a similar effect. Therefore, the carboxyl terminus appears to have a major role in specifying the pore properties of IRKs.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030; UNIV NAPLES FEDERICO II,SCH MED 2,DEPT HUMAN COMMUN SCI,PHARMACOL SECT,I-80121 NAPLES,ITALY	Baylor College of Medicine; University of Naples Federico II			Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/ABH-4262-2020; Taglialatela, Maurizio/AAB-8621-2022; Taglialatela, Maurizio/A-2062-2019	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930, P01HL037044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36930, HL37044] Funding Source: Medline; NINDS NIH HHS [NS23877] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMANN A, 1987, EMBO J, V6, P3419, DOI 10.1002/j.1460-2075.1987.tb02665.x; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; ELLINOR T, 1993, NATURE, V363, P455; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HELLEN G, 1991, SCIENCE, V251, P939; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KIRSCH GE, 1993, NEURON, V11, P503, DOI 10.1016/0896-6273(93)90154-J; KIRSCH GE, 1992, BIOPHYS J, V62, P136, DOI 10.1016/S0006-3495(92)81800-3; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; NICHOLS CG, 1993, TRENDS PHARMACOL SCI, V14, P320; NICHOLS CG, 1993, P PHYSL SOC, P46; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; ROOT MJ, 1993, NEURON, V11, P459, DOI 10.1016/0896-6273(93)90150-P; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; TAGLIALATELA M, 1993, PFLUG ARCH EUR J PHY, V423, P104, DOI 10.1007/BF00374967; TAGLIALATELA M, IN PRESS J BIOL CHEM; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	39	144	145	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					844	847		10.1126/science.8171340	http://dx.doi.org/10.1126/science.8171340			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171340				2022-12-01	WOS:A1994NJ94900034
J	TUN, RYM; PEAKMAN, M; ALVIGGI, L; HUSSAIN, MJ; LO, SSS; SHATTOCK, M; PYKE, DA; BOTTAZZO, GF; VERGANI, D; LESLIE, RDG				TUN, RYM; PEAKMAN, M; ALVIGGI, L; HUSSAIN, MJ; LO, SSS; SHATTOCK, M; PYKE, DA; BOTTAZZO, GF; VERGANI, D; LESLIE, RDG			IMPORTANCE OF PERSISTENT CELLULAR AND HUMORAL IMMUNE CHANGES BEFORE DIABETES DEVELOPS - PROSPECTIVE-STUDY OF IDENTICAL-TWINS	BRITISH MEDICAL JOURNAL			English	Article							ACTIVATED LYMPHOCYTES-T; INSULIN; MELLITUS; ANTIBODIES; AUTOANTIBODIES; MARKERS; DECARBOXYLASE; RELATIVES; DISEASE; ANTIGEN	Objectives-To determine the pattern of cellular and humoral immune changes associated with insulin dependent diabetes before diabetes develops. Design-Prospective study over 10 years of 25 non-diabetic identical twins of patients with insulin dependent diabetes. The non-diabetic twins were followed up either till they developed diabetes or to the end of the study. Setting-Teaching hospital. Subjects-25 non-diabetic identical cotwins of patients with diabetes; 46 controls of the same sex and similar age tested over the same period. Of the 25 twins (total follow up 144 patient years), 10 developed diabetes (prediabetic twins); the remainder were followed up for a mean of 7.7 years. Main outcome measures-Results of glucose tolerance tests or fasting blood glucose concentrations at each sample point. Measurements of activated T lymphocytes, expressing the HLA-DR antigen, islet cell antibodies, and insulin autoantibodies in samples. Results-All 10 prediabetic twins had both cellular and humoral changes initially and in most samples before diabetes was diagnosed (activated T lymphocytes in 39/40, islet cell antibodies in 45/47, and insulin autoantibodies to islet cells and insulin were detected infrequently (in 8/54, 6/69, and 0/69 samples, respectively). The combination of cellular and humoral (islet cell antibodies or insulin autoantibodies) immune changes were detected in all 10 of the prediabetic twins but in only one of the 15 nondiabetic twins (P<0.001). The positive predictive value in this cohort of increased percentages of activated T cells and the presence of antibodies to islet cells or insulin on two consecutive occasions was 100%. Conclusion-Most of the twins had cellular or humoral immune changes at some stage. A combination of cellular and humoral immune changes and their tendency to persist is highly predictive of insulin dependent diabetes and distinguishes twins who develop diabetes from those who do not.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT DIABET & METAB,LONDON EC1A 7BE,ENGLAND; UNIV LONDON KINGS COLL,DEPT IMMUNOL,LONDON WC2R 2LS,ENGLAND; LONDON HOSP,COLL MED,DEPT IMMUNOL,LONDON E1 1BB,ENGLAND	University of London; Queen Mary University London; University of London; King's College London; University of London; Queen Mary University London			Vergani, Diego/H-7610-2019; Leslie, Richard/AAF-6977-2020	Leslie, Richard/0000-0002-1786-1531	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALSAKKAF L, 1992, ACTA DIABETOL, V28, P189, DOI 10.1007/BF00778996; ALSAKKAF L, 1989, DIABETOLOGIA, V32, P322, DOI 10.1007/BF00265550; ALVIGGI L, 1984, LANCET, V2, P4; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BAEKKESKOV S, 1987, J CLIN INVEST, V79, P926, DOI 10.1172/JCI112903; BARMEIER H, 1991, DIABETOLOGIA, V34, P727, DOI 10.1007/BF00401518; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BINGLEY PJ, 1993, DIABETES CARE, V16, P45, DOI 10.2337/diacare.16.1.45; BOTTAZZO GF, 1980, LANCET, V1, P668; CHRISTIE MR, 1992, DIABETES, V41, P782, DOI 10.2337/diabetes.41.7.782; GORSUCH AN, 1981, LANCET, V2, P1363; JACKSON RA, 1982, NEW ENGL J MED, V306, P785, DOI 10.1056/NEJM198204013061305; JOHNSTON C, 1983, BMJ-BRIT MED J, V286, P253, DOI 10.1136/bmj.286.6361.253; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LESLIE RDG, 1991, BRIT MED J, V302, P1103, DOI 10.1136/bmj.302.6785.1103; LOBOYEO A, 1987, CLIN EXP IMMUNOL, V67, P96; MILLWARD BA, 1986, BRIT MED J, V292, P793, DOI 10.1136/bmj.292.6523.793; OLMOS P, 1988, DIABETOLOGIA, V31, P747, DOI 10.1007/BF00274777; PEAKMAN M, 1989, J CLIN LAB IMMUNOL, V30, P1; ROBERT JJ, 1991, DIABETES CARE, V14, P718, DOI 10.2337/diacare.14.8.718; SRIKANTA S, 1984, DIABETES, V33, P717, DOI 10.2337/diabetes.33.8.717; TARN AC, 1988, LANCET, V1, P845; THIVOLET C, 1992, DIABETOLOGIA, V35, P570, DOI 10.1007/BF00400486; THIVOLET C, 1991, DIABETOLOGIA, V34, P186, DOI 10.1007/BF00418274; WILKIN T, 1985, LANCET, V1, P480; 1979, DIABETES, V28, P1038	27	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1994	308	6936					1063	1068		10.1136/bmj.308.6936.1063	http://dx.doi.org/10.1136/bmj.308.6936.1063			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173426	Green Published			2022-12-01	WOS:A1994NH48900020
J	HENDRY, SHC; YOSHIOKA, T				HENDRY, SHC; YOSHIOKA, T			A NEUROCHEMICALLY DISTINCT 3RD CHANNEL IN THE MACAQUE DORSAL LATERAL GENICULATE-NUCLEUS	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; MONKEY VISUAL-CORTEX; BROAD-BAND CHANNELS; STRIATE CORTEX; GALAGO-CRASSICAUDATUS; LAMINAR ORGANIZATION; CONTRAST-SENSITIVITY; RHESUS-MONKEY; RESPONSE PROPERTIES; SQUIRREL-MONKEY	The primate visual system is often divided into two channels, designated M and P, whose signals are relayed to the cerebral cortex by neurons in the magnocellular and parvicellular layers of the dorsal lateral geniculate nucleus. We have identified a third population of geniculocortical neurons in the dorsal lateral geniculate nucleus of macaques, which is immunoreactive for the a subunit of type II calmodulin-dependent protein kinase. This large third population occupies interlaminar regions (intercalated layers) ventral to each principal layer. Retrograde labeling of kinase-immunoreactive cells from the primary visual cortex shows that they provide the geniculocortical input to cytochrome oxidase-rich puffs in layers II and III.	JOHNS HOPKINS UNIV, DEPT NEUROSCI, BALTIMORE, MD 21218 USA	Johns Hopkins University	HENDRY, SHC (corresponding author), JOHNS HOPKINS UNIV, ZANVYL KRIEGER MIND BRAIN INST, BALTIMORE, MD 21218 USA.				NATIONAL EYE INSTITUTE [R01EY006432, R23EY006432] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06432] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BENSON DL, 1991, J NEUROSCI, V11, P1540; Clark WEL, 1941, J ANAT, V75, P419; DEBRUYN EJ, 1993, J NEUROPHYSIOL, V69, P3, DOI 10.1152/jn.1993.69.1.3; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FERRERA VP, 1992, NATURE, V358, P756, DOI 10.1038/358756a0; FITZPATRICK D, 1983, J NEUROSCI, V3, P673; GUILLERY RW, 1970, Z ZELLFORSCH MIK ANA, V103, P90, DOI 10.1007/BF00335403; HENDRY SHC, 1986, P NATL ACAD SCI USA, V83, P1536, DOI 10.1073/pnas.83.5.1536; HUBEL DH, 1987, J NEUROSCI, V7, P3378; HUBEL DH, 1990, J NEUROSCI, V10, P2223, DOI 10.1523/jneurosci.10-07-02223.1990; IRVIN GE, 1986, BRAIN RES, V362, P254, DOI 10.1016/0006-8993(86)90450-6; ITAYA SK, 1984, BRAIN RES, V304, P303, DOI 10.1016/0006-8993(84)90334-2; KAAS JH, 1978, J COMP NEUROL, V182, P517, DOI 10.1002/cne.901820308; KRUBITZER L, 1990, VISUAL NEUROSCI, V5, P609, DOI 10.1017/S0952523800000778; LACHICA EA, 1992, J COMP NEUROL, V319, P141, DOI 10.1002/cne.903190112; LACHICA EA, 1993, J COMP NEUROL, V329, P163, DOI 10.1002/cne.903290203; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; LIVINGSTONE MS, 1982, P NATL ACAD SCI-BIOL, V79, P6098, DOI 10.1073/pnas.79.19.6098; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P309; MALPELI JG, 1981, J NEUROPHYSIOL, V46, P1102, DOI 10.1152/jn.1981.46.5.1102; Martin Kevan A. C., 1992, Current Biology, V2, P555, DOI 10.1016/0960-9822(92)90037-B; MAUNSELL JHR, 1992, J NEUROPHYSIOL, V68, P1332, DOI 10.1152/jn.1992.68.4.1332; MERIGAN WH, 1991, J NEUROSCI, V11, P3422; MERIGAN WH, 1990, VISUAL NEUROSCI, V5, P347, DOI 10.1017/S0952523800000432; MERIGAN WH, 1991, J NEUROSCI, V11, P994; NORTON TT, 1982, J NEUROPHYSIOL, V47, P715, DOI 10.1152/jn.1982.47.4.715; NORTON TT, 1988, J NEUROPHYSIOL, V59, P1639, DOI 10.1152/jn.1988.59.6.1639; RAUSELL E, 1991, J NEUROSCI, V11, P226; SCHILLER PH, 1978, J NEUROPHYSIOL, V41, P788, DOI 10.1152/jn.1978.41.3.788; SCHILLER PH, 1990, VISUAL NEUROSCI, V5, P321, DOI 10.1017/S0952523800000420; SCHILLER PH, 1983, VISION RES, V23, P1631, DOI 10.1016/0042-6989(83)90177-3; SCHILLER PH, 1990, TRENDS NEUROSCI, V13, P392, DOI 10.1016/0166-2236(90)90117-S; SHAPLEY R, 1986, TRENDS NEUROSCI, V9, P229, DOI 10.1016/0166-2236(86)90064-0; TSO DY, 1988, J NEUROSCI, V8, P1712; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; VANESSEN DC, 1992, SCIENCE, V255, P419, DOI 10.1126/science.1734518; VANESSEN DC, 1979, ANNU REV NEUROSCI, V2, P227, DOI 10.1146/annurev.ne.02.030179.001303; WEBER JT, 1983, J COMP NEUROL, V213, P135, DOI 10.1002/cne.902130203; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115; YOSHIOKA T, IN PRESS VISUAL NEUR; YOUNG MP, 1992, NATURE, V358, P152, DOI 10.1038/358152a0; ZEKI S, 1983, PROC R SOC SER B-BIO, V217, P449, DOI 10.1098/rspb.1983.0020; ZEKI SM, 1978, J PHYSIOL-LONDON, V277, P273, DOI 10.1113/jphysiol.1978.sp012272	44	233	235	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 22	1994	264	5158					575	577		10.1126/science.8160015	http://dx.doi.org/10.1126/science.8160015			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	8160015				2022-12-01	WOS:A1994NH01000039
J	ABBADIE, C; KABRUN, N; BOUALI, F; SMARDOVA, J; STEHELIN, D; VANDENBUNDER, B; ENRIETTO, PJ				ABBADIE, C; KABRUN, N; BOUALI, F; SMARDOVA, J; STEHELIN, D; VANDENBUNDER, B; ENRIETTO, PJ			HIGH-LEVELS OF C-REL EXPRESSION ARE ASSOCIATED WITH PROGRAMMED CELL-DEATH IN THE DEVELOPING AVIAN EMBRYO AND IN BONE-MARROW CELLS IN-VITRO	CELL			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; V-REL; RETICULOENDOTHELIOSIS VIRUS; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; HEMATOPOIETIC-CELLS; PROTEIN COMPLEXES; LYMPHOID-CELLS; MESSENGER-RNAS	To determine the physiological processes in which the transcription factor c-Rel may act, we have examined its pattern of expression in the avian embryo by in situ hybridization. These studies showed that c-rel is expressed ubiquitously at low levels and at high levels in isolated cells undergoing programmed cell death by apoptosis or autophagocytosis. To further establish a functional link between expression of c-rel and cell death, we examined the biological consequences of c-rel overexpression in vitro. In primary avian fibroblasts, overexpression of c-rel leads to transformation and dramatic life span extension. In contrast, bone marrow cells expressing high levels of c-rel undergo a process of programmed cell death displaying features of both apoptosis and autophagocylic cell death. Thus, these experiments suggest a critical role for c-rel not only in the control of cell proliferation, but also in the induction of cell death.	UNIV LILLE 1, BIOL DEV LAB, F-59655 VILLENEUVE DASCQ, FRANCE; SUNY STONY BROOK, DEPT MICROBIOL, STONY BROOK, NY 11794 USA	Universite de Lille - ISITE; Universite de Lille; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	ABBADIE, C (corresponding author), INST PASTEUR, ONCOL MOLEC LAB, CNRS, UNITE RECH ASSOCIEE 1160, 1 RUE CALMETTE, F-59019 LILLE, FRANCE.		ABBADIE, Corinne/F-4949-2018	ABBADIE, Corinne/0000-0002-8174-2393	NATIONAL CANCER INSTITUTE [T32CA009176, R01CA051792] Funding Source: NIH RePORTER; NCI NIH HHS [CA51792, 5T32CA09176] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.M., 1994, CURRENT PROTOCOLS MO; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BREWTON RG, 1988, DEV BIOL, V126, P327, DOI 10.1016/0012-1606(88)90142-X; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GRUMONT RJ, 1990, CELL GROWTH DIFFER, V1, P345; GRUMONT RJ, 1990, ONCOGENE RES, V5, P245; HANNINK M, 1990, ONCOGENE, V5, P1843; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HAYAT MA, 1973, ELECTRON MICROSCOPY, V1; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HINCHLIFFE JR, 1973, J EMBRYOL EXP MORPH, V30, P753; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HURLE JM, 1986, J EMBRYOL EXP MORPH, V94, P231; HYAT MA, 1974, ELECTRON MICROSCOPY; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1991, ONCOGENE, V6, P615; KOCHEL T, 1992, ONCOGENE, V7, P567; LARSEN J, 1992, ONCOGENE, V7, P1903; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; Lucas A.M., 1961, ATLAS AVIAN HEMATOLO; MACCABE JA, 1991, J EXP ZOOL, V257, P208, DOI 10.1002/jez.1402570209; MOORE BE, 1989, ONCOGENE, V4, P845; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OPPENHEIM RW, 1988, SCIENCE, V240, P919, DOI 10.1126/science.3363373; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; QUEVA C, 1992, DEVELOPMENT, V114, P125; REDDY EPA, 1988, ONCOGENE HDB; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; ROWE DA, 1982, DEV BIOL, V93, P83, DOI 10.1016/0012-1606(82)90241-X; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SIMEK S, 1988, ONCOGENE RES, V2, P103; STEWARD R, 1985, COLD SPRING HARB SYM, V50, P223, DOI 10.1101/SQB.1985.050.01.028; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TOMEI LD, 1991, APOPTOSIS MOL BASIS; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	76	222	224	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					899	912		10.1016/0092-8674(93)90534-W	http://dx.doi.org/10.1016/0092-8674(93)90534-W			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252626				2022-12-01	WOS:A1993MK96600010
J	KREK, W; LIVINGSTON, DM; SHIRODKAR, S				KREK, W; LIVINGSTON, DM; SHIRODKAR, S			BINDING TO DNA AND THE RETINOBLASTOMA GENE-PRODUCT PROMOTED BY COMPLEX-FORMATION OF DIFFERENT E2F FAMILY MEMBERS	SCIENCE			English	Article							TRANSCRIPTION FACTOR E2F; CELL-CYCLE; SUSCEPTIBILITY GENE; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; CLONING	The E2F family of transcription factors functions in the control of the mammalian cell cycle. Here it is shown that two family members, E2F-1 and DP-1, form specific heterodimers in vivo, a process that enhances DNA binding, transactivation, and the binding of the retinoblastoma gene product. These results suggest that heterodimerization regulates E2F function and contributes to cell cycle control.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School								Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG DM, UNPUB; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P35; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KREK W, UNPUB; LEES J, IN PRESS MOL CELL BI; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NEVINS JR, 1992, SCIENCE, V258, P424; Qin X., UNPUB; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SHIRODKAR S, UNPUB	27	244	253	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1557	1560		10.1126/science.8248803	http://dx.doi.org/10.1126/science.8248803			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248803				2022-12-01	WOS:A1993MK32900036
J	ROCKEY, DC; CELLO, JP				ROCKEY, DC; CELLO, JP			EVALUATION OF THE GASTROINTESTINAL-TRACT IN PATIENTS WITH IRON-DEFICIENCY ANEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENTEROSCOPY; DIAGNOSIS; ENDOSCOPY; GASTRITIS	Background. Idiopathic iron-deficiency anemia in adults is assumed to be the result of occult chronic blood loss from the gastrointestinal tract. The aim of this study was to determine an effective clinical strategy for managing this common clinical problem. Methods. We prospectively studied 1 00 consecutive patients with iron-deficiency anemia, using colonoscopy and esophagogastroduodenoscopy and, in patients with negative endoscopic studies, enteroclysis (radiographic examination of the small intestine). Results. Gastrointestinal endoscopy revealed at least one lesion potentially responsible for blood loss in 62 of the 100 patients. Endoscopic examination of the upper gastrointestinal tract showed a bleeding source in 36 patients, and colonoscopy showed a lesion in 25; 1 patient had lesions in both the upper and lower gastrointestinal tracts. The most common abnormality in the upper gastrointestinal tract was peptic ulceration (duodenal ulcer in 11 patients, gastric ulcer in 5, and anastomotic ulcer in 3). Cancers, detected in 11 patients, were the most common colonic lesions. Enteroclysis was performed in 26 of the 38 patients with negative endoscopic studies, and the results were normal in all instances. Symptoms at a specific site in the gastrointestinal tract were predictive of disease in the corresponding portion of the bowel. In addition, the combination of positive tests for fecal occult blood and symptoms in the lower gastrointestinal tract had a positive predictive value of 86 percent for detecting a lesion in the lower gastrointestinal tract. Conclusions. Gastrointestinal lesions (in both the upper gastrointestinal tract and the colon) are frequently found in patients with iron-deficiency anemia. Since site-specific symptoms are predictive of abnormalities in the corresponding portion of the bowel, the initial evaluation should be directed by the location of the symptoms. Concomitant lesions of the upper and lower gastrointestinal tract are rare; thus, detection of a likely source of blood loss during the initial examination may obviate the need for further procedures.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,MED SERV,DIV GASTROENTEROL,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco								Ahlquist DA, 1991, TXB GASTROENTEROLOGY, V1, P616; CALVEY HD, 1987, AGE AGEING, V16, P399, DOI 10.1093/ageing/16.6.399; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; COOK IJ, 1986, BRIT MED J, V292, P1380, DOI 10.1136/bmj.292.6532.1380; COX DR, 1970, ANAL BINARY DATA, P43; CROKER JR, 1981, AGE AGEING, V10, P40, DOI 10.1093/ageing/10.1.40; FOUTCH PG, 1990, GASTROINTEST ENDOSC, V36, P337; FRIES JF, 1989, GASTROENTEROLOGY, V96, P647, DOI 10.1016/S0016-5085(89)80061-7; GRAHAM DY, 1988, AM J GASTROENTEROL, V83, P1081; HERSHKO C, 1984, BLUT, V49, P347, DOI 10.1007/BF00320209; HETZEL DJ, 1988, GASTROENTEROLOGY, V95, P903, DOI 10.1016/0016-5085(88)90162-X; KERLIN P, 1979, AUST NZ J MED, V9, P402, DOI 10.1111/j.1445-5994.1979.tb04167.x; Krevsky B, 1991, Gastroenterology, V100, P838; LAINE L, 1988, GASTROENTEROLOGY, V94, P1254, DOI 10.1016/0016-5085(88)90661-0; MAGLINTE DDT, 1987, RADIOLOGY, V163, P297, DOI 10.1148/radiology.163.2.3550876; MCCARTHY DM, 1989, GASTROENTEROLOGY, V96, P662, DOI 10.1016/S0016-5085(89)80063-0; MORRIS AJ, 1992, GUT, V33, P887, DOI 10.1136/gut.33.7.887; NEWLAND RC, 1981, CANCER, V47, P424; Peterson WL, 1989, GASTROINTESTINAL DIS, V1, P415; RESS AM, 1992, AM J SURG, V163, P94, DOI 10.1016/0002-9610(92)90259-T; SAUERBRUCH T, 1984, ENDOSCOPY, V16, P101, DOI 10.1055/s-2007-1018546; TAN C C, 1991, SMJ Singapore Medical Journal, V32, P157; WROBLEWSKI M, 1990, SCAND J GASTROENTERO, V25, P489, DOI 10.3109/00365529009095520; ZUCKERMAN G, 1992, AM J GASTROENTEROL, V87, P62; 1990, SAS STAT USERS GUIDE; 1990, SAS LANGUAGE PROCEDU; 1988, MANUAL STAGING CANCE, P69	27	393	409	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1993	329	23					1691	1695		10.1056/NEJM199312023292303	http://dx.doi.org/10.1056/NEJM199312023292303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ707	8179652				2022-12-01	WOS:A1993MJ70700003
J	WILSON, GF; KACZMAREK, LK				WILSON, GF; KACZMAREK, LK			MODE-SWITCHING OF A VOLTAGE-GATED CATION CHANNEL IS MEDIATED BY A PROTEIN KINASE-A REGULATED TYROSINE PHOSPHATASE	NATURE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; BAG CELL NEURONS; ION CHANNELS; ABDOMINAL-GANGLION; APLYSIA; PHOSPHORYLATION; EXPRESSION; AFTERDISCHARGE; MODULATION; CD45	Tyrosine kinases and tyrosine phosphatases are abundant in central nervous system tissue, yet the role of these enzymes in the modulation of neuronal excitability is unknown. Patch-clamp studies of an Aplysia voltage-gated cation channel now demonstrate that a tyrosine phosphatase endogenous to excised patches determines both the gating mode of the channel and the response of the channel to protein kinase A. Moreover, a switch in gating modes similar to that triggered by the phosphatase occurs at the onset of a prolonged change in the excitability of Aplysia bag cell neurons.	YALE UNIV,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University								ALEXANDER D R, 1990, New Biologist, V2, P1049; ALONSO A, 1989, NATURE, V342, P175, DOI 10.1038/342175a0; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; GREEN DJ, 1983, NATURE, V306, P784, DOI 10.1038/306784a0; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HELLER E, 1980, P NATL ACAD SCI-BIOL, V77, P2328, DOI 10.1073/pnas.77.4.2328; Hille B., 1992, IONIC CHANNELS EXCIT; HOEHN K, 1993, NEURON, V10, P543, DOI 10.1016/0896-6273(93)90341-N; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KACZMAREK LK, 1981, J NEUROSCI, V1, P626; KACZMAREK LK, 1978, P NATL ACAD SCI USA, V75, P5200, DOI 10.1073/pnas.75.10.5200; KACZMAREK LK, 1979, J NEUROBIOL, V10, P535, DOI 10.1002/neu.480100604; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KAUER JA, 1985, J NEUROSCI, V5, P1339; KRAMER RH, 1990, NEURON, V2, P335; KUPFERMANN I, 1970, J NEUROPHYSIOL, V33, P865, DOI 10.1152/jn.1970.33.6.865; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P171, DOI 10.1113/jphysiol.1980.sp013357; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARTRIDGE LD, 1987, PFLUG ARCH EUR J PHY, V410, P627, DOI 10.1007/BF00581323; REINHART PH, 1991, J NEUROSCI, V11, P1627; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; SIGWORTH FJ, 1983, SINGLE CHANNEL RECOR, P301; STRAFSTROM CE, 1985, NEUROPHYSIOL, V53, P153; STRONG JA, 1987, NATURE, V325, P714, DOI 10.1038/325714a0; SUGANUMA M, 1992, TOXICON, V30, P873, DOI 10.1016/0041-0101(92)90385-I; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022	40	112	113	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					433	438		10.1038/366433a0	http://dx.doi.org/10.1038/366433a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247151				2022-12-01	WOS:A1993MK09800054
J	WELCH, PJ; WANG, JYJ				WELCH, PJ; WANG, JYJ			A C-TERMINAL PROTEIN-BINDING DOMAIN IN THE RETINOBLASTOMA PROTEIN REGULATES NUCLEAR C-ABL TYROSINE KINASE IN THE CELL-CYCLE	CELL			English	Article							E2F TRANSCRIPTION FACTOR; LARGE T-ANTIGEN; GENE-PRODUCT; SUSCEPTIBILITY GENE; CDC2 KINASE; ESCHERICHIA-COLI; FUSION PROTEINS; HUMAN LEUKEMIAS; RB GENE; PHOSPHORYLATION	The ubiquitously expressed c-Abl tyrosine kinase is localized to the nucleus and binds to DNA. The DNA binding activity is regulated by cdc2-mediated phosphorylation, suggesting a cell cycle function for c-Abl. Here we show that the tyrosine kinase activity of nuclear c-Abl is regulated in the cell cycle through a specific interaction with the retinoblastoma protein (RB). A domain in the C-terminus of RB, outside of the A/B pocket, binds to the ATP-binding lobe of the c-Abl tyrosine kinase, resulting in kinase inhibition. The RB-cAbl interaction is not affected by the viral oncoproteins that bind to RB. Hyperphosphorylation of RB correlates with release of c-Abl and activation of the tyrosine kinase in S phase cells. The nuclear c-Abl tyrosine kinase can enhance transcription, and this activity is inhibited by RB. Nuclear c-Abl is an S phase-activated tyrosine kinase that may participate directly in the regulation of transcription.	UNIV CALIF SAN FRANCISCO,CTR MOLEC GENET,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	WELCH, PJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOL,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA43054, R01 CA043054, R01 CA058320, CA58320] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA058320, R01CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BASKARAN R, 1993, IN PRESS P NATL ACAD; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN J, 1981, J MOL BIOL, V152, P663, DOI 10.1016/0022-2836(81)90122-4; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSEN MF, 1990, CANCER GENET CYTOGEN, V49, P15, DOI 10.1016/0165-4608(90)90159-8; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LIN BTY, 1992, CIBA F SYMP, V170, P227; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RICHARDSON JM, 1987, CANCER RES, V47, P4066; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1982, J BIOL CHEM, V257, P13181; WANG JYJ, 1992, BIOCHIM BIOPHYS ACTA, V1114, P179, DOI 10.1016/0304-419X(92)90014-P; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WEINBERG RA, 1992, CANCER SURV, V12, P43; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	75	378	390	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					779	790		10.1016/0092-8674(93)90497-E	http://dx.doi.org/10.1016/0092-8674(93)90497-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242749	Bronze			2022-12-01	WOS:A1993MH74900022
J	LORCA, T; CRUZALEGUI, FH; FESQUET, D; CAVADORE, JC; MERY, J; MEANS, A; DOREE, M				LORCA, T; CRUZALEGUI, FH; FESQUET, D; CAVADORE, JC; MERY, J; MEANS, A; DOREE, M			CALMODULIN-DEPENDENT PROTEIN KINASE-II MEDIATES INACTIVATION OF MPF AND CSF UPON FERTILIZATION OF XENOPUS EGGS	NATURE			English	Article							LIGHT CHAIN KINASE; PROTOONCOGENE PRODUCT; LIMITED PROTEOLYSIS; SKELETAL-MUSCLE; MEIOTIC ARREST; ACTIVATION; CALCIUM; CYCLIN; DEGRADATION; OOCYTES	IN vertebrates, unfertilized eggs are arrested at second meiotic metaphase by a cytostatic factor (CSF)1, an essential component of which is the product of the c-mos proto-oncogene2. CSF prevents ubiquitin-dependent degradation of mitotic cyclins and thus inactivation of the M phase-promoting factor (MPF)3,4. Fertilization or parthenogenetic activation triggers a transient increase in the cytoplasmic free Ca2+ (reviewed in refs 5 and 6), inactivates both CSF and MPF, and releases eggs from meiotic metaphase arrest7-10. A calmodulin-dependent process is required for cyclin degradation to occur in cell-free extracts prepared from metaphase II-arrested eggs (CSF extracts) when the free Ca2+ concentration is transiently raised in the physiological micromolar range10. Here we show that when a constitutively active mutant of calmodulin-dependent protein kinase II (CaM K(II)) is added to a CSF extract, cyclin degradation and Cdc2 kinase inactivation occur even in the absence of Ca2+, and the extract loses its ability to cause metaphase arrest when transferred into embryos. Furthermore, specific inhibitors of CaM K(II) prevent cyclin degradation after calcium addition. Finally, the direct microinjection of constitutively active CaM K(II) into unfertilized eggs inactivates Cdc2 kinase and CSF, even in the absence of a Ca2+ transient. The target for Ca2+-calmodulin is thus CaM K(II).	INSERM, F-34100 MONTPELLIER, FRANCE; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Baylor College of Medicine; Duke University	LORCA, T (corresponding author), CNRS, BP 5051, F-34033 MONTPELLIER, FRANCE.		Fesquet, didier/M-9750-2019; Fesquet, Didier/A-1490-2009	Fesquet, didier/0000-0001-5657-9689; Lorca, Thierry/0000-0003-2007-8924				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; CHEUNG WY, 1971, J BIOL CHEM, V246, P2859; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DEPAOLIROACH AA, 1979, FEBS LETT, V105, P321, DOI 10.1016/0014-5793(79)80639-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; JAFFE LF, 1983, DEV BIOL, V99, P265, DOI 10.1016/0012-1606(83)90276-2; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1992, J CELL SCI, V102, P55; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEYERHOF PG, 1977, DEV BIOL, V61, P214, DOI 10.1016/0012-1606(77)90293-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; WANGH LJ, 1989, J CELL SCI, V93, P1; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEBER M, 1991, DEV BIOL, V148, P393, DOI 10.1016/0012-1606(91)90347-6; WOODGETT JR, 1983, EUR J BIOCHEM, V136, P481, DOI 10.1111/j.1432-1033.1983.tb07766.x	29	405	412	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1993	366	6452					270	273		10.1038/366270a0	http://dx.doi.org/10.1038/366270a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232587				2022-12-01	WOS:A1993MH32500065
J	BRESSLER, SL; COPPOLA, R; NAKAMURA, R				BRESSLER, SL; COPPOLA, R; NAKAMURA, R			EPISODIC MULTIREGIONAL CORTICAL COHERENCE AT MULTIPLE FREQUENCIES DURING VISUAL TASK-PERFORMANCE	NATURE			English	Article							OSCILLATORY NEURONAL RESPONSES; CORTEX; CAT; SYNCHRONIZATION; MONKEY; PATTERNS; STRIATE	THE way in which the brain integrates fragmentary neural events at multiple locations to produce unified perceptual experience and behaviour is called the binding problem1,2. Binding has been proposed to involve correlated activity at different cortical sites during perceptuomotor behaviour3-5, particularly by synchronization of narrow-band oscillations in the gamma-frequency range (30-80 Hz)6,7. In the rabbit olfactory system, inhalation induces increased gamma-correlation between sites in olfactory bulb and cortex8. In the cat visual system, coherent visual stimuli increase gamma-correlation between sites in both the same and different visual cortical areas9-12. In monkeys, some groups have found that gamma-ocillations transiently synchronize within striate cortex13, superior temporal sulcus14 and somatosensorimotor cortex15,16. Others have report that visual stimuli produce increased broad-band power, but not gamma-oscillations, in several visual cortical areas17,18. But the absence of narrow-band oscillations in itself does not disprove inter-regional synchronization, which may be a broad-band phenomenon. We now describe episodes of increased broad-band coherence among local field potentials from sensory, motor and higher-order cortical sites of macaque monkeys performing a visual discrimination task. Widely distributed sites become coherent without involving other interverting sites. Spatially selective multiregional cortical binding, in the form of broad-band synchronization, may thus play a role in primate perceptuomotor behaviour.	ST ELIZABETH HOSP,NIMH,CTR NEUROSCI,WASHINGTON,DC 20032; NIMH,NEUROPSYCHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	BRESSLER, SL (corresponding author), FLORIDA ATLANTIC UNIV,CTR COMPLEX SYST,BOCA RATON,FL 33431, USA.			Coppola, Richard/0000-0003-0273-0675; Nakamura, Richard/0000-0002-7846-6017				Abeles M., 1982, LOCAL CORTICAL CIRCU; BRESSLER SL, 1993, COMPUTATION AND NEURAL SYSTEMS, P515; BRESSLER SL, 1990, TRENDS NEUROSCI, V13, P161, DOI 10.1016/0166-2236(90)90039-D; BRESSLER SL, 1987, BRAIN RES, V409, P285, DOI 10.1016/0006-8993(87)90713-X; Crick F., 1990, Seminars in the Neurosciences, V2, P263; Damasio AR, 1989, NEURAL COMPUT, V1, P123, DOI 10.1162/neco.1989.1.1.123; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; FREEMAN WJ, 1987, BRAIN RES, V422, P267, DOI 10.1016/0006-8993(87)90933-4; GEVINS AS, 1987, SCIENCE, V235, P580, DOI 10.1126/science.3810158; GLASER EM, 1976, PRINCIPLES NEUROBIOL, P168; GRAY CM, 1992, VISUAL NEUROSCI, V8, P337, DOI 10.1017/S0952523800005071; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GREVINS AS, 1988, FUNCTIONAL BRAIN IMA, P99; KREITER AK, 1992, EUR J NEUROSCI, V4, P369, DOI 10.1111/j.1460-9568.1992.tb00884.x; Livanov M.N., 1977, SPATIAL ORG CEREBRAL; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; PFURTSCHELLER G, 1992, NEUROREPORT, V3, P1057, DOI 10.1097/00001756-199212000-00006; SANES JN, 1993, P NATL ACAD SCI USA, V90, P4470, DOI 10.1073/pnas.90.10.4470; SHEER DE, 1970, MOLECULAR MECHANISMS, P177; SINGER WA, 1993, REV PHYSL, V55, P349; TOVEE MJ, 1992, NEUROREPORT, V3, P369, DOI 10.1097/00001756-199204000-00020; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; YOUNG MP, 1992, J NEUROPHYSIOL, V67, P1464, DOI 10.1152/jn.1992.67.6.1464	26	378	382	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					153	156		10.1038/366153a0	http://dx.doi.org/10.1038/366153a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232553				2022-12-01	WOS:A1993MG21600056
J	SCOFIELD, SR; ENGLISH, JJ; JONES, JDG				SCOFIELD, SR; ENGLISH, JJ; JONES, JDG			HIGH-LEVEL EXPRESSION OF THE ACTIVATOR TRANSPOSASE GENE INHIBITS THE EXCISION OF DISSOCIATION IN TOBACCO COTYLEDONS	CELL			English	Article							MAIZE ELEMENT ACTIVATOR; ZEA-MAYS-L; TRANSGENIC TOBACCO; DNA MODIFICATION; PUTATIVE TRANSPOSASE; AC; PLANTS; PROTEIN; TRANSCRIPTION; SEQUENCES	A fusion of the strong cauliflower mosaic virus 35S promoter to the Activator (Ac) transposase (TPASE) gene does not trigger excision of Dissociation (Ds) continuously during tobacco cotyledon development, although once activated, the 35S promoter remains active throughout embryogeny. Epistasis studies where 35S:TPASE is in trans with later-acting fusions indicate that transient effectiveness for excision results from this fusion inhibiting its own action and that of other TPASE sources. Inhibition depends on the strength of TPASE expression, since fusions of the 35S promoter to a TPASE cDNA accumulate 30-fold lower amounts of TPASE mRNA than the 35S:TPASE gene fusion and do not inhibit excision. We discuss the role of TPASE levels in the curious relationship between Ac activity and Ac dosage in maize.	JOHN INNES INST, SAINSBURY LAB, NORWICH NR4 7UH, NORFOLK, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Jones, Jonathan DG/J-5129-2012; Wilson, Matthew H/K-3193-2013; Scofield, Steven/C-3868-2016	Jones, Jonathan DG/0000-0002-4953-261X; 				BECKER D, 1992, P NATL ACAD SCI USA, V89, P5552, DOI 10.1073/pnas.89.12.5552; BENNETZEN JL, 1987, MOL GEN GENET, V208, P45, DOI 10.1007/BF00330420; CHANDLER VL, 1986, P NATL ACAD SCI USA, V83, P1767, DOI 10.1073/pnas.83.6.1767; CHOMET PS, 1987, EMBO J, V6, P295, DOI 10.1002/j.1460-2075.1987.tb04753.x; COUPLAND G, 1988, EMBO J, V7, P3653, DOI 10.1002/j.1460-2075.1988.tb03246.x; COUPLAND G, 1989, P NATL ACAD SCI USA, V86, P9385, DOI 10.1073/pnas.86.23.9385; De Greve H, 1982, J Mol Appl Genet, V1, P499; DEPICKER A, 1982, Journal of Molecular and Applied Genetics, V1, P561; ENGLISH J, 1993, PLANT CELL, V5, P501, DOI 10.1105/tpc.5.5.501; FEDOROFF NV, 1989, MOBILE DNA, P375; FELDMAR S, 1991, EMBO J, V10, P4003, DOI 10.1002/j.1460-2075.1991.tb04975.x; FUSSWINKEL H, 1991, MOL GEN GENET, V225, P186, DOI 10.1007/BF00269846; HARPSTER MH, 1988, MOL GEN GENET, V212, P182, DOI 10.1007/BF00322463; HEFFRON F, 1979, CELL, V18, P1153, DOI 10.1016/0092-8674(79)90228-9; HEHL R, 1990, PLANT CELL, V2, P709, DOI 10.1105/tpc.2.8.709; HEINLEIN M, 1991, MAYDICA, V36, P309; JEFFERSON RA, 1987, EMBO J, V6, P3901; JONES JDG, 1990, PLANT CELL, V2, P701, DOI 10.1105/tpc.2.8.701; JONES JDG, 1989, SCIENCE, V244, P204, DOI 10.1126/science.244.4901.204; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KEITH B, 1986, EMBO J, V5, P2419, DOI 10.1002/j.1460-2075.1986.tb04516.x; KLOSGEN RB, 1986, MOL GEN GENET, V203, P237, DOI 10.1007/BF00333960; KUNZE R, 1988, MOL GEN GENET, V214, P325, DOI 10.1007/BF00337730; KUNZE R, 1989, EMBO J, V8, P3177, DOI 10.1002/j.1460-2075.1989.tb08476.x; KUNZE R, 1987, EMBO J, V6, P1555, DOI 10.1002/j.1460-2075.1987.tb02400.x; MALIGA P, 1988, MOL GEN GENET, V214, P456, DOI 10.1007/BF00330480; MATZKE MA, 1990, DEV GENET, V11, P214, DOI 10.1002/dvg.1020110307; MCCLINTOCK B, 1948, CARNEGIE I WASH, V47, P155; McClintock B., 1963, Year Book of the Carnegie Institution of Washington 1962-1963, V62, P486; MCCLINTOCK B, 1950, P NATL ACAD SCI USA, V36, P344, DOI 10.1073/pnas.36.6.344; MCCLINTOCK B, 1951, COLD SPRING HARB SYM, V16, P13, DOI 10.1101/SQB.1951.016.01.004; McClintock B., 1964, Yearbook of the Carnegie Institution of Washington 1963-64, P592; MCCLINTOCK B, 1946, CARNEGIE I WASH YB, V45, P176; MCCLINTOCK B, 1947, CARNEGIE I WASHINGTO, V46, P146; McClintock B, 1955, CARNEGIE I WASH YB, V54, P245; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; ROMMENS CMT, 1992, MOL GEN GENET, V231, P433, DOI 10.1007/BF00292713; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWARTZ D, 1984, MOL GEN GENET, V196, P81, DOI 10.1007/BF00334096; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; SIMONS RW, 1982, PLANT CELL, V4, P573; STARLINGER P, 1987, PLANT TRANSPOSABLE E, P91; Steel RGD, 1981, PRINCIPLES PROCEDURE; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cb.06.110190.003335	46	55	56	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 5	1993	75	3					507	517		10.1016/0092-8674(93)90385-4	http://dx.doi.org/10.1016/0092-8674(93)90385-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8221890				2022-12-01	WOS:A1993MF83000013
J	NGUYEN, T; SAMBROOK, P; KELLY, P; JONES, G; LORD, S; FREUND, J; EISMAN, J				NGUYEN, T; SAMBROOK, P; KELLY, P; JONES, G; LORD, S; FREUND, J; EISMAN, J			PREDICTION OF OSTEOPOROTIC FRACTURES BY POSTURAL INSTABILITY AND BONE-DENSITY	BRITISH MEDICAL JOURNAL			English	Article							MINERAL DENSITY; HIP FRACTURE; NORMAL WOMEN; FALLS; RISK; POPULATION; AGE; COMMUNITY; PEOPLE; SWAY	Objective-To investigate the utility of risk factors such as bone mineral density, lifestyle, and postural stability in the prediction of osteoporotic fractures. Design-Longitudinal, epidemiological, and population based survey. Setting-City of Dubbo, New South Wales. Subjects-All residents of Dubbo aged greater-than-or-equal-to 60 on 1 January 1989. Main outcome measure-Incidence of fracture for individual subjects. Results-The overall incidence of atraumatic fractures in men and women was 1.9% and 3.1% per annum respectively. The predominant sites of fracture were hip (18.9%), distal radius (18.5%), ribs and humerus (11.9% in each case), and ankle and foot (9.1% and 6.6% respectively). Major predictors of fractures in men and women were femoral neck bone mineral density, body sway, and quadriceps strength. Age, years since menopause, height, weight, and lifestyle factors were also correlated with bone mineral density and body sway and hence were indirect risk factors for fracture. Discriminant function analysis correctly identified 96% and 93% (sensitivities 88% and 81%) of men and women, respectively, who subsequently developed atraumatic fractures. Predictions based on this model indicated that a woman with a bone mineral density in the lowest quartile in the hip together with high body sway had a 8.4% probability of fracture per annum. This represented an almost 14-fold increase in risk of fracture compared with a woman in the highest bone mineral density quartile with low postural sway. An individual with all three predictors in the ''highest risk'' quartile had a 13.1% risk of fracture per annum. Conclusions-Bone mineral density, body sway, and muscle strength are independent and powerful synergistic predictors of fracture incidence.	UNIV NEW S WALES,SCH COMMUNITY MED,KENSINGTON,NSW 2033,AUSTRALIA; ST VINCENTS HOSP,DEPT NUCL MED,SYDNEY,NSW 2010,AUSTRALIA	University of New South Wales Sydney; St Vincents Hospital Sydney	NGUYEN, T (corresponding author), ST VINCENTS HOSP,GARVAN INST MED RES,DIV BONE & MINERAL RES,DARLINGHURST,NSW 2010,AUSTRALIA.		Nguyen, Tuan V/B-6147-2008; Eisman, John A/C-2886-2014; Lord, Stephen R/C-9612-2011; Nguyen, Tuan V./AAD-9503-2020	Nguyen, Tuan V/0000-0002-3246-6281; Nguyen, Tuan V./0000-0002-3246-6281; Lord, Stephen R/0000-0002-7111-8802				ANGUS R, 1989, BONE MINER, V4, P265; ANGUS RM, 1989, J AM DIET ASSOC, V89, P209; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; BROCKLEHURST JC, 1982, AGE AGEING, V11, P1, DOI 10.1093/ageing/11.1.1; COOPER AP, 1824, TREATISE DISLOCATION; COOPER C, 1991, OSTEOPOROSIS INT, V2, P48, DOI 10.1007/BF01627079; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; Cox D.R., 1989, MONOGRAPHS STAT APPL, V2nd ed.; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DESCHEPPER J, 1991, J NUCL MED, V32, P216; DICHGANS J, 1972, SCIENCE, V178, P1217, DOI 10.1126/science.178.4066.1217; FERNIE GR, 1982, AGE AGEING, V11, P11, DOI 10.1093/ageing/11.1.11; GALLAGHER JC, 1987, J BONE MINER RES, V2, P491; GRISSO JA, 1991, J BONE MINER RES, V6, P865; HAND DJ, 1982, DISCRIMINATION CLASS; HANLEY JA, 1982, RADIOLOGY, V50, P23; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; HERMANDEZAVILA M, 1991, AM J CLIN NUTR, V54, P157; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; KRALL EA, 1991, J BONE MINER RES, V6, P331; LIBANATI CR, 1992, J CLIN ENDOCR METAB, V74, P351, DOI 10.1210/jc.74.2.351; LINDSAY R, 1992, J BONE MINER RES, V7, P55; LORD SR, 1992, GERONTOLOGY, V38, P338, DOI 10.1159/000213351; LORD SR, 1991, J AM GERIATR SOC, V39, P1194, DOI 10.1111/j.1532-5415.1991.tb03574.x; LORD SR, 1991, J GERONTOL, V46, pM57; MAZESS RB, 1990, J BONE MINER RES, V5, P645; MAZESS RB, 1991, AM J CLIN NUTR, V53, P132, DOI 10.1093/ajcn/53.1.132; MELTON LJ, 1986, AM J EPIDEMIOL, V124, P254, DOI 10.1093/oxfordjournals.aje.a114383; MeltonIII L. J., 1988, OSTEOPOROSIS ETIOLOG, P133; POCOCK N, 1989, J BONE MINER RES, V4, P441; POCOCK NA, 1986, J CLIN INVEST, V78, P618, DOI 10.1172/JCI112618; POCOCK NA, 1989, BONE, V10, P329, DOI 10.1016/8756-3282(89)90128-2; Semmes J., 1960, YALE J BIOL MED, V33, P249; SIMONS LA, 1990, AUST NZ J MED, V20, P783, DOI 10.1111/j.1445-5994.1990.tb00423.x; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; SNOWHARTER C, 1990, J BONE MINER RES, V5, P589; VANHEMERT AM, 1990, AM J EPIDEMIOL, V132, P123, DOI 10.1093/oxfordjournals.aje.a115624; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; 1990, SAS STAT USERS GUIDE	40	486	494	0	21	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1111	1115		10.1136/bmj.307.6912.1111	http://dx.doi.org/10.1136/bmj.307.6912.1111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8251809	Bronze, Green Published			2022-12-01	WOS:A1993ME91800017
J	CHEN, DS				CHEN, DS			FROM HEPATITIS TO HEPATOMA - LESSONS FROM TYPE-B VIRAL-HEPATITIS	SCIENCE			English	Editorial Material							HUMAN HEPATOCELLULAR CARCINOMAS; ANTIGEN CARRIER MOTHERS; VACCINATION PROGRAM; VIRUS-INFECTION; VERTICAL TRANSMISSION; P53 GENE; TAIWAN; MUTATION; CHILDREN; INFANTS		NATL TAIWAN UNIV,COLL MED,DEPT INTERNAL MED,TAIPEI,TAIWAN	National Taiwan University	CHEN, DS (corresponding author), NATL TAIWAN UNIV HOSP,HEPATITIS RES CTR,TAIPEI 100,TAIWAN.			CHEN, DING-SHINN/0000-0001-7791-6154				BEASLEY RP, 1982, HEPATOLOGY, V2, pS21; BLUMBERG BS, 1965, J AMER MED ASSOC, V191, P541, DOI 10.1001/jama.1965.03080070025007; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Chen D-S, 1987, NEOPLASMS LIVER, P71; CHEN DS, 1987, JAMA-J AM MED ASSOC, V257, P2597; CHEN DS, 1993, J GASTROEN HEPATOL, V8, P470, DOI 10.1111/j.1440-1746.1993.tb01551.x; CHEN DS, IN PRESS 1993 P INT; HSU HM, 1988, JAMA-J AM MED ASSOC, V260, P2231, DOI 10.1001/jama.260.15.2231; HSU HY, 1986, J MED VIROL, V18, P301, DOI 10.1002/jmv.1890180402; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KANE M, 1993, MAY INT S VIR HEP LI; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; MURAKAMI Y, 1991, CANCER RES, V51, P5520; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; SHEU JC, 1985, GASTROENTEROLOGY, V89, P259, DOI 10.1016/0016-5085(85)90324-5; STEVENS CE, 1979, J MED VIROL, V3, P237, DOI 10.1002/jmv.1890030310; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; TSAI SL, 1992, J CLIN INVEST, V89, P87, DOI 10.1172/JCI115590; TSEN YJ, 1991, J MED VIROL, V34, P96, DOI 10.1002/jmv.1890340205	19	295	306	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					369	370		10.1126/science.8211155	http://dx.doi.org/10.1126/science.8211155			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	8211155				2022-12-01	WOS:A1993MB85900039
J	JADRESIC, L; CARTWRIGHT, K; COWIE, N; WITCOMBE, B; STEVENS, D				JADRESIC, L; CARTWRIGHT, K; COWIE, N; WITCOMBE, B; STEVENS, D			INVESTIGATION OF URINARY-TRACT INFECTION IN CHILDHOOD	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSIS; CHILDREN	Objectives-To determine the number of laboratory confirmed urinary tract infections in children and to ascertain general practitioners' practices and attitudes towards their investigation and management. Design-Prospective one year survey of urine specimens submitted for bacteriological investigation; review of radiology department records; questionnaire survey of general practitioners. Setting-Gloucester health district. Subjects-432 children aged < 15 and 7143 children aged < 2 registered with a general practice in Gloucester health district and their 195 general practitioners. Results-4317 urine specimens were submitted from children aged < 15, of which 563 from 442 children were culture positive. The rate (number/100 children/practice) of culture positive urine specimens in these children varied more than 10-fold between general practices, and this correlated closely with the rate of referral of urine specimens for investigation. A follow up specimen to check for clearance of infection was taken in 22% (125/563) of infections. Of the 821 specimens submitted from children aged < 2, 103 from 89 children were positive. Of these children, 28 underwent radiological imaging. Most general practitioners would aim to obtain bacteriological confirmation of urinary tract infection on weekdays but only a minority said they would do so at weekends. They were apparently more likely to refer boys and younger children for renal tract imaging after a first urinary tract infection. Conclusions-Urinary tract infection in children was underdiagnosed, and after a confirmed infection only a minority of patients received renal tract imaging or microbiological follow up. Greater awareness of the importance of investigation and management of urinary tract infection in children is needed, and the practical difficulties faced by general practitioners must be resolved.	GLOUCESTERSHIRE ROYAL HOSP,DEPT RADIOL,GLOUCESTER GL1 3NN,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,DEPT MED AUDIT,GLOUCESTER GL1 3NN,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,PUBL HLTH LAB,GLOUCESTR GL1 3NN,ENGLAND	Gloucestershire Royal Hospital; Gloucestershire Royal Hospital; Gloucestershire Royal Hospital	JADRESIC, L (corresponding author), GLOUCESTERSHIRE ROYAL HOSP,DEPT PEDIAT,GLOUCESTER GL1 3NN,ENGLAND.							BERG UB, 1983, ARCH DIS CHILD, V58, P963, DOI 10.1136/adc.58.12.963; DITCHBURN RK, 1990, BRIT J GEN PRACT, V40, P406; FILLY R, 1974, RADIOLOGY, V113, P145, DOI 10.1148/113.1.145; HODSON C J, 1960, Clin Radiol, V11, P219, DOI 10.1016/S0009-9260(60)80047-5; JONES KV, 1990, ARCH DIS CHILD, V65, P327, DOI 10.1136/adc.65.3.327; KASS EH, 1957, ARCH INTERN MED, V100, P709, DOI 10.1001/archinte.1957.00260110025004; LITTLEWOOD JM, 1972, ARCH DIS CHILD, V47, P218, DOI 10.1136/adc.47.252.218; Smellie J, 1975, Kidney Int Suppl, V4, pS65; SMELLIE JM, 1985, BRIT MED J, V290, P1957, DOI 10.1136/bmj.290.6486.1957; SMELLIE JM, 1964, BMJ-BRIT MED J, V2, P1222, DOI 10.1136/bmj.2.5419.1222; VICKERS D, 1991, LANCET, V338, P767, DOI 10.1016/0140-6736(91)90662-9; WHITE RHR, 1987, ARCH DIS CHILD, V62, P421, DOI 10.1136/adc.62.4.421; WINBERG J, 1982, PEDIATR CLIN N AM, V29, P810; 1991, J R COLL PHYSICIANS, V25, P36; 1987, BMJ, V294, P237	15	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1993	307	6907					761	764		10.1136/bmj.307.6907.761	http://dx.doi.org/10.1136/bmj.307.6907.761			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ478	8219946	Green Published, Bronze			2022-12-01	WOS:A1993LZ47800020
J	SISCOVICK, DS; RAGHUNATHAN, TE; PSATY, BM; KOEPSELL, TD; WICKLUND, KG; LIN, XH; COBB, L; RAUTAHARJU, PM; COPASS, MK; WAGNER, EH				SISCOVICK, DS; RAGHUNATHAN, TE; PSATY, BM; KOEPSELL, TD; WICKLUND, KG; LIN, XH; COBB, L; RAUTAHARJU, PM; COPASS, MK; WAGNER, EH			DIURETIC THERAPY FOR HYPERTENSION AND THE RISK OF PRIMARY CARDIAC-ARREST	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; SERUM MAGNESIUM; SKELETAL-MUSCLE; ARRHYTHMIAS; POTASSIUM; ABNORMALITIES; TRIAMTERENE	Background. The results of trials of the primary prevention of coronary heart disease have suggested that treating hypertension with high doses of thiazide diuretic drugs might increase the risk of sudden death from cardiac causes. In contrast, treatment with low doses of thiazide reduces the risk of coronary heart disease. Methods. To examine the association between thiazide treatment for hypertension and the occurrence of primary cardiac arrest, we conducted a population-based case-control study among enrollees of a health maintenance organization. The case patients were 114 persons with hypertension who had a primary cardiac arrest from 1977 through 1990. The control patients were a stratified random sample of 535 persons with hypertension. The patients' treatment was assessed with the use of a computerized pharmacy data base. Records of their ambulatory care were reviewed to determine other clinical characteristics. Results. The risk of primary cardiac arrest among patients receiving combined thiazide and potassium-sparing diuretic therapy was lower than that among patients treated with a thiazide without potassium-sparing therapy (odds ratio, 0.3; 95 percent confidence interval, 0.1 to 0.7). As compared with low-dose thiazide therapy (25 mg daily), moderate-dose therapy (50 mg daily) was associated with a moderate increase in risk (odds ratio, 1.7; 95 percent confidence interval, 0.7 to 4.5), and high-dose therapy (100 mg daily) was associated with a larger increase in risk (odds ratio, 3.6; 95 percent confidence interval, 1.2 to 10.8) (P value for trend, 0.02). The addition of a potassium-sparing drug to low-dose thiazide therapy was associated with a reduced risk of cardiac arrest (odds ratio, 0.4; 95 percent confidence interval, 0.1 to 1.5). Conclusions. Both the dose of thiazide drugs and the addition of potassium-sparing drugs influence the risk of primary cardiac arrest. These results may explain the differences in the effect of antihypertensive therapy on mortality from coronary heart disease in previous clinical trials.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; UNIV ALBERTA, CTR EPICORE, DIV CARDIOL, EDMONTON, AB, CANADA; GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, SEATTLE, WA 98101 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Alberta; Group Health Cooperative	SISCOVICK, DS (corresponding author), UNIV WASHINGTON, CARDIOVASC HLTH RES UNIT, METROPOLITAN PK 2 BLDG, SUITE 1360, 1730 MINOR AVE, SEATTLE, WA 98101 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042456] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42456-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON PO, 1984, CLIN PHARMACOL THER, V36, P197, DOI 10.1038/clpt.1984.162; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1979, Circulation, V59, P607; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; CARLSEN JE, 1990, BRIT MED J, V300, P975, DOI 10.1136/bmj.300.6730.975; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DORUP I, 1988, BRIT MED J, V296, P455, DOI 10.1136/bmj.296.6620.455; DYCKNER T, 1980, ACTA MED SCAND, V207, P59; ELMFELDT D, 1983, ACTA MED SCAND, P79; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; FISCH C, 1973, CIRCULATION, V47, P408, DOI 10.1161/01.CIR.47.2.408; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HOLLIFIELD JW, 1989, AM J CARDIOL, V63, pB21, DOI 10.1016/0002-9149(89)90934-X; HOLLIFIELD JW, 1984, AM J MED, V77, P28, DOI 10.1016/S0002-9343(84)80005-4; KJELSBERG MO, 1985, AM J CARDIOL, V55, P1; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KULLER L, 1985, AM J EPIDEMIOL, V122, P1045, DOI 10.1093/oxfordjournals.aje.a114186; KULLER LH, 1986, CIRCULATION, V73, P114, DOI 10.1161/01.CIR.73.1.114; LITTLE R, 1987, STATISTICAL ANAL MIS; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; MARTIN BJ, 1987, ARCH INTERN MED, V147, P1768, DOI 10.1001/archinte.147.10.1768; MCCLOSKEY LW, 1992, ARCH INTERN MED, V152, P513, DOI 10.1001/archinte.152.3.513; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MIALL WE, 1983, BMJ-BRIT MED J, V287, P1249; PSATY BM, 1989, JAMA-J AM MED ASSOC, V261, P2087, DOI 10.1001/jama.261.14.2087; RAUTAHARJU PM, 1981, CIRCULATION, V64, P249, DOI 10.1161/01.CIR.64.2.249; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V267, P1083, DOI 10.1001/jama.267.8.1083; SISCOVICK DS, 1993, ANN EMERG MED, V22, P92, DOI 10.1016/S0196-0644(05)80258-6; SPENCE JD, 1985, LANCET, V2, P73; WIDMANN L, 1988, EUR J CLIN PHARMACOL, V33, P577, DOI 10.1007/BF00542490	31	345	350	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	1994	330	26					1852	1857		10.1056/NEJM199406303302603	http://dx.doi.org/10.1056/NEJM199406303302603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT530	8196728				2022-12-01	WOS:A1994NT53000003
J	GABRIEL, SE; OFALLON, WM; KURLAND, LT; BEARD, CM; WOODS, JE; MELTON, LJ				GABRIEL, SE; OFALLON, WM; KURLAND, LT; BEARD, CM; WOODS, JE; MELTON, LJ			RISK OF CONNECTIVE-TISSUE DISEASES AND OTHER DISORDERS AFTER BREAST IMPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN ADJUVANT DISEASE; SYSTEMIC LUPUS-ERYTHEMATOSUS; AUGMENTATION MAMMOPLASTY; COSMETIC SURGERY; AUTOIMMUNE-DISEASE; REVISED CRITERIA; SILICONE; SCLERODERMA; CLASSIFICATION; HYPERTENSION	Background. We conducted a population-based, retrospective study to examine the risk of a variety of connective-tissue diseases and other disorders after breast implantation. Methods. All women in Olmsted County, Minnesota, who received a breast implant between January 1, 1964, and December 31, 1991 (the case subjects), were studied. For each case subject, two women of the same age (within three years) from the same population who had not received a breast implant and who underwent a medical evaluation within two years of the date of the implantation in the case subject were selected as control subjects. Each woman's inpatient and outpatient medical record was reviewed for the occurrence of various connective-tissue diseases, certain other disorders thought to have an autoimmune pathogenesis (e.g., Hashimoto's thyroiditis), and cancer other than breast cancer, as well as related symptoms and abnormal results of laboratory tests. The case subjects were categorized according to whether they received implants for cosmetic reasons, for reconstruction after mastectomy for breast cancer, or for reconstruction after subcutaneous mastectomy for cancer prophylaxis. Additional control subjects (women treated for breast cancer who did not have breast reconstruction) were studied for comparison with the case subjects. Results. A total of 749 women who had received a breast implant were followed for a mean of 7.8 years, and 1498 community controls were followed for a mean of 8.3 years. In 5 case subjects, as compared with 10 subjects in the control group, one of the specified connective-tissue diseases was diagnosed (relative risk, 1.06; 95 percent confidence interval, 0.34 to 2.97). Twenty-five case subjects had signs or symptoms of arthritis, as compared with 39 control subjects (relative risk, 1.35; 95 percent confidence interval, 0.81 to 2.23). Among the various signs or symptoms examined, only morning stiffness was significantly increased among the women who had received a breast implant (relative risk, 1.81; 95 percent confidence interval, 1.11 to 2.95). Conclusions. We found no association between breast implants and the connective-tissue diseases and other disorders that were studied.	MAYO CLIN & MAYO FDN,DIV RHEUMATOL & INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT SURG,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	GABRIEL, SE (corresponding author), MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30582] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALUSIK S, 1989, COR VASA, V31, P139; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; BROZENA SJ, 1988, ARCH DERMATOL, V124, P1383, DOI 10.1001/archderm.124.9.1383; COLLINS N, 1988, CLIN EPIDEMIOLOGY ES, P208; COX DR, 1953, BIOMETRIKA, V40, P354, DOI 10.1093/biomet/40.3-4.354; COX DR, 1972, J R STAT SOC B, V34, P187; DEAPEN DM, 1986, PLAST RECONSTR SURG, V77, P361, DOI 10.1097/00006534-198603000-00001; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; ENDO LP, 1987, SEMIN ARTHRITIS RHEU, V17, P112, DOI 10.1016/0049-0172(87)90033-3; FOCK KM, 1984, J RHEUMATOL, V11, P98; GABRIEL SE, IN PRESS J CLIN EPID; GOLDMAN JA, 1992, ARTHRITIS RHEUM, V35, pS65; GUTIERREZ FJ, 1990, AM J MED, V89, P390; HITOSHI S, 1991, JPN J MED, V30, P97; KUMAGAI Y, 1984, ARTHRITIS RHEUM-US, V27, P1, DOI 10.1002/art.1780270101; KUMAGAI Y, 1979, ARTHRITIS RHEUM, V22, P532, DOI 10.1002/art.1780220514; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LEIBSON CL, 1992, MILBANK Q, V70, P127, DOI 10.2307/3350087; MAY DS, 1991, PLAST RECONSTR SURG, V87, P193, DOI 10.1097/00006534-199101000-00045; MCCULLAGH P, 1983, MONOGRAPHS STATISTIC, P181; MICHET CJ, 1985, MAYO CLIN PROC, V60, P105, DOI 10.1016/S0025-6196(12)60294-8; OKANO Y, 1984, ANN RHEUM DIS, V43, P520, DOI 10.1136/ard.43.3.520; PHILLIPS SJ, 1990, MAYO CLIN PROC, V65, P344, DOI 10.1016/S0025-6196(12)62535-X; Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, 1980, ARTHRITIS RHEUM, V23, P581; SAHN EE, 1990, ARCH DERMATOL, V126, P1198, DOI 10.1001/archderm.126.9.1198; SCHUSTERMAN MA, 1993, ANN PLAS SURG, V31, P1; SPIERA H, 1988, JAMA-J AM MED ASSOC, V260, P236, DOI 10.1001/jama.260.2.236; SPIERA H, 1993, J RHEUMATOL, V20, P958; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TAURA N, 1976, J JAP SOC INTERN MED, V65, P840; VANNUNEN SA, 1982, ARTHRITIS RHEUM, V25, P694, DOI 10.1002/art.1780250613; VARGA J, 1989, ANN INTERN MED, V111, P377, DOI 10.7326/0003-4819-111-5-377; WALSH FW, 1989, ARCH INTERN MED, V149, P1194, DOI 10.1001/archinte.149.5.1194; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011; WIGLEY FM, 1992, ARTHRITIS RHEUM, V35, pS46; Ziegler V, 1986, Dermatol Monatsschr, V172, P86	37	403	408	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	1994	330	24					1697	1702		10.1056/NEJM199406163302401	http://dx.doi.org/10.1056/NEJM199406163302401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR109	8190133				2022-12-01	WOS:A1994NR10900001
J	HU, SH; PARKER, MW; LEI, JY; WILCE, MCJ; BENIAN, GM; KEMP, BE				HU, SH; PARKER, MW; LEI, JY; WILCE, MCJ; BENIAN, GM; KEMP, BE			INSIGHTS INTO AUTOREGULATION FROM THE CRYSTAL-STRUCTURE OF TWITCHIN KINASE	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; CAENORHABDITIS-ELEGANS; PEPTIDE INHIBITOR; SEQUENCE; BINDING; PRODUCE	MANY protein kinases are self-regulated by an intrasteric mechanism where part of the enzyme's structure directly inhibits the active site(1,2). This inhibitory structure is called a pseudosubstrate and specific regulators are required to remove it from the active site to allow substrates access. Removal of the pseudosubstrate sequence from members of the myosin light-chain kinase subfamily(1), including twitchin kinase, activates them but it is not known whether the pseudosubtrate sequence binds to the active site. Native twitchin is a 753K protein (6,839 residues) located in muscle A-bands of the nematode Caenorhabditis elegans(3,4) and because of its size has not been easy to study. We have determined the crystal structure, refined to 2.8 Angstrom resolution, of a recombinant fragment (residues 5,890 to 6,262) of twitchin kinase(3,4) that contains the catalytic core and a 60 residue carboxy-terminal tail. The C-terminal tail extends through the active site, wedged between the small and large lobes of the structure and making extensive contacts with the catalytic core which accounts for autoinhibition and provides direct support for the intrasteric mechanism of protein kinase regulation.	ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; EMORY UNIV,DEPT PATHOL,ATLANTA,GA 30322	St. Vincent's Institute of Medical Research; Emory University			Parker, Michael W/F-9069-2013; Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Parker, Michael W/0000-0002-3101-1138; Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENIAN GM, 1993, GENETICS, V134, P1097; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; GERSTEIN M, 1993, J MOL BIOL, V234, P357, DOI 10.1006/jmbi.1993.1592; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HU SH, 1994, J MOL BIOL, V236, P1259, DOI 10.1016/0022-2836(94)90026-4; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, IN PRESS FRONTIERS M; KNIGHTON DR, 1993, ACTA CRYSTALLOGR D, V49, P357, DOI 10.1107/S0907444993000502; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; VELLIEUX FMD, 1993, P NATL ACAD SCI USA, V90, P2355, DOI 10.1073/pnas.90.6.2355; WATERSTON RH, 1980, DEV BIOL, V77, P271, DOI 10.1016/0012-1606(80)90475-3; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	22	182	187	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 16	1994	369	6481					581	584		10.1038/369581a0	http://dx.doi.org/10.1038/369581a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	8202162				2022-12-01	WOS:A1994NR29400056
J	SCHNEIDER, JW; GU, W; ZHU, L; MAHDAVI, V; NADALGINARD, B				SCHNEIDER, JW; GU, W; ZHU, L; MAHDAVI, V; NADALGINARD, B			REVERSAL OF TERMINAL DIFFERENTIATION MEDIATED BY P107 IN RB(-/-) MUSCLE-CELLS	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; LARGE T-ANTIGEN; CYCLIN-A; MYOGENIC DIFFERENTIATION; SUSCEPTIBILITY GENE; PROTEIN; EXPRESSION; RHABDOMYOSARCOMAS; PROLIFERATION; SUPPRESSION	The terminal differentiation of mammalian muscle cells requires the tumor suppressor retinoblastoma protein (Rb). Unlike their wild-type counterparts, multinucleated myotubes from mouse cells deficient in Rb (Rb--/-) were induced by serum to reenter the cell cycle. Development of the myogenic phenotype in Rb--/- cells correlated with increased expression of p107, which interacted with myogenic transcription factors. Serum-induced cell cycle reentry, on the other hand, correlated with decreased p107 expression. Thus, although p107 could substitute for Rb as a cofactor for differentiation, it could not maintain the terminally differentiated state in Rb--/- myotubes.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT CARDIOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital								AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COPPOLA JA, 1990, ONCOGENE, V5, P1731; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DECHIARA A, 1993, J NATL CANCER I, V85, P152, DOI 10.1093/jnci/85.2.152; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FARMER K, 1992, J BIOL CHEM, V267, P5631; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GARFINKEL LI, 1982, J BIOL CHEM, V257, P1078; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Gu W.Q., UNPUB; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P296; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LASSAR AB, 1992, TRANSCRIPTIONAL REGU, P1037; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; MCALLISTER RM, 1969, CANCER-AM CANCER SOC, V24, P520, DOI 10.1002/1097-0142(196909)24:3<520::AID-CNCR2820240313>3.0.CO;2-M; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	42	354	360	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 3	1994	264	5164					1467	1471		10.1126/science.8197461	http://dx.doi.org/10.1126/science.8197461			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	8197461				2022-12-01	WOS:A1994NP22100045
J	BREO, DL				BREO, DL			THE CANCER REVOLUTION - FROM BLACK-BOX TO GENETIC-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	1994	271	18					1452	1454		10.1001/jama.271.18.1452	http://dx.doi.org/10.1001/jama.271.18.1452			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ693	8176807				2022-12-01	WOS:A1994NJ69300036
J	QIAN, F; VAUX, DL; WEISSMAN, IL				QIAN, F; VAUX, DL; WEISSMAN, IL			EXPRESSION OF THE INTEGRIN ALPHA-4-BETA-1 ON MELANOMA-CELLS CAN INHIBIT THE INVASIVE STAGE OF METASTASIS FORMATION	CELL			English	Article							ADHESION MOLECULES; MONOCLONAL-ANTIBODY; MALIGNANT-MELANOMA; COUNTER-RECEPTOR; HOMING RECEPTOR; FUNCTIONAL-ROLE; BINDING-SITE; VLA-4; FIBRONECTIN; PROTEINS	Among a series of adhesion molecules, expression of integrin alpha 4 beta 1 showed a unique inverse correlation with the invasive potential of B16 melanoma cell lines. When an alpha 4 cDNA was introduced into an alpha 4(-)beta 1(+) highly invasive melanoma line, alpha 4 beta 1 heterodimers were expressed on the surface. Matrigel invasion by the alpha 4(+)beta 1(+) cells was reduced. Pulmonary metastasis was also suppressed when the transfectants were placed subcutaneously, but not when injected intravenously. Expression of alpha 4 beta 1 promoted homotypic intercellular adhesion. The homotypic adhesion was abrogated, and the alpha 4(+)beta 1(+) (less invasive cell lines) increased matrigel invasion following the anti-alpha 4 MAb treatment. These results suggest that integrin alpha 4 beta 1 could play a role in controlling melanoma cell metastasis at the invasive stage.			QIAN, F (corresponding author), STANFORD UNIV, SCH MED, DEPT PATHOL, EXPTL ONCOL LAB, STANFORD, CA 94305 USA.		Vaux, David L/C-7249-2013	Vaux, David L/0000-0003-2703-1651				ARIHIRO K, 1993, JPN J CANCER RES, V84, P726, DOI 10.1111/j.1349-7006.1993.tb02036.x; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; BEDNARCZYK JL, 1992, CLIN EXP METASTAS, V10, P281; BEDNARCZYK JL, 1993, J CELL BIOCHEM, V51, P465, DOI 10.1002/jcb.2400510412; CAMPANERO MR, 1992, EUR J IMMUNOL, V22, P3111, DOI 10.1002/eji.1830221213; CAMPANERO MR, 1990, J CELL BIOL, V110, P157; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; Coman DR, 1944, CANCER RES, V4, P625; DAMJANOVICH L, 1992, AM J RESP CELL MOL, V6, P197, DOI 10.1165/ajrcmb/6.2.197; DENTON KJ, 1992, J PATHOL, V167, P187, DOI 10.1002/path.1711670205; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FIDLER IJ, 1975, CANCER RES, V35, P218; GALLATIN WM, 1983, NATUURE, V304, P233; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GUTMAN GA, 1972, IMMUNOLOGY, V23, P465; Hariharan I K, 1988, Oncogene Res, V3, P387; HAUSMAN RE, 1983, INT J CANCER, V32, P603, DOI 10.1002/ijc.2910320514; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOLERS VM, 1989, J EXP MED, V169, P1589, DOI 10.1084/jem.169.5.1589; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HU MCT, 1992, P NATL ACAD SCI USA, V89, P8254, DOI 10.1073/pnas.89.17.8254; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; KILSHAW PJ, 1991, EUR J IMMUNOL, V21, P2591, DOI 10.1002/eji.1830211041; KOBAYASHI H, 1992, CANCER RES, V52, P3610; KORETZ K, 1991, AM J PATHOL, V138, P741; KOUKOULIS GK, 1991, AM J PATHOL, V139, P787; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; LESLEY J, 1982, IMMUNOGENETICS, V15, P313, DOI 10.1007/BF00364339; LETARTE M, 1993, LEUKEMIA, V7, P93; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; NIGAM AK, 1993, BRIT J CANCER, V68, P507, DOI 10.1038/bjc.1993.377; PAPAYANNOPOULOU T, 1992, BLOOD, V79, P1686; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PIGNATELLI M, 1991, J PATHOL, V165, P25, DOI 10.1002/path.1711650106; PIGNATELLI M, 1990, BRIT J CANCER, V61, P636, DOI 10.1038/bjc.1990.141; PULIDO R, 1991, J BIOL CHEM, V266, P10241; QIAN F, 1989, CANCER RES, V49, P4870; REEVES ME, 1992, CANCER RES, V52, P1546; RINCON J, 1992, INT J CANCER, V51, P452, DOI 10.1002/ijc.2910510319; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUIZ P, 1993, CELL ADHES COMMUN, V1, P67, DOI 10.3109/15419069309095682; SHORE EM, 1991, J BIOL CHEM, V266, P19672; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SUNKARA PS, 1987, CANCER RES, V47, P933; SUZUKI S, 1993, JPN J CANCER RES, V84, P168, DOI 10.1111/j.1349-7006.1993.tb02851.x; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WANG N, 1993, SCIENCE, V260, P124; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; ZUTTER MM, 1990, AM J PATHOL, V137, P863	66	218	233	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 6	1994	77	3					335	347		10.1016/0092-8674(94)90149-X	http://dx.doi.org/10.1016/0092-8674(94)90149-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	8181055				2022-12-01	WOS:A1994NK97000005
J	WILLIAMS, HC; STRACHAN, DP; HAY, RJ				WILLIAMS, HC; STRACHAN, DP; HAY, RJ			CHILDHOOD ECZEMA - DISEASE OF THE ADVANTAGED	BRITISH MEDICAL JOURNAL			English	Article							SKIN-TEST REACTIVITY; ENVIRONMENTAL-FACTORS; ALLERGIC DISORDERS; ATOPIC DISEASE; PREVALENCE; POPULATION; SYMPTOMS; INFANCY	Objective-To determine whether the increased prevalence of childhood eczema in advantaged socioeconomic groups is due to increased parental reporting. Design-Comparison of parental reports of eczema with visible eczema recorded by medical officers during a detailed physical examination. Setting-National birth cohort study. Subjects-8279 children from England, Wales, and Scotland born during 3-9 March 1958 and followed up at the ages of 7, 11, and 16. Main outcome measures-Prevalence of eczema according to parental report compared with medical officer's examination at the ages of 7, 11, and 16. Results-Prevalence of both reported and examined eczema increased with rising social class at the ages of 7, 11, and 16 years. The point prevalence of examined eczema at age 7 was 4.8%, 3.6%, 3.6%, 2.4%, 2.2%, and 2.4% in social classes I, II, III nonmanual, III manual, TV, and V respectively (chi(2) value for linear trend 12.6, P < 0.001). This trend persisted after adjustment for potential confounders such as region and family size and was not present for examined psoriasis or acne. Conclusions-Eczema is more prevalent among British schoolchildren in social classes I and II than those in lower classes, Exposures associated with social class are probably at least as important as genetic factors in the expression of childhood eczema.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,ST JOHNS INST DERMATOL,LONDON SE1 9RT,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; St Georges University London				williams, hywel/0000-0002-5646-3093				ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; ATKINS E, 1981, EMPIRICAL BASIS PRIM, P25; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BORELLI S, 1965, ENTZUNDLICHE DERMATO, V2, P254; BOWKER NC, 1976, BRIT J DERMATOL, V95, P137, DOI 10.1111/j.1365-2133.1976.tb00816.x; BURR ML, 1989, J EPIDEMIOL COMMUN H, V43, P125, DOI 10.1136/jech.43.2.125; COLOFF MJ, 1992, CLIN EXP ALLERGY, V122, P545; DEAN AG, 1990, EPIINFO VERSION 5 2; FORSTER J, 1990, KLIN PADIATR, V202, P136, DOI 10.1055/s-2007-1025506; FREEMAN GL, 1964, AM J DIS CHILD, V107, P549, DOI 10.1001/archpedi.1964.02080060551001; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; Golding J, 1987, Paediatr Perinat Epidemiol, V1, P67, DOI 10.1111/j.1365-3016.1987.tb00091.x; Golding J, 1986, BIRTH 5 STUDY HLTH B; JOHNSON MLT, 1978, VITAL HLTH STAT, V11, P212; LARSSON PA, 1980, ACTA DERM-VENEREOL, V60, P415; LEETE R, 1977, POPULATION TRENDS, V9, P1; MEDING B, 1987, BRIT J DERMATOL, V116, P627, DOI 10.1111/j.1365-2133.1987.tb05895.x; Peters T J, 1987, Paediatr Perinat Epidemiol, V1, P80, DOI 10.1111/j.1365-3016.1987.tb00092.x; RAJKA G, 1986, INT J DERMATOL, V25, P301, DOI 10.1111/j.1365-4362.1986.tb02249.x; SHEPHERD PM, 1985, NATIONAL CHILD DEV S; SMIT HA, 1993, MONOGR ALLERGY, V31, P29; SMITH JM, 1974, MED CLIN N AM, V58, P3; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRACHAN DP, 1990, J EPIDEMIOL COMMUN H, V44, P231, DOI 10.1136/jech.44.3.231; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; WATERS WE, 1971, BRIT MED J, V2, P77, DOI 10.1136/bmj.2.5753.77; WUTHRICH B, 1989, INT ARCH ALLER A IMM, V90, P3, DOI 10.1159/000235067; 1988, EPIDEMIOLOGICAL GRAP; 1979, MORBIDITY STATISTICS	31	193	194	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 30	1994	308	6937					1132	1135		10.1136/bmj.308.6937.1132	http://dx.doi.org/10.1136/bmj.308.6937.1132			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK182	8173454	Green Published			2022-12-01	WOS:A1994NK18200018
J	PINCUS, T; BROOKS, RH; CALLAHAN, LF				PINCUS, T; BROOKS, RH; CALLAHAN, LF			PREDICTION OF LONG-TERM MORTALITY IN PATIENTS WITH RHEUMATOID-ARTHRITIS ACCORDING TO SIMPLE QUESTIONNAIRE AND JOINT COUNT MEASURES	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH ASSESSMENT QUESTIONNAIRE; CORONARY-ARTERY DISEASE; FOLLOW-UP; RADIOGRAPHIC DAMAGE; FORMAL EDUCATION; WORK DISABILITY; NATURAL-HISTORY; WALKING TIME; BUTTON TEST; MORBIDITY	Objective: To describe mortality over 15 years in a cohort of patients with rheumatoid arthritis, according to a simple questionnaire and joint count. Design: A cohort study with 15 years of follow-up. Setting: University hospital outpatient clinic. Patients: A cohort of 75 patients with rheumatoid arthritis. Measurements: Quantitative baseline measures: demographic, articular (joint counts), clinical, questionnaire, and physical measures, including modified questionnaire and joint count measures with substantially fewer items. Results: Although few deaths were seen in the first 3 years after baseline, the standard mortality ratio over 15 years was 1.62, similar to findings in other series. Significant predictors of mortality included age, formal education level, joint count, activities-of-daily-living questionnaire scores, disease adjustment scores, morning stiffness, comorbid cardiovascular disease, grip strength, modified walking time, and button test. Five-year survival in patients with the poorest status according to these quantitative measures was 40% to 60%, comparable to expected survival at that time of patients with three-vessel coronary artery disease or with stage 4 Hodgkin disease. Simplified measures, including a count using only 28 joints and a questionnaire using only 8 activities of daily living, were similar to the more elaborate traditional measures for predicting mortality. Conclusion: Higher mortality rates in patients with rheumatoid arthritis are predicted by more severe clinical disease, as in other chronic diseases. Severe rheumatoid arthritis may be identified using quantitative functional status questionnaires and joint counts, which can be ascertained in about 10 to 15 minutes in any clinical setting.			PINCUS, T (corresponding author), VANDERBILT UNIV, MED CTR,SCH MED,DEPT MED,DIV RHEUMATOL & IMMUNOL, T-3219 MED CTR N, NASHVILLE, TN 37232 USA.		Callahan, Leigh/X-3799-2018	Callahan, Leigh/0000-0001-6362-7220	NCRR NIH HHS [5M01RR-0095] Funding Source: Medline; NIADDK NIH HHS [AM-21393] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R18AM021393] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLEBECK P, 1981, SCAND J RHEUMATOL, V10, P301, DOI 10.3109/03009748109095320; [Anonymous], 1982, EPIDEMIOLOGIC RES; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; ATWATER EC, 1967, ARTHRITIS RHEUM, V10, P259, DOI 10.1002/art.1780100313; BRENNER H, 1991, J CLIN EPIDEMIOL, V44, P807, DOI 10.1016/0895-4356(91)90133-T; BROOKS RH, 1988, ARTHRIT CARE RES, V1, P23; Callahan L F, 1989, Arthritis Care Res, V2, P122, DOI 10.1002/anr.1790020406; CALLAHAN LF, 1988, ARTHRITIS RHEUM-US, V31, P1346, DOI 10.1002/art.1780311102; Clawson D K, 1971, Clin Orthop Relat Res, V77, P203; COBB S, 1953, NEW ENGL J MED, V249, P553, DOI 10.1056/NEJM195310012491402; COX DR, 1972, J R STAT SOC B, V34, P187; DIXON WJ, 1981, BMDP STATISTICAL SOF; DUTHIE JJR, 1964, ANN RHEUM DIS, V23, P193, DOI 10.1136/ard.23.3.193; EBERHARDT KB, 1990, RHEUMATOL INT, V10, P135, DOI 10.1007/BF02274837; EGGER MJ, 1985, ARTHRITIS RHEUM, V28, P613, DOI 10.1002/art.1780280603; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P843, DOI 10.7326/0003-4819-99-6-843; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; FRIES JF, 1990, J RHEUMATOL, V17, P12; FUCHS HA, 1992, J RHEUMATOL, V19, P1655; FUCHS HA, 1989, J RHEUMATOL, V16, P585; FUCHS HA, 1989, ARTHRITIS RHEUM, V32, P531, DOI 10.1002/anr.1780320504; Fuchs V. R., 1982, EC ASPECTS HLTH; GORDON DA, 1973, AM J MED, V54, P445, DOI 10.1016/0002-9343(73)90040-5; Hawley D J, 1992, Arthritis Care Res, V5, P130, DOI 10.1002/art.1790050304; ISOMAKI H, 1984, SCAND J RHEUMATOL, V13, P33, DOI 10.3109/03009748409102665; KAPLAN HS, 1972, HODGKINS DISEASE, P360; KAZIS LE, 1990, J CLIN EPIDEMIOL, V43, P1243, DOI 10.1016/0895-4356(90)90025-K; KELSEY JL, 1988, ANNU REV PUBL HEALTH, V9, P379, DOI 10.1146/annurev.pu.09.050188.002115; KITAGAWA EM, 1973, DIFFERENTIAL MORTALI, P1; LEIGH JP, 1991, J RHEUMATOL, V18, P1307; LICHTENSTEIN MJ, 1991, J RHEUMATOL, V18, P989; LUUKKAINEN R, 1983, CLIN EXP RHEUMATOL, V1, P295; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; MASI AT, 1983, AM J MED, V75, P16, DOI 10.1016/0002-9343(83)90471-0; MCCARTY DJ, 1990, J RHEUMATOL, V17, P1115; MCCARTY DJ, 1985, ARTHRITIS ALLIED CON, P675; MEENAN RF, 1987, J RHEUMATOL, V14, P411; MIKKELSE.WM, 1969, ARTHRITIS RHEUM, V12, P87, DOI 10.1002/art.1780120205; MITCHELL DM, 1986, ARTHRITIS RHEUM-US, V29, P706, DOI 10.1002/art.1780290602; OSULLIVAN JB, 1972, ANN INTERN MED, V76, P573, DOI 10.7326/0003-4819-76-4-573; PINCUS T, 1987, J RHEUMATOL, V14, P240; PINCUS T, 1984, ARTHRITIS RHEUM-US, V27, P864, DOI 10.1002/art.1780270805; PINCUS T, 1990, J RHEUMATOL, V17, P1582; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; PINCUS T, 1988, J RHEUMATOL, V15, P1457; PINCUS T, 1988, J CLIN EPIDEMIOL, V41, P1037, DOI 10.1016/0895-4356(88)90072-8; PINCUS T, 1992, SEMIN ARTHRITIS RHEU, V21, P2, DOI 10.1016/0049-0172(92)90008-2; PINCUS T, 1985, J CHRON DIS, V38, P973, DOI 10.1016/0021-9681(85)90095-5; PINCUS T, 1986, J RHEUMATOL, V13, P841; PINCUS T, 1989, ANN INTERN MED, V110, P259, DOI 10.7326/0003-4819-110-4-259; PINCUS T, 1991, ANN INTERN MED, V115, P825, DOI 10.7326/0003-4819-115-10-825; PINCUS T, 1992, J RHEUMATOL, V19, P1051; Pincus T, 1989, Scand J Rheumatol Suppl, V79, P67; Pincus T, 1988, J MUSCULOSKEL MED, V5, P27; PROUDFIT WL, 1978, PROG CARDIOVASC DIS, V21, P53, DOI 10.1016/S0033-0620(78)80004-8; RASKER JJ, 1984, CLIN RHEUMATOL, V3, P11, DOI 10.1007/BF02715690; REILLY PA, 1990, ANN RHEUM DIS, V49, P363, DOI 10.1136/ard.49.6.363; ROPES M W, 1958, Bull Rheum Dis, V9, P175; SCOTT DL, 1987, LANCET, V1, P1108; SCOTT DL, 1984, ANN RHEUM DIS, V43, P8, DOI 10.1136/ard.43.1.8; SHARP JT, 1991, ARTHRITIS RHEUM, V34, P660, DOI 10.1002/art.1780340606; SHERRER YS, 1986, ARTHRITIS RHEUM, V29, P494, DOI 10.1002/art.1780290406; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; VANDERHEIJDE MFM, 1988, SEMIN ARTHRITIS RHEU, V17, P284, DOI 10.1016/0049-0172(88)90013-3; WEINBLATT E, 1978, NEW ENGL J MED, V299, P60, DOI 10.1056/NEJM197807132990202; WILSKE KR, 1989, J RHEUMATOL, V16, P565; WOLFE F, 1991, J RHEUMATOL, V18, P643; WOLFE F, 1988, J RHEUMATOL, V15, P1480; WOLFE F, 1991, J RHEUMATOL, V18, P1290; WOLFE F, 1986, J RHEUMATOL, V13, P277; WOLFE F, 1991, PROGNOSIS RHEUMATIC, P37; YELIN E, 1980, ANN INTERN MED, V93, P551, DOI 10.7326/0003-4819-93-4-551; YOUNG A, 1987, Clinical Rheumatology, V6, P12, DOI 10.1007/BF02203380; 1987, SAS STAT GUIDE PERSO; 1977, VITAL STATISTICS US, V2	76	334	346	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					26	34		10.7326/0003-4819-120-1-199401010-00005	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250453				2022-12-01	WOS:A1994MP28000005
J	SPIRIO, L; OLSCHWANG, S; GRODEN, J; ROBERTSON, M; SAMOWITZ, W; JOSLYN, G; GELBERT, L; THLIVERIS, A; CARLSON, M; OTTERUD, B; LYNCH, H; WATSON, P; LYNCH, P; LAURENTPUIG, P; BURT, R; HUGHES, JP; THOMAS, G; LEPPERT, M; WHITE, R				SPIRIO, L; OLSCHWANG, S; GRODEN, J; ROBERTSON, M; SAMOWITZ, W; JOSLYN, G; GELBERT, L; THLIVERIS, A; CARLSON, M; OTTERUD, B; LYNCH, H; WATSON, P; LYNCH, P; LAURENTPUIG, P; BURT, R; HUGHES, JP; THOMAS, G; LEPPERT, M; WHITE, R			ALLELES OF THE APC GENE - AN ATTENUATED FORM OF FAMILIAL POLYPOSIS	CELL			English	Article							MULTIPLE INTESTINAL NEOPLASIA; GERM-LINE MUTATIONS; ADENOMATOUS POLYPOSIS; COLON CANCER; GEL-ELECTROPHORESIS; COLORECTAL CANCERS; IDENTIFICATION; CHROMOSOME-5; LOCUS; DNA	An attenuated form of familial adenomatous polyposis coli, AAPC, causes relatively few colonic polyps, but still carries a significant risk of colon cancer. The mutant alleles responsible for this attenuated phenotype have been mapped in several families to the adenomatous polyposis coli (APC) locus on human chromosome 5q. Four distinct mutations in the APC gene have now been identified in seven AAPC families. These mutations that predict truncation products, either by single base pair changes or frameshifts, are similar to mutations identified in families with classical APC. However, they differ in that the four mutated sites are located very close to one another and nearer the 5' end of the APC gene than any base substitutions or small deletions yet discovered in patients with classical APC.	INST CURIE,GENET TUMEURS LAB,F-75231 PARIS,FRANCE; UNIV CINCINNATI,MED CTR,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; UNIV UTAH,SCH MED,DEPT PATHOL,SALT LAKE CITY,UT 84112; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,PRINCETON,NJ 08543; CREIGHTON UNIV,SCH MED,DEPT PREVENT MED PUBL HLTH,OMAHA,NE 68178; CREIGHTON UNIV,SCH MED,DEPT MED GASTROENTEROL,OMAHA,NE 68178; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED ONCOL,HOUSTON,TX 77030; HOP BICETRE,SERV GASTROENTEROL,F-94270 LE KREMLIN BICETR,FRANCE; UNIV UTAH,SCH MED,DIV GASTROENTEROL,SALT LAKE CITY,UT 84112; ST MARKS HOSP,SALT LAKE CITY,UT 84124	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University System of Ohio; University of Cincinnati; Utah System of Higher Education; University of Utah; Fred Hutchinson Cancer Center; Bristol-Myers Squibb; Creighton University; Creighton University; University of Texas System; UTMD Anderson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Utah System of Higher Education; University of Utah	SPIRIO, L (corresponding author), UNIV UTAH,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.		Olschwang, Sylviane/G-2716-2013	Olschwang, Sylviane/0000-0001-7078-3029				BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOURNE HR, 1991, NATURE, V353, P696, DOI 10.1038/353696b0; BOURNE HR, 1991, NATURE, V351, P188, DOI 10.1038/351188a0; BURT RW, 1988, GASTROENTEROL CLIN N, V17, P657; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; GORDON A, 1992, NATURE, V358, P288, DOI 10.1038/358288a0; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JOSLYN G, 1993, IN PRESS P NATL ACAD; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LINDGREN V, 1992, AM J HUM GENET, V50, P988; LYNCH HT, 1992, DIS COLON RECTUM, V35, P411, DOI 10.1007/BF02049396; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MOSER AR, 1992, J CELL BIOL, V116, P517; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SPIRIO L, 1992, AM J HUM GENET, V51, P92; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, CANCER RES, V53, P2728; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VARESCO L, 1993, AM J HUM GENET, V52, P280; 1979, 3 UT CANC REG REP	41	494	500	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					951	957		10.1016/0092-8674(93)90538-2	http://dx.doi.org/10.1016/0092-8674(93)90538-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252630	Bronze			2022-12-01	WOS:A1993MK96600014
J	SCHALL, JD; HANES, DP				SCHALL, JD; HANES, DP			NEURAL BASIS OF SACCADE TARGET SELECTION IN FRONTAL EYE FIELD DURING VISUAL-SEARCH	NATURE			English	Article							RHESUS-MONKEYS; NEURONS; MOVEMENTS	CONSPICUOUS visual features commonly attract gaze1,2, but how the brain selects targets for eye movements is not known. We investigated target selection in rhesus monkeys performing a visual search task3 by recording neurons in the frontal eye field, an area known to be responsible for generating purposive eye movements4,5. Neurons with combined visual- and eye movement-related activity were analysed. We found that the initial visual responses to search stimulus arrays were the same whether the target or a distractor was in the response field. We also found that the neural activity evolved to specify target location before the execution of eye movements, ultimately peaking when the target was in the response field and being suppressed when the target was beside but not distant from the response field. These results demonstrate a possible mechanism by which a desired target is fixated and inappropriate eye movements are prevented.			SCHALL, JD (corresponding author), VANDERBILT UNIV,DEPT PSYCHOL,WILSON HALL,NASHVILLE,TN 37240, USA.							ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; BRUCE CJ, 1985, J NEUROPHYSIOL, V54, P714, DOI 10.1152/jn.1985.54.3.714; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; CAVE KR, 1990, COGNITIVE PSYCHOL, V22, P225, DOI 10.1016/0010-0285(90)90017-X; CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; ENGEL FL, 1977, VISION RES, V17, P95, DOI 10.1016/0042-6989(77)90207-3; GLIMCHER PW, 1992, NATURE, V355, P542, DOI 10.1038/355542a0; KOCH C, 1985, HUM NEUROBIOL, V4, P219; Leichnetz G R, 1988, Rev Oculomot Res, V2, P365; OTTES FP, 1987, EXP BRAIN RES, V66, P465, DOI 10.1007/BF00270679; SCHALL JD, 1991, J NEUROPHYSIOL, V66, P530, DOI 10.1152/jn.1991.66.2.530; SCHALL JD, 1991, J NEUROPHYSIOL, V66, P559, DOI 10.1152/jn.1991.66.2.559; SEGRAVES MA, 1987, J NEUROPHYSIOL, V58, P1387, DOI 10.1152/jn.1987.58.6.1387; SEGRAVES MA, 1992, J NEUROPHYSIOL, V68, P1967, DOI 10.1152/jn.1992.68.6.1967; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104; Yarbus A. L., 1967, EYE MOVEMENTS VISION	16	330	332	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					467	469		10.1038/366467a0	http://dx.doi.org/10.1038/366467a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247155				2022-12-01	WOS:A1993MK09800065
J	HABRAKEN, Y; SUNG, P; PRAKASH, L; PRAKASH, S				HABRAKEN, Y; SUNG, P; PRAKASH, L; PRAKASH, S			YEAST EXCISION-REPAIR GENE RAD2 ENCODES A SINGLE-STRANDED-DNA ENDONUCLEASE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; COMPLEX; PROTEIN; HOMOLOG; SSL2	IN eukaryotes nucleotide excision repair of DNA damaged by ultraviolet radiation requires several gene products; defects in this process result in the cancer-prone syndrome xeroderma pigmentosum (XP) in humans1,2. The RAD2 gene is one of at least seven genes indispensable for excision repair in the yeast Saccharomyces cerevisiae2, and its encoded protein shares remarkable homology with the XP group-G gene product3. Here we overproduce the RAD2-encoded protein in S. cerevisiae, purify it to near homogeneity, and show that RAD2 protein in the presence of magnesium degrades circular single-stranded DNA. The RAD2 endonuclease is specific for single-stranded DNA as it does not act on double-stranded DNA. Given the absolute requirement for RAD2 in the incision step of excision repair, our findings directly implicate RAD2 protein and its human homologue XPG protein as a catalytic component that incises the damaged DNA strand during excision repair. Furthermore, our results indicate that eukaryotes probably employ two distinct endonuclease activities to mediate the dual incision at the damage site.	UTMB,SEALY CTR MOLEC SCI,MED RES BLDG,ROUTE J61,11TH ST & MECH,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444				BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KINGSMAN SM, 1987, METHOD ENZYMOL, V152, P330; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0	16	125	128	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 25	1993	366	6453					365	368		10.1038/366365a0	http://dx.doi.org/10.1038/366365a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247134				2022-12-01	WOS:A1993MJ70500055
J	VERKASALO, PK; PUKKALA, E; HONGISTO, MY; VALJUS, JE; JARVINEN, P; HEIKKILA, KV; KOSKENVUO, M				VERKASALO, PK; PUKKALA, E; HONGISTO, MY; VALJUS, JE; JARVINEN, P; HEIKKILA, KV; KOSKENVUO, M			RISK OF CANCER IN FINNISH CHILDREN LIVING CLOSE TO POWER-LINES	BRITISH MEDICAL JOURNAL			English	Article							ELECTRICAL WIRING CONFIGURATIONS; CHILDHOOD-CANCER; MAGNETIC-FIELDS; LEUKEMIA; EXPOSURE; TUMORS	Objective-To investigate the risk of cancer in children living close to overhead power lines with magnetic fields of greater-than-or-equal-to 0.01 microteslas (muT). Design-Cohort study. Setting-The whole of Finland. Subjects-8300 boys and 66500 girls aged 0-19 years living during 1970-89 within 500 m of overhead power lines of 110-400 kV in magnetic fields calculated to be greater-than-or-equal-to 0.01 muT. Subjects were identified by record linkages of nationwide registers. Main outcome measures-Numbers of observed cases in follow up for cancer and standardised incidence ratios for all cancers and particularly for nervous system tumours, leukemia, and lymphoma. Results-In the whole cohort 140 cases of cancer were observed (145 expected; standardised incidence ratio 0.97, 95% confidence interval 0.81 to 1.1). No statistically significant increases in all cancers and in leukaemia and lymphoma were found in children at any exposure level. A statistically significant excess of nervous system tumours was found in boys (but not in girls) who were exposed to magnetic fields of greater-than-or-equal-to 0.20 muT or cumulative exposure of greater-than-or-equal-to 0.40 muT years. Conclusions-Residential magnetic fields of transmission power lines do not constitute a major public health problem regarding childhood cancer. The small numbers do not allow further conclusions about the risk of cancer in stronger magnetic fields.	UNIV TURKU,DEPT PUBL HLTH,LEMMINKAISENKATU 1,SF-20520 TURKU 52,FINLAND; UNIV HELSINKI,DEPT PUBL HLTH,SF-00014 HELSINKI,FINLAND; FINNISH CANC REGISTRY,INST STAT & EPIDEMIOL CANC RES,SF-00170 HELSINKI,FINLAND; IMATRAN VOIMA OY,SF-01019 VANTAA,FINLAND	University of Turku; University of Helsinki; Finnish Cancer Registry			Heikkilä, Kauko/E-5578-2019	Heikkilä, Kauko/0000-0002-9256-8028				DOLL R, 1992, DOCUMENTS NRPB, V3, P35; FEYCHTING M, 1992, IMM692 KAR I PUBL; Floderus B, 1992, OCCUPATIONAL EXPOSUR; FULTON JP, 1980, AM J EPIDEMIOL, V111, P292, DOI 10.1093/oxfordjournals.aje.a112899; HIGGINSON J, 1992, HUMAN CANCER EPIDEMI, P479; JUUTILAINEN J, 1990, INT ARCH OCC ENV HEA, V62, P289, DOI 10.1007/BF00640835; JUUTILAINEN J, 1989, 289 IM VOIM OY RES R; LI FP, 1982, CANCER EPIDEMIOL, P1012; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; MYERS A, 1990, BRIT J CANCER, V62, P1008, DOI 10.1038/bjc.1990.428; OLSEN JH, 1993, BRIT MED J, V307, P891, DOI 10.1136/bmj.307.6909.891; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; VALJUS J, 1993, ELECTRICITY AND MAGNETISM IN BIOLOGY AND MEDICINE, P426; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; 1951, MANUAL TUMOR NOMENCL; 1992, PUBLICATION NATIONAL, V51	17	177	178	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					895	899		10.1136/bmj.307.6909.895	http://dx.doi.org/10.1136/bmj.307.6909.895			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241851	Green Published, Bronze			2022-12-01	WOS:A1993MB84700015
J	EMPTAGE, NJ; CAREW, TJ				EMPTAGE, NJ; CAREW, TJ			LONG-TERM SYNAPTIC FACILITATION IN THE ABSENCE OF SHORT-TERM FACILITATION IN APLYSIA NEURONS	SCIENCE			English	Article							PLEURAL SENSORY NEURONS; HETEROSYNAPTIC FACILITATION; TRANSMITTER RELEASE; PROTEIN-SYNTHESIS; K+ CURRENTS; CAMP; SEROTONIN; SENSITIZATION; EXCITABILITY; MODULATION	Serotonin (5-HT) induces both short-term and long-term facilitation of the identified synaptic connections between sensory and motor neurons of Aplysia. Three independent experimental approaches showed that long-term facilitation can normally be expressed in the absence of short-term facilitation: (i) The 5-HT antagonist cyproheptadine blocked the induction of short-term but not long-term facilitation; (ii) concentrations of 5-HT below threshold for the induction of short-term facilitation nonetheless induced long-term facilitation; and (iii) localized application of 5-HT to the sensory neuron cell body and proximal synapses induced long-term facilitation in distal synapses that were not exposed to 5-HT and had not expressed short-term facilitation. These results suggest that short-term and long-term synaptic facilitation are induced in parallel in the sensory neurons and that the short-term process, because it is induced and expressed at the synapse, can occur locally, but the long-term process, because of its dependence on a nuclear signal, is expressed throughout the neuron.	YALE UNIV, DEPT PSYCHOL, NEW HAVEN, CT 06520 USA; YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06520 USA	Yale University; Yale University					NIMH NIH HHS [R01-MH-14-1083] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Atkinson R. C., 1968, PSYCHOL LEARNING MOT, P89, DOI [10.1016/S0079-7421(08)60422-3, DOI 10.1016/S0079-7421(08)60422-3]; BADDELEY AD, 1970, J VERB LEARN VERB BE, V9, P176, DOI 10.1016/S0022-5371(70)80048-2; BAILEY CH, 1989, J NEUROSCI, V9, P1774; BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978, DOI 10.1152/jn.1990.64.3.978; BAXTER DA, 1989, J NEUROPHYSIOL, V62, P665, DOI 10.1152/jn.1989.62.3.665; BUONOMANO DV, 1990, SCIENCE, V249, P420, DOI 10.1126/science.2165631; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P345; CLARK G A, 1987, Society for Neuroscience Abstracts, V13, P390; CLARK GA, 1984, P NATL ACAD SCI-BIOL, V81, P2577, DOI 10.1073/pnas.81.8.2577; CLEARY LJ, 1985, SOC NEUR ABSTR, V11, P692; CROW T, 1993, J NEUROPHYSIOL, V69, P636, DOI 10.1152/jn.1993.69.2.636; DALE N, 1987, J NEUROSCI, V7, P2232; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; EMPTAGE NJ, UNPUB; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GOLDSMITH BA, 1992, P NATL ACAD SCI USA, V89, P11481, DOI 10.1073/pnas.89.23.11481; HAMMER M, 1989, NEUROSCI LETT, V104, P235, DOI 10.1016/0304-3940(89)90360-1; HAWKINS RD, 1984, PSYCHOL REV, V91, P375, DOI 10.1037/0033-295X.91.3.375; HEBB DO, 1949, ORG BEHAVIOR; HOCHNER B, 1992, P NATL ACAD SCI USA, V89, P11476, DOI 10.1073/pnas.89.23.11476; James W., 1890, PRINCIPLES PSYCHOL; MERCER AR, 1991, SCIENCE, V254, P1811, DOI 10.1126/science.1662413; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NAZIF FA, 1991, BRAIN RES, V539, P324, DOI 10.1016/0006-8993(91)91638-H; OCORR KA, 1985, P NATL ACAD SCI USA, V82, P2548, DOI 10.1073/pnas.82.8.2548; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766; SCHOLZ KP, 1988, SCIENCE, V240, P1664, DOI 10.1126/science.2837826; SCHWARTZ JH, 1981, J NEUROSCI, V1, P606; SHALLICE T, 1970, Q J EXP PSYCHOL, V22, P261, DOI 10.1080/00335557043000203; Squire L.R., 1987, MEMORY BRAIN; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; STARK LL, UNPUB; SUGITA S, 1992, J NEUROPHYSIOL, V68, P643, DOI 10.1152/jn.1992.68.2.643; WALTERS ET, 1987, J NEUROSCI, V7, P408; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543, DOI 10.1152/jn.1983.50.6.1543; ZHANG ZS, 1991, J COMP NEUROL, V311, P259, DOI 10.1002/cne.903110207; [No title captured]	39	181	183	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1993	262	5131					253	256		10.1126/science.8211146	http://dx.doi.org/10.1126/science.8211146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA665	8211146				2022-12-01	WOS:A1993MA66500039
J	BENNETT, M; REED, R				BENNETT, M; REED, R			CORRESPONDENCE BETWEEN A MAMMALIAN SPLICEOSOME COMPONENT AND AN ESSENTIAL YEAST SPLICING FACTOR	SCIENCE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; RNA POLYMERASE-II; BINDING DOMAIN; SNRNP PROTEIN; U2 SNRNP; SUBUNIT; GENE; RECOGNITION; REGULATORS; ACTIVATOR	None of the mammalian splicing factors that have been cloned corresponds to the yeast pre-messenger RNA splicing factors, the PRP proteins. Here, a generalizable strategy was used to isolate a complementary DNA encoding the mammalian spliceosome-associated protein (SAP) SAP 62. It is demonstrated that SAP 62 is the likely functional homolog of the yeast PRP11 protein. Both PRP11 and SAP 62 associate stably with the spliceosome, contain a single zinc finger, and display significant amino acid sequence similarity. Unlike PRP11, SAP 62 contains 22 proline-rich heptapeptide repeats at the carboxyl-terminus.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIGMS NIH HHS [GM43375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM043375, R01GM043375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; ANDERSON GJ, 1989, NATURE, V342, P819, DOI 10.1038/342819a0; ARENAS JE, 1993, P NATL ACAD SCI USA, V90, P6771, DOI 10.1073/pnas.90.14.6771; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; BEHRENS SE, IN PRESS P NATL ACAD; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BENNETT MA, UNPUB; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; BROSI R, IN PRESS J BIOL CHEM; CHAMPIONARNAUD P, UNPUB; CHANG TH, 1988, MOL CELL BIOL, V8, P2379, DOI 10.1128/MCB.8.6.2379; CHAPON C, 1992, EMBO J, V11, P3279, DOI 10.1002/j.1460-2075.1992.tb05406.x; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GARCIABLANCO MA, 1990, P NATL ACAD SCI USA, V87, P3082, DOI 10.1073/pnas.87.8.3082; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LEGRAIN P, 1990, EMBO J, V9, P2775, DOI 10.1002/j.1460-2075.1990.tb07465.x; LEGRAIN P, 1993, SCIENCE, V262, P108, DOI 10.1126/science.8211114; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REED RW, UNPUB; ROKEACH LA, 1989, J BIOL CHEM, V264, P5024; RUBY S, COMMUNICATION; RUBY SW, IN PRESS GENES DEV; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAPPERT K, 1991, MOL GEN GENET, V226, P277, DOI 10.1007/BF00273613; SILLEKENS PTG, 1988, NUCLEIC ACIDS RES, V16, P8307, DOI 10.1093/nar/16.17.8307; STAKNIS D, UNPUB; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WELLS SP, COMMUNICATION; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	46	78	81	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 1	1993	262	5130					105	108		10.1126/science.8211113	http://dx.doi.org/10.1126/science.8211113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ635	8211113				2022-12-01	WOS:A1993LZ63500033
J	NORTHROP, JP; HO, SN; CHEN, L; THOMAS, DJ; TIMMERMAN, LA; NOLAN, GP; ADMON, A; CRABTREE, GR				NORTHROP, JP; HO, SN; CHEN, L; THOMAS, DJ; TIMMERMAN, LA; NOLAN, GP; ADMON, A; CRABTREE, GR			NF-AT COMPONENTS DEFINE A FAMILY OF TRANSCRIPTION FACTORS TARGETED IN T-CELL ACTIVATION	NATURE			English	Article							NUCLEAR FACTOR; ANTIGEN RECEPTOR; MAMMALIAN-CELLS; LYMPHOCYTE; IDENTIFICATION; CALCINEURIN; COMPLEX; INVITRO; EVENTS; ASSAY	THE NF-AT transcription complex(1) is required far the expression of a group of proteins that collectively coordinate the immune response(2-4). Here we purify two proteins encoded by separate genes that represent the pre-existing (p) and cytosolic (c) components of NF-AT. Expression of the full-length complementary DNA encoding NF-AT(c) activates the interleukin (IL-2) promoter in non-T lymphocytes, whereas a dominant negative of NF-AT(c), specifically blocks activation of the IL-2 promoter in T lymphocytes, indicating that NF-AT(c) is required for IL-2 gene expression. NF-AT(c) RNA expression is largely restricted to lymphoid tissues and is induced upon T-cell activation. The other protein, NF-AT(p), is highly homologous to NF-AT(c) over a limited domain which shows similarity to the Dorsal/Rel family(5), but has a wider tissue distribution. Agents that increase intracellular Ca2+ or activate protein kinase C independently modify NF-AT(c), indicating that distinct signalling pathways converge on NF-AT(c) to regulate its function.	STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Stanford University; Stanford University; University of California System; University of California Berkeley	NORTHROP, JP (corresponding author), STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305, USA.		Nolan, Garry/AAE-7903-2019	Nolan, Garry/0000-0002-8862-9043				CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MIYATA T, 1979, J MOL EVOL, V12, P214; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; RIEGEL JS, 1990, J IMMUNOL, V144, P3611; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YASEEN NR, 1993, J BIOL CHEM, V268, P14285	20	543	560	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 9	1994	369	6480					497	502		10.1038/369497a0	http://dx.doi.org/10.1038/369497a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	8202141				2022-12-01	WOS:A1994NQ28600061
J	GRISSO, JA; KELSEY, JL; STROM, BL; OBRIEN, LA; MAISLIN, G; LAPANN, A; SAMELSON, L; HOFFMAN, S; ANTHONY, J; HIBBERD, A; CLANCY, M; COTLER, J; DELONG, W; ECKER, M; FRIEDENBERG, ZB; GOOD, R; HUMMER, C; JUNKIN, D; MARKMAN, W; MOOAR, P; STEIN, H; WOHL, M; WYNNE, B; ZASLOW, D; ANDREWS, D; PAVILION, A; DICK, H; HABERMANN, E; INSLER, H; MENEZES, P; ROSENTHAL, R; SADLER, A; SHELTON, M; TEICHER, J; ZICKEL, R				GRISSO, JA; KELSEY, JL; STROM, BL; OBRIEN, LA; MAISLIN, G; LAPANN, A; SAMELSON, L; HOFFMAN, S; ANTHONY, J; HIBBERD, A; CLANCY, M; COTLER, J; DELONG, W; ECKER, M; FRIEDENBERG, ZB; GOOD, R; HUMMER, C; JUNKIN, D; MARKMAN, W; MOOAR, P; STEIN, H; WOHL, M; WYNNE, B; ZASLOW, D; ANDREWS, D; PAVILION, A; DICK, H; HABERMANN, E; INSLER, H; MENEZES, P; ROSENTHAL, R; SADLER, A; SHELTON, M; TEICHER, J; ZICKEL, R			RISK-FACTORS FOR HIP FRACTURE IN BLACK-WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THIAZIDE DIURETICS; BONE-DENSITY; WHITE WOMEN; ESTROGEN; THERAPY; SURVIVAL; CALCIUM; RATES; FALLS; RACE	Background. Although more than 1 percent of black women 80 years of age or older have hip fractures each year, little is known about risk factors for hip fracture in these women. Methods. We carried out a case-control study involving 144 black women admitted with a first hip fracture to 1 of 30 hospitals in New York and Philadelphia. The controls were 218 black women living in the community who were matched to the case patients according to age and ZIP Code or telephone exchange and 181 hospitalized black women matched according to age and hospital. Information was obtained through personal interviews and was studied by multivariable logistic-regression analysis. Results. When the case patients were compared with the control subjects from the community, the women in the lowest quintile for body-mass index had a markedly increased risk of hip fracture as compared with the women in the highest quintile (odds ratio, 13.5; 95 percent confidence interval, 4.2 to 43.3). Postmenopausal estrogen therapy for one year or more was protective for women under 75 years of age (odds ratio, 0.1; 95 percent confidence interval, < 0.1 to 0.5). Factors associated with an increased risk of hip fracture included a history of stroke (odds ratio, 3.1; 95 percent confidence interval, 1.2 to 8.1), use of aids in walking (odds ratio, 5.6; 95 percent confidence interval, 2.7 to 11.5), and consumption of seven or more alcoholic drinks per week (odds ratio, 4.6; 95 percent confidence interval, 1.5 to 14.1). The results were similar when the case patients were compared with the hospitalized control subjects. Conclusions. Among black women thinness, previous stroke, use of aids in walking, and alcohol consumption are associated with an increased risk of hip fracture. Postmenopausal estrogen therapy protects against hip fracture in women under 75 years of age.	STANFORD UNIV,MED CTR,SCH MED,DEPT HLTH RES & POLICY,STANFORD,CA 94305; COLUMBIA UNIV,DIV EPIDEMIOL,NEW YORK,NY; MERCY CATHOLIC MED CTR,PHILADELPHIA,PA; TEMPLE UNIV,HLTH SCI CTR,PHILADELPHIA,PA 19140; THOMAS JEFFERSON UNIV HOSP,PHILADELPHIA,PA; COOPER HOSP UNIV MED CTR,CAMDEN,NJ; CHESTNUT HILL HOSP,PHILADELPHIA,PA; UNIV PENN,PRESBYTERIAN MED CTR,PHILADELPHIA,PA 19104; BRYN MAWR HOSP,BRYN MAWR,PA; CROZER CHESTER MED CTR,CHESTER,PA; SACRED HEART HOSP,ALLENTOWN,PA; ABINGTON MEM HOSP,ABINGTON,PA; JEANES HOSP,PHILADELPHIA,PA; MED COLL PENN,PHILADELPHIA,PA 19129; FRANKFORD HOSP,PHILADELPHIA,PA; ALBERT EINSTEIN MED CTR,PHILADELPHIA,PA; PHILADELPHIA COLL OSTEOPATH MED,PHILADELPHIA,PA; ST JOSEPHS HOSP,READING,PA; COLUMBIA PRESBYTERIAN MED CTR,NEW YORK,NY 10032; MONTEFIORE MED CTR,NEW YORK,NY; BRONX LEBANON HOSP CTR,BRONX,NY; INTERFAITH MED CTR,BROOKLYN,NY; LONG ISL JEWISH MED CTR,NEW HYDE PK,NY; JACOBI HOSP,BRONX,NY; HARLEM HOSP MED CTR,NEW YORK,NY; BROOKDALE HOSP MED CTR,BROOKLYN,NY; ST LUKES ROOSEVELT HOSP,NEW YORK,NY	Stanford University; Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Rutgers State University Camden; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Presbyterian Medical Center; Abington Memorial Hospital; Drexel University; Yeshiva University; Columbia University; NewYork-Presbyterian Hospital; Montefiore Medical Center; BronxCare Health System; Northwell Health; Mount Sinai St. Luke's; Mount Sinai West	GRISSO, JA (corresponding author), UNIV PENN,SCH MED,CTR CLIN EPIDEMIOL & BIOSTAT,DIV GEN INTERNAL MED,317R NURSING EDUC BLDG,PHILADELPHIA,PA 19104, USA.		Maislin, Greg/S-5322-2019		NIAMS NIH HHS [R01-AR35409] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035409] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1982, EPIDEMIOLOGIC RES; BELL NH, 1993, J BONE MINER RES, V8, P1111; CAULEY JA, 1993, ANN INTERN MED, V118, P666, DOI 10.7326/0003-4819-118-9-199305010-00002; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; DAWSONHUGHES B, 1993, J BONE MINER RES, V8, P779; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; FARMER ME, 1984, AM J PUBLIC HEALTH, V74, P1374, DOI 10.2105/AJPH.74.12.1374; FARMER ME, 1989, J AM GERIATR SOC, V37, P9, DOI 10.1111/j.1532-5415.1989.tb01562.x; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; FELSON DT, 1991, JAMA-J AM MED ASSOC, V265, P370, DOI 10.1001/jama.265.3.370; FURSTENBERG AL, 1987, J CHRON DIS, V40, P931, DOI 10.1016/0021-9681(87)90142-1; GAIL MH, 1981, BIOMETRIKA, V68, P703, DOI 10.1093/biomet/68.3.703; GARROW JS, 1985, INT J OBESITY, V9, P147; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; Hatten J, 1980, Health Care Financ Rev, V2, P53; HERZOG AR, 1988, J GERONTOL, V43, pS200, DOI 10.1093/geronj/43.6.S200; HOFFMAN S, 1993, OSTEOPOROSIS INT, V3, P171, DOI 10.1007/BF01623672; KAHN RL, 1960, AM J PSYCHIAT, V117, P326, DOI 10.1176/ajp.117.4.326; KAYE JM, 1990, GERONTOLOGIST, V30, P100, DOI 10.1093/geront/30.1.100; KELLIE SE, 1990, AM J PUBLIC HEALTH, V80, P326, DOI 10.2105/AJPH.80.3.326; KELSEY JL, 1987, NEW ENGL J MED, V316, P404, DOI 10.1056/NEJM198702123160709; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KUMANYIKA S, 1987, EPIDEMIOL REV, V9, P31, DOI 10.1093/oxfordjournals.epirev.a036307; MAGAZINER J, 1989, AM J PUBLIC HEALTH, V79, P274, DOI 10.2105/AJPH.79.3.274; MEIER DE, 1992, J BONE MINER RES, V7, P1181, DOI 10.1002/jbmr.5650071010; NIEVES JW, 1992, OSTEOPOROSIS INT, V2, P122, DOI 10.1007/BF01623818; ORTIZ O, 1992, AM J CLIN NUTR, V55, P8, DOI 10.1093/ajcn/55.1.8; PRUZANSKY ME, 1989, J ORTHOP RES, V7, P192, DOI 10.1002/jor.1100070206; RAY WA, 1989, LANCET, V1, P687; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; 1990, DHHS HRSA HRSPDV901; 1983, AMA DRUG EVALUATION	34	110	111	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1555	1559		10.1056/NEJM199406023302202	http://dx.doi.org/10.1056/NEJM199406023302202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NN215	8177244				2022-12-01	WOS:A1994NN21500002
J	GRINSTAFF, MW; HILL, MG; LABINGER, JA; GRAY, HB				GRINSTAFF, MW; HILL, MG; LABINGER, JA; GRAY, HB			MECHANISM OF CATALYTIC OXYGENATION OF ALKANES BY HALOGENATED IRON PORPHYRINS	SCIENCE			English	Article							TERT-BUTYL HYDROPEROXIDE; SELECTIVE AIR-OXIDATION; MOLECULAR-OXYGEN; HYDROXYLATION; COMPLEXES; SUBSTITUENTS	Halogenation of an iron porphyrin causes severe saddling of the macrocyclic structure and a large positive shift in the iron(III)/(II) redox couple. Although perhalogenated iron(II) porphyrins such as Fe(TFPPBr8) [H2TFPPBr8, beta-octabromo-tetrakis(pentafluorophenyl)-porphyrin] are relatively resistant to autoxidation, they rapidly reduce alkyl hydroperoxides. These and related reactivity studies suggest that catalysis of alkane oxygenation by Fe(TFPPBr8)Cl occurs through a radical-chain mechanism in which the radicals are generated by oxidation and reduction of alkyl hydroperoxides.	CALTECH,ARTHUR AMOS NOYES LAB CHEM PHYS,PASADENA,CA 91125	California Institute of Technology			Grinstaff, Mark/U-2829-2017	Grinstaff, Mark/0000-0002-5453-3668				BARKIGIA KM, 1990, J AM CHEM SOC, V112, P8851, DOI 10.1021/ja00180a029; BARTOLI JF, 1991, J CHEM SOC CHEM COMM, P440, DOI 10.1039/c39910000440; BOTTOMLEY LA, 1981, INORG CHEM, V20, P1348, DOI 10.1021/ic50219a003; BRUICE TC, 1991, J AM CHEM SOC, V113, P2747; CHANG CK, 1981, J CHEM SOC CHEM COMM, P778, DOI 10.1039/c39810000778; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; de Montellano P. R. Ortiz, 1986, CYTOCHROME P 450 STR; ELLIS PE, 1989, J CHEM SOC CHEM COMM, P1315, DOI 10.1039/c39890001315; ELLIS PE, 1990, COORDIN CHEM REV, V105, P181, DOI 10.1016/0010-8545(90)80022-L; ELLIS PE, 1989, CATAL LETT, V3, P389, DOI 10.1007/BF00771267; FUJII H, 1993, J AM CHEM SOC, V115, P4641, DOI 10.1021/ja00064a027; GOLD A, 1988, INORG CHIM ACTA, V150, P177, DOI 10.1016/S0020-1693(00)90594-2; GRAY HK, UNPUB; GRINSTAFF MW, UNPUB; LABINGER JA, IN PRESS CATAL LETT; LYONS JE, 1993, J CATAL, V141, P311, DOI 10.1006/jcat.1993.1139; LYONS JE, 1991, CATAL LETT, V8, P45, DOI 10.1007/BF00764382; MANDON D, 1992, INORG CHEM, V31, P2044, DOI 10.1021/ic00037a012; MANSUY D, 1993, COORDIN CHEM REV, V125, P129, DOI 10.1016/0010-8545(93)85013-T; MARSH RE, 1993, ACTA CRYSTALLOGR C, V49, P1339, DOI 10.1107/S0108270193000642; NAPPA MJ, 1985, INORG CHEM, V24, P4711, DOI 10.1021/ic00220a056; SCHAEFER WP, 1993, ACTA CRYSTALLOGR C, V49, P1342, DOI 10.1107/S0108270193000587; SCHAEFER WP, 1993, ACTA CRYSTALLOGR, V49, P1743; Sheldon R A., 1981, METAL CATALYZED OXID; TRAYLOR PS, 1984, J CHEM SOC CHEM COMM, P279, DOI 10.1039/c39840000279; TRAYLOR TG, 1993, J AM CHEM SOC, V115, P2775, DOI 10.1021/ja00060a027; TRAYLOR TG, 1987, INORG CHEM, V26, P1338, DOI 10.1021/ic00255a028; TRAYLOR TG, 1992, J AM CHEM SOC, V114, P1398; WIJESEKERA T, 1990, ANGEW CHEM, V29, P1928	29	323	327	4	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 27	1994	264	5163					1311	1313		10.1126/science.8191283	http://dx.doi.org/10.1126/science.8191283			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN767	8191283				2022-12-01	WOS:A1994NN76700040
J	NAIR, APK; HAHN, S; BANHOLZER, R; HIRSCH, HH; MORONI, C				NAIR, APK; HAHN, S; BANHOLZER, R; HIRSCH, HH; MORONI, C			CYCLOSPORINE-A INHIBITS GROWTH OF AUTOCRINE TUMOR-CELL LINES BY DESTABILIZING INTERLEUKIN-3 MESSENGER-RNA	NATURE			English	Article							MAST-CELLS; GM-CSF; EXPRESSION; CLONING; TRANSFORMATION; ACTIVATION; INVITRO; TRANSCRIPTION; CALCINEURIN; PROMOTER	IN T cells, cyclosporin A (CsA) exerts its immunosuppressive effect by preventing transcriptional induction of the expression of interleukin(IL)-2. This is achieved by a mechanism that involves binding of a CsA-cyclophilin complex to calcineurin, which in turn inhibits the phosphatase-controlled translocation of transcription factor NFAT to the nucleus(1-8). We have previously identified IL-3 as an autocrine oncogenic regulator in tumour cell lines generated by introducing the v-H-ras oncogene into IL-3-dependent mast cells(9-12). Here we report that CsA specifically blocks autocrine tumour cell growth. The mechanism involves down-regulation of IL-3 expression by destabilization of the messenger RNA and requires ongoing transcription. Transcripts from exogenous IL-3 genes lacking the (A + U)-rich element (ARE) in the 3' untranslated terminal repeat could not be destabilized, suggesting that at least part of this sequence, which is known to mediate decay of short-lived mRNA(13), participates in a CsA-sensitive regulatory mechanism.			NAIR, APK (corresponding author), UNIV BASEL,INST MED MICROBIOL,PETERSPL 10,CH-4003 BASEL,SWITZERLAND.			Hirsch, Hans H./0000-0003-0883-0423				ABRAMS JS, 1988, J IMMUNOL, V140, P131; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; ERB P, 1990, J IMMUNOL, V144, P790; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kelso A, 1989, GROWTH FACTORS, V1, P165, DOI 10.3109/08977198909029126; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; VANSNICK J, 1988, EUR J IMMUNOL, V18, P193; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68	28	105	107	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					239	242		10.1038/369239a0	http://dx.doi.org/10.1038/369239a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	8183344				2022-12-01	WOS:A1994NM06700058
J	ARONSON, JK				ARONSON, JK			WHATS IN A BRAND-NAME	BRITISH MEDICAL JOURNAL			English	Article											ARONSON, JK (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT CLIN PHARMACOL,OXFORD OX2 6HE,ENGLAND.							1993, CHEM DRUGGIST, V34	1	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 30	1994	308	6937					1140	1141		10.1136/bmj.308.6937.1140	http://dx.doi.org/10.1136/bmj.308.6937.1140			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK182	8173456	Green Published			2022-12-01	WOS:A1994NK18200020
J	OLSEN, JH; HERTZ, H; BLINKENBERG, K; VERDER, H				OLSEN, JH; HERTZ, H; BLINKENBERG, K; VERDER, H			VITAMIN-K REGIMENS AND INCIDENCE OF CHILDHOOD-CANCER IN DENMARK	BRITISH MEDICAL JOURNAL			English	Article									UNIV COPENHAGEN HOSP,DEPT PAEDIAT,DK-2100 COPENHAGEN,DENMARK; NATL BOARD HLTH,DK-1012 COPENHAGEN,DENMARK; HOLBAEK CENT HOSP,DEPT PAEDIAT,DK-4300 HOLBAEK,DENMARK	University of Copenhagen; Holbaek Hospital	OLSEN, JH (corresponding author), DANISH CANC SOC,DIV CANC EPIDEMIOL,DK-2100 COPENHAGEN,DENMARK.			Olsen, Jorgen Helge/0000-0001-9633-5662				BROWN PD, 1989, INT J EPIDEMIOL, V18, P546, DOI 10.1093/ije/18.3.546; DRAPER GJ, 1992, BRIT MED J, V305, P709, DOI 10.1136/bmj.305.6855.709; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301	5	38	38	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					895	896		10.1136/bmj.308.6933.895	http://dx.doi.org/10.1136/bmj.308.6933.895			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173370	Green Published			2022-12-01	WOS:A1994NE60000023
J	MCDANIEL, R; EBERTKHOSLA, S; HOPWOOD, DA; KHOSLA, C				MCDANIEL, R; EBERTKHOSLA, S; HOPWOOD, DA; KHOSLA, C			ENGINEERED BIOSYNTHESIS OF NOVEL POLYKETIDES	SCIENCE			English	Article							STREPTOMYCES-COELICOLOR A3(2); FATTY-ACID BIOSYNTHESIS; SYNTHASE GENE-CLUSTER; NUCLEOTIDE-SEQUENCE; ANTIBIOTIC ACTINORHODIN; DEDUCED FUNCTION; GLAUCESCENS; CLONING; ORGANIZATION; ANTHRAQUINONES	Polyketide synthases (PKSs) are multifunctional enzymes that catalyze the biosynthesis of a huge variety of carbon chains differing in their length and patterns of functionality and cyclization. Many polyketides are valuable therapeutic agents. A Streptomyces host-vector system has been developed for efficient construction and expression of recombinant PKSs. Using this expression system, several novel compounds have been synthesized in vivo in significant quantities. Characterization of these metabolites has provided new insights into key features of actinomycete aromatic PKS specificity. Thus, carbon chain length is dictated, at least in part, by a protein that appears to be distinctive to this family of PKSs, whereas the acyl carrier proteins of different PKSs can be interchanged without affecting product structure. A given ketoreductase can recognize and reduce polyketide chains of different length; this ketoreduction always occurs at the C-9 position. The regiospecificity of the first cyclization of the nascent polyketide chain is either determined by the ketoreductase, or the chain-extending enzymes themselves. However, the regiospecificity of the second cyclization is determined by a distinct cyclase, which can discriminate between substrates of different chain lengths.	STANFORD UNIV, DEPT CHEM ENGN, STANFORD, CA 94305 USA; JOHN INNES INST, JOHN INNES CTR, DEPT GENET, NORWICH NR4 7UH, NORFOLK, ENGLAND	Stanford University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center				Khosla, Chaitan/0000-0001-6529-495X				BARTEL PL, 1990, J BACTERIOL, V172, P4816, DOI 10.1128/jb.172.9.4816-4826.1990; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, UNPUB; CAMERON DW, 1981, AUST J CHEM, V34, P2401, DOI 10.1071/CH9812401; CHATER KF, 1992, CIBA F SYMP, V171, P144; COLE SP, 1987, J ANTIBIOT, V40, P340, DOI 10.7164/antibiotics.40.340; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; FERNANDEZMORENO MA, 1991, CELL, V66, P769, DOI 10.1016/0092-8674(91)90120-N; FU H, UNPUB; GRAMAJO HC, 1993, MOL MICROBIOL, V7, P837, DOI 10.1111/j.1365-2958.1993.tb01174.x; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1992, CIBA F SYMP, V171, P88; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HUTCHINSON CR, 1992, ACTINOMYCETOLOGY, V6, P49; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KHOSLA C, 1992, MOL MICROBIOL, V6, P3237, DOI 10.1111/j.1365-2958.1992.tb01778.x; KIESER T, 1991, METHOD ENZYMOL, V204, P430; KRUPA J, 1989, LIEBIGS ANN CHEM, P699; LYDIATE DJ, 1985, GENE, V35, P223, DOI 10.1016/0378-1119(85)90001-0; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; MALPARTIDA F, 1986, MOL GEN GENET, V205, P66, DOI 10.1007/BF02428033; MALPARTIDA F, 1984, NATURE, V309, P462, DOI 10.1038/309462a0; MALPARTIDA F, 1987, NATURE, V325, P818, DOI 10.1038/325818a0; MALPARTIDA F, COMMUNICATION; MCDANIEL R, IN PRESS J AM CHEM S; MUTH G, 1989, MOL GEN GENET, V219, P341, DOI 10.1007/BF00259605; O'Hagan D., 1991, POLYKETIDE METABOLIT; ROBINSON JA, 1991, PHILOS T ROY SOC B, V332, P107, DOI 10.1098/rstb.1991.0038; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SHERMAN DH, 1992, J BACTERIOL, V174, P6184, DOI 10.1128/JB.174.19.6184-6190.1992; SHERMAN DH, 1991, TETRAHEDRON, V47, P6029, DOI 10.1016/S0040-4020(01)86494-2; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; VOELKER TA, 1992, SCIENCE, V257, P72, DOI 10.1126/science.1621095; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; YUE S, 1986, J BACTERIOL, V167, P581, DOI 10.1128/jb.167.2.581-586.1986; ZHANG HL, 1990, J ORG CHEM, V55, P1682, DOI 10.1021/jo00292a053	40	385	426	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1993	262	5139					1546	1550		10.1126/science.8248802	http://dx.doi.org/10.1126/science.8248802			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248802				2022-12-01	WOS:A1993MK32900033
J	SHEN, B; HUTCHINSON, CR				SHEN, B; HUTCHINSON, CR			ENZYMATIC-SYNTHESIS OF A BACTERIAL POLYKETIDE FROM ACETYL AND MALONYL COENZYME-A	SCIENCE			English	Article							ACYL CARRIER PROTEIN; 6-METHYLSALICYLIC ACID SYNTHASE; CELL-SUSPENSION CULTURES; STREPTOMYCES-GLAUCESCENS; TETRACENOMYCIN-C; PETROSELINUM-HORTENSE; FLAVANONE SYNTHASE; GENE-CLUSTER; PENICILLIUM-PATULUM; NUCLEOTIDE-SEQUENCE	Microorganisms and plants manufacture a large collection of medically and commercially useful natural products called polyketides by a process that resembles fatty acid biosynthesis. Genetically engineered microorganisms with modified polyketide synthase (PKS) genes can produce new metabolites that may have new or improved pharmacological activity. A potentially general method to prepare cell-free systems for studying bacterial type II PKS enzymes has been developed that facilitates the purification and reconstitution of their constituent proteins. Selective expression of different combinations of the Streptomyces glaucescens tetracenomycin (Tcm) tcmJKLMN genes in a tcmGHIJKLMNO null background has been used to show that the Tcm PKS consists of at least the TcmKLMN proteins. Addition of the TcmJ protein to the latter four enzymes resulted in a greater than fourfold increase of overall activity and thus represents the optimal Tcm PKS. Polyclonal antibodies raised against each of the TcmKLMN proteins strongly inhibit the Tcm PKS, as do known inhibitors targeted to the active site Cys and Ser residues of a fatty acid synthase. This system exhibits a strict starter unit specificity because neither propionyl, butyryl, or isobutyryl coenzyme A substitute for acetyl coenzyme A in assembly of the Tcm decaketide. Because the Tcm PKS activity is significantly diminished by removal of the TcmM acyl carrier protein and can be restored by addition of separately purified TcmM to two different types of TcmM-deficient PKS, it should be possible to use such preparations to assay for each of the constituents of the Tcm PKS.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; UNIV WISCONSIN,SCH PHARM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [R01CA035381] Funding Source: NIH RePORTER; NCI NIH HHS [CA35381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1984, FATTY ACID METABOLIS, P29; Ali A., UNPUB; BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; DECKER H, 1993, J BACTERIOL, V175, P3876, DOI 10.1128/JB.175.12.3876-3886.1993; DECKER H, 1992, J BACTERIOL, V174, P3887; DIMROTH P, 1970, EUR J BIOCHEM, V13, P98, DOI 10.1111/j.1432-1033.1970.tb00904.x; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; GRAMAJO HC, 1991, J BACTERIOL, V173, P6475, DOI 10.1128/jb.173.20.6475-6483.1991; GUILFOILE PG, 1992, J BACTERIOL, V174, P3651, DOI 10.1128/JB.174.11.3651-3658.1992; HARRIS TM, 1986, PURE APPL CHEM, V58, P283, DOI 10.1351/pac198658020283; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HUNAITI AR, 1984, ARCH BIOCHEM BIOPHYS, V229, P426, DOI 10.1016/0003-9861(84)90172-3; HUTCHINSON CR, 1993, INDUSTRIAL MICROORGANISMS: BASIC AND APPLIED MOLECULAR GENETICS, P203; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Katz L., 1992, ANNU REP MED CHEM, V27, P129; KAWAGUCHI A, 1981, J BIOCHEM-TOKYO, V89, P337, DOI 10.1093/oxfordjournals.jbchem.a133207; KHOSLA C, 1992, MOL MICROBIOL, V6, P3237, DOI 10.1111/j.1365-2958.1992.tb01778.x; KHOSLA C, 1993, J BACTERIOL, V175, P2197, DOI 10.1128/JB.175.8.2197-2204.1993; KIM YS, 1980, J BIOL CHEM, V255, P686; KREUZALER F, 1975, EUR J BIOCHEM, V56, P205, DOI 10.1111/j.1432-1033.1975.tb02223.x; KREUZALER F, 1978, FEBS LETT, V94, P175, DOI 10.1016/0014-5793(78)80931-4; KREUZALER F, 1979, EUR J BIOCHEM, V99, P89, DOI 10.1111/j.1432-1033.1979.tb13235.x; LANZ T, 1991, J BIOL CHEM, V266, P9971; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MAYORGA ME, 1992, MOL GEN GENET, V235, P205, DOI 10.1007/BF00279362; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MONAGHAN RL, 1990, ANNU REV MICROBIOL, V44, P271; MOTAMEDI H, 1987, P NATL ACAD SCI USA, V84, P4445, DOI 10.1073/pnas.84.13.4445; OHAGEN D, 1991, POLYKETIDE METABOLIT; OKI T, 1981, J ANTIBIOT, V34, P783, DOI 10.7164/antibiotics.34.783; Omura S, 1981, Methods Enzymol, V72, P520; ROBERTS GA, 1993, EUR J BIOCHEM, V214, P305, DOI 10.1111/j.1432-1033.1993.tb17925.x; SCHOPPNER A, 1984, J BIOL CHEM, V259, P6806; SCHRODER G, 1988, EUR J BIOCHEM, V172, P161, DOI 10.1111/j.1432-1033.1988.tb13868.x; SCHUZ R, 1983, J BIOL CHEM, V258, P6730; SCOTTI C, 1993, GENE, V130, P65, DOI 10.1016/0378-1119(93)90347-6; SHEN B, 1992, J BACTERIOL, V174, P3818, DOI 10.1128/JB.174.11.3818-3821.1992; SHEN B, 1993, J NAT PROD, V56, P1288, DOI 10.1021/np50098a013; SHEN B, 1993, BIOCHEMISTRY-US, V32, P11149, DOI 10.1021/bi00092a026; SHEN B, 1993, BIOCHEMISTRY-US, V32, P6656, DOI 10.1021/bi00077a019; SIEBERS J, 1979, THESIS U GOTTINGEN G; SINGH N, 1987, ENZYME MECHANISMS, P534; SPENCER JB, 1992, BIOCHEM J, V288, P839, DOI 10.1042/bj2880839; SPENCER JB, 1992, BIOCHEMISTRY-US, V31, P9107, DOI 10.1021/bi00152a055; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; SUMMERS RG, UNPUB; SUMMERS RG, IN PRESS J BACTERIOL; TSAY JT, 1992, J BIOL CHEM, V267, P6807; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WANG IK, 1991, CAN J MICROBIOL, V37, P86, DOI 10.1139/m91-013; WEBER W, 1979, ARCH MICROBIOL, V121, P111, DOI 10.1007/BF00689973; YOSHIMOTO A, 1993, J ANTIBIOT, V46, P56, DOI 10.7164/antibiotics.46.56; [No title captured]	55	113	120	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1535	1540		10.1126/science.8248801	http://dx.doi.org/10.1126/science.8248801			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248801				2022-12-01	WOS:A1993MK32900030
J	TAVLADORAKI, P; BENVENUTO, E; TRINCA, S; DEMARTINIS, D; CATTANEO, A; GALEFFI, P				TAVLADORAKI, P; BENVENUTO, E; TRINCA, S; DEMARTINIS, D; CATTANEO, A; GALEFFI, P			TRANSGENIC PLANTS EXPRESSING A FUNCTIONAL SINGLE-CHAIN FV-ANTIBODY ARE SPECIFICALLY PROTECTED FROM VIRUS ATTACK	NATURE			English	Article							BUSHY STUNT VIRUS; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; MOSAIC-VIRUS; PROTEIN; INFECTION; GENE; RESOLUTION; DOMAINS; TOBACCO	EXPRESSION Of Viral genes in transgenic plants is a very effective tool for attenuating plant viral infection1-3. Nevertheless, the lack of generality and risk issues related to the expression of viral genes in plants4 might limit the exploitation of this strategy. Expression in plants of antibodies against essential viral proteins could provide an alternative approach to engineer viral resistance. Recently, expression of complete5-7 or engineered7-9 antibodies has been successfully achieved in plants. The engineered single-chain Fv antibody scFv (refs 10, 11) is particularly suitable for expression in plants because of its small size and the lack of assembly requirements. Here we present evidence that constitutive expression in transgenic plants of a scFv antibody, directed against the plant icosahedral tombusvirus artichoke mottled crinkle virus, causes reduction of infection incidence and delay in symptom development.	ENEA, DIPARTIMENTO RIC & SVILUPPO AGROIND, DIV INGN GENET, CP 2400, I-00100 ROME, ITALY; SISSA, I-34013 TRIESTE, ITALY	Italian National Agency New Technical Energy & Sustainable Economics Development; International School for Advanced Studies (SISSA)			DE MARTINIS, DOMENICO/G-2311-2015; Cattaneo, Antonino/AAA-7252-2019; CATTANEO, ANTONINO/K-4471-2016	DE MARTINIS, DOMENICO/0000-0002-7194-0564; Galeffi, Patrizia/0000-0002-0101-1751; TAVLADORAKI, Paraskevi/0000-0002-2570-6662; CATTANEO, ANTONINO/0000-0002-6975-8923				BEACHY RN, 1990, ANNU REV PHYTOPATHOL, V28, P451, DOI 10.1146/annurev.py.28.090190.002315; BENVENUTO E, 1991, PLANT MOL BIOL, V17, P865, DOI 10.1007/BF00037067; BIOCCA S, 1990, EMBO J, V9, P101, DOI 10.1002/j.1460-2075.1990.tb08085.x; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; DENEVE M, 1993, TRANSGENIC RES, V2, P227, DOI 10.1007/BF01977353; DEZOETEN GA, 1991, PHYTOPATHOLOGY, V81, P585; DURING K, 1990, PLANT MOL BIOL, V15, P281, DOI 10.1007/BF00036914; HANLEYBOWDOIN L, 1992, GENETIC ENG PLANT VI, P251; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; HOGLE J, 1983, J MOL BIOL, V171, P95, DOI 10.1016/S0022-2836(83)80315-5; JEFFERSON RA, 1987, EMBO J, V6, P3901; KIHLBERG BM, 1992, J BIOL CHEM, V267, P25583; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; MAULE AJ, 1983, J GEN VIROL, V64, P2655, DOI 10.1099/0022-1317-64-12-2655; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OTSUKI Y, 1969, VIROLOGY, V38, P497, DOI 10.1016/0042-6822(69)90167-6; OWEN M, 1992, BIO-TECHNOL, V10, P790, DOI 10.1038/nbt0792-790; PLUCKTHUN A, 1989, METHOD ENZYMOL, V178, P497; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; SELA I, 1986, METHOD ENZYMOL, V119, P734; TAVAZZA M, 1989, PLANT MOL BIOL, V13, P685, DOI 10.1007/BF00016023; TAVAZZA R, 1988, J PLANT PHYSIOL, V133, P640, DOI 10.1016/S0176-1617(88)80022-1; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WERGE TM, 1990, FEBS LETT, V274, P193, DOI 10.1016/0014-5793(90)81362-R; WILSON TMA, 1993, P NATL ACAD SCI USA, V90, P3134, DOI 10.1073/pnas.90.8.3134; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; ZHU XY, 1991, LABORATORY GUIDE CEL, P18	30	326	405	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	1993	366	6454					469	472		10.1038/366469a0	http://dx.doi.org/10.1038/366469a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247156				2022-12-01	WOS:A1993MK09800066
J	GHISLAIN, M; UDVARDY, A; MANN, C				GHISLAIN, M; UDVARDY, A; MANN, C			SACCHAROMYCES-CEREVISIAE 26S PROTEASE MUTANTS ARREST CELL-DIVISION IN G2/METAPHASE	NATURE			English	Article							N-END RULE; SACCHAROMYCES-CEREVISIAE; UBIQUITIN PATHWAY; INVIVO FUNCTION; YEAST; CYCLE; DEGRADATION; MITOSIS; MEMBER; FAMILY	WE isolated two mutants from the yeast Saccharomyces cerevisiae, cim3-1 and cim5-1, that arrest cell division in G2/metaphase at 37-degrees-C. CIM3 (identical to SUG1; ref. 1) and CIM5 are similar to each other and are members of a family of putative ATPases that have been proposed to be 26S protease subunits2. We show here that CIM5 is the functional yeast homologue of the human MSS1 protein3 and that homologues of CIM3 and CIM5 are present in a highly purified preparation of the Drosophila 26S protease4. The short-lived ubiquitin-proline-beta-galactosidase fusion protein is stabilized in cim mutants, but Leu-beta-galactosidase is not. The CLB2 and CLB3 cyclins also accumulate in the cim mutants. Thus the 26S protease is required in vivo for the degradation of ubiquitinated substrates and for anaphase chromosome separation.	CTR ETUD SACLAY, DEPT BIOL CELLULAIRE & MOLEC, SERV BIOCHIM & GENET MOLEC, F-91191 GIF SUR YVETTE, FRANCE; HUNGARIAN ACAD SCI, INST BIOCHEM, BIOL RES CTR, H-6701 SZEGED, HUNGARY	Hungarian Academy of Sciences; Hungarian Biological Research Center				Mann, Carl/0000-0001-7212-1512				BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; HARTWELL LH, 1985, GENETICS, V110, P381; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K	30	383	386	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1993	366	6453					358	362		10.1038/366358a0	http://dx.doi.org/10.1038/366358a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247132				2022-12-01	WOS:A1993MJ70500053
J	HOLTON, TA; BRUGLIERA, F; LESTER, DR; TANAKA, Y; HYLAND, CD; MENTING, JGT; LU, CY; FARCY, E; STEVENSON, TW; CORNISH, EC				HOLTON, TA; BRUGLIERA, F; LESTER, DR; TANAKA, Y; HYLAND, CD; MENTING, JGT; LU, CY; FARCY, E; STEVENSON, TW; CORNISH, EC			CLONING AND EXPRESSION OF CYTOCHROME-P450 GENES-CONTROLLING FLOWER COLOR	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; FLAVONOIDS; HYBRIDA	BLUE and violet flowers generally contain derivatives of delphinidin; red and pink flowers generally contain derivatives of cyanidin or pelargonidin1. Differences in hydroxylation patterns of these three major classes of anthocyanidins are controlled by the cytochrome P450 enzymes flavonoid 3'-hydroxylase and flavonoid 3',5'-hydroxylase. Here we report on the isolation of complementary DNA clones of two different flavonoid 3',5'-hydroxylase genes that are expressed in petunia flowers. Restriction-fragment length polymorphism mapping and complementation of mutant petunia lines showed that the flavonoid 3',5'-hydroxylase genes correspond to the genetic loci Hf1 and Hf2.	SUNTORY LTD,SHIMAMOTO,OSAKA 618,JAPAN; INRA,GENET & AMELIORAT PLANTES STN,F-21034 DIJON,FRANCE	Suntory Holdings Ltd; INRAE	HOLTON, TA (corresponding author), CALGENE PACIFIC PTY LTD,16 GIPPS ST,COLLINGWOOD,VIC 3066,AUSTRALIA.		Holton, Timothy A/A-7198-2011; Lester, Daniel/AAC-6429-2020	Lester, Daniel/0000-0003-2927-1384; Menting, John/0000-0003-3638-3544; Holton, Timothy/0000-0002-6651-8166				ASHIKARI T, 1989, APPL MICROBIOL BIOT, V30, P515; BOZAK KR, 1990, P NATL ACAD SCI USA, V87, P3904, DOI 10.1073/pnas.87.10.3904; BRUGLIERA F, IN PRESS PL J; CORNU A, 1990, GENETIC MAPS LOCUS M; DOONER HK, 1991, ANNU REV GENET, V25, P173, DOI 10.1146/annurev.ge.25.120191.001133; FORKMANN G, 1991, PLANT BREEDING, V106, P1, DOI 10.1111/j.1439-0523.1991.tb00474.x; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JERVIS L, 1989, J BIOTECHNOL, V11, P161, DOI 10.1016/0168-1656(89)90117-X; LAZO GR, 1991, BIO-TECHNOL, V9, P963, DOI 10.1038/nbt1091-963; MENTING JGT, 1992, THESIS LA TROBE U; MITZUTANI M, 1993, BIOCHEM BIOPH RES CO, V190, P875; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; RIVIERE JL, 1987, BIOCHIMIE, V69, P743, DOI 10.1016/0300-9084(87)90195-7; STEWART CB, 1989, PLANT PHYSIOL, V90, P534, DOI 10.1104/pp.90.2.534; STOTZ G, 1982, Z NATURFORSCH C, V37, P19; TURPEN T H, 1986, Biotechniques, V4, P14; WALLROTH M, 1986, MOL GEN GENET, V202, P6, DOI 10.1007/BF00330509; WIERING H, 1974, Genen en Phaenen, V17, P117	21	260	323	7	76	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					276	279		10.1038/366276a0	http://dx.doi.org/10.1038/366276a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232589				2022-12-01	WOS:A1993MH32500067
J	LUPSKI, JR; CHANCE, PF; GARCIA, CA				LUPSKI, JR; CHANCE, PF; GARCIA, CA			INHERITED PRIMARY PERIPHERAL NEUROPATHIES - MOLECULAR-GENETICS AND CLINICAL IMPLICATIONS OF CMT1A AND HNPP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARIE-TOOTH DISEASE; TREMBLER-J MOUSE; HEREDITARY MOTOR; TYPE-1A DUPLICATION; MYELIN PROTEIN; LINKAGE; MUTATION; FAMILIES; 17P11.2; PMP-22		BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,CTR HUMAN GENOME,HOUSTON,TX 77030; TEXAS CHILDRENS HOSP,HOUSTON,TX 77030; UNIV UTAH,MED CTR,DEPT PEDIAT,DIV MED GENET,SALT LAKE CITY,UT 84112; LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT NEUROL,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT PATHOL,NEW ORLEANS,LA 70112	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Utah System of Higher Education; University of Utah; Louisiana State University System; Louisiana State University System	LUPSKI, JR (corresponding author), BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,ANDERSON 609E,HOUSTON,TX 77030, USA.		Chance, Phillip/AAX-5826-2020					BEHSE F, 1972, BRAIN, V95, P777, DOI 10.1093/brain/95.4.777; BELLONE E, 1992, J MED GENET, V29, P492; BENOTHMANE K, 1993, GENOMICS, V17, P370; BIRD TD, 1982, AM J HUM GENET, V34, P388; BRADLEY WG, 1975, BRAIN, V98, P381, DOI 10.1093/brain/98.3.381; BRICE A, 1992, J MED GENET, V29, P807, DOI 10.1136/jmg.29.11.807; CHANCE PF, 1992, NEUROLOGY, V42, P2295, DOI 10.1212/WNL.42.12.2295; CHANCE PF, 1990, AM J HUM GENET, V47, P915; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; CHANCE PF, 1992, NEUROLOGY, V42, P2037, DOI 10.1212/WNL.42.10.2037; Charcot JM, 1886, REV MED-PARIS, V6, P97; COLLINS FS, 1992, CLIN RES, V39, P615; DAVIES DM, 1954, LANCET, V2, P266; De Jong J, 1947, PSYCHIAT NEUROL BL A, V50, P60; DEBRUYNE J, 1980, J NEUROL SCI, V47, P385, DOI 10.1016/0022-510X(80)90091-X; Dejerine J J, 1893, COMPTES RENDUS SOC B, V45, P63; Dyck P, 1993, PERIPHERAL NEUROPATH; Dyck P.J, 1993, PNP, P1094; DYCK PJ, 1968, ARCH NEUROL-CHICAGO, V18, P619, DOI 10.1001/archneur.1968.00470360041003; DYCK PJ, 1968, ARCH NEUROL-CHICAGO, V18, P603, DOI 10.1001/archneur.1968.00470360025002; DYCK PJ, 1981, ANN NEUROL, V10, P222, DOI 10.1002/ana.410100304; EARL CJ, 1964, Q J MED, V33, P481; GARCIA C A, 1990, Neurology, V40, P301; HALLAM PJ, 1992, ANN NEUROL, V31, P570, DOI 10.1002/ana.410310518; HAYASAKA K, 1992, BIOCHEM BIOPH RES CO, V186, P827, DOI 10.1016/0006-291X(92)90820-B; HAYASAKA K, 1993, NAT GENET, V5, P31, DOI 10.1038/ng0993-31; HENTATI A, 1992, GENOMICS, V12, P155, DOI 10.1016/0888-7543(92)90419-S; HOOGENDIJK JE, 1992, LANCET, V339, P181; KAKU DA, 1993, NEUROLOGY, V43, P1806, DOI 10.1212/WNL.43.9.1806; KAKU DA, IN PRESS NEUROLOGY; KILLIAN JM, 1979, ANN NEUROL, V5, P515, DOI 10.1002/ana.410050604; LUPSKI JR, 1993, AM J MED GENET, V45, P92, DOI 10.1002/ajmg.1320450122; LUPSKI JR, 1992, NAT GENET, V1, P29, DOI 10.1038/ng0492-29; LUPSKI JR, 1992, CLIN RES, V40, P645; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; LUPSKI JR, 1992, BRAIN PATHOL, V2, P337, DOI 10.1111/j.1750-3639.1992.tb00710.x; LUPSKI JR, 1991, CURRENT NEUROLOGY, P1; MACMILLAN JC, 1992, J MED GENET, V29, P12, DOI 10.1136/jmg.29.1.12; MADRID R, 1975, J NEUROL SCI, V25, P415, DOI 10.1016/0022-510X(75)90263-4; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; McKusick V.A., 1992, MENDELIAN INHERITANC; NICHOLSON GA, 1991, NEUROLOGY, V41, P547, DOI 10.1212/WNL.41.4.547; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; RAEYMAEKERS P, 1992, J MED GENET, V29, P5, DOI 10.1136/jmg.29.1.5; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; ROA BB, 1993, NAT GENET, V5, P189, DOI 10.1038/ng1093-189; ROA BB, 1993, NEW ENGL J MED, V329, P96, DOI 10.1056/NEJM199307083290205; ROA BB, 1993, NAT GENET, V5, P269, DOI 10.1038/ng1193-269; ROA BB, 1991, AM J MED SCI, V306, P177; Roa Benjamin B., 1993, V384, P187; SKRE H, 1974, CLIN GENET, V6, P98; STAAL A, 1965, NEUROLOGY, V15, P1008, DOI 10.1212/WNL.15.11.1008; SUTER U, 1993, TRENDS NEUROSCI, V16, P50, DOI 10.1016/0166-2236(93)90015-E; SUTER U, 1992, P NATL ACAD SCI USA, V89, P4382, DOI 10.1073/pnas.89.10.4382; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; TIMMERMAN V, 1992, J NEUROL SCI, V109, P41, DOI 10.1016/0022-510X(92)90091-X; TIMMERMAN V, 1992, NAT GENET, V1, P171, DOI 10.1038/ng0692-171; TOOTH H, 1986, PERONEAL TYPE PROGRE; UPADHYAYA M, 1993, HUM GENET, V91, P392; VALENTIJN LJ, 1992, NAT GENET, V2, P288, DOI 10.1038/ng1292-288; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; VANCE JM, 1989, EXP NEUROL, V104, P186, DOI 10.1016/S0014-4886(89)80013-5; WISE CA, 1993, AM J HUM GENET, V53, P853	64	77	77	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2326	2330		10.1001/jama.270.19.2326	http://dx.doi.org/10.1001/jama.270.19.2326			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230595				2022-12-01	WOS:A1993MF99300027
J	KUNDIG, TM; SCHORLE, H; BACHMANN, MF; HENGARTNER, H; ZINKERNAGEL, RM; HORAK, I				KUNDIG, TM; SCHORLE, H; BACHMANN, MF; HENGARTNER, H; ZINKERNAGEL, RM; HORAK, I			IMMUNE-RESPONSES IN INTERLEUKIN-2 DEFICIENT MICE	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; VESICULAR STOMATITIS-VIRUS; T-CELL PROLIFERATION; NATURAL-KILLER CELLS; DIFFERENTIATION FACTOR; INFECTION; ACTIVATION; INVIVO; EXPRESSION; MECHANISMS	The role of costimulatory signals in T cell induction was evaluated in mice lacking the interleukin-2 (IL-2) gene. In vitro secondary antiviral T cell responses were absent unless IL-2 was added, confirming the crucial role of IL-2 in vitro. In vivo, primary and secondary cytotoxic T cell responses against vaccinia and lymphocytic choriomeningitis virus were within normal ranges. B cell reactivity to vesicular stomatitis virus was not impaired. T helper cell responses were delayed but biologically functional. Natural killer cell activity was markedly reduced but inducible. These normal in vivo immune responses in IL-2-deficient mice question the importance of IL-2 as defined by in vitro studies.	UNIV WURZBURG,INST VIROL & IMMUNOBIOL,W-8700 WURZBURG,GERMANY	University of Wurzburg	KUNDIG, TM (corresponding author), UNIV ZURICH,INST EXPTL CHIRURG,SCHMELZBERGSTR 12,CH-8006 ZURICH,SWITZERLAND.		Schorle, Hubert/M-5001-2016; Schorle, Hubert/S-1713-2019	Schorle, Hubert/0000-0001-8272-0076; 				ASHMAN RB, 1979, J EXP MED, V150, P1277, DOI 10.1084/jem.150.5.1277; BENNINK JR, 1978, NATURE, V276, P829, DOI 10.1038/276829a0; BIRON CA, 1990, J EXP MED, V171, P173, DOI 10.1084/jem.171.1.173; BLANDEN RV, 1974, TRANSPLANT REV, V19, P56; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; BULLER RML, 1987, NATURE, V328, P77, DOI 10.1038/328077a0; CHARAN S, 1986, J VIROL, V57, P1139, DOI 10.1128/JVI.57.3.1139-1144.1986; CHARAN S, 1986, J IMMUNOL, V136, P3057; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; Claman H N, 1980, Adv Immunol, V30, P121, DOI 10.1016/S0065-2776(08)60195-9; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; FERNANDEZBOTRAN R, 1987, J EXP MED, V166, P1774; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GROMO G, 1987, NATURE, V327, P424, DOI 10.1038/327424a0; ISHIDA Y, 1989, J EXP MED, V170, P1103, DOI 10.1084/jem.170.4.1103; KASAIAN MT, 1990, J EXP MED, V171, P745, DOI 10.1084/jem.171.3.745; KASAIAN MT, 1989, J IMMUNOL, V142, P1287; KAST WM, 1986, J EXP MED, V164, P723, DOI 10.1084/jem.164.3.723; KUNDIG TM, UNPUB; LEFRANCOIS L, 1984, J VIROL, V51, P208, DOI 10.1128/JVI.51.1.208-214.1984; LEIST TP, 1989, SCAND J IMMUNOL, V30, P679, DOI 10.1111/j.1365-3083.1989.tb02476.x; LEIST TP, 1987, J IMMUNOL, V138, P2278; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; MEUER SC, 1984, P NATL ACAD SCI-BIOL, V81, P1509, DOI 10.1073/pnas.81.5.1509; MIMS CA, 1987, PATHOGENESIS INFECTI; MIZOUCHI T, 1989, J IMMUNOL, V142, P270; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; MOSKOPHIDIS D, 1989, P NATL ACAD SCI USA, V86, P3291, DOI 10.1073/pnas.86.9.3291; MOSKOPHIDIS D, 1987, EUR J IMMUNOL, V17, P937, DOI 10.1002/eji.1830170707; NOGUCHI M, 1993, CELL, V73, P247; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; OEHREN S, 1992, J EXP MED, V176, P1273; OGARRA A, 1986, P NATL ACAD SCI USA, V83, P5228, DOI 10.1073/pnas.83.14.5228; SADLACK B, IN PRESS CELL; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; TAKATSU K, 1987, P NATL ACAD SCI USA, V84, P4234, DOI 10.1073/pnas.84.12.4234; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; WAGNER H, 1978, J EXP MED, V148, P1523, DOI 10.1084/jem.148.6.1523; WAGNER RR, 1987, RHABDOVIRUSES; WIDMER MB, 1987, J EXP MED, V166, P1447, DOI 10.1084/jem.166.5.1447; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P897, DOI 10.1084/jem.147.3.897	49	404	414	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1059	1061		10.1126/science.8235625	http://dx.doi.org/10.1126/science.8235625			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235625				2022-12-01	WOS:A1993MG18700037
J	LAWSON, CL				LAWSON, CL			TANDEM BINDING IN CRYSTALS OF A TRP REPRESSOR-OPERATOR HALF-SITE COMPLEX	NATURE			English	Article							ESCHERICHIA-COLI; DNA; CRYSTALLOGRAPHY; DETECTOR	THE crystal structure of trp repressor tandemly bound in a 2:1 complex to a 16-base-pair palindromic DNA containing a central trp operator half-site has been determined and refined to 2.4 angstrom resolution. Despite dramatically different DNA sequence contexts and crystallization conditions, the protein/DNA interface is essentially identical to that seen in the original trp repressor/operator complex structure1. Water-mediated sequence recognition by trp repressor is likely to be related to the unusual end-on approach of the recognition helix (E), which allows sharing of the major groove by tandem dimers. The tandem complex model accounts for the mutational sensitivity of all trp operator base pairs. The structure also provides the first detailed view of the tandem interaction, revealing a key role for the amino-terminal arms.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544	Princeton University	LAWSON, CL (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.			Lawson, Catherine/0000-0002-3261-7035				BASS S, 1987, GENE DEV, V1, P565, DOI 10.1101/gad.1.6.565; BENNETT GN, 1978, J MOL BIOL, V121, P179, DOI 10.1016/S0022-2836(78)80004-7; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAREY J, 1993, J MOL BIOL, V234, P496, DOI 10.1006/jmbi.1993.1602; CAREY J, 1989, J BIOL CHEM, V264, P1941; CAREY J, 1991, J BIOL CHEM, V266, P24509; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; HARAN TE, 1992, EMBO J, V11, P3021, DOI 10.1002/j.1460-2075.1992.tb05372.x; HODEL A, IN PRESS ACTA CRYS A; HURLBURT BK, 1990, J BIOL CHEM, V265, P7853; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LAWSON CL, 1988, PROTEINS, V3, P18, DOI 10.1002/prot.340030103; LUISI BF, 1990, BIOCHIM BIOPHYS ACTA, V1048, P113, DOI 10.1016/0167-4781(90)90047-6; MARMORSTEIN RQ, 1989, NUCLEIC ACIDS MOL BI, V3, P56; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P226; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SIGLER PB, 1992, TRANSCRIPTIONAL REGU, V1, P475; STAACKE D, 1990, EMBO J, V9, P1963, DOI 10.1002/j.1460-2075.1990.tb08324.x; STRAUSS MG, 1990, NUCL INSTRUM METH A, V297, P275, DOI 10.1016/0168-9002(90)91376-M; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	29	151	153	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					178	182		10.1038/366178a0	http://dx.doi.org/10.1038/366178a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232559				2022-12-01	WOS:A1993MG21600064
J	BROSI, R; GRONING, K; BEHRENS, SE; LUHRMANN, R; KRAMER, A				BROSI, R; GRONING, K; BEHRENS, SE; LUHRMANN, R; KRAMER, A			INTERACTION OF MAMMALIAN SPLICING FACTOR SF3A WITH U2 SNRNP AND RELATION OF ITS 60-KD SUBUNIT TO YEAST PRP9	SCIENCE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; HEAT-SHOCK; COMPLEX-FORMATION; HELA-CELLS; RNA; PROTEINS; U1; PURIFICATION; SPLICEOSOME; PRECURSORS	In the assembly of a prespliceosome, U2 small nuclear ribonucleoprotein (snRNP) functions in pre-messenger RNA (mRNA) splicing together with splicing factors (SFs) 3a, SF3b, and several other proteins. The 17S but not the 12S form of U2 snRNP is active in splicing-complex formation. Here it is shown that the SF3a subunits correspond to three of the 17S U2 snRNP-specific polypeptides. SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP, which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome. Furthermore, the 60-kilodalton subunit of SF3a is related to the yeast splicing protein PRP9.	UNIV GENEVA,DEPT BIOL CELLULAIRE,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA,SWITZERLAND; PHILIPPS UNIV,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY	University of Geneva; Philipps University Marburg								ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; BACH M, 1990, METHOD ENZYMOL, V181, P232; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; BEHRENS SE, UNPUB; BEHRENS SE, IN PRESS P NATL ACAD; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BENNETT M, 1993, SCIENCE, V262, P105, DOI 10.1126/science.8211113; BENNETT MA, UNPUB; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BOND U, 1988, EMBO J, V7, P3509, DOI 10.1002/j.1460-2075.1988.tb03227.x; BROSI R, 1993, J BIOL CHEM, V268, P17640; BROSI R, UNPUB; CHANG TH, 1988, MOL CELL BIOL, V8, P2379, DOI 10.1128/MCB.8.6.2379; CHAPON C, 1992, EMBO J, V11, P3279, DOI 10.1002/j.1460-2075.1992.tb05406.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; KRAMER A, 1988, GENE DEV, V2, P1155, DOI 10.1101/gad.2.9.1155; KRAMER A, 1990, METHOD ENZYMOL, V181, P215; KRAMER A, UNPUB; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LEGRAIN P, 1993, SCIENCE, V262, P108, DOI 10.1126/science.8211114; LEGRAIN P, INPRESS GENES DEV; LEHMEIER T, 1990, NUCLEIC ACIDS RES, V18, P6475, DOI 10.1093/nar/18.22.6475; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; Moore M., 1993, RNA WORLD, P303; RUBY SW, IN PRESS GENES DEV; Sambrook J., 1989, MOL CLONING LAB MANU; SHUKLA RR, 1990, J BIOL CHEM, V265, P20377; TEMSAMANI J, 1991, J BIOL CHEM, V266, P20356; UTANS U, 1992, GENE DEV, V6, P631, DOI 10.1101/gad.6.4.631; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	39	127	127	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 1	1993	262	5130					102	105		10.1126/science.8211112	http://dx.doi.org/10.1126/science.8211112			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ635	8211112				2022-12-01	WOS:A1993LZ63500032
J	WANG, TC; CARDIFF, RD; ZUKERBERG, L; LEES, E; ARNOLD, A; SCHMIDT, EV				WANG, TC; CARDIFF, RD; ZUKERBERG, L; LEES, E; ARNOLD, A; SCHMIDT, EV			MAMMARY HYPERPLASIA AND CARCINOMA IN MMTV-CYCLIN D1 TRANSGENIC MICE	NATURE			English	Article							CELL-CYCLE; MOUSE STRAIN; ONCOGENE; PROTEIN; EXPRESSION; GENE; INT-2; CHROMOSOME-11Q13; OVEREXPRESSION; ABNORMALITIES	Physical associations between cyclins, viral oncogenes and tumour suppressor genes imply a central role for cyclins in growth control(1,2). Cyclin D1 was identified as a candidate oncogene (PRAD1) in tumour-specific DNA rearrangements(3,4) and is suspected to be a contributor to several types of neoplasms including breast cancer(5,6). Cyclin D1 also rescues G1 cyclin-defective Saccharomyces cerevisiae(7), and is a growth-regulated genes. Despite evidence suggesting that cyclin D1 is an oncogene, its ability to transform cells directly in culture remains controversial(9-16). To evaluate its potential to deregulate growth in vivo in a physiologically relevant tissue we overexpressed cyclin D1 in mammary cells in transgenic mice. We report here that overexpression of cyclin D1 resulted in abnormal mammary cell proliferation including the development of mammary adenocarcinomas. We conclude that overexpression of cyclin D1 deregulates cell proliferation and can induce tumorigenic changes in mammary tissues, suggesting that cyclin D1 indeed plays an important oncogenic role in breast cancer.	MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02129 USA; UNIV CALIF DAVIS, SCH MED, DEPT PATHOL, DAVIS, CA 95616 USA; MASSACHUSETTS GEN HOSP, DEPT MED, ENDOCRINE ONCOL LAB, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CHILDRENS SERV, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, DEPT MED, GASTROINTESTINAL UNIT, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; University of California System; University of California Davis; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital								BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JIANG W, 1993, ONCOGENE, V8, P3447; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LOVEC H, 1994, ONCOGENE, V9, P323; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORRIS DW, 1990, J VIROL, V64, P1794, DOI 10.1128/JVI.64.4.1794-1802.1990; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PATHAK VK, 1987, J NATL CANCER I, V78, P327; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROSEN PP, 1993, CANCER, V71, P3798, DOI 10.1002/1097-0142(19930615)71:12<3798::AID-CNCR2820711203>3.0.CO;2-S; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SCHUURING E, 1992, ONCOGENE, V7, P355; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	25	888	906	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	1994	369	6482					669	671		10.1038/369669a0	http://dx.doi.org/10.1038/369669a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	8208295				2022-12-01	WOS:A1994NT45900061
J	LOO, S; RINE, J				LOO, S; RINE, J			SILENCERS AND DOMAINS OF GENERALIZED REPRESSION	SCIENCE			English	Article							MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; TRANSCRIPTIONAL STATES; DIFFERENTIAL REPAIR; CHROMATIN STRUCTURE; UV DAMAGE; YEAST; HML; EXPRESSION	Gene expression can be affected by the chromosomal position of the gene. An example of this position effect is silencing of the HML and HMR mating-type loci of Saccharomyces cerevisiae. An in vitro assay revealed that silencing induced a transcription-independent general occlusion of the DNA at HMR from sequence-specific interactions of proteins with DNA. The minimum boundaries of the silenced chromatin structure were determined, as were the contributions of the E and I silencers to the size of the silenced domain. Examination of endonuclease-sensitive sites provided evidence that neither the integrity of the chromosomal duplex nor covalent linkage of the silencers to HMR was important for maintenance of the silenced structure in vitro.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031105, R37GM031105] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30ESO1896-12] Funding Source: Medline; NIGMS NIH HHS [GM31105] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; AXELROD A, 1991, MOL CELL BIOL, V11, P1080, DOI 10.1128/MCB.11.2.1080; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BUTNER K, 1986, MOL CELL BIOL, V6, P4440, DOI 10.1128/MCB.6.12.4440; CHENCLELAND TA, 1993, J BIOL CHEM, V268, P1118; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HERSKOWITZ I, 1992, MOL CELLULAR BIOL YE, V2, P583; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KLAR AJS, 1984, COLD SPRING HARB SYM, V49, P77, DOI 10.1101/SQB.1984.049.01.011; KLAR AJS, 1981, CELL, V25, P517, DOI 10.1016/0092-8674(81)90070-2; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; MAHONEY DJ, 1991, GENE DEV, V5, P605, DOI 10.1101/gad.5.4.605; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SCHNELL R, 1986, MOL CELL BIOL, V6, P494, DOI 10.1128/MCB.6.2.494; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; SUSSEL L, 1993, MOL CELL BIOL, V13, P3919, DOI 10.1128/MCB.13.7.3919; TARTOF KD, 1984, CELL, V37, P869, DOI 10.1016/0092-8674(84)90422-7; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; TERLETH C, 1990, MOL CELL BIOL, V10, P4678, DOI 10.1128/MCB.10.9.4678	43	189	192	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	1994	264	5166					1768	1771		10.1126/science.8209257	http://dx.doi.org/10.1126/science.8209257			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR600	8209257				2022-12-01	WOS:A1994NR60000045
J	SHEN, WH; MOORE, CCD; IKEDA, Y; PARKER, KL; INGRAHAM, HA				SHEN, WH; MOORE, CCD; IKEDA, Y; PARKER, KL; INGRAHAM, HA			NUCLEAR RECEPTOR STEROIDOGENIC FACTOR-1 REGULATES THE MULLERIAN-INHIBITING SUBSTANCE GENE - A LINK TO THE SEX DETERMINATION CASCADE	CELL			English	Article							THYROID-HORMONE RECEPTOR; POU-SPECIFIC DOMAIN; DNA-BINDING; DETERMINING REGION; FACTOR-I; RETINOIC ACID; KEY REGULATOR; NGFI-B; EXPRESSION; SRY	Normal mate sex differentiation requires that Sertoli cells in the embryonic testes produce Mullerian inhibiting substance (MIS), a TGF beta-like hormone that causes Mullerian duct regression. In primary Sertoli cells, the orphan nuclear receptor, steroidogenic factor 1 (SF-1), regulates the MIS gene by binding to a conserved upstream regulatory element. In heterologous (HeLa) cells, MIS gene activation by SF-1 requires removal of the SF-1 ligand-binding domain, implicating a Sertoli cell-specific ligand or cofactor. Finally, the sexually dimorphic expression of SF-1 during development coincides with MIS expression and Mullerian duct regression. We propose that SF-1 regulates MIS in vivo and participates directly in the process of mammalian sex determination.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,PROGRAM BIOMED SCI,SAN FRANCISCO,CA 94143; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	University of California System; University of California San Francisco; Duke University; Howard Hughes Medical Institute; Duke University; Duke University	SHEN, WH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143, USA.				NIDDK NIH HHS [NIDDK K11, NIDDK RO1] Funding Source: Medline; PHS HHS [R01] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEXANDERBRIDGES M, 1992, J CELL BIOCHEM, V48, P129, DOI 10.1002/jcb.240480204; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BOGAN JS, 1994, CELL, V76, P603, DOI 10.1016/0092-8674(94)90501-0; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CATE RL, 1990, HDB EXPT PHARM PEPTI, V95, P179; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1994, P NATL ACAD SCI USA, V91, P3368, DOI 10.1073/pnas.91.8.3368; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUERRIER D, 1990, J REPROD FERTIL, V88, P695; HAQQ C, 1992, GENOMICS, V12, P665, DOI 10.1016/0888-7543(92)90291-Y; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HONDA S, 1993, J BIOL CHEM, V268, P7494; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1994, IN PRESS MOL ENDOCRI; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JOSSO N, 1991, TRENDS ENDOCRIN MET, V2, P227, DOI 10.1016/1043-2760(91)90029-M; Jost A., 1973, Recent Progress Hormone Res, V29, P1; KAUFMAN MH, 1992, ATLAS MOUSE DEVELOPM; KNEBELMANN B, 1991, P NATL ACAD SCI USA, V88, P3767, DOI 10.1073/pnas.88.9.3767; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LEE MM, 1992, ENDOCRINOLOGY, V130, P847, DOI 10.1210/en.130.2.847; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LUO X, 1994, IN PRESS CELL, V77; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MCELREAVEY K, 1993, P NATL ACAD SCI USA, V90, P3368, DOI 10.1073/pnas.90.8.3368; MOORE CCD, 1992, SEMIN PERINATOL, V16, P266; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; PEPINSKY RB, 1988, J BIOL CHEM, V263, P18961; PESCHON JJ, 1992, MOL ENDOCRINOL, V6, P1403, DOI 10.1210/me.6.9.1403; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VILAIN E, 1992, AM J HUM GENET, V50, P1008; WILSON CA, 1993, MOL ENDOCRINOL, V7, P247, DOI 10.1210/me.7.2.247; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; ZWINGMAN T, 1993, P NATL ACAD SCI USA, V90, P814, DOI 10.1073/pnas.90.3.814	55	477	493	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 3	1994	77	5					651	661		10.1016/0092-8674(94)90050-7	http://dx.doi.org/10.1016/0092-8674(94)90050-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NQ123	8205615				2022-12-01	WOS:A1994NQ12300006
J	DUJON, B; ALEXANDRAKI, D; ANDRE, B; ANSORGE, W; BALADRON, V; BALLESTA, JPG; BANREVI, A; BOLLE, PA; BOLOTINFUKUHARA, M; BOSSIER, P; BOU, G; BOYER, J; BUITRAGO, MJ; CHERET, G; COLLEAUX, L; DALGNANFORNIER, B; DELREY, F; DION, C; DOMDEY, H; DUSTERHOFT, A; DUSTERHUS, S; ENTLAN, KD; ERFLE, H; ESTEBAN, PF; FELDMANN, H; FERNANDES, L; FOBO, GM; FRITZ, C; FUKUHARA, H; GABEL, C; GAILLON, L; CARCIACANTALEJO, JM; GARCIARAMIREZ, JJ; GENT, ME; GHAZVINI, M; GOFFEAU, A; GONZALEZ, A; GROTHUES, D; GUERREIRO, P; HEGEMANN, J; HEWITT, N; HILGER, F; HOLLENBERG, CP; HORAITIS, O; INDGE, KJ; JACQUIER, A; JAMES, CM; JAUNIAUX, JC; JIMENEZ, A; KEUCHEL, H; KIRCHRATH, L; KLEINE, K; KOTTER, P; LEGRAIN, P; LIEBL, S; LOUIS, EJ; SILVA, AME; MARCK, C; MONNIER, AL; MOSTL, D; MULLER, S; OBERMAIER, B; OLIVER, SG; PALLIER, C; PASCOLO, S; PFEIFFER, F; PHILIPPSEN, P; PLANTA, RJ; POHL, FM; POHL, TM; POHLMANN, R; PORTETELLE, D; PURNELLE, B; PUZOS, V; RAD, MR; RASMUSSEN, SW; REMACHA, M; REVUELTA, JL; RICHARD, GF; RIEGER, M; RODRIGUESPOUSADA, C; ROSE, M; RUPP, T; SANTOS, MA; SCHWAGER, C; SENSEN, C; SKALA, J; SOARES, H; SOR, F; STEGEMANN, J; TETTELIN, H; THIERRY, A; TZERMIA, M; URRESTARAZU, LA; VANDYCK, L; VANVLIETREEDIJK, JC; VALENS, M; VANDENBOL, M; VILELA, C; VISSERS, S; VON WETTSTEIN, D; VOSS, H; WIEMANN, S; XU, G; ZIMMERMANN, J; HAASEMANN, M; BECKER, I; MEWES, HW				DUJON, B; ALEXANDRAKI, D; ANDRE, B; ANSORGE, W; BALADRON, V; BALLESTA, JPG; BANREVI, A; BOLLE, PA; BOLOTINFUKUHARA, M; BOSSIER, P; BOU, G; BOYER, J; BUITRAGO, MJ; CHERET, G; COLLEAUX, L; DALGNANFORNIER, B; DELREY, F; DION, C; DOMDEY, H; DUSTERHOFT, A; DUSTERHUS, S; ENTLAN, KD; ERFLE, H; ESTEBAN, PF; FELDMANN, H; FERNANDES, L; FOBO, GM; FRITZ, C; FUKUHARA, H; GABEL, C; GAILLON, L; CARCIACANTALEJO, JM; GARCIARAMIREZ, JJ; GENT, ME; GHAZVINI, M; GOFFEAU, A; GONZALEZ, A; GROTHUES, D; GUERREIRO, P; HEGEMANN, J; HEWITT, N; HILGER, F; HOLLENBERG, CP; HORAITIS, O; INDGE, KJ; JACQUIER, A; JAMES, CM; JAUNIAUX, JC; JIMENEZ, A; KEUCHEL, H; KIRCHRATH, L; KLEINE, K; KOTTER, P; LEGRAIN, P; LIEBL, S; LOUIS, EJ; SILVA, AME; MARCK, C; MONNIER, AL; MOSTL, D; MULLER, S; OBERMAIER, B; OLIVER, SG; PALLIER, C; PASCOLO, S; PFEIFFER, F; PHILIPPSEN, P; PLANTA, RJ; POHL, FM; POHL, TM; POHLMANN, R; PORTETELLE, D; PURNELLE, B; PUZOS, V; RAD, MR; RASMUSSEN, SW; REMACHA, M; REVUELTA, JL; RICHARD, GF; RIEGER, M; RODRIGUESPOUSADA, C; ROSE, M; RUPP, T; SANTOS, MA; SCHWAGER, C; SENSEN, C; SKALA, J; SOARES, H; SOR, F; STEGEMANN, J; TETTELIN, H; THIERRY, A; TZERMIA, M; URRESTARAZU, LA; VANDYCK, L; VANVLIETREEDIJK, JC; VALENS, M; VANDENBOL, M; VILELA, C; VISSERS, S; VON WETTSTEIN, D; VOSS, H; WIEMANN, S; XU, G; ZIMMERMANN, J; HAASEMANN, M; BECKER, I; MEWES, HW			COMPLETE DNA-SEQUENCE OF YEAST CHROMOSOME-XI	NATURE			English	Article							OPEN READING FRAMES; SACCHAROMYCES-CEREVISIAE; KB SEGMENT; LEFT ARM; REVEALS 5; GENE; HOMOLOG; PROTEIN; GENOME; FRAGMENT	The complete DNA sequence of the yeast Saccharomyces cerevisiae chromosome XI has been determined. In addition to a compact arrangement of potential protein coding sequences, the 666,448-base-pair sequence has revealed general chromosome patterns; in particular, alternating regional variations in average base composition correlate with variations in local gene density along the chromosome. Significant discrepancies with the previously published genetic map demonstrate the need for using independent physical mapping criteria.	UNIV PARIS 06, INST PASTEUR, DEPT MOLEC BIOL, UFR 927, F-75724 PARIS 15, FRANCE; INST MOLEC BIOL & BIOTECHNOL, FDN RES & TECHNOL HELLAS, GR-71110 IRAKLION, GREECE; FREE UNIV BRUSSELS, PHYSIOL CELLULAIRE & GENET LEVURES LAB, B-1050 BRUSSELS, BELGIUM; EUROPEAN MOLEC BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV SALAMANCA, DEPT GENET & MICROBIOL, E-37007 SALAMANCA, SPAIN; UNIV AUTONOMA MADRID, E-28049 MADRID, SPAIN; FAC CIENCIAS MADRID, CSIC, CTR MOLEC BIOL, E-28049 MADRID, SPAIN; FAC SCI AGRON ETAT GEMBLOUX, MICROBIOL LAB, B-5030 GEMBLOUX, BELGIUM; UNIV PARIS 11, IGM, GENET MOLEC LAB, CNRS, URA 1354, F-91405 ORSAY, FRANCE; INST GULBENKIAN CIENCIAS, GENET MOLEC LAB, P-2781 OEIRAS, PORTUGAL; CTR UNIV ORSAY, INST CURIE, BIOL SECT, F-91405 ORSAY 15, FRANCE; LAB MOLEK BIOL, D-82152 MARTINSRIED, GERMANY; UNIV GIESSEN, INST MIKROBIOL & MOLEK BIOL, D-35392 GIESSEN, GERMANY; QUIAGEN GMBH, D-40724 HILDEN, GERMANY; UNIV FRANKFURT, INST MIKROBIOL, D-60439 FRANKFURT, GERMANY; UNIV MUNICH, INST PHYSIOL CHEM PHYS BIOCHEM & ZELLBIOL, D-80336 MUNICH, GERMANY; MAX PLANCK INST BIOCHEM, MIPS, D-82152 MARTINSRIED, GERMANY; UNIV DUSSELDORF, INST MIKROBIOL, D-40225 DUSSELDORF, GERMANY; BIOTECHNOL & MOLEK BIOL FORSCH, D-69259 WILHELMSFELD, GERMANY; UNIV MANCHESTER, INST SCI & TECHNOL, MANCHESTER BIOTECHNOL CTR, MANCHESTER M60 1QD, LANCS, ENGLAND; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; COMMISS EUROPEAN COMMUNITIES, B-1049 BRUSSELS, BELGIUM; DEUTSCH KREBSFORSCHUNGSZENTRUM, INSERM,U375, UNITE ANGEW TUMORVIROL & VIROL APPL ONCOL,ABT 0610, D-69009 HEIDELBERG, GERMANY; JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND; CTR ETUD SACLAY, CEA,DSV,DEPT BIOL CELLULAIRE & MOLEC, SERV BIOCHEM & GENET MOLEC, F-91191 GIF SUR YVETTE, FRANCE; UNIV BASEL, BIOZENTRUM, INST ANGEW MIKROBIOL, CH-4056 BASEL, SWITZERLAND; VRIJE UNIV AMSTERDAM, BIOCENTRUM AMSTERDAM, INST MOLEC BIOL SCI, DEPT BIOCHEM & MOLEC BIOL, 1081 HV AMSTERDAM, NETHERLANDS; UNIV KONSTANZ, FAK BIOL, D-78434 CONSTANCE, GERMANY; GESELL ANAL TECH & CONSULTING, D-78467 CONSTANCE, GERMANY; CARLSBERG LAB, DEPT PHYSIOL, DK-2500 COPENHAGEN, DENMARK	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Foundation for Research & Technology - Hellas (FORTH); Universite Libre de Bruxelles; Vrije Universiteit Brussel; European Molecular Biology Laboratory (EMBL); University of Salamanca; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); University of Liege; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Instituto Gulbenkian de Ciencia; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Justus Liebig University Giessen; Goethe University Frankfurt; University of Munich; Max Planck Society; Heinrich Heine University Dusseldorf; University of Manchester; Universite Catholique Louvain; Helmholtz Association; German Cancer Research Center (DKFZ); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Oxford; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Basel; University of Amsterdam; Vrije Universiteit Amsterdam; University of Konstanz	DUJON, B (corresponding author), UNIV PARIS 06, INST PASTEUR, DEPT MOLEC BIOL, CNRS, UNITE MOLEC LEVURES 1149, F-75724 PARIS 15, FRANCE.		Richard, Guy-Franck/ABB-9185-2021; Ansorge, Wilhelm/AAN-8780-2020; Sensen, Christoph W./C-1798-2013; Santos, Maria Angeles/H-2239-2015; Pfeiffer, Friedhelm/K-1757-2019; Dujon, Bernard A/F-4971-2010; COLLEAUX, LAURENCE/AAA-8144-2022; Baladron, Victoriano/L-1758-2014; Soares, Helena/G-3065-2010; Revuelta, Jose Luis/ABG-1502-2020; Esteban, Pedro Felipe/ABF-9680-2021; Louis, Edward/B-7920-2008; fernandes, lisete/E-6522-2016; Garcia-Ramirez, Jose J/L-2153-2014; André, Bruno/D-1725-2010; Revuelta, Jose L/C-2324-2012; COLLEAUX, Laurence/H-6455-2017; Remacha, Miguel/G-1250-2016; Wiemann, Stefan/E-4424-2013; Bossier, Peter GM/A-8118-2008; del Rey, Francisco/L-7132-2014; Mewes, Hans-Werner/A-8204-2019; Bou, German/H-6683-2015	Sensen, Christoph W./0000-0001-9604-8962; Santos, Maria Angeles/0000-0002-1257-7611; Pfeiffer, Friedhelm/0000-0003-4691-3246; COLLEAUX, LAURENCE/0000-0002-0987-7648; Baladron, Victoriano/0000-0003-4574-8760; Soares, Helena/0000-0001-6180-7041; Revuelta, Jose Luis/0000-0001-7838-5308; Esteban, Pedro Felipe/0000-0002-8760-7512; Louis, Edward/0000-0003-1157-3608; fernandes, lisete/0000-0002-3384-2031; Garcia-Ramirez, Jose J/0000-0002-8348-3727; Revuelta, Jose L/0000-0001-7838-5308; Wiemann, Stefan/0000-0003-4683-3174; Bossier, Peter GM/0000-0002-6165-9111; del Rey, Francisco/0000-0002-6517-7400; Buitrago, Maria Jose/0000-0003-1878-6067; JACQUIER, ALAIN/0000-0001-5707-9184; Mewes, Hans-Werner/0000-0002-9713-6398; Guerreiro, Paulo/0000-0002-0070-7757; Maia e Silva, Alexandra/0000-0001-8385-8739; Bou, German/0000-0001-8837-0062; Garcia-Cantalejo, Jesus/0000-0001-6465-1273; Rodrigues-Pousada, Claudina/0000-0002-5075-3639; Bolotin-Fukuhara, Monique/0000-0002-5285-5006	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEXANDRAKI D, IN PRESS YEAST; ANSORGE W, 1986, J BIOCHEM BIOPH METH, V13, P315, DOI 10.1016/0165-022X(86)90038-2; BERNARDI G, 1993, GENE, V135, P57, DOI 10.1016/0378-1119(93)90049-9; BOSSIER P, IN PRESS YEAST; BOU G, 1993, YEAST, V9, P1349, DOI 10.1002/yea.320091209; BOYER J, 1993, YEAST, V9, P279, DOI 10.1002/yea.320090307; CHERET G, 1993, YEAST, V9, P1259, DOI 10.1002/yea.320091113; CHURCH GM, 1988, SCIENCE, V240, P185, DOI 10.1126/science.3353714; COLLEAUX L, 1992, YEAST, V8, P325, DOI 10.1002/yea.320080410; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DERSHOWITZ A, 1993, MOL CELL BIOL, V13, P39; DUSTERHOFT A, 1992, YEAST, V8, P749, DOI 10.1002/yea.320080908; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; FORROVA H, 1992, YEAST, V8, P419, DOI 10.1002/yea.320080509; GARCIACANTALEJO J, 1994, YEAST, V10, P221; HONORE N, 1993, MOL MICROBIOL, V7, P207, DOI 10.1111/j.1365-2958.1993.tb01112.x; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; JAMES CM, 1994, YEAST, V10, P257, DOI 10.1002/yea.320100212; JAMES CM, 1994, YEAST, V10, P247, DOI 10.1002/yea.320100211; KARLIN S, 1993, NUCLEIC ACIDS RES, V21, P703, DOI 10.1093/nar/21.3.703; KOONIN EV, 1994, EMBO J, V13, P493, DOI 10.1002/j.1460-2075.1994.tb06287.x; KUNST F, 1991, RES MICROBIOL, V142, P905, DOI 10.1016/0923-2508(91)90072-I; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; LOUIS EJ, 1992, GENETICS, V131, P559; MCCOMBIE WR, 1992, NAT GENET, V1, P124, DOI 10.1038/ng0592-124; MEYEROWITZ EM, 1985, SCIENCE, V229, P1214, DOI 10.1126/science.229.4719.1214; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PALLIER C, 1993, YEAST, V9, P1149, DOI 10.1002/yea.320091016; PASCOLO S, 1992, YEAST, V8, P987, DOI 10.1002/yea.320081109; POHL FM, 1987, METHOD ENZYMOL, V155, P250; PURNELLE B, 1992, YEAST, V8, P977, DOI 10.1002/yea.320081108; PURNELLE B, 1994, YEAST, V10, P125, DOI 10.1002/yea.320100112; PURNELLE B, 1993, YEAST, V9, P1379, DOI 10.1002/yea.320091212; RASMUSSEN SW, IN PRESS YEAST; RHODE PR, 1989, GENE DEV, V3, P1926, DOI 10.1101/gad.3.12a.1926; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SINGERKRUGER B, IN PRESS J CELL BIOL; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; THIERRY A, 1992, NUCLEIC ACIDS RES, V20, P5625, DOI 10.1093/nar/20.21.5625; TZERMIA M, IN PRESS YEAST; VANDENBOL M, IN PRESS YEAST; VANVLIETREEDIJK JC, 1993, YEAST, V9, P1139, DOI 10.1002/yea.320091015; VASSAROTTI A, 1992, TRENDS BIOTECHNOL, V10, P15, DOI 10.1016/0167-7799(92)90160-W; VASSAROTTI A, IN PRESS J BIOTECH; VOYTAS DF, 1992, NATURE, V358, P717, DOI 10.1038/358717a0; WICKSTEED BL, 1994, YEAST, V10, P39, DOI 10.1002/yea.320100105; WIEMANN S, 1993, YEAST, V9, P1343, DOI 10.1002/yea.320091208; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	52	323	682	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					371	378		10.1038/369371a0	http://dx.doi.org/10.1038/369371a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	8196765				2022-12-01	WOS:A1994NP17400047
J	HARDY, MA; GOODMAN, ER				HARDY, MA; GOODMAN, ER			TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL-TRANSPLANTATION; ANTIBODIES; EXPERIENCE				HARDY, MA (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY, USA.							BARKER CF, 1991, TXB SURGERY, P383; CACCIARELLI T, 1993, CLIN NEPHROL, V39, P335; CRAMER DV, 1993, TRANSPLANT P, V25, P23; DEIERHOI MH, 1993, ANN SURG, V217, P476, DOI 10.1097/00000658-199305010-00007; DEMETRIS AJ, 1992, HEPATOLOGY, V16, P671, DOI 10.1002/hep.1840160310; Goodman E R, 1992, Clin Transpl, P285; HARDY MA, 1991, ANN SURG, V214, P522, DOI 10.1097/00000658-199110000-00016; LINDHOLM A, 1993, TRANSPLANTATION, V56, P307, DOI 10.1097/00007890-199308000-00010; LOBO PI, 1993, TRANSPLANTATION, V55, P1063, DOI 10.1097/00007890-199305000-00023; MERION RM, 1991, HEPATOLOGY, V14, P572, DOI 10.1002/hep.1840140327; NELSON PW, 1992, AM J SURG, V164, P541, DOI 10.1016/S0002-9610(05)81197-3; NYBERG G, 1993, TRANSPLANT P, V25, P1062; STARNES VA, 1992, J THORAC CARDIOV SUR, V104, P1060; 1993, UNITED NETWORK ORGAN, V9, P46; 1993, 1993 UN NETW ORG SHA	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	1994	271	21					1716	1717						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN117	8182869				2022-12-01	WOS:A1994NN11700048
J	NOVOGRODSKY, A; VANICHKIN, A; PATYA, M; GAZIT, A; OSHEROV, N; LEVITZKI, A				NOVOGRODSKY, A; VANICHKIN, A; PATYA, M; GAZIT, A; OSHEROV, N; LEVITZKI, A			PREVENTION OF LIPOPOLYSACCHARIDE-INDUCED LETHAL TOXICITY BY TYROSINE KINASE INHIBITORS	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; MOUSE PERITONEAL-MACROPHAGES; NITRIC-OXIDE; ENDOTOXIC-SHOCK; INTERLEUKIN-1; PHOSPHORYLATION; RESISTANT; RECEPTOR; MICE; MONOCYTOGENES	Septic shock results from excessive stimulation of the host immune system, especially macrophages, by lipopolysaccharide (LPS), or endotoxin, which resides on the outer membrane of bacteria. Protein tyrosine kinase inhibitors of the tyrphostin AG 126 family protect mice against LPS-induced lethal toxicity. The protection correlates with the ability of these agents to block LPS-induced production of tumor necrosis factor alpha (tNF-alpha) and nitric oxide in macrophages as well as LPS-induced production of TNF-alpha in vivo. Furthermore, this inhibitory effect correlated with the potency of AG 126 to block LPS-induced tyrosine phosphorylation of a p42(MAPK) protein substrate in the murine macrophage.	TEL AVIV UNIV,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL; HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem	NOVOGRODSKY, A (corresponding author), FELSENSTEIN MED RES CTR,BEILINSON CAMPUS,IL-49100 PETAH TIQWA,ISRAEL.							BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOHMER F, UNPUB; COYNE DW, 1990, BIOCHEM BIOPH RES CO, V173, P718, DOI 10.1016/S0006-291X(05)80094-4; DING AH, 1988, J IMMUNOL, V141, P2407; DONG Z, 1993, J EXP MED, V177, P1971; DONG ZY, 1993, J LEUKOCYTE BIOL, V53, P53, DOI 10.1002/jlb.53.1.53; DONG ZY, 1993, J IMMUNOL, V151, P2717; EVERAERDT B, 1989, BIOCHEM BIOPH RES CO, V163, P378, DOI 10.1016/0006-291X(89)92146-3; GADINA M, 1991, J EXP MED, V173, P1305, DOI 10.1084/jem.173.6.1305; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GAZIT A, UNPUB; GEUNTER CA, 1969, J APPL PHYSIOL, V26, P780; GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; GUY GR, 1991, J BIOL CHEM, V266, P14343; HOFFBARD AV, 1990, BLOOD, V75, P88; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; KILBOURN RG, 1992, J NATL CANCER I, V84, P827, DOI 10.1093/jnci/84.11.827; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KOHMO M, 1990, BIOCHEM J, V267, P91; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; MARCZIN N, 1993, AM J PHYSIOL, V265, pH110; MUNOZ E, 1992, EUR J IMMUNOL, V22, P1391, DOI 10.1002/eji.1830220610; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; Parrillo J E, 1993, N Engl J Med, V328, P1471; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RAETZ CR, 1990, ANN REV BIOCH, V59, P124; REMICK DG, 1989, LAB INVEST, V60, P766; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TSUNAWAKI S, 1984, J BIOL CHEM, V259, P4305; VICTOR I, 1993, J BIOL CHEM, V268, P18994; WALLACH D, 1988, J IMMUNOL, V140, P2994; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; ZANG X, 1993, J EXP MED, V177, P511; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001	40	339	352	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 27	1994	264	5163					1319	1322		10.1126/science.8191285	http://dx.doi.org/10.1126/science.8191285			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN767	8191285				2022-12-01	WOS:A1994NN76700043
J	TOMFOHRDE, J; SILVERMAN, A; BARNES, R; FERNANDEZVINA, MA; YOUNG, M; LORY, D; MORRIS, L; WUEPPER, KD; STASTNY, P; MENTER, A; BOWCOCK, A				TOMFOHRDE, J; SILVERMAN, A; BARNES, R; FERNANDEZVINA, MA; YOUNG, M; LORY, D; MORRIS, L; WUEPPER, KD; STASTNY, P; MENTER, A; BOWCOCK, A			GENE FOR FAMILIAL PSORIASIS SUSCEPTIBILITY MAPPED TO THE DISTAL END OF HUMAN-CHROMOSOME 17Q	SCIENCE			English	Article							PEDIGREE-MEMBER METHOD; LINKAGE ANALYSIS; IMMUNE-SYSTEM; INSULIN GENE; DNA; HLA; AMPLIFICATION; ASSOCIATIONS; SELECTION; ALLELES	A gene involved in psoriasis susceptibility was localized to the distal region of human chromosome 17q as a result of a genome-wide linkage analysis with polymorphic microsatellites and eight multiply affected psoriasis kindreds. In the family which showed the strongest evidence for linkage, the recombination fraction between a psoriasis susceptibility locus and D17S784 was 0.04 with a maximum two-point lod score of 5.33. There was also evidence for genetic heterogeneity and although none of the linked families showed any association with HLA-Cw6, two unlinked families showed weak levels of association. This study demonstrates that in some families, psoriasis susceptibility is due to variation at a single major genetic locus other than the human lymphocyte antigen locus.	UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX 75235 USA; BAYLOR UNIV, MED CTR, CTR PSORIASIS, DALLAS, TX 75246 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA; OREGON HLTH SCI UNIV, DEPT DERMATOL, PORTLAND, OR 97201 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor University; Baylor University Medical Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Oregon Health & Science University			menter md, alan/A-8250-2009	Bowcock, Anne/0000-0001-8691-9090	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047145] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL47145] Funding Source: Medline; NIAID NIH HHS [P01-AI2327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAADSGAARD O, 1990, J INVEST DERMATOL, V95, pS32, DOI 10.1111/1523-1747.ep12505715; BAKER BS, 1993, BRIT J DERMATOL, V128, P493, DOI 10.1111/j.1365-2133.1993.tb00224.x; BARKER JNWN, 1991, LANCET, V338, P227, DOI 10.1016/0140-6736(91)90357-U; BECKMANN JS, 1993, HUM MOL GENET, V2, P2019, DOI 10.1093/hmg/2.12.2019; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BOS JD, 1988, BRIT J DERMATOL, V118, P141, DOI 10.1111/j.1365-2133.1988.tb01768.x; BOWCOCK A, 1993, GENOMICS, V15, P376, DOI 10.1006/geno.1993.1071; BRANDRUP F, 1978, ARCH DERMATOL, V114, P874, DOI 10.1001/archderm.114.6.874; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHRISTOPHERS E, 1989, ACTA DERM-VENEREOL, P88; CIVATTE J, 1977, ANN DERMATOL VENER, V104, P525; DUVIC M, 1990, J INVEST DERMATOL, V95, pS38, DOI 10.1111/1523-1747.ep12505743; DUYK GM, 1990, P NATL ACAD SCI USA, V87, P8995, DOI 10.1073/pnas.87.22.8995; ESPINOZA LR, 1980, J RHEUMATOL, V7, P445; FEDER J, 1985, AM J HUM GENET, V37, P635; FERNANDEZVINA M, 1991, HUM IMMUNOL, V30, P60, DOI 10.1016/0198-8859(91)90072-H; FERNANDEZVINA MA, 1991, IMMUNOGENETICS, V34, P299, DOI 10.1007/BF00211994; GYAPAY G, IN PRESS NATURE GENE; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HENSELER T, 1985, J AM ACAD DERMATOL, V13, P450, DOI 10.1016/S0190-9622(85)70188-0; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; KARVONEN J, 1976, ANN CLIN RES, V8, P298; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LI C, 1992, GENOMICS, V13, P665, DOI 10.1016/0888-7543(92)90139-J; LI C, 1991, P NATL ACAD SCI USA, V88, P7739, DOI 10.1073/pnas.88.17.7739; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MENTER A, 1991, LANCET, V338, P231, DOI 10.1016/0140-6736(91)90358-V; Ott J., 1991, ANAL HUMAN GENETIC L; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PIETRZYK JJ, 1982, ARCH DERMATOL RES, V273, P295, DOI 10.1007/BF00409258; SCHROEDER M, IN PRESS GENET EPIDE; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; THOMSON G, 1989, GENET EPIDEMIOL, V6, P155, DOI 10.1002/gepi.1370060129; TIILIKAINEN A, 1980, BRIT J DERMATOL, V102, P179, DOI 10.1111/j.1365-2133.1980.tb05690.x; WATSON W, 1972, ARCH DERMATOL, V105, P197, DOI 10.1001/archderm.105.2.197; WEEKS DE, 1988, AM J HUM GENET, V42, P315; WEEKS DE, 1992, AM J HUM GENET, V50, P859; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	40	321	332	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	1994	264	5162					1141	1145		10.1126/science.8178173	http://dx.doi.org/10.1126/science.8178173			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM146	8178173				2022-12-01	WOS:A1994NM14600031
J	HARRIS, B; LOVETT, L; NEWCOMBE, RG; READ, GF; WALKER, R; RIADFAHMY, D				HARRIS, B; LOVETT, L; NEWCOMBE, RG; READ, GF; WALKER, R; RIADFAHMY, D			MATERNITY BLUES AND MAJOR ENDOCRINE CHANGES - CARDIFF PUERPERAL MOOD AND HORMONE STUDY .2.	BRITISH MEDICAL JOURNAL			English	Article							SALIVARY CORTISOL DETERMINATIONS; DEXAMETHASONE SUPPRESSION TEST; POST PARTUM; PROGESTERONE; PLASMA; METABOLITES; CHILDBIRTH; ESTRADIOL	Objectives-To define relation between mood and concentrations of progesterone and cortisol during perinatal period to test hypothesis that rapid physiological withdrawal of steroid hormones after delivery is associated with depression. Design-Prospective study of Primiparous women from two weeks before expected date of delivery to 35 days postpartum. Setting-Antenatal clinic in university hospital, obstetric inpatient unit, patients' homes. Subjects-120 of 156 primiparous women interviewed. Remainder excluded because of major marital, socioeconomic, or medical problems or because caesarean section required. Main outcome measures-Concentrations of progesterone and cortisol in saliva samples; women's moods assessed by various scores for depression. Results-Changes in salivary progesterone and cortisol concentrations were similar to those already characterised for plasma. Peak mean score for maternity blues (5.3 on Stein scale) was on day five postpartum (P < 0.02 compared with mean scores on other postpartum days). High postpartum scores for maternity blues were associated with high antenatal progesterone concentrations on day before delivery (P < 0.05), with high rate of rise of antenatal progesterone concentrations (P<0.05), with decreasing progesterone concentrations from day of delivery to day of peak blues score (P greater-than-or-equal-to 0.01), and with low progesterone concentrations on day of peak blues score (P<0.01). Seventy eight women were designated as having maternity blues (peak score greater-than-or-equal-to 8 on Stein scale) while 39 had no blues. Women with blues had significantly higher antenatal progesterone concentrations and lower postnatal concentrations than women without blues (geometric mean progesterone concentrations: one day before delivery 3860 pmol/l v 3210 pmol/l respectively, P=0.03; ten days postpartum 88 pmol/l v 114 pmol/l, P=0.048). Cortisol concentrations were not significantly associated with mood. Conclusion-Maternal mood in the days immediately after delivery is related to withdrawal of naturally occurring progesterone.	UNIV WALES COLL MED,DEPT MED COMP & STAT,CARDIFF CF4 4XN,S GLAM,WALES; LEIGHTON HOSP,DEPT PSYCHIAT,CREWE CW1 4QJ,ENGLAND; UNIV HOSP WALES,TENOVUS INST,STEROID ASSAY LAB,CARDIFF CF4 4XW,S GLAM,WALES	Cardiff University; Cardiff University	HARRIS, B (corresponding author), UNIV WALES COLL CARDIFF,COLL MED,DEPT PSYCHOL MED,CARDIFF CF6 2YA,WALES.		Newcombe, Robert G/B-4897-2009		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON PJB, 1985, J ENDOCRINOL, V104, P7, DOI 10.1677/joe.0.1040007; ARAFAT ES, 1988, AM J OBSTET GYNECOL, V159, P1203, DOI 10.1016/0002-9378(88)90448-6; BACKSTROM T, 1976, J STEROID BIOCHEM, V7, P469, DOI 10.1016/0022-4731(76)90114-X; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; COOK N, 1986, PSYCHIAT RES, V18, P143, DOI 10.1016/0165-1781(86)90026-0; COX JL, 1982, BRIT J PSYCHIAT, V140, P111, DOI 10.1192/bjp.140.2.111; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; DALTON K, 1989, INT J PRENATAL PERIN, P322; GYERMEK L, 1975, ANESTHESIOLOGY, V42, P331, DOI 10.1097/00000542-197503000-00017; HANDLEY SL, 1980, BRIT J PSYCHIAT, V136, P498, DOI 10.1192/bjp.136.5.498; HARRIS B, 1993, HORM RES, V39, P138, DOI 10.1159/000182714; HARRIS B, 1990, BIOL PSYCHIAT, V27, P897, DOI 10.1016/0006-3223(90)90471-D; KENDELL RE, 1981, J AFFECT DISORDERS, V3, P317, DOI 10.1016/0165-0327(81)90001-X; KENNERLEY H, 1989, BRIT J PSYCHIAT, V155, P356, DOI 10.1192/bjp.155.3.356; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MARTIN MC, 1986, BASIC CLIN ENDOCRINO, P476; METZ A, 1983, LANCET, V1, P495; MONHEIT A G, 1980, Clinical Obstetrics and Gynecology, V23, P973; NOTT PN, 1976, BRIT J PSYCHIAT, V128, P379, DOI 10.1192/bjp.128.4.379; OHARA MW, 1991, ARCH GEN PSYCHIAT, V48, P801; PITT B, 1973, BRIT J PSYCHIAT, V122, P431, DOI 10.1192/bjp.122.4.431; READ GF, 1983, IMMUNOASSAYS CLIN CH, P163; RIADFAHMY D, 1987, J REPROD MED, V32, P254; RILEY DM, 1979, EMOTIONS REPRODUCTIO, P829; Selye H, 1941, P SOC EXP BIOL MED, V46, P116; SELYE H, 1946, J CLIN ENDOCR METAB, V6, P117, DOI 10.1210/jcem-6-2-117; STEIN G, 1981, J PSYCHOSOM RES, V25, P395, DOI 10.1016/0022-3999(81)90054-4; STEIN GS, 1980, J PSYCHOSOM RES, V24, P1165; TREADWAY CR, 1969, AM J PSYCHIAT, V125, P1380, DOI 10.1176/ajp.125.10.1380; Victoroff VM, 1952, DIS NERV SYST, V13, P291; WALKER RF, 1979, CLIN CHEM, V25, P2030	31	116	119	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					949	953		10.1136/bmj.308.6934.949	http://dx.doi.org/10.1136/bmj.308.6934.949			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NF485	8173402	Green Published			2022-12-01	WOS:A1994NF48500017
J	RYDER, SD; OREILLY, S; MILLER, RJ; ROSS, J; JACYNA, MR; LEVI, AJ				RYDER, SD; OREILLY, S; MILLER, RJ; ROSS, J; JACYNA, MR; LEVI, AJ			LONG-TERM ACID SUPPRESSING TREATMENT IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							PEPTIC-ULCER DISEASE; HELICOBACTER-PYLORI; H2-RECEPTOR ANTAGONISTS; DOUBLE-BLIND; CIMETIDINE; DYSPEPSIA; THERAPY; PLACEBO; PREVENTION; EFFICACY	Objective-To determine the current practice in selected general practices for prescribing long term (>6 months) treatment to suppress gastric acid secretion. Setting-Seven general practices in the Harrow area that always or usually refer to Northwick Park Hospital. Subjects-60148 patients on lists of the general practices. Design-Identification of patients receiving long term treatment through repeat prescribing data followed by a manual and computer survey of patients' notes for indications and investigations Patient compliance and views on treatment were sought by a postal questionnaire. Main outcome measures-Indications for treatment, treatment given, investigations undertaken before and during treatment. Results-492 patients (0.82% of the population) were taking long term acid suppressing treatment The most common diagnosis was duodenal ulcer disease (183 (37%) of all patients); oesophageal disease (118 (24%)) was also common. 93 patients (19%) were treated for abdominal pain where no diagnosis had been reached or who had only a diagnosis of gastritis on endoscopy. Ranitidine was prescribed in 394 (80%) patients. 298 (74%) patients found treatment helpful, but 108 (27%) had a poor understanding of their diagnosis. 317 patients (78%) took their drug as prescribed. 37 patients were also taking prescribed non-steroidal anti-inflammatory drugs and an additional 43 patients took regular aspirin or ibuprofen without prescription. Conclusions-Long term acid suppressing treatment is common, and a substantial number of patients are taking these drugs long term without a diagnosis having been reached. It is hoped that protocols for investigation and treatment will improve these figures. Patients need to be better informed about their disease and the possible adverse effects of taking non-steroidal anti-inflammatory drugs in acid related upper gastrointestinal disease.	NORTHWICK PK HOSP & CLIN RES CTR,DEPT GASTROENTEROL,HARROW HA1 3UJ,MIDDX,ENGLAND	Imperial College London				Ryder, Stephen David/0000-0001-9649-4444				BAUM C, 1985, ARTHRITIS RHEUM, V28, P686, DOI 10.1002/art.1780280613; CHIVERTON SG, 1988, BAILLIERE CLIN GASTR, V2, P655, DOI 10.1016/S0950-3528(88)80012-5; COCCO AE, 1981, NEW ENGL J MED, V304, P1281, DOI 10.1056/NEJM198105213042108; DOOLEY CP, 1991, ALIMENT PHARM THERAP, V5, P129; FRESTON JW, 1987, AM J GASTROENTEROL, V82, P1242; FRY J, 1984, BRIT MED J, V2, P809; GILLILAND AEW, 1990, FAM PRACT, V7, P43, DOI 10.1093/fampra/7.1.43; GOTTHARD R, 1988, SCAND J GASTROENTERO, V23, P7, DOI 10.3109/00365528809093840; GRAHAM DY, 1986, LANCET, V1, P462; HEATLEY RV, 1992, ALIMENT PHARM THERAP, V6, P291; HIRSCHOWITZ BI, 1986, J CLIN GASTROENTEROL, V8, P359, DOI 10.1097/00004836-198606002-00006; HIXSON LJ, 1992, ARCH INTERN MED, V152, P726, DOI 10.1001/archinte.152.4.726; JOHANNESSEN T, 1988, SCAND J GASTROENTERO, V23, P327, DOI 10.3109/00365528809093874; KLINKENBERGKNOL EC, 1992, HEPATO-GASTROENTEROL, V39, P27; KRAUSE U, 1963, ACTA CHIR SCAND S310, V125, P1; LANZA FL, 1989, AM J GASTROENTEROL, V84, P633; MENDELOWITZ PC, 1990, ANN INTERN MED, V112, P140, DOI 10.7326/0003-4819-112-2-140; MILLAR MR, 1992, ANTIMICROB AGENTS CH, V36, P185, DOI 10.1128/AAC.36.1.185; Norrelund N, 1980, Ugeskr Laeger, V142, P1750; RAUTELIN H, 1992, ANTIMICROB AGENTS CH, V36, P163, DOI 10.1128/AAC.36.1.163; SAULTZ JW, 1985, MIL MED, V150, P300, DOI 10.1093/milmed/150.6.300; TALLEY NJ, 1986, GASTROENTEROLOGY, V91, P149, DOI 10.1016/0016-5085(86)90451-8; WALAN A, 1987, SCAND J GASTROE S132, V22, P12; WORMSLEY KG, 1991, ALIMENT PHARM THERAP, V5, P37; 1990, MEREC B, V1, P9	25	89	90	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					827	830		10.1136/bmj.308.6932.827	http://dx.doi.org/10.1136/bmj.308.6932.827			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND243	8167491	Green Published			2022-12-01	WOS:A1994ND24300025
J	BARRY, M				BARRY, M			METAL RESIDUES AFTER CREMATION	BRITISH MEDICAL JOURNAL			English	Article									QUEEN ELIZABETH II HOSP,WELWYN GARDEN CIT AL7 4HQ,ENGLAND									BULSTRODE CJK, 1992, 1990 P I MECH ENG JO; SMITH EHJ, 1964, J BONE JOINT SURG BR, V46, P664; Thomas HO, 1976, J BONE JOINT SURG BR, V58, P135; 1977, BRIT MED J, V2, P1620	4	8	8	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	1994	308	6925					390	390		10.1136/bmj.308.6925.390	http://dx.doi.org/10.1136/bmj.308.6925.390			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV862	8179681	Green Published			2022-12-01	WOS:A1994MV86200023
J	HALL, RR; PARMAR, MKB; RICHARDS, AB; SMITH, PH				HALL, RR; PARMAR, MKB; RICHARDS, AB; SMITH, PH			PROPOSAL FOR CHANGES IN CYSTOSCOPIC FOLLOW-UP OF PATIENTS WITH BLADDER-CANCER AND ADJUVANT INTRAVESICAL CHEMOTHERAPY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRANSITIONAL CELL-CARCINOMA; RESEARCH-COUNCIL SUBGROUP; WORKING PARTY; RECURRENCE	A famous surgeon observed that the most important instrument for the management of superficial bladder cancer was a typewriter because it facilitated the organisation of the regular follow up examinations that are so important in controlling this disease. Cystoscopic follow up must be lifelong, and the cost, in the broadest sense, to both patient and health service is considerable. A recent study has suggested that the conventional frequency of bladder examinations may not be necessary and that most patients could be spared many cystoscopies. Instillation of cytotoxic drugs in the bladder has been shown to reduce the recurrence of tumours destroyed endoscopically and the development of new tumours elsewhere in the bladder. Because intravesical instillations are inconvenient, expensive, and may be toxic they have been reserved for patients thought to be at greatest risk of recurrence. However, two clinical trials have shown that a single cytotoxic instillation may be beneficial for low risk patients. If this is verified in everyday practice, the routine use of intravesical chemotherapy for all patients at the time of initial treatment could reduce the need for cystoscopies even further. Such changes should improve the quality of life of the 7000 new patients with superficial bladder cancer each year in England and Wales and allow savings to be made in the NHS.	MRC, CANC TRIALS OFF, CAMBRIDGE CB2 2BB, ENGLAND; BASINGSTOKE DIST GEN HOSP, BASINGSTOKE RG24 9NA, ENGLAND; ST JAMES UNIV HOSP, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND	Saint James's University Hospital	HALL, RR (corresponding author), FREEMAN RD HOSP, NEWCASTLE UPON TYNE NE7 7DN, TYNE & WEAR, ENGLAND.							ABEL PD, 1988, BRIT J UROL, V62, P339, DOI 10.1111/j.1464-410X.1988.tb04361.x; BIRCH BRP, 1989, BRIT J UROL, V64, P109, DOI 10.1111/j.1464-410X.1989.tb05967.x; BOUFFIOUX C, 1991, SCAND J UROL NEPHROL, P167; KURTH KH, 1984, J UROLOGY, V132, P258, DOI 10.1016/S0022-5347(17)49582-6; Kurth KH, 1992, PROBL UROL, V6, P471; NEWLING D, 1990, BRIT J CANCER, V61, P497, DOI 10.1038/bjc.1990.112; OOSTERLINCK W, 1993, J UROLOGY, V149, P749, DOI 10.1016/S0022-5347(17)36198-0; PARMAR MKB, 1989, J UROLOGY, V142, P284, DOI 10.1016/S0022-5347(17)38731-1; RICHARDS B, 1991, BRIT J UROL, V67, P369, DOI 10.1111/j.1464-410X.1991.tb15164.x; ROBERTSON AJ, 1990, J CLIN PATHOL, V43, P17, DOI 10.1136/jcp.43.1.17; SCHULMAN CC, 1982, EUR UROL, V8, P207, DOI 10.1159/000473519; TOLLEY DA, 1988, BRIT MED J, V296, P1759, DOI 10.1136/bmj.296.6639.1759; TOLLEY DA, 1993, 49 ANN M BRIT ASS UR, P46; 1992, TNM CLASSIFICATION T	14	63	63	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 22	1994	308	6923					257	260		10.1136/bmj.308.6923.257	http://dx.doi.org/10.1136/bmj.308.6923.257			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT539	8179678	Green Published			2022-12-01	WOS:A1994MT53900026
J	SHANNON, M				SHANNON, M			PREDICTORS OF MAJOR TOXICITY AFTER THEOPHYLLINE OVERDOSE	ANNALS OF INTERNAL MEDICINE			English	Article						THEOPHYLLINE; DRUG TOXICITY; SEIZURES; ARRHYTHMIA; HEMOPERFUSION	ORAL ACTIVATED-CHARCOAL; SERUM CONCENTRATIONS; CLINICAL-FEATURES; HEMOPERFUSION; INTOXICATION; MANAGEMENT; INFANTS	Objective: To identify patients at high risk for major toxicity after theophylline intoxication who might benefit from early charcoal hemoperfusion. Design: A 67-month prospective study Setting: Massachusetts Poison Control System. Patients: 249 consecutive patients referred after theophylline intoxication (defined by a peak serum theophylline concentration greater-than-or-equal 167 mumol/L [30 mg/L]). Interventions: Uniform, protocol-directed management recommendations. Main Outcome Measures: Identification of risk factors for major toxicity. Results: 119 patients (48%) not receiving theophylline therapy had acute intoxication; among those receiving such therapy, 92 (37%) had theophylline intoxication because of chronic overmedication and 38 (15%) had acute intoxication. Major toxicity developed in 62 patients (25%); 13 patients (5%) died. Major toxicity was more common in patients with intoxication due to chronic overmedication than in those with acute intoxication who were not receiving theophylline therapy (49% compared with 10%, risk ratio, 4.85; 95% CI, 2.96 to 7.94), even though the former group had lower peak serum theophylline concentrations (283 mumol/L compared with 777 mumol/L, P = 0.001). Logistic regression analysis identified two major factors associated with the development of major toxicity: 1) peak serum theophylline concentrations in cases of acute intoxication and 2) patient age in cases of chronic overmedication. Receiver-operating characteristic curve analysis indicated that major toxicity occurred in patients with a peak serum theophylline concentration of greater than 555 mumol/L (100 mg/L) after acute intoxication and in patients older than 60 years (regardless of peak serum theophylline concentration) after chronic overmedication. Conclusions: Predictors for major toxicity after theophylline intoxication differ by type of overdose.	MASSACHUSETTS POISON CONTROL CTR, BOSTON, MA USA		SHANNON, M (corresponding author), HARVARD UNIV, CHILDRENS HOSP, SCH MED, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.							AITKEN ML, 1987, CHEST, V91, P10, DOI 10.1378/chest.91.1.10; AMITAI Y, 1987, J TOXICOL-CLIN TOXIC, V25, P539, DOI 10.3109/15563658708992656; AMITAI Y, 1986, ANN INTERN MED, V105, P386, DOI 10.7326/0003-4819-105-3-386; BERTINO JS, 1987, ARCH INTERN MED, V147, P757, DOI 10.1001/archinte.147.4.757; BIBERSTEIN MP, 1984, WESTERN J MED, V141, P485; CAMPOS N, 1989, AM J EPIDEMIOL, V129, P439, DOI 10.1093/oxfordjournals.aje.a115148; DAVI MJ, 1978, J PEDIATR-US, V92, P91, DOI 10.1016/S0022-3476(78)80084-5; DAWSON AH, 1989, MED J AUSTRALIA, V151, P689, DOI 10.5694/j.1326-5377.1989.tb139649.x; DERBY LE, 1990, PHARMACOTHERAPY, V10, P112; EASON J, 1989, RESP MED, V83, P219, DOI 10.1016/S0954-6111(89)80035-6; EMERMAN CL, 1990, ANN EMERG MED, V19, P643, DOI 10.1016/S0196-0644(05)82468-0; GAUDREAULT P, 1986, MED TOXICOL ADV DRUG, V1, P169, DOI 10.1007/BF03259836; GAUDREAULT P, 1983, J PEDIATR-US, V102, P474, DOI 10.1016/S0022-3476(83)80682-9; GOLDBERG MJ, 1986, J ALLERGY CLIN IMMUN, V78, P811, DOI 10.1016/0091-6749(86)90066-7; GREENBERG A, 1984, AM J MED, V76, P854, DOI 10.1016/0002-9343(84)90997-5; HEATH A, 1987, MED TOXICOL ADV DRUG, V2, P294, DOI 10.1007/BF03259871; KNODEL AR, 1984, WESTERN J MED, V140, P741; KULIG KW, 1987, ANN EMERG MED, V16, P842, DOI 10.1016/S0196-0644(87)80519-X; LITOVITZ TL, 1992, AM J EMERG MED, V10, P452, DOI 10.1016/0735-6757(92)90075-9; LYNN KL, 1988, NEW ZEAL MED J, V101, P4; MCNEIL BJ, 1975, NEW ENGL J MED, V293, P211, DOI 10.1056/NEJM197507312930501; MURCIANO D, 1989, NEW ENGL J MED, V320, P1521, DOI 10.1056/NEJM198906083202304; MYERS TF, 1980, J PEDIATR-US, V96, P99, DOI 10.1016/S0022-3476(80)80339-8; OLSON KR, 1985, AM J EMERG MED, V3, P386, DOI 10.1016/0735-6757(85)90195-0; PARK GD, 1983, AM J MED, V74, P961, DOI 10.1016/0002-9343(83)90790-8; ROSSING TH, 1989, ANN INTERN MED, V110, P502, DOI 10.7326/0003-4819-110-7-502; ROTHMAN KJ, 1979, NIH791649 PUBL; RUSSO ME, 1979, NEW ENGL J MED, V300, P24, DOI 10.1056/NEJM197901043000107; SAHNEY S, 1983, PEDIATRICS, V71, P615; SESSLER CN, 1990, AM J MED, V88, P567, DOI 10.1016/0002-9343(90)90519-J; SHANNON M, 1987, PEDIATRICS, V80, P368; SHANNON M, 1992, J PEDIATR-US, V121, P125, DOI 10.1016/S0022-3476(05)82558-2; SHANNON M, 1990, ARCH INTERN MED, V150, P2045, DOI 10.1001/archinte.150.10.2045; SKINNER MH, 1990, DRUG SAFETY, V5, P275, DOI 10.2165/00002018-199005040-00004; TSIU SJ, 1990, ANN ALLERGY, V64, P241; ZWILLICH CW, 1975, ANN INTERN MED, V82, P784, DOI 10.7326/0003-4819-82-6-784	36	60	64	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1161	1167		10.7326/0003-4819-119-12-199312150-00002	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239246				2022-12-01	WOS:A1993MM12100002
J	THEA, DM; STLOUIS, ME; ATIDO, U; KANJINGA, K; KEMBO, B; MATONDO, M; TSHIAMALA, T; KAMENGA, C; DAVACHI, F; BROWN, C; RAND, WM; KEUSCH, GT				THEA, DM; STLOUIS, ME; ATIDO, U; KANJINGA, K; KEMBO, B; MATONDO, M; TSHIAMALA, T; KAMENGA, C; DAVACHI, F; BROWN, C; RAND, WM; KEUSCH, GT			A PROSPECTIVE-STUDY OF DIARRHEA AND HIV-1 INFECTION AMONG 429 ZAIRIAN INFANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERSISTENT DIARRHEA; AFRICAN CHILDREN; RURAL BANGLADESH; MALNUTRITION; ASSOCIATION; DURATION; MOTHERS; AIDS; BORN	Background. Persistent diarrhea is a prominent feature of the acquired immunodeficiency syndrome in adults, but its cause and its effect on children with human immunodeficiency virus (HIV) infection are largely unknown, particularly in Africa. Methods. We studied a birth cohort of 429 infants born to HIV-positive or HIV-negative mothers in Zaire to determine the incidence of acute, recurrent (greater-than-or-equal-to 2 episodes), and persistent (greater-than-or-equal-to 14 days) diarrhea; outcome; and risk factors. Results. Of the 238 infants whose mothers were HIV-positive, 53 were infected, 139 were uninfected, and the HIV status of 46 could not be determined. As compared with uninfected infants, infected infants had higher incidence rates for acute diarrhea (170 vs. 100 episodes per 100 child-years, P = 0.003), recurrent diarrhea (21 vs. 11, P = 0.12), and persistent diarrhea (19 vs. 4, P<0.003). Persistent diarrhea developed in 11 HIV-infected infants; all but 1 died. It also developed in 19 uninfected infants; all but 1 survived. The prevalence of stool pathogens was similar in the two groups. In a multivariate model, persistent diarrhea in an infant was independently associated with symptomatic HIV type 1 infection in the mother (relative hazard, 1.5; P = 0.08). The incidence of persistent diarrhea in the uninfected infants of seropositive mothers was nearly double that in the uninfected infants of seronegative mothers (4.9 vs. 2.7 episodes per 100 child-years), and the risk increased if the mother died (relative hazard, 10.4). Significant growth impairment and severe immunosuppression occurred in the six to eight weeks before the onset of persistent diarrhea. Conclusions. In Zaire, infants with HIV infection have an 11-fold increased risk of death from diarrhea, largely persistent diarrhea, which is often preceded by recurrent episodes of acute diarrhea, malnutrition, or immunosuppression. illness and death of the mother increase that risk, even among her uninfected infants.	TUFTS UNIV NEW ENGLAND MED CTR, DIV GEOG MED & INFECT DIS, BOX 041, 750 WASHINGTON ST, BOSTON, MA 02111 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA; INT COOPERAT AIDS RES UNIT, PROJET SIDA, KINSHASA, DEM REP CONGO; MAMA YEMO HOSP, DEPT PEDIAT, KINSHASA, DEM REP CONGO; NIAID, BETHESDA, MD 20892 USA	Tufts Medical Center; Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Thea, Donald/0000-0002-6933-1030; /0000-0001-5724-2965	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI026698] Funding Source: NIH RePORTER; NIAID NIH HHS [P01-AI-26698] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAIRAGI R, 1987, INT J EPIDEMIOL, V16, P477, DOI 10.1093/ije/16.3.477; BENEDETTI J, 1990, BMDP STATISTICAL SOF, P739; BHANDARI N, 1989, BMJ-BRIT MED J, V298, P1284, DOI 10.1136/bmj.298.6683.1284; BLACK RE, 1984, AM J CLIN NUTR, V39, P87, DOI 10.1093/ajcn/39.1.87; BROWN KH, 1989, PEDIATRICS, V83, P31; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; COHEN MB, 1993, J CLIN MICROBIOL, V31, P351, DOI 10.1128/JCM.31.2.351-353.1993; FAUVEAU V, 1992, ACTA PAEDIATR, V81, P12, DOI 10.1111/j.1651-2227.1992.tb12365.x; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; HOPKINS A, 1990, BMDP STATISTICAL SOF, P769; HUTTLY SRA, 1989, INT J EPIDEMIOL, V18, P964, DOI 10.1093/ije/18.4.964; KEUSCH GT, 1990, NESTLE NUTR WORKS SE, V19, P37; KIRKWOOD B, 1988, ESSENTIALS MED STAT, P129; MALEK ANA, 1989, 5TH P INT C AIDS MON, P392; NSANGA B, 1989, 5TH P INT C AIDS MON, P324; PAVIA AT, 1992, PEDIATR INFECT DIS J, V11, P996, DOI 10.1097/00006454-199211120-00002; PREBLE EA, 1990, SOC SCI MED, V31, P671, DOI 10.1016/0277-9536(90)90249-R; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; ROTHMAN K, 1979, DHHS NIH791649 PUBL; SAMBROOK J, 1989, MOL CLONING, V1, P90; SCHORLING JB, 1990, INT J EPIDEMIOL, V19, P728, DOI 10.1093/ije/19.3.728; SEPULVEDA J, 1988, AM J EPIDEMIOL, V127, P365, DOI 10.1093/oxfordjournals.aje.a114810; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; 1989, MMWR MORB MORTAL S7, V38, P1; [No title captured]; 1984, PROGRAMME CONTROL DI	26	124	124	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1993	329	23					1696	1702		10.1056/NEJM199312023292304	http://dx.doi.org/10.1056/NEJM199312023292304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ707	8232458				2022-12-01	WOS:A1993MJ70700004
J	FLAHERTY, JP; GARCIAHOUCHINS, S; CHUDY, R; ARNOW, PM				FLAHERTY, JP; GARCIAHOUCHINS, S; CHUDY, R; ARNOW, PM			AN OUTBREAK OF GRAM-NEGATIVE BACTEREMIA TRACED TO CONTAMINATED O-RINGS IN REPROCESSED DIALYZERS	ANNALS OF INTERNAL MEDICINE			English	Article						BACTEREMIA; GRAM-NEGATIVE BACTERIA; HEMODIALYSIS; DISINFECTION; EQUIPMENT CONTAMINATION	HIGH-FLUX DIALYSIS; PYROGENIC REACTIONS; HEMODIALYSIS	Objective: To investigate an outbreak of gram-negative bacteremia in an outpatient hemodialysis unit and to identify the source of contaminating bacteria and the route by which bacteria gained access to the bloodstream. Design: A matched-pair, case-control study and a bacteriologic investigation of the hemodialysis unit and the implicated dialyzers. Setting: A university outpatient hemodialysis unit. Patients: Eleven patients receiving long-term hemodialysis who had a total of 12 episodes of primary gram-negative bacteremia and 12 matched controls. Measurements: Clinical and demographic data were obtained for patients and controls. Dialysis unit procedures were observed for compliance with aseptic technique. Cultures of potential environmental sources of bacteria were obtained. Hemodialyzers from bacteremic and nonbacteremic patients were dismantled, and the component parts were cultured. Inoculation of O-rings (from Hemoflow F-80 dialyzer) with bacteria and simulated dialysis were done. Results: During January to October 1988, 12 episodes of primary gram-negative bacteremia caused by Pseudomonas cepacia, Xanthomonas maltophilia, Citrobacter freundii, Acinetobacter calcoaceticus var. anitratus, or Enterobacter cloacae occurred in 11 patients. In 11 episodes, symptoms developed within 3 hours of starting hemodialysis. Intravenous antibiotics were administered for 11 episodes, 3 episodes resulted in hospitalization, and all patients recovered. Case patients were more likely to have received high-flux dialysis with Hemoflow F-80 dialyzers (odds ratio congruent-to 11) than were controls. O-rings from dialyzers used by bacteremic patients were culture positive for the organism responsible for bacteremia. Three of the four dialyzers were disinfected using the standard automated method and were recultured 72 hours later; the O-rings of all three dialyzers remained culture positive. Simulated dialysis using dialyzers with contaminated O-rings caused blood pathway contamination despite intervening reprocessing. When the disinfection method for F-80 dialyzers included removal and complete disinfection of the O-rings, O-ring and blood pathway cultures were consistently negative. After this procedure was made routine, no episodes of primary gram-negative bacteremia occurred during the next 6 months. Conclusions: Because dialyzers with removable headers and O-rings are widely used in patients receiving long-term hemodialysis, disinfection procedures should include measures to ensure adequate disinfection of O-rings.	UNIV CHICAGO, CHICAGO, IL 60637 USA	University of Chicago								ALTER MJ, 1988, JAMA-J AM MED ASSOC, V260, P2073, DOI 10.1001/jama.260.14.2073; ALTER MJ, 1991, T AM SOC ART INT ORG, V37, P97; BECKSAGUE CM, 1990, AM J NEPHROL, V10, P397, DOI 10.1159/000168155; Bland L A, 1989, ASAIO Trans, V35, P314, DOI 10.1097/00002480-198907000-00044; BOLAN G, 1985, J INFECT DIS, V152, P1013, DOI 10.1093/infdis/152.5.1013; FAVERO MS, 1975, HEALTH LAB SCI, V12, P321; FLEMING SJ, 1991, AM J NEPHROL, V11, P27, DOI 10.1159/000168268; GOETZ A, 1983, ARCH INTERN MED, V143, P1909, DOI 10.1001/archinte.143.10.1909; GORDON SM, 1992, J AM SOC NEPHROL, V2, P1436; JONES DM, 1970, BRIT MED J, V3, P135, DOI 10.1136/bmj.3.5715.135; KUEHNEL E, 1976, DIALYSIS TRANSPLANT, V5, P44; LOWRY PW, 1990, J INFECT DIS, V161, P85, DOI 10.1093/infdis/161.1.85; MURPHY J, 1987, AM SOC ARTIF INTERN, V16, P51; POLLAK VE, 1986, NEPHRON, V42, P217, DOI 10.1159/000183670; ROBSON MD, 1986, AM J NEPHROL, V6, P101, DOI 10.1159/000167063; SHUSTERMAN NH, 1989, AM J KIDNEY DIS, V14, P81, DOI 10.1016/S0272-6386(89)80181-7; SMOLLICH BP, 1991, NEPHROL DIAL TRANSPL, V6, P83; TOBIN BM, 1970, BRIT MED J, V3, P226, DOI 10.1136/bmj.3.5716.226-b; UMAN SJ, 1977, AM J MED, V62, P667, DOI 10.1016/0002-9343(77)90868-3; VONALBERTINI B, 1991, AM J NEPHROL, V11, P169, DOI 10.1159/000168298; WAGNILD JP, 1977, AM J MED, V62, P672, DOI 10.1016/0002-9343(77)90869-5; 1981, AM NATIONAL STANDARD; 1986, MMWR, V35, P417	23	53	57	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1072	1078		10.7326/0003-4819-119-11-199312010-00003	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239225				2022-12-01	WOS:A1993MJ33500003
J	MCKUSICK, VA				MCKUSICK, VA			MEDICAL GENETICS - A 40-YEAR PERSPECTIVE ON THE EVOLUTION OF A MEDICAL SPECIALTY FROM A BASIC SCIENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN GENOME; CLINICAL MEDICINE; MORBID ANATOMY				MCKUSICK, VA (corresponding author), JOHNS HOPKINS UNIV HOSP, CTR MED GENET, BALTIMORE, MD 21205 USA.							ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; Burnet FM, 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; DONAHUE RP, 1968, P NATL ACAD SCI USA, V61, P949, DOI 10.1073/pnas.61.3.949; GIANNELLI F, 1993, NUCLEIC ACIDS RES, V21, P3075, DOI 10.1093/nar/21.13.3075; Gorlin RJ, 1990, PLAST RECONSTR SURG, V3rd; HALDANE JBS, 1948, PROC R SOC SER B-BIO, V135, P147, DOI 10.1098/rspb.1948.0002; HOBBS HH, 1992, MOL GENET, V1, P445; Jones KL, 1988, SMITHS RECOGNIZABLE; MACKAY IR, 1963, AUTOIMMUNE DISEASES; MCCURDY PR, 1971, NEW ENGL J MED, V285, P218, DOI 10.1056/NEJM197107222850409; McKusick V.A., 1992, MENDELIAN INHERITANC; MCKUSICK VA, 1975, AM J HUM GENET, V27, P261; MCKUSICK VA, 1989, JAMA-J AM MED ASSOC, V261, P3155, DOI 10.1001/jama.261.21.3155; MCKUSICK VA, 1992, AM J HUM GENET, V50, P663; MCKUSICK VA, 1989, NEW ENGL J MED, V320, P910, DOI 10.1056/NEJM198904063201406; MCKUSICK VA, 1969, PERSPECT BIOL MED, V12, P298; MCKUSICK VA, 1993, J MED GENET, V30, P1, DOI 10.1136/jmg.30.1.1; MCKUSICK VA, 1985, J MED GENET, V22, P431, DOI 10.1136/jmg.22.6.431; MCKUSICK VA, 1987, MEDICINE, V66, P1; MCKUSICK VA, 1988, MEDICINE, V67, P1; MCKUSICK VA, 1991, FASEB J, V5, P12, DOI 10.1096/fasebj.5.1.1991580; MCKUSICK VA, 1987, MEDICINE, V66, P237, DOI 10.1097/00005792-198707000-00001; MCKUSICK VA, 1986, MEDICINE, V65, P1; MCKUSICK VA, 1970, CONGENITAL MALFORMAT, V3, P407; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NOWEOLL PC, 1907, SCIENCE, V132, P149; SCHROTT HG, 1973, CLIN GENET, V4, P38; SCHROTT HG, 1975, NEUROLOGY, V25, P789, DOI 10.1212/WNL.25.8.789; SEEGMILLER JE, 1967, SCIENCE, V155, P1682, DOI 10.1126/science.155.3770.1682; SOLOMON E, 1979, LANCET, V1, P923; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WAIKAN Y, 1978, P NATL ACAD SCI USA, V75, P5631, DOI 10.1073/pnas.75.11.5631; Weatherall David J., 1991, NEW GENETICS CLIN PR	34	20	23	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2351	2356		10.1001/jama.270.19.2351	http://dx.doi.org/10.1001/jama.270.19.2351			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230599				2022-12-01	WOS:A1993MF99300031
J	ALBERG, DG; SCHREIBER, SL				ALBERG, DG; SCHREIBER, SL			STRUCTURE-BASED DESIGN OF A CYCLOPHILIN-CALCINEURIN BRIDGING LIGAND	SCIENCE			English	Article							CIS-TRANS ISOMERASE; CYCLOSPORINE-A; CONFORMATION; BINDING; IMMUNOPHILIN; INHIBITION; MECHANISM; PATHWAYS; RECEPTOR; MODEL	The affinity of a flexible ligand that adopts a specific conformation when bound to its receptor should be increased with the appropriate use of conformational restraints. By determining the structure of protein-ligand complexes, such restraints can in principle be designed into the bound ligand in a rational way. A tricyclic variant (TCsA) of the immunosuppressant cyclosporin A (CsA), which inhibits the proliferation of T lymphocytes by forming a cyclophilin-CsA-calcineurin complex, was designed with the known three-dimensional structure of a cyclophilin-CsA complex. The conformational restraints in TCsA appear to be responsible for its greater affinity for cyclophilin and calcineurin relative to CsA.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038627, R37GM038627] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38627] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI JD, 1988, J MED CHEM, V31, P1805, DOI 10.1021/jm00117a022; ANDRUS MN, UNPUB; BALDWIN JE, 1986, TETRAHEDRON, V42, P6551, DOI 10.1016/S0040-4020(01)88118-7; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; JORGENSEN WL, 1991, SCIENCE, V254, P954, DOI 10.1126/science.1719636; KESSLER H, 1990, HELV CHIM ACTA, V73, P1818, DOI 10.1002/hlca.19900730703; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; LIPTON MJ, COMMUNICATION; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LOOSLI HR, 1985, HELV CHIM ACTA, V68, P682, DOI 10.1002/hlca.19850680319; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; PATCHETT AA, 1992, J ANTIBIOT, V45, P94, DOI 10.7164/antibiotics.45.94; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; ROSEN MK, 1993, J AM CHEM SOC, V115, P821, DOI 10.1021/ja00055a082; SCHOLTZ JM, 1989, SYNTHESIS-STUTTGART, P542; SCHREIBER SL, 1988, TETRAHEDRON LETT, V29, P6577, DOI 10.1016/S0040-4039(00)82401-6; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SPITZFADEN C, 1992, FEBS LETT, V300, P291, DOI 10.1016/0014-5793(92)80866-F; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WENGER R, 1985, TRANSPLANT P, V18, P213; WUTHRICH K, 1991, SCIENCE, V254, P953, DOI 10.1126/science.1948082; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903; [No title captured]	34	57	74	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 8	1993	262	5131					248	250		10.1126/science.8211144	http://dx.doi.org/10.1126/science.8211144			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA665	8211144				2022-12-01	WOS:A1993MA66500037
J	CHAIT, BT; WANG, R; BEAVIS, RC; KENT, SBH				CHAIT, BT; WANG, R; BEAVIS, RC; KENT, SBH			PROTEIN LADDER SEQUENCING	SCIENCE			English	Article							DESORPTION MASS-SPECTROMETRY; SOLID-PHASE PEPTIDE; LASER DESORPTION; MATRIX; ACID; HYDROLYSIS; PICOMOLE; ENZYME; SITE	A new approach to protein sequencing is described. It consists of two steps: (i) ladder-generating chemistry, the controlled generation from a polypeptide chain by wet chemistry of a family of sequence-defining peptide fragments, each differing from the next by one amino acid; and (ii) data readout, a one-step readout of the resulting protein sequencing ladder by matrix-assisted laser-desorption mass spectrometry. Each amino acid was identified from the mass difference between successive peaks, and the position in the data set defined the sequence of the original peptide chain. This method was used to directly locate a phosphoserine residue in a phosphopeptide. The protein ladder sequencing method lends itself to very high sample throughput at very low per cycle cost.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; MEM UNIV NEWFOUNDLAND, DEPT PHYS, ST JOHNS A1B 3X7, NEWFOUNDLAND, CANADA	Scripps Research Institute; Rockefeller University; Memorial University Newfoundland			Wang, Rong/A-8721-2009		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038274] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline; NIGMS NIH HHS [GM38274] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD R, 1991, ANAL BIOCHEM, V199, P51, DOI 10.1016/0003-2697(91)90268-X; AEBERSOLD R, 1990, ELECTROPHORESIS, V11, P517, DOI 10.1002/elps.1150110702; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHAIT BT, 1987, METHODS PROTEIN SEQU, P483; EDMAN P, 1949, ARCH BIOCHEM, V22, P475; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HUNKAPILLER MW, 1986, MICROCHARACTERIZATIO, P223; INGLIS AS, 1991, ANAL BIOCHEM, V195, P183, DOI 10.1016/0003-2697(91)90316-L; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; KATAKUSE I, 1982, BIOMED MASS SPECTROM, V9, P64, DOI 10.1002/bms.1200090204; Konigsberg W, 1972, Methods Enzymol, V25, P326, DOI 10.1016/S0076-6879(72)25028-5; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PROUD CG, 1977, FEBS LETT, V80, P435, DOI 10.1016/0014-5793(77)80493-6; RYLATT DB, 1979, FEBS LETT, V98, P71, DOI 10.1016/0014-5793(79)80154-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schroeder W A, 1972, Methods Enzymol, V25, P298, DOI 10.1016/S0076-6879(72)25026-1; SELF R, 1983, BIOMED MASS SPECTROM, V10, P78, DOI 10.1002/bms.1200100206; SHIVELY JE, 1989, TRENDS BIOCHEM SCI, V14, P246, DOI 10.1016/0968-0004(89)90056-X; SMITH LA, 1983, BIOMED MASS SPECTROM, V10, P98, DOI 10.1002/bms.1200100210; Tarr G E, 1977, Methods Enzymol, V47, P335; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; TSUGITA A, 1992, EUR J BIOCHEM, V206, P691, DOI 10.1111/j.1432-1033.1992.tb16975.x; Wang R., UNPUB; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; WONG SC, 1993, TECHNIQUES PROTEIN C, V4, P371; YAN SCB, 1989, TRENDS BIOCHEM SCI, V14, P264, DOI 10.1016/0968-0004(89)90060-1	38	260	276	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	1993	262	5130					89	92		10.1126/science.8211132	http://dx.doi.org/10.1126/science.8211132			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ635	8211132	Green Submitted			2022-12-01	WOS:A1993LZ63500027
J	KINZLER, KW; VOGELSTEIN, B				KINZLER, KW; VOGELSTEIN, B			CLINICAL IMPLICATIONS OF BASIC RESEARCH - CANCER-THERAPY MEETS P53	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KINZLER, KW (corresponding author), JOHNS HOPKINS UNIV,CTR ONCOL,BALTIMORE,MD 21231, USA.							LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7	1	84	88	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	1994	331	1					49	50		10.1056/NEJM199407073310113	http://dx.doi.org/10.1056/NEJM199407073310113			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU951	8202105				2022-12-01	WOS:A1994NU95100013
J	FARINAS, I; JONES, KR; BACKUS, C; WANG, XY; REICHARDT, LF				FARINAS, I; JONES, KR; BACKUS, C; WANG, XY; REICHARDT, LF			SEVERE SENSORY AND SYMPATHETIC DEFICITS IN MICE LACKING NEUROTROPHIN-3	NATURE			English	Article							NERVE GROWTH-FACTOR; MOLECULAR-CLONING; FACTOR FAMILY; RECEPTOR; NEURONS; MEMBER; SYSTEM; BRAIN; BDNF; NGF	During development, neurotrophins help shape the nervous system by regulating neuronal survival and differentiation. Neurotrophin-3 (refs 1-5) is the most abundant neurotrophin during early development(6). Neurons responsive to neurotrophin-3 in vitro include primary sensory, sympathetic(1-4), motor(7), enteric(1) locus coeruleus(8), hippocampal and cerebellar neurons (ref. 9 for example). Here we report that mice lacking neurotrophin-3 have severe deficits in sensory and sympathetic populations. These mice lack muscle spindles and show abnormal limb positions. In contrast, motor neurons, the enteric nervous system, and the major anatomical regions of the central nervous system seem to develop normally. Comparisons with mutants deficient in other neurotrophins or their receptors(13-15) indicate that some neurons require more than one neurotrophin during embryogenesis and suggest that neurotrophin-3 functions by binding receptors in addition to its primary receptor trkC (ref. 16). In particular, neurotrophin-3 is essential for survival of sympathetic and sensory neurons that later become dependent on nerve growth factor or brain-derived neurotrophic factor.	UNIV CALIF SAN FRANCISCO,SCH MED,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	FARINAS, I (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143, USA.		; Farinas, Isabel/L-7118-2014	JONES, KEVIN/0000-0002-3802-7562; Farinas, Isabel/0000-0003-2903-4960				ARENAS E, 1994, NATURE, V367, P368, DOI 10.1038/367368a0; BARBACID M, 1993, ONCOGENE, V8, P2033; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DICICCOBLOOM E, 1993, NEURON, V11, P1101, DOI 10.1016/0896-6273(93)90223-E; EMFORS P, 1994, NATURE, V368, P147; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IP NY, 1993, J NEUROSCI, V13, P3394; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; Joyner AL, 1993, GENE TARGETING PRACT; KALCHEIM C, 1992, P NATL ACAD SCI USA, V89, P1661, DOI 10.1073/pnas.89.5.1661; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; LAMBALLE F, 1994, J NEUROSCI, V14, P14; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MU XJ, 1993, J NEUROSCI, V13, P4029; PIRVOLA U, 1992, P NATL ACAD SCI USA, V89, P9915, DOI 10.1073/pnas.89.20.9915; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; TESSAROLLO L, 1993, DEVELOPMENT, V118, P463; YAN Q, 1988, J NEUROSCI, V8, P3481; ZELENA J, 1964, Prog Brain Res, V13, P175, DOI 10.1016/S0079-6123(08)60144-2	30	553	565	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 23	1994	369	6482					658	661		10.1038/369658a0	http://dx.doi.org/10.1038/369658a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	8208292				2022-12-01	WOS:A1994NT45900058
J	MACIAS, MJ; MUSACCHIO, A; PONSTINGL, H; NILGES, M; SARASTE, M; OSCHKINAT, H				MACIAS, MJ; MUSACCHIO, A; PONSTINGL, H; NILGES, M; SARASTE, M; OSCHKINAT, H			STRUCTURE OF THE PLECKSTRIN HOMOLOGY DOMAIN FROM BETA-SPECTRIN	NATURE			English	Article							PH DOMAIN; PROTEINS; SPECTROSCOPY; COMPLEX; NMR	The 'pleckstrin homology' or PH domain is a 100-residue protein module. It is present in many kinases, different isoforms of phospholipase C, GTPase-activating proteins and nucleotide-exchange factors(1-4). Its function is not known, but many proteins that contain a PH domain interact with GTP-binding proteins(5). The PH domain in beta-adrenergic receptor kinase may be involved in binding to the beta gamma subunits of a trimeric G-protein(3,4,6,7). We report here the three-dimensional structure of the PH domain of the cytoskeletal protein spectrin using homonuclear nuclear magnetic resonance. The core of the molecule is an antiparallel beta-sheet consisting of seven strands. The C terminus is folded into a long alpha-helix, and another helix is present in one of the surface loops. The molecule is electrostatically polarized and contains a pocket which may be involved in the binding of a ligand. There is a distant relationship to the peptidyl-prolyl-cis-trans-isomerase FKBP in which this pocket is involved in the binding of the macrocyclic compound FK506 (refs 8-11).	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Macias, Maria J/K-3898-2014; Nilges, Michael/E-4803-2011	Macias, Maria J/0000-0002-6915-963X; Nilges, Michael/0000-0002-1451-8092; Musacchio, Andrea/0000-0003-2362-8784; Oschkinat, Hartmut/0000-0002-4384-9544				AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; GIESINGER C, 1988, J AM CHEM SOC, V110, P7870; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; MEADOWS RP, 1993, BIOCHEMISTRY-US, V32, P754, DOI 10.1021/bi00054a004; MEYER BJ, 1993, CELL, V73, P629; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TOPSCHUG M, 1990, NATURE, V346, P674; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302	14	220	225	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 23	1994	369	6482					675	677		10.1038/369675a0	http://dx.doi.org/10.1038/369675a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	8208297				2022-12-01	WOS:A1994NT45900063
J	IZES, JK				IZES, JK			HEARTPAINS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 22	1994	271	24					1902	1902						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR598	8201724				2022-12-01	WOS:A1994NR59800006
J	LEWIN, GR; MCKINTOSH, E; MCMAHON, SB				LEWIN, GR; MCKINTOSH, E; MCMAHON, SB			NMDA RECEPTORS AND ACTIVITY-DEPENDENT TUNING OF THE RECEPTIVE-FIELDS OF SPINAL-CORD NEURONS	NATURE			English	Article							PERIPHERAL-NERVE INJURY; RAT DORSAL HORN; SENSORY MAP; CAT; PLASTICITY; REORGANIZATION; REGENERATION; ANTAGONIST; ACTIVATION; KAINATE	AFTER peripheral nerve section, sensory neurons regenerate but do not regain their original topographical position in the skin(1). Here we report that in the early stages of sciatic nerve regeneration, the cutaneous receptive fields (RFs) of dorsal horn neurons are larger than normal, reflecting the disorganized topography of the regenerated afferents. When nerve regeneration is complete, small contiguous RFs emerge, indicating a central compensation for the disrupted peripheral somatotopy. If the NMDA receptor antagonist MK801 is given during regeneration, RFs do not show this reorganization, but remain large and diffuse. We suggest that the coincident activity of afferents, newly innervating adjacent or overlapping cutaneous territory, acts through postsynaptic NMDA receptors(2) to strengthen the central effectiveness of these inputs at the expense of other non-adjacent and non-coincidently activated inputs. In this way, dorsal horn neurons may attain and retain restricted RFs in the face of a spatially dispersed afferent input.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT PHYSIOL,LONDON SE1 7EH,ENGLAND; SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	University of London; King's College London; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Lewin, Gary R/B-8028-2011	Lewin, Gary/0000-0002-2890-6352; McMahon, Stephen/0000-0003-4656-5536				AGRAWAL SG, 1986, BRIT J PHARMACOL, V87, P345, DOI 10.1111/j.1476-5381.1986.tb10823.x; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DAVIES SN, 1987, BRAIN RES, V424, P402, DOI 10.1016/0006-8993(87)91487-9; DEVOR M, 1978, NATURE, V276, P75, DOI 10.1038/276075a0; DEVOR M, 1981, J NEUROSCI, V1, P679, DOI 10.1523/JNEUROSCI.01-07-00679.1981; DICKENSON AH, 1987, NEUROPHARMACOLOGY, V26, P1235, DOI 10.1016/0028-3908(87)90275-9; DOUGHERTY PM, 1992, J NEUROSCI, V12, P3025, DOI 10.1523/JNEUROSCI.12-08-03025.1992; DYKES RW, 1979, J NEUROPHYSIOL, V42, P1461, DOI 10.1152/jn.1979.42.5.1461; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; HAO JX, 1991, EXP NEUROL, V113, P182, DOI 10.1016/0014-4886(91)90174-B; HEADLEY PM, 1987, J PHYSIOL-LONDON, V385, P169, DOI 10.1113/jphysiol.1987.sp016490; HEBB DO, 1949, ORG BEHAVIOR; HORCH K, 1979, J NEUROPHYSIOL, V42, P1437; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; KANO M, 1991, NEUROREPORT, V2, P77, DOI 10.1097/00001756-199102000-00003; LEWIN GR, 1993, EUR J NEUROSCI, V5, P1083, DOI 10.1111/j.1460-9568.1993.tb00962.x; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; LISNEY SJW, 1983, BRAIN RES, V259, P31, DOI 10.1016/0006-8993(83)91064-8; McMahon S B, 1993, Curr Opin Neurobiol, V3, P602, DOI 10.1016/0959-4388(93)90062-4; MORRIS RGM, 1990, PHILOS T ROY SOC B, V329, P187, DOI 10.1098/rstb.1990.0164; RANDIC M, 1993, J NEUROSCI, V13, P5228, DOI 10.1523/JNEUROSCI.13-12-05228.1993; SCHAIBLE HG, 1991, EUR J NEUROSCI, V3, P981, DOI 10.1111/j.1460-9568.1991.tb00034.x; SHLAGGER BL, 1993, NATURE, V364, P623; THOMPSON SWN, 1990, EUR J NEUROSCI, V2, P638, DOI 10.1111/j.1460-9568.1990.tb00453.x; TULLE TR, 1993, J NEUROSCI, V13, P5009; WATKINS JC, 1989, NMDA RECEPTOR, P1; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C	29	28	28	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 9	1994	369	6480					482	485		10.1038/369482a0	http://dx.doi.org/10.1038/369482a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	8202138				2022-12-01	WOS:A1994NQ28600056
J	MEYER, K; LEUBE, MP; GRILL, E				MEYER, K; LEUBE, MP; GRILL, E			A PROTEIN PHOSPHATASE 2C INVOLVED IN ABA SIGNAL-TRANSDUCTION IN ARABIDOPSIS-THALIANA	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; POLYMORPHISM LINKAGE MAP; ABSCISIC-ACID; GUARD-CELLS; MOLECULAR-CLONING; STOMATAL CLOSURE; CYTOSOLIC CA-2+; K+ CHANNELS; GENE; CALCINEURIN	The plant hormone abscisic acid (ABA) mediates various responses such as stomatal closure, the maintenance of seed dormancy, and the inhibition of plant growth. All three responses are affected in the ABA-insensitive mutant abi1 of Arabidopsis thaliana, suggesting that an early step in the signaling of ABA is controlled by the ABI1 locus. The ABI1 gene was cloned by chromosome walking, and a missense mutation was identified in the structural gene of the abi1 mutant. The ABI1 gene encodes a protein with high similarity to protein serine or threonine phosphatases of type 2C with the novel feature of a putative Ca2+ binding site. Thus, the control of the phosphorylation state of cell signaling components by the ABI1 product could mediate pleiotropic hormone responses.	SWISS FED INST TECHNOL, INST PLANT SCI, CH-8092 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich				Meyer, Knut/0000-0002-9534-2489				BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; BLATT MR, 1993, ANNU REV PLANT PHYS, V44, P543, DOI 10.1146/annurev.pp.44.060193.002551; BLATT MR, 1990, NATURE, V346, P766, DOI 10.1038/346766a0; BURNS JM, 1993, J BIOL CHEM, V268, P17155; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DAVIES WJ, 1991, ABSCISIC ACID; ESTELLE MA, 1987, MOL GEN GENET, V206, P200, DOI 10.1007/BF00333575; FOOR F, 1992, NATURE, V360, P682; Gibson S. I., 1992, Methods in Arabidopsis research., P119; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; GRILL E, UNPUB; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; HORNBERG C, 1984, NATURE, V310, P321, DOI 10.1038/310321a0; Huang H, 1992, PLANT MOL BIOL REP, V10, P372, DOI 10.1007/BF02668914; IRVING HR, 1992, P NATL ACAD SCI USA, V89, P1790, DOI 10.1073/pnas.89.5.1790; JENKINS GI, 1991, MOL BIOL PLANT DEV; KLEE HJ, 1987, MOL GEN GENET, V210, P282, DOI 10.1007/BF00325695; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; Koornneef M, 1984, ARABIDOPSIS INF SERV, V21, P5; LEUBE MP, UNPUB; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MEYER KH, UNPUB; MUNDY J, 1990, P NATL ACAD SCI USA, V87, P1406, DOI 10.1073/pnas.87.4.1406; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHROEDER JI, 1990, P NATL ACAD SCI USA, V87, P9305, DOI 10.1073/pnas.87.23.9305; SIMOENS C, 1986, NUCLEIC ACIDS RES, V14, P8073, DOI 10.1093/nar/14.20.8073; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; STASKAWICZ B, 1987, J BACTERIOL, V169, P5789, DOI 10.1128/jb.169.12.5789-5794.1987; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x	46	604	639	6	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	1994	264	5164					1452	1455		10.1126/science.8197457	http://dx.doi.org/10.1126/science.8197457			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	8197457				2022-12-01	WOS:A1994NP22100040
J	HYLEK, EM; SINGER, DE				HYLEK, EM; SINGER, DE			RISK-FACTORS FAR INTRACRANIAL HEMORRHAGE IN OUTPATIENTS TAKING WARFARIN	ANNALS OF INTERNAL MEDICINE			English	Article							ORAL ANTICOAGULANT-THERAPY; CEREBRAL AMYLOID ANGIOPATHY; ATRIAL-FIBRILLATION; INTRACEREBRAL HEMATOMAS; STROKE; COMPLICATIONS; PREVENTION; HYPERTENSION; INTENSITIES; POPULATION	Objective: To explore the rational use of anticoagulants, especially among the elderly, balancing antithrombotic efficacy and risk for hemorrhage. Previous prospective studies have not provided powerful assessments of risk factors for intracranial hemorrhage, the dominant complication in reversing the anticoagulant decision. Design: Case-control analysis. Setting: A large general hospital and its anticoagulant therapy unit. Patients: 121 consecutive adult patients taking warfarin who were hospitalized with intracranial hemorrhage were each matched to three contemporaneous controls randomly selected from among outpatients managed by our hospital anticoagulant therapy unit. Results: 77 patients had intracerebral hemorrhage (46% fatal) and 44 had subdural hemorrhage (20% fatal). The prothrombin time ratio (PTR) was the dominant risk factor for intracranial hemorrhage. For each 0.5 increase in PTR over the entire range, the risk for intracerebral hemorrhage doubled (odds ratio, 2.1; 95% CI, 1.4 to 2.9). For subdural hemorrhage, the risk was unchanged over the PTR range from 1.0 to 2.0 but rose dramatically above a PTR of 2.0 (approximate international normalized ratio, 4.0). Age was the only other significant independent risk factor for subdural hemorrhage (odds ratio, 2.0 per decade; CI, 1.3 to 3.1). For intracerebral hemorrhage, age was of borderline significance (odds ratio, 1.3 per decade; CI, 1.0 to 1.6) after controlling for PTR and the two other independent risk factors: history of cerebrovascular disease (odds ratio, 3.1; CI, 1.7 to 5.6) and presence of a prosthetic heart valve (odds ratio, 2.8; CI, 1.3 to 5.8). Conclusions: The results emphasize the importance of maintaining the prothrombin time ratios under 2.0 and the need for especially careful use of warfarin in the elderly.			HYLEK, EM (corresponding author), MASSACHUSETTS GEN HOSP, GEN INTERNAL MED UNIT, BULFINCH 1, BOSTON, MA 02114 USA.			Hylek, Elaine/0000-0001-8263-8304				BRODERICK J, 1993, STROKE, V24, P49, DOI 10.1161/01.STR.24.1.49; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; FLEISS JL, 1981, STATISTICAL METHODS, P123; FRANKE CL, 1990, STROKE, V21, P726, DOI 10.1161/01.STR.21.5.726; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; HART RG, 1984, STROKE, V15, P779; HIRSH J, 1992, ARCH INTERN MED, V152, P257, DOI 10.1001/archinte.152.2.257; HOSMER DW, 1989, APPL LOGISTIC REGRES, P187; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; LANDEFELD CS, 1989, AM J MED, V87, P144; LEVINE M, 1986, STROKE, V17, P111, DOI 10.1161/01.STR.17.1.111; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; LOELIGER EA, 1982, LANCET, V1, P64; MASUDA J, 1988, STROKE, V19, P205, DOI 10.1161/01.STR.19.2.205; MATTLE H, 1989, J NEUROL NEUROSUR PS, V52, P829, DOI 10.1136/jnnp.52.7.829; MCBRIDE R, 1994, LANCET, V343, P687; MEADE TW, 1990, AM J CARDIOL, V65, pC7, DOI 10.1016/0002-9149(90)90108-D; PETERSEN P, 1989, LANCET, V1, P175; RADBERG JA, 1991, STROKE, V22, P571, DOI 10.1161/01.STR.22.5.571; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P63; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SNEDECOR GW, 1980, STATISTICAL METHODS, P206; TURPIE AGG, 1988, LANCET, V1, P1242; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; VONSATTEL JPG, 1991, ANN NEUROL, V30, P637, DOI 10.1002/ana.410300503; WHISNANT JP, 1978, ANN NEUROL, V3, P107, DOI 10.1002/ana.410030204; WINTZEN AR, 1984, ANN NEUROL, V16, P553, DOI 10.1002/ana.410160505; WINTZEN AR, 1982, ARCH NEUROL-CHICAGO, V39, P69, DOI 10.1001/archneur.1982.00510140003001; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121; 1990, NEW ENGL J MED, V322, P863; 1994, IN PRESS ARCH INTERN	37	742	762	3	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1994	120	11					897	902		10.7326/0003-4819-120-11-199406010-00001	http://dx.doi.org/10.7326/0003-4819-120-11-199406010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN110	8172435				2022-12-01	WOS:A1994NN11000001
J	LI, T; NICOLAOU, KC				LI, T; NICOLAOU, KC			CHEMICAL SELF-REPLICATION OF PALINDROMIC DUPLEX DNA	NATURE			English	Article							TEMPLATE-DIRECTED SYNTHESIS; TRIPLE-HELIX; HEXADEOXYNUCLEOTIDE; SYSTEMS; LINKAGE	MOLECULAR replication, a fundamental process of life, has in recent years been the subject of laboratory investigations using simple chemical systems(1-10). Whereas the work of Rebek's group(4,5) has focused on molecular architectures not known in living systems, self-replicating and template-based self-assembling systems based on nucleotides(6-8) are regarded as potential models for exploring the evolution of replicating systems on the early Earth. Previous replicating oligonucleotides have been of the single-stranded, self-complementary type: small oligonucleotide fragments are assembled on a pre-existing template and linked to form an exact copy of the template. This process cannot easily be reiterated, however, because of the strong binding of the newly formed strand to the original template. Furthermore, DNA replication in living systems operates by complementarity rather than self-complementarity-each newly assembled strand is complementary to, rather than identical to, its template-and the replication process starts and finishes with double helices. Here we report the self-replication of palindromic (symmetrical) duplex DNA-like oligonucleotides, 24 monomers long, in the absence of enzymes by means of a cycle that transfers information from template to copy and is potentially capable of extension to include non-symmetrical sequences, selection and mutation. Replication proceeds by a chemical process involving the formation of an intermediate triplex structure, and is sequence-selective in the sense that mismatches impair its efficiency. These results indicate that DNA-like double-helical molecules can replicate without assistance from proteins, a finding that may be relevant both to the appearance of replicating systems on the early Earth and to the development of new approaches to DNA amplification.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego			Li, Tianhu/G-3531-2010					ACEVEDO OL, 1987, J MOL BIOL, V197, P187, DOI 10.1016/0022-2836(87)90117-3; CHEN CB, 1985, J MOL BIOL, V181, P271, DOI 10.1016/0022-2836(85)90091-9; ESCHENMOSER A, 1992, CHEM SOC REV, V21, P1, DOI 10.1039/cs9922100001; ESCHENMOSER A, 1994, CHEM BIOL; FENG Q, 1992, SCIENCE, V256, P1179, DOI 10.1126/science.256.5060.1179; FERRIS JP, 1993, J AM CHEM SOC, V115, P12270, DOI 10.1021/ja00079a006; GEDULIN B, 1993, NOBEL S, V84, P91; GOODWIN JT, 1992, J AM CHEM SOC, V114, P9197, DOI 10.1021/ja00049a067; HOFFMANN S, 1992, ANGEW CHEM INT EDIT, V31, P1013, DOI 10.1002/anie.199210131; HUNZIKER J, 1993, HELV CHIM ACTA, V76, P259, DOI 10.1002/hlca.19930760119; INOUE T, 1983, SCIENCE, V219, P859, DOI 10.1126/science.6186026; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KANAVARIOTI A, 1992, J THEOR BIOL, V158, P207, DOI 10.1016/S0022-5193(05)80719-2; KANAVARIOTI A, 1993, J AM CHEM SOC, V115, P8537, DOI 10.1021/ja00072a003; KANAYA E, 1986, BIOCHEMISTRY-US, V25, P7423, DOI 10.1021/bi00371a026; LEUBKE KJ, 1989, J AM CHEM SOC, V111, P8733; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; MILLER SL, 1987, COLD SPRING HARB SYM, V52, P17, DOI 10.1101/SQB.1987.052.01.005; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; TJIVIKUA T, 1990, J AM CHEM SOC, V112, P1249, DOI 10.1021/ja00159a057; VONKIEDROWSKI G, 1991, ANGEW CHEM INT EDIT, V30, P423, DOI 10.1002/anie.199104231; VONKIEDROWSKI G, 1986, ANGEW CHEM INT EDIT, V25, P932, DOI 10.1002/anie.198609322; VONKIEDROWSKI G, 1989, ANGEW CHEM INT EDIT, V28, P1235, DOI 10.1002/anie.198912351	23	177	185	3	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					218	221		10.1038/369218a0	http://dx.doi.org/10.1038/369218a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	8183341				2022-12-01	WOS:A1994NM06700051
J	TULP, A; VERWOERD, D; DOBBERSTEIN, B; PLOEGH, HL; PIETERS, J				TULP, A; VERWOERD, D; DOBBERSTEIN, B; PLOEGH, HL; PIETERS, J			ISOLATION AND CHARACTERIZATION OF THE INTRACELLULAR MHC CLASS-II COMPARTMENT	NATURE			English	Article							HLA-DR MOLECULES; INVARIANT CHAIN; HISTOCOMPATIBILITY ANTIGENS; TRANSFERRIN RECEPTOR; SURFACE EXPRESSION; FUSION INVITRO; EARLY ENDOSOME; CELL LINE; TRANSPORT; BINDING	An intracellular compartment has been isolated to which MHC class II molecules are transported on their way to the plasma membrane. They arrive with an associated invariant chain which is then proteolytically processed while MHC class II molecules acquire antigenic peptide. These loaded class II molecules then leave the compartment devoid of invariant chain and bound for the plasma membrane. This compartment represents a new stage in the endocytic/lysosomal pathway.	NETHERLANDS CANC INST,DEPT IMMUNOL,1066 CX AMSTERDAM,NETHERLANDS; NETHERLANDS CANC INST,DEPT CELLULAR BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS; UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,W-6900 HEIDELBERG,GERMANY; MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139	Netherlands Cancer Institute; Netherlands Cancer Institute; Ruprecht Karls University Heidelberg; Massachusetts Institute of Technology (MIT)				Pieters, Jean/0000-0002-5284-9757				ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREW K, 1975, J BIOL CHEM, V250, P1434; CHEN QY, 1992, INT J CANCER, V51, P218, DOI 10.1002/ijc.2910510209; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CRESSWELL P, 1987, CRIT REV IMMUNOL, V7, P31; FEANY MB, 1993, NATURE, V364, P537, DOI 10.1038/364537a0; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HANNIG K, 1977, CELL SEPARATION METH, V6, P95; HARDING CV, 1993, J IMMUNOL, V151, P3988; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HUBBARD AL, 1975, J CELL BIOL, V64, P438, DOI 10.1083/jcb.64.2.438; KELLY RB, 1993, NATURE, V364, P487, DOI 10.1038/364487a0; KOLDOVSKY O, 1971, BIOCHEM J, V125, P697, DOI 10.1042/bj1250697; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARHAM P, 1979, J IMMUNOL, V123, P342; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; PIETERS J, 1993, J CELL SCI, V106, P831; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SHAW S, 1985, HUM IMMUNOL, V12, P191, DOI 10.1016/0198-8859(85)90336-2; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; Teyton L, 1992, Trends Cell Biol, V2, P52, DOI 10.1016/0962-8924(92)90163-H; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TULP A, 1993, ELECTROPHORESIS, V14, P1295, DOI 10.1002/elps.11501401198; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143; VANDERIJN M, 1983, CYTOGENET CELL GENET, V36, P525, DOI 10.1159/000131967	49	406	410	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 12	1994	369	6476					120	126		10.1038/369120a0	http://dx.doi.org/10.1038/369120a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK971	8177317	Green Submitted			2022-12-01	WOS:A1994NK97100040
J	PATCHETT, P; ROBERTS, D				PATCHETT, P; ROBERTS, D			LESSON OF THE WEEK - DIABETIC-PATIENTS WHO DO NOT HAVE DIABETES - INVESTIGATION OF REGISTER OF DIABETIC-PATIENTS IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE				PATCHETT, P (corresponding author), WATERLOO HOUSE SURG,MILLOM LA18 4DE,CUMBRIA,ENGLAND.							GIBBINS RL, 1988, BRIT MED J, V297, P187, DOI 10.1136/bmj.297.6642.187; HARRIS MI, 1985, DIABETES CARE, V8, P562, DOI 10.2337/diacare.8.6.562; HARRIS MI, 1992, INT TXB DIABETES MEL, V1, P3; HURWITZ B, 1993, BRIT MED J, V306, P624, DOI 10.1136/bmj.306.6878.624; KEMPLE TJ, 1991, BRIT MED J, V302, P451, DOI 10.1136/bmj.302.6774.451; KIPENSKI M, 1992, BR J GEN PRACT, V42, P508; MARBLE D, 1985, JOSLINS DIABETES MEL, P339; NABARRO J, 1987, J ROY COLL GEN PRACT, V37, P389; OBRIEN E, 1988, BRIT MED J, V297, P1211, DOI 10.1136/bmj.297.6658.1211; ODONNELL MJ, 1988, DIABETIC MED, V5, P494, DOI 10.1111/j.1464-5491.1988.tb01034.x; ROBERTSON DA, 1992, BRIT MED J, V305, P635, DOI 10.1136/bmj.305.6854.635; YUDKIN JS, 1990, BRIT MED J, V301, P397, DOI 10.1136/bmj.301.6749.397	12	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 7	1994	308	6938					1225	1226		10.1136/bmj.308.6938.1225	http://dx.doi.org/10.1136/bmj.308.6938.1225			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK956	8180544	Green Published			2022-12-01	WOS:A1994NK95600027
J	GAFVELIN, G; VONHEIJNE, G				GAFVELIN, G; VONHEIJNE, G			TOPOLOGICAL FRUSTRATION IN MULTISPANNING ESCHERICHIA-COLI INNER MEMBRANE-PROTEINS	CELL			English	Article							CHARGED AMINO-ACIDS; ESCHERICHIA-COLI; LEADER PEPTIDASE; PLASMA-MEMBRANE; INSERTION; DOMAIN; SEQUENCE; EXPORT; GENE; SECA	The topology of E. coli inner membrane proteins depends primarily on the distribution of positively charged residues in the molecule. We have constructed model proteins with four potential transmembrane stretches and have systematically explored the topological effects of lysines placed in the loops connecting the transmembrane spans. Our results indicate that membrane insertion is locally determined, with individual ''helical hairpins'' inserting independently of each other. Topologically ''frustrated'' molecules, where the charge distribution is such that different parts of the molecule would prefer to insert with incompatible orientations, adopt ''leave-one-out'' topologies in which only 3 of the 4 potential transmembrane stretches span the membrane. These results are relevant for our general understanding of both membrane protein biogenesis and the evolution of multispanning membrane proteins.			GAFVELIN, G (corresponding author), KAROLINSKA INST,NOVUM,CTR STRUCT BIOCHEM,S-14157 HUDDINGE,SWEDEN.		von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				ANDERSSON H, 1993, J BIOL CHEM, V268, P21389; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; DALBEY RE, 1987, SCIENCE, V235, P783, DOI 10.1126/science.3544218; DALBEY RE, 1986, J BIOL CHEM, V261, P3844; EHRMANN M, 1991, J BIOL CHEM, V266, P16530; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KUHN A, 1988, EUR J BIOCHEM, V177, P267, DOI 10.1111/j.1432-1033.1988.tb14372.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE JI, 1992, J BIOL CHEM, V267, P938; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SIPOS L, 1993, EUR J BIOCHH, V213, P1133; TAYLOR EW, 1993, FEBS LETT, V325, P161, DOI 10.1016/0014-5793(93)81065-8; VONHEIJNE G, 1988, P NATL ACAD SCI USA, V85, P3363; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; VONHEIJNE G, 1994, IN PRESS ANN REV BIO, V23; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	31	141	142	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 6	1994	77	3					401	412		10.1016/0092-8674(94)90155-4	http://dx.doi.org/10.1016/0092-8674(94)90155-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	8181060				2022-12-01	WOS:A1994NK97000011
J	TURNER, CA; MACK, DH; DAVIS, MM				TURNER, CA; MACK, DH; DAVIS, MM			BLIMP-1, A NOVEL ZINC FINGER-CONTAINING PROTEIN THAT CAN DRIVE THE MATURATION OF B-LYMPHOCYTES INTO IMMUNOGLOBULIN-SECRETING CELLS	CELL			English	Article							MESSENGER-RNA; J-CHAIN; TRANSCRIPTIONAL ACTIVATION; ESCHERICHIA-COLI; MAMMALIAN-CELLS; GENE; EXPRESSION; SEQUENCE; KRUPPEL; FAMILY	We describe a novel gene, Blimp-1 (for B lymphocyte-induced maturation protein), transcripts of which are rapidly induced during the differentiation of B lymphocytes into immunoglobulin secretory cells and whose expression is characteristic of late B and plasma cell lines. The 856 amino acid open reading frame contains five Kruppel-type zinc finger motifs and proline-rich and acidic regions similar to those of known transcription factors. Serological studies show an similar to 100 kd protein that localizes to the nucleus. Stable or transient transfection of Blimp-1 into B cell lymphoma lines leads to the expression of many of the phenotypic changes associated with B cell differentiation into an early plasma cell stage, including induction of J chain message and immunoglobulin secretion, up-regulation of Syndecan-1, and increased cell size and granularity. Thus, Blimp-1 appears to be a pleiotropic regulatory factor capable of at least partially driving the terminal differentiation of B cells.	STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University				Davis, Mark/0000-0001-6868-657X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019512] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-19512] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTABA AR, 1987, EMBO J, V6, P3065, DOI 10.1002/j.1460-2075.1987.tb02613.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BELLEFROID EJ, 1993, EMBO J, V12, P1363, DOI 10.1002/j.1460-2075.1993.tb05781.x; BLACKMAN MA, 1986, CELL, V47, P609, DOI 10.1016/0092-8674(86)90625-2; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHAVRIER P, 1988, MOL CELL BIOL, V8, P1319, DOI 10.1128/MCB.8.3.1319; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHOWDHURY K, 1988, NUCLEIC ACIDS RES, V16, P9995, DOI 10.1093/nar/16.21.9995; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CUNLIFFE V, 1990, EMBO J, V9, P197, DOI 10.1002/j.1460-2075.1990.tb08096.x; DAVIS AC, 1989, IMMUNOL TODAY, V10, P118, DOI 10.1016/0167-5699(89)90244-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRANZE A, 1991, GENOMICS, V9, P728, DOI 10.1016/0888-7543(91)90367-N; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; HANLEYHYDE JM, 1986, ANNU REV IMMUNOL, V4, P621, DOI 10.1146/annurev.iy.04.040186.003201; HARLOW E, 1988, ANTIBODIES LABORATOR; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOY MV, 1993, CELL, V72, P587; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KIM KJ, 1979, J IMMUNOL, V122, P549; LAMSON G, 1984, J EXP MED, V160, P877, DOI 10.1084/jem.160.3.877; LASKOV R, 1981, EUR J IMMUNOL, V11, P462, DOI 10.1002/eji.1830110605; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LIN KH, 1991, BIOTECHNIQUES, V11, P748; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MATSUI K, 1989, J IMMUNOL, V142, P2918; MELCHERS F, 1976, COLD SPRING HARB SYM, V41, P147; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RANDALL TD, 1992, EUR J IMMUNOL, V4, P171; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; WALL R, 1977, ANAL BIOCHEM, V82, P115, DOI 10.1016/0003-2697(77)90140-3; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219	60	621	658	1	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 22	1994	77	2					297	306		10.1016/0092-8674(94)90321-2	http://dx.doi.org/10.1016/0092-8674(94)90321-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168136				2022-12-01	WOS:A1994NH63400014
J	FERNANDEZSARABIA, MJ; BISCHOFF, JR				FERNANDEZSARABIA, MJ; BISCHOFF, JR			BCL-2 ASSOCIATES WITH THE RAS-RELATED PROTEIN R-RAS P23	NATURE			English	Article							PROGRAMMED CELL-DEATH; MEMBRANE PROTEIN; C-MYC; GENE; SURVIVAL; PRODUCT; EXPRESSION; PREVENTION; LINES	APOPTOSIS is an important but poorly understood mechanism of cell regulation. Growth factor deprivation can trigger apoptosis in a variety of cells1-3, suggesting the existence of a signal transduction pathway responding to external signals and leading to apoptosis. Overexpression of the proto-oncogene bcl-2 can override these signals and block apoptosis4-14, indicating that the bcl-2 protein (Bcl-2) is an important component of the apoptotic response. The identification of Bcl-2-binding proteins might help explain how Bcl-2 acts to regulate apoptosis. Here we use the yeast two-hybrid system15 to show that the human ras-related protein R-ras p23 (refs 16-18) binds to Bcl-2. This association is also detected in immunoprecipitates from human cell extracts. The association requires full-length Bcl-2 but the C-terminal 60 amino acids of R-ras p23 are sufficient for the interaction. These results provide evidence of a putative component of a signal transduction pathway involved in the regulation of apoptosis.			FERNANDEZSARABIA, MJ (corresponding author), ONYX PHARMACEUT,3031 RES DR,BLDG A,RICHMOND,CA 94806, USA.							ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Lee S, 1993, CURR OPIN CELL BIOL, V5, P286, DOI 10.1016/0955-0674(93)90118-A; LEROSEY I, 1991, J BIOL CHEM, V266, P4315; LOWE DG, 1988, P NATL ACAD SCI USA, V85, P1015, DOI 10.1073/pnas.85.4.1015; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MONICA K, 1990, NATURE, V346, P189, DOI 10.1038/346189a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; SEIGEL RM, 1992, P NATL ACAD SCI USA, V89, P7003; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TANAKA S, 1993, J BIOL CHEM, V268, P10920; UX DL, 1993, P NATL ACAD SCI USA, V90, P786; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432	24	216	227	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					274	275		10.1038/366274a0	http://dx.doi.org/10.1038/366274a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232588				2022-12-01	WOS:A1993MH32500066
J	RAVICHANDRAN, KS; LEE, KK; ZHOU, SY; CANTLEY, LC; BURN, P; BURAKOFF, SJ				RAVICHANDRAN, KS; LEE, KK; ZHOU, SY; CANTLEY, LC; BURN, P; BURAKOFF, SJ			INTERACTION OF SHC WITH THE ZETA-CHAIN OF THE T-CELL RECEPTOR UPON T-CELL ACTIVATION	SCIENCE			English	Article							MITOGENIC SIGNAL TRANSDUCTION; PROTEIN TYROSINE KINASE; ANTIGEN RECEPTOR; CYTOPLASMIC TAIL; RAS; DOMAIN; PHOSPHORYLATION; IDENTIFICATION; INDUCTION; PATHWAYS	The shc oncogene product is tyrosine-phosphorylated by Src family kinases and after its phosphorylation interacts with the adapter protein Grb2 (growth factor receptor-bound protein 2). In turn, Grb2 interacts with the guanine nucleotide exchange factor for Ras, mSOS. Because several Src family kinases participate in T cell activation and Shc functions upstream of Ras, the role of Shc in T cell signaling was examined. Shc was phosphorylated on tyrosine after activation through the T cell receptor (TCR), and subsequently interacted with Grb2 and mSOS. The Src homology region 2 (SH2) domain of Shc directly interacted with the tyrosine-phosphorylated zeta chain of the TCR. Thus, Shc may couple TCR activation to the Ras signaling pathway.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV PEDIAT ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES NEW TECHNOL, DEPT BIOL, CH-4002 BASEL, SWITZERLAND	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Roche Holding			Ravichandran, Kattur Soundarapandian/AAG-7319-2019; Cantley, Lewis C/D-1800-2014	Ravichandran, Kattur Soundarapandian/0000-0003-2397-461X; Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-17258] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMREIN KE, IN PRESS P NATL ACAD; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HSI ED, 1989, J BIOL CHEM, V264, P10836; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, UNPUB; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SONGYANG Z, UNPUB; SZEBERENYI J, 1992, MOL CELL BIOL, V7, P2105; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	348	354	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1993	262	5135					902	905		10.1126/science.8235613	http://dx.doi.org/10.1126/science.8235613			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235613				2022-12-01	WOS:A1993MF43800036
J	KELLY, WF; MAHMOOD, R; KELLY, MJ; TURNER, S; ELLIOTT, K				KELLY, WF; MAHMOOD, R; KELLY, MJ; TURNER, S; ELLIOTT, K			INFLUENCE OF SOCIAL DEPRIVATION ON ILLNESS IN DIABETIC-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article									UNIV TEESSIDE,SCH COMP & MATH,MIDDLESBROUGH TS1 3BA,ENGLAND; CLEVELAND CTY COUNCIL,RES & INTELLIGENCE UNIT,MIDDLESBROUGH TS1 2YW,ENGLAND	University of Teesside	KELLY, WF (corresponding author), MIDDLESBROUGH GEN HOSP,CTR DIABET CARE,MIDDLESBROUGH TS5 5AZ,ENGLAND.							Black D., 1980, MANNERS CUSTOMS POLI; MARSH GN, 1986, BRIT MED J, V292, P1173, DOI 10.1136/bmj.292.6529.1173; PHILLIMORE PR, 1991, SOC SCI MED, V33, P139, DOI 10.1016/0277-9536(91)90174-B; Townsend P, 1988, HLTH DEPRIVATION INE; Townsend P.B., 1992, INEQUALITIES HLTH BL, Vthird	5	48	49	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1115	1116		10.1136/bmj.307.6912.1115	http://dx.doi.org/10.1136/bmj.307.6912.1115			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ME918	8251810	Green Published, Bronze			2022-12-01	WOS:A1993ME91800018
J	OTA, IM; VARSHAVSKY, A				OTA, IM; VARSHAVSKY, A			A YEAST PROTEIN SIMILAR TO BACTERIAL 2-COMPONENT REGULATORS	SCIENCE			English	Article							N-END RULE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; SIGNAL; GENES; FAMILY; DNA; PHOSPHORYLATION; POLYSACCHARIDE	Many bacterial signaling pathways involve a two-component design. In these pathways, a sensor kinase, when activated by a signal, phosphorylates its own histidine, which then serves as a phosphoryl donor to an aspartate in a response regulator protein. The Sln1 protein of the yeast Saccharomyces cerevisiae has sequence similarities to both the histidine kinase and the response regulator proteins of bacteria. A missense mutation in SLN1 is lethal in the absence but not in the presence of the N-end rule pathway, a ubiquitin-dependent proteolytic system. The finding of SLN1 demonstrates that a mode of signal transduction similar to the bacterial two-component design operates in eukaryotes as well.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology								ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; ALEX L, COMMUNICATION; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARKER WC, 1992, NUCLEIC ACIDS RES, V20, P2023, DOI 10.1093/nar/20.suppl.2023; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BASSON ME, 1987, GENETICS, V117, P645; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOTTESMAN S, 1991, MOL MICROBIOL, V5, P1599, DOI 10.1111/j.1365-2958.1991.tb01906.x; GROSS R, 1989, MOL MICROBIOL, V3, P1661, DOI 10.1111/j.1365-2958.1989.tb00152.x; HAZELBAUER GL, 1993, CELL, V73, P15, DOI 10.1016/0092-8674(93)90156-K; HRABAK EM, 1992, J BACTERIOL, V174, P3011, DOI 10.1128/JB.174.9.3011-3020.1992; HUANG JM, 1991, J BIOL CHEM, V266, P9023; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; KOSHLAND DE, 1988, BIOCHEMISTRY-US, V27, P5829, DOI 10.1021/bi00416a001; LIN ECC, 1991, ANNU REV GENET, V25, P361, DOI 10.1146/annurev.ge.25.120191.002045; MADURA K, 1993, J BIOL CHEM, V268, P12046; MAGASANIK B, 1988, TRENDS BIOCHEM SCI, V13, P475, DOI 10.1016/0968-0004(88)90234-4; NAGASAWA S, 1992, MOL MICROBIOL, V6, P799, DOI 10.1111/j.1365-2958.1992.tb01530.x; OTA IM, 1992, P NATL ACAD SCI USA, V89, P2355, DOI 10.1073/pnas.89.6.2355; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POPOV KM, 1992, J BIOL CHEM, V267, P13127; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHNEIDERPOETSCH HAW, 1992, PHOTOCHEM PHOTOBIOL, V56, P839, DOI 10.1111/j.1751-1097.1992.tb02241.x; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; SIKORSKI RS, 1989, GENETICS, V122, P19; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; TANG JL, 1991, MOL GEN GENET, V226, P409, DOI 10.1007/BF00260653; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WANNER BL, 1992, J BACTERIOL, V174, P2053, DOI 10.1128/JB.174.7.2053-2058.1992	38	370	383	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1993	262	5133					566	569		10.1126/science.8211183	http://dx.doi.org/10.1126/science.8211183			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC935	8211183				2022-12-01	WOS:A1993MC93500040
J	POTASHKIN, J; NAIK, K; WENTZHUNTER, K				POTASHKIN, J; NAIK, K; WENTZHUNTER, K			U2AF HOMOLOG REQUIRED FOR SPLICING IN-VIVO	SCIENCE			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; MESSENGER-RNA INTRONS; BIOCHEMICAL-CHARACTERIZATION; AUXILIARY FACTOR; A-PROTEIN; U1 RNA; COMPLEX; BINDING; IDENTIFICATION; RECOGNITION	Several fission yeast temperature-sensitive mutants defective in pre-mRNA processing (prp- mutants) at the nonpermissive temperature have been identified. Here, the prp2+ gene has been cloned by its ability to complement the temperature-sensitive growth defect of a prp2- mutant. The gene also corrects the pre-mRNA splicing defect of prp2- mutants and encodes a 59-kilodalton polypeptide (PRP2). A molecular characterization indicates that PRP2 is a previously uncharacterized yeast splicing factor with extensive similarity to the mammalian splicing factor U2AF65. Thus, this study provides evidence that a U2AF homolog participates in RNA processing in vivo.			POTASHKIN, J (corresponding author), UNIV HLTH SCI CHICAGO MED SCH, DEPT PHARMACOL & MOLEC BIOL, N CHICAGO, IL 60064 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047487] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM47487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CSANK C, 1990, NUCLEIC ACIDS RES, V18, P5133, DOI 10.1093/nar/18.17.5133; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; GEORGE DG, 1990, METHOD ENZYMOL, V183, P333; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; HAYNES SR, 1992, NEW BIOL, V4, P421; KAUFER NF, 1985, NATURE, V318, P78, DOI 10.1038/318078a0; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; MORENO S, 1991, METHOD ENZYMOL, V194, P795; POTASHKIN J, 1989, EMBO J, V8, P551, DOI 10.1002/j.1460-2075.1989.tb03409.x; POTASHKIN J, UNPUB; PRABHALA G, 1992, YEAST, V8, P171, DOI 10.1002/yea.320080303; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROSENBERG GH, 1991, MOL GEN GENET, V226, P305, DOI 10.1007/BF00273617; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RUSSELL P, 1989, MOL BIOL FISSION YEA, P244; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	25	93	95	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1993	262	5133					573	575		10.1126/science.8211184	http://dx.doi.org/10.1126/science.8211184			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC935	8211184				2022-12-01	WOS:A1993MC93500042
J	GOUVERNEUR, VE; HOUK, KN; DEPASCUALTERESA, B; BENO, B; JANDA, KD; LERNER, RA				GOUVERNEUR, VE; HOUK, KN; DEPASCUALTERESA, B; BENO, B; JANDA, KD; LERNER, RA			CONTROL OF THE EXO-PATHWAY AND ENDO-PATHWAY OF THE DIELS-ALDER REACTION BY ANTIBODY CATALYSIS	SCIENCE			English	Article							SYNTHETIC APPLICATIONS; TRANSITION STRUCTURES; TRANS-1-N-ACYLAMINO-1,3-DIENES; N-ACYLAMINO-1,3-DIENES; STEREOSELECTIVITY; SUBSTITUENT; BUTADIENE	Catalytic antibodies that control the reaction pathways of the Diels-Alder cycloaddition have been generated. One antibody catalyzes the favored endo and the other the disfavored exo pathway to yield the respective cis and trans adducts in enantiomerically pure form. A comparison of the x-ray structure of the hapten with the calculated geometry of the transition structure showed that [2.2.2] bicyclic compounds are excellent mimics of the transition state of the Diels-Alder reaction. To achieve catalysis and the high degree of stereoselectivity shown here, the antibody must simultaneously control the conformation of the individual reactants and their relation to each other. In the case of the disfavored process, binding energy must be used to reroute the reaction along a higher energy pathway. The rerouting of reaction pathways has become a major focus of antibody catalysis and other disfavored reactions can be expected to be catalyzed so long as the energy barrier is not extreme. The energy requirements needed for absolute control of all of the stereoisomers of many Diels-Alder reactions fall in the energy range (approximately 20 kilocalories per mole) deliverable by antibody binding.	SCRIPPS RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA; UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA	Scripps Research Institute; University of California System; University of California Los Angeles	GOUVERNEUR, VE (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		de Pascual-Teresa, Beatriz/J-4318-2012	de Pascual-Teresa, Beatriz/0000-0002-1101-0373				BERNARDI F, 1988, J AM CHEM SOC, V110, P3050, DOI 10.1021/ja00218a009; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; BROWN FK, 1984, TETRAHEDRON LETT, V25, P4609, DOI 10.1016/S0040-4039(01)91212-2; Carruthers W., 1990, CYCLOADDITION REACTI; DANISHEFSKY S, 1979, J ORG CHEM, V44, P1180, DOI 10.1021/jo01321a040; Desimoni G., 1983, ACS MONOGRAPH, V180; Diels O, 1928, LIEBIGS ANN CHEM, V460, P98; Diels O, 1925, LIEBIGS ANN CHEM, V443, P242; Engvall E, 1980, Methods Enzymol, V70, P419; FRIGUELLI F, 1990, DIENES DIELS ADLER R; Frisch M. J, 1992, GAUSSIAN 92; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; HOUK KN, 1989, J AM CHEM SOC, V111, P9172, DOI 10.1021/ja00208a006; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; KAGAN HB, 1992, CHEM REV, V92, P1007, DOI 10.1021/cr00013a013; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LONCHARICH RJ, 1989, J ORG CHEM, V54, P1129, DOI 10.1021/jo00266a026; OVERMAN CLE, 1977, TETRAHEDRON LETT, P1253; OVERMAN LE, 1980, J AM CHEM SOC, V102, P1454, DOI 10.1021/ja00524a057; OVERMAN LE, 1983, J AM CHEM SOC, V105, P5373, DOI 10.1021/ja00354a031; OVERMAN LE, 1978, J ORG CHEM, V43, P2164, DOI 10.1021/jo00405a017; OVERMAN LE, 1978, J AM CHEM SOC, V100, P3182, DOI 10.1021/ja00478a038; OVERMAN LE, 1981, J AM CHEM SOC, V103, P2816, DOI 10.1021/ja00400a054; OVERMAN LE, 1979, J ORG CHEM, V44, P4183, DOI 10.1021/jo01337a036; OVERMAN LE, 1978, J AM CHEM SOC, V100, P5179, DOI 10.1021/ja00484a046; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; PINDUR U, 1993, CHEM REV, V93, P741, DOI 10.1021/cr00018a006; SUCKLING CJ, 1992, BIOORG MED CHEM LETT, V2, P49, DOI 10.1016/S0960-894X(00)80653-8; TROST BM, 1991, COMPREHENSIVE ORGANI, V5, P316	29	200	202	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 8	1993	262	5131					204	208		10.1126/science.8211138	http://dx.doi.org/10.1126/science.8211138			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	MA665	8211138				2022-12-01	WOS:A1993MA66500024
J	NICHOLS, R; ANDREWS, PC; ZHANG, P; BERGSTROM, DE				NICHOLS, R; ANDREWS, PC; ZHANG, P; BERGSTROM, DE			A UNIVERSAL NUCLEOSIDE FOR USE AT AMBIGUOUS SITES IN DNA PRIMERS	NATURE			English	Article							HYBRIDIZATION PROBES; DUPLEX STABILITY; OLIGONUCLEOTIDES; DEOXYINOSINE; BASE; ANALOGS	A NON-DISCRIMINATORY base analogue, or universal base, would be an invaluable component of oligonucleotide probes and primers for solving the design problems that arise as a result of the degeneracy of the genetic code, or when only fragmentary peptide sequence data are available. We have designed an alternative to previous universal nucleoside candidates(1-9), a new analogue, 1-(2'-deoxy-beta-D-ribofuranosyl)-3-nitropyrrole (designated M; Fig. 1), which maximizes stacking while minimizing hydrogen-bonding interactions without sterically disrupting a DNA duplex. Oligonucleotides containing M at several sites were used as primers for sequencing and the polymerase chain reaction. The sequencing primer d(5'-CGT AAM CAM AAM ACM AT-3') is as effective as the exact match d(5'-CGT AAT CAG AAA ACA AT-3'). It is also possible to sequence using a primer containing M at several contiguous positions, for example d(5'-CGT AAT MMM MMM MMM AT-3'). Melting curves show that duplexes formed on hybridization of the sequences d(5';CCT TTT TMT TTT TGG-3') and d(5'-CCA AAA AXA AAA AGG-3'), where X is A, C, G or T, melted at a lower temperature than the corresponding duplexes containing only d(A.T) and d(C.G) base pairs, but showing little variation among different X bases (T-m range 3 degrees C).	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48109; PURDUE UNIV,DEPT MED CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907; WALTHER CANC INST,INDIANAPOLIS,IN 46208	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Walther Cancer Institute				Andrews, Philip/0000-0001-6843-5420				BROWN DM, 1991, CARBOHYD RES, V216, P129; ERITJA R, 1986, NUCLEIC ACIDS RES, V14, P8135, DOI 10.1093/nar/14.20.8135; FRANCOIS P, 1990, TETRAHEDRON LETT, V31, P6347, DOI 10.1016/S0040-4039(00)97060-6; FUKUDA T, 1986, Z NATURFORSCH B, V41, P1571, DOI 10.1515/znb-1986-1217; GABBAY EJ, 1977, BIOORG CHEM, V3, P33; HABENER JF, 1988, P NATL ACAD SCI USA, V85, P1735, DOI 10.1073/pnas.85.6.1735; INONE H, 1985, NUCLEIC ACIDS RES, V13, P7119; KAWASE Y, 1986, NUCLEIC ACIDS RES, V14, P7727, DOI 10.1093/nar/14.19.7727; LIN PKT, 1989, NUCLEIC ACIDS RES, V17, P10373, DOI 10.1093/nar/17.24.10373; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; MILLICAN TA, 1984, NUCLEIC ACIDS RES, V12, P7435, DOI 10.1093/nar/12.19.7435; NICHOLS R, 1988, J BIOL CHEM, V263, P12167; OHTSUKA E, 1985, J BIOL CHEM, V260, P2605; SEELA F, 1986, NUCLEIC ACIDS RES, V14, P1825, DOI 10.1093/nar/14.4.1825	14	102	178	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 9	1994	369	6480					492	493		10.1038/369492a0	http://dx.doi.org/10.1038/369492a0			2	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	8202140	Green Published			2022-12-01	WOS:A1994NQ28600059
J	SCHOMER, DF; MARKS, MP; STEINBERG, GK; JOHNSTONE, IM; BOOTHROYD, DB; ROSS, MR; PELC, NJ; ENZMANN, DR				SCHOMER, DF; MARKS, MP; STEINBERG, GK; JOHNSTONE, IM; BOOTHROYD, DB; ROSS, MR; PELC, NJ; ENZMANN, DR			THE ANATOMY OF THE POSTERIOR COMMUNICATING ARTERY AS A RISK FACTOR FOR ISCHEMIC CEREBRAL INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNAL CAROTID-ARTERY; CT FINDINGS; OCCLUSION; ANGIOGRAPHY; PROGNOSIS; STENOSIS	Background. After the occlusion of an internal carotid artery the principal source of collateral flow is through the arteries of the circle of Willis, but the size and patency of these arteries are quite variable. Study of the anatomy of the collateral pathways in patients with internal-carotid-artery occlusion with or without infarction in the watershed area of the deep white matter may identify patterns that afford protection from ischemic infarction. Methods. Using conventional magnetic resonance imaging and three-dimensional phase-contrast magnetic resonance angiography, we evaluated 29 consecutive patients (32 hemispheres at risk) with angiographically proved occlusion of the internal carotid artery. Four collateral pathways to the occluded vessel were evaluated: the proximal segment of the anterior cerebral artery, the posterior communicating artery, the ophthalmic artery, and leptomeningeal collateral vessels from the posterior cerebral artery. Results. Only features of the ipsilateral posterior communicating artery were related to the risk of watershed infarction. The presence of posterior communicating arteries measuring at least 1 mm in diameter was associated with the absence of watershed infarction (13 hemispheres, no infarcts; P < 0.001). Conversely, there were 4 water-shed infarcts in the 6 hemispheres with posterior communicating arteries measuring less than 1 mm in dimeter and 10 infarcts in the 13 hemispheres with no detectable flow in the ipsilateral posterior communicating artery. Conculsions. A small (< 1 mm in diameter) or absent ipsilateral posterior communicating artery is a risk factor for ischemic cerebral infarction in patients with internal-carotid-artery occlusion.	STANFORD UNIV,MED CTR S072,DEPT RADIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT NEUROSURG,STANFORD,CA 94305; STANFORD UNIV,DEPT STAT,STANFORD,CA 94305	Stanford University; Stanford University; Stanford University				Pelc, Norbert/0000-0002-8922-8989; Steinberg, Gary/0000-0001-6374-1058; Boothroyd, Derek Brian/0000-0001-5387-6995				Baird A E, 1991, Clin Exp Neurol, V28, P50; CAVESTRI R, 1991, ITAL J NEUROL SCI, V12, P383, DOI 10.1007/BF02335778; HARRISON MJG, 1988, J NEUROL NEUROSUR PS, V51, P269, DOI 10.1136/jnnp.51.2.269; HEDERA P, 1992, STROKE, V23, P1069, DOI 10.1161/01.STR.23.8.1069; HEISERMAN JE, 1992, RADIOLOGY, V185, P667, DOI 10.1148/radiology.185.3.1438743; MARKS MP, 1992, RADIOLOGY, V182, P467, DOI 10.1148/radiology.182.2.1732966; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Osborne AG, 1980, INTRO CEREBRAL ANGIO, P146; PERLER BA, 1991, J VASC SURG, V14, P821, DOI 10.1067/mva.1991.32077; PRICE RR, 1992, INVEST RADIOL, V27, pS27, DOI 10.1097/00004424-199212002-00006; RAUTENBERG W, 1990, J NEUROL SCI, V98, P213, DOI 10.1016/0022-510X(90)90262-L; ROSS MR, 1993, AM J NEURORADIOL, V14, P19; SCHWARTZ RB, 1992, AM J ROENTGENOL, V159, P1057, DOI 10.2214/ajr.159.5.1414775; STEINBERG GK, 1993, J NEUROSURG, V79, P161, DOI 10.3171/jns.1993.79.2.0161; TAKAHASHI S, 1992, NEURORADIOLOGY, V34, P504, DOI 10.1007/BF00598961; 1990, SAS STAT USERS GUIDE, V1	16	262	279	1	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1565	1570		10.1056/NEJM199406023302204	http://dx.doi.org/10.1056/NEJM199406023302204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	8177246	Bronze			2022-12-01	WOS:A1994NN21500004
J	DIETRICH, RA; DELANEY, TP; UKNES, SJ; WARD, ER; RYALS, JA; DANGL, JL				DIETRICH, RA; DELANEY, TP; UKNES, SJ; WARD, ER; RYALS, JA; DANGL, JL			ARABIDOPSIS MUTANTS SIMULATING DISEASE RESISTANCE RESPONSE	CELL			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; ERYSIPHE-GRAMINIS-HORDEI; DOWNY MILDEW FUNGUS; CELL-DEATH; SALICYLIC-ACID; PLANT-DISEASE; GENE; INFECTION; BARLEY; IDENTIFICATION	We describe six Arabidopsis mutants, defining at least four loci, that spontaneously form necrotic lesions on leaves. Lesions resemble those resulting from disease, but occur in the absence of pathogen. In five mutants, lesion formation correlates with expression of histochemical and molecular markers of plant disease resistance responses and with expression of genes activated during development of broad disease resistance in plants (systemic acquired resistance [SAR]). We designate this novel mutant class Isd (for lesions simulating disease resistance response). Strikingly, four Isd mutants express substantial resistance to virulent fungal pathogen isolates. Isd mutants vary in cell type preferences for lesion onset and spread. Lesion formation can be conditional and can be induced specifically by biotic and chemical activators of SAR in Isd1 mutants.	CIBA GEIGY CORP, AGR BIOTECHNOL RES UNIT, RES TRIANGLE PK, NC 27709 USA		DIETRICH, RA (corresponding author), MAX DELBRUCK LAB, CARL VON LINNE WEG 10, D-50829 COLOGNE, GERMANY.		Delaney, Terrence P/A-2947-2008					AIST JR, 1977, PHYTOPATHOLOGY, V67, P455, DOI 10.1094/Phyto-67-455; ALEXANDER D, 1993, P NATL ACAD SCI USA, V90, P7327, DOI 10.1073/pnas.90.15.7327; BECKER F, 1993, PLANT J, V3, P875, DOI 10.1111/j.1365-313X.1993.00875.x; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BROGLIE K, 1991, SCIENCE, V254, P1194, DOI 10.1126/science.254.5035.1194; BRUZZESE E, 1983, PLANT PATHOL, V32, P335, DOI 10.1111/j.1365-3059.1983.tb02841.x; CRUTE IR, 1993, CURR PLANT SCI BIOT, V14, P437; CRUTE IR, 1985, MECHANISMS RESISTANC, P80; Dangl J. L., 1992, Methods in Arabidopsis research., P393; DANGL JL, 1992, PLANT CELL, V4, P1359, DOI 10.1105/tpc.4.11.1359; DANGL JL, 1992, PLANT J, V2, P3, DOI 10.1111/j.1365-313X.1992.00003.x; Dangl JL, 1993, ADV PLANT PATHOL, V10, P127; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; DELONG A, 1993, CELL, V74, P757, DOI 10.1016/0092-8674(93)90522-R; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; Emerson RA, 1923, CORNELL U AGR EXP ST, V70, P3; ESCHRICH W., 1964, STAIN TECHNOL, V39, P303; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; GORG R, 1993, PLANT J, V3, P857, DOI 10.1111/j.1365-313X.1993.00857.x; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; HAHLBROCK K, 1987, INNOVATIVE APPROACHE, P229; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; JOHAL GS, 1992, SCIENCE, V258, P985, DOI 10.1126/science.1359642; Keen N. T., 1982, Advances in plant pathology Vol.1., P35; KEEN NT, 1988, ANNU REV MICROBIOL, V42, P421, DOI 10.1146/annurev.mi.42.100188.002225; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KEOGH RC, 1980, T BRIT MYCOL SOC, V74, P329, DOI 10.1016/S0007-1536(80)80163-X; KIRALY Z, 1972, NATURE, V239, P456, DOI 10.1038/239456a0; KIYOSAWA S., 1970, Bull. natn. Inst. agric. Sci., Tokyo, V21, P61; KOCH E, 1990, PLANT CELL, V2, P437, DOI 10.1105/tpc.2.5.437; KOGA H, 1988, PHYSIOL MOL PLANT P, V32, P395, DOI 10.1016/S0885-5765(88)80033-X; KOGA H, 1980, CAN J BOT, V58, P536, DOI 10.1139/b80-065; Kosuge T., 1983, GENETIC ENG PLANTS A, P431, DOI [10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_]; KUC J, 1982, BIOSCIENCE, V32, P854, DOI 10.2307/1309008; Lacy G. H., 1982, PHYTOPATHOGENIC PROK, V2, P149; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LANGFORD AN, 1948, CAN J RES C, V26, P35, DOI 10.1139/cjr48c-006; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MARCHETTI MA, 1983, PHYTOPATHOLOGY, V73, P603, DOI 10.1094/Phyto-73-603; MAUCH F, 1988, PLANT PHYSIOL, V88, P936, DOI 10.1104/pp.88.3.936; MAYAMA S, 1978, PHYSIOL PLANT PATHOL, V13, P347, DOI 10.1016/0048-4059(78)90051-6; Metraux J. P., 1991, Advances in molecular genetics of plant-microbe interactions. Vol. 1. Proceedings of the 5th international symposium on the molecular genetics of plant-microbe interactions, Interlaken, Switzerland, September 9-14, 1990., P432; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; NEUFFER MG, 1975, J HERED, V66, P265, DOI 10.1093/oxfordjournals.jhered.a108627; NEUFFER MG, 1984, GENE STRUCTURE FUNCT, P123; PARKER JE, 1993, PLANT J, V4, P821, DOI 10.1046/j.1365-313X.1993.04050821.x; PRYOR T, 1987, TRENDS GENET, V3, P157, DOI 10.1016/0168-9525(87)90217-4; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROSS AF, 1961, VIROLOGY, V14, P340, DOI 10.1016/0042-6822(61)90319-1; RYALS J, 1994, IN PRESS PLANT PHYSL; STAKMAN EC, 1914, U MINN AGR EXP STA B, V138, P1; STANGHEL.ME, 1966, PHYTOPATHOLOGY, V56, P444; UKNES S, 1992, PLANT CELL, V4, P645, DOI 10.1105/tpc.4.6.645; UKNES S, 1993, MOL PLANT MICROBE IN, V6, P692, DOI 10.1094/MPMI-6-692; UKNES S, 1993, MOL BIOL SYSTEMIC AC, P1; ULLSTRUP AJ, 1967, PHYTOPATHOLOGY, V57, P1282; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WERNSMAN EA, 1987, PRINCIPLES CULTIVAR, P669; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WHITE RF, 1979, VIROLOGY, V99, P410, DOI 10.1016/0042-6822(79)90019-9; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WOLTER M, 1993, MOL GEN GENET, V239, P122, DOI 10.1007/BF00281610; WOODS AM, 1988, PHYSIOL MOL PLANT P, V32, P483, DOI 10.1016/S0885-5765(88)80040-7; Yalpani Nasser, 1993, Trends in Microbiology, V1, P88, DOI 10.1016/0966-842X(93)90113-6	70	582	637	4	75	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	1994	77	4					565	577		10.1016/0092-8674(94)90218-6	http://dx.doi.org/10.1016/0092-8674(94)90218-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	8187176				2022-12-01	WOS:A1994NM83200011
J	ATKINSON, MA; BOWMAN, MA; KAO, KJ; CAMPBELL, L; DUSH, PJ; SHAH, SC; SIMELL, O; MACLAREN, NK				ATKINSON, MA; BOWMAN, MA; KAO, KJ; CAMPBELL, L; DUSH, PJ; SHAH, SC; SIMELL, O; MACLAREN, NK			LACK OF IMMUNE RESPONSIVENESS TO BOVINE SERUM-ALBUMIN IN INSULIN-DEPENDENT DIABETES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RHEUMATOID-ARTHRITIS; DIETARY ANTIGENS; MILK-PROTEINS; MELLITUS; IDDM; ANTIBODIES; CHILDREN; RISK; PERMEABILITY; TRIGGER	Background. Epidemiologic studies have implicated the ingestion of cow's milk in the pathogenesis of insulin-dependent diabetes mellitus (IDDM). Moreover, in a recent study, 100 percent of patients with new-onset IDDM had antibodies against bovine serum albumin (BSA), with a majority directed against a 17-amino-acid BSA peptide (ABBOS). Cellular immune mechanisms are thought to be the principal mediators of pancreatic beta-cell destruction in IDDM. Methods. We measured the responses of peripheral-blood mononuclear cells to BSA and ABBOS or serum IgG anti-BSA antibodies (by particle-concentration fluorescence immunoassay) in 71 patients with IDDM, 55 subjects at various degrees of risk for IDDM, 36 patients with other autoimmune disorders (chronic autoimmune thyroiditis, rheumatoid arthritis, and systemic lupus erythematosus), and 48 normal subjects. Results. The responses of peripheral-blood mononuclear cells to BSA or ABBOS were positive in 2 of 24 patients with new-onset IDDM, 1 of 25 first-degree relatives of patients with IDDM who were negative for islet-cell antibodies, 2 of 30 first-degree relatives of patients with IDDM who were positive for islet-cell antibodies, 1 of 28 patients with established IDDM, and 1 of 29 normal subjects. Similarly, anti-BSA antibodies were not detected significantly more often in patients with new-onset IDDM (3 of 31, 10 percent) than in normal subjects (1 of 37, 3 percent; P = 0.32). However, many patients with autoimmune disease and subjects at increased risk for IDDM had anti-BSA antibodies (frequency, 10 to 31 percent). Conclusions. Anti-BSA antibodies may reflect a general defect in the process of immunologic tolerance associated with a predisposition to autoimmunity rather than immunity specific to beta cells. The absence of cellular immunity to BSA and ABBOS in IDDM does not support a role for this antigen in the pathogenesis of the disorder.	UNIV S FLORIDA,DEPT PEDIAT,TAMPA,FL 33620; UNIV FLORIDA,COLL MED,DEPT PATHOL & LAB MED,GAINESVILLE,FL 32610; UNIV TURKU,DEPT PEDIAT,SF-20500 TURKU 50,FINLAND	State University System of Florida; University of South Florida; State University System of Florida; University of Florida; University of Turku			Campbell, Lesley V/B-2271-2008		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045342] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD19469] Funding Source: Medline; NIDDK NIH HHS [R29DK45342] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARVOLA T, 1992, PEDIATR RES, V32, P301, DOI 10.1203/00006450-199209000-00011; ATKINSON MA, 1990, SCI AM, V263, P62, DOI 10.1038/scientificamerican0790-62; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; ATKINSON MA, 1990, SCI AM, V263, P66; BELLON T, 1989, SCAND J IMMUNOL, V30, P563, DOI 10.1111/j.1365-3083.1989.tb02463.x; BONIFACIO E, 1988, J IMMUNOL METHODS, V106, P83, DOI 10.1016/0022-1759(88)90274-8; BORCHJOHNSEN K, 1984, LANCET, V2, P1083; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CHAPMAN J, 1993, INT ARCH ALLERGY IMM, V100, P42, DOI 10.1159/000236385; DAHLJORGENSEN K, 1991, DIABETES CARE, V14, P1081, DOI 10.2337/diacare.14.11.1081; DOSCH HM, 1988, PANDEX S PCFIA, P5; ELLIOTT RB, 1984, DIABETOLOGIA, V26, P297, DOI 10.1007/BF00283653; ELLIOTT RB, 1988, DIABETOLOGIA, V31, P62; GLERUM M, 1989, DIABETES RES CLIN EX, V10, P103; GONZALEZCABRERO J, 1987, CLIN EXP IMMUNOL, V68, P694; HARRISON LC, 1992, J CLIN INVEST, V89, P1161, DOI 10.1172/JCI115698; ISOLAURI E, 1989, J PEDIATR GASTR NUTR, V8, P466, DOI 10.1097/00005176-198905000-00008; JALONEN T, 1991, PEDIATR RES, V30, P290, DOI 10.1203/00006450-199109000-00019; JAMES SP, 1990, CURRENT PROTOCOLS IM; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; KARJALAINEN J, 1993, J AUTOIMMUN S1, V15, P62; KELLER RJ, 1990, J AUTOIMMUN, V3, P321, DOI 10.1016/0896-8411(90)90150-Q; KOSTRABA JN, 1993, DIABETES, V42, P288, DOI 10.2337/diabetes.42.2.288; KOSTRABA JN, 1992, DIABETES CARE, V15, P626, DOI 10.2337/diacare.15.5.626; MACLAREN N, 1992, NEW ENGL J MED, V327, P348, DOI 10.1056/NEJM199207303270509; MARTIN JM, 1991, ANN MED, V23, P447, DOI 10.3109/07853899109148088; MAYER EJ, 1988, DIABETES, V37, P1625, DOI 10.2337/diabetes.37.12.1625; MICHAELIS D, 1985, EXP CLIN ENDOCRINOL, V85, P61, DOI 10.1055/s-0029-1210420; MULLER W, 1983, PEDIATR RES, V17, P724, DOI 10.1203/00006450-198309000-00008; PATERAKI E, 1986, CLIN RHEUMATOL, V5, P338, DOI 10.1007/BF02054252; PEARSON JR, 1983, PEDIATR RES, V17, P406, DOI 10.1203/00006450-198305000-00017; PEREZMACEDA B, 1991, CLIN CHIM ACTA, V203, P153, DOI 10.1016/0009-8981(91)90287-M; PIETROPAOLO M, 1993, J CLIN INVEST, V92, P359, DOI 10.1172/JCI116574; RILEY WJ, 1990, NEW ENGL J MED, V323, P1167, DOI 10.1056/NEJM199010253231704; ROEP BO, 1991, LANCET, V337, P1439, DOI 10.1016/0140-6736(91)93127-U; Tamura N, 1982, Gastroenterol Jpn, V17, P469; Tamura N, 1982, Gastroenterol Jpn, V17, P310; VIRTANEN SM, 1991, DIABETES CARE, V14, P415, DOI 10.2337/diacare.14.5.415	39	163	163	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1993	329	25					1853	1858		10.1056/NEJM199312163292505	http://dx.doi.org/10.1056/NEJM199312163292505			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML588	8247037	Bronze			2022-12-01	WOS:A1993ML58800005
J	ALDOUS, MB; EDMONSON, MB				ALDOUS, MB; EDMONSON, MB			MATERNAL AGE AT 1ST CHILDBIRTH AND RISK OF LOW-BIRTH-WEIGHT AND PRETERM DELIVERY IN WASHINGTON-STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DELAYED CHILDBEARING; UNITED-STATES; PREGNANCY; POPULATION; PREVALENCE; OLDER; WOMEN	Objective.-To study the consequences of delayed first childbearing in a large, population-based US sample, with separate analysis of women aged 40 years or more and adjustment for socioeconomic factors, smoking, medical and reproductive conditions, and route of delivery. Design and Setting.-Retrospective survey of Washington State birth certificates from 1984 through 1988. Subjects.-First liveborn singleton infants of women aged at least 20 years. Of eligible white infants, all those born to women aged 35 to 39 years (n=4019) and 40 years or more (n=410) and a maternal age-stratified random sample of white infants of younger women were studied. All eligible black infants were studied. Outcome Measures.-Low (<2500 g) and very low (<1500 g) birth weight and preterm delivery (<37 weeks of gestation). Results.-Adjusted odds ratios for delivering a low-birth-weight white infant increased progressively with each 5-year maternal age group, reaching 2.3 (95% confidence interval, 1.6 to 3.4) for women aged 40 years or more compared with those aged 20 to 24 years. The maternal age effects for very low birth weight and preterm delivery were similar; for each, the odds ratio was 1.8 for the oldest group. No significant maternal age effect was found among births of black infants, but only 127 births to women aged 35 years or more were studied. Conclusion.-Increasing maternal age at first childbirth is an independent risk factor for low birth weight and preterm delivery of white infants in the United States.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, MATERNAL & CHILD HLTH PROGRAM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ALES KL, 1990, SURG GYNECOL OBSTET, V171, P209; BARKAN SE, 1987, AM J EPIDEMIOL, V125, P101, DOI 10.1093/oxfordjournals.aje.a114491; BERKOWITZ GS, 1993, JAMA-J AM MED ASSOC, V269, P745, DOI 10.1001/jama.1993.03500060045020; BERKOWITZ GS, 1990, NEW ENGL J MED, V322, P659, DOI 10.1056/NEJM199003083221004; CNATTINGIUS S, 1993, AM J OBSTET GYNECOL, V168, P16, DOI 10.1016/S0002-9378(12)90878-9; CNATTINGIUS S, 1992, Journal of the American Medical Association, V268, P886, DOI 10.1001/jama.268.7.886; EISNER V, 1979, AM J PUBLIC HEALTH, V69, P887, DOI 10.2105/AJPH.69.9.887; FORMAN MR, 1984, JAMA-J AM MED ASSOC, V252, P3135, DOI 10.1001/jama.252.22.3135; FRIEDE A, 1988, OBSTET GYNECOL, V72, P152; FROST F, 1984, AM J PUBLIC HEALTH, V74, P505, DOI 10.2105/AJPH.74.5.505; GERONIMUS AT, 1991, PUBLIC HEALTH REP, V106, P393; GRIMES DA, 1981, OBSTET GYNECOL, V58, P614; Harrell F. E., 1986, SUGI SUPPLEMENTAL LI, P269; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; ISRAEL SL, 1964, OBSTET GYNECOL, V24, P411, DOI 10.1097/00006250-196409000-00014; KANE SH, 1967, OBSTET GYNECOL, V29, P409; KIRZ DS, 1985, AM J OBSTET GYNECOL, V152, P7, DOI 10.1016/S0002-9378(85)80166-6; LEE KS, 1988, AM J OBSTET GYNECOL, V158, P84, DOI 10.1016/0002-9378(88)90783-1; MONTGOMERY TA, 1962, CALIF MED, V96, P190; MORRISON I, 1975, AM J OBSTET GYNECOL, V121, P465, DOI 10.1016/0002-9378(75)90076-9; NAEYE RL, 1983, OBSTET GYNECOL, V61, P210; SPELLACY WN, 1986, OBSTET GYNECOL, V68, P452; STEIN ZA, 1985, AM J EPIDEMIOL, V121, P327, DOI 10.1093/oxfordjournals.aje.a114004; VEENTURA SJ, 1989, VITAL HLTH STAT, V21; VENTURA SJ, 1992, MONTHLY VITAL STAT S, V40, P1; YOUNG TK, 1991, CAN MED ASSOC J, V144, P318; 1990, VITAL STATISTICS US, V1; 1992, STATISTICAL ABSTRACT; 1990, MONTHLY VITAL STAT S, V39, P1	29	95	96	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1993	270	21					2574	2577		10.1001/jama.270.21.2574	http://dx.doi.org/10.1001/jama.270.21.2574			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ266	8230642				2022-12-01	WOS:A1993MJ26600024
J	FARAHBAKHSH, ZT; HIDEG, K; HUBBELL, WL				FARAHBAKHSH, ZT; HIDEG, K; HUBBELL, WL			PHOTOACTIVATED CONFORMATIONAL-CHANGES IN RHODOPSIN - A TIME-RESOLVED SPIN-LABEL STUDY	SCIENCE			English	Article							SCHIFF-BASE COUNTERION; BOVINE RHODOPSIN; METARHODOPSIN-II; DIFFERENCE SPECTROSCOPY; DISK MEMBRANE; PROTEIN; MUTANTS; TRANSDUCIN; SPECTRA; LOOPS	Rhodopsin has been selectively spin-labeled near the cytoplasmic termini of helices C and G. Photoactivation with a light flash induces an electron paramagnetic resonance spectral change in the millisecond time domain, coincident with the appearance of the active metarhodopsin II intermediate. The spectral change is consistent with a small movement near the cytoplasmic termination of the C helix and reverses upon formation of the MIII state. These results provide an important link between the optical changes associated with the retinal chromophore and protein conformational states.	UNIV CALIF LOS ANGELES,JULES STEIN EYE INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV PECS,CENT RES LAB,H-7643 PECS,HUNGARY	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Pecs					NATIONAL EYE INSTITUTE [R37EY005216, T32EY007026, R01EY005216] Funding Source: NIH RePORTER; NEI NIH HHS [EY07026, EY05216] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; CHABRE M, 1978, P NATL ACAD SCI USA, V75, P5471, DOI 10.1073/pnas.75.11.5471; CHABRE M, 1985, ANNU REV BIOPHYS BIO, V14, P331, DOI 10.1146/annurev.biophys.14.1.331; CHEN YS, 1978, MEMBRANE BIOCHEM, V1, P107, DOI 10.3109/09687687809064162; CHOTHIA C, 1985, TRENDS BIOCHEM SCI, V10, P116, DOI 10.1016/0968-0004(85)90270-1; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; DEGRIP WJ, 1988, PHOTOCHEM PHOTOBIOL, V48, P497, DOI 10.1111/j.1751-1097.1988.tb02852.x; DELMELLE M, 1977, BIOCHIM BIOPHYS ACTA, V464, P370, DOI 10.1016/0005-2736(77)90011-6; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; FARAHBAKHSH, 1992, PHOTOCHEM PHOTOBIOL, V56, P1019; FARAHBAKHSH ZT, 1992, PHOTOCHEM PHOTOBIOL, V56, P1019, DOI 10.1111/j.1751-1097.1992.tb09725.x; FINDLAY JBC, 1984, VISION RES, V24, P1501, DOI 10.1016/0042-6989(84)90312-2; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GANTER UM, 1992, PHOTOCHEM PHOTOBIOL, V56, P57, DOI 10.1111/j.1751-1097.1992.tb09602.x; HIDEG K, UNPUB; HOFMANN KP, 1986, PHOTOBIOCH PHOTOBIOP, V13, P309; HOFMANN KP, 1985, J BIOL CHEM, V260, P7990; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; KLINGER AL, 1992, BIOPHYS J, V63, P1244, DOI 10.1016/S0006-3495(92)81700-9; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1982, BIOCHIM BIOPHYS ACTA, V679, P95, DOI 10.1016/0005-2728(82)90259-6; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MOFFAT JK, 1971, J MOL BIOL, V55, P135, DOI 10.1016/0022-2836(71)90187-2; OGAWA S, 1967, P NATL ACAD SCI USA, V58, P19, DOI 10.1073/pnas.58.1.19; PELLICONE C, 1985, FEBS LETT, V184, P179; Rafferty C N, 1977, Biophys Struct Mech, V2, P227; RESEK J, IN PRESS BIOCHEMISTR; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; ROTHSCHILD KJ, 1987, BIOPHYS J, V51, P345, DOI 10.1016/S0006-3495(87)83341-6; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SUBRAMANIAM S, 1993, EMBO J, V12, P1; THORGEIRSSON TE, 1992, PHOTOCHEM PHOTOBIOL, V56, P1135, DOI 10.1111/j.1751-1097.1992.tb09738.x; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; ZHUKOVSKY EA, 1992, BIOCHEMISTRY-US, V31, P10400, DOI 10.1021/bi00157a030	37	144	145	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1416	1419		10.1126/science.8248781	http://dx.doi.org/10.1126/science.8248781			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248781				2022-12-01	WOS:A1993MJ04600031
J	NORTON, ME; MERRILL, J; COOPER, BAB; KULLER, JA; CLYMAN, RI				NORTON, ME; MERRILL, J; COOPER, BAB; KULLER, JA; CLYMAN, RI			NEONATAL COMPLICATIONS AFTER THE ADMINISTRATION OF INDOMETHACIN FOR PRETERM LABOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PATENT DUCTUS-ARTERIOSUS; PREMATURE LABOR; INTRAVENTRICULAR HEMORRHAGE; BLOOD-FLOW; INFANTS; TRIAL; BIRTH; OLIGOHYDRAMNIOS; CIRCULATION; PREVENTION	Background. The use of indomethacin as a tocolytic agent in pregnant women appears to be accompanied by a low incidence of neonatal complications. However, the neonatal effects of indomethacin have been studied primarily in infants born after 32 weeks' gestation. This study was designed to examine the incidence of neonatal complications in very premature infants. Methods. We identified 57 infants delivered at or before 30 weeks' gestation whose mothers had been treated with indomethacin for preterm labor and matched them with 57 infants whose mothers had not received indomethacin. The infants in the two groups were matched for sex, gestational age at delivery (mean [+/-SD], 27.6+/-2.0 weeks), exposure to betamethasone for 24 hours or more before delivery, and rupture of membranes 24 hours or more before delivery. Results. There were no significant differences between the two groups in birth weight, Apgar scores, cord-blood gas values, frequency of multiple gestation, or incidence of respiratory distress syndrome. The proportion of infants who required exogenous surfactant was similar, as were ventilator settings at 24 hours, the incidence of chronic lung disease, and the incidence of sepsis. The infants exposed to indomethacin had a lower urine output and higher serum creatinine concentrations during the first three days after delivery. More indomethacin-exposed infants had necrotizing enterocolitis (29 percent vs. 8 percent, P = 0.005), intracranial hemorrhage grade II to IV (28 percent vs. 9 percent, P = 0.02), and patent ductus arteriosus (62 percent vs. 44 percent, P = 0.65). More indomethacin-exposed infants with a patent ductus arteriosus required surgical ligation because of either a lack of initial response or a reopening of the duct after postnatal indomethacin therapy (50 percent vs. 20 percent of the unexposed infants, P = 0.05). Conclusions. Antenatal indomethacin therapy for preterm labor appears to increase the risk of serious neonatal complications in infants born at or before 30 weeks' gestation.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,BOX 0544,RM 1403 HSE,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; CALIF SCH PROFESS PSYCHOL,ALAMEDA,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL 46691] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046691] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAERTS W, 1990, DEV MED CHILD NEUROL, V32, P910; BAERTS W, 1990, DEV MED CHILD NEUROL, V32, P1032; BANDSTRA ES, 1988, PEDIATRICS, V82, P533; BESINGER RE, 1991, AM J OBSTET GYNECOL, V164, P981, DOI 10.1016/0002-9378(91)90569-D; CASSADY G, 1989, NEW ENGL J MED, V320, P1511, DOI 10.1056/NEJM198906083202302; CLYMAN RI, 1985, CIRCULATION, V71, P141, DOI 10.1161/01.CIR.71.1.141; CRONEN PW, 1982, J PEDIATR SURG, V17, P474, DOI 10.1016/S0022-3468(82)80092-4; EDWARDS AD, 1990, LANCET, V335, P1491, DOI 10.1016/0140-6736(90)93030-S; ERONEN M, 1991, AM J OBSTET GYNECOL, V164, P141, DOI 10.1016/0002-9378(91)90644-7; FEIGEN LP, 1981, J PHARMACOL EXP THER, V219, P679; FRIEDMAN Z, 1978, J CLIN PHARMACOL, V18, P272, DOI 10.1002/j.1552-4604.1978.tb02446.x; GLEASON CA, 1987, SEMIN PERINATOL, V11, P12; GOLDENBERG RL, 1989, AM J OBSTET GYNECOL, V160, P1196, DOI 10.1016/0002-9378(89)90188-9; Hosmer D, 2013, APPL LOGISTIC REGRES; KRASNA IH, 1992, J PEDIATR SURG, V27, P805, DOI 10.1016/0022-3468(92)90369-I; KURKI T, 1991, OBSTET GYNECOL, V78, P1093; MCDONALD MM, 1984, PEDIATRICS, V74, P26; MENT LR, 1988, J PEDIATR-US, V112, P948, DOI 10.1016/S0022-3476(88)80225-7; MEYERS RL, 1991, PEDIATR RES, V29, P569; MOISE KJ, 1990, AM J OBSTET GYNECOL, V162, P549, DOI 10.1016/0002-9378(90)90427-9; MOISE KJ, 1988, NEW ENGL J MED, V319, P327, DOI 10.1056/NEJM198808113190602; MOMMA K, 1989, PEDIATR RES, V25, P69, DOI 10.1203/00006450-198901000-00016; MORALES WJ, 1989, OBSTET GYNECOL, V74, P567; NIEBYL JR, 1986, AM J OBSTET GYNECOL, V155, P747, DOI 10.1016/S0002-9378(86)80012-6; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; ROBERT A, 1977, PROSTAGLANDINS, V14, P333, DOI 10.1016/0090-6980(77)90178-2; Rudolph A M, 1978, Adv Prostaglandin Thromboxane Res, V4, P231; RUMACK CM, 1981, OBSTET GYNECOL, V58, pS52; VANBEL F, 1990, RADIOLOGY, V174, P165, DOI 10.1148/radiology.174.1.2403678; VANHAESEBROUCK P, 1988, J PEDIATR-US, V113, P738, DOI 10.1016/S0022-3476(88)80392-5; ZUCKERMAN H, 1974, OBSTET GYNECOL, V44, P787	31	309	314	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1993	329	22					1602	1607		10.1056/NEJM199311253292202	http://dx.doi.org/10.1056/NEJM199311253292202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ546	8232428				2022-12-01	WOS:A1993MJ54600002
J	MIURA, M; ZHU, H; ROTELLO, R; HARTWIEG, EA; YUAN, JY				MIURA, M; ZHU, H; ROTELLO, R; HARTWIEG, EA; YUAN, JY			INDUCTION OF APOPTOSIS IN FIBROBLASTS BY IL-1-BETA-CONVERTING ENZYME, A MAMMALIAN HOMOLOG OF THE C-ELEGANS CELL-DEATH GENE CED-3	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; BCL-2; PREVENTION; MONOCYTES; SELECTION; RECEPTOR; SURVIVAL; PROTEIN	The mammalian interleukin-1beta-converting enzyme (ICE) has sequence similarity to the C. elegans cell death gene ced-3. We show here that overexpression of the murine ICE (mICE) gene or of the C. elegans ced-3 gene causes Rat-1 cells to undergo programmed cell death. Point mutations in a region homologous between mICE and CED-3 eliminate the ability of mICE and ced-3 to cause cell death. The cell death caused by mICE can be suppressed by overexpression of the crmA gene, a specific inhibitor of ICE, as well as by bcl-2, a mammalian oncogene that can act to prevent programmed cell death. Our results suggest that ICE may function during mammalian development to cause programmed cell death.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	MIURA, M (corresponding author), MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,BOSTON,MA 02129, USA.			Zhu, Hong/0000-0002-2575-4031				AMANO T, 1974, EXP CELL RES, V85, P399, DOI 10.1016/0014-4827(74)90142-6; [Anonymous], EPSTEIN BARR VIRUS; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1991, BLOOD, V77, P1627; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FONTANA A, 1982, RHEUMATOL INT, V2, P49, DOI 10.1007/BF00541245; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOGOQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485; HORVITZ HR, 1982, NEUROSCI COMMENT, V1, P56; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; MAEKAWA T, 1991, ONCOGENE, V6, P627; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NETT MA, 1992, J IMMUNOL, V149, P3254; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Sambrook J., 1989, MOL CLONING LAB MANU; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WOOD DD, 1983, ARTHRITIS RHEUM, V26, P975, DOI 10.1002/art.1780260806; Wyllie A.H., 1981, CELL DEATH BIOL PATH, P9; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; YUAN JY, 1993, CELL, V75, P653	43	1390	1490	0	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					653	660		10.1016/0092-8674(93)90486-A	http://dx.doi.org/10.1016/0092-8674(93)90486-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242741	Bronze			2022-12-01	WOS:A1993MH74900011
J	BRZOBOHATY, B; MOORE, I; KRISTOFFERSEN, P; BAKO, L; CAMPOS, N; SCHELL, J; PALME, K				BRZOBOHATY, B; MOORE, I; KRISTOFFERSEN, P; BAKO, L; CAMPOS, N; SCHELL, J; PALME, K			RELEASE OF ACTIVE CYTOKININ BY A BETA-GLUCOSIDASE LOCALIZED TO THE MAIZE ROOT-MERISTEM	SCIENCE			English	Article							ZEA-MAYS-L; MITOSIS	A beta-glucoside encoded by a cloned Zea mays complementary DNA (Zm-p60.1) cleaved the biologically inactive hormone conjugates cytokinin-O-glucosides and kinetin-N3-glucoside, releasing active cytokinin. Tobacco protoplasts that transiently expressed Zm-p60.1 could use the inactive cytokinin glucosides to initiate cell division. The ability of protoplasts to sustain growth in response to cytokinin glucosides persisted indefinitely after the likely disappearance of the expression vector. In the roots of maize seedlings, Zm-p60.1 was localized to the meristematic cells and may function in vivo to supply the developing maize embryo with active cytokinin.	MAX PLANCK INST ZUCHTUNGSFORSCH, CARL VON LINNE WEG 10, D-50829 COLOGNE 30, GERMANY; INST BIOPHYS, CS-61265 BRNO, CZECHOSLOVAKIA; DANISCO BIOTECHNOL, DK-1001 COPENHAGEN, DENMARK	Max Planck Society; Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences			Ding, Cheng-Qiang/B-6287-2011; Palme, Klaus/A-9524-2013; Brzobohaty, Bretislav/D-7212-2012; Campos, Narciso/L-3608-2017	Palme, Klaus/0000-0002-2728-3835; Brzobohaty, Bretislav/0000-0002-1552-1314; Campos, Narciso/0000-0002-9685-0549				BRZOBOHATY B, UNPUB; CAMPOS N, 1992, PLANT J, V2, P675, DOI 10.1111/j.1365-313X.1992.tb00136.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES FAL, 1975, NEW PHYTOL, V74, P263, DOI 10.1111/j.1469-8137.1975.tb02614.x; COHEN JD, 1982, ANNU REV PLANT PHYS, V33, P403, DOI 10.1146/annurev.pp.33.060182.002155; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESAU K, 1977, ANATOMY SEED PLANTS, P227; ESEN A, 1992, PLANT PHYSIOL, V98, P174, DOI 10.1104/pp.98.1.174; ESTRUCH JJ, 1991, EMBO J, V10, P2889, DOI 10.1002/j.1460-2075.1991.tb07838.x; LETHAM DS, 1983, ANNU REV PLANT PHYS, V34, P163, DOI 10.1146/annurev.pp.34.060183.001115; MEYER Y, 1979, PLANTA, V147, P181, DOI 10.1007/BF00388735; MOORE I, 1989, THESIS U EDINBURGH; NAGY JI, 1976, Z PFLANZENPHYSIOL, V78, P453, DOI 10.1016/S0044-328X(76)80093-1; NOWACKI J, 1980, PLANT PHYSIOL, V65, P422, DOI 10.1104/pp.65.3.422; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLIEMANN W, 1991, NATURWISSENSCHAFTEN, V78, P392, DOI 10.1007/BF01133410; SMITH AR, 1978, J EXP BOT, V29, P1067, DOI 10.1093/jxb/29.5.1067; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WIRTZ U, 1987, DNA-J MOLEC CELL BIO, V6, P245, DOI 10.1089/dna.1987.6.245	19	299	309	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1993	262	5136					1051	1054		10.1126/science.8235622	http://dx.doi.org/10.1126/science.8235622			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235622				2022-12-01	WOS:A1993MG18700034
J	CARMICHAEL, JK				CARMICHAEL, JK			HIV LESSONS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											CARMICHAEL, JK (corresponding author), UNIV ARIZONA, COLL MED, DEPT INTERNAL MED, INFECT DIS SECT, 1501 N CAMPBELL AVE, TUCSON, AZ 85719 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1993	119	9					944	944		10.7326/0003-4819-119-9-199311010-00013	http://dx.doi.org/10.7326/0003-4819-119-9-199311010-00013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD711	8215006				2022-12-01	WOS:A1993MD71100012
J	ROBINSON, R				ROBINSON, R			ECONOMIC-EVALUATION AND HEALTH-CARE - COST-EFFECTIVENESS ANALYSIS	BRITISH MEDICAL JOURNAL			English	Article							PREVENTION; DISEASE	When different health care interventions are not expected to produce the same outcomes both the costs and the consequences of the options need to be assessed. This can be done by cost-effectiveness analysis, whereby the costs are compared with outcomes measured in natural units-for example, per life saved, per life year gained, and per pain or symptom free day. Many cost-effective analyses rely on existing published studies for effectiveness data as it is often too costly or time consuming to collect data on cost and effectiveness during a clinical trial. Where there is uncertainty about the costs and effectiveness of procedures sensitivity analysis can be used, which examines the sensitivity of the results to alternative assumptions about key variables. In this article Ray Robinson describes these methods of analysis and discusses possibilities for how the benefits of alternative interventions should be valued.			ROBINSON, R (corresponding author), UNIV SOUTHAMPTON,INST HLTH POLICY STUDIES,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND.							BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; BRIGGS A, 1993, JAN JOINT M HLTH EC; Cairns J, 1992, Health Econ, V1, P76, DOI 10.1002/hec.4730010111; CHURCHILL DN, 1984, MED DECIS MAKING, V4, P489, DOI 10.1177/0272989X8400400411; CULYER AJ, 1981, SOC SCI MED-MED ECON, V15, P3, DOI 10.1016/0160-7995(81)90003-4; CULYER AJ, 1982, RESOURCES HLTH TECHN; Drummond MF, 1987, METHOD EC EVALUATION; HULL R, 1981, NEW ENGL J MED, V304, P1561, DOI 10.1056/NEJM198106253042602; LUDBROOK A, 1981, APPL ECON, V13, P337, DOI 10.1080/00036848100000004; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; MANDELBLATT JS, 1988, JAMA-J AM MED ASSOC, V259, P2409, DOI 10.1001/jama.259.16.2409; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; Percival S P, 1992, Qual Health Care, V1, P38, DOI 10.1136/qshc.1.1.38; SCULPHER MJ, 1993, BRIT J OBSTET GYNAEC, V100, P244, DOI 10.1111/j.1471-0528.1993.tb15238.x; SINTONEN H, 1990, J HEALTH ECON, V9, P85, DOI 10.1016/0167-6296(90)90042-2; SUDRE P, 1992, INT J EPIDEMIOL, V21, P146, DOI 10.1093/ije/21.1.146; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238	18	125	132	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1993	307	6907					793	795		10.1136/bmj.307.6907.793	http://dx.doi.org/10.1136/bmj.307.6907.793			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LZ478	8219957	Green Published, Bronze			2022-12-01	WOS:A1993LZ47800036
J	JENSEN, MC; BRANTZAWADZKI, MN; OBUCHOWSKI, N; MODIC, MT; MALKASIAN, D; ROSS, JS				JENSEN, MC; BRANTZAWADZKI, MN; OBUCHOWSKI, N; MODIC, MT; MALKASIAN, D; ROSS, JS			MAGNETIC-RESONANCE-IMAGING OF THE LUMBAR SPINE IN PEOPLE WITHOUT BACK PAIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CATEGORICAL-DATA; PREVALENCE; WOMEN	Background. The relation between abnormalities in the lumbar spine and low back pain is controversial. We examined the prevalence of abnormal findings on magnetic resonance imaging (MRI) scans of the lumbar spine in people without back pain. Methods. We performed MRI examinations on 98 asymptomatic people. The scans were read independently by two neuroradiologists who did not know the clinical status of the subjects. To reduce the possibility of bias in interpreting the studies, abnormal MRI scans from 27 people with back pain were mixed randomly with the scans from the asymptomatic people. We used the following standardized terms to classify the five intervertebral disks in the lumbosacral spine: normal, bulge (circumferential symmetric extension of the disk beyond the interspace), protrusion (focal or asymmetric extension of the disk beyond the interspace), and extrusion (more extreme extension of the disk beyond the interspace). nonintervertebral disk abnormalities, such as facet arthropathy, were also documented. Results. Thirty-six percent of the 98 asymptomatic subjects had normal disks at all levels. With the results of the two readings averaged, 52 percent of the subjects had a bulge at at least one level, 27 percent had a protrusion, and 1 percent had an extrusion. Thirty-eight percent had an abnormality of more than one intervertebral disk. The prevalence of bulges, but not of protrusions, increased with age. The most common nonintervertebral disk abnormalities were Schmorl's nodes (herniation of the disk into the vertebral-body end plate), found in 19 percent of the subjects; annular defects (disruption of the outer fibrous ring of the disk), in 14 percent; and facet arthropathy (degenerative disease of the posterior articular processes of the vertebrae), in 8 percent. The findings were similar in men and women. Conclusions. On MRI examination of the lumbar spine, many people without back pain have disk bulges or protrusions but not extrusions. Given the high prevalence of these findings and of back pain, the discovery by MRI of bulges or protrusions in people with low back pain may frequently be coincidental.	HOAG MEM HOSP,DEPT RADIOL,NEWPORT BEACH,CA 92663; RIVERSIDE MAGNET RESONANCE IMAGING,RIVERSIDE,CA; CLEVELAND CLIN,CLEVELAND,OH 44106	Cleveland Clinic Foundation				Ross, Jeffrey/0000-0001-5865-6828				BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; DEYO RA, 1987, SPINE, V12, P264, DOI 10.1097/00007632-198704000-00013; HELMS CA, 1982, COMPUT RADIOL, V6, P359, DOI 10.1016/0730-4862(82)90007-5; HIRSCH C, 1952, ACTA ORTHOP SCAND, V22, P184; HITSELBE.WE, 1968, J NEUROSURG, V28, P204, DOI 10.3171/jns.1968.28.3.0204; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LIANG KY, 1992, J R STAT SOC B, V54, P3; MCCARRON RF, 1987, SPINE, V12, P760, DOI 10.1097/00007632-198710000-00009; MCRAE DL, 1956, ACTA RADIOL, V46, P9, DOI 10.3109/00016925609170806; POWELL MC, 1986, LANCET, V2, P1366; ROBERTSON JT, 1993, SURG NEUROL, V39, P5, DOI 10.1016/0090-3019(93)90102-7; WEINREB JC, 1989, RADIOLOGY, V170, P125, DOI 10.1148/radiology.170.1.2521192; WIESEL SW, 1984, SPINE, V9, P549, DOI 10.1097/00007632-198409000-00003; YU S, 1989, RADIOLOGY, V170, P523, DOI 10.1148/radiology.170.2.2911680; YU SW, 1988, AM J NEURORADIOL, V9, P367	15	1470	1516	4	79	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 14	1994	331	2					69	73		10.1056/NEJM199407143310201	http://dx.doi.org/10.1056/NEJM199407143310201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW712	8208267	Bronze			2022-12-01	WOS:A1994NW71200001
J	SEBASTIAN, A; HARRIS, ST; OTTAWAY, JH; TODD, KM; MORRIS, RC				SEBASTIAN, A; HARRIS, ST; OTTAWAY, JH; TODD, KM; MORRIS, RC			IMPROVED MINERAL BALANCE AND SKELETAL METABOLISM IN POSTMENOPAUSAL WOMEN TREATED WITH POTASSIUM BICARBONATE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERUM ALKALINE-PHOSPHATASE; BONE GLA-PROTEIN; HYDROXYPROLINE EXCRETION; SODIUM-BICARBONATE; CALCIUM BALANCE; HEALTHY-MEN; ACIDOSIS; OSTEOPOROSIS; RESORPTION; OSTEOCALCIN	Background. In normal subjects, a low level of metabolic acidosis and positive acid balance (the production of more acid than is excreted) are typically present and correlate in degree with the amount of endogenous acid produced by the metabolism of foods in ordinary diets abundant in protein. Over a lifetime, the counteraction of retained endogenous acid by base mobilized from the skeleton may contribute to the decrease in bone mass that occurs normally with aging. Methods. To test that possibility, we administered potassium bicarbonate to 18 postmenopausal women who were given a constant diet (652 mg [16 mmol] of calcium and 96 g of protein per 60 kg of body weight). The potassium bicarbonate was given orally for 18 days in doses (60 to 120 mmol per day) that nearly completely neutralized the endogenous acid. Results. During the administration of potassium bicarbonate, the calcium and phosphorus balance became less negative or more positive - that is, less was excreted in comparision with the amount ingested (mean [+/-SD] change in calcium balance, +56+/-76 mg [1.4+/-1.9 mmol] per day per 60 kg; P = 0.009; change in phosphorus balance, +47+/-64 mg [1.5+/-2.1 mmol] per day per 60 kg; P = 0.007) because of reductions in urinary calcium and phosphorus excretion. The changes in calcium and phosphorus balance were positively correlated (P<0.001). Serum osteocalcin concentrations increased from 5.5+/-2.8 ng per milliliter (P<0.001), and urinary hydroxyproline excretion decreased from 28.9+/-12.3 to 26.7+/-10.8 mg per day (220+/-94 to 204+/-82 mu mol per day; P = 0.05). Net renal acid excretion decreased from 70.9+/-10.1 to 12.8+/-21.8 mmol per day, indicating nearly complete neutralization of endogenous acid. Conclusions. In postmenopausal women, the oral administration of potassium bicarbonate at a dose sufficient to neutralize endogenous acid improves calcium and phosphorus balance, reduces bone resorption, and increases the rate of bone formation.	UNIV CALIF SAN FRANCISCO,MOFFITT LONG HOSP,GEN CLIN RES CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SEBASTIAN, A (corresponding author), UNIV CALIF SAN FRANCISCO,MOFFITT LONG HOSP,DEPT MED,BOX 0126,SAN FRANCISCO,CA 94143, USA.				NIDDK NIH HHS [R01 DK32631, P01DK 39964] Funding Source: Medline; PHS HHS [M01 00079] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032631, P01DK039964] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNETT TR, 1986, ENDOCRINOLOGY, V119, P119, DOI 10.1210/endo-119-1-119; BARZEL US, 1969, CLIN SCI, V36, P517; BARZEL US, 1976, CALC TISS RES, V21, P417; BARZEL US, 1969, CALC TISS RES, V4, P94, DOI 10.1007/BF02279111; BARZEL US, 1971, ISRAEL J MED SCI, V7, P499; Bernstein D, 1970, OSTEOPOROSIS, P207; BROWN JP, 1984, LANCET, V1, P1091; BURNELL JM, 1971, J CLIN INVEST, V50, P327, DOI 10.1172/JCI106499; BUSHINSKY DA, 1992, AM J PHYSIOL, V263, pF510, DOI 10.1152/ajprenal.1992.263.3.F510; BUSHINSKY DA, 1992, AM J PHYSIOL, V262, pF425, DOI 10.1152/ajprenal.1992.262.3.F425; BUSHINSKY DA, 1989, REGULATION ACID BASE, P69; CHARLES P, 1985, J CLIN INVEST, V76, P2254, DOI 10.1172/JCI112234; DEACON AC, 1987, CLIN CHIM ACTA, V166, P297, DOI 10.1016/0009-8981(87)90433-5; DELLING G, 1973, VIRCHOWS ARCH A, V358, P321, DOI 10.1007/BF00543273; EPSTEIN S, 1988, ENDOCR REV, V9, P437, DOI 10.1210/edrv-9-4-437; GOLDHABER P, 1987, AM J PHYSIOL, V253, pE90, DOI 10.1152/ajpendo.1987.253.1.E90; HYLDSTRUP L, 1988, SCAND J CLIN LAB INV, V48, P611, DOI 10.3109/00365518809085780; Jaffe HL, 1932, J EXP MED, V56, P823, DOI 10.1084/jem.56.6.823; JOHANSEN JS, 1988, J CLIN ENDOCR METAB, V67, P273, DOI 10.1210/jcem-67-2-273; JONES JW, 1982, KIDNEY INT, V21, P402, DOI 10.1038/ki.1982.36; KLEIN L, 1964, METABOLISM, V13, P272, DOI 10.1016/0026-0495(64)90106-4; KLEINMAN JG, 1987, CLIN DISORDERS FLUID, P159; KRIEGER NS, 1992, AM J PHYSIOL, V262, pF442, DOI 10.1152/ajprenal.1992.262.3.F442; KURTZ I, 1983, KIDNEY INT, V24, P670, DOI 10.1038/ki.1983.210; LEMANN J, 1989, KIDNEY INT, V35, P688, DOI 10.1038/ki.1989.40; LEMANN J, 1966, J CLIN INVEST, V45, P1608, DOI 10.1172/JCI105467; LEMANN J, 1965, J CLIN INVEST, V44, P507, DOI 10.1172/JCI105164; LEMANN J, 1967, J CLIN INVEST, V46, P1318, DOI 10.1172/JCI105624; LENNON EJ, 1966, J CLIN INVEST, V45, P1601, DOI 10.1172/JCI105466; LUTZ J, 1984, AM J CLIN NUTR, V39, P281, DOI 10.1093/ajcn/39.2.281; SAKHAEE K, 1983, KIDNEY INT, V24, P348, DOI 10.1038/ki.1983.165; TETI A, 1989, J CLIN INVEST, V84, P773, DOI 10.1172/JCI114235; WACHMAN A, 1968, LANCET, V1, P958; WEIGLEY ES, 1984, J AM DIET ASSOC, V84, P417; WORSFOLD M, 1988, CLIN CHIM ACTA, V178, P225, DOI 10.1016/0009-8981(88)90228-8	35	398	408	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 23	1994	330	25					1776	1781		10.1056/NEJM199406233302502	http://dx.doi.org/10.1056/NEJM199406233302502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR295	8190153				2022-12-01	WOS:A1994NR29500002
J	DAVIS, A; SAGE, CR; DOUGHERTY, CA; FARRELL, KW				DAVIS, A; SAGE, CR; DOUGHERTY, CA; FARRELL, KW			MICROTUBULE DYNAMICS MODULATED BY GUANOSINE TRIPHOSPHATE HYDROLYSIS ACTIVITY OF BETA-TUBULIN	SCIENCE			English	Article							GTP-BINDING PROTEIN; SITE; ENCODES; FAMILY	Microtubule dynamic instability underlies many cellular functions, including spindle morphogenesis and chromosome movement. The role of guanosine triphosphate (GTP) hydrolysis in dynamic instability was investigated by introduction of four mutations into yeast beta-tubulin at amino acids 103 to 109, a site thought to participate in GTP hydrolysis. Three of the mutations increased both the assembly-dependent rate of GTP hydrolysis and the average length of steady-state microtubules over time, a measure of dynamic instability. The fourth mutation did not substantially affect the rate of GTP hydrolysis or the steady-state microtubule lengths. These results demonstrate that the rate of GTP hydrolysis can modulate microtubule length and hence dynamic instability.			DAVIS, A (corresponding author), UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,SANTA BARBARA,CA 93106, USA.				NIGMS NIH HHS [GM 41751] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041751] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES G, 1992, MOL BIOL CELL, V1, P1; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; CARLIER MF, 1981, BIOCHEMISTRY-US, V20, P1918, DOI 10.1021/bi00510a030; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; DAVIS A, 1993, BIOCHEMISTRY-US, V32, P8823, DOI 10.1021/bi00085a013; DAVIS A, UNPUB; DUSTIN P, 1987, MICROTUBULES; FARRELL KW, 1987, J CELL BIOL, V104, P1035, DOI 10.1083/jcb.104.4.1035; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; KATZ WS, 1988, MOL CELL BIOL, V8, P2730, DOI 10.1128/MCB.8.7.2730; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEVI A, 1974, BIOCHIM BIOPHYS ACTA, V365, P450, DOI 10.1016/0005-2795(74)90022-1; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; SAGE CR, UNPUB; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; STERNLICHT H, 1987, FEBS LETT, V214, P226, DOI 10.1016/0014-5793(87)80061-3; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001	22	58	59	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					839	842		10.1126/science.8171338	http://dx.doi.org/10.1126/science.8171338			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171338				2022-12-01	WOS:A1994NJ94900032
J	YOUVAN, DC				YOUVAN, DC			IMAGING SEQUENCE SPACE	NATURE			English	Article							MOLECULAR-BIOLOGY; SPECTROSCOPY				YOUVAN, DC (corresponding author), PALO ALTO INST MOLEC MED,2462 WYANDOTTE ST,MT VIEW,CA 94043, USA.							ARKIN AP, 1990, BIO-TECHNOL, V8, P746, DOI 10.1038/nbt0890-746; ARKIN AP, 1992, BIO-TECHNOL, V10, P297, DOI 10.1038/nbt0392-297; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; DELAGRAVE S, 1993, BIO-TECHNOL, V11, P1548, DOI 10.1038/nbt1293-1548; DELAGRAVE S, 1993, PROTEIN ENG, V6, P327, DOI 10.1093/protein/6.3.327; GOLDMAN ER, 1992, BIO-TECHNOL, V10, P1557, DOI 10.1038/nbt1292-1557; YANG MM, 1988, BIO-TECHNOL, V6, P939, DOI 10.1038/nbt0888-939; YANG MM, IN PRESS AM BIOTECH; YOUVAN DC, IN PRESS METH ENZYM	9	25	35	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					79	80		10.1038/369079a0	http://dx.doi.org/10.1038/369079a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164746				2022-12-01	WOS:A1994NJ86000059
J	REID, RT; LIVE, DH; FAULKNER, DJ; BUTLER, A				REID, RT; LIVE, DH; FAULKNER, DJ; BUTLER, A			A SIDEROPHORE FROM A MARINE BACTERIUM WITH AN EXCEPTIONAL FERRIC ION AFFINITY CONSTANT	NATURE			English	Article							IRON TRANSPORT COMPOUNDS; COORDINATION CHEMISTRY; GROWTH; PHYTOPLANKTON; ALTEROMONAS; INHIBITION; ANALOGS; WATERS	VIRTUALLY all microorganisms require iron for growth. The paucity of iron in surface ocean water (approximately 0.02-1.0 nM (refs 1, 2)) has spurred a lively debate concerning iron limitation of primary productivity3-6, yet little is known about the molecular mechanisms used by marine microorganisms to sequester iron. Terrestrial bacteria use a siderophore-mediated ferric uptake systems7. A siderophore is a low-molecular-mass compound with a high affinity for ferric ion which is secreted by microorganisms in response to low-iron environments; siderophore biosynthesis is regulated by iron levels, with repression by high iron. Although open-ocean marine microorganisms (such as phytoplankton8 and bacteria9) produce siderophores, the nature of these siderophores has not been investigated. We report here the first structure determination, to our knowledge, of the siderophores from an open-ocean bacterium, alterobactin A and B from Alteromonas luteoviolacea. A. luteoviolacea is found in oligotrophic10 and coastal11 waters. Alterobactin A has an exceptionally high affinity constant for ferric ion. We suggest that at least some marine microorganisms may have developed higher-affinity iron chelators as part of an efficient iron-uptake mechanism which is more effective than that of their terrestrial counterparts.	UNIV CALIF SANTA BARBARA,DEPT CHEM,SANTA BARBARA,CA 93106; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093	University of California System; University of California Santa Barbara; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Diego; Scripps Institution of Oceanography			Butler, Alison/D-5094-2015	Butler, Alison/0000-0002-3525-7864				ABDALLAH MA, 1989, 27 INT C COORD CHEM; ANDEREGG G, 1963, HELV CHIM ACTA, V46, P1409, DOI 10.1002/hlca.19630460436; ANDERSEN RJ, 1974, MAR BIOL, V27, P281, DOI 10.1007/BF00394363; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BRONZLI P, 1990, J AM CHEM SOC, V112, P3719; BRULAND KW, 1991, LIMNOL OCEANOGR, V36, P1555, DOI 10.4319/lo.1991.36.8.1555; CHABEREK S, 1959, ORGANIC SEQUESTERING; GAUTHIER MJ, 1976, CAN J MICROBIOL, V22, P1612, DOI 10.1139/m76-237; HARRIS DC, 1982, QUANTITATIVE CHEM; HARRIS WR, 1979, J AM CHEM SOC, V101, P2213, DOI 10.1021/ja00502a053; HARRIS WR, 1979, J AM CHEM SOC, V101, P2722, DOI 10.1021/ja00504a038; JALAL MAF, 1989, J AM CHEM SOC, V111, P292, DOI 10.1021/ja00183a044; LOOMIS LD, 1991, INORG CHEM, V30, P9036; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; Martell A. E., 1974, CRITICAL STABILITY C, V1; MARTIN JH, 1991, LIMNOL OCEANOGR, V36, P1793, DOI 10.4319/lo.1991.36.8.1793; MARTIN JH, 1988, NATURE, V331, P341, DOI 10.1038/331341a0; MARTIN JH, 1990, NATURE, V345, P156, DOI 10.1038/345156a0; MAYOR S, 1985, MAGN RESON CHEM, V23, P470, DOI 10.1002/mrc.1260230613; Neilands J B, 1990, Adv Inorg Biochem, V8, P63; Perrin D. D., 2012, BUFFERS PH METAL ION; PRICE NM, 1991, DEEP-SEA RES, V38, P1361, DOI 10.1016/0198-0149(91)90011-4; REID RT, 1991, LIMNOL OCEANOGR, V36, P1783, DOI 10.4319/lo.1991.36.8.1783; RICH DH, 1980, J MED CHEM, V23, P27, DOI 10.1021/jm00175a006; SALITURO FG, 1987, J MED CHEM, V30, P286, DOI 10.1021/jm00385a010; SCHWARZENBACH G, 1963, HELV CHIM ACTA, V46, P1390, DOI 10.1002/hlca.19630460434; SUNDA WG, 1991, NATURE, V351, P55, DOI 10.1038/351055a0; TAKAHASHI A, 1987, J ANTIBIOT, V40, P1671, DOI 10.7164/antibiotics.40.1671; TEINTZE M, 1981, BIOCHEMISTRY-US, V20, P6457, DOI 10.1021/bi00525a026; TRICK CG, 1989, CURR MICROBIOL, V18, P375, DOI 10.1007/BF01571131; TRICK CG, 1983, SCIENCE, V219, P306, DOI 10.1126/science.219.4582.306; WONG GB, 1983, J AM CHEM SOC, V105, P810, DOI 10.1021/ja00342a027	32	187	191	2	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					455	458		10.1038/366455a0	http://dx.doi.org/10.1038/366455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247152				2022-12-01	WOS:A1993MK09800061
J	BACHMANN, MF; ROHRER, UH; KUNDIG, TM; BURKI, K; HENGARTNER, H; ZINKERNAGEL, RM				BACHMANN, MF; ROHRER, UH; KUNDIG, TM; BURKI, K; HENGARTNER, H; ZINKERNAGEL, RM			THE INFLUENCE OF ANTIGEN ORGANIZATION ON B-CELL RESPONSIVENESS	SCIENCE			English	Article							VESICULAR STOMATITIS-VIRUS; MAJOR SURFACE GLYCOPROTEIN; REACTIVE LYMPHOCYTES-B; TRANSGENIC MICE; SELF-TOLERANCE; MONOCLONAL-ANTIBODIES; MYASTHENIA-GRAVIS; CLONAL DELETION; IMMUNE-RESPONSE; VIRAL-ANTIGENS	The influence of antigen epitope density and order on B cell induction and antibody production was assessed with the glycoprotein of vesicular stomatitis virus serotype Indiana [VSV-G(IND)]. VSV-G(IND) can be found in a highly repetitive form in the envelope of VSV-IND and in a poorly organized form on the surface of infected cells. In VSV-G (IND) transgenic mice, B cells were unresponsive to the poorly organized VSV-G (IND) present as self antigen but responded promptly to the same antigen presented in the highly organized form. Thus, antigen organization influences B cell tolerance.	UNIV ZURICH,DEPT PATHOL,INST EXPTL IMMUNOL,STERNWARTSTR 2,CH-8091 ZURICH,SWITZERLAND	University of Zurich								ADAMS E, 1990, P NATL ACAD SCI USA, V87, P5687, DOI 10.1073/pnas.87.15.5687; ADELSTEIN S, 1991, SCIENCE, V251, P1223, DOI 10.1126/science.1900950; ARNOLD B, 1988, P NATL ACAD SCI USA, V85, P2269, DOI 10.1073/pnas.85.7.2269; BACHMANN MF, 1993, J VIROL, V67, P3917, DOI 10.1128/JVI.67.7.3917-3922.1993; BASTEN A, 1991, IMMUNOL REV, V122, P5, DOI 10.1111/j.1600-065X.1991.tb00593.x; BROMBACHER F, 1991, J EXP MED, V174, P1335, DOI 10.1084/jem.174.6.1335; BURNS WH, 1975, NATURE, V256, P654, DOI 10.1038/256654a0; CHARAN S, 1987, J VIROL, V61, P2509, DOI 10.1128/JVI.61.8.2509-2514.1987; CHARAN S, 1986, J IMMUNOL, V136, P3057; COUTINHO A, 1975, ADV IMMUNOL, P113; DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671; DINTZIS RZ, 1989, J IMMUNOL, V143, P1239; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FAMBROUGH DM, 1973, SCIENCE, V182, P293, DOI 10.1126/science.182.4109.293; GOODMANSNITKOFF G, 1981, J EXP MED, V153, P489; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Kelley J M, 1972, J Virol, V10, P1231; KUNDIG TM, 1993, J VIROL, V67, P3680; LEFRANCOIS L, 1982, VIROLOGY, V121, P157, DOI 10.1016/0042-6822(82)90125-8; LEFRANCOIS L, 1982, VIROLOGY, V121, P168, DOI 10.1016/0042-6822(82)90126-X; LEIST TP, 1987, J IMMUNOL, V138, P2278; LINDSTROM J, 1985, ANNU REV IMMUNOL, V3, P109; MOLLER G, 1975, TRANSPLANT REV, V23, P126; MOSKOPHIDIS D, 1984, J IMMUNOL, V133, P3366; NEMAZEE D, 1991, IMMUNOL REV, V122, P117, DOI 10.1111/j.1600-065X.1991.tb00600.x; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1975, TRANSPLANT REV, V23, P138; ODERMATT B, 1991, P NATL ACAD SCI USA, V88, P8252, DOI 10.1073/pnas.88.18.8252; PIKE BL, 1982, P NATL ACAD SCI-BIOL, V79, P2013, DOI 10.1073/pnas.79.6.2013; RATH S, 1988, J IMMUNOL METHODS, V106, P245, DOI 10.1016/0022-1759(88)90204-9; ROOST HP, 1990, EUR J IMMUNOL, V20, P2547, DOI 10.1002/eji.1830201204; ROOST HP, 1991, THESIS U ZURICH; WAGNER RR, 1987, RHABDOVIRUSES; YEWDELL JW, 1986, J EXP MED, V163, P1529, DOI 10.1084/jem.163.6.1529; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0; ZINKERNAGEL RM, 1991, IMMUNOL REV, V122, P133, DOI 10.1111/j.1600-065X.1991.tb00601.x	38	558	593	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1448	1451		10.1126/science.8248784	http://dx.doi.org/10.1126/science.8248784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248784				2022-12-01	WOS:A1993MJ04600041
J	CHIEN, CT; BUCK, S; STERNGLANZ, R; SHORE, D				CHIEN, CT; BUCK, S; STERNGLANZ, R; SHORE, D			TARGETING OF SIR1 PROTEIN ESTABLISHES TRANSCRIPTIONAL SILENCING AT HM LOCI AND TELOMERES IN YEAST	CELL			English	Article							UPSTREAM ACTIVATING SEQUENCES; N-TERMINAL ACETYLTRANSFERASE; MATING-TYPE INFORMATION; DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; REGULATORY PROTEIN; GENES; REPLICATION; REPRESSION	Previous studies suggest that the yeast SIR1 protein is involved in the establishment of transcriptional silencing at the HM mating-type loci. Here we show that a GAL4 DNA-binding domain-SIR1 hybrid protein (G(BD)-SIR1), when targeted to an HMR locus containing GAL4-binding sites (UAS(G)), can establish silencing and bypass the requirement for the silencer element HMR-E. Silencing mediated by G(BD)-SIR1 requires the trans-acting factors that normally participate in repression, namely, SIR2, SIR3, SIR4, and histone H4. However, G(BD) hybrids with SIR2, SIR3, or SIR4 cannot establish silencing. Telomeric silencing, which does not require SIR1 and is normally unstable, is greatly improved by tethering G(BD)-SIR1 to the telomere. These experiments support a model in which native SIR1 protein is brought to the HM loci by proteins bound to the silencers. Telomeres appear to lack the ability to recruit SIR1, and that is why telomeric silencing is unstable.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA	Columbia University	CHIEN, CT (corresponding author), SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA.		Shore, David/F-6240-2015; Chien, Cheng-Ting/AAA-5200-2021	Shore, David/0000-0002-9859-143X; Chien, Cheng-Ting/0000-0002-7906-7173	NIGMS NIH HHS [GM28220, GM40094] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM028220, R01GM028220, R01GM040094] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRAM RJ, 1986, EMBO J, V5, P603, DOI 10.1002/j.1460-2075.1986.tb04253.x; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; CHAMBERS A, 1989, MOL CELL BIOL, V9, P5516, DOI 10.1128/MCB.9.12.5516; CHENCLELAND TA, 1993, J BIOL CHEM, V268, P1118; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HARDY CFJ, 1992, MOL CELL BIOL, V12, P1209, DOI 10.1128/MCB.12.3.1209; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MAHONEY DJ, 1991, GENE DEV, V5, P605, DOI 10.1101/gad.5.4.605; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RINE J, 1987, GENETICS, V116, P9; Rivier DH, 1992, CURR OPIN GENET DEV, V2, P286, DOI 10.1016/S0959-437X(05)80286-2; ROCKMILL B, 1991, METHOD ENZYMOL, V194, P146; ROSE MD, 1990, METHODS YEAST GENETI; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; STONE EM, 1991, THESIS STATE U NEW Y; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; SUSSEL L, 1993, MOL CELL BIOL, V13, P3919, DOI 10.1128/MCB.13.7.3919; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TORNOW J, 1990, GENE, V90, P79, DOI 10.1016/0378-1119(90)90441-S; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713	62	177	181	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 5	1993	75	3					531	541		10.1016/0092-8674(93)90387-6	http://dx.doi.org/10.1016/0092-8674(93)90387-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8221892				2022-12-01	WOS:A1993MF83000015
J	KIM, K; SOLDATI, D; BOOTHROYD, JC				KIM, K; SOLDATI, D; BOOTHROYD, JC			GENE REPLACEMENT IN TOXOPLASMA-GONDII WITH CHLORAMPHENICOL ACETYLTRANSFERASE AS SELECTABLE MARKER	SCIENCE			English	Article							PLASMODIUM-FALCIPARUM; EXPRESSION; CLINDAMYCIN	A system for stable transformation of Toxoplasma gondii tachyzoites was developed that exploited the susceptibility of Toxoplasma to chloramphenicol. Introduction of the chloramphenicol acetyltransferase (CAT) gene fused to Toxoplasma flanking sequences followed by chloramphenicol selection resulted in parasites stably expressing CAT. A construct incorporating the tandemly repeated gene, B1, targeted efficiently to its homologous chromosomal locus. Knockout of the single-copy gene, ROP1, was also successful. Stable transformation should permit the identification and analysis of Toxoplasma genes important in the interaction of this opportunistic parasite with its host.	STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University			Soldati-Favre, Dominique/A-2999-2009	Kim, Kami/0000-0003-3384-152X; Boothroyd, John C./0000-0001-9719-745X				BURG JL, 1989, J CLIN MICROBIOL, V27, P1787, DOI 10.1128/JCM.27.8.1787-1792.1989; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; DIVO AA, 1985, ANTIMICROB AGENTS CH, V27, P21, DOI 10.1128/AAC.27.1.21; GARDNER MJ, 1991, MOL BIOCHEM PARASIT, V48, P77, DOI 10.1016/0166-6851(91)90166-4; KIM KK, UNPUB; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; MINEO JR, 1993, J IMMUNOL, V150, P3951; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PFEFFERKORN ER, 1992, ANTIMICROB AGENTS CH, V36, P1091, DOI 10.1128/AAC.36.5.1091; SIBLEY LD, 1992, MOL BIOCHEM PARASIT, V51, P291, DOI 10.1016/0166-6851(92)90079-Y; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; SOLDATI D, UNPUB; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902	15	229	242	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					911	914		10.1126/science.8235614	http://dx.doi.org/10.1126/science.8235614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235614				2022-12-01	WOS:A1993MF43800040
J	SUN, H; CHARLES, CH; LAU, LF; TONKS, NK				SUN, H; CHARLES, CH; LAU, LF; TONKS, NK			MKP-1 (3CH134), AN IMMEDIATE-EARLY GENE-PRODUCT, IS A DUAL-SPECIFICITY PHOSPHATASE THAT DEPHOSPHORYLATES MAP KINASE IN-VIVO	CELL			English	Article							PROTEIN-KINASE; VACCINIA VIRUS; GROWTH-FACTOR; ACTIVATION; PHOSPHORYLATION; SIGNAL	Mitogenic stimulation of cells induces rapid and transient activation of MAP kinases. Here we report that a growth factor-inducible gene, 3CH134, encodes a dual specificity phosphatase that dephosphorylates and inactivates p42MAPK both in vitro and in vivo. In vitro, 3CH134 protein dephosphorylates both T183 and Y185 in p42MAPK. In serum-stimulated normal fibroblasts, the kinetics of inactivation of p42MAPK coincides with the appearance of newly synthesized 3CH134 protein, and the protein synthesis inhibitor cycloheximide leads to persistent activation of MAP kinase. Expression of 3CH134 in COS cells leads to selective dephosphorylation of p42MAPK from the spectrum of phosphotyrosyl proteins. 3CH134 blocks phosphorylation and activation of p42MAPK Mediated by serum, oncogenic Ras, or activated Raf, whereas the catalytically inactive mutant of the phosphatase, Cys-258-->Ser, augments MAP kinase phosphorylation under similar conditions. The mutant 3CH134 protein also forms a physical complex with the phosphorylated form of p42MAPK. These findings suggest that 3CH134 is a physiological MAP kinase phosphatase; we propose the name MKP-1 for this phosphatase.	UNIV ILLINOIS, COLL MED, DEPT GENET, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	SUN, H (corresponding author), COLD SPRING HARBOR LAB, DEMEREC BLDG, 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA.			Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [CA53840, CA52220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053840, R01CA052220, R01CA053840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1993, CURR BIOL, V3, P513, DOI 10.1016/0960-9822(93)90043-N; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SANGHERA JS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P153, DOI 10.1016/0167-4889(91)90078-C; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	28	1075	1107	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 5	1993	75	3					487	493		10.1016/0092-8674(93)90383-2	http://dx.doi.org/10.1016/0092-8674(93)90383-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8221888				2022-12-01	WOS:A1993MF83000011
J	JOHNSON, G				JOHNSON, G			CHILDLESS WOMEN REVISITED	BRITISH MEDICAL JOURNAL			English	Article											JOHNSON, G (corresponding author), WIGMORE LANE HLTH CTR,LUTON LU2 8BG,ENGLAND.							GREENHALL E, 1990, FERTIL STERIL, V54, P978; JOHNSON G, 1987, BRIT MED J, V294, P804, DOI 10.1136/bmj.294.6575.804; JONES C, 1992, POPULATION TRENDS, V67, P10; TEMPLETON A, 1990, BRIT MED J, V301, P148, DOI 10.1136/bmj.301.6744.148	4	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1116	1117		10.1136/bmj.307.6912.1116	http://dx.doi.org/10.1136/bmj.307.6912.1116			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8251811	Green Published, Bronze			2022-12-01	WOS:A1993ME91800019
J	MADISON, EL; KOBE, A; GETHING, MJ; SAMBROOK, JF; GOLDSMITH, EJ				MADISON, EL; KOBE, A; GETHING, MJ; SAMBROOK, JF; GOLDSMITH, EJ			CONVERTING TISSUE-PLASMINOGEN ACTIVATOR TO A ZYMOGEN - A REGULATORY TRIAD OF ASP-HIS-SER	SCIENCE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CRYSTAL-STRUCTURE; ALPHA-CHYMOTRYPSIN; BOVINE TRYPSINOGEN; RESOLUTION; INHIBITOR; CATALYSIS; MECHANISM; FIBRINOLYSIS; REFINEMENT	Unlike most serine proteases of the chymotrypsin family, tissue-type plasminogen activator (tPA) is secreted from cells as an active, single-chain enzyme with a catalytic efficiency only slightly lower than that of the proteolytically cleaved form. A zymogenic mutant of tPA has been engineered that displays a reduction in catalytic efficiency by a factor of 141 in the single-chain form while retaining full activity in the cleaved form. The residues introduced in the mutant, serine 292 and histidine 305, are proposed to form a hydrogen-bonded network with aspartate 477, similar to the aspartate 194-histidine 40-serine 32 network found to stabilize the zymogen chymotrypsinogen.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ANTONINI E, 1983, J MOL BIOL, V165, P543, DOI 10.1016/S0022-2836(83)80219-8; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; CALIFF RM, 1988, AM J MED, V85, P353, DOI 10.1016/0002-9343(88)90586-4; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARTER P, 1991, BIOCHEMISTRY-US, V30, P6142, DOI 10.1021/bi00239a009; COLLEN D, 1986, CIRCULATION, V73, P511, DOI 10.1161/01.CIR.73.3.511; COLLEN D, 1987, J CELL BIOCHEM, V33, P77, DOI 10.1002/jcb.240330202; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; FUJINAGA M, 1987, J MOL BIOL, V195, P397, DOI 10.1016/0022-2836(87)90659-0; GERARD RD, 1989, ANNU REV PHYSIOL, V51, P245, DOI 10.1146/annurev.physiol.51.1.245; GERTLER A, 1974, BIOCHEMISTRY-US, V13, P1302, DOI 10.1021/bi00703a038; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; KERR MA, 1976, BIOCHEMISTRY-US, V15, P5566, DOI 10.1021/bi00670a022; KOSSIAKOFF AA, 1977, BIOCHEMISTRY-US, V16, P654, DOI 10.1021/bi00623a016; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LONSDALEECCLES JD, 1978, BIOCHEMISTRY-US, V17, P2805, DOI 10.1021/bi00607a016; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PETERSEN LC, 1990, BIOCHEMISTRY-US, V29, P3451, DOI 10.1021/bi00466a005; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PETERSON LC, 1993, BIOCHIM BIOPHYS ACTA, V952, P245; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; ROBINSON NC, 1973, BIOCHEMISTRY-US, V12, P420, DOI 10.1021/bi00727a010; Sambrook J., 1989, MOL CLONING LAB MANU; SILVERBERG M, 1982, BLOOD, V60, P64; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9; WELLS TNC, 1985, NATURE, V316, P656, DOI 10.1038/316656a0	36	81	94	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					419	421		10.1126/science.8211162	http://dx.doi.org/10.1126/science.8211162			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	8211162				2022-12-01	WOS:A1993MB85900057
J	WAGNER, S; GREEN, MR				WAGNER, S; GREEN, MR			HTLV-I TAX PROTEIN STIMULATION OF DNA-BINDING OF BZIP PROTEINS BY ENHANCING DIMERIZATION	SCIENCE			English	Article							VIRUS TYPE-I; LONG TERMINAL REPEAT; CELLULAR FACTORS; LEUCINE ZIPPER; TRANSCRIPTIONAL ACTIVATOR; 21-BASE-PAIR REPEATS; TRANS-ACTIVATION; GENE-EXPRESSION; CDNA CLONES; INVITRO	The Tax protein of human T cell leukemia virus type-1 (HTLV-I) transcriptionally activates the HTLV-I promoter. This activation requires binding sites for activating transcription factor (ATF) proteins, a family of cellular proteins that contain basic region-leucine zipper (bZIP) DNA binding domains. Data are presented showing that Tax increases the in vitro DNA binding activity of multiple ATF proteins. Tax also stimulated DNA binding by other bZIP proteins, but did not affect DNA binding proteins that lack a bZIP domain. The increase in DNA binding occurred because Tax promotes dimerization of the bZIP domain in the absence of DNA, and the elevated concentration of the bZIP homodimer then facilitates the DNA binding reaction. These results help explain how Tax activates viral transcription and transforms cells.			WAGNER, S (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.							ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BANNISTER AJ, 1992, NUCLEIC ACIDS RES, V20, P3523, DOI 10.1093/nar/20.13.3523; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUNTER T, 1988, CELL, V55, P125; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOENIG H, 1992, EMBO (European Molecular Biology Organization) Journal, V11, P2241; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MOCH H, 1992, J VIROL, V66, P7354; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; OKA T, 1992, J VIROL, V66, P6686, DOI 10.1128/JVI.66.11.6686-6694.1992; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Wagner S, UNPUB; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P9030; XU YL, 1990, J BIOL CHEM, V265, P20285; YIP MT, 1990, MOL BIOL MED, V7, P33; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	56	309	314	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					395	399		10.1126/science.8211160	http://dx.doi.org/10.1126/science.8211160			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	8211160				2022-12-01	WOS:A1993MB85900049
J	CASKEY, CT				CASKEY, CT			PRESYMPTOMATIC DIAGNOSIS - A 1ST STEP TOWARD GENETIC HEALTH-CARE	SCIENCE			English	Editorial Material							CYSTIC-FIBROSIS GENE; IDENTIFICATION; DISEASE; DNA		BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030	Baylor College of Medicine	CASKEY, CT (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.							ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; BENNETT WM, 1990, SEMIN NEPHROL, V10, P552; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BLITZER MG, 1992, CLIN LAB MED, V12, P463, DOI 10.1016/S0272-2712(18)30500-6; Cao A, 1991, CURR OPIN GENET DEV, V1, P48, DOI 10.1016/0959-437X(91)80040-S; CASKEY CT, 1993, JAMA-J AM MED ASSOC, V269, P1986, DOI 10.1001/jama.269.15.1986; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KING MC, 1993, JAMA-J AM MED ASSOC, V269, P1975, DOI 10.1001/jama.269.15.1975; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; MITANI K, 1993, TRENDS BIOTECHNOL, V11, P162, DOI 10.1016/0167-7799(93)90108-L; O'Flynn M E, 1992, Curr Probl Pediatr, V22, P159; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; WILLI SM, 1991, PEDIATR CLIN N AM, V38, P555	18	22	22	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 1	1993	262	5130					48	49		10.1126/science.8211129	http://dx.doi.org/10.1126/science.8211129			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ635	8211129				2022-12-01	WOS:A1993LZ63500023
J	CHRISTIE, CDC; MARX, ML; MARCHANT, CD; REISING, SF				CHRISTIE, CDC; MARX, ML; MARCHANT, CD; REISING, SF			THE 1993 EPIDEMIC OF PERTUSSIS IN CINCINNATI - RESURGENCE OF DISEASE IN A HIGHLY IMMUNIZED POPULATION OF CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; EFFICACY; VACCINE; OUTBREAK; BORDETELLA; INFECTION; COMMUNITY; DIAGNOSIS; ANTIBODY; CULTURE	Background. In 1993 there was a resurgence of pertussis in the United States. Altogether, 6335 cases were reported, the most in 26 years. Methods. Using active microbiologic surveillance, we investigated the epidemic of pertussis in Greater Cincinnati in 1993. The population of 1.7 million in this area is served by a single children's hospital and pertussis laboratory. We prospectively followed patients given a new diagnosis of pertussis in July through September 1993 to determine the characteristics of the epidemic. Results. From 1979 to 1992, there was a cumulative total of 542 cases of pertussis. In 1993, 352 cases were diagnosed, an increase of 259 percent over the 1992 total. Sixty-three percent of the cases had positive cultures for Bordetella pertussis, 18 percent were positive on direct fluorescent-antibody testing only, and 19 percent were diagnosed clinically. The outbreak began in the suburbs during the summer and spread through Greater Cincinnati. Of 255 total cases diagnosed in July through September (195 excess cases over the maximal base-line level of 20 per month in the previous 14 years), 75 percent were in white patients and 67 percent of the patients had private insurance or paid for care out of pocket. In 1993, as compared with 1979 through 1992, there was a shift in incidence from younger infants to older children; the percentages of cases according to age group were as follows: 0 to 6 months, 53 percent from 1979 through 1992 and 35 percent in 1993 (P<0.001); 7 months to 5 years, 33 percent and 43 percent (P<0.002); 6 to 12 years, 5 percent and 11 percent (P<0.001); and more than 12 years, 5 percent and 11 percent (P<0.003). Immunization records revealed that 74 percent (75 of 101) of the children with pertussis who were 19 months to 12 years old had received four or five doses of the combined diphtheria-pertussis-tetanus (DPT) vaccine, and that 82 percent (103 of 126) of those 7 to 71 months old had received at least three doses of DPT vaccine. The whole-cell vaccines used came from both of the major manufacturers (Connaught Laboratories and Lederle Laboratories), Disease was not severe, but 80 of the 255 children (31 percent) given diagnoses during the three epidemic months were hospitalized. There were no deaths. Conclusions. Since the 1993 pertussis epidemic in Cincinnati occurred primarily among children who had been appropriately immunized, it is clear that the whole-cell pertussis vaccine failed to give full protection against the disease.	UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH; CHILDRENS HOSP,MED CTR,DIV EPIDEMIOL,CINCINNATI,OH 45229; CHILDRENS HOSP,MED CTR,DIV CLIN MICROBIOL,CINCINNATI,OH 45229; TUFTS UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02111; TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111; DEPT PUBL HLTH,MASSACHUSETTS PUBL HLTH BIOL LABS,BOSTON,MA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Tufts University; Tufts Medical Center; Massachusetts Department of Public Health	CHRISTIE, CDC (corresponding author), CHILDRENS HOSP,MED CTR,DIV INFECT DIS,3333 BURNET AVE,CINCINNATI,OH 45229, USA.			Christie, Celia DC/0000-0002-8981-3934; Marchant, Colin/0000-0002-9710-6228				BASS JW, 1987, PEDIATR INFECT DIS J, V6, P141, DOI 10.1097/00006454-198702000-00001; BERGQUIST SO, 1987, PEDIATR INFECT DIS J, V6, P458, DOI 10.1097/00006454-198705000-00009; BERGQUIST SO, 1987, PEDIATR INFECT DIS J, V6, P1035; BIELLIK RJ, 1988, J INFECT DIS, V157, P1134, DOI 10.1093/infdis/157.6.1134; BROOME CV, 1981, J INFECT DIS, V144, P187, DOI 10.1093/infdis/144.2.187; BROOME CV, 1978, DHEW NIH791830 PUBL, P19; Cherry J D, 1984, Curr Probl Pediatr, V14, P1; CHERRY J D, 1988, Pediatrics, V81, P939; CHRISTIE CD, 1994, 1994 ANN M SOC HOSP, P31; CHRISTIE CD, 1990, J PEDIATR, V80, P23; CHRISTIE CDC, 1989, AM J DIS CHILD, V143, P1199, DOI 10.1001/archpedi.1989.02150220097027; DEAN J, 1991, EPI INFO VERSION 5 0; EDMONSON MB, 1990, JAMA-J AM MED ASSOC, V263, P2467, DOI 10.1001/jama.263.18.2467; EDWARDS KM, 1991, PEDIATRICS, V88, P1019; EWANOWICH CA, 1993, J CLIN MICROBIOL, V31, P1715, DOI 10.1128/JCM.31.7.1715-1725.1993; FARIZO KM, 1992, CLIN INFECT DIS, V14, P708, DOI 10.1093/clinids/14.3.708; FINE PEM, 1987, REV INFECT DIS, V9, P866; GILCHRIST MJR, 1991, MANUAL CLIN MICROBIO, P471; GILLIGAN PH, 1983, CLIN MICROBIOL NEWSL, V5, P115; HALPERIN SA, 1989, J CLIN MICROBIOL, V27, P752, DOI 10.1128/JCM.27.4.752-757.1989; HALSEY N, 1985, B WORLD HEALTH ORGAN, V63, P1151; HEININGER U, 1993, 33RD INT C ANT AG CH, P372; HERWALDT LA, 1991, ARCH INTERN MED, V151, P1510, DOI 10.1001/archinte.151.8.1510; HOPPE JE, 1988, EUR J CLIN MICROBIOL, V7, P616, DOI 10.1007/BF01964238; JENKINSON D, 1988, BRIT MED J, V296, P612, DOI 10.1136/bmj.296.6622.612; KRAMER MS, 1989, CLIN PHARMACOL THER, V46, P309; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LINNEMANN CC, 1977, ANNU REV MED, V28, P179, DOI 10.1146/annurev.me.28.020177.001143; MARCHANT CD, 1994, J INFECT DIS, V169, P1297, DOI 10.1093/infdis/169.6.1297; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; NELSON JD, 1978, AM J DIS CHILD, V132, P371, DOI 10.1001/archpedi.1978.02120290043006; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; ONORATO IM, 1992, JAMA-J AM MED ASSOC, V267, P2745, DOI 10.1001/jama.267.20.2745; REGAN J, 1977, J CLIN MICROBIOL, V6, P303; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; 1984, MMWR-MORBID MORTAL W, V33, P573; 1994, MMWR-MORBID MORTAL W, V43, P57; 1991, REPORT COMMITTEE INF, P360; 1993, MMWR-MORBID MORTAL W, V42, P959; 1990, MMWR-MORBID MORTAL W, V39, P57; 1993, MMWR-MORBID MORTAL W, V42, P952; 1987, MMWR-MORBID MORTAL W, V36, P168; 1987, WORLD HLTH       JAN, P7; 1982, MMWR-MORBID MORTAL W, V31, P333	44	96	97	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	1994	331	1					16	21		10.1056/NEJM199407073310104	http://dx.doi.org/10.1056/NEJM199407073310104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU951	8202096				2022-12-01	WOS:A1994NU95100004
J	CONNETT, GJ; LEE, BW				CONNETT, GJ; LEE, BW			TREATING CHILDHOOD ASTHMA IN SINGAPORE - WHEN WEST MEETS EAST	BRITISH MEDICAL JOURNAL			English	Article							ESOPHAGEAL	Though Western medicines and ideas about asthma have become popular in many Asian nations, local beliefs about treatment prevail. The multiracial society of Singapore shows a variety of beliefs about causes of asthma attacks (for example, the balance of yin and yang) and types of treatment-herbal remedies, inhaled versus eaten medicines, the influence of Ramadan. Many of the cultural practices mentioned are probably preserved among south east Asian minorities residing in the United Kingdom. Eastern treatments typically take a holistic approach to asthma and do not ignore the psychosomatic component of the disorder.	NATL UNIV SINGAPORE,DEPT PAEDIAT,SINGAPORE 0511,SINGAPORE	National University of Singapore			Connett, Gary/AAU-3686-2020	Connett, Gary/0000-0003-1310-3239				de San Lazaro C, 1986, Arch Dis Child, V61, P97; FITCH KD, 1971, BRIT MED J, V4, P577, DOI 10.1136/bmj.4.5787.577; KONG XT, 1993, ARCH DIS CHILD, V68, P468, DOI 10.1136/adc.68.4.468; RAUSCHER H, 1989, RESPIRATION, V55, P11; SHEEHAN MP, 1992, BRIT J DERMATOL, V126, P179, DOI 10.1111/j.1365-2133.1992.tb07817.x; WILSON NM, 1985, EUR J RESPIR DIS, V66, P25; WILSON NM, 1985, THORAX, V40, P592, DOI 10.1136/thx.40.8.592; ZHU SL, 1989, ASIAN PAC J ALLERGY, V7, P5	8	13	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 14	1994	308	6939					1282	1284		10.1136/bmj.308.6939.1282	http://dx.doi.org/10.1136/bmj.308.6939.1282			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM147	8205023	Green Published			2022-12-01	WOS:A1994NM14700023
J	NEUFELD, TP; RUBIN, GM				NEUFELD, TP; RUBIN, GM			THE DROSOPHILA PEANUT GENE IS REQUIRED FOR CYTOKINESIS AND ENCODES A PROTEIN SIMILAR TO YEAST PUTATIVE BUD NECK FILAMENT PROTEINS	CELL			English	Article							CEREVISIAE CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; CONTRACTILE RING; BUDDING YEAST; COMPOUND EYE; LOCALIZATION; MORPHOGENESIS; MELANOGASTER; PRODUCT; SITE	We have identified a Drosophila gene, peanut (pnut), that is related in sequence to the CDC3, CDC10, CDC11, and CDC12 genes of S. cerevisiae. These genes are required for cytokinesis, and their products are present at the bud neck during cell division. We find that pnut is also required for cytokinesis: in pnut mutants, imaginal tissues fail to proliferate and instead develop clusters of large, multinucleate cells. Pnut protein is localized to the cleavage furrow of dividing cells during cytokinesis and to the intercellular bridge connecting postmitotic daughter cells. In addition to its role in cytokinesis, pnut displays genetic interactions with seven in absentia, a gene required for neuronal fate determination in the compound eye, suggesting that pnut may have pleiotropic functions. Our results suggest that this class of proteins is involved in aspects of cytokinesis that have been conserved between flies and yeast.			NEUFELD, TP (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.			Neufeld, Thomas/0000-0001-5659-4811; Rubin, Gerald/0000-0001-8762-8703				BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BYERS B, 1968, PROTOPLASMA, V66, P413, DOI 10.1007/BF01255868; BYERS B, 1976, J CELL BIOL, V70, pA35; BYERS B, 1976, J CELL BIOL, V69, P717, DOI 10.1083/jcb.69.3.717; BYERS TJ, 1987, J CELL BIOL, V105, P2103, DOI 10.1083/jcb.105.5.2103; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; EDAMATSU M, 1992, J BIOCHEM-TOKYO, V112, P637, DOI 10.1093/oxfordjournals.jbchem.a123952; FLESCHER EG, 1993, J CELL BIOL, V122, P373, DOI 10.1083/jcb.122.2.373; FORD SK, 1991, DEV GENET, V12, P281, DOI 10.1002/dvg.1020120405; FRANCESCHINI N, 1971, KYBERNETIK, V9, P159, DOI 10.1007/BF02215177; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; HAARER BK, 1987, MOL CELL BIOL, V7, P3678, DOI 10.1128/MCB.7.10.3678; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HAY B, 1990, DEVELOPMENT, V109, P425; HIME G, 1992, DEVELOPMENT, V114, P165; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KATO K, 1991, J NEUROSCI, V2, P704; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LEHNER CF, 1992, J CELL SCI, V103, P1021; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; MULLINS JM, 1977, J CELL BIOL, V73, P672, DOI 10.1083/jcb.73.3.672; MULLINS MC, 1991, P NATL ACAD SCI USA, V88, P9387, DOI 10.1073/pnas.88.21.9387; NOTTENBURG C, 1990, GENE, V95, P279, DOI 10.1016/0378-1119(90)90372-X; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PICKETTHEAPS JD, 1966, J CELL SCI, V1, P109; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; RICKOLL WL, 1980, ROUX ARCH DEV BIOL, V188, P163, DOI 10.1007/BF00849045; ROBERTSON HM, 1988, GENETICS, V118, P461; SANGER F, 1977, P NATL ACAD SCI USA, V86, P8333; SANGER JM, 1985, CELL TISSUE RES, V240, P287; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHEJTER ED, 1993, ANNU REV CELL BIOL, V9, P67, DOI 10.1146/annurev.cb.09.110193.000435; SCHROEDER TE, 1990, ANN NY ACAD SCI, V582, P78; SCHROEDER TE, 1972, J CELL BIOL, V53, P419, DOI 10.1083/jcb.53.2.419; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER M, 1991, J CELL BIOL, V114, P515, DOI 10.1083/jcb.114.3.515; WOLFF T, 1991, DEVELOPMENT, V113, P841; XU T, 1993, DEVELOPMENT, V117, P1223; YONEMURA S, 1991, J CELL SCI, V100, P73; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	51	277	284	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 6	1994	77	3					371	379		10.1016/0092-8674(94)90152-X	http://dx.doi.org/10.1016/0092-8674(94)90152-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	8181057				2022-12-01	WOS:A1994NK97000008
J	ROWLEY, N; PRIPBUUS, C; WESTERMANN, B; BROWN, C; SCHWARZ, E; BARRELL, B; NEUPERT, W				ROWLEY, N; PRIPBUUS, C; WESTERMANN, B; BROWN, C; SCHWARZ, E; BARRELL, B; NEUPERT, W			MDJ1P, A NOVEL CHAPERONE OF THE DNAJ FAMILY, IS INVOLVED IN MITOCHONDRIAL BIOGENESIS AND PROTEIN-FOLDING	CELL			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; ENDOPLASMIC-RETICULUM; INTERMEMBRANE SPACE; INVITRO TRANSCRIPTION; PRECURSOR PROTEINS; TRANSLATION SYSTEM; IMPORT; TRANSLOCATION	Mdj1p, a novel member of the DnaJ family, is a heat shock protein that is associated with the inner membrane of mitochondria of Saccharomyces cerevisiae. Disruption of the MDJ1 gene resulted in a petite phenotype, loss of mitochondrial DNA, and inviability at 37 degrees C. Import of precursor proteins was not affected by a lack of Mdj1p, but folding of newly imported proteins was markedly impaired. The efficiency of refolding of a tester protein, dihydrofolate reductase, was significantly reduced in mitochondria lacking Mdj1p after incubation at elevated temperature. We conclude that Mdj1p is an important mitochondrial chaperone that participates in the folding of newly imported proteins and in the protection of proteins against heat denaturation and aggregation.	INST PHYSIOL CHEM, D-80336 MUNICH, GERMANY		ROWLEY, N (corresponding author), MRC, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.		Westermann, Benedikt/H-7766-2013; PRIP-BUUS, Carina/P-9084-2017	Westermann, Benedikt/0000-0002-2991-1604; Prip-Buus, Carina/0000-0002-2153-7857				AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P403; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; Gibson T., 1984, THESIS U CAMBRIDGE C; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RILES L, 1993, GENETICS, V134, P81; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SCHWARZ E, IN PRESS GENE; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SMITH V, 1993, METHOD ENZYMOL, V218, P173; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; YOUNG MR, 1993, MOL CELL BIOL, V13, P5637, DOI 10.1128/MCB.13.9.5637; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	64	198	201	1	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 22	1994	77	2					249	259		10.1016/0092-8674(94)90317-4	http://dx.doi.org/10.1016/0092-8674(94)90317-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168133	Green Published			2022-12-01	WOS:A1994NH63400010
J	EISELE, JL; BERTRAND, S; GALZI, JL; DEVILLERSTHIERY, A; CHANGEUX, JP; BERTRAND, D				EISELE, JL; BERTRAND, S; GALZI, JL; DEVILLERSTHIERY, A; CHANGEUX, JP; BERTRAND, D			CHIMERIC NICOTINIC SEROTONERGIC RECEPTOR COMBINES DISTINCT LIGAND-BINDING AND CHANNEL SPECIFICITIES	NATURE			English	Article							GATED ION CHANNEL; MARMORATA ACETYLCHOLINE-RECEPTOR; ALPHA-SUBUNIT; DELTA-SUBUNIT; XENOPUS OOCYTES; 5-HYDROXYTRYPTAMINE; EXPRESSION; SEQUENCES; CALCIUM; NEURONS	THE neuronal nicotinic alpha7 (nAChR) and 5-hydroxytryptamine (5HT3) receptors1-3 are ligand-gated ion channels with a homologous topological organization and have activation and desensitization reactions in common. Yet these homo-oligomeric receptors differ in the pharmacology of their binding sites for agonists and competitive antagonists3,4, and in their sensitivity to Ca2+ ions. The alpha7 channel is highly permeable to Ca2+ ions5,6 and external Ca2+ ions potentiate, in an allosteric manner, the permeability response to acetylcholine, as shown for other neuronal nAChRs7,8. The 5HT3 channel, in contrast, is not permeable to Ca2+ ions, but blocked by them3,9. To assign these properties to delimited domains of the primary structure, we constructed several recombinant chimaeric alpha7-5HT3 receptors. We report here that one of the constructs expresses a functional receptor that contains the serotonergic channel still blocked by Ca2+ ions, but is activated by nicotinic ligands and potentiated by external Ca2+ ions.	UNIV GENEVA, MED CTR, FAC MED, DEPT PHYSIOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	EISELE, JL (corresponding author), INST PASTEUR, CNRS, UNITE NEUROBIOL MOLEC D1284, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.							BERTRAND D, 1992, NEUROSCI LETT, V146, P87, DOI 10.1016/0304-3940(92)90179-B; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; BERTRAND D, 1991, ELECTROPHYSIOLOGY NE; BRADLEY PB, 1986, NEUROPHARMACOLOGY, V25, P563, DOI 10.1016/0028-3908(86)90207-8; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DEVILLERSTHIERY A, 1983, P NATL ACAD SCI-BIOL, V80, P2067, DOI 10.1073/pnas.80.7.2067; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; HIGASHI H, 1982, J PHYSIOL-LONDON, V323, P543, DOI 10.1113/jphysiol.1982.sp014091; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KUHSE J, 1990, NEURON, V5, P867, DOI 10.1016/0896-6273(90)90346-H; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MAYNE KM, 1987, MOL BRAIN RES, V2, P191, DOI 10.1016/0169-328X(87)90026-X; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MULLE C, 1992, NEURON, V8, P937, DOI 10.1016/0896-6273(92)90208-U; NODA M, 1983, NATURE, V301, P251, DOI 10.1038/301251a0; PETERS JA, 1988, EUR J PHARMACOL, V151, P491, DOI 10.1016/0014-2999(88)90550-X; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SEGUELA P, 1993, J NEUROSCI, V13, P596; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SUMIKAWA K, 1992, MOL BRAIN RES, V13, P349, DOI 10.1016/0169-328X(92)90218-Z; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; VANDENBERG RJ, 1992, P NATL ACAD SCI USA, V89, P1765, DOI 10.1073/pnas.89.5.1765; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030; YANG J, 1992, J PHYSIOL-LONDON, V448, P237, DOI 10.1113/jphysiol.1992.sp019039; YANG J, 1990, J GEN PHYSIOL, V96, P1177, DOI 10.1085/jgp.96.6.1177; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	35	346	368	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	1993	366	6454					479	483		10.1038/366479a0	http://dx.doi.org/10.1038/366479a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247158				2022-12-01	WOS:A1993MK09800069
J	GORLICH, D; RAPOPORT, TA				GORLICH, D; RAPOPORT, TA			PROTEIN TRANSLOCATION INTO PROTEOLIPOSOMES RECONSTITUTED FROM PURIFIED COMPONENTS OF THE ENDOPLASMIC-RETICULUM MEMBRANE	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; RIBOSOME-BINDING-ACTIVITY; SEQUENCE RECEPTOR; POLYPEPTIDE TRANSLOCATION; NASCENT PREPROLACTIN; MICROSOMAL-MEMBRANES; SECRETORY PROTEINS; ESCHERICHIA-COLI; ROUGH MICROSOMES; YEAST	We have reproduced the process of protein transport across and of protein integration into the mammalian endoplasmic reticulum membrane by the use of proteoliposomes reconstituted from pure phospholipids and purified membrane proteins. The transport of some proteins requires only two membrane protein complexes: the signal recognition particle receptor, needed for targeting of a nascent chain to the membrane, and a novel complex, the Sec61p complex, that consists of Sec61p and two smaller polypeptides. The translocation of other proteins also needs the presence of the translocating chain-associating membrane (TRAM) protein. The integration of two membrane proteins of different topologies into the membrane does not require additional components. These results indicate a surprising simplicity of the basic translocation machinery. They suggest that the Sec61p complex binds the ribosome during translocation and forms the postulated protein-conducting channel.	MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; COLLINS PG, 1991, J CELL BIOL, V114, P639, DOI 10.1083/jcb.114.4.639; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; ICHIMURA T, 1992, FEBS LETT, V296, P7, DOI 10.1016/0014-5793(92)80391-S; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAUFFER L, 1985, NATURE, V318, P334, DOI 10.1038/318334a0; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MEYER DI, 1982, NATURE, V297, P503; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; NUNNARI JM, 1991, NATURE, V352, P638, DOI 10.1038/352638a0; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SAVITZ AJ, 1993, J CELL BIOL, V120, P853, DOI 10.1083/jcb.120.4.853; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; Wiech H, 1990, Semin Cell Biol, V1, P55; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; ZIMMERMAN DL, 1991, CELL REGUL, V2, P851, DOI 10.1091/mbc.2.10.851	49	540	548	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					615	630		10.1016/0092-8674(93)90483-7	http://dx.doi.org/10.1016/0092-8674(93)90483-7			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242738	Bronze, Green Accepted			2022-12-01	WOS:A1993MH74900008
J	LI, XX; WU, YJ; ZHANG, DZ; GILLIKIN, JW; BOSTON, RS; FRANCESCHI, VR; OKITA, TW				LI, XX; WU, YJ; ZHANG, DZ; GILLIKIN, JW; BOSTON, RS; FRANCESCHI, VR; OKITA, TW			RICE PROLAMINE PROTEIN BODY BIOGENESIS - A BIP-MEDIATED PROCESS	SCIENCE			English	Article							MOLECULAR CHAPERONE; MAIZE ENDOSPERM; PEPTIDE-BINDING; POLYRIBOSOMES; TRANSLOCATION; EXPRESSION; HOMOLOG; BODIES	Rice prolamines are sequestered within the endoplasmic reticulum (ER) lumen even though they lack a lumenal retention signal. Immunochemical and biochemical data show that BiP, a protein that binds lumenal polypeptides, is localized on the surface of the aggregated prolamine protein bodies (PBs). BiP also forms complexes with nascent chains of prolamines in polyribosomes and with free prolamines with distinct adenosine triphosphate sensitivities. Thus, BiP retains prolamines in the lumen by facilitating their folding and assembly into PBs.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, DEPT GENET & CELL BIOL, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, DEPT BOT, PULLMAN, WA 99164 USA; N CAROLINA STATE UNIV, DEPT BOT, RALEIGH, NC 27695 USA	Washington State University; Washington State University; Washington State University; University of North Carolina; North Carolina State University				Okita, Tom/0000-0002-2246-0599				ABE S, 1991, PROTOPLASMA, V165, P139, DOI 10.1007/BF01322284; ARGOS P, 1982, J BIOL CHEM, V257, P9984; BOSTON RS, 1991, PLANT CELL, V3, P497, DOI 10.1105/tpc.3.5.497; BURR B, 1976, P NATL ACAD SCI USA, V73, P515, DOI 10.1073/pnas.73.2.515; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FONTES EBP, 1991, PLANT CELL, V3, P483, DOI 10.1105/tpc.3.5.483; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KIM WT, 1988, PLANT PHYSIOL, V88, P649, DOI 10.1104/pp.88.3.649; KRISHNAN HB, 1986, PLANTA, V169, P471, DOI 10.1007/BF00392095; LARKINS BA, 1976, PLANT PHYSIOL, V57, P740, DOI 10.1104/pp.57.5.740; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; Li X., UNPUB; LI XX, 1993, CELL, V72, P869, DOI 10.1016/0092-8674(93)90576-C; LI XX, 1993, PLANT CELL PHYSIOL, V34, P385; MAROCCO A, 1991, PLANT CELL, V3, P507, DOI 10.1105/tpc.3.5.507; MIERNYK JA, 1992, PLANT CELL, V4, P821, DOI 10.1105/tpc.4.7.821; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; OKITA TW, 1989, PLANT NITROGEN METAB, pCH9; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; YAMAGATA H, 1986, PLANT CELL PHYSIOL, V27, P135	24	150	168	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1993	262	5136					1054	1056		10.1126/science.8235623	http://dx.doi.org/10.1126/science.8235623			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235623				2022-12-01	WOS:A1993MG18700035
J	GUZDER, SN; SUNG, P; BAILLY, V; PRAKASH, L; PRAKASH, S				GUZDER, SN; SUNG, P; BAILLY, V; PRAKASH, L; PRAKASH, S			RAD25 IS A DNA HELICASE REQUIRED FOR RNA REPAIR AND RNA-POLYMERASE-II TRANSCRIPTION	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; GENE; ENDONUCLEASE; INITIATION; ENCODES; RAD10; PROTEIN; ATPASE; STRAND; CTD	THE RAD25 gene of Saccharomyces cerevisiae functions in nucleotide excision repair of ultraviolet-damaged DNA and is also required for cell viability(1). The RAD25 protein shows remarkable homology to the protein encoded by the human nucleotide-excision-repair gene XPB (ERCC3), mutations in which cause the cancer-prone disease xeroderma pigmentosum and also Cockayne's syndrome(1). Here we purify RAD25 protein from S. cerevisiae and show that it contains single-stranded DNA-dependent ATPase and DNA helicase activities. Extract from the conditional lethal mutant rad25-ts(24) exhibits a thermolabile transcriptional defect which can be corrected by the addition of RAD25 protein, indicating a direct and essential role of RAD25 in RNA polymerase II transcription. The protein encoded by the rad25(799am) allele is defective in DNA repair but is proficient in RNA polymerase II transcription, indicating that RAD25 DNA-repair activity is separable from its transcription function. The rad25 Arg-392 encoded product, which contains a mutation in the ATP-binding motif, is defective in RNA polymerase II transcription, suggesting that the RAD25-encoded DNA helicase functions in DNA duplex opening during transcription initiation.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444				BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CONOWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LEADON SA, 1992, J BIOL CHEM, V267, P23175; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.biochem.59.1.289; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SUNG P, 1994, J BIOL CHEM, V269, P8303; SWEDER KS, 1993, SCIENCE, V262, P439, DOI 10.1126/science.8211165; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; SWEDER KS, 1994, J BIOL CHEM, V269, P1852; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555	26	166	168	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 16	1994	369	6481					578	581		10.1038/369578a0	http://dx.doi.org/10.1038/369578a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	8202161				2022-12-01	WOS:A1994NR29400055
J	MISHKIN, M				MISHKIN, M			METALLIC SURGICAL CLIPS AND MAGNETIC-RESONANCE-IMAGING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ANEURYSM				MISHKIN, M (corresponding author), THOMAS JEFFERSON UNIV HOSP,PHILADELPHIA,PA, USA.							BECKER RL, 1988, AM J NEURORADIOL, V9, P885; DUJOVNY M, 1985, NEUROSURGERY, V17, P543, DOI 10.1227/00006123-198510000-00002; KANAL E, 1993, RADIOLOGY, V187, P612, DOI 10.1148/radiology.187.3.8497603; KLUCZNIK RP, 1993, RADIOLOGY, V187, P885; NEW PFG, 1983, RADIOLOGY, V147, P1139; 1993, ACR B, V5, P11	6	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1886	1886		10.1001/jama.271.23.1886	http://dx.doi.org/10.1001/jama.271.23.1886			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	8196150				2022-12-01	WOS:A1994NP95900039
J	KAJIWARA, K; BERSON, EL; DRYJA, TP				KAJIWARA, K; BERSON, EL; DRYJA, TP			DIGENIC RETINITIS-PIGMENTOSA DUE TO MUTATIONS AT THE UNLINKED PERIPHERIN/RDS AND ROM1 LOCI	SCIENCE			English	Article							SYNDROME TYPE-I; SLOW RDS GENE; NULL MUTATION; LOCALIZATION; LINKAGE; DEGENERATION; FAMILY; CHROMOSOME-11; DYSTROPHY; HETEROGENEITY	In spite of recent advances in identifying genes causing monogenic human disease, very little is known about the genes involved in polygenic disease. Three families were identified with mutations in the unlinked photoreceptor-specific genes ROM1 and peripherin/RDS, in which only double heterozygotes develop retinitis pigmentosa (RP). These findings indicate that the allelic and nonallelic heterogeneity known to be a feature of monogenic RP is complicated further by interactions between unlinked mutations causing digenic RP. Recognition of the inheritance pattern exemplified by these three families might facilitate the identification of other examples of digenic inheritance in human disease.	HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HOWE LAB OPHTHALMOL,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB STUDY RETINAL DEGENERAT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary					NATIONAL EYE INSTITUTE [R01EY008683, R37EY000169, R01EY000169] Funding Source: NIH RePORTER; NEI NIH HHS [EY00169, EY08683] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALMAGHTHEH M, 1994, HUM MOL GENET, V3, P351, DOI 10.1093/hmg/3.2.351; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; BASCOM RA, 1992, AM J HUM GENET, V51, P1028; BASCOM RA, 1993, HUM MOL GENET, V2, P385, DOI 10.1093/hmg/2.4.385; BERSON EL, 1979, ARCH OPHTHALMOL-CHIC, V97, P1286, DOI 10.1001/archopht.1979.01020020028006; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022; BERSON EL, 1976, T AM ACAD OPHTHALMOL, V81, P659; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; CHEN JD, 1989, AM J HUM GENET, V45, P401; DRYJA TP, 1992, EYE, V6, P1; FARRAR GJ, 1991, GENOMICS, V11, P870, DOI 10.1016/0888-7543(91)90009-4; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; FARRAR GJ, 1992, AM J HUM GENET SA94, V51, P363; HAYS TS, 1989, MOL CELL BIOL, V9, P875, DOI 10.1128/MCB.9.3.875; INGLEHEARN CF, 1993, NAT GENET, V4, P51, DOI 10.1038/ng0593-51; JAY M, 1992, J MED GENET, V29, P906, DOI 10.1136/jmg.29.12.906; JORDAN SA, 1993, NAT GENET, V4, P54, DOI 10.1038/ng0593-54; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; KAJIWARA K, 1993, NAT GENET, V3, P208, DOI 10.1038/ng0393-208; KAJIWARA K, UNPUB; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; KARPE G, 1945, ACTA OPHTHALMOL, V23, P1; KIMBERLING WJ, 1992, GENOMICS, V14, P988, DOI 10.1016/S0888-7543(05)80121-1; KIMBERLING WJ, 1990, GENOMICS, V7, P245, DOI 10.1016/0888-7543(90)90546-7; KUSCH M, 1986, GENETICS, V113, P621; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LEWIS RA, 1990, GENOMICS, V7, P250, DOI 10.1016/0888-7543(90)90547-8; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; NICHOLS BE, 1993, NAT GENET, V3, P202, DOI 10.1038/ng0393-202; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; REICHEL E, 1989, AM J OPHTHALMOL, V108, P540, DOI 10.1016/0002-9394(89)90431-5; ROSENFELD PJ, 1992, NAT GENET, V1, P209, DOI 10.1038/ng0692-209; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; STEARNS T, 1988, GENETICS, V119, P249; TRAVIS GH, 1991, GENOMICS, V10, P733, DOI 10.1016/0888-7543(91)90457-P; WELEBER RG, 1981, INVEST OPHTH VIS SCI, V20, P392; WELEBER RG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1531, DOI 10.1001/archopht.1993.01090110097033; WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213; YANDELL DW, 1989, CANCER CEL, V7, P223	40	554	570	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 10	1994	264	5165					1604	1608		10.1126/science.8202715	http://dx.doi.org/10.1126/science.8202715			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ285	8202715				2022-12-01	WOS:A1994NQ28500041
J	COGNE, M; LANSFORD, TR; BOTTARO, A; ZHANG, J; GORMAN, J; YOUNG, F; CHENG, HL; ALT, FW				COGNE, M; LANSFORD, TR; BOTTARO, A; ZHANG, J; GORMAN, J; YOUNG, F; CHENG, HL; ALT, FW			CLASS SWITCH CONTROL REGION AT THE 3' END OF THE IMMUNOGLOBULIN HEAVY-CHAIN LOCUS	CELL			English	Article							BETA-GLOBIN LOCUS; MURINE-B-CELLS; GROWTH FACTOR-BETA; CONSTANT-REGION; C-EPSILON; INTERFERON-GAMMA; IGH ENHANCER; GENE; EXPRESSION; TRANSCRIPTS	We replaced the IgH 3' enhancer (3'E(H)) region with a neomycin resistance gene in ES cells and generated chimeric mice in which all mature lymphocytes were either heterozygous (3'E(H)(+/-)) or homozygous (3'E(H)(-/-)) for the mutation. In vitro activated 3'E(H)(-/-) B cells responded similarly to 3'E(H)(+/-) B cells with respect to proliferation and secretion of IgM and IgG1 but were specifically deficient in IgG2a, IgG2b, IgG3, and IgE secretion. These isotype deficiencies correlated with a deficiency in accumulation of transcripts from and class switching to affected C-H genes. In vivo, chimeric mice containing only 3'E(H)(-/-) B cells were deficient in serum IgG2a and IgG3. We propose that the 3'E(H)(-/-) mutation disrupts the activity of a regulatory region that influences heavy chain class switching to several different C-H genes that lie as far as 100 kb upstream of the mutation.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; FAC SCI POITIERS, INST BIOL MOLEC & INGN GENET, CNRS, URA 1172, F-86022 POITIERS, FRANCE; UNIV SIENA, POLICLIN SCOTTE, DIPARTIMENTO BIOL MOLEC, I-53100 SIENA, ITALY	Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); University of Siena	COGNE, M (corresponding author), HARVARD UNIV, CHILDRENS HOSP, SCH MED, HOWARD HUGHES MED INST, CTR BLOOD RES, BOSTON, MA 02115 USA.		cogné, michel/D-7370-2015; Bottaro, Andrea/L-1831-2017	cogné, michel/0000-0002-8519-4427; Bottaro, Andrea/0000-0003-1712-6796; Lansford, Rusty/0000-0002-2159-3699	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020047, U01AI031541, R37AI020047, U19AI031541] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31541, AI-20047] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1982, NATURE, V296, P325, DOI 10.1038/296325a0; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; BURSTEIN HJ, 1991, J IMMUNOL, V147, P2950; CALVO CF, 1991, J IMMUNOL, V146, P1353; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; CORY S, 1980, CELL, V19, P37, DOI 10.1016/0092-8674(80)90386-4; CROCE CM, 1985, BLOOD, V65, P1; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DAVIS MM, 1980, SCIENCE, V209, P1360, DOI 10.1126/science.6774415; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; ESSER C, 1989, EMBO J, V8, P483, DOI 10.1002/j.1460-2075.1989.tb03401.x; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; FIERING S, 1993, P NATL ACAD SCI USA, V90, P8469, DOI 10.1073/pnas.90.18.8469; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GIANNINI SL, 1993, J IMMUNOL, V150, P1772; GREGOR PD, 1986, MOL CELL BIOL, V6, P1903, DOI 10.1128/MCB.6.6.1903; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HAMILTON RG, 1987, CLIN CHEM, V33, P1707; HIRANO T, 1988, INT ARCH ALLER A IMM, V85, P47, DOI 10.1159/000234473; HONJO T, 1978, P NATL ACAD SCI USA, V75, P2140, DOI 10.1073/pnas.75.5.2140; HUMMEL M, 1987, J IMMUNOL, V138, P3539; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; KATAOKA T, 1980, P NATL ACAD SCI-BIOL, V77, P919, DOI 10.1073/pnas.77.2.919; KATAOKA T, 1981, CELL, V23, P357, DOI 10.1016/0092-8674(81)90131-8; KEARNEY JF, 1976, J IMMUNOL, V117, P1567; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KLEIN S, 1984, EMBO J, V3, P2473, DOI 10.1002/j.1460-2075.1984.tb02158.x; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; LAYTON JE, 1984, J EXP MED, V160, P1850, DOI 10.1084/jem.160.6.1850; LEBMAN DA, 1990, J IMMUNOL, V144, P952; LI SC, 1994, INT IMMUNOL, V6, P491, DOI 10.1093/intimm/6.4.491; LIEBERSON R, 1991, NUCLEIC ACIDS RES, V19, P933, DOI 10.1093/nar/19.4.933; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; LUTZKER S, 1988, MOL CELL BIOL, V8, P1849, DOI 10.1128/MCB.8.4.1849; LUTZKER S, 1988, MOBILE DNA, P691; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATTHIAS P, 1993, MOL CELL BIOL, V13, P1547, DOI 10.1128/MCB.13.3.1547; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NIKAIDO T, 1982, J BIOL CHEM, V257, P7322; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; PARKS DR, 1986, HDB EXPT IMMUNOLOGY; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; RABBITTS TH, 1980, NATURE, V283, P351, DOI 10.1038/283351a0; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; ROTHMAN P, 1990, INT IMMUNOL, V2, P621, DOI 10.1093/intimm/2.7.621; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAFFER A, 1991, IMMUNODEFICIENCY REV, V3, P15; SEN R, 1989, IMMUNOGLOBULIN GENES, P327; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SIDERAS P, 1992, J IMMUNOL, V149, P244; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SNAPPER CM, 1988, J IMMUNOL, V140, P2121; SNAPPER CM, 1993, IMMUNOL TODAY, V14, P15, DOI 10.1016/0167-5699(93)90318-F; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; WABL MR, 1984, P NATL ACAD SCI-BIOL, V81, P2452, DOI 10.1073/pnas.81.8.2452; WINTER E, 1987, EMBO J, V6, P1663, DOI 10.1002/j.1460-2075.1987.tb02415.x; XU LX, 1993, P NATL ACAD SCI USA, V90, P3705, DOI 10.1073/pnas.90.8.3705; XU MZ, 1992, EMBO J, V11, P145, DOI 10.1002/j.1460-2075.1992.tb05037.x; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x; ZALLER DM, 1985, P NATL ACAD SCI USA, V82, P5088, DOI 10.1073/pnas.82.15.5088; ZHANG J, 1993, EMBO J, V12, P3529, DOI 10.1002/j.1460-2075.1993.tb06027.x	76	234	239	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	1994	77	5					737	747		10.1016/0092-8674(94)90057-4	http://dx.doi.org/10.1016/0092-8674(94)90057-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NQ123	8205622				2022-12-01	WOS:A1994NQ12300013
J	ROWLANDS, T; BAUMANN, P; JACKSON, SP				ROWLANDS, T; BAUMANN, P; JACKSON, SP			THE TATA-BINDING PROTEIN - A GENERAL TRANSCRIPTION FACTOR IN EUKARYOTES AND ARCHAEBACTERIA	SCIENCE			English	Article							POLYMERASE-III TRANSCRIPTION; DEPENDENT RNA-POLYMERASES; ACTIVATION DOMAIN BINDS; CRYSTAL-STRUCTURE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; MUTATIONAL ANALYSIS; FUNCTIONAL DOMAINS; PYROCOCCUS-WOESEI	The TATA-binding protein TBP appears to be essential for all transcription in eukaryotic cell nuclei, which suggests that its function was established early in evolution. Archaebacteria constitute a kingdom of organisms distinct from eukaryotes and eubacteria. Archaebacterial gene regulatory sequences often map to TATA box-like motifs. Here it is shown that the archaebacterium Pyrococcus woesei expresses a protein with structural and functional similarity to eukaryotic TBP molecules. This suggests that TBP's role in transcription was established before the archaebacterial and eukaryotic lineages diverged and that the transcription systems of archaebacteria and eukaryotes are fundamentally homologous.	UNIV CAMBRIDGE,WELLCOME CANC RES CAMPAIGN INST,CAMBRIDGE CB2 1QR,CAMBS,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,CAMBS,ENGLAND	University of Cambridge; University of Cambridge			Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; Baumann, Peter/0000-0003-4892-1485	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURLEY S, COMMUNICATION; CAMMARANO P, 1992, J MOL EVOL, V34, P396, DOI 10.1007/BF00162996; CARLES C, 1991, J BIOL CHEM, V266, P24092; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; CRETI R, 1993, NUCLEIC ACIDS RES, V21, P2942, DOI 10.1093/nar/21.12.2942; CRETI R, 1991, J MOL EVOL, V33, P332, DOI 10.1007/BF02102864; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; HAIN J, 1992, NUCLEIC ACIDS RES, V20, P5423, DOI 10.1093/nar/20.20.5423; HAUSNER W, 1991, J MOL BIOL, V222, P495, DOI 10.1016/0022-2836(91)90492-O; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HUDEPOHL U, 1990, P NATL ACAD SCI USA, V87, P5851, DOI 10.1073/pnas.87.15.5851; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; JACKSON SP, IN PRESS TRENDS GENE; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLENK HP, 1992, P NATL ACAD SCI USA, V89, P407, DOI 10.1073/pnas.89.1.407; LANGER D, 1993, NUCLEIC ACIDS RES, V21, P2251, DOI 10.1093/nar/21.9.2251; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MCANDREW MB, 1993, GENE, V124, P165, DOI 10.1016/0378-1119(93)90390-O; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIKOLOV DB, 1992, NATURE, V369, P49; OUZOUNIS C, 1992, CELL, V71, P189, DOI 10.1016/0092-8674(92)90347-F; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; THOMM M, 1988, NUCLEIC ACIDS RES, V16, P151, DOI 10.1093/nar/16.1.151; White R.C., UNPUB; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844	50	162	164	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 27	1994	264	5163					1326	1329		10.1126/science.8191287	http://dx.doi.org/10.1126/science.8191287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN767	8191287				2022-12-01	WOS:A1994NN76700045
J	YORK, IA; ROOP, C; ANDREWS, DW; RIDDELL, SR; GRAHAM, FL; JOHNSON, DC				YORK, IA; ROOP, C; ANDREWS, DW; RIDDELL, SR; GRAHAM, FL; JOHNSON, DC			A CYTOSOLIC HERPES-SIMPLEX VIRUS PROTEIN INHIBITS ANTIGEN PRESENTATION TO CD8(+) T-LYMPHOCYTES	CELL			English	Article							HUMAN ADENOVIRUS TYPE-5; MONOCLONAL-ANTIBODIES; GLYCOPROTEIN-D; DELETION MUTANTS; CELLS; GENE; EXPRESSION; DNA; IDENTIFICATION; RECOMBINANT	Herpes simplex virus (HSV) infection of human fibroblasts rapidly renders the cells resistant to lysis by HSV-specific CD8(+) cytotoxic T lymphocytes (CTLs), which normally recognize cell surface major histocompatibility complex (MHC) class I proteins presenting viral peptides. Within 3 hr of infection with HSV, MHC class I protein complexes are retained in the endoplasmic reticulum (ER)/cis Golgi and show properties of complexes lacking antigenic peptide. The HSV immediate-early protein ICP47 is both necessary and sufficient to block transport of class I proteins and to inhibit lysis by CD8(+) CTLs. The target for ICP47 is not known, but since ICP47 does not associate with membranes, it appears that ICP47 inhibits the production or stabilization of antigenic peptides or their translocation into the ER/cis Golgi. Thus, by expressing ICP47, HSV can evade detection by CD8(+) T lymphocytes, perhaps explaining the predominance of CD4(+) rather than CD8(+) HSV-specific CTLs in vivo.	MCMASTER UNIV,DEPT BIOL,HAMILTON L8N 3Z5,ON,CANADA; MCMASTER UNIV,DEPT BIOCHEM,MOLEC VIROL & IMMUNOL PROGRAM,HAMILTON L8N 3Z5,ON,CANADA; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	McMaster University; McMaster University; Fred Hutchinson Cancer Center	YORK, IA (corresponding author), MCMASTER UNIV,DEPT PATHOL,1200 MAIN ST W,HAMILTON L8N 3Z5,ON,CANADA.		York, Ian/X-9351-2019	York, Ian/0000-0002-3478-3344; Andrews, David/0000-0002-9266-7157	NCI NIH HHS [CA15029] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON M, 1985, CELL, V43, P251; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ATKINSON PH, 1971, J BIOL CHEM, V246, P5162; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BONNEAU RH, 1993, VIROLOGY, V195, P62, DOI 10.1006/viro.1993.1346; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; CARTER VC, 1984, J VIROL, V49, P766, DOI 10.1128/JVI.49.3.766-771.1984; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; DELUCA NA, 1985, J VIROL, V56, P558, DOI 10.1128/JVI.56.2.558-570.1985; DELVAL M, 1992, J EXP MED, V176, P729, DOI 10.1084/jem.176.3.729; DIXON RAF, 1980, J VIROL, V36, P189, DOI 10.1128/JVI.36.1.189-203.1980; EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357; FALK K, 1993, IMMUNOGENETICS, V38, P161, DOI 10.1007/BF00190906; FEENSTRA V, 1990, J VIROL, V64, P2096, DOI 10.1128/JVI.64.5.2096-2102.1990; FRANK I, 1989, J VIROL, V63, P3435; FRIEDMAN HM, 1984, NATURE, V309, P633, DOI 10.1038/309633a0; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; GOODING LR, 1979, J IMMUNOL, V122, P1002; GOODING LR, 1992, CELL, V71, P5; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HANKE T, 1991, J VIROL, V65, P1177, DOI 10.1128/JVI.65.3.1177-1186.1991; JANIAK F, 1994, IN PRESS BIOCH J; JANIAK F, 1994, IN PRESS J BIOL CHEM; JOHNSON DC, 1987, J VIROL, V61, P2208, DOI 10.1128/JVI.61.7.2208-2216.1987; JOHNSON DC, 1988, J VIROL, V62, P1347, DOI 10.1128/JVI.62.4.1347-1354.1988; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KOELLE DM, 1993, J CLIN INVEST, V91, P961, DOI 10.1172/JCI116317; LIGAS MW, 1988, J VIROL, V62, P1486, DOI 10.1128/JVI.62.5.1486-1494.1988; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MAVROMARANAZOS P, 1986, J VIROL, V60, P807, DOI 10.1128/JVI.60.2.807-812.1986; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; MCFADDEN G, 1993, IN PRESS ADV CANCER; MCGEOCH DJ, 1985, J MOL BIOL, V181, P1, DOI 10.1016/0022-2836(85)90320-1; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MINSON AC, 1986, J GEN VIROL, V67, P1001, DOI 10.1099/0022-1317-67-6-1001; MURCHIE MJ, 1982, J GEN VIROL, V62, P1, DOI 10.1099/0022-1317-62-1-1; PALFREYMAN JW, 1984, J GEN VIROL, V65, P865, DOI 10.1099/0022-1317-65-5-865; PARHAM P, 1979, J IMMUNOL, V123, P342; PFIZENMAIER K, 1977, J IMMUNOL, V119, P939; POSAVAD CM, 1992, J VIROL, V66, P6264, DOI 10.1128/JVI.66.11.6264-6272.1992; POSAVAD CM, 1993, J IMMUNOL, V151, P4865; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; RIDDELL SR, 1991, J IMMUNOL, V146, P2795; RINALDO CR, 1978, J IMMUNOL, V120, P130; ROIZMAN B, 1990, P1795; SACKS WR, 1987, J VIROL, V61, P629; SCHMID DS, 1992, HERPES SIMPLEX VIRUS, P57; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SEARS AE, 1985, J VIROL, V55, P338, DOI 10.1128/JVI.55.2.338-346.1985; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SMIBERT CA, 1990, J VIROL, V64, P3882, DOI 10.1128/JVI.64.8.3882-3894.1990; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; STAM NJ, 1986, J IMMUNOL, V137, P2299; TIGGES MA, 1992, J VIROL, V66, P1622, DOI 10.1128/JVI.66.3.1622-1634.1992; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; UMENE K, 1986, J GEN VIROL, V67, P1035, DOI 10.1099/0022-1317-67-6-1035; VESTEY JP, 1989, CLIN EXP IMMUNOL, V77, P384; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; WATSON RJ, 1980, NATURE, V285, P329, DOI 10.1038/285329a0; WAYS JP, 1986, J IMMUNOL, V137, P217; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; YORK IA, 1993, J INFECT DIS, V168, P1127, DOI 10.1093/infdis/168.5.1127; ZWEERINK HJ, 1981, INFECT IMMUN, V31, P624, DOI 10.1128/IAI.31.2.624-630.1981	67	459	478	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					525	535		10.1016/0092-8674(94)90215-1	http://dx.doi.org/10.1016/0092-8674(94)90215-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	8187174				2022-12-01	WOS:A1994NM83200008
J	FERGUSON, A; SEDGWICK, DM				FERGUSON, A; SEDGWICK, DM			JUVENILE-ONSET INFLAMMATORY BOWEL-DISEASE - HEIGHT AND BODY-MASS INDEX IN ADULT LIFE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CROHNS-DISEASE; ULCERATIVE-COLITIS; SCOTTISH CHILDREN; GROWTH; ADOLESCENTS; SURGERY; PROGNOSIS; RESECTION	Objective-To establish the frequency of permanent growth failure in juvenile onset inflammatory bowel disease. Design-Measurement of height and weight in a geographically based cohort at a mean of 14 (range 5.2-29.5) years after diagnosis. Comparison with data from surveys of British adults in 1980 and 1987. Setting-NHS hospitals throughout Scotland. Subjects-105 Children admitted to hospital during 1968-83 who fulfilled diagnostic criteria for Crohn's disease or ulcerative colitis and lived in specified regions. 87 were aged over 18 and living in Britain at follow up. Main outcome measures-Height, weight, body mass index, and sexual maturity. Results-All patients were sexually mature. 67 of the 70 patients examined were of normal height, and three women with Crohn's disease were abnormally short. Weight and body mass index were normal in all patients with ulcerative colitis. Patients with Crohn's disease had significantly lower weight than those with ulcerative colitis (men 66.8 (9.5) kg v 78.4 (13.8) kg, P = 0.04; women 51.5 (8.2) kg v 63.0 (12.1) kg, P<0.02) irrespective of disease activity. Body mass index was also significantly lower than the normal distribution (P<0.01). Growth retardation was not mentioned as a problem for any of the 17 patients interviewed only by telephone. Conclusions-Despite growth retardation in the teenage years most young people with inflammatory bowel disease will eventually achieve normal height. Reasons for lower weight in patients with Crohn's disease remain to be established.			FERGUSON, A (corresponding author), WESTERN GEN HOSP, DEPT MED, GASTROINTESTINAL UNIT, EDINBURGH EH4 2XU, SCOTLAND.							BARTON JR, 1990, Q J MED, V75, P423; BARTON JR, 1989, GUT, V30, P618, DOI 10.1136/gut.30.5.618; BARTON JR, 1989, BRIT MED J, V298, P865, DOI 10.1136/bmj.298.6677.865; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; CASTILE RG, 1980, J PEDIATR SURG, V15, P462, DOI 10.1016/S0022-3468(80)80754-8; CLEMMONS DR, 1985, AM J CLIN NUTR, V41, P191, DOI 10.1093/ajcn/41.2.191; FARTHING MJG, 1981, GUT, V22, P933, DOI 10.1136/gut.22.11.933; FERGUSON A, IN PRESS J R COLL PH; FERGUSON A, IN PRESS GUT; GREGORY J, 1990, DIET NUTRITIONAL SUR; GRIFFITHS AM, 1993, GUT, V34, P939, DOI 10.1136/gut.34.7.939; HOMER DR, 1977, PEDIATRICS, V59, P717; KANOF ME, 1988, GASTROENTEROLOGY, V95, P1523, DOI 10.1016/S0016-5085(88)80072-6; KIRSCHNER BS, 1990, ACTA PAEDIATR SCAND, P98; KIRSCHNER BS, 1986, GASTROENTEROLOGY, V91, P830, DOI 10.1016/0016-5085(86)90683-9; KNIGHT I, 1984, HEIGHTS WEIGHTS ADUL; KUSHNER RF, 1991, AM J CLIN NUTR, V53, P161, DOI 10.1093/ajcn/53.1.161; LIPSON AB, 1990, EUR J PEDIATR, V149, P687, DOI 10.1007/BF01959522; MARKOWITZ J, 1993, J PEDIATR GASTR NUTR, V16, P373, DOI 10.1097/00005176-199305000-00005; MCLAIN BI, 1990, ARCH DIS CHILD, V65, P760, DOI 10.1136/adc.65.7.760; MOTIL KJ, 1993, GASTROENTEROLOGY, V105, P681, DOI 10.1016/0016-5085(93)90883-E; SEDGWICK DM, 1991, BRIT J SURG, V78, P171, DOI 10.1002/bjs.1800780212; SEDGWICK DM, 1991, BRIT J SURG, V78, P176, DOI 10.1002/bjs.1800780213; SEIDMAN EG, 1987, DIGEST DIS SCI, V32, pS82, DOI 10.1007/BF01312470	24	64	64	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 14	1994	308	6939					1259	1263		10.1136/bmj.308.6939.1259	http://dx.doi.org/10.1136/bmj.308.6939.1259			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM147	8205017	Green Published			2022-12-01	WOS:A1994NM14700015
J	EVANS, TC; CRITTENDEN, SL; KODOYIANNI, V; KIMBLE, J				EVANS, TC; CRITTENDEN, SL; KODOYIANNI, V; KIMBLE, J			TRANSLATIONAL CONTROL OF MATERNAL GLP-1 MESSENGER-RNA ESTABLISHES AN ASYMMETRY IN THE C-ELEGANS EMBRYO	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; CAENORHABDITIS-ELEGANS; DROSOPHILA EMBRYO; CELL-INTERACTIONS; CYTOPLASMIC LOCALIZATION; PATTERN-FORMATION; BODY PATTERN; GERM-LINE; NOTCH; PROTEIN	In C. elegans, the glp-1 gene encodes a membrane receptor that is required for anterior cell fates in the early embryo. We report that GLP-1 protein is focalized to anterior blastomeres in 2- to 28-cell embryos. By contrast, glp-1 mRNA is present in all blastomeres until the 8-cell stage. Furthermore, the glp-1 3' untranslated region can restrict translation of a reporter mRNA to anterior blastomeres. Therefore, the translation of maternal glp-1 mRNA is temporally and spatially regulated in the C. elegans embryo. The regulation of maternal glp-1 mRNA has striking parallels to the regulation of maternal hunchback mRNA in the Drosophila embryo. Thus, the establishment of embryonic asymmetry in diverse organisms may involve conserved mechanisms of maternal mRNA regulation.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	EVANS, TC (corresponding author), UNIV WISCONSIN, MOLEC BIOL LAB, MADISON, WI 53706 USA.							AHRINGER J, 1992, EMBO J, V11, P2303, DOI 10.1002/j.1460-2075.1992.tb05289.x; ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; Ausubel F.M., 1994, CURRENT PROTOCOLS MO; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; BRENNER S, 1974, GENETICS, V77, P71; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Evans T.C., 1992, Seminars in Developmental Biology, V3, P381; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KODOYIANNI V, 1992, MOL BIOL CELL, V3, P1199, DOI 10.1091/mbc.3.11.1199; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MACDONALD PM, 1992, SEMIN DEV BIOL, V3, P413; MACLEOD AR, 1977, J MOL BIOL, V114, P133, DOI 10.1016/0022-2836(77)90287-X; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MORTON DG, 1992, GENETICS, V130, P771; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; PADDOCK SW, 1993, BIOTECHNIQUES, V14, P42; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; ROUSSELL DL, 1993, P NATL ACAD SCI USA, V90, P9300, DOI 10.1073/pnas.90.20.9300; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TREIER M, 1989, EMBO J, V8, P1517, DOI 10.1002/j.1460-2075.1989.tb03536.x; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	58	198	201	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 22	1994	77	2					183	194		10.1016/0092-8674(94)90311-5	http://dx.doi.org/10.1016/0092-8674(94)90311-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168128				2022-12-01	WOS:A1994NH63400004
J	HEMMATIBRIVANLOU, A; MELTON, DA				HEMMATIBRIVANLOU, A; MELTON, DA			INHIBITION OF ACTIVIN RECEPTOR SIGNALING PROMOTES NEURALIZATION IN XENOPUS	CELL			English	Article							NEURAL DIFFERENTIATION; NERVOUS-SYSTEM; MESSENGER-RNA; HOMEO PROTEIN; VEGETAL POLE; BODY AXIS; EMBRYOS; LAEVIS; EXPRESSION; INDUCTION	Expression of a truncated activin type II receptor, which blocks signaling by activin, neuralizes explants of embryonic cells that would otherwise become epidermal cells. This neuralization is direct and does not require the presence of mesoderm. The induced neural tissue expresses general molecular markers of the central nervous system as well as an array of neural markers along the anteroposterior axis. In the context of the whole embryo, expression of this truncated activin receptor diverts prospective ectoderm and endoderm to a neural fate. We propose that inhibition of the activin type II receptor signaling causes the cells of Xenopus embryos to adopt a neural fate. These results, along with previous experiments performed in Drosophila, suggest that the formation of the nervous system in vertebrates and invertebrates occurs by a common strategy.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1992, DEVELOPMENT, V115, P67; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BRADLEY LC, 1993, MECH DEVELOP, V40, P73, DOI 10.1016/0925-4773(93)90089-G; CONDIE BG, 1987, DEVELOPMENT, V101, P93; DIXON JE, 1989, DEVELOPMENT, V106, P749; DOHRMANN CE, 1993, DEV BIOL, V157, P474, DOI 10.1006/dbio.1993.1150; DONIACH T, 1992, SCIENCE, V257, P542, DOI 10.1126/science.1636091; FERREIRO B, 1993, MECH DEVELOP, V40, P25, DOI 10.1016/0925-4773(93)90085-C; GODSAVE SF, 1991, DEVELOPMENT, V111, P523; GOOD PJ, 1989, NUCLEIC ACIDS RES, V17, P8000, DOI 10.1093/nar/17.19.8000; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; GRUNZ H, 1990, CELL DIFFER DEV, V32, P117, DOI 10.1016/0922-3371(90)90105-6; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1992, NEURON, V9, P417, DOI 10.1016/0896-6273(92)90180-L; HEMMATIBRIVANLOU A, 1992, DEV DYNAM, V194, P1, DOI 10.1002/aja.1001940102; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KLEIN PS, 1994, IN PRESS ENDOCRINE R; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; MALACINSKI G, 1975, DEV BIOL, V56, P24; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MOODY SA, 1990, ANAT EMBRYOL, V182, P347, DOI 10.1007/BF02433495; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NIEUWKOOP PD, 1985, J EMBRYOL EXP MORPH, V89, P333; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; RAO Y, 1991, GENE DEV, V5, P1577, DOI 10.1101/gad.5.9.1577; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; SAHA MS, 1993, MOL BRAIN RES, V17, P307, DOI 10.1016/0169-328X(93)90016-I; SATO SM, 1989, DEV BIOL, V134, P263, DOI 10.1016/0012-1606(89)90096-1; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SCHARF SR, 1983, DEV BIOL, V99, P75, DOI 10.1016/0012-1606(83)90255-5; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; Sporn M. B., 1990, PEPTIDE GROWTH FACTO; STUTZ F, 1986, J MOL BIOL, V187, P349, DOI 10.1016/0022-2836(86)90438-9; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225; WYLIE CC, 1987, DEV BIOL, V119, P496, DOI 10.1016/0012-1606(87)90052-2; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	54	372	381	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					273	281		10.1016/0092-8674(94)90319-0	http://dx.doi.org/10.1016/0092-8674(94)90319-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168134				2022-12-01	WOS:A1994NH63400012
J	MAGNUSON, R; SOLOMON, J; GROSSMAN, AD				MAGNUSON, R; SOLOMON, J; GROSSMAN, AD			BIOCHEMICAL AND GENETIC-CHARACTERIZATION OF A COMPETENCE PHEROMONE FROM BACILLUS-SUBTILIS	CELL			English	Article							SIGNAL TRANSDUCTION SYSTEM; BACILLUS-SUBTILIS; MYXOCOCCUS-XANTHUS; REGULATORY GENE; OLIGOPEPTIDE PERMEASE; SURFACTIN PRODUCTION; NUCLEOTIDE-SEQUENCE; SPORULATION; COMA; PROTEIN	We have purified and characterized a modified peptide pheromone that accumulates in culture medium as B. subtilis grows to high density. This pheromone is required for the development of genetic competence. When added to cells at low density, the pheromone induces the premature development of competence. The peptide moiety of the pheromone matches nine of the last ten amino acids predicted from a 55 codon open reading frame, comX. comX and comQ, the gene immediately upstream of comX, are required for production of the pheromone. Response to the pheromone requires the comP-comA two-component regulatory system and the oligopeptide permease encoded by spoOK. SpoOK could transport the pheromone into the cell, or function as a receptor, binding the pheromone and sending a transmembrane signal, leading to activation of the ComA transcription factor and induction of competence development.			MAGNUSON, R (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NCRR NIH HHS [RR00317] Funding Source: Medline; NIGMS NIH HHS [GM41934] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041934] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKRIGG A, 1970, BIOCHEM J, V117, P397, DOI 10.1042/bj1170397; AKRIGG A, 1967, BIOCHEM BIOPH RES CO, V28, P1062, DOI 10.1016/0006-291X(67)90090-3; ALBANO M, 1989, J BACTERIOL, V171, P5386, DOI 10.1128/jb.171.10.5386-5404.1989; ALBANO M, 1989, J BACTERIOL, V171, P5376, DOI 10.1128/jb.171.10.5376-5385.1989; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; ANTONIEWSKI C, 1990, J BACTERIOL, V172, P86, DOI 10.1128/JB.172.1.86-93.1990; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CLEWELL DB, 1993, CELL, V73, P9, DOI 10.1016/0092-8674(93)90153-H; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; COX GB, 1989, J BACTERIOL, V171, P1531, DOI 10.1128/jb.171.3.1531-1534.1989; COX GB, 1988, J BACTERIOL, V170, P2283, DOI 10.1128/jb.170.5.2283-2286.1988; Davis R., 1980, ADV BACTERIAL GENETI; DSOUZA C, 1993, J BACTERIOL, V175, P3502, DOI 10.1128/jb.175.11.3502-3510.1993; DUBNAU D, 1991, MICROBIOL REV, V55, P395, DOI 10.1128/MMBR.55.3.395-424.1991; DUBNAU D, 1991, SEMIN DEV BIOL, V2, P3; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FERRARI FA, 1983, J BACTERIOL, V154, P1513, DOI 10.1128/JB.154.3.1513-1515.1983; FUMA S, 1993, NUCLEIC ACIDS RES, V21, P93, DOI 10.1093/nar/21.1.93; GROSSMAN AD, 1988, P NATL ACAD SCI USA, V85, P4369, DOI 10.1073/pnas.85.12.4369; GROSSMAN AD, 1991, SEMIN DEV BIOL, V2, P31; HAHN J, 1991, J BACTERIOL, V173, P7275, DOI 10.1128/jb.173.22.7275-7282.1991; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HUI FM, 1991, J BACTERIOL, V173, P372, DOI 10.1128/jb.173.1.372-381.1991; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; ITAYA M, 1989, NUCLEIC ACIDS RES, V17, P4410, DOI 10.1093/nar/17.11.4410; JAACKS KJ, 1989, J BACTERIOL, V171, P4121, DOI 10.1128/JB.171.8.4121-4129.1989; JOENJE H, 1972, BIOCHIM BIOPHYS ACTA, V262, P189, DOI 10.1016/0005-2787(72)90232-8; KAISER D, 1993, CELL, V73, P873, DOI 10.1016/0092-8674(93)90268-U; KAPLAN HB, 1991, J BACTERIOL, V173, P1460, DOI 10.1128/jb.173.4.1460-1470.1991; KIM SK, 1992, ANNU REV MICROBIOL, V46, P117, DOI 10.1146/annurev.mi.46.100192.001001; KIM SK, 1990, P NATL ACAD SCI USA, V87, P3635, DOI 10.1073/pnas.87.10.3635; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; KUSPA A, 1992, J BACTERIOL, V174, P3319, DOI 10.1128/jb.174.10.3319-3326.1992; LACKS S, 1973, J BACTERIOL, V114, P152; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; Miller JH., 1972, EXPT MOL GENETICS; MITANI T, 1977, BIOCHEM BIOPH RES CO, V77, P1118, DOI 10.1016/S0006-291X(77)80094-6; MSADEK T, 1991, J BACTERIOL, V173, P2366, DOI 10.1128/JB.173.7.2366-2377.1991; MUELLER JP, 1992, J BACTERIOL, V174, P4361, DOI 10.1128/JB.174.13.4361-4373.1992; NAKANO MM, 1989, J BACTERIOL, V171, P5347, DOI 10.1128/jb.171.10.5347-5353.1989; NAKANO MM, 1991, J BACTERIOL, V173, P1770, DOI 10.1128/jb.173.5.1770-1778.1991; NAKANO MM, 1991, J BACTERIOL, V173, P5487, DOI 10.1128/jb.173.17.5487-5493.1991; NAKANO MM, 1988, J BACTERIOL, V170, P5662, DOI 10.1128/jb.170.12.5662-5668.1988; NAKANO MM, 1991, J BACTERIOL, V173, P7269, DOI 10.1128/jb.173.22.7269-7274.1991; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; RHIE HG, 1989, J BACTERIOL, V171, P3268, DOI 10.1128/jb.171.6.3268-3276.1989; ROGGIANI M, 1993, J BACTERIOL, V175, P3182, DOI 10.1128/JB.175.10.3182-3187.1993; ROGGIANI M, 1990, J BACTERIOL, V172, P4056, DOI 10.1128/jb.172.7.4056-4063.1990; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; RUHFEL RE, 1993, J BACTERIOL, V175, P5253, DOI 10.1128/JB.175.16.5253-5259.1993; SADAIE Y, 1983, J BACTERIOL, V153, P813, DOI 10.1128/JB.153.2.813-821.1983; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; SHIMKETS LJ, 1990, J BACTERIOL, V172, P5299, DOI 10.1128/jb.172.9.5299-5306.1990; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; STEED PM, 1993, J BACTERIOL, V175, P6797, DOI 10.1128/jb.175.21.6797-6809.1993; TANIMOTO K, 1993, J BACTERIOL, V175, P5260, DOI 10.1128/JB.175.16.5260-5264.1993; TOMASZ A, 1966, P NATL ACAD SCI USA, V55, P58, DOI 10.1073/pnas.55.1.58; TOMASZ A, 1964, P NATL ACAD SCI USA, V51, P480, DOI 10.1073/pnas.51.3.480; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7523, DOI 10.1128/JB.175.23.7523-7532.1993; VANSINDEREN D, 1990, MOL GEN GENET, V224, P396, DOI 10.1007/BF00262434; VANSINDEREN D, 1993, MOL MICROBIOL, V8, P833; VASANTHA N, 1980, J BACTERIOL, V144, P1119, DOI 10.1128/JB.144.3.1119-1125.1980; WALDBURGER C, 1993, J BACTERIOL, V175, P6321, DOI 10.1128/JB.175.19.6321-6327.1993; WEINRAUCH Y, 1989, J BACTERIOL, V171, P5362, DOI 10.1128/jb.171.10.5362-5375.1989; WEINRAUCH Y, 1990, GENE DEV, V4, P860, DOI 10.1101/gad.4.5.860; WEINRAUCH Y, 1991, J BACTERIOL, V173, P5685, DOI 10.1128/jb.173.18.5685-5693.1991; YANG M, 1986, J BACTERIOL, V166, P133; YOUNGMAN P, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P65	73	370	382	1	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					207	216		10.1016/0092-8674(94)90313-1	http://dx.doi.org/10.1016/0092-8674(94)90313-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168130				2022-12-01	WOS:A1994NH63400006
J	MORRISON, NA; QI, JC; TOKITA, A; KELLY, PJ; CROFTS, L; NGUYEN, TV; SAMBROOK, PN; EISMAN, JA				MORRISON, NA; QI, JC; TOKITA, A; KELLY, PJ; CROFTS, L; NGUYEN, TV; SAMBROOK, PN; EISMAN, JA			PREDICTION OF BONE-DENSITY FROM VITAMIN-D RECEPTOR ALLELES	NATURE			English	Article							OSTEOCALCIN GENE; PHYSICAL-FITNESS; MINERAL DENSITY; FEMORAL-NECK; MASS; TWIN; OSTEOPOROSIS; DETERMINANTS; SPINE; WOMEN	BONE density achieved in early adulthood is the major determinant of risk of osteoporotic fracture. Up to 60% of women1,2 suffer osteoporotic fractures as a result of low bone density2, which is under strong genetic control-3-6 acting through effects on bone turnover 7, 8. Here we show that common allelic variants in the gene encoding the vitamin D receptor9 can be used to predict differences in bone density, accounting for up to 75% of the total genetic effect on bone density in healthy individuals. The genotype associated with lower bone density was overrepresented in postmenopausal women with bone densities more than 2 standard deviations below values in young normal women. The molecular mechanisms by which bone density is regulated by the vitamin D receptor gene are not certain, although allelic differences in the 3' untranslated region may alter messenger RNA levels. These findings could open new avenues to the development and targeting of prophylactic interventions. It follows that other pathophysiological processes considered to be subject to complex multifactorial genetic regulation may also be modulated by a single gene with pleiotropic transcriptional actions.			MORRISON, NA (corresponding author), ST VINCENTS HOSP,GARVAN INST MED RES,DIV BONE & MINERAL RES,DARLINGHURST,NSW 2010,AUSTRALIA.							ARVEILER B, 1988, NUCLEIC ACIDS RES, V16, P6252, DOI 10.1093/nar/16.13.6252; BELL NH, 1985, J CLIN INVEST, V76, P470, DOI 10.1172/JCI111995; DEMAY MB, 1989, J BIOL CHEM, V264, P2279; DEQUEKER J, 1987, BONE, V8, P207, DOI 10.1016/8756-3282(87)90166-9; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; HASEMAN JK, 1970, BEHAV GENET, V1, P11, DOI 10.1007/BF01067367; KELLY PJ, 1991, J CLIN ENDOCR METAB, V72, P808, DOI 10.1210/jcem-72-4-808; KELLY PJ, 1990, OSTEOPOROSIS INT, V1, P1; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; MOLLER M, 1978, CALC TISS RES, V25, P197, DOI 10.1007/BF02010768; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; POCOCK N, 1989, J BONE MINER RES, V4, P441; POCOCK NA, 1986, J CLIN INVEST, V78, P618, DOI 10.1172/JCI112618; POCOCK NA, 1987, MED J AUSTRALIA, V146, P293, DOI 10.5694/j.1326-5377.1987.tb120264.x; POCOCK NA, 1988, J BONE MINER RES, V3, P601; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476	21	1646	1815	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					284	287		10.1038/367284a0	http://dx.doi.org/10.1038/367284a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8161378				2022-12-01	WOS:A1994MR49400060
J	ELDEIRY, WS; TOKINO, T; VELCULESCU, VE; LEVY, DB; PARSONS, R; TRENT, JM; LIN, D; MERCER, WE; KINZLER, KW; VOGELSTEIN, B				ELDEIRY, WS; TOKINO, T; VELCULESCU, VE; LEVY, DB; PARSONS, R; TRENT, JM; LIN, D; MERCER, WE; KINZLER, KW; VOGELSTEIN, B			WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION	CELL			English	Article							WILD-TYPE P53; DNA-BINDING SITE; CELL-LINE; COLORECTAL CARCINOMAS; ENHANCED EXPRESSION; GENE-EXPRESSION; GROWTH ARREST; PROTEIN; TRANSCRIPTION; CANCER	The ability of p53 to activate transcription from specific sequences suggests that genes induced by p53 may mediate its biological role as a tumor suppressor. Using a subtractive hybridization approach, we identified a gene, named WAF1, whose induction was associated with wild-type but not mutant p53 gene expression in a human brain tumor cell line. The WAF1 gene was localized to chromosome 6p21.2, and its sequence, structure, and activation by p53 was conserved in rodents. Introduction of WAF1 cDNA suppressed the growth of human brain, lung, and colon tumor cells in culture. Using a yeast enhancer trap, a p53-binding site was identified 2.4 kb upstream of WAF1 coding sequences. The WAF1 promoter, including this p53-binding site, conferred p53-dependent inducibility upon a heterologous reporter gene. These studies define a gene whose expression is directly induced by p53 and that could be an important mediator of p53-dependent tumor growth suppression.	JOHNS HOPKINS UNIV,SCH MED,PROGRAM HUMAN GENET & MOLEC BIOL,BALTIMORE,MD 21231; NATL CTR HUMAN GENOME RES,CANC GENET LAB,BETHESDA,MD 20892; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Jefferson University	ELDEIRY, WS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231, USA.		Velculescu, Victor/ABF-4846-2020; El-Deiry, Wafik/AAJ-6080-2020; Tokino, Takashi/AAI-9887-2021	Velculescu, Victor/0000-0003-1195-438X; El-Deiry, Wafik/0000-0002-9577-8266; Parsons, Ramon/0000-0002-6656-3514	NATIONAL CANCER INSTITUTE [R01CA043460, T32CA009071, R37CA043460] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43460, CA-09071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Battey, 1986, BASIC METHODS MOL BI; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CALRKE AR, 1993, NATURE, V362, P849; CLIBY W, 1993, CANCER RES, V53, P2393; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HALEVY O, 1991, ONCOGENE, V6, P1593; HAMPSON IN, 1992, NUCLEIC ACIDS RES, V20, P2899, DOI 10.1093/nar/20.11.2899; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KERN SE, 1991, SCIENCE, V252, P1707; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MELTZER PS, 1992, NAT GENET, V1, P24, DOI 10.1038/ng0492-24; MERCER W E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P251; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORITA R, 1991, CANCER RES, V51, P820; MUNHOLLAND JM, 1992, EMBO J, V11, P177, DOI 10.1002/j.1460-2075.1992.tb05040.x; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAEGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SATO T, 1991, CANCER RES, V51, P5118; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STERNER DA, 1993, MOL CELL BIOL, V13, P2677, DOI 10.1128/MCB.13.5.2677; TRUNT R, 1993, J BIOL CHEM, V268, P2284; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	73	7728	7919	10	603	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					817	825		10.1016/0092-8674(93)90500-P	http://dx.doi.org/10.1016/0092-8674(93)90500-P			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242752				2022-12-01	WOS:A1993MH74900025
J	CHENG, H; LEDERER, WJ; CANNELL, MB				CHENG, H; LEDERER, WJ; CANNELL, MB			CALCIUM SPARKS - ELEMENTARY EVENTS UNDERLYING EXCITATION-CONTRACTION COUPLING IN HEART-MUSCLE	SCIENCE			English	Article							CA-2+ RELEASE CHANNEL; CARDIAC SARCOPLASMIC-RETICULUM; TRANSIENT INWARD CURRENT; RYANODINE RECEPTOR CHANNEL; SKELETAL-MUSCLE; INTRACELLULAR CALCIUM; PURKINJE-FIBERS; GUINEA-PIG; VENTRICULAR MYOCYTES; MOLECULAR-CLONING	Spontaneous local increases in the concentration of intracellular calcium, called ''calcium sparks,'' were detected in quiescent rat heart cells with a laser scanning confocal microscope and the fluorescent calcium indicator fluo-3. Estimates of calcium flux associated with the sparks suggest that calcium sparks result from spontaneous openings of single sarcoplasmic reticulum (SR) calcium-release channels, a finding supported by ryanodine-dependent changes of spark kinetics. At resting intracellular calcium concentrations, these SR calcium-release channels had a low rate of opening (approximately 0.0001 per second). An increase in the calcium content of the SR, however, was associated with a fourfold increase in opening rate and resulted in some sparks triggering propagating waves of increased intracellular calcium concentration. The calcium spark is the consequence of elementary events underlying excitation-contraction coupling and provides an explanation for both spontaneous and triggered changes in the intracellular calcium concentration in the mammalian heart.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,660 W REDWOOD ST,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR MED BIOTECHNOL,BALTIMORE,MD 21201; ST GEORGE HOSP,SCH MED,DEPT PHARMACOL & CLIN PHARMACOL,LONDON SW17 0RE,ENGLAND	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; St Georges University London			Heping, Cheng/AAE-2680-2019; Lederer, William/B-1285-2010	Heping, Cheng/0000-0002-9604-6702; 				ARLOCK P, 1985, J PHYSIOL-LONDON, V360, P105, DOI 10.1113/jphysiol.1985.sp015606; BERLIN JR, 1987, AM J PHYSIOL, V253, pH1540, DOI 10.1152/ajpheart.1987.253.6.H1540; BERLIN JR, 1989, CIRC RES, V65, P115, DOI 10.1161/01.RES.65.1.115; BERS DM, 1993, AM J PHYSIOL, V264, pC1587, DOI 10.1152/ajpcell.1993.264.6.C1587; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BUCK E, 1992, J BIOL CHEM, V267, P23560; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CANNELL MB, 1985, FED PROC, V44, P2964; CHENG HY, UNPUB, P5019; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; FABIATO A, 1985, J GEN PHYSIOL, V85, P189, DOI 10.1085/jgp.85.2.189; FABIATO A, 1975, J PHYSIOL-LONDON, V249, P469, DOI 10.1113/jphysiol.1975.sp011026; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; HUME JR, 1991, SCIENCE, V251, P1370, DOI 10.1126/science.251.4999.1370-a; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1988, J BIOL CHEM, V263, P10843; KASS RS, 1978, J PHYSIOL-LONDON, V281, P187, DOI 10.1113/jphysiol.1978.sp012416; LAI FA, 1989, J BIOL CHEM, V264, P16776; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LEDERER WJ, 1991, SCIENCE, V251, P1371, DOI 10.1126/science.251.4999.1371; LEVESQUE PC, 1991, ANN NY ACAD SCI, V639, P386, DOI 10.1111/j.1749-6632.1991.tb17327.x; LEW WYW, 1991, CIRC RES, V69, P1139, DOI 10.1161/01.RES.69.4.1139; LIPP P, 1988, J PHYSIOL-LONDON, V397, P601, DOI 10.1113/jphysiol.1988.sp017021; MARBAN E, 1985, CIRC RES, V56, P133, DOI 10.1161/01.RES.56.1.133; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MEISSNER G, 1992, ADV EXP MED BIOL, V311, P277; MINTA A, 1989, J BIOL CHEM, V264, P8171; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; ONEILL SC, 1990, AM J PHYSIOL, V258, pC1165, DOI 10.1152/ajpcell.1990.258.6.C1165; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; SAH P, 1993, NEUROSCIENCE, V54, P157, DOI 10.1016/0306-4522(93)90391-R; SHAM JSK, 1992, SCIENCE, V255, P850, DOI 10.1126/science.1311127; SIPIDO KR, 1991, J PHYSIOL-LONDON, V435, P605, DOI 10.1113/jphysiol.1991.sp018528; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; SUTKO JL, 1985, FED PROC, V44, P2984; TAKAMATSU T, 1990, CELL CALCIUM, V11, P111, DOI 10.1016/0143-4160(90)90064-2; TINKER A, 1992, J GEN PHYSIOL, V100, P495, DOI 10.1085/jgp.100.3.495; VALDEOLMILLOS M, 1989, PFLUG ARCH EUR J PHY, V413, P676, DOI 10.1007/BF00581820; WIER WG, 1986, J PHYSIOL-LONDON, V376, P507, DOI 10.1113/jphysiol.1986.sp016167; WIER WG, 1987, SCIENCE, V235, P325, DOI 10.1126/science.3798114; WIER WG, 1985, FED PROC, V44, P2989; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	52	1589	1658	8	196	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					740	744		10.1126/science.8235594	http://dx.doi.org/10.1126/science.8235594			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235594				2022-12-01	WOS:A1993MD95200042
J	MCLAUGHLIN, JR; KING, WD; ANDERSON, TW; CLARKE, EA; ASHMORE, JP				MCLAUGHLIN, JR; KING, WD; ANDERSON, TW; CLARKE, EA; ASHMORE, JP			PATERNAL RADIATION EXPOSURE AND LEUKEMIA IN OFFSPRING - THE ONTARIO CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							SELLAFIELD NUCLEAR-PLANT; ATOMIC-BOMB SURVIVORS; WEST CUMBRIA; CHILDHOOD LEUKEMIA; DESCRIPTIVE EPIDEMIOLOGY; CHILDREN BORN; YOUNG-PEOPLE; LYMPHOMA; OCCUPATIONS; SEASCALE	Objectives-To test the hypothesis that there is an association between childhood leukaemia and the occupational exposure of fathers to ionising radiation before a child's conception. Design-Case-control study with eight matched controls per case. Setting-Regions of Ontario, Canada, with an operating nuclear facility. Subjects-Cases were children (age 0-14) who died from or were diagnosed as having leukaemia from 1950 to 1988 and were born to mothers living in the vicinity of an operating nuclear facility. Controls were identified from birth certificates, matched by date of birth and residence at birth. There were 112 cases and 890 controls. Main outcome measures-Paternal radiation exposure was determined by a record linkage to the Canadian National Dose Registry. Results-Six fathers of cases and 53 fathers of controls had had a total whole body dose >0.0 mSv before the child's conception, resulting in an odds ratio of 0.87 (95% confidence interval 0.32 to 2.34). There was no evidence of an increased leukaemia risk in relation to any exposure period (lifetime or six months or three months before conception) or exposure type (total whole body dose, external whole body dose, or tritium dose), except for radon exposure to uranium miners, which had a large odds ratio that was not significantly different from the null value. Conclusions-The findings of this study in Ontario did not support the hypothesis that childhood leukaemia is associated with the occupational exposure of fathers to ionising radiation before the child's conception.	ONTARIO CANC TREATMENT & RES FDN,DIV EPIDEMIOL & STAT,TORONTO M5G 2L7,ON,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6M 1K6,BC,CANADA; HLTH & WELF CANADA,BUR RADIAT & MED DEVICES,OTTAWA K1A 0L2,ONTARIO,CANADA	University of British Columbia			McLaughlin, John R/E-4577-2013					ALEXANDER FE, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715-a; ASHMORE JP, 1985, RADIAT PROT DOSIM, V11, P95; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P125; CLARKE EA, 1987, 20 YEARS CANCER INCI, P11; COUROT M, 1970, TESTIS, P390; CRAFT AW, 1984, LANCET, V2, P96; DOLL R, 1989, J ROY STAT SOC A STA, V152, P341, DOI 10.2307/2983131; GARDNER MJ, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715; GARDNER MJ, 1987, BRIT MED J, V295, P819, DOI 10.1136/bmj.295.6602.819; GARDNER MJ, 1990, BRIT MED J, V300, P429, DOI 10.1136/bmj.300.6722.429; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; KINLEN LJ, 1993, BRIT MED J, V306, P1153, DOI 10.1136/bmj.306.6886.1153; LINET MS, 1991, BRIT J CANCER, V63, P424, DOI 10.1038/bjc.1991.98; Little M. P., 1992, Journal of Radiological Protection, V12, P203, DOI 10.1088/0952-4746/12/4/001; LITTLE M P, 1991, Journal of Radiological Protection, V11, P231, DOI 10.1088/0952-4746/11/4/002; MCKINNEY PA, 1991, BRIT MED J, V302, P681, DOI 10.1136/bmj.302.6778.681; MCLAUGHLIN JR, 1993, CANCER CAUSE CONTROL, V4, P51, DOI 10.1007/BF00051714; MCLAUGHLIN JR, 1992, OCCUPATIONAL EXPOSUR; MULLER J, 1983, STUDY MORTALITY ONTA; ROBLES SC, 1988, J CLIN EPIDEMIOL, V41, P495, DOI 10.1016/0895-4356(88)90052-2; ROMAN E, 1993, BMJ-BRIT MED J, V306, P615, DOI 10.1136/bmj.306.6878.615; SORAHAN T, 1993, AM J IND MED, V23, P343, DOI 10.1002/ajim.4700230211; STILLER CA, 1985, LEUKEMIA RES, V9, P671, DOI 10.1016/0145-2126(85)90273-5; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; YOSHIMOTO Y, 1990, AM J HUM GENET, V46, P1041; YOSHIMOTO Y, 1990, JAMA-J AM MED ASSOC, V264, P596, DOI 10.1001/jama.264.5.596; 1988, HLTH RISKS RADON OTH, V4, P492; 1993, LOGXACT; 1986, CENSUS CANADA ONTA 2; 1975, MANUAL INT STATISTIC, V1; 1991, EGRET; 1980, NUCLEAR GENERATING D	34	70	72	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1993	307	6910					959	966		10.1136/bmj.307.6910.959	http://dx.doi.org/10.1136/bmj.307.6910.959			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC441	8241906	Green Published, Bronze			2022-12-01	WOS:A1993MC44100016
J	WILLIAMS, DJ; WILLIAMS, AC; KRUCHEK, DG				WILLIAMS, DJ; WILLIAMS, AC; KRUCHEK, DG			PROBLEMS IN ASSESSING CONTENTS OF METERED-DOSE INHALERS	BRITISH MEDICAL JOURNAL			English	Article							BETA-AGONISTS; ASTHMA		ST PETERS HOSP,CHERTSEY KT16 0PZ,SURREY,ENGLAND		WILLIAMS, DJ (corresponding author), YORK HOUSE MED CTR,HEATHCOT PRACTICE,WOKING GU22 7XL,ENGLAND.							BUCHANAN N, 1987, CHILDHOOD ASTHMA WHA, P73; GLAXO GROUP LTD, 1989, Patent No. 4817822; PEARCE N, 1991, CLIN EXP ALLERGY, V21, P401, DOI 10.1111/j.1365-2222.1991.tb01679.x; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; VATHENEN AS, 1988, LANCET, V1, P554	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1993	307	6907					771	772		10.1136/bmj.307.6907.771	http://dx.doi.org/10.1136/bmj.307.6907.771			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ478	8219948	Bronze, Green Published			2022-12-01	WOS:A1993LZ47800023
J	BAKER, DW; STEVENS, CD; BROOK, RH				BAKER, DW; STEVENS, CD; BROOK, RH			REGULAR SOURCE OF AMBULATORY CARE AND MEDICAL-CARE UTILIZATION BY PATIENTS PRESENTING TO A PUBLIC HOSPITAL EMERGENCY DEPARTMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CITY MINORITY POPULATION; HEALTH-CARE; ACCESS; ROOM; CONSEQUENCES; HYPERTENSION	Objective.-To determine the regular source of care and the relationship between usual provider and use of medical services among ambulatory emergency department patients. Design.-Cross-sectional survey. Setting.-A public hospital in Los Angeles County, California. Patients.-A total of 1190 stable, ambulatory adults presenting to the emergency department during a 2-week period. Main Outcome Measures.-Self-reported regular source of care, usual health status, and recent physician visits. Results.-A total of 16% of the patients identified ah emergency department as their regular source of care. One fourth of this group reported fair or poor health. African Americans and Latinos were more likely than whites to identify an emergency department as their regular source of care. Patients who identified an emergency department as their regular source of care had 25% fewer physician visits and were less likely to have seen a physician during the preceding 3 months than patients who were usually seen in an office or clinic (relative risk, 0.45;95% confidence interval, 0.28 to 0.70). Of all patients, 56% identified; a regular source of care other than an emergency department, but 24% to 36% of all their recent physician visits still occurred in an emergency department. Conclusion.-Our patients rely heavily on emergency departments for ambulatory physician visits, regardless of their reported regular source of care. However, patients who identify an emergency department as their regular source of ambulatory care used physician services less frequently than patients with access to providers in other settings. These issues require further evaluation with population-based surveys.	UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT EMERGENCY MED,TORRANCE,CA; VALUE HLTH SCI,SANTA MONICA,CA; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT HLTH SERV,LOS ANGELES,CA 90024; RAND CORP,HLTH SCI PROGRAM,SANTA MONICA,CA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; RAND Corporation	BAKER, DW (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT MED,DIV GEN INTERNAL MED,TORRANCE,CA 90509, USA.							ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; ADAY LA, 1975, ACCESS MED CARE; ADAY LA, 1980, HLTH CARE US EQUITAB; ALPERT JJ, 1969, MED CARE, V7, P55, DOI 10.1097/00005650-196901000-00007; BAKER DW, 1991, JAMA-J AM MED ASSOC, V266, P1085, DOI 10.1001/jama.266.8.1085; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1091, DOI 10.1001/jama.266.8.1091; BLOOM BL, 1981, VITAL HLTH STAT 10, V148; BUESCHING DP, 1985, ANN EMERG MED, V14, P672, DOI 10.1016/S0196-0644(85)80886-6; CORNELIUS L, 1991, USUAL SOURCES MED CA, V2; DAVIS K, 1981, ANNU REV PUBL HEALTH, V2, P159, DOI 10.1146/annurev.pu.02.050181.001111; FLEMING NS, 1983, MED CARE, V21, P892, DOI 10.1097/00005650-198309000-00006; GOUGH HG, 1977, MED EDUC, V11, P380, DOI 10.1111/j.1365-2923.1977.tb00636.x; GRUMBACH K, 1993, AM J PUBLIC HEALTH, V83, P372, DOI 10.2105/AJPH.83.3.372; GUTTERMAN JJ, 1985, ANN EMERG MED, V14, P1191; HABENSTREIT B, 1986, NEW YORK STATE J MED, V86, P517; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P434, DOI 10.2105/AJPH.81.4.434; JACOBS AR, 1991, JAMA-J AM MED ASSOC, V216, P307; Jones S L, 1985, J Emerg Nurs, V11, P145; KELLERMAN AL, 1991, JAMA-J AM MED ASSOC, V266, P1123, DOI 10.1001/jama.266.8.1123; PERKOFF GT, 1970, MED CARE, V8, P309, DOI 10.1097/00005650-197008040-00007; SCHOENBORN CA, 1988, VITAL HLTH STAT 10, V166; SHEA S, 1992, AM J PUBLIC HEALTH, V82, P1607, DOI 10.2105/AJPH.82.12.1607; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STOCK LM, 1994, ANN EMERG MED, V23, P294, DOI 10.1016/S0196-0644(94)70043-5; VAYDA E, 1975, CAN MED ASSOC J, V112, P961; WEINERMAN RE, 1966, AM J PUBLIC HEALTH, V56, P1037; WOLCOTT BW, 1979, JACEP-J AM COLL EMER, V8, P241; 1980, EMERGENCY DEP REGION, P13; 1992, STATA VERSION 3 0; 1983, RW JOHNSON F UPDATE	31	204	204	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 22	1994	271	24					1909	1912		10.1001/jama.271.24.1909	http://dx.doi.org/10.1001/jama.271.24.1909			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NR598	8201734				2022-12-01	WOS:A1994NR59800026
J	MALATY, HM; ENGSTRAND, L; PEDERSEN, NL; GRAHAM, DY				MALATY, HM; ENGSTRAND, L; PEDERSEN, NL; GRAHAM, DY			HELICOBACTER-PYLORI INFECTION - GENETIC AND ENVIRONMENTAL-INFLUENCES	ANNALS OF INTERNAL MEDICINE			English	Article						HELICOBACTER PYLORI; HELICOBACTER INFECTIONS; TWINS; ENVIRONMENTAL EXPOSURE; HEREDITARY DISEASES	DUODENAL-ULCER DISEASE; CAMPYLOBACTER-PYLORI; PEPSINOGEN-I; EPIDEMIOLOGY; CHILDREN; ANTIBODY; SEROEPIDEMIOLOGY; POPULATION; FAMILIES; IDENTIFICATION	Objective: To investigate the importance of genetic effects for acquiring Helicobacter pylori infection. Design: Cross-sectional study on monozygotic and dizygotic twins, reared apart and reared together. Setting: Twins from a subregistry of the Swedish Twin Registry, which includes entries for about 25 000 twin pairs who were born in Sweden. Measurements: Helicobacter pylori status was assessed as the presence of anti-H pylori IgG in 269 pairs of twins, including 36 monozygotic twin pairs reared apart, 64 monozygotic twin pairs reared together, 88 dizygotic twin pairs reared apart, and 81 dizygotic twin pairs reared together. Results: The probandwise concordance rate for H. pylori infection was higher in monozygotic twin pairs (81%) than in dizygotic twin pairs (63%) (P = 0.001). Probandwise concordance rates for H. pylori infection among 124 pairs of twins reared apart were 82% and 66% for monozygotic and dizygotic twins, respectively (P = 0.003). The correlation coefficient was 0.66 for monozygotic twins reared apart, and it provides the best single estimate of the relative importance of genetic effects (heritability) for variation in the acquisition of H. pylori infection. The heritability estimate from model-fitting analyses was 0.57, a similar result. The remaining variance was accounted for by shared rearing environmental (20%) and nonshared environmental factors (23%). The latter contribute to differences, not similarities, among family members. Conclusion: This twin study showed that genetic effects influence the acquisition of H. pylori infection because of greater similarities within the monozygotic twin pairs. Further, sharing the same rearing environment also contributes to the familiar tendency for acquiring H. pylori infection.	UNIV UPPSALA HOSP, DEPT CLIN MICROBIOL, S-75185 UPPSALA, SWEDEN; KAROLINSKA INST, DIV EPIDEMIOL, S-17177 STOCKHOLM, SWEDEN; BAYLOR COLL MED, HOUSTON, TX USA	Uppsala University; Uppsala University Hospital; Karolinska Institutet; Baylor College of Medicine	MALATY, HM (corresponding author), VET AFFAIRS MED CTR, 111D, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.		Graham, David/AAL-2165-2021		NIA NIH HHS [AG-10175, AG-04563] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG004563, R01AG010175] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASAKA M, 1992, GASTROENTEROLOGY, V102, P760, DOI 10.1016/0016-5085(92)90156-S; BLASER MJ, 1992, CLIN INFECT DIS, V15, P386, DOI 10.1093/clind/15.3.386; DEGIACOMA C, 1991, J PEDIATR-US, V119, P205, DOI 10.1016/S0022-3476(05)80728-0; DEHESA M, 1991, J CLIN MICROBIOL, V29, P1128, DOI 10.1128/JCM.29.6.1128-1131.1991; DIXON MF, 1991, J GASTROEN HEPATOL, V6, P125, DOI 10.1111/j.1440-1746.1991.tb01451.x; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; DWYER B, 1988, SCAND J INFECT DIS, V20, P349, DOI 10.3109/00365548809032465; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; FRASER AG, 1992, ALIMENT PHARM THERAP, V6, P389; GRAHAM DY, 1991, DIGEST DIS SCI, V36, P1084, DOI 10.1007/BF01297451; GRAHAM DY, 1991, J GASTROEN HEPATOL, V6, P105, DOI 10.1111/j.1440-1746.1991.tb01448.x; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; GRAHAM DY, 1992, EUR J GASTROEN HEPAT, V4, pS1; GRAHAM DY, 1989, GASTROEN CLIN BIOL, V13, pB84; HOPKINS RJ, 1990, ARCH INTERN MED, V150, P2347, DOI 10.1001/archinte.150.11.2347; JENSEN KG, 1972, PEPTIC ULCER GENETIC, P1; JONES DM, 1986, J MED MICROBIOL, V22, P57, DOI 10.1099/00222615-22-1-57; JONES DM, 1987, BRIT MED J, V294, P615, DOI 10.1136/bmj.294.6572.615-a; MALATY HM, 1991, SCAND J GASTROENTERO, V26, P927, DOI 10.3109/00365529108996244; MALATY HM, 1992, GASTROENTEROLOGY, V103, P813, DOI 10.1016/0016-5085(92)90011-M; MARSHALL BJ, 1990, REV INFECT DIS, V12, pS87; MCCONNELL RB, 1980, GENETICS HETEROGENEI, P31; MEGRAUD F, 1992, DIGEST DIS SCI, V37, P769, DOI 10.1007/BF01296437; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; MITCHELL HM, 1987, LANCET, V2, P681; MORRIS A, 1986, NEW ZEAL MED J, V99, P657; Neale M.C., 1992, METHODOLOGY GENETIC; NEIEDERMAN JC, 1964, CLIN GENET, V9, P81; NORA JJ, 1989, MED GENETICS PRINCIP, P261; ODERDA G, 1991, DIGEST DIS SCI, V36, P572, DOI 10.1007/BF01297021; ODERDA G, 1989, LANCET, V1, P690; PEDERSEN NL, 1984, ACTA GENET MED GEMEL, V33, P243, DOI 10.1017/S0001566000007285; PEDERSEN NL, 1991, ACTA GENET MED GEMEL, V40, P7, DOI 10.1017/S0001566000006681; PLOMIN R, 1990, BEHAVIORAL GENETICS; ROTTER JI, 1979, NEW ENGL J MED, V300, P63, DOI 10.1056/NEJM197901113000203; ROTTER JI, 1993, PROGR MED GENETICS, P1; SCHUBERT TT, 1989, AM J GASTROENTEROL, V84, P637; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078	39	213	217	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1994	120	12					982	986		10.7326/0003-4819-120-12-199406150-00002	http://dx.doi.org/10.7326/0003-4819-120-12-199406150-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ964	8185146				2022-12-01	WOS:A1994NQ96400002
J	POWARS, DR				POWARS, DR			SICKLE-CELL DISEASE IN NONBLACK PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HAPLOTYPES; ANEMIA; GENE				POWARS, DR (corresponding author), UNIV SO CALIF,LOS ANGELES CTY MED CTR,LOS ANGELES,CA 90033, USA.							DELIYANNIS GA, 1955, BRIT MED J, V2, P301, DOI 10.1136/bmj.2.4934.301; LEHMANN H, 1974, MANS HEMOGLOBINS; LIVINGSTONE F B, 1989, American Journal of Human Biology, V1, P289, DOI 10.1002/ajhb.1310010309; Livingstone FB, 1967, ABNORMAL HEMOGLOBINS; ONER C, 1992, HUM GENET, V89, P99, DOI 10.1007/BF00207052; OZSOYLU S, 1977, SCAND J HAEMATOL, V19, P85; PAGNIER J, 1984, P NATL ACAD SCI-BIOL, V81, P1771, DOI 10.1073/pnas.81.6.1771; ROGERS ZR, 1989, JAMA-J AM MED ASSOC, V261, P2991, DOI 10.1001/jama.261.20.2991; SCHILERO G, 1991, SCOPE, V15, P1; SCHROEDER WA, 1990, J AFR HIST, V31, P163, DOI 10.1017/S0021853700024981	10	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1885	1885		10.1001/jama.271.23.1885	http://dx.doi.org/10.1001/jama.271.23.1885			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	8196149				2022-12-01	WOS:A1994NP95900036
J	BERTOLETTI, A; SETTE, A; CHISARI, FV; PENNA, A; LEVRERO, M; DECARLI, M; FIACCADORI, F; FERRARI, C				BERTOLETTI, A; SETTE, A; CHISARI, FV; PENNA, A; LEVRERO, M; DECARLI, M; FIACCADORI, F; FERRARI, C			NATURAL VARIANTS OF CYTOTOXIC EPITOPES ARE T-CELL RECEPTOR ANTAGONISTS FOR ANTIVIRAL CYTOTOXIC T-CELLS	NATURE			English	Article							ANTIGEN-PRESENTING CELLS; CLASS-I MHC; INFECTED-CELLS; VIRUS; HEPATITIS; COMPLEXES; SELECTION; RESPONSES; SURFACE; ESCAPE	IT has been suggested that mutations within immunodominant cytotoxic T-lymphocyte (CTL) epitopes may be exploited by viruses to evade protective immune responses critical for clearance(1-4). Viral escape could originate from passive mechanisms, such as mutations within crucial CTL epitopes, either affecting major histocompatibility complex binding or T-cell antigen receptor (TCR) recognition. Additionally, it has recently been shown that substitutions of TCR contact sites can yield analogue peptides that can still interact with the T-cell receptor but be unable to deliver a full stimulatory signal, thus inducing anergy(5) or acting as an antagonist for the TCR(6-8). We report here that hepatitis B virus isolates derived from two chronically infected patients display variant epitopes that act as natural TCR antagonists with the capacity to inhibit the CTL response to the wild-type epitope. During natural infection, TCR antagonist mutations of CTL epitopes could contribute to the development of viral persistence, especially if the antiviral CTL response is monospecific or the epitope is strongly immunodominant.	UNIV PARMA, CATTEDRA MALATTIE INFETT, I-43100 PARMA, ITALY; CYTEL CORP, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; UNIV ROMA LA SAPIENZA, FDN A CESALPINO, ROME, ITALY; UNIV ROMA LA SAPIENZA, MED CLIN 1, ROME, ITALY; UNIV FLORENCE, CATTEDRA IMMUNOL CLIN & ALLERGOL, I-50134 FLORENCE, ITALY	University of Parma; Scripps Research Institute; Sapienza University Rome; Sapienza University Rome; University of Florence			Chisari, Francis V/A-3086-2008; Ferrari, Carlo/D-5663-2017; Sette, Alessandro/AFO-8916-2022; Bertoletti, Antonio/AAD-4830-2022; Levrero, Massimo/G-5680-2016	Ferrari, Carlo/0000-0002-5461-6842; Bertoletti, Antonio/0000-0002-2942-0485; Ferrari, Carlo/0000-0002-7843-4963; Levrero, Massimo/0000-0002-4978-0875; Chisari, Francis/0000-0002-4832-1044				ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; BERTOLETTI A, 1991, P NATL ACAD SCI USA, V88, P10445, DOI 10.1073/pnas.88.23.10445; BERTOLETTI A, 1993, J VIROL, V67, P2376, DOI 10.1128/JVI.67.4.2376-2380.1993; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GUILHOT S, 1992, J VIROL, V66, P2670, DOI 10.1128/JVI.66.5.2670-2678.1992; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; KORBA BE, 1987, J VIROL, V61, P1318, DOI 10.1128/JVI.61.5.1318-1324.1987; MCMICHAEL A, 1993, SCIENCE, V260, P1771, DOI 10.1126/science.8511585; MISSALE G, 1993, J EXP MED, V177, P751, DOI 10.1084/jem.177.3.751; NAYERSINA R, 1993, J IMMUNOL, V150, P4659; PENNA A, 1991, J EXP MED, V174, P1565, DOI 10.1084/jem.174.6.1565; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PLEOGH H, 1993, NATURE, V364, P16; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RUPPERT J, 1993, P NATL ACAD SCI USA, V90, P2671, DOI 10.1073/pnas.90.7.2671; RUPPERT J, 1993, CELL, V74, P1; SETTE A, IN PRESS MOL IMMUN; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; SYMER DE, 1992, J EXP MED, V176, P1421, DOI 10.1084/jem.176.5.1421; TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1	29	501	514	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					407	410		10.1038/369407a0	http://dx.doi.org/10.1038/369407a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	8196768				2022-12-01	WOS:A1994NP17400059
J	ROCA, J; WANG, JC				ROCA, J; WANG, JC			DNA TRANSPORT BY A TYPE-II DNA TOPOISOMERASE - EVIDENCE IN FAVOR OF A 2-GATE MECHANISM	CELL			English	Article							NALIDIXIC-ACID; GYRASE; CLEAVAGE; PROTEIN; PURIFICATION; HELIX	DNA substrates in which a supercoiled DNA is singly linked to a nicked or relaxed DNA ring were used to analyze the transport of one DNA ring through another by yeast DNA topoisomerase II. The enzyme binds preferentially to the supercoiled DNA and promotes decatenation efficiently upon binding of a nonhydrolyzable ATP analog. Analysis of the reaction products shows that the nicked or relaxed DNA ring released is not associated with the enzyme-supercoiled DNA complex. These results favor a two-gate model in which the DNA ring being transported can exit from the interior of the enzyme through a gate on the opposite side of the entrance gate, which is irreversibly closed upon binding of the nonhydrolizable ATP analog.			ROCA, J (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.		Roca, Joaquim/AAP-1077-2020	Roca, Joaquim/0000-0003-1462-954X	NIGMS NIH HHS [GM24544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024544, R01GM024544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARZILAI R, 1973, J MOL BIOL, V74, P739, DOI 10.1016/0022-2836(73)90062-4; CARON PR, 1994, DNA TOPOISOMERASES T; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; HOROWITZ DS, 1987, J BIOL CHEM, V262, P5339; Hsieh TS, 1990, DNA TOPOLOGY ITS BIO, P243; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; LEE CH, 1981, P NATL ACAD SCI-BIOL, V78, P2838, DOI 10.1073/pnas.78.5.2838; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1983, J BIOL CHEM, V258, P5365; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MIZUUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P1847, DOI 10.1073/pnas.77.4.1847; MORRISON A, 1979, CELL, V17, P175, DOI 10.1016/0092-8674(79)90305-2; MORRISON A, 1980, MECHANISTIC STUDIES, P785; POMMIER Y, 1989, BIOCHEMISTRY-US, V28, P1002; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; ROWE TC, 1984, J BIOL CHEM, V259, P9177; SANDER M, 1983, J BIOL CHEM, V258, P8421; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; THOMAS CA, 1979, ANAL BIOCHEM, V93, P158, DOI 10.1016/S0003-2697(79)80130-X; TSE YC, 1980, J BIOL CHEM, V255, P5560; VOLOGODSKII AV, 1992, J MOL BIOL, V227, P1224, DOI 10.1016/0022-2836(92)90533-P; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1970, BIOPOLYMERS, V9, P489, DOI 10.1002/bip.1970.360090410; WANG JC, 1980, MECHANISTIC STUDIES, P769; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	36	243	246	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	1994	77	4					609	616		10.1016/0092-8674(94)90222-4	http://dx.doi.org/10.1016/0092-8674(94)90222-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	8187179				2022-12-01	WOS:A1994NM83200015
J	KOZONO, H; WHITE, J; CLEMENTS, J; MARRACK, P; KAPPLER, J				KOZONO, H; WHITE, J; CLEMENTS, J; MARRACK, P; KAPPLER, J			PRODUCTION OF SOLUBLE MHC CLASS-II PROTEINS WITH COVALENTLY BOUND SINGLE PEPTIDES	NATURE			English	Article							T-CELL HYBRIDOMAS; TRANSGENIC MICE; ANTIGEN; RECOGNITION; THYMOCYTES; COMPLEX; CD8; MOLECULES; SELECTION; TOLERANCE	THE alpha beta T-cell receptors (TCRs) react with complex ligands composed of peptides bound to major histocompatibility complex (MHC) proteins. In the absence of foreign antigens the peptides bound to MHC molecules come from the proteins of the host itself(1-5). Interactions between TCRs and these self-peptide-MHC ligands work positively to drive T-cell development in the thymus(6-9) and negatively to delete or inactivate T cells with potential self-reactivity(10-12). On the cell surface, MHC proteins are associated with many different self peptides, making it impossible to know which self peptide was involved in positive or negative interactions with a particular T cell. These studies as well as in vitro studies on TCR-peptide-MHC interactions would be aided by a means of producing MHC molecules containing a single peptide. We have tackled this problem for MHC class II proteins by genetically attaching the peptide by a flexible peptide linker to the amino terminus of the class II beta-chain. Here we report that a secreted, soluble form of this covalent peptide-MHC complex can be expressed in insect cells. The peptide is engaged by the peptide-binding groove of the secreted MHC molecule and this complex is recognized by T cells bearing receptors specific for that combination.	UNIV COLORADO,HLTH SCI CTR,DEPT IMMUNOL,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT BIOPHYS,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT GENET,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80206	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	KOZONO, H (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,HOWARD HUGHES MED INST,DEPT MED,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	, Haruo/0000-0003-3352-0638; Marrack, Philippa/0000-0003-1883-3687				BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HANSBURG D, 1983, J IMMUNOL, V131, P319; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LECHLER RI, 1985, J IMMUNOL, V135, P2914; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; MARRACK P, 1993, J EXP MED, V178, P2173, DOI 10.1084/jem.178.6.2173; MATHIS DJ, 1983, CELL, V32, P745, DOI 10.1016/0092-8674(83)90060-0; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NEWCOMB JR, 1993, J IMMUNOL, V150, P499; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SHARMA SD, 1991, P NATL ACAD SCI USA, V88, P11465, DOI 10.1073/pnas.88.24.11465; SHERMAN LA, 1992, SCIENCE, V258, P815, DOI 10.1126/science.1439792; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; STEM LJ, 1992, CELL, V68, P465; WHITE J, 1983, J IMMUNOL, V130, P1033; WHITE J, 1993, J EXP MED, V177, P119, DOI 10.1084/jem.177.1.119	25	261	297	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 12	1994	369	6476					151	154		10.1038/369151a0	http://dx.doi.org/10.1038/369151a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK971	8177320				2022-12-01	WOS:A1994NK97100050
J	NOMURA, A; SHIGEMOTO, R; NAKAMURA, Y; OKAMOTO, N; MIZUNO, N; NAKANISHI, S				NOMURA, A; SHIGEMOTO, R; NAKAMURA, Y; OKAMOTO, N; MIZUNO, N; NAKANISHI, S			DEVELOPMENTALLY-REGULATED POSTSYNAPTIC LOCALIZATION OF A METABOTROPIC GLUTAMATE-RECEPTOR IN RAT ROD BIPOLAR CELLS	CELL			English	Article							PROTEIN-KINASE-C; CULTURED MUSCLE-CELLS; ALPHA-SUBUNIT GENE; MAMMALIAN RETINA; EXPRESSION; CONDUCTANCE; IMMUNOREACTIVITY; TRANSMITTER; DIVERSITY; MOUSE	The retinal bipolar cell receiving glutamate transmission from photoreceptors mediates a key process in segregating visual signals into ON center and OFF center pathways. This transmission involves a G protein-coupled metabotropic glutamate receptor (mGluR). Immunocytochemical and immunoelectron microscopic studies indicate the restricted localization of a specific mGluR subtype, mGluR6, at the postsynaptic site of the rat rod bipolar cell. This specialization is developmentally regulated: mGluR6 is initially distributed in both the soma and dendrites and is finally concentrated on the postsynaptic site. The mGluR6 localization is reversed when photoreceptors degenerate in the mutant rat with retinal dystrophy. Evidence is thus presented indicating specialized, developmentally regulated receptor distribution in the central nervous system and the crucial role of mGluR6 in photoreceptor-bipolar cell synaptic transmission.	KYOTO UNIV,FAC MED,DEPT OPHTHALMOL,KYOTO 606,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT ANAT,TOKYO 113,JAPAN	Kyoto University; Tokyo Medical & Dental University (TMDU)	NOMURA, A (corresponding author), KYOTO UNIV,FAC MED,DEPT MORPHOL BRAIN SCI,KYOTO 606,JAPAN.		Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444				ASHMORE JF, 1980, J PHYSIOL-LONDON, V300, P115, DOI 10.1113/jphysiol.1980.sp013155; BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664; BOYCOTT BB, 1973, J COMP NEUROL, V148, P91, DOI 10.1002/cne.901480106; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; DEVRIES SH, 1993, CELL, V72, P139, DOI 10.1016/S0092-8674(05)80033-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOLDMAN D, 1989, NEURON, V3, P219, DOI 10.1016/0896-6273(89)90035-4; GREFERATH U, 1990, J COMP NEUROL, V301, P433, DOI 10.1002/cne.903010308; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; KAITZ M, 1979, VISION RES, V19, P79, DOI 10.1016/0042-6989(79)90124-X; KANEKO A, 1989, J PHYSIOL-LONDON, V410, P613, DOI 10.1113/jphysiol.1989.sp017551; KARSCHIN A, 1990, J NEUROPHYSIOL, V63, P860, DOI 10.1152/jn.1990.63.4.860; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; MCMAHAN UJ, 1990, COLD SH Q B, V55, P407; MILLER RF, 1986, TRENDS NEUROSCI, V9, P211, DOI 10.1016/0166-2236(86)90061-5; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAWY S, 1991, NEURON, V7, P677, DOI 10.1016/0896-6273(91)90380-I; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; NEGISHI K, 1988, NEUROSCI LETT, V94, P247, DOI 10.1016/0304-3940(88)90025-0; NEW HV, 1986, NATURE, V323, P809, DOI 10.1038/323809a0; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; PENG HB, 1991, NEURON, V6, P237; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SHIELLS RA, 1990, P ROY SOC B-BIOL SCI, V242, P91, DOI 10.1098/rspb.1990.0109; SHIGEMOTO R, 1993, NEUROSCI LETT, V163, P53, DOI 10.1016/0304-3940(93)90227-C; SZEL A, 1992, EXP EYE RES, V55, P47; TESSIERLAVIGNE M, 1991, PRINCIPLES NEURAL SC, P400; VARDI N, 1993, VISUAL NEUROSCI, V10, P473, DOI 10.1017/S0952523800004697; WASSLE H, 1991, VISUAL NEUROSCI, V7, P99, DOI 10.1017/S095252380001097X; WEIDMAN TA, 1968, ARCH OPHTHALMOL-CHIC, V79, P470, DOI 10.1001/archopht.1968.03850040472015	35	363	368	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 6	1994	77	3					361	369		10.1016/0092-8674(94)90151-1	http://dx.doi.org/10.1016/0092-8674(94)90151-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	8181056				2022-12-01	WOS:A1994NK97000007
J	RENNER, C; JUNG, W; SAHIN, U; DENFELD, R; POHL, C; TRUMPER, L; HARTMANN, F; DIEHL, V; VANLIER, R; PFREUNDSCHUH, M				RENNER, C; JUNG, W; SAHIN, U; DENFELD, R; POHL, C; TRUMPER, L; HARTMANN, F; DIEHL, V; VANLIER, R; PFREUNDSCHUH, M			CURE OF XENOGRAFTED HUMAN TUMORS BY BISPECIFIC MONOCLONAL-ANTIBODIES AND HUMAN T-CELLS	SCIENCE			English	Article							HUMAN OVARIAN-CARCINOMA; HUMAN LYMPHOCYTES-T; HODGKINS-DISEASE; ACTIVATION; CD28; ANTI-CD28; LYSIS; RECEPTOR; SIGNAL	Tumor immunotherapy should increase both the number of T cells that kill the tumor and the likelihood that those cells are activated at the tumor site. Bispecific monoclonal antibodies (Bi-mAbs) were designed that bound to a Hodgkin's tumor-associated antigen (CD30) on the tumor and to either CD3 or CD28 on the T cell. Immunodeficient mice were cured of established human tumors when mice were treated with both the CD3-CD30 and the CD28-CD30 Bi-mAbs and then given human peripheral brood lymphocytes that had been incubated with the CD3-CD30 Bi-mAb and cells that expressed CD30. The enrichment of human T cells within the tumor and the fact that established tumors can be cured may indicate in situ activation of both the T cell receptor and the costimulatory pathway.	UNIV SAARLAND,MED KLIN & POLIKLIN,D-66421 HOMBURG,GERMANY; UNIV COLOGNE,MED KLIN 1,D-50921 COLOGNE,GERMANY; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,1006 AMSTERDAM,NETHERLANDS	Saarland University; University of Cologne			Sahin, Ugur/L-4818-2017	Sahin, Ugur/0000-0003-0363-1564; van Lier, Rene/0000-0002-3201-7144				BAROJA ML, 1989, CELL IMMUNOL, V120, P205, DOI 10.1016/0008-8749(89)90188-3; CARDE P, 1990, EUR J CANCER, V26, P474, DOI 10.1016/0277-5379(90)90019-P; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GARRIDO MA, 1990, J IMMUNOL, V144, P2891; HOMBACH A, 1993, INT J CANCER, V55, P830, DOI 10.1002/ijc.2910550523; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNG G, 1987, P NATL ACAD SCI USA, V84, P4611, DOI 10.1073/pnas.84.13.4611; Jung W., UNPUB; LANZAVECCHIA A, 1987, EUR J IMMUNOL, V17, P105, DOI 10.1002/eji.1830170118; LEDBETTER JA, 1990, BLOOD, V75, P1531; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MEZZANZANICA D, 1991, CANCER RES, V51, P5716; MEZZANZANICA D, 1988, INT J CANCER, V41, P609, DOI 10.1002/ijc.2910410422; MOISER DE, 1988, NATURE, V335, P256; MOLLER SA, 1991, CANCER IMMUNOL IMMUN, V33, P210, DOI 10.1007/BF01744939; MORETTA A, 1989, IMMUNOL REV, V111, P145, DOI 10.1111/j.1600-065X.1989.tb00545.x; NIJHUIS EWP, 1990, CANCER IMMUNOL IMMUN, V32, P245, DOI 10.1007/BF01741708; PEREZ P, 1985, NATURE, V316, P354, DOI 10.1038/316354a0; POHL C, 1993, INT J CANCER, V54, P418, DOI 10.1002/ijc.2910540312; POHL C, 1993, INT J CANCER, V54, P820, DOI 10.1002/ijc.2910540517; PUPA SM, 1988, INT J CANCER, V42, P455, DOI 10.1002/ijc.2910420324; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; TAKAHASHI H, 1993, SCIENCE, V259, P1460, DOI 10.1126/science.8451642; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; VANLIER RAW, 1988, EUR J IMMUNOL, V18, P167; VONFLIEDNER V, 1992, CELL IMMUNOL, V139, P198, DOI 10.1016/0008-8749(92)90112-3	30	156	180	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					833	835		10.1126/science.8171337	http://dx.doi.org/10.1126/science.8171337			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171337				2022-12-01	WOS:A1994NJ94900030
J	MANDELBOIM, O; BERKE, G; FRIDKIN, M; FELDMAN, M; EISENSTEIN, M; EISENBACH, L				MANDELBOIM, O; BERKE, G; FRIDKIN, M; FELDMAN, M; EISENSTEIN, M; EISENBACH, L			CTL INDUCTION BY A TUMOR-ASSOCIATED ANTIGEN OCTAPEPTIDE DERIVED FROM A MURINE LUNG-CARCINOMA	NATURE			English	Article							VIRAL PEPTIDES; LYMPHOCYTES-T; CELLS; GENE; PROTEIN; RECIPIENTS; REJECTION; LINES	MANY mouse and human tumours express major histocompatibility complex (MHC) class I-associated antigens that constitute targets for syngeneic cytotoxic T lymphocytes (CTL). Genes encoding such antigens were isolated from a mouse mastocytoma and from human melanomas by genetic methods(1,2). Isolation and characterization of MHC class I-associated peptides has enabled specific anchor residues to be identified that are typical of peptides that bind to distinct class I molecules(3). Moreover, CTL specific to particular MHC-peptide combinations have been used to identify naturally occurring antigenic peptides in cell extracts and enabled them to be sequenced directly(4-6). Most known MHC ligands are of viral origin or are self peptides derived from normal proteins(7). Here we use total acid extraction and repeated fractionation to isolate and sequence Lewis lung carcinoma (3LL)-specific peptide(s), which shows sequence homology to the connexin 37 protein. Synthetic octamers based on these sequences bind to 'empty' H-2K(b) molecules on RMA-S cells, sensitize RMA-S cells to lysis by specific anti-3LL CTL, and induce anti-tumour CTL. The tumour-associated peptide originates from mutated connexin 37 expressed in 3LL.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science				Eisenbach, Lea R/0000-0002-4816-1968; Mandelboim, Ofer/0000-0002-9354-1855				EGHABALI B, 1991, P NATL ACAD SCI USA, V88, P10701; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FRANKS LM, 1984, BRIT J CANCER, V49, P423, DOI 10.1038/bjc.1984.68; FREEMONT DH, 1992, SCIENCE, V257, P919; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2852; LEVITT M, 1983, J MOL BIOL, V170, P723, DOI 10.1016/S0022-2836(83)80129-6; MANDELBOIM O, 1992, J IMMUNOL, V148, P3666; PLAKSIN D, 1992, INT J CANCER, V52, P771, DOI 10.1002/ijc.2910520517; PLAKSIN D, 1988, P NATL ACAD SCI USA, V85, P4463, DOI 10.1073/pnas.85.12.4463; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; VANBLEEK GM, 1990, NATURE, V348, P213; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WILLECKE K, 1991, EUR J CELL BIOL, V56, P1; WILLECKE K, 1991, J CELL BIOL, V114, P1049, DOI 10.1083/jcb.114.5.1049; ZHANG W, 1992, P NATL ACAD SCI USA, V89, P4803; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218	23	252	266	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					67	71		10.1038/369067a0	http://dx.doi.org/10.1038/369067a0			5	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164742				2022-12-01	WOS:A1994NJ86000055
J	SULLIVAN, AK; HOLDRIGHT, DR; WRIGHT, CA; SPARROW, JL; CUNNINGHAM, D; FOX, KM				SULLIVAN, AK; HOLDRIGHT, DR; WRIGHT, CA; SPARROW, JL; CUNNINGHAM, D; FOX, KM			CHEST PAIN IN WOMEN - CLINICAL, INVESTIGATIVE, AND PROGNOSTIC FEATURES	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; FOLLOW-UP; CARDIOVASCULAR-DISEASE; SEX-DIFFERENCES; BYPASS-SURGERY; ARTERY SURGERY; RISK-FACTORS; MEN; ARTERIOGRAMS; EXERCISE	Objective-To characterise clinical, investigative, and prognostic features of women referred with chest pain who subsequently underwent coronary angiography. Design-Analysis of all women with angina referred to one consultant during 1987-91 who subsequently underwent coronary angiography, with follow up to present day. Setting-Cardiothoracic centre. Subjects-Women with normal coronary arteries; women with coronary artery disease shown on angiography; men with coronary artery disease matched for age; men referred with chest pain during the same period subsequently found to have normal coronary arteries. Main outcome measures-Risk factor analysis; results of exercise testing and coronary angiography; intervention; morbidity and mortality. Results-Women comprised 23% (202/886) of patients referred with chest pain who subsequently underwent angiography. 83/202 women had normal coronary angiograms compared with 55/684 men (41% v 8%, P < 0.001). Diabetes mellitus was the only risk factor more frequently encountered in women with coronary artery disease (P = 0.001). The specificity and positive predictive value of exercise testing before angiography were significantly lower in women than men (71% v 93%, P<0.001 and 76% v 95%, P < 0.001, respectively). Revascularisation procedures were as common in women with coronary artery disease as in men (81 (68%) v 70 (59%)), and there was no difference in event rate during follow up. Many patients with normal coronary arteries, irrespective of sex, had symptoms during follow up (61 (73%) women, 36 (65%) men) and continued to take antianginal drugs (27 (33%) women, 14 (28%) men); 14 (17%) women and six (11%) men required hospital readmission for severe symptoms. Conclusions-In this series, although women comprised the minority of patients referred with chest pain, a diagnosis of normal coronary arteries was five times more common in women than men. Risk factor analysis and exercise testing were of limited value in predicting coronary artery disease in women. There was no sex bias regarding revascularisation procedures, and outcome was similar. A diagnosis of non-cardiac chest pain in patients with normal coronary arteries was of little benefit to the patient with regard to morbidity.	ROYAL BROMPTON NATL HEART & LUNG HOSP,LONDON SW3 6NP,ENGLAND	Imperial College London								AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BAROLSKY SM, 1979, CIRCULATION, V60, P1021, DOI 10.1161/01.CIR.60.5.1021; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; CHAMBERS J, 1990, DIFFICULT CARDIOLOGY, P301; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; DAVIS KB, 1987, CORONARY HEART DISEA, P247; DETRY JMR, 1977, CIRCULATION, V56, P756, DOI 10.1161/01.CIR.56.5.756; GROSSMAN W, 1991, CARDIAC CATHETERIZAT, P28; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; ISNER JM, 1981, AM HEART J, V102, P645, DOI 10.1016/0002-8703(81)90088-0; Kannel W.B., 1984, J CARDIAC REHABIL, V4, P267; KANNEL WB, 1987, AM HEART J, V114, P413, DOI 10.1016/0002-8703(87)90511-4; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KENNEDY JW, 1982, CIRCULATION, V66, P16; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; PASTERNAK RC, 1980, AM J MED, V68, P813, DOI 10.1016/0002-9343(80)90199-0; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; RUDERMAN NB, 1984, PROG CARDIOVASC DIS, V26, P373, DOI 10.1016/0033-0620(84)90011-2; SKETCH MH, 1975, AM J CARDIOL, V36, P169, DOI 10.1016/0002-9149(75)90521-4; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; STOKES J, 1987, CIRCULATION, V75, P65; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TYRAS DH, 1978, ANN THORAC SURG, V25, P449, DOI 10.1016/S0003-4975(10)63583-7; WAXLER EB, 1971, AM J CARDIOL, V28, P25, DOI 10.1016/0002-9149(71)90030-0; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; 1991, CORONARY HEART DISEA, P30	28	196	208	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					883	886		10.1136/bmj.308.6933.883	http://dx.doi.org/10.1136/bmj.308.6933.883			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173366	Green Published			2022-12-01	WOS:A1994NE60000019
J	FERGUSON, AE; TAPPIN, DM; GIRDWOOD, RWA; KENNEDY, R; COCKBURN, F				FERGUSON, AE; TAPPIN, DM; GIRDWOOD, RWA; KENNEDY, R; COCKBURN, F			BREAST-FEEDING IN SCOTLAND	BRITISH MEDICAL JOURNAL			English	Article							INFECTIONS	Objective-To measure the prevalence of breast feeding and to examine the value of using information collected on Guthrie cards (used for detecting inherited metabolic disease and hypothyroidism when newborn infants are 7 days old) to calculate this prevalence. Design-Analysis, by geographical area and maternity unit, of information on breast feeding collected on Guthrie cards for 131 759 babies born 1990 and 1991, and comparison with prevalences from other sources. Setting-Scotland. Results-Of the 131 759 babies, only 46 949 (35.6%) were breast feeding on day 7. The prevalence of breast feeding ranged from 59.1% (376/636) in Shetland to 21.1% (1836/8719) in Lanarkshire and < 8% in some postcode districts of cities. Analysis of the data by hospital of birth showed that the prevalence ranged from 51.2% (2701/5275) to 16.4% (507/3090). Conclusion-The prevalence of breast feeding in Scotland is low and varies among areas and maternity units. Intervention to increase this prevalence is essential, and information collected on Guthrie cards is a useful indication of mothers' intentions to breast feed.	STOBHILL GEN HOSP,SCOTTISH INBORN ERRORS SCREENING LAB,GLASGOW G21 3UW,SCOTLAND		FERGUSON, AE (corresponding author), ROYAL HOSP SICK CHILDREN,DEPT CHILD HLTH,GLASGOW G3 8SJ,SCOTLAND.							CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; DOWNHAM MAPS, 1976, BRIT MED J, V2, P274, DOI 10.1136/bmj.2.6030.274; EMERY JL, 1990, ARCH DIS CHILD-FETAL, V65, P369, DOI 10.1136/adc.65.4_Spec_No.369; FORMAN MR, 1984, INT J EPIDEMIOL, V13, P447, DOI 10.1093/ije/13.4.447; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; ROBINSON M, 1951, LANCET, V1, P788; VICTORA CG, 1987, LANCET, V2, P319; WHITE A, 1990, INFANT FEEDING 1990; 1988, SUCCESSFUL BREAST FE; 1988, LANCET, V1, P975; 1988, REPORT C LAUNCH JOIN	11	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					824	825		10.1136/bmj.308.6932.824	http://dx.doi.org/10.1136/bmj.308.6932.824			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND243	8167490	Green Published			2022-12-01	WOS:A1994ND24300023
J	MILLER, JD; WILHELM, H; GIERASCH, L; GILMORE, R; WALTER, P				MILLER, JD; WILHELM, H; GIERASCH, L; GILMORE, R; WALTER, P			GTP-BINDING AND HYDROLYSIS BY THE SIGNAL RECOGNITION PARTICLE DURING INITIATION OF PROTEIN TRANSLOCATION	NATURE			English	Article							METHIONINE-RICH DOMAIN; ENDOPLASMIC-RETICULUM; MICROSOMAL MEMBRANE; DOCKING PROTEIN; 54-KD PROTEIN; RECEPTOR; SEQUENCE; SUBUNIT; CONTAINS; POLYPEPTIDE	THE signal recognition particle (SRP) consists of one RNA and six protein subunits1,2. The N-terminal domain of the 54K subunit contains a putative GTP-binding site, whereas the C-terminal domain binds signal sequences and SRP RNA3-7. Binding of SRP to the signal sequence as it emerges from the ribosome creates a cytosolic targeting complex containing the nascent polypeptide chain, the translating ribosome, and SRP8. This complex is directed to the endoplasmic reticulum membrane as a result of its interaction with the SRP receptor9-11, a membrane protein composed of two subunits, SRalpha and SRbeta, each of which also contains a GTP-binding domain12,13. In the presence of GTP, SRP receptor binding to SRP causes the latter to dissociate from both the signal sequence and the ribosome13,14. GTP is then hydrolysed so that SRP can be released from the SRP receptor and returned to the cytosol15. Here we show that the 54K subunit (M(r) 54,000) of SRP (SRP54) is a GTP-binding protein stabilized in a nucleotide-free state by signal sequences and that the SRP receptor both increases the affinity of SRP54 for GTP and activates its GTPase. We propose that nucleotide-mediated conformational changes in SRP54 regulate the release of signal sequences and the docking of ribosomes at the endoplasmic reticulum.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV MASSACHUSETTS, DEPT BIOCHEM, WORCESTER, MA 01655 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Massachusetts System; University of Massachusetts Worcester	MILLER, JD (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Gierasch, Lila M/D-1494-2009					BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHEN LL, 1987, J BIOL CHEM, V262, P1427; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, IN PRESS J CELL BIOL; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HIGH S, 1991, J CELL BIOL, V113, P229, DOI 10.1083/jcb.113.2.229; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; NATH JP, 1985, BIOCHEMISTRY-US, V24, P1555, DOI 10.1021/bi00327a040; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; PASHEV IG, 1991, TRENDS BIOCHEM SCI, V16, P323, DOI 10.1016/0968-0004(91)90133-G; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; SEGEL IH, 1975, ENZYME KINETICS, P105; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WATANABE M, 1986, NATURE, V323, P71, DOI 10.1038/323071a0; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	32	156	157	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1993	366	6453					351	354		10.1038/366351a0	http://dx.doi.org/10.1038/366351a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247130				2022-12-01	WOS:A1993MJ70500051
J	GIBSON, NA; HOLLMAN, AS; PATON, JY				GIBSON, NA; HOLLMAN, AS; PATON, JY			VALUE OF RADIOLOGICAL FOLLOW-UP OF CHILDHOOD PNEUMONIA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL HOSP SICK CHILDREN,DEPT CHILD HLTH,GLASGOW G3 8SJ,SCOTLAND; ROYAL HOSP SICK CHILDREN,DEPT RADIOL,GLASGOW G3 8SJ,SCOTLAND	University of Glasgow; University of Glasgow								KRAMER MS, 1992, PEDIATRICS, V90, P11; PHELAN PD, 1990, RESPIRATORY ILLNESS; SINGLETON EB, 1988, RADIOGRAPHIC ATLAS P; 1990, PATIENT DOSE REDUCTI	4	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1117	1117		10.1136/bmj.307.6912.1117	http://dx.doi.org/10.1136/bmj.307.6912.1117			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8251812	Green Published, Bronze			2022-12-01	WOS:A1993ME91800020
J	SILLITO, AM; JONES, HE; GERSTEIN, GL; WEST, DC				SILLITO, AM; JONES, HE; GERSTEIN, GL; WEST, DC			FEATURE-LINKED SYNCHRONIZATION OF THALAMIC RELAY CELL FIRING INDUCED BY FEEDBACK FROM THE VISUAL-CORTEX	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; DEPENDENT NEURONAL OSCILLATIONS; CROSS-CORRELATION ANALYSIS; PRINCIPAL CELLS; CAT; INTERNEURONS; MORPHOLOGY; EXCITATION; DYNAMICS; PATHWAY	THE function of the massive feedback projection from visual cortex to its thalamic relay nucleus(1,2) has so far eluded any clear overview. This feedback exerts a range of effects(3-6), including an increase in the inhibition elicited by moving contours(7,8), but the functional logic of the direct connections to the thalamic cells that relay the retinal input to the cortex(9-11) remains largely unknown. In contrast to its thalamic nucleus, the visual cortex is characterized by cells that are strongly sensitive to the orientation of moving contours. Here we report that when driven by moving oriented visual stimuli the cortical feedback induces correlated firing in relay cells. This cortically induced correlation of relay cell activity produces coherent firing in those groups of relay cells with receptive field alignments appropriate to signalling the particular orientation of the moving contour to the cortex. Synchronization of relay cell firing means that they will elicit temporally overlapping excitatory postsynaptic potentials in their cortical target cells, thus increasing the chance that the cortical cells will fire. Effectively this increases the gain of the input for feature-linked events detected by the cortex. We propose that this feedback loop serves to lock or focus the appropriate circuitry onto the stimulus feature.	UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104	University of Pennsylvania	SILLITO, AM (corresponding author), INST OPHTHALMOL,DEPT VISUAL SCI,BATH ST,LONDON EC1V 9EL,ENGLAND.							ABELES M, 1988, J NEUROPHYSIOL, V60, P909, DOI 10.1152/jn.1988.60.3.909; ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AHLSEN G, 1982, BRAIN RES, V234, P454, DOI 10.1016/0006-8993(82)90886-1; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; GRAY CM, 1990, EUR J NEUROSCI, V2, P607, DOI 10.1111/j.1460-9568.1990.tb00450.x; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HUBEL DH, 1962, J PHYSL, V160, P16; LINDSTROM S, 1990, EXP BRAIN RES, V79, P313, DOI 10.1007/BF00608240; MARROCCO RT, 1985, EXP BRAIN RES, V59, P50; MONTERO VM, 1991, EXP BRAIN RES, V86, P257; MURPHY PC, 1987, NATURE, V329, P727, DOI 10.1038/329727a0; PALM G, 1988, BIOL CYBERN, V59, P1, DOI 10.1007/BF00336885; ROBSON JA, 1983, J COMP NEUROL, V216, P89, DOI 10.1002/cne.902160108; SILLITO A M, 1992, P349; SILLITO AM, 1993, EXP BRAIN RES, V93, P6; TSO DY, 1986, J NEUROSCI, V6, P1160; TSUMOTO T, 1978, BRAIN RES, V345, P364; VARELA FJ, 1987, EXP BRAIN RES, V66, P10; WEBER AJ, 1989, J COMP NEUROL, V289, P156, DOI 10.1002/cne.902890113; WILSON JR, 1984, PROC R SOC SER B-BIO, V221, P411, DOI 10.1098/rspb.1984.0042	21	447	451	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 9	1994	369	6480					479	482		10.1038/369479a0	http://dx.doi.org/10.1038/369479a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	8202137				2022-12-01	WOS:A1994NQ28600055
J	PETRONIS, KR; CARROLL, CE; HELD, PJ; PORT, FK				PETRONIS, KR; CARROLL, CE; HELD, PJ; PORT, FK			EFFECT OF RACE ON ACCESS TO RECOMBINANT-HUMAN-ERYTHROPOIETIN IN LONG-TERM HEMODIALYSIS-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIALYSIS	Objective.-To quantify access to recombinant human erythropoietin (EPO) among patients with dialysis-dependent end-stage renal disease (ESRD). Design.-National random sample of hemodialysis patients from a random sample of dialysis units, using data abstracted from patients' medical records. Setting.-All US hemodialysis units. Participants.-A total of 4024 Medicare-entitled in-center hemodialysis patients. Main Outcome Measures.-The relative odds that black patients received EPO (compared with white patients). Results.-There was no evidence in this national study that black hemodialysis patients were more or less likely to receive EPO than white patients (P=.74) Conclusions.-Three years after Food and Drug Administration approval and Medicare coverage of EPO, there was no evidence of racial disparity in access to EPO among Medicare patients with ESRD who were receiving long-term hemodialysis. However, there was evidence of greater need for EPO among black patients.	URBAN INST,CTR HLTH POLICY,WASHINGTON,DC; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109	Urban Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIDDK NIH HHS [N01-DK-8-2234] Funding Source: Medline; PHS HHS [17-C-90085/3-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK082234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1982, EPIDEMIOLOGIC RES; DAUGIRDAS JT, 1993, AM J KIDNEY DIS, V22, P267, DOI 10.1016/S0272-6386(12)70317-7; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; Hosmer D, 2013, APPL LOGISTIC REGRES; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; 1991, USRDS1991 NIH NAT I, pCH2; 1993, USRDS1993 NIH NAT I, pCH11; 1991, USRDS1991 NIH NAT I, pCH11	9	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	1994	271	22					1760	1763		10.1001/jama.271.22.1760	http://dx.doi.org/10.1001/jama.271.22.1760			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN725	8196119				2022-12-01	WOS:A1994NN72500025
J	SCHLAPPI, M; RAINA, R; FEDOROFF, N				SCHLAPPI, M; RAINA, R; FEDOROFF, N			EPIGENETIC REGULATION OF THE MAIZE SPM TRANSPOSABLE ELEMENT - NOVEL ACTIVATION OF A METHYLATED PROMOTER BY TNPA	CELL			English	Article							SUPPRESSOR-MUTATOR ELEMENT; DNA METHYLATION; TRANSGENE EXPRESSION; BINDING-PROTEIN; ZEA-MAYS; TOBACCO; TRANSPOSITION; SEQUENCE; TRANSFORMATION; EXCISION	Spm is epigenetically inactivated by C-methylation near its transcription start site. We have investigated the interaction between TnpA, an autoregulatory protein that can reactivate a silent Spm, and the promoter of the element. The promoter undergoes rapid de novo methylation and inactivation in stably transformed plants, but only if it includes a GC-rich sequence downstream of the promoter. TnpA activates the inactive, methylated promoter and leads to reduced methylation. By contrast, TnpA represses the active, unmethylated Spm promoter. Only the internal DNA-binding and dimerization domains of the protein are required for repression, while activation requires an additional C-terminal sequence. TnpA is therefore a unique regulatory protein with a conventional transcriptional repressor activity and a novel ability to activate a methylated, inactive promoter.			SCHLAPPI, M (corresponding author), CARNEGIE INST WASHINGTON, DEPT EMBRYOL, BALTIMORE, MD 21210 USA.				NIGMS NIH HHS [GM4296] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AINLEY WM, 1990, PLANT MOL BIOL, V14, P949, DOI 10.1007/BF00019392; BANKS JA, 1988, GENE DEV, V2, P1364, DOI 10.1101/gad.2.11.1364; BANKS JA, 1989, DEV GENET, V10, P425, DOI 10.1002/dvg.1020100604; BOLKER M, 1989, EMBO J, V8, P2403, DOI 10.1002/j.1460-2075.1989.tb08370.x; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BRAATEN BA, 1994, CELL, V76, P577, DOI 10.1016/0092-8674(94)90120-1; BRAUN RE, 1986, MOL GEN GENET, V202, P246, DOI 10.1007/BF00331644; BREYNE P, 1992, PLANT CELL, V4, P463, DOI 10.1105/tpc.4.4.463; COMAI L, 1990, PLANT MOL BIOL, V15, P373, DOI 10.1007/BF00019155; COOK D, 1992, MAIZE GEN COOP NEWSL, V66, P11; FEDOROFF N, 1989, GENETICS, V121, P591; FEDOROFF NV, 1988, GENETICS, V120, P559; FEDOROFF NV, 1994, IN PRESS HOMOLOGOUS; FREY M, 1990, EMBO J, V9, P4037, DOI 10.1002/j.1460-2075.1990.tb07625.x; GATZ C, 1992, PLANT J, V2, P397, DOI 10.1046/j.1365-313X.1992.t01-37-00999.x; GIERL A, 1988, EMBO J, V7, P4045, DOI 10.1002/j.1460-2075.1988.tb03298.x; GRANT SR, 1990, EMBO J, V9, P2029, DOI 10.1002/j.1460-2075.1990.tb07369.x; HAUGHN GW, 1988, MOL GEN GENET, V211, P266, DOI 10.1007/BF00330603; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; MASSON P, 1989, P NATL ACAD SCI USA, V86, P2219, DOI 10.1073/pnas.86.7.2219; MASSON P, 1991, PLANT CELL, V3, P73, DOI 10.1105/tpc.3.1.73; MASSON P, 1989, CELL, V58, P755, DOI 10.1016/0092-8674(89)90109-8; MASSON P, 1987, GENETICS, V117, P117; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; McClintock B., 1959, Yearbook of the Carnegie Institution of Washington 1958-59, P452; McClintock B., 1957, Year Book of the Carnegie Institution of Washington 1956-1957, P393; MCCLINTOCK B, 1961, AM NAT, V45, P265; MCCLINTOCK B, 1958, CARNEGIE I WASHINGTO, V57, P415; McClintock B, 1971, CARNEGIE I WASHINGTO, V70, P5; McClintock B., 1954, CARNEGIE I WASH YB, V53, P254; McClintock B., 1956, CARNEGIE I WASHINGTO, V55, P323; MCCLINTOCK B, 1961, CARNEGIE I WASHINGTO, V60, P469; McClintock B, 1955, CARNEGIE I WASH YB, V54, P245; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; NOU XW, 1993, MOL MICROBIOL, V7, P545, DOI 10.1111/j.1365-2958.1993.tb01145.x; PEACH C, 1991, PLANT MOL BIOL, V17, P49, DOI 10.1007/BF00036805; RAINA R, 1993, P NATL ACAD SCI USA, V90, P6355, DOI 10.1073/pnas.90.13.6355; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; ROBERTS D, 1985, CELL, V43, P117, DOI 10.1016/0092-8674(85)90017-0; ROGERS SG, 1988, METHODS PLANT MOL BI, P425; RUSSELL JA, 1992, IN VITRO CELL DEV-PL, V28P, P97; SCHIEFELBEIN JW, 1985, P NATL ACAD SCI USA, V82, P4783, DOI 10.1073/pnas.82.14.4783; SCHLAPPI M, 1993, GENETICS, V133, P1009; SCHLAPPI M, 1992, MAIZE GENET COOP NEW, V66, P12; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHWARZSOMMER Z, 1985, EMBO J, V4, P2439, DOI 10.1002/j.1460-2075.1985.tb03953.x; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; TRENTMANN SM, 1993, MOL GEN GENET, V238, P201, DOI 10.1007/BF00279548; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YIN JCP, 1988, J MOL BIOL, V199, P35, DOI 10.1016/0022-2836(88)90377-4	54	72	72	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 6	1994	77	3					427	437		10.1016/0092-8674(94)90157-0	http://dx.doi.org/10.1016/0092-8674(94)90157-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	8181061				2022-12-01	WOS:A1994NK97000013
J	GAZIANO, JM; BURING, JE; BRESLOW, JL; GOLDHABER, SZ; ROSNER, B; VANDENBURGH, M; WILLETT, W; HENNEKENS, CH				GAZIANO, JM; BURING, JE; BRESLOW, JL; GOLDHABER, SZ; ROSNER, B; VANDENBURGH, M; WILLETT, W; HENNEKENS, CH			MODERATE ALCOHOL INTAKE, INCREASED LEVELS OF HIGH-DENSITY-LIPOPROTEIN AND ITS SUBFRACTIONS, AND DECREASED RISK OF MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; APOLIPOPROTEIN-A-I; CARDIOVASCULAR MORTALITY; PRECIPITATION PROCEDURE; CIGARETTE-SMOKING; ARTERY DISEASE; CONSUMPTION; CHOLESTEROL; MEN; FRAMINGHAM	Background. Previous studies have suggested that moderate alcohol intake exerts a protective effect against coronary heart disease. Alterations in plasma lipoprotein levels represent one plausible mechanism of this apparent protective effect. Methods. We therefore examined the interrelation among alcohol consumption, plasma lipoprotein levels, and the risk of myocardial infarction in 340 patients who had had myocardial infarctions and an equal number of age- and sex-matched controls. The case patients were men or women less than 76 years of age with no history of coronary disease who were discharged from one of six hospitals in the Boston area with a diagnosis of a confirmed myocardial infarction. Alcohol consumption was estimated by means of a food-frequency questionnaire. Results. We observed a significant inverse association between alcohol consumption and the risk of myocardial infarction (P for trend, <0.001 after control for known coronary risk factors). In multivariate analyses, the relative risk for the highest intake category (subjects who consumed three or more drinks per day) as compared with the lowest (those who had less than one drink a month) was 0.45 (95 percent confidence interval, 0.26 to 0.80). The levels of total high-density lipoprotein cholesterol (HDL) and its HDL2 and HDL3 subtractions were strongly associated with alcohol consumption (P for trend, <0.001 for each). The addition of HDL or either of its subtractions to the multivariate model substantially reduced the inverse association between alcohol intake and myocardial infarction, whereas the addition of the other plasma lipid measurements did not materially alter the relation. Conclusions. These data confirm the inverse association ot moderate alcohol intake with the risk of myocardial infarction and support the view that the effect is mediated, in large part, by increases in both HDL2 and HDL3.	HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; VET AFFAIRS MED CTR, DEPT MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT ENDOCRINOL, BOSTON, MA 02115 USA; ROCKEFELLER UNIV, BIOCHEM GENET & METAB LAB, NEW YORK, NY 10021 USA	Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Rockefeller University	GAZIANO, JM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, 900 COMMONWEALTH AVE E, BOSTON, MA 02115 USA.		CLIHON, Residencia Medica/K-4896-2013; Breslow, Jan L/B-7544-2008	CLIHON, Residencia Medica/0000-0001-6734-2513; 	NHLBI NIH HHS [HL-24423, HL-21006, HL-07575] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1982, EPIDEMIOLOGIC RES; AVOGARO P, 1982, ARTERY, V10, P317; BALLANTYNE FC, 1982, METABOLISM, V31, P433, DOI 10.1016/0026-0495(82)90230-X; BARR DP, 1951, AM J MED, V11, P480, DOI 10.1016/0002-9343(51)90183-0; BLUM CB, 1980, J CLIN INVEST, V66, P1240, DOI 10.1172/JCI109975; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; CAMARGO C A JR, 1985, Journal of the American Medical Association, V253, P2854, DOI 10.1001/jama.253.19.2854; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; CASTELLI WP, 1977, LANCET, V2, P153; COLDITZ GA, 1985, AM HEART J, V109, P886, DOI 10.1016/0002-8703(85)90654-4; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CULLEN K, 1982, INT J EPIDEMIOL, V11, P67, DOI 10.1093/ije/11.1.67; DAI WS, 1985, AM J EPIDEMIOL, V122, P620, DOI 10.1093/oxfordjournals.aje.a114141; DANIELSSON B, 1978, SCAND J CLIN LAB INV, V38, P113, DOI 10.1080/00365517809156078; DEUTSCHER S, 1984, AM HEART J, V108, P988, DOI 10.1016/0002-8703(84)90465-4; DIEHL AK, 1988, ATHEROSCLEROSIS, V69, P145, DOI 10.1016/0021-9150(88)90008-1; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; ERNST N, 1980, CIRCULATION, V62, P41; FRASER GE, 1981, AM J EPIDEMIOL, V114, P462, DOI 10.1093/oxfordjournals.aje.a113212; FRASER GE, 1983, ATHEROSCLEROSIS, V46, P275, DOI 10.1016/0021-9150(83)90178-8; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GIDEZ LI, 1982, J LIPID RES, V23, P1206; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GLUECK CJ, 1980, AM J CLIN NUTR, V33, P2287, DOI 10.1093/ajcn/33.11.2287; GOFMAN JW, 1966, CIRCULATION, V34, P679, DOI 10.1161/01.CIR.34.4.679; GORDON T, 1985, AM HEART J, V110, P331, DOI 10.1016/0002-8703(85)90152-8; GORDON T, 1983, AM HEART J, V105, P667, DOI 10.1016/0002-8703(83)90492-1; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HAFFNER SM, 1985, ARTERIOSCLEROSIS, V5, P169, DOI 10.1161/01.ATV.5.2.169; HARTUNG GH, 1983, JAMA-J AM MED ASSOC, V249, P747, DOI 10.1001/jama.249.6.747; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HAYNES SG, 1978, AM J EPIDEMIOL, V107, P362, DOI 10.1093/oxfordjournals.aje.a112556; HENNEKENS CH, 1978, AM J EPIDEMIOL, V107, P196, DOI 10.1093/oxfordjournals.aje.a112525; HERBERT PN, 1985, J CLIN INVEST, V76, P403, DOI 10.1172/JCI111986; HULLEY SB, 1981, CIRCULATION, V64, P57; KLATSKY AL, 1974, ANN INTERN MED, V81, P294, DOI 10.7326/0003-4819-81-3-294; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1981, BRIT MED J, V282, P1741, DOI 10.1136/bmj.282.6278.1741; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; MUSLINER TA, 1982, ARTERIOSCLEROSIS, V2, P160, DOI 10.1161/01.ATV.2.2.160; Pell S, 1973, J Occup Med, V15, P120; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSENBERG L, 1981, AM J PUBLIC HEALTH, V71, P82, DOI 10.2105/AJPH.71.1.82; ROSENGREN A, 1988, ACTA MED SCAND, V223, P111; ROSS RK, 1981, LANCET, V1, P858; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SHAPER AG, 1988, LANCET, V2, P1267; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STASON WB, 1976, AM J EPIDEMIOL, V104, P603, DOI 10.1093/oxfordjournals.aje.a112338; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; TALL AR, 1982, J BIOL CHEM, V257, P198; TASKINEN MR, 1982, METABOLISM, V31, P1168, DOI 10.1016/0026-0495(82)90169-X; TAYLOR KG, 1981, ATHEROSCLEROSIS, V38, P11, DOI 10.1016/0021-9150(81)90098-8; THORARINSSON AA, 1979, J STUD ALCOHOL, V40, P704, DOI 10.15288/jsa.1979.40.704; VALIMAKI M, 1986, ATHEROSCLEROSIS, V59, P147, DOI 10.1016/0021-9150(86)90043-2; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; [No title captured]; 1980, DHHS NIH801527 DDEP, P28; 1974, DHEW NIH75628 NAT HE, P51	64	822	840	2	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1993	329	25					1829	1834		10.1056/NEJM199312163292501	http://dx.doi.org/10.1056/NEJM199312163292501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML588	8247033				2022-12-01	WOS:A1993ML58800001
J	GUADAGNO, TM; OHTSUBO, M; ROBERTS, JM; ASSOIAN, RK				GUADAGNO, TM; OHTSUBO, M; ROBERTS, JM; ASSOIAN, RK			A LINK BETWEEN CYCLIN-A EXPRESSION AND ADHESION-DEPENDENT CELL-CYCLE PROGRESSION	SCIENCE			English	Article							PROTEIN-KINASE; DNA-REPLICATION; GENE-EXPRESSION; DIVISION CYCLE; MESSENGER-RNA; S-PHASE; CDC2; PROLIFERATION; GROWTH; EVENTS	Cell adhesion has an essential role in regulating proliferation during the G1 phase of the cell cycle, and loss of this adhesion requirement is a classic feature of oncogenic transformation. The appearance of cyclin A messenger RNA and protein in late G1 was dependent on cell adhesion in both NRK and NIH 3T3 fibroblasts. In contrast, the expression of Cdc2, Cdk2, cyclin D1, and cyclin E was independent of adhesion in both cell lines. Transfection of NRK cells with a cyclin A complementary DNA resulted in adhesion-independent accumulation of cyclin A protein and cyclin A-associated kinase activity. These transfected cells also entered S phase and complete multiple rounds of cell division in the absence of cell adhesion. Thus, cyclin A is a target of the adhesion-dependent signals that control cell proliferation.	FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, SEATTLE, WA 98104 USA; COLUMBIA UNIV, CTR REPROD SCI, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA	Fred Hutchinson Cancer Center; Columbia University; Columbia University				ohtsubo, motoaki/0000-0002-2479-3178	NIGMS NIH HHS [GM48224] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048224] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BENECKE BJ, 1978, CELL, V14, P931, DOI 10.1016/0092-8674(78)90347-1; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; CARLSON KE, UNPUB; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; DOU QP, 1993, CANCER RES, V53, P1493; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HARTWELL LH, 1973, GENETICS, V74, P267; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOCK RA, 1989, BLOOD, V74, P876; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUHISA T, 1981, EXP CELL RES, V135, P393, DOI 10.1016/0014-4827(81)90176-2; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	53	381	390	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1993	262	5139					1572	1575		10.1126/science.8248807	http://dx.doi.org/10.1126/science.8248807			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248807				2022-12-01	WOS:A1993MK32900041
J	KABATA, H; KUROSAWA, O; ARAI, I; WASHIZU, M; MARGARSON, SA; GLASS, RE; SHIMAMOTO, N				KABATA, H; KUROSAWA, O; ARAI, I; WASHIZU, M; MARGARSON, SA; GLASS, RE; SHIMAMOTO, N			VISUALIZATION OF SINGLE MOLECULES OF RNA-POLYMERASE SLIDING ALONG DNA	SCIENCE			English	Article							DIFFUSION-DRIVEN MECHANISMS; REPRESSOR-OPERATOR INTERACTION; ONE-DIMENSIONAL DIFFUSION; PROTEIN TRANSLOCATION; NUCLEIC-ACIDS; LAC REPRESSOR; ECORI ENDONUCLEASE; PROMOTER SELECTION; GENE-TRANSCRIPTION; ACTIN-FILAMENTS	Transcription requires that RNA polymerase binds to promoters buried in nonspecific sites on DNA. The search for promoters may be facilitated if the polymerase slides along the molecule of DNA. Single molecules of Escherichia coli RNA polymerase were visualized, and their movements on immobilized bacteriophage lambda and T7 DNAs were examined. Deviating from drifts by bulk flow, about 40 percent of the enzyme molecules moved along the extended DNA. The results provide direct evidence for sliding as a mechanism for relocation of the enzyme on DNA.	NATL INST GENET,DNA RES CTR,MISHIMA,SHIZUOKA 411,JAPAN; GRAD UNIV ADV STUDIES,SCH LIFE SCI,MISHIMA 411,JAPAN; SEIKEI UNIV,DEPT ELECT ENGN & ELECTR,TOKYO 103,JAPAN; ADVANCE CO,TOKYO 103,JAPAN; UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT BIOCHEM,NOTTINGHAM NG7 2UH,ENGLAND	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; Seikei University; University of Nottingham			Shimamoto, Nobuo/AAJ-4999-2020	Shimamoto, Nobuo/0000-0001-7579-0084				BEINLSTEV BN, 1980, NUCLEIC ACIDS RES, V8, P1391; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BURGESS RR, 1971, ANNU REV BIOCHEM, V40, P711, DOI 10.1146/annurev.bi.40.070171.003431; Coligan JE, 1991, CURRENT PROTOCOL IMM; EHBRECHT HJ, 1985, J BIOL CHEM, V260, P6160; FICKERT R, 1992, J MOL BIOL, V226, P59, DOI 10.1016/0022-2836(92)90124-3; FUJIOKA M, 1991, BIOCHEMISTRY-US, V30, P1801, DOI 10.1021/bi00221a011; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; IGARASHI K, 1991, J MOL BIOL, V218, P1, DOI 10.1016/0022-2836(91)90865-4; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; MARGARSON SA, UNPUB; NARDONE G, 1986, J BIOL CHEM, V261, P2128; NICKELL C, 1992, BIOCHEMISTRY-US, V31, P4189, DOI 10.1021/bi00132a006; PARK CS, 1982, J BIOL CHEM, V257, P6944; PARK CS, 1982, J BIOL CHEM, V257, P6950; RICCHETTI M, 1988, P NATL ACAD SCI USA, V85, P4610, DOI 10.1073/pnas.85.13.4610; RUUSALA T, 1992, P NATL ACAD SCI USA, V89, P4903, DOI 10.1073/pnas.89.11.4903; SHIMAMOTO N, 1992, STRUCTURAL TOOLS ANA, P241; SINGER P, 1987, J BIOL CHEM, V262, P14178; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WASHIZU M, 1990, IEEE T IND APPL, V26, P1165, DOI 10.1109/28.62403; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0	31	231	239	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1561	1563		10.1126/science.8248804	http://dx.doi.org/10.1126/science.8248804			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248804				2022-12-01	WOS:A1993MK32900037
J	MA, CY; ZHOU, Y; BEACHY, PA; MOSES, K				MA, CY; ZHOU, Y; BEACHY, PA; MOSES, K			THE SEGMENT POLARITY GENE HEDGEHOG IS REQUIRED FOR PROGRESSION OF THE MORPHOGENETIC FURROW IN THE DEVELOPING DROSOPHILA EYE	CELL			English	Article							PATTERN-FORMATION; CELL-INTERACTIONS; IMAGINAL DISKS; EGF RECEPTOR; PATCHED GENE; BETA FAMILY; PROTEIN; EXPRESSION; MUTATIONS; HOMOLOG	Cell-type specification in the Drosophila compound eye begins at the morphogenetic furrow. The furrow sweeps across the developing eye epithelium and is coincident with four classes of cellular events: coordinated changes in cell shape, changes in gene expression, synchronization of the cell cycle, and the specification of a regular array of ommatidial founder cells. The molecular mechanisms that induce these events in the developing eye have hitherto been unknown. We identify here a gene specifically required for furrow progression, hedgehog (hh). We show that hh expression posterior to the morphogenetic furrow is continuously required for its progression. We propose that forward diffusion of hh protein induces anterior cells to enter the furrow.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University	MA, CY (corresponding author), UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089, USA.				NEI NIH HHS [1RO1EYO922-02] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BAKER NE, 1992, J NEUROGENET, V8, P85, DOI 10.3109/01677069209084154; BASLER K, 1991, BIOESSAYS, V13, P621, DOI 10.1002/bies.950131202; Bernard F, 1937, B BIOL FR BELG S, V23; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BROWER DL, 1986, EMBO J, V5, P2649, DOI 10.1002/j.1460-2075.1986.tb04547.x; BROWN NL, 1991, DEVELOPMENT, V113, P1245; BRYANT PJ, 1993, SCIENCE, V259, P229; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; DOE CQ, 1985, PHILOS T R SOC B, V312, P67, DOI 10.1098/rstb.1985.0178; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GARCIABELLIDO A, 1969, J EXP ZOOL, V170, P61, DOI 10.1002/jez.1401700106; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN SM, 1975, ROUX ARCH DEVEL BIOL, V177, P61; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; Hardie R.C., 1985, Progress in Sensory Physiology, V5, P1; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HYDE CAT, 1972, J EMBRYOL EXP MORPH, V27, P367; INGHAM PW, 1985, GENETICS, V111, P463; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; Jan YN, 1992, CURR OPIN GENET DEV, V2, P608, DOI 10.1016/S0959-437X(05)80180-7; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NOWEL MS, 1980, J EMBRYOL EXP MORPH, V60, P329; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SCHALLER HC, 1981, P NATL ACAD SCI-BIOL, V78, P7000, DOI 10.1073/pnas.78.11.7000; SHELTON PMJ, 1974, J EMBRYOL EXP MORPH, V32, P337; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; WHITE RH, 1961, J EXP ZOOL, V148, P223, DOI 10.1002/jez.1401480305; WHITE RH, 1963, J EXP ZOOL, V152, P139, DOI 10.1002/jez.1401520204; Wieschaus E., 1986, P199; WOLFF T, 1991, DEVELOPMENT, V113, P841; XU T, 1993, DEVELOPMENT, V117, P1223; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	62	353	369	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					927	938		10.1016/0092-8674(93)90536-Y	http://dx.doi.org/10.1016/0092-8674(93)90536-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252628	Bronze			2022-12-01	WOS:A1993MK96600012
J	DEHAY, C; GIROUD, P; BERLAND, M; SMART, I; KENNEDY, H				DEHAY, C; GIROUD, P; BERLAND, M; SMART, I; KENNEDY, H			MODULATION OF THE CELL-CYCLE CONTRIBUTES TO THE PARCELLATION OF THE PRIMATE VISUAL-CORTEX	NATURE			English	Article							CORTICAL AREAS; NEOCORTEX; NEURONS; MONKEY; SPECIFICATION; BRAIN; RAT	AN as-vet unresolved issue in developmental neurobiology is whether the discrete areas that form the mammalian cortex emerge from a uniform cortical plate or whether they are already specified in the germinal zone1,2. A feature of the primate striate cortex is that the number of neurons per unit area is twice that of anywhere else in the cerebral cortex3. Here we take advantage of this unique structural feature to investigate whether the extra striate cortical cells are due to increased neuron production during neurogenesis. We labelled precursors undergoing terminal cell division with H-3-thymidine and allowed them to migrate to the cortical plate. Cell counts revealed that their rate of production in the germinal zone of striate cortex is higher than in that giving rise to extrastriate cortex. Also, we used H-3-thymidine pulse injections to investigate cell cycle dynamics and found that this phase of increased production of striate cortical cells is associated with changes in the parameters of the cell cycle. These results show that cortical area identity is at least partially determined at the level of the ventricular zone.	INSERM,U371,18 AVE DOYEN LEPINE,F-69500 BRON,FRANCE; HOP CLAUDE BERNARD,FAC MED LYON NORD,SERV GYNECOL & OBSTET,F-69600 OULLINS,FRANCE; UNIV DUNDEE,DUNDEE DD1 4HN,SCOTLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Dundee			Kennedy, Henry/B-9636-2013; Dehay, Colette/H-4437-2014; Giroud, Pascale/B-9313-2013	Kennedy, Henry/0000-0002-2796-7663; Dehay, Colette/0000-0002-5196-1464; 				ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; ARIMATSU Y, 1992, P NATL ACAD SCI USA, V89, P8879, DOI 10.1073/pnas.89.19.8879; BARBE MF, 1991, J NEUROSCI, V11, P519; BISCONTE JC, 1975, EXP BRAIN RES, V22, P37; COHENTANNOUDJI M, 1992, THESIS PARIS U; DEHAY C, 1989, NATURE, V337, P265, DOI 10.1038/337265a0; FERRI RT, 1993, CEREB CORTEX, V3, P187, DOI 10.1093/cercor/3.3.187; FINLAY BL, 1983, SCIENCE, V219, P1349, DOI 10.1126/science.6828866; JOHNSTON JG, 1989, P NATL ACAD SCI USA, V86, P1066, DOI 10.1073/pnas.86.3.1066; KENNEDY H, 1993, CEREB CORTEX, V3, P171, DOI 10.1093/cercor/3.3.171; Korr H, 1980, Adv Anat Embryol Cell Biol, V61, P1; KOSTOVIC I, 1984, J NEUROSCI, V4, P25; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; MACAULEY A, 1993, DEVELOPMENT, V117, P873; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; RAKIC P, 1976, EXPL BRAINR ES S, V1, P439; ROCKEL AJ, 1980, BRAIN, V103, P221, DOI 10.1093/brain/103.2.221; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SCHULTZE B, 1981, CELL TISSUE KINET, V14, P309, DOI 10.1111/j.1365-2184.1981.tb00535.x; TAKAHASHI T, 1993, J NEUROSCI, V13, P820; WAECHTER RV, 1972, BRAIN RES, V46, P235, DOI 10.1016/0006-8993(72)90018-2; WILLIAMS R W, 1987, Society for Neuroscience Abstracts, V13, P1044	26	122	122	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					464	466		10.1038/366464a0	http://dx.doi.org/10.1038/366464a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247154				2022-12-01	WOS:A1993MK09800064
J	LI, E; BEARD, C; JAENISCH, R				LI, E; BEARD, C; JAENISCH, R			ROLE FOR DNA METHYLATION IN GENOMIC IMPRINTING	NATURE			English	Article							DETERMINES METHYLATION; TRANSGENIC MICE; GENE; GAMETOGENESIS; EMBRYOGENESIS; EXPRESSION; RNA	THE paternal and maternal genomes are not equivalent and both are required for mammalian development1,2. The difference between the parental genomes is believed to be due to gamete-specific differential modification, a process known as genomic imprinting. The study of transgene methylation has shown that methylation patterns can be inherited in a parent-of-origin-specific manner3-7, suggesting that DNA methylation may play a role in genomic imprinting. The functional significance of DNA methylation in genomic imprinting was strengthened by the recent finding that CpG islands (or sites) in three imprinted genes, H19, insulin-like growth factor 2 (Igf-2), and Igf-2 receptor (Igf-2r), are differentially methylated depending on their parental origin8-12. We have examined the expression of these three imprinted genes in mutant mice that are deficient in DNA methyltransferase activity13. We report here that expression of all three genes was affected in mutant embryos: the normally silent paternal allele of the H19 gene was activated, whereas the normally active paternal allele of die Igf-2 gene and the active maternal allele of the Igf-2r gene were repressed. Our results demonstrate that a normal level of DNA methylation is required for controlling differential expression of the paternal and maternal alleles of imprinted genes.	MIT,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Hu, Ruogu/B-2203-2008	Edsall, Lee Elizabeth/0000-0002-0326-2829				BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SASAKI H, 1991, DEVELOPMENT, V111, P573; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8	21	1714	1775	4	190	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 25	1993	366	6453					362	365		10.1038/366362a0	http://dx.doi.org/10.1038/366362a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247133				2022-12-01	WOS:A1993MJ70500054
J	KANE, DJ; SARAFIAN, TA; ANTON, R; HAHN, H; GRALLA, EB; VALENTINE, JS; ORD, T; BREDESEN, DE				KANE, DJ; SARAFIAN, TA; ANTON, R; HAHN, H; GRALLA, EB; VALENTINE, JS; ORD, T; BREDESEN, DE			BCL-2 INHIBITION OF NEURAL DEATH - DECREASED GENERATION OF REACTIVE OXYGEN SPECIES	SCIENCE			English	Article							MITOCHONDRIAL GLUTATHIONE; RAT HEPATOCYTES; TOXICITY; CELLS; PROLIFERATION; MECHANISM; ASSAY	The proto-oncogene bcl-2 inhibits apoptotic and necrotic neural cell death. Expression of Bcl-2 in the GT1-7 neural cell line prevented death as a result of glutathione depletion. Intracellular reactive oxygen species and lipid peroxides rose rapidly in control cells depleted of glutathione, whereas cells expressing Bcl-2 displayed a blunted increase and complete survival. Modulation of the increase in reactive oxygen species influenced the degree of cell death. Yeast mutants null for superoxide dismutase were partially rescued by expression of Bcl-2. Thus, Bcl-2 prevents cell death by decreasing the net cellular generation of reactive oxygen species.	UNIV CALIF LOS ANGELES,BRAIN RES INST,DEPT NEUROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT PATHOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Örd, Tõnis/G-8113-2012; Valentine, Joan S/B-6665-2008	Örd, Tõnis/0000-0001-8778-2508; Valentine, Joan S/0000-0002-7174-925X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS027812] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28222] Funding Source: Medline; NINDS NIH HHS [NS27812] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANE D, UNPUB; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KU RH, 1986, ARCH BIOCHEM BIOPHYS, V247, P183, DOI 10.1016/0003-9861(86)90547-3; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MEREDITH J, 1982, J BIOL CHEM, V257, P3747; MOREL I, 1992, FREE RADICAL BIO MED, V13, P499, DOI 10.1016/0891-5849(92)90144-6; RICHARDS WL, 1985, EXP CELL RES, V159, P235, DOI 10.1016/S0014-4827(85)80052-5; ROSENKRANZ AR, 1992, J IMMUNOL METHODS, V156, P39, DOI 10.1016/0022-1759(92)90008-H; SHRIEVE DC, 1988, J BIOL CHEM, V263, P14107; STARKE PE, 1985, J BIOL CHEM, V260, P86; YAGI K, 1976, BIOCHEM MED METAB B, V15, P212, DOI 10.1016/0006-2944(76)90049-1; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	20	1644	1685	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1274	1277		10.1126/science.8235659	http://dx.doi.org/10.1126/science.8235659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235659				2022-12-01	WOS:A1993MH32400042
J	BREO, DL				BREO, DL			RESEARCHERS LUPSKI AND CHANCE STUDY A BAFFLING GENETIC-DISEASE - THEIR OWN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; LUPSKI JR, 1993, NEW ENGL J MED, V329, P96	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2374	2375		10.1001/jama.270.19.2374	http://dx.doi.org/10.1001/jama.270.19.2374			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230603				2022-12-01	WOS:A1993MF99300035
J	MACCOLLIN, M; MOHNEY, T; TROFATTER, J; WERTELECKI, W; RAMESH, V; GUSELLA, J				MACCOLLIN, M; MOHNEY, T; TROFATTER, J; WERTELECKI, W; RAMESH, V; GUSELLA, J			DNA DIAGNOSIS OF NEUROFIBROMATOSIS-2 - ALTERED CODING SEQUENCE OF THE MERLIN TUMOR-SUPPRESSOR IN AN EXTENDED PEDIGREE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BILATERAL ACOUSTIC NEUROFIBROMATOSIS; TYPE-2 NEUROFIBROMATOSIS; UNITED-KINGDOM; CHROMOSOME-22; DISEASE; SCHWANNOMAS; DELETIONS; MUTATIONS; MARKERS; LINKAGE	Objective.-To define the DNA mutation causing neurofibromatosis 2 (NF2), a severe genetic disorder involving the development of multiple nervous system tumors in adulthood, in a large, well-studied NF2 pedigree previously used to chromosomally map and to isolate the disease gene. Design.-Single-strand conformational polymorphism (SSCP) and DNA sequence analysis of the NF2 gene amplified from affected and unaffected family members. Participants.-Affected, unaffected, and at-risk members of a large pedigree segregating NF2, an autosomal dominant disorder caused by inactivation of the merlin tumor suppressor encoded in chromosome band 22q12. Results.-A DNA alteration in the merlin coding sequence caused a shift on SSCP gels that was characteristic of the disease chromosome in this NF2 pedigree, being transmitted with the disorder, present only in affected members of the pedigree, absent in unaffected members of the family, and absent from 158 unrelated individuals. The alteration caused substitution of a tyrosine for an asparagine at position 220 of the merlin protein, in a region highly conserved in closely related members of the family of cytoskeletal-associated proteins. The DNA change could also be detected by restriction enzyme digestion with Rsa I. Conclusion.-Current practice dictates screening of all those ''at risk'' for NF2 with magnetic resonance imaging, but the frequency and duration of screening are problematic because of the variable course of the disease. The identification of a DNA alteration in the NF2 gene will permit predictive molecular testing of individuals at risk in this specific family, sparing the expense and emotional burden of protracted screening programs. This information, by providing diagnostic certainty, should also reduce psychological and financial burdens and improve medical care for affected family members. A similar approach to defining the underlying lesion and developing a predictive test is applicable in any documented NF2 family.	MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA 02129; UNIV SO ALABAMA,DEPT MED GENET,MOBILE,AL 36688	Harvard University; Massachusetts General Hospital; University of South Alabama					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24279] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; BIJLSMA EK, 1992, GENE CHROMOSOME CANC, V5, P201, DOI 10.1002/gcc.2870050305; COUTURIER J, 1990, CANCER GENET CYTOGEN, V45, P55, DOI 10.1016/0165-4608(90)90066-J; EVANS DGR, 1992, J MED GENET, V29, P847, DOI 10.1136/jmg.29.12.847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FIEDLER W, 1991, GENOMICS, V10, P786, DOI 10.1016/0888-7543(91)90464-P; FONTAINE B, 1991, ANN NEUROL, V29, P183, DOI 10.1002/ana.410290211; FONTAINE B, 1991, GENOMICS, V10, P280, DOI 10.1016/0888-7543(91)90513-E; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; HARPER PS, 1990, LANCET, V335, P1205, DOI 10.1016/0140-6736(90)92713-R; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MULVIHILL JJ, 1990, ANN INTERN MED, V113, P39, DOI 10.7326/0003-4819-113-1-39; NAROD SA, 1992, AM J HUM GENET, V51, P486; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Park James K., 1992, Human Mutation, V1, P293, DOI 10.1002/humu.1380010405; ROULEAU GA, 1990, AM J HUM GENET, V46, P323; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; ROULEAU GA, 1987, NATURE, V329, P246, DOI 10.1038/329246a0; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, SCIENCE, V236, P317, DOI 10.1126/science.3105060; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; WERTELECKI W, 1988, NEW ENGL J MED, V319, P278, DOI 10.1056/NEJM198808043190505; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; WOLFF RK, 1992, AM J HUM GENET, V51, P478; 1988, ARCH NEUROL-CHICAGO, V45, P515	28	57	59	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2316	2320		10.1001/jama.270.19.2316	http://dx.doi.org/10.1001/jama.270.19.2316			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230593				2022-12-01	WOS:A1993MF99300025
J	RASOOLY, A; NOVICK, RP				RASOOLY, A; NOVICK, RP			REPLICATION-SPECIFIC INACTIVATION OF THE PT181 PLASMID INITIATOR PROTEIN	SCIENCE			English	Article							ORIGIN; INVITRO	Replication of the Staphylococcus aureus plasmid pT181, which occurs by the rolling circle mechanism, is accompanied by the covalent attachment of a almost-equal-to 12-residue oligodeoxynucleotide to one subunit of the dimeric plasmid-coded initiator protein, RepC. This oligonucleotide represents the plasmid sequence immediately 3' to the initiating nick site. The resulting heterodimeric protein lacks the topoisomerase and replication activities of unmodified RepC, suggesting that the regulation of plasmid DNA replication requires post-replicational inactivation of the initiator protein as well as control of its synthesis.	PUBL HLTH RES INST CITY NEW YORK INC,DEPT PLASMID BIOL,NEW YORK,NY 10016				Rasooly, Avraham/AAH-4518-2021	Novick, richard/0000-0003-4418-7893	NIGMS NIH HHS [GM14372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGONETTI J, 1990, MOL BIOL STAPHYLOCOC, P283; GENNARO ML, 1989, J MOL BIOL, V205, P355, DOI 10.1016/0022-2836(89)90346-X; KHAN SA, 1981, P NATL ACAD SCI-BIOL, V78, P4902, DOI 10.1073/pnas.78.8.4902; KOEPSEL RR, 1985, J BIOL CHEM, V260, P8571; KOEPSEL RR, 1985, P NATL ACAD SCI USA, V82, P6845, DOI 10.1073/pnas.82.20.6845; KUMAR CC, 1985, P NATL ACAD SCI USA, V82, P638, DOI 10.1073/pnas.82.3.638; MANCHCITRON J, 1986, PLASMID, V108, pB16; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; NOVICK RP, 1984, EMBO J, V3, P2399, DOI 10.1002/j.1460-2075.1984.tb02146.x; NOVICK RP, UNPUB; THOMAS CD, 1990, J BIOL CHEM, V265, P5519	11	57	57	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1048	1050		10.1126/science.8235621	http://dx.doi.org/10.1126/science.8235621			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235621				2022-12-01	WOS:A1993MG18700033
J	MIRANKER, A; ROBINSON, CV; RADFORD, SE; APLIN, RT; DOBSON, CM				MIRANKER, A; ROBINSON, CV; RADFORD, SE; APLIN, RT; DOBSON, CM			DETECTION OF TRANSIENT PROTEIN-FOLDING POPULATIONS BY MASS-SPECTROMETRY	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HYDROGEN-EXCHANGE BEHAVIOR; EGG-WHITE LYSOZYME; STRUCTURAL CHARACTERIZATION; RIBONUCLEASE-A; CYTOCHROME-C; NMR; INTERMEDIATE; PROTECTION; ELEMENTS	Hydrogen-deuterium exchange measurements are becoming increasingly important in studies of the dynamics of protein molecules and, particularly, of their folding behavior. Electrospray ionization mass spectrometry (ESI-MS) has been used to obtain the distribution of masses within a population of protein molecules that had undergone hydrogen exchange in solution. This information is complementary to that from nuclear magnetic resonance spectroscopy (NMR) experiments, which measure the average occupancy of individual sites over the distribution of protein molecules. In experiments with hen lysozyme, a combination of ESI-MS and NMR was used to distinguish between alternative mechanisms of hydrogen exchange, providing insight into the nature and populations of transient folding intermediates. These results have helped to detail the pathways available to a protein during refolding.	UNIV OXFORD, NEW CHEM LAB, OXFORD OX1 3QT, ENGLAND; UNIV OXFORD, DYSON PERRINS LAB, OXFORD OX1 3QY, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, OXFORD OX1 3QY, ENGLAND	University of Oxford; University of Oxford; University of Oxford	MIRANKER, A (corresponding author), UNIV OXFORD, OXFORD CTR MOLEC SCI, S PARKS RD, OXFORD OX1 3QT, ENGLAND.			Radford, Sheena/0000-0002-3079-8039; robinson, carol/0000-0001-7829-5505				BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; DELEPIERRE M, 1987, J MOL BIOL, V197, P111, DOI 10.1016/0022-2836(87)90613-9; DOBSON CM, 1984, BIOCHEMISTRY-US, V23, P4267, DOI 10.1021/bi00314a001; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.bb.21.060192.001331; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; Imoto T., 1972, ENZYMES, V7, P665; ITZHAKI L, UNPUB; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; KATO S, 1982, BIOCHEMISTRY-US, V21, P38, DOI 10.1021/bi00530a007; KATTA V, 1991, RAPID COMMUN MASS SP, V5, P214, DOI 10.1002/rcm.1290050415; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.bi.59.070190.003215; KOSSIAKOFF AA, 1991, BIOCHEMISTRY-US, V30, P1211, DOI 10.1021/bi00219a008; LU JR, 1992, BIOCHEMISTRY-US, V31, P4749, DOI 10.1021/bi00135a002; MCCAMMON JA, 1976, NATURE, V262, P325, DOI 10.1038/262325a0; MCEWEN CN, 1992, RAPID COMMUN MASS SP, V6, P173, DOI 10.1002/rcm.1290060304; MIRANKER A, 1991, NATURE, V349, P633, DOI 10.1038/349633a0; PEDERSEN TG, 1991, J MOL BIOL, V218, P413, DOI 10.1016/0022-2836(91)90722-I; POST CB, 1989, PROTEINS, V5, P337, DOI 10.1002/prot.340050409; RADFORD SE, 1992, PROTEINS, V14, P237, DOI 10.1002/prot.340140210; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RODER H, 1989, METHOD ENZYMOL, V176, P446; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SCHMID FX, 1979, J MOL BIOL, V135, P199, DOI 10.1016/0022-2836(79)90347-4; SEGAWA SI, 1981, BIOPOLYMERS, V20, P1691, DOI 10.1002/bip.1981.360200810; SMITH LJ, 1993, J MOL BIOL, V229, P930, DOI 10.1006/jmbi.1993.1097; SUCKAU D, 1993, P NATL ACAD SCI USA, V90, P790, DOI 10.1073/pnas.90.3.790; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WOODWARD C, 1982, MOL CELL BIOCHEM, V48, P135, DOI 10.1007/BF00421225; ZHANG YP, 1992, BIOCHEMISTRY-US, V31, P11572, DOI 10.1021/bi00161a041; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522	34	545	550	1	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1993	262	5135					896	900		10.1126/science.8235611	http://dx.doi.org/10.1126/science.8235611			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235611				2022-12-01	WOS:A1993MF43800034
J	FEANY, MB; BUCKLEY, KM				FEANY, MB; BUCKLEY, KM			THE SYNAPTIC VESICLE PROTEIN SYNAPTOTAGMIN PROMOTES FORMATION OF FILOPODIA IN FIBROBLASTS	NATURE			English	Article							ALPHA-LATROTOXIN RECEPTOR; SYNAPSIN-I; SYNAPTOPHYSIN; EXPRESSION; NEURONS; BINDING; CELLS; IDENTIFICATION; PC12-CELLS; BIOGENESIS	NEURONAL filopodia are actin-rich cytoplasmic extensions that are involved in motility and recognition in growth cones and maturing axonal endings. A detailed understanding of neuronal growth will depend on clarification of the membrane fusion events occurring during filopodial extension. The synaptic vesicle protein synaptotagmin seems to be intimately involved in exocytotic membrane fusion1-3. Here we show that fibroblast cell lines transfected with synaptotagmin form long, highly branched, actin-rich filopodial processes, with the expressed synaptotagmin being incorporated into the plasma membrane. In contrast, cell lines expressing either of two other synaptic vesicle proteins, SV2 or synaptophysin, generate only rudimentary processes, and, like neurons, sort SV2 and synaptophysin to small intracellular vesicles. As presynaptic calcium entry regulates synaptic vesicle fusion, our results indicate that synaptotagmin might link neuronal activity with synaptic growth.			FEANY, MB (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.			Feany, Mel/0000-0003-0315-7970; Buckley, Kathleen/0000-0003-0283-4917				BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BEBBINGTON C, 1987, DNA CLONING, V3; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERGMANN M, 1991, NEUROSCIENCE, V42, P569, DOI 10.1016/0306-4522(91)90399-9; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHUN JJM, 1988, NEURON, V1, P297; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; FOURNIER S, 1988, J NEUROCHEM, V51, P1599, DOI 10.1111/j.1471-4159.1988.tb01130.x; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; INOUE A, 1992, J BIOL CHEM, V267, P10613; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; LECLERC N, 1989, J COMP NEUROL, V280, P197, DOI 10.1002/cne.902800204; LEUBE RE, 1989, CELL, V59, P433, DOI 10.1016/0092-8674(89)90028-7; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; MASON CA, 1986, NEUROSCIENCE, V19, P1319, DOI 10.1016/0306-4522(86)90146-6; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MULLER SR, 1990, DNA CELL BIOL, V9, P221, DOI 10.1089/dna.1990.9.221; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0	33	60	60	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					537	540		10.1038/364537a0	http://dx.doi.org/10.1038/364537a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8166886				2022-12-01	WOS:A1993LQ66700058
J	BALASCH, J; ARROYO, V; FABREGUES, F; SALO, J; JIMENEZ, W; PARE, JC; VANRELL, JA				BALASCH, J; ARROYO, V; FABREGUES, F; SALO, J; JIMENEZ, W; PARE, JC; VANRELL, JA			NEUROHORMONAL AND HEMODYNAMIC-CHANGES IN SEVERE CASES OF THE OVARIAN HYPERSTIMULATION SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						OVARIAN HYPERSTIMULATION SYNDROME; HEMODYNAMICS; VASODILATION; RENIN-ANGIOTENSIN SYSTEM; VASOPRESSINS	INVITRO FERTILIZATION; PLASMA NOREPINEPHRINE; NITRIC-OXIDE; RENIN; HORMONE; VASODILATION; CIRRHOSIS; PRORENIN; RELEASE; PATHOGENESIS	Objective: To evaluate systemic hemodynamics, endogenous vasoactive neurohormonal factors (renin-angiotensin and sympathetic nervous systems, antidiuretic hormone, atrial natriuretic factor, and renal prostaglandins), and renal function in the severe ovarian hyperstimulation syndrome. Design: Prospective longitudinal study. Setting: Assisted-reproduction unit of a tertiary care hospital in Barcelona, Spain. Patients: 31 consecutive patients having in vitro fertilization with development of ascites because of severe ovarian hyperstimulation syndrome. Measurements: Mean arterial pressure; cardiac output; peripheral vascular resistance; hematocrit concentration; renal function; plasma renin activity; plasma aldosterone, norepinephrine, antidiuretic hormone, and atrial natriuretic peptide determinations; and urinary excretion of prostaglandin E(2) and 6-keto-prostaglandin-F-1 were measured during the syndrome and 4 to 5 weeks after recovery (baseline). Results: During the syndrome, patients showed increased hematocrits (mean of the paired difference, 0.047; 95% CI, 0.029 to 0.064), decreased mean arterial pressure (-16.6 mm Hg; CI, -19.8 to -13.6), increased cardiac output (2.6 L/min; CI, 2.13 to 3.17), and reduced peripheral vascular resistance (-709 dyne/s.cm(-5); CI, -792 to -627). This was accompanied by marked increases of plasma renin (14.4 ng/L.s; CI, 9.87 to 18.90), norepinephrine (1.857 nmol/L; CI, 0.533 to 3.161), antidiuretic hormone (3.3 pg/mL; CI, 1.89 to 4.71), and atrial natriuretic peptide levels (9.7 fmol/mL; CI, 6.1 to 13.2). Hemoconcentration developed in 16 patients (mean of the paired difference in hematocrit concentration, 0.082; CI, 0.063 to 0.101) but not in 15 others (0.009; CI, 0.003 to 0.021). Both groups showed similar values for arterial pressure, cardiac output, and peripheral vascular resistance, but patients with hemoconcentration had higher (P < 0.05) levels of renin (mean, 20.97 ng/L.s [CI, 13.3 to 28.63] compared with 7.83 ng/L.s [CI, 4.08 to 11.58]), norepinephrine (3.907 nmol/L [CI, 3.057 to 4.757] compared with 2.417 [CI, 2.035 to 2.799]), and antidiuretic hormone (6.0 pg/mL [CI, 4.1 to 7.9] compared with 2.4 [CI, 1.7 to 3.03]). Conclusions: In addition to increased capillary permeability, severe ovarian hyperstimulation syndrome is consistently associated with arteriolar vasodilation. The simultaneous occurrence of these disorders leads to hyperdynamic circulatory dysfunction with marked stimulation of the sympathetic nervous system, renin-angiotensin system, and antidiuretic hormone.	UNIV BARCELONA, FAC MED, HOSP CLIN & PROV, LIVER UNIT, BARCELONA, SPAIN; UNIV BARCELONA, FAC MED, HOSP CLIN & PROV, HORMONAL LAB, BARCELONA, SPAIN; UNIV BARCELONA, FAC MED, HOSP CLIN & PROV, CARDIOL UNIT, BARCELONA, SPAIN	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona	BALASCH, J (corresponding author), UNIV BARCELONA, FAC MED, HOSP CLIN & PROV, DEPT OBSTET & GYNECOL, CASANOVA 143, E-08036 BARCELONA, SPAIN.		Salo, Joan/AAB-3175-2020; Arroyo, Vicente/F-9189-2015	Salo, Joan/0000-0001-5292-9274; Arroyo, Vicente/0000-0002-2728-1848; Jimenez, Wladimiro/0000-0002-9376-0214				BALASCH J, 1991, FERTIL STERIL, V56, P1077; BALASCH J, 1992, FERTIL STERIL, V58, P991; BERGH PA, 1992, J ASSIST REPROD GEN, V9, P429, DOI 10.1007/BF01204048; BORENSTEIN R, 1989, FERTIL STERIL, V51, P791; BOSCH J, 1980, GASTROENTEROLOGY, V78, P92; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHANDRARATNA PA, 1984, AM J CARDIOL, V53, P234, DOI 10.1016/0002-9149(84)90718-5; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; CONRAD KP, 1993, FASEB J, V7, P566, DOI 10.1096/fasebj.7.6.7682524; Garza R., 1977, HDB RADIOIMMUNOASSAY; GINES P, 1988, HEPATOLOGY, V8, P636, DOI 10.1002/hep.1840080333; GLORIOSO N, 1986, SCIENCE, V233, P1422, DOI 10.1126/science.3529392; GOLAN A, 1988, FERTIL STERIL, V50, P912; Golan A, 1989, Obstet Gynecol Surv, V44, P430, DOI 10.1097/00006254-198906000-00004; GREGA GJ, 1984, EDEMA, P405; GROSSMAN SH, 1982, HYPERTENSION, V4, P566, DOI 10.1161/01.HYP.4.4.566; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; ITSKOVITZ J, 1987, P NATL ACAD SCI USA, V84, P7285, DOI 10.1073/pnas.84.20.7285; KARPATI L, 1980, CLIN SCI, V59, P369, DOI 10.1042/cs0590369; KEETON TK, 1980, PHARMACOL REV, V32, P81; MAGNESS RR, 1989, AM J PHYSIOL, V256, pE536, DOI 10.1152/ajpendo.1989.256.4.E536; NAVOT D, 1992, FERTIL STERIL, V58, P249; NAVOT D, 1987, FERTIL STERIL, V48, P57; ONG ACM, 1991, CLIN ENDOCRINOL, V34, P43, DOI 10.1111/j.1365-2265.1991.tb01734.x; PEREZAYUSO RM, 1984, KIDNEY INT, V26, P72, DOI 10.1038/ki.1984.136; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; POLISHUK WZ, 1969, FERTIL STERIL, V20, P443; PRIDE SM, 1984, AM J OBSTET GYNECOL, V148, P670, DOI 10.1016/0002-9378(84)90771-3; RIMOLA A, 1988, CLIN SCI, V74, P613, DOI 10.1042/cs0740613; ROBERTSON AL, 1972, CIRC RES, V31, P923, DOI 10.1161/01.RES.31.6.923; ROBERTSON GL, 1992, KIDNEY PHYSL PATHOPH, P1595; SCHENKER JG, 1978, FERTIL STERIL, V30, P255; SCHRIER RW, 1991, OBSTET GYNECOL, V77, P632; SEALEY JE, 1986, AM J MED, V81, P1041, DOI 10.1016/0002-9343(86)90402-X; SMITZ J, 1990, HUM REPROD, V5, P933, DOI 10.1093/oxfordjournals.humrep.a137223; SPARKS HV, 1984, EDEMA, P425; YARALI H, 1993, FERTIL STERIL, V59, P657; 1991, LANCET, V338, P1111	38	56	58	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1994	121	1					27	33		10.7326/0003-4819-121-1-199407010-00005	http://dx.doi.org/10.7326/0003-4819-121-1-199407010-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN271	8198344				2022-12-01	WOS:A1994PN27100005
J	YOON, HS; HAJDUK, PJ; PETROS, AM; OLEJNICZAK, ET; MEADOWS, RP; FESIK, SW				YOON, HS; HAJDUK, PJ; PETROS, AM; OLEJNICZAK, ET; MEADOWS, RP; FESIK, SW			SOLUTION STRUCTURE OF A PLECKSTRIN-HOMOLOGY DOMAIN	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; BINDING-PROTEIN; 3-DIMENSIONAL STRUCTURE; N-15-LABELED PROTEINS; DISTANCE GEOMETRY; CRYSTAL-STRUCTURE; CHEMICAL-SHIFTS; C-ALPHA; KINASE; NMR	Pleckstrin(1), the major protein kinase C substrate of platelets, contains domains of about 100 amino acids at the amino and carboxy termini that have been found in a number of proteins, including serine/threonine kinases, GTPase-activating proteins, phospholipases and cytoskeletal proteins(2-5). These conserved sequences, termed pleckstrin-homology (PH) domains, are thought to be involved in signal transduction. But the details of the function and binding partners of the PH domains have not been characterized. Here we report the solution structure of the N-terminal pleckstrin-homology domain of pleckstrin determined using heteronuclear three-dimensional nuclear magnetic resonance spectroscopy. The structure consists of an up-and-down beta-barrel of seven antiparallel beta-strands and a C-terminal amphiphilic alpha-helix that caps one end of the barrel. The overall topology of the domain is similar to that of the retinol-binding protein family of structures(6-10).	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064	Abbott Laboratories			Yoon, Ho Sup/A-2193-2011	Yoon, Ho Sup/0000-0002-8243-3904				BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, X PLOR 3 1 MANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CLUBB RT, 1992, J MAGN RESON, V97, P213, DOI 10.1016/0022-2364(92)90252-3; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; GRZESLEK S, 1992, J AM CHEM SOC, V114, P6261; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HUBER R, 1987, J MOL BIOL, V195, P423, DOI 10.1016/0022-2836(87)90661-9; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; PAPLZ MZ, 1986, NATURE, V324, P383; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TYRES M, 1988, NATURE, V333, P470; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC	30	200	203	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 23	1994	369	6482					672	675		10.1038/369672a0	http://dx.doi.org/10.1038/369672a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	8208296	Green Accepted			2022-12-01	WOS:A1994NT45900062
J	WENDLING, F; MARASKOVSKY, E; DEBILI, N; FLORINDO, C; TEEPE, M; TITEUX, M; METHIA, N; BRETONGORIUS, J; COSMAN, D; VAINCHENKER, W				WENDLING, F; MARASKOVSKY, E; DEBILI, N; FLORINDO, C; TEEPE, M; TITEUX, M; METHIA, N; BRETONGORIUS, J; COSMAN, D; VAINCHENKER, W			C-MPL LIGAND IS A HUMORAL REGULATOR OF MEGAKARYOCYTOPOIESIS	NATURE			English	Article							COLONY-STIMULATING FACTOR; FACTOR RECEPTOR SUPERFAMILY; MOLECULAR-CLONING; GAMMA-CHAIN; B-CELLS; GROWTH; PURIFICATION; MEMBER; THROMBOPOIETIN; IDENTIFICATION	MEGAKARYOCYTOPOIESIS is the cellular developmental process that leads to platelet production. At least two humoral growth factors mag be necessary for megakaryocyte proliferation and maturation. One is a megakaryocyte-colony stimulating factor (MK-CSF) which induces the proliferation and differentiation of megakaryocyte progenitors(1,2), and the second, thrombopoietin, is a megakaryocyte maturation factor(3). Neither of these factors has been fully characterized. The proto-oncogene c-mpl, an orphan member of the haematopoietin receptor family(4-6), is specifically involved in megakaryocyte regulation(7). Here we present evidence that the c-mpl-encoded receptor binds a ligand (c-Mpl ligand) which is a humoral factor implicated in platelet homeostasis. Our results suggest that c-Mpl ligand, thrombopoietin and MK-CSF might be the same molecule.	HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	WENDLING, F (corresponding author), INST GUSTAVE ROUSSY,INSERM,U362,F-94805 VILLEJUIF,FRANCE.			Vainchenker, William/0000-0003-4705-202X				BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; DEBILI N, 1993, BLOOD, V82, P84, DOI 10.1182/blood.V82.1.84.bloodjournal82184; FANSLOW WC, 1992, J IMMUNOL, V149, P655; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; HOFFMAN R, 1985, J CLIN INVEST, V75, P1174, DOI 10.1172/JCI111813; HOFFMAN R, 1989, BLOOD, V74, P1196; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; MAZUR EM, 1985, EXP HEMATOL, V13, P1164; MAZUR EM, 1990, BLOOD, V76, P290; MCDONALD TP, 1988, EXP HEMATOL, V16, P201; MCDONALD TP, 1973, P SOC EXP BIOL MED, V144, P1006; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; METCALF D, 1984, HEMATOPOIETIC COLONY, P124; METHIA N, 1993, BLOOD, V82, P1395; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WILLIAMS N, 1982, J CELL PHYSIOL, V110, P101, DOI 10.1002/jcp.1041100116; ZIEGLER SF, 1991, NEW BIOL, V3, P1242	23	648	697	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 16	1994	369	6481					571	574		10.1038/369571a0	http://dx.doi.org/10.1038/369571a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	8202160				2022-12-01	WOS:A1994NR29400053
J	LEEVERS, SJ; PATERSON, HF; MARSHALL, CJ				LEEVERS, SJ; PATERSON, HF; MARSHALL, CJ			REQUIREMENT FOR RAS IN RAF ACTIVATION IS OVERCOME BY TARGETING RAF TO THE PLASMA-MEMBRANE	NATURE			English	Article							PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; PHOSPHORYLATION; ASSOCIATION; P21(RAS); P21RAS; MUTANT; CELLS	A CONSERVED tyrosine kinase-activated signal transduction pathway has recently been identified that comprises the plasma membrane-bound small guanine-nucleotide-binding protein Ras and the protein kinases Raf, MAP-kinase kinase and MAP kinase(1,2). GTP-bound Ras interacts directly with the amino-terminal regulatory domain of Raf(3-8), but although Ras and Raf can be coimmunoprecipitated from ligand-stimulated cells(9,10), Ras-GTP does not stimulate the kinase activity of Raf in vitro(6). Furthermore, we have failed to detect Ras in preparations of active detergent-solubilized Raf, demonstrating that once it is activated, Raf does not require Ras. Whereas Raf is normally cytosolic, in cells expressing active Ras, Raf is associated with the plasma membrane. This led us to investigate whether Ras is required to localize Raf to the plasma membrane in order for Raf to become activated. We fused the membrane localization signal of K-Ras(4B) to the carboxy terminus of Raf. This protein is constitutively active and can be further activated by epidermal growth factor, independently of Ras. Our results indicate that Ras functions as a regulated, membrane-bound anchor for Raf, and that other signal(s) also contribute to Raf activation.	INST CANC RES,CHESTER BEATTY LABS,CELL & MOLEC BIOL SECT,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOTJEK AB, 1993, CELL, V74, P205; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; ZHANG XF, 1993, NATURE, V364, P398	29	950	966	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					411	414		10.1038/369411a0	http://dx.doi.org/10.1038/369411a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	8196769				2022-12-01	WOS:A1994NP17400060
J	WU, LJ; ERRINGTON, J				WU, LJ; ERRINGTON, J			BACILLUS-SUBTILIS SPOIIIE PROTEIN REQUIRED FOR DNA SEGREGATION DURING ASYMMETRIC CELL-DIVISION	SCIENCE			English	Article							ESCHERICHIA-COLI; GENE-EXPRESSION; SPORULATION GENE; NUCLEOTIDE-SEQUENCE; ENDOSPORE FORMATION; COAT MORPHOGENESIS; SIGMA-F; REPLICATION; TRANSCRIPTION; DEPENDENCE	Sporulation in Bacillus subtilis begins with an asymmetric cell division, producing a smaller prespore and a larger mother cell, both of which contain intact copies of the chromosome. The spoIIIE gene is required for chromosome segregation into the prespore compartment. The effects of the spoIIIE36 mutation on sigma(F)-dependent transcription are an indirect consequence of the failure of certain genes to enter the cellular compartment in which their transcription factor has become active. SpoIIIE may also be required to prevent sigma(F) from becoming active in the mother cell.	UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND	University of Oxford			Errington, Jeff/G-1832-2011	Errington, Jeff/0000-0002-6977-9388; Wu, Ling Juan/0000-0003-2432-8820				ALLMANSBERGER R, UNPUB; Anagnostopoulos C., 1993, P425; BARER MR, UNPUB; BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447; BENJAMIN P, 1983, P NATL ACAD SCI-BIOL, V80, P6214, DOI 10.1073/pnas.80.20.6214; BUTLER PD, 1987, J GEN MICROBIOL, V133, P2359; BYLUND JE, 1993, J BACTERIOL, V175, P1886, DOI 10.1128/JB.175.7.1886-1890.1993; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DANIEL RA, 1993, J MOL BIOL, V232, P468, DOI 10.1006/jmbi.1993.1403; EAST AK, 1989, GENE, V81, P35, DOI 10.1016/0378-1119(89)90334-X; ERRINGTON J, 1986, J GEN MICROBIOL, V132, P2967; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; FOULGER D, 1989, MOL MICROBIOL, V3, P1247, DOI 10.1111/j.1365-2958.1989.tb00275.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HUISMAN O, 1981, NATURE, V290, P797, DOI 10.1038/290797a0; ILLING N, 1991, J BACTERIOL, V173, P3159, DOI 10.1128/JB.173.10.3159-3169.1991; JAFFE A, 1986, J BACTERIOL, V165, P66, DOI 10.1128/jb.165.1.66-71.1986; KARMAZYNCAMPELLI C, 1989, GENE DEV, V3, P150, DOI 10.1101/gad.3.2.150; LAFFAN JJ, 1988, P NATL ACAD SCI USA, V85, P7452, DOI 10.1073/pnas.85.20.7452; LEWIS PJ, IN PRESS P NATL ACAD; LEWIS PM, UNPUB; LOBNEROLESEN A, 1992, J BACTERIOL, V174, P7883; LOSICK R, 1986, ANNU REV GENET, V20, P625, DOI 10.1146/annurev.ge.20.120186.003205; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MCGINNESS T, 1979, J MOL BIOL, V134, P251, DOI 10.1016/0022-2836(79)90035-4; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; ROELS S, 1992, J BACTERIOL, V174, P575, DOI 10.1128/jb.174.2.575-585.1992; RYTER A, 1965, ANN I PASTEUR PARIS, V108, P40; SETLOW B, 1991, J BACTERIOL, V173, P6270, DOI 10.1128/jb.173.19.6270-6278.1991; SETLOW P, UNPUB; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERLINI JM, 1969, BIOCHEM J, V113, P29, DOI 10.1042/bj1130029; STEVENS CM, 1992, J BACTERIOL, V174, P586, DOI 10.1128/jb.174.2.586-594.1992; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STRAGIER P, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P243; SUN DX, 1991, J BACTERIOL, V173, P2977, DOI 10.1128/JB.173.9.2977-2984.1991; SUN DX, 1991, J BACTERIOL, V173, P7867, DOI 10.1128/jb.173.24.7867-7874.1991; SUSSMAN MD, 1991, J BACTERIOL, V173, P291, DOI 10.1128/jb.173.1.291-300.1991; VANITERSON W, 1976, MICROBIOLOGY 1976, P128; WINSTON S, 1980, P NATL ACAD SCI-BIOL, V77, P2834, DOI 10.1073/pnas.77.5.2834; WU LB, UNPUB	45	280	290	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 22	1994	264	5158					572	575		10.1126/science.8160014	http://dx.doi.org/10.1126/science.8160014			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	8160014				2022-12-01	WOS:A1994NH01000038
J	SAGIE, A; LARSON, MG; LEVY, D				SAGIE, A; LARSON, MG; LEVY, D			THE NATURAL-HISTORY OF BORDERLINE ISOLATED SYSTOLIC HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-PRESSURE; MEN; RISK; DISEASE; TRIAL; DEATH	Background. Patients with isolated systolic hypertension are at increased risk for cardiovascular disorders. We attempted to determine whether those with borderline isolated systolic hypertension (defined as a systolic blood pressure of 140 to 159 mm Hg and a diastolic blood pressure below 90 mm Hg) have a greater risk of progression to definite (more severe) hypertension and of major morbid or fatal events than people with normal blood pressure (<140/90 mm Hg). Methods. A total of 2767 of the original participants in the Framingham Heart Study were monitored with biennial examinations for up to 34 years for the development of definite hypertension (defined as a systolic blood pressure of greater-than-or-equal-to 160 mm Hg, a diastolic blood pressure of greater-than-or-equal-to 90 mm Hg, or the initiation of antihypertensive therapy) and for major cardiovascular events. Results. Borderline isolated systolic hypertension was the most common type of untreated hypertension among adults over the age of 60. After 20 years of follow-up, 80 percent of those with borderline isolated systolic hypertension had progression to definite hypertension, as compared with 45 percent of the normotensive participants (P<0.001). After adjustment for age, sex, and risk factors for cardiovascular disease, participants with borderline isolated systolic hypertension had an excess long-term risk of cardiovascular disease (hazard ratio, 147; 95 percent confidence interval, 1.24 to 1.74) and death from cardiovascular disease (hazard ratio, 1.57; 95 percent confidence interval, 1.24 to 2.00), as compared with normotensive participants. In an analysis of pooled data from biennial examinations to study short-term sequelae, subjects with borderline isolated systolic hypertension had an increased risk of progression to definite hypertension (odds ratio, 3.84; 95 percent confidence interval, 3.35 to 4.41) and of cardiovascular disease (odds ratio, 1.39; 95 percent confidence interval, 1.06 to 1.82). Conclusions. In both the short term and the long term, subjects with borderline isolated systolic hypertension are at increased risk of progression to definite hypertension and the development of cardiovascular disease.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA; NHLBI, BETHESDA, MD 20892 USA; BOSTON UNIV, SCH MED, DIV EPIDEMIOL, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DIV PREVENT MED, BOSTON, MA 02118 USA; BETH ISRAEL HOSP, DIV CARDIOL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center			Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021	Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254				[Anonymous], 1985, Hypertension, V7, P641; BRONTESTEWART B, 1954, J PATHOL BACTERIOL, V68, P407, DOI 10.1002/path.1700680214; COLANDREA MA, 1970, CIRCULATION, V41, P239, DOI 10.1161/01.CIR.41.2.239; Cox DR, 1984, ANAL SURVIVAL DATA, P1; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; FROOM P, 1983, CIRCULATION, V68, P467, DOI 10.1161/01.CIR.68.3.467; Hosmer D.W., 1989, APPL LOGISTIC REGRES, P1; Hypertension Prevention Trial Research Group, 1990, ARCH INTERN MED, V150, P153, DOI [10.1001/archinte.1990.00390130131021, DOI 10.1001/ARCHINTE.1990.00390130131021]; KANNEL WB, 1980, CIRCULATION, V61, P1179, DOI 10.1161/01.CIR.61.6.1179; KANNEL WB, 1974, PROG CARDIOVASC DIS, V27, P5; KANNEL WB, 1987, DHHS NIH872703 PUBL; LEITSCHUH M, 1991, HYPERTENSION, V17, P22, DOI 10.1161/01.HYP.17.1.22; MOSES C, 1954, CIRC RES, V2, P243, DOI 10.1161/01.RES.2.3.243; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; PSATY BM, 1992, JAMA-J AM MED ASSOC, V268, P1287, DOI 10.1001/jama.268.10.1287; RUTAN GH, 1988, CIRCULATION, V77, P504, DOI 10.1161/01.CIR.77.3.504; SCHATZKIN A, 1984, AM HEART J, V107, P1300, DOI 10.1016/0002-8703(84)90302-8; SHEKELLE RB, 1974, STROKE, V5, P71, DOI 10.1161/01.STR.5.1.71; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; The 1988 report of the Joint National Committee on Detection, 1988, ARCH INTERN MED, V148, P1203; WILKING S V B, 1988, Journal of the American Medical Association, V260, P3451, DOI 10.1001/jama.260.23.3451; 1980, BLOOD PRESSURE STUDY, P64; 1991, SAS P217 TECHN REP, P1; 1993, ARCH INTERN MED, V153, P154; 1959, BUILD BLOOD PRESSURE, V1, P121; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1993, HYPERTENSION, V22, P392; 1990, SAS STAT USERS GUIDE, V2, P1027; 1985, HYPERTENSION, V7, P457; 1978, AHA MONOGRAPH, V60	33	214	220	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1912	1917		10.1056/NEJM199312233292602	http://dx.doi.org/10.1056/NEJM199312233292602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM885	8247055				2022-12-01	WOS:A1993MM88500002
J	SADOSHIMA, J; XU, YH; SLAYTER, HS; IZUMO, S				SADOSHIMA, J; XU, YH; SLAYTER, HS; IZUMO, S			AUTOCRINE RELEASE OF ANGIOTENSIN-II MEDIATES STRETCH-INDUCED HYPERTROPHY OF CARDIAC MYOCYTES IN-VITRO	CELL			English	Article							GENE-EXPRESSION; CONVERTING ENZYME; PRESSURE-OVERLOAD; GROWTH; RENIN; RAT; SYSTEM; CELLS; IMMUNOREACTIVITY; REGRESSION	Hypertrophy is a fundamental adaptive process employed by postmitotic cardiac and skeletal muscle in response to mechanical load. How muscle cells convert mechanical stimuli into growth signals has been a long-standing question. Using an in vitro model of load (stretch)-induced cardiac hypertrophy, we demonstrate that mechanical stretch causes release of angiotensin II (Ang II) from cardiac myocytes and that Ang II acts as an initial mediator of the stretch-induced hypertrophic response. The results not only provide direct evidence for the autocrine mechanism in load-induced growth of cardiac muscle cells, but also define the pathophysiological role of the local (cardiac) renin-angiotensin system.	BETH ISRAEL HOSP, DIV CARDIOVASC, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM CELL & DEV BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	SADOSHIMA, J (corresponding author), BETH ISRAEL HOSP, DIV MOLEC MED, BOSTON, MA 02215 USA.			Sadoshima, Junichi/0000-0003-3724-4132				BAKER KM, 1990, AM J PHYSIOL, V259, pH324, DOI 10.1152/ajpheart.1990.259.2.H324; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.ph.54.030192.001303; BEINLICH CJ, 1991, J MOL CELL CARDIOL, V23, P1031, DOI 10.1016/0022-2828(91)91638-8; BLOCH KD, 1986, CELL, V47, P695, DOI 10.1016/0092-8674(86)90512-X; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CAMPBELL DJ, 1987, J CLIN INVEST, V79, P1, DOI 10.1172/JCI112768; CELIO MR, 1981, P NATL ACAD SCI-BIOL, V78, P3897, DOI 10.1073/pnas.78.6.3897; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; DESILVA PE, 1988, ANAL BIOCHEM, V174, P80, DOI 10.1016/0003-2697(88)90521-0; DOSTAL DE, 1992, AM J PHYSIOL, V263, pC838, DOI 10.1152/ajpcell.1992.263.4.C838; DZAU VJ, 1993, RENIN ANGIOTENSIN SY; HAMMOND GL, 1982, SCIENCE, V216, P529, DOI 10.1126/science.6461921; HOLMQUIST B, 1979, ANAL BIOCHEM, V95, P540, DOI 10.1016/0003-2697(79)90769-3; INAGAMI T, 1993, RENIN ANGIOTENSIN SY; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KIFOR I, 1991, ENDOCRINOLOGY, V128, P1277, DOI 10.1210/endo-128-3-1277; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; LINDPAINTNER K, 1991, CIRC RES, V68, P905, DOI 10.1161/01.RES.68.4.905; LINZ W, 1989, CLIN EXP HYPERTENS A, V11, P1325, DOI 10.3109/10641968909038172; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; OKAMURA T, 1981, P NATL ACAD SCI-BIOL, V78, P6940, DOI 10.1073/pnas.78.11.6940; PFEFFER JM, 1982, P NATL ACAD SCI-BIOL, V79, P3310, DOI 10.1073/pnas.79.10.3310; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; RAVAZZOLA M, 1980, NATURE, V284, P66, DOI 10.1038/284066a0; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, P NATL ACAD SCI USA, V89, P9905, DOI 10.1073/pnas.89.20.9905; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHNEIDER M D, 1991, Progress in Growth Factor Research, V3, P1, DOI 10.1016/0955-2235(91)90010-2; VANDENBURGH H, 1979, SCIENCE, V203, P265, DOI 10.1126/science.569901; VANDENBURGH HH, 1992, AM J PHYSIOL, V262, pR350, DOI 10.1152/ajpregu.1992.262.3.R350; WATKINS SC, 1990, HISTOCHEM J, V22, P507, DOI 10.1007/BF01007236; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069	37	1123	1147	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					977	984		10.1016/0092-8674(93)90541-W	http://dx.doi.org/10.1016/0092-8674(93)90541-W			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252633	Bronze			2022-12-01	WOS:A1993MK96600017
J	KERLIKOWSKE, K; GRADY, D; BARCLAY, J; SICKLES, EA; EATON, A; ERNSTER, V				KERLIKOWSKE, K; GRADY, D; BARCLAY, J; SICKLES, EA; EATON, A; ERNSTER, V			POSITIVE PREDICTIVE VALUE OF SCREENING MAMMOGRAPHY BY AGE AND FAMILY HISTORY OF BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; MEDICAL AUDIT; DEATH RATES; OLDER WOMEN; LOW-COST; COMMUNITY; MORTALITY; PROGRAM; TRIAL; CARCINOMA	Objective.-To determine the positive predictive value (PPV) of low-cost screening mammography according to age and family history of breast cancer. Design.-Cross-sectional. Setting.-Six counties in northern California. Participants.-A total of 31 814 women aged 30 years and older referred for mammography to the University of California, San Francisco, Mobile Mammography Screening Program from April 18, 1985, through November 20, 1992. Measurements.-Breast cancer risk profile, two standard mammographic views per breast, and follow-up of abnormal screening examinations. Results.-Although women aged 50 years or older constituted only 38.3% of all women who received first-screening mammography, 74% of breast cancers were detected in this group. Ten cancers were diagnosed per 1000 first-screening examinations in women aged 50 years or older, with 14.8 diagnostic procedures per cancer diagnosed compared with two cancers per 1000 screening examinations and 48.3 diagnostic tests per cancer diagnosed in women younger than 50 years. The PPV of first-screening mammography (number of breast cancers detected per abnormal examination) increased with age: .03 for those aged 30 to 39 years; .04 for those aged 40 to 49; .09 for those aged 50 to 59; .17 for those aged 60 to 69; and .1 9 for those aged 70 years or older (chi2 for trend, P<.001). Women aged 50 to 59 years had a higher PPV for first-screening mammography than women aged 40 to 49 years (.09 vs.04; P=.004), and women with a family history of breast cancer had higher PPVs compared with women without history (40 to 49 years of age, 13 vs .04, P=.01; and 50 to 59 years of age, .22 vs .09, P=.01). Conclusion.-Five times as many cancers per 1000 first-screening mammographic examinations were diagnosed in women aged 50 years or older compared with women aged less than 50 years. The highest PPVs for mammography were in women aged 50 years or older and in women aged 40 years or older with a family history of breast cancer. Efforts to promote screening mammography should focus on women in these groups, in whom the majority of breast cancers occur and for whom mammography has the highest PPVs.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT VET AFFAIRS,GEN INTERNAL MED SECT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ALGHISI A, 1990, TUMORI, V76, P22, DOI 10.1177/030089169007600105; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; ARNESSON LG, 1989, BRIT J SURG, V76, P672, DOI 10.1002/bjs.1800760707; BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; CIATTO S, 1990, J CLIN EPIDEMIOL, V43, P419, DOI 10.1016/0895-4356(90)90129-D; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; COLLETTE HJA, 1988, SCREENING BREAST CAN, P17; COSTANZA ME, 1992, CANCER, V69, P1925, DOI 10.1002/1097-0142(19920401)69:7+<1925::AID-CNCR2820691709>3.0.CO;2-U; DERSHAW DD, 1992, RADIOLOGY, V184, P415, DOI 10.1148/radiology.184.2.1620839; DEWAARD F, 1984, J CHRON DIS, V37, P1, DOI 10.1016/0021-9681(84)90123-1; Elwood JM, 1993, ONLINE J CURR CLIN T; Farrow J H, 1970, Cancer, V25, P468, DOI 10.1002/1097-0142(197002)25:2<468::AID-CNCR2820250226>3.0.CO;2-0; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; GOODNO JA, 1990, AM J OBSTET GYNECOL, V162, P1393, DOI 10.1016/0002-9378(90)90897-G; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HUMPHREY LL, 1988, WESTERN J MED, V149, P95; HURLEY SF, 1992, EPIDEMIOL REV, V14, P101, DOI 10.1093/oxfordjournals.epirev.a036082; KETCHAM AS, 1990, CANCER, V65, P387, DOI 10.1002/1097-0142(19900201)65:3<387::AID-CNCR2820650302>3.0.CO;2-Y; KOPANS DB, 1992, AM J ROENTGENOL, V158, P521, DOI 10.2214/ajr.158.3.1310825; KOPANS DB, 1992, J GERONTOL, V47, P59; KUNI CC, 1993, AM J PREV MED, V9, P185, DOI 10.1016/S0749-3797(18)30736-0; LAGIOS MD, 1989, CANCER, V63, P618, DOI 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; LINVER MN, 1992, RADIOLOGY, V184, P39, DOI 10.1148/radiology.184.1.1609100; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MONTICCIOLO DL, 1990, AM J ROENTGENOL, V155, P751, DOI 10.2214/ajr.155.4.2119104; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; OMALLEY MS, 1990, DOES SCREENING BREAS; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; PEETERS PHM, 1989, INT J CANCER, V43, P226, DOI 10.1002/ijc.2910430209; PILLSBURY SG, 1991, AM J OBSTET GYNECOL, V164, P1643, DOI 10.1016/0002-9378(91)91449-7; REINIG JW, 1991, RADIOLOGY, V180, P393, DOI 10.1148/radiology.180.2.2068301; ROBERTS MM, 1990, LANCET, V335, P241; RUBIN E, 1990, SOUTHERN MED J, V83, P178, DOI 10.1097/00007611-199002000-00011; Shapiro S, 1988, PERIODIC SCREENING B; SICKLES EA, 1986, RADIOLOGY, V160, P95, DOI 10.1148/radiology.160.1.3715053; SICKLES EA, 1992, RADIOL CLIN N AM, V30, P265; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; SICKLES EA, 1987, RADIOL CLIN N AM, V25, P1015; STACEYCLEAR A, 1992, LANCET, V340, P991; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; VERBEEK ALM, 1991, BRIT J CANCER, V63, P261, DOI 10.1038/bjc.1991.61; Warren D L, 1989, J Ky Med Assoc, V87, P169; WOOLF SH, 1992, CANCER, V69, P1913, DOI 10.1002/1097-0142(19920401)69:7+<1913::AID-CNCR2820691707>3.0.CO;2-6; 1990, JAMA-J AM MED ASSOC, V264, P54; 1988, NCI902789 PUBL; 1988, MANUAL STAGING CANCE; 1993, CANCER INCIDENCE MOR; 1988, LANCET, V2, P411; 1988, MMWR MORB MORTAL WKL, V37, P357; 1992, MMWR MORB MORTAL WKL, V41, P454	56	291	297	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1993	270	20					2444	2450		10.1001/jama.270.20.2444	http://dx.doi.org/10.1001/jama.270.20.2444			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG671	8230621				2022-12-01	WOS:A1993MG67100025
J	SANDELL, LL; ZAKIAN, VA				SANDELL, LL; ZAKIAN, VA			LOSS OF A YEAST TELOMERE - ARREST, RECOVERY, AND CHROMOSOME LOSS	CELL			English	Article							CELL-CYCLE ARREST; MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; DNA-SEQUENCES; DROSOPHILA; TRANSMISSION; ELONGATION; DAMAGE; GENES; RAD9	Yeast strains were constructed in which a single telomere could be eliminated from the end of a dispensable chromosome. In wild-type cells, elimination of a telomere caused a RAD9-mediated cell cycle arrest, indicating that telomeres help cells to distinguish intact chromosomes from damaged DNA. However, many cells recovered from the arrest without repairing the damaged chromosome, replicating and segregating it for as many as ten cell divisions prior to its eventual loss. Telomere elimination caused a dramatic increase in loss of the chromosome in all strains examined, demonstrating that yeast telomeres are also essential for maintaining chromosome stability. Thus, in spite of checkpoint and DNA damage repair systems, many chromosomes that lose a telomere are themselves destined for loss.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	SANDELL, LL (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.		Sandell, Lisa L/M-4238-2013	Sandell, Lisa L/0000-0002-1735-8223	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026938, R01GM026938] Funding Source: NIH RePORTER; NIA NIH HHS [AG00057] Funding Source: Medline; NIGMS NIH HHS [GM26938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIESSMANN H, 1988, EMBO J, V7, P1081, DOI 10.1002/j.1460-2075.1988.tb02916.x; BIESSMANN H, 1990, P NATL ACAD SCI USA, V87, P1758, DOI 10.1073/pnas.87.5.1758; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; DUTCHER SK, 1981, MOL CELL BIOL, V1, P245, DOI 10.1128/MCB.1.3.245; HABER JE, 1984, GENETICS, V106, P207; HARLEY CB, 1989, TRENDS GENET, V5, P326; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HENIKOFF S, 1987, GENETICS, V117, P711; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KENDAL WS, 1988, CANCER RES, V48, P1060; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEVIS RW, 1989, CELL, V58, P791, DOI 10.1016/0092-8674(89)90112-8; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Luria SE, 1943, GENETICS, V28, P491; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MASON JM, 1984, P NATL ACAD SCI-BIOL, V81, P6090, DOI 10.1073/pnas.81.19.6090; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; McClintock B, 1941, GENETICS, V26, P234; MCCUSKER JH, 1981, GENETICS, V99, P383; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; MORTIMER RK, 1981, P NATL ACAD SCI-BIOL, V78, P5778, DOI 10.1073/pnas.78.9.5778; Muller H, 1938, COLLECTING NET, V13, P181; Muller H. J., 1941, Cold Spring Harbor Symposia on Quantitative Biology, V9, P151; Muller HJ., 1938, COLLECT NET, V13, P181; PAQUIN CE, 1986, MOL CELL BIOL, V6, P70, DOI 10.1128/MCB.6.1.70; RUNGE KW, 1991, MOL CELL BIOL, V11, P2919, DOI 10.1128/MCB.11.6.2919; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; SCHIESTL RH, 1989, MOL CELL BIOL, V9, P1882, DOI 10.1128/MCB.9.5.1882; SMITH KA, 1992, P NATL ACAD SCI USA, V89, P5427, DOI 10.1073/pnas.89.12.5427; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; Therman E., 1986, HUMAN CHROMOSOMES ST; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZHANG P, 1993, GENETICS, V133, P361	36	701	711	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					729	739		10.1016/0092-8674(93)90493-A	http://dx.doi.org/10.1016/0092-8674(93)90493-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242745	Bronze			2022-12-01	WOS:A1993MH74900018
J	GOULD, SJ; ELDREDGE, N				GOULD, SJ; ELDREDGE, N			PUNCTUATED EQUILIBRIUM COMES OF AGE	NATURE			English	Review							CHESAPEAKE GROUP MOLLUSKS; PHYLETIC GRADUALISM; PALEONTOLOGICAL DOCUMENTATION; EVOLUTIONARY PATTERNS; MORPHOLOGICAL STASIS; NEOGENE BRYOZOAN; SPECIES LEVEL; TURKANA BASIN; SPECIATION; TEMPO	The intense controversies that surrounded the youth of punctuated equilibrium have helped it mature to a useful extension of evolutionary theory. As a complement to phyletic gradualism, its most important implications remain the recognition of stasis as a meaningful and predominant pattern within the history of species, and in the recasting of macroevolution as the differential success of certain species (and their descendants) within clades.	AMER MUSEUM NAT HIST, DEPT INVERTEBRATES, NEW YORK, NY 10024 USA	American Museum of Natural History (AMNH)	GOULD, SJ (corresponding author), HARVARD UNIV, MUSEUM COMPARAT ZOOL, CAMBRIDGE, MA 02138 USA.							AGER D V, 1976, Proceedings of the Geologists' Association, V87, P131; AGER DV, 1983, PALAEONTOLOGY, V26, P555; AVISE JC, 1977, P NATL ACAD SCI USA, V74, P5083, DOI 10.1073/pnas.74.11.5083; Barnosky A.D., 1987, Current Mammalogy, V1, P109; Bergstrom J., 1978, Geologica et Palaeontologica, V12, P1; Brandon R.N., 1990, ADAPTATION ENV; BRETT CE, 1992, GEOL SOC AM ANN M BO, P139; BUDD AF, 1992, PALEOBIOLOGY, V18, P425, DOI 10.1017/S0094837300010988; CHALINE J, 1986, PALEOBIOLOGY, V12, P203, DOI 10.1017/S009483730001366X; CHEETHAM AH, 1987, PALEOBIOLOGY, V13, P286; CHEETHAM AH, 1986, PALEOBIOLOGY, V12, P190, DOI 10.1017/S0094837300013658; COOPE GR, 1979, ANNU REV ECOL SYST, V10, P247, DOI 10.1146/annurev.es.10.110179.001335; CRONIN TM, 1985, SCIENCE, V227, P60, DOI 10.1126/science.227.4682.60; Dawkins R., 1986, LONGMAN, V32, P361; Eldredge N., 1972, P82; Eldredge N., 1984, LIVING FOSSILS; ELDREDGE N, 1979, B CARNEGIE MUS NAT H, V13, P7; ELDREDGE N, 1982, MONKEY BUSINESS SCI; Eldredge N., 1989, MACROEVOLUTIONARY DY; ERWIN D, 1992, SPECIATION FOSSIL RE, P138; FINNEY SC, 1986, GEOLOGICAL SOC SPECI, V20, P103; Flynn L. J., 1986, CONTRIBUTIONS GEOLOG, V3, P273; FORTEY RA, 1985, SPEC PAP PALAEONTOL, P17; FRYER G, 1983, BIOL J LINN SOC, V20, P195, DOI 10.1111/j.1095-8312.1983.tb00363.x; FUTUYMA DJ, 1987, AM NAT, V130, P465, DOI 10.1086/284724; GINGERICH PD, 1976, AM J SCI, V276, P1, DOI 10.2475/ajs.276.1.1; Gould S.J., 1982, P83; GOULD S J, 1977, Paleobiology, V3, P115; GOULD SJ, 1986, AM SCI, V74, P60; GOULD SJ, 1988, J PALEONTOL, V62, P319, DOI 10.1017/S0022336000059126; Gould SJ, 1983, HENS TEETH HORSES TO; HALDANE JBS, 1949, EVOLUTION, V3, P51, DOI 10.2307/2405451; HALLAM A, 1978, PALEOBIOLOGY, V4, P16, DOI 10.1017/S0094837300005650; Hanson NorwoodRussell., 1969, PERCEPTION DISCOVERY, P91; Hoffman A., 1998, ARGUMENTS EVOLUTION; JACKSON JBC, 1990, SCIENCE, V248, P579, DOI 10.1126/science.248.4955.579; JOHNSON JG, 1975, J PALEONTOL, V49, P646; JOHNSON JG, 1982, J PALEONTOL, V56, P1329; KELLEY PH, 1984, J PALEONTOL, V58, P1235; KELLEY PH, 1983, J PALEONTOL, V57, P581; Kellogg V. L., 1907, DARWINISM TODAY; Kuhn Thomas S., 1962, STRUCTURE SCI REVOLU, V1st; LEMEN CA, 1989, EVOLUTION, V43, P1538, DOI 10.1111/j.1558-5646.1989.tb02602.x; Levinton J. S., 1988, GENETICS PALEONTOLOG; LICH DK, 1990, PALEOBIOLOGY, V16, P384, DOI 10.1017/S0094837300010083; Lloyd E.A., 1988, STRUCTURE CONFIRMATI; MacGillavry H. J., 1968, Bijdragen tot de Dierkunde, V38, P69; MACLEOD N, 1991, PALEOBIOLOGY, V17, P167, DOI 10.1017/S0094837300010472; Martin R.A., 1992, Historical Biology, V6, P73; MAYDEN RL, 1986, SYST ZOOL, V35, P591, DOI 10.2307/2413118; Mayr E., 1992, DYNAMICS EVOLUTION, P21; Mayr E, 1963, ANIMAL SPECIES EVOLU; MAYR E, 1992, DYNAMICS EVOLUTION P; MICHAUX B, 1989, BIOL J LINN SOC, V38, P239, DOI 10.1111/j.1095-8312.1989.tb01577.x; MINDELL DP, 1990, J EVOLUTION BIOL, V3, P125, DOI 10.1046/j.1420-9101.1990.3010125.x; MINDELL DP, 1989, CLADISTICS, V5, P49, DOI 10.1111/j.1096-0031.1989.tb00482.x; Moore R.C, 1952, INVERTEBRATE FOSSILS; MORRIS PJ, 1992, GEOL SOC AM ANN M BO, P313; NEHM RH, 1992, PALEONTOL SOC SP PUB, V6, P222; Prothero D. R., 1992, SKEPTIC, V1, P38; PROTHERO DR, 1989, EVOLUTION PERISSODAC, P142; RAUP DM, 1982, SCIENCE, V215, P1501, DOI 10.1126/science.215.4539.1501; Ridley M., 1993, EVOLUTION; RUSE M, 1992, DYNAMICS EVOLUTION, P139; SCHANKLER DM, 1981, NATURE, V293, P135, DOI 10.1038/293135a0; SHAPIRO EA, 1978, GEOL SOC AM ANN M BO, P490; SHELDON PR, 1990, NATURE, V345, P772, DOI 10.1038/345772a0; Simpson G.G., 1953, MAJOR FEATURES EVOLU, DOI DOI 10.7312/SIMP93764; Simpson G.G., 1951, HORSES; SMITH AB, 1985, SPEC PAP PALAEONTOL, P29; SMITH JM, 1983, ANNU REV GENET, V17, P11, DOI 10.1146/annurev.ge.17.120183.000303; SORHANNUS U, 1990, HIST BIOL, V31, P241; STANLEY SM, 1987, PALEOBIOLOGY, V13, P113; STANLEY SM, 1975, P NATL ACAD SCI USA, V72, P646, DOI 10.1073/pnas.72.2.646; STANLEY SM, 1973, EVOLUTION, V27, P1, DOI 10.1111/j.1558-5646.1973.tb05912.x; STANLEY SM, 1978, PALEOBIOLOGY, V4, P26, DOI 10.1017/S0094837300005662; STANLEY SM, 1979, MARCROEVOLUTION; Thomas E, 1980, UTRECHT MICROPALEONT, V23, P1; Valentine J.W., 1992, P17; Vrba E.S., 1984, P62; VRBA ES, 1985, S AFR J SCI, V81, P229; VRBA ES, 1986, PALEOBIOLOGY, V12, P217, DOI 10.1017/S0094837300013671; VRBA ES, 1980, S AFR J SCI, V76, P61; WAGNER PJ, 1992, GEOL SOC AM ANN M BO, P139; WEI KY, 1988, PALEOBIOLOGY, V14, P345, DOI 10.1017/S0094837300012094; WEST RM, 1979, PALEOBIOLOGY, V5, P252, DOI 10.1017/S0094837300006540; Williams G. C., 1966, P307; Williams G. C., 1992, NATURAL SELECTION DO; WILLIAMSON PG, 1985, BIOL J LINN SOC, V26, P307, DOI 10.1111/j.1095-8312.1985.tb02042.x; WILLIAMSON PG, 1981, NATURE, V293, P437, DOI 10.1038/293437a0	90	608	625	4	278	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1993	366	6452					223	227		10.1038/366223a0	http://dx.doi.org/10.1038/366223a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232582				2022-12-01	WOS:A1993MH32500051
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSALS FOR FOLIC-ACID FORTIFICATION AND LABELING OF CERTAIN FOODS TO REDUCE RISK OF NEURAL-TUBE DEFECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1993, FED REG         1014, V58, P53305; 1993, FED REG         1014, V58, P53254	2	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2283	2283		10.1001/jama.270.19.2283	http://dx.doi.org/10.1001/jama.270.19.2283			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230583				2022-12-01	WOS:A1993MF99300005
J	PRATTER, MR; BARTTER, T; AKERS, S; DUBOIS, J				PRATTER, MR; BARTTER, T; AKERS, S; DUBOIS, J			AN ALGORITHMIC APPROACH TO CHRONIC COUGH	ANNALS OF INTERNAL MEDICINE			English	Article						PREDNISONE; ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE RESORPTION	SOLE PRESENTING MANIFESTATION; CHRONIC PERSISTENT COUGH; ASTHMA; RESPONSIVENESS; DIAGNOSIS; FREQUENCY; SPECTRUM; THERAPY	Objectives: To evaluate a stepwise approach to chronic cough that emphasized initial treatment of all patients with an antihistamine-decongestant for postnasal drip and to determine the value of routine bronchoprovocation challenge in the evaluation of chronic cough. Design: Prospective trial using an algorithm for chronic cough in immunocompetent nonsmoking outpatients. Setting: University-based pulmonary practice. Patients: Forty-five patients met the inclusion criteria. The mean duration of cough was 140 weeks (range, 3 to 2080 weeks), and the mean severity of cough as assessed by patients on a four-point scale was ''severe.'' Results: Marked improvement and resolution (mean, 3.1 and 7.1 weeks, respectively), with resolution in 96% of patients. Antihistamine-decongestant therapy was beneficial in 39 of 45 patients and was the only therapy needed for 16 patients. Bronchoprovocation challenge had a negative predictive value of 100% and a positive predictive value of 74% for cough caused by asthma. No significant relationship was found between the time to cough resolution and duration or severity of cough. Eighteen percent of patients experienced a recurrence of cough at a follow-up interval of 3 months. Conclusions: A sequential approach to chronic cough that emphasizes initial treatment with an antihistamine-decongestant is effective. Bronchoprovocation challenge is useful in evaluating patients with chronic cough but can be delayed until the initial response to antihistamine-decongestant therapy has been assessed. The 18% incidence of recurrence highlights the fact that cough often is the manifestation of a chronic or recurring process that requires chronic or episodic therapy.			PRATTER, MR (corresponding author), UMDNJ, COOPER HOSP UNIV MED CTR, ROBERT WOOD JOHNSON MED SCH, SUITE 312, 3 COOPER PLAZA, CAMDEN, NJ 08103 USA.							AKERS SM, 1992, CHEST, V101, P853, DOI 10.1378/chest.101.3.853; BRAMAN SS, 1985, PRIMARY CARE, V12, P217; CORRAO W M, 1986, Comprehensive Therapy, V12, P14; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; DEMEESTER TR, 1980, J THORAC CARDIOV SUR, V79, P656; DIPEDE C, 1991, CHEST, V99, P916, DOI 10.1378/chest.99.4.916; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARGREAVE FE, 1985, CHEST, V87, pS202, DOI 10.1378/chest.87.5_Supplement.202S; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; IRWIN RS, 1989, AM REV RESPIR DIS, V140, P1294, DOI 10.1164/ajrccm/140.5.1294; IRWIN RS, 1977, ARCH INTERN MED, V137, P1186, DOI 10.1001/archinte.137.9.1186; IRWIN RS, 1981, AM REV RESPIR DIS, V123, P413; IRWIN RS, 1991, CHEST, V99, P1477, DOI 10.1378/chest.99.6.1477; JOHNSON D, 1991, J ASTHMA, V28, P85, DOI 10.3109/02770909109082732; PENDER E S, 1990, Journal of Emergency Medicine, V8, P727, DOI 10.1016/0736-4679(90)90287-6; POE RH, 1989, CHEST, V95, P723, DOI 10.1378/chest.95.4.723; PRATTER MR, 1988, CHEST, V93, P898, DOI 10.1378/chest.93.5.898; PRATTER MR, 1991, CHEST, V100, P1187, DOI 10.1378/chest.100.5.1187; TOWNLEY RJ, 1987, J ALLERGY CLIN IMMUN, V80, P111, DOI 10.1016/0091-6749(87)90116-3; WYNDER EL, 1965, AM REV RESPIR DIS, V91, P679	21	203	222	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1993	119	10					977	983		10.7326/0003-4819-119-10-199311150-00003	http://dx.doi.org/10.7326/0003-4819-119-10-199311150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG672	8214994				2022-12-01	WOS:A1993MG67200003
J	SCHMIEDEN, V; KUHSE, J; BETZ, H				SCHMIEDEN, V; KUHSE, J; BETZ, H			MUTATION OF GLYCINE RECEPTOR SUBUNIT CREATES BETA-ALANINE RECEPTOR RESPONSIVE TO GABA	SCIENCE			English	Article							NEURONAL NICOTINIC RECEPTOR; GATED ION CHANNELS; RAT SPINAL-CORD; STRYCHNINE-BINDING-SITE; CENTRAL-NERVOUS-SYSTEM; ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; XENOPUS OOCYTES; MESSENGER-RNA; AMINO-ACIDS	The amino acid at position 160 of the ligand-binding subunit, alpha1, is an important determinant of agonist and antagonist binding to the glycine receptor. Exchange of the neighboring residues, phenylalanine at position 159 and tyrosine at position 161, increased the efficacy of amino acid agonists. Whereas wild-type alpha1 channels expressed in Xenopus oocytes required 0.7 millimolar beta-alanine for a half-maximal response, the doubly mutated (F159Y, Y161F) alpha1 subunit had an affinity for beta-alanine (which was more potent than glycine) that was 110-fold that of the wild type. Also, gamma-aminobutyric acid and D-serine, amino acids that do not activate wild-type alpha1 receptors, efficiently gated the mutant channel. Thus, aromatic hydroxyl groups are crucial for ligand discrimination at inhibitory amino acid receptors.	MAX PLANCK INST BRAIN RES,DEPT NEUROCHEM,DEUTSCHORDENSTR 46,D-60528 FRANKFURT 71,GERMANY	Max Planck Society			Kuhse, Jochen/T-3864-2019					BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BETZ H, 1992, Q REV BIOPHYS, V25, P381, DOI 10.1017/S0033583500004340; DELOREY TM, 1992, J BIOL CHEM, V267, P16747; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GRAHAM D, 1983, EUR J BIOCHEM, V131, P519, DOI 10.1111/j.1432-1033.1983.tb07292.x; GRAHAM D, 1985, BIOCHEMISTRY-US, V24, P990, DOI 10.1021/bi00325a027; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HORIKOSHI T, 1988, MOL BRAIN RES, V4, P97, DOI 10.1016/0169-328X(88)90002-2; KUBO T, 1985, EUR J BIOCHEM, V149, P5, DOI 10.1111/j.1432-1033.1985.tb08885.x; KUDO Y, 1988, BRIT J PHARMACOL, V94, P1051, DOI 10.1111/j.1476-5381.1988.tb11621.x; KUHSE J, 1990, NEURON, V5, P867, DOI 10.1016/0896-6273(90)90346-H; KUHSE J, 1991, FEBS LETT, V283, P73, DOI 10.1016/0014-5793(91)80557-J; KUHSE J, 1990, J BIOL CHEM, V265, P22317; LANGOSCH D, 1990, EUR J BIOCHEM, V194, P1, DOI 10.1111/j.1432-1033.1990.tb19419.x; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; OCONNOR VM, 1992, THESIS U COLLEGE LON; PARKER I, 1988, PROC R SOC SER B-BIO, V233, P201, DOI 10.1098/rspb.1988.0019; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; RUIZGOMEZ A, 1990, BIOCHEMISTRY-US, V29, P7033, DOI 10.1021/bi00482a012; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; SCHMIEDEN V, UNPUB; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; VANDENBERG RJ, 1992, P NATL ACAD SCI USA, V89, P1765, DOI 10.1073/pnas.89.5.1765; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; YOUNG AB, 1974, MOL PHARMACOL, V10, P790; YOUNG AB, 1973, P NATL ACAD SCI USA, V70, P2832, DOI 10.1073/pnas.70.10.2832	38	131	134	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 8	1993	262	5131					256	258		10.1126/science.8211147	http://dx.doi.org/10.1126/science.8211147			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA665	8211147				2022-12-01	WOS:A1993MA66500040
J	VENABLE, RM; ZHANG, YH; HARDY, BJ; PASTOR, RW				VENABLE, RM; ZHANG, YH; HARDY, BJ; PASTOR, RW			MOLECULAR-DYNAMICS SIMULATIONS OF A LIPID BILAYER AND OF HEXADECANE - AN INVESTIGATION OF MEMBRANE FLUIDITY	SCIENCE			English	Article							BIOLOGICAL-MEMBRANES; ROTATIONAL DIFFUSION; PHOSPHOLIPID BILAYER; RELAXATION; PARAMETERS; CRYSTALS; MICELLE; CHAIN; MODEL	Molecular dynamics simulations of a fluid-phase dipalmitoyl phosphatidylcholine lipid bilayer in water and of neat hexadecane are reported and compared with nuclear magnetic resonance spin-lattice relaxation and quasi-elastic neutron scattering data. On the 100-picosecond time scale of the present simulations, there is effectively no difference in the reorientational dynamics of the carbons in the membrane interior and in pure hexadecane. Given that the calculated fast reorientational correlation times and the ''microscopic'' lateral diffusion of the lipids show excellent agreement with the experimental results, it is concluded that the apparently high viscosity of the membrane is more closely related to molecular interactions on the surface rather than in the interior.	US FDA,CTR BIOL EVALUAT & RES,BIOPHYS LAB,8800 ROCKVILLE PIKE,BETHESDA,MD 20892	US Food & Drug Administration (FDA)								AHLSTROM P, IN PRESS J PHYS CHEM; BOCIAN DF, 1978, ANNU REV PHYS CHEM, V29, P307, DOI 10.1146/annurev.pc.29.100178.001515; BROOKS CL, 1988, PROTEINS THEORETICAL; BROWN MF, 1983, P NATL ACAD SCI-BIOL, V80, P4325, DOI 10.1073/pnas.80.14.4325; BROWN MF, 1984, J CHEM PHYS, V80, P2808, DOI 10.1063/1.447030; Cevc G, 1987, PHOSPHOLIPID BILAYER; CHARIFSON PS, 1990, J COMPUT CHEM, V10, P1182; DAMODARAN KV, 1992, BIOCHEMISTRY-US, V31, P7656, DOI 10.1021/bi00148a029; DELOOF H, 1991, BIOCHEMISTRY-US, V30, P2099, DOI 10.1021/bi00222a015; EGBERTS B, 1988, THESIS RIJKSUNIVERSI; EGBERTS E, 1988, J CHEM PHYS, V89, P3718, DOI 10.1063/1.454893; Finkelstein A., 1987, WATER MOVEMENT LIPID; FISCHER TM, 1992, BIOPHYS J, V63, P1328, DOI 10.1016/S0006-3495(92)81710-1; HARDY BJ, IN PRESS J COMPUT CH; HELLER H, 1993, J PHYS CHEM-US, V97, P8343, DOI 10.1021/j100133a034; HUGHES BD, 1982, BIOPHYS J, V37, P673; JONSSON B, 1986, J CHEM PHYS, V85, P2259, DOI 10.1063/1.451122; KLEIN ML, 1992, J CHEM SOC FARADAY T, V88, P1701, DOI 10.1039/ft9928801701; MARCELJA S, 1974, BIOCHIM BIOPHYS ACTA, V367, P165, DOI 10.1016/0005-2736(74)90040-6; OVERTON E, 1895, VIERTELJAHRESSCHR NA, V40, P159; PASTOR RW, 1991, P NATL ACAD SCI USA, V88, P892, DOI 10.1073/pnas.88.3.892; PASTOR RW, 1988, J CHEM PHYS, V89, P1112, DOI 10.1063/1.455218; PASTOR RW, 1988, J CHEM PHYS, V89, P1128, DOI 10.1063/1.455219; PASTOR RW, IN PRESS COMPUTER SI; PETERS R, 1982, P NATL ACAD SCI-BIOL, V79, P4317, DOI 10.1073/pnas.79.14.4317; RAGHAVAN K, 1992, LANGMUIR, V8, P233, DOI 10.1021/la00037a043; RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5; ROMMEL E, 1988, J PHYS CHEM-US, V92, P2981, DOI 10.1021/j100321a053; SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111; SCHINDLER H, 1975, BIOCHEMISTRY-US, V14, P2283, DOI 10.1021/bi00682a001; SEELIG A, 1974, BIOCHEMISTRY-US, V13, P4839, DOI 10.1021/bi00720a024; SMALL DM, 1986, PHYSICAL CHEM LIPIDS; STOUCH TR, 1991, J COMPUT CHEM, V12, P1033, DOI 10.1002/jcc.540120816; STOUCH TR, 1993, MOL SIMULAT, V10, P317; VAZ WLC, 1991, BIOPHYS J, V60, P1553, DOI 10.1016/S0006-3495(91)82190-7; VENABLE RM, UNPUB; WATANABE K, 1989, J PHYS CHEM-US, V93, P6897, DOI 10.1021/j100356a006; WENDOLOSKI JJ, 1989, SCIENCE, V243, P636, DOI 10.1126/science.2916118; 1969, LANDOLTBORNSTEIN TAB; [No title captured]	40	320	320	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 8	1993	262	5131					223	226		10.1126/science.8211140	http://dx.doi.org/10.1126/science.8211140			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA665	8211140				2022-12-01	WOS:A1993MA66500029
J	OFFIT, K; LOCOCO, F; LOUIE, DC; PARSA, NZ; LEUNG, D; PORTLOCK, C; YE, BH; LISTA, F; FILIPPA, DA; ROSENBAUM, A; LADANYI, M; JHANWAR, S; DALLAFAVERA, R; CHAGANTI, RSK				OFFIT, K; LOCOCO, F; LOUIE, DC; PARSA, NZ; LEUNG, D; PORTLOCK, C; YE, BH; LISTA, F; FILIPPA, DA; ROSENBAUM, A; LADANYI, M; JHANWAR, S; DALLAFAVERA, R; CHAGANTI, RSK			REARRANGEMENT OF THE BCL-6 GENE AS A PROGNOSTIC MARKER IN DIFFUSE LARGE-CELL LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; CONSECUTIVELY ASCERTAINED SPECIMENS; BONE-MARROW TRANSPLANTATION; FINGER ENCODING GENE; CLINICAL CORRELATIONS; CYTOGENETIC ANALYSIS; TRANSLOCATIONS; CLASSIFICATION; CHEMOTHERAPY; ABERRATIONS	Background. About 40 percent of non-Hodgkin's lymphomas are diffuse lymphomas with a large-cell component (DLLC). Current therapy can induce a longterm remission in half the patients with DLLC, but more intensive treatment has the potential to improve outcome, particularly in patients at high risk for treatment failure. Clinical and cytogenetic markers can identify subgroups at high or low risk. Rearrangement of a novel candidate proto-oncogene, bcl-6, is a possible prognostic indicator in DLLC. Methods. We performed Southern blot hybridization to detect bcl-6 and bcl-2 gene rearrangement in samples of lymphoma from 102 patients with B-cell DLLC. The results were correlated with the patients' histologic features, age, disease stage, tumor sites and bulk of disease, serum lactate dehydrogenase level, and treatment outcome. Results. Rearranged bcl-6 was found in 23 cases, and rearranged bcl-2 in 21 cases. Nineteen of the patients with rearranged bcl-6 had extranodal DLLC, two had primary splenic lymphomas, and only one had bone marrow involvement. Thirty-six months after diagnosis, the proportion with freedom from progression of disease was projected to be 82 percent (95 percent confidence interval, 66 to 98 percent) among the patients with rearranged bcl-6, as compared with 56 percent (95 percent confidence interval, 43 to 70 percent) for the patients with germ-line bcl-6 and bcl-2 and 31 percent (95 percent confidence interval, 8 to 53 percent) for the patients with rearranged bcl-2. The status of the bcl-6 gene was an independent prognostic marker of survival and freedom from disease progression in a multivariate model and added predictive value to established prognostic signs. Conclusions. Rearrangement of the bcl-6 gene correlated with a favorable clinical outcome in DLLC and may thus serve as a prognostic marker in patients with this form of malignant lymphoma.	MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT EPIDEMIOL & BIOSTAT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CYTOGENET SERV,NEW YORK,NY 10021; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO BIOPATOL UMANA,SEZ EMATOL,ROME,ITALY; CTR STUDI & RIC SANITA ESERCITO,ROME,ITALY	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Columbia University; Sapienza University Rome	OFFIT, K (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,BOX 192,1275 YORK AVE,NEW YORK,NY 10021, USA.		Ladanyi, Marc/AAG-8585-2019; LEUNG, Denis Heng Yan/D-1439-2009	leung, denis heng yan/0000-0002-2620-3442; lista, florigio/0000-0001-5700-4772	NCI NIH HHS [CA-44029, CA-34775, CA-08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034775, P30CA008748, R01CA044029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1982, CANCER, V49, P2112; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1992, BLOOD, V79, P2527; BASTARD C, 1994, BLOOD, V83, P2423; CARBONE PP, 1971, CANCER RES, V31, P1860; CARRATO A, 1987, P AM SOC CLIN ONCOL, V6, P198; CLARK HM, 1992, J PATHOL, V166, P129, DOI 10.1002/path.1711660208; COIFFIER B, 1991, J CLIN ONCOL, V9, P211, DOI 10.1200/JCO.1991.9.2.211; COX DR, 1972, J R STAT SOC B, V34, P187; DANIEU L, 1986, CANCER RES, V46, P5372; DEVESA SS, 1992, CANCER RES, V52, pS5432; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; GRIBBEN JG, 1993, BLOOD, V81, P3449; GULATI SC, 1988, J CLIN ONCOL, V6, P1303, DOI 10.1200/JCO.1988.6.8.1303; International Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993, NEW ENGL J MED, V329, P987; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEMPIN S, 1983, P AM SOC CLIN ONCOL, V2, P56; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; LEROUX D, 1990, LEUKEMIA, V4, P373; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; LOWENTHAL DA, 1987, P AM SOC CLIN ONCOL, V6, P197; MCKEITHAN TW, 1990, SEMIN ONCOL, V17, P30; MCMASTER ML, 1991, CANCER-AM CANCER SOC, V68, P233, DOI 10.1002/1097-0142(19910715)68:2<233::AID-CNCR2820680203>3.0.CO;2-Q; MITELMAN F, 1991, CATALOG CHROMOSOME A; OBRIEN JP, 1992, BLOOD, V80, pA157; OFFIT K, 1991, HEMATOL ONCOL CLIN N, V5, P853, DOI 10.1016/S0889-8588(18)30389-7; OFFIT K, 1989, BRIT J HAEMATOL, V72, P178, DOI 10.1111/j.1365-2141.1989.tb07680.x; OFFIT K, 1989, BLOOD, V74, P1876; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; OFFIT K, 1991, BLOOD, V77, P1508; RAGHOEBIER S, 1991, BLOOD, V78, P2680; RUDDERS RA, 1978, CANCER, V42, P406, DOI 10.1002/1097-0142(197808)42:2<406::AID-CNCR2820420205>3.0.CO;2-H; SIMON R, 1988, ANN INTERN MED, V109, P939, DOI 10.7326/0003-4819-109-12-939; STRAUS DJ, 1991, AM J MED, V90, P328, DOI 10.1016/0002-9343(91)90573-G; VANKRIEKEN JHJM, 1990, BLOOD, V76, P797; WARRELL RP, 1989, P AN M AM SOC CLIN, V8, P270; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YE BHH, 1993, CANCER RES, V53, P2732; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605	40	303	313	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 14	1994	331	2					74	80		10.1056/NEJM199407143310202	http://dx.doi.org/10.1056/NEJM199407143310202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW712	8208268				2022-12-01	WOS:A1994NW71200002
J	LOK, S; KAUSHANSKY, K; HOLLY, RD; KUIJPER, JL; LOFTONDAY, CE; OORT, PJ; GRANT, FJ; HEIPEL, MD; BURKHEAD, SK; KRAMER, JM; BELL, LA; SPRECHER, CA; BLUMBERG, H; JOHNSON, R; PRUNKARD, D; CHING, AFT; MATHEWES, SL; BAILEY, MC; FORSTROM, JW; BUDDLE, MM; OSBORN, SG; EVANS, SJ; SHEPPARD, PO; PRESNELL, SR; OHARA, PJ; HAGEN, FS; ROTH, GJ; FOSTER, DC				LOK, S; KAUSHANSKY, K; HOLLY, RD; KUIJPER, JL; LOFTONDAY, CE; OORT, PJ; GRANT, FJ; HEIPEL, MD; BURKHEAD, SK; KRAMER, JM; BELL, LA; SPRECHER, CA; BLUMBERG, H; JOHNSON, R; PRUNKARD, D; CHING, AFT; MATHEWES, SL; BAILEY, MC; FORSTROM, JW; BUDDLE, MM; OSBORN, SG; EVANS, SJ; SHEPPARD, PO; PRESNELL, SR; OHARA, PJ; HAGEN, FS; ROTH, GJ; FOSTER, DC			CLONING AND EXPRESSION OF MURINE THROMBOPOIETIN CDNA AND STIMULATION OF PLATELET PRODUCTION IN-VIVO	NATURE			English	Article							FACTOR RECEPTOR SUPERFAMILY; MOLECULAR-CLONING; C-MPL; GROWTH; MEGAKARYOCYTOPOIESIS; SEQUENCE; MEMBER; IDENTIFICATION; PROTOONCOGENE; INTERLEUKIN-6	THE major regulator of circulating platelet levels is believed to be a cytokine termed thrombopoietin(1,2). It is thought to be a lineage-specific cytokine affecting the proliferation and maturation of committed cells resulting in the production of megakaryocytes and platelets. Despite considerable efforts by a number of laboratories, the unequivocal identification of thrombopoietin has proven elusive. Here we report the functional cloning of a murine complementarg DNA encoding a ligand for the receptor encoded by the c-mpl proto-oncogene (c-Mpl)3-5. The encoded polypeptide has a predicted molecular mass of 35,000 (M(r) 35K). The protein has a novel two-domain structure with an amino-terminal domain homologous with erythropoietin and a carboxy-terminal domain rich in serine, threonine and proline residues and containing seven potential N-linked glycosylation sites. Intraperitoneal injections of mice with recombinant protein increase circulating platelet levels by greater than fourfold after 7 days. These results along with those presented in the accompanying report strongly suggest that the ligand for c-Mpl is thrombopoietin.	ZYMOGENET INC,SEATTLE,WA 98105; UNIV WASHINGTON,SCH MED,DIV HEMATOL,SEATTLE,WA 98195	Zymogenet Inc.; University of Washington; University of Washington Seattle								BARR PJ, 1994, CELL, V66, P1; BENSON D, 1993, NUCLEIC ACIDS RES, V21, P2963, DOI 10.1093/nar/21.13.2963; BOISSEL JP, 1993, J BIOL CHEM, V268, P1583; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARRINGTON PA, 1991, BLOOD, V77, P34; CHOW FPR, 1993, EXP HEMATOL, V21, P255; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; ISHIBASHI T, 1989, BLOOD, V74, P1241; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; LACOMBE C, 1988, J CLIN INVEST, V81, P620, DOI 10.1172/JCI113363; MCDONALD TP, 1988, EXP HEMATOL, V16, P201; MCDONALD TP, 1992, AM J PEDIAT HEMATOL, V14, P8; METHIA N, 1993, BLOOD, V82, P1395; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEBEN TY, 1993, BLOOD, V81, P901; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; RECNY MA, 1987, J BIOL CHEM, V262, P17156; SENDA T, 1992, EMBO J, V11, P3193, DOI 10.1002/j.1460-2075.1992.tb05396.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; Wilks AF, 1989, GROWTH FACTORS, V2, P31, DOI 10.3109/08977198909069079	27	1008	1047	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 16	1994	369	6481					565	568		10.1038/369565a0	http://dx.doi.org/10.1038/369565a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	8202158				2022-12-01	WOS:A1994NR29400051
J	THIERFELDER, L; WATKINS, H; MACRAE, C; LAMAS, R; MCKENNA, W; VOSBERG, HP; SEIDMAN, JG; SEIDMAN, CE				THIERFELDER, L; WATKINS, H; MACRAE, C; LAMAS, R; MCKENNA, W; VOSBERG, HP; SEIDMAN, JG; SEIDMAN, CE			ALPHA-TROPOMYOSIN AND CARDIAC TROPONIN-T MUTATIONS CAUSE FAMILIAL HYPERTROPHIC CARDIOMYOPATHY - A DISEASE OF THE SARCOMERE	CELL			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; CHROMOSOMAL LOCALIZATION; CLINICAL MANIFESTATIONS; PATHO-PHYSIOLOGY; ADULT ISOFORMS; MUSCLE; GENE; EXPRESSION; ORGANIZATION; EXONS	We demonstrate that missense mutations (Asp175Asn; Glu180Gly) in the alpha-tropomyosin gene cause familial hypertrophic cardiomyopathy (FHC) linked to chromosome 15q2. These findings implicated components of the troponin complex as candidate genes at other FHC loci, particularly cardiac troponin T, which was mapped in this study to chromosome 1q. Missense mutations (Ile79Asn; Arg92Gln) and a mutation in the splice donor sequence of intron 15 of the cardiac troponin T gene are also shown to cause FHC. Because alpha-tropomyosin and cardiac troponin T as well as beta myosin heavy chain mutations cause the same phenotype, we conclude that FHC is a disease of the sarcomere. Further, because the splice site mutation is predicted to function as a null allele, we suggest that abnormal stoichiometry of sarcomeric proteins can cause cardiac hypertrophy.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOL,BOSTON,MA 02115; MIL HOSP,NEONTOL UNIT,SANTIAGO,CHILE; ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON SW17 0RE,ENGLAND; MAX PLANCK INST PHYSIOL & CLIN RES,D-61231 BAD NAUHEIM,GERMANY	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; St Georges University London; Max Planck Society	THIERFELDER, L (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.		McKenna, William J/C-3243-2008	McKenna, William J/0000-0001-7994-2460; Watkins, Hugh/0000-0002-5287-9016	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046320, R01HL042467] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42467, HL46320] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission)		ANAN H, 1994, J CLIN INVEST, V93, P280; ANDERSON PAW, 1991, CIRC RES, V69, P73; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; BRISSON JR, 1986, BIOCHEMISTRY-US, V25, P4548, DOI 10.1021/bi00364a014; BUCHER EA, 1989, J BIOL CHEM, V264, P12482; CARRIER L, 1993, NAT GENET, V4, P311, DOI 10.1038/ng0793-311; CHOU YHW, 1992, NAT GENET, V1, P295, DOI 10.1038/ng0792-295; COOPER TA, 1985, J BIOL CHEM, V260, P1140; DAVIES MJ, 1990, BRIT HEART J, V63, P263; FANANAPAZIR L, 1994, CIRCULATION, V89, P22, DOI 10.1161/01.CIR.89.1.22; FYRBERG E, 1990, J MOL BIOL, V216, P657, DOI 10.1016/0022-2836(90)90390-8; GAHLMANN R, 1987, J BIOL CHEM, V262, P16122; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HARDY S, 1991, EUR J BIOCHEM, V202, P431, DOI 10.1111/j.1432-1033.1991.tb16392.x; ISHII Y, 1991, J BIOL CHEM, V266, P6894; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; JIN JP, 1989, J BIOL CHEM, V264, P14471; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LESYK J, 1987, BIOCHEMISTRY-US, V26, P7035; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; MALOUF NN, 1992, J BIOL CHEM, V267, P9269; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MCAULIFFE JJ, 1991, PEDIATR RES, V29, P580, DOI 10.1203/00006450-199106010-00012; MESNARD L, 1993, FEBS LETT, V328, P139, DOI 10.1016/0014-5793(93)80981-Y; MOGAMI K, 1981, JPN J GENET, V56, P51, DOI 10.1266/jjg.56.51; OLSEN EGJ, 1992, CARDIOMYOPATHIES REA; OTT J, 1976, AM J HUM GENET, V28, P528; PAN BS, 1991, J BIOL CHEM, V266, P12432; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PEARLSTONE JR, 1977, J BIOL CHEM, V252, P983; PEARLSTONE JR, 1986, J BIOL CHEM, V261, P6795; PIERCE JC, 1992, METHOD ENZYMOL, V216, P549; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; ROSENZWEIG A, 1991, NEW ENGL J MED, V325, P1753, DOI 10.1056/NEJM199112193252501; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SCHLEEF M, 1993, GENOMICS, V17, P519, DOI 10.1006/geno.1993.1361; SMILLIE LB, 1988, J BIOL CHEM, V263, P18816; TAKENAGA K, 1988, MOL CELL BIOL, V8, P5561, DOI 10.1128/MCB.8.12.5561; THIERFELDER L, 1993, P NATL ACAD SCI USA, V90, P6270, DOI 10.1073/pnas.90.13.6270; VAUGHAN KT, 1993, GENOMICS, V16, P34, DOI 10.1006/geno.1993.1136; WATKINS H, 1993, NAT GENET, V3, P333, DOI 10.1038/ng0493-333; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	47	830	863	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 3	1994	77	5					701	712		10.1016/0092-8674(94)90054-X	http://dx.doi.org/10.1016/0092-8674(94)90054-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NQ123	8205619				2022-12-01	WOS:A1994NQ12300010
J	STRATTON, KR; HOWE, CJ; JOHNSTON, RB; MAJEWSKI, D				STRATTON, KR; HOWE, CJ; JOHNSTON, RB; MAJEWSKI, D			ADVERSE EVENTS ASSOCIATED WITH CHILDHOOD VACCINES OTHER THAN PERTUSSIS AND RUBELLA - SUMMARY OF A REPORT FROM THE INSTITUTE-OF-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In September 1993, the Institute of Medicine released a report entitled Adverse Events Associated With Childhood Vaccines: Evidence Bearing on Causality. The report examined putative serious adverse consequences associated with administration of diphtheria and tetanus toxoids; measles, mumps, and measles-mumps-rubella vaccines; oral polio vaccine and inactivated polio vaccine; hepatitis B vaccines; and Haemophilus influenzae type b (Hib) vaccines. The committee spent 18 months reviewing all available scientific and medical data, from individual case reports (published and unpublished) to controlled clinical trials. The committee found that the evidence favored the rejection of a causal relation between diphtheria and tetanus toxoids and encephalopathy, infantile spasms, and sudden infant death syndrome, and between conjugate Hib vaccines and susceptibility to Hib disease. The committee found that the evidence favored acceptance of a causal relation between diphtheria and tetanus toxoids and Guillain-Barre syndrome and brachial neuritis, between measles vaccine and anaphylaxis, between oral polio vaccine and Guillain-Barre syndrome, and between unconjugated Hib vaccine and susceptibility to Hib disease. The committee found that the evidence established causality between diphtheria and tetanus toxoids and anaphylaxis, between measles vaccine and death from measles vaccine-strain viral infection, between measles-mumps-rubella vaccine and thrombocytopenia and anaphylaxis, between oral polio vaccine and poliomyelitis and death from polio vaccine-strain viral infection, and between hepatitis B vaccine and anaphylaxis. For five vaccine-related adverse events, there was no evidence identified. For the remaining 33 vaccine-related adverse events, the evidence was inadequate to accept or reject a causal relation.	NATL ACAD SCI,INST MED,WASHINGTON,DC; MARCH DIMES BIRTH DEFECTS FDN,WHITE PLAINS,NY; YALE UNIV,SCH MED,NEW HAVEN,CT	National Academies of Sciences, Engineering & Medicine; Yale University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015130] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-15130] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELLINI WJ, 1992, LAB INVEST, V66, pA19; COFFIN CM, 1993, PEDIATR PATHOL, V13, P102; COHN J, 1976, SCAND J HAEMATOL, V16, P226; HOWSON CP, 1992, JAMA-J AM MED ASSOC, V267, P392, DOI 10.1001/jama.267.3.392; HOWSON CP, 1992, PEDIATRICS, V89, P318; Howson CP, 1991, ADVERSE EFFECTS PERT; MARINER WK, 1992, HEALTH AFFAIR, V11, P255, DOI 10.1377/hlthaff.11.1.255; NKOWANE BM, 1987, JAMA-J AM MED ASSOC, V257, P1335, DOI 10.1001/jama.257.10.1335; POLLARD JD, 1978, J NEUROL SCI, V37, P113, DOI 10.1016/0022-510X(78)90232-0; Stratton K.R., 1994, ADVERSE EVENTS ASS C; THURSTON A, 1987, J ROY COLL GEN PRACT, V37, P41; WIGGINS CA, 1989, ANN ALLERGY, V62, P1	12	116	120	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	1994	271	20					1602	1605		10.1001/jama.271.20.1602	http://dx.doi.org/10.1001/jama.271.20.1602			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL758	8182813				2022-12-01	WOS:A1994NL75800029
J	GREENBERG, JT; GUO, AL; KLESSIG, DF; AUSUBEL, FM				GREENBERG, JT; GUO, AL; KLESSIG, DF; AUSUBEL, FM			PROGRAMMED CELL-DEATH IN PLANTS - A PATHOGEN-TRIGGERED RESPONSE ACTIVATED COORDINATELY WITH MULTIPLE DEFENSE FUNCTIONS	CELL			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; SYRINGAE PV-SYRINGAE; TOBACCO MOSAIC-VIRUS; SALICYLIC-ACID; ARABIDOPSIS-THALIANA; HYPERSENSITIVE REACTION; DISEASE RESISTANCE; VIRAL-INFECTION; INDUCTION; APOPTOSIS	In plants, the hypersensitive response (HR) to pathogens involves rapid cell death, which is hypothesized to arise from the activation of a cell death program. We describe mutant A. thaliana plants that contain lesions in a single accelerated cell death (ACD) gene called ACD2 and that bypass the need for pathogen exposure to induce the HR. acd2 plants that develop spontaneous lesions show typical HR characteristics both within the necrotic tissue and within the healthy part of the plant, including: modification of plant cell walls, resistance to bacterial pathogens, and accumulation of defense-related gene transcripts, the signal molecule salicylic acid and an antimicrobial compound. We propose that the ACD2 gene is involved in a pathway(s) that negatively regulates a genetically programmed HR.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; RUTGERS STATE UNIV,DEPT MOLEC BIOL & BIOCHEM,PISCATAWAY,NJ 08855	Harvard University; Massachusetts General Hospital; Rutgers State University New Brunswick	GREENBERG, JT (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114, USA.			Greenberg, Jean/0000-0002-7213-7618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048707, R01GM048707] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48707] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; ASHMAN RB, 1976, J HERED, V67, P220, DOI 10.1093/oxfordjournals.jhered.a108713; BECKER F, 1993, PLANT J, V3, P875, DOI 10.1111/j.1365-313X.1993.00875.x; BOWLER C, 1989, EMBO J, V8, P31, DOI 10.1002/j.1460-2075.1989.tb03345.x; CALLIS J, 1990, J BIOL CHEM, V265, P12486; DAVIS KR, 1991, MOL PLANT MICROBE IN, V4, P477, DOI 10.1094/MPMI-4-477; DELONG A, 1993, CELL, V74, P757, DOI 10.1016/0092-8674(93)90522-R; DEMPSEY DA, 1993, PHYTOPATHOLOGY, V83, P1021, DOI 10.1094/Phyto-83-1021; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; EDGINGTON SM, 1993, BIO-TECHNOL, V11, P787, DOI 10.1038/nbt0793-787; Emerson RA, 1923, CORNELL U AGR EXP ST, V70, P3; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; HE SY, 1993, CELL, V73, P1255, DOI 10.1016/0092-8674(93)90354-S; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENNIG J, 1993, PLANT J, V4, P593, DOI 10.1046/j.1365-313X.1993.04040593.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOISINGTON DA, 1982, DEV BIOL, V93, P381, DOI 10.1016/0012-1606(82)90125-7; HORNBROOK AR, 1970, RADIAT BOT, V10, P113, DOI 10.1016/S0033-7560(70)80031-X; HORVITZ HR, 1982, NEUROSCI COMMENT, V1, P56; JONES JDG, 1994, CURR BIOL, V4, P867; JORGENSEN JH, 1992, EUPHYTICA, V63, P141, DOI 10.1007/BF00023919; Kerr J.F.R., 1987, P93; MALAMY J, 1992, PLANT CELL, V4, P359, DOI 10.1105/tpc.4.3.359; MALAMY J, 1992, PLANT J, V2, P643, DOI 10.1111/j.1365-313X.1992.tb00133.x; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MAUCH F, 1993, PLANT PHYSIOL, V102, P1193, DOI 10.1104/pp.102.4.1193; MELAN MA, 1993, PLANT PHYSIOL, V101, P441, DOI 10.1104/pp.101.2.441; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MORTIMORE CG, 1979, CAN J PLANT SCI, V59, P147; NEUFFER MG, 1975, J HERED, V66, P265, DOI 10.1093/oxfordjournals.jhered.a108627; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; PRYOR T, 1987, TRENDS GENET, V3, P157, DOI 10.1016/0168-9525(87)90217-4; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RASMUSSEN JB, 1991, PLANT PHYSIOL, V97, P1342, DOI 10.1104/pp.97.4.1342; ROSS AF, 1961, VIROLOGY, V14, P340, DOI 10.1016/0042-6822(61)90319-1; SCHRODER M, 1992, PLANT J, V2, P161, DOI 10.1111/j.1365-313X.1992.00161.x; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STROMINGER JL, 1977, MICROBIOLOGY 1977, P177; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; TSUJI J, 1992, PLANT PHYSIOL, V98, P1304, DOI 10.1104/pp.98.4.1304; UKNES S, 1992, PLANT CELL, V4, P645, DOI 10.1105/tpc.4.6.645; UKNES S, 1993, MOL PLANT MICROBE IN, V6, P692, DOI 10.1094/MPMI-6-692; ULLSTRUP AJ, 1967, PHYTOPATHOLOGY, V57, P1282; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WALBOT V, 1991, PLANT CELL, V3, P851, DOI 10.1105/tpc.3.9.851; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WOLFF T, 1991, DEVELOPMENT, V113, P825; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YU GL, 1993, MOL PLANT MICROBE IN, V6, P434, DOI 10.1094/MPMI-6-434	53	547	632	2	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					551	563		10.1016/0092-8674(94)90217-8	http://dx.doi.org/10.1016/0092-8674(94)90217-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	8187175				2022-12-01	WOS:A1994NM83200010
J	EATEN, D; BANNISTER, P; MULLEY, GP; CONNOLLY, MJ				EATEN, D; BANNISTER, P; MULLEY, GP; CONNOLLY, MJ			AXILLARY SWEATING IN CLINICAL-ASSESSMENT OF DEHYDRATION IN ILL ELDERLY PATIENTS	BRITISH MEDICAL JOURNAL			English	Article									UNIV MANCHESTER,DEPT GERIATR MED,CHEADLE SK8 2NY,CHESHIRE,ENGLAND; BARNES HOSP,ROBERT BARNES MED UNIT,CHEADLE SK8 2NY,CHESHIRE,ENGLAND; ST JAMESS UNIV HOSP,DEPT MED ELDERLY,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	University of Manchester; Saint James's University Hospital; University of Leeds								BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; GROSS C R, 1992, Journal of Emergency Medicine, V10, P267, DOI 10.1016/0736-4679(92)90331-M; LARRABEE WF, 1984, POSTGRAD MED, V76, P37, DOI 10.1080/00325481.1984.11698794; LOWENSTEIN SR, 1986, ANN EMERG MED, V15, P528, DOI 10.1016/S0196-0644(86)80987-8; SHUSTER S, 1975, BRIT J DERMATOL, V93, P639, DOI 10.1111/j.1365-2133.1975.tb05113.x	5	44	44	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 14	1994	308	6939					1271	1271		10.1136/bmj.308.6939.1271	http://dx.doi.org/10.1136/bmj.308.6939.1271			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM147	8205020	Green Published			2022-12-01	WOS:A1994NM14700019
J	FERREIRA, A; KOSIK, KS; GREENGARD, P; HAN, HQ				FERREIRA, A; KOSIK, KS; GREENGARD, P; HAN, HQ			ABERRANT NEURITES AND SYNAPTIC VESICLE PROTEIN-DEFICIENCY IN SYNAPSIN II-DEPLETED NEURONS	SCIENCE			English	Article							HIPPOCAMPAL-NEURONS; F-ACTIN; ANTISENSE OLIGONUCLEOTIDES; BUNDLING PROTEIN; ASSOCIATION; SUPPRESSION; POLARITY; CULTURE; INVITRO; BINDING	Synapsin I and synapsin II are neuron-specific phosphoproteins that have a role in the regulation of neurotransmitter release and in the formation of nerve terminals. After depletion of synapsin II by antisense oligonucleotides, rat hippocampal neurons in culture were unable to consolidate their minor processes and did not elongate axons. These aberrant morphological changes were accompanied by an abnormal distribution of intracellular filamentous actin (F-actin). In addition, synapsin II suppression resulted in a selective decrease in the amounts of several synaptic vesicle-associated proteins. These data suggest that synapsin II participates in cytoskeletal organization during the early stages of nerve cell development.	ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115	Rockefeller University; Harvard University; Brigham & Women's Hospital; Harvard Medical School				Ferreira, Adriana/0000-0003-3705-3918				BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAINES AJ, 1986, NATURE, V319, P145, DOI 10.1038/319145a0; BAINES AJ, 1985, NATURE, V315, P410, DOI 10.1038/315410a0; BENFENATI F, 1992, NEURON, V8, P377, DOI 10.1016/0896-6273(92)90303-U; BENFENATI F, UNPUB; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CACERES A, 1992, NEURON, V9, P607, DOI 10.1016/0896-6273(92)90025-9; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CHILCOTE TJ, 1992, MOL BIOL CELL, V3, pA154; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DOTTI CG, 1988, J NEUROSCI, V8, P1454; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; FESCE R, 1992, J BIOL CHEM, V267, P11281; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; GOLDENRING JR, 1986, J BIOL CHEM, V261, P8495; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HAN HQ, 1991, NATURE, V349, P697, DOI 10.1038/349697a0; HAN HQ, IN PRESS P NATL ACAD; HIGASHIDA H, UNPUB; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KREBS KE, 1987, AM J PHYSIOL, V253, pC500, DOI 10.1152/ajpcell.1987.253.4.C500; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; SCHAEFFER E, 1994, P NATL ACAD SCI USA, V91, P3882, DOI 10.1073/pnas.91.9.3882; STEINER JP, 1987, J BIOL CHEM, V262, P905; VAITORTA F, 1992, J BIOL CHEM, V267, P11281; VALTORTA F, 1992, J BIOL CHEM, V267, P7195	30	99	101	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 13	1994	264	5161					977	979		10.1126/science.8178158	http://dx.doi.org/10.1126/science.8178158			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK974	8178158				2022-12-01	WOS:A1994NK97400039
J	AMIGORENA, S; DRAKE, JR; WEBSTER, P; MELLMAN, I				AMIGORENA, S; DRAKE, JR; WEBSTER, P; MELLMAN, I			TRANSIENT ACCUMULATION OF NEW CLASS-II MHC MOLECULES IN A NOVEL ENDOCYTIC COMPARTMENT IN B-LYMPHOCYTES	NATURE			English	Article							BINDING PROTEIN RAB4; INVARIANT CHAIN; ANTIGEN PRESENTATION; SURFACE EXPRESSION; T-CELLS; ENDOSOMES; TRANSPORT; COMPLEX; PEPTIDE; LYSOSOMES	Endocytosis of antigen by antigen-presenting cells results in the production of peptides that bind to newly synthesized class II molecules of the major histocompatibility complex. A new population of class II-enriched vesicles has been discovered in B lymphocytes that accumulate internalized antigen but are distinct from endosomes and lysosomes. These vesicles also transiently accumulate newly synthesized class II and class II-peptide complexes and appear to be a compartment specialized for the transport and loading of class II molecules.	YALE UNIV, SCH MED, CTR CELL IMAGING, NEW HAVEN, CT 06520 USA	Yale University	AMIGORENA, S (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, 333 CEDAR ST, POB 208002, NEW HAVEN, CT 06520 USA.		Mellman, Ira/ABG-5896-2020	Amigorena, Sebastian/0000-0001-8583-8416				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; BLAKE O, 1990, CELL, V63, P707; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; FUCHS R, 1989, J BIOL CHEM, V264, P2212; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HANZEL D, 1992, SEMIN CELL BIOL, V2, P341; HARDING CV, 1990, P NATL ACAD SCI USA, V87, P5553, DOI 10.1073/pnas.87.14.5553; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JENSEN PE, 1991, J EXP MED, V174, P1111, DOI 10.1084/jem.174.5.1111; KELLY RB, 1993, NATURE, V364, P487, DOI 10.1038/364487a0; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LOSS GE, 1993, J IMMUNOL, V150, P3187; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; RODRIGUEZBOULAN E, 1989, METHOD CELL BIOL, V32, P37; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313	38	424	432	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 12	1994	369	6476					113	120		10.1038/369113a0	http://dx.doi.org/10.1038/369113a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK971	8177316				2022-12-01	WOS:A1994NK97100039
J	MA, PCM; ROULD, MA; WEINTRAUB, H; PABOT, CO				MA, PCM; ROULD, MA; WEINTRAUB, H; PABOT, CO			CRYSTAL-STRUCTURE OF MYOD BHLH DOMAIN-DNA COMPLEX - PERSPECTIVES ON DNA RECOGNITION AND IMPLICATIONS FOR TRANSCRIPTIONAL ACTIVATION	CELL			English	Article							C-MYC; FUNCTIONAL DOMAINS; BINDING DOMAIN; REFINEMENT; RESOLUTION; SELECTION; SITE	The crystal structure of a MyoD basic-helix-loop-helix (bHLH) domain-DNA complex has been solved and refined at 2.8 Angstrom resolution. This structure proves that bHLH and bHLH-leucine zipper (bHLH-ZIP) proteins are remarkably similar; it helps us understand subtle differences in binding preferences for these proteins; and it has surprising implications for our understanding of transcription. Specifically, Ala-114 and Thr-115, which are required for positive control in the myogenic proteins, are buried at the protein-DNA interface. These residues are not available for direct protein-protein contacts, but they may determine the conformation of Arg-111. Comparisons with Max suggest that the conformation of this arginine, which is different in the two structures, may play an important role in myogenic transcription.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST LAB,SEATTLE,WA 98104	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Fred Hutchinson Cancer Center	MA, PCM (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NIGMS NIH HHS [GM31471] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031471] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR MANUAL VERSION; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DAVIS RL, 1992, SCIENCE, V256, P1014; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1985, SCIENCE, V230, P1383; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; ROULD MA, 1992, ACTA CRYSTALLOGR A, V48, P751, DOI 10.1107/S0108767392003404; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STAROVASNIK MA, 1992, BIOCHEMISTRY-US, V31, P9891, DOI 10.1021/bi00156a006; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WINTER B, 1992, EMBO J, V11, P1843, DOI 10.1002/j.1460-2075.1992.tb05236.x; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104	29	390	417	0	55	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 6	1994	77	3					451	459		10.1016/0092-8674(94)90159-7	http://dx.doi.org/10.1016/0092-8674(94)90159-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	8181063				2022-12-01	WOS:A1994NK97000015
J	PASCAL, SM; SINGER, AU; GISH, G; YAMAZAKI, T; SHOELSON, SE; PAWSON, T; KAY, LE; FORMANKAY, JD				PASCAL, SM; SINGER, AU; GISH, G; YAMAZAKI, T; SHOELSON, SE; PAWSON, T; KAY, LE; FORMANKAY, JD			NUCLEAR-MAGNETIC-RESONANCE STRUCTURE OF AN SH2 DOMAIN OF PHOSPHOLIPASE C-GAMMA-1 COMPLEXED WITH A HIGH-AFFINITY BINDING PEPTIDE	CELL			English	Article							GROWTH-FACTOR-RECEPTOR; SRC HOMOLOGY-2 DOMAIN; SIGNAL TRANSDUCTION; TYROSINE KINASE; LARGER PROTEINS; POINT MUTATION; EGF RECEPTOR; C-ABL; SPECTROSCOPY; EXPRESSION	The solution structure of the C-terminal SH2 domain of phospholipase C-gamma 1 (PLC-gamma 1), in complex with a phosphopeptide corresponding to its Tyr-1021 high affinity binding site on the platelet-derived growth factor receptor, has been determined by nuclear magnetic resonance spectroscopy. The topology of the SH2-phosphopeptide complex is similar to previously reported Src and Lck SH2 complexes. However, the binding site for residues C-terminal to the phosphotyrosine (pTyr) is an extended groove that contacts peptide residues at the +1 to +6 positions relative to the pTyr. This striking difference from Src and Lck reflects the fact that the PLC-gamma 1 complex involves binding of a phosphopeptide with predominantly hydrophobic residues C-terminal to the pTyr and therefore serves as a prototype for a second class of SH2-phosphopeptide interactions.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA; UNIV TORONTO, PROT ENGN NETWORK CTR EXCELLENCE, TORONTO M5S 1A8, ON, CANADA; UNIV TORONTO, DEPT MED GENET, TORONTO M5S 1A8, ON, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ON, CANADA; UNIV TORONTO, DEPT CHEM, TORONTO M5S 1A8, ON, CANADA; BRIGHAM & WOMENS HOSP, JOSLIN DIABET CTR, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	PASCAL, SM (corresponding author), HOSP SICK CHILDREN, DIV BIOCHEM RES, 555 UNIV AVE, TORONTO M5G 1X8, ON, CANADA.		Pawson, Tony J/E-4578-2013; Gish, Gerald D/C-7228-2017	Forman-Kay, Julie/0000-0001-8265-972X				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BRUNGER AT, 1992, XPLOR VERSION 31 SYS; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DELAGLIO F, 1993, NMRPIPE SYSTEM SOFTW; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FARROW NA, 1994, IN PRESS BIOCHEMISTR; FORMANKAY JD, 1990, BIOCHEMISTRY-US, V29, P1566, DOI 10.1021/bi00458a030; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAROSE L, 1993, ONCOGENE, V8, P2493; LOGAN TM, 1992, FEBS LETT, V314, P413, DOI 10.1016/0014-5793(92)81517-P; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MONTELIONE GT, 1992, J AM CHEM SOC, V114, P10974, DOI 10.1021/ja00053a051; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OVERDUIN M, 1992, P NATL ACAD SCI USA, V89, P11673, DOI 10.1073/pnas.89.24.11673; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; YAMAZAKI T, 1993, J AM CHEM SOC, V115, P11054, DOI 10.1021/ja00076a099; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	60	234	239	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 6	1994	77	3					461	472		10.1016/0092-8674(94)90160-0	http://dx.doi.org/10.1016/0092-8674(94)90160-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	8181064				2022-12-01	WOS:A1994NK97000016
J	FINK, M; FREEMAN, AH; DIXON, AK; CONI, NK				FINK, M; FREEMAN, AH; DIXON, AK; CONI, NK			COMPUTED-TOMOGRAPHY OF THE COLON IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT RADIOL,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED ELDERLY,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge; Addenbrooke's Hospital; University of Cambridge			Fink, Michelle/I-7102-2013	Fink, Michelle/0000-0001-6531-1908				BALTHAZAR EJ, 1991, AM J ROENTGENOL, V156, P23, DOI 10.2214/ajr.156.1.1898566; COOK IJ, 1986, BRIT MED J, V292, P1380, DOI 10.1136/bmj.292.6532.1380; DAY JJ, 1993, CLIN RADIOL, V48, P48, DOI 10.1016/S0009-9260(05)80108-4; MCINTYRE AS, 1993, GUT, V34, P1102, DOI 10.1136/gut.34.8.1102	4	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 16	1994	308	6935					1018	1018		10.1136/bmj.308.6935.1018	http://dx.doi.org/10.1136/bmj.308.6935.1018			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167514	Green Published			2022-12-01	WOS:A1994NH08900021
J	MCWHIRTER, JP; PENNINGTON, CR				MCWHIRTER, JP; PENNINGTON, CR			INCIDENCE AND RECOGNITION OF MALNUTRITION IN-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							SURGICAL PATIENTS; NORMS	Objectives-To determine incidence of malnutrition among patients on admission to hospital, to monitor their changes in nutritional status during stay, and to determine awareness of nutrition in different clinical units. Design-Prospective study of consecutive admissions. Setting-Acute teaching hospital. Subjects-500 patients admitted to hospital: 100 each from general surgery, general medicine, respiratory medicine, orthopaedic surgery, and medicine for the elderly. Main outcome measures-Nutritional status of patients on admission and reassessment on discharge, review of case notes for information about nutritional status. Results-On admission, 200 of the 500 patients were undernourished (body mass index less than 20) and 34% were overweight (body mass index >25). The 112 patients reassessed on discharge had mean weight loss of 5.4%, with greatest weight loss in those initially most undernourished. But the 10 patients referred for nutritional support showed mean weight gain of 7.9%. Review of case notes revealed that, of the 200 undernourished patients, only 96 had any nutritional information documented. Conclusion-Malnutrition remains a largely unrecognised problem in hospital and highlights the need for education on clinical nutrition.			MCWHIRTER, JP (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND.							ARORA NS, 1982, AM REV RESPIR DIS, V126, P5; BISHOP CW, 1981, AM J CLIN NUTR, V34, P2530, DOI 10.1093/ajcn/34.11.2530; BISTRIAN BR, 1974, JAMA-J AM MED ASSOC, V230, P858, DOI 10.1001/jama.230.6.858; BISTRIAN BR, 1976, JAMA-J AM MED ASSOC, V235, P1567, DOI 10.1001/jama.235.15.1567; BURR ML, 1984, BRIT J NUTR, V51, P165, DOI 10.1079/BJN19840020; Garrow JS., 1981, TREAT OBESITY SERIOU; Gregory F., 1990, DIETARY NUTR SURVEY; HEYMSFIELD SB, 1978, AM HEART J, V95, P584, DOI 10.1016/0002-8703(78)90300-9; HILL GL, 1977, LANCET, V1, P689; KEYS AJ, 1950, BIOL HUMAN STARVATIO, P140; PINCHCOFSKY GD, 1985, J AM COLL NUTR, V4, P471, DOI 10.1080/07315724.1985.10720089; REILLY JJ, 1988, J PARENTER ENTERAL N, V12, P372; ROBINSON G, 1987, JPEN-PARENTER ENTER, V11, P49, DOI 10.1177/014860718701100149; WALKER MA, 1988, HLTH B EDINB, V1, P42; WEBB AR, 1989, JPEN-PARENTER ENTER, V13, P30, DOI 10.1177/014860718901300130; WINDSOR JA, 1988, ANN SURG, V17, P181	16	902	958	0	41	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					945	948		10.1136/bmj.308.6934.945	http://dx.doi.org/10.1136/bmj.308.6934.945			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173401	Green Published			2022-12-01	WOS:A1994NF48500016
J	NORDSTROM, M; LINDBLAD, B; ANDERSON, H; BERGQVIST, D; KJELLSTROM, T				NORDSTROM, M; LINDBLAD, B; ANDERSON, H; BERGQVIST, D; KJELLSTROM, T			DEEP VENOUS THROMBOSIS AND OCCULT MALIGNANCY - AN EPIDEMIOLOGIC-STUDY	BRITISH MEDICAL JOURNAL			English	Article							VEIN THROMBOSIS; CANCER; DIAGNOSIS	Objective-To determine the risk of subsequent cancer in patients with deep venous thrombosis confirmed by venography. Design-Follow up of all patients who had venography for suspected deep venous thrombosis during 1984-88. Patients were traced through a cancer registry up to 1 January 1991. Subjects-4399 patients who had phlebography in one hospital. Setting-General hospital in Malmo, Sweden, serving a population of 230 000. Main outcome measure-Number of cancers recorded. Results-4399 patients had venography for suspected deep venous thrombosis; 604 were known to have a malignancy at the time of venography and were excluded from further analysis. 1383 had deep venous thrombosis, 150 of whom subsequently developed cancer. 182 of the 2412 patients without thrombosis developed cancer. During the first six months after venography 66 patients with thrombosis developed malignancy compared with 37 patients without thrombosis (P < 0.0001). 38 of the cancers in the deep venous thrombosis group were detected by history, physical examination, and laboratory tests. Three patients had postoperative or post-traumatic deep venous thromboses. Only two of the remaining patients would have benefited from early detection by extensive screening. After six months the incidence of cancer was identical in patients with and without thrombosis. Conclusion-Deep venous thrombosis is associated with a significantly higher frequency of malignancy during the first six months after diagnosis. Malignancies can be found with simple clinical and diagnostic methods and extensive screening is not required.	UNIV HOSP LUND,REG TUMOUR REGISTRY,LUND,SWEDEN; HELSINGBORG HOSP,DEPT MED,HELSINGBORG,SWEDEN; UNIV UPPSALA,ACAD HOSP,DEPT SURG,S-75105 UPPSALA,SWEDEN	Lund University; Skane University Hospital; Helsingborgs Hospital; Uppsala University	NORDSTROM, M (corresponding author), LUND UNIV,MALMO GEN HOSP,DEPT MED & SURG,S-21401 MALMO,SWEDEN.							Breslow NE, 1987, IARC SCI PUBL, V82, P109; Carlsson U, 1986, Lakartidningen, V83, P598; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; LEVINE M, 1990, SEMIN ONCOL, V17, P160; LEVINE MN, 1985, CAN MED ASSOC J, V133, P977; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; MONREAL M, 1991, CANCER, V67, P541, DOI 10.1002/1097-0142(19910115)67:2<541::AID-CNCR2820670237>3.0.CO;2-J; MYRUP B, 1991, UGESKRIFT LAEGER, V43, P2996; NASCHITZ JE, 1989, INT ANGIOL, V8, P28; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; RANFT J, 1991, INT ANGIOL, V10, P66; Trousseau A., 1865, CLIN MED HOTEL DIEU, V3, P654; Trousseau A., 1865, CLIN MED HOTEL DIEU, V3, P654; WRIGHT IS, 1952, CIRCULATION, V5, P161, DOI 10.1161/01.CIR.5.2.161	17	190	199	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					891	894		10.1136/bmj.308.6933.891	http://dx.doi.org/10.1136/bmj.308.6933.891			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173368	Green Published			2022-12-01	WOS:A1994NE60000021
J	DIAMOND, T; VINE, J; SMART, R; BUTLER, P				DIAMOND, T; VINE, J; SMART, R; BUTLER, P			THYROTOXIC BONE-DISEASE IN WOMEN - A POTENTIALLY REVERSIBLE DISORDER	ANNALS OF INTERNAL MEDICINE			English	Article							L-THYROXINE THERAPY; MINERAL CONTENT; SERUM OSTEOCALCIN; THYROID-HORMONES; HYPERTHYROIDISM; DENSITY; METABOLISM; FRACTURES; TURNOVER	Objective: To measure changes in spinal and femoral neck bone mineral densities in patients treated for Graves thyrotoxicosis. Design: Cohort study. Setting: Tertiary care center. Patients: Fifteen women with active Graves thyrotoxicosis. Six patients were premenopausal and nine were postmenopausal. All patients had evidence of thyrotoxicosis as indicated by a raised total serum thyroxine, suppressed serum thyroid-stimulating hormone, and an elevated technetium-99m pertechnetate thyroid scan. A control group of 15 healthy volunteers matched for age, sex, and menopausal status were followed during the same period. Measurements: Bone mineral density was measured by dual-energy x-ray absorptiometry at baseline and after 12 months of antithyroid therapy when euthyroidism had been achieved. Results: After 12 months of therapy, total serum thyroxine, total serum triiodothyronine, serum alkaline phosphatase, and serum bone Gla-protein activities had returned to normal in all patients (P < 0.001 for all comparison between initial and final biochemical measurements). During this interval, the mean lumbar spine bone mineral increased from an initial value of 1.01 g/cm2 to 1.07 g/cm2, an increase of 6.6% per year (95% CI, 3.6% to 9.6%) (P < 0.001 compared with controls). Increases in femoral neck (1.2%/y; CI, -2.1 % to 4.5%; P = 0.2 compared with controls) and femoral trochanter bone mineral (3.2%/y; CI, 2.4% to 8.7%; P = 0.2 compared with controls) were not statistically significant. Using forced-entry multiple regression analysis, the severity of the thyrotoxicosis was independently associated with the percentage increment in lumbar spine bone mineral density after 12 months of antithyroid therapy. Conclusion: Effective treatment of Graves thyrotoxicosis was associated with increases in lumbar spine and femoral neck bone mineral. Although the changes in bone mineral were modest, our data suggest that thyrotoxic bone loss may be a reversible disorder.			DIAMOND, T (corresponding author), ST GEORGE HOSP, DEPT ENDOCRINOL, KOGARAH, NSW 2217, AUSTRALIA.							ADAMS P, 1967, ENDOCRINOLOGY, V81, P735, DOI 10.1210/endo-81-4-735; ADLIN EV, 1991, AM J MED, V90, P360, DOI 10.1016/0002-9343(91)90577-K; AUWERX J, 1986, Q J MED, V60, P737; BAUER DC, 1992, J BONE MINER RES, V7, pS121; BAYLEY TA, 1980, J CLIN ENDOCR METAB, V50, P916, DOI 10.1210/jcem-50-5-916; BRITTO JM, 1992, ANN SCI M AUSTR NZ B, P27; DIAMOND T, 1991, J CLIN ENDOCR METAB, V72, P1184, DOI 10.1210/jcem-72-6-1184; FRASER SA, 1971, LANCET, V1, P981; GARREL DR, 1986, J CLIN ENDOCR METAB, V62, P1052, DOI 10.1210/jcem-62-5-1052; HARVEY RD, 1991, J CLIN ENDOCR METAB, V72, P1189, DOI 10.1210/jcem-72-6-1189; KROLNER B, 1983, CLIN ENDOCRINOL, V18, P439, DOI 10.1111/j.1365-2265.1983.tb02873.x; LARNACH TA, 1992, CALCIFIED TISSUE INT, V51, P255, DOI 10.1007/BF00334484; LEE MS, 1990, J CLIN ENDOCR METAB, V70, P766, DOI 10.1210/jcem-70-3-766; MOSEKILDE L, 1990, ENDOCRIN METAB CLIN, V19, P35, DOI 10.1016/S0889-8529(18)30338-4; MUNDY GR, 1976, J CLIN INVEST, V58, P529, DOI 10.1172/JCI108497; ONGPHIPHADHANAKUL B, 1992, J BONE MINER RES, V7, P1227; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; RIBOT C, 1990, CLIN ENDOCRINOL, V33, P143, DOI 10.1111/j.1365-2265.1990.tb00477.x; ROSEN CJ, 1992, 74TH ANN M END SOC S, P436; SEEMAN E, 1982, J CLIN INVEST, V69, P1302, DOI 10.1172/JCI110570; SOLOMON B, 1992, 74TH ANN M END SOC S, P157; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; TAELMAN P, 1990, CLIN ENDOCRINOL, V33, P107, DOI 10.1111/j.1365-2265.1990.tb00471.x; TOH SH, 1985, ARCH INTERN MED, V145, P883, DOI 10.1001/archinte.145.5.883; von Recklinghausen FC, 1891, FESTSCHRIFT R VIRCHO, P1; WILKINSON MR, 1986, ARCH INTERN MED, V146, P268, DOI 10.1001/archinte.146.2.268; YAKAMOTO M, 1992, 6TH INT C BON MORPH, P39	27	89	92	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					8	11		10.7326/0003-4819-120-1-199401010-00002	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00002			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250460				2022-12-01	WOS:A1994MP28000002
J	ALBRIGHT, AL; BARRON, WB; FASICK, MP; POLINKO, P; JANOSKY, J				ALBRIGHT, AL; BARRON, WB; FASICK, MP; POLINKO, P; JANOSKY, J			CONTINUOUS INTRATHECAL BACLOFEN INFUSION FOR SPASTICITY OF CEREBRAL ORIGIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SPINAL-CORD; PALSY	Objective.-To determine if continuous intrathecal baclofen infusion (CIBI) would provide continuous relief of spasticity in patients with spasticity of cerebral origin, especially children with cerebral palsy. Design.-Prospective, unblinded trial, before and after CIBI. Setting.-Children's Hospital of Pittsburgh (Pa). Patients.-Thirty-seven patients, 5 to 27 years of age, with spasticity of cerebral origin. Intervention.-Continuous intrathecal baclofen infusion for 3 to 48 months. Main Outcome Measures.-Muscle tone, range of motion, upper extremity timed tasks, activities of daily living (ADLs). Results.-Six and 12 months after CIBI, muscle tone was significantly decreased in the upper (P=.04) and lower (P=.001) extremities. There was a significant relationship between baclofen dosage and muscle tone in the upper (P=.02) and lower (P=.001) extremities. Hamstring motion, upper extremity function, and ADLs were significantly improved in 25 patients who were capable of self-care. Conclusion.-Spasticity of cerebral origin can be effectively treated with CIBI. Because baclofen dosages can be titrated for the desired clinical response, CIBI is particularly useful for patients who need some spasticity to stand and ambulate.	CHILDRENS HOSP PITTSBURGH,DEPT OCCUPAT THERAPY,PITTSBURGH,PA; CHILDRENS HOSP PITTSBURGH,DEPT SOCIAL SERV,PITTSBURGH,PA; UNIV PITTSBURGH,SCH MED,DEPT NEUROSURG,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT CLIN EPIDEMIOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	ALBRIGHT, AL (corresponding author), CHILDRENS HOSP PITTSBURGH,DEPT NEUROSURG,3705 5TH AVE,PITTSBURGH,PA 15213, USA.				PHS HHS [5M01R-R00084] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBRIGHT AL, 1991, JAMA-J AM MED ASSOC, V265, P1418, DOI 10.1001/jama.265.11.1418; ASHWORTH B, 1964, PRACTITIONER, V192, P540; BROSETA J, 1990, STEREOT FUNCT NEUROS, V54-5, P147, DOI 10.1159/000100205; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; DAVIDOFF RA, 1985, ANN NEUROL, V17, P107, DOI 10.1002/ana.410170202; DRALLE D, 1985, LANCET, V2, P1003; Feldman RG, 1980, SPASTICITY DISORDERE, P41; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; LOUBSER PG, 1991, PARAPLEGIA, V29, P48, DOI 10.1038/sc.1991.7; MULLER H, 1992, DEV MED CHILD NEUROL, V34, P739; OCHS G, 1989, J NEUROL NEUROSUR PS, V52, P933, DOI 10.1136/jnnp.52.8.933; OTSUKA M, 1980, J EXP BIOL, V89, P201; PANETH N, 1984, EPIDEMIOLOGY CEREBRA, P35; PARK TS, 1992, NEW ENGL J MED, V326, P745; PEACOCK WJ, 1987, PEDIATR NEUROSCI, V13, P61, DOI 10.1159/000120302; PENN RD, 1992, J NEUROSURG, V77, P236, DOI 10.3171/jns.1992.77.2.0236; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Zieglgansberger W, 1988, LOCAL SPINAL THERAPY, DOI [10.1007/978-3-642-72954-6_4, DOI 10.1007/978-3-642-72954-6_4]; Zierski J, 1988, Acta Neurochir Suppl (Wien), V43, P94	19	237	242	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1993	270	20					2475	2477		10.1001/jama.270.20.2475	http://dx.doi.org/10.1001/jama.270.20.2475			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG671	8230625				2022-12-01	WOS:A1993MG67100030
J	OSTFELD, RS; CANHAM, CD; PUGH, SR				OSTFELD, RS; CANHAM, CD; PUGH, SR			INTRINSIC DENSITY-DEPENDENT REGULATION OF VOLE POPULATIONS	NATURE			English	Article							ANIMAL POPULATIONS; SMALL MAMMALS; CYCLES	CONSIDERABLE controversy exists over the role of density-dependent processes in controlling animal population size. In populations that fluctuate cyclically or erratically, for example many voles and insects1,2, theory predicts that either density-dependence is weak1,3, or that density-dependent responses lag behind density4-6. One key mechanism for lagged density-dependence is a delay in regeneration of food resources following heavy exploitation. Here we show that meadow vole (Microtus pennsylvanicus) populations respond immediately to high density by reducing breeding effort and hence population growth, disproving the hypothesis that density-dependence is weak. In addition, vole populations do not show a delay in growth following marked reduction in plant biomass (their source of food and cover). We conclude that intrinsic density-dependence processes tend to stabilize vole populations, and that cyclic dynamics are not caused by lagged effects of resource exploitation.	BOSTON UNIV, COLL GEN STUDIES, BOSTON, MA 02215 USA	Boston University	OSTFELD, RS (corresponding author), INST ECOSYST STUDIES, BOX AB, MILLBROOK, NY 12545 USA.		Canham, Charles D/F-6161-2011	Canham, Charles D/0000-0001-8361-9148; Ostfeld, Richard/0000-0002-3707-9301				AKCAKAYA HR, 1992, ECOL MONOGR, V62, P119, DOI 10.2307/2937172; Andrewartha H.G., 1954, DISTRIBUTION ABUNDAN; BROWN MW, 1989, ECOLOGY, V70, P776, DOI 10.2307/1940227; CHITTY D, 1987, CAN J ZOOL, V65, P2555, DOI 10.1139/z87-385; COCKBURN A, 1988, SOCIAL BEHAVIOUR FLU; DEMPSTER JP, 1986, OIKOS, V46, P413, DOI 10.2307/3565842; Elton C., 1942, VOLES MICE LEMMINGS; GAINES MS, 1980, ANNU REV ECOL SYST, V11, P163, DOI 10.1146/annurev.es.11.110180.001115; GASTON KJ, 1987, OECOLOGIA, V74, P404, DOI 10.1007/BF00378937; HANSKI I, 1991, J ANIM ECOL, V60, P353, DOI 10.2307/5465; HANSKI I, 1990, PHILOS T R SOC B, V330, P141, DOI 10.1098/rstb.1990.0188; HANSKI I, 1993, NATURE, V364, P232, DOI 10.1038/364232a0; HANSSON L, 1988, TRENDS ECOL EVOL, V3, P195, DOI 10.1016/0169-5347(88)90006-7; HASLER J F, 1975, Biologist (Charleston), V57, P52; HASSELL MP, 1987, J ANIM ECOL, V56, P705, DOI 10.2307/5078; HASSELL MP, 1986, TRENDS ECOL EVOL, V1, P90, DOI 10.1016/0169-5347(86)90031-5; Keller B.L., 1985, Special Publication American Society of Mammalogists, P725; Krebs C.J., 1974, ADV ECOL RES, V8, P267, DOI DOI 10.1016/S0065-2504(08)60280-9; LIDICKER WZ, 1985, SPEC PUBL AM SOC MAM, V8, P420; May R.M., 1976, P4; MCCRAVY KW, 1992, J MAMMAL, V73, P151, DOI 10.2307/1381877; MIHOK S, 1992, CAN J ZOOL, V70, P1561, DOI 10.1139/z92-215; OSTFELD RS, 1992, WILDLIFE 2001 : POPULATIONS, P851; SCHAFFER WM, 1973, EVOLUTION, V27, P111, DOI 10.1111/j.1558-5646.1973.tb05923.x; STENSETH NC, 1986, THEOR POPUL BIOL, V29, P365, DOI 10.1016/0040-5809(86)90015-8; STILING P, 1989, ECOLOGY, V70, P779, DOI 10.2307/1940228; STRONG DR, 1986, TRENDS ECOL EVOL, V1, P39, DOI 10.1016/0169-5347(86)90071-6; TURCHIN P, 1990, NATURE, V344, P660, DOI 10.1038/344660a0; WOIWOD IP, 1992, J ANIM ECOL, V61, P619, DOI 10.2307/5617	29	84	90	0	23	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 18	1993	366	6452					259	261		10.1038/366259a0	http://dx.doi.org/10.1038/366259a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232583				2022-12-01	WOS:A1993MH32500061
J	LEGRAIN, P; CHAPON, C				LEGRAIN, P; CHAPON, C			INTERACTION BETWEEN PRP11 AND SPP91 YEAST SPLICING FACTORS AND CHARACTERIZATION OF A PRP9-PRP11-SPP91 COMPLEX	SCIENCE			English	Article							PRE-MESSENGER-RNA; U1 SNRNP; PROTEIN; GENES; BINDING; SYSTEM	Several proteins are involved in the early steps of the spliceosome assembly pathway. Protein-protein interactions have been identified between two Saccharomyces cerevisiae yeast splicing factors, PRP9 and SPP91. Here it is demonstrated that protein-protein interactions occur between SPP91 and PRP11. The combination of the prp9-1 mutant and a truncated prp11 mutant exhibits a synthetic lethal phenotype, suggestive of a common biochemical defect. The PRP9 and PRP11 proteins do not interact directly, but the PRP9 and PRP11 molecules can simultaneously bind SPP91 to form a three-molecule complex. Structurally and functionally related proteins are found in mammalian cells and are associated in a single biochemical fraction. This strongly suggests that the PRP9-SPP91-PRP11 complex is a key element of the splicing machinery.			LEGRAIN, P (corresponding author), INST PASTEUR,DEPT BIOL MOLEC,UNITE GENET MOLEC,F-75724 PARIS,FRANCE.							ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; ARENAS JE, 1993, P NATL ACAD SCI USA, V90, P6771, DOI 10.1073/pnas.90.14.6771; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; BEHRENS SE, IN PRESS P NATL ACAD; BENNETT M, 1993, SCIENCE, V262, P105, DOI 10.1126/science.8211113; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; BROSI R, IN PRESS J BIOL CHEM; CHANG TH, 1988, MOL CELL BIOL, V8, P2379, DOI 10.1128/MCB.8.6.2379; CHAPON C, 1992, EMBO J, V11, P3279, DOI 10.1002/j.1460-2075.1992.tb05406.x; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; LEGRAIN P, 1990, EMBO J, V9, P2775, DOI 10.1002/j.1460-2075.1990.tb07465.x; LEGRAIN P, 1993, GENE DEV, V7, P1390, DOI 10.1101/gad.7.7b.1390; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LEGRAIN P, UNPUB; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MOORE MJ, 1993, RNA WORLD, V24; NELISSEN RLH, 1991, NUCLEIC ACIDS RES, V19, P449, DOI 10.1093/nar/19.3.449; RUBY S, COMMUNICATION; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; SCHAPPERT K, 1991, MOL GEN GENET, V226, P277, DOI 10.1007/BF00273613; SILLEKENS PTG, 1988, NUCLEIC ACIDS RES, V16, P8307, DOI 10.1093/nar/16.17.8307	26	67	71	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 1	1993	262	5130					108	110		10.1126/science.8211114	http://dx.doi.org/10.1126/science.8211114			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ635	8211114				2022-12-01	WOS:A1993LZ63500034
J	BUNDRED, NJ; DOVER, MS; ALUWIHARE, N; FARAGHER, EB; MORRISON, JM				BUNDRED, NJ; DOVER, MS; ALUWIHARE, N; FARAGHER, EB; MORRISON, JM			SMOKING AND PERIDUCTAL MASTITIS	BRITISH MEDICAL JOURNAL			English	Article							CIGARETTE-SMOKING		SELLY OAK HOSP,DEPT HISTOPATHOL,BIRMINGHAM B29 6JD,ENGLAND; SELLY OAK HOSP,DEPT SURG,BIRMINGHAM B29 6JD,ENGLAND		BUNDRED, NJ (corresponding author), UNIV HOSP S MANCHESTER,DEPT MED STAT,MANCHESTER M20 8LR,LANCS,ENGLAND.							BUNDRED NJ, 1992, BRIT J SURG, V79, P58, DOI 10.1002/bjs.1800790121; DIXON JMJ, 1985, BRIT J SURG, V70, P601; SCHAFER P, 1988, INT J EPIDEMIOL, V17, P810, DOI 10.1093/ije/17.4.810; THOMAS WG, 1982, BRIT J SURG, V69, P423, DOI 10.1002/bjs.1800690724; 1990, 1990 S BIRM HLTH AUT	5	27	28	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1993	307	6907					772	773		10.1136/bmj.307.6907.772	http://dx.doi.org/10.1136/bmj.307.6907.772			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ478	8219949	Green Published, Bronze			2022-12-01	WOS:A1993LZ47800024
J	DUPONT, WD; PAGE, DL; PARL, FF; VNENCAKJONES, CL; PLUMMER, WD; RADOS, MS; SCHUYLER, PA				DUPONT, WD; PAGE, DL; PARL, FF; VNENCAKJONES, CL; PLUMMER, WD; RADOS, MS; SCHUYLER, PA			LONG-TERM RISK OF BREAST-CANCER IN WOMEN WITH FIBROADENOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATYPICAL HYPERPLASIA; DISEASE; DIAGNOSIS; COHORT	Background. Fibroadenomas are benign breast tumors that are commonly diagnosed in young women and are associated with a slight increase in the risk of breast cancer. These lesions vary considerably in their histologic characteristics. We assessed the correlation between the histologic features of fibroadenomas and the risk of subsequent breast cancer. Methods. We conducted a retrospective cohort study of a consecutive series of patients with fibroadenoma diagnosed between 1950 and 1968. Follow-up data were obtained for 1835 patients (90 percent of those eligible). Fibroadenomas with cysts, sclerosing adenosis, epithelial calcifications, or papillary apocrine changes were classified as complex. The rate of subsequent breast cancer among the patients was compared with the rates in two control groups, women listed in the Connecticut Tumor Registry and women chosen from among the patients' sisters-in-law. Results. The risk of invasive breast cancer was 2.17 times higher among the patients with fibroadenoma than among the controls (95 percent confidence interval, 1.5 to 3.2). The relative risk increased to 3.10 among patients with complex fibroadenomas (95 percent confidence interval, 1.9 to 5.1) and remained elevated for decades after diagnosis. Patients with benign proliferative disease in the parenchyma adjacent to the fibroadenoma had a relative risk of 3.88 (95 percent confidence interval, 2.1 to 7.3). Patients with a family history of breast cancer in whom complex fibroadenoma was diagnosed had a relative risk of 3.72, as compared with controls with a family history (95 percent confidence interval, 1.4 to 10). Two thirds of the patients had noncomplex fibroadenomas and no family history of breast cancer and did not have an increased risk. Conclusions. Fibroadenoma is a long-term risk factor for breast cancer. The risk is increased in women with complex fibroadenomas, proliferative disease, or a family history of breast cancer.	VANDERBILT UNIV,SCH MED,DEPT PATHOL,NASHVILLE,TN 37212	Vanderbilt University	DUPONT, WD (corresponding author), VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,A-1124 MED CTR N,NASHVILLE,TN 37232, USA.		Dupont, William D./I-4430-2012		NATIONAL CANCER INSTITUTE [R01CA050468] Funding Source: NIH RePORTER; NCI NIH HHS [CA-31698, CA-50468] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRESLOW NE, 1983, J AM STAT ASSOC, V78, P1, DOI 10.2307/2287093; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CARTER CL, 1988, AM J EPIDEMIOL, V128, P467, DOI 10.1093/oxfordjournals.aje.a114995; DIXON WJ, 1992, BMDP STATISTICAL SOF; DUPONT WD, 1993, CANCER, V71, P1258, DOI 10.1002/1097-0142(19930215)71:4<1258::AID-CNCR2820710415>3.0.CO;2-I; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUPONT WD, 1989, HUM PATHOL, V20, P723, DOI 10.1016/0046-8177(89)90063-4; Fechner R.E., 1988, DIAGNOSTIC HISTOPATH, P72; HESTON JF, 1986, NIH862652 DEPT HLTH, V70; HUTCHINSON WB, 1980, J NATL CANCER I, V65, P13; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KING MC, 1993, JAMA-J AM MED ASSOC, V269, P1975, DOI 10.1001/jama.269.15.1975; KRIEGER N, 1992, AM J EPIDEMIOL, V135, P619, DOI 10.1093/oxfordjournals.aje.a116341; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P941, DOI 10.1001/jama.267.7.941; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P1780; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; MCDIVITT RW, 1992, CANCER-AM CANCER SOC, V69, P1408, DOI 10.1002/1097-0142(19920315)69:6<1408::AID-CNCR2820690617>3.0.CO;2-C; MOSKOWITZ M, 1980, RADIOLOGY, V134, P289, DOI 10.1148/radiology.134.2.7352201; Page D, 1988, DIAGNOSTIC HISTOPATH; PAGE DL, 1992, HUM PATHOL, V23, P1095, DOI 10.1016/0046-8177(92)90026-Y; PALLI D, 1991, INT J CANCER, V47, P703, DOI 10.1002/ijc.2910470513; STORER BE, 1985, J AM STAT ASSOC, V80, P139, DOI 10.2307/2288064; 1990, SAS STAT USERS GUIDE, V2	23	274	290	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	1994	331	1					10	15		10.1056/NEJM199407073310103	http://dx.doi.org/10.1056/NEJM199407073310103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU951	8202095				2022-12-01	WOS:A1994NU95100003
J	BREIMAN, RF; BUTLER, JC; TENOVER, FC; ELLIOTT, JA; FACKLAM, RR				BREIMAN, RF; BUTLER, JC; TENOVER, FC; ELLIOTT, JA; FACKLAM, RR			EMERGENCE OF DRUG-RESISTANT PNEUMOCOCCAL INFECTIONS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; STREPTOCOCCUS-PNEUMONIAE; PENICILLIN-RESISTANT; ANTIBIOTIC-RESISTANCE; INVASIVE DISEASE; VACCINE EFFICACY; MENINGITIS; POPULATIONS; CEFTRIAXONE; FAILURE	Objective.-To estimate drug susceptibility patterns of Streptococcus pneumoniae in selected hospitals in the United States and to characterize the epidemiology of invasive drug-resistant pneumococcal infections. Design.-Minimum inhibitory concentrations (MICs) for a variety of commonly used antimicrobial drugs were determined for pneumococcal isolates submitted to the Centers for Disease Control and Prevention (CDC). Risk factors for drug-resistant pneumococcal infection were evaluated. Setting.-Hospital laboratories in the United States submitting pneumococcal isolates to the CDC between October 1, 1991, and September 30, 1992. Participants.-A total of 544 persons with pneumococci isolated from normally sterile sites. Results.-A total of 13 hospitals in 12 states actively participated in an ongoing pneumococcal surveillance study. Resistance to penicillin was detected in 6.6% of isolates, including 1.3% of isolates with MICs of 2.0 mu g/mL or more (compared with <0.02% of isolates with MIC greater than or equal to 2.0 mu g/mL identified by CDC surveillance from 1979 to 1987). A total of 16.4% were resistant to at least one of the following drugs or drug classes: penicillin, cephalosporins, macrolides, combination trimethoprim and sulfamethoxazole, and chloramphenicol. Six serotypes (6B, 23F, 14, 9V, 19A, and 19F) accounted for nearly 85% of strains resistant to at least one drug class. Children were more likely than adults to be infected with strains resistant to trimethoprim-sulfamethoxazole, erythromycin, or chloramphenicol. Conclusions.-Emergence of drug-resistant pneumococcal infections will present critical challenges to clinicians for treating patients with pneumococcal disease. Widened and intensified surveillance is needed. These data suggest that current recommendations for use of 23-valent pneumococcal capsular polysaccharide vaccines should be aggressively promoted and that development and evaluation of new conjugate pneumococcal vaccines may be a crucial part of strategies for prevention.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	BREIMAN, RF (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333, USA.							[Anonymous], 1993, M7A3 NAT COMM CLIN L; APPELBAUM PC, 1987, EUR J CLIN MICROBIOL, V6, P367, DOI 10.1007/BF02013089; BOLAN G, 1986, ANN INTERN MED, V104, P1, DOI 10.7326/0003-4819-104-1-1; BRADLEY JS, 1991, PEDIATR INFECT DIS J, V10, P871; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; COFFEY TJ, 1991, MOL MICROBIOL, V5, P2255, DOI 10.1111/j.1365-2958.1991.tb02155.x; COURVALIN P, 1986, MOL GEN GENET, V205, P291, DOI 10.1007/BF00430441; DOWSON CG, 1989, MOL MICROBIOL, V3, P95, DOI 10.1111/j.1365-2958.1989.tb00108.x; DOWSON CG, 1990, P NATL ACAD SCI USA, V87, P5858, DOI 10.1073/pnas.87.15.5858; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; FIGUEIREDO AMS, 1992, ANTIMICROB AGENTS CH, V36, P886, DOI 10.1128/AAC.36.4.886; HAKENBECK R, 1980, ANTIMICROB AGENTS CH, V17, P364, DOI 10.1128/AAC.17.3.364; HANSMAN D, 1967, LANCET, V2, P264; ISTRE GR, 1987, J INFECT DIS, V156, P732, DOI 10.1093/infdis/156.5.732; JACKSON MA, 1984, PEDIATR INFECT DIS J, V3, P129, DOI 10.1097/00006454-198403000-00010; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; LAIBLE G, 1991, MOL MICROBIOL, V5, P1993, DOI 10.1111/j.1365-2958.1991.tb00821.x; LONKS JR, 1991, 31ST INT C ANT AG CH; MCDOUGAL LK, 1992, ANTIMICROB AGENTS CH, V36, P2176, DOI 10.1128/AAC.36.10.2176; MUNOZ R, 1992, MOL MICROBIOL, V6, P2461; MUNOZ R, 1991, J INFECT DIS, V164, P302, DOI 10.1093/infdis/164.2.302; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; PEETERS CCAM, 1991, IMMUNOL LETT, V30, P267, DOI 10.1016/0165-2478(91)90036-A; RADETSKY MS, 1981, LANCET, V2, P771; RAMIREZ J, 1992, 32ND INT C ANT AG CH; RAUCH AM, 1990, AM J DIS CHILD, V144, P923, DOI 10.1001/archpedi.1990.02150320087033; REICHLER M, 1991, 31ST INT C ANT AG CH; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SIMBERKOFF MS, 1986, J INFECT DIS, V153, P78, DOI 10.1093/infdis/153.1.78; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P662; SPIKA JS, 1991, J INFECT DIS, V163, P1273, DOI 10.1093/infdis/163.6.1273; VERSALOVIC J, 1993, J INFECT DIS, V167, P850, DOI 10.1093/infdis/167.4.850; WARD J, 1981, REV INFECT DIS, V3, P254; WEINGARTEN RD, 1990, REV INFECT DIS, V12, P118; 1990, M7A2 NAT COMM CLIN L; 1989, MMWR MORB MORTAL WKL, V38, P64; 1994, MMWR MORB MORTAL WKL, V43, P23; 1989, MMWR MORB MORTAL WKL, V38, P733	40	504	516	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1831	1835		10.1001/jama.271.23.1831	http://dx.doi.org/10.1001/jama.271.23.1831			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	8196139				2022-12-01	WOS:A1994NP95900026
J	CAULFIELD, M; LAVENDER, P; FARRALL, M; MUNROE, P; LAWSON, M; TURNER, P; CLARK, AJL				CAULFIELD, M; LAVENDER, P; FARRALL, M; MUNROE, P; LAWSON, M; TURNER, P; CLARK, AJL			LINKAGE OF THE ANGIOTENSINOGEN GENE TO ESSENTIAL-HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIGREE-MEMBER METHOD; BLOOD-PRESSURE; PREECLAMPSIA; DISEASE; SYSTEM; RAT	Background. The renin-angiotensin system is a powerful presser system with a major influence on salt and water homeostasis. Angiotensinogen (also called renin substrate) is a key component of this system; it is cleaved by renin to yield angiotensin I, which is then cleaved by angiotensin-converting enzyme to yield angiotensin II, The observation that plasma angiotensinogen levels correlate with blood pressure and track through families suggests that angiotensinogen may have a role in essential hypertension. We therefore investigated whether there is linkage between the angiotensinogen gene on chromosome 1q42-43 and essential hypertension. Methods. Samples of DNA from 63 white European families in which two or more members had essential hypertension were tested for linkage of the angiotensinogen gene to this disorder. Affected cousins, nephews, nieces, and half-siblings were included when possible. To test for linkage, we used as a marker a dinucleotide-repeat sequence flanking this gene, and we employed the affected-pedigree-member method of linkage analysis. Two molecular variants of the angiotensinogen gene, one encoding threonine instead of methionine at position 235 (M235T) and the other encoding methionine rather than threonine at position 174 (T174M), were also tested for possible association with essential hypertension. Results. We found significant linkage (t = 5.00, P<0.001) and association (chi-square = 53.3, P<0.001) of the angiotensinogen-gene locus to essential hypertension in the 63 multiplex families. This linkage was consistently maintained in the subgroup of subjects with diastolic pressure above 100 mm Hg and in the subgroups classified according to sex. It has been proposed previously that T174M and M235T are associated with essential hypertension. However, we found no association in our population between either polymorphism and this disorder. Conclusions. This study provides strong and consistent support for the linkage to essential hypertension of regions within or close to the angiotensinogen gene. Precisely how mutations in this region may result in hypertension remains to be determined.	ST BARTHOLOMEWS HOSP,DEPT CHEM ENDOCRINOL,LONDON,ENGLAND; ROYAL POSTGRAD MED SCH,MRC,MOLEC MED GRP,LONDON,ENGLAND	University of London; Queen Mary University London; Imperial College London	CAULFIELD, M (corresponding author), ST BARTHOLOMEWS HOSP,DEPT CLIN PHARMACOL,LONDON EC1A 7BE,ENGLAND.			Caulfield, Mark/0000-0001-9295-3594; Munroe, Patricia/0000-0002-4176-2947; Lavender, Paul/0000-0001-8710-0263				ARNGRIMSSON R, 1993, NAT GENET, V4, P114, DOI 10.1038/ng0693-114; BISHOP DT, 1990, AM J HUM GENET, V46, P254; GAILLARD I, 1989, DNA-J MOLEC CELL BIO, V8, P87, DOI 10.1089/dna.1.1989.8.87; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JEUNEMAITRE X, 1992, HUM GENET, V88, P301; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KOTELEVTSEV YV, 1991, MOL CLONING LABORATO, V19, P6978; KURTZ TW, 1993, AM J MED, V94, P77, DOI 10.1016/0002-9343(93)90124-8; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; MACGREGOR GA, 1981, NATURE, V291, P329, DOI 10.1038/291329a0; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MARSH DG, 1992, NAT GENET, V2, P252, DOI 10.1038/ng1292-252; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PICKERING G, 1965, BMJ-BRIT MED J, V2, P1021, DOI 10.1136/bmj.2.5469.1021; Sambrook J., 1989, MOL CLONING LAB MANU; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; Ward R, 1990, HYPERTENSION PATHOPH, P81; WATT GCM, 1992, J HYPERTENS, V10, P473, DOI 10.1097/00004872-199205000-00011; WEEKS DE, 1988, AM J HUM GENET, V42, P315; WEEKS DE, 1992, AM J HUM GENET, V50, P859; WILLIAMS RR, 1989, J HYPERTENS, V7, pS8, DOI 10.1097/00004872-198900076-00003; 1992, NAT GENET, V1, P231	25	513	537	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	1994	330	23					1629	1633		10.1056/NEJM199406093302301	http://dx.doi.org/10.1056/NEJM199406093302301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP220	8177268				2022-12-01	WOS:A1994NP22000001
J	HELLMAN, S; WEICHSELBAUM, RR				HELLMAN, S; WEICHSELBAUM, RR			RADIATION ONCOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							B-CELL LYMPHOMA; IONIZING-RADIATION; THERAPY; RADIOTHERAPY; EXPERIENCE; ANTIBODY; CANCER				HELLMAN, S (corresponding author), UNIV CHICAGO,PRITZKER SCH MED,CHICAGO,IL 60637, USA.							[Anonymous], 1991, NEW ENGL J MED, V324, P1685; AUSTINSEYMOUR M, 1989, J NEUROSURG, V70, P13, DOI 10.3171/jns.1989.70.1.0013; CUMMINGS BJ, 1991, INT J RADIAT ONCOL, V21, P1115, DOI 10.1016/0360-3016(91)90265-6; GILL SS, 1991, INT J RADIAT ONCOL, V20, P599, DOI 10.1016/0360-3016(91)90076-G; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; HORIOT JC, 1992, RADIOTHER ONCOL, V25, P231, DOI 10.1016/0167-8140(92)90242-M; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; KAUFMAN DS, 1993, NEW ENGL J MED, V329, P1377, DOI 10.1056/NEJM199311043291903; LOEFFLER JS, 1990, RADIOTHER ONCOL, V17, P311, DOI 10.1016/0167-8140(90)90005-H; PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702; SAUNDERS MI, 1991, INT J RADIAT ONCOL, V21, P871, DOI 10.1016/0360-3016(91)90722-G; SCHARFEN CO, 1992, INT J RADIAT ONCOL, V24, P583; SEDDON JM, 1990, OPHTHALMOLOGY, V97, P769; VOKES EE, 1990, J CLIN ONCOL, V8, P911, DOI 10.1200/JCO.1990.8.5.911; WEICHSELBAUM RR, 1991, J NATL CANCER I, V83, P480, DOI 10.1093/jnci/83.7.480; WEICHSELBAUM RR, 1992, INT J RADIAT ONCOL, V24, P565, DOI 10.1016/0360-3016(92)91075-X	16	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	1994	271	21					1712	1714		10.1001/jama.271.21.1712	http://dx.doi.org/10.1001/jama.271.21.1712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN117	8182867				2022-12-01	WOS:A1994NN11700046
J	SCHWARTZ, RM; LUBY, NM; SCANLON, JW; KELLOGG, RJ				SCHWARTZ, RM; LUBY, NM; SCANLON, JW; KELLOGG, RJ			EFFECT OF SURFACTANT ON MORBIDITY, MORTALITY, AND RESOURCE USE IN NEWBORN-INFANTS WEIGHING 500 TO 1500 G	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; BOVINE SURFACTANT; CONTROLLED TRIAL; SYNTHETIC SURFACTANT; REPLACEMENT THERAPY; PREMATURE-INFANTS; PREVENTION; SURVIVAL; BIRTH	Background. The administration of surfactant decreased mortality, morbidity, and costs of care for very-low-birth-weight infants in clinical trials. The extent to which these benefits can be achieved in the usual clinical settings is not known. Methods. We analyzed clinical and financial data obtained from 1985 to 1990 at 14 perinatal centers in the United States on 5629 neonates weighing 500 to 1500 g. The infants were divided into groups according to whether they were born before or after surfactant was introduced into clinical practice. Regression models controlling for race, sex, and birth weight were used to assess mortality, morbidity, and use of resources. Mortality rates specific for these variables were projected to the nation as a whole with reference to the 1985 U.S. birth cohort. Results. The odds of death in the hospital for very-low-birth-weight infants were reduced by 30 percent after surfactant was introduced. Among infants with bronchopulmonary dysplasia, mortality declined 40 percent. Projections of mortality nationwide declined 5 percent. Eighty percent of the decline in the U.S. infant mortality rate between 1989 and 1990 could be attributed solely to the use of surfactant. Among the survivors, the overall odds of morbidity did not change, whether or not we adjusted for changes in race, sex, and birth weight. The odds of respiratory distress syndrome and pulmonary interstitial emphysema among the survivors declined by 20 percent and 40 percent, respectively, with surfactant. Inflation-adjusted charges per survivor declined by 10 percent, or $5,800, whereas the cost of care for each infant who died declined by 31 percent, or $4,400. Conclusions. The introduction of surfactant has led to decreased mortality and morbidity in very-low-birth-weight infants and to decreased use of resources both for infants who survive and for those who die.	COLUMBIA HOSP WOMEN, DIV NEONATOL, WASHINGTON, DC USA		SCHWARTZ, RM (corresponding author), NATL PERINATAL INFORMAT CTR, 1 STATE ST, SUITE 102, PROVIDENCE, RI 02908 USA.				PHS HHS [N01-H0-29024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; CORBET A, 1991, J PEDIATR-US, V118, P277, DOI 10.1016/S0022-3476(05)80502-5; HALLMAN M, 1991, ANN MED, V23, P693, DOI 10.3109/07853899109148105; HENNES HM, 1991, AM J DIS CHILD, V145, P102, DOI 10.1001/archpedi.1991.02160010108027; HENNES HM, 1992, AM J DIS CHILD, V146, P534; Hilts Philip J, 1991, N Y Times Web, P7; HILTS PJ, 1991, NY TIMES        0406, P8; HOEKSTRA RE, 1991, PEDIATRICS, V88, P10; HORBAR JD, 1989, NEW ENGL J MED, V320, P959; LIECHTY EA, 1991, PEDIATRICS, V88, P19; LONG W, 1991, J PEDIATR-US, V118, P595, DOI 10.1016/S0022-3476(05)83388-8; LONG W, 1991, NEW ENGL J MED, V325, P1696, DOI 10.1056/NEJM199112123252404; MANISCALCO WM, 1989, PEDIATRICS, V83, P1; MUGFORD M, 1991, ARCH DIS CHILD-FETAL, V66, P757, DOI 10.1136/adc.66.7_Spec_No.757; PHIBBS CS, 1992, 1991 P EX NEON TREAT, P109; RAJU TNK, 1987, LANCET, V1, P651; ROBERTSON B, 1988, PEDIATRICS, V82, P683; SCHWARTZ RM, 1989, FAM PLANN PERSPECT, V21, P170, DOI 10.2307/2135808; SOLL RF, 1990, PEDIATRICS, V85, P1092; WEGMAN ME, 1991, PEDIATRICS, V88, P1081; 1976, IMPROVING OUTCOME PR; 1994, ICD9CM INT CLASSIFIC; 1991, PEDIATRICS, V87, P946	23	225	227	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	1994	330	21					1476	1480		10.1056/NEJM199405263302102	http://dx.doi.org/10.1056/NEJM199405263302102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM068	8164699				2022-12-01	WOS:A1994NM06800002
J	REDFIELD, RJ				REDFIELD, RJ			MALE MUTATION-RATES AND THE COST OF SEX FOR FEMALES	NATURE			English	Article							DELETERIOUS MUTATIONS; RECOMBINATION; REPRODUCTION; EVOLUTION; ADVANTAGE	ALTHOUGH we do not know why sex evolved, the twofold cost of meiosis for females provides a standard against which postulated benefits of sex can be evaluated(1). The most reliable benefit is sex's ability to reduce the impact of deleterious mutations(2,3). But deleterious mutations may themselves generate a large and previously overlooked female-specific cost of sex. DNA sequence comparisons have confirmed Haldane's suggestion that most mutations arise in the male germ line(4,5); recent estimates of alpha, the ratio of male to female mutation rates, are ten, six and two in humans, primates and rodents, respectively(6-8). Consequently, male gametes may give progeny more mutations than the associated sexual recombination eliminates. Here I describe computer simulations showing that the cost of male mutations can easily exceed the benefits of recombination, causing females to produce fitter progeny by parthenogenesis than by mating. The persistence of sexual reproduction by females thus becomes even more problematic.	CANADIAN INST ADV RES,PROGRAM EVOLUT BIOL,VANCOUVER V6T 1Z4,BC,CANADA	Canadian Institute for Advanced Research (CIFAR)	REDFIELD, RJ (corresponding author), UNIV BRITISH COLUMBIA,DEPT ZOOL,6270 UNIV BLVD,VANCOUVER V6T 1Z4,BC,CANADA.		Redfield, Rosemary/K-5633-2012	Redfield, Rosemary/0000-0001-8940-587X				CHANG BHJ, 1994, P NATL ACAD SCI USA, V91, P827, DOI 10.1073/pnas.91.2.827; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; HALDANE JBS, 1947, ANN EUGENIC, V13, P262; Haldane JBS, 1937, AM NAT, V71, P337, DOI 10.1086/280722; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; HOWARD RS, 1994, NATURE, V367, P554, DOI 10.1038/367554a0; KIMURA M, 1966, GENETICS, V54, P1303; KONDRASHOV AS, 1984, GENET RES, V44, P199, DOI 10.1017/S0016672300026392; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1993, HUM MUTAT, V2, P229, DOI 10.1002/humu.1380020312; Maynard-Smith J., 1978, MODELS ECOLOGY; MIYATA T, 1987, COLD SPRING HARB SYM, V52, P863, DOI 10.1101/SQB.1987.052.01.094; MONTANDON AJ, 1992, HUM GENET, V89, P319; MUKAI T, 1969, GENETICS, V61, P749; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; SHIMMIN LC, 1993, NATURE, V362, P745, DOI 10.1038/362745a0; SMITH JM, 1968, AM NAT, V102, P469, DOI 10.1086/282559	18	79	80	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 12	1994	369	6476					145	147		10.1038/369145a0	http://dx.doi.org/10.1038/369145a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK971	8177318				2022-12-01	WOS:A1994NK97100048
J	RIDDIHOUGH, G				RIDDIHOUGH, G			A TWIST IN THE TAIL OF HUMAN ENDOTHELIN	NATURE			English	Article																		JANES RW, 1994, NATURE STRUCT BIOL, V1, P331; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0	2	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					84	84		10.1038/369084a0	http://dx.doi.org/10.1038/369084a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164749	Bronze			2022-12-01	WOS:A1994NJ86000060
J	BEUTLER, B; VANHUFFEL, C				BEUTLER, B; VANHUFFEL, C			UNRAVELING FUNCTION IN THE TNF LIGAND AND RECEPTOR FAMILIES	SCIENCE			English	Editorial Material							APOPTOSIS; RESOLUTION; BINDING; ANTIGEN; CDNA; FAS				BEUTLER, B (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.			Van Huffel, Christophe/0000-0001-6127-3027				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; BAENS M, 1993, J IMMUNOL, V16, P214; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; HELLER RA, 1993, CELL, V73, P216, DOI 10.1016/0092-8674(93)90223-D; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; MARSTERS SA, 1992, J BIOL CHEM, V267, P5747; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MICHL J, 1991, CURR OPIN IMMUNOL, V3, P373, DOI 10.1016/0952-7915(91)90040-8; Moore M., COMMUNICATION; PEPPEL K, 1993, J IMMUNOL, V151, P5699; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	29	434	458	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					667	668		10.1126/science.8171316	http://dx.doi.org/10.1126/science.8171316			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171316				2022-12-01	WOS:A1994NH71300021
J	KENYON, C; CHANG, J; GENSCH, E; RUDNER, A; TABTIANG, R				KENYON, C; CHANG, J; GENSCH, E; RUDNER, A; TABTIANG, R			A C-ELEGANS MUTANT THAT LIVES TWICE AS LONG AS WILD-TYPE	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; LIFE-SPAN; GENETIC-ANALYSIS; DAUER LARVA; SENESCENCE	WE have found that mutations in the gene daf-2 can cause fertile, active, adult Caenorhabditis elegans hermaphrodites to live more than twice as long as wild type. This lifespan extension, the largest yet reported in any organism1, requires the activity of a second gene, daf-16. Both genes also regulate formation of the dauer larva, a developmentally arrested larval form that is induced by crowding and starvation and is very long-lived2-4. Our findings raise the possibility that the longevity of the dauer is not simply a consequence of its arrested growth, but instead results from a regulated lifespan extension mechanism that can be uncoupled from other aspects of dauer formation. daf-2 and daf-16 provide entry points into understanding how lifespan can be extended.			KENYON, C (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOPHYS, SAN FRANCISCO, CA 94143 USA.							Finch CE., 1990, LONGEVITY SENESCENCE; HODGKIN J, 1986, GENETICS, V114, P15; JOHNSON TE, 1982, P NATL ACAD SCI-BIOL, V79, P6603, DOI 10.1073/pnas.79.21.6603; JOHNSON TE, 1987, P NATL ACAD SCI USA, V84, P3777, DOI 10.1073/pnas.84.11.3777; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KLASS M, 1976, NATURE, V260, P523, DOI 10.1038/260523a0; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; ROSE MR, 1984, CAN J ZOOL, V62, P1661, DOI 10.1139/z84-243; SERVICE PM, 1985, PHYSIOL ZOOL, V58, P380, DOI 10.1086/physzool.58.4.30156013; SULSTON J, 1975, J COMP NEUROL, V163, P215, DOI 10.1002/cne.901630207; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SWANSON MM, 1981, DEV BIOL, V84, P27, DOI 10.1016/0012-1606(81)90367-5; THOMAS JH, 1993, GENETICS, V134, P1105; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; VOWELS JJ, 1992, GENETICS, V130, P105; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q; White J., 1988, NEMATODE CAENORHABDI, V17, P81; Woolson R. F, 1987, STATISTICAL METHODS; ZUCKERMAN BM, 1980, NEMATODES BIOL MODEL	22	2356	2436	8	352	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	1993	366	6454					461	464		10.1038/366461a0	http://dx.doi.org/10.1038/366461a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247153				2022-12-01	WOS:A1993MK09800063
J	HATA, Y; SLAUGHTER, CA; SUDHOF, TC				HATA, Y; SLAUGHTER, CA; SUDHOF, TC			SYNAPTIC VESICLE FUSION COMPLEX CONTAINS UNC-18 HOMOLOG BOUND TO SYNTAXIN	NATURE			English	Article							GLUTATHIONE-S-TRANSFERASE; CAENORHABDITIS-ELEGANS; ESCHERICHIA-COLI; PURIFICATION; CLEAVAGE; PROTEINS; CLONING; FAMILY	THREE synaptic proteins, syntaxin, SNAP-25 and synaptobrevin, were recently identified as targets of clostridial neurotoxins that irreversibly inhibit synaptic vesicle fusion1-4. Experiments searching for membrane receptors for N-ethylmaleimide-sensitive fusion protein (NSF), which has an important role in membrane fusion, revealed an ATP-dependent interaction of the same three synaptic proteins with NSF and its soluble attachment proteins5. Thus, two independent approaches identify syntaxin, synaptobrevin and SNAP-25 as components of the synaptic vesicle fusion machinery, but their mode of action is unclear6. We have now discovered a brain protein of relative molecular mass 67,000 (67K) which binds stably to syntaxin. Amino-acid sequencing and complementary DNA cloning revealed that the 67K protein is encoded by the mammalian homologue of the Caenorhabditis elegans gene unc-18. In C. elegans, unc-18 belongs to a group of genes defined by mutations with a paralytic phenotype and accumulations of acetylcholine, suggesting a defect in neurotransmitter release7,8. The binding of the mammalian homologue of unc-18 (Munc-18) to syntaxin requires the N terminus of syntaxin whereas that of SNAP-25 involves a more C-terminal sequence. Our data suggest that Munc-18 is a previously unidentified essential component of the synaptic vesicle fusion protein complex.	UNIV TEXAS,HLTH SCI CTR,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT MOLEC GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, IN PRESS EMBO J; BRENNER S, 1974, GENETICS, V77, P71; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; INOUE A, 1992, J BIOL CHEM, V267, P10613; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NONE TML, 1993, CELL, V73, P1291; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; PELHAM HRB, 1993, NATURE, V364, P582, DOI 10.1038/364582a0; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOLLNER T, IN PRESS CELL; SUDHOF TC, 1993, CELL, V75, P1; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; WALCHSOLIMENA C, IN PRESS NEURON	30	584	606	0	76	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 25	1993	366	6453					347	351		10.1038/366347a0	http://dx.doi.org/10.1038/366347a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247129				2022-12-01	WOS:A1993MJ70500050
J	HARPER, JW; ADAMI, GR; WEI, N; KEYOMARSI, K; ELLEDGE, SJ				HARPER, JW; ADAMI, GR; WEI, N; KEYOMARSI, K; ELLEDGE, SJ			THE P21 CDK-INTERACTING PROTEIN CIP1 IS A POTENT INHIBITOR OF G1 CYCLIN-DEPENDENT KINASES	CELL			English	Article							CELL-CYCLE; TYROSINE PHOSPHORYLATION; YEAST; PHASE; CDC2; IDENTIFICATION; EXPRESSION; ACTIVATION; P34CDC2; SYSTEM	The cyclin-dependent kinase Cdk2 associates with cyclins A, D, and E and has been implicated in the control of the G1 to S phase transition in mammals. To identify potential Cdk2 regulators, we have employed an improved two-hybrid system to isolate human genes encoding Cdk-interacting proteins (Cips). CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates. p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes. Cotransfection experiments indicate that CIP1 and SV40 T antigen function in a mutually antagonistic manner to control cell cycle progression.	BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELL GROWTH & REGULAT, BOSTON, MA 02115 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	HARPER, JW (corresponding author), BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA.		Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; Harper, Jeffrey/0000-0002-6944-7236	NATIONAL INSTITUTE ON AGING [R01AG011066, R01AG011085] Funding Source: NIH RePORTER; NIA NIH HHS [AG-11085, R01-AG 11066] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOU QP, 1993, CANCER RES, V53, P1493; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARLOW E, ANTIBODDIES LAEBORAT; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNT T, 1989, CURR OPIN CELL BIOL, V1, P274; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEACH FS, 1993, CANCER RES, V53, P1986; MALLER JL, 1991, CELL, V71, P323; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TSAI LH, 1991, NATURE, V353, P555; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	49	5426	5659	10	270	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 19	1993	75	4					805	816						12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242751				2022-12-01	WOS:A1993MH74900024
J	MICKLEM, G; ROWLEY, A; HARWOOD, J; NASMYTH, K; DIFFLEY, JFX				MICKLEM, G; ROWLEY, A; HARWOOD, J; NASMYTH, K; DIFFLEY, JFX			YEAST ORIGIN RECOGNITION COMPLEX IS INVOLVED IN DNA-REPLICATION AND TRANSCRIPTIONAL SILENCING	NATURE			English	Article							S-CEREVISIAE; HO GENE; PLASMID; PHASE	THE HMR E silencer represses transcription of silent mating-type genes in the budding yeast Saccharomyces cerevisiae and contains three redundant regulatory elements A, E and B (ref. 1). The A element contains the 11 base pair consensus sequence that is essential for the firing of DNA replication origins2. A multisubunit protein called the origin recognition complex (ORC) binds specifically to this consensus sequence within yeast origins in vitro3 and in vivo4. We isolated mutants in A element-mediated silencing and report here that one of the genes we identified, RRR1, encodes ORC2, the 72K subunit of ORC. RRR1/ORC2 is an essential gene, but the rrr1-316 allele, which is viable, is defective in the replication of nuclear DNA and the maintenance of the 2-mum episomal DNA. This is, to our knowledge, the first genetic evidence that ORC is involved in DNA replication and silencing.	CRF, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND; RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA; MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); MRC Laboratory Molecular Biology				Diffley, John/0000-0001-5184-7680; Micklem, Gos/0000-0002-6883-6168; Nasmyth, Kim/0000-0001-7030-4403				BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAND AH, 1987, CELL, V51, P701; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BROACH JR, 1991, MOL BIOL YEAST SACCH, P297; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LIVINGSTON DM, 1977, J MOL BIOL, V116, P249, DOI 10.1016/0022-2836(77)90215-7; MICKLEM TG, 1989, THESIS CAMBRIDGE U; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5	25	207	212	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1993	366	6450					87	89		10.1038/366087a0	http://dx.doi.org/10.1038/366087a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	8232543				2022-12-01	WOS:A1993MF00700062
J	TANAKA, K				TANAKA, K			NEURONAL MECHANISMS OF OBJECT RECOGNITION	SCIENCE			English	Article							INFERIOR TEMPORAL NEURONS; LONG-TERM-MEMORY; INFEROTEMPORAL CORTEX; VISUOTOPIC ORGANIZATION; VISUAL-CORTEX; MACAQUE; MONKEY; PRIMATE; RESPONSES; ATTENTION	Recognition of objects from their visual images is a key function of the primate brain. This recognition is not a template matching between the input image and stored images like the vision in lower animals but is a flexible process in which considerable change in images, resulting from different illumination, viewing angle, and articulation of the object, can be tolerated. Recent experimental findings about the representation of object images in the inferotemporal cortex, a brain structure that is thought to be essential for object vision, are summarized and discussed in relation to the computational frames proposed for object recognition.			TANAKA, K (corresponding author), INST PHYS & CHEM RES, INFORMAT SCI LAB, 2-1 HIROSAWA, WAKO, SAITAMA 35101, JAPAN.		Tanaka, Keiji/N-5917-2015	Tanaka, Keiji/0000-0002-1910-3427				BALLARD DH, 1986, BEHAV BRAIN SCI, V9, P67, DOI 10.1017/S0140525X00021555; BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; BOUSSAOUD D, 1991, J COMP NEUROL, V306, P554, DOI 10.1002/cne.903060403; CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; CRICK F, 1984, P NATL ACAD SCI-BIOL, V81, P4586, DOI 10.1073/pnas.81.14.4586; DEAN P, 1976, PSYCHOL BULL, V83, P41, DOI 10.1037/0033-2909.83.1.41; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Edelman S, 1991, Curr Opin Neurobiol, V1, P270; EDELMAN S, 1990, MIT ARTIFICIAL INTEL, V1239; EDELMAN S, 1993, CS9310 WEIZM I SCI T; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P9136, DOI 10.1073/pnas.88.20.9136; ERICKSON RP, 1968, PSYCHOL REV, V75, P447, DOI 10.1037/h0026752; Foldiak P, 1991, NEURAL COMPUT, V3, P194, DOI 10.1162/neco.1991.3.2.194; FUJITA I, 1992, NATURE, V360, P343, DOI 10.1038/360343a0; FUSTER JM, 1982, J NEUROSCI, V2, P361; FUSTER JM, 1981, SCIENCE, V212, P952, DOI 10.1126/science.7233192; GALLANT JL, 1993, SCIENCE, V259, P100, DOI 10.1126/science.8418487; GATTASS R, 1988, J NEUROSCI, V8, P1831; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; GROSS CG, 1972, HDB SENSORY PHYSL 3B, V8, P451; HINTON GE, 1988, PARALLEL DISTRIBUTED, V1, pCH3; Ito M., 1993, Society for Neuroscience Abstracts, V19, P771; KOBATAKE E, 1992, NEUROSCI RES, V13, P257, DOI 10.1016/0168-0102(92)90038-E; KOBATAKE K, 1991, SOC NEUR ABSTR, V17, P443; KOBATAKE K, 1992, SOC NEUR ABSTR, V18, P146; KOCH C, 1985, HUM NEUROBIOL, V4, P219; MAGUIRE WM, 1984, J NEUROSCI, V4, P1690; Marr D., 1982, VISION; MILLER EK, 1993, J NEUROSCI, V13, P1460; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; MISHKIN M, 1982, PHILOS T R SOC B, V298, P85, DOI 10.1098/rstb.1982.0074; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; MIYASHITA Y, 1988, NATURE, V335, P817, DOI 10.1038/335817a0; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; Palmer S. E., 1981, ATTENTION PERFORM, V9, P135; POGGIO T, 1990, NATURE, V343, P263, DOI 10.1038/343263a0; RICHES IP, 1991, J NEUROSCI, V11, P1763; RICHMOND BJ, 1987, J NEUROPHYSIOL, V58, P1292, DOI 10.1152/jn.1987.58.6.1292; ROCK I, 1987, COGNITIVE PSYCHOL, V19, P280, DOI 10.1016/0010-0285(87)90013-2; ROLLS ET, 1987, NEURAL MOL BASES LEA; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SALEEM KS, 1993, CEREB CORTEX, V3, P454, DOI 10.1093/cercor/3.5.454; SCHWARTZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P5776, DOI 10.1073/pnas.80.18.5776; SNIPPE HP, 1992, BIOL CYBERN, V66, P543, DOI 10.1007/BF00204120; SPITZER H, 1988, SCIENCE, V240, P338, DOI 10.1126/science.3353728; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170; TOVEE MJ, 1992, NEUROREPORT, V3, P369, DOI 10.1097/00001756-199204000-00020; ULLMAN S, 1991, IEEE T PATTERN ANAL, V13, P992, DOI 10.1109/34.99234; ULLMAN S, 1989, COGNITION, V32, P193, DOI 10.1016/0010-0277(89)90036-X; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; YOUNG MP, 1992, J NEUROPHYSIOL, V67, P1464, DOI 10.1152/jn.1992.67.6.1464	55	302	304	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1993	262	5134					685	688		10.1126/science.8235589	http://dx.doi.org/10.1126/science.8235589			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235589				2022-12-01	WOS:A1993MD95200030
J	PAYNE, JN; MILNER, PC; SAUL, C; BOWNS, IR; HANNAY, DR; RAMSAY, LE				PAYNE, JN; MILNER, PC; SAUL, C; BOWNS, IR; HANNAY, DR; RAMSAY, LE			LOCAL CONFIDENTIAL INQUIRY INTO AVOIDABLE FACTORS IN DEATHS FROM STROKE AND HYPERTENSIVE DISEASE	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; GENERAL-PRACTICE; NORTHWEST LONDON; CARE; MANAGEMENT; SCOTLAND; QUALITY; HEART; AUDIT	Objective-To audit avoidable deaths from stroke and hypertensive disease. Design-Details of care before death were obtained from general practitioners and other doctors, anonymised, and assessed by two experts against agreed Minimum standards of good practice for detecting and managing hypertension. Setting-Health authority with population of 250000. Subjects-All patients under 75 years who died of stroke, hypertensive disease, or hypertension related causes during November 1990 to October 1991. Main outcome measures-Presence of important avoidable factors and departures from minimum standards of good practice. Results-Adequate information was obtained for 88% (123/139) of eligible cases. Agreement between the assessors was mostly satisfactory. 29% (36/123, 95% confidence interval 21% to 37%) of all cases and 44% (36/81, 34% to 55%) of those with definite hypertension had avoidable factors that may have contributed to death. These were most commonly failures of follow up and continuing smoking. Assessment against standards of minimum good practice showed that care was inadequate but not necessarily deemed to have contributed to death, in a large proportion of patients with definite hypertension. Common shortcomings were inadequate follow up, clinical investigation, and recording of smoking and other relevant risk behaviours. Conclusions-This method of audit can identify shortcomings in care of patients dying of hypertension related disease.	ROTHERHAM HLTH AUTHOR,DEPT PUBL HLTH,ROTHERHAM,ENGLAND; BARNSLEY HLTH AUTHOR,DEPT PUBL HLTH,BARNSLEY,ENGLAND; UNIV SHEFFIELD,SCH MED,DEPT GEN PRACTICE,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; UNIV SHEFFIELD,SCH MED,DEPT PHARMACOL & THERAPEUT,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND	University of Sheffield; University of Sheffield			Payne, Nick/A-3073-2010					Buck N, 1987, REPORT CONFIDENTIAL; CHAPMAN A, 1989, PRACTITIONER, V233, P1018; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DOLL R, 1964, BMJ-BRIT MED J, V1, P1460, DOI 10.1136/bmj.1.5396.1460; DOLL R, 1964, BRIT MED J, V1, P1399, DOI 10.1136/bmj.1.5395.1399; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; GORDON T, 1972, J AMER MED ASSOC, V221, P661, DOI 10.1001/jama.221.7.661; HALL JA, 1985, J ROY COLL GEN PRACT, V35, P243; KURJI KH, 1984, BMJ-BRIT MED J, V288, P903, DOI 10.1136/bmj.288.6421.903; MANT D, 1989, BRIT MED J, V298, P1360, DOI 10.1136/bmj.298.6684.1360; MICHAEL G, 1984, BMJ-BRIT MED J, V288, P906, DOI 10.1136/bmj.288.6421.906; RITCHIE LD, 1983, BMJ-BRIT MED J, V286, P107, DOI 10.1136/bmj.286.6359.107; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; STERN D, 1986, J ROY COLL GEN PRACT, V36, P549; STRASSER T, 1986, J HYPERTENS, V4, P383; TAFFINDER AP, 1984, PRACTITIONER, V228, P595; WILSON JB, 1978, PRACTITIONER, V220, P689; 1992, BMJ, V304, P405; 1985, BMJ, V291, P97; 1992, HLTH NATION; [No title captured]; 1991, 1985 1987 DEP HLTH W	25	47	46	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1027	1030		10.1136/bmj.307.6911.1027	http://dx.doi.org/10.1136/bmj.307.6911.1027			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251776	Green Published, Bronze			2022-12-01	WOS:A1993MD55600015
J	NICHOLSON, KG; KENT, J; IRELAND, DC				NICHOLSON, KG; KENT, J; IRELAND, DC			RESPIRATORY VIRUSES AND EXACERBATIONS OF ASTHMA IN ADULTS	BRITISH MEDICAL JOURNAL			English	Article							RHINOVIRUS INFECTION; PULMONARY-FUNCTION; WHEEZY BRONCHITIS; CHILDREN; TRACT; PRECIPITANTS; VOLUNTEERS; AIRWAYS	Objective-To study the role of respiratory viruses in exacerbations of asthma in adults. Design-Longitudinal study of 138 adults with asthma. Setting-Leicestershire Health Authority. Subjects-48 men and 90 women 19-46 years of age with a mean duration of wheeze of 19.6 years. 75% received regular treatment with bronchodilators; 89% gave a history of eczema, hay fever, allergic rhinitis, nasal polyps, or allergies; 38% had been admitted to hospital with asthma. Main outcome measures-Symptomatic colds and asthma exacerbations; objective exacerbations of asthma with greater-than-or-equal-to 50 l/min reduction in mean peak expiratory flow rate when morning and night time readings on days 1-7 after onset of symptoms were compared with rates during an asymptomatic control period; laboratory confirmed respiratory tract infections. Results-Colds were reported in 80% (223/280) of episodes with symptoms of wheeze, chest tightness, or breathlessness, and 89% (223/250) of colds were associated with asthma symptoms. 24% of 115 laboratory confirmed non-bacterial infections were associated with reductions in mean peak expiratory flow rate greater-than-or-equal-to 50 l/min through days 1-7 and 48% had mean decreases greater-than-or-equal-to 25 l/min. 44% of episodes with mean decreases in flow rate greater-than-or-equal-to 50 l/min were associated with laboratory confirmed infections. Infections with rhinoviruses, coronaviruses OC43 and 229E, influenza B, respiratory syncytial virus, parainfluenza virus, and chlamydia were all associated with objective evidence of an exacerbation of asthma. Conclusions-These findings show that asthma symptoms and reductions in peak flow are often associated with colds and respiratory viruses; respiratory virus infections commonly cause or are associated with exacerbations of asthma in adults.			NICHOLSON, KG (corresponding author), UNIV LEICESTER,SCH MED,DEPT MICROBIOL,LEICESTER LE1 9HN,ENGLAND.							BEARE AS, 1977, CHEMOPROPHYLAXIS VIR, V2, P27; BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679; BLAIR HT, 1976, AM REV RESPIR DIS, V114, P95; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FRIDY WW, 1974, ANN INTERN MED, V80, P150, DOI 10.7326/0003-4819-80-2-150; HALL WJ, 1978, ANN INTERN MED, V88, P203, DOI 10.7326/0003-4819-88-2-203; HORN MEC, 1979, ARCH DIS CHILD, V54, P587, DOI 10.1136/adc.54.8.587; HORNER GJ, 1973, AM REV RESPIR DIS, V108, P150; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; HUHTI E, 1974, ANN ALLERGY, V33, P145; IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204; JOHANSON WG, 1969, AM REV RESPIR DIS, V100, P141; KRAAIJEVELD CA, 1980, J CLIN MICROBIOL, V12, P493, DOI 10.1128/JCM.12.4.493-497.1980; LAMBERT HP, 1972, BMJ-BRIT MED J, V3, P323, DOI 10.1136/bmj.3.5822.323; LO YMD, 1988, LANCET, V2, P679; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124; MINOR TE, 1974, J PEDIATR-US, V85, P472, DOI 10.1016/S0022-3476(74)80447-6; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; NICHOLSON KG, 1990, EPIDEMIOL INFECT, V105, P609, DOI 10.1017/S0950268800048251; PICKEN JJ, 1972, AM J MED, V52, P738, DOI 10.1016/0002-9343(72)90079-4; WISELKA MJ, 1992, LANCET, V339, P367; WISELKA MJ, 1991, THORAX, V46, P706, DOI 10.1136/thx.46.10.706; 1962, AM REV RESPIR DIS, V85, P762	25	859	888	0	27	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1993	307	6910					982	986		10.1136/bmj.307.6910.982	http://dx.doi.org/10.1136/bmj.307.6910.982			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC441	8241910	Green Published, Bronze			2022-12-01	WOS:A1993MC44100020
J	FISCHER, DG; TAL, N; NOVICK, D; BARAK, S; RUBINSTEIN, M				FISCHER, DG; TAL, N; NOVICK, D; BARAK, S; RUBINSTEIN, M			AN ANTIVIRAL SOLUBLE FORM OF THE LDL RECEPTOR-INDUCED BY INTERFERON	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; BETA-INTERFERON; FAMILIAL HYPERCHOLESTEROLEMIA; GAMMA-INTERFERON; ALPHA-INTERFERON; BINDING-PROTEIN; TREATED CELLS; HUMAN-URINE; NECROSIS; PURIFICATION	Interferons, which induce several intracellular antiviral proteins, also induce an extracellular soluble protein that inhibits vesicular stomatitis virus (VSV) infection. This 28-kilodalton soluble protein was purified to homogeneity and identified by protein sequencing as the ligand-binding domain of the human 160-kilodalton low density lipoprotein receptor (LDLR). The existence of an antiviral soluble LDLR was confirmed by immunoaffinity chromatography with monoclonal antibody to LDLR. This soluble receptor mediates most of the interferon-triggered antiviral activity against VSV, apparently by interfering with virus assembly or budding, and not by inhibiting virus attachment to cells.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BOUE F, 1990, CANCER IMMUNOL IMMUN, V32, P67, DOI 10.1007/BF01741727; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CONSTANTOULAKIS P, 1993, SCIENCE, V259, P1314, DOI 10.1126/science.7680491; DOLEI A, 1981, ANTIVIR RES, V1, P367; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; GAVIN JR, 1972, SCIENCE, V178, P168, DOI 10.1126/science.178.4057.168; GERRARD TL, 1989, J INTERFERON RES, V9, P115, DOI 10.1089/jir.1989.9.115; GOODING LR, 1992, CELL, V71, P5; HAWKINS M, 1985, CANCER RES, V45, P5914; HORISBERGER MA, 1991, VIROLOGY, V180, P185, DOI 10.1016/0042-6822(91)90022-4; JONES CM, 1982, J INTERFERON RES, V2, P377, DOI 10.1089/jir.1982.2.377; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; LANDSBERGER D, 1992, AM J HUM GENET, V50, P427; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; MASSARO ER, 1986, J INTERFERON RES, V6, P655, DOI 10.1089/jir.1986.6.655; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NOVICK D, 1982, J IMMUNOL, V129, P2244; NOVICK D, 1983, EMBO J, V2, P1527, DOI 10.1002/j.1460-2075.1983.tb01618.x; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; OHTSUKI K, 1980, NATURE, V287, P65, DOI 10.1038/287065a0; OLSEN EA, 1988, J AM ACAD DERMATOL, V19, P286, DOI 10.1016/S0190-9622(88)70173-5; ROSENZWEIG IB, 1987, ATHEROSCLEROSIS, V67, P261, DOI 10.1016/0021-9150(87)90287-5; RUBIN LA, 1985, J IMMUNOL, V135, P3172; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALLACH D, 1983, CELL IMMUNOL, V76, P390, DOI 10.1016/0008-8749(83)90382-9; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; WEIL J, 1983, NATURE, V301, P437, DOI 10.1038/301437a0; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	34	60	62	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 8	1993	262	5131					250	253		10.1126/science.8211145	http://dx.doi.org/10.1126/science.8211145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA665	8211145				2022-12-01	WOS:A1993MA66500038
J	LAMBE, M; HSIEH, CC; TRICHOPOULOS, D; EKBOM, A; PAVIA, M; ADAMI, HO				LAMBE, M; HSIEH, CC; TRICHOPOULOS, D; EKBOM, A; PAVIA, M; ADAMI, HO			TRANSIENT INCREASE IN THE RISK OF BREAST-CANCER AFTER GIVING BIRTH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FULL-TERM PREGNANCY; REPRODUCTIVE FACTORS; AGE; PARITY; DIAGNOSIS; 1ST	Background. The effect of pregnancy on the risk of breast cancer is not clear. We tested the hypothesis that the risk of breast cancer increases transiently after pregnancy but then falls to a level below that of age-matched nulliparous women. Methods. We conducted a case-control study of a nationwide cohort in Sweden, using a computerized record linkage between the Cancer Registry and the Fertility Registry. The study; subjects were women born from 1925 through 1960 who were resident citizens of Sweden at the time of the 1960 census. A total of 12,666 patients with breast cancer were compared with 62,121 age-matched control subjects. We used conditional logistic regression to estimate odds ratios for the development of breast cancer at different ages, according to maternal age at first delivery (in uniparous as compared with nulliparous women) and age at second delivery (in biparous as compared with uniparous women). Results. Uniparous women were at higher risk of breast cancel than nulliparous women for up to 15 years after childbirth and at lower risk thereafter. The excess risk was most pronounced among women who were older at the time of their first delivery (odds ratio 5 years after delivery among women 35 years old at first delivery, 1.26; 95 percent confidence interval, 1.10 to 1.44). Women who had two pregnancies had a less striking increase in risk. Conclusions. Pregnancy has a dual effect on the risk of breast cancer: it transiently increases the risk after childbirth but reduces the risk in later years. In women with two pregnancies, the short-term adverse effect is masked by the long-term protection imparted by the first pregnancy. A plausible biologic interpretation is that pregnancy increases the short-term risk of breast dancer by stimulating the growth of cells that have undergone the early stages of malignant transformation but that it confers longterm protection by inducing the differentiation of normal mammary stem cells that have the potential for neoplastic change.	UNIV UPPSALA HOSP,CANC EPIDEMIOL UNIT,S-75185 UPPSALA,SWEDEN; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; UNIV REGGIO CALABRIA,FAC MED CATANZARO,CATTEDRA IGIENE,CATANZARO,ITALY	Uppsala University; Uppsala University Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	LAMBE, M (corresponding author), UNIV UPPSALA HOSP,DEPT SOCIAL MED,S-75185 UPPSALA,SWEDEN.			Lambe, Mats/0000-0002-4624-3767; PAVIA, Maria/0000-0003-3879-1322				Adami H O, 1990, Int J Cancer Suppl, V5, P22; BERNSTEIN L, 1986, J NATL CANCER I, V76, P1035; Breslow NE., 1980, IARC SCI PUBLICATION, V32; BRUZZI P, 1988, BRIT MED J, V297, P1096, DOI 10.1136/bmj.297.6656.1096; HSIEH CC, 1990, INT J CANCER, V46, P796, DOI 10.1002/ijc.2910460508; JANERICH DT, 1982, AM J EPIDEMIOL, V116, P737, DOI 10.1093/oxfordjournals.aje.a113462; JOHANSSON L, 1983, 14 STAT SWED; KALACHE A, 1993, LANCET, V341, P33, DOI 10.1016/0140-6736(93)92497-H; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; KVALE G, 1987, AM J EPIDEMIOL, V126, P842, DOI 10.1093/oxfordjournals.aje.a114721; KVALE G, 1987, AM J EPIDEMIOL, V126, P831, DOI 10.1093/oxfordjournals.aje.a114720; LOGAN WPD, 1953, LANCET, V2, P1199; LUBIN JH, 1982, J NATL CANCER I, V68, P211; MACMAHON B, 1993, CANCER, V71, P3185, DOI 10.1002/1097-0142(19930515)71:10<3185::AID-CNCR2820711047>3.0.CO;2-C; MANTEL N, 1959, J NATL CANCER I, V22, P719; MILLER WR, 1993, LANCET, V341, P25, DOI 10.1016/0140-6736(93)92489-G; NEGRI E, 1988, AM J EPIDEMIOL, V128, P1207, DOI 10.1093/oxfordjournals.aje.a115075; PANAGIOTOPOULOU K, 1990, CANCER CAUSE CONTROL, V1, P119, DOI 10.1007/BF00053162; PATHAK DR, 1986, INT J CANCER, V37, P21, DOI 10.1002/ijc.2910370105; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; RUSSO J, 1990, LAB INVEST, V62, P244; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; TRICHOPOULOS D, 1983, INT J CANCER, V31, P701, DOI 10.1002/ijc.2910310604; VATTEN LJ, 1992, EUR J CANCER, V28A, P1148, DOI 10.1016/0959-8049(92)90476-I; Walker AM, 1991, OBSERVATION INFERENC; WILLIAMS EMI, 1990, BRIT MED J, V300, P578, DOI 10.1136/bmj.300.6724.578; WOODS KL, 1980, BRIT MED J, V281, P419, DOI 10.1136/bmj.281.6237.419; 1951, STATISTICAL ABSTRACT; 1989, 70 NAT BOARD HLTH WE; 1990, CANCER INCIDENCE SWE; 1962, CENSUS POPULATION 19, V4	32	407	417	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	1994	331	1					5	9		10.1056/NEJM199407073310102	http://dx.doi.org/10.1056/NEJM199407073310102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU951	8202106				2022-12-01	WOS:A1994NU95100002
J	WEN, L; ROBERTS, SJ; VINEY, JL; WONG, FS; MALLICK, C; FINDLY, RC; PENG, QS; CRAFT, JE; OWEN, MJ; HAYDAY, AC				WEN, L; ROBERTS, SJ; VINEY, JL; WONG, FS; MALLICK, C; FINDLY, RC; PENG, QS; CRAFT, JE; OWEN, MJ; HAYDAY, AC			IMMUNOGLOBULIN-SYNTHESIS AND GENERALIZED AUTOIMMUNITY IN MICE CONGENITALLY DEFICIENT IN ALPHA-BETA(+)T CELLS	NATURE			English	Article							B-CELL; DNA ANTIBODIES; ALPHA-BETA; AUTOANTIBODIES; REPERTOIRE; RECEPTOR; IGM; EXPRESSION; INFECTION; STRAINS	Through cognate B-cell-T-cell interactions and provision of cytokines, CD4(+) T-cell antigen receptor (TCR) alpha beta(+) T cells regulate immunoglobulin isotype synthesis(1), Murine IgG1 and IgE secretion is therefore substantially T-cell-dependent, whereas IgM and IgG3 secretion is not(2,3). Here we report that in the absence of alpha beta T cells, B cells expand, differentiate and secrete copious amounts of antibodies of 'T-dependent' isotypes. Moreover, the antibodies are reactive towards self-antigens, as in patients with systemic lupus erythematosus, so autoantibodies of 'T-dependent' type can develop without the help of CD4(+) alpha beta T cells. This phenotype is not evident in mice or humans that ape congenitally deficient in specific alpha beta T-cell functions, but bears comparison with B-cell hyperactivity and autoimmunity in transplant rejection and in immunodeficiencies such as AIDS(4,5).	YALE UNIV,IMMUNOBIOL SECT,NEW HAVEN,CT 06511; YALE UNIV,RHEUMATOL SECT,NEW HAVEN,CT 06511; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; PFIZER INC,DIV CENT RES,GROTON,CT 06340	Yale University; Yale University; Cancer Research UK; Pfizer	WEN, L (corresponding author), YALE UNIV,DEPT BIOL,219 PROSPECT ST,NEW HAVEN,CT 06511, USA.			Wong, F. Susan/0000-0002-2812-8845; Wen, Li/0000-0002-8805-2934				ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DEPAOLI P, 1991, CLIN EXP IMMUNOL, V83, P187, DOI 10.1111/j.1365-2249.1991.tb05612.x; DRESSER DW, 1978, NATURE, V274, P480, DOI 10.1038/274480a0; FATENEJAD S, 1993, P NATL ACAD SCI USA, V90, P12010, DOI 10.1073/pnas.90.24.12010; FISH F, 1982, J IMMUNOL, V128, P409; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; ISAKSON PC, 1982, J EXP MED, V155, P734, DOI 10.1084/jem.155.3.734; JEVNIKAR AM, 1994, J EXP MED, V179, P1137, DOI 10.1084/jem.179.4.1137; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KLINMAN DM, 1990, J IMMUNOL, V144, P506; KLINMAN DM, 1992, J IMMUNOL, V148, P1353; KOH DR, 1992, SCIENCE, V256, P1210, DOI 10.1126/science.256.5060.1210; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LIKE A, 1988, DIABETES, V31, P816; MARTINEZALONSO C, 1980, EUR J IMMUNOL, V10, P698, DOI 10.1002/eji.1830100908; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; MORROW WJW, 1991, CLIN IMMUNOL IMMUNOP, V58, P163, DOI 10.1016/0090-1229(91)90134-V; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; PRITCHARD H, 1973, CLIN EXP IMMUNOL, V13, P125; PURKERSON JM, 1992, J EXP MED, V175, P973, DOI 10.1084/jem.175.4.973; RAJAGOPALAN S, 1990, P NATL ACAD SCI USA, V87, P7020, DOI 10.1073/pnas.87.18.7020; SANO Y, 1993, IMMUNOLOGY, V80, P388; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SOUROUJON M, 1988, J IMMUNOL, V140, P4173; TSUJI M, 1994, P NATL ACAD SCI USA, V91, P345, DOI 10.1073/pnas.91.1.345; VANSNICK JL, 1980, J EXP MED, V151, P45, DOI 10.1084/jem.151.1.45; WORTIS HH, 1968, NATURE, V220, P927	29	159	161	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 23	1994	369	6482					654	658		10.1038/369654a0	http://dx.doi.org/10.1038/369654a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	8208291				2022-12-01	WOS:A1994NT45900057
J	ANDERSEN, JC				ANDERSEN, JC			RESPONSE OF RESISTANT IDIOPATHIC THROMBOCYTOPENIC PURPURA TO PULSED HIGH-DOSE DEXAMETHASONE THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS GAMMA-GLOBULIN; IMMUNE THROMBOCYTOPENIA; ADULTS; MANAGEMENT; MYELOMA; CHEMOTHERAPY; IGG	Background. Most patients with chronic idiopathic thrombocytopenic purpura have a response to corticosteroids or intravenous immune globulin, but improvement is often transitory. Splenectomy may provide only a short-term benefit. Because pulsed high-dose therapy with potent synthetic corticosteroids is inexpensive, well tolerated, and effective in patients with secretory B-cell neoplasms, a similar regimen was examined for its efficacy in patients with chronic idiopathic thrombocytopenic purpura that was resistant to other treatments. Methods. Ten consecutively referred patients who had persistent symptomatic idiopathic thrombocytopenic purpura after undergoing at least two standard therapies were treated with six cycles of dexamethasone (40 mg per day for 4 sequential days every 28 days). Results. All patients had increased platelet counts (mean [+/-SD] count before treatment, 12,000+/-8200 per cubic millimeter; after treatment, 248,000+/-130,000 per cubic millimeter). The platelet counts remained above 100,000 per cubic millimeter for at least six months after the last cycle of treatment. There were no serious side effects. Features of hyperadrenocorticism due to prior corticosteroid therapy resolved during treatment. The cost of the drug was approximately $100 per patient. Conclusions. Although the possibility of spontaneous remission and a delayed benefit from prior therapy cannot be excluded in this small group of patients, pulsed high-dose treatment with dexamethasone may provide a low-cost therapeutic option with minimal side effects in patients with refractory idiopathic thrombocytopenic purpura.	WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,DETROIT,MI 48201	Wayne State University	ANDERSEN, JC (corresponding author), WAYNE STATE UNIV,HARPER HOSP,403 VIOLET S,3990 JOHN R ST,DETROIT,MI 48201, USA.							AHN YS, 1984, ANN INTERN MED, V100, P192, DOI 10.7326/0003-4819-100-2-192; AHN YS, 1987, ANN INTERN MED, V107, P177, DOI 10.7326/0003-4819-107-2-177; ALEXANIAN R, 1986, ANN INTERN MED, V105, P8, DOI 10.7326/0003-4819-105-1-8; ASTER RH, 1969, BRIT J HAEMATOL, V16, P61, DOI 10.1111/j.1365-2141.1969.tb00379.x; BALLEM PJ, 1987, J CLIN INVEST, V80, P33, DOI 10.1172/JCI113060; BERCHTOLD P, 1989, BLOOD, V74, P2309; BLANCHETTE VS, 1984, TRANSFUSION, V14, P388; BORNE AEG, 1988, BRIT MED J, V296, P249; BUDMAN DR, 1977, ANN INTERN MED, V86, P220, DOI 10.7326/0003-4819-86-2-220; BUSSEL JB, 1987, VOX SANG, V52, P206, DOI 10.1111/j.1423-0410.1987.tb03029.x; BUSSEL JB, 1988, BLOOD, V72, P121; BUZAID AC, 1988, J CLIN ONCOL, V6, P889, DOI 10.1200/JCO.1988.6.5.889; DALTON WS, 1986, CANCER RES, V46, P5125; FIGUEROA M, 1993, NEW ENGL J MED, V328, P1226, DOI 10.1056/NEJM199304293281703; GUTHRIE TH, 1989, SEMIN HEMATOL, V26, P3; HARRINGTON WJ, 1951, J LAB CLIN MED, V38, P1; IMBACH P, 1981, LANCET, V1, P1228; KELSEY PR, 1985, BRIT J HAEMATOL, V60, P197, DOI 10.1111/j.1365-2141.1985.tb07400.x; KOLLER CA, 1980, MED CLIN N AM, V64, P761; LOBUGLIO AF, 1983, NEW ENGL J MED, V309, P459, DOI 10.1056/NEJM198308253090804; MCVERRY BA, 1985, BRIT J HAEMATOL, V61, P145, DOI 10.1111/j.1365-2141.1985.tb04070.x; MCVERRY BA, 1985, BRIT J HAEMATOL, V59, P203, DOI 10.1111/j.1365-2141.1985.tb02985.x; PICOZZI VJ, 1980, AM J MED, V69, P690, DOI 10.1016/0002-9343(80)90419-2; Rothfield NF, 1989, ARTHRITIS ALLIED CON, P1022; SALAMA A, 1986, AM J HEMATOL, V22, P241, DOI 10.1002/ajh.2830220304; SCHMIDT RE, 1984, BLUT, V48, P19, DOI 10.1007/BF00320713; SCHMIDT RE, 1981, LANCET, V2, P475; SHULMAN NR, 1965, ANN NY ACAD SCI, V124, P499, DOI 10.1111/j.1749-6632.1965.tb18984.x; SONNENBLICK M, 1986, ONCOLOGY, V43, P349, DOI 10.1159/000226400; STROTHER SV, 1984, ARCH INTERN MED, V144, P2198, DOI 10.1001/archinte.144.11.2198; UNKELESS JC, 1989, J CLIN INVEST, V83, P355, DOI 10.1172/JCI113891; WILSON WH, 1993, J CLIN ONCOL, V11, P1573, DOI 10.1200/JCO.1993.11.8.1573	32	201	212	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1560	1564		10.1056/NEJM199406023302203	http://dx.doi.org/10.1056/NEJM199406023302203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	8177245	Bronze			2022-12-01	WOS:A1994NN21500003
J	POWER, C				POWER, C			NATIONAL TRENDS IN BIRTH-WEIGHT - IMPLICATIONS FOR FUTURE ADULT DISEASE	BRITISH MEDICAL JOURNAL			English	Article											POWER, C (corresponding author), INST CHILD HLTH,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.							ALBERMAN E, 1991, ARCH DIS CHILD, V66, P1304, DOI 10.1136/adc.66.11.1304; ALBERMAN E, 1991, J ROY SOC MED, V84, P257, DOI 10.1177/014107689108400505; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; Barker DJP, 1992, FETAL INFANT ORIGINS; 1983, MORTALITY STATIS DH3	5	63	63	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 14	1994	308	6939					1270	1271		10.1136/bmj.308.6939.1270	http://dx.doi.org/10.1136/bmj.308.6939.1270			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM147	8205019	Green Published			2022-12-01	WOS:A1994NM14700018
J	NOVICK, D; COHEN, B; RUBINSTEIN, M				NOVICK, D; COHEN, B; RUBINSTEIN, M			THE HUMAN INTERFERON-ALPHA/BETA RECEPTOR - CHARACTERIZATION AND MOLECULAR-CLONING	CELL			English	Article							TYROSINE KINASE; MONOCLONAL-ANTIBODIES; CYTOKINE RECEPTORS; GAMMA RECEPTOR; HUMAN-URINE; BINDING; CELLS; PURIFICATION; PROTEINS; SEQUENCE	We describe a universal ligand-binding receptor for human interferons alpha and interferon beta (type I IFNs). A soluble 40 kDa IFN-alpha/beta receptor (p40) that blocks the activity of type I IFNs was purified from urine and sequenced. Antibodies raised against p40 completely block the activity of several type I IFNs and immunoprecipitate both a cellular 102 kDa IFN-alpha/beta receptor and its cross-linked complexes with IFN-alpha 2. The receptor is a disulfide-linked dimer, consisting of 51 kDa subunits. We isolated and expressed a 1.5 kb cDNA, coding for the IFN-alpha/beta receptor. Its 331 amino acid sequence includes a leader and a transmembrane region, while its ectodomain corresponds to p40. IFN-alpha/beta receptor is physically associated with the cytoplasmic Tyr kinase JAK1, hence, in addition to ligand binding, it is directly involved in signal transduction.			NOVICK, D (corresponding author), WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL.							AGUET M, 1980, NATURE, V284, P459, DOI 10.1038/284459a0; AGUET M, 1984, VIROLOGY, V132, P211, DOI 10.1016/0042-6822(84)90105-3; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BENOIT P, 1993, J IMMUNOL, V150, P707; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; EASTGATE JA, 1990, FEBS LETT, V260, P213, DOI 10.1016/0014-5793(90)80106-S; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; FISCHER DG, 1993, SCIENCE, V262, P250, DOI 10.1126/science.8211145; GUTKIND JS, 1991, MOL CELL BIOL, V11, P1500, DOI 10.1128/MCB.11.3.1500; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; JOSHI AR, 1982, J BIOL CHEM, V257, P3884; KNIGHT E, 1976, P NATL ACAD SCI USA, V73, P520, DOI 10.1073/pnas.73.2.520; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; MALISZEWSKI CR, 1990, J IMMUNOL, V144, P3028; MARCON L, 1988, CLIN EXP IMMUNOL, V73, P29; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NAGATA S, 1980, NATURE, V287, P401, DOI 10.1038/287401a0; NOVICK D, 1982, J IMMUNOL, V129, P2244; NOVICK D, 1991, HYBRIDOMA, V10, P137, DOI 10.1089/hyb.1991.10.137; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; NOVICK D, 1992, FEBS LETT, V314, P445, DOI 10.1016/0014-5793(92)81523-O; NOVICK D, 1987, J BIOL CHEM, V262, P8483; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; ORCHANSKY P, 1984, J INTERFERON RES, V4, P275, DOI 10.1089/jir.1984.4.275; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; RUBINSTEIN M, 1978, SCIENCE, V202, P1289, DOI 10.1126/science.725605; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; Sambrook J., 1989, MOL CLONING LAB MANU; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STEWART TA, 1993, SCIENCE, V260, P1942, DOI 10.1126/science.8100367; Stewart W, 1979, INTERFERON SYSTEM; TANIGUCHI T, 1980, GENE, V10, P11, DOI 10.1016/0378-1119(80)90138-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	49	584	619	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 6	1994	77	3					391	400		10.1016/0092-8674(94)90154-6	http://dx.doi.org/10.1016/0092-8674(94)90154-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	8181059				2022-12-01	WOS:A1994NK97000010
J	OHKUMA, Y; ROEDER, RG				OHKUMA, Y; ROEDER, RG			REGULATION OF TFIIH ATPASE AND KINASE-ACTIVITIES BY TFIIE DURING ACTIVE INITIATION COMPLEX-FORMATION	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR TFIIE; CARBOXYL-TERMINAL-DOMAIN; PREINITIATION COMPLEX; LARGEST SUBUNIT; NONPHOSPHORYLATED FORM; TATA FACTOR; PHOSPHORYLATION; PURIFICATION; MOTIFS	THE general transcripton factor TFIIE, together with other general transcription factors, is essential for transcription initiation by RNA polymerase II1-5 TFIIE stimulates the TFIIH-dependent kinase activity that phosphorylates the carboxy-terminal domain of the largest subunit of RNA polymerase II6, and possesses a helicase activity(7). Here we show that human TFIIH has DNA-dependent ATPase activity and we characterize the stimulatory effect of TFIIE on both the ATPase and kinase activities. We demonstrate that extensive phosphorylation of RNA polymerase II occurs in a TFIIE-dependent manner in both the absence and presence of DNA but, in the latter case, only at a late stage of preinitiation complex assembly. We also show that TFIIH specifically phosphorylates three general transcription factors, human TFIID tau (TBP), TFIIE-alpha and TFIIF-alpha (RAP74).			OHKUMA, Y (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.							CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1992, J BIOL CHEM, V267, P2786; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; RAPPAPORT J, 1987, J BIOL CHEM, V262, P17510; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SEKI M, 1986, BIOCHEMISTRY-US, V25, P3239, DOI 10.1021/bi00359a024; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; ZAWAL L, 1993, PROG NUCLEIC ACID RE, V44, P67	29	143	144	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					160	163		10.1038/368160a0	http://dx.doi.org/10.1038/368160a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8166891				2022-12-01	WOS:A1994NA03000070
J	HEBERLEIN, U; WOLFF, T; RUBIN, GM				HEBERLEIN, U; WOLFF, T; RUBIN, GM			THE TGF-BETA-HOMOLOG DPP AND THE SEGMENT POLARITY GENE HEDGEHOG ARE REQUIRED FOR PROPAGATION OF A MORPHOGENETIC WAVE IN THE DROSOPHILA RETINA	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; DECAPENTAPLEGIC GENE; PATTERN-FORMATION; CELL-DEATH; IMAGINAL DISKS; MOLECULAR-ORGANIZATION; EGF RECEPTOR; GERM LAYERS; EYE; EXPRESSION	Development of the Drosophila retina occurs asynchronously; differentiation, its front marked by the morphogenetic furrow, progresses across the eye disc epithelium over a 2 day period. We have investigated the mechanisms by which this front advances, and our results suggest that developing retinal cells drive the progression of morphogenesis utilizing the products of the hedgehog (hh) and decapentaplegic (dpp) genes. Analysis of hh and dpp genetic mosaics indicates that the products of these genes act as diffusible signals in this process. Expression of dpp in the morphogenetic furrow is closely correlated with the progression of the furrow under a variety of conditions. We show that hh, synthesized by differentiating cells, induces the expression of dpp, which appears to be a primary mediator of furrow movement.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	HEBERLEIN, U (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,GALLO CTR,SAN FRANCISCO,CA 94110, USA.			Rubin, Gerald/0000-0001-8762-8703				ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BROWN NL, 1991, DEVELOPMENT, V113, P1245; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; Bryant PJ., 1978, GENET BIOL DROSOPHIL, P229; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; FRISTROM D, 1968, J CELL BIOL, V39, P488, DOI 10.1083/jcb.39.2.488; GELBART WM, 1989, DEVELOPMENT, V107, P65; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; HEBERLEIN U, 1991, DEV BIOL, V144, P353, DOI 10.1016/0012-1606(91)90427-5; HEBERLEIN U, 1993, IN PRESS DEV BIOL; HOFFMANN FM, 1992, MOL REPROD DEV, V32, P173, DOI 10.1002/mrd.1080320214; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; Poulson D. F., 1950, BIOL DROSOPHILA, P168; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; RENFRANZ PJ, 1989, DEV BIOL, V136, P411, DOI 10.1016/0012-1606(89)90267-4; REUTER R, 1990, DEVELOPMENT, V110, P1031; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; Whittle J R, 1990, Semin Cell Biol, V1, P241; WILKINS AS, 1991, DEV BIOL, V145, P1, DOI 10.1016/0012-1606(91)90208-K; WOLFF T, 1991, DEVELOPMENT, V113, P841; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XU T, 1993, DEVELOPMENT, V117, P1223	55	360	374	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					913	926		10.1016/0092-8674(93)90535-X	http://dx.doi.org/10.1016/0092-8674(93)90535-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252627				2022-12-01	WOS:A1993MK96600011
J	OSTERMANN, J; ORCI, L; TANI, K; AMHERDT, M; RAVAZZOLA, M; ELAZAR, Z; ROTHMAN, JE				OSTERMANN, J; ORCI, L; TANI, K; AMHERDT, M; RAVAZZOLA, M; ELAZAR, Z; ROTHMAN, JE			STEPWISE ASSEMBLY OF FUNCTIONALLY ACTIVE-TRANSPORT VESICLES	CELL			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; CLATHRIN-COATED VESICLES; CELL-FREE SYSTEM; GOLGI STACK; BREFELDIN-A; VESICULAR TRANSPORT; BETA-COP; INTERCOMPARTMENTAL TRANSPORT; SUCCESSIVE COMPARTMENTS	Budding of COP-coated vesicles (the likely carriers of newly synthesized proteins from the endoplasmic reticulum through the Golgi stack) from Golgi cisternae requires ADP-ribosylation factor (ARF), coatomer proteins from the cytosol, GTP, and fatty acyl-coenzyme A (CoA). The assembly of coated buds on the membranes requires coatomer, ARF, and GTP. When palmitoyl-CoA is added, membrane fission occurs at the coated bud, releasing coated vesicles. We show that COP-coated vesicles can be generated stepwise in vitro and isolated in a functionally active form, demonstrating that the minimal set of cytosolic components required for their formation as well as principal steps in their assembly have been identified.	UNIV GENEVA, SCH MED, INST HISTOL & EMBRYOL, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	OSTERMANN, J (corresponding author), MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA.							BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BRAELL WA, 1984, CELL, V39, P511, DOI 10.1016/0092-8674(84)90458-6; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P7344, DOI 10.1073/pnas.87.18.7344; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; FRIES E, 1981, J CELL BIOL, V90, P697, DOI 10.1083/jcb.90.3.697; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KUGE O, 1993, IN PRESS J CELL BIOL; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PEARSE BMF, 1981, ANNU REV BIOCHEM, V50, P85, DOI 10.1146/annurev.bi.50.070181.000505; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; POLOKOFF MA, 1978, J BIOL CHEM, V253, P7173; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1984, J CELL BIOL, V99, P260, DOI 10.1083/jcb.99.1.260; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SMYTHE E, 1989, J CELL BIOL, V108, P843, DOI 10.1083/jcb.108.3.843; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; TANIGAWA G, 1993, IN PRESS J CELL BIOL; TSAI SC, 1993, J BIOL CHEM, V268, P10820; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WEISS O, 1989, J BIOL CHEM, V264, P21066; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	66	261	266	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					1015	1025		10.1016/0092-8674(93)90545-2	http://dx.doi.org/10.1016/0092-8674(93)90545-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252615				2022-12-01	WOS:A1993MK96600021
J	SILVER, RT				SILVER, RT			INTERFERON-ALPHA-2B - A NEW TREATMENT FOR POLYCYTHEMIA-VERA	ANNALS OF INTERNAL MEDICINE			English	Note							ALPHA				SILVER, RT (corresponding author), CORNELL UNIV, MED CTR,NEW YORK HOSP, CLIN ONCOL CHEMOTHERAPY RES SECT,525 E 68 ST, BOX 581, NEW YORK, NY 10021 USA.		Silver MD, Richard T/GRE-5925-2022					ARIAD S, 1991, BLOOD, V77, P670; BERK PD, 1986, SEMIN HEMATOL, V23, P132; DONOVAN PB, 1984, AM J HEMATOL, V17, P329, DOI 10.1002/ajh.2830170402; KEUTZER JC, 1991, BLOOD S, V78, P1204; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; MEANS RT, 1991, BLOOD, V78, P2564; NAND S, 1990, AM J HEMATOL, V34, P32, DOI 10.1002/ajh.2830340108; SACCHI S, 1991, ANN HEMATOL, V63, P206, DOI 10.1007/BF01703444; SILVER RT, 1990, BLOOD, V76, P664; TALPAZ M, 1983, ANN INTERN MED, V99, P789, DOI 10.7326/0003-4819-99-6-789	10	57	61	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1091	1092		10.7326/0003-4819-119-11-199312010-00006	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239228				2022-12-01	WOS:A1993MJ33500006
J	KABACK, M; LIMSTEELE, J; DABHOLKAR, D; BROWN, D; LEVY, N; ZEIGER, K				KABACK, M; LIMSTEELE, J; DABHOLKAR, D; BROWN, D; LEVY, N; ZEIGER, K			TAY-SACHS-DISEASE - CARRIER SCREENING, PRENATAL-DIAGNOSIS, AND THE MOLECULAR ERA - AN INTERNATIONAL PERSPECTIVE, 1970 TO 1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEXOSAMINIDASE-A DEFICIENCY; ALPHA-CHAIN; GM2 GANGLIOSIDOSIS; HUMAN-GENETICS; BETA-CHAIN; MUTATIONS; THALASSEMIA; PSEUDODEFICIENCY; CHROMOSOME-5; POPULATIONS	Objectives.-To provide an update of the international experience with carrier screening and prenatal diagnosis for Tay-Sachs disease (TSD), to assess the impact of these efforts, and to review the recent developments in DNA technology with application to TSD carrier detection and screening. Design.-Through the International TSD Testing, Quality Control, and Data Collection Center, all testing centers in the world were surveyed annually to assess overall experience with carrier testing and prenatal diagnosis. Quality control and laboratory surveillance of testing centers were performed through an annual assessment, using samples provided by the center. Setting.-Tay-Sachs disease testing centers around the world. Participants.-Nearly 1 million young adults from both Jewish and non-Jewish populations. Intervention.-Gene product screening (enzyme testing) and DNA-based mutation analysis (in some populations). Main Outcome Measure.-Impact of screening program on disease incidence. Results.-Data from all centers in the international TSD network on experience with TSD carrier testing and prenatal diagnosis since 1974 indicated that more than 36 000 heterozygotes were identified and 1056 couples found to be at risk for TSD in their offspring. A total of 2416 pregnancies at increased risk for TSD were monitored by amniocentesis or chorionic villus sampling. A dramatic decrease in the incidence of TSD in the Jewish populations was demonstrated. With both serum and leukocyte proficiency testing, there have been only 16 instances (of 845 cumulative laboratory evaluations) of one or more errors reported by a laboratory since 1983 resulting in nonaccreditation. Conclusions.-This analysis represents a prototypic effort in coordinating adult education, carrier testing, and genetic counseling directed toward prospective prevention of a uniformly fatal childhood disease and demonstrates that such an effort can dramatically affect disease incidence.			KABACK, M (corresponding author), UNIV CALIF SAN DIEGO, CHILDRENS HOSP & HLTH CTR, DEPT PEDIAT & REPROD MED, 8110 BIRMINGHAM WAY, SAN DIEGO, CA 92123 USA.							Akerman B. R., 1992, Human Mutation, V1, P303, DOI 10.1002/humu.1380010407; AKLI S, 1991, GENOMICS, V11, P124, DOI 10.1016/0888-7543(91)90109-R; AKLI S, IN PRESS EUR J HUM G; ARONSON SM, 1964, TAY SACHS DISEASE; BACH G, 1992, GENETIC DIVERSITY JE; Becker M H, 1975, J Community Health, V1, P3, DOI 10.1007/BF01318939; BERNHEIMER H, 1968, Wiener Klinische Wochenschrift, V80, P163; BEUTLER E, 1993, AM J HUM GENET, V52, P85; BEUTLER E, 1976, BIOCHEM J, V159, P541, DOI 10.1042/bj1590541; BOEDECKER HJ, 1975, EXP CELL RES, V93, P468, DOI 10.1016/0014-4827(75)90473-5; BROIDE E, IN PRESS AM J MED GE; BURG J, 1985, ANN HUM GENET, V49, P41, DOI 10.1111/j.1469-1809.1985.tb01674.x; CAO A, 1989, CLIN GENET, V36, P277; CAO A, 1989, BRIT J HAEMATOL, V71, P309; CAO Z, IN PRESS AM J HUM GE; CASKEY CT, 1990, AM J HUM GENET, V46, P393; CHASE A, 1977, PROGR CLIN BIOL RES, V18, P107; CHASE GA, 1972, AM J HUM GENET, V24, P339; CHERN CJ, 1977, SOMAT CELL GENET, V3, P553, DOI 10.1007/BF01539065; CHILDS B, 1976, AM J HUM GENET, V28, P550; CLOW CL, 1977, PEDIATRICS, V59, P86; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; FIGUEROA ML, 1992, NEW ENGL J MED, V327, P1632, DOI 10.1056/NEJM199212033272304; GEIGER B, 1976, BIOCHEMISTRY-US, V15, P3484, DOI 10.1021/bi00661a014; Kaback M., 1972, SPHINGOLIPIDS SPHING, V19, P613; Kaback M M, 1977, Prog Clin Biol Res, V18, P267; KABACK MM, 1977, PROG CLIN BIOL RES, V18; KABACK MM, 1974, BIRTH DEFECTS, V10, P124; KABACK MM, IN PRESS INT J TECHN; KABACK MM, 1972, METHOD ENZYMOL, V28, P862; KABACK MM, 1981, LYSOSOMES LYSOSOMAL; Klenk E, 1939, H-S Z PHYSIOL CHEM, V262, P128, DOI 10.1515/bchm2.1939.262.3-5.128; KOLODNY EH, 1969, BIOCHEM BIOPH RES CO, V37, P526, DOI 10.1016/0006-291X(69)90947-4; KYTZIA HJ, 1983, EMBO J, V2, P1201, DOI 10.1002/j.1460-2075.1983.tb01567.x; LANDELS EC, 1993, J MED GENET, V30, P479, DOI 10.1136/jmg.30.6.479; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; LOUKOPOULOS D, 1991, AM J HUM GENET, V49, P79; MCDOWELL GA, 1992, AM J HUM GENET, V51, P1071; MERZ B, 1987, JAMA-J AM MED ASSOC, V258, P2636, DOI 10.1001/jama.1987.03400190018005; MODELL B, 1980, BMJ-BRIT MED J, V280, P1347, DOI 10.1136/bmj.280.6228.1347; MOTULSKY AG, 1971, BIRTH DEFECTS, V5, P22; Mules Emilie H., 1992, Human Mutation, V1, P298, DOI 10.1002/humu.1380010406; MYEROWITZ R, 1985, P NATL ACAD SCI USA, V82, P7830, DOI 10.1073/pnas.82.23.7830; MYRIANTHOPOULOS N, 1967, TAY SACHS DISEASE IN; Myrianthopoulos N C, 1977, Prog Clin Biol Res, V18, P95; MYRIANTHOPOULOS NC, 1966, AM J HUM GENET, V18, P313; MYRIANTHOPOULOS NC, 1962, CEREBRAL SPHINGOLIPI; NAVON R, 1986, AM J MED GENET, V24, P179, DOI 10.1002/ajmg.1320240123; NAVON R, 1971, BRIT MED J, V4, P17, DOI 10.1136/bmj.4.5778.17; OBRIEN JS, 1970, NEW ENGL J MED, V283, P15, DOI 10.1056/NEJM197007022830104; OBRIEN JS, 1971, SCIENCE, V172, P61, DOI 10.1126/science.172.3978.61; OBRIEN JS, 1978, AM J HUM GENET, V30, P602; OBRIEN JS, 1973, FED PROC, V32, P191; OKADA S, 1969, SCIENCE, V165, P698, DOI 10.1126/science.165.3894.698; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAW BH, 1990, AM J HUM GENET, V47, P698; PETERSEN GM, 1983, AM J HUM GENET, V35, P1258; PROIA RL, 1988, P NATL ACAD SCI USA, V85, P1883, DOI 10.1073/pnas.85.6.1883; PROIA RL, 1987, J BIOL CHEM, V262, P5677; RAPIN I, 1976, ARCH NEUROL-CHICAGO, V33, P120, DOI 10.1001/archneur.1976.00500020048008; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; ROTTER JI, 1987, NATURE, V329, P289, DOI 10.1038/329289a0; Sachs B, 1887, J NERV MENT DIS, V14, P541, DOI [10.1097/00005053-188714090-00001, DOI 10.1097/00005053-188709000-00001]; SAIFER A, 1973, CLIN CHIM ACTA, V43, P417, DOI 10.1016/0009-8981(73)90481-6; SANDHOFF K, 1969, FEBS LETT, V4, P351, DOI 10.1016/0014-5793(69)80274-7; Sandhoff K., 1989, METABOLIC BASIS INHE; SCHNECK L, 1970, LANCET, V1, P582; SLOME D, 1933, GENET, V27, P363; SVENNERHOLM L, 1962, BIOCHEM BIOPH RES CO, V9, P436, DOI 10.1016/0006-291X(62)90030-X; Tatar S E, 1977, Prog Clin Biol Res, V18, P367; TERRY RD, 1960, NATURE, V188, P1000, DOI 10.1038/1881000a0; TRIGGSRAINE BL, 1991, AM J HUM GENET, V49, P1041; TRIGGSRAINE BL, 1992, AM J HUM GENET, V51, P793; TRIGGSRAINE BL, 1990, NEW ENGL J MED, V323, P6, DOI 10.1056/NEJM199007053230102; 1990, NEW ENGL J MED, V323, P70; 1991, SCREENING TAY SACHS; 1992, CYSTIC FIBROSIS DNA; 1983, SCREENING COUNSELING	78	193	196	2	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2307	2315		10.1001/jama.270.19.2307	http://dx.doi.org/10.1001/jama.270.19.2307			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230592				2022-12-01	WOS:A1993MF99300024
J	GOODRICH, JA; HOEY, T; THUT, CJ; ADMON, A; TJIAN, R				GOODRICH, JA; HOEY, T; THUT, CJ; ADMON, A; TJIAN, R			DROSOPHILA TAF(II)40 INTERACTS WITH BOTH A VP16 ACTIVATION DOMAIN AND THE BASAL TRANSCRIPTION FACTOR-TFIIB	CELL			English	Article							TATA-BINDING PROTEIN; POLYMERASE-II TRANSCRIPTION; RNA-POLYMERASE; GAL4 DERIVATIVES; TRANS-ACTIVATOR; MECHANISM; INVITRO; GENE; COACTIVATORS; EXPRESSION	Enhancement of RNA polymerase II transcription by the viral transactivator VP16 requires the TFIID complex, which consists of the TATA-binding protein (TBP) and TBP-associated factors (TAFs). Here we report the molecular cloning, expression, and biochemical characterization of Drosophila TAF(II)40 (dTAF(II)40), a subunit of TFIID. In vitro protein-protein interaction assays revealed direct binding between dTAF(II)40 and a 39 amino acid VP16 activation domain. In addition, affinity chromatography indicated a direct binding of the basal factor TFIIB to immobilized dTAF(II)40. Since VP16 also binds TFIIB, our results suggest a ternary interaction among an activator, a coactivator, and a basal transcription factor. Antibodies directed against dTAF(II)40 inhibited activation by GAL4-VP16 without affecting basal transcription. These results, taken together with previous studies of Sp1 and dTAF(II)110, establish that different activators interact with distinct TAFs in the TFIID complex and that TAFs can contact both activators and basal factors.			GOODRICH, JA (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Admon, Arie/0000-0003-0504-3950				ALTSCHUL SF, 1990, J MOL BIOL, V215, P4203; APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BIGGIN MD, 1988, CELL, V53, P713, DOI 10.1016/0092-8674(88)90089-X; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; Gill Grace, 1992, Current Biology, V2, P565, DOI 10.1016/0960-9822(92)90046-D; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAHN S, 1993, NATURE, V363, P672, DOI 10.1038/363672a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PONTIUS BW, 1993, TRENDS BIOCHEM SCI, V18, P181, DOI 10.1016/0968-0004(93)90111-Y; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STRECK RD, 1986, EMBO J, V5, P3615, DOI 10.1002/j.1460-2075.1986.tb04690.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	56	392	397	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 5	1993	75	3					519	530		10.1016/0092-8674(93)90386-5	http://dx.doi.org/10.1016/0092-8674(93)90386-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8221891				2022-12-01	WOS:A1993MF83000014
J	JENNINGS, PA; WRIGHT, PE				JENNINGS, PA; WRIGHT, PE			FORMATION OF A MOLTEN GLOBULE INTERMEDIATE EARLY IN THE KINETIC FOLDING PATHWAY OF APOMYOGLOBIN	SCIENCE			English	Article							ALPHA-LACTALBUMIN; CYTOCHROME-C; STRUCTURAL CHARACTERIZATION; NATIVE APOMYOGLOBIN; HYDROGEN-EXCHANGE; NMR-SPECTROSCOPY; RIBONUCLEASE-A; PROTON NMR; PROTEIN; MYOGLOBIN	Hydrogen exchange pulse labeling and stopped-flow circular dichroism were used to establish that the structure of the earliest detectable intermediate formed during refolding of apomyoglobin corresponds closely to that of a previously characterized equilibrium molten globule. This compact, cooperatively folded intermediate was formed in less than 5 milliseconds and contained stable, hydrogen-bonded secondary structure localized in the A, G, and H helices and part of the B helix. The remainder of the B helix folded on a much slower time scale, followed by the C and E helices and the CD loop. The data indicate that a molten globule intermediate was formed on the kinetic folding pathway.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Wright, Peter/0000-0002-1368-0223	NCRR NIH HHS [RR04953] Funding Source: Medline; NIDDK NIH HHS [DK-34909] Funding Source: Medline; NIGMS NIH HHS [GM14541] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034909, R01DK034909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014541] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1970, BIOCHEMISTRY-US, V9, P4723, DOI 10.1021/bi00826a015; BALDWIN R L, 1991, Current Biology, V1, P218, DOI 10.1016/0960-9822(91)90061-Z; BALDWIN RL, 1991, CIBA F SYMP, V161, P190; BARRICK D, 1993, BIOCHEMISTRY-US, V32, P3790, DOI 10.1021/bi00065a035; BASHFORD D, 1988, PROTEINS, V4, P211, DOI 10.1002/prot.340040308; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BROOKS CL, 1992, J MOL BIOL, V227, P375, DOI 10.1016/0022-2836(92)90893-O; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHELVANAYAGAM G, 1992, J MOL BIOL, V227, P901, DOI 10.1016/0022-2836(92)90230-H; CHENG XD, 1991, J MOL BIOL, V220, P381, DOI 10.1016/0022-2836(91)90020-7; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; COCCO MJ, 1992, BIOCHEMISTRY-US, V31, P6481, DOI 10.1021/bi00143a018; COCCO MJ, 1990, BIOCHEMISTRY-US, V29, P11067, DOI 10.1021/bi00502a008; COHEN FE, 1980, NATURE, V286, P632, DOI 10.1038/286632a0; COHEN FE, 1979, J MOL BIOL, V132, P275, DOI 10.1016/0022-2836(79)90260-2; CREIGHTON T E, 1991, Current Biology, V1, P8, DOI 10.1016/0960-9822(91)90110-I; ELOVE GA, 1992, BIOCHEMISTRY-US, V31, P6876, DOI 10.1021/bi00145a003; ELOVE GA, 1991, PROTEIN REFOLDING, P51; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.bb.21.060192.001331; GERRITSEN M, 1985, BIOPOLYMERS, V24, P1271, DOI 10.1002/bip.360240714; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRIKO YV, 1988, J MOL BIOL, V202, P127, DOI 10.1016/0022-2836(88)90525-6; HUGHSON FM, 1989, BIOCHEMISTRY-US, V28, P4415, DOI 10.1021/bi00436a044; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; LU JR, 1992, BIOCHEMISTRY-US, V31, P4749, DOI 10.1021/bi00135a002; MABBUTT BC, 1985, BIOCHIM BIOPHYS ACTA, V832, P175, DOI 10.1016/0167-4838(85)90329-2; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; PTITSYN OB, 1975, BIOPHYS CHEM, V3, P1, DOI 10.1016/0301-4622(75)80033-0; PTITSYN OB, 1991, FEBS LETT, V285, P176, DOI 10.1016/0014-5793(91)80799-9; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; PTITSYN OB, 1973, VESTN AN SSSR+, P57; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SCHREIER AA, 1976, J MOL BIOL, V105, P409, DOI 10.1016/0022-2836(76)90101-7; SHIN HC, 1993, BIOCHEMISTRY-US, V32, P6356, DOI 10.1021/bi00076a008; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; THERIAULT Y, UNPUB; UDGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197, DOI 10.1073/pnas.87.21.8197; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VARLEY P, 1993, SCIENCE, V260, P1110, DOI 10.1126/science.8493553; WALTHO JP, 1993, BIOCHEMISTRY-US, V32, P6337, DOI 10.1021/bi00076a006	48	781	788	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					892	896		10.1126/science.8235610	http://dx.doi.org/10.1126/science.8235610			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235610				2022-12-01	WOS:A1993MF43800033
J	LI, R; HAVEL, C; WATSON, JA; MURRAY, AW				LI, R; HAVEL, C; WATSON, JA; MURRAY, AW			THE MITOTIC FEEDBACK-CONTROL GENE MAD2 ENCODES THE ALPHA-SUBUNIT OF A PRENYLTRANSFERASE	NATURE			English	Article							PROTEIN TRANSFERASES; RAS PROTEIN; YEAST; YPT1; ATTACHMENT; TRANSPORT; MECHANISM; HOMOLOGY; INVITRO; MUTANTS	THE mad2-1 mutation inactivates the cell-cycle feedback control that prevents budding yeast cells from leaving mitosis until spindle assembly is complete1. The gene product of MAD2 shows significant sequence similarity to the alpha-subunit of prenyltransferases2. Here we isolate a new temperature-sensitive mad2 mutant, mad2-2ts, and find that Mad2p is required for the membrane association of Ypt1p and Sec4p, two prenylated small GTP-binding proteins involved in protein trafficking. Extracts from mad2-2ts mutant cells fail to geranylgeranylate a number of substrates at the non-permissive temperature. mad2-2ts is synthetically lethal with bet2-1, a mutation in the gene that encodes for the beta-subunit of the Ypt1p and Sec4p geranylgeranyl transferase3,4. Therefore MAD2 and BET2 gene products may physically interact to form a geranylgeranyl transferase complex. In addition, the difference between the phenotypes of mad2-1 and mad2-2ts suggests that MAD2 has distinct roles in protein transport and the mitotic feedback control.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ARMSTRONG SA, IN PRESS J BIOL CHEM; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BARNES G, 1992, MOL BIOL CELL, V3, P29, DOI 10.1091/mbc.3.1.29; BOGUSKI MS, 1992, NEW BIOL, V4, P408; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; FINEGOLD AA, 1990, SCIENCE, V249, P165, DOI 10.1126/science.1695391; GLOMSET J, 1992, CURR OPIN LIPIDOL, V2, P118; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P315; HAVEL CM, 1992, ARCH BIOCHEM BIOPHYS, V295, P410, DOI 10.1016/0003-9861(92)90535-5; JIANG Y, 1993, NATURE, V366, P84, DOI 10.1038/366084a0; KELLER RK, 1986, J BIOL CHEM, V261, P2053; KOHL NE, 1991, J BIOL CHEM, V266, P18884; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x	21	42	46	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					82	84		10.1038/366082a0	http://dx.doi.org/10.1038/366082a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	8232541				2022-12-01	WOS:A1993MF00700060
J	OLSEN, JH; NIELSEN, A; SCHULGEN, G				OLSEN, JH; NIELSEN, A; SCHULGEN, G			RESIDENCE NEAR HIGH-VOLTAGE FACILITIES AND RISK OF CANCER IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							ELECTRICAL WIRING CONFIGURATIONS; CHILDHOOD-CANCER; MAGNETIC-FIELDS; LEUKEMIA; EXPOSURE	Objective-To investigate whether residence before and after birth near 50 Hz high voltage installations increases a child's risk of cancer and whether risk correlates with the strength of the magnetic field. Design-A population based case-control study. Setting-Denmark. Subjects-1707 children under the age of 15 with leukaemia, tumour of the central nervous system, or malignant lymphoma diagnosed in 1968-86 and 4788 children taken from the central population register. Main outcome measures-Proximity before and after birth to existing or former 50-400 kV electrical transmission connections and substations and associated historical electromagnetic fields calculated on the basis of current load on line, phase ordering of line, and distance from the dwelling. Results-A significant association was seen between all major types of childhood cancer combined and exposure to magnetic fields from high voltage installations of greater-than-or-equal-to 0.4 muT (odds ratio 5.6). At greater-than-or-equal-to 0.25 muT no significant association was seen (odds ratio 1.5). A possible association was also seen with cases of Hodgkin's disease separately at greater-than-or-equal-to 0.1 muT. Conclusion-On the basis these results and additional descriptive data on electricity consumption and incidence of childhood cancer in Denmark since the 1940s it was concluded that the proportion of childhood cancer possibly caused by 50 Hz electromagnetic fields must be small.	UNIV FREIBURG,INST MED BIOMETRY & INFORMAT,W-7800 FREIBURG,GERMANY	University of Freiburg	OLSEN, JH (corresponding author), DANISH CANC SOC,DIV CANC EPIDEMIOL,STRANDBLVD 49,DK-2100 COPENHAGEN 0,DENMARK.			Olsen, Jorgen Helge/0000-0001-9633-5662				BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; BLETTNER M, 1984, METHOD INFORM MED, V24, P37; Breslow NE., 1980, IARC SCI PUBLICATION, V32; BROWN PD, 1989, INT J EPIDEMIOL, V18, P546, DOI 10.1093/ije/18.3.546; COLEMAN MP, 1989, BRIT J CANCER, V60, P793, DOI 10.1038/bjc.1989.362; FEYCHTING M, 1992, IMM692 KAR I REP; FULTON JP, 1980, AM J EPIDEMIOL, V111, P292, DOI 10.1093/oxfordjournals.aje.a112899; Jensen O M, 1985, Natl Cancer Inst Monogr, V68, P245; LAUSEN B, 1992, BIOMETRICS, V48, P73, DOI 10.2307/2532740; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; MYERS A, 1990, BRIT J CANCER, V62, P1008, DOI 10.1038/bjc.1990.428; OLSEN JH, 1991, EUR J CANCER, V27, P958, DOI 10.1016/0277-5379(91)90258-F; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SKOTTE J, 1993, IN PRESS EXPOSURE EL; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; 1992, DOCUMENTS NRPB, V3; 1990, ELSAM N90NR254A REP	18	201	204	1	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					891	895		10.1136/bmj.307.6909.891	http://dx.doi.org/10.1136/bmj.307.6909.891			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241850	Bronze, Green Published			2022-12-01	WOS:A1993MB84700014
J	RETTIG, J; HEINEMANN, SH; WUNDER, F; LORRA, C; PARCEJ, DN; DOLLY, JO; PONGS, O				RETTIG, J; HEINEMANN, SH; WUNDER, F; LORRA, C; PARCEJ, DN; DOLLY, JO; PONGS, O			INACTIVATION PROPERTIES OF VOLTAGE-GATED K+ CHANNELS ALTERED BY PRESENCE OF BETA-SUBUNIT	NATURE			English	Article							POTASSIUM CHANNELS; RAT-BRAIN; FUNCTIONAL EXPRESSION; DENDROTOXIN ACCEPTOR; BINDING-PROPERTIES; MOLECULAR-BIOLOGY; XENOPUS OOCYTES; IK(A) CHANNELS; ION CHANNELS; BOVINE BRAIN	Structural and functional diversity of voltage-gated K(v)1-type potassium channels in rat brain is enhanced by the association of two different types of subunits, the membrane-bound, pore-forming alpha-subunits and a peripheral beta-subunit. We have cloned a beta-subunit (K-v beta 1) that is specifically expressed in the rat nervous system. Association of K-v beta 1 with alpha-subunits confers rapid A-type inactivation on non-inactivating K(v)1 channels (delayed rectifiers) in expression systems in vitro. This effect is mediated by an inactivating ball domain in the K-v beta 1 amino terminus.	MAX PLANCK INST BIOPHYS CHEM,MEMBRANBIOPHYS ABT,D-37077 GOTTINGEN,GERMANY; MAX PLANCK GESELL ZFDW,AG MOLEK & ZELLULARE BIOPHYS,D-07747 JENA,GERMANY; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,WOLFSON LABS,LONDON SW7 2AY,ENGLAND	Max Planck Society; Max Planck Society; Imperial College London	RETTIG, J (corresponding author), ZENTRUM MOLEK NEUROBIOL HAMBURG,INST NEURALE SIGNALVERARBEITUNG,MARTINISTR 52,D-20246 HAMBURG,GERMANY.		Dolly, Oliver/G-1532-2012; Parcej, David/AAW-7306-2020; Dolly, Oliver/ABH-6677-2020; Rettig, Jens/K-5103-2013	Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320; Rettig, Jens/0000-0001-6160-3954; Wunder, Frank/0000-0002-1311-2357; Heinemann, Stefan H./0000-0002-4144-0251				BECKH S, 1990, EMBO J, V9, P777, DOI 10.1002/j.1460-2075.1990.tb08173.x; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CHABALA LD, 1993, J GEN PHYSIOL, V102, P713, DOI 10.1085/jgp.102.4.713; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P21, DOI 10.1113/jphysiol.1971.sp009365; CROW T, 1988, TRENDS NEUROSCI, V11, P136, DOI 10.1016/0166-2236(88)90138-5; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; GUTMAN GA, 1993, NEUROSCIENCES, V5, P101; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; KUES WA, 1992, EUR J NEUROSCI, V4, P1296, DOI 10.1111/j.1460-9568.1992.tb00155.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; NEEFY A, 1993, SCIENCE, V262, P575; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PARCEJ DN, 1989, BIOCHEM J, V257, P899, DOI 10.1042/bj2570899; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; RAICHLE ME, 1983, ANN NEUROL, V13, P2, DOI 10.1002/ana.410130103; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; REID PF, 1992, FEBS LETT, V302, P31, DOI 10.1016/0014-5793(92)80277-N; RETTIG J, 1992, EMBO J, V11, P2473, DOI 10.1002/j.1460-2075.1992.tb05312.x; RUDY B, 1988, NEURON, V1, P649, DOI 10.1016/0896-6273(88)90164-X; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; STOCKER M, 1991, P ROY SOC B-BIOL SCI, V245, P101, DOI 10.1098/rspb.1991.0094; STUHMER W, 1988, FEBS LETT, V242, P199, DOI 10.1016/0014-5793(88)81015-9; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	43	750	764	0	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					289	294		10.1038/369289a0	http://dx.doi.org/10.1038/369289a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	8183366				2022-12-01	WOS:A1994NN10900039
J	PITTET, D; TARARA, D; WENZEL, RP				PITTET, D; TARARA, D; WENZEL, RP			NOSOCOMIAL BLOOD-STREAM INFECTION IN CRITICALLY ILL PATIENTS - EXCESS LENGTH OF STAY, EXTRA COSTS, AND ATTRIBUTABLE MORTALITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-STREAM INFECTIONS; FACTORS INFLUENCING PROGNOSIS; GRAM-NEGATIVE BACTEREMIA; HOSPITAL STAY; EPISODES; RISK	Objective.-To determine the excess length of stay, extra costs, and mortality attributable to nosocomial bloodstream infection in critically ill patients. Design.-Pairwise-matched (1:1) case-central study. Setting.-Surgical intensive care unit (SICU) in a tertiary health care institution. Patients.-All patients admitted in the SICU between July 1, 1988, and June 30, 1990, were eligible. Cases were defined as patients with nosocomial bloodstream infection; controls were selected according to matching variables in a stepwise fashion. Methods.-Matching variables were primary diagnosis for admission, age, sex, length of stay before the day of infection in cases, and total number of discharge diagnoses. Matching was successful for 89% of the cohort; 86 matched case-control pairs were studied. Main Outcome Measures.-Crude and attributable mortality, excess length of hospital and SICU stay, and overall costs. Results.-Nosocomial bloodstream infection complicated 2.67 per 100 admissions to the SICU during the study period. The crude mortality rates from cases and controls were 50% and 15%, respectively (P<.01); thus, the estimated attributable mortality rate was 35% (95% confidence interval, 25% to 45%). The median length of hospital stay significantly differed between cases and controls (40 vs 26 days, respectively; P<.01). When only matched pairs who survived bloodstream infection were considered (n=41), cases stayed in the hospital a median of 54 days vs 30 days for controls (P<.01), and cases stayed in the SICU a median of 15 days vs 7 days for controls (P<.01). Thus, extra hospital and SICU length of stay attributable to bloodstream infection was 24 and 8 days, respectively. Extra costs attributable to the infection averaged $40 000 per survivor. Conclusions.-The attributable mortality from nosocomial bloodstream infection is high in critically ill patients. The infection is associated with a doubling of the SICU stay, an excess length of hospital stay of 24 days in survivors, and a significant economic burden.	UNIV IOWA HOSP & CLIN,DEPT INTERNAL MED,DIV GEN MED CLIN EPIDEMIOL & HLTH SERV RES,IOWA CITY,IA 52242	University of Iowa								BANERJEE SN, 1991, AM J MED, V91, pS86, DOI 10.1016/0002-9343(91)90349-3; BISHOP YMM, 1975, DISCRETE MULTIVARIAT, P492; BODEY GP, 1965, ARCH INTERN MED, V116, P266, DOI 10.1001/archinte.1965.03870020106019; BRODERICK A, 1990, AM J EPIDEMIOL, V131, P734, DOI 10.1093/oxfordjournals.aje.a115558; BRYAN CS, 1986, AM J EPIDEMIOL, V123, P113, DOI 10.1093/oxfordjournals.aje.a114205; BRYAN CS, 1983, REV INFECT DIS, V5, P629; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P363; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; DASCHNER FD, 1982, INTENS CARE MED, V8, P5; DELEON SP, 1984, AM J MED, V77, P639, DOI 10.1016/0002-9343(84)90354-1; DOMINGUEZDEVILLOTA E, 1987, INTENS CARE MED, V13, P390; DONOWITZ LG, 1982, CRIT CARE MED, V10, P355, DOI 10.1097/00003246-198206000-00001; DUGGAN JM, 1985, J HOSP INFECT, V6, P406, DOI 10.1016/0195-6701(85)90057-X; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GATELL JM, 1988, REV INFECT DIS, V10, P203; HALEY RW, 1991, AM J MED, V91, pS32, DOI 10.1016/0002-9343(91)90341-T; KREGER BE, 1980, AM J MED, V68, P332, DOI 10.1016/0002-9343(80)90101-1; LANDRY SL, 1989, AM J INFECT CONTROL, V17, P323, DOI 10.1016/0196-6553(89)90001-1; MARTIN MA, 1989, ANN INTERN MED, V110, P9, DOI 10.7326/0003-4819-110-1-9; MCCABE WR, 1962, ARCH INTERN MED, V110, P856, DOI 10.1001/archinte.1962.03620240038007; MCGOWAN JE, 1985, REV INFECT DIS, V7, pS357; MCGOWAN JE, 1975, J INFECT DIS, V132, P316, DOI 10.1093/infdis/132.3.316; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; PITTET D, 1993, PREVENTION CONTROL N, P512; PITTET D, 1992, HOSPITAL INFECTIONS, P405; ROSE R, 1977, SOUTHERN MED J, V70, P1267, DOI 10.1097/00007611-197711000-00005; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SPENGLER RF, 1978, JAMA-J AM MED ASSOC, V240, P2455, DOI 10.1001/jama.240.22.2455; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P54; WENZEL RP, 1988, INT J EPIDEMIOL, V17, P225, DOI 10.1093/ije/17.1.225; WEY SB, 1988, ARCH INTERN MED, V148, P2642, DOI 10.1001/archinte.148.12.2642; 1990, MMWR MORB MORTAL WKL, V39, P31; 1989, PHS891260 PUBL	33	1093	1116	1	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	1994	271	20					1598	1601		10.1001/jama.271.20.1598	http://dx.doi.org/10.1001/jama.271.20.1598			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL758	8182812				2022-12-01	WOS:A1994NL75800028
J	WEST, MA; LUCOCQ, JM; WATTS, C				WEST, MA; LUCOCQ, JM; WATTS, C			ANTIGEN-PROCESSING AND CLASS-II MHC PEPTIDE-LOADING COMPARTMENTS IN HUMAN B-LYMPHOBLASTOID CELLS	NATURE			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; INTRACELLULAR-TRANSPORT; INVARIANT CHAIN; LATE ENDOSOMES; LYMPHOCYTES-B; MOLECULES; TRANSFERRIN; COMPLEX; PH; LOCALIZATION	THE peptide/class II major histocompatibility complex (MHC) complexes recognized by CD4(+) T cells have been characterized at the structural(1) and biochemical(2-4) levels and studies on the transport and maturation of class II MHC indicate that specialized sites may be involved in peptide acquisition(5-11). Here we report the characterization of the compartments involved in antigen processing and class II MHC loading relative to distinct functional domains of the endocytic pathway in antigen-specific human B lymphocytes(12-14). Peroxidase-mediated crosslinking analysis(15) in intact cells demonstrates that peptide loading of class II MHC takes place in a compartment accessible to membrane immunoglobulin but not to transferrin receptors, although processing may be initiated within the latter domain. The density of membrane vesicles carrying newly assembled class II MHC complexes was distinct from early and late endosomes and dense lysosomes. Endocytosed antigen-gold complexes enter a class II MHC-rich compartment morphologically very similar to that described previously(9) and within the time frame of biochemically detectable peptide loading.	UNIV BERN,DEPT ANAT,CH-3000 BERN,SWITZERLAND	University of Bern	WEST, MA (corresponding author), UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.			Watts, Colin/0000-0001-6183-2087; lucocq, john/0000-0002-5191-0093	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; BLUM JS, 1991, J BIOL CHEM, V266, P22091; Brodsky F M, 1992, Trends Cell Biol, V2, P109, DOI 10.1016/0962-8924(92)90015-F; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DAVIDSON HW, 1989, J CELL BIOL, V109, P85, DOI 10.1083/jcb.109.1.85; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DAVIDSON HW, 1990, J IMMUNOL, V144, P4101; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HARDING CV, 1993, J IMMUNOL, V151, P3988; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; KILLISCH I, 1992, J CELL SCI, V103, P211; KISHIDA Y, 1975, J CELL BIOL, V64, P331, DOI 10.1083/jcb.64.2.331; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; LUCOCQ JM, 1993, FINE STRUCTURE IMMUN, P279; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; RENFREW CA, 1991, J BIOL CHEM, V266, P4348; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; ROOSNEK E, 1988, J IMMUNOL, V140, P4079; RUDENSKY AY, 1992, NATURE, V359, P429, DOI 10.1038/359429a0; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438	30	342	342	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 12	1994	369	6476					147	151		10.1038/369147a0	http://dx.doi.org/10.1038/369147a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK971	8177319				2022-12-01	WOS:A1994NK97100049
J	POSTLETHWAIT, JH; JOHNSON, SL; MIDSON, CN; TALBOT, WS; GATES, M; BALLINGER, EW; AFRICA, D; ANDREWS, R; CARL, T; EISEN, JS; HORNE, S; KIMMEL, CB; HUTCHINSON, M; JOHNSON, M; RODRIGUEZ, A				POSTLETHWAIT, JH; JOHNSON, SL; MIDSON, CN; TALBOT, WS; GATES, M; BALLINGER, EW; AFRICA, D; ANDREWS, R; CARL, T; EISEN, JS; HORNE, S; KIMMEL, CB; HUTCHINSON, M; JOHNSON, M; RODRIGUEZ, A			A GENETIC-LINKAGE MAP FOR THE ZEBRAFISH	SCIENCE			English	Article							ARBITRARY PRIMERS; MUTATIONS; INDUCTION; DNA; IDENTIFICATION; RECOMBINATION; MARKERS; GENOMES; SYSTEM; LINES	To facilitate molecular genetic analysis of vertebrate development, haploid genetics was used to construct a recombination map for the zebrafish Danio (Brachydanio) rerio. The map consists of 401 random amplified polymorphic DNAs (RAPDs) and 13 simple sequence repeats spaced at an average interval of 5.8 centimorgans. Strategies that exploit the advantages of haploid genetics and RAPD markers were developed that quickly mapped lethal and Visible mutations and that placed cloned genes on the map. This map is useful for the position-based cloning of mutant genes, the characterization of chromosome rearrangements, and the investigation of evolution in vertebrate genomes.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	University of Oregon	POSTLETHWAIT, JH (corresponding author), UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS023915, R01NS023915] Funding Source: NIH RePORTER; NIAID NIH HHS [1RO1AI26734] Funding Source: Medline; NICHD NIH HHS [HD07470] Funding Source: Medline; NINDS NIH HHS [NS23915] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIMENKO MA, UNPUB; ALJANABI SM, 1993, GENETICS, V134, P1249; BENNETT MD, 1976, PHILOS T R SOC B, V274, P227, DOI 10.1098/rstb.1976.0044; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; BROOKS LD, 1986, GENETICS, V114, P525; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DIETRICH W, 1992, GENETICS, V131, P423; ENDO A, 1968, J HERED, V59, P382, DOI 10.1093/oxfordjournals.jhered.a107755; FELSENFELD AL, 1990, DEVELOPMENT, V108, P443; GOFF DJ, 1992, GENOMICS, V14, P200, DOI 10.1016/S0888-7543(05)80309-X; GRAF JD, 1989, GENETICS, V123, P389; GRUNWALD DJ, 1992, GENET RES, V59, P93, DOI 10.1017/S0016672300030305; GRUNWALD DJ, 1992, GENET RES, V59, P103, DOI 10.1017/S0016672300030317; Haldane JBS, 1919, J GENET, V8, P299; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HAMMERSCHMIDT M, 1993, DEVELOPMENT, V119, P1107; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HINEGARDNER R, 1972, AM NAT, V106, P621, DOI 10.1086/282801; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; HULBERT SH, 1988, GENETICS, V120, P947; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JOHNSON SB, UNPUB; JOHNSON SL, 1994, GENOMICS, V19, P152, DOI 10.1006/geno.1994.1026; KESSELI RV, 1992, APPLICATIONS RAPD TE, P31; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; KIRSCHBAUM F, 1975, Wilhelm Roux's Archives of Developmental Biology, V177, P129, DOI 10.1007/BF00848526; Kosambi D. D., 1944, ANN EUGENICS, V12, P172; LANDER ES, 1987, GENOMICS, V1, P185; MEYER A, 1993, P ROY SOC B-BIOL SCI, V252, P231, DOI 10.1098/rspb.1993.0070; MICHELMORE RW, 1991, P NATL ACAD SCI USA, V88, P9828, DOI 10.1073/pnas.88.21.9828; MORIZOT DC, 1991, GENETICS, V127, P399; MORIZOT DC, 1990, ISOZYMES STRUCTURE F, P207; MULLINS MC, 1993, CURR OPIN GENET DEV, V3, P648, DOI 10.1016/0959-437X(93)90102-U; Neale D., 1991, Probe. Newsletter of the USDA Plant Genome Research Program, V1, P1; ONO H, 1992, P NATL ACAD SCI USA, V89, P11886, DOI 10.1073/pnas.89.24.11886; PARAN I, 1993, THEOR APPL GENET, V85, P985, DOI 10.1007/BF00215038; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; RAFALSKI JA, 1993, TRENDS GENET, V9, P275, DOI 10.1016/0168-9525(93)90013-8; REITER RS, 1992, P NATL ACAD SCI USA, V89, P1477, DOI 10.1073/pnas.89.4.1477; ROSSANT J, 1992, GENE DEV, V6, P1, DOI 10.1101/gad.6.1.1; SCHULTEMERKER S, IN PRESS DEVELOPMENT; Sepich Diane S., 1993, Society for Neuroscience Abstracts, V19, P1294; SILVER LM, 1992, MAMM GENOME, V3, pS241, DOI 10.1007/BF00648435; STREISINGER G, 1986, GENETICS, V112, P311; STREISINGER G, 1981, NATURE, V291, P293, DOI 10.1038/291293a0; STUART GW, 1990, DEVELOPMENT, V109, P577; TALBOT WS, UNPUB; TANKSLEY SD, 1992, GENETICS, V132, P1141; THISSE C, 1993, DEVELOPMENT, V119, P1203; TINGEY SV, 1992, APPL RAPD TECHNOLOGY, P3; TREVARROW W, 1993, SOC NEUR ABSTR, V19, P217; WALKER C, 1983, GENETICS, V103, P125; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; WICKING C, 1991, TRENDS GENET, V7, P288, DOI 10.1016/0168-9525(91)90177-R; WILLIAMS JGK, 1993, NUCLEIC ACIDS RES, V21, P2697, DOI 10.1093/nar/21.11.2697; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531	58	332	368	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					699	703		10.1126/science.8171321	http://dx.doi.org/10.1126/science.8171321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171321				2022-12-01	WOS:A1994NH71300031
J	SINGHVI, R; KUMAR, A; LOPEZ, GP; STEPHANOPOULOS, GN; WANG, DIC; WHITESIDES, GM; INGBER, DE				SINGHVI, R; KUMAR, A; LOPEZ, GP; STEPHANOPOULOS, GN; WANG, DIC; WHITESIDES, GM; INGBER, DE			ENGINEERING CELL-SHAPE AND FUNCTION	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; MOUSE FIBROBLASTS; GROWTH; HEPATOCYTES; DIFFERENTIATION; FIBRONECTIN; EXPRESSION; SECRETION; INDUCTION; MEMBRANES	An elastomeric stamp, containing defined features on the micrometer scale, was used to imprint gold surfaces with specific patterns of self-assembled monolayers of alkanethiols and, thereby, to create islands of defined shape and size that support extracellular matrix protein adsorption and cell attachment. Through this technique, it was possible to place cells in predetermined locations and arrays, separated by defined distances, and to dictate their shape. Limiting the degree of cell extension provided control over cell growth and protein secretion. This method is experimentally simple and highly adaptable. It should be useful for applications in biotechnology that require analysis of individual cells cultured at high density or repeated access to cells placed in specified locations.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; MIT,CTR BIOTECHNOL PROC ENGN,CAMBRIDGE,MA 02139; MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Ingber, Donald E/AAC-5894-2019					BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; BROWN KD, 1992, GENET ENG NEWS, V12, P1; CARON JM, 1990, MOL CELL BIOL, V10, P1239, DOI 10.1128/MCB.10.3.1239; CARTER SB, 1967, NATURE, V213, P256, DOI 10.1038/213256a0; COLLINS VP, 1979, EUR J CELL BIOL, V29, P288; DANHEISER SL, 1993, ENG NEWS, V13, P1; EMERMAN JT, 1977, IN VITRO CELL DEV B, V13, P316, DOI 10.1007/BF02616178; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GOSPODAROWICZ D, 1978, CANCER RES, V38, P4155; HARRIS A, 1973, EXP CELL RES, V77, P285, DOI 10.1016/0014-4827(73)90579-X; INGBER DE, 1987, IN VITRO CELL DEV B, V23, P387; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; KABAT D, 1985, J CELL BIOL, V101, P2274, DOI 10.1083/jcb.101.6.2274; KUMAR A, IN PRESS APPL PHYSL; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; LOPEZ GP, 1993, LANGMUIR, V9, P1513, DOI 10.1021/la00030a015; LOPEZ GP, 1993, J AM CHEM SOC, V115, P10774, DOI 10.1021/ja00076a038; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; MOONEY D, 1992, J CELL PHYSIOL, V151, P497, DOI 10.1002/jcp.1041510308; ONEILL C, 1990, J CELL SCI, V95, P577; ONEILL C, 1986, CELL, V44, P489, DOI 10.1016/0092-8674(86)90470-8; ONEILL CH, 1979, CELL, V16, P909, DOI 10.1016/0092-8674(79)90106-5; PONTEN J, 1980, EXP CELL RES, V129, P367, DOI 10.1016/0014-4827(80)90505-4; PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164; PRIME KL, IN PRESS J AM CHEM S; WESTERMARK B, 1978, EXP CELL RES, V111, P295, DOI 10.1016/0014-4827(78)90173-8	28	1235	1335	4	249	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					696	698		10.1126/science.8171320	http://dx.doi.org/10.1126/science.8171320			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171320				2022-12-01	WOS:A1994NH71300030
J	MATTHES, JWA; LEWIS, PA; DAVIES, DP; BETHEL, JA				MATTHES, JWA; LEWIS, PA; DAVIES, DP; BETHEL, JA			RELATION BETWEEN BIRTH-WEIGHT AT TERM AND SYSTOLIC BLOOD-PRESSURE IN ADOLESCENCE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EARLY LIFE EXPERIENCE; ADULT LIFE; CARDIOVASCULAR-DISEASE; GROWTH; RISK; MORTALITY; FETAL; AGE	Objective-To examine whether birth weight is related to systolic blood pressure during adolescence. Design-Retrospective (comparative) cohort study. The observers who traced and studied the subjects were unaware of their case-control status. Subjects-330 subjects were born in Cardiff in 1975-7. Cases who were low bit;th weight at term (<2500g) were matched with controls of normal birth weight (3000-3800 g) at term. Main outcome measures-Systolic blood pressure measured by random zero sphygmomanometry in the subject's right arm with the subject supine, corrected for size and age. Results-The mean age at examination was 15.7 years. The mean systolic blood pressure of the cases was 105.8 mm Hg and of the controls 107.5 mm Hg. The corrected difference (95% confidence interval) in systolic blood pressure between the cases and controls was 1 mm Hg (-3 to +1 mm Hg; two tailed probability 0.33). Conclusion-Systolic blood pressure in adolescents of low birth weight is not significantly different from that of adolescents of normal birth weights.	UNIV WALES COLL MED, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University								[Anonymous], 1987, PEDIATRICS, V79, P1; ARISTIMUNO GG, 1984, CIRCULATION, V69, P895, DOI 10.1161/01.CIR.69.5.895; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; COOK JTE, 1993, BRIT MED J, V306, P302, DOI 10.1136/bmj.306.6873.302; DAVIES DP, 1979, ARCH DIS CHILD, V54, P703, DOI 10.1136/adc.54.9.703; DAVIES DP, 1991, BRIT MED J, V303, P1474, DOI 10.1136/bmj.303.6815.1474-b; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; ELFORD J, 1992, J EPIDEMIOL COMMUN H, V46, P1, DOI 10.1136/jech.46.1.1-a; GILLMAN MW, 1993, J PEDIATR-US, V122, P837, DOI 10.1016/S0022-3476(09)90005-1; HACK M, 1993, J PEDIATR-US, V122, P887, DOI 10.1016/S0022-3476(09)90012-9; Higgins M, 1988, Acta Med Scand Suppl, V723, P23; KOLACEK S, 1993, ACTA PAEDIATR, V82, P377, DOI 10.1111/j.1651-2227.1993.tb12701.x; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; MACHIN D, 1987, STATISTICAL TABLES D; NORUSIS M, 1990, STATISTICAL PACKAGE; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; TIMIO M, 1988, HYPERTENSION, V12, P457, DOI 10.1161/01.HYP.12.4.457; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L	28	73	75	2	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 23	1994	308	6936					1074	1077		10.1136/bmj.308.6936.1074	http://dx.doi.org/10.1136/bmj.308.6936.1074			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173427	Green Published			2022-12-01	WOS:A1994NH48900022
J	GRIDLEY, G; KLIPPEL, JH; HOOVER, RN; FRAUMENI, JF				GRIDLEY, G; KLIPPEL, JH; HOOVER, RN; FRAUMENI, JF			INCIDENCE OF CANCER AMONG MEN WITH THE FELTY SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article							RENAL-TRANSPLANT RECIPIENTS; RHEUMATOID-ARTHRITIS; MALIGNANT NEOPLASMS; HODGKINS-DISEASE; NEUTROPENIA; MORTALITY; RISK; MANIFESTATIONS; LYMPHOMA; SPLENECTOMY	Objective: To estimate the incidence of cancer (especially lymphoproliferative malignancies) in patients with the Felty syndrome. Design: A retrospective cohort study. Setting: A computerized database of all discharge records for 1969 to 1990 from a Veterans Affairs hospital. Patients: 906 men with a discharge diagnosis of the Felty syndrome. Measurements: Standardized incidence ratios (SIR) (ratios of observed-to-expected events) estimated the risk for specific cancers. Hospital records confirmed the diagnoses of the Felty syndrome and cancer. Results: We observed a twofold increase in total cancer incidence (137 patients; SIR = 2.09; 95% CI, 1.8 to 2.5). The risk for non-Hodgkin lymphoma (19 patients; SIR = 12.8, CI, 7.7 to 20.0) was much greater than the twofold increase in risk for lymphoma generally reported for rheumatoid arthritis. The risk for leukemia was increased but only within 5 years of the first hospitalization for the Felty syndrome, (13 patients; SIR = 7.67; CI, 4.1 to 13.1). Conclusion: The increased risk for non-Hodgkin lymphoma after the Felty syndrome in our study is similar to the risk associated with the Sjogren syndrome and may reflect similar immunostimulatory mechanisms.	NATL INST ARTHRITIS & MUSCULOSKELETAL & SKIN DISOR, BETHESDA, MD 20892 USA		GRIDLEY, G (corresponding author), NCI, EPN 443, BETHESDA, MD 20892 USA.							ABDOU NI, 1983, ARTHRITIS RHEUM, V26, P947, DOI 10.1002/art.1780260802; ALLEBECK P, 1982, SCAND J RHEUMATOL, V11, P81, DOI 10.3109/03009748209098167; BUTLER RC, 1987, J ROY SOC MED, V80, P168, DOI 10.1177/014107688708000314; CAMPION G, 1990, MEDICINE, V69, P69, DOI 10.1097/00005792-199069020-00001; FRAUMENI JF, 1975, AM J MED, V59, P145, DOI 10.1016/0002-9343(75)90333-2; GEOGHEGAN GE, 1984, BIOMETRICS MONOGRAPH, V18; GONZALESCHAMBERS R, 1992, ARTHRITIS RHEUM, V35, P516, DOI 10.1002/art.1780350505; GREENE MH, 1981, LANCET, V1, P1196, DOI 10.1016/S0140-6736(81)92359-X; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; HELMERS R, 1991, CHEST, V100, P235, DOI 10.1378/chest.100.1.235; HIRAYAMA K, 1987, NATURE, V327, P426, DOI 10.1038/327426a0; HOOVER R, 1973, LANCET, V2, P55; ISOMAKI HA, 1978, J CHRON DIS, V31, P691, DOI 10.1016/0021-9681(78)90071-1; KAMEL OW, 1993, NEW ENGL J MED, V328, P1317, DOI 10.1056/NEJM199305063281806; KASSAN SS, 1978, ANN INTERN MED, V89, P888, DOI 10.7326/0003-4819-89-6-888; KATUSIC S, 1985, AM J MED, V78, P50, DOI 10.1016/0002-9343(85)90246-3; LIDDELL FDK, 1984, J EPIDEMIOL COMMUN H, V38, P85, DOI 10.1136/jech.38.1.85; LINCH DC, 1984, SCAND J HAEMATOL, V33, P342; LOUGHRAN TP, 1987, MEDICINE, V66, P397, DOI 10.1097/00005792-198709000-00005; MEADOWS AT, 1989, MED PEDIATR ONCOL, V17, P477; MONSON RR, 1976, J CHRON DIS, V29, P459, DOI 10.1016/0021-9681(76)90086-2; NASSIF PS, 1992, BRIT J OPHTHALMOL, V76, P173, DOI 10.1136/bjo.76.3.173; PALADINI G, 1991, Recenti Progressi in Medicina, V82, P133; Pedersen-Bjergaard J, 1988, Eur J Haematol Suppl, V48, P39; PORTER D, 1991, ANN RHEUM DIS, V50, P275, DOI 10.1136/ard.50.5.275; RIES LAG, 1991, NIH912789 NCI PUBL; ROBINETTE CD, 1977, LANCET, V2, P127; ROSENSTEIN ED, 1991, SEMIN ARTHRITIS RHEU, V21, P129, DOI 10.1016/0049-0172(91)90002-H; SNOWDEN N, 1991, Q J MED, V78, P65; SYMMONS DPM, 1988, J RHEUMATOL, V15, P1319; TUCKER MA, 1985, ANN INTERN MED, V102, P37, DOI 10.7326/0003-4819-102-1-37; TURA S, 1993, J CLIN ONCOL, V11, P925, DOI 10.1200/JCO.1993.11.5.925	32	80	80	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					35	39		10.7326/0003-4819-120-1-199401010-00006	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250454				2022-12-01	WOS:A1994MP28000006
J	KEENE, GS; PARKER, MJ; PRYOR, GA				KEENE, GS; PARKER, MJ; PRYOR, GA			MORTALITY AND MORBIDITY AFTER HIP-FRACTURES	BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL	Objective-To study the mortality and morbidity associated with proximal femoral fractures with reference to fracture type (intracapsular and extracapsular). Design-Consecutive prospective study with 12 month follow ups. Setting-Two British trauma receiving centres. Patients-1000 consecutive acute proximal femoral fractures (fractured necks of femur) in 972 patients. Results-Significantly higher mortality at one year was seen in patients with extracapsular fractures (188/490; 38%) than in those with intracapsular fractures (147/510; 29%; p < 0.01). Greater morbidity was experienced during the study period by patients with extracapsular fractures, who were less mobile and less independent at the time of their injury. Conclusions-The rise in average age of presentation with proximal femoral fracture is associated with a persistently high mortality (33%) and morbidity, greater in patients with an extracapsular fracture. Comparison with other studies, principally from outside Britain, is difficult, but despite advancing standards of care the mortality and morbidity of femoral neck fractures remains high, placing an ever increasing burden on the health service.	PETERBOROUGH DIST GEN HOSP,DEPT ORTHOPAED & TRAUMA SURG,PETERBOROUGH PE3 6DA,ENGLAND		KEENE, GS (corresponding author), ADDENBROOKES HOSP,DEPT ORTHOPAED & TRAUMA SURG,CAMBRIDGE CB2 2QQ,ENGLAND.							ALFFRAM PA, 1964, ACTA ORTHOP SCAND S, V65; Baker B R, 1978, J R Coll Gen Pract, V28, P557; CEDER L, 1980, CLIN ORTHOPAEDICS, V152, P173; COOPER A, 1824, TREATISE DISLOCATION, P108; DAHL E, 1980, ACTA ORTHOP SCAND, V51, P163, DOI 10.3109/17453678008990781; DOLK T, 1989, UPSALA J MED SCI, V94, P209, DOI 10.3109/03009738909178565; ELABDIEN BSZ, 1984, ACTA ORTHOP SCAND, V55, P284, DOI 10.3109/17453678408992357; EVANS JG, 1979, AGE AGEING, V8, P246, DOI 10.1093/ageing/8.4.246; FITTS WT, 1959, SURG GYNECOL OBSTET, V108, P7; GARDEN RS, 1961, J BONE JOINT SURG BR, V43, P647, DOI 10.1302/0301-620X.43B4.647; GRAHAM HJ, 1992, BRIT MED J, V305, P30, DOI 10.1136/bmj.305.6844.30; IONS GK, 1987, J BONE JOINT SURG BR, V69, P384, DOI 10.1302/0301-620X.69B3.3584189; JENSEN JS, 1979, ACTA ORTHOP SCAND, V50, P161, DOI 10.3109/17453677908989751; KENZORA JE, 1984, CLIN ORTHOPAEDICS, V186, P45; KREUTZFELDT J, 1984, AGE AGEING, V13, P111, DOI 10.1093/ageing/13.2.111; LINTON P, 1944, ACTA CHIR SCAND S, V86; LIVESLEY B, 1992, BRIT MED J, V305, P2, DOI 10.1136/bmj.305.6844.2-a; Melton LI, 1983, OSTEOPOROTIC SYNDROM; PARKER MJ, 1991, ACTA ORTHOP SCAND, V62, P563, DOI 10.3109/17453679108994497; Parker MJ., 1993, HIP FRACTURE MANAGEM; PARKER MJ, 1922, J R SOC MED, V85, P152; SKINNER PW, 1988, J BONE JOINT SURG BR, V70, P677; THOMAS TG, 1974, BRIT MED J, V3, P456, DOI 10.1136/bmj.3.5928.456; WALLACE WA, 1987, INT MED S, V12, P3; WHITE BL, 1987, J BONE JOINT SURG AM, V69A, P1335; 1989, FRACTURED NECK FEMUR	26	615	640	0	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1248	1250		10.1136/bmj.307.6914.1248	http://dx.doi.org/10.1136/bmj.307.6914.1248			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8166806	Bronze, Green Published			2022-12-01	WOS:A1993MH00100020
J	GUILLEMOT, F; LO, LC; JOHNSON, JE; AUERBACH, A; ANDERSON, DJ; JOYNER, AL				GUILLEMOT, F; LO, LC; JOHNSON, JE; AUERBACH, A; ANDERSON, DJ; JOYNER, AL			MAMMALIAN ACHAETE-SCUTE HOMOLOG-1 IS REQUIRED FOR THE EARLY DEVELOPMENT OF OLFACTORY AND AUTONOMIC NEURONS	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; GROWTH-FACTOR RECEPTOR; DROSOPHILA-MELANOGASTER; DNA-BINDING; NEGATIVE REGULATOR; CELL-ADHESION; GENE-COMPLEX; ADULT-MOUSE; STEM-CELLS; DIFFERENTIATION	The mouse Mash-1 gene, like its Drosophila homologs of the achaete-scute complex (AS-C), encodes a transcription factor expressed in neural precursors. We created a null allele of this gene by homologous recombination in embryonic stem cells. Mice homozygous for the mutation die at birth with apparent breathing and feeding defects. The brain and spinal cord of the mutants appear normal, but their olfactory epithelium and sympathetic, parasympathetic, and enteric ganglia are severely affected. In the olfactory epithelium, neuronal progenitors die at an early stage, whereas the nonneuronal supporting cells are present. In sympathetic ganglia, the mutation arrests the development of neuronal precursors, preventing the generation of sympathetic neurons, but does not affect glial precursor cells. These observations suggest that Mash-1, like its Drosophila homologs of the AS-C, controls a basic operation in development of neuronal progenitors in distinct neural lineages.	CALTECH,DIV BIOL 21676,HOWARD HUGHES MED INST,PASADENA,CA 91106; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	California Institute of Technology; Howard Hughes Medical Institute; University of Toronto	GUILLEMOT, F (corresponding author), MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO M5G 1X5,ONTARIO,CANADA.		Guillemot, Francois/AAV-1482-2021	/0000-0002-8605-2746				AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIRREN SJ, 1993, IN PRESS DEVELOPMENT, V119; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CALOF AL, 1989, NEURON, V3, P115, DOI 10.1016/0896-6273(89)90120-7; CAMPOSORTEGA JA, 1991, ANNU REV NEUROSCI, V14, P399, DOI 10.1146/annurev.ne.14.030191.002151; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; COCHARD P, 1978, P NATL ACAD SCI USA, V75, P2986, DOI 10.1073/pnas.75.6.2986; Cook HC, 1990, THEORY PRACTICE HIST, P177; CUSCHIERI A, 1975, J ANAT, V119, P277; CUSCHIERI A, 1975, J ANAT, V119, P471; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOMINGUEZ M, 1993, EMBO J, V12, P2049, DOI 10.1002/j.1460-2075.1993.tb05854.x; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FARBMAN AI, 1980, DEV BIOL, V74, P205, DOI 10.1016/0012-1606(80)90062-7; FERREIRO B, 1992, MECH DEVELOP, V40, P25; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; GEISERT EE, 1989, NEUROSCI LETT, V102, P137, DOI 10.1016/0304-3940(89)90068-2; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GONZALEZ F, 1989, EMBO J, V8, P3553, DOI 10.1002/j.1460-2075.1989.tb08527.x; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRAZIADEI GAM, 1980, NEUROSCIENCE, V5, P1239; Graziadei P. P., 1978, DEV SENSORY SYSTEMS, V9, P55; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; GUIILLEMOT F, 1993, MECH DEVELOP, V42, P171; GUILLEMOT F, 1992, DEVELOPMENT, V114, P743; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cellbio.8.1.227; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; JARMAN AP, 1993, IN PRESS DEVELOPMENT, V119; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN SL, 1983, J COMP NEUROL, V217, P17, DOI 10.1002/cne.902170103; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; LEVEY MS, 1991, J NEUROSCI, V11, P3556; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LUSKIN MB, 1993, J NEUROSCI, V13, P1730; MACKAYSIM A, 1991, J NEUROSCI, V11, P979; MAHANTHAPPA NK, 1993, NEURON, V10, P293, DOI 10.1016/0896-6273(93)90319-M; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCONNELL SK, 1991, ANNU REV NEUROSCI, V14, P269, DOI 10.1146/annurev.ne.14.030191.001413; MICHELSOHN AM, 1992, NEURON, V8, P589, DOI 10.1016/0896-6273(92)90285-L; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; MOTRO B, 1991, DEVELOPMENT, V113, P1207; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PACHNIS V, 1993, IN PRESS DEVELOPMENT, V119; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; PHAM TD, 1991, J COMP NEUROL, V314, P789, DOI 10.1002/cne.903140411; PIXLEY SK, 1992, NEURON, V8, P1191, DOI 10.1016/0896-6273(92)90139-5; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SASAI Y, 1992, GENE DEV, V6, P2650; Sieber-Blum M., 1990, Comments on Developmental Neurobiology, V1, P225; SMART IHM, 1971, J ANAT, V109, P243; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; STEMPLE DL, 1991, NEUROSCI LETT, V124, P57, DOI 10.1016/0304-3940(91)90821-A; SUZUKI Y, 1991, CELL TISSUE RES, V266, P239, DOI 10.1007/BF00318179; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAN Q, 1988, J NEUROSCI, V8, P3481; YIP JW, 1987, DEV BRAIN RES, V32, P155, DOI 10.1016/0165-3806(87)90149-0; ZIMMERMAN K, 1993, IN PRESS DEVELOPMENT, V119	77	894	910	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 5	1993	75	3					463	476		10.1016/0092-8674(93)90381-Y	http://dx.doi.org/10.1016/0092-8674(93)90381-Y			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8221886				2022-12-01	WOS:A1993MF83000009
J	MCCAFFREY, PG; LUO, C; KERPPOLA, TK; JAIN, J; BADALIAN, TM; HO, AM; BURGEON, E; LANE, WS; LAMBERT, JN; CURRAN, T; VERDINE, GL; RAO, A; HOGAN, PG				MCCAFFREY, PG; LUO, C; KERPPOLA, TK; JAIN, J; BADALIAN, TM; HO, AM; BURGEON, E; LANE, WS; LAMBERT, JN; CURRAN, T; VERDINE, GL; RAO, A; HOGAN, PG			ISOLATION OF THE CYCLOSPORINE-SENSITIVE T-CELL TRANSCRIPTION FACTOR NFATP	SCIENCE			English	Article							LYMPHOCYTES-T; INTERLEUKIN-2 ENHANCER; NUCLEAR FACTOR; ACTIVATION; BINDING; FOS; CALCINEURIN; SEQUENCE; PROTEIN; FK-506	Nuclear factor of activated T cells (NFAT) is a transcription factor that regulates expression of the cytokine interleukin-2 (IL-2) in activated T cells. The DNA-binding specificity of NFAT is conferred by NFATp, a phosphoprotein that is a target for the immunosuppressive compounds cyclosporin A and FK506. Here, the purification of NFATp from murine T cells and the isolation of a complementary DNA clone encoding NFATp are reported. A truncated form of NFATp, expressed as a recombinant protein in bacteria, binds specifically to the NFAT site of the murine IL-2 promoter and forms a transcriptionally active complex with recombinant c-Fos and c-Jun. Antisera to tryptic peptides of the purified protein or to the recombinant protein fragment react with T cell NFATp. The molecular cloning of NFATp should allow detailed analysis of a T cell transcription factor that is central to initiation of the immune response.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115; ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; HARVARD UNIV,MICROCHEM FACIL,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Roche Holding; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard University			Kerppola, Tom/AAG-4457-2022; Kerppola, Tom/AFK-6155-2022; Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011; Curran, Tom/C-1164-2008	Kerppola, Tom/0000-0002-0611-9446; Kerppola, Tom/0000-0002-0611-9446; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NCI NIH HHS [CA42471] Funding Source: Medline; NIGMS NIH HHS [GM46227] Funding Source: Medline; NINDS NIH HHS [NS25078] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042471, R01CA042471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS025078] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LARSON CJ, 1992, NUCLEIC ACIDS RES, V20, P3525, DOI 10.1093/nar/20.13.3525; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; ROONEY JM, UNPUB; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; VALGEARCHER VE, 1990, J IMMUNOL, V145, P4355; WALTER G, 1980, P NATL ACAD SCI-BIOL, V77, P5197, DOI 10.1073/pnas.77.9.5197	32	416	429	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					750	754		10.1126/science.8235597	http://dx.doi.org/10.1126/science.8235597			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235597				2022-12-01	WOS:A1993MD95200045
J	PARKER, L; CRAFT, AW; SMITH, J; DICKINSON, H; WAKEFORD, R; BINKS, K; MCELVENNY, D; SCOTT, L; SLOVAK, A				PARKER, L; CRAFT, AW; SMITH, J; DICKINSON, H; WAKEFORD, R; BINKS, K; MCELVENNY, D; SCOTT, L; SLOVAK, A			GEOGRAPHICAL-DISTRIBUTION OF PRECONCEPTIONAL RADIATION-DOSES TO FATHERS EMPLOYED AT THE SELLAFIELD NUCLEAR INSTALLATION, WEST CUMBRIA	BRITISH MEDICAL JOURNAL			English	Article							CONFIDENCE-LIMITS; CHILDREN BORN; YOUNG-PEOPLE; LEUKEMIA; LYMPHOMA; SEASCALE; FOLLOW; COHORT; PLANT	Objective-To examine whether the geographical distribution of births associated with preconceptional exposure of fathers to radiation at the Sellafield nuclear installation is consistent with the suggestion that this exposure explains the excess of childhood lymphoid malignancy in the adjacent village of Seascale. Design-Retrospective birth cohort study. Setting-Cumbria, West Cumbria health district, and Seascale civil parish. Subjects-The 10 363 children born in Cumbria during 1950-89 to fathers employed at Sellafield. Main outcome measures-The doses of external whole body ionising radiation received by fathers at Sellafield in the total time and in the six months before conception of their children; the proportions of the collective doses associated with Seascale and the rest of West Cumbria. Results-9256 children were born to fathers who had been exposed to radiation before the child's conception. Of these, 7318 had fathers who were exposed in the six months before conception. Overall 7% (38 person-Sv) of the collective total preconceptional dose and 7% (3 person-Sv) of the collective dose for the six months before conception were associated with children born in Seascale. Of all the children whose fathers worked at Sellafield, 842 (8%) were born in Seascale. The mean individual doses before conception were consistently lower in Seascale than in the rest of West Cumbria. Conclusions-The distribution of the paternal preconceptional radiation dose is statistically incompatible with this exposure providing a causal explanation for the cluster of childhood leukaemias in Seascale.	BRITISH NUCL FUELS PLC,HLTH & SAFETY DIRECTORATE,WARRINGTON WA3 6AS,CHESHIRE,ENGLAND; WESTLAKES RES INST,DEPT OCCUPAT HLTH & MED STAT,WHITEHAVEN CA24 3JZ,CUMBRIA,ENGLAND	University of Central Lancashire	PARKER, L (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT CHILD HLTH,CHILDRENS CANC UNIT,NEWCASTLE TYNE NE2 4HH,ENGLAND.		Wakeford, Richard/I-1978-2019	Wakeford, Richard/0000-0002-2934-0987; PARKER, LOUISE/0000-0002-5188-8113				BRENNER DJ, 1990, INT J RADIAT BIOL, V57, P1031, DOI 10.1080/09553009014551141; BRENNER DJ, 1990, STATISTICIAN, V39, P391, DOI DOI 10.2307/2349083; DRAPER GJ, 1993, BRIT MED J, V306, P89, DOI 10.1136/bmj.306.6870.89; FINDLAY W, 1987, PASCAL INTRO METHODI; GARDNER MJ, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715; GARDNER MJ, 1987, BRIT MED J, V295, P819, DOI 10.1136/bmj.295.6602.819; GARDNER MJ, 1990, BRIT MED J, V300, P429, DOI 10.1136/bmj.300.6722.429; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; KENDALL GM, 1986, NRPBM136 NAT RAD PRO; KINLEN LJ, 1993, BRIT MED J, V306, P1153, DOI 10.1136/bmj.306.6886.1153; KINLEN LJ, 1993, BRIT MED J, V306, P1718, DOI 10.1136/bmj.306.6894.1718; LITTLE M P, 1990, Journal of Radiological Protection, V10, P185, DOI 10.1088/0952-4746/10/3/002; Little M. P., 1992, Journal of Radiological Protection, V12, P203, DOI 10.1088/0952-4746/12/4/001; LITTLE M P, 1991, Journal of Radiological Protection, V11, P231, DOI 10.1088/0952-4746/11/4/002; LITTLE M P, 1991, Journal of Radiological Protection, V11, P77, DOI 10.1088/0952-4746/11/2/001; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P959, DOI 10.1136/bmj.307.6910.959; ROMAN E, 1993, BMJ-BRIT MED J, V306, P615, DOI 10.1136/bmj.306.6878.615; ROSE K S B, 1990, Journal of Radiological Protection, V10, P177, DOI 10.1088/0952-4746/10/3/001; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; YOSHIMOTO Y, 1990, AM J HUM GENET, V46, P1041; 1991, ARC VERSION 601; 1992, BOUNDARY LINE DIGITA; 1989, 4TH DIMENSION DESIGN; 1991, INFO 9 42; 1984, INVESTIGATION POSSIB; 1992, POSTZON	27	76	76	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1993	307	6910					966	971		10.1136/bmj.307.6910.966	http://dx.doi.org/10.1136/bmj.307.6910.966			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC441	8241907	Bronze, Green Published			2022-12-01	WOS:A1993MC44100017
J	PARGE, HE; ARVAI, AS; MURTARI, DJ; REED, SI; TAINER, JA				PARGE, HE; ARVAI, AS; MURTARI, DJ; REED, SI; TAINER, JA			HUMAN CKSHS2 ATOMIC-STRUCTURE - A ROLE FOR ITS HEXAMERIC ASSEMBLY IN CELL-CYCLE CONTROL	SCIENCE			English	Article							PROTEIN-KINASE COMPLEX; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; DIVISION CYCLE; FISSION YEAST; GENE CDC28; PHOSPHORYLATION; P34CDC2; ACTIVATION; SEQUENCE	The cell cycle regulatory protein CksHs2 binds to the catalytic subunit of the cyclin-dependent kinases (Cdk's) and is essential for their biological function. The crystal structure of the protein was determined at 2.1 angstrom resolution. The CksHs2 structure is an unexpected hexamer formed by the symmetric assembly of three interlocked dimers into an unusual 12-stranded beta barrel fold that may represent a prototype for this class of protein structures. Sequence-conserved regions form the unusual beta strand exchange between the subunits of the dimer, and the metal and anion binding sites associated with the hexamer assembly. The two other sequence-conserved regions line a 12 angstrom diameter tunnel through the beta barrel and form the six exposed, charged helix pairs. Six kinase subunits can be modeled to bind the assembled hexamer without collision, and therefore this CksHs2 hexamer may participate in cell cycle control by acting as the hub for Cdk multimerization in vivo.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429				ARVAI AS, UNPUB; AZZI L, 1992, EUR J BIOCHEM, V203, P353, DOI 10.1111/j.1432-1033.1992.tb16557.x; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bondt H. L. D., 1993, NATURE, V363, P595; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HILL CP, 1991, BIOCHEMISTRY-US, V30, P917, DOI 10.1021/bi00218a006; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUHN LA, 1992, J MOL BIOL, V228, P13, DOI 10.1016/0022-2836(92)90487-5; LESLIE AGW, 1986, CCP4 NEWSLETTER, V18, P33; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MALLER J, 1991, CURR OPIN CELL BIOL, V3, P369; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNOR PM, 1992, CANCER BIOL, V3, P409; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REED SI, 1980, GENETICS, V95, P561; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3	59	113	118	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					387	395		10.1126/science.8211159	http://dx.doi.org/10.1126/science.8211159			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	8211159				2022-12-01	WOS:A1993MB85900048
J	CHIRUVOLU, S; WALKER, S; ISRAELACHVILI, J; SCHMITT, FJ; LECKBAND, D; ZASADZINSKI, JA				CHIRUVOLU, S; WALKER, S; ISRAELACHVILI, J; SCHMITT, FJ; LECKBAND, D; ZASADZINSKI, JA			HIGHER-ORDER SELF-ASSEMBLY OF VESICLES BY SITE-SPECIFIC BINDING	SCIENCE			English	Article							ELECTRON-MICROSCOPY; MEMBRANE-FUSION; RECOGNITION; LIPOSOMES; ADHESION; BILAYERS; FORCES; SYSTEM	The association of lipid molecules into spherical vesicles in solution as a result of nonspecific intermolecular forces constitutes a primary self-assembly process. Such vesicles can undergo a secondary self-assembly into higher order structures in a controlled and reversible manner by means of site-specific ligand-receptor (biotin-streptavidin) coupling. Cryoelectron microscopy shows these structures to be composed of tethered, rather than adhering, vesicles in their original, unstressed state. In contrast, vesicles aggregated by nonspecific, such as van der Waals, forces are deformed and stressed, producing unstable structures. Vesicle association by site-specific binding provides a practical mechanism for the production of stable, yet controllable, microstructured biomaterials.	UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY SM, 1990, LANGMUIR, V6, P1326, DOI 10.1021/la00097a024; BELLARE JR, 1988, J ELECTRON MICR TECH, V10, P87, DOI 10.1002/jemt.1060100111; BLANKENBURG R, 1989, BIOCHEMISTRY-US, V28, P8214, DOI 10.1021/bi00446a037; Cevc G., 1985, PHOSPHOLIPID BILAYER; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V906, P309, DOI 10.1016/0304-4157(87)90016-5; EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003; Fendler J. H., 1982, MEMBRANE MIMETIC CHE; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; GRATZL M, 1976, FEBS LETT, V62, P142, DOI 10.1016/0014-5793(76)80038-5; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HASHIMOTO K, 1986, BIOCHIM BIOPHYS ACTA, V856, P556, DOI 10.1016/0005-2736(86)90147-1; HELM CA, 1992, BIOCHEMISTRY-US, V31, P1794, DOI 10.1021/bi00121a030; HUI SW, 1988, BIOCHIM BIOPHYS ACTA, V941, P130, DOI 10.1016/0005-2736(88)90173-3; Israelachvili J., 1992, INTERMOLECULAR SURFA; ISRAELACHVILI JN, 1986, SURFACTANTS SOLUTION, V4, P3; LASIC DD, 1993, LIPOSOMES PHYSICS AP; LEE KD, 1993, BIOPHYS J, V64, P905, DOI 10.1016/S0006-3495(93)81453-X; LOUGHREY HC, 1990, BIOCHIM BIOPHYS ACTA, V1028, P73, DOI 10.1016/0005-2736(90)90267-R; MARRA J, 1986, BIOPHYS J, V50, P815, DOI 10.1016/S0006-3495(86)83522-6; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MULLER W, 1993, SCIENCE, V262, P1706, DOI 10.1126/science.8259513; PAPAHADJOPOULOS D, 1990, J BIOENERG BIOMEMBR, V22, P157, DOI 10.1007/BF00762944; POWERS DD, 1992, BIOTECHNOL PROGR, V8, P436, DOI 10.1021/bp00017a011; SERVUSS RM, 1987, PHYSICS COMPLEX SUPE, P85; SOWERS AE, 1987, CELL FUSION; WENNERSTROM H, 1979, PHYS REP, V52, P1, DOI 10.1016/0370-1573(79)90087-5; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; Wilchek M, 1990, AVIDIN BIOTIN TECHNO; WIMLEY WC, 1990, BIOCHEMISTRY-US, V29, P1296, DOI 10.1021/bi00457a027	29	174	178	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 17	1994	264	5166					1753	1756		10.1126/science.8209255	http://dx.doi.org/10.1126/science.8209255			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR600	8209255				2022-12-01	WOS:A1994NR60000040
J	LAPTHORN, AJ; HARRIS, DC; LITTLEJOHN, A; LUSTBADER, JW; CANFIELD, RE; MACHIN, KJ; MORGAN, FJ; ISAACS, NW				LAPTHORN, AJ; HARRIS, DC; LITTLEJOHN, A; LUSTBADER, JW; CANFIELD, RE; MACHIN, KJ; MORGAN, FJ; ISAACS, NW			CRYSTAL-STRUCTURE OF HUMAN CHORIONIC-GONADOTROPIN	NATURE			English	Article							HUMAN CHORIOGONADOTROPIN-BETA; SITE-DIRECTED MUTAGENESIS; HUMAN LUTEINIZING-HORMONE; RECEPTOR-BINDING; GLYCOPROTEIN HORMONES; DISULFIDE BONDS; TERMINAL REGION; ALPHA-SUBUNIT; IMMUNOLOGICAL PROPERTIES; BIOLOGICAL PROPERTIES	The three-dimensional structure of human chorionic gonadotropin shows that each of its two different subunits has a similar topology, with three disulphide bonds forming a cystine knot. This same folding motif Is found in some protein growth factors. The heterodimer is stabilized by a segment of the beta-subunit which wraps around the alpha-subunit and is covalently linked like a seat belt by the disulphide Cys 26-Cys 110. This extraordinary feature appears to be essential not only for the association of these heterodimers but also for receptor binding by the glycoprotein hormones.	UNIV GLASGOW,DEPT CHEM,GLASGOW G12 8QQ,SCOTLAND; COLUMBIA UNIV,DEPT MED,NEW YORK,NY 10032; ST VINCENTS INST MED RES,MELBOURNE,VIC 3065,AUSTRALIA; LATROBE UNIV,DEPT BIOCHEM,MELBOURNE,VIC 3083,AUSTRALIA	University of Glasgow; Columbia University; St. Vincent's Institute of Medical Research; La Trobe University				Lapthorn, Adrian/0000-0002-2197-8134; Littlejohn, Allison/0000-0003-1784-3365				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIRKEN S, 1988, ENDOCRINOLOGY, V123, P572, DOI 10.1210/endo-123-1-572; Blithe D.L., 1994, GLYCOPROTEIN HORMONE, P156; BRICOGNE G, 1990, ACTA CRYSTALLOGR A, V46, P284, DOI 10.1107/S0108767389012882; BRUNGER AT, 1992, XPLOR MANUAL; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CHEN F, 1991, BIOCHEMISTRY-US, V30, P10171, DOI 10.1021/bi00106a014; CHEN F, 1991, J BIOL CHEM, V266, P6904; CHEN HC, 1982, J BIOL CHEM, V257, P4446; HARRIS DC, 1989, J BIOL CHEM, V264, P6705; HOLMGREN A, 1976, EUR J BIOCHEM, V70, P377, DOI 10.1111/j.1432-1033.1976.tb11027.x; HUANG JN, 1993, MOL CELL ENDOCRINOL, V90, P211, DOI 10.1016/0303-7207(93)90154-C; HUTH JR, 1992, J BIOL CHEM, V267, P8870; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KEUTMANN HT, 1988, BIOCHEMISTRY-US, V27, P8939, DOI 10.1021/bi00425a010; KEUTMANN HT, 1992, MOL CELL ENDOCRINOL, V86, pC1, DOI 10.1016/0303-7207(92)90168-6; KEUTMANN HT, 1983, BIOCHEMISTRY-US, V22, P3067, DOI 10.1021/bi00282a007; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; KEUTMANN HT, 1989, MOL ENDOCRINOL, V3, P526, DOI 10.1210/mend-3-3-526; LUSTBADER JW, 1989, BIOCHEMISTRY-US, V28, P9239, DOI 10.1021/bi00450a001; MANJUNATH P, 1982, J BIOL CHEM, V257, P7109; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MERZ WE, 1979, EUR J BIOCHEM, V101, P541, DOI 10.1111/j.1432-1033.1979.tb19749.x; MISE T, 1981, J BIOL CHEM, V256, P6587; MISE T, 1980, J BIOL CHEM, V255, P8516; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MURRAYRUST J, 1993, STRUCTURE, V1, P153, DOI 10.1016/0969-2126(93)90029-G; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; PARSONS TF, 1979, J BIOL CHEM, V254, P6010; PUETT D, 1994, GLYCOPROTEIN HORMONE, P122; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REBOIS RV, 1987, J BIOL CHEM, V262, P3891; RYAN RJ, 1987, RECENT PROG HORM RES, V43, P383; Sairam M.R., 1983, Hormonal Proteins and Peptides, V11, P1; SAIRAM MR, 1989, FASEB J, V3, P1915, DOI 10.1096/fasebj.3.8.2542111; SAIRAM MR, 1992, MOL CELL ENDOCRINOL, V85, P227, DOI 10.1016/0303-7207(92)90261-4; SAIRAM MR, 1985, SCIENCE, V229, P65, DOI 10.1126/science.2990039; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Ward D.N., 1979, ANIMAL MODELS RES FE, P151; WEISS J, 1992, NEW ENGL J MED, V326, P179, DOI 10.1056/NEJM199201163260306; XIA HY, 1994, ENDOCRINOLOGY, V134, P1768, DOI 10.1210/en.134.4.1768; 1992, SERC CCP4 DAR LAB CO	51	787	833	2	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 9	1994	369	6480					455	461		10.1038/369455a0	http://dx.doi.org/10.1038/369455a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	8202136				2022-12-01	WOS:A1994NQ28600047
J	MILES, SH				MILES, SH			PHYSICIANS AND THEIR PATIENTS SUICIDES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LIFE-SUSTAINING TREATMENT; ASSISTED SUICIDE; ETHICAL DILEMMAS; HOPELESSLY ILL; EUTHANASIA; COUNTERTRANSFERENCE; QUALITY; DEATH; CARE; PREFERENCES		UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN; CTR BIOMED ETH,MINNEAPOLIS,MN	University of Minnesota System; University of Minnesota Twin Cities	MILES, SH (corresponding author), HENNEPIN CTY MED CTR,DEPT MED,MINNEAPOLIS,MN, USA.							ANGELL M, 1989, NEW ENGL J MED, V321, P120; BACH JR, 1992, ARCH PHYS MED REHAB, V73, P179; BENOLIEL JQ, 1987, OMEGA-J DEATH DYING, V18, P341, DOI 10.2190/4Y6G-XQAP-0XYN-LRW9; BONICA JJ, 1991, MT SINAI J MED, V58, P191; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; BUTLER RN, 1975, AM J PSYCHIAT, V132, P893; CAIN J, 1990, OBSTET GYNECOL, V76, P149; CAINE ED, 1993, JAMA-J AM MED ASSOC, V270, P875, DOI 10.1001/jama.270.7.875; CAMPBELL CS, 1992, J MED ETHICS, V18, P128, DOI 10.1136/jme.18.3.128; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CHEMTOB CM, 1988, AM J PSYCHIAT, V145, P224; CLARKE PJ, 1981, AM J ORTHOPSYCHIAT, V51, P71, DOI 10.1111/j.1939-0025.1981.tb01349.x; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; CONWELL Y, 1991, NEW ENGL J MED, V325, P1101; CRUZ MTC, 1993, AM J LAW MED, V18, P369; DIEKSTRA RFW, 1993, ANN MED, V25, P5, DOI 10.3109/07853899309147850; GOLDSTEIN LS, 1984, AM J PSYCHOTHER, V38, P392, DOI 10.1176/appi.psychotherapy.1984.38.3.392; Gomez Carlos F., 1991, REGULATING DEATH EUT; GOODWIN JS, 1990, JAMA-J AM MED ASSOC, V264, P326; GREENE MG, 1989, GERONTOLOGIST, V29, P808, DOI 10.1093/geront/29.6.808; HELME T, 1993, BRIT J PSYCHIAT, V163, P456, DOI 10.1192/bjp.163.4.456; HENDIN H, 1981, AM J PSYCHOTHER, V35, P469, DOI 10.1176/appi.psychotherapy.1981.35.4.469; JORSTAD J, 1987, ACTA PSYCHIAT SCAN S, V336, P76; KASS LR, 1980, JAMA-J AM MED ASSOC, V244, P1811, DOI 10.1001/jama.244.16.1811; KASS LR, 1991, PUBLIC INTEREST  WIN, P25; Lifton Robert Jay, 1986, NAZI DOCTORS, P417; MALTSBERGER JT, 1974, ARCH GEN PSYCHIAT, V30, P625; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; MODESTIN J, 1987, BRIT J MED PSYCHOL, V60, P379, DOI 10.1111/j.2044-8341.1987.tb02757.x; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P1198, DOI 10.1001/jama.1990.03440090027010; PELLEGRINO ED, 1993, JAMA-J AM MED ASSOC, V270, P874, DOI 10.1001/jama.270.7.874; PICK IB, 1985, INT J PSYCHOANAL, V66, P157; QUILL TE, 1991, ARCH INTERN MED, V151, P463; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; ROENN HS, 1993, ANN INTERN MED, V119, P121; ROSNER F, 1992, NEW YORK STATE J MED, V92, P388; ROTOV M, 1970, AM J PSYCHOTHER, V24, P216; SCHEIDERMAYER DL, 1989, NEW ENGL J MED, V321, P120; SCHNEIDERMAN LJ, 1993, J CLIN ETHIC, V4, P28; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; STARR TJ, 1986, J GEN INTERN MED, V1, P373, DOI 10.1007/BF02596420; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; UHLMANN RF, 1991, ARCH INTERN MED, V151, P495, DOI 10.1001/archinte.151.3.495; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Wolk-Wasserman D, 1987, Crisis, V8, P69	48	48	48	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	1994	271	22					1786	1788		10.1001/jama.271.22.1786	http://dx.doi.org/10.1001/jama.271.22.1786			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NN725	8196123				2022-12-01	WOS:A1994NN72500030
J	PREUSS, D; RHEE, SY; DAVIS, RW				PREUSS, D; RHEE, SY; DAVIS, RW			TETRAD ANALYSIS POSSIBLE IN ARABIDOPSIS WITH MUTATION OF THE QUARTET (QRT) GENES	SCIENCE			English	Article							POLLEN; EXPRESSION; TOMATO	Two Arabidopsis thaliana genes, QRT1 and QRT2, are required for pollen separation during normal development. In qrt mutants, the outer walls of the four meiotic products of the pollen mother cell are fused, and pollen grains are released in tetrads. Pollen is viable and fertile, and the cytoplasmic pollen contents are discrete. Pollination with a single tetrad usually yields four seeds, and genetic analysis confirmed that marker loci segregate in a 2:2 ratio within these tetrads. These mutations allow tetrad analysis to be performed in Arabidopsis and define steps in pollen cell wall development.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University	PREUSS, D (corresponding author), STANFORD UNIV, DEPT BIOCHEM, STANFORD, CA 94305 USA.							Blackmore S, 1988, ONTOGENY SYSTEMATICS, P83; CHERRY JM, 1992, PLANT MOL BIOL REP, V10, P308; ESCHRICH W., 1964, STAIN TECHNOL, V39, P303; FOGEL S, 1981, MOL BIOL YEAST SACCH, P289; HESLOPHARRISON J, 1970, STAIN TECHNOL, V45, P115, DOI 10.3109/10520297009085351; Jefferson RA., 1987, PLANT MOL BIOL REP, V5, P387, DOI DOI 10.1007/BF02667740; KNAPP EDGAR, 1960, CANADIAN JOUR GENETICS AND CYTOL, V2, P89; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; MCCORMICK S, 1993, PLANT CELL, V5, P1265, DOI 10.1105/tpc.5.10.1265; MORTIMER RK, 1981, MOL BIOL YEAST SACCH, P11; PERKINS DD, 1962, GENET RES, V3, P315, DOI 10.1017/S0016672300035084; PERKINS DD, 1953, GENETICS, V38, P187; PERKINS DD, 1974, GENETICS, V77, P459; PERKINS DD, 1949, GENETICS, V34, P607; PERKINS DD, 1955, J CELL COMPAR PHY S2, V45; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; REGAN SM, 1990, PLANT CELL, V2, P877, DOI 10.1105/tpc.2.9.877; STIEGLITZ H, 1977, DEV BIOL, V57, P87, DOI 10.1016/0012-1606(77)90356-6; TWELL D, 1990, DEVELOPMENT, V109, P705; TWELL D, 1989, MOL GEN GENET, V217, P240, DOI 10.1007/BF02464887	22	270	295	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	1994	264	5164					1458	1460		10.1126/science.8197459	http://dx.doi.org/10.1126/science.8197459			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	8197459				2022-12-01	WOS:A1994NP22100042
J	YANKULOV, K; BLAU, J; PURTON, T; ROBERTS, S; BENTLEY, DL				YANKULOV, K; BLAU, J; PURTON, T; ROBERTS, S; BENTLEY, DL			TRANSCRIPTIONAL ELONGATION BY RNA-POLYMERASE-II IS STIMULATED BY TRANSACTIVATORS	CELL			English	Article							C-MYC GENE; IMMUNODEFICIENCY-VIRUS TYPE-1; LONG TERMINAL REPEAT; HIV-1 TAT; XENOPUS-OOCYTES; SEQUENCE REQUIREMENTS; PREMATURE TERMINATION; DROSOPHILA-MELANOGASTER; MAMMALIAN-CELLS; ADENOVIRUS E1A	We report that a variety of transactivators stimulate elongation by RNA polymerase II. Activated transcription complexes have high processivity and are able to read through pausing and termination sites efficiently. In contrast, nonactivated and ''squelched'' transcription mostly arrests prematurely. Activators differ in the extent to which they stimulate processivity; for example, GAL4-VP16 and GAL4-E1a are more effective than GAL4-AH. The stimulation of elongation can be as important as the stimulation of initiation in activating expression of a reporter gene. We suggest that setting the competence of polymerase II to elongate is an integral part of the initiation step that is controlled by activators cooperating with the general transcription factors.			YANKULOV, K (corresponding author), IMPERIAL CANC RES FUND, MOLEC GENET DIFFERENTIAT LAB, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.			Yankulov, Krassimir/0000-0001-9440-9234; Bentley, David/0000-0002-8414-4647				BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENTLEY DL, 1989, GENE DEV, V3, P1179, DOI 10.1101/gad.3.8.1179; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; Drapkin R, 1993, CURR OPIN CELL BIOL, V5, P469, DOI 10.1016/0955-0674(93)90013-G; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EMERMAN M, 1987, EMBO J, V6, P3755, DOI 10.1002/j.1460-2075.1987.tb02710.x; FLINT KJ, 1991, ONCOGENE, V6, P2019; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HAIR A, 1993, MOL CELL BIOL, V13, P7925, DOI 10.1128/MCB.13.12.7925; HENIKOFF S, 1987, GENETICS, V117, P711; HERRMANN CH, 1989, MOL CELL BIOL, V9, P5412, DOI 10.1128/MCB.9.12.5412; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LASPIA MF, 1990, GENE DEV, V4, P2397, DOI 10.1101/gad.4.12b.2397; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LU XB, 1993, J VIROL, V67, P1752, DOI 10.1128/JVI.67.4.1752-1760.1993; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MELLITS KH, 1988, EMBO J, V7, P2849, DOI 10.1002/j.1460-2075.1988.tb03141.x; MEULIA T, 1993, MOL CELL BIOL, V13, P5647, DOI 10.1128/MCB.13.9.5647; MIDDLETON KM, 1990, MOL CELL BIOL, V10, P727, DOI 10.1128/MCB.10.2.727; MILLER AD, 1983, P NATL ACAD SCI-BIOL, V80, P4709, DOI 10.1073/pnas.80.15.4709; MIRKOVITCH J, 1992, MOL BIOL CELL, V3, P1085, DOI 10.1091/mbc.3.10.1085; MOBERG KH, 1992, ONCOGENE, V7, P411; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; ROBERTS S, 1992, GENE DEV, V6, P1562, DOI 10.1101/gad.6.8.1562; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; SPENCER CA, 1993, MOL CELL BIOL, V13, P1296, DOI 10.1128/MCB.13.2.1296; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAMM I, 1977, P NATL ACAD SCI USA, V74, P5011, DOI 10.1073/pnas.74.11.5011; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TOOHEY MG, 1989, GENE DEV, V3, P265, DOI 10.1101/gad.3.3.265; TREISMAN R, 1985, NATURE, V315, P72, DOI 10.1038/315072a0; WRIGHT S, 1991, P NATL ACAD SCI USA, V88, P11383, DOI 10.1073/pnas.88.24.11383; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	61	226	228	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	1994	77	5					749	759		10.1016/0092-8674(94)90058-2	http://dx.doi.org/10.1016/0092-8674(94)90058-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NQ123	8205623				2022-12-01	WOS:A1994NQ12300014
J	LI, TY; JANDA, KD; ASHLEY, JA; LERNER, RA				LI, TY; JANDA, KD; ASHLEY, JA; LERNER, RA			ANTIBODY-CATALYZED CATIONIC CYCLIZATION	SCIENCE			English	Article							CANDIDA-ALBICANS; CYCLASE; OXIDOSQUALENE; STRATEGY; BAIT	Two major goals for the design of new catalysts are the facilitation of chemical transformations and control of product outcome. An antibody has been induced that efficiently catalyzes a cationic cyclization in which an acyclic olefinic sulfonate ester substrate is converted almost exclusively (98 percent) to a cyclic alcohol. The key to the catalysis of the reaction and the restriction of the product complexity is the use of antibody binding energy to rigidly enforce a concerted mechanism in accord with the design of the hapten. Thus, the ability to direct binding energy allows the experimenter to dictate a reaction mechanism which is an otherwise difficult task in chemistry. New catalysts, for cationic cyclization may be of general use in the formation of carbon-carbon and carbon-heteroatom bonds leading to multiring molecules including steroids and heterocyclic compounds.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043858, R29GM043858] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43858] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; ASHLEY JA, 1992, J ORG CHEM, V57, P6691, DOI 10.1021/jo00051a003; Bartlett P. A., 1984, ASYMMETRIC SYNTHESIS, V3, P341; BARTON DHR, 1975, J CHEM SOC PERK T 1, P1134, DOI 10.1039/p19750001134; BUNTEL CJ, 1992, J AM CHEM SOC, V114, P9711, DOI 10.1021/ja00050a090; COLIN EW, 1981, SILICON ORGANIC SYNT, P15; COOK MJ, 1971, J CHEM SOC B, P1330, DOI 10.1039/j29710001330; COREY EJ, 1966, J AM CHEM SOC, V88, P4750, DOI 10.1021/ja00972a056; COREY EJ, 1991, J AM CHEM SOC, V113, P8172, DOI 10.1021/ja00021a056; CORNFORT.JW, 1965, J AM CHEM SOC, V87, P3224, DOI 10.1021/ja01092a038; Engvall E, 1980, Methods Enzymol, V70, P419; ESCHENMOSER A, 1955, HELV CHIM ACTA, V38, P1890, DOI 10.1002/hlca.19550380728; EVANS DA, 1979, TETRAHEDRON LETT, P411; FLEMING I, 1976, J CHEM SOC CHEM COMM, P182, DOI 10.1039/c39760000182; GASSMAN PG, 1968, J CHEM SOC CHEM COMM, P69; JANDA KD, 1991, J AM CHEM SOC, V113, P5427, DOI 10.1021/ja00014a039; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; JANDA KD, 1990, BIOTECHNOL PROGR, V6, P178, DOI 10.1021/bp00003a002; JANDA KD, 1987, 198TH NAT M AM CHEM; JOHNSON WS, 1968, ACCOUNTS CHEM RES, V1, P1, DOI 10.1021/ar50001a001; JOHNSON WS, 1987, J AM CHEM SOC, V109, P5582; JOHNSON ZBW, 1964, J AM CHEM SOC, V86, P1959; KASANO M, 1991, CHEM PHARM BULL, V39, P239; KATRITZKY AR, 1992, HETEROCYCLES, V33, P1011; KELLY R, 1990, GENE, V87, P177, DOI 10.1016/0378-1119(90)90299-7; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; MANDAVA N, 1968, CAN J CHEMISTRY, V46, P2761, DOI 10.1139/v68-458; MARCH J, 1985, ADV ORG CHEM, P312; MAUDGAL RK, 1958, J AM CHEM SOC, V80, P2589, DOI 10.1021/ja01543a063; MULLHEIN LJ, 1972, CHEM SOC REV, V259, P259; OLAH GA, 1992, CARBONIUM IONS; SCHROEPFER GJ, 1982, ANNU REV BIOCHEM, V51, P555, DOI 10.1146/annurev.bi.51.070182.003011; SCHULTZ PG, 1993, ACCOUNTS CHEM RES, V26, P39; SHARPLESS KB, 1968, THESIS STANFORD U; SHEVLIN CG, 1994, BIOORG MED CHEM LETT, V4, P297, DOI 10.1016/S0960-894X(01)80132-3; SHOKAT KM, 1989, NATURE, V338, P269, DOI 10.1038/338269a0; STORK G, 1955, J AM CHEM SOC, V77, P5968; Sutherland J. K., 1991, COMP ORG SYNTH, V5, P341; UNO T, 1992, J AM CHEM SOC, V114, P6573, DOI 10.1021/ja00042a055; VANTAMELEN EE, 1982, J AM CHEM SOC, V104, P6480, DOI 10.1021/ja00387a070; WILLETT JD, 1967, J BIOL CHEM, V242, P4182; WOODWARD RB, 1953, J AM CHEM SOC, V75, P2023, DOI 10.1021/ja01104a535	43	72	73	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 27	1994	264	5163					1289	1293		10.1126/science.8191282	http://dx.doi.org/10.1126/science.8191282			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	NN767	8191282				2022-12-01	WOS:A1994NN76700034
J	YIN, XM; OLTVAI, ZN; KORSMEYER, SJ				YIN, XM; OLTVAI, ZN; KORSMEYER, SJ			BH1 AND BH2 DOMAINS OF BCL-2 ARE REQUIRED FOR INHIBITION OF APOPTOSIS AND HETERODIMERIZATION WITH BAX	NATURE			English	Article							PROGRAMMED CELL-DEATH; CHROMOSOMAL BREAKPOINT; PROTOONCOGENE BCL-2; SEQUENCE SIMILARITY; GENE; PROTEIN; EXPRESSION; SURVIVAL; THYMOCYTES; PREVENTION	BCL-2 was isolated from the t(14;18) chromosomal breakpoint in follicular B-cell lymphoma(1-3). Bcl-2 has the unique oncogenic role of extending cell survival by inhibiting a variety of apoptotic deaths(4-13). An emerging family of Bcl-2 -related proteins share two highly conserved regions(14-20) referred to here as Bcl-2 homology 1 and 2 (BH1 and BH2) domains (Fig. 1). This includes Bax which heterodimerizes with Bcl-2 and when overexpressed counteracts Bcl-2(14). We report here that site-specific mutagenesis of Bcl-2 establishes the two domains as novel dimerization motifs. Substitution of Gly 145 in BH1 domain or Trp 188 in BH2 domain completely abrogated Bcl-2's death-repressor activity in interleukin-3 deprivation, gamma-irradiation and glucocorticoid-induced apoptosis. Mutations that affected Bcl-2's function also disrupted its heterodimerization with Bax, yet still permitted Bcl-2 homodimerization. These results establish a functional role for the BH1 and BH2 domains and suggest Bcl-2 exerts its action through heterodimerization with Bax.			YIN, XM (corresponding author), WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DIV MOLEC ONCOL,ST LOUIS,MO 63110, USA.							ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CORMACK B, 1991, CURRENT PROTOCOLS MO; CREIGHTON TE, 1984, PROTEINS STRUCTURES, pCH1; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LIN EY, 1993, J IMMUNOL, V151, P1979; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; UCKER DS, 1989, J IMMUNOL, V143, P3461; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VEIS DJ, 1993, J IMMUNOL, V151, P2546; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251	30	1195	1301	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					321	323		10.1038/369321a0	http://dx.doi.org/10.1038/369321a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	8183370				2022-12-01	WOS:A1994NN10900050
J	PAOLELLA, DN; PALMER, CR; SCHEPARTZ, A				PAOLELLA, DN; PALMER, CR; SCHEPARTZ, A			DNA TARGETS FOR CERTAIN BZIP PROTEINS DISTINGUISHED BY AN INTRINSIC BEND	SCIENCE			English	Article							LEUCINE ZIPPER; GEL-ELECTROPHORESIS; CAP PROTEIN; BINDING; HETERODIMERS; REPRESSOR; REGIONS; YEAST; FOS; JUN	In spite of the large amount of sequence conservation among the DNA binding segments of basic region leucine zipper (bZIP) proteins, these proteins can discriminate differently between target sequences that differ in half-site spacing. Here it is shown that the half-site spacing preferences of bZIP proteins are the result of (i) the differential intrinsic curvature in target binding sites that differ by insertion or deletion of a single base pair and (ii) the ability of some bZIP proteins to overcome this intrinsic curvature through a mechanism dependent on basic segment residues.	YALE UNIV,DEPT CHEM,TRAINING PROGRAM BIOPHYS,NEW HAVEN,CT 06511; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Yale University; Yale University								DALMAWEISZHAUSZ DD, 1991, NUCLEIC ACIDS RES, V19, P611, DOI 10.1093/nar/19.3.611; DEGROOT RP, 1994, UNPUB ONCOGENE, V9, P463; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MCKNIGHT SL, 1991, SCI AM, V264, P54, DOI 10.1038/scientificamerican0491-54; METALLO SJ, UNPUB; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PAOLELLA DN, UNPUB; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; SHAKKED Z, UNPUB XRAY CRYSTALLO; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	30	75	76	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 20	1994	264	5162					1130	1133		10.1126/science.8178171	http://dx.doi.org/10.1126/science.8178171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM146	8178171				2022-12-01	WOS:A1994NM14600028
J	THOMPSON, JS; LING, XF; GRUNSTEIN, M				THOMPSON, JS; LING, XF; GRUNSTEIN, M			HISTONE H3 AMINO-TERMINUS IS REQUIRED FOR TELOMERIC AND SILENT MATING LOCUS REPRESSION IN YEAST	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL STATES; N-TERMINUS; INVIVO	HETEROCHROMATIN is a cytologically visible form of condensed chromatin capable of repressing genes in eukaryotic cells. For the yeast Saccharomyces cerevisiae, despite the absence of observable heterochromatin, there is genetic and chromatin structure data which indicate that there are heterochromatin-like repressive structures(1-2). Genes experience position effects at the silent mating loci and the telomeres, resulting in a repressed state that is inherited in an epigenetic manner. The histone H4 amino terminus is required for repression at these loci(3,4). Additional studies have indicated that the histone H3 N terminus is not important for silent mating locus repression(5,6), but redundancy of repressive elements at the silent mating loci may be responsible for masking its role. Here we report that histone H3 is required for full repression at yeast telomeres and at partially disabled silent mating loci, and that the acetylatable lysine residues of H3 play an important role in silencing.	UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	THOMPSON, JS (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.		Thompson, Jeff/HGB-3965-2022	Thompson, Jeff/0000-0002-9281-2596; Ling, Bruce/0000-0002-5386-3884				APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; SCHUSTER T, 1986, CELL, V45, P445, DOI 10.1016/0092-8674(86)90330-2; THOMPSON JS, 1994, MOL CELL BIOL, V14, P446, DOI 10.1128/MCB.14.1.446; THOMPSON JS, 1993, COLD SPRING HARB SYM, V58, P247, DOI 10.1101/SQB.1993.058.01.029; TURNER BM, 1992, J CELL, V69, P375; van Holde K.E., 1989, CHROMATIN	18	210	214	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	1994	369	6477					245	247		10.1038/369245a0	http://dx.doi.org/10.1038/369245a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	8183346				2022-12-01	WOS:A1994NM06700060
J	SMELLIE, JM; POULTON, A; PRESCOD, NP				SMELLIE, JM; POULTON, A; PRESCOD, NP			RETROSPECTIVE STUDY OF CHILDREN WITH RENAL SCARRING ASSOCIATED WITH REFLUX AND URINARY-INFECTION	BRITISH MEDICAL JOURNAL			English	Article							VESICOURETERAL REFLUX; PYELONEPHRITIS; MANAGEMENT; THERAPY; SCARS	Objective-To review the histories of children with bilateral renal scarring and severe vesicoureteric reflux to determine whether an improvement in early management might reduce the risk of scarring. Design-Retrospective study of medical records and discussion with parents. Setting-Outpatient departments of two teaching hospitals. Patients-52 children aged 1-12 years participating in a randomised comparison of medical and surgical management. All had a history of symptomatic urinary tract infection. Two thirds presented with fever and two with hypertension or renal failure. In only one out of 32 children examined by antenatal ultrasonography was an abnormality suspected. Results-There was delay in diagnosis or appropriate imaging or effective treatment of urinary infection in 50 of the 52 children. In 41 there was delay in diagnosis; there was delay in treating a confirmed infection in 45; no antibacterial prophylaxis was prescribed before imaging in 28; and investigation of the urinary tract was delayed in 33. The severity of scarring was significantly related to delay in diagnosis (X(2) for trend 7-43, P=0.01). Four children of mothers known to have reflux nephropathy were not investigated until they developed urinary tract infection. Conclusions-Efforts to reduce the incidence and severity of renal scarring should be directed towards rapid diagnosis and effective early management of urinary tract infection in infancy and childhood. Siblings and offspring of known patients with severe reflux nephropathy should be investigated for reflux.	HOSP SICK CHILDREN,DEPT PAEDIAT NEPHROL,LONDON WC1N 3JH,ENGLAND; GUYS HOSP,DEPT PAEDIAT NEPHROL,LONDON SE1 9RT,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust								AGGARWAL VK, 1989, ARCH DIS CHILD, V64, P1538, DOI 10.1136/adc.64.11.1538; Bailey R R, 1984, Contrib Nephrol, V39, P40; BURGE DM, 1992, J UROLOGY, V148, P1743, DOI 10.1016/S0022-5347(17)37018-0; GORDON AC, 1990, BRIT J UROL, V65, P407, DOI 10.1111/j.1464-410X.1990.tb14766.x; HAYCOCK GB, 1986, ARCH DIS CHILD, V61, P1155, DOI 10.1136/adc.61.12.1155; JADRESIC L, 1993, BRIT MED J, V307, P761, DOI 10.1136/bmj.307.6907.761; MILLER T, 1981, KIDNEY INT, V19, P654, DOI 10.1038/ki.1981.65; RANSLEY PG, 1981, KIDNEY INT, V20, P733, DOI 10.1038/ki.1981.204; RANSLEY PG, 1978, BRIT J RADIOL      S, V14, P1; RISDON RA, 1993, PEDIATR NEPHROL, V7, P361, DOI 10.1007/BF00857538; Smellie J, 1975, Kidney Int Suppl, V4, pS65; SMELLIE JM, 1981, KIDNEY INT, V20, P717, DOI 10.1038/ki.1981.201; SMELLIE JM, 1992, J UROLOGY, V148, P1676, DOI 10.1016/S0022-5347(17)37000-3; SMELLIE JM, 1985, BRIT MED J, V290, P1957, DOI 10.1136/bmj.290.6486.1957; SMELLIE JM, 1992, PEDIATR NEPHROL, V6, P223, DOI 10.1007/BF00878353; SMELLIE JM, 1992, FORFAR ARNEILS TXB P, P1031; WIKSTAD I, 1990, PEDIATR NEPHROL, V4, P331, DOI 10.1007/BF00862511; WINBERG J, 1982, PEDIATR CLIN N AM, V29, P801; WINTER AL, 1983, J UROLOGY, V129, P1190, DOI 10.1016/S0022-5347(17)52634-8; 1990, BRIT J GEN PRACT, V40, P146; 1991, J R COLL PHYSICIANS, V25, P36; 1987, BRIT MED J, V295, P237; 1980, PEDIATRICS, V67, P392; 1990, BRIT MED J, V301, P1082	24	125	128	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 7	1994	308	6938					1193	1196		10.1136/bmj.308.6938.1193	http://dx.doi.org/10.1136/bmj.308.6938.1193			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK956	8180534	Green Published			2022-12-01	WOS:A1994NK95600016
J	DRANOFF, G; CRAWFORD, AD; SADELAIN, M; REAM, B; RASHID, A; BRONSON, RT; DICKERSIN, GR; BACHURSKI, CJ; MARK, EL; WHITSETT, JA; MULLIGAN, RC				DRANOFF, G; CRAWFORD, AD; SADELAIN, M; REAM, B; RASHID, A; BRONSON, RT; DICKERSIN, GR; BACHURSKI, CJ; MARK, EL; WHITSETT, JA; MULLIGAN, RC			INVOLVEMENT OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PULMONARY HOMEOSTASIS	SCIENCE			English	Article							SURFACTANT PROTEIN-A; MURINE GM-CSF; LANGERHANS CELLS; MOUSE; PHAGOCYTOSIS; RECEPTOR; INVITRO; MICE; ENHANCEMENT; EXPRESSION	The in vivo function of murine granulocyte-macrophage colony-stimulating factor (GM-CSF) was investigated in mice, carrying a null allele of the GM-CSF gene, that were generated by gene targeting techniques in embryonic stem cells. Although steady-state hematopoiesis was unimpaired in homozygous mutant animals, all animals developed the progressive accumulation of surfactant lipids and proteins in the alveolar space, the defining characteristic of the idiopathic human disorder pulmonary alveolar proteinosis. Extensive lymphoid hyperplasia associated with lung airways and blood vessels was also found, yet no infectious agents could be detected. These results demonstrate that GM-CSF is not an essential growth factor for basal hematopoiesis and reveal an unexpected, critical role for GM-CSF in pulmonary homeostasis.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111; CHILDRENS HOSP,DIV PULM BIOL,CINCINNATI,OH 45229; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CLIN ONCOL,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Tufts University; Tufts University; Cincinnati Children's Hospital Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Neugeboren, Beverly/0000-0003-3127-9369; Bachurski, Cindy/0000-0002-3118-0636	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037569] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37569] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS JS, 1988, J IMMUNOL, V140, P131; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ARNAOUT MA, 1986, J CLIN INVEST, V78, P597, DOI 10.1172/JCI112615; BILYK N, 1993, J EXP MED, V177, P1773, DOI 10.1084/jem.177.6.1773; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BURGESS AW, 1977, J BIOL CHEM, V252, P1998; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; COLLINS HL, 1992, EUR J IMMUNOL, V22, P1447, DOI 10.1002/eji.1830220617; DAMOREBRUNO MA, 1992, AM J PHYSIOL, V262, pL40, DOI 10.1152/ajplung.1992.262.1.L40; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DONAHUE RE, 1986, NATURE, V321, P872, DOI 10.1038/321872a0; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; DRANOFF G, UNPUB; FLEISCHMANN J, 1986, BLOOD, V68, P708; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; GROOPMAN JE, 1987, NEW ENGL J MED, V317, P593, DOI 10.1056/NEJM198709033171003; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; JOHNSON GR, 1980, EXP HEMATOL, V8, P549; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; METCALF D, 1987, EXP HEMATOL, V15, P1; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1986, J CELL PHYSIOL, V128, P421, DOI 10.1002/jcp.1041280311; Metcalf D, 1988, MOL CONTROL BLOOD CE; MORRISSEY PJ, 1987, J IMMUNOL, V139, P1113; OGARRA A, 1989, CELL IMMUNOL, V123, P189, DOI 10.1016/0008-8749(89)90279-7; PRYHUBER GS, 1991, PEDIATR RES, V30, P597, DOI 10.1203/00006450-199112000-00023; ROBERTSON SA, 1992, BIOL REPROD, V46, P1069, DOI 10.1095/biolreprod46.6.1069; ROSEN SH, 1958, NEW ENGL J MED, V258, P1123, DOI 10.1056/NEJM195806052582301; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; TAZI A, 1993, J CLIN INVEST, V91, P566, DOI 10.1172/JCI116236; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEISBART RH, 1988, NATURE, V332, P647, DOI 10.1038/332647a0; WEISBART RH, 1986, J IMMUNOL, V137, P3584; WEISER WY, 1987, J EXP MED, V166, P1436, DOI 10.1084/jem.166.5.1436; WITMERPACK MD, 1987, J EXP MED, V166, P1484, DOI 10.1084/jem.166.5.1484; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; WRIGHT JR, 1987, AM REV RESPIR DIS, V135, P426; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224	45	714	729	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					713	716		10.1126/science.8171324	http://dx.doi.org/10.1126/science.8171324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171324				2022-12-01	WOS:A1994NH71300035
J	CHIAVARELLI, M; GUNDRY, SR; RAZZOUK, AJ; BAILEY, LL				CHIAVARELLI, M; GUNDRY, SR; RAZZOUK, AJ; BAILEY, LL			CARDIAC TRANSPLANTATION FOR INFANTS WITH HYPOPLASTIC LEFT-HEART SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FONTAN OPERATION; ALLOTRANSPLANTATION; RECONSTRUCTION	Objective.-To determine whether cardiac transplantation improves the natural history of infants with hypoplastic left-heart syndrome and to examine differences in outcome as a function of the pretransplant period. Design.-Retrospective cohort study. Historical, clinical, and laboratory data were collected during the pretransplant period, the in-hospital period, and for up to 6 years following transplantation. Data were analyzed using the product-limit estimate and the log rank test. Setting.-A tertiary, acute care, university teaching hospital. Patients.-All 111 infants with hypoplastic left-heart syndrome who entered and completed a protocol leading to transplantation from November 19,1985, to December 31, 1991. Infants who died while waiting for transplantation were included. Intervention.-Orthotopic cardiac allotransplantation. Main Outcome Measures.-Pretransplant waiting mortality and its influence on posttransplant survival, operative (in-hospital or within 30 postoperative days in discharged patients) and intermediate-term mortality (5 years), and reoperation rates for cardiac surgery. Results.-Transplantation procedures were performed in 84 infants (76%; 95% confidence interval [CI], 66% to 83%) ranging in age from 3 hours to 151 days. Twenty-seven infants registered for transplantation died while awaiting a donor heart. Operative mortality was 13% (CI, 7% to 23%), and 69 patients were late survivors (62% [CI, 52% to 71%] of the study group and 82% [CI, 72% to 89%] of the transplant recipients). Overall 5-year actuarial survival was 61% (CI, 52% to 70%). Transplant recipients had a 5-year survival of 81% (CI, 71% to 88%). Freedom from reoperation was 89% (CI, 76% to 95%) at 5 years. Conclusions.-Cardiac transplantation for hypoplastic left-heart syndrome has a significant positive impact on the natural history of this uniformly lethal lesion.	LOMA LINDA UNIV,MED CTR,DEPT SURG,LOMA LINDA,CA 92354; LOMA LINDA UNIV,MED CTR,LOMA LINDA INT HEART INST,LOMA LINDA,CA 92354; SUNY HLTH SCI CTR,DIV CARDIOTHORAC SURG,BROOKLYN,NY	Loma Linda University; Loma Linda University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center								ALLAN LD, 1991, LANCET, V337, P959, DOI 10.1016/0140-6736(91)91582-F; BAILEY LL, 1993, J THORAC CARDIOV SUR, V105, P805; BAILEY LL, 1986, NEW ENGL J MED, V315, P949, DOI 10.1056/NEJM198610093151507; BAUM MF, 1991, J HEART LUNG TRANSPL, V10, P848; BOVE EL, 1991, ANN THORAC SURG, V52, P701, DOI 10.1016/0003-4975(91)90981-U; CHIAVARELLI M, 1992, ARCH SURG-CHICAGO, V127, P1072; DRISCOLL DJ, 1992, CIRCULATION, V85, P469, DOI 10.1161/01.CIR.85.2.469; FIXLER DE, 1993, J AM COLL CARDIOL, V21, P1722, DOI 10.1016/0735-1097(93)90393-F; FONTAN F, 1990, CIRCULATION, V81, P1520, DOI 10.1161/01.CIR.81.5.1520; FYLER DC, 1980, PEDIATRICS, V65, P436; JOHNSTON J, 1990, WESTERN J MED, V152, P70; JONAS RA, 1992, 72ND ANN M AM ASS TH; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MURDISON KA, 1990, CIRCULATION, V82, P199; Norwood W I, 1989, Cardiol Clin, V7, P377; NORWOOD WI, 1983, NEW ENGL J MED, V308, P23, DOI 10.1056/NEJM198301063080106; NORWOOD WI, 1991, ANN THORAC SURG, V52, P688, DOI 10.1016/0003-4975(91)90978-Y; NORWOOD WI, 1992, ANN THORAC SURG, V54, P1025, DOI 10.1016/0003-4975(92)90065-C; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RUIZ CE, 1993, NEW ENGL J MED, V328, P1605, DOI 10.1056/NEJM199306033282205	20	44	44	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2944	2947		10.1001/jama.270.24.2944	http://dx.doi.org/10.1001/jama.270.24.2944			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM119	8254855				2022-12-01	WOS:A1993MM11900029
J	WOOD, RC; MACDONALD, KL; WHITE, KE; HEDBERG, CW; HANSON, M; OSTERHOLM, MT				WOOD, RC; MACDONALD, KL; WHITE, KE; HEDBERG, CW; HANSON, M; OSTERHOLM, MT			RISK-FACTORS FOR LACK OF DETECTABLE ANTIBODY FOLLOWING HEPATITIS-B VACCINATION OF MINNESOTA HEALTH-CARE WORKERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOMOSEXUAL MEN; EFFICACY; IMMUNOGENICITY; PERSISTENCE; REVACCINATION; EPIDEMIOLOGY; IMMUNIZATION; INJECTION; VIRUS; STAFF	Objective.-To assess the presence of antibody to hepatitis B surface antigen (anti-HBs) at postvaccination testing in Minnesota health care workers receiving recombinant hepatitis B vaccines, and to identify risk factors for lacking anti-HBs following hepatitis B vaccination. Design.-Retrospective cohort study. Setting.-Ten acute care hospitals in Minnesota. Participants.-A total of 595 health care workers who had received hepatitis B vaccine (Recombivax HB or Engerix-B) between June 1987 and December 1991 and who underwent postvaccination testing for anti-HBs within 6 months after receiving the third dose of vaccine. Main Outcome Measure.-Presence or absence of anti-HBs following hepatitis B vaccination. Results.-Five variables were independently associated with lacking anti-HBs by multivariate analysis: vaccine brand, smoking status, gender, age, and body mass index. Stratifying by vaccine brand demonstrated that age (P=.01), body mass index (P<.01), and smoking status (P<.01) were associated with lacking anti-HBs only for Recombivax HB recipients; and gender (P=.03) was associated with lacking anti-HBs only for Engerix-B recipients. After controlling for smoking status, age, gender, and body mass index, recipients of Recombivax HB were more likely to lack anti-HBs than recipients of Engerix-B (relative risk, 2.3; 95% confidence interval, 1.1 to 4.7; P=.02). Conclusions.-Results indicate that certain populations of health care workers are at increased risk of not responding to hepatitis B vaccination. Further studies evaluating immunogenicity of currently available recombinant hepatitis B vaccines in persons at high risk for primary vaccine failure are needed.	MINNESOTA DEPT HLTH, DIV DIS PREVENT & CONTROL, ACUTE DIS EPIDEMIOL SECT, 717 DELAWARE ST SE, MINNEAPOLIS, MN 55440 USA; MEM BLOOD CTR MINNEAPOLIS, MINNEAPOLIS, MN USA; CTR DIS CONTROL & PREVENT, EPIDEMIOL PROGRAM OFF, DIV FIELD EPIDEMIOL, EPIDEM INTELLIGENCE SERV, ATLANTA, GA USA	Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA								ANDRE F E, 1988, Southeast Asian Journal of Tropical Medicine and Public Health, V19, P501; ANDRE FE, 1989, AM J MED, V87, pS14, DOI 10.1016/0002-9343(89)90525-1; Breslow N.E., 1980, STAT METHODS CANC RE, P192; COURSAGET P, 1986, LANCET, V2, P1143; COURSAGET P, 1991, LANCET, V337, P1180, DOI 10.1016/0140-6736(91)92857-X; DENTICO P, 1991, VACCINE, V9, P438, DOI 10.1016/0264-410X(91)90132-P; GILKS WR, 1989, LANCET, V2, P1273; Hadler S C, 1990, Infect Dis Clin North Am, V4, P29; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; HADLER SC, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P766; JILG W, 1988, J HEPATOL, V6, P201, DOI 10.1016/S0168-8278(88)80032-1; JILG W, 1990, LANCET, V335, P173, DOI 10.1016/0140-6736(90)90050-F; KRUGMAN S, 1988, VACCINES, P458; LEVY BS, 1977, AM J EPIDEMIOL, V105, P127, DOI 10.1093/oxfordjournals.aje.a112364; MACDONALD KL, 1991, 31ST INT C ANT AG CH; NOMMENSEN FE, 1990, LANCET, V335, P479, DOI 10.1016/0140-6736(90)90716-I; NOMMENSEN FE, 1989, LANCET, V2, P847; OSTERHOLM M, 1979, MINN MED, V62, P683; OSTERHOLM M T, 1985, Journal of the American Medical Association, V254, P3207, DOI 10.1001/jama.254.22.3207; Prevention and control of influenza, 1990, MMWR MORB MORTAL WKL, V39, P1; PRINSEN H, 1987, POSTGRAD MED J, V63, P147; ROGAN PD, 1991, J INFECTION, V22, P5, DOI 10.1016/0163-4453(91)90786-R; SHAPIRO CN, 1990, EPIDEMIOL REV, V12, P221, DOI 10.1093/oxfordjournals.epirev.a036055; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; Snedicor G.W., 1967, STATISTICAL METHODS, P128; STEVENS CE, 1991, SEMIN PEDIATR INFECT, V2, P135; STREET AC, 1990, INFECT CONT HOSP EP, V11, P525; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; UKENA T, 1985, NEW ENGL J MED, V313, P579; WAINWRIGHT RB, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P762; WEBER DJ, 1985, JAMA-J AM MED ASSOC, V254, P3187, DOI 10.1001/jama.254.22.3187; WEST DJ, 1989, AM J INFECT CONTROL, V17, P172, DOI 10.1016/0196-6553(89)90213-7; WESTMORELAND D, 1990, EPIDEMIOL INFECT, V104, P499, DOI 10.1017/S0950268800047506; WIEDERMANN G, 1987, POSTGRAD MED J, V63, P109; ZAJAC BA, 1986, J INFECTION, V13, P39, DOI 10.1016/S0163-4453(86)92668-X; ZOULEK G, 1984, INT S VIRAL HEPATITI, P142; 1991, FED REGISTER, V56, P64004; 1991, JAMA-J AM MED ASSOC, V266, P1338; 1989, MMWR MORB MORTAL WKL, V38, pS9	39	214	227	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2935	2939		10.1001/jama.270.24.2935	http://dx.doi.org/10.1001/jama.270.24.2935			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM119	8254853				2022-12-01	WOS:A1993MM11900027
J	GORDON, C; MCGURK, G; DILLON, P; ROSEN, C; HASTIE, ND				GORDON, C; MCGURK, G; DILLON, P; ROSEN, C; HASTIE, ND			DEFECTIVE MITOSIS DUE TO A MUTATION IN THE GENE FOR A FISSION YEAST 26S PROTEASE SUBUNIT	NATURE			English	Article							CYCLIN	WE have isolated a mutant, mts2, in the fission yeast Schizosaccharomyces pombe which is defective in chromosome segregation. The predicted amino-acid sequence of the cloned mts2+ gene product is 75% identical to the S4 subunit of the human 26S ATP/ubiquitin-dependent protease1. The human S4 subunit complementary DNA expressed from an S. pombe expression plasmid can rescue an S. pombe mts2 gene disruption. Both observations demonstrate that the mts2+ gene is the S. pombe homologue of the human S4 subunit. In addition, we provide genetic evidence for a physical interaction between the S4 and the related S7 subunit in the 26S multiprotein protease. We show that polyubiquitin-conjugated proteins accumulate in the mts2 mutant at the restrictive temperature, demonstrating that the mutant has an in vivo defect in the ubiquitin-dependent proteolysis pathway. Finally, the phenotype for the mts2 mutant indicates that protein degradation by the 26S protease is essential not for entry into but for the completion of mitosis.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT GENE REGULAT, NUTLEY, NJ 07110 USA; HUMAN GENOME SCI, ROCKVILLE, MD 20850 USA	Roche Holding; GlaxoSmithKline; Human Genome Sciences Inc	GORDON, C (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.							BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; BUENO A, 1993, MOL CELL BIOL, V13, P2286, DOI 10.1128/MCB.13.4.2286; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAGAN IM, 1988, J CELL SCI, V89, P343; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; SAZER S, 1990, J CELL SCI, V97, P509; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; YANAGIDA M, 1989, J CELL SCI, P213	17	220	223	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1993	366	6453					355	357		10.1038/366355a0	http://dx.doi.org/10.1038/366355a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247131				2022-12-01	WOS:A1993MJ70500052
J	PAPA, FR; HOCHSTRASSER, M				PAPA, FR; HOCHSTRASSER, M			THE YEAST DOA4 GENE ENCODES A DEUBIQUITINATING ENZYME RELATED TO A PRODUCT OF THE HUMAN TRE-2 ONCOGENE	NATURE			English	Article							N-END RULE; UBIQUITIN-CONJUGATING ENZYME; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REGULATOR; FUNCTIONAL-ANALYSIS; PROTEIN; INVIVO; CELLS; TRANSFORMATION; DEGRADATION	Modification of specific intracellular proteins by ubiquitin targets them for degradation. We describe a yeast enzyme, Doa4, that is integral to the degradation of ubiquitinated proteins and is required in diverse physiological processes. Doa4 appears to function late in the proteolytic pathway by cleaving ubiquitin from substrate remnants still bound to protease. The human tre-2 oncogene encodes a deubiquitinating enzyme similar to Doa4, indicating a role for the ubiquitin system in mammalian growth control.			PAPA, FR (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.			Papa, Feroz/0000-0002-3684-9108; Hochstrasser, Mark/0000-0002-1131-5484				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1992, J BIOL CHEM, V267, P23364; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COOK WJ, 1992, J BIOL CHEM, V267, P16467; DAYHOFF MO, 1988, METHOD ENZYMOL, V91, P534; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; DEVIRGILIO C, 1993, EUR J BIOCHEM, V212, P315; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1991, REV CELL BIOL, V7, P25; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GUPTA K, 1993, ONCOGENE, V8, P2307; HADARI T, 1992, J BIOL CHEM, V267, P719; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; JENTSCH S, 1992, ANNU REV GENET, V26, P177; JONNALAGADDA S, 1989, J BIOL CHEM, V264, P10637; KLEIN G, 1993, FASEB J, V7, P821, DOI 10.1096/fasebj.7.10.8344481; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MILLER AD, 1984, CELL, V36, P51; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NAKAMURA T, 1992, ONCOGENE, V7, P733; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; ONNO M, 1993, DNA CELL BIOL, V12, P107, DOI 10.1089/dna.1993.12.107; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Rose I. A., 1988, UBIQUITIN, P135; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K	45	345	352	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 25	1993	366	6453					313	319		10.1038/366313a0	http://dx.doi.org/10.1038/366313a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247125				2022-12-01	WOS:A1993MJ70500039
J	EVENSON, JW; KARPLUS, M				EVENSON, JW; KARPLUS, M			EFFECTIVE COUPLING IN BIOLOGICAL ELECTRON-TRANSFER - EXPONENTIAL OR COMPLEX DISTANCE DEPENDENCE	SCIENCE			English	Article							PHOTOSYNTHETIC REACTION CENTER; RHODOPSEUDOMONAS-VIRIDIS; TUNNELING PATHWAYS; CYTOCHROME-C; MOLECULES; PROTEINS	Calculations for a simple model electron transfer system and tuna cytochrome c demonstrate a dichotomy in the distance dependence of the effective coupling. In one regime, the effective coupling varies exponentially with distance and depends primarily on the average properties of the bridging material; in the other regime, the effective coupling has a complex distance dependence and is more sensitive to the details of the bridging material. Experiments and theory indicate that both regimes may occur in biological systems, providing a perspective on a recent controversy over the nature of the distance dependence.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT PHYS,CAMBRIDGE,MA 02138	Harvard University; Harvard University								[Anonymous], 1971, INTRO PROBABILITY TH; BAUM RM, 1993, CHEM ENG NEWS, P20; BERATAN DN, 1992, J PHYS CHEM-US, V96, P2852, DOI 10.1021/j100186a014; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BRUN AM, 1992, J PHYS CHEM-US, V96, P710, DOI 10.1021/j100181a036; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DEVAULT D, 1984, QUANTUM MECHANICAL T; Economou E. N., 1990, GREENS FUNCTIONS QUA; EVENSON JW, 1992, J CHEM PHYS, V96, P5272, DOI 10.1063/1.462712; EVENSON JW, UNPUB; HUSH NS, 1961, T FARADAY SOC, V57, P557, DOI 10.1039/tf9615700557; HUSH NS, 1958, J CHEM PHYS, V28, P964; Marcus R.A., 1960, DISCUSS FARADAY SOC, V29, P21, DOI [10.1039/DF9602900021, DOI 10.1039/DF9602900021]; MARCUS RA, 1956, J CHEM PHYS, V24, P966, DOI 10.1063/1.1742723; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARCUS RA, 1965, J CHEM PHYS, V43, P679, DOI 10.1063/1.1696792; MCCONNELL H, 1961, J CHEM PHYS, V35, P508, DOI 10.1063/1.1731961; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NEWTON MD, 1991, CHEM REV, V91, P767, DOI 10.1021/cr00005a007; ONUCHIC JN, 1991, J CHEM PHYS, V95, P1131, DOI 10.1063/1.461142; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; SIDDARTH P, 1993, J PHYS CHEM-US, V97, P2400, DOI 10.1021/j100112a047; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; THOMPSON MA, 1991, J AM CHEM SOC, V113, P8210, DOI 10.1021/ja00022a003; TREUTLEIN H, 1992, P NATL ACAD SCI USA, V89, P75, DOI 10.1073/pnas.89.1.75; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007	26	109	110	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1247	1249		10.1126/science.8235654	http://dx.doi.org/10.1126/science.8235654			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235654				2022-12-01	WOS:A1993MH32400033
J	JOKLIK, WK; MOSS, B; FIELDS, BN; BISHOP, DHL; SANDAKHCHIEV, LS				JOKLIK, WK; MOSS, B; FIELDS, BN; BISHOP, DHL; SANDAKHCHIEV, LS			WHY THE SMALLPOX VIRUS STOCKS SHOULD NOT BE DESTROYED	SCIENCE			English	Editorial Material							VACCINIA VIRUS; MYXOMA VIRUS; COWPOX VIRUS; PROTEIN; RECEPTOR; ENCODES; PATHOGENESIS; INHIBITION		NERC, INST VIROL & ENVIRONM MICROBIOL, OXFORD OX1 3SR, ENGLAND; NPO VECTOR, INST MOLEC BIOL, KOLTSOV 632159, RUSSIA; NIAID, VIRAL DIS LAB, BETHESDA, MD 20892 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); State Research Center of Virology & Biotechnology VECTOR; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard Medical School	JOKLIK, WK (corresponding author), DUKE UNIV, DURHAM, NC 27710 USA.		Sandakhchiev, Lev S/B-7035-2012	Moss, Bernard/0000-0002-2154-8564				ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; [Anonymous], 1980, REPORT INVESTIGATION; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; Colwell Report, 1974, REPORT COMMITTEE INQ; Fenner Frank, 1993, P176; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; MAHY BWJ, 1991, ASM NEWS, V57, P577; PALUMBO GJ, 1989, VIROLOGY, V172, P262, DOI 10.1016/0042-6822(89)90128-1; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SANDAKHCHIEV LS, UNPUB; SENKEVICH TG, IN PRESS VIROLOGY; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; TURNER PC, 1990, CURR TOP MICROBIOL, V163, P125; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; ZEZEK Z, 1988, MONOGRAPHS VIROLOGY, V17; 1980, HIST INT PUBLIC HLTH, V4; 1986, 4TH M COMM ORTH INF	22	25	25	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1993	262	5137					1225	1226		10.1126/science.8235652	http://dx.doi.org/10.1126/science.8235652			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235652				2022-12-01	WOS:A1993MH32400027
J	COLE, DG; CHINN, SW; WEDAMAN, KP; HALL, K; VUONG, T; SCHOLEY, JM				COLE, DG; CHINN, SW; WEDAMAN, KP; HALL, K; VUONG, T; SCHOLEY, JM			NOVEL HETEROTRIMERIC KINESIN-RELATED PROTEIN PURIFIED FROM SEA-URCHIN EGGS	NATURE			English	Article							DRIVEN MICROTUBULE MOTILITY; HEAVY-CHAIN; PEPTIDE ANTIBODIES; MITOTIC APPARATUS; LIGHT-CHAINS; IDENTIFICATION; LOCALIZATION; SEQUENCE; ATPASE	KINESIN heavy chain and kinesin-related polypeptides (KRPs) comprise a family of motor proteins with diverse intracellular transport functions1-7. Using pan-kinesin peptide antibodies that react with these proteins8,9, we have previously purified from sea urchin eggs a trimeric microtubule-binding and bundling protein, KRP(85/95) (ref. 8) comprising subunits of M(r) 115,000 (115K), 95K and 85K. We report here that kinesin-related genes encode the 85K and 95K subunits, and that the protein can be immunoprecipitated from cytosol as a trimeric complex using an 85K monoclonal antibody. We also find that purified KRP(85/95) directs movements towards the 'plus' ends of microtubules. To our knowledge, this protein is the first kinesin-related motor to be purified from its natural host cell in a native multimeric state.	UNIV CALIF DAVIS,DIV BIOL SCI,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis								AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; COHN SA, 1989, J BIOL CHEM, V264, P4290; COLE DG, 1992, J CELL SCI, V101, P291; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; HYMAN AA, IN PRESS METH CELL B, V39; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; JOHNSON CS, 1990, CELL MOTIL CYTOSKEL, V16, P204, DOI 10.1002/cm.970160307; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; PATTERSON SD, 1992, ANAL BIOCHEM, V202, P193, DOI 10.1016/0003-2697(92)90227-X; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; SAWIN KE, 1992, J CELL SCI, V101, P303; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; STEWART RJ, 1991, P NATL ACAD SCI USA, V88, P8470, DOI 10.1073/pnas.88.19.8470; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1992, TRENDS BIOCHEM SCI, V17, P300, DOI 10.1016/0968-0004(92)90440-K; WEDAMAN KP, 1993, J MOL BIOL, V231, P155, DOI 10.1006/jmbi.1993.1267; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	22	220	228	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					268	270		10.1038/366268a0	http://dx.doi.org/10.1038/366268a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232586				2022-12-01	WOS:A1993MH32500064
J	OKANO, Y; STEEN, VD; MEDSGER, TA				OKANO, Y; STEEN, VD; MEDSGER, TA			AUTOANTIBODY REACTIVE WITH RNA POLYMERASE-III IN SYSTEMIC-SCLEROSIS	ANNALS OF INTERNAL MEDICINE			English	Article						RNA POLYMERASE-III; SCLERODERMA, SYSTEMIC; AUTOANTIBODIES; SKIN DISEASE; BIOLOGICAL MARKERS	ANTICENTROMERE ANTIBODIES; CLINICAL CORRELATIONS; SERUM AUTOANTIBODIES; TRANSCRIPTION; SCLERODERMA; ASSOCIATIONS; STIMULATION; PROTEINS; MARKERS	Objective: To determine the clinical significance of anti-RNA polymerase III antibody in systemic sclerosis (SSc). Design: A point prevalence study of autoantibody to RNA polymerase III and longitudinal examination of its clinical significance in patients with SSc and in controls. Setting: University medical center rheumatology practice. Patients: Two hundred fifty-two consecutive new patients with SSc and 170 controls (150 patients with other connective tissue diseases and 20 normal volunteers). Measurements: The presence of anti-RNA polymerase III antibody was determined by immunoprecipitation, immunoblotting, and immunodepletion studies. Main Results: Serum specimens from 57 of the 252 patients with SSc (23%; 95% CI, 18% to 28%) reacted with RNA polymerase III, compared with none of the specimens from 170 controls (0%; 95% CI, 0% to 2%). In 40 of these 57 specimens, immunoprecipitation studies also showed the presence of RNA polymerase I or II, or both. Anti-RNA polymerase III antibody was detected in sera from 50 of the 111 patients (45%) who had SSc with diffuse cutaneous involvement (dcSSc), 7 of 114 patients (6%) who had SSc with limited cutaneous involvement, and none of 27 patients with an SSc overlap syndrome (P < 0.001). Among patients with dcSSc, anti-RNA polymerase III antibody was more common than antitopoisomerase I antibody (45% compared with 27%; P = 0.008). Patients with anti-RNA polymerase III antibody had a statistically significant higher mean maximum skin thickness score but statistically significant lower frequencies of telangiectasias, inflammatory myopathy, restrictive lung disease, and serious cardiac abnormalities than did patients with antitopoisomerase I antibody. Conclusion: Anti-RNA polymerase III antibody is a new marker autoantibody for many patients who have SSc with diffuse or extensive cutaneous involvement.	UNIV PITTSBURGH, SCH MED,DEPT MED,DIV RHEUMATOL & CLIN IMMUNOL, 985 SCAIFE HALL, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R18AR021393] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01RR00056] Funding Source: Medline; NIAMS NIH HHS [AR21393] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; CATOGGIO LJ, 1983, ANN RHEUM DIS, V42, P23, DOI 10.1136/ard.42.1.23; FRITZLER MJ, 1980, AM J MED, V69, P520, DOI 10.1016/0002-9343(80)90462-3; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HIRAKATA M, 1993, J CLIN INVEST, V91, P2665, DOI 10.1172/JCI116505; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; KUWANA M, 1993, J CLIN INVEST, V91, P1399, DOI 10.1172/JCI116343; MCCARTY GA, 1983, ARTHRITIS RHEUM, V26, P1, DOI 10.1002/art.1780260101; Medsger Jr TA, 1989, ARTHRITIS ALLIED CON, V11th, P1118; MEDSGER TA, 1971, ANN INTERN MED, V74, P714, DOI 10.7326/0003-4819-74-5-714; MEDSGER TA, 1985, CURRENT TOPICS RHEUM, P16; OKANO Y, 1992, ARTHRITIS RHEUM, V35, pS38; OKANO Y, 1992, ARTHRITIS RHEUM-US, V35, P95, DOI 10.1002/art.1780350114; OKANO Y, 1990, ARTHRITIS RHEUM, V33, P1822, DOI 10.1002/art.1780331210; OKANO Y, 1991, J IMMUNOL, V146, P535; REIMER G, 1988, ARTHRITIS RHEUM, V31, P525, DOI 10.1002/art.1780310409; REIMER G, 1986, J IMMUNOL, V137, P3802; REIMER G, 1987, J CLIN INVEST, V79, P65, DOI 10.1172/JCI112809; RODNAN G P, 1979, Clinics in Rheumatic Diseases, V5, P5; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; STEEN VD, 1988, ARTHRITIS RHEUM, V31, P196, DOI 10.1002/art.1780310207; STEEN VD, 1984, ARTHRITIS RHEUM, V27, P125, DOI 10.1002/art.1780270202; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINER ES, 1988, ARTHRITIS RHEUM, V31, P378, DOI 10.1002/art.1780310309; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x	27	183	185	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1993	119	10					1005	1013		10.7326/0003-4819-119-10-199311150-00007	http://dx.doi.org/10.7326/0003-4819-119-10-199311150-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG672	8214977				2022-12-01	WOS:A1993MG67200007
J	MUELLER, MW; ALLMAIER, M; ESKES, R; SCHWEYEN, RJ				MUELLER, MW; ALLMAIER, M; ESKES, R; SCHWEYEN, RJ			TRANSPOSITION OF GROUP-II INTRON AL1 IN YEAST AND INVASION OF MITOCHONDRIAL GENES AT NEW LOCATIONS	NATURE			English	Article							NUCLEAR GENES; RNA; TETRAHYMENA; PODOSPORA; DELETION; MATURASE; MOBILITY; INVITRO; ORIGIN; DNA	INTRON mobility at the RNA level1-8 by splicing reversal at allelic (homing) and non-allelic locations (transposition) has been reported in vitro9-12. In the living cell, however, only intron homing by unidirectional gene conversion has been described5,6,13,14. Supposing that intron insertions at non-allelic sites might occur in vivo, we speculated that group II splice-site-associated macro-deletions15-18 in fungal mitochondrial DNA might result from group II intron transposition to new locations followed by recombination. We used polymerase chain reaction techniques to detect this critical, infrequent intermediate in mtDNA populations. Here we report on group II intron aI1 transposition to non-allelic, splicing-compatible locations within the cox1 gene of yeast mtDNA. The identified integration sites are preceded by motifs similar to the upstream exon A1. Sequences flanking intron aI1 are not co-converted to the insertion sites and cis- and trans-acting mutations within aI1 reduce intron mobility below detection levels. These findings suggest the involvement of an RNA intermediate in group II intron transposition.			MUELLER, MW (corresponding author), UNIV VIENNA,INST MICROBIOL & GENET,VIENNA BIOCTR,A-1030 VIENNA,AUSTRIA.							AHNE A, 1988, J MOL BIOL, V202, P725, DOI 10.1016/0022-2836(88)90553-0; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BELCOUR L, 1991, P NATL ACAD SCI USA, V88, P3579, DOI 10.1073/pnas.88.9.3579; CARIGNANI G, 1983, CELL, V35, P733, DOI 10.1016/0092-8674(83)90106-X; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; COPERTINO DW, 1991, EMBO J, V10, P433, DOI 10.1002/j.1460-2075.1991.tb07965.x; DEFONTAINE A, 1991, NUCLEIC ACIDS RES, V19, P185, DOI 10.1093/nar/19.1.185; DOOLITTLE WF, 1985, TRENDS GENET, V1, P64; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; Gargouri A., 1983, MITOCHONDRIA 1983, P259; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LEVRAJUILLET E, 1989, MOL GEN GENET, V217, P168, DOI 10.1007/BF00330957; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MUELLER M W, 1991, Journal of Molecular Biology, V222, P145; OSIEWACZ HD, 1984, CURR GENET, V8, P299, DOI 10.1007/BF00419728; PERLMAN PS, 1989, SCIENCE, V246, P1106, DOI 10.1126/science.2479980; QUIRK SM, 1989, CELL, V56, P455, DOI 10.1016/0092-8674(89)90248-1; ROGERS JH, 1989, TRENDS GENET, V5, P213, DOI 10.1016/0168-9525(89)90084-X; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; WEILLER GF, 1986, THESIS U MUNCHEN; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9	30	84	86	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					174	176		10.1038/366174a0	http://dx.doi.org/10.1038/366174a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232557				2022-12-01	WOS:A1993MG21600062
J	SCHAFMEISTER, CE; MIERCKE, LJW; STROUD, RM				SCHAFMEISTER, CE; MIERCKE, LJW; STROUD, RM			STRUCTURE AT 2.5 ANGSTROM OF A DESIGNED PEPTIDE THAT MAINTAINS SOLUBILITY OF MEMBRANE-PROTEINS	SCIENCE			English	Article							HELIX DIPOLE MODEL; ALPHA-HELICES; DENOVO DESIGN; RESOLUTION; STABILIZATION; PURIFICATION; REFINEMENT; PACKING	A 24-amino acid peptide designed to solubilize integral membrane proteins has been synthesized. The design was for an amphipathic alpha helix with a ''flat'' hydrophobic surface that would interact with a transmembrane protein as a detergent. When mixed with peptide, 85 percent of bacteriorhodopsin and 60 percent of rhodopsin remained in solution over a period of 2 days in their native forms. The crystal structure of peptide alone showed it to form an antiparallel four-helix bundle in which monomers interact, flat surface to flat surface, as predicted.			SCHAFMEISTER, CE (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NIGMS NIH HHS [GM24485] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024485, R37GM024485] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASARI G, 1992, J MOL BIOL, V224, P725, DOI 10.1016/0022-2836(92)90556-Y; CHAMBERS JL, 1977, ACTA CRYSTALLOGR B, V33, P1824, DOI 10.1107/S0567740877007146; CHOTHIA C, 1977, P NATL ACAD SCI USA, V74, P4130, DOI 10.1073/pnas.74.10.4130; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DEGRIP WJ, 1979, CHEM PHYS LIPIDS, V23, P321, DOI 10.1016/0009-3084(79)90010-0; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; FAIRMAN R, 1989, PROTEINS, V5, P1, DOI 10.1002/prot.340050102; FINZEL BC, 1985, J MOL BIOL, V186, P627, DOI 10.1016/0022-2836(85)90135-4; GARAVITO RM, 1988, DETERGENT PHENOMENA, P89; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HERRMANN KW, 1962, J PHYS CHEM-US, V66, P295, DOI 10.1021/j100808a025; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOLMES MA, 1991, J MOL BIOL, V220, P723, DOI 10.1016/0022-2836(91)90113-K; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; KUHLBRANDT W, 1988, Q REV BIOPHYS, V21, P429, DOI 10.1017/S0033583500004625; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MICHEL H, 1988, DETERGENT PHENOMENA, P73; MILDER SJ, 1991, BIOCHEMISTRY-US, V30, P1751, DOI 10.1021/bi00221a004; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PERUTZ MF, 1988, PROTEINS, V4, P294, DOI 10.1002/prot.340040408; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; SACK J, 1988, J MOL GRAPHICS, V6, P225; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; STOECKENIUS W, 1982, ANNU REV BIOCHEM, V51, P587, DOI 10.1146/annurev.bi.51.070182.003103; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; ZULAUF M, 1988, DETERGENT PHENOMENA, P53	35	163	175	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1993	262	5134					734	738		10.1126/science.8235592	http://dx.doi.org/10.1126/science.8235592			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235592				2022-12-01	WOS:A1993MD95200040
J	HAMOSH, A; COREY, M				HAMOSH, A; COREY, M			CORRELATION BETWEEN GENOTYPE AND PHENOTYPE IN PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONDUCTANCE REGULATOR CFTR; NONSENSE MUTATION; DELTA-F508 MUTATION; PANCREATIC FUNCTION; EPITHELIAL-CELLS; GENETIC-ANALYSIS; COMMON MUTATION; CLINICAL STATUS; F508 DELETION; MESSENGER-RNA	Background. Cystic fibrosis is the most common lethal autosomal recessive disorder among whites. Seventy-two percent of patients with this disease are homozygotes or compound heterozygotes for eight mutations of the cystic fibrosis transmembrane conductance regulator gene on chromosome 7: DELTAF508, G542X, R553X, W1282X, N1303K, 621+1G-->T, 1717-1G-->A, and R117H. We studied the relation between genotype and phenotype in patients from 14 countries. Methods. Each of 399 patients who were compound heterozygotes for DELTAF508 and one other mutation was matched with the DELTAF508 homozygote of the same sex who was the closest in age from the same center. A paired analysis was performed of the following outcome variables: age at diagnosis, sweat chloride concentration, growth percentiles, pulmonary-function values, chest-film score, pseudomonas colonization, nasal polyps, pancreatic sufficiency, pancreatitis, diabetes mellitus, meconium ileus, distal intestinal obstruction syndrome, rectal prolapse, cirrhosis, and gallbladder disease. Results. The compound heterozygotes having the genotype R117H/DELTAF508 clearly differed from the age- and sex-matched DELTAF508 homozygotes: they more often had pancreatic sufficiency (87 percent vs. 4 percent, P<0.001), were older when the diagnosis was first made (mean [+/-SD] age, 10.2+/-10.5 vs. 2.5+/-4.3 years; P = 0.002), and had lower sweat chloride concentrations (80+/-18 vs. 108+/-14 mmol per liter, P<0.001). There were no statistically significant differences between DELTAF508 homozygotes and other compound heterozygotes with regard to any variable tested. Conclusions. Prenatal and prognostic counseling for patients with the R117H/DELTAF508 genotype should include the likelihood that they will have long-term pancreatic sufficiency. Patients with the other genotypes should expect the early onset of pancreatic insufficiency. For none of the genotypes studied can predictions be made about the occurrence of common complications or the severity or course of pulmonary disease.			HAMOSH, A (corresponding author), JOHNS HOPKINS UNIV HOSP, CMSC 1004, 600 N WOLFE ST, BALTIMORE, MD 21287 USA.		Dörk, Thilo/J-8620-2012; Ferrari, Maurizio/D-9107-2013; Kadasi, Ludevit/A-4677-2013	Dörk, Thilo/0000-0002-9458-0282; 	NIDDK NIH HHS [DK02151, DK41980, DK44003] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002151, R37DK044003, P50DK041980, R01DK044003] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMOS JA, 1992, PEDIATR PULM, P142; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; BORGO G, 1990, J MED GENET, V27, P665, DOI 10.1136/jmg.27.11.665; BRASFIELD D, 1979, PEDIATRICS, V63, P24; CAMPBELL PW, 1991, J PEDIATR-US, V118, P239, DOI 10.1016/S0022-3476(05)80490-1; CAMPBELL PW, 1992, J PEDIATR-US, V120, P261, DOI 10.1016/S0022-3476(05)80438-X; CARROLL TP, IN PRESS CELL PHYSL; CHRISPIN AR, 1974, PEDIATR RADIOL, V2, P101, DOI 10.1007/BF01314939; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; DORK T, 1991, HUM GENET, V87, P441; DUMUR V, 1990, LANCET, V336, P512, DOI 10.1016/0140-6736(90)92066-Q; GASKIN K, 1982, J PEDIATR-US, V100, P857, DOI 10.1016/S0022-3476(82)80501-5; GASPARINI P, 1992, J MED GENET, V29, P558, DOI 10.1136/jmg.29.8.558; HAMOSH A, 1992, AM J HUM GENET, V51, P245; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HAMOSH A, 1992, HUM MOL GENET, V1, P542, DOI 10.1093/hmg/1.7.542; HAMOSH A, 1993, CYSTIC FIBROSIS CURR, V1, P69; JOHANSEN HK, 1991, LANCET, V337, P631, DOI 10.1016/0140-6736(91)92449-C; JONES CT, 1992, HUM MOL GENET, V1, P11, DOI 10.1093/hmg/1.1.11; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; LIECHTIGALLATI S, 1992, PEDIATR RES, V32, P175, DOI 10.1203/00006450-199208000-00010; OSBORNE L, 1992, HUM GENET, V89, P653, DOI 10.1007/BF00221957; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; SANTIS G, 1992, PEDIATR PULMONOL S8, V14, P239; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SHWACHMAN H, 1958, AMA J DIS CHILD, V96, P6, DOI 10.1001/archpedi.1958.02060060008002; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; 1990, EGRET EPIDEMIOLOGICA; 1988, SAS STAT USERS GUIDE	38	407	412	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1993	329	18					1308	1313						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD557	8166795				2022-12-01	WOS:A1993MD55700004
J	PADOVAN, E; CASORATI, G; DELLABONA, P; MEYER, S; BROCKHAUS, M; LANZAVECCHIA, A				PADOVAN, E; CASORATI, G; DELLABONA, P; MEYER, S; BROCKHAUS, M; LANZAVECCHIA, A			EXPRESSION OF 2 T-CELL RECEPTOR-ALPHA CHAINS - DUAL RECEPTOR T-CELLS	SCIENCE			English	Article							ALLELIC EXCLUSION; GENES; RECOGNITION; CLONES; RAG-1	Although many T cells carry two in-frame V(alpha) rearrangements, the products of both V(alpha) rearrangements have never been shown simultaneously on the surface of normal cells. With the use of monoclonal antibodies to V(alpha)2, V(alpha)12, and V(alpha)24, up to one-third of mature T cells expressed two V(alpha) chains as part of two functional and independent T cell receptors (TCRs). Thus, the ''one cell, one receptor'' rule does not apply to a large subset of alphabeta T cells. Cells that belong to this dual TCR subset may be specific for a broader range of antigens than cells with a single receptor, which may be important for autoimmunity and alloreactivity.	BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND; DIBIT HS RAFFAELE,I-20132 MILAN,ITALY; F HOFFMANN LA ROCHE & CO LTD,PHARMA RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND	Roche Holding			Casorati, Giulia/J-7141-2018; Dellabona, Paolo/G-5416-2012	Casorati, Giulia/0000-0002-5102-4112; Dellabona, Paolo/0000-0002-1414-633X; Padovan, Elisabetta/0000-0002-8212-508X				ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BOITEL B, 1992, J EXP MED, V175, P765, DOI 10.1084/jem.175.3.765; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BRANDLE D, 1992, P NATL ACAD SCI USA, V89, P9529, DOI 10.1073/pnas.89.20.9529; BURNET FM, 1959, CLONAL SELECTION THE; CASANOVA JL, 1991, J EXP MED, V174, P1371, DOI 10.1084/jem.174.6.1371; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; COUEZ D, 1991, INT IMMUNOL, V3, P719, DOI 10.1093/intimm/3.7.719; Furutani M, 1989, Int Immunol, V1, P281, DOI 10.1093/intimm/1.3.281; KUIDA K, 1991, INT IMMUNOL, V3, P75, DOI 10.1093/intimm/3.1.75; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4	14	446	449	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					422	424		10.1126/science.8211163	http://dx.doi.org/10.1126/science.8211163			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	8211163				2022-12-01	WOS:A1993MB85900058
J	SCHUNKERT, H; HENSE, HW; HOLMER, SR; STENDER, M; PERZ, S; KEIL, U; LORELL, BH; RIEGGER, GAJ				SCHUNKERT, H; HENSE, HW; HOLMER, SR; STENDER, M; PERZ, S; KEIL, U; LORELL, BH; RIEGGER, GAJ			ASSOCIATION BETWEEN A DELETION POLYMORPHISM OF THE ANGIOTENSIN-CONVERTING-ENZYME GENE AND LEFT-VENTRICULAR HYPERTROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC-HYPERTROPHY; BLOOD-PRESSURE; MASS; RAT; HYPERTENSION; RISK; CARDIOMYOPATHY; TWINS; SIZE	Background. Epidemiologic studies have shown that left ventricular hypertrophy is often found in the absence of an elevated cardiac workload. To investigate whether such hypertrophy is determined in part by genetic factors, we studied the association between this condition, as assessed by electrocardiographic criteria, and a deletion (D)-insertion (I) polymorphism of the angiotensin-converting-enzyme (ACE) gene. Methods. A population-based random sample of 711 women and 717 men 45 to 59 years of age was studied cross-sectionally in Augsburg, Germany. Electrocardiographic indexes, including the Sokolow-Lyon index, Minnesota Code 3.1, and the Rautaharju equations, were used to detect left ventricular hypertrophy. The status of the ACE gene with respect to the deletion-insertion allele was determined by the polymerase chain reaction in all subjects with left ventricular hypertrophy and an identical number of control subjects without the condition who were matched for age, sex, and blood-pressure status. Results. We identified 141 women and 149 men with evidence of left ventricular hypertrophy. Among these subjects, an excess were homozygous for the D allele of the ACE gene (odds ratio, 1.76; 95 percent confidence interval, 1.22 to 2.53; P = 0.003). The association of the DD genotype with left ventricular hypertrophy was stronger in men (odds ratio, 2.63; 95 percent confidence interval, 1.50 to 4.64; P<0.001) than in women and was most prominent when blood-pressure measurements were normal (odds ratio, 4.05; 95 percent confidence interval, 1.76 to 9.28; P = 0.001). This association was evident for each of the scores recorded in the electrocardiographic testing for left ventricular hypertrophy. Conclusions. The findings suggest that left ventricular hypertrophy is partially determined by genetic disposition. They identify the DD genotype of ACE as a potential genetic marker associated with an elevated risk of left ventricular hypertrophy in middle-aged men.	UNIV REGENSBURG, MED KLIN 2, REGENSBURG, GERMANY; GESELL STRAHLEN & UMWELTFORSCH MBH, FORSCHUNGSZENTRUM, INST EPIDEMIOL, MUNICH, GERMANY; GESELL STRAHLEN & UMWELTFORSCH MBH, FORSCHUNGSZENTRUM, MEDIS INST, MUNICH, GERMANY; UNIV MUNSTER, INST EPIDEMIOL & SOZIALMED, MUNSTER, GERMANY; BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, HARVARD THORNDIKE LAB, DEPT INTERNAL MED, DIV CARDIOVASC, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Regensburg; University of Munster; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School								ADAMS TD, 1985, CIRCULATION, V71, P39, DOI 10.1161/01.CIR.71.1.39; [Anonymous], 1982, EPIDEMIOLOGIC RES; BOTHIG S, 1989, INT J EPIDEMIOL, V18, pS29; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; DAHLOF B, 1992, CLIN EXP HYPERTENS A, V14, P173, DOI 10.3109/10641969209036180; DRAYER JIM, 1983, ARCH INTERN MED, V143, P90, DOI 10.1001/archinte.143.1.90; FARHY RD, 1992, BIOCHEM BIOPH RES CO, V182, P283, DOI 10.1016/S0006-291X(05)80142-1; GANAU A, 1990, CIRCULATION, V81, P25, DOI 10.1161/01.CIR.81.1.25; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; HARRAP SB, 1993, HYPERTENSION, V21, P455, DOI 10.1161/01.HYP.21.4.455; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KATZ AM, 1990, J MOL CELL CARDIOL, V22, P739, DOI 10.1016/0022-2828(90)90086-H; KEIL U, 1988, ACTA MED SCAND, P119; KHAIRALLAH PA, 1983, PERSPECTIVE CARDIOVA, V8, P337; LAUER MS, 1991, JAMA-J AM MED ASSOC, V266, P231, DOI 10.1001/jama.266.2.231; LEADON SA, 1982, ANAL BIOCHEM, V120, P282, DOI 10.1016/0003-2697(82)90349-9; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; LINDPAINTNER K, 1991, CIRC RES, V68, P905, DOI 10.1161/01.RES.68.4.905; LINDPAINTNER K, 1985, CIRC RES, V57, P610, DOI 10.1161/01.RES.57.4.610; MARIAN AJ, 1993, LANCET, V342, P1085, DOI 10.1016/0140-6736(93)92064-Z; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; Prineas R.J., 1982, MINNESOTA CODE MANUA; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; RAUTAHARJU PM, 1988, AM J CARDIOL, V62, P59, DOI 10.1016/0002-9149(88)91365-3; RAYNOLDS MV, 1993, LANCET, V342, P1073, DOI 10.1016/0140-6736(93)92061-W; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; SCHUNKERT H, 1993, CIRCULATION, V87, P1328, DOI 10.1161/01.CIR.87.4.1328; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STUDER R, 1992, CIRCULATION, V86, P119; Sullivan JM, 1993, J AM COLL CARDIOL, V22, P508, DOI 10.1016/0735-1097(93)90057-8; VERHAAREN HA, 1991, AM J CARDIOL, V68, P661, DOI 10.1016/0002-9149(91)90361-N	40	680	692	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 9	1994	330	23					1634	1638		10.1056/NEJM199406093302302	http://dx.doi.org/10.1056/NEJM199406093302302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP220	8177269				2022-12-01	WOS:A1994NP22000002
J	JARMAN, AP; GRELL, EH; ACKERMAN, L; JAN, LY; JAN, YN				JARMAN, AP; GRELL, EH; ACKERMAN, L; JAN, LY; JAN, YN			ATONAL IS THE PRONEURAL GENE FOR DROSOPHILA PHOTORECEPTORS	NATURE			English	Article							NEURONAL DIFFERENTIATION; NEURAL DEVELOPMENT; NERVOUS-SYSTEM; VISUAL-SYSTEM; EYE; RETINA; MELANOGASTER; NEUROGENESIS; EXPRESSION; HEDGEHOG	THE Drosophila peripheral nervous system comprises four major types of sensory element: external sense organs (such as mechanosensory bristles), chordotonal organs (internal stretch receptors), multiple dendritic neurons, and photoreceptors. During development, the selection of neural precursors for external sense organs requires the proneural genes of the achaete-scute complex, which encode basic-helix-loop-helix transcription factors(1-3). These genes do not, however, control precursor selection for chordotonal organs or photoreceptors(4,5), raising the question of whether other proneural genes exist(6) or a different mechanism of neurogenesis operates. Here we show that atonal (ato), originally isolated as a proneural gene for chordotonal organs(7), is also the proneural gene for photoreceptors. Pattern formation in the Drosophila eye involves a succession of cell fate specifications. Of the eight photoreceptors within each ommatidium of the compound eye, the photoreceptor R8 is the first to appear in the eye imaginal disc, right behind the morphogenetic furrow(8-10). The appearance of other photoreceptors (R1-7) follows in a defined sequence that is thought to arise by induction from R8 (refs 8, 9, 11, 12). We find that photoreceptor formation requires the function of atonal at the morphogenetic furrow and that atonal is specifically required for R8 selection. Formation of other photoreceptors does not directly require atonal function, but does depend on R8 selection by atonal. Thus, photoreceptors are selected by two mechanisms: R8 by a proneural mechanism, and R1-7 by local recruitment.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	JARMAN, AP (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Jan, Yuh Nung/0000-0003-1367-6299; Jarman, Andrew/0000-0003-4036-5701; Jan, Lily/0000-0003-3938-8498				BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BASLER K, 1991, BIOESSAYS, V13, P621, DOI 10.1002/bies.950131202; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; FISCHBACH KF, 1984, DEV BIOL, V104, P219, DOI 10.1016/0012-1606(84)90050-2; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1993, DEV BIOL, V160, P51, DOI 10.1006/dbio.1993.1285; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JIMENEZ F, 1987, J NEUROGENET, V4, P179, DOI 10.3109/01677068709102340; KARPILOW J, 1989, GENE DEV, V3, P1834, DOI 10.1101/gad.3.12a.1834; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MCIVER S, 1985, COMPREHENSIVE INSECT, V6; MEYEROWITZ EM, 1978, DEV BIOL, V62, P112, DOI 10.1016/0012-1606(78)90096-9; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	25	414	418	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					398	400		10.1038/369398a0	http://dx.doi.org/10.1038/369398a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	8196767				2022-12-01	WOS:A1994NP17400056
J	PAGES, F; RAGUENEAU, M; ROTTAPEL, R; TRUNEH, A; NUNES, J; IMBERT, J; OLIVE, D				PAGES, F; RAGUENEAU, M; ROTTAPEL, R; TRUNEH, A; NUNES, J; IMBERT, J; OLIVE, D			BINDING OF PHOSPHATIDYLINOSITOL-3-OH KINASE TO CD28 IS REQUIRED FOR T-CELL SIGNALING	NATURE			English	Article							MOLECULAR-CLONING; ACTIVATION; EXPRESSION; 3-KINASE; IDENTIFICATION; ACCUMULATION; PROTEINS; SUBUNIT; HOMOLOG; SYSTEM	THE engagement of CD28 with its ligand B7.1/CD80 results in potent costimulation of T-cell activation initiated through the CD3/T-cell receptor complex(1,2). The biochemical basis of CD28 costimulatory function is poorly understood. The signalling pathways used by CD28 are unlike those used by the CD3/T-cell receptor in that they are resistant to cyclosporin A and independent of changes in cyclic AMP concentrations(3). These differences suggest that each pathway provides unique biochemical information which is required for T-cell activation. We report here that CD28 becomes tyrosine-phosphorylated following interaction with B7.1/CD80, which induces formation of a complex with phosphatidylinositol-3-OH kinase, mediated by the SH2 domains of the p85 subunit of the kinase. Phosphatidylinositol-3-OH kinase is a heterodimer of this 85K regulatory subunit and a 110K catalytic subunit, and is a common substrate for most receptor tyrosine kinases and some cytokine receptors(4,5), binding through its SH2 domain to phosphotyrosine in the motif Tyr-X-X-Met in the CD28 sequence, which is highly conserved between human, mouse and rat(6-8) and lies in the intracellular domain. We show that CD28 mutants that have their kinase-binding site deleted or the tyrosine at position 173 substituted by phenylalanine do not associate with the kinase after CD28 stimulation and cannot stimulate production of interleukin-2. Our results suggest that phosphatidylinositol-3-OH kinase is critical for signalling by CD28.	INSERM,U119,F-13009 MARSEILLE,FRANCE; SMITHKLINE BEECHAM PHARMACEUT,KING OF PRUSSIA,PA 19406	Institut National de la Sante et de la Recherche Medicale (Inserm); GlaxoSmithKline			NUNES, Jacques A/F-4952-2013; Imbert, Jean/G-3248-2013; Imbert, Jean/AAG-1165-2020; Truneh, Alem/ABB-7891-2020	NUNES, Jacques A/0000-0003-4865-0400; Imbert, Jean/0000-0002-0478-9593; Imbert, Jean/0000-0002-0478-9593; Rottapel, Robert/0000-0002-6024-5558				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; CLARK GJ, 1992, IMMUNOGENETICS, V35, P54; COUEZ D, 1994, MOL IMMUNOL, V31, P47, DOI 10.1016/0161-5890(94)90137-6; GROSS JA, 1990, J IMMUNOL, V144, P3201; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; JUNE CH, 1987, P NATL ACAD SCI USA, V84, P1384; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; NUNES J, 1993, INT IMMUNOL, V5, P311, DOI 10.1093/intimm/5.3.311; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; THOMPSON PA, 1992, ONCOGENE, V7, P719; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WRD SG, 1993, EUR J IMMUNOL, V23, P2572	17	350	376	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					327	329		10.1038/369327a0	http://dx.doi.org/10.1038/369327a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	8183372				2022-12-01	WOS:A1994NN10900052
J	TURRIGIANO, G; ABBOTT, LF; MARDER, E				TURRIGIANO, G; ABBOTT, LF; MARDER, E			ACTIVITY-DEPENDENT CHANGES IN THE INTRINSIC-PROPERTIES OF CULTURED NEURONS	SCIENCE			English	Article							LONG-TERM POTENTIATION; CALCIUM; INDUCTION; BEHAVIOR; CURRENTS	Learning and memory arise through activity-dependent modifications of neural circuits. Although the activity dependence of synaptic efficacy has been studied extensively, less is known about how activity shapes the intrinsic electrical properties of neurons. Lobster stomatogastric ganglion neurons fire in bursts when receiving synaptic and modulatory input but fire tonically when pharmacologically isolated. Long-term isolation in culture changed their intrinsic activity from tonic firing to burst firing. Rhythmic stimulation reversed this transition through a mechanism that was mediated by a rise in intracellular calcium concentration. These data suggest that neurons regulate their conductances to maintain stable activity patterns and that the intrinsic properties of a neuron depend on its recent history of activation.	BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254	Brandeis University	TURRIGIANO, G (corresponding author), BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254, USA.				NIMH NIH HHS [MH46742] Funding Source: Medline; NINDS NIH HHS [NS17813] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH046742, R01MH046742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017813] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBOTT LF, 1993, NEURAL COMPUT, V5, P83; ALKON DL, 1984, SCIENCE, V226, P1037, DOI 10.1126/science.6093258; FIELDS RD, 1990, J NEUROSCI, V10, P2950; FRANKLIN JL, 1992, J NEUROSCI, V12, P1726; Harris-Warrick RM, 1992, DYNAMICAL BIOL NETWO; HARRISWARRICK RM, 1991, ANNU REV NEUROSCI, V14, P39, DOI 10.1146/annurev.ne.14.030191.000351; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HONG SJ, 1993, BRAIN RES, V605, P121, DOI 10.1016/0006-8993(93)91363-W; KATER SB, 1991, J NEUROSCI, V11, P891; LEMASSON G, 1993, SCIENCE, V259, P1915, DOI 10.1126/science.8456317; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALENKA RC, 1992, NEURON, V9, P121, DOI 10.1016/0896-6273(92)90227-5; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SIEGEL M, UNPUB; Turrigiano G. G., 1993, Society for Neuroscience Abstracts, V19, P17; TURRIGIANO GG, 1993, J NEUROPHYSIOL, V69, P1993, DOI 10.1152/jn.1993.69.6.1993; TURRIGIANO GG, UNPUB	19	364	368	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 13	1994	264	5161					974	977		10.1126/science.8178157	http://dx.doi.org/10.1126/science.8178157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK974	8178157				2022-12-01	WOS:A1994NK97400038
J	FIELDS, BN				FIELDS, BN			AIDS - TIME TO TURN TO BASIC SCIENCE	NATURE			English	Editorial Material											FIELDS, BN (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,200 LONGWOOD AVE,BOSTON,MA 02115, USA.								0	35	34	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 12	1994	369	6476					95	96		10.1038/369095a0	http://dx.doi.org/10.1038/369095a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK971	8177331				2022-12-01	WOS:A1994NK97100021
J	HILLMAN, JG				HILLMAN, JG			AUDIT OF ELDERLY PEOPLES EYE PROBLEMS AND NON-ATTENDANCE AT HOSPITAL EYE SERVICE	BRITISH MEDICAL JOURNAL			English	Article								Because eye disease is common in elderly people' and the number of people aged greater-than-or-equal-to 80 in Britain is increasing, 2 outpatient referrals to the hospital eye service will probably rise. Many studies have discussed the reasons why people do not keep their outpatient appointments and ways in which non-attendance could be reduced. Few have given details of the morbidity that arises in patients who have not kept appointments.3 Could general practitioners have an important influence on non-attendance?			HILLMAN, JG (corresponding author), MED CTR BRIDLINGTON,BRIDLINGTON Y016 4LZ,ENGLAND.							GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P192; JONES RB, 1988, PUBLIC HEALTH, V102, P385, DOI 10.1016/S0033-3506(88)80110-0; 1991, GLOBAL POPULATION ES, P364	3	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1994	308	6934					953	953		10.1136/bmj.308.6934.953	http://dx.doi.org/10.1136/bmj.308.6934.953			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173403	Green Published			2022-12-01	WOS:A1994NF48500018
J	VAPORCIYAN, AA; DELISSER, HM; YAN, HC; MENDIGUREN, II; THOM, SR; JONES, ML; WARD, PA; ALBELDA, SM				VAPORCIYAN, AA; DELISSER, HM; YAN, HC; MENDIGUREN, II; THOM, SR; JONES, ML; WARD, PA; ALBELDA, SM			INVOLVEMENT OF PLATELET ENDOTHELIAL-CELL ADHESION MOLECULE-1 IN NEUTROPHIL RECRUITMENT IN-VIVO	SCIENCE			English	Article							BETA-2 INTEGRINS; INJURY; CD31; ROLES; LUNG	During inflammation, neutrophils migrate from the vascular lumen into extravascular sites. In vitro assays have suggested that platelet-endothelial cell adhesion molecule-1 [PECAM-1 (CD31)], a member of the immunoglobulin superfamily, is required for the transmigration of neutrophils across endothelial monolayers. Antibody to human PECAM-1, which cross-reacts with rat PECAM-1, was found to block not only in vivo accumulation of rat neutrophils into the peritoneal cavity and the alveolar compartment of the lung but also neutrophil accumulation in human skin grafts transplanted onto immunodeficient mice. On the basis of these findings in three different models of inflammation, it appears that PECAM-1 is required for neutrophil transmigration in vivo and may thus be a potential therapeutic target.	UNIV PENN,MED CTR,DEPT MED,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV PENN,MED CTR,INST ENVIRONM MED,PHILADELPHIA,PA 19104	University of Pennsylvania; The Wistar Institute; University of Michigan System; University of Michigan; University of Pennsylvania			DeLisser, Horace/AFM-1942-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046311, P01HL031963, R29HL046311] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-430020-02, HL-46311, HL-31963] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; DELISSER HM, 1993, J BIOL CHEM, V268, P16307; JOHNSON KJ, 1981, J IMMUNOL, V126, P2365; JOHNSON KJ, 1974, J CLIN INVEST, V54, P349, DOI 10.1172/JCI107770; MERWIN JR, UNPUB; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; MULLIGAN MS, 1992, J IMMUNOL, V148, P1847; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OHTO H, 1985, BLOOD, V66, P873; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; TAWIA SA, 1993, HUM REPROD, V8, P175; TRIPPESTAD A, 1971, CLIN EXP IMMUNOL, V8, P639; VARANI J, 1985, LAB INVEST, V53, P656; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; YAN HC, 1993, J CLIN INVEST, V91, P986, DOI 10.1172/JCI116320	19	425	436	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1580	1582		10.1126/science.8248808	http://dx.doi.org/10.1126/science.8248808			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248808				2022-12-01	WOS:A1993MK32900043
J	MAYO, SL; BALDWIN, RL				MAYO, SL; BALDWIN, RL			GUANIDINIUM CHLORIDE INDUCTION OF PARTIAL UNFOLDING IN AMIDE PROTON-EXCHANGE IN RNASE-A	SCIENCE			English	Article							PANCREATIC RIBONUCLEASE-A; HYDROGEN-EXCHANGE; MAGNETIC-RESONANCE; FREE-ENERGY; PROTEIN; DENATURATION; TRANSITION; RATES; NMR	Amide (NH) proton exchange rates were measured in 0.0 to 0.7 M guanidinium chloride (GdmCl) for 23 slowly exchanging peptide NH protons of ribonuclease A (RNase A) at pH* 5.5 (uncorrected pH measured in D2O), 34-degrees-C. The purpose was to find out whether GdmCl induces exchange through binding to exchange intermediates that are partly or wholly unfolded. It was predicted that, when the logarithm of the exchange rate is plotted as a function of the molarity of GdmCl, the slope should be a measure of the amount of buried surface area exposed to GdmCl in the exchange intermediate. The results indicate that these concentrations of GdmCl do induce exchange by means of a partial unfolding mechanism for all 23 protons; this implies that exchange reactions can be used to study the unfolding and stability of local regions. Of the 23 protons, nine also show a second mechanism of exchange at lower concentrations of GdmCl, a mechanism that is nearly independent of GdmCl concentration and is termed ''limited structural fluctuation.''	STANFORD UNIV, MED CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019988, R01GM019988] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 19988] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; COVINGTON AK, 1966, J PHYS CHEM-US, V70, P3820, DOI 10.1021/j100884a011; ENGLANDER JJ, 1979, ANAL BIOCHEM, V92, P517, DOI 10.1016/0003-2697(79)90693-6; ENGLANDER SW, 1992, SCIENCE, V256, P1684, DOI 10.1126/science.256.5064.1684; ENGLANDER SW, 1983, Q REV BIOPHYS, V16, P521, DOI 10.1017/S0033583500005217; HILTON BD, 1981, BIOCHEMISTRY-US, V20, P4697, DOI 10.1021/bi00519a027; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9609, DOI 10.1021/bi00088a013; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9600, DOI 10.1021/bi00088a012; LOFTUS D, 1986, BIOCHEMISTRY-US, V25, P1428, DOI 10.1021/bi00354a036; MAYO SL, UNPUB; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; Pace C N, 1986, Methods Enzymol, V131, P266; PACE CN, 1990, BIOCHEMISTRY-US, V29, P2564, DOI 10.1021/bi00462a019; PACE CN, 1975, CRC CRIT REV BIOCH, V31; RICHARDS FM, 1979, CARLSBERG RES COMMUN, V44, P47, DOI 10.1007/BF02906521; RICO M, 1989, EUR J BIOCHEM, V183, P623, DOI 10.1111/j.1432-1033.1989.tb21092.x; RICO M, COMMUNICATION; ROBERTSON AD, 1991, BIOCHEMISTRY-US, V30, P9907, DOI 10.1021/bi00105a014; ROBERTSON AD, 1989, BIOCHEMISTRY-US, V28, P5930, DOI 10.1021/bi00440a033; RODER H, 1989, METHOD ENZYMOL, V176, P446; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P4901, DOI 10.1021/bi00135a022; SCHELLMAN JA, 1987, BIOPOLYMERS, V26, P549, DOI 10.1002/bip.360260408; SEGAWA SI, 1984, BIOPOLYMERS, V23, P2473; SHAKHNOVICH EI, 1989, BIOPOLYMERS, V28, P1667, DOI 10.1002/bip.360281003; WAGNER G, 1979, J MOL BIOL, V130, P31, DOI 10.1016/0022-2836(79)90550-3; WESTMORELAND DG, 1975, J BIOL CHEM, V250, P7456; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010; WOODWARD C, 1982, MOL CELL BIOCHEM, V48, P135, DOI 10.1007/BF00421225	29	200	201	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1993	262	5135					873	876		10.1126/science.8235609	http://dx.doi.org/10.1126/science.8235609			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235609				2022-12-01	WOS:A1993MF43800027
J	BARLOW, RB; BIRGE, RR; KAPLAN, E; TALLENT, JR				BARLOW, RB; BIRGE, RR; KAPLAN, E; TALLENT, JR			ON THE MOLECULAR-ORIGIN OF PHOTORECEPTOR NOISE	NATURE			English	Article							PRIMARY PHOTOCHEMICAL EVENTS; CIRCADIAN-RHYTHMS; EXTRACELLULAR PH; SCHIFF-BASE; RHODOPSIN; RETINA; TOAD; PERFORMANCE; SENSITIVITY; SYSTEM	RETINAL photoreceptors are noisy. They generate discrete electrical events in the dark indistinguishable from those evoked by light1,2 and thereby limit visual sensitivity at low levels of illumination3,4. The random spontaneous events are strongly temperature-dependent and have been attributed to thermal isomerizations of the vitamin A chromophore of rhodopsin, the light-sensitive molecule in photoreceptors1,5,6. But thermal generation of dark events in both vertebrate and invertebrate photoreceptors requires activation energies in the range of 23 to 27 kcal mol-1, which are significantly less than the energy barrier of 45 kcal mol-1 for photoisomerization of the chromophore of native rhodopsin7-9. We propose that photoreceptor noise results from the thermal isomerization of a relatively unstable form of rhodopsin, one in which the Schiff-base linkage between the chromophore and protein is unprotonated. This molecular mechanism is supported by both theoretical calculations of the properties of rhodopsin and experimental measurements of the properties of photoreceptor noise.	SYRACUSE UNIV,DEPT BIOENGN & NEUROSCI,SYRACUSE,NY 13244; SYRACUSE UNIV,DEPT CHEM,SYRACUSE,NY 13244; MARINE BIOL LAB,WOODS HOLE,MA 02543	Syracuse University; Syracuse University; Marine Biological Laboratory - Woods Hole	BARLOW, RB (corresponding author), SYRACUSE UNIV,INST SENSORY RES,SYRACUSE,NY 13244, USA.							AHO AC, 1988, NATURE, V334, P348, DOI 10.1038/334348a0; ASHMORE JF, 1977, J PHYSL, V332, P272; BARLOW HB, 1956, J OPT SOC AM, V46, P634, DOI 10.1364/JOSA.46.000634; BARLOW HB, 1988, NATURE, V334, P296, DOI 10.1038/334296a0; BARLOW RB, 1982, NATURE, V296, P65, DOI 10.1038/296065a0; BARLOW RB, 1983, J NEUROSCI, V3, P856; BARLOW RB, 1987, J GEN PHYSIOL, V89, P353, DOI 10.1085/jgp.89.3.353; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529; BIRGE RR, 1993, BIOPHYS J, V64, P1371, DOI 10.1016/S0006-3495(93)81501-7; BIRGE RR, 1990, BIOCHIM BIOPHYS ACTA, V1016, P293, DOI 10.1016/0005-2728(90)90163-X; BORGULA GA, 1989, VISION RES, V29, P1069, DOI 10.1016/0042-6989(89)90054-0; CHESLER M, 1987, AM J PHYSIOL, V253, pR666, DOI 10.1152/ajpregu.1987.253.4.R666; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; COPENHAGEN DR, 1987, J PHYSIOL-LONDON, V393, P667, DOI 10.1113/jphysiol.1987.sp016847; CORSON DW, 1980, BRAIN RES, V193, P558; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P9165, DOI 10.1021/bi00086a023; FAHRENBACH WH, 1969, Z ZELLFORSCH MIK ANA, V93, P451; HUBBARD R, 1966, J BIOL CHEM, V241, P1814; KAPLAN E, 1980, NATURE, V286, P393, DOI 10.1038/286393a0; KASS L, 1988, J COMP PHYSIOL A, V164, P95, DOI 10.1007/BF00612723; LILLYWHITE PG, 1977, J COMP PHYSIOL, V122, P189, DOI 10.1007/BF00611889; LISMAN JE, 1980, J GEN PHYSIOL, V73, P219; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; OAKLEY B, 1989, J PHYSIOL-LONDON, V419, P353, DOI 10.1113/jphysiol.1989.sp017876; POWERS MK, 1991, VISUAL NEUROSCI, V7, P179, DOI 10.1017/S0952523800004016; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHICK GA, 1987, BIOCHEMISTRY-US, V26, P2556, DOI 10.1021/bi00383a022; SCHNEIDER M, 1987, Investigative Ophthalmology and Visual Science, V28, P186; SMITH WC, 1992, INVEST OPHTH VIS SCI, V32, P1004; TALLENT JR, 1992, J AM CHEM SOC, V114, P1581, DOI 10.1021/ja00031a007; Yeandle S., 1958, AM J OPHTHALMOL, V46, P82	32	104	105	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					64	66		10.1038/366064a0	http://dx.doi.org/10.1038/366064a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	8232538				2022-12-01	WOS:A1993MF00700054
J	TISCH, R; YANG, XD; SINGER, SM; LIBLAU, RS; FUGGER, L; MCDEVITT, HO				TISCH, R; YANG, XD; SINGER, SM; LIBLAU, RS; FUGGER, L; MCDEVITT, HO			IMMUNE-RESPONSE TO GLUTAMIC-ACID DECARBOXYLASE CORRELATES WITH INSULITIS IN NONOBESE DIABETIC MICE	NATURE			English	Article							MOUSE; IDENTIFICATION; AUTOANTIGEN; PRODUCTS; ANTIBODY; CLONING	KNOWING the autoantigen target(s) in an organ-specific autoimmune disease is essential to understanding its pathogenesis. Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease characterized by lymphocytic infiltration of the islets of Langerhans (insulitis) and destruction of insulin-secreting pancreatic beta-cells1. Several beta-cell proteins have been identified as autoantigens, but their importance in the diabetogenic process is not known2. The non-obese diabetic (NOD) mouse is a murine model for spontaneous IDDM3. Here we determine the temporal sequence of T-cell and antibody responses in NOD mice to a panel of five murine beta-cell antigens and find that antibody and T-cell responses specific for the two isoforms of glutamic acid decarboxylase (GAD) are first detected in 4-week-old NOD mice. This GAD-specific reactivity coincides with the earliest detectable response to an islet extract, and with the onset of insulitis. Furthermore, NOD mice receiving intrathymic injections of GAD65 exhibit markedly reduced T-cell proliferative responses to GAD and to the rest of the panel, in addition to remaining free of diabetes. These results indicate that the spontaneous response to beta-cell antigens arises very early in life and that the anti-GAD immune response has a critical role in the disease process during this period.	STANFORD UNIV,MED CTR,DEPT MED,STANFORD,CA 94305	Stanford University	TISCH, R (corresponding author), STANFORD UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305, USA.		Liblau, Roland/J-3530-2014; Singer, Steven/V-7778-2019	Singer, Steven/0000-0001-5719-7535				ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BOITARD C, 1992, P NATL ACAD SCI USA, V89, P172, DOI 10.1073/pnas.89.1.172; CASTANO L, 1991, J CLIN ENDOCR METAB, V73, P1197, DOI 10.1210/jcem-73-6-1197; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; GERLING IC, 1992, DIABETES, V41, P1672, DOI 10.2337/diabetes.41.12.1672; HARRISON LC, 1992, IMMUNOL TODAY, V13, P348, DOI 10.1016/0167-5699(92)90170-C; HAYWARD AR, 1989, J IMMUNOL, V143, P1555; HONEYMAN MC, 1993, J EXP MED, V177, P535, DOI 10.1084/jem.177.2.535; LEFFERT JD, 1989, P NATL ACAD SCI USA, V86, P3127, DOI 10.1073/pnas.86.9.3127; Luckow VA, 1992, BACULOVIRUS EXPRESSI; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; MILLER BJ, 1988, J IMMUNOL, V140, P52; PROCHAZKA M, 1992, DIABETES, V41, P98, DOI 10.2337/diabetes.41.1.98; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; SHIZURU JA, 1988, SCIENCE, V240, P659, DOI 10.1126/science.2966437	19	933	963	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					72	75		10.1038/366072a0	http://dx.doi.org/10.1038/366072a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	8232539				2022-12-01	WOS:A1993MF00700057
J	BRUNNER, HG; NELEN, M; BREAKEFIELD, XO; ROPERS, HH; VANOOST, BA				BRUNNER, HG; NELEN, M; BREAKEFIELD, XO; ROPERS, HH; VANOOST, BA			ABNORMAL-BEHAVIOR ASSOCIATED WITH A POINT MUTATION IN THE STRUCTURAL GENE FOR MONOAMINE OXIDASE-A	SCIENCE			English	Article							CEREBROSPINAL-FLUID MONOAMINE; HUMAN-SKIN FIBROBLASTS; NORRIE DISEASE; PRENATAL-DIAGNOSIS; X-CHROMOSOME; NORWAY RATS; AGGRESSION; INHIBITORS; DELETION; ACID	Genetic and metabolic studies have been done on a large kindred in which several males are affected by a syndrome of borderline mental retardation and abnormal behavior. The types of behavior that occurred include impulsive aggression, arson, attempted rape, and exhibitionism. Analysis of 24-hour urine samples indicated markedly disturbed monoamine metabolism. This syndrome was associated with a complete and selective deficiency of enzymatic activity of monoamine oxidase A (MAOA). In each of five affected males, a point mutation was identified in the eighth exon of the MAOA structural gene, which changes a glutamine to a termination codon. Thus, isolated complete MAOA deficiency in this family is associated with a recognizable behavioral phenotype that includes disturbed regulation of impulsive aggression.	UNIV HOSP NIJMEGEN,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS; MASSACHUSETTS GEN HOSP,CTR NEUROSCI,BOSTON,MA 02129	Radboud University Nijmegen; Harvard University; Massachusetts General Hospital	BRUNNER, HG (corresponding author), UNIV HOSP NIJMEGEN,DEPT HUMAN GENET,GEERT GROOTEPLEIN 20,6525 GA NIJMEGEN,NETHERLANDS.		Nelen, Marcel R./L-4542-2015; Brunner, Han/C-9928-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021921] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 21921] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199; BLEEKERWAGEMAKERS EM, 1988, OPHTHALMIC PAED GEN, V9, P137, DOI 10.3109/13816818809031489; BLIER P, 1986, J PHARMACOL EXP THER, V237, P987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREAKEFIELD XO, 1981, GENETIC RES STRATEGI, P129; BROWN GL, 1979, PSYCHIAT RES, V1, P131, DOI 10.1016/0165-1781(79)90053-2; BRUNNER HG, 1993, AM J HUM GENET, V52, P1032; CHEN ZY, 1992, NUCLEIC ACIDS RES, V19, P537; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCCARO EF, 1989, BRIT J PSYCHIAT, V155, P52, DOI 10.1192/S0007125000291769; COHEN RM, 1982, PSYCHOPHARMACOLOGY, V78, P137, DOI 10.1007/BF00432251; COLLINS FA, 1992, AM J MED GENET, V42, P127, DOI 10.1002/ajmg.1320420126; DELACHAPELLE A, 1985, CLIN GENET, V28, P317; DONNAI D, 1988, J MED GENET, V25, P73, DOI 10.1136/jmg.25.2.73; EDELSTEIN SB, 1981, BIOCHEM BIOPH RES CO, V98, P836, DOI 10.1016/0006-291X(81)91187-6; EDELSTEIN SB, 1986, CELL MOL NEUROBIOL, V6, P121, DOI 10.1007/BF00711066; EDELSTEIN SB, 1978, J NEUROCHEM, V31, P1247, DOI 10.1111/j.1471-4159.1978.tb06249.x; EICHELMAN B, 1975, PHARMACOL BIOCHEM BE, V3, P601, DOI 10.1016/0091-3057(75)90180-X; EICHELMAN BS, 1973, BIOL PSYCHIAT, V6, P143; GREENSHAW AJ, 1989, BIOL PSYCHIAT, V25, P1014, DOI 10.1016/0006-3223(89)90289-8; HIGLEY JD, 1992, ARCH GEN PSYCHIAT, V49, P436; HOTAMISLIGIL GS, 1991, AM J HUM GENET, V49, P383; HSU YPP, 1988, J NEUROCHEM, V51, P1321, DOI 10.1111/j.1471-4159.1988.tb03105.x; KANTAK KM, 1980, PHARMACOL BIOCHEM BE, V12, P173, DOI 10.1016/0091-3057(80)90351-2; KRUESI MJP, 1990, ARCH GEN PSYCHIAT, V47, P419; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LINNOILA M, 1983, LIFE SCI, V33, P2609, DOI 10.1016/0024-3205(83)90344-2; MORDEN B, 1968, PHYSIOL BEHAV, V3, P425, DOI 10.1016/0031-9384(68)90073-5; MURPHY DL, 1983, ANTIDEPRESSANTS, P209; NIKULINA EM, 1992, AGGRESSIVE BEHAV, V18, P65, DOI 10.1002/1098-2337(1992)18:1<65::AID-AB2480180108>3.0.CO;2-Y; PICKAR D, 1982, ARCH GEN PSYCHIAT, V39, P535; POPOVA NK, 1991, AGGRESSIVE BEHAV, V17, P207, DOI 10.1002/1098-2337(1991)17:4<207::AID-AB2480170403>3.0.CO;2-2; Reis D J, 1972, Res Publ Assoc Res Nerv Ment Dis, V50, P266; SIMS KB, 1989, NEURON, V2, P1069, DOI 10.1016/0896-6273(89)90231-6; SLEIGHT AJ, 1988, BRIT J PHARMACOL, V93, P303, DOI 10.1111/j.1476-5381.1988.tb11435.x; TRONCONE LRP, 1991, PHYSIOL BEHAV, V50, P173, DOI 10.1016/0031-9384(91)90517-R; TUFIK S, 1978, PHARMACOLOGY, V16, P98, DOI 10.1159/000136753; VALZELLI L, 1982, PHARMACOL RES COMMUN, V14, P1, DOI 10.1016/S0031-6989(82)80047-7; Valzelli L., 1981, PSYCHOBIOLOGY AGGRES; VANDENOUWELAND AMW, 1992, NAT GENET, V2, P99, DOI 10.1038/ng1092-99; WINSLOW JT, 1983, PSYCHOPHARMACOLOGY, V81, P286, DOI 10.1007/BF00427564; ZHU DP, 1989, AM J MED GENET, V33, P485, DOI 10.1002/ajmg.1320330415	43	1089	1122	3	157	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 22	1993	262	5133					578	580		10.1126/science.8211186	http://dx.doi.org/10.1126/science.8211186			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC935	8211186				2022-12-01	WOS:A1993MC93500044
J	CHEN, LHY				CHEN, LHY			EXTENDING THE POISSON APPROXIMATION	SCIENCE			English	Editorial Material							STEIN METHOD				CHEN, LHY (corresponding author), NATL UNIV SINGAPORE, DEPT MATH, LOWER KENT RIDGE RD, SINGAPORE 0511, SINGAPORE.		Chen, Louis/E-7050-2016					ARRATIA R, 1990, ANN STAT, V18, P539, DOI 10.1214/aos/1176347615; ARRATIA R, 1989, ANN PROBAB, V17, P9, DOI 10.1214/aop/1176991491; Arratia R., 1990, STAT SCI, V5, P403, DOI 10.1214/ss/1177012015; Barbour, 1988, J APPL PROBAB A, V25, P175; Barbour A.D., 1992, POISSON APPROXIMATIO; BARBOUR AD, 1992, ANN PROBAB, V20, P1843, DOI 10.1214/aop/1176989531; CHEN LHY, 1975, ANN PROBAB, V3, P534, DOI 10.1214/aop/1176996359; CHEN LHY, 1992, ANN PROBAB, V20, P1867, DOI 10.1214/aop/1176989532; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STEIN C, 1972, 6TH P BERK S MATH ST, V2, P583; WATERMAN MS, 1989, APPLIED MATH SCI, V77	12	3	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1993	262	5132					379	380		10.1126/science.8211157	http://dx.doi.org/10.1126/science.8211157			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	8211157				2022-12-01	WOS:A1993MB85900045
J	DESAUVAGE, FJ; HASS, PE; SPENCER, SD; MALLOY, BE; GURNEY, AL; SPENCER, SA; DARBONNE, WC; HENZEL, WJ; WONG, SC; KUANG, WJ; OLES, KJ; HULTGREN, B; SOLBERG, LA; GOEDDEL, DV; EATON, DL				DESAUVAGE, FJ; HASS, PE; SPENCER, SD; MALLOY, BE; GURNEY, AL; SPENCER, SA; DARBONNE, WC; HENZEL, WJ; WONG, SC; KUANG, WJ; OLES, KJ; HULTGREN, B; SOLBERG, LA; GOEDDEL, DV; EATON, DL			STIMULATION OF MEGAKARYOCYTOPOIESIS AND THROMBOPOIESIS BY THE C-MPL LIGAND	NATURE			English	Article							FACTOR RECEPTOR SUPERFAMILY; REBOUND-THROMBOCYTOSIS; PARTIAL-PURIFICATION; HUMAN ERYTHROPOIETIN; COLONY FORMATION; MESSENGER-RNA; GM-CSF; INVITRO; SEQUENCE; INVIVO	Physiological platelet synthesis is thought to require the humoral activities of meg-CSF and thrombopoietin, which respectively promote proliferation and maturation of megakaryocytic cells. A meg-CSF/thrombopoietin-like protein that is present in plasma of irradiated pigs has been purified and cloned. This protein binds to and activates the c-mpl protein, a member of the cytokine receptor superfamily. The isolated Mpl ligand shares homology with erythropoietin and stimulates both megakaryocytopoiesis and thrombopoiesis.	MAYO CLIN, DIV HEMATOL ONCOL, JACKSONVILLE, FL 32224 USA; GENENTECH INC, DEPT MOLEC BIOL, San Francisco, CA 94080 USA; GENENTECH INC, DEPT CARDIOVASC RES, San Francisco, CA 94080 USA; GENENTECH INC, DEPT PROT CHEM, San Francisco, CA 94080 USA; MAYO CLIN & MAYO FDN, DIV HEMATOL ONCOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Mayo Clinic			de Sauvage, Frederic/ABE-8400-2020; Solberg, Lawrence A/A-3824-2014	de Sauvage, Frederic/0000-0002-5275-2584; Solberg, Lawrence A/0000-0001-9550-5180; Henzel, William/0000-0003-2940-3797				BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BONDURANT MC, 1986, MOL CELL BIOL, V6, P2731, DOI 10.1128/MCB.6.7.2731; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; DANREA AD, 1991, MOL CELL BIOL, V11, P1980; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; EBBE S, 1974, BLOOD, V44, P605, DOI 10.1182/blood.V44.4.605.605; ERICKSONMILLER CL, 1993, BRIT J HAEMATOL, V84, P197, DOI 10.1111/j.1365-2141.1993.tb03052.x; GORDON MS, 1992, BLOOD, V80, P302; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRANT BW, 1987, BLOOD, V69, P1334; HARRINGTON MG, 1990, METHOD ENZYMOL, V182, P488; HEGYI E, 1990, INT J CELL CLONING, V8, P236, DOI 10.1002/stem.5530080407; HILL RJ, 1992, BLOOD, V80, P346; HILL RJ, 1992, EXP HEMATOL, V20, P354; HOFFMAN R, 1981, NEW ENGL J MED, V305, P533, DOI 10.1056/NEJM198109033051001; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAZUR EM, 1985, EXP HEMATOL, V13, P1164; MAZUR EM, 1981, J CLIN INVEST, V68, P733, DOI 10.1172/JCI110309; MCDONALD TP, 1973, P SOC EXP BIOL MED, V144, P1006; MCDONALD TP, 1971, J LAB CLIN MED, V77, P134; MCDONALD TP, 1976, SCAND J HAEMATOL, V16, P326; METHIA N, 1993, BLOOD, V82, P1395; NAKEFF A, 1975, ACTA HAEMATOL-BASEL, V54, P340, DOI 10.1159/000208096; NARHI LO, 1991, J BIOL CHEM, V266, P23022; ODELL TT, 1961, P SOC EXP BIOL MED, V108, P428; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHEINER DP, 1980, BLOOD, V56, P183; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHREINER DP, 1970, J CLIN INVEST, V49, P1709, DOI 10.1172/JCI106388; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SPECTOR B, 1961, P SOC EXP BIOL MED, V108, P146; SPIVAK JL, 1989, BLOOD, V73, P90; STRANEVA JE, 1989, EXP HEMATOL, V17, P1122; STRANEVA JE, 1992, EXP HEMATOL, V20, P47; TAKEUCHI M, 1990, J BIOL CHEM, V265, P12127; TSUKADA J, 1993, BLOOD, V81, P866; VIGFON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WANG FF, 1985, ENDOCRINOLOGY, V116, P2286, DOI 10.1210/endo-116-6-2286; WILLIAMS N, 1982, J CELL PHYSIOL, V110, P101, DOI 10.1002/jcp.1041100116; WILLIAMS N, 1989, BLOOD CELLS, V15, P123; WONG SC, 1993, TECHNIQUES PROTEIN C, V4, P371	48	1182	1276	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	1994	369	6481					533	538		10.1038/369533a0	http://dx.doi.org/10.1038/369533a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	8202154				2022-12-01	WOS:A1994NR29400040
J	ABE, T; EARLY, A; SIEGERT, F; WEIJER, C; WILLIAMS, J				ABE, T; EARLY, A; SIEGERT, F; WEIJER, C; WILLIAMS, J			PATTERNS OF CELL-MOVEMENT WITHIN THE DICTYOSTELIUM SLUG REVEALED BY CELL-TYPE-SPECIFIC, SURFACE LABELING OF LIVING CELLS	CELL			English	Article							ANTERIOR-LIKE CELLS; MONOCLONAL-ANTIBODIES; PRESTALK ZONE; DISCOIDEUM; CULMINATION; MIGRATION; IDENTIFICATION; GLYCOPROTEIN; LOCALIZATION; POPULATIONS	There are cells scattered in the rear, prespore region of the Dictyostelium slug that share many of the properties of the prestalk cells and that are therefore called anterior-like cells (ALCs). By placing the gene encoding a cell surface protein under the central of an ALC-specific promoter and immunologically labeling the living cells, we analyze the movement of ALCs within the slug. There Is a posterior to anterior cellular flow, and the ALCs change their movement pattern as they enter the prestalk zone. Prestalk cells are periodically shed from the migrating slug. They must be replaced if the correct ratio of prestalk to prespore eels is to be maintained, and we present evidence for the transdifferentiation of prespore into prestalk cells, with ALCs functioning as intermediates in the transition. The slug has, therefore, a surprisingly dynamic structure, both with respect to cellular differentiation and cell movement.	UNIV MUNICH,INST ZOOL,D-80333 MUNICH,GERMANY	University of Munich	ABE, T (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			Weijer, Cornelis/0000-0003-2192-8150				AKIYAMA Y, 1987, DIFFERENTIATION, V35, P83, DOI 10.1111/j.1432-0436.1987.tb00153.x; BLACHKE A, 1986, DIFFERENTIATION, V32, P1; BONNER JT, 1952, AM NAT, V86, P79, DOI 10.1086/281707; BONNER JT, 1957, Q REV BIOL, V32, P232, DOI 10.1086/401874; BUHL B, 1991, DIFFERENTIATION, V46, P147, DOI 10.1111/j.1432-0436.1991.tb00875.x; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; CHUNG S, 1981, CELL, V24, P785, DOI 10.1016/0092-8674(81)90104-5; DEVINE KM, 1985, DEV BIOL, V107, P364, DOI 10.1016/0012-1606(85)90318-5; EARLY AE, 1988, MOL CELL BIOL, V8, P3458, DOI 10.1128/MCB.8.8.3458; EARLY AE, 1993, DEVELOPMENT, V118, P353; EARLY AE, 1989, NUCLEIC ACIDS RES, V17, P6473; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRANCIS D, 1971, J EXP ZOOL, V176, P265, DOI 10.1002/jez.1401760303; GASKELL MJ, 1992, DIFFERENTIATION, V51, P171, DOI 10.1111/j.1432-0436.1992.tb00693.x; GREGG JH, 1982, DIFFERENTIATION, V21, P200, DOI 10.1111/j.1432-0436.1982.tb01214.x; GREGG JH, 1982, EXP CELL RES, V142, P229, DOI 10.1016/0014-4827(82)90427-X; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HARLOW E, 1988, ANTIBODIES LABORATOR, P354; HARWOOD AJ, 1991, DIFFERENTIATION, V46, P7, DOI 10.1111/j.1432-0436.1991.tb00860.x; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; JERMYN KA, 1991, DEVELOPMENT, V111, P779; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; KAKUTANI T, 1986, DEV BIOL, V115, P439, DOI 10.1016/0012-1606(86)90264-2; MCROBBIE SJ, 1988, DEV BIOL, V125, P59, DOI 10.1016/0012-1606(88)90058-9; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; NOMURA A, 1991, PATTERN RECOGN LETT, V12, P183, DOI 10.1016/0167-8655(91)90048-Q; RAPER K, 1940, J E MITCHELL SCI SOC, V59, P241; RAPER KENNETH B., 1952, BULL TORREY BOT CLUB, V79, P25, DOI 10.2307/2482103; RUBIN J, 1975, J EMBRYOL EXP MORPH, V33, P227; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SIEGERT F, 1994, J CELL SCI, V107, P97; SIEGERT F, 1991, PHYSICA D, V49, P224, DOI 10.1016/0167-2789(91)90210-Z; SIEGERT F, 1992, P NATL ACAD SCI USA, V89, P6433, DOI 10.1073/pnas.89.14.6433; STEINBOCK O, 1993, P NATL ACAD SCI USA, V90, P7332, DOI 10.1073/pnas.90.15.7332; STERNFELD J, 1981, DIFFERENTIATION, V20, P10, DOI 10.1111/j.1432-0436.1981.tb01150.x; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; STERNFELD J, 1992, ROUX ARCH DEV BIOL, V201, P354, DOI 10.1007/BF00365123; TAKEUCHI I, 1977, DEV DIFFERENTIATION, P1; TI ZC, 1990, J BIOTECHNOL, V16, P233, DOI 10.1016/0168-1656(90)90039-E; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X	42	80	82	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 3	1994	77	5					687	699		10.1016/0092-8674(94)90053-1	http://dx.doi.org/10.1016/0092-8674(94)90053-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NQ123	8205618	Green Published			2022-12-01	WOS:A1994NQ12300009
J	NAKAMURA, Y; RUSSELL, SM; MESS, SA; FRIEDMANN, M; ERDOS, M; FRANCOIS, C; JACQUES, Y; ADELSTEIN, S; LEONARD, WJ				NAKAMURA, Y; RUSSELL, SM; MESS, SA; FRIEDMANN, M; ERDOS, M; FRANCOIS, C; JACQUES, Y; ADELSTEIN, S; LEONARD, WJ			HETERODIMERIZATION OF THE IL-2 RECEPTOR BETA-CHAIN AND GAMMA-CHAIN CYTOPLASMIC DOMAINS IS REQUIRED FOR SIGNALING	NATURE			English	Article							HUMAN INTERLEUKIN-2 RECEPTOR; CELL GROWTH-FACTOR; FUNCTIONAL COMPONENT; DISTINCT; EXPRESSION; CLONING; BINDING; GENE; INVOLVEMENT; RESPONSES	THE interaction of interleukin-2 (IL-2) and IL-2 receptors critically regulates the T-cell immune response following antigen activation(1,2). IL-2 can signal through high or intermediate affinity receptors which contain IL-2R alpha (refs 3, 4) + beta (refs 5-8) + gamma (ref. 9) or beta + gamma chains, respectively. IL-2R gamma is a common gamma chain, gamma(c), also shared by the IL-7 (ref. 10) and IL-4 (refs 11, 12) receptors, which when mutated results in X-linked severe combined immunodeficiency(13). Using chimaeric receptor constructs together with monoclonal or bispecific antibodies we demonstrate here that IL-2 signalling requires ligand-induced extracellular-domain-mediated heterodimerization of the beta- and gamma(c)-chain cytoplasmic domains. Anti-IL-2R alpha monoclonal antibodies trigger proliferation of cells transfected with chimaeric constructs in which the extracellular domains of IL-2R beta and gamma(c), are replaced by that of IL-2R alpha. Other experiments using chimaeric constructs indicated that IL-2 binds monomerically and monovalently to IL-2R alpha and that the beta-transmembrane domain is not required for receptor chain interactions. Finally, we provide a method for mapping residues in the gamma(c) cytoplasmic domain even in cells that constitutively express gamma(c).	NHLBI,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892; INST BIOL,INSERM,U211,F-44035 NANTES,FRANCE	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Institut National de la Sante et de la Recherche Medicale (Inserm)			Adelstein, Stephen/I-7936-2016; Russell, Sarah M/B-9341-2009; Leonard, Warren/AAA-1397-2022	Adelstein, Stephen/0000-0001-7221-6298; Russell, Sarah M/0000-0001-5826-9641; 				ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; CAO XQ, 1993, P NATL ACAD SCI USA, V90, P8464, DOI 10.1073/pnas.90.18.8464; Exley M, 1991, Semin Immunol, V3, P283; FRANCOIS C, 1993, IMMUN, V150, P4610; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KAHN CR, 1977, J CLIN INVEST, V60, P1094, DOI 10.1172/JCI108861; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KUMAKI S, 1993, BIOCHEM BIOPH RES CO, V193, P356, DOI 10.1006/bbrc.1993.1631; LEONARD WJ, 1983, P NATL ACAD SCI-BIOL, V80, P6957, DOI 10.1073/pnas.80.22.6957; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; LEONARD WJ, 1984, NATURE, V311, P625; MINAMI Y, 1993, CELL, V73, P5; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694	30	299	315	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					330	333		10.1038/369330a0	http://dx.doi.org/10.1038/369330a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	8183373				2022-12-01	WOS:A1994NN10900053
J	AURORA, R; SRINIVASAN, R; ROSE, GD				AURORA, R; SRINIVASAN, R; ROSE, GD			RULES FOR ALPHA-HELIX TERMINATION BY GLYCINE	SCIENCE			English	Article							STAPHYLOCOCCAL NUCLEASE; GLOBULAR-PROTEINS; AMINO-ACIDS; STABILITY; LYSOZYME; POSITION; PEPTIDES; BARNASE; CHAINS; MODEL	A predictive rule for protein folding is presented that involves two recurrent glycine-based motifs that cap the carboxyl termini of cr. helices. In proteins, helices that terminated in glycine residues were found predominantly in one of these two motifs. These glycine structures had a characteristic pattern of polar and apolar residues. Visual inspection of known helical sequences was sufficient to distinguish the two motifs from each other and from internal glycines that fail to terminate helices. These glycine motifs-in which the local sequence selects between available structures-represent an example of a stereochemical rule for protein folding.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	Washington University (WUSTL)				Aurora, Rajeev/0000-0002-6609-6055	NIGMS NIH HHS [GM 29458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BELL JA, 1992, BIOCHEMISTRY-US, V31, P3590, DOI 10.1021/bi00129a006; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BORK P, 1991, BIOCHEM BIOPH RES CO, V180, P666, DOI 10.1016/S0006-291X(05)81117-9; BRUCH MD, 1991, PROTEINS, V10, P130, DOI 10.1002/prot.340100206; CHAKRABARTTY A, 1993, P NATL ACAD SCI USA, V90, P11332, DOI 10.1073/pnas.90.23.11332; COCCO MJ, IN PRESS PROTEIN SCI; CREAMER TP, 1992, P NATL ACAD SCI USA, V89, P5937, DOI 10.1073/pnas.89.13.5937; DASGUPTA S, 1993, INT J PEPT PROT RES, V41, P499; FOROOD B, 1993, P NATL ACAD SCI USA, V90, P838, DOI 10.1073/pnas.90.3.838; GREEN SM, 1992, BIOCHEMISTRY-US, V31, P5717, DOI 10.1021/bi00140a005; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; HOBHOM U, 1992, PROTEIN SCI, V1, P409; HOROVITZ A, 1991, J MOL BIOL, V219, P5, DOI 10.1016/0022-2836(91)90852-W; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KIM PS, 1984, NATURE, V307, P329, DOI 10.1038/307329a0; LATTMAN EE, 1993, P NATL ACAD SCI USA, V90, P439, DOI 10.1073/pnas.90.2.439; LECOMTE JTJ, 1991, J AM CHEM SOC, V113, P9663, DOI 10.1021/ja00025a037; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESSER GJ, 1990, PROTEINS, V8, P6, DOI 10.1002/prot.340080104; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; LYU PC, 1993, BIOCHEMISTRY-US, V32, P421, DOI 10.1021/bi00053a006; LYU PCC, 1992, J AM CHEM SOC, V114, P6560, DOI 10.1021/ja00042a047; MILNERWHITE EJ, 1988, J MOL BIOL, V199, P503, DOI 10.1016/0022-2836(88)90621-3; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; NAGARAJARAM HA, 1993, FEBS LETT, V321, P79, DOI 10.1016/0014-5793(93)80625-5; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; PICKETT SD, 1993, J MOL BIOL, V231, P825, DOI 10.1006/jmbi.1993.1329; PREISSNER R, 1991, BIOCHEM BIOPH RES CO, V180, P660, DOI 10.1016/S0006-291X(05)81116-7; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; REMINGTON SJ, 1978, J MOL BIOL, V118, P81, DOI 10.1016/0022-2836(78)90245-0; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RICHMOND TJ, 1984, J MOL BIOL, V178, P63, DOI 10.1016/0022-2836(84)90231-6; ROSE GD, 1993, ANNU REV BIOPH BIOM, V22, P381, DOI 10.1146/annurev.bb.22.060193.002121; Schellman C., 1980, PROTEIN FOLDING, P53; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SERRANO L, 1992, J MOL BIOL, V227, P544, DOI 10.1016/0022-2836(92)90906-Z; SERRANO L, 1992, J MOL BIOL, V224, P847, DOI 10.1016/0022-2836(92)90566-3; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; YUMOTO N, 1993, BIOCHEM BIOPH RES CO, V196, P1490, DOI 10.1006/bbrc.1993.2420; ZHOU HXX, 1994, PROTEINS, V18, P1, DOI 10.1002/prot.340180103; ZIMM BH, 1959, J CHEM PHYS, V31, P536	50	269	269	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	1994	264	5162					1126	1130		10.1126/science.8178170	http://dx.doi.org/10.1126/science.8178170			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM146	8178170				2022-12-01	WOS:A1994NM14600027
J	BAZETTJONES, DP; LEBLANC, B; HERFORT, M; MOSS, T				BAZETTJONES, DP; LEBLANC, B; HERFORT, M; MOSS, T			SHORT-RANGE DNA LOOPING BY THE XENOPUS HMG-BOX TRANSCRIPTION FACTOR, XUBF	SCIENCE			English	Article							RNA POLYMERASE-I; RIBOSOMAL GENE ENHANCERS; RDNA PROMOTER; LAEVIS; COMPLEX; CONTAINS; DOMAINS; SEQUENCES; BINDING	Xenopus UBF (xUBF) interacts with DNA by way of multiple HMG-box domains. When xUBF binds to the ribosomal promoter, the carboxyl-terminal acidic tail and amino-terminal HMG-box interact. Binding also leads to negative DNA supercoiling and the formation of a disk-like structure, the enhancesome. Within the enhancesome, an xUBF dimer makes a low-density protein core around which DNA is looped into a single 180-base pair turn, probably by in-phase bending. The enhancesome structure suggests a mechanism for xUBF-dependent recruitment of the TATA box-binding protein complex without direct interaction between the two factors.	UNIV LAVAL,HOTEL DIEU,DEPT BIOCHIM,QUEBEC CITY G1R 2J6,PQ,CANADA; UNIV LAVAL,HOTEL DIEU,CTR RECH CANCEROL,QUEBEC CITY G1R 2J6,PQ,CANADA; UNIV CALGARY,HLTH SCI CTR,FAC MED,DEPT MED BIOCHEM & ANAT,CALGARY T2N 4N1,AB,CANADA	Laval University; Laval University; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba				Moss, Thomas (Tom)/0000-0003-2047-4783				BACHVAROV D, 1991, NUCLEIC ACIDS RES, V19, P2331, DOI 10.1093/nar/19.9.2331; BAZETTJONES DP, 1989, MOL CELL BIOL, V9, P336, DOI 10.1128/MCB.9.1.336; BAZETTJONES DP, 1993, MICROBEAM ANAL, V2, P69; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; DEWINTER RFJ, 1987, J MOL BIOL, V196, P813, DOI 10.1016/0022-2836(87)90407-4; FIREK S, 1989, MOL CELL BIOL, V9, P3777, DOI 10.1128/MCB.9.9.3777; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GUIMOND A, 1992, NUCLEIC ACIDS RES, V20, P3361, DOI 10.1093/nar/20.13.3361; HALTINER MM, 1986, MOL CELL BIOL, V6, P227, DOI 10.1128/MCB.6.1.227; ICARDLIEPKALNS C, 1993, BIOCHEM BIOPH RES CO, V193, P453, DOI 10.1006/bbrc.1993.1645; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; KUHN A, 1992, P NATL ACAD SCI USA, V89, P7340, DOI 10.1073/pnas.89.16.7340; LEBLANC B, 1993, EMBO J, V12, P513, DOI 10.1002/j.1460-2075.1993.tb05683.x; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; MCSTAY B, 1991, GENE DEV, V5, P1957, DOI 10.1101/gad.5.11.1957; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MCSTAY B, 1990, GENE DEV, V4, P1240, DOI 10.1101/gad.4.7.1240; Moss T, 1985, Oxf Surv Eukaryot Genes, V2, P207; MOSS T, 1983, NATURE, V304, P562, DOI 10.1038/304562a0; MOSS T, 1992, BIOCHEM CELL BIOL, V70, P324, DOI 10.1139/o92-050; NACHALIEL N, 1989, NUCLEIC ACIDS RES, V17, P9811, DOI 10.1093/nar/17.23.9811; PIKAARD CS, 1990, MOL CELL BIOL, V10, P4816, DOI 10.1128/MCB.10.9.4816; PIKAARD CS, 1989, GENE DEV, V3, P1779, DOI 10.1101/gad.3.11.1779; PUTNAM CD, 1992, MOL CELL BIOL, V12, P4970, DOI 10.1128/MCB.12.11.4970; READ C, 1992, J BIOL CHEM, V267, P10961; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SCHNAPP A, 1991, J BIOL CHEM, V266, P24588; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; STRUCK MM, 1992, J MOL BIOL, V224, P253, DOI 10.1016/0022-2836(92)90588-B; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WINDLE JJ, 1986, MOL CELL BIOL, V6, P4585, DOI 10.1128/MCB.6.12.4585; XIE WQ, 1992, MOL CELL BIOL, V12, P1266, DOI 10.1128/MCB.12.3.1266	35	205	205	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 20	1994	264	5162					1134	1137		10.1126/science.8178172	http://dx.doi.org/10.1126/science.8178172			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM146	8178172				2022-12-01	WOS:A1994NM14600029
J	WANG, LY; ORSER, BA; BRAUTIGAN, DL; MACDONALD, JF				WANG, LY; ORSER, BA; BRAUTIGAN, DL; MACDONALD, JF			REGULATION OF NMDA RECEPTORS IN CULTURED HIPPOCAMPAL-NEURONS BY PROTEIN PHOSPHATASE-1 AND PHOSPHATASE-2A	NATURE			English	Article							MOUSE-BRAIN NEURONS; SYNAPTIC PLASTICITY; POTASSIUM CHANNEL; OKADAIC ACID; CALYCULIN-A; PHOSPHORYLATION; KINASE; MODULATION; GLYCINE; DEPHOSPHORYLATION	PHOSPHORYLATION Of glutamate receptors is probably an important mechanism for modulating excitatory transmission(1-4). However, there is little direct evidence to indicate which protein phosphatases can dephosphorylate glutamate(5) or other ligandgated channels(6), although it is known that protein phosphatases 1 and 2A play a major part in modulating voltage(7-10) and second-messenger-gated channels(11). Here we report that in cultured hippocampal neurons, the N-methgl-D-aspartate (NMDA) receptor can be regulated by endogenous and exogenous serine/threonine protein phosphatases. Phosphatase inhibitors enhanced NMDA currents recorded using the perforated patch technique(13) or in cell-attached patches, whereas protein phosphatases 1 or 2A decreased the open probability of these channels in inside-out patches.	UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,DEPT ANAESTHESIA,TORONTO M5S 1A8,ON,CANADA; BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912	University of Toronto; University of Toronto; Brown University	WANG, LY (corresponding author), UNIV TORONTO,DEPT PHYSIOL,MED SCI BLDG,TORONTO M5S 1A8,ON,CANADA.							BENARI Y, 1992, TRENDS NEUROSCI, V15, P333, DOI 10.1016/0166-2236(92)90049-E; BENVENISTE M, 1990, J PHYSIOL-LONDON, V428, P333, DOI 10.1113/jphysiol.1990.sp018215; BRAUTIGAN DL, 1985, J BIOL CHEM, V260, P4295; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, REV BIOCH, V58, P453; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; GORDON SE, 1992, NEURON, V9, P739, DOI 10.1016/0896-6273(92)90036-D; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JOHNSON JW, 1992, J PHYSIOL-LONDON, V455, P339, DOI 10.1113/jphysiol.1992.sp019305; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KATEO Y, 1986, J AM CHEM SOC, V108, P2780; MEI L, 1991, J BIOL CHEM, V266, P16063; Nairn A C, 1992, Curr Opin Neurobiol, V2, P296, DOI 10.1016/0959-4388(92)90118-5; OH Y, 1993, AM J PHYSIOL, V264, pC1489, DOI 10.1152/ajpcell.1993.264.6.C1489; Orser Beverly A., 1993, Canadian Journal of Anaesthesia, V40, pA61; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; REINHART PH, 1991, J NEUROSCI, V11, P1627; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SUGANUMA M, 1990, CANCER RES, V50, P3521; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0	29	183	188	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					230	232		10.1038/369230a0	http://dx.doi.org/10.1038/369230a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	8183343				2022-12-01	WOS:A1994NM06700055
J	TERNS, MP; DAHLBERG, JE				TERNS, MP; DAHLBERG, JE			RETENTION AND 5' CAP TRIMETHYLATION OF U3 SNRNA IN THE NUCLEUS	SCIENCE			English	Article							SMALL NUCLEOLAR RNA; XENOPUS-LAEVIS; RIBOSOMAL-RNA; SEQUENCE; INVITRO; ANTIBODY; GENES; CELLS	It is shown here that maturation of the m(7)G-capped precursors of U3 small nuclear RNA (snRNA) occurs by a previously unknown pathway. In contrast to the 5' m(7)G-capped precursors of other snRNAs, this RNA is not exported to the cytoplasm but is retained in the nuclei of Xenopus laevis oocytes, where it undergoes trimethylation of its 5' cap. The m(7)G caps of most snRNA precursors are trimethylated only after transport of the RNAs to the cytoplasm. The nuclear retention and maturation of this nucleolar RNA raises the possibility that other m(7)G-capped RNAs are also retained and modified in the nucleus.	UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Terns, Michael/N-6435-2016		NIGMS NIH HHS [GM30220, GM14704] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014704, R37GM030220, R01GM030220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASERGA SJ, 1992, GENE DEV, V6, P1120, DOI 10.1101/gad.6.6.1120; BRINGMANN P, 1983, EMBO J, V2, P1129, DOI 10.1002/j.1460-2075.1983.tb01557.x; CAIZERGUESFERRER M, 1990, MOL BIOL REP, V14, P107, DOI 10.1007/BF00360434; Cheng Y., UNPUB; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; FILIPOWICZ W, 1993, MOL BIOL REP, V18, P149, DOI 10.1007/BF00986770; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAMM J, 1989, EMBO J, V8, P4179, DOI 10.1002/j.1460-2075.1989.tb08603.x; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; Izaurralde E, 1992, Semin Cell Biol, V3, P279, DOI 10.1016/1043-4682(92)90029-U; JEPPESEN C, 1988, NUCLEIC ACIDS RES, V16, P2127, DOI 10.1093/nar/16.5.2127; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KISS T, 1991, CELL, V65, P517, DOI 10.1016/0092-8674(91)90469-F; LUBBEN B, 1993, NUCLEIC ACIDS RES, V21, P5377, DOI 10.1093/nar/21.23.5377; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; LUND E, 1989, EMBO J, V8, P287, DOI 10.1002/j.1460-2075.1989.tb03375.x; LUND E, COMMUNICATION; MUNNS TW, 1982, BIOCHEMISTRY-US, V21, P2922, DOI 10.1021/bi00541a018; PARKER KA, 1987, MOL CELL BIOL, V7, P2899, DOI 10.1128/MCB.7.8.2899; PEUCLIS BA, 1993, CELL, V73, P1233; REDDY R, 1992, PROG MOL SUBCELL BIO, V12, P1; SAVINO R, 1992, NUCLEIC ACIDS RES, V20, P5435, DOI 10.1093/nar/20.20.5435; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SHIMBA S, 1992, J BIOL CHEM, V267, P13772; SINGH R, 1990, MOL CELL BIOL, V10, P939, DOI 10.1128/MCB.10.3.939; SOLLNERWEBB B, 1993, CELL, V75, P403, DOI 10.1016/0092-8674(93)90374-Y; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; TERNS MP, 1992, MOL CELL BIOL, V12, P3032, DOI 10.1128/MCB.12.7.3032; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176	33	111	113	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 13	1994	264	5161					959	961		10.1126/science.8178154	http://dx.doi.org/10.1126/science.8178154			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK974	8178154				2022-12-01	WOS:A1994NK97400033
J	LILLIOJA, S; MOTT, DM; SPRAUL, M; FERRARO, R; FOLEY, JE; RAVUSSIN, E; KNOWLER, WC; BENNETT, PH; BOGARDUS, C				LILLIOJA, S; MOTT, DM; SPRAUL, M; FERRARO, R; FOLEY, JE; RAVUSSIN, E; KNOWLER, WC; BENNETT, PH; BOGARDUS, C			INSULIN-RESISTANCE AND INSULIN SECRETORY DYSFUNCTION AS PRECURSORS OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS - PROSPECTIVE STUDIES OF PIMA-INDIANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPAIRED GLUCOSE-TOLERANCE; BODY-FAT DISTRIBUTION; RISK-FACTORS; FOLLOW-UP; BETA-CELL; NIDDM; PATHOGENESIS; POPULATION; AMERICANS; OBESITY	Background. The relative roles of obesity, insulin resistance, insulin secretory dysfunction, and excess hepatic glucose production in the development of non-insulin-dependent diabetes mellitus (NIDDM) are controversial. We conducted a prospective study to determine which of these factors predicted the development of the disease in a group of Pima Indians. Methods. A body-composition assessment, oral and intravenous glucose-tolerance tests, and a hyperinsulinemic-euglycemic clamp study were performed in 200 nondiabetic Pima Indians (87 women and 113 men; mean [+/-SD] age, 26+/-6 years). The subjects were followed yearly thereafter for an average of 5.3 years. Results. Diabetes developed in 38 subjects during follow-up. Obesity, insulin resistance (independent of obesity), and low acute plasma insulin response to intravenous glucose (with the degree of obesity and insulin resistance taken into account) were predictors of NIDDM. The six-year cumulative incidence of NIDDM was 39 percent in persons with values below the median for both insulin action and acute insulin response, 27 percent in those with values below the median for insulin action but above that for acute insulin response, 13 percent in those with values above the median for insulin action and below that for acute insulin response, and 0 in those with values originally above the median for both characteristics. Conclusions. Insulin resistance is a major risk factor for the development of NIDDM. A low acute insulin response to glucose is an additional but weaker risk factor.	NIDDKD, PHOENIX EPIDEMIOL & CLIN RES BRANCH, CLIN DIABET & NUTR SECT,4212 N 16TH ST,RM 541, PHOENIX, AZ 85016 USA; SANDOZ INC, SANDOZ RES INST, E HANOVER, NJ 07936 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Novartis; Sandoz			Lillioja, Stephen/A-8185-2012; Ravussin, Eric/N-1985-2017; Bennett, Peter/AAH-9605-2021; Steib, Lori/B-6628-2014	Ravussin, Eric/0000-0003-2129-547X; Steib, Lori/0000-0001-8274-318X; Lillioja, Stephen/0000-0001-5333-5240				BANERJI MA, 1992, DIABETES CARE, V15, P1295, DOI 10.2337/diacare.15.10.1295; BERGSTROM RW, 1990, DIABETES, V39, P104, DOI 10.2337/diabetes.39.1.104; BEST JD, 1981, DIABETES, V30, P847, DOI 10.2337/diabetes.30.10.847; BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533; CHARLES MA, 1991, DIABETES, V40, P796, DOI 10.2337/diabetes.40.7.796; CHEN M, 1976, J CLIN ENDOCR METAB, V42, P1168, DOI 10.1210/jcem-42-6-1168; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; EFENDIC S, 1984, ENDOCR REV, V5, P395, DOI 10.1210/edrv-5-3-395; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; Goldman R., 1961, TECHNIQUES MEASURING, P78; GOTTESMAN I, 1983, AM J PHYSIOL, V244, pE632, DOI 10.1152/ajpendo.1983.244.6.E632; GROOP L, 1988, DIABETES, V37, P99, DOI 10.2337/diabetes.37.1.99; HAFFNER SM, 1990, DIABETES, V39, P283, DOI 10.2337/diabetes.39.3.283; KADOWAKI T, 1984, DIABETOLOGIA, V26, P44, DOI 10.1007/BF00252262; KEEN H, 1982, DIABETOLOGIA, V22, P73, DOI 10.1007/BF00254832; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; KOSAKA K, 1977, DIABETES, V26, P944, DOI 10.2337/diab.26.10.944; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; LILLIOJA S, 1991, J CLIN ENDOCR METAB, V73, P866, DOI 10.1210/jcem-73-4-866; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1988, DIABETES METAB REV, V4, P517, DOI 10.1002/dmr.5610040508; LUNDGREN H, 1990, DIABETIC MED, V7, P407, DOI 10.1111/j.1464-5491.1990.tb01415.x; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SICREE RA, 1987, DIABETES, V36, P179, DOI 10.2337/diabetes.36.2.179; Siri W.E., 1961, TECHNIQUES MEASURING, P223; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; 1985, WHO TECH REP SER, V727, P9; 1986, SUGI SUPPLEMENTAL LI, P437	32	1268	1292	1	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1993	329	27					1988	1992		10.1056/NEJM199312303292703	http://dx.doi.org/10.1056/NEJM199312303292703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN573	8247074	Green Published			2022-12-01	WOS:A1993MN57300003
J	DEMARCHI, S; CECCHIN, E; BASILE, A; BERTOTTI, A; NARDINI, R; BARTOLI, E				DEMARCHI, S; CECCHIN, E; BASILE, A; BERTOTTI, A; NARDINI, R; BARTOLI, E			RENAL TUBULAR DYSFUNCTION IN CHRONIC ALCOHOL-ABUSE - EFFECTS OF ABSTINENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTNATAL-DEVELOPMENT; ETHANOL; PLASMA; KIDNEY; INTOXICATION; DOPAMINE; ACIDOSIS; LIVER	Background. Alcohol abuse may be accompanied by a variety of disorders of electrolyte and acid-base metabolism. The role of the kidney in the pathogenesis of these disturbances is obscure. We sought to evaluate the alcohol-induced abnormalities of renal function and improvement during abstinence and to assess the relation between renal dysfunction and electrolyte and acid-base disorders. Methods. We measured biochemical constituents of blood and renal function before and after four weeks of abstinence in 61 patients with chronic alcoholism who had little or no liver disease. Results. On admission, 18 patients (30 percent) had hypophosphatemia and hypomagnesemia, 13 patients (21 percent) had hypocalcemia, and 8 patients (13 percent) had hypokalemia. Twenty-two patients (36 percent) had a variety of simple and mixed acid-base disorders. Twenty of these patients had metabolic acidosis, and among them, 80 percent had alcoholic acidosis. A wide range of defects in renal tubular function, with normal glomerular filtration rate, was detected in these patients. The defects included decreases in the threshold and maximal reabsorptive ability for glucose (38 percent of patients) and in the renal threshold for phosphate excretion (36 percent); increases in the fractional excretion of beta2-microglobulin (38 percent), uric acid (12 percent), calcium (23 percent), and magnesium (21 percent); and aminoaciduria (38 percent). Seventeen patients (28 percent) had a defect in tubular acidification, and five an impairment in urinary concentrating ability. Urinary excretion of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase was increased in 41 and 34 percent of patients, respectively. The abnormalities of blood chemistry and renal tubular function disappeared after four weeks of abstinence. Conclusions. Transient defects in renal tubular function are common in patients with chronic alcoholism and may contribute to their abnormalities of serum electrolyte and blood acid-base profiles.	GEN HOSP,DEPT INTERNAL MED,SAN VITO TAGLIAMENTO,ITALY; UNIV UDINE,SCH MED,DEPT INTERNAL MED,I-33100 UDINE,ITALY; INST HYG,CHEM LAB,UDINE,ITALY	University of Udine								ALBERT MS, 1967, ANN INTERN MED, V66, P312, DOI 10.7326/0003-4819-66-2-312; ASSADI FK, 1990, PEDIATR NEPHROL, V4, P48, DOI 10.1007/BF00858439; ASSADI FK, 1991, ALCOHOL, V8, P259, DOI 10.1016/0741-8329(91)90321-M; BANNAN LT, 1984, CLIN SCI, V66, P659, DOI 10.1042/cs0660659; BLACHLEY J, 1990, FLUIDS ELECTROLYTES, P649; CARUANA RJ, 1988, MEDICINE, V67, P84, DOI 10.1097/00005792-198803000-00002; CRABB DW, 1991, ADV EXP MED BIOL, V284, P277; DAPRADA M, 1976, LIFE SCI, V19, P1161, DOI 10.1016/0024-3205(76)90251-4; DEMARCHI S, 1984, BRIT MED J, V288, P1457, DOI 10.1136/bmj.288.6428.1457-c; DEMARCHI S, 1984, AM J NEPHROL, V4, P280, DOI 10.1159/000166826; DEMARCHI S, 1986, BRIT MED J, V293, P138, DOI 10.1136/bmj.293.6539.138-a; GONZALEZCALVIN JL, 1983, BIOCHEM PHARMACOL, V32, P1723, DOI 10.1016/0006-2952(83)90116-8; HALPERIN ML, 1983, METABOLISM, V32, P308, DOI 10.1016/0026-0495(83)90197-X; HOWES LG, 1986, CLIN SCI, V71, P9, DOI 10.1042/cs0710009; JUNG K, 1987, CLIN CHIM ACTA, V168, P287, DOI 10.1016/0009-8981(87)90004-0; KNOCHEL JP, 1988, KIDNEY LIVER DISEASE, P132; LAITINEN K, 1991, NEW ENGL J MED, V324, P721, DOI 10.1056/NEJM199103143241103; LEMIEUX G, 1980, AM J PHYSIOL, V239, pF420, DOI 10.1152/ajprenal.1980.239.5.F420; LIEBER CS, 1988, NEW ENGL J MED, V319, P1639; LINKOLA J, 1978, ACTA PHYSIOL SCAND, V104, P180, DOI 10.1111/j.1748-1716.1978.tb06265.x; MONSON JP, 1978, BRIT MED J, V1, P24, DOI 10.1136/bmj.1.6104.24; OSTER JR, 1975, NEPHRON, V14, P281, DOI 10.1159/000180458; PARE P, 1984, ARCH INTERN MED, V144, P941, DOI 10.1001/archinte.144.5.941; PARENTI P, 1991, BIOCHIM BIOPHYS ACTA, V1070, P2; QULALI M, 1991, ARCH BIOCHEM BIOPHYS, V288, P406, DOI 10.1016/0003-9861(91)90213-3; RODRIGO R, 1991, CELL BIOCHEM FUNCT, V9, P215, DOI 10.1002/cbf.290090310; ROTHMAN A, 1992, BIOCHEM PHARMACOL, V43, P2034, DOI 10.1016/0006-2952(92)90648-3; ROUT UK, 1991, BIOL NEONATE, V59, P93; SCHAEFER RM, 1987, MINER ELECTROL METAB, V13, P1; SCHARDIJN GHC, 1987, KIDNEY INT, V32, P635, DOI 10.1038/ki.1987.255; SHAFIK IM, 1992, OXFORD TXB CLIN NEPH, V3, P1802; WILLIAMSON DH, 1962, BIOCHEM J, V82, P90, DOI 10.1042/bj0820090; WRENN KD, 1991, AM J MED, V91, P119, DOI 10.1016/0002-9343(91)90003-G; 1982, MED DISORDERS ALCOHO	34	135	139	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1927	1934		10.1056/NEJM199312233292605	http://dx.doi.org/10.1056/NEJM199312233292605			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MM885	8247056				2022-12-01	WOS:A1993MM88500005
J	TICHELLI, A; GRATWOHL, A; EGGER, T; ROTH, J; PRUNTE, A; NISSEN, C; SPECK, B				TICHELLI, A; GRATWOHL, A; EGGER, T; ROTH, J; PRUNTE, A; NISSEN, C; SPECK, B			CATARACT FORMATION AFTER BONE-MARROW TRANSPLANTATION	ANNALS OF INTERNAL MEDICINE			English	Article						BONE MARROW TRANSPLANTATION; CATARACT; CATARACT EXTRACTION; WHOLE-BODY IRRADIATION	TOTAL-BODY IRRADIATION; DELAYED COMPLICATIONS; OCULAR COMPLICATIONS; CHILDREN; HEALTH; SURVIVORS; LIFE	Objective: To evaluate the incidence, time course and factors associated with cataract formation in bone marrow transplant recipients. Design: Prospective cohort study Setting: University Hospitals, Basel Switzerland Patients: 197 patients treated with allogeneic or autologous bone marrow grafts at least 180 days before the start of the study. Intervention: Three regimens for bone marrow transplant were used: 74 patients received single-dose, total-body irradiation (TBI), 90 patients received fractionated TBI, and 33 received chemotherapy alone. Results: Three and one half years after single-dose TBI, 51 of the 74 patients (69%) were alive and cataracts had developed in all of these 51 patients. Cataracts developed in 18 of the 90 (20%) patients treated with fractionated TBI, with an 83% (95% CI, 63% to 100%) risk for lens opacification at 6 years. Cataracts developed in only 1 of the 33 (3%) patients treated with chemotherapy alone. Incidence of cataracts is higher and lens opacification occurs earlier after single-dose TBI than after fractionated TBI (P < 0.01). With Cox regression analysis, the use of irradiation (relative risk, 21.0), the mode of irradiation (relative risk, 7.4), and the use of steroid treatment (relative risk, 2.9) for more than 3 months after bone marrow transplantation increased the risk for cataract formation. In contrast, age, sex, and chronic graft-versus-host disease did not influence the rate of cataract development. The probability of requiring cataract surgery after 6 years was 85% (CI, 75% to 95%) for the patients treated with single-dose TBI and 20% (CI, 0% to 49%) for those prepared with fractionated irradiation. Conclusions: Patients treated with TBI, regardless of fractionation, are likely to have cataracts within 10 years, and some will need surgical repair. Long-term steroid treatment accelerates cataract formation. Preventive measures, such as lens shielding during TBI, should be considered.	UNIV HOSP BASEL, CH-4031 BASEL, SWITZERLAND	University of Basel								BERNAUER W, 1991, ANN INTERN MED, V115, P925, DOI 10.7326/0003-4819-115-12-925; BLACK RL, 1960, JAMA-J AM MED ASSOC, V174, P166, DOI 10.1001/jama.1960.63030020005014; BRAY LC, 1991, BRIT J OPHTHALMOL, V75, P611, DOI 10.1136/bjo.75.10.611; CALISSENDORFF B, 1991, BONE MARROW TRANSPL, V7, P427; CHOSHI K, 1983, RADIAT RES, V96, P560, DOI 10.2307/3576122; COX DR, 1972, J R STAT SOC B, V34, P187; DEEG HJ, 1984, INT J RADIAT ONCOL, V10, P957, DOI 10.1016/0360-3016(84)90163-9; DEEG HJ, 1984, BRIT J HAEMATOL, V57, P185, DOI 10.1111/j.1365-2141.1984.tb08521.x; DEEG HJ, 1990, HEMATOL ONCOL CLIN N, V4, P641; DIETERLE A, 1990, TRANSPLANTATION, V49, P1093, DOI 10.1097/00007890-199006000-00013; GRATWHOL AA, 1977, ANN INTERN MED, V87, P703, DOI 10.7326/0003-4819-87-6-703; GRATWOHL A, 1988, BONE MARROW TRANSPL, V3, P577; HAVRE DC, 1965, ARCH OPHTHALMOL-CHIC, V73, P818; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOBAYASHI Y, 1974, AM J DIS CHILD, V128, P671, DOI 10.1001/archpedi.1974.02110300081010; KOLB HJ, 1990, BONE MARROW TRANSPL, V6, P61; LAPPI M, 1990, GRAEF ARCH CLIN EXP, V228, P218, DOI 10.1007/BF00920023; LIVESEY SJ, 1989, EYE, V3, P271, DOI 10.1038/eye.1989.37; Meier P, 1985, ASAIO J, V8, P3; MERRIAM G R Jr, 1962, Trans Am Ophthalmol Soc, V60, P35; MERRIAM GR, 1983, B NEW YORK ACAD MED, V59, P372; NIEMI M, 1990, Bone Marrow Transplantation, V5, P83; OZSAHIN M, 1992, CANCER, V69, P2853, DOI 10.1002/1097-0142(19920601)69:11<2853::AID-CNCR2820691135>3.0.CO;2-2; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SANDERS J, 1989, BONE MARROW TRANSPL, V4, P27; Sanders J E, 1990, Radiother Oncol, V18 Suppl 1, P82, DOI 10.1016/0167-8140(90)90181-U; SONNEVELD P, 1979, RADIOLOGY, V133, P227, DOI 10.1148/133.1.227; SPECK B, 1988, TRANSPLANT P, V20, P505; SPECK B, 1986, EXP HEMATOL, V14, P126; THOMAS ED, 1984, ANNU REV MED, V35, P1; TICHELLI A, 1991, SCHWEIZ MED WSCHR, V121, P1473; TICHELLI A, 1987, Bone Marrow Transplantation, V2, P250; VANWEELSIPMAN MH, 1990, RADIOTHER ONCOL S1, V18, P2155; VOGLER WR, 1990, BONE MARROW TRANSPL, V6, P405; WINGARD JR, 1991, ANN INTERN MED, V114, P113, DOI 10.7326/0003-4819-114-2-113; WOLCOTT DL, 1986, TRANSPLANTATION, V41, P478, DOI 10.1097/00007890-198604000-00013	36	82	83	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1175	1180		10.7326/0003-4819-119-12-199312150-00004	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239248				2022-12-01	WOS:A1993MM12100004
J	PANTALONI, D; CARLIER, MF				PANTALONI, D; CARLIER, MF			HOW PROFILIN PROMOTES ACTIN FILAMENT ASSEMBLY IN THE PRESENCE OF THYMOSIN-BETA-4	CELL			English	Article							BOUND ADENOSINE 5'-TRIPHOSPHATE; ACANTHAMOEBA PROFILIN; ATP HYDROLYSIS; F-ACTIN; POLYMERIZATION; BINDING; PROFILACTIN; PROTEIN; CELLS; GELSOLIN	The role of profilin in the regulation of actin assembly has been reexamined. The affinity of profilin for ATP-actin appears 10-fold higher than previously thought. in the presence of ATP, the participation of the profilin-actin complex to filament elongation at the barbed end is linked to a decrease in the steady-state concentration of globular actin. This surprising effect is made possible by the involvement of the irreversible ATP hydrolysis accompanying actin polymerization. As a consequence, in the presence of thymosin beta4 (Tbeta4), low amounts of profilin promote extensive actin assembly off of the pool of actin-Tbeta4 complex. When barbed ends are capped, profilin simply sequesters globular actin. A model is proposed for the function of profilin in actin-based motility.			PANTALONI, D (corresponding author), CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE.							CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CARLIER MF, 1986, J BIOL CHEM, V261, P2041; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DINUBILE MJ, 1985, J BIOL CHEM, V260, P7402; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; KAISER DA, 1986, J CELL BIOL, V102, P221, DOI 10.1083/jcb.102.1.221; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAL AA, 1985, J BIOL CHEM, V260, P132; LARSSON H, 1988, BIOCHIM BIOPHYS ACTA, V953, P95, DOI 10.1016/0167-4838(88)90013-1; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; MALM B, 1984, FEBS LETT, V173, P399, DOI 10.1016/0014-5793(84)80813-3; MCLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18; MCLEOD JF, 1989, J BIOL CHEM, V264, P1260; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; PANTALONI D, 1985, P NATL ACAD SCI USA, V82, P7207, DOI 10.1073/pnas.82.21.7207; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; SAFER D, 1991, J BIOL CHEM, V266, P4029; SCHAFER DA, 1992, J CELL BIOL, V118, P335, DOI 10.1083/jcb.118.2.335; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TILNEY LG, 1973, J CELL BIOL, V59, P109, DOI 10.1083/jcb.59.1.109; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; TOBACMAN LS, 1983, J BIOL CHEM, V258, P8806; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3	38	476	490	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					1007	1014		10.1016/0092-8674(93)90544-Z	http://dx.doi.org/10.1016/0092-8674(93)90544-Z			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252614				2022-12-01	WOS:A1993MK96600020
J	YAO, TP; FORMAN, BM; JIANG, ZY; CHERBAS, L; CHEN, JD; MCKEOWN, M; CHERBAS, P; EVANS, RM				YAO, TP; FORMAN, BM; JIANG, ZY; CHERBAS, L; CHEN, JD; MCKEOWN, M; CHERBAS, P; EVANS, RM			FUNCTIONAL ECDYSONE RECEPTOR IS THE PRODUCT OF ECR AND ULTRASPIRACLE GENES	NATURE			English	Article							RETINOIC ACID; RESPONSE ELEMENTS; INDUCIBLE GENE; DNA-BINDING; EARLY PUFF; ENCODES 2; DROSOPHILA; TRANSCRIPTION; SUPERFAMILY; ACTIVATION	ALTHOUGH the biological activity of the insect moulting hormone ecdysone, is manifested through a hormonally regulated transcriptional cascade associated with chromosomal puffing1-3, a direct association of the receptor with the puff has yet to be established. The cloned ecdysone receptor4 (EcR) is by itself incapable of high-affinity DNA binding or transcriptional activation. Rather, these activities are dependent on heterodimer formation with Ultraspiracle5 (USP) the insect homologue of vertebrate retinoid X receptor6. Here we report that native EcR and USP are co-localized on ecdysone-responsive loci of polytene chromosomes. Moreover, we show that natural ecdysones selectively promote physical association between EcR and USP, and conversely, that high-affinity hormone binding requires both EcR and USP. Replacement of USP with retinoid X receptor produces heterodimers with distinct pharmacological and functional properties. These results redefine the ecdysone receptor as a dynamic complex whose activity may be altered by combinatorial interactions among subunits and ligand.	UNIV CALIF SAN DIEGO,GRAD PROGRAM BIOMED SCI,LA JOLLA,CA 92037; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	University of California System; University of California San Diego; Indiana University System; Indiana University Bloomington	YAO, TP (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Ashburner M, 1972, Results Probl Cell Differ, V4, P101; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; CHERBAS P, 1988, P NATL ACAD SCI USA, V85, P2096, DOI 10.1073/pnas.85.7.2096; CHRISTIANSON AMK, 1992, P NATL ACAD SCI USA, V89, P11503, DOI 10.1073/pnas.89.23.11503; CHRISTOPHERSON KS, 1992, P NATL ACAD SCI USA, V89, P6314, DOI 10.1073/pnas.89.14.6314; CLEVER U, 1960, EXP CELL RES, V20, P623, DOI 10.1016/0014-4827(60)90141-5; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, IN PRESS P NATN ACAD; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x	22	747	802	9	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					476	479		10.1038/366476a0	http://dx.doi.org/10.1038/366476a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247157				2022-12-01	WOS:A1993MK09800068
J	FLANAGAN, CA; SCHNIEDERS, EA; EMERICK, AW; KUNISAWA, R; ADMON, A; THORNER, J				FLANAGAN, CA; SCHNIEDERS, EA; EMERICK, AW; KUNISAWA, R; ADMON, A; THORNER, J			PHOSPHATIDYLINOSITOL 4-KINASE - GENE STRUCTURE AND REQUIREMENT FOR YEAST-CELL VIABILITY	SCIENCE			English	Article							PROTEIN KINASE-C; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; INOSITOL TRISPHOSPHATE; CONSERVED FEATURES; CATALYTIC SUBUNIT; KINETIC-ANALYSIS; POINT MUTATION; ALPHA-FACTOR; PURIFICATION	Phosphatidylinositol (PtdIns) 4-kinase catalyzes the first step in the biosynthesis of PtdIns-4,5-bisphosphate (PtdIns[4,5]P2). Hydrolysis of PtdIns[4,5]P2 in response to extracellular stimuli is thought to initiate intracellular signaling cascades that modulate cell proliferation and differentiation. The PIK1 gene encoding a PtdIns 4-kinase from the yeast Saccharomyces cerevisiae was isolated by polymerase chain reaction (PCR) with oligonucleotides based on the sequence of peptides derived from the purified enzyme. The sequence of the PIK1 gene product bears similarities to that of PtdIns 3-kinases from mammals (p110) and yeast (Vps34p). Expression of PIK1 from a multicopy plasmid elevated PtdIns 4-kinase activity and enhanced the response to mating pheromone. A pik1 null mutant was inviable, indicating that PtdIns4P and presumably PtdIns[4,5]P2 are indispensable phospholipids.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X; Admon, Arie/0000-0003-0504-3950	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021841, T32GM007232, R01GM021841] Funding Source: NIH RePORTER; NCI NIH HHS [CA09041] Funding Source: Medline; NIGMS NIH HHS [GM21841, GM07232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUGER KR, 1989, J BIOL CHEM, V264, P20181; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CULBERTSON MR, 1975, GENETICS, V80, P23; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; CYERT MS, UNPUB; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENRY SA, 1984, ANNU REV GENET, V18, P207; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOU WM, 1988, BIOCHIM BIOPHYS ACTA, V959, P67; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATAKAMI Y, 1992, BIOCHIM BIOPHYS ACTA, V1122, P123, DOI 10.1016/0167-4838(92)90314-4; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LI YS, 1989, BIOCHEM BIOPH RES CO, V160, P202, DOI 10.1016/0006-291X(89)91641-0; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PORTER FD, 1988, J BIOL CHEM, V263, P8989; RAGHUNATHAN V, 1992, FEBS LETT, V297, P46, DOI 10.1016/0014-5793(92)80324-A; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RINE J, 1991, METHOD ENZYMOL, V194, P239; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SIKORSKI RS, 1989, GENETICS, V122, P19; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STACK JH, COMMUNICATION; TALWALKAR RT, 1974, BIOCHIM BIOPHYS ACTA, V360, P306, DOI 10.1016/0005-2760(74)90060-5; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WELLS GB, 1983, J BIOL CHEM, V258, P200; WHEELER GE, 1972, BIOCHEM J, V127, pP64; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; YAMAKAWA A, 1991, J BIOL CHEM, V266, P17580; YAMAKAWA A, 1992, J BIOL CHEM, V267, P25620	66	180	184	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1993	262	5138					1444	1448		10.1126/science.8248783	http://dx.doi.org/10.1126/science.8248783			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248783				2022-12-01	WOS:A1993MJ04600040
J	DIAZBENJUMEA, FJ; COHEN, SM				DIAZBENJUMEA, FJ; COHEN, SM			INTERACTION BETWEEN DORSAL AND VENTRAL CELLS IN THE IMAGINAL DISC DIRECTS WING DEVELOPMENT IN DROSOPHILA	CELL			English	Article							CHICK-EMBRYO HINDBRAIN; ENGRAILED EXPRESSION; LINEAGE RESTRICTIONS; CLONAL ANALYSIS; GENITAL DISK; MELANOGASTER; COMPARTMENTS; GENE; FIELDS; REGENERATION	The adult appendages of Drosophila develop from imaginal discs. An early step in disc patterning involves the formation of developmental boundaries that subdivide the discs into compartments. Anterior and posterior compartments are established in the embryo. Later in development a new boundary originates to subdivide the wing disc into dorsal and ventral compartments, which correspond to the dorsal and ventral surfaces of the adult wing. We report here that spatially localized expression of the homeobox gene apterous (ap) specifies the identity of dorsal cells in the wing. The boundary of cell lineage restriction between dorsal and ventral compartments coincides with the limit of the domain of ap expression. Using genetic mosaics, we show that juxtaposition of dorsal and ventral cells induces formation of the wing margin. We present evidence that the dorsal-ventral boundary promotes growth and serves as a pattern-organizing center in the wing disc.			DIAZBENJUMEA, FJ (corresponding author), EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAM, MEYERHOFSTR 1, D-69017 HEIDELBERG, GERMANY.		Cohen, Stephen M/G-9930-2011; Diaz-Benjumea, Fernando/K-7667-2014	Cohen, Stephen M/0000-0003-2858-9163; Diaz-Benjumea, Fernando/0000-0003-3007-2489				BAKER NE, 1988, DEVELOPMENT, V102, P489; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BROWER DL, 1985, CELL, V41, P361, DOI 10.1016/S0092-8674(85)80008-8; BROWER DL, 1984, NATURE, V310, P496, DOI 10.1038/310496a0; Bryant P.J., 1978, P230; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; BRYANT PJ, 1993, SCIENCE, V259, P471, DOI 10.1126/science.8424169; BRYANT PJ, 1988, DEV BIOL, V127, P197, DOI 10.1016/0012-1606(88)90201-1; BUTTERWORTH FM, 1965, GENETICS, V52, P1153; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DEROBERTIS EM, 1991, DEVELOPMENT, V112, P669; DUBENDORFER K, 1982, ROUX ARCH DEV BIOL, V191, P42, DOI 10.1007/BF00848545; FERRUS A, 1975, GENETICS, V79, P589; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1993, DEVELOPMENT, V118, P527; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JAMES AA, 1981, DEV BIOL, V85, P39, DOI 10.1016/0012-1606(81)90234-7; KORNBERG T, 1981, DEV BIOL, V86, P363, DOI 10.1016/0012-1606(81)90194-9; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LAWRENCE PA, 1977, DEV BIOL, V56, P40, DOI 10.1016/0012-1606(77)90153-1; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LUMSDEN A, 1991, PHILOS T R SOC B, V331, P281, DOI 10.1098/rstb.1991.0017; MARTINEZARIAS A, 1985, NATURE, V313, P639, DOI 10.1038/313639a0; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MEINHARDT H, 1991, SEMIN DEV BIOL, V12, P129; MORATA G, 1979, DEV BIOL, V70, P355, DOI 10.1016/0012-1606(79)90033-2; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OBROCHTA DA, 1985, NATURE, V313, P138, DOI 10.1038/313138a0; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; SCHUPBACH T, 1978, ROUX ARCH DEV BIOL, V185, P249, DOI 10.1007/BF00848355; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SIMCOX AA, 1989, DEVELOPMENT, V107, P715; SKAER H, 1992, DEVELOPMENT, V116, P745; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STRUHL G, 1977, NATURE, V270, P723, DOI 10.1038/270723a0; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WIESCHAUS E, 1976, DEV BIOL, V50, P249, DOI 10.1016/0012-1606(76)90150-0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; XU T, 1993, DEVELOPMENT, V117, P1223	56	305	308	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 19	1993	75	4					741	752		10.1016/0092-8674(93)90494-B	http://dx.doi.org/10.1016/0092-8674(93)90494-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242746	Bronze			2022-12-01	WOS:A1993MH74900019
J	HACCARD, O; SARCEVIC, B; LEWELLYN, A; HARTLEY, R; ROY, L; IZUMI, T; ERIKSON, E; MALLER, JL				HACCARD, O; SARCEVIC, B; LEWELLYN, A; HARTLEY, R; ROY, L; IZUMI, T; ERIKSON, E; MALLER, JL			INDUCTION OF METAPHASE ARREST IN CLEAVING XENOPUS-EMBRYOS BY MAP KINASE	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; MATURATION-PROMOTING FACTOR; MEIOTIC MATURATION; OOCYTE MATURATION; M-PHASE; TYROSINE PHOSPHORYLATION; ONCOGENE PRODUCT; EGGS; INVITRO; CELLS	The natural arrest of vertebrate unfertilized eggs in second meiotic metaphase results from the activity of cytostatic factor (CSF). The product of the c-mos(xe) proto-oncogene is thought to be a component of CSF and can induce metaphase arrest when injected into blastomeres of two-cell embryos. The c-Mos(xe) protein can directly activate the mitogen-activated protein kinase kinase (MAP kinase kinase) in vitro, leading to activation of MAP kinase. MAP kinase and c-Mos(xe) are active in unfertilized eggs and are rapidly inactivated after fertilization. Microinjection of thiophosphorylated MAP kinase into one blastomere of a two-cell embryo induced metaphase arrest similar to that induced by c-Mos(xe). However, only arrest with c-Mos(xe) was associated with activation of endogenous MAP kinase. These results indicate that active MAP kinase is a component of CSF in Xenopus and suggest that the CSF activity of C-Mos(xe) is mediated by MAP kinase.	UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Sarcevic, Boris/0000-0002-8063-1050; Haccard, Olivier/0000-0002-4305-2746	NCI NIH HHS [F32CA0981] Funding Source: Medline; NIGMS NIH HHS [GM26743] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BARRETT CB, 1990, MOL CELL BIOL, V10, P4408; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GABRIELLI BG, 1993, SCIENCE, V259, P1766, DOI 10.1126/science.8456304; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GERHART JC, 1984, J CELL BIOL, V98, P185; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P266; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MURRAY AW, 1993, CURR BIOL, V3, P291, DOI 10.1016/0960-9822(93)90182-N; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; ROY L, UNPUB; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SARCEVIC B, IN PRESS J BIOL CHEM; SEGER R, 1992, J BIOL CHEM, V267, P25628; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHINA N, 1992, EMBO J, V11, P3977; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VANRENTERGHEM B, 1993, J BIOL CHEM, V268, P19935; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	49	249	254	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1262	1265		10.1126/science.8235656	http://dx.doi.org/10.1126/science.8235656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235656				2022-12-01	WOS:A1993MH32400038
J	BRENNER, S; ELGAR, G; SANDFORD, R; MACRAE, A; VENKATESH, B; APARICIO, S				BRENNER, S; ELGAR, G; SANDFORD, R; MACRAE, A; VENKATESH, B; APARICIO, S			CHARACTERIZATION OF THE PUFFERFISH (FUGU) GENOME AS A COMPACT MODEL VERTEBRATE GENOME	NATURE			English	Article							MAMMALIAN GENOMES; DNA-SEQUENCE; MICROSATELLITES; EVOLUTION	CLONING and sequencing techniques now allow us to characterize genes directly instead of having to deduce their properties from their effects. This new genetics reaches its apotheosis in the plan to obtain the complete DNA sequence of the human genome, but this is far beyond the capacity of present sequencing methods. Small 'model' genomes, such as those of Escherichia coli (4.7 megabases (Mb)1 and yeast (14 Mb)2, or even those of Caenorhabditis elegans (100 Mb) and Drosophila (165 Mb), are better scaled to existing technology. The yeast genome will contain genes with functions common to all eukaryotic cells, and those of simple multicellular organisms may throw light on the genetic specification of more complex functions. However, vertebrates differ in their morphology and development, so the ideal model would be a vertebrate genome of minimum size and complexity but with maximum homology to the human genome. Here we report the characterization of the small genome (400 Mb) of the tetraodontoid fish, Fugu rubripes5. A random sequencing approach supported by gene probing shows that the haploid genome contains 400 Mb of DNA, of which more that 90% is unique. This genome is 7.5 times smaller than the human genome and because it has a similar gene repertoire it is the best model genome for the discovery of human genes.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, SCH CLIN, MRC, MOLEC GENET UNIT, CAMBRIDGE CB2 2QQ, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	BRENNER, S (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, SCH CLIN, DEPT MED, CAMBRIDGE CB2 2QQ, ENGLAND.			Elgar, Greg/0000-0001-7323-1596; Aparicio, Samuel/0000-0002-0487-9599; Venkatesh, Byrappa/0000-0003-3620-0277				AJIOKA JW, 1991, CHROMOSOMA, V100, P459; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HINEGARD.R, 1968, AM NAT, V102, P517, DOI 10.1086/282564; HINEGARDNER R, 1972, AM NAT, V106, P621, DOI 10.1086/282801; KARN J, 1984, GENE, V32, P217, DOI 10.1016/0378-1119(84)90049-0; LANZA F, 1990, J BIOL CHEM, V265, P18098; MOORE SS, 1991, GENOMICS, V10, P654, DOI 10.1016/0888-7543(91)90448-N; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PARSONS JD, 1992, COMPUT APPL BIOSCI, V8, P461; PIZON V, 1984, EUR J BIOCHEM, V140, P25, DOI 10.1111/j.1432-1033.1984.tb08062.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH CL, 1987, SCIENCE, V236, P1448, DOI 10.1126/science.3296194; STALLINGS RL, 1991, GENOMICS, V10, P807, DOI 10.1016/0888-7543(91)90467-S; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; 1984, PUFFERFISHES AVAILAB	19	488	535	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1993	366	6452					265	268		10.1038/366265a0	http://dx.doi.org/10.1038/366265a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232585				2022-12-01	WOS:A1993MH32500063
J	SELLEM, CH; LECELLIER, G; BELCOUR, L				SELLEM, CH; LECELLIER, G; BELCOUR, L			TRANSPOSITION OF A GROUP-II INTRON	NATURE			English	Article							PODOSPORA-ANSERINA; MITOCHONDRIAL PLASMID; RNA; DNA; SENESCENCE; GENE; PROTEIN; INVITRO	AMONG mobile genetic elements, self-splicing introns are of particular interest. They belong to either group I or group II depending on their three-dimensional structure1-3. Homing, the systematic intron invasion of an intronless gene when it encounters its homologous intron-bearing allele, is the only means for intron mobility so far demonstrated4. It depends on the activity of the intron-encoded protein and is very specific for the acceptor site4-7. Intron transposition, the transfer of an intron to a novel site, predicted on the basis of phylogenetic studies8,9 and in vitro reverse-splicing experiments, has been proposed to be responsible for evolutionary intron spreading2,10-14. Here we present results from polymerase chain reaction experiments consistent with transposition of a group II intron. This event is proposed to account for the site-specific deletion in the mitochondrial chromosome of the fungus Podospora anserina that is associated with the premature death syndrome15 and might also be involved in the senescence process16 affecting this species.			BELCOUR, L (corresponding author), CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE.		Lecellier, Gael/D-3782-2009	Lecellier, Gael/0000-0003-3331-6311				AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BELCOUR L, 1977, MOL GEN GENET, V153, P11, DOI 10.1007/BF01035991; BELCOUR L, 1991, P NATL ACAD SCI USA, V88, P3579, DOI 10.1073/pnas.88.9.3579; BELCOUR L, 1981, CURR GENET, V3, P13, DOI 10.1007/BF00419575; CECH TR, 1985, INT REV CYTOL, V93, P3, DOI 10.1016/S0074-7696(08)61370-4; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CUMMINGS DJ, 1990, CURR GENET, V17, P375, DOI 10.1007/BF00334517; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; DUJON B, 1986, EXTRACHROMOSOMAL ELE, P5; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1985, CELL, V41, P383, DOI 10.1016/S0092-8674(85)80011-8; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; KUCH U, 1981, CURR GENET, V3, P151; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; MACREADIE IG, 1985, CELL, V41, P395, DOI 10.1016/S0092-8674(85)80012-X; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, CURR GENET, V10, P69, DOI 10.1007/BF00418495; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; OSIEWACZ HD, 1984, CURR GENET, V8, P299, DOI 10.1007/BF00419728; RIZET G, 1953, CR HEBD ACAD SCI, V237, P8328; SAINSARDCHANET A, 1990, NUCLEIC ACIDS RES, V18, P779, DOI 10.1093/nar/18.4.779; SAISARTCHANET A, IN PRESS J MOL BIOL; SCHMIDT U, 1900, EMBO J, V9, P2289; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; WRIGHT RM, 1983, CURR GENET, V7, P457, DOI 10.1007/BF00377611; WRIGHT RM, 1982, CELL, V29, P505, DOI 10.1016/0092-8674(82)90167-2	30	103	106	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					176	178		10.1038/366176a0	http://dx.doi.org/10.1038/366176a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232558				2022-12-01	WOS:A1993MG21600063
J	MCNALLY, FJ; VALE, RD				MCNALLY, FJ; VALE, RD			IDENTIFICATION OF KATANIN, AN ATPASE THAT SEVERS AND DISASSEMBLES STABLE MICROTUBULES	CELL			English	Article							FLUORESCENCE ENERGY-TRANSFER; XENOPUS EGG EXTRACTS; DYNAMIC INSTABILITY; INDIVIDUAL MICROTUBULES; GOLGI-APPARATUS; PROTEIN; CELLS; TUBULIN; VISUALIZATION; STABILIZATION	Eukaryotic cells rapidly reorganize their microtubule cytoskeleton during the cell cycle, differentiation, and cell migration. In this study, we have purified a heterodimeric protein, katanin, that severs and disassembles microtubules to tubulin dimers. The disassembled tubulin can repolymerize, indicating that it is not irreversibly modified or denatured in the reaction. Katanin is a microtubule-stimulated ATPase and requires ATP hydrolysis to sever microtubules. Katanin represents a novel type of enzyme that utilizes energy from nucleotide hydrolysis to break tubulin-tubulin bonds within a microtubule polymer, a process that may aid in disassembling complex microtubule arrays within cells.			MCNALLY, FJ (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.				NIGMS NIH HHS [GM38499, GM49752] Funding Source: Medline; NINDS NIH HHS [NS07067-15] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038499, R01GM049752, R37GM038499] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAAS PW, 1989, J CELL BIOL, V109, P3085, DOI 10.1083/jcb.109.6.3085; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BORDAS J, 1983, J MOL BIOL, V164, P89, DOI 10.1016/0022-2836(83)90089-X; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUSTER D, 1991, J CELL SCI, P109; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CHAPIN SJ, 1992, CELL MOTIL CYTOSKEL, V23, P236, DOI 10.1002/cm.970230403; DRESCHEL DN, 1992, MOL BIOL CELL, V3, P1141; DYE RB, 1992, CELL MOTIL CYTOSKEL, V21, P171, DOI 10.1002/cm.970210302; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; FEBVRECHEVALIER C, 1992, J CELL BIOL, V118, P585, DOI 10.1083/jcb.118.3.585; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; GEIGER B, 1982, J CELL BIOL, V95, P137, DOI 10.1083/jcb.95.1.137; GREENE LE, 1980, J BIOL CHEM, V255, P543; GUNDERSEN GG, 1988, P NATL ACAD SCI USA, V85, P5946, DOI 10.1073/pnas.85.16.5946; HO WC, 1990, EUR J CELL BIOL, V52, P315; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; KARSENTI E, 1993, CURR BIOL, V3, P208, DOI 10.1016/0960-9822(93)90334-K; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KITANISHIYUMURA T, 1987, CELL MOTIL CYTOSKEL, V8, P106, DOI 10.1002/cm.970080203; KUPFER A, 1982, P NATL ACAD SCI-BIOL, V79, P2603, DOI 10.1073/pnas.79.8.2603; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MITCHISON TJ, 1992, MOL BIOL CELL, V3, P1309, DOI 10.1091/mbc.3.12.1309; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; RAPPAPORT R, 1985, J EXP ZOOL, V234, P167, DOI 10.1002/jez.1402340120; SABRY JH, 1991, J CELL BIOL, V115, P381, DOI 10.1083/jcb.115.2.381; SANDERS MA, 1989, J CELL BIOL, V108, P1751, DOI 10.1083/jcb.108.5.1751; SCHOLEY JM, 1984, J BIOL CHEM, V259, P6516; SHIINA N, 1992, EMBO J, V11, P4723, DOI 10.1002/j.1460-2075.1992.tb05577.x; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIMON JR, 1992, CELL MOTIL CYTOSKEL, V21, P1, DOI 10.1002/cm.970210102; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TAYLOR DL, 1981, J CELL BIOL, V89, P362, DOI 10.1083/jcb.89.2.362; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; YAMAMOTO K, 1982, J CELL BIOL, V95, P711, DOI 10.1083/jcb.95.3.711	45	400	414	0	31	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 5	1993	75	3					419	429		10.1016/0092-8674(93)90377-3	http://dx.doi.org/10.1016/0092-8674(93)90377-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8221885				2022-12-01	WOS:A1993MF83000005
J	MILLS, CM; HILL, SA; MARKS, R				MILLS, CM; HILL, SA; MARKS, R			ALTERED INFLAMMATORY RESPONSES IN SMOKERS	BRITISH MEDICAL JOURNAL			English	Article							SMOKING				MILLS, CM (corresponding author), UNIV HOSP WALES,DEPT DERMATOL,CARDIFF CF4 4XN,WALES.							MILLS CM, 1993, CLIN EXP DERMATOL, V18, P100, DOI 10.1111/j.1365-2230.1993.tb00986.x; MOTLEY RJ, 1987, DIGESTION, V37, P125, DOI 10.1159/000199478; NADLER JL, 1983, LANCET, V1, P1248; PEARSE AD, 1990, INT J COSMETIC SCI, V12, P63, DOI 10.1111/j.1467-2494.1990.tb00521.x; Roth GM, 1944, J AMER MED ASSOC, V125, P761, DOI 10.1001/jama.1944.02850290001001	5	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					911	911		10.1136/bmj.307.6909.911	http://dx.doi.org/10.1136/bmj.307.6909.911			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241856	Green Published, Bronze			2022-12-01	WOS:A1993MB84700021
J	CORMACK, BP; STRUHL, K				CORMACK, BP; STRUHL, K			REGIONAL CODON RANDOMIZATION - DEFINING A TATA-BINDING PROTEIN SURFACE REQUIRED FOR RNA POLYMERASE-III TRANSCRIPTION	SCIENCE			English	Article							YEAST; COMPONENTS; TFIIIB; LESS; PROMOTERS; HOMOLOGY; COMPLEX; ENCODES	The TATA-binding protein (TBP) is required for transcription by all three nuclear RNA polymerases. TBP was subjected to regional codon randomization, a codon-based mutagenesis method that generates complex yet compact protein libraries. Analysis of 186 temperature-sensitive TBP mutants yielded 65 specifically defective in transcription by RNA polymerase III (Pol III). These mutants map to a limited TBP surface that may interact with Tds4, a component of the Pol III transcription factor TFIIIB. Strains that contain the Pol III-defective derivatives have increased amounts of messenger RNA, which suggests that competition among TBP-interacting factors for limiting quantities of TBP determines the ratio of Pol II and Pol III transcription in vivo.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030186, R37GM030186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; GLASER SM, 1992, J IMMUNOL, V1499, P3903; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE WS, 1991, CELL, V67, P367; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	24	96	99	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 8	1993	262	5131					244	248		10.1126/science.8211143	http://dx.doi.org/10.1126/science.8211143			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA665	8211143				2022-12-01	WOS:A1993MA66500036
J	CHEN, BS; CHOI, GH; NUSS, DL				CHEN, BS; CHOI, GH; NUSS, DL			ATTENUATION OF FUNGAL VIRULENCE BY SYNTHETIC INFECTIOUS HYPOVIRUS TRANSCRIPTS	SCIENCE			English	Article							CHESTNUT BLIGHT FUNGUS; ENDOTHIA-PARASITICA; BIOLOGICAL-CONTROL; VIRAL CDNA; EXPRESSION; STRAINS; VIRUS	Noninfectious, cytoplasmically transmissible viral double-stranded RNAs of the genus Hypovirus cause reduced virulence (hypovirulence) in the chestnut blight fungus Cryphonectria parasitica, providing the basis for virus-mediated biological control of a fungal disease. Synthetic transcripts corresponding to a full-length hypovirus RNA coding strand are infectious when introduced into fungal spheroplasts by electroporation. Hypovirus infections were readily established in Cryphonectria parasitica and in related fungal species not previously reported to harbor viruses. These results demonstrate the use of a synthetic mycovirus transcript to expand fungal host range, thereby broadening the potential application of virus-mediated hypovirulence to control fungal pathogenesis.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding								ANAGNOSTAKIS SL, 1979, PHYTOPATHOLOGY, V69, P1226, DOI 10.1094/Phyto-69-1226; ANAGNOSTAKIS SL, 1982, SCIENCE, V215, P466, DOI 10.1126/science.215.4532.466; APPEL DN, 1984, PLANT DIS, V68, P851, DOI 10.1094/PD-69-851; BARR ME, 1978, DIAPORTHALES N AM; BUCK KW, 1985, FUNGAL VIROLOGY OVER; CHEN B, IN PRESS VIROLOGY; CHEN BS, 1993, EMBO J, V12, P2991, DOI 10.1002/j.1460-2075.1993.tb05967.x; CHOI GH, 1992, SCIENCE, V257, P800, DOI 10.1126/science.1496400; CHOI GH, 1992, EMBO J, V11, P473, DOI 10.1002/j.1460-2075.1992.tb05077.x; CHURCHILL ACL, 1991, CURR GENET, V17, P25; CRAVEN MG, 1993, J VIROL, V67, P6513, DOI 10.1128/JVI.67.11.6513-6521.1993; HILLMAN BI, 1990, PHYTOPATHOLOGY, V80, P950, DOI 10.1094/Phyto-80-950; HODGES CS, 1980, MYCOLOGIA, V72, P542, DOI 10.2307/3759528; JAYNES RA, 1980, PHYTOPATHOLOGY, V70, P453, DOI 10.1094/Phyto-70-453; LARSON TG, 1992, EMBO J, V11, P4539, DOI 10.1002/j.1460-2075.1992.tb05555.x; MICALES JA, 1986, MYCOTAXON, V26, P99; Roane MK, 1986, CHESTNUT BLIGHT OTHE, P1; SHAPIRA R, 1991, EMBO J, V10, P731, DOI 10.1002/j.1460-2075.1991.tb08004.x; VANALFEN NK, 1975, SCIENCE, V189, P890, DOI 10.1126/science.189.4206.890; VANALFEN NK, 1986, HYPOVIRULENCE ENDOTH; WICKNER RB, 1989, FASEB J, V3, P2257, DOI 10.1096/fasebj.3.11.2550303	21	104	115	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 17	1994	264	5166					1762	1764		10.1126/science.8209256	http://dx.doi.org/10.1126/science.8209256			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR600	8209256				2022-12-01	WOS:A1994NR60000043
J	ESGUERRA, M; WANG, J; FOSTER, CD; ADELMAN, JP; NORTH, RA; LEVITAN, IB				ESGUERRA, M; WANG, J; FOSTER, CD; ADELMAN, JP; NORTH, RA; LEVITAN, IB			CLONED CA2+-DEPENDENT K+ CHANNEL MODULATED BY A FUNCTIONALLY ASSOCIATED PROTEIN-KINASE	NATURE			English	Article							ACTIVATED POTASSIUM CHANNELS; PHOSPHORYLATION; CAMP; BRAIN; DEPHOSPHORYLATION; CELLS	CALCIUM-DEPENDENT potassium (K-Ca) channels carry ionic currents that regulate important cellular functions(1-3). Like some other ion channels(4-10), K-Ca channels are modulated by protein phosphorylation(2,11,15-21). The recent cloning of complementary DNAs encoding Slo K-Ca channels(12-14) has enabled K-Ca channel modulation to be investigated. We report here that protein phosphorylation modulates the activity of Drosophila Slo K-Ca channels expressed in Xenopus oocytes. Application of ATP-gamma S to detached membrane patches increases Slo channel activity by shifting channel voltage sensitivity. This modulation is blocked by a specific inhibitor of cyclic AMP-dependent protein kinase (PKA). Mutation of a single serine residue in the channel protein also blocks modulation by ATP-gamma S, demonstrating that phosphorylation of the Slo channel protein itself modulates channel activity. The results also indicate that K-Ca channels in oocyte membrane patches can be modulated by an endogenous PKA-like protein kinase which remains functionally associated with the channels in the detached patch.	BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Brandeis University; Brandeis University; Oregon Health & Science University			North, Richard/GQA-6156-2022	Esguerra, Manuel/0000-0002-6934-5424				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BLUMENTHAL EM, 1992, J NEUROSCI, V12, P290; BUSCH AE, 1992, SCIENCE, V255, P1705, DOI 10.1126/science.1553557; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CARR DW, 1992, J BIOL CHEM, V267, P16816; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; EMERICK MC, 1989, BIOCHEMISTRY-US, V28, P8367, DOI 10.1021/bi00447a016; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LANCASTER B, 1991, J NEUROSCI, V11, P23; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LECHLEITER JD, 1988, NEURON, V1, P227, DOI 10.1016/0896-6273(88)90143-2; LEVITAN IBA, 1994, REV PHYSL, V56, P193; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; PENNEFATHER P, 1985, P NATL ACAD SCI USA, V82, P3040, DOI 10.1073/pnas.82.9.3040; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; REINHART PH, 1991, J NEUROSCI, V11, P1627; SADOSHIMA JI, 1988, AM J PHYSIOL, V255, pH754, DOI 10.1152/ajpheart.1988.255.4.H754; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0	29	102	105	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 16	1994	369	6481					563	565		10.1038/369563a0	http://dx.doi.org/10.1038/369563a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	8202157				2022-12-01	WOS:A1994NR29400050
J	KAY, GF; BARTON, SC; SURANI, MA; RASTAN, S				KAY, GF; BARTON, SC; SURANI, MA; RASTAN, S			IMPRINTING AND X-CHROMOSOME COUNTING MECHANISMS DETERMINE XIST EXPRESSION IN EARLY MOUSE DEVELOPMENT	CELL			English	Article							INACTIVATION CENTER; PREFERENTIAL INACTIVATION; EMBRYOS; GENE; METHYLATION; GENOMES; BLASTOCYSTS; MEMBRANES; NUCLEUS	In mice, X inactivation is preceded by in cis Xist expression. Initially, normal female embryos express the paternal Xist allele exclusively, preceding imprinted X inactivation in the trophectoderm Later expression of Xist alleles is random, preceding random X inactivation in the epiblast lineage. In this study using uniparental embryos, we demonstrate that Xist expression is initially dictated solely by parental imprinting, causing expression of all paternal alleles. Maternal alleles remain repressed, irrespective of X chromosome number. At the compacting morula stage, this parental imprint is erased, and the mechanism counting the X chromosomes imposes appropriate Xist expression with respect to chromosome number. Our results also suggest that Xist expression may itself be regulated by a novel imprinted maternally expressed gene.	MRC, CLIN RES CTR, COMPARAT BIOL SECT, HARROW HA1 3UJ, MIDDX, ENGLAND; WELLCOME CANCER RES CAMPAIGN, INST CANC & DEV BIOL, CAMBRIDGE CB2 1QR, ENGLAND; UNIV CAMBRIDGE, PHYSIOL LAB, CAMBRIDGE CB2 1QR, ENGLAND	Medical Research Council Clinical Trials Unit; University of Cambridge			Kay, Graham F/A-4130-2011	Surani, Azim/0000-0002-8640-4318	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BABINET C, 1990, DEVELOPMENT, P81; BARTON SC, 1984, NATURE, V311, P374, DOI 10.1038/311374a0; BARTON SC, 1993, METHOD ENZYMOL, V225, P732; BARTON SC, 1985, J EMBRYOL EXP MORPH, V90, P267; BIRD AP, 1993, CURR BIOL, V3, P275, DOI 10.1016/0960-9822(93)90177-P; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; EPSTEIN CJ, 1978, NATURE, V274, P500, DOI 10.1038/274500a0; JOHNSON MH, 1981, CELL, V24, P71, DOI 10.1016/0092-8674(81)90502-X; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KAUFMAN MH, 1989, CYTOGENET CELL GENET, V52, P15, DOI 10.1159/000132830; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KELLY SJ, 1977, J EXP ZOOL, V200, P365, DOI 10.1002/jez.1402000307; LATHAM KE, 1994, GENE DEV, V8, P290, DOI 10.1101/gad.8.3.290; LATHAM KE, 1991, DEVELOPMENT, V113, P561; LYON MF, 1991, TRENDS GENET, V7, P69, DOI 10.1016/0168-9525(91)90271-Q; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MANN JR, 1988, DEVELOPMENT, V104, P129; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; McLaren A., 1976, MAMMALIAN CHIMAERAS; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; MONK M, 1991, DEVELOPMENT, V112, P189; MONK M, 1978, J EMBRYOL EXP MORPH, V46, P53; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RASTAN S, 1980, NATURE, V288, P172, DOI 10.1038/288172a0; REIK W, 1993, DEVELOPMENT, V119, P933; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SURANI MA, 1990, DEVELOPMENT, P89; SURANI MAH, 1986, CELL, V45, P127, DOI 10.1016/0092-8674(86)90544-1; SURANI MAH, 1983, SCIENCE, V222, P1034, DOI 10.1126/science.6648518; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; TAKAGI N, 1978, CYTOGENET CELL GENET, V20, P240, DOI 10.1159/000130856; THORNHILL AR, 1993, DEVELOPMENT, V118, P171; WALSH W, 1994, IN PRESS MECH DEV; WEST JD, 1977, CELL, V12, P873, DOI 10.1016/0092-8674(77)90151-9	45	214	214	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	1994	77	5					639	650		10.1016/0092-8674(94)90049-3	http://dx.doi.org/10.1016/0092-8674(94)90049-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NQ123	8205614				2022-12-01	WOS:A1994NQ12300005
J	SU, B; JACINTO, E; HIBI, M; KALLUNKI, T; KARIN, M; BEN-NERIAH, Y				SU, B; JACINTO, E; HIBI, M; KALLUNKI, T; KARIN, M; BEN-NERIAH, Y			JNK IS INVOLVED IN SIGNAL INTEGRATION DURING COSTIMULATION OF T-LYMPHOCYTES	CELL			English	Article							CELL ACTIVATION GENES; C-JUN; PROTEIN-KINASE; DNA-BINDING; CYCLOSPORINE-A; INTERLEUKIN-2 PROMOTER; NUCLEAR FACTOR; CD28 RECEPTOR; CLONAL ANERGY; MAP KINASES	T lymphocyte activation and interleukin-2 (IL-2) production require at least two signals, generated by phorbol ester (TPA) and Ca2+ ionophore or costimulation of the T cell receptor (TCR) and the CD28 auxiliary receptor. We investigated how these stimuli affect mitogen activated protein (MAP) kinases. Full activation of the MAP kinases that phosphorylate the Jun activation domain, JNK1 and JNK2, required costimulation of T cells with either TPA and Ca2+ ionophore or antibodies to TCR and CD28. Alone, each stimulus resulted in little or no activation. Similar to its effect on IL-2 induction, cyclosporin A (CsA) inhibited the synergistic activation of JNK, and a competitive inhibitor of Jun phosphorylation by JNK inhibited IL-2 promoter activation. By contrast, the MAP kinases ERK1 and ERK2 were fully activated by TPA or TCR stimulation and were not affected by Ca2+, CD28, or CsA. Hence, integration of signals that lead to T cell activation occurs at the level of JNK activation.			SU, B (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, BIOMED SCI PROGRAM, DEPT PHARMACOL, LA JOLLA, CA 92093 USA.		Hibi, Masahiko/I-6215-2014; Ben-Neriah, Yinon/L-6285-2019	Hibi, Masahiko/0000-0002-9142-4444; Kallunki, Tuula/0000-0002-8571-383X; Jacinto, Estela/0000-0001-7118-1759	NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NCI NIH HHS [CA-50528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOWNWARD J, 1990, NATURE, V346, P651; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUNTER KC, 1989, J IMMUNOL, V142, P3286; HANSEN JA, 1980, IMMUNOGENETICS, V10, P247, DOI 10.1007/BF01561573; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IMBODEN JB, 1988, PROG ALLERGY, V42, P246; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KYRLAKIS S, 1992, NATURE, V358, P417; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATILLA PS, 1990, EMBO J, V9, P4425; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO A, 1991, CRIT REV IMMUNOL, V10, P495; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V173, P753; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VANWAUWE JP, 1980, J IMMUNOL, V124, P2708; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YANG-YEN H-F, 1990, New Biologist, V2, P351; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	59	871	891	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 3	1994	77	5					727	736		10.1016/0092-8674(94)90056-6	http://dx.doi.org/10.1016/0092-8674(94)90056-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NQ123	8205621				2022-12-01	WOS:A1994NQ12300012
J	PARTHASARATHY, RV; MARTIN, CR				PARTHASARATHY, RV; MARTIN, CR			SYNTHESIS OF POLYMERIC MICROCAPSULE ARRAYS AND THEIR USE FOR ENZYME IMMOBILIZATION	NATURE			English	Article							GLUCOSE-OXIDASE; TEMPLATE SYNTHESIS; COVALENT ELECTROPOLYMERIZATION; ELECTRONIC CONDUCTIVITIES; POLYPYRROLE FILMS; MICROTUBULES; SENSORS	CURRENT methods for immobilizing enzymes for use in bioreactors and biosensors(1-20) include adsorption on or covalent attachment to a support(2-4), micro-encapsulation(5,6), and entrapment within a membrane/film(7,8,11-20) or gel(9). The ideal immobilization method should employ mild chemical conditions, allow for large quantities of enzyme to be immobilized, provide a large surface area for enzyme-substrate contact within a small total volume, minimize barriers to mass transport of substrate and product, and provide a chemically and mechanically robust system. Here we describe a method for enzyme immobilization that satisfies all of these criteria. We have developed a template-based synthetic method that yields hollow polymeric microcapsules of uniform diameter and length. These microcapsules are arranged in a high-density array in which the individual capsules protrude from a surface like the bristles of a brush. We have developed procedures for filling these microcapsules with high concentrations of enzymes. The enzyme-loaded microcapsule arrays function as enzymatic bioreactors in both aqueous solution and organic solvents.	COLORADO STATE UNIV,DEPT CHEM,FT COLLINS,CO 80523	Colorado State University			Way, James Douglas/A-9408-2010; Martin, Charles/AAA-1040-2019	Way, James Douglas/0000-0001-9612-8508; 				ALMEIDA NF, 1993, BIOTECHNOL BIOENG, V42, P1037, DOI 10.1002/bit.260420904; BAKER RW, 1991, MEMBRANE SEPARATION, V2, P151; BARTLETT PN, 1987, J ELECTROANAL CHEM, V224, P37, DOI 10.1016/0022-0728(87)85082-9; BARTLETT PN, 1992, J CHEM SOC FARADAY T, V88, P2677, DOI 10.1039/ft9928802677; BURGMAYER P, 1986, HDB CONDUCTING POLYM, V1, pCH15; CAI ZH, 1989, J AM CHEM SOC, V111, P4138, DOI 10.1021/ja00193a077; DALVIE SK, 1992, BIOTECHNOL BIOENG, V40, P1174; ELLERBY LM, 1992, SCIENCE, V255, P1113, DOI 10.1126/science.1312257; FORTIER G, 1991, BIOTECHNOL BIOENG, V37, P854, DOI 10.1002/bit.260370909; FOULDS NC, 1986, J CHEM SOC FARAD T 1, V82, P1259, DOI 10.1039/f19868201259; FOULDS NC, 1988, ANAL CHEM, V60, P2473, DOI 10.1021/ac00173a008; GEORGER JH, 1987, J AM CHEM SOC, V109, P6169, DOI 10.1021/ja00254a042; GU KF, 1988, BIOREACTOR IMMOBILIZ, P59; KAJIYA Y, 1991, ANAL CHEM, V63, P49, DOI 10.1021/ac00001a009; KLEI HE, 1985, IMMOBILIZED CELLS EN, pCH4; KOOPAL CGJ, 1992, SYNTHETIC MET, V51, P397, DOI 10.1016/0379-6779(92)90295-T; MAIDAN R, 1992, ANAL CHEM, V64, P2889, DOI 10.1021/ac00047a003; MARCHESIELLO M, 1992, ELECTROCHIM ACTA, V37, P1987, DOI 10.1016/0013-4686(92)87113-E; MARCHESIELLO M, 1993, J ELECTROANAL CHEM, V358, P35, DOI 10.1016/0022-0728(93)80429-L; MARTIN CR, 1990, J AM CHEM SOC, V112, P8976, DOI 10.1021/ja00180a050; MARTIN CR, 1991, ADV MATER, V3, P457, DOI 10.1002/adma.19910030914; MARTIN CR, 1993, SYNTHETIC MET, V55, P1165, DOI 10.1016/0379-6779(93)90218-L; MARTIN CR, IN PRESS ELECTROCHIM; PENNER RM, 1988, J PHYS CHEM-US, V92, P5274, DOI 10.1021/j100329a042; POOL R, 1990, SCIENCE, V247, P1410; SOBER HA, 1968, HDB BIOCH, pC11; SUN ZS, 1992, ANAL CHEM, V64, P1112, DOI 10.1021/ac00034a008; TATSUMA T, 1993, J ELECTROANAL CHEM, V356, P245, DOI 10.1016/0022-0728(93)80523-K; UMANA M, 1986, ANAL CHEM, V58, P2979, DOI 10.1021/ac00127a018; WOLOWACZ SE, 1992, ANAL CHEM, V64, P1541, DOI 10.1021/ac00038a008; WOODWARD J, 1985, IMMOBILIZED CELLS EN; YONHIN BFY, 1993, ANAL CHEM, V65, P2067, DOI 10.1021/ac00063a022; ZAKS A, 1988, J BIOL CHEM, V263, P3194; 1972, WORTHINGTON ENZYME M, P41	34	324	350	2	181	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					298	301		10.1038/369298a0	http://dx.doi.org/10.1038/369298a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	8183367				2022-12-01	WOS:A1994NN10900042
J	SETH, A; STERN, LJ; OTTENHOFF, THM; ENGEL, I; OWEN, MJ; LAMB, JR; KLAUSNER, RD; WILEY, DC				SETH, A; STERN, LJ; OTTENHOFF, THM; ENGEL, I; OWEN, MJ; LAMB, JR; KLAUSNER, RD; WILEY, DC			BINARY AND TERNARY COMPLEXES BETWEEN T-CELL RECEPTOR, CLASS-II MHC AND SUPERANTIGEN IN-VITRO	NATURE			English	Article							ANTIGEN RECEPTOR; LYMPHOCYTES-T; ENTEROTOXIN-B; PROTEINS; PEPTIDE; RECOGNITION; AFFINITY; HETERODIMERS; SURFACE; ANERGY	SUPERANTIGENS are proteins that in association with class II major histocompatibility complex (MHC)-bearing cells can stimulate virtually all T cells that express particular classes of the variable beta-domains of the T-cell receptor (TCR)(1). This mechanism of T-cell activation circumvents the usual requirement for peptide-specific MHC recognition. Staphylococcus aureus enterotoxin B (SEB) is a bacterial superantigen that causes food poisoning and shock(2-5). We have characterized the tertiary complex of SEB, a soluble T-cell receptor, and a soluble class II MHC molecule DR1, and the three binary complexes TCR-SEB, SEB-DR1, and the peptide-specific complex DR1-TCR. We report here that in each case the specificity of the interaction among the soluble molecules is the same as observed in biological assays. Native gel electrophoresis and plasmon resonance affinity measurements indicate that SEB-TCR complex can form in the absence of class II MHC and that SEB-TCR interaction increases the binding of DR1. The observation that a superantigen can form complexes with TCR in both the absence and presence of class II MHC may provide a mechanism for its ability to induce anergy in some circumstances and activation in others(6,7) (reviewed in ref. 8).	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892; IMPERIAL CANC RES FUND,LYMPHOCYTE MOLEC BIOL LAB,LONDON WC2A 3PX,ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT IMMUNOL,LONDON W2 1PG,ENGLAND	Harvard University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Cancer Research UK; Imperial College London	SETH, A (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; DAVIS MM, 1993, CURR OPIN IMMUNOL, V5, P45, DOI 10.1016/0952-7915(93)90079-8; DEUTSCHER MP, 1990, GUIDE PROTEIN PURIFI, P1; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FLEISCHER B, 1991, J IMMUNOL, V146, P11; Gascoigne N R, 1993, Semin Immunol, V5, P13, DOI 10.1006/smim.1993.1003; HERRMANN T, 1991, J IMMUNOL, V146, P2504; HEWITT CRA, 1992, J EXP MED, V175, P1493, DOI 10.1084/jem.175.6.1493; IRWIN MJ, 1993, IMMUNOL REV, V131, P61, DOI 10.1111/j.1600-065X.1993.tb01530.x; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; LABRECQUE N, 1993, RES IMMUNOL, V144, P175, DOI 10.1016/0923-2494(93)80113-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOFAS S, 1990, J CHEM SOC CHEM COMM, V21, P1526; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; Micusan V V, 1993, Semin Immunol, V5, P3, DOI 10.1006/smim.1993.1002; OHEHIR RE, 1990, P NATL ACAD SCI USA, V87, P8884, DOI 10.1073/pnas.87.22.8884; SCHOLL PR, 1989, J IMMUNOL, V143, P2583; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0	26	168	175	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					324	327		10.1038/369324a0	http://dx.doi.org/10.1038/369324a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	8183371				2022-12-01	WOS:A1994NN10900051
J	KIM, YJ; BJORKLUND, S; LI, Y; SAYRE, MH; KORNBERG, RD				KIM, YJ; BJORKLUND, S; LI, Y; SAYRE, MH; KORNBERG, RD			A MULTIPROTEIN MEDIATOR OF TRANSCRIPTIONAL ACTIVATION AND ITS INTERACTION WITH THE C-TERMINAL REPEAT DOMAIN OF RNA-POLYMERASE-II	CELL			English	Article							TATA-LESS PROMOTER; SACCHAROMYCES-CEREVISIAE; HEPTAPEPTIDE REPEAT; TFIID COMPLEX; GAL4; INITIATION; INVITRO; PROTEIN; BINDING; PURIFICATION	A mediator was isolated from yeast that enabled a response to the activator proteins GAL4-VP16 and GCN4 in a transcription system reconstituted with essentially homogeneous basal factors and RNA polymerase II. The mediator comprised some 20 polypeptides, including the three subunits of TFIIF and other polypeptides cross-reactive with antisera against GAL11, SUG1, SRB2, SRB4, SRB5, and SRB6 proteins. Mediator not only enabled activated transcription but also conferred 8-fold greater activity in basal transcription and 12-fold greater efficiency of phosphorylation of RNA polymerase II by the TFIIH-associated C-terminal repeat domain (CTD) kinase, indicative of mediator-CTD interaction. A holoenzyme form of RNA polymerase II was independently isolated that supported a response to activator proteins with purified basal factors. The holoenzyme proved to consist of mediator associated with core 12-subunit RNA polymerase II.			KIM, YJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305, USA.			Kim, Young-Joon/0000-0001-5061-587X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FASSLER JS, 1989, MOL CELL BIOL, V9, P5602, DOI 10.1128/MCB.9.12.5602; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HENRY NL, 1992, J BIOL CHEM, V267, P23388; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; KEAVENEY M, 1993, NATURE, V365, P562, DOI 10.1038/365562a0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; NISHIZAWA M, 1990, P NATL ACAD SCI USA, V87, P5373, DOI 10.1073/pnas.87.14.5373; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; POON D, 1993, J BIOL CHEM, V268, P15325; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SAKURAI H, 1993, P NATL ACAD SCI USA, V90, P8382, DOI 10.1073/pnas.90.18.8382; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4911; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	36	910	935	3	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					599	608		10.1016/0092-8674(94)90221-6	http://dx.doi.org/10.1016/0092-8674(94)90221-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	8187178				2022-12-01	WOS:A1994NM83200014
J	KYRIAKIS, JM; BANERJEE, P; NIKOLAKAKI, E; DAI, TA; RUBIE, EA; AHMAD, MF; AVRUCH, J; WOODGETT, JR				KYRIAKIS, JM; BANERJEE, P; NIKOLAKAKI, E; DAI, TA; RUBIE, EA; AHMAD, MF; AVRUCH, J; WOODGETT, JR			THE STRESS-ACTIVATED PROTEIN-KINASE SUBFAMILY OF C-JUN KINASES	NATURE			English	Article							NECROSIS-FACTOR-ALPHA; TUMOR-NECROSIS; MAP KINASE; PHOSPHORYLATION; INSULIN; TYROSINE; REQUIRES; FAMILY; DOMAIN	THE mitogen-activated protein (MAP) kinases Erk-1 and Erk-2 are proline-directed kinases that are themselves activated through concomitant phosphorylation of tyrosine and threonine residues(1-4). The kinase p54 (M(r) 54,000), which was first isolated from cycloheximide-treated rats, is proline-directed like Erks-1/2, and requires both Tyr and Ser/Thr phosphorylation(3,5,6) for activity. p54 is, however, distinct from Erks-1/2 in its substrate specificity, being unable to phosphorylate pp90(rsk) but more active in phosphorylating the c-Jun transactivation domain(5,7,8). Molecular cloning of p54 reveals a unique subfamily of extracellularly regulated kinases. Although they are 40-45% identical in sequence to Erks-1/2, unlike Erks-1/2 the p54s are only poorly activated in most cells by mitogens or phorbol esters. However, p54s are the principal c-Jun N-terminal kinases activated by cellular stress and tumour necrosis factor (TNF)-alpha, hence they are designated stress-activated protein kinases, or SAPKs. SAPKs are also activated by sphingomyelinase, which elicits a subset of cellular responses to TNF-alpha (ref. 9). SAPKs therefore define a new TNF-alpha and stress-activated signalling pathway, possibly initiated by sphingomyelin-based second messengers, which regulates the activity of c-Jun.	PRINCESS MARGARET HOSP, ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	KYRIAKIS, JM (corresponding author), MASSACHUSETTS GEN HOSP E, MED SERV, DIABET RES LAB, 149 13TH ST, BOSTON, MA 02129 USA.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; KYRIAKIS JM, IN PRESS FRONTIERS M; LEVIN DE, 1993, J NIH RES, V5, P49; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0	31	2472	2530	2	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 12	1994	369	6476					156	160		10.1038/369156a0	http://dx.doi.org/10.1038/369156a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK971	8177321				2022-12-01	WOS:A1994NK97100052
J	PERKINS, TT; QUAKE, SR; SMITH, DE; CHU, S				PERKINS, TT; QUAKE, SR; SMITH, DE; CHU, S			RELAXATION OF A SINGLE DNA MOLECULE OBSERVED BY OPTICAL MICROSCOPY	SCIENCE			English	Article							ENTANGLED POLYMER-SOLUTIONS; LIGHT-SCATTERING; TRANSLATIONAL DIFFUSION; ELONGATIONAL FLOW; GOOD SOLVENT; MACROMOLECULES; TEMPERATURE; POLYSTYRENE; PARTICLES; DYNAMICS	Single molecules of DNA, visualized in video fluorescence microscopy, were stretched to full extension in a flow, and their relaxation was measured when the flow stopped. The molecules, attached by one end to a 1-micrometer bead, were manipulated in an aqueous solution with optical tweezers. Inverse Laplace transformations of the relaxation data yielded spectra of decaying exponentials with distinct peaks, and the longest time component (tau) increased with length (L) as tau similar to L(1.66 +/- 0.10). A rescaling analysis showed that most of the relaxation curves had a universal shape and their characteristic times (lambda(t)) increased as lambda t similar to L(1.65 +/- 0.13). These results are in qualitative agreement with the theoretical prediction of dynamical scaling.	STANFORD UNIV,DEPT PHYS,STANFORD,CA 94305	Stanford University			Smith, Douglas E/A-3131-2017	Smith, Douglas E/0000-0002-8206-3632; Perkins, Thomas/0000-0003-4826-9490	PHS HHS [33289] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAM M, 1976, J PHYS-PARIS, V37, P1045, DOI 10.1051/jphys:019760037090104500; ADAM M, 1977, MACROMOLECULES, V10, P1229, DOI 10.1021/ma60060a014; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; Brandrup J., 1989, POLYM HDB, V3rd ed.; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; CHU S, 1980, INT C QUANTUM ELECTR, V8, P202; CROTHERS DM, 1965, J MOL BIOL, V12, P525, DOI 10.1016/S0022-2836(65)80310-2; De Gennes P-G., 1979, SCALING CONCEPTS POL; DEGENNES PG, 1974, J CHEM PHYS, V60, P5030, DOI 10.1063/1.1681018; DEGENNES PG, 1976, MACROMOLECULES, V9, P594, DOI 10.1021/ma60052a012; DEGENNES PG, 1976, MACROMOLECULES, V9, P587, DOI 10.1021/ma60052a011; DESCLOIZEAUX J, 1978, J PHYS LETT-PARIS, V39, P99; Doi M., 1986, THEORY POLYM DYNAMIC; Flory P.J., 1989, STAT MECH CHAIN MOL; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; KELLER A, 1985, COLLOID POLYM SCI, V263, P181, DOI 10.1007/BF01415506; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; MATSUMOTO M, 1992, J POLYM SCI POL PHYS, V30, P779, DOI 10.1002/polb.1992.090300716; MENASVETA MJ, 1991, MACROMOLECULES, V24, P3427, DOI 10.1021/ma00011a060; NARH KA, 1992, J POLYM SCI POL PHYS, V30, P335, DOI 10.1002/polb.1992.090300403; NEMOTO N, 1984, MACROMOLECULES, V17, P425, DOI 10.1021/ma00133a029; PECORA R, 1991, SCIENCE, V251, P893, DOI 10.1126/science.2000490; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PERKINS TW, UNPUB; PRESS WH, 1989, NUMERICAL RECIPES C, P309; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; ROUSE PE, 1953, J CHEM PHYS, V21, P1272, DOI 10.1063/1.1699180; RYE HS, 1993, ANAL BIOCHEM, V208, P144, DOI 10.1006/abio.1993.1020; RYSKIN G, 1987, J FLUID MECH, V178, P423, DOI 10.1017/S0022112087001290; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; TSUNASHIMA Y, 1983, MACROMOLECULES, V16, P584, DOI 10.1021/ma00238a020; TSUNASHIMA Y, 1983, MACROMOLECULES, V16, P1184, DOI 10.1021/ma00241a027; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462; ZIMM BH, 1956, J CHEM PHYS, V24, P279, DOI 10.1063/1.1742463	34	556	611	3	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					822	826		10.1126/science.8171336	http://dx.doi.org/10.1126/science.8171336			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171336				2022-12-01	WOS:A1994NJ94900026
J	PARSONS, RW; JAMROZIK, KD; HOBBS, MST; THOMPSON, DL				PARSONS, RW; JAMROZIK, KD; HOBBS, MST; THOMPSON, DL			EARLY IDENTIFICATION OF PATIENTS AT LOW-RISK OF DEATH AFTER MYOCARDIAL-INFARCTION AND POTENTIALLY SUITABLE FOR EARLY HOSPITAL DISCHARGE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL	Objectives-To find (a) whether data available shortly after admission for acute myocardial infarction can provide a reliable prognostic indicator of survival at 28 days, and (b) whether such an indicator might be used to identify patients at low risk of death and suitable for early discharge. Design-Retrospective analysis of data collected on patients admitted to a coronary care unit for acute myocardial infarction. A validation sample was selected at random from these patients. Setting-Coronary care units in Perth, Western Australia. Subjects-6746 patients aged under 65 and resident in the Perth Statistical Division who during 1984-92 were admitted to a coronary care unit with symptoms of myocardial infarction. Main outcome measures-Sensitivity and specificity of several models for predicting survival at 28 days after myocardial infarction, and detailed performance characteristics of a particular model. Results-Patients with a pulse rate of 100 beats/min or less, aged 60 or under, and with symptoms typical of myocardial infarction, no past history of myocardial infarction or diabetes, and no significant Q wave in the admission electrocardiogram had a very high chance of survival at 28 days (99.2%). These patients made up one third of all patients studied. Conclusion-The prognostic index identifies patients very soon after admission who are at low risk of death and potentially eligible for early discharge from hospital or the coronary care unit. Computing the index does not need complex cardiac investigations.	QUEEN ELIZABETH II MED CTR, DEPT CARDIOVASC MED, PERTH, WA 6009, AUSTRALIA	University of Western Australia	PARSONS, RW (corresponding author), UNIV WESTERN AUSTRALIA, DEPT PUBL HLTH, PERTH, WA 6009, AUSTRALIA.							ABRAHAM AS, 1975, NEW ENGL J MED, V292, P719, DOI 10.1056/NEJM197504032921403; AHLMARK G, 1979, ACTA MED SCAND, V206, P87; BLOCH A, 1974, AM J CARDIOL, V34, P152, DOI 10.1016/0002-9149(74)90193-3; DUBOIS C, 1988, AM J CARDIOL, V61, P216, DOI 10.1016/0002-9149(88)90918-6; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; GRODEN B. M., 1967, SCOT MED J, V12, P435; HANDS ME, 1986, CIRCULATION, V73, P885, DOI 10.1161/01.CIR.73.5.885; HARPUR JE, 1971, LANCET, V2, P1331; HAYES MJ, 1974, BRIT MED J, V2, P10; HUTTER AM, 1973, NEW ENGL J MED, V288, P1141, DOI 10.1056/NEJM197305312882201; LEVINE SA, 1952, JAMA-J AM MED ASSOC, V148, P1365, DOI 10.1001/jama.1952.02930160001001; Mallory GK, 1939, AM HEART J, V18, P647; MARIK PE, 1991, HEART LUNG, V20, P16; MCNEER JF, 1978, NEW ENGL J MED, V298, P229, DOI 10.1056/NEJM197802022980501; MOLSTAD P, 1993, J INTERN MED, V233, P393, DOI 10.1111/j.1365-2796.1993.tb00690.x; NORRIS RM, 1969, LANCET, V1, P274; OH W, 1976, SMJ Singapore Medical Journal, V17, P40; PRINEAS RJ, 1982, MANUAL ELECTROCARDIO; PRYOR DB, 1983, ANN INTERN MED, V99, P528, DOI 10.7326/0003-4819-99-4-528; Rose G, 1972, Mod Concepts Cardiovasc Dis, V41, P59; Swan H J, 1976, Am J Cardiol, V37, P413, DOI 10.1016/0002-9149(76)90292-7; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; WENGER NK, 1982, CIRCULATION, V65, P421, DOI 10.1161/01.CIR.65.3.421; WENGER NK, 1973, JAMA-J AM MED ASSOC, V224, P511, DOI 10.1001/jama.224.4.511; 1991, SAS RELEASE 6 07; 1990, EGRET EPIDEMIOLOGICA; 1988, J CLIN EPIDEMIOL, V41, P105, DOI [10.1016/0895-4356(88)90084-4, DOI 10.1016/0895-4356(88)90084-4]; 1990, MONICA MANUAL	28	22	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	1994	308	6935					1006	1010		10.1136/bmj.308.6935.1006	http://dx.doi.org/10.1136/bmj.308.6935.1006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167512	Green Published			2022-12-01	WOS:A1994NH08900018
J	RUDLAND, SV; JACOBS, AG				RUDLAND, SV; JACOBS, AG			VISITING BAGS - A LABILE THERMAL ENVIRONMENT	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To define usual colour and site of storage of visiting bags in general practitioners' cars and to investigate effect of these variables on temperature inside bag. Design-Questionnaire to general practitioners; serial temperature measurements from paired black visiting bags at different storage sites and from bags of different colour. Setting-South Devon coastal town during May and June. Subjects-200 general practitioners, of whom 145 returned legible questionnaires. Main outcome measures-Bag colour, duration and site of storage, temperature inside black bags at defined storage sites, and effects of bag colour on internal temperature. Results-111 (77%) of the general practitioners carried a black visiting bag, and 76 kept their bag in their car all day. The bag was coolest in the car boot, but irrespective of storage site, maximum internal temperature of the bag was always over 25-degrees-C and reached up to 80-degrees-C. Spraying a black bag silver significantly reduced the bag's internal temperature (mean difference 8.37-degrees-C (95% confidence interval 6.68 to 9.86-degrees-C) df=59, t=10.29, P<0.001). Conclusions-General practitioners should use a silver coloured visiting bag; when visiting, they should store it in their car boot; at other times they should remove it to a cooler site.			RUDLAND, SV (corresponding author), BARTON SURG, DAWLISH EX7 9HQ, DEVON, ENGLAND.							Abu Reid I, 1990, INT PHARM J, V4, P6; Carson N E, 1981, Aust Fam Physician, V10, P966; DUNCAN G, 1989, PRACTITIONER, V233, P1435; HOGERZEIL HV, 1991, LANCET, V338, P754, DOI 10.1016/0140-6736(91)91470-F; ILIFFE S, 1991, BRIT MED J, V302, P1584, DOI 10.1136/bmj.302.6792.1584; LONGLAND PW, 1989, PHARM J, V243, P589; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; READ N, 1990, GP TRAINING HDB, P213; 1993, ABPI DATA SHEET COMP; 1992, III333592EN EUR COMM; 1989, DRUG THER B, V27, P17; 1990, ESSENTIAL DRUG MONIT, V11, P3	12	17	17	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 9	1994	308	6934					954	956		10.1136/bmj.308.6934.954	http://dx.doi.org/10.1136/bmj.308.6934.954			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF485	8173404	Green Published			2022-12-01	WOS:A1994NF48500019
J	FAIRALL, L; SCHWABE, JWR; CHAPMAN, L; FINCH, JT; RHODES, D				FAIRALL, L; SCHWABE, JWR; CHAPMAN, L; FINCH, JT; RHODES, D			THE CRYSTAL-STRUCTURE OF A 2 ZINC-FINGER PEPTIDE REVEALS AN EXTENSION TO THE RULES FOR ZINC-FINGER DNA RECOGNITION	NATURE			English	Article							PROTEIN; BINDING; GENE; SPECIFICITY; DOMAINS; PROGRAM	THE Cys2-His2 zinc-finger is the most widely occurring DNA-binding motif1-3. The first structure of a zinc-finger/DNA complex revealed a fairly simple mechanism for DNA recognition4 suggesting that the zinc-finger might represent a candidate template for designing proteins to recognize DNA-5. Residues at three key positions in an alpha-helical 'reading head' play a dominant role in base-recognition and have been targets for mutagenesis experiments aimed at deriving a recognition code6-8. Here we report the structure of a two zinc-finger DNA-binding domain from the protein Tramtrack complexed with DNA. The amino-terminal zinc-finger and its interaction with DNA illustrate several novel features. These include the use of a serine residue, which is semi-conserved and located outside the three key positions, to make a base contact. Its role in base-recognition correlates with a large, local, protein-induced deformation of the DNA helix at a flexible A-T-A sequence and may give insight into previous mutagenesis experiments9,10. It is apparent from this structure that zinc-finger/DNA recognition is more complex than was originally perceived.			FAIRALL, L (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Schwabe, John WR/A-9132-2008; Fairall, Louise/G-6763-2013	Schwabe, John WR/0000-0003-2865-4383; Fairall, Louise/0000-0001-9456-3047				BERG JM, 1993, CURR OPIN STRUC BIOL, V3, P11, DOI 10.1016/0959-440X(93)90195-Q; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BRUNGER AT, 1992, XPLOR V 3 ZERO MANUA; DESJARALAIS JR, 1992, PROTEINS, V13, P282; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; GREER J, 1985, METHOD ENZYMOL, V115, P206; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LESLIE AGW, 1992, 26 JOINT CCP4 ESF EA; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332	30	314	359	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					483	487		10.1038/366483a0	http://dx.doi.org/10.1038/366483a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247159				2022-12-01	WOS:A1993MK09800070
J	LU, X; LANE, DP				LU, X; LANE, DP			DIFFERENTIAL INDUCTION OF TRANSCRIPTIONALLY ACTIVE P53 FOLLOWING UV OR IONIZING-RADIATION - DEFECTS IN CHROMOSOME INSTABILITY SYNDROMES	CELL			English	Article							WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; ATAXIA-TELANGIECTASIA; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; TRANSFORMED-CELLS; CHO CELLS; T-ANTIGEN; EXPRESSION	Accumulation of p53 protein was seen in the nuclei of mammalian cells following DNA damage caused by ultraviolet radiation (UV), X-ray, or a restriction enzyme. Promoters containing p53-binding sites show a dramatic transcriptional response to DNA damage. The p53 response to X-ray is rapid, reaching a peak at 2 hr after radiation, but is very transitory and reduced in magnitude compared with that seen in response to UV. We find no substantive defect in the p53 response of cells from ataxia telangiectasia or xeroderma pigmentosum complementation group A patients. In contrast, 2 out of 11 primary cultures from Bloom's patients showed a complete absence of p53 accumulation following UV irradiation or SV40 infection and a grossly delayed and aberrant response following X-ray.			LU, X (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND.		Lane, David P/C-4920-2008	Lu, Xin/0000-0002-6587-1152; Lane, David/0000-0003-0551-3545				ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BRYANT PE, 1992, MUTAT RES, V268, P27, DOI 10.1016/0027-5107(92)90079-H; BURKI HJ, 1980, MUTAT RES, V69, P347; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DING RC, 1992, J BIOL CHEM, V267, P12804; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FORNACE AJ, 1982, MUTAT RES, V94, P263, DOI 10.1016/0027-5107(82)90290-1; FRANHENBERG F, 1969, PHYS MED BIOL, V14, P487; FRIEDBERG EC, 1985, DNA REPAIR, P505; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HALL PA, 1993, ONCOGENE, V8, P203; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW EE, 1988, ANTIBODDIES LABORATO; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, ONCOGENE, V5, P973; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MURNANE JP, 1993, SEMIN CANCER BIOL, V4, P93; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Sambrook J., 1989, MOL CLONING LAB MANU; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SIRVASTAVA S, 1990, NATURE, V348, P747; STURZBECHER HW, 1988, ONCOGENE, V3, P405; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	55	835	852	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					765	778		10.1016/0092-8674(93)90496-D	http://dx.doi.org/10.1016/0092-8674(93)90496-D			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242748	Bronze			2022-12-01	WOS:A1993MH74900021
J	LOWE, G; GOLD, GH				LOWE, G; GOLD, GH			NONLINEAR AMPLIFICATION BY CALCIUM-DEPENDENT CHLORIDE CHANNELS IN OLFACTORY RECEPTOR-CELLS	NATURE			English	Article							SENSITIVE ADENYLATE-CYCLASE; 2ND MESSENGER PATHWAYS; CYCLIC-NUCLEOTIDES; ODORANT; CILIA; ACTIVATION; CONDUCTANCE; NEWT; RAT; TRANSDUCTION	THE sense of smell is highly evolved in mammals, allowing discrimination between a vast number of odorants, with detection thresholds as low as 10(-17) M (ref. 1). Although several features of mammalian olfactory transduction have been revealed by biochemical and molecular biological studies2-11, the odorant-induced membrane current has remained elusive. In amphibians this current is mediated by cyclic-nucleotide-gated channels12-15, which depolarize the cell by Na+ and Ca+ influx16,17 and consequent Cl- efflux through Ca2+-dependent Cl- channels18,19. The Cl- current may be absent in mammals, however, because its proposed role is linked to the aquatic habitat of amphibians18. Here we show that the transduction current in rat olfactory receptor cells is initiated by cyclic-nucleotide-gated channels. The Cl- current is also present and endows the transduction current with a steep sigmoidal dependence on cyclic AMP concentration in both rat and in an amphibian, indicating a new function for the Cl- channel: nonlinear amplification of the transduction signal, whereby suprathreshold responses are boosted relative to basal transduction noise.			LOWE, G (corresponding author), MONELL CHEM SENSES CTR,3500 MARKET ST,PHILADELPHIA,PA 19104, USA.							BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BENARIE N, 1993, BIOCHEM J, V292, P379, DOI 10.1042/bj2920379; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BREER H, 1991, CHEM SENSES, V16, P19, DOI 10.1093/chemse/16.1.19; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; FRINGS S, 1991, J GEN PHYSIOL, V97, P1, DOI 10.1085/jgp.97.1.1; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; HUQUE T, 1986, BIOCHEM BIOPH RES CO, V137, P36, DOI 10.1016/0006-291X(86)91172-1; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KLEENE SJ, 1993, NEURON, V11, P123, DOI 10.1016/0896-6273(93)90276-W; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; LOWE G, 1993, J PHYSIOL-LONDON, V462, P175, DOI 10.1113/jphysiol.1993.sp019550; LYNCH JW, 1989, BIOPHYS J, V55, P755, DOI 10.1016/S0006-3495(89)82874-7; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NERBONNE JM, 1984, NATURE, V310, P74, DOI 10.1038/310074a0; PASSE DH, 1985, NEUROSCI BIOBEHAV R, V9, P431, DOI 10.1016/0149-7634(85)90021-1; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESTREPO D, 1992, AM J PHYSIOL, V263, pC667, DOI 10.1152/ajpcell.1992.263.3.C667; RONNETT GV, 1991, P NATL ACAD SCI USA, V88, P2366, DOI 10.1073/pnas.88.6.2366; SHIRLEY SG, 1986, BIOCHEM J, V240, P605, DOI 10.1042/bj2400605; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; ZUFALL F, 1993, P NATL ACAD SCI USA, V90, P935	30	276	279	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					283	286		10.1038/366283a0	http://dx.doi.org/10.1038/366283a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232590				2022-12-01	WOS:A1993MH32500069
J	WHITE, TD; SUWA, G; HART, WK; WALTER, RC; WOLDEGABRIEL, G; DEHEINZELIN, J; CLARK, JD; ASFAW, B; VRBA, E				WHITE, TD; SUWA, G; HART, WK; WALTER, RC; WOLDEGABRIEL, G; DEHEINZELIN, J; CLARK, JD; ASFAW, B; VRBA, E			NEW DISCOVERIES OF AUSTRALOPITHECUS AT MAKA IN ETHIOPIA	NATURE			English	Article							MIDDLE AWASH VALLEY; AFARENSIS; MORPHOLOGY; EVOLUTION; STRATIGRAPHY; HOMINIDS; AGE	THE taxonomy of Australopithecus afarensis, the oldest known hominid species, has been a matter of debate since its description in 1978 (ref. 1). Some authorities regard all specimens assigned to A. afarensis as belonging to a single taxon2-4 whereas others regard the Tanzanian and Ethiopian specimens as each representing a different species5,6. Further controversy surrounds the issues of sexual dimorphism and locomotion among these hominids. Resolution of these problems would shed light on hominid phylogeny in general and on the ancestry of later Australopithecus and Homo. Fossils discovered in the Afar of Ethiopia in 1990 constitute the first major addition to the 3-4 million year (Myr) hominid record since the 1970s. We report here the discovery of new fossils from Maka, dated to 3.4 Myr ago, which provide powerful support for the interpretation of A. afarensis as a single, ecologically diverse, sexually dimorphic, bipedal Pliocene primate species whose known range encompassed Ethiopia and Tanzania.	UNIV TOKYO,DEPT ANTHROPOL,BUNKYO KU,TOKYO 113,JAPAN; MIAMI UNIV,DEPT GEOL,OXFORD,OH 45056; INST HUMAN ORIGINS,CTR GEOCHRONOL,BERKELEY,CA 94709; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; INST ROYAL SCI NAT BELGIQUE,B-1040 BRUSSELS,BELGIUM; UNIV CALIF BERKELEY,DEPT ANTHROPOL,BERKELEY,CA 94720; PALEOANTHROPOL LAB,ADDIS ABABA,ETHIOPIA; YALE UNIV,DEPT GEOL & GEOPHYS,NEW HAVEN,CT 06511	University of Tokyo; University System of Ohio; Miami University; United States Department of Energy (DOE); Los Alamos National Laboratory; University of California System; University of California Berkeley; Yale University	WHITE, TD (corresponding author), UNIV CALIF BERKELEY,DEPT ANTHROPOL,HUMAN EVOLUT STUDIES LAB,BERKELEY,CA 94720, USA.		Klein, Richard G/B-5910-2009; Walter, Robert/AAD-7642-2020	Walter, Robert/0000-0001-8761-5355				ADAMSON DA, 1987, J HUM EVOL, V16, P597, DOI 10.1016/0047-2484(87)90015-7; ASFAW B, 1987, J HUM EVOL, V16, P611, DOI 10.1016/0047-2484(87)90016-9; BOAZ NT, 1988, YEARB PHYS ANTHROPOL, V31, P85; Brown F.H., 1992, QUATERN INT, V13-14, P55, DOI DOI 10.1016/1040-6182(92)90010-Y; CLARK JD, 1984, NATURE, V307, P423, DOI 10.1038/307423a0; CONROY GC, 1978, NATURE, V275, P67; COPPENS Y, 1983, SINGLE; CRONIN JE, 1981, NATURE, V292, P113, DOI 10.1038/292113a0; DAY MH, 1982, NATURE, V300, P574, DOI 10.1038/300574a0; DEINO A, 1990, J GEOL, V98, P567, DOI 10.1086/629425; GORTANI M, 1973, MISSIONE GEOLOGICA A; HAILEAB B, 1992, J HUM EVOL, V22, P453, DOI 10.1016/0047-2484(92)90080-S; HALL CM, 1984, NATURE, V308, P26, DOI 10.1038/308026a0; HART WK, 1992, QUATERN INT, V13, P77; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P373, DOI 10.1002/ajpa.1330570402; JOHANSON DC, 1978, KIRTLANDIA, V28, P1; JOHANSON DC, 1979, SCIENCE, V202, P321; Kalb J.E., 1982, Newsletters on Stratigraphy, V11, P95; KALB JE, 1982, NATURE, V298, P25, DOI 10.1038/298025a0; KALB JE, 1982, NATURE, V298, P17, DOI 10.1038/298017a0; LATIMER B, 1989, AM J PHYS ANTHROPOL, V78, P369, DOI 10.1002/ajpa.1330780306; Latimer B., 1991, P169; LEAKEY MD, 1981, PHIL T R SOC B, V292, P9; LEAKEY RE, 1976, AM SCI, V64, P174; LEONARD WR, 1987, AM J PHYS ANTHROPOL, V73, P41, DOI 10.1002/ajpa.1330730105; LOVEJOY CO, 1988, SCI AM, V256, P118; Mayr E, 1982, HIST AM PHYSICAL ANT, P231; Olson T. R., 1981, ASPECTS HUMAN EVOLUT, P99; Rose M.D., 1991, P37; SENUT B, 1983, B MEM SOC ANTHRO PAR, V10, P325, DOI 10.3406/bmsap.1983.3906; STERN JT, 1983, AM J PHYS ANTHROPOL, V60, P279, DOI 10.1002/ajpa.1330600302; Susman R.L., 1991, P121; TAIEB M, 1974, THESIS U PARIS; Tobias P.V., 1980, Palaeontologia Africana, V23, P1; TUTTLE RH, 1988, ANNU REV ANTHROPOL, V17, P391; WALTER RC, 1993, J HUM EVOL, V25, P229, DOI 10.1006/jhev.1993.1046; WALTER RC, 1991, NATURE, V354, P145, DOI 10.1038/354145a0; WALTER RC, 1985, GEOL SOC AM ABSTR, V17, P743; WHITE TD, 1985, ANCESTORS HARD EVIDE, P139; WOLDEGABRIEL G, 1987, GEOLOGY, V15, P432; WOLDEGABRIEL G, 1992, QUATERN INT, V13, P69, DOI DOI 10.1016/1040-6182(92)90011-P; ZIHLMAN A, 1981, HOMINID EVOLUTION PA, P213; [No title captured]	43	133	134	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					261	265		10.1038/366261a0	http://dx.doi.org/10.1038/366261a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MH325	8232584				2022-12-01	WOS:A1993MH32500062
J	AHMAD, M; CASHMORE, AR				AHMAD, M; CASHMORE, AR			HY4 GENE OF A-THALIANA ENCODES A PROTEIN WITH CHARACTERISTICS OF A BLUE-LIGHT PHOTORECEPTOR	NATURE			English	Article							COLI DNA PHOTOLYASE; ARABIDOPSIS-THALIANA; INSERTION MUTAGENESIS; HYPOCOTYL ELONGATION; DOMAINS	SPECIFIC responses to blue light are found throughout the biological kingdom. These responses-which in higher plants include phototropism, inhibition of hypocotyl elongation, and stomatal opening1-are in many cases thought to be mediated by flavin-type photoreceptors2. But no such blue-light photoreceptor has yet been identified or isolated, although blue-light responses in plants were reported by Darwin over a century ago3, long before the discovery of the now relatively well characterized red/far-red light photoreceptor, phytochrome. Here we describe the isolation of a gene corresponding to the HY4 locus of Arabidopsis thaliana. The hy4 mutant5 is one of several mutants6 that are selectively insensitive to blue light during the blue-light-dependent inhibition of hypocotyl elongation response, which suggests that they lack an essential component of the cryptochrome-associated light-sensing pathway. The HY4 gene, isolated by gene tagging, was shown to encode a protein with significant homology to microbial DNA photolyases. As photolyases are a rare class of flavoprotein that catalyse blue-light-dependent reactions7, the protein encoded by HY4 has a structure consistent with that of a flavin-type blue-light photoreceptor.			AHMAD, M (corresponding author), UNIV PENN,INST PLANT SCI,DEPT BIOL,PHILADELPHIA,PA 19104, USA.			Ahmad, Margaret/0000-0003-4524-5813				Ausubel F.M., 1989, SHORT PROTOCOLS MOL; DARWIN C, 1981, POWER MOVEMENT PLANT; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; Galland Paul, 1991, P65; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; KOBAYASHI T, 1989, NUCLEIC ACIDS RES, V17, P4731, DOI 10.1093/nar/17.12.4731; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; LI YF, 1990, BIOCHEMISTRY-US, V29, P5698, DOI 10.1021/bi00476a009; LISCUM E, 1991, PLANT CELL, V3, P685, DOI 10.1105/tpc.3.7.685; MALHOTRA K, 1992, J BIOL CHEM, V267, P2909; Maniatis T., 1982, MOL CLONING; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PANG QS, 1991, PLANT PHYSIOL, V95, P536, DOI 10.1104/pp.95.2.536; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; REYMOND P, 1992, P NATL ACAD SCI USA, V89, P4718, DOI 10.1073/pnas.89.10.4718; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; YAJIMA H, 1991, NUCLEIC ACIDS RES, V19, P5359, DOI 10.1093/nar/19.19.5359; YAMAMOTO K, 1992, MOL GEN GENET, V232, P1, DOI 10.1007/BF00299129; YASUHIRA S, 1992, J BIOL CHEM, V267, P25644	23	970	1031	8	186	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					162	166		10.1038/366162a0	http://dx.doi.org/10.1038/366162a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232555				2022-12-01	WOS:A1993MG21600059
J	AINSWORTH, MA; HOGAN, DL; KOSS, MA; ISENBERG, JI				AINSWORTH, MA; HOGAN, DL; KOSS, MA; ISENBERG, JI			CIGARETTE-SMOKING INHIBITS ACID-STIMULATED DUODENAL MUCOSAL BICARBONATE SECRETION	ANNALS OF INTERNAL MEDICINE			English	Article						PEPTIC ULCER; SMOKING; DUODENAL ULCER; MUCOUS MEMBRANE; BICARBONATES	MAXIMAL GASTRIC-SECRETION; ULCER PATIENTS; PEPTIC-ULCER; HEALING RATE; NON-SMOKERS; CIMETIDINE; PROSTAGLANDIN-E2; ALCOHOL; RELAPSE; DISEASE	Objective: To determine the effect of cigarette smoking on proximal duodenal mucosal bicarbonate secretion, an important defense mechanism against acid and peptic damage. Design: Prospective study. Setting: Clinical research laboratory in a university hospital. Patients: Thirteen healthy adults (7 smokers and 6 nonsmokers) who had no history of peptic ulcer disease. Interventions: Participants smoked (1 cigarette/15 min during a period of 1 hour, smokers only) or sham smoked (puffing on an unlit cigarette) during duodenal perfusion with either saline, hydrochloric acid, or prostaglandin E2 (PGE2). Measurements: Collection of proximal duodenal secretions using a modified duodenal tube with occluding balloons and quantitation of duodenal mucosal bicarbonate secretion. Results: During sham smoking both smokers and nonsmokers had comparable basal as well as H+-stimulated and PGE2-stimulated duodenal mucosal bicarbonate secretion. Compared with sham smoking, smoking did not significantly alter basal bicarbonate secretion (201 mumol/cm per hour [95% CI, 152 to 250 mumol/cm per hour] compared with 178 mumol/cm per hour [CI, 134 to 222 mumol/cm per hour], respectively). However, compared with sham smoking, smoking markedly reduced (P < 0.01) the increase in duodenal bicarbonate secretion in response to luminal acidification by approximately 80% (from 242 mumol/cm per hour [CI, 41 to 443 mumol/cm per hour] to 53 mumol/cm per hour [CI, -107 to 197 mumol/cm per hour]); a decrease was observed in each participant. In contrast, smoking had no significant effect on the response to luminal PGE2. Conclusions. Cigarette smoking markedly inhibited acid-stimulated human duodenal mucosal bicarbonate secretion. This adverse effect of smoking may, at least in part, explain the role of cigarette smoking in the pathogenesis and natural history of duodenal ulcer disease.	UNIV CALIF SAN DIEGO, MED CTR,DEPT MED,DIV GASTROENTEROL, 225 DICKINSON ST, SAN DIEGO, CA 92103 USA; ODENSE UNIV HOSP, DK-5000 ODENSE, DENMARK	University of California System; University of California San Diego; University of Southern Denmark; Odense University Hospital			Ainsworth, Mark Andrew/CAA-2707-2022; Ainsworth, Mark Andrew/AAO-6988-2020	Ainsworth, Mark Andrew/0000-0002-4899-1048; Ainsworth, Mark Andrew/0000-0002-4899-1048	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM033491] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 33491] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSWORTH MA, 1990, SCAND J GASTROENTERO, V25, P1066, DOI 10.3109/00365529008997636; BOCHENEK WJ, 1973, AM J DIG DIS, V18, P729; BROWN P, 1976, MED J AUSTRALIA, V2, P290, DOI 10.5694/j.1326-5377.1976.tb130184.x; BYNUM TE, 1972, GUT, V13, P361, DOI 10.1136/gut.13.5.361; CHIVERTON SG, 1989, J CLIN GASTROENTEROL, V11, pS29; CRYER B, 1992, ANN INTERN MED, V116, P636, DOI 10.7326/0003-4819-116-8-636; DEBAS HT, 1971, GUT, V12, P93, DOI 10.1136/gut.12.2.93; DOLL R, 1964, BRIT MED J, V1, P1399, DOI 10.1136/bmj.1.5395.1399; FLEMSTROM G, 1984, CLIN GASTROENTEROL, V13, P327; FLEMSTROM G, 1987, PHYSL GASTROINTESTIN, P1011; FRIEDMAN GD, 1974, NEW ENGL J MED, V290, P469, DOI 10.1056/NEJM197402282900901; GRANSTAM SO, 1990, J CLIN GASTROENTEROL, V12, pS19, DOI 10.1097/00004836-199001001-00005; GUGLER R, 1982, GUT, V23, P866, DOI 10.1136/gut.23.10.866; HARRISON AR, 1979, SMOKING HLTH REPORT; HULL DH, 1985, GUT, V26, P1333, DOI 10.1136/gut.26.12.1333; ISENBERG JI, 1986, GASTROENTEROLOGY, V91, P370, DOI 10.1016/0016-5085(86)90571-8; KNUTSON L, 1989, GUT, V30, P1708, DOI 10.1136/gut.30.12.1708; KORMAN MG, 1983, GASTROENTEROLOGY, V85, P871; KORMAN MG, 1982, DIGEST DIS SCI, V27, P712, DOI 10.1007/BF01393766; KORMAN MG, 1981, GASTROENTEROLOGY, V80, P1451; MALESCI A, 1988, SCAND J GASTROENTERO, V23, P602, DOI 10.3109/00365528809093919; MASSARRAT S, 1981, GUT, V22, P97, DOI 10.1136/gut.22.2.97; MCCREADY DR, 1985, GUT, V26, P1192, DOI 10.1136/gut.26.11.1192; MILLBOURN E, 1950, ACTA ANAT, V9, P1; MURTHY SNS, 1977, GASTROENTEROLOGY, V73, P758; OSTENSEN H, 1985, SCAND J GASTROENTERO, V20, P1227, DOI 10.3109/00365528509089281; PARENTE F, 1985, GUT, V26, P1327, DOI 10.1136/gut.26.12.1327; QUIGLEY EMM, 1987, GASTROENTEROLOGY, V92, P1876, DOI 10.1016/0016-5085(87)90619-6; QUIMBY GF, 1986, ANN INTERN MED, V104, P616, DOI 10.7326/0003-4819-104-5-616; SELLING JA, 1987, ANN INTERN MED, V106, P368, DOI 10.7326/0003-4819-106-3-368; SOLOMON TE, 1972, NEW ENGL J MED, V286, P1212, DOI 10.1056/NEJM197206012862211; SONNENBERG A, 1981, GASTROENTEROLOGY, V81, P1061; SONTAG S, 1984, NEW ENGL J MED, V311, P689, DOI 10.1056/NEJM198409133111101; STERN AI, 1984, GASTROENTEROLOGY, V86, P60; Trowell OA, 1934, LANCET, V1, P808; WENZL E, 1987, GASTROENTEROLOGY, V92, P709, DOI 10.1016/0016-5085(87)90022-9; WHITECROSS DP, 1974, SCAND J GASTROENTERO, V9, P399; WHITFIELD PF, 1985, BRIT J SURG, V72, P955, DOI 10.1002/bjs.1800721207; WHITFIELD PF, 1987, GUT, V28, P557, DOI 10.1136/gut.28.5.557; Wilkinson A, 1969, Gut, V10, P415; WILKINSON AR, 1971, LANCET, V2, P628; 1978, FEDERAL TRADE COMMIS, P17	42	26	27	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1993	119	9					882	886		10.7326/0003-4819-119-9-199311010-00003	http://dx.doi.org/10.7326/0003-4819-119-9-199311010-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD711	8214999				2022-12-01	WOS:A1993MD71100003
J	RIZZUTO, R; BRINI, M; MURGIA, M; POZZAN, T				RIZZUTO, R; BRINI, M; MURGIA, M; POZZAN, T			MICRODOMAINS WITH HIGH CA2+ CLOSE TO IP(3)-SENSITIVE CHANNELS THAT ARE SENSED BY NEIGHBORING MITOCHONDRIA	SCIENCE			English	Article							RAT-HEART MITOCHONDRIA; CALCIUM OSCILLATIONS; FLUORESCENT-PROBES; ACINAR-CELLS; CA-2+; RECEPTOR; HEPATOCYTES; STORES; HETEROGENEITY; ACTIVATION	Microdomains of high intracellular calcium ion concentration, [Ca2+]i, have been hypothesized to occur in living cells exposed to stimuli that generate inositol 1,4,5-trisphosphate (IP3). Mitochondrially targeted recombinant aequorin was used to show that IP3-induced Ca2+ mobilization from intracellular stores caused increases of mitochondrial Ca2+ concentration, [Ca2+]m, the speed and amplitude of which are not accounted for by the relatively small increases in mean [Ca2+]i. A similar response was obtained by the addition of IP3 to permeabilized cells but not by perfusion of cells with Ca2+ at concentrations similar to those measured in intact cells. It is concluded that in vivo, domains of high [Ca2+]i are transiently generated close to IP3-gated channels and sensed by nearby mitochondria; this may provide an efficient mechanism for optimizing mitochondrial activity upon cell stimulation.			RIZZUTO, R (corresponding author), UNIV PADUA,DEPT BIOMED SCI,CNR,CTR STUDY MITOCHONDRIAL PHYSIOL,VIA TRIESTE 75,I-35121 PADUA,ITALY.		Brini, Marisa/K-5189-2016; Rizzuto, Rosario/B-6312-2008	Brini, Marisa/0000-0001-5141-0243; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [126] Funding Source: Medline	Telethon(Fondazione Telethon)		Augustine G J, 1992, Curr Opin Neurobiol, V2, P302, DOI 10.1016/0959-4388(92)90119-6; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; Cobbold PH, 1991, CELLULAR CALCIUM PRA, P55; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; FABIATO A, 1991, CELLULAR CALCIUM PRA, P159; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCCORMACK JG, 1989, BIOCHIM BIOPHYS ACTA, V973, P420, DOI 10.1016/S0005-2728(89)80384-6; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PIETROBON D, 1990, EUR J BIOCHEM, V193, P599, DOI 10.1111/j.1432-1033.1990.tb19378.x; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; RIZZUTO R, 1987, BIOCHEM J, V246, P271, DOI 10.1042/bj2460271; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RIZZUTO R, UNPUB; RIZZUTO R, IN PRESS METHODS CEL; ROBERTS WM, 1990, J NEUROSCI, V10, P3554; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; SATIN LS, 1989, J MEMBRANE BIOL, V112, P213, DOI 10.1007/BF01870952; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; TAKEI K, 1992, J NEUROSCI, V12, P489; TAYLOR CW, 1992, TRENDS BIOCHEM SCI, V17, P403, DOI 10.1016/0968-0004(92)90009-X; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	37	981	997	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					744	747		10.1126/science.8235595	http://dx.doi.org/10.1126/science.8235595			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235595				2022-12-01	WOS:A1993MD95200043
J	CHUNG, CH				CHUNG, CH			PROTEASES IN ESCHERICHIA-COLI	SCIENCE			English	Editorial Material							ATP-DEPENDENT PROTEASE; REGULATORY SUBUNIT; HIGH-TEMPERATURES; ACTIVATED ATPASE; GENE-PRODUCT; LA; PROTEOLYSIS; PURIFICATION; CONTAINS; DEGRADATION				CHUNG, CH (corresponding author), SEOUL NATL UNIV, COLL NAT SCI, DEPT MOLEC BIOL, SEOUL 151742, SOUTH KOREA.							CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GOLDBERG AL, 1981, METHOD ENZYMOL, V80, P680; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; KATAYAMA Y, 1988, J BIOL CHEM, V263, P15226; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; LEE CS, 1990, FEBS LETT, V262, P310, DOI 10.1016/0014-5793(90)80216-6; LEE YS, 1988, J BIOL CHEM, V263, P6643; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LIPINSKA B, 1990, J BACTERIOL, V172, P1791, DOI 10.1128/jb.172.4.1791-1797.1990; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MENON AS, 1987, J BIOL CHEM, V262, P722; NOVAK P, 1986, J BIOL CHEM, V261, P420; PARK JH, 1988, J BACTERIOL, V170, P921, DOI 10.1128/jb.170.2.921-926.1988; Park S.C., UNPUB; PARK SK, IN PRESS J BIOL CHEM; SEOL JH, 1991, BIOCHEM BIOPH RES CO, V176, P730; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; SWAMY KHS, 1983, ARCH BIOCHEM BIOPHYS, V224, P543, DOI 10.1016/0003-9861(83)90242-4; SWAMY KHS, 1981, NATURE, V292, P652, DOI 10.1038/292652a0; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; WAXMAN L, 1982, P NATL ACAD SCI-BIOL, V79, P4883, DOI 10.1073/pnas.79.16.4883; WAXMAN L, 1985, J BIOL CHEM, V260, P2022; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257; WOO KM, 1989, J BIOL CHEM, V264, P2088; WOO KM, 1992, J BIOL CHEM, V267, P20429; YOO SJ, 1993, FEBS LETT, V327, P17, DOI 10.1016/0014-5793(93)81029-Y	39	51	51	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1993	262	5132					372	374		10.1126/science.8211156	http://dx.doi.org/10.1126/science.8211156			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	8211156				2022-12-01	WOS:A1993MB85900041
J	LAWRENCE, CE; ALTSCHUL, SF; BOGUSKI, MS; LIU, JS; NEUWALD, AF; WOOTTON, JC				LAWRENCE, CE; ALTSCHUL, SF; BOGUSKI, MS; LIU, JS; NEUWALD, AF; WOOTTON, JC			DETECTING SUBTLE SEQUENCE SIGNALS - A GIBBS SAMPLING STRATEGY FOR MULTIPLE ALIGNMENT	SCIENCE			English	Article							HELIX-TURN-HELIX; AMINO-ACID-SEQUENCES; UNALIGNED DNA FRAGMENTS; PROTEIN-BINDING SITES; KLEBSIELLA-PNEUMONIAE; REGULATORY PROTEINS; MOLECULAR-STRUCTURE; SUBSTITUTION MATRICES; BIOLOGICAL SEQUENCES; NUCLEOTIDE-SEQUENCE	A wealth of protein and DNA sequence data is being generated by genome projects and other sequencing efforts. A crucial barrier to deciphering these sequences and understanding the relations among them is the difficulty of detecting subtle local residue patterns common to multiple sequences. Such patterns frequently reflect similar molecular structures and biological properties. A mathematical definition of this ''local multiple alignment'' problem suitable for full computer automation has been used to develop a new and sensitive algorithm, based on the statistical method of iterative sampling. This algorithm finds an optimized local alignment model for N sequences in N-linear time, requiring only seconds on current workstations, and allows the simultaneous detection and optimization of multiple patterns and pattern repeats. The method is illustrated as applied to helix-turn-helix proteins, lipocalins, and prenyltransferases.	HARVARD UNIV, DEPT STAT, CAMBRIDGE, MA 02138 USA; NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, BIOMETR LAB, ALBANY, NY 12201 USA	Harvard University; State University of New York (SUNY) System; Wadsworth Center	LAWRENCE, CE (corresponding author), NIH, NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20894 USA.		Altschul, Stephen/R-4000-2019		NIMH NIH HHS [NIMH MH-31154] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH031154] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AITCHISON J, 1972, STATISTICAL PREDICTI; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; AKRIGG D, 1992, COMPUT APPL BIOSCI, V8, P295; ALEXANDROV NN, 1992, COMPUT APPL BIOSCI, V8, P339; ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; ALTSCHUL SF, 1989, SIAM J APPL MATH, V49, P197, DOI 10.1137/0149012; ALTSCHUL SF, 1985, MOL BIOL EVOL, V2, P526; ALTSCHUL SF, 1989, J MOL BIOL, V207, P647, DOI 10.1016/0022-2836(89)90234-9; BACON DJ, 1986, J MOL BIOL, V191, P153, DOI 10.1016/0022-2836(86)90252-4; BAINS W, 1986, NUCLEIC ACIDS RES, V14, P159, DOI 10.1093/nar/14.1.159; BARBIER CS, 1992, J BACTERIOL, V174, P2881, DOI 10.1128/JB.174.9.2881-2890.1992; BARTON GJ, 1990, J MOL BIOL, V212, P389, DOI 10.1016/0022-2836(90)90133-7; BARTON GJ, 1987, J MOL BIOL, V198, P327, DOI 10.1016/0022-2836(87)90316-0; BERENS C, 1992, J BIOL CHEM, V267, P1945; BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; BERGER MP, 1991, COMPUT APPL BIOSCI, V7, P479; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; Boguski M. S., 1992, PROTEIN ENG PRACTICA, P57; BOGUSKI MS, 1992, NEW BIOL, V4, P408; BOGUSKI MS, 1992, NEW BIOL, V4, P247; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BROWN M, 1993, 1ST P INT C INT SYST, P47; BRUNELLE A, 1989, J MOL BIOL, V209, P607, DOI 10.1016/0022-2836(89)90598-6; BRYANT SH, 1993, PROTEINS, V16, P92, DOI 10.1002/prot.340160110; CARDON LR, 1992, J MOL BIOL, V223, P159, DOI 10.1016/0022-2836(92)90723-W; CARRILLO H, 1988, SIAM J APPL MATH, V48, P1073, DOI 10.1137/0148063; CHAPPEY C, 1991, COMPUT APPL BIOSCI, V7, P195; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CONTRERAS A, 1988, NUCLEIC ACIDS RES, V16, P4025, DOI 10.1093/nar/16.9.4025; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; Dayhoff M., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DEPIEREUX E, 1992, COMPUT APPL BIOSCI, V8, P501; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; DODD IB, 1988, PROTEIN ENG, V2, P174, DOI 10.1093/protein/2.3.174; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P191; DRUMMOND M, 1986, EMBO J, V5, P441, DOI 10.1002/j.1460-2075.1986.tb04230.x; DRUMMOND MH, 1990, MOL MICROBIOL, V4, P29, DOI 10.1111/j.1365-2958.1990.tb02012.x; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; GELFAND AE, 1990, J AM STAT ASSOC, V85, P389; GEMAN S, 1984, IEEE T PATTERN ANAL, V6, P721, DOI 10.1109/TPAMI.1984.4767596; GOODMAN LA, 1974, BIOMETRIKA, V61, P215, DOI 10.2307/2334349; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GUSFIELD D, 1993, B MATH BIOL, V55, P141, DOI 10.1007/BF02460299; HALL P, 1989, J ROY STAT SOC B MET, V51, P459; HAUSSLER D, 1992, CIS UCSCCRL9223 U CA; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HENIKOFF S, 1991, NEW BIOL, V3, P1148; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; HENNEKE CM, 1989, COMPUT APPL BIOSCI, V5, P141; HERTZ GZ, 1990, COMPUT APPL BIOSCI, V6, P81; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; JOHNSON MS, 1986, J MOL EVOL, V23, P267, DOI 10.1007/BF02115583; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOSTREWA D, 1992, J MOL BIOL, V226, P209, DOI 10.1016/0022-2836(92)90134-6; LAMERICHS RMJN, 1989, P NATL ACAD SCI USA, V86, P6863, DOI 10.1073/pnas.86.18.6863; LAWRENCE CE, 1990, PROTEINS, V7, P41, DOI 10.1002/prot.340070105; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; LEUNG MY, 1991, J MOL BIOL, V221, P1367, DOI 10.1016/0022-2836(91)90938-3; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; LITTLE R, 1987, STATISTICAL ANAL MIS; LIU J, 1992, R426 DEP STAT RES RE; Liu J., UNPUB; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; MONACO HL, 1992, BIOPOLYMERS, V32, P457, DOI 10.1002/bip.360320425; MURATA M, 1985, P NATL ACAD SCI USA, V82, P3073, DOI 10.1073/pnas.82.10.3073; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; NORTH ACT, 1989, INT J BIOL MACROMOL, V11, P56, DOI 10.1016/0141-8130(89)90041-X; ORCHARD T, 1972, 6TH P BERK S MATH ST, V1, P697; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PARRYSMITH DJ, 1991, COMPUT APPL BIOSCI, V7, P233; PARRYSMITH DJ, 1992, COMPUT APPL BIOSCI, V8, P451; Peitsch M C, 1990, New Biol, V2, P197; POHL FM, 1971, NATURE-NEW BIOL, V234, P277, DOI 10.1038/newbio234277a0; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; QUEEN C, 1982, NUCLEIC ACIDS RES, V10, P449, DOI 10.1093/nar/10.1.449; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROLFES RJ, 1988, J BIOL CHEM, V263, P19653; ROYTBERG MA, 1992, COMPUT APPL BIOSCI, V8, P57; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; SANKOFF D, 1975, SIAM J APPL MATH, V28, P35, DOI 10.1137/0128004; SAWYER L, 1987, NATURE, V327, P659, DOI 10.1038/327659a0; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHELL MA, 1990, J BIOL CHEM, V265, P3844; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; SHEWCHUK LM, 1989, BIOCHEMISTRY-US, V28, P2340, DOI 10.1021/bi00431a053; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; SOBEL E, 1986, NUCLEIC ACIDS RES, V14, P363, DOI 10.1093/nar/14.1.363; SPIRO S, 1990, MOL MICROBIOL, V4, P1831, DOI 10.1111/j.1365-2958.1990.tb02031.x; STADEN R, 1989, COMPUT APPL BIOSCI, V5, P293; STORMO GD, 1989, P NATL ACAD SCI USA, V86, P1183, DOI 10.1073/pnas.86.4.1183; SUBBIAH S, 1989, J MOL BIOL, V209, P539, DOI 10.1016/0022-2836(89)90592-5; TANNER MA, 1987, J AM STAT ASSOC, V82, P528, DOI 10.2307/2289457; TAYLOR WR, 1990, METHOD ENZYMOL, V183, P456; TREISMAN J, 1992, BIOESSAYS, V14, P145, DOI 10.1002/bies.950140302; VINGRON M, 1993, P NATL ACAD SCI USA, V90, P8777, DOI 10.1073/pnas.90.19.8777; VINGRON M, 1991, J MOL BIOL, V218, P33, DOI 10.1016/0022-2836(91)90871-3; VINGRON M, 1989, COMPUT APPL BIOSCI, V5, P115; WATERMAN MS, 1984, B MATH BIOL, V46, P567, DOI 10.1007/BF02459504; WATERMAN MS, 1984, B MATH BIOL, V46, P515; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X; YUAN HS, 1991, P NATL ACAD SCI USA, V88, P9558, DOI 10.1073/pnas.88.21.9558; YUDKIN MD, 1987, PROTEIN ENG, V1, P371, DOI 10.1093/protein/1.5.371; YUDKIN MD, 1989, MOL MICROBIOL, V3, P257, DOI 10.1111/j.1365-2958.1989.tb01815.x; [No title captured]	116	1249	1376	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1993	262	5131					208	214		10.1126/science.8211139	http://dx.doi.org/10.1126/science.8211139			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA665	8211139				2022-12-01	WOS:A1993MA66500025
J	KAY, MA; ROTHENBERG, S; LANDEN, CN; BELLINGER, DA; LELAND, F; TOMAN, C; FINEGOLD, M; THOMPSON, AR; READ, MS; BRINKHOUS, KM; WOO, SLC				KAY, MA; ROTHENBERG, S; LANDEN, CN; BELLINGER, DA; LELAND, F; TOMAN, C; FINEGOLD, M; THOMPSON, AR; READ, MS; BRINKHOUS, KM; WOO, SLC			IN-VIVO GENE-THERAPY OF HEMOPHILIA-B - SUSTAINED PARTIAL CORRECTION IN FACTOR-IX-DEFICIENT DOGS	SCIENCE			English	Article							RETROVIRAL VECTORS; EXPRESSION; TRANSPLANTATION; MYOBLASTS; PROTEIN; SAFE; LINE	The liver represents a model organ for gene therapy. A method has been developed for hepatic gene transfer in vivo by the direct infusion of recombinant retroviral vectors into the portal vasculature, which results in the persistent expression of exogenous genes. To determine if these technologies are applicable for the treatment of hemophilia B patients, preclinical efficacy studies were done in a hemophilia B dog model. When the canine factor IX complementary DNA was transduced directly into the hepatocytes of affected dogs in vivo, the animals constitutively expressed low levels of canine factor IX for more than 5 months. Persistent expression of the clotting factor resulted in reductions of whole blood clotting and partial thromboplastin times of the treated animals. Thus, long-term treatment of hemophilia B patients may be feasible by direct hepatic gene therapy in vivo.	BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; BAYLOR COLL MED,DEPT MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT SURG,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; PUGET SOUND BLOOD CTR,SEATTLE,WA 98104	Baylor College of Medicine; Howard Hughes Medical Institute; University of North Carolina; University of North Carolina Chapel Hill; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Puget Sound Blood Center				Kay, Mark/0000-0002-2799-2615	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044080] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-01648-46, HL 40162] Funding Source: Medline; NIDDK NIH HHS [DK 44080] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELROD JH, 1990, P NATL ACAD SCI USA, V87, P5173, DOI 10.1073/pnas.87.13.5173; BRINKHOUS KM, 1954, JAMA-J AM MED ASSOC, V154, P481, DOI 10.1001/jama.1954.02940400019005; BRINKHOUS KM, 1992, THROMB RES, V67, P329, DOI 10.1016/0049-3848(92)90008-X; BRINKHOUS KM, 1973, BLOOD, V41, P577, DOI 10.1182/blood.V41.4.577.577; BRINKHOUS KM, UNPUB; DAI Y, 1992, P NATL ACAD SCI USA, V89, P10892, DOI 10.1073/pnas.89.22.10892; EVANS JP, 1989, P NATL ACAD SCI USA, V86, P10095, DOI 10.1073/pnas.86.24.10095; GERRARD AJ, 1993, NAT GENET, V3, P180, DOI 10.1038/ng0293-180; KAY MA, 1992, P NATL ACAD SCI USA, V89, P89, DOI 10.1073/pnas.89.1.89; KAY MA, 1992, HUM GENE THER, V3, P641, DOI 10.1089/hum.1992.3.6-641; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANGDELL RD, 1953, J LAB CLIN MED, V41, P637; LYNCH CM, 1991, J VIROL, V65, P3887, DOI 10.1128/JVI.65.7.3887-3890.1991; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYANOHARA A, 1992, NEW BIOL, V4, P238; ROBERTS HR, 1991, CLIN ASPECTS THERAPY, P1325; THOMPSON AR, 1977, J CLIN INVEST, V59, P900, DOI 10.1172/JCI108712; THOMPSON AR, 1991, CURR STUD HEMATOL BL, V58, P59; YAO SN, 1992, P NATL ACAD SCI USA, V89, P3357, DOI 10.1073/pnas.89.8.3357	21	284	308	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 1	1993	262	5130					117	119		10.1126/science.8211118	http://dx.doi.org/10.1126/science.8211118			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ635	8211118				2022-12-01	WOS:A1993LZ63500037
J	KULKARNI, ML; SURESHKUMAR, C; VENKATARAMANA, V				KULKARNI, ML; SURESHKUMAR, C; VENKATARAMANA, V			COLORINGS, FLAVORINGS, AND SUGARS IN CHILDRENS MEDICINES IN INDIA	BMJ-BRITISH MEDICAL JOURNAL			English	Article											KULKARNI, ML (corresponding author), JJM MED COLL, DEPT PAEDIAT, DAVANAGERE 577004, INDIA.							HOLMES A, 1987, BRIT DENT J, V163, P240, DOI 10.1038/sj.bdj.4806259; KOLLY M, 1989, ANN ALLERGY, V62, P21; KUMAR A, 1991, PEDIATRICS, V87, P352; POLLOCK I, 1989, BRIT MED J, V299, P649, DOI 10.1136/bmj.299.6700.649; 1989, PEDIATRICS, V73, P405	5	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1993	307	6907					773	773		10.1136/bmj.307.6907.773	http://dx.doi.org/10.1136/bmj.307.6907.773			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ478	8219950	Bronze, Green Published			2022-12-01	WOS:A1993LZ47800025
J	SPENCE, DPS; HOTCHKISS, J; WILLIAMS, CSD; DAVIES, PDO				SPENCE, DPS; HOTCHKISS, J; WILLIAMS, CSD; DAVIES, PDO			TUBERCULOSIS AND POVERTY	BRITISH MEDICAL JOURNAL			English	Article							PULMONARY TUBERCULOSIS	Objective-To examine whether the historical link between tuberculosis and poverty still exists. Design-Retrospective study examining the notifications of all forms of tuberculosis by council ward over a six year period and correlating this with four indices of poverty; council housing, free school meals, the Townsend overall deprivation index, and the Jarman index. Setting-The 33 electoral wards of the city of Liver-pool. Subjects-344 residents of Liverpool with tuberculosis. Results-The rate of tuberculosis was correlated with all measures of poverty, the strongest correlation being with the Jarman index (r=0.73, p<0.0001). This link was independent of the high rates of tuberculosis seen in ethnic minorities. Conclusion-Tuberculosis remains strongly associated with poverty.	PUBL HLTH OBSERV,LIVERPOOL,ENGLAND; SEFTON GEN HOSP,S LIVERPOOL CHEST CLIN,CTR CARDIOTHORAC,TB RES UNIT,LIVERPOOL L15 2HE,ENGLAND		SPENCE, DPS (corresponding author), FAZAKERLEY DIST GEN HOSP,CTR AINTREE CHEST,LIVERPOOL L9 7AL,ENGLAND.							Black D., 1980, INEQUALITIES HLTH; BRUNDNEY K, 1991, AM REV RESPIR DIS, V144, P745; CITRON KM, 1987, OXFORD TXB MED, V5, P278; DAVIS PDO, 1992, THORAX, V47, P875; FRASER WM, 1947, DUNCAN LIVERPOOL; HOLLAND WW, 1969, BRIT MED J, V2, P205, DOI 10.1136/bmj.2.5651.205; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; LEITCH AG, 1992, RESP MED, V86, P173, DOI 10.1016/S0954-6111(06)80240-4; MCMURRAY DN, 1986, AM REV RESPIR DIS, V133, P1081; MCMURRAY DN, 1992, J NUTR, V122, P738, DOI 10.1093/jn/122.suppl_3.738; NISAR M, 1992, TUBERCLE LUNG DIS, V73, P200, DOI 10.1016/0962-8479(92)90086-Y; PLATT MJ, 1991, OBSERVATORY REPORT S, V2; SCHOEMAN JH, 1991, INT J EPIDEMIOL, V20, P435, DOI 10.1093/ije/20.2.435; SEATON A, 1989, CROFTON DOUGLAS RESP, P375; STILLITOE K, 1978, POPULATION TRENDS, V13, P25; Townsend P, 1988, HLTH DEPRIVATION INE; WHITEHEAD M, 1988, INEQUALITIES HLTH, P215; WINKELSTEIN W, 1967, ARCH ENVIRON HEALTH, V14, P162, DOI 10.1080/00039896.1967.10664708; 1990, PUBLIC HLTH COMMON D; 1988, COMMUNICABLE DISEASE; 1991, INFORMATION UNIT SMA; 1992, CENSUS 1991 PRELIMIN; 1990, MMWR, V39, P1; 1992, THORAX, V47, P770	24	191	196	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1993	307	6907					759	761		10.1136/bmj.307.6907.759	http://dx.doi.org/10.1136/bmj.307.6907.759			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ478	8219945	Green Published, Bronze			2022-12-01	WOS:A1993LZ47800019
J	HALACHMI, S; MARDEN, E; MARTIN, G; MACKAY, H; ABBONDANZA, C; BROWN, M				HALACHMI, S; MARDEN, E; MARTIN, G; MACKAY, H; ABBONDANZA, C; BROWN, M			ESTROGEN RECEPTOR-ASSOCIATED PROTEINS - POSSIBLE MEDIATORS OF HORMONE-INDUCED TRANSCRIPTION	SCIENCE			English	Article							HUMAN GLUCOCORTICOID RECEPTOR; DNA-BINDING; TRANSACTIVATION DOMAINS; FUNCTIONAL DOMAINS; GENE ACTIVATION; IDENTIFICATION; EXPRESSION; MULTIPLE; INHIBITION; REGION	The estrogen receptor is a transcription factor which, when bound to estradiol, binds DNA and regulates expression of estrogen-responsive genes. A 160-kilodalton estrogen receptor-associated protein, ERAP160, was identified that exhibits estradiol-dependent binding to the receptor. Mutational analysis of the receptor shows that its ability to activate transcription parallels its ability to bind ERAP160. Antiestrogens are unable to promote ERAP160 binding and can block the estrogen-dependent interaction of the receptor and ERAP160 in a dose-dependent manner. This evidence suggests that ERAP160 may mediate estradiol-dependent transcriptional activation by the estrogen receptor. Furthermore, the ability of antiestrogens to block estrogen receptor-ERAP160 complex formation could account for their therapeutic effects in breast cancer.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; DANA FARBER CANC INST,DIV NEOPLAST DIS MECHANISMS,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02115; FAC MED & CHIRURG NAPLES,INST PATOL GEN & ONCOL,I-80138 NAPLES,ITALY	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Naples Federico II			Brown, Myles/B-6906-2008; Brown, Myles/AAX-5332-2021	Brown, Myles/0000-0002-8213-1658; ABBONDANZA, Ciro/0000-0001-5346-4835; Halachmi, Shlomit/0000-0001-5921-9515				ABBONDANZA C, 1993, STEROIDS, V58, P4, DOI 10.1016/0039-128X(93)90011-B; ALLAN GF, 1992, J BIOL CHEM, V267, P19513; BANIAHMAD A, 1993, J CELL BIOCHEM, V51, P151, DOI 10.1002/jcb.240510206; BASTIAN LS, 1991, MOL ENDOCRINOL, V5, P619, DOI 10.1210/mend-5-5-619; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BROWN M, 1990, J BIOL CHEM, V265, P11238; BROWN MA, UNPUB; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GRONEMEYER H, 1993, J RECEPTOR RES, V13, P667, DOI 10.3109/10799899309073686; HALACHMI S, UNPUB; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; RATKO TA, 1989, CANCER RES, V49, P4472; REESE JC, 1991, J BIOL CHEM, V266, P10880; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WHITE JH, 1988, COLD SPRING HARB SYM, V53, P819, DOI 10.1101/SQB.1988.053.01.093; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735	37	573	588	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 3	1994	264	5164					1455	1458		10.1126/science.8197458	http://dx.doi.org/10.1126/science.8197458			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	8197458				2022-12-01	WOS:A1994NP22100041
J	GORE, JM; DALEN, JE				GORE, JM; DALEN, JE			CARDIOVASCULAR-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHOLESTEROL; ASPIRIN		UNIV ARIZONA, HLTH SCI CTR, TUCSON, AZ USA	University of Arizona; University of Arizona Health Sciences	GORE, JM (corresponding author), UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA USA.							[Anonymous], 1993, Lancet, V342, P767; HAMPTON J, 1993, LANCET, V342, P759; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; MILLER VT, 1993, NEUROLOGY, V43, P32, DOI 10.1212/WNL.43.1_Part_1.32; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TURPIE AGG, 1993, NEW ENGL J MED, V329, P524, DOI 10.1056/NEJM199308193290802; WARSHAFSKY S, 1993, ANN INTERN MED, V119, P599, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00009; 1993, LANCET, V342, P1255	10	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	1994	271	21					1660	1661		10.1001/jama.271.21.1660	http://dx.doi.org/10.1001/jama.271.21.1660			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN117	8182837				2022-12-01	WOS:A1994NN11700016
J	LAUNBJERG, J; FRUERGAARD, P; MADSEN, JK; MORTENSEN, LS; HANSEN, JF				LAUNBJERG, J; FRUERGAARD, P; MADSEN, JK; MORTENSEN, LS; HANSEN, JF			10-YEAR MORTALITY IN PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							CORONARY-CARE UNIT; CHEST PAIN; CONFIRMED DIAGNOSIS; 5-YEAR MORTALITY; UNSTABLE ANGINA; RISK-FACTORS; FOLLOW-UP; PROGNOSIS; SURVIVAL	Objective-To describe the 10 year mortality in patients with suspected acute myocardial infarction. Design-Follow up of all patients below 76 years of age admitted with acute chest pain to 16 coronary care units participating in the Danish verapamil infarction trial in 1979-81. Subjects-Of the 5993 patients included, 2586 had definite infarction, 402 had probable infarction, and 3005 did not have infarction. Main outcome measures-Death and cause of death. Standardised mortality ratio (observed mortality/expected mortality in background population). Results-The estimated 10 year mortalities were 58.8%, 55.5%, and 42.8% in patients with definite, probable, and no infarction, respectively (P<0.0001). Stratified Cox's analysis identified a hazard ratio for mortality of 1.25 (95% confidence interval 1.08 to 1.44) for probable infarction compared with no infarction and of 1.15 (1.00 to 1.32) for definite compared with probable infarction. The standardised mortality ratio in the first year was 7.1 (6.5 to 7.8) for definite infarction, 5.0 (3.6 to 6.3) for probable infarction, and 4.7 (4.2 to 5.2) for no infarction. From the second year and onwards the annual standardised mortality ratio in the three groups did not differ significantly. Cardiac causes of deaths were recorded in 89%, 84%, and 71% of the deaths in patients with definite, probable, and no infarction, respectively. Conclusions-The 10 year mortality of patients with and without infarction is significantly higher than in the background population. Most deaths are caused by coronary heart disease, and these patients should consequently be further evaluated at the time of discharge and followed up closely.	CENT HOSP HILLEROD,DEPT MED B,DK-3400 HILLEROD,DENMARK; UNIC,DANISH COMP CTR RES & EDUC,DK-8200 AARHUS,DENMARK; HVIDOVRE UNIV HOSP,DEPT CARDIOL,DK-2650 HVIDOVRE,DENMARK	University of Copenhagen	LAUNBJERG, J (corresponding author), UNIV COPENHAGEN HOSP,RIGSHOSP,DEPT MED B2124,BLEGDAMSVEJ,DK-2100 COPENHAGEN,DENMARK.							DAVIES HA, 1982, JAMA-J AM MED ASSOC, V248, P2274, DOI 10.1001/jama.248.18.2274; ENGBY B, 1985, ACTA MED SCAND, V217, P465; FRORUP E, 1988, STATISTICAL YB, V92, P37; GRANBORG J, 1986, AM J CARDIOL, V57, P203, DOI 10.1016/0002-9149(86)90891-X; Henning R, 1981, Eur Heart J, V2, P65; HERLITZ J, 1988, CARDIOLOGY, V75, P250, DOI 10.1159/000174381; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; LAUNBJERG J, 1993, CORONARY ARTERY DIS, V4, P195, DOI 10.1097/00019501-199302000-00010; LAUNBJERG J, 1991, AM HEART J, V122, P1270, DOI 10.1016/0002-8703(91)90565-Y; LAUNBJERG J, 1990, CLIN PHYSIOL, V10, P273, DOI 10.1111/j.1475-097X.1990.tb00096.x; MADSEN JK, 1982, ACTA MED SCAND, V211, P453; MADSEN JK, 1987, AM J CARDIOL, V59, P1064, DOI 10.1016/0002-9149(87)90849-6; MARTIN CA, 1983, CIRCULATION, V68, P961, DOI 10.1161/01.CIR.68.5.961; MERRILEES MA, 1984, BRIT MED J, V288, P356, DOI 10.1136/bmj.288.6414.356; METCALFE MJ, 1990, BRIT HEART J, V63, P267; MULCAHY R, 1985, AM HEART J, V109, P753, DOI 10.1016/0002-8703(85)90634-9; PARISI AF, 1989, CIRCULATION, V80, P1176, DOI 10.1161/01.CIR.80.5.1176; POHJOLA S, 1980, BRIT HEART J, V43, P176, DOI 10.1136/hrt.43.2.176; Rose G.A., 1982, CARDIOVASCULAR SURVE; SCHROEDER JS, 1980, NEW ENGL J MED, V303, P1, DOI 10.1056/NEJM198007033030101; SMYLLIE HC, 1986, BRIT MED J, V293, P541, DOI 10.1136/bmj.293.6546.541-a; WIELGOSZ AT, 1984, AM HEART J, V108, P67, DOI 10.1016/0002-8703(84)90546-5; WILCOX RG, 1981, BRIT MED J, V282, P431, DOI 10.1136/bmj.282.6262.431; WONG ND, 1989, AM J EPIDEMIOL, V130, P469, DOI 10.1093/oxfordjournals.aje.a115360; 1984, EUR HEART J, V5, P516; 1983, NEW ENGL J MED, V309, P331	26	23	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 7	1994	308	6938					1196	1199		10.1136/bmj.308.6938.1196	http://dx.doi.org/10.1136/bmj.308.6938.1196			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK956	8180535	Green Published			2022-12-01	WOS:A1994NK95600017
J	CROUCHER, C; AZZOPARDI, D				CROUCHER, C; AZZOPARDI, D			COMPLIANCE WITH RECOMMENDATIONS FOR GIVING VITAMIN-K TO NEWBORN-INFANTS	BRITISH MEDICAL JOURNAL			English	Article									QUEEN CHARLOTTES & CHELSEA HOSP,DEPT PAEDIAT & NEONATAL MED,LONDON W6 0XG,ENGLAND	Imperial College London								EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; PIETERSMADEBRUYN ALJM, 1990, HAEMOSTASIS, V20, P8; 1992, PROPHYLAXIS VITAMIN; 1992, VITAMIN K PROPHYLAXI	5	37	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1994	308	6933					894	895		10.1136/bmj.308.6933.894	http://dx.doi.org/10.1136/bmj.308.6933.894			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE600	8173369	Green Published			2022-12-01	WOS:A1994NE60000022
J	STEGEMAN, CA; TERVAERT, JWC; SLUITER, WJ; MANSON, WL; DEJONG, PE; KALLENBERG, CGM				STEGEMAN, CA; TERVAERT, JWC; SLUITER, WJ; MANSON, WL; DEJONG, PE; KALLENBERG, CGM			ASSOCIATION OF CHRONIC NASAL CARRIAGE OF STAPHYLOCOCCUS-AUREUS AND HIGHER RELAPSE RATES IN WEGENER GRANULOMATOSIS	ANNALS OF INTERNAL MEDICINE			English	Article							DISEASE-ACTIVITY; SULFAMETHOXAZOLE-TRIMETHOPRIM; PREFERENTIAL INDUCTION; AUTOANTIBODY SECRETION; POLYCLONAL ACTIVATION; PERITONEAL-DIALYSIS; LYSOSOMAL-ENZYMES; ENTEROTOXIN-A; HLA-DR; INFECTION	Objective: To examine possible risk factors for relapse, including chronic nasal carriage of Staphylococcus aureus and serial antineutrophil cytoplasmic antibody (ANCA) determinations in patients with Wegener granulomatosis. Design: Observational cohort study. Setting: Outpatient clinic at a university-affiliated hospital. Patients: Consecutive patients (n = 71) with biopsy-proven Wegener granulomatosis who were seen during follow-up at the outpatient clinic from January 1988 to July 1991. Fourteen patients were ineligible or dropped out; 57 patients were analyzed. Measurements: Serial ANCA determinations and swab cultures of both anterior nares for S. aureus taken at each visit every 4 to 6 weeks. Occurrence of infections and relapses of Wegener granulomatosis were identified according to strict, predefined criteria. Results: Thirty-six of the 57 patients (63%; 95% CI, 49% to 76%) were found to be chronic nasal carriers of S. aureus (greater-than-or-equal-to 75% of nasal cultures positive for S. aureua). Proportional-hazards regression analysis identified chronic nasal carriage of S. aureus (adjusted relative risk, 7.16; CI, 1.63 to 31.50), creatinine clearance above 60 mL . min-1 (adjusted relative risk, 2.94; CI, 1.27 to 6.67), and a history of previous relapses of Wegener granulomatosis (adjusted relative risk, 1.33; CI, 0.98 to 1.78) as independent risk factors for relapse. Twenty-two of 33 patients persistently or intermittently positive for ANCA had a relapse as opposed to only 1 of 21 persistently negative patients. Relapses of Wegener granulomatosis were not related to diagnosed infections. Conclusion: Chronic nasal carriage of S. aureus identifies a subgroup of patients with Wegener granulomatosis who are more prone to relapses of the disease, suggesting a role for S. aureus in its pathophysiology and a possible clue for treatment.			STEGEMAN, CA (corresponding author), UNIV GRONINGEN HOSP, DEPT INTERNAL MED, DIV NEPHROL, OOSTERSINGE 59, 9713 EZ GRONINGEN, NETHERLANDS.		tervaert, jan willem cohen/AAB-1111-2019	Stegeman, Coen/0000-0002-0224-0927				ARMSTRONGESTHER CA, 1976, ANN HUM BIOL, V3, P221, DOI 10.1080/03014467600001381; BATES EJ, 1991, IMMUNOLOGY, V72, P448; CAMPANELLI D, 1990, J EXP MED, V172, P1709, DOI 10.1084/jem.172.6.1709; CARLSSON R, 1988, J IMMUNOL, V140, P2484; CHINTAGUMPALA MM, 1991, J IMMUNOL, V147, P3876; COX DR, 1972, J R STAT SOC B, V34, P187; CUEVAS J, 1982, CLIN NEPHROL, V18, P109; DEREMEE RA, 1985, MAYO CLIN PROC, V60, P27, DOI 10.1016/S0025-6196(12)65279-3; DEREMEE RA, 1988, ARTHRITIS RHEUM, V31, P1068, DOI 10.1002/art.1780310821; DZIARSKI R, 1982, J IMMUNOL, V128, P1026; DZIARSKI R, 1982, J IMMUNOL, V128, P1018; EGNER W, 1990, CLIN EXP IMMUNOL, V82, P244; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GASKIN G, 1991, NEPHROL DIAL TRANSPL, V6, P689, DOI 10.1093/ndt/6.10.689; HAUSER C, 1984, CLIN EXP IMMUNOL, V57, P227; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; HOFFMAN GS, 1991, AM REV RESPIR DIS, V143, P401, DOI 10.1164/ajrccm/143.2.401; ISRAEL HL, 1988, ARCH INTERN MED, V148, P2293, DOI 10.1001/archinte.148.10.2293; JACOBS SI, 1961, J CLIN PATHOL, V14, P519, DOI 10.1136/jcp.14.5.519; KALLENBERG CGM, 1991, IMMUNOL TODAY, V12, P61, DOI 10.1016/0167-5699(91)90159-Q; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KUROSS S, 1981, CLIN NEPHROL, V16, P172; LUZAR MA, 1990, NEW ENGL J MED, V322, P505, DOI 10.1056/NEJM199002223220804; MAXWELL JG, 1969, AM J SURG, V118, P849, DOI 10.1016/0002-9610(69)90245-1; MILLIAN SJ, 1960, AM J PUBLIC HEALTH N, V50, P791, DOI 10.2105/AJPH.50.6_Pt_1.791; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; NOBLE WC, 1967, J HYG-CAMB, V65, P567, DOI 10.1017/S002217240004609X; PEDERSEN RS, 1990, SCAND J UROL NEPHROL, V24, P223, DOI 10.3109/00365599009180863; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINCHING AJ, 1980, BRIT MED J, V281, P836, DOI 10.1136/bmj.281.6244.836; PINCHING AJ, 1983, Q J MED, V52, P435; POTEMPA J, 1986, J BIOL CHEM, V261, P14330; RAO NV, 1991, J BIOL CHEM, V266, P9540; SEWELL CM, 1982, JAMA-J AM MED ASSOC, V248, P1493, DOI 10.1001/jama.248.12.1493; TERVAERT JWC, 1989, ARCH INTERN MED, V149, P2461, DOI 10.1001/archinte.149.11.2461; TERVAERT JWC, 1990, KIDNEY INT, V37, P799, DOI 10.1038/ki.1990.48; TERVAERT JWC, 1990, LANCET, V336, P709; TUAZON CU, 1984, AM J MED, V76, P166, DOI 10.1016/0002-9343(84)90260-2; VALERIANOMARCET J, 1991, ARCH INTERN MED, V151, P1649, DOI 10.1001/archinte.151.8.1649; VANDERWOUDE FJ, 1985, LANCET, V1, P425; Wegener F., 1936, VERHANDLUNGEN DTSCH, V29, P202; WILLIAMS RE, 1963, BACTERIOL REV, V27, P56, DOI 10.1128/MMBR.27.1.56-71.1963; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204	47	553	579	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					12	17		10.7326/0003-4819-120-1-199401010-00003	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250451				2022-12-01	WOS:A1994MP28000003
J	WINAWER, SJ; ZAUBER, AG; HO, MN; OBRIEN, MJ; GOTTLIEB, LS; STERNBERG, SS; WAYE, JD; SCHAPIRO, M; BOND, JH; PANISH, JF; ACKROYD, F; SHIKE, M; KURTZ, RC; HORNSBYLEWIS, L; GERDES, H; STEWART, ET				WINAWER, SJ; ZAUBER, AG; HO, MN; OBRIEN, MJ; GOTTLIEB, LS; STERNBERG, SS; WAYE, JD; SCHAPIRO, M; BOND, JH; PANISH, JF; ACKROYD, F; SHIKE, M; KURTZ, RC; HORNSBYLEWIS, L; GERDES, H; STEWART, ET			PREVENTION OF COLORECTAL-CANCER BY COLONOSCOPIC POLYPECTOMY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SCREENING SIGMOIDOSCOPY; SUBSEQUENT CARCINOMA; NATURAL-HISTORY; POLYPS; RISK; MORTALITY; INDIVIDUALS; POPULATION; ADENOMAS; RECTUM	Background. The current practice of removing adenomatous polyps of the colon and rectum is based on the belief that this will prevent colorectal cancer. To address the hypothesis that colonoscopic polypectomy reduces the incidence of colorectal cancer, we analyzed the results of the National Polyp Study with reference to other published results. Methods. The study cohort consisted of 1418 patients who had a complete colonoscopy during which one or more adenomas of the colon or rectum were removed. The patients subsequently underwent periodic colonoscopy during an average follow-up of 5.9 years, and the incidence of colorectal cancer was ascertained. The incidence rate of colorectal cancer was compared with that in three reference groups, including two cohorts in which colonic polyps were not removed and one general-population registry, after adjustment for sex, age, and polyp size. Results. Ninety-seven percent of the patients were followed clinically for a total of 8401 person-years, and 80 percent returned for one or more of their scheduled colonoscopies. Five asymptomatic early-stage colorectal cancers (malignant polyps) were detected by colonoscopy (three at three years, one at six years, and one at seven years). No symptomatic cancers were detected. The numbers of colorectal cancers expected on the basis of the rates in the three reference groups were 48.3, 43.4, and 20.7, for reductions in the incidence of colorectal cancer of 90, 88, and 76 percent, respectively (P<0.001). Conclusions. Colonoscopic polypectomy resulted in a lower-than-expected incidence of colorectal cancer. These results support the view that colorectal adenomas progress to adenocarcinomas, as well as the current practice of searching for and removing adenomatous polyps to prevent colorectal cancer.	BOSTON CITY HOSP,MALLORY INST PATHOL,BOSTON,MA 02118; MT SINAI MED CTR,NEW YORK,NY 10029; VALLEY PRESBYTERIAN HOSP,VAN NUYS,CA; VET AFFAIRS MED CTR,MINNEAPOLIS,MN; CEDARS SINAI MED CTR,LOS ANGELES,CA 90048; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; MILWAUKEE CTY MED CTR,MILWAUKEE,WI	Boston Medical Center; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Cedars Sinai Medical Center; Harvard University; Massachusetts General Hospital	WINAWER, SJ (corresponding author), MEM SLOAN KETTERING CANC CTR,GASTROENTEROL & NUTR SERV,NATL POLYP STUDY HEADQUARTERS,NEW YORK,NY 10021, USA.		O'Brien, Michael J/R-7179-2019	O'Brien, Michael J/0000-0003-1124-3537	NATIONAL CANCER INSTITUTE [R01CA026852] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26852] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; BRESLOW NE, 1987, IARC SCI PUBL, V32, P65; EIDE TJ, 1986, INT J CANCER, V38, P173, DOI 10.1002/ijc.2910380205; GILBERTSEN VA, 1978, CANCER, V41, P1137, DOI 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G; GLOECKLERRIES LA, 1990, DHHS NIH902789 PUBL; LOTFI AM, 1986, MAYO CLIN PROC, V61, P337, DOI 10.1016/S0025-6196(12)61950-8; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; MURAKAMI R, 1990, INT J CANCER, V46, P159, DOI 10.1002/ijc.2910460203; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; OBRIEN MJ, 1990, GASTROENTEROLOGY, V98, P371, DOI 10.1016/0016-5085(90)90827-N; SCHOTTENFELD D, 1982, CANCER EPIDEMIOL, P703; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SIMONS BD, 1992, J NATL CANCER I, V84, P962, DOI 10.1093/jnci/84.12.962; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; VASEN HF, 1993, DIS COLON RECTUM, V36, P1, DOI 10.1007/BF02050292; WINAWER S J, 1992, Gastroenterology, V102, pA409; WINAWER SJ, 1990, B WORLD HEALTH ORGAN, V68, P789; WINAWER SJ, 1992, CANCER, V70, P1236, DOI 10.1002/1097-0142(19920901)70:3+<1236::AID-CNCR2820701508>3.0.CO;2-4; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1993, J NATL CANCER I, V85, P1311, DOI 10.1093/jnci/85.16.1311; WINAWER SJ, 1993, NEW ENGL J MED, V328, P1416, DOI 10.1056/NEJM199305133281909	24	3470	3567	6	118	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1993	329	27					1977	1981		10.1056/NEJM199312303292701	http://dx.doi.org/10.1056/NEJM199312303292701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN573	8247072				2022-12-01	WOS:A1993MN57300001
J	SONTAG, E; FEDOROV, S; KAMIBAYASHI, C; ROBBINS, D; COBB, M; MUMBY, M				SONTAG, E; FEDOROV, S; KAMIBAYASHI, C; ROBBINS, D; COBB, M; MUMBY, M			THE INTERACTION OF SV40 SMALL TUMOR-ANTIGEN WITH PROTEIN PHOSPHATASE-2A STIMULATES THE MAP KINASE PATHWAY AND INDUCES CELL-PROLIFERATION	CELL			English	Article							SMALL-T-ANTIGEN; SIGNAL-REGULATED KINASES; NERVE GROWTH-FACTOR; SIMIAN VIRUS-40; INFECTED-CELLS; PHOSPHORYLATION; ACTIVATION; INSULIN; TRANSFORMATION; IDENTIFICATION	Interaction with SV40 small tumor antigen (small t) compromised the ability of multimeric protein phosphatase 2A to inactivate the mitogen-activated protein kinase ERK1 and the mitogen-activated protein kinase kinase MEK1. Transient expression of small t in CV-1 cells activated MEK and ERK but did not affect Raf activity. Small t stimulated the growth of quiescent CV-1 cells almost as effectively as did serum. Coexpression of kinase-deficient ERK2 blocked most, but not all, of the proliferation caused by small t. Activation of the mitogen-activated protein kinase pathway and stimulation of cell growth were dependent on the interaction of small t with protein phosphatase 2A. These findings indicate that SV40 small t is capable of inducing cell growth through blockade of protein phosphatase and deregulation of the mitogen-activated protein kinase cascade.			SONTAG, E (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.		SONTAG, ESTELLE/AAE-9805-2020	Cobb, Melanie/0000-0003-0833-5473	NCI NIH HHS [CA54726] Funding Source: Medline; NHLBI NIH HHS [HL31107] Funding Source: Medline; NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054726] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BIKEL I, 1986, MOL CELL BIOL, V6, P1172, DOI 10.1128/MCB.6.4.1172; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; BOSSERT A, 1985, J VIROL, V56, P325, DOI 10.1128/JVI.56.1.325-327.1985; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHANG LS, 1984, VIROLOGY, V133, P341, DOI 10.1016/0042-6822(84)90400-8; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ELLMAN M, 1984, J VIROL, V50, P623, DOI 10.1128/JVI.50.2.623-628.1984; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTIN RG, 1979, CELL, V17, P635, DOI 10.1016/0092-8674(79)90271-X; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN H, 1993, IN PRESS CELL, V75; TURK B, 1993, J VIROL, V67, P3671, DOI 10.1128/JVI.67.6.3671-3673.1993; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YANG YC, 1979, J VIROL, V32, P147, DOI 10.1128/JVI.32.1.147-154.1979; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	61	472	480	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					887	897		10.1016/0092-8674(93)90533-V	http://dx.doi.org/10.1016/0092-8674(93)90533-V			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252625	Bronze			2022-12-01	WOS:A1993MK96600009
J	MARKOVITZ, JH; MATTHEWS, KA; KANNEL, WB; COBB, JL; DAGOSTINO, RB				MARKOVITZ, JH; MATTHEWS, KA; KANNEL, WB; COBB, JL; DAGOSTINO, RB			PSYCHOLOGICAL PREDICTORS OF HYPERTENSION IN THE FRAMINGHAM-STUDY - IS THERE TENSION IN HYPERTENSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; HIGH BLOOD-PRESSURE; MIDDLE-AGED WOMEN; SUBSTANCE USE; RISK-FACTORS; RELAXATION; ANXIETY; ANGER; BIOFEEDBACK; KNOWLEDGE	Objective.-To test the hypothesis that heightened anxiety, heightened anger intensity, and suppressed expression of anger increase the risk of hypertension, using the Framingham Heart Study. Design.-A cohort of men and women without evidence of hypertension at baseline were followed up for 18 to 20 years. Baseline measures of anxiety (tension), anger symptoms, and expression of anger (anger-in and anger-out) were taken, along with biological and behavioral predictors of hypertension (initial systolic blood pressure, heart rate, relative weight, age, hematocrit, alcohol intake, smoking, education, and glucose intolerance). Participants.-A total of 1123 initially normotensive persons (497 men, 626 women) were included. Analyses were stratified by age (45 to 59 or greater-than-or-equal-to 60 years) and gender. Main Outcome Measures.-Hypertension was defined as either taking medication for hypertension or blood pressures higher than 160/95 mm Hg at a biennial examination. Results.-In univariate analyses, middle-aged men who went on to develop hypertension had greater baseline anxiety levels than men who remained normotensive (P=.04). Older hypertensive men had fewer anger symptoms at baseline (P=.04) and were less likely to hold their anger in (P=.01) than normotensives. In multivariate Cox regression analysis including biological predictors, anxiety remained an independent predictor of hypertension in middle-aged men (P=.02). Among older men, anger symptoms and anger-in did not remain significant predictors in the multivariate analysis. Further analysis showed that only middle-aged men with very high levels of anxiety were at increased risk (relative risk, 2.19; 95% confidence interval, 1.22 to 3.94). No psychological variable predicted hypertension in middle-aged or older women in either univariate or multivariate analyses. Conclusions.-The results indicate that among middle-aged men, but not women, anxiety levels are predictive of later incidence of hypertension.	UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA 15260; BOSTON UNIV,DEPT MATH,BOSTON,MA 02215; BOSTON UNIV,SCH MED,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA 02118	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Boston University; Boston University	MARKOVITZ, JH (corresponding author), UNIV ALABAMA,SCH MED,DEPT MED,DIV PREVENT MED,1717 11TH AVE S,7TH FLOOR,BIRMINGHAM,AL 35205, USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038712, R01HL038712, R01HL040423] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL40423-04, HL38712, N01-HC38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander F, 1939, PSYCHOSOM MED, V1, P175; ANDERSON NB, 1989, J HYPERTENS, V7, P161; [Anonymous], 1988, BMJ, V297, P319; BLANCHARD EB, 1989, BEHAV THER, V20, P405, DOI 10.1016/S0005-7894(89)80059-0; COTTIER C, 1984, ARCH INTERN MED, V144, P1954, DOI 10.1001/archinte.144.10.1954; DIAMOND EL, 1982, PSYCHOL BULL, V92, P410, DOI 10.1037/0033-2909.92.2.410; EAKER ED, 1992, AM J EPIDEMIOL, V135, P854, DOI 10.1093/oxfordjournals.aje.a116381; EGAN KJ, 1983, J HUM STRESS, V9, P4, DOI 10.1080/0097840X.1983.9935024; GOLDSTEIN HS, 1988, PSYCHOSOM MED, V50, P321, DOI 10.1097/00006842-198807000-00001; HAVLIK RJ, 1980, CIRCULATION, V61, P710, DOI 10.1161/01.CIR.61.4.710; HAYNES SG, 1978, AM J EPIDEMIOL, V107, P362, DOI 10.1093/oxfordjournals.aje.a112556; HENRY JP, 1988, SOC SCI MED, V26, P293, DOI 10.1016/0277-9536(88)90393-0; IRVINE MJ, 1989, PSYCHOSOM MED, V51, P537, DOI 10.1097/00006842-198909000-00005; JACOB R G, 1991, Annals of Behavioral Medicine, V13, P5; JENKINS CD, 1983, J HUM STRESS, V9, P4, DOI 10.1080/0097840X.1983.9936124; JOHNSON EH, 1987, J PSYCHOSOM RES, V31, P731, DOI 10.1016/0022-3999(87)90022-5; KAHN HA, 1972, AM HEART J, V84, P171, DOI 10.1016/0002-8703(72)90331-6; KATON W, 1986, J CLIN PSYCHIAT, V47, P21; LANGFORD HG, 1987, BIBLIOTHECA CARDIOLO, V41, P57; MARKOVITZ JH, 1991, J HYPERTENS, V9, P399, DOI 10.1097/00004872-199105000-00003; MATTHEWS KA, 1989, AM J EPIDEMIOL, V129, P1132, DOI 10.1093/oxfordjournals.aje.a115235; MCCELLAND DC, 1979, J ABNORM PSYCHOL, V88, P182; MCGRADY A, 1989, PSYCHOSOM MED, V51, P277, DOI 10.1097/00006842-198905000-00002; MILLER SB, 1992, J PSYCHOSOM RES, V36, P149, DOI 10.1016/0022-3999(92)90023-U; NOYES R, 1978, COMPR PSYCHIAT, V19, P407, DOI 10.1016/0010-440X(78)90069-X; PERNINI C, 1991, J HYPERTENS, V9, P499; PERNINI C, 1990, HYPERTENSION, V16, P627; PERNINI C, 1988, J CARDIOVASC PHAR S3, V12, pS130; REAVEN GM, 1987, LANCET, V2, P435; ROBBINS MA, 1990, EXP AGING RES, V16, P199; ROBERTS J, 1981, VITAL HLTH STAT, V11; ROSE RM, 1978, DCTFA73WA3211 FED AV; ROSTRUP M, 1992, J PSYCHOSOM RES, V36, P117, DOI 10.1016/0022-3999(92)90020-3; SCHNEIDER RH, 1986, PSYCHOSOM MED, V48, P242, DOI 10.1097/00006842-198603000-00009; SOMMERSFLANAGAN J, 1989, J NERV MENT DIS, V177, P15, DOI 10.1097/00005053-198901000-00003; SPARROW D, 1982, CIRCULATION, V65, P789, DOI 10.1161/01.CIR.65.4.789; Spielberger C.D., 1985, ANGER HOSTILITY CARD, P5; Spielberger CD, 1970, STAI MANUAL; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; WADDEN TA, 1983, J NERV MENT DIS, V171, P683, DOI 10.1097/00005053-198311000-00007; WELLS KB, 1989, AM J PSYCHIAT, V146, P1440; WELLS KB, 1989, GEN HOSP PSYCHIAT, V11, P320, DOI 10.1016/0163-8343(89)90119-9; YALOW RS, 1988, AM J MED, V85, P22, DOI 10.1016/0002-9343(88)90394-4; 1991, JAMA-J AM MED ASSOC, V265, P255	44	162	172	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1993	270	20					2439	2443						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MG671	8230620				2022-12-01	WOS:A1993MG67100024
J	TAKI, S; MEIERING, M; RAJEWSKY, K				TAKI, S; MEIERING, M; RAJEWSKY, K			TARGETED INSERTION OF A VARIABLE REGION GENE INTO THE IMMUNOGLOBULIN HEAVY-CHAIN LOCUS	SCIENCE			English	Article							TRANSGENIC MICE; ALLELIC EXCLUSION; LYMPHOCYTES-B; GERM-LINE; ANTIBODIES; MU; CELLS; DNA; IGM; EXPRESSION	A mutant mouse strain has been generated in which a rearranged immunoglobulin heavy (H) chain variable (V) region gene is placed into the heavy chain locus in its natural position, replacing the J(H) elements. In homozygous mutant mice, essentially all B cells in the spleen express the transgenic V(H) region in their antibodies. The proper location of the transgene relative to the constant region genes allows it to participate in isotype switching and undergo somatic hypermutation. Immunoglobulin transgenic mice generated in this fashion by gene targeting should prove useful for the exploration of immunoregulatory mechanisms.	UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY	University of Cologne				Taki, Shinsuke/0000-0001-5143-3496				ALT F, 1987, EMBO J, V3, P1209; ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BRINK R, 1992, J EXP MED, V176, P991, DOI 10.1084/jem.176.4.991; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHIEN NC, 1988, J EXP MED, V167, P954, DOI 10.1084/jem.167.3.954; Coffman R L, 1982, Immunol Rev, V69, P5; COHN M, 1969, IMMUNOCHEMISTRY, V6, P111, DOI 10.1016/0019-2791(69)90183-9; DESAYMARD C, 1984, MOL IMMUNOL, V21, P961, DOI 10.1016/0161-5890(84)90154-8; DIAMOND B, 1992, ANNU REV IMMUNOL, V10, P731, DOI 10.1146/annurev.iy.10.040192.003503; DURDIK J, 1989, P NATL ACAD SCI USA, V86, P2346, DOI 10.1073/pnas.86.7.2346; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GROSSCHEDL R, 1984, CELL, V38, P647, DOI 10.1016/0092-8674(84)90259-9; GRUTZMANN R, 1981, THESIS U COLOGNE; GUISE JW, 1988, J IMMUNOL, V140, P3988; HAYAKAWA K, 1992, ANN NY ACAD SCI, V651, P346; HERZENBERG LA, 1992, ANN NY ACAD SCI, V651, P1; HOOIJKAAS H, 1984, EUR J IMMUNOL, V14, P1127, DOI 10.1002/eji.1830141212; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KEARNEY JF, 1981, EUR J IMMUNOL, V11, P877, DOI 10.1002/eji.1830111106; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; KOHNO A, 1983, IMMUNOGENETICS, V18, P513, DOI 10.1007/BF00364392; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MANZ J, 1988, J EXP MED, V168, P1368; MASMOUDI H, 1990, INT IMMUNOL, V2, P515, DOI 10.1093/intimm/2.6.515; MEIERING M, UNPUB; NEMAZEE D, 1991, IMMUNOL REV, V122, P117, DOI 10.1111/j.1600-065X.1991.tb00600.x; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; PAPOIAN R, 1977, IMMUNOLOGY, V32, P75; PERLMUTTER RM, 1984, ADV IMMUNOL, V35, P1, DOI 10.1016/S0065-2776(08)60572-6; RUSCONI S, 1985, NATURE, V314, P330, DOI 10.1038/314330a0; SCHITTEK B, 1992, J EXP MED, V176, P427, DOI 10.1084/jem.176.2.427; SCHLOMCHIK MJ, 1987, NATURE, V328, P805; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; TAKI S, 1992, ANN NY ACAD SCI, V651, P328; TAKI S, 1992, EUR J IMMUNOL, V22, P987, DOI 10.1002/eji.1830220417; TAKI S, UNPUB; TONEGAWA S, 1983, NATURE, V302, P79; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0; WOOD C, 1983, P NATL ACAD SCI-BIOL, V80, P3030, DOI 10.1073/pnas.80.10.3030	52	100	145	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1268	1271		10.1126/science.8235657	http://dx.doi.org/10.1126/science.8235657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235657				2022-12-01	WOS:A1993MH32400040
J	NIGHTINGALE, SL				NIGHTINGALE, SL			MEDICAL DEVICE TRACKING RULE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1993, FED REG         0816, V58, P43442	1	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2283	2283		10.1001/jama.270.19.2283	http://dx.doi.org/10.1001/jama.270.19.2283			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230583				2022-12-01	WOS:A1993MF99300006
J	OTTERVANGER, JP; VANWITSEN, TB; VALKENBURG, HA; STRICKER, BHC				OTTERVANGER, JP; VANWITSEN, TB; VALKENBURG, HA; STRICKER, BHC			POSTMARKETING STUDY OF CARDIOVASCULAR ADVERSE REACTIONS ASSOCIATED WITH SUMATRIPTAN	BRITISH MEDICAL JOURNAL			English	Article									NETHERLANDS CTR MONITORING ADVERSE DRUG REACT,POB 5406,2280 HK RIJSWIJK,NETHERLANDS; UNIV GRONINGEN,CTR PHARM,SOCIAL PHARM SECT,GRONINGEN,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS	University of Groningen; Erasmus University Rotterdam								BROWN EG, 1991, EUR NEUROL, V31, P339, DOI 10.1159/000116762; MACINTYRE PD, 1993, CIRCULATION, V87, P401, DOI 10.1161/01.CIR.87.2.401; OTTERVANGER JP, 1993, LANCET, V341, P861, DOI 10.1016/0140-6736(93)93064-8; STRICKER BHC, 1992, BRIT MED J, V305, P118, DOI 10.1136/bmj.305.6845.118-a; WILLETT F, 1992, BRIT MED J, V304, P1415, DOI 10.1136/bmj.304.6839.1415	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1185	1185		10.1136/bmj.307.6913.1185	http://dx.doi.org/10.1136/bmj.307.6913.1185			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8251846	Bronze, Green Published			2022-12-01	WOS:A1993MF82400025
J	OLSEN, JH; GARWICZ, S; HERTZ, H; JONMUNDSSON, G; LANGMARK, F; LANNING, M; LIE, SO; MOE, PJ; MOLLER, T; SANKILA, R; TULINIUS, H				OLSEN, JH; GARWICZ, S; HERTZ, H; JONMUNDSSON, G; LANGMARK, F; LANNING, M; LIE, SO; MOE, PJ; MOLLER, T; SANKILA, R; TULINIUS, H			2ND MALIGNANT NEOPLASMS AFTER CANCER IN CHILDHOOD OR ADOLESCENCE	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA; SURVIVORS; CHILDREN; RISK	Objective-To assess the relative risk of developing a second malignant neoplasm in people with a diagnosis of cancer in childhood and adolescence. Design-Register based follow up study. Setting-Populations of Nordic countries. Subjects-30 880 people under the age of 20 with a first malignant neoplasm diagnosed during the period 1943-87. Main outcome measures-Relative and attributable risks of second malignant neoplasms by type of first cancer, age at first diagnosis, calendar period, sex, and country. Expected figures were based on the appropriate national incidence rates for cancer. Results-247 cases of second malignant neoplasms were observed in 238 patients, yielding a relative risk for cancer of 3-6 (95% confidence interval 3.1 to 4.1). The risk changed significantly from 2.6 in people first diagnosed during the 1940s and 1950s to 6.9 among cohort members included in the late 1970s and 1980s. Increases were observed for most types of cancer. Highest levels of the relative risk were seen during the 10 years immediately after first malignant diagnosis. The incidence of second malignant neoplasms attributable to the first cancer and associated treatments, however, showed a consistent rise throughout the 45 years of follow up. Conclusion-The estimated risks for a second malignant neoplasm were significantly lower than those found in most large hospital based studies but compatible with the results from a similar population based study in the United Kingdom. Extent of risk and cancer pattern were similar among the Nordic countries and are believed to be representative for a large part of the European population.			OLSEN, JH (corresponding author), DANISH CANC SOC,DIV CANC EPIDEMIOL,STRANDBOULEVARDEN 49,DK-2100 COPENHAGEN,DENMARK.			Olsen, Jorgen Helge/0000-0001-9633-5662				[Anonymous], 1976, INT CLASSIFICATION D; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; Boice J D Jr, 1985, Natl Cancer Inst Monogr, V68, P3; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BROWN PD, 1989, INT J EPIDEMIOL, V18, P546, DOI 10.1093/ije/18.3.546; HAKULINEN T, 1986, ACTA PATHOL MIC S288, V94, P12; HAWKINS MM, 1987, BRIT J CANCER, V56, P399; Jensen O M, 1985, Natl Cancer Inst Monogr, V68, P245; LI FP, 1975, CANCER, V35, P1230, DOI 10.1002/1097-0142(197504)35:4<1230::AID-CNCR2820350430>3.0.CO;2-Q; MIKE V, 1982, LANCET, V2, P1326; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; NYGAARD R, 1991, ACTA PAEDIATR SCAND, V80, P1220, DOI 10.1111/j.1651-2227.1991.tb11812.x; OLSEN JH, 1986, CANCER, V57, P2250; Parkin D. M, 1988, IARC SCI PUBLICATION, V87; ROTHMAN KJ, 1979, DHSS NIH791649 PUB; TARBELL NJ, 1993, LANCET, V341, P1428, DOI 10.1016/0140-6736(93)90880-P; TERRACINI B, 1987, EUR J CANCER CLIN ON, V23, P499, DOI 10.1016/0277-5379(87)90309-9; TSUNEMATSU Y, 1985, JPN J CLIN ONCOL, V15, P223; TUCKER MA, 1987, J NATL CANCER I, V78, P459, DOI 10.1093/jnci/78.3.459; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; TUCKER MA, 1991, CANCER RES, V51, P2885; TUCKER MA, 1984, RAD CARCINOGENESIS E, P211; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203; 1976, SYSTEMATIZED NOMENCL; 1956, WHOHSCANC241; 1968, MANUAL TUMOR NOMENCL; 1989, INCIDENCE CANCER NOR, P7	27	147	149	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1030	1036		10.1136/bmj.307.6911.1030	http://dx.doi.org/10.1136/bmj.307.6911.1030			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251777	Green Published, Bronze			2022-12-01	WOS:A1993MD55600016
J	TSOU, CL				TSOU, CL			CONFORMATIONAL FLEXIBILITY OF ENZYME ACTIVE-SITES	SCIENCE			English	Editorial Material							THERMAL-DENATURATION; INACTIVATION; DISSOCIATION; GUANIDINE				TSOU, CL (corresponding author), ACAD SINICA,INST BIOPHYS,NATL LAB BIOMACROMOLEC,15 DATUN RD,BEIJING 100101,PEOPLES R CHINA.							CREIGHTON TE, 1990, BIOCHEM J, V270, P1; EDWARDS RA, 1990, BIOCHEMISTRY-US, V29, P11001, DOI 10.1021/bi00501a019; ENGELHARD M, 1976, EUR J BIOCHEM, V67, P447, DOI 10.1111/j.1432-1033.1976.tb10709.x; HO YS, 1979, NATURE, V277, P245, DOI 10.1038/277245a0; KOSHLAND DE, 1976, FEBS LETT, V62, pE47, DOI 10.1016/0014-5793(76)80853-8; LEE HJ, 1988, BIOCHIM BIOPHYS ACTA, V955, P119, DOI 10.1016/0167-4838(88)90185-9; LIN YZ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P247, DOI 10.1016/0167-4838(90)90212-X; LINDSAY CD, 1990, EUR J BIOCHEM, V192, P133, DOI 10.1111/j.1432-1033.1990.tb19206.x; LIU W, 1987, BIOCHIM BIOPHYS ACTA, V916, P455, DOI 10.1016/0167-4838(87)90192-0; MA YZ, 1991, BIOCHEM J, V277, P207, DOI 10.1042/bj2770207; MILLER JF, 1978, BIOCHEM BIOPH RES CO, V81, P610, DOI 10.1016/0006-291X(78)91579-6; NOZAIS M, 1992, BIOCHEMISTRY-US, V31, P1210, DOI 10.1021/bi00119a034; TSOU CL, 1986, TRENDS BIOCHEM SCI, V11, P427, DOI 10.1016/0968-0004(86)90178-7; TSOU CL, 1989, CHINESE SCI BULL, V34, P393; TSOU CL, 1988, ADV ENZYMOL, V61, P388; WEST SM, 1990, BIOCHEM J, V265, P45, DOI 10.1042/bj2650045; XIAO J, 1993, BIOCHIM BIOPHYS ACTA, V1164, P54, DOI 10.1016/0167-4838(93)90111-4; YAO QZ, 1984, BIOCHEMISTRY-US, V23, P2740, DOI 10.1021/bi00307a032; ZHANG YL, 1993, BIOCHIM BIOPHYS ACTA, V1164, P61, DOI 10.1016/0167-4838(93)90112-5; ZHOU HM, 1993, BIOCHEM J, V291, P103, DOI 10.1042/bj2910103	20	197	212	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					380	381		10.1126/science.8211158	http://dx.doi.org/10.1126/science.8211158			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	8211158				2022-12-01	WOS:A1993MB85900046
J	BONNIN, MJ; PEPE, PE; KIMBALL, KT; CLARK, PS				BONNIN, MJ; PEPE, PE; KIMBALL, KT; CLARK, PS			DISTINCT CRITERIA FOR TERMINATION OF RESUSCITATION IN THE OUT-OF-HOSPITAL SETTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUDDEN CARDIAC-ARREST; IMPROVING SURVIVAL; LIFE-SUPPORT; EMERGENCY; FIELD; GUIDELINES; CPR	Objective.-To identify distinct criteria for appropriate on-scene termination of resuscitation efforts for out-of-hospital cardiac arrest when on-scene interventions fail to restore spontaneous circulation. Design.-For 18 months, all out-of-hospital cardiac arrests were evaluated prospectively for survival to hospital discharge and for all established survival predictors including age, gender, presenting cardiac rhythm, whether it was a witnessed event, performance of basic cardiopulmonary resuscitation by bystanders, and interval to paramedic arrival and return of spontaneous circulation (ROSC). Setting.-A large municipality with a single, centralized emergency medical services program. Patients.-All normothermic adults treated for out-of-hospital, unmonitored, primary cardiac arrest. Interventions.-Standard advanced cardiac life support provided at the scene by paramedics. Main Outcome Measures.-The number and circumstances of patients achieving survival to hospital discharge following failure to achieve on-scene ROSC. Results.-Of 1461 consecutive primary cardiac arrests, 139 were monitored (paramedic witnessed), including 59 that occurred en route to the hospital. Of the 1322 unmonitored patients, 370 achieved ROSC at the scene. Only six (0.6%) of the 952 who did not achieve ROSC at the scene survived, and all six were readily identifiable as having persistent ventricular fibrillation. Excluding those patients with persistent ventricular fibrillation, all survivors achieved ROSC within 25 minutes after paramedic arrival. Conclusions.-Excluding patients with persistent ventricular fibrillation, resuscitative efforts can be terminated at the scene when normothermic adults with unmonitored, out-of-hospital, primary cardiac arrest do not regain spontaneous circulation within 25 minutes following standard advanced cardiac life support. These criteria should now be validated in several large centers with high survival rates.	CITY HOUSTON CTR RESUSCITAT & EMERGENCY MED SERV,410 BAGBY,SUITE 300,HOUSTON,TX 77002; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine								APRAHAMIAN C, 1986, ANN EMERG MED, V15, P445, DOI 10.1016/S0196-0644(86)80185-8; AUERBACH PS, 1987, JAMA-J AM MED ASSOC, V258, P1487, DOI 10.1001/jama.258.11.1487; BECKER LB, 1993, ANN EMERG MED, V22, P354, DOI 10.1016/S0196-0644(05)80465-2; BONNIN MJ, 1989, ANN EMERG MED, V18, P507, DOI 10.1016/S0196-0644(89)80834-0; COBB LA, 1976, MED CLIN N AM, V60, P283, DOI 10.1016/S0025-7125(16)31909-5; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; CURRY DG, 1989, MED CONTROL MANUAL; EISENBERG MS, 1985, ANN EMERG MED, V14, P1106, DOI 10.1016/S0196-0644(85)80932-X; Eliastam M, 1977, JACEP, V6, P525, DOI 10.1016/S0361-1124(77)80422-X; FOSNOCHT DE, 1993, ANN EMERG MED, V22, P919; FRANK M, 1989, ANN EMERG MED, V18, P594, DOI 10.1016/S0196-0644(89)80853-4; GEEHR EC, 1986, NEW ENGL J MED, V314, P1189; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; JAKOBSSON J, 1987, ACTA MED SCAND, V222, P123; KELLERMANN AL, 1993, ANN EMERG MED, V22, P47, DOI 10.1016/S0196-0644(05)80249-5; KELLERMANN AL, 1988, ANN EMERG MED, V17, P589, DOI 10.1016/S0196-0644(88)80398-6; KELLERMANN AL, 1987, AM J EMERG MED, V5, P548, DOI 10.1016/0735-6757(87)90197-5; LEVINE RL, 1992, JAMA-J AM MED ASSOC, V267, P2935, DOI 10.1001/jama.267.21.2935; LEWIS LM, 1990, AM J EMERG MED, V8, P118, DOI 10.1016/0735-6757(90)90196-7; LOW R, 1993, PREHOSPITAL DISAST S, V8, pS69; MOORE TJ, 1989, HEART FAILURE CRITIC, P186; OCONNOR R, 1993, PREHOSP DISAST ME S2, V8, pS57; OMARCAIGH AS, 1993, MAYO CLIN PROC, V68, P332, DOI 10.1016/S0025-6196(12)60126-8; PEPE PE, 1993, ANN EMERG MED, V22, P17, DOI 10.1016/S0196-0644(05)80244-6; PEPE PE, 1993, CRIT CARE MED, V21, P1279, DOI 10.1097/00003246-199309000-00009; PEPE PE, 1985, ANN EMERG MED, V14, P1085, DOI 10.1016/S0196-0644(85)80927-6; PEPE PE, 1990, PROBL CRIT CARE, V4, P470; PEPE PE, 1990, UPDATE EMERGENCY INT, P565; PEPE PE, 1990, PREHOSP DISASTER MED, V5, P59; SCHMIDT TA, 1993, ANN EMERG MED, V22, P918; SMITH JP, 1985, ANN EMERG MED, V14, P1093; SMITH JP, 1985, WESTERN J MED, V143, P402; STONE CK, 1993, PREHOSP DISAST ME S2, V8, pS68; VANHOEYWEGHEN R, 1989, RESUSCITATION, V17, pS137, DOI 10.1016/0300-9572(89)90098-1; WARNER LL, 1985, CHEST, V87, P22, DOI 10.1378/chest.87.1.22; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; WEAVER WD, 1991, NEW ENGL J MED, V325, P1437, DOI 10.1056/NEJM199111143252008; WOLFORD RW, 1988, ANN EMERG MED, V17, P410; 1986, JAMA-J AM MED ASSOC, V255, P2841; 1992, JAMA-J AM MED ASSOC, V268, P2171; 1989, RESPONSE TIME 1ST RE; 1989, PREHOSP DISAST MED, V4, P163; 1991, CPH145 US DEP COMM E	45	148	149	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1993	270	12					1457	1462		10.1001/jama.270.12.1457	http://dx.doi.org/10.1001/jama.270.12.1457			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX173	8204131				2022-12-01	WOS:A1993LX17300031
J	BRONNER, G; CHULAGRAFF, Q; DOE, CQ; COHEN, B; WEIGEL, D; TAUBERT, H; JACKLE, H				BRONNER, G; CHULAGRAFF, Q; DOE, CQ; COHEN, B; WEIGEL, D; TAUBERT, H; JACKLE, H			SP1/EGR-LIKE ZINC-FINGER PROTEIN REQUIRED FOR ENDODERM SPECIFICATION AND GERM-LAYER FORMATION IN DROSOPHILA	NATURE			English	Article							EMBRYONIC TERMINI; SEGMENTATION GENE; MELANOGASTER; GASTRULATION; TAILLESS; DOMAINS; MEMBER; CELLS; SP1	Much of out present knowledge of the biological processes involved in pattern formation in Drosophila is derived from segmentation analysis(1,2). Comparatively little is known about the genetic requirement and mechanisms underlying the formation and separation of germ layers by morphogenetic movements during gastrulation(3). Here we show that the Drosophila gene huckebein (hkb), a member of the gap-gene class of segmentation genes(4,5), is required for germ-layer formation at blastoderm. Absence of the hkb product, an Spl/egr-like zinc-finger protein, causes the ectodermal and mesodermal primordia to expand at the expense of endoderm anlagen. Conversely, ectopic expression of hkb inhibits the formation of the major gastrulation fold which gives rise to the mesoderm and prevents normal segmentation in the ectoderm. Thus, hkb is necessary for endoderm development and its activity defines spatial limits within the blastoderm embryo in which the germ layers are established.	UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	BRONNER, G (corresponding author), MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,POSTFACH 2841,D-37018 GOTTINGEN,GERMANY.		Weigel, Detlef/GSJ-0799-2022; Weigel, Detlef/C-1418-2008; Weigel, Detlef/AAR-3312-2021	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; 				BEDDINGTON RSP, 1993, CURR OPIN GENET DEV, V3, P655, DOI 10.1016/0959-437X(93)90103-V; BELLEN HJ, 1989, GENE DEV, V3, P1301; BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; BROWN NH, 1988, J MOL BIOL, V168, P17; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; COSTA M, 1992, DEV DROSOPHILA; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; FOE VE, 1989, DEVELOPMENT, V107, P1; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HOCH M, 1993, CURR OPIN GENET DEV, V3, P566, DOI 10.1016/0959-437X(93)90092-4; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KRUMLAUF R, 1993, CURR OPIN GENET DEV, V3, P621, DOI 10.1016/0959-437X(93)90098-A; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; LEPTIN M, 1992, GASTRULATION, P23; MOHLER J, 1989, EMBO J, V8, P1539, DOI 10.1002/j.1460-2075.1989.tb03538.x; MORATA G, 1993, CURR OPIN GENET DEV, V3, P606, DOI 10.1016/0959-437X(93)90096-8; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROTHE M, 1992, NATURE, V359, P156, DOI 10.1038/359156a0; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STJOHNSTON D, 1992, CELL, V68, P201; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; TECHNAU G M, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P196, DOI 10.1007/BF00848247; TURNER FR, 1977, DEV BIOL, V57, P403, DOI 10.1016/0012-1606(77)90225-1; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WIMMER EA, 1993, NATURE, V366, P690, DOI 10.1038/366690a0; WOLPERT L, 1992, GASTRULATION, P7; [No title captured]	30	113	113	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 23	1994	369	6482					664	668		10.1038/369664a0	http://dx.doi.org/10.1038/369664a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	8208294				2022-12-01	WOS:A1994NT45900060
J	IWAMURA, Y; IRIKI, A; TANAKA, M				IWAMURA, Y; IRIKI, A; TANAKA, M			BILATERAL HAND REPRESENTATION IN THE POSTCENTRAL SOMATOSENSORY CORTEX	NATURE			English	Article							VERTICAL NEURONAL ARRAYS; CONSCIOUS MONKEY; RECEPTIVE-FIELD; RHESUS-MONKEY; CALLOSAL CONNECTIONS; CORPUS-CALLOSUM; PARIETAL CORTEX; M FASCICULARIS; ORGANIZATION; GYRUS	IN accordance with its important role in prehensile activity, a large cortical area is devoted to representation of the digits. Within this large cortical zone in the macaque somatosensory cortex, the complexity of neuronal receptive field characteristics increases from area 3b to areas 1 and 2 (refs 1-7). This increase in complexity continues into the upper bank of the intraparietal sulcus, where the somatosensory cortex adjoins the parietal association cortex. In this bank, callosal connections are much denser than in the more anterior part of this cortical zone(8-17). We have now discovered a substantial number of neurons with receptive fields on the bilateral hands. It was previously thought that neuronal receptive fields were restricted to the contralateral side in this cortical zone. Neurons with bilateral receptive fields were not found after lesioning the postcentral gyrus in the contralateral hemisphere. The majority of these neurons had receptive fields of the most complex types, representing multiple digits, indicating that the interhemispheric h anser of information occurs at higher levels of the hierarchical processing in each hemisphere.			IWAMURA, Y (corresponding author), TOHO UNIV,SCH MED,DEPT PHYSIOL,5-21-16 OMORI NISHI,TOKYO 143,JAPAN.							Berlucchi G., 1990, HDB NEUROPSYCHOLOGY, V4, P9; BURBAUD P, 1991, J NEUROPHYSIOL, V66, P429, DOI 10.1152/jn.1991.66.2.429; CAMINITI R, 1985, J COMP NEUROL, V237, P85, DOI 10.1002/cne.902370107; DUFFY FH, 1971, SCIENCE, V172, P273, DOI 10.1126/science.172.3980.273; EBNER FF, 1962, J NEUROPHYSIOL, V25, P380, DOI 10.1152/jn.1962.25.3.380; HUNTER M, 1975, BRAIN RES, V93, P223, DOI 10.1016/0006-8993(75)90347-9; HYVARINEN J, 1978, J PHYSIOL-LONDON, V257, P199; IWAMURA Y, 1980, BRAIN RES, V197, P516, DOI 10.1016/0006-8993(80)91139-7; IWAMURA Y, 1983, EXP BRAIN RES, V51, P315; IWAMURA Y, 1985, EXP BRAIN RES, V58, P400; IWAMURA Y, 1985, EXP BRAIN RES, V58, P412; IWAMURA Y, 1993, EXP BRAIN RES, V92, P360; IWAMURA Y, 1983, EXP BRAIN RES, V51, P327; JONES EG, 1980, NEUROSCI LETT, V19, P167, DOI 10.1016/0304-3940(80)90189-5; JONES EG, 1969, BRAIN, V92, P717, DOI 10.1093/brain/92.4.717; JONES EG, 1979, J COMP NEUROL, V188, P113, DOI 10.1002/cne.901880110; KAROL EA, 1971, BRAIN, V94, P471, DOI 10.1093/brain/94.3.471; KILLACKEY HP, 1983, J COMP NEUROL, V219, P384, DOI 10.1002/cne.902190403; MANZONI T, 1989, EXP BRAIN RES, V76, P251; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; PANDYA DN, 1982, J COMP NEUROL, V204, P196, DOI 10.1002/cne.902040208; PANDYA DN, 1969, BRAIN RES, V14, P49, DOI 10.1016/0006-8993(69)90030-4; PONS TP, 1985, J COMP NEUROL, V241, P445, DOI 10.1002/cne.902410405; POWELL TPS, 1959, B JOHNS HOPKINS HOSP, V105, P108; RIDLEY RM, 1978, EXP BRAIN RES, V31, P475; ROBINSON CJ, 1980, J COMP NEUROL, V192, P69, DOI 10.1002/cne.901920105; ROBINSON CJ, 1980, J COMP NEUROL, V192, P43, DOI 10.1002/cne.901920104; SAKATA H, 1973, BRAIN RES, V64, P85, DOI 10.1016/0006-8993(73)90172-8; SEITZER B, 1986, EXPL BRAIN RES, V62, P459; SHANKS MF, 1985, BRAIN RES REV, V9, P43, DOI 10.1016/0165-0173(85)90018-9	30	229	231	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 16	1994	369	6481					554	556		10.1038/369554a0	http://dx.doi.org/10.1038/369554a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	8202155				2022-12-01	WOS:A1994NR29400047
J	HABECKER, BA; LANDIS, SC				HABECKER, BA; LANDIS, SC			NORADRENERGIC REGULATION OF CHOLINERGIC DIFFERENTIATION	SCIENCE			English	Article							RAT SWEAT GLANDS; NEUROTRANSMITTER PLASTICITY INVIVO; SYMPATHETIC NEURONS; PRIMARY CULTURES; ACETYLCHOLINE SYNTHESIS; RECEPTOR GENE; INNERVATION; TARGET; INDUCTION; PHENOTYPE	When the sympathetic nerves that innervate rat sweat glands reach their targets, they are induced to switch from using norepinephrine as their neurotransmitter to acetylcholine. Catecholamines (such as norepinephrine) released by nerves growing to the sweat gland induce this phenotypic conversion by stimulating production of a cholinergic differentiation factor [sweat gland factor (SGF)] by gland cells. Here, culture of gland cells with sympathetic, but not sensory, neurons induced SGF production. Blockage of alpha(1)- or beta-adrenergic receptors prevented acquisition of the cholinergic phenotype in sympathetic neurons co-cultured with sweat glands, and sweat glands from sympathectomized animals lacked SGF. Thus, reciprocal instructive interactions, mediated in part by small molecule neurotransmitters, direct the development of this synapse.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROSCI,CLEVELAND,OH 44106	Case Western Reserve University				Habecker, Beth/0000-0002-4658-8730	NINDS NIH HHS [NS-023678] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023678] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARANGO V, 1990, BRAIN RES, V516, P113, DOI 10.1016/0006-8993(90)90904-P; BUCKLAND PR, 1990, NUCLEIC ACIDS RES, V18, P682, DOI 10.1093/nar/18.3.682; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEGG DO, 1989, DEV BIOL, V134, P30, DOI 10.1016/0012-1606(89)90075-4; COLLIE G, 1985, IN VITRO CELL DEV, V21, P257; FONNUM F, 1969, BIOCHEM J, V115, P465, DOI 10.1042/bj1150465; GLOSSMANN F, 1981, EUR J PHARMACOL, V75, P149; GRANT M, IN PRESS J NEUROSCI; GRANT MP, 1991, J NEUROSCI, V11, P3763; GRUENERT DC, 1990, IN VITRO CELL DEV B, V26, P411; HABECKER B, UNPUB; Hawrot E, 1979, Methods Enzymol, V58, P574; LANDIS SC, 1988, DEV BIOL, V126, P129, DOI 10.1016/0012-1606(88)90246-1; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; LANDIS SC, 1983, DEV BIOL, V98, P349, DOI 10.1016/0012-1606(83)90365-2; LANDIS SC, 1980, DEV BIOL, V77, P348; LEBLANC G, 1986, J NEUROSCI, V6, P260; MACHIDA CA, 1990, J BIOL CHEM, V265, P12960; MAINS RE, 1973, J CELL BIOL, V59, P329, DOI 10.1083/jcb.59.2.329; PATTERSON PH, 1977, DEV BIOL, V60, P473, DOI 10.1016/0012-1606(77)90144-0; PATTERSON PH, 1977, DEV BIOL, V56, P263, DOI 10.1016/0012-1606(77)90269-X; RAO MS, 1992, DEVELOPMENT, V116, P731; RAO MS, 1990, NEURON, V5, P899, DOI 10.1016/0896-6273(90)90350-O; RAO MS, 1993, J NEUROBIOL, V24, P215, DOI 10.1002/neu.480240208; RAO MS, 1992, DEV BIOL, V150, P2811; ROHRER H, 1988, DEV BIOL, V128, P240, DOI 10.1016/0012-1606(88)90286-2; ROHRER H, 1992, DEVELOPMENT, V114, P689; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SCHOTZINGER RJ, 1988, NATURE, V335, P637, DOI 10.1038/335637a0; SCHOTZINGER RJ, 1990, NEURON, V5, P91, DOI 10.1016/0896-6273(90)90037-G; STEVENS LM, 1987, DEV BIOL, V123, P179, DOI 10.1016/0012-1606(87)90440-4; Tresser S. J., 1992, Society for Neuroscience Abstracts, V18, P1475; WALICKE PA, 1981, J NEUROSCI, V1, P333; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YODLOWSKI ML, 1984, J NEUROSCI, V4, P1535; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	36	70	72	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 10	1994	264	5165					1602	1604		10.1126/science.8202714	http://dx.doi.org/10.1126/science.8202714			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ285	8202714				2022-12-01	WOS:A1994NQ28500040
J	BESSA, O; ALLEN, DI				BESSA, O; ALLEN, DI			TIGHT PANTS SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									INDIANA UNIV,SCH MED,INDIANAPOLIS,IN	Indiana University System; Indiana University-Purdue University Indianapolis								BESSA O, 1993, ARCH INTERN MED, V153, P1396, DOI 10.1001/archinte.1993.00410110088016; SPIRO HM, 1977, CLIN GASTROENTEROLOG	2	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	1994	271	20					1628	1628						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL758	8182819				2022-12-01	WOS:A1994NL75800037
J	HEITMANN, BL; SORENSEN, TIA; KEIDING, N; SKAKKEBAEK, NE				HEITMANN, BL; SORENSEN, TIA; KEIDING, N; SKAKKEBAEK, NE			PREDICTING THE ADULT HEIGHT OF SHORT CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							GROWTH-HORMONE THERAPY		UNIV COPENHAGEN,STAT RES UNIT,DK-2200 COPENHAGEN N,DENMARK; UNIV COPENHAGEN HOSP,RIGSHOSP,DEPT GROWTH & REPROD,DK-2100 COPENHAGEN,DENMARK	University of Copenhagen; Rigshospitalet; University of Copenhagen	HEITMANN, BL (corresponding author), KOMMUNE HOSP COPENHAGEN,INST PREVENT MED,COPENHAGEN HLTH SERV,DK-1399 COPENHAGEN K,DENMARK.			Heitmann, Berit Lilienthal/0000-0002-6809-4504				CHRISTENSEN U, 1981, HUM BIOL, V53, P403; LESAGE C, 1991, J PEDIATR-US, V119, P29, DOI 10.1016/S0022-3476(05)81034-0; SORENSEN TIA, 1988, AM J EPIDEMIOL, V127, P104, DOI 10.1093/oxfordjournals.aje.a114770; STANHOPE R, 1992, HORM RES, V38, P9, DOI 10.1159/000182563; WIT JM, 1989, ACTA PAEDIATR SCAND, V78, P426, DOI 10.1111/j.1651-2227.1989.tb11103.x	5	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 7	1994	308	6938					1207	1207		10.1136/bmj.308.6938.1207	http://dx.doi.org/10.1136/bmj.308.6938.1207			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK956	8180539	Green Published			2022-12-01	WOS:A1994NK95600021
J	MCCLELLAND, DBL; PHILLIPS, P				MCCLELLAND, DBL; PHILLIPS, P			ERRORS IN BLOOD-TRANSFUSION IN BRITAIN - SURVEY OF HOSPITAL HEMATOLOGY DEPARTMENTS	BRITISH MEDICAL JOURNAL			English	Article											MCCLELLAND, DBL (corresponding author), ROYAL INFIRM,EDINBURGH & S E SCOTLAND BLOOD TRANSFUS SERV,EDINBURGH EH3 9HB,SCOTLAND.							LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; MURPHY WG, 1989, VOX SANG, V57, P59, DOI 10.1111/j.1423-0410.1989.tb04985.x; Roberts B, 1991, STANDARD HAEMATOLOGY; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x	4	85	85	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 7	1994	308	6938					1205	1206		10.1136/bmj.308.6938.1205	http://dx.doi.org/10.1136/bmj.308.6938.1205			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK956	8180537	Green Published			2022-12-01	WOS:A1994NK95600019
J	PERKINS, TT; SMITH, DE; CHU, S				PERKINS, TT; SMITH, DE; CHU, S			DIRECT OBSERVATION OF TUBE-LIKE MOTION OF A SINGLE POLYMER-CHAIN	SCIENCE			English	Article							INDIVIDUAL DNA-MOLECULES; GEL-ELECTROPHORESIS; DYNAMICS; MODEL; PARTICLES; SYSTEMS; MELT	Tube-like motion of a single, fluorescently labeled molecule of DNA in an entangled solution of unlabeled lambda-phage DNA molecules was observed by fluorescence microscopy. One end of a 16- to 100-micrometer-long DNA was attached to a 1-micrometer bead and moved with optical tweezers. The molecule was stretched into various conformations having bends, kinks, and loops. As the polymer relaxed, it closely followed a path defined by its initial contour. The relaxation time of the disturbance caused by the bead was roughly 1 second, whereas tube-like motion in small loops persisted for longer than 2 minutes. Tube deformation, constraint release, and excess chain segment diffusion were also observed. These observations provide direct evidence for several key assumptions in the reptation model developed by de Gennes, Edwards, and Doi.	STANFORD UNIV, DEPT PHYS, STANFORD, CA 94305 USA	Stanford University			Smith, Douglas E/A-3131-2017	Smith, Douglas E/0000-0002-8206-3632; Perkins, Thomas/0000-0003-4826-9490	PHS HHS [33289] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; De Gennes P-G., 1979, SCALING CONCEPTS POL; DEGENNES PG, 1971, J CHEM PHYS, V55, P572, DOI 10.1063/1.1675789; DEGENNES PG, 1976, MACROMOLECULES, V9, P587, DOI 10.1021/ma60052a011; DEGENNES PG, 1983, PHYS TODAY, V36, P33, DOI 10.1063/1.2915700; DIMARZIO EA, 1979, FARADAY DISCUSS, V68, P210, DOI 10.1039/dc9796800210; DOI M, 1978, J CHEM SOC FARAD T 2, V74, P1789, DOI 10.1039/f29787401789; DOI M, 1978, J CHEM SOC FARAD T 2, V74, P1802, DOI 10.1039/f29787401802; Doi M., 1986, THEORY POLYM DYNAMIC; EDWARDS SF, 1967, P PHYS SOC LOND, V92, P9, DOI 10.1088/0370-1328/92/1/303; Ferry J. D., 1980, VISCOELASTIC PROPERT; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HIGGINS JS, 1985, J CHEM SOC FARAD T 2, V81, P757, DOI 10.1039/f29858100757; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; Kron S., 1990, INT C QUANTUM ELECTR, V8, P202; LODGE TP, 1990, ADV CHEM PHYS, V79, P1; MARET G, 1983, BIOPOLYMERS, V22, P2727, DOI 10.1002/bip.360221215; PECORA R, 1991, SCIENCE, V251, P893, DOI 10.1126/science.2000490; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; RICHTER D, 1990, PHYS REV LETT, V64, P1389, DOI 10.1103/PhysRevLett.64.1389; RUSSELL TP, 1993, NATURE, V365, P235, DOI 10.1038/365235a0; RYE HS, 1993, ANAL BIOCHEM, V208, P144, DOI 10.1006/abio.1993.1020; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; WENDEL H, 1982, MACROMOLECULES, V15, P1318, DOI 10.1021/ma00233a020	27	425	445	2	120	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 6	1994	264	5160					819	822		10.1126/science.8171335	http://dx.doi.org/10.1126/science.8171335			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171335				2022-12-01	WOS:A1994NJ94900025
J	MILANO, CA; ALLEN, LF; ROCKMAN, HA; DOLBER, PC; MCMINN, TR; CHIEN, KR; JOHNSON, TD; BOND, RA; LEFKOWITZ, RJ				MILANO, CA; ALLEN, LF; ROCKMAN, HA; DOLBER, PC; MCMINN, TR; CHIEN, KR; JOHNSON, TD; BOND, RA; LEFKOWITZ, RJ			ENHANCED MYOCARDIAL-FUNCTION IN TRANSGENIC MICE OVEREXPRESSING THE BETA(2)-ADRENERGIC RECEPTOR	SCIENCE			English	Article							T-ANTIGEN TRANSGENES; SENSITIVITY; EXPRESSION	Transgenic mice were created with cardiac-specific overexpression of the beta(2)-adrenergic receptor. This resulted in increased basal myocardial adenylyl cyclase activity, enhanced atrial contractility, and increased left ventricular function in vivo; these parameters at baseline in the transgenic animals were equal to those observed in control animals maximally stimulated with isoproterenol. These results illustrate a useful approach for studying the effect of gene expression on card iac contractility. Because oh ron ic heart failure in humans is accompanied by a reduction in the number of myocardial beta-adrenergic receptors and in inotropic responsiveness, these results suggest a potential gene therapy approach to this disease state.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,AMER HEART ASSOC,BUGHER FDN CTR MOLEC BIOL,LA JOLLA,CA 92093; BAYLOR COLL MED,DEPT ANESTHESIOL,HOUSTON,TX 77030; UNIV HOUSTON,DEPT PHARMACOL,HOUSTON,TX 77030	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Baylor College of Medicine; University of Houston System; University of Houston			Lefkowitz, Robert/AAW-2649-2021		NATIONAL CANCER INSTITUTE [F32CA009350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018468, R01HL016037, R37HL016037, R01HL018468] Funding Source: NIH RePORTER; NCI NIH HHS [5F32-CA09350] Funding Source: Medline; NHLBI NIH HHS [HL-18468, HL-16037] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTIN B, 1993, CARDIOVASC RES, V27, P1606, DOI 10.1093/cvr/27.9.1606; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISTOW MR, 1985, J MOL CELL CARDIOL, V17, P41, DOI 10.1016/0022-2828(85)90007-0; BRISTOW MR, 1990, CIRCULATION, V82, P12; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; GUZMAN RJ, 1993, CIRC RES, V73, P1202, DOI 10.1161/01.RES.73.6.1202; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; LEVY FO, 1993, P NATL ACAD SCI USA, V90, P10798, DOI 10.1073/pnas.90.22.10798; METZGER JM, 1993, P NATL ACAD SCI USA, V90, P9036, DOI 10.1073/pnas.90.19.9036; MILANO CA, UNPUB; PAULETTO P, 1985, AM HEART J, V109, P1269, DOI 10.1016/0002-8703(85)90350-3; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; REN Q, 1993, J BIOL CHEM, V268, P16483; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	25	621	650	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 22	1994	264	5158					582	586		10.1126/science.8160017	http://dx.doi.org/10.1126/science.8160017			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	8160017				2022-12-01	WOS:A1994NH01000041
J	SIGG, D; STEFANI, E; BEZANILLA, F				SIGG, D; STEFANI, E; BEZANILLA, F			GATING CURRENT NOISE PRODUCED BY ELEMENTARY TRANSITIONS IN SHAKER POTASSIUM CHANNELS	SCIENCE			English	Article							SODIUM-CHANNELS; CHARGE; FLUCTUATIONS; MOVEMENT	Gating currents provide a direct record of the spatial rearrangement of charges occurring within the protein of voltage-sensitive ion channels. If the elementary charges move as very brief discrete pulses of current, they will produce fluctuations in the macroscopic gating current. The variance of such fluctuations in gating currents was measured in Shaker potassium channels expressed in Xenopus oocytes with a sufficiently high recording bandwidth to estimate the magnitude and time distribution of the elementary transition charge movements. Channel activation occurred in two sequential stages. The first stage consisted of numerous, fast transitions, each moving small amounts of charge that contributed little to the fluctuation in gating current, whereas the second stage, which contributed the bulk of the fluctuation, was represented by a number of discrete, correlated transitions, one or more of which carried a charge of at least 2.4 elementary charges across the membrane field.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Baylor College of Medicine				Sigg, Daniel/0000-0003-4944-2988	NIAMS NIH HHS [AR39874] Funding Source: Medline; NIGMS NIH HHS [GM30376, GM08042] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030376, R37GM030376, T32GM008042] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; BEZANILLA F, 1985, J MEMBRANE BIOL, V88, P97, DOI 10.1007/BF01868424; BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; BEZANILLA F, 1982, ABNORMAL NERVES MUSC, P62; COLQUHOUN D, 1977, PROC R SOC SER B-BIO, V199, P231, DOI 10.1098/rspb.1977.0137; CONTI F, 1989, EUR BIOPHYS J BIOPHY, V17, P53, DOI 10.1007/BF00257102; CROUZY SC, 1993, BIOPHYS J, V64, P68, DOI 10.1016/S0006-3495(93)81341-9; DURRELL SR, 1992, BIOPHYS J, V62, P238; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; LEVITT DG, 1989, BIOPHYS J, V55, P489, DOI 10.1016/S0006-3495(89)82842-5; LIEBOVITCH LS, 1987, BIOCHIM BIOPHYS ACTA, V896, P173, DOI 10.1016/0005-2736(87)90177-5; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLHAUSER GL, 1988, P NATL ACAD SCI USA, V85, P1503, DOI 10.1073/pnas.85.5.1503; NEHER E, 1977, ANNU REV BIOPHYS BIO, V6, P345, DOI 10.1146/annurev.bb.06.060177.002021; PEROZO E, 1993, NEURON, V11, P1; Rice S. O., 1954, SELECTED PAPERS NOIS; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	22	83	84	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 22	1994	264	5158					578	582		10.1126/science.8160016	http://dx.doi.org/10.1126/science.8160016			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	8160016				2022-12-01	WOS:A1994NH01000040
J	SULTAN, AH; KAMM, MA; HUDSON, CN; THOMAS, JM; BARTRAM, CI				SULTAN, AH; KAMM, MA; HUDSON, CN; THOMAS, JM; BARTRAM, CI			ANAL-SPHINCTER DISRUPTION DURING VAGINAL DELIVERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC FECAL INCONTINENCE; PELVIC FLOOR MUSCULATURE; ANORECTAL INCONTINENCE; FOLLOW-UP; CHILDBIRTH; DAMAGE; ENDOSONOGRAPHY; INNERVATION; INJURY	Background. Lacerations of the anal sphincter or injury to sphincter innervation during childbirth are major causes of fecal incontinence, but the incidence and importance of occult sphincter damage during routine vaginal delivery are unknown. We sought to determine the incidence of damage to the anal sphincter and the relation of injury to symptoms, anorectal physiologic function, and the mode of delivery. Methods. We studied 202 consecutive women six weeks before delivery, 150 of them six weeks after delivery, and 32 with abnormal findings six months after delivery. Symptoms of anal incontinence and fecal urgency were assessed, and anal endosonography, manometry, perineometry, and measurement of the terminal motor latency of the pudendal nerves were performed. Results. Ten of the 79 primiparous women (13 percent) and 11 of the 48 multiparous women (23 percent) who delivered vaginally had anal incontinence or fecal urgency when studied six weeks after delivery. Twenty-eight of the 79 primiparous women (35 percent) had a sphincter defect on endosonography at six weeks; the defect persisted in all 22 women studied at six months. Of the 48 multiparous women, 19 (40 percent) had a sphincter defect before delivery and 21 (44 percent) afterward. None of the 23 women who underwent cesarean section had a new sphincter defect after delivery. Eight of the 10 women who underwent forceps delivery had sphincter defects, but none of the 5 women who underwent vacuum extractions had such defects. Internal-sphincter defects were associated with a significantly lower mean (+/-SD) resting anal pressure (61+/-11 vs. 48+/-10 mm Hg, P<0.001) six weeks post partum, and external-sphincter defects were associated with a significantly lower squeeze pressure (increase above resting pressure, 70+/-38 vs. 44+/-13 mm Hg; P<0.001). There was a strong association (P<0.001) between sphincter defects and the development of bowel symptoms. Conclusions. Occult sphincter defects are common after vaginal delivery, especially forceps delivery, and are often associated with disturbance of bowel function.	ST MARKS HOSP,CITY RD,LONDON EC1V 2PS,ENGLAND; ST BARTHOLOMEWS HOMERTON HOSP,LONDON,ENGLAND	Imperial College London; University of London; Queen Mary University London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN RE, 1990, BRIT J OBSTET GYNAEC, V97, P770, DOI 10.1111/j.1471-0528.1990.tb02570.x; BEERSIEK F, 1979, J NEUROL SCI, V42, P111, DOI 10.1016/0022-510X(79)90156-4; BROWNING GGP, 1983, BRIT MED J, V286, P1873, DOI 10.1136/bmj.286.6381.1873; BURNETT SJD, 1991, BRIT J RADIOL, V64, P225, DOI 10.1259/0007-1285-64-759-225; CAPUTO RM, 1992, CURR OPIN OBSTET GYN, V4, P565; CHERRY DA, 1988, SURG CLIN N AM, V68, P1217; COATS PM, 1980, BRIT J OBSTET GYNAEC, V87, P408, DOI 10.1111/j.1471-0528.1980.tb04569.x; HAADEM K, 1988, EUR J OBSTET GYN R B, V27, P27, DOI 10.1016/S0028-2243(88)80007-8; HAADEM K, 1991, OBSTET GYNECOL, V78, P823; HENRY MM, 1982, BRIT J SURG, V69, P470, DOI 10.1002/bjs.1800690813; JOHANSON RB, 1993, BRIT J OBSTET GYNAEC, V100, P524, DOI 10.1111/j.1471-0528.1993.tb15301.x; JONES PN, 1987, INT J COLORECTAL DIS, V2, P93, DOI 10.1007/BF01647699; LAURBERG S, 1989, DIS COLON RECTUM, V32, P737, DOI 10.1007/BF02562120; LAW PJ, 1989, GASTROINTEST RADIOL, V14, P349, DOI 10.1007/BF01889235; LAW PJ, 1991, BRIT J SURG, V78, P312, DOI 10.1002/bjs.1800780315; NEILL ME, 1980, J NEUROL NEUROSUR PS, V43, P343, DOI 10.1136/jnnp.43.4.343; NIELSEN MB, 1992, BRIT J SURG, V79, P104, DOI 10.1002/bjs.1800790204; ORROM WJ, 1990, BRIT J SURG, V77, P876, DOI 10.1002/bjs.1800770810; ROGERS J, 1988, GUT, V29, P1131, DOI 10.1136/gut.29.8.1131; SNOOKS SJ, 1985, BRIT J OBSTET GYNAEC, V92, P824, DOI 10.1111/j.1471-0528.1985.tb03053.x; SNOOKS SJ, 1990, BRIT J SURG, V77, P1358, DOI 10.1002/bjs.1800771213; SNOOKS SJ, 1984, LANCET, V2, P546; SULTAN AH, 1993, BRIT J SURG, V80, P508, DOI 10.1002/bjs.1800800435; SULTAN AH, 1992, GUT, V33, pS29; SULTAN AH, 1993, ATLAS GASTROINTESTIN, P115; SULTAN AH, IN PRESS DIS COLON R; SULTAN AH, IN PRESS BR J SURG; SUN WM, 1989, GASTROENTEROLOGY, V97, P130, DOI 10.1016/0016-5085(89)91425-X; SWASH M, 1992, COLOPROCTOLOGY PELVI, P184; Swash M, 1992, COLOPROCTOLOGY PELVI, P196; Thacker S B, 1983, Obstet Gynecol Surv, V38, P322, DOI 10.1097/00006254-198306000-00003; VACCA A, 1989, EFFECTIVE CARE PREGN, V2, P1216	32	1097	1125	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1905	1911		10.1056/NEJM199312233292601	http://dx.doi.org/10.1056/NEJM199312233292601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM885	8247054				2022-12-01	WOS:A1993MM88500001
J	OLSCHWANG, S; TIRET, A; LAURENTPUIG, P; MULERIS, M; PARC, R; THOMAS, G				OLSCHWANG, S; TIRET, A; LAURENTPUIG, P; MULERIS, M; PARC, R; THOMAS, G			RESTRICTION OF OCULAR FUNDUS LESIONS TO A SPECIFIC SUBGROUP OF APC MUTATIONS IN ADENOMATOUS POLYPOSIS-COLI PATIENTS	CELL			English	Article							RETINAL-PIGMENT EPITHELIUM; GARDNER SYNDROME; CONGENITAL HYPERTROPHY; DNA MARKERS; EXTRACOLONIC MANIFESTATIONS; COLORECTAL-CANCER; LONG ARM; GENE; CHROMOSOME-5; DELETION	In humans, alteration of the tumor suppressor gene, APC, causes adenomatous polyposis coll, a condition causing predisposition to colorectal cancer. The syndrome inconsistantly associates characteristic patches of congenital hypertrophy of the retinal pigment epithelium (CHRPE). Ocular examination revealed that patients expressing CHRPE tend to cluster within specific families. The exact APC mutation was identified in 42 unrelated patients. In all cases these mutations were predicted to lead to the synthesis of a truncated protein. The extent of CHRPE was found to be dependent on the position of the mutation along the coding sequence. CHRPE lesions are almost always absent if the mutation occurs before exon 9, but are systematically present if it occurs after this exon. Thus, the range of phenotypic expression observed among affected patients may result in part from different allelic manifestations of APC mutations.	HOP NECKER ENFANTS MALAD,SERV OPHTHALMOL,F-75015 PARIS,FRANCE; INST CURIE,STRUCT & MUTAGENESE CHROMOSOM LAB,F-75005 PARIS,FRANCE; HOP ST ANTOINE,SERV CHIRURG DIGEST,F-75571 PARIS 12,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	OLSCHWANG, S (corresponding author), INST CURIE,GENET TUMEURS LAB,26 RUE ULM,F-75005 PARIS,FRANCE.		Olschwang, Sylviane/G-2716-2013; Laurent-Puig, Pierre/K-3641-2019; laurent-puig, pierre/B-2226-2013	Olschwang, Sylviane/0000-0001-7078-3029; Laurent-Puig, Pierre/0000-0001-8475-5459; laurent-puig, pierre/0000-0001-8475-5459				AIELLO LP, 1993, ARCH OPHTHALMOL-CHIC, V111, P302, DOI 10.1001/archopht.1993.01090030020012; BABA S, 1990, DIS COLON RECTUM, V33, P660, DOI 10.1007/BF02150741; BELL B, 1993, DIGEST DIS SCI, V38, P185, DOI 10.1007/BF01296795; BLAIR NP, 1980, AM J OPHTHALMOL, V90, P661, DOI 10.1016/S0002-9394(14)75133-5; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BULOW S, 1986, SCAND J SOC MED, V14, P67; BURN J, 1991, J MED GENET, V28, P289, DOI 10.1136/jmg.28.5.289; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CHAMOT L, 1993, AM J OPHTHALMOL, V115, P154, DOI 10.1016/S0002-9394(14)73918-2; COSTES B, 1993, HUM MOL GENET, V2, P393, DOI 10.1093/hmg/2.4.393; CROSS I, 1992, J MED GENET, V29, P175, DOI 10.1136/jmg.29.3.175; DUNLOP MG, 1990, AM J HUM GENET, V47, P982; DUNLOP MG, 1991, LANCET, V337, P313, DOI 10.1016/0140-6736(91)90940-Q; GARDNER EJ, 1953, AM J HUM GENET, V5, P139; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMELIN R, 1993, ONCOGENE, V8, P2213; HEINEMANN MH, 1991, GRAEF ARCH CLIN EXP, V229, P213, DOI 10.1007/BF00167870; Herrera L, 1990, FAMILIAL ADENOMATOUS; HODGSON SV, 1993, J MED GENET, V30, P369, DOI 10.1136/jmg.30.5.369; HOULSTON R, 1990, LANCET, V335, P484, DOI 10.1016/0140-6736(90)90724-J; IWAMA T, 1990, BRIT J SURG, V77, P273, DOI 10.1002/bjs.1800770312; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOBAYASHI T, 1991, AM J MED GENET, V41, P460, DOI 10.1002/ajmg.1320410416; KROPILAK M, 1989, DIS COLON RECTUM, V32, P778, DOI 10.1007/BF02562128; KRUSH AJ, 1988, AM J MED GENET, V29, P323, DOI 10.1002/ajmg.1320290211; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LEWIS RA, 1984, OPHTHALMOLOGY, V91, P916; LYNCH HT, 1985, CA-CANCER J CLIN, V35, P95, DOI 10.3322/canjclin.35.2.95; MOORE AT, 1992, OPHTHALMIC PAED GEN, V13, P67, DOI 10.3109/13816819209087606; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MYIOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; OLSCHWANG S, 1991, GASTROENTEROLOGY, V101, P154, DOI 10.1016/0016-5085(91)90472-W; OLSCHWANG S, 1991, LANCET, V337, P1171, DOI 10.1016/0140-6736(91)92849-W; PARKER JA, 1990, CAN J OPHTHALMOL, V25, P159; PAUL P, 1993, HUM MOL GENET, V2, P925, DOI 10.1093/hmg/2.7.925; PETERSEN GM, 1991, GASTROENTEROLOGY, V100, P1658, DOI 10.1016/0016-5085(91)90666-9; RAMOS R, 1990, FAMILIAL ADENOMATOUS, P133; Sambrook J., 1989, MOL CLONING LAB MANU; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; THOMPSON LH, 1973, P NATL ACAD SCI USA, V70, P3094, DOI 10.1073/pnas.70.11.3094; TRABOULSI EI, 1988, OPHTHALMOLOGY, V95, P964; TRABOULSI EI, 1987, NEW ENGL J MED, V316, P661, DOI 10.1056/NEJM198703123161104; TRABOULSI EI, 1990, AM J OPHTHALMOL, V110, P550, DOI 10.1016/S0002-9394(14)77880-8; VARESCO L, 1993, AM J HUM GENET, V52, P280; VARESCO L, 1989, P NATL ACAD SCI USA, V86, P10118, DOI 10.1073/pnas.86.24.10118; WILLIAMSON R, 1991, CYTOGENET CELL GENET, V58, P1190, DOI 10.1159/000133727	56	263	268	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					959	968		10.1016/0092-8674(93)90539-3	http://dx.doi.org/10.1016/0092-8674(93)90539-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252631	Bronze			2022-12-01	WOS:A1993MK96600015
J	FOX, E; STOCKING, C				FOX, E; STOCKING, C			ETHICS CONSULTANTS RECOMMENDATIONS FOR LIFE-PROLONGING TREATMENT OF PATIENTS IN A PERSISTENT VEGETATIVE STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; ILL PATIENTS; DECISIONS; PHYSICIANS; PRINCIPLES; CONSENSUS; SERVICE; SUPPORT; IMPACT	Objective.-Surprisingly little is known about the content of ethics consultants' recommendations. We chose to study this issue using hypothetical persistent vegetative state (PVS) cases. We addressed four questions: What recommendations do ethics consultants give regarding life-prolonging treatment (LPT) in PVS cases? To what degree is there consensus? What factors influence recommendations? Do recommendations conform to established guidelines? Design.-Questionnaire survey. Our questionnaire asked subjects what they would recommend for seven hypothetical vignettes involving a PVS patient that varied with respect to advance directives and family wishes. We also questioned subjects about demographic characteristics, ethics consultation experience, and personal preference for LPT in PVS. Subjects.-Attendees at an annual meeting of the Society for Bioethics Consultation (n=154). Results.-The response rate was 77%. Eighty-one percent of respondents were ethics committee members and 62% were ethics consultants. There was general agreement among respondents for only one of seven vignettes: in the case of a PVS patient whose advance directive and family agree that LPT be stopped, 93% recommended stopping all LPT. Responses to other vignettes varied considerably. Although patient wishes were an important factor influencing recommendations, none of the respondents adhered invariably to the patient's advance directive. Recommendations were also influenced by family wishes, resource allocation considerations, legal constraints, and personal preference for LPT in PVS. Guidelines we examined were generally too equivocal to be useful for evaluating ethics consultants' recommendations. Conclusions.-The finding of wide variability in ethics consultants' recommendations suggests a need to clarify standards for ethics consultation.	UNIV CHICAGO, CTR CLIN MED ETH, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago				Fox, Ellen/0000-0001-9029-7052				[Anonymous], 1990, CRIT CARE MED, V18, P1435; [Anonymous], 1989, NEUROLOGY, V39, P125; [Anonymous], 1993, ANN NEUROL, V33, P386; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; BOYD K, 1991, LANCET, V337, P96; BRENNAN TA, 1988, JAMA-J AM MED ASSOC, V260, P803, DOI 10.1001/jama.260.6.803; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; FLETCHER JC, 1989, ETHICS CONSULTATION, P185; FRADER J, 1993, NEWSLETTER SOC BIOET, P2; La Puma J, 1992, QRB Qual Rev Bull, V18, P17; LANKEN PN, 1991, ANN INTERN MED, V115, P478; LAPUMA J, 1988, JAMA-J AM MED ASSOC, V260, P808, DOI 10.1001/jama.260.6.808; LAPUMA J, 1992, AM J MED, V92, P346, DOI 10.1016/0002-9343(92)90262-A; LAPUMA J, 1987, WESTERN J MED, V146, P633; LYNN J, 1986, BY NO EXTRAORDINARY; MEADOW W, 1992, PEDIATRICS, V89, P1083; MICETICH K, 1986, BY NO EXTRAORDINARY, P39; MILLER DK, 1992, J GEN INTERN MED, V7, P475, DOI 10.1007/BF02599446; PERKINS HS, 1988, AM J MED, V85, P761; PERKINS HS, 1990, AM J MED, V89, P185, DOI 10.1016/0002-9343(90)90298-R; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SABINE M, 1992, J GEN INTERN MED, V7, P46; SELF DJ, 1991, THEOR MED, V12, P117, DOI 10.1007/BF00489792; SIEGLER M, 1988, MED ETHICS ANNOTATED; SMITH DG, 1987, ARCH INTERN MED, V147, P1242, DOI 10.1001/archinte.147.7.1242; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; STANLEY JM, 1989, J MED ETHICS, V15, P129, DOI 10.1136/jme.15.3.129; TULSKY JA, 1992, AM J MED, V92, P343, DOI 10.1016/0002-9343(92)90261-9; UHLMANN RF, 1987, ANN INTERN MED, V106, P879, DOI 10.7326/0003-4819-106-6-879; 1987, GUIDELINES TERMINATI; 1989, CURRENT OPINIONS; 1990, JAMA-J AM MED ASSOC, V263, P426	34	49	49	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1993	270	21					2578	2582		10.1001/jama.270.21.2578	http://dx.doi.org/10.1001/jama.270.21.2578			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ266	8230643				2022-12-01	WOS:A1993MJ26600025
J	KAELL, AT; REDECHA, PR; ELKON, KB; GOLIGHTLY, MG; SCHULMAN, PE; DATTWYLER, RJ; KAELL, DL; INMAN, RD; CHRISTIAN, CL; VOLKMAN, DJ				KAELL, AT; REDECHA, PR; ELKON, KB; GOLIGHTLY, MG; SCHULMAN, PE; DATTWYLER, RJ; KAELL, DL; INMAN, RD; CHRISTIAN, CL; VOLKMAN, DJ			OCCURRENCE OF ANTIBODIES TO BORRELIA-BURGDORFERI IN PATIENTS WITH NONSPIROCHETAL SUBACUTE BACTERIAL-ENDOCARDITIS	ANNALS OF INTERNAL MEDICINE			English	Article						BORRELIA BURGDORFERI; ENDOCARDITIS, SUBACUTE BACTERIAL; LYME DISEASE; RHEUMATOID FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY	LINKED IMMUNOSORBENT-ASSAY; LYME-DISEASE SPIROCHETE; SEROLOGIC TESTS; INFECTIVE ENDOCARDITIS; T-CELL; ARTHRITIS; REACTIVITY; DIAGNOSIS; ANTIGENS	Objective: To determine the prevalence and specificity of antibodies to Borrelia burgdorferi in patients with nonspirochetal subacute bacterial endocarditis and assess whether increased levels of antibodies to B. burgdorferi were attributable to rheumatoid factor. Design: Retrospective case-control study. Setting: Urban referral center in an area devoid of infected ticks as a source of endocarditis sera. Patients: Sera from 30 consecutive patients with culture-proven subacute endocarditis between 1979 and 1981 were compared with 30 control sera collected between 1989 and 1990. In addition, sera from 20 consecutive patients with rheumatoid arthritis who were positive for rheumatoid factor were collected between 1991 and 1992. Sera were compared with a convenience sample from 15 patients who met the criteria for Lyme disease. Measurements: Antibodies to B. burgdorferi were assessed by enzyme-linked immunosorbent assay (ELISA) and immunoblot analysis, IgM rheumatoid factor was quantified using solid-phase radioimmunoassay or latex agglutination techniques. Results. Thirteen of 30 patients with endocarditis (43%) compared with 3 of 30 normal controls (10%) had increased levels of antibodies to B. burgdorferi (P < 0.01). Of these 13 patients, only 1 had an immunoblot consistent with previous infection. The other's had nonspecific immunoblots: 5 showed isolated 60-kd reactivity; 1 patient had isolated 41-kd reactivity; and 6 had no bands of reactivity. Immunoblots of the 3 controls with increased antibodies showed only isolated 41-kd reactivity. Thus, the specificity of the B. burgdorferi antibody test in patients with endocarditis was only 60% (95% Cl, 42% to 78%), compared with 90% (CI, 79% to 100%) in controls. No correlation was noted between IgM rheumatoid factor and antibodies to B. burgdorferi in patients with endocarditis (r = 0.2; P > 0.2). Only 1 of 20 patients with rheumatoid arthritis without known bacterial infections had antibodies to B. burgdorferi. Conclusions: Although a positive ELISA test for B. burgdorferi may be a ''true positive,'' a positive serologic test alone does not ensure that the clinical problem is due to Lyme borreliosis. Cross-reactive antibodies to shared epitopes between B. burgdorferi and the endocarditis organism may account for the high false-positive results.	CORNELL UNIV, MED CTR, NEW YORK, NY 10021 USA; TORONTO WESTERN HOSP, TORONTO M5T 2S8, ONTARIO, CANADA	Cornell University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	KAELL, AT (corresponding author), SUNY STONY BROOK, STONY BROOK, NY 11794 USA.		Dattwyler, Raymond/ABH-2292-2021; Kaell, Alan T/AAI-2462-2019	Dattwyler, Raymond/0000-0002-1983-1301; Kaell, Alan/0000-0001-8473-4551; Inman, Robert/0000-0002-4750-1422	NIAID NIH HHS [P01 AI2972301] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; AZEVEDO J, 1987, EUR HEART J SUPPL, V5, P71; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BARBOUR AG, 1989, ANN INTERN MED, V110, P501, DOI 10.7326/0003-4819-110-7-501; BARBOUR AG, 1986, INFECT IMMUN, V52, P549, DOI 10.1128/IAI.52.2.549-554.1986; BECK G, 1990, BIOCHEM BIOPH RES CO, V167, P89, DOI 10.1016/0006-291X(90)91734-A; CHURCHILL MA, 1977, ANN INTERN MED, V87, P754, DOI 10.7326/0003-4819-87-6-754; COOKE W D, 1990, Arthritis and Rheumatism, V33, pS84; CORPUZ M, 1991, ARCH INTERN MED, V151, P1837, DOI 10.1001/archinte.151.9.1837; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; CRAFT JE, 1986, J CLIN INVEST, V78, P934, DOI 10.1172/JCI112683; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DEJOY SQ, 1989, J EXP MED, V170, P369, DOI 10.1084/jem.170.2.369; DUFFY J, 1988, MAYO CLIN PROC, V63, P1116, DOI 10.1016/S0025-6196(12)65506-2; ELKON KB, 1983, AM J MED, V75, P785, DOI 10.1016/0002-9343(83)90408-4; Goebel K M, 1988, Scand J Rheumatol Suppl, V75, P314; GRODZICKI RL, 1988, J INFECT DIS, V157, P790, DOI 10.1093/infdis/157.4.790; HANSEN K, 1988, J CLIN MICROBIOL, V26, P338, DOI 10.1128/JCM.26.2.338-346.1988; HANSEN K, 1988, INFECT IMMUN, V56, P2047, DOI 10.1128/IAI.56.8.2047-2053.1988; HARDIN JA, 1990, CLIN ASPECTS AUTOIMM, V4, P23; KAELL AT, 1990, JAMA-J AM MED ASSOC, V264, P2916, DOI 10.1001/jama.264.22.2916; KUJALA GA, 1987, J RHEUMATOL, V14, P772; LAVOIE PE, 1988, ANN NY ACAD SCI, V539, P460, DOI 10.1111/j.1749-6632.1988.tb31907.x; LUFT BJ, 1991, J IMMUNOL, V146, P2776; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1989, J INFECT DIS, V159, P43, DOI 10.1093/infdis/159.1.43; MAGNARELLI LA, 1990, J CLIN MICROBIOL, V28, P1276, DOI 10.1128/JCM.28.6.1276-1279.1990; MAYO DR, 1991, NEW ENGL J MED, V324, P419; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; ROSA PA, 1989, J INFECT DIS, V160, P1018, DOI 10.1093/infdis/160.6.1018; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SALATA RA, 1989, MEDICINE, V68, P225, DOI 10.1097/00005792-198907000-00005; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SHANAFELT MC, 1991, J IMMUNOL, V146, P3985; STEERE AC, 1991, NEW ENGL J MED, V324, P129; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; TAKAYAMA K, 1987, INFECT IMMUN, V55, P2311, DOI 10.1128/IAI.55.9.2311-2313.1987; TERPENNING MS, 1987, AM J MED, V83, P626, DOI 10.1016/0002-9343(87)90890-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIAMS RC, 1962, J CLIN INVEST, V41, P666, DOI 10.1172/JCI104523; 1989, MMWR MORBID MORTAL W, V38, P668; 1991, MMWR MORBID MORTAL W, V39, P19	43	21	21	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1079	1083		10.7326/0003-4819-119-11-199312010-00004	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239226				2022-12-01	WOS:A1993MJ33500004
J	KHAVARI, PA; PETERSON, CL; TAMKUN, JW; MENDEL, DB; CRABTREE, GR				KHAVARI, PA; PETERSON, CL; TAMKUN, JW; MENDEL, DB; CRABTREE, GR			BRG1 CONTAINS A CONSERVED DOMAIN OF THE SWI2/SNF2 FAMILY NECESSARY FOR NORMAL MITOTIC GROWTH AND TRANSCRIPTION	NATURE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PUTATIVE HELICASES; GLOBAL ACTIVATOR; GENE-EXPRESSION; PROTEINS; DROSOPHILA; SNF2/SWI2; ENCODES; REPAIR; SWI1	SEQUENCE-SPECIFIC DNA binding activators of gene transcription may be assisted by SWI2(SNF2)1,2, which contains a DNA-dependent ATPase domain3. We have isolated a human complementary, DNA encoding a 205K nuclear protein, BRG1, that contains extensive homology to SWI2 and Drosophila brahma4,5. We report here that a SWI2/BRG1 chimaera with the DNA-dependent ATPase domain replaced by corresponding human sequence restored normal mitotic growth and capacity for transcriptional activation to swi2- yeast cells. Point mutation of the conserved ATP binding site lysine abolished this complementation. This mutation in SW12 exerted a dominant negative effect on transcription in yeast. A lysine to arginine substitution at the corresponding residue of BRG1 also generated a transcriptional dominant negative in human cells. BRG1 is exclusively nuclear and present in a high M(r) complex of about 2 x 10(6). These results show that the SWI2 family DNA-dependent ATPase domain has functional conservation between yeast and humans and suggest that a SWI/SNF protein complex is required for the activation of selective mammalian genes.	STANFORD UNIV, BECKMAN CTR MOLEC & GENET MED, HOWARD HUGHES MED INST, B211 HHMI, STANFORD, CA 94305 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01650 USA; UNIV CALIF SANTA CRUZ, DEPT BIOL, SANTA CRUZ, CA 95064 USA	Howard Hughes Medical Institute; Stanford University; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Santa Cruz								DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HAYNES SR, 1989, DEV BIOL, V134, P246, DOI 10.1016/0012-1606(89)90094-8; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P291, DOI 10.1016/0968-0004(93)90037-N; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NEIGEBORN L, 1984, GENETICS, V108, P845; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKABE I, 1992, NUCLEIC ACIDS RES, V20, P4649, DOI 10.1093/nar/20.17.4649; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	31	541	555	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	1993	366	6451					170	174		10.1038/366170a0	http://dx.doi.org/10.1038/366170a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232556				2022-12-01	WOS:A1993MG21600061
J	ERIE, DA; HAJISEYEDJAVADI, O; YOUNG, MC; VONHIPPEL, PH				ERIE, DA; HAJISEYEDJAVADI, O; YOUNG, MC; VONHIPPEL, PH			MULTIPLE RNA-POLYMERASE CONFORMATIONS AND GREA - CONTROL OF THE FIDELITY OF TRANSCRIPTION	SCIENCE			English	Article							DNA-REPLICATION FIDELITY; ESCHERICHIA-COLI; KINETIC MECHANISM; TERNARY COMPLEXES; STRUCTURAL-ANALYSIS; ELONGATION-FACTOR; KLENOW FRAGMENT; I KLENOW; BACTERIOPHAGE-T4; EXONUCLEASE	Pre-steady state kinetics of misincorporation were used to investigate the addition of single nucleotides to nascent RNA by Escherichia coli RNA polymerase during transcription elongation. The results were fit with a branched kinetic mechanism that permits conformational switching, at each template position, between an activated and an unactivated enzyme complex, both of which can bind nucleotide triphosphates (NTPs) from solution. The complex exists most often in the long-lived activated state, and only becomes unactivated when transcription is slowed. This model permits multiple levels of nucleotide discrimination in transcription, since the complex can be ''kinetically trapped'' in the unactivated state in the absence of the correct NTP or if the 3' terminal residue is incorrectly matched. The transcription cleavage factor GreA (or an activity enhanced by GreA) increased the fidelity of transcription by preferential cleavage of transcripts containing misincorporated residues in the unactivated state of the elongation complex. This cleavage mechanism by GreA may prevent the formation of ''dead-end'' transcription complexes in vivo.	UNIV OREGON, DEPT CHEM, EUGENE, OR 97403 USA	University of Oregon	ERIE, DA (corresponding author), UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA.			von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012915, R37GM015792, R01GM015792, R01GM029158] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-15792, GM-12915] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Benkovic S. J, 1973, ENZYMES, P201; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CHAMBERLIN MJ, IN PRESS HARVEY L 88; CHAN CL, IN PRESS TRANSCRIPTI; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; EICHHORN G L, 1991, Biophysical Journal, V59, p565A; EICHHORN GL, COMMUNICATION; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; Koshland D., 1959, ENZYMES, V1, P305; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDICK R, COMMUNICATION; LANDICK R, 1987, ESCHERICHIA COLI SAL, V2, P1276; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; MATSUZAKI H, IN PRESS J MOL BIOL; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REINES D, 1992, J BIOL CHEM, V267, P3795; RHODES G, 1974, J BIOL CHEM, V249, P6675; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	37	257	262	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1993	262	5135					867	873		10.1126/science.8235608	http://dx.doi.org/10.1126/science.8235608			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235608				2022-12-01	WOS:A1993MF43800026
J	BATH, PMW; PRASAD, A; BROWN, MM; MACGREGOR, GA				BATH, PMW; PRASAD, A; BROWN, MM; MACGREGOR, GA			SURVEY OF USE OF ANTICOAGULATION IN PATIENTS WITH ATRIAL-FIBRILLATION	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,SCH MED,BLOOD PRESSURE UNIT,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,DIV CLIN NEUROSCI,LONDON SW17 0RE,ENGLAND	St Georges University London; St Georges University London			Bath, Philip/F-9020-2011	Bath, Philip/0000-0003-2734-5132				BARNABY J, 1993, BRIT MED J, V306, P207, DOI 10.1136/bmj.306.6871.207-b; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; LOWE GDO, 1992, BRIT MED J, V305, P1445, DOI 10.1136/bmj.305.6867.1445; RAMSAY LE, 1993, LANCET, V341, P1376, DOI 10.1016/0140-6736(93)90945-D	4	82	82	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1045	1045		10.1136/bmj.307.6911.1045	http://dx.doi.org/10.1136/bmj.307.6911.1045			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8166802	Bronze, Green Published			2022-12-01	WOS:A1993MD55600020
J	LEI, KJ; SHELLY, LL; PAN, CJ; SIDBURY, JB; CHOU, JY				LEI, KJ; SHELLY, LL; PAN, CJ; SIDBURY, JB; CHOU, JY			MUTATIONS IN THE GLUCOSE-6-PHOSPHATASE GENE THAT CAUSE GLYCOGEN-STORAGE-DISEASE TYPE-1A	SCIENCE			English	Article							MICROSOMAL GLUCOSE-6-PHOSPHATASE; MULTIFUNCTIONAL GLUCOSE-6-PHOSPHATASE; ENDOPLASMIC-RETICULUM; SYSTEM; SPECIFICITY; PROTEINS	Glycogen storage disease (GSD) type 1a is caused by the deficiency Of D-glucose-6-phosphatase (G6Pase), the key enzyme in glucose homeostasis. Despite both a high incidence and morbidity, the molecular mechanisms underlying this deficiency have eluded characterization. In the present study, the molecular and biochemical characterization of the human G6Pase complementary DNA, its gene, and the expressed protein, which is indistinguishable from human microsomal G6Pase, are reported. Several mutations in the G6Pase gene of affected individuals that completely inactivate the enzyme have been identified. These results establish the molecular basis of this disease and open the way for future gene therapy.	NICHHD, HUMAN GENET BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ARION WJ, 1980, J BIOL CHEM, V255, P396; ARION WJ, 1972, J BIOL CHEM, V247, P2558; BEAUDET AL, 1991, HARRISONS PRINCIPLES, P1854; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; COUNTAWAY JL, 1988, J BIOL CHEM, V263, P2673; GLUECKSOHNWAELSCH S, 1979, CELL, V16, P225, DOI 10.1016/0092-8674(79)90001-1; HERS H. G., 1964, ADVAN METAB DISORDERS, V1, P1; Hers HG, 1989, METABOLIC BASIS INHE, P425; HOLLIDAY R, 1993, MUTAT RES, V285, P61, DOI 10.1016/0027-5107(93)90052-H; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JORGENSON RA, 1980, J BIOL CHEM, V255, P5907; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; LEI JK, UNPUB; NORDLIE RC, 1983, J BIOL CHEM, V258, P9739; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, P349; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SCHULZE HU, 1986, J BIOL CHEM, V261, P6571; SHELLY LL, UNPUB; SINGH J, 1981, BIOCHIM BIOPHYS ACTA, V678, P477, DOI 10.1016/0304-4165(81)90129-X; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADDELL ID, 1991, BIOCHEM J, V275, P133, DOI 10.1042/bj2750133	24	300	311	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1993	262	5133					580	583		10.1126/science.8211187	http://dx.doi.org/10.1126/science.8211187			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC935	8211187	Green Submitted			2022-12-01	WOS:A1993MC93500045
J	TZIANABOS, AO; ONDERDONK, AB; ROSNER, B; CISNEROS, RL; KASPER, DL				TZIANABOS, AO; ONDERDONK, AB; ROSNER, B; CISNEROS, RL; KASPER, DL			STRUCTURAL FEATURES OF POLYSACCHARIDES THAT INDUCE INTRAABDOMINAL ABSCESSES	SCIENCE			English	Article							STREPTOCOCCUS-PNEUMONIAE TYPE-1; GROUP-B STREPTOCOCCUS; BACTEROIDES-FRAGILIS; CAPSULAR POLYSACCHARIDE; IMMUNOCHEMICAL CHARACTERIZATION; NEISSERIA-MENINGITIDIS; ANTIGENS; STRAINS; COMPLEX	The capsular polysaccharide complex from Bacteroides fragilis promotes the formation of intra-abdominal abscesses-a pathologic host response to infecting microorganisms. This complex consists of two distinct polysaccharides, each with repeating units that have positively charged amino groups and negatively charged carboxyl or phosphate groups. Analysis of these polysaccharides as well as other charged carbohydrates before and after chemical modification revealed that these oppositely charged groups are required for the induction of intra-abdominal abscesses in a rat model.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV INFECT DIS,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	TZIANABOS, AO (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHANNING LAB,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007061] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUMANN H, 1992, BIOCHEMISTRY-US, V31, P4081, DOI 10.1021/bi00131a026; BHATTACHARJEE AK, 1975, J BIOL CHEM, V250, P1926; GORBACH SL, 1974, NEW ENGL J MED, V290, P1177, DOI 10.1056/NEJM197405232902106; HEYNS K., 1967, CARBOHYD RES, V3, P340, DOI 10.1016/S0008-6215(00)82210-7; JENNINGS HJ, 1980, BIOCHEMISTRY-US, V19, P4712, DOI 10.1021/bi00561a026; JENNINGS HJ, 1985, J IMMUNOL, V134, P2651; JENNINGS HJ, 1983, BIOCHEMISTRY-US, V22, P1258, DOI 10.1021/bi00274a042; KASPER DL, 1975, J INFECT DIS, V132, P440, DOI 10.1093/infdis/132.4.440; KASPER DL, 1983, J BACTERIOL, V153, P991, DOI 10.1128/JB.153.2.991-997.1983; LINDBERG B, 1980, CARBOHYD RES, V78, P111, DOI 10.1016/S0008-6215(00)83664-2; LINDBERG B, 1977, CARBOHYD RES, V58, P177, DOI 10.1016/S0008-6215(00)83413-8; ONDERDONK AB, 1977, J INFECT DIS, V136, P82, DOI 10.1093/infdis/136.1.82; PANTOSTI A, 1991, INFECT IMMUN, V59, P2075, DOI 10.1128/IAI.59.6.2075-2082.1991; PANTOSTI A, 1993, J CLIN MICROBIOL, V31, P1850, DOI 10.1128/JCM.31.7.1850-1855.1993; POLK BF, 1977, ANN INTERN MED, V86, P569, DOI 10.7326/0003-4819-86-5-569; REED L. J., 1938, AMER JOUR HYG, V27, P493; Reeves RE, 1941, J BIOL CHEM, V139, P511; SHAPIRO ME, 1986, J IMMUNOL, V137, P341; TAYLOR RL, 1972, BIOCHEMISTRY-US, V11, P1383, DOI 10.1021/bi00758a009; TZIANABOS AO, 1992, J BIOL CHEM, V267, P18230; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WESSELS MR, 1987, J BIOL CHEM, V262, P8262	22	210	220	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					416	419		10.1126/science.8211161	http://dx.doi.org/10.1126/science.8211161			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	8211161				2022-12-01	WOS:A1993MB85900056
J	ENA, J; DICK, RW; JONES, RN; WENZEL, RP				ENA, J; DICK, RW; JONES, RN; WENZEL, RP			THE EPIDEMIOLOGY OF INTRAVENOUS VANCOMYCIN USAGE IN A UNIVERSITY HOSPITAL - A 10-YEAR STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; ADVERSE DRUG-REACTIONS; ANTIMICROBIAL AGENTS; OPERATIONAL ASSESSMENT; ANTIBIOTIC USE; INFECTIONS; SURVEILLANCE; BACTEREMIA; GUIDELINES; MORTALITY	Objectives.-To examine the trends of intravenous vancomycin usage during a 10-year period, to classify the indications for which physicians prescribed the antibiotic, and to identify the independent predictors for empirical use of vancomycin. Design.-A descriptive epidemiological study, a cross-sectional study, and a case-control study were performed. Setting.-A 900-bed university-teaching hospital. Main Outcome Measures.-The annual crude usage (grams) and incidence density (grams/1 000 patient-days) of vancomycin were measured for 10 years (July 1981 to July 1991). In 109 randomly selected patient medical records, we evaluated the proportion of usage of vancomycin classified as prophylaxis, empirical therapy, or specifically directed therapy. Univariate and multivariate analyses were performed to identify determinants of empirical administration of vancomycin vs a penicillase-resistant penicillin to 64 case patients and 64 control patients. Results.-The rate of vancomycin usage increased 20-fold from 5.72 g/1000 patient-days in 1981 to 121.25 g/1000 patient-days in 1991. The use of vancomycin was significantly higher (P<.0001) in hematology-oncology areas compared with that in other hospital areas. The rates for each indication for vancomycin were 35.0% for prophylaxis, 31.8% for empirical therapy, and 33.2% for therapy specifically directed by culture results. In a multivariate analysis, the presence of ''plastic'' medical devices was the best independent predictor for patients receiving vancomycin: intravenous lines (odds ratio [OR], 6.23; 95% confidence interval [CI], 2.28 to 17.06; P<.001), Hickman catheters (OR, 76.12; 95% CI, 15.06 to 384.73; P<.001), and other medical devices (OR, 10.50; 95% CI, 2.54 to 43.38; P=.001). Conclusions.-Vancomycin use has increased linearly in the last decade primarily related to the presence of indwelling vascular devices in hematology-oncology patients. Use of vancomycin is equally divided among empirical therapy, prophylaxis, and specific therapy for a documented infection.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,DIV GEN MED CLIN EPIDEMIOL & HLTH SERV RES,C41-GH,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,ANTI INFECT RES CTR,DEPT PATHOL,IOWA CITY,IA 52242; UNIV IOWA HOSP & CLIN,DEPT PHARM,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa								ARCHER GL, 1990, PRINCIPLES PRACTICE, P1511; BRODERICK A, 1990, AM J EPIDEMIOL, V131, P734, DOI 10.1093/oxfordjournals.aje.a115558; CASTLE M, 1977, JAMA-J AM MED ASSOC, V237, P2819, DOI 10.1001/jama.237.26.2819; FARBER BF, 1983, J THORAC CARDIOV SUR, V85, P933; FARBER BF, 1983, ANTIMICROB AGENTS CH, V23, P138, DOI 10.1128/AAC.23.1.138; Fleiss JL., 1981, STAT METHODS RATES P, P14; FRENCH GL, 1988, J ANTIMICROB CHEMOTH, V21, P581, DOI 10.1093/jac/21.5.581; GRUBB WB, 1986, EUR J CLIN MICROBIOL, V5, P728, DOI 10.1007/BF02013314; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; HUTCHINSON TA, 1979, JAMA-J AM MED ASSOC, V242, P633, DOI 10.1001/jama.242.7.633; JONES SR, 1977, AM J MED SCI, V273, P79, DOI 10.1097/00000441-197701000-00008; KARP JE, 1986, AM J MED, V81, P237, DOI 10.1016/0002-9343(86)90257-3; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; KUNIN CM, 1973, ANN INTERN MED, V79, P555, DOI 10.7326/0003-4819-79-4-555; LANDRY SL, 1989, AM J INFECT CONTROL, V17, P323, DOI 10.1016/0196-6553(89)90001-1; MAKI DG, 1978, AM J MED SCI, V275, P271, DOI 10.1097/00000441-197805000-00005; MARR JJ, 1988, J INFECT DIS, V157, P869, DOI 10.1093/infdis/157.5.869; MARTIN MA, 1989, ANN INTERN MED, V110, P9, DOI 10.7326/0003-4819-110-1-9; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MORRISON AJ, 1986, INFECT CONT HOSP EP, V7, P550, DOI 10.1017/S0195941700065309; ROBERTS AW, 1972, AM J HOSP PHARM, V29, P828, DOI 10.1093/ajhp/29.10.828; SANDFORD JP, 1991, GUIDE ANTIMICROBIAL; SCHECKLER WE, 1970, J AMER MED ASSOC, V213, P264, DOI 10.1001/jama.213.2.264; SORRELL TC, 1985, J ANTIMICROB CHEMOTH, V16, P235, DOI 10.1093/jac/16.2.235; UTTLEY AHC, 1988, LANCET, V1, P57; VEACH LA, 1990, J CLIN MICROBIOL, V28, P2064, DOI 10.1128/JCM.28.9.2064-2068.1990; WIDMER AF, 1991, EUR J CLIN MICROBIOL, V10, P46, DOI 10.1007/BF01967101; WILKINSON L, 1990, SYSTAT SYSTEM STATIS; WINSTON DJ, 1980, AM J MED, V69, P255, DOI 10.1016/0002-9343(80)90386-1; 1990, EGRET EPIDEMIOLOGY G; 1991, J INNFECT DIS, V163, P951; 1984, CDC SURVEILLANCE S2, V33, pSS922	32	150	153	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					598	602		10.1001/jama.269.5.598	http://dx.doi.org/10.1001/jama.269.5.598			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8240468				2022-12-01	WOS:A1993KJ44400025
J	COHEN, JS; FIHN, SD; BOYKO, EJ; JONSEN, AR; WOOD, RW				COHEN, JS; FIHN, SD; BOYKO, EJ; JONSEN, AR; WOOD, RW			ATTITUDES TOWARD ASSISTED SUICIDE AND EUTHANASIA AMONG PHYSICIANS IN WASHINGTON-STATE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOPELESSLY ILL; AID	Background. Despite considerable public interest in legalizing physician-assisted suicide and euthanasia, little is known about physicians' attitude's toward these practices. Methods. We sent questionnaires to 1355 randomly selected physicians in the state of Washington, including all hematologists and oncologists and a disproportionately high number of internists, family practitioners, psychiatrists, and general surgeons. To avoid ambiguity in our survey, instead of ''physician-assisted suicide,'' we used the phrase ''prescription of medication [e.g., narcotics or barbiturates] or the counseling of an ill patient so he or she may use an overdose to end his or her own life.'' Instead of ''euthanasia,'' we used the phrase ''deliberate administration of an overdose of medication to an ill patient at his or her request with the primary intent to end his or her life.'' Results. Of the 1355 eligible physicians who received our questionnaire, 938 (69 percent) responded. Forty-eight percent of the respondents agreed with the statement that euthanasia is never ethically justified, and 42 percent disagreed. Fifty-four percent thought euthanasia should be legal in some situations, but only 33 percent stated that they would be willing to perform euthanasia. Thirty-nine percent of respondents agreed with the statement that physician-assisted suicide is never ethically justified, and 50 percent disagreed. Fifty-three percent thought assisted suicide should be legal in some situations, but only 40 percent stated that they would be willing to assist a patient in committing suicide. Of the groups surveyed, hematologists and oncologists were most likely to oppose euthanasia and assisted suicide, and psychiatrists were most likely to support these practices. Conclusions. The attitudes toward physician-assisted suicide and euthanasia of physicians in Washington State are polarized. A slight majority favors legalizing physician-assisted suicide and euthanasia in at least some situations, but most would be unwilling to participate in these practices themselves.	UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; VET AFFAIRS MED CTR, DIV GEN MED, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA USA; UNIV WASHINGTON, DEPT MED HIST & ETH, SEATTLE, WA 98195 USA	University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	COHEN, JS (corresponding author), VET AFFAIRS MED CTR, GEN INTERNAL MED SECT, 1 VET DR, MINNEAPOLIS, MN 55417 USA.		Boyko, Edward J/G-2484-2017; Fihn, Stephan/ABA-1040-2020	Boyko, Edward J/0000-0002-3695-192X; 				ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; Battin M, 1992, Law Med Health Care, V20, P133; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CARALIS PV, 1992, CRIT CARE MED, V20, P683, DOI 10.1097/00003246-199205000-00023; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CELOCRUZ MT, 1992, AM J LAW MED, V18, P369; CONVERSE PE, 1964, IDEOLOGY DISCONTENT; CROSBY C, 1992, INTERNIST        MAR, P16; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; HEILIG S, 1988, SAN FRANCISCO MED, V61, P24; HEILIG S, 1988, SAN FRANCISCO MED, V61, P34; HENDIN H, 1993, AM J PSYCHIAT, V150, P143; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P419; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; OVERMYER M, 1991, PHYSICIANS MANAGE, V31, P40; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; SNEDECOR GW, 1980, STATISTICAL METHODS, P93; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; 1988, WITHHOLDING WITHDRAW; 1991, INFORMAL SURVEY WSMA; 1992, ANN INTERN MED, V117, P947	28	197	198	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 14	1994	331	2					89	94		10.1056/NEJM199407143310206	http://dx.doi.org/10.1056/NEJM199407143310206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW712	8208272				2022-12-01	WOS:A1994NW71200006
J	GEE, SH; MONTANARO, F; LINDENBAUM, MH; CARBONETTO, S				GEE, SH; MONTANARO, F; LINDENBAUM, MH; CARBONETTO, S			DYSTROGLYCAN-ALPHA, A DYSTROPHIN-ASSOCIATED GLYCOPROTEIN, IS A FUNCTIONAL AGRIN RECEPTOR	CELL			English	Article							CULTURED MUSCLE-CELLS; TORPEDO ELECTRIC ORGAN; NICOTINIC ACETYLCHOLINE-RECEPTOR; DUCHENNE MUSCULAR-DYSTROPHY; ORIGINAL SYNAPTIC SITES; SKELETAL-MUSCLE; NEUROMUSCULAR-JUNCTIONS; MOTOR NEURONS; BASAL LAMINA; CHROMOSOMAL LOCALIZATION	Aggregation of acetylcholine receptors (AChRs) on skeletal muscle fibers is thought to be mediated by the basal lamina protein agrin. Structural similarities shared by agrin and laminin suggested that the laminin receptor dystroglycan-alpha, part of a dystrophin-receptor complex, might also bind agrin. We show here that dystroglycan-alpha and dystrophin-related protein (DRP/utrophin) are concentrated within AChR aggregates in cultures of C2 myotubes and that agrin binds specifically to dystroglycan-alpha in in vitro assays. This binding is calcium dependent and is inhibited by monoclonal antibody (MAb) IIH6 against dystroglycan-alpha, heparin, and laminin, but not by fibronectin. In S27 cells, which do not aggregate AChRs spontaneously, agrin and laminin binding to dystroglycan-alpha are dramatically decreased. Moreover, MAb IIH6 significantly inhibits agrin-induced AChR aggregation on C2 cells. We conclude that dystroglycan-alpha is an agrin-binding protein and part of a dystrophin-receptor complex involved in AChR aggregation.			GEE, SH (corresponding author), MCGILL UNIV,MONTREAL GEN HOSP,RES INST,NEUROSCI RES CTR,MONTREAL H3G 1A4,PQ,CANADA.		Montanaro, Federica/GRJ-5139-2022	Montanaro, Federica/0000-0002-3338-0498				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P757, DOI 10.1113/jphysiol.1977.sp011880; ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; BEWICK GS, 1992, NEUROREPORT, V3, P857, DOI 10.1097/00001756-199210000-00009; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN MW, 1992, J NEUROSCI, V12, P2982, DOI 10.1523/JNEUROSCI.12-08-02982.1992; DOUVILLE PJ, 1988, J BIOL CHEM, V263, P14964; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FERTUCK H C, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1376, DOI 10.1073/pnas.71.4.1376; FERTUCK HC, 1976, J CELL BIOL, V69, P144, DOI 10.1083/jcb.69.1.144; FRANK E, 1979, J CELL BIOL, V83, P143, DOI 10.1083/jcb.83.1.143; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; GEE SH, 1993, J BIOL CHEM, V268, P14972; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GORDON H, 1989, DEV BIOL, V135, P1, DOI 10.1016/0012-1606(89)90152-8; GORDON H, 1993, J NEUROSCI, V13, P586; HENDERSON LP, 1984, J NEUROSCI, V4, P3140; HIRANO Y, 1989, J NEUROSCI, V9, P1555; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KLIETSCH R, 1993, CIRC RES, V72, P349, DOI 10.1161/01.RES.72.2.349; LINDENBAUM MH, 1993, CURR BIOL, V3, P109, DOI 10.1016/0960-9822(93)90167-M; MA JY, 1993, J BIOL CHEM, V268, P25108; MAGILLSOLC C, 1990, J EXP BIOL, V153, P1; MAGILLSOLC C, 1988, J CELL BIOL, V107, P1825, DOI 10.1083/jcb.107.5.1825; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; NASTUK MA, 1991, NEURON, V7, P807, DOI 10.1016/0896-6273(91)90283-6; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PENG HB, 1982, J NEUROSCI, V2, P1760; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; REIST NE, 1987, J CELL BIOL, V105, P2457, DOI 10.1083/jcb.105.6.2457; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1992, J NEUROSCI, V12, P3535; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SALPETER MM, 1985, PROG NEUROBIOL, V25, P297, DOI 10.1016/0301-0082(85)90018-8; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANES JR, 1978, J CELL BIOL, V78, P176, DOI 10.1083/jcb.78.1.176; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SHIMIZU T, 1989, BIOMED RES-TOKYO, V10, P405, DOI 10.2220/biomedres.10.405; SILBERSTEIN L, 1982, NATURE, V295, P143, DOI 10.1038/295143a0; SUNADA Y, 1994, IN PRESS J BIOL CHEM; SWOPE SL, 1993, J BIOL CHEM, V268, P25152; TAWIL NJ, 1990, BIOCHEMISTRY-US, V29, P6540, DOI 10.1021/bi00479a028; TIMPL R, 1982, METHOD ENZYMOL, V82, P831; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; TURNER DC, 1989, J NEUROSCI, V9, P3287; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VOGEL Z, 1983, J NEUROSCI, V3, P1058; WAKAYAMA Y, 1989, J NEUROL SCI, V91, P191, DOI 10.1016/0022-510X(89)90087-7; WALLACE BG, 1990, J NEUROSCI, V10, P3576; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1988, J CELL BIOL, V107, P267, DOI 10.1083/jcb.107.1.267; YANG B, 1994, J BIOL CHEM, V269, P6040; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; ZUBRZYCKAGAARN EE, 1991, EXP CELL RES, V192, P278, DOI 10.1016/0014-4827(91)90187-Y	75	458	471	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 3	1994	77	5					675	686		10.1016/0092-8674(94)90052-3	http://dx.doi.org/10.1016/0092-8674(94)90052-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NQ123	8205617				2022-12-01	WOS:A1994NQ12300008
J	MARCUSSON, EG; HORAZDOVSKY, BF; CEREGHINO, JL; GHARAKHANIAN, E; EMR, SD				MARCUSSON, EG; HORAZDOVSKY, BF; CEREGHINO, JL; GHARAKHANIAN, E; EMR, SD			THE SORTING RECEPTOR FOR YEAST VACUOLAR CARBOXYPEPTIDASE-Y IS ENCODED BY THE VPS10 GENE	CELL			English	Article							LYSOSOME-LIKE VACUOLE; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; PROTEIN-KINASE; GOLGI-COMPLEX; MUTANTS; TRANSPORT; DNA; BIOGENESIS; VPS34	The S. cerevisiae VPS10 (vacuolar protein sorting) gene encodes a type I transmembrane protein of 1577 amino acids required for the sorting of the soluble vacuolar protein carboxypeptidase Y (CPY). Mutations in VPS10 result in the selective missorting and secretion of CPY; all other vacuolar proteins tested are delivered to the vacuole in vps10 mutants. Chemical cross-linking studies demonstrate that Vps10p and the Golgi-modified precursor form of CPY directly interact. A single amino acid change in the CPY vacuolar sorting signal prevents this interaction. Vps10p also interacts with a hybrid protein containing the CPY sorting signal fused to the normally secreted enzyme invertase. Subcellular fractionation indicates that the majority of Vps10p is localized to a late Golgi compartment where vacuolar proteins are sorted. We propose that VPS10 encodes a CPY sorting receptor that executes multiple rounds of sorting by cycling between the late Golgi and a prevacuolar endosome-like compartment.	UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego	MARCUSSON, EG (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093, USA.			Marcusson, Eric/0000-0002-0504-8674	NIGMS NIH HHS [GM15638, GM32703] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032703, F32GM015638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; HORAZDOVSKY BF, 1994, IN PRESS EMBO J, V13; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JONES EW, 1977, GENETICS, V85, P23; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Miller JH., 1972, EXPT MOL GENETICS; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; SHERMAN F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VANDYCK L, 1992, YEAST, V8, P769, DOI 10.1002/yea.320080910; VIDA TA, 1993, J CELL BIOL, V121, P1245, DOI 10.1083/jcb.121.6.1245; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353	36	406	418	1	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					579	586		10.1016/0092-8674(94)90219-4	http://dx.doi.org/10.1016/0092-8674(94)90219-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	8187177				2022-12-01	WOS:A1994NM83200012
J	WHITE, K; GRETHER, ME; ABRAMS, JM; YOUNG, L; FARRELL, K; STELLER, H				WHITE, K; GRETHER, ME; ABRAMS, JM; YOUNG, L; FARRELL, K; STELLER, H			GENETIC-CONTROL OF PROGRAMMED CELL-DEATH IN DROSOPHILA	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; EMBRYONIC-DEVELOPMENT; SEGMENTATION GENE; NEURONAL DEATH; RNA-SYNTHESIS; CHICK-EMBRYO; MELANOGASTER; PROTEIN; LOCUS; SURVIVAL	A gene, reaper (rpr), that appears to play a central control function for the initiation of programmed cell death (apoptosis) in Drosophila was identified. Virtually all programmed cell death that normally occurs during Drosophila embryogenesis was blocked in embryos homozygous for a small deletion that includes the reaper gene. Mutant embryos contained many extra cells and failed to hatch, but many other aspects of development appeared quite normal. Deletions that include reaper also protected embryos from apoptosis caused by x-irradiation and developmental defects. However, high doses of x-rays induced some apoptosis in mutant embryos, and the resulting corpses were phagocytosed by macrophages. These data suggest that the basic cell death program is intact although it was not activated in mutant embryos. The DNA encompassed by the deletion was cloned and the reaper gene was identified on the basis of the ability of cloned DNA to restore apoptosis to cell death defective embryos in germ line transformation experiments. The reaper gene appears to encode a small peptide that shows no homology to known proteins, and reaper messenger RNA is expressed in cells destined to undergo apoptosis.	MIT,HOWARD HUGHES MED INST,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			White, Kristin/D-7936-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008536] Funding Source: NIH RePORTER; NINDS NIH HHS [5 F32 NS08536] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBOTT MK, 1991, GENETICS, V129, P783; ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ABRAMS JM, UNPUB; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BALDARELLI RM, 1988, DEV BIOL, V125, P85, DOI 10.1016/0012-1606(88)90061-9; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BATE CM, 1976, J EMBRYOL EXP MORPH, V35, P107; BATE M, 1981, J NEUROSCI, V1, P103, DOI 10.1523/JNEUROSCI.01-01-00103.1981; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CAVANER R, 1987, NUCLEIC ACIDS RES, V15, P1353; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CMAPOS KF, 1992, DEVELOPMENT, V114, P355; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FISCHBACH KF, 1984, DEV BIOL, V104, P219, DOI 10.1016/0012-1606(84)90050-2; Freeman Robert S., 1993, Current Opinion in Neurobiology, V3, P25, DOI 10.1016/0959-4388(93)90031-S; FRISTROM D, 1969, MOL GEN GENET, V103, P363, DOI 10.1007/BF00383486; GARCIABELLIDO A, 1983, MOL GEN GENET, V192, P253, DOI 10.1007/BF00327675; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIORGI F, 1976, J EMBRYOL EXP MORPH, V35, P521; GRETHER M, UNPUB; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIMURA K, 1990, J NEUROSCI, V10, P403; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LOCKSHIN RA, 1969, J INSECT PHYSIOL, V15, P1505, DOI 10.1016/0022-1910(69)90172-3; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACKAY WJ, 1989, GENETICS, V122, P643; MAGRASSI L, 1988, DEVELOPMENT, V104, P447; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINEZARIAS A, 1985, J EMBRYOL EXP MORPH, V87, P99; MURPHY C, 1974, DEV BIOL, V39, P23, DOI 10.1016/S0012-1606(74)80005-9; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; POTTEN CS, 1978, CELL TISSUE KINET, V11, P149, DOI 10.1111/j.1365-2184.1978.tb00883.x; PROKOP A, 1991, DEVELOPMENT, V111, P79; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROBERTSON HM, 1988, GENETICS, V118, P461; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; STELLER H, 1987, CELL, V50, P1139, DOI 10.1016/0092-8674(87)90180-2; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TEPASS U, 1990, ROUX ARCH DEV BIOL, V199, P189, DOI 10.1007/BF01682078; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; TRUMAN JW, COMMUNICATION; UMANSKY SR, 1991, APOPTOSIS MOL BASIS; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHITE K, UNPUB; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WOLFF T, 1991, DEVELOPMENT, V113, P825; WURGLER FE, 1976, GENETICS BIOL DROSOP; YUAN J, 1991, DEV BIOL, V138, P33; [No title captured]	62	874	911	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					677	683		10.1126/science.8171319	http://dx.doi.org/10.1126/science.8171319			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	8171319				2022-12-01	WOS:A1994NH71300025
J	TINKER, RL; WILLIAMS, KP; KASSAVETIS, GA; GEIDUSCHEK, EP				TINKER, RL; WILLIAMS, KP; KASSAVETIS, GA; GEIDUSCHEK, EP			TRANSCRIPTIONAL ACTIVATION BY A DNA-TRACKING PROTEIN - STRUCTURAL CONSEQUENCES OF ENHANCEMENT AT THE T4 LATE PROMOTER	CELL			English	Article							BACTERIOPHAGE-T4 LATE PROMOTER; RNA-POLYMERASE; ESCHERICHIA-COLI; REPLICATION APPARATUS; ACCESSORY PROTEINS; PRIMER-TEMPLATE; GENE; SUBUNIT; COMPLEX; RECOGNITION	Transcriptional initiation at bacteriophage T4 late promoters is activated from enhancer-like distal sites by the T4 gene 44, 62, and 45 DNA polymerase accessory proteins (gp44, gp62, and gp45, respectively). Enhancement is ATP hydrolysis-dependent and requires protein tracking along DNA. The structural analysis of the entranced transcription initiation complex shows gp45 located at the upstream end of this promoter complex in the vicinity of its transcriptional coactivator, the T4 gene 33 protein. The ATP-cleaving gene 44 protein-gene 62 protein complex serves as the assembly factor for gp45, but does not stably associate with the enhanced promoter complex. Transcriptional enhancement quantitatively favors, but does not qualitatively change, DNA strand separation in the transcription bubble. A model of the transcriptional activation that rationalizes its DNA-tracking and activation-polarity properties is presented.			TINKER, RL (corresponding author), UNIV CALIF SAN DIEGO, CTR MOLEC GENET, DEPT BIOL, LA JOLLA, CA 92093 USA.							BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CHRISTENSEN AC, 1983, BACTERIOPHAGE T, V4, P184; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15721; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1984, P NATL ACAD SCI-BIOL, V81, P5101, DOI 10.1073/pnas.81.16.5101; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MALIK S, 1988, J BIOL CHEM, V263, P1174; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; MUNN MM, 1991, J BIOL CHEM, V266, P20024; PIPERNO JR, 1978, J BIOL CHEM, V253, P5180; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RABUSSAY D, 1983, BACTERIOPHAGE T, V4, P163; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; Sambrook J., 1989, MOL CLONING LAB MANU; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TICHELAAR W, 1990, J STRUCT BIOL, V103, P180, DOI 10.1016/1047-8477(90)90021-4; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WILLIAM SKP, 1994, IN PRESS MOL BIOL T, V4; WILLIAM SKP, 1987, J BIOL CHEM, V262, P12365; WILLIAMS KP, 1989, J BACTERIOL, V171, P3579, DOI 10.1128/jb.171.6.3579-3582.1989; WILLIAMS KP, 1990, THESIS U CALIFORNIA; WINKELMAN JW, 1994, IN PRESS J BACTERIOL	44	58	58	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 22	1994	77	2					225	237		10.1016/0092-8674(94)90315-8	http://dx.doi.org/10.1016/0092-8674(94)90315-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168131				2022-12-01	WOS:A1994NH63400008
J	BASTARRACHEA, J; HORTOBAGYI, GN; SMITH, TL; KAU, SWC; BUZDAR, AU				BASTARRACHEA, J; HORTOBAGYI, GN; SMITH, TL; KAU, SWC; BUZDAR, AU			OBESITY AS AN ADVERSE PROGNOSTIC FACTOR FOR PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-WEIGHT; STAGE-II; DOXORUBICIN; CARCINOMA; SURVIVAL; CYCLOPHOSPHAMIDE; MASTECTOMY; RELAPSE; THERAPY; TABLES	Objective: To determine whether obesity is an independent prognostic factor among women receiving adjuvant chemotherapy for lymph node-positive breast cancer and to determine how obesity relates to other commonly used prognostic indicators. Design: Retrospective review of the clinical characteristics and clinical course of 735 patients with stages II and III primary breast cancer who were treated using three consecutive postoperative adjuvant chemotherapy protocols. Univariate and multivariate analyses were used to determine the prognostic implications of obesity defined by weight and height tables and body mass index. In addition, we analyzed the relation between obesity and other known prognostic indicators for patients with primary breast cancer. Setting: A comprehensive cancer center. Patients: 735 patients with lymph node-positive primary breast cancer who were treated using three consecutive fluorouracil-doxorubicin-cyclophosphamide-containing adjuvant chemotherapy protocols and for whom complete data on weight, height, standard prognostic factors, and outcome were available. Main Outcome Measurements: Disease-free and overall survival for the entire group and obese and nonobese subgroups. Results: 24 percent of patients were more than 20% overweight. With a median follow-up of 10.7 years, the estimated 10-year, disease-free rate for patients not more than 20% overweight was 54% (95% CI, 50% to 58%) compared with 40% (CI, 33% to 47%) for remaining patients classified as obese. Although obese patients tended to have somewhat less favorable prognoses based on standard prognostic criteria, a proportional-hazards regression model adjusting for other factors indicated that risk for disease recurrence among obese patients was 1.33 times that of the nonobese population (CI, 1.05 to 1.68). Conclusions: Obesity is an indicator of poor prognosis for patients with primary breast cancer even after the administration of adjuvant chemotherapy. The effect of dietary interventions to reduce body weight on the outcome of breast cancer therapy must be investigated.	UNIV TEXAS, MD ANDERSON CANC CTR, 1515 HOLCOMBE BLVD, BOX 56, HOUSTON, TX 77025 USA	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE R, 1976, TOHOKU J EXP MED, V120, P351, DOI 10.1620/tjem.120.351; ANG PT, 1989, J CLIN ONCOL, V7, P1677, DOI 10.1200/JCO.1989.7.11.1677; [Anonymous], 1983, Stat Bull Metrop Life Found, V64, P3; BEAHRS OH, 1988, AM JOINT COMMITTEE C; BOYD NF, 1981, JNCI-J NATL CANCER I, V67, P785; BURT JR, 1983, P AN M AM SOC CLIN, pC6; BUZDAR A, 1981, ADJUVANT THERAPY CAN, V3, P419; BUZDAR AU, 1978, CANCER, V41, P1064, DOI 10.1002/1097-0142(197803)41:3<1064::AID-CNCR2820410340>3.0.CO;2-Q; BUZDAR AU, 1984, CANCER, V53, P384, DOI 10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G; BUZDAR AU, 1987, ADJUVANT THERAPY CAN, V5, P411; CAMORIANO JK, 1990, J CLIN ONCOL, V8, P1327, DOI 10.1200/JCO.1990.8.8.1327; CHLEBOWSKI RT, 1986, BREAST CANCER RES TR, V7, P23, DOI 10.1007/BF01886732; COX DR, 1972, J R STAT SOC B, V34, P187; de Waard F, 1982, Nutr Cancer, V4, P85, DOI 10.1080/01635588209513743; DEWAARD F, 1964, CANCER, V17, P141, DOI 10.1002/1097-0142(196402)17:2<141::AID-CNCR2820170202>3.0.CO;2-Z; DONEGAN WL, 1978, CANCER, V41, P1590, DOI 10.1002/1097-0142(197804)41:4<1590::AID-CNCR2820410449>3.0.CO;2-N; EBERLEIN T, 1985, BREAST CANCER RES TR, V5, P81, DOI 10.1007/BF01807654; GARFINKEL L, 1988, CANCER, V62, P1844, DOI 10.1002/1097-0142(19881015)62:1+<1844::AID-CNCR2820621328>3.0.CO;2-O; GARN SM, 1984, AM J CLIN NUTR, V39, P490, DOI 10.1093/ajcn/39.3.490; GOODWIN PJ, 1988, BREAST CANCER RES TR, V11, P59, DOI 10.1007/BF01807559; GOODWIN PJ, 1990, BREAST CANCER RES TR, V16, P205, DOI 10.1007/BF01806329; HEASMAN KZ, 1985, BREAST CANCER RES TR, V5, P195, DOI 10.1007/BF01805994; HEBERT JR, 1988, INT J CANCER, V42, P315, DOI 10.1002/ijc.2910420302; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KODAMA M, 1987, ANTICANCER RES, V559, P71; LIPPMAN ME, 1978, NEW ENGL J MED, V298, P1223, DOI 10.1056/NEJM197806012982203; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCGUIRE WL, 1987, BREAST CANCER RES TR, V10, P5, DOI 10.1007/BF01806129; MOORE DH, 1983, ADV CANCER RES, V40, P189, DOI 10.1016/S0065-230X(08)60681-8; NEWMAN SC, 1986, AM J EPIDEMIOL, V123, P767, DOI 10.1093/oxfordjournals.aje.a114305; POWIS G, 1987, CANCER CHEMOTH PHARM, V20, P219, DOI 10.1007/BF00570489; RODVOLD KA, 1988, J CLIN ONCOL, V6, P1321, DOI 10.1200/JCO.1988.6.8.1321; SENIE RT, 1992, ANN INTERN MED, V116, P26, DOI 10.7326/0003-4819-116-1-26; SUISSA S, 1989, CANCER RES, V49, P3113; TARTTER PI, 1981, CANCER, V47, P2222, DOI 10.1002/1097-0142(19810501)47:9<2222::AID-CNCR2820470919>3.0.CO;2-5; THIJSSEN JHH, 1975, J STEROID BIOCHEM, V6, P729, DOI 10.1016/0022-4731(75)90060-6; ZUMOFF B, 1983, J SURG ONCOL, V22, P217, DOI 10.1002/jso.2930220402; 1973, VITAL HLTH STATIST 1; 1942, STAT B METROP LIFE F, V23, P6; 1959, STAT B METROP LIFE F, V40, P1	40	124	128	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					18	25		10.7326/0003-4819-120-1-199401010-00004	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250452				2022-12-01	WOS:A1994MP28000004
J	GROEGER, JS; LUCAS, AB; THALER, HT; FRIEDLANDERKLAR, H; BROWN, AE; KIEHN, TE; ARMSTRONG, D				GROEGER, JS; LUCAS, AB; THALER, HT; FRIEDLANDERKLAR, H; BROWN, AE; KIEHN, TE; ARMSTRONG, D			INFECTIOUS MORBIDITY ASSOCIATED WITH LONG-TERM USE OF VENOUS ACCESS DEVICES IN PATIENTS WITH CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						CATHETERIZATION, CENTRAL VENOUS; PORTS, IMPLANTED, SUBCUTANEOUS; FUNGEMIA; BACTEREMIA; NEOPLASMS	PROLONGED PARENTERAL NUTRITION; MARROW TRANSPLANT RECIPIENTS; QUANTITATIVE BLOOD CULTURES; PEDIATRIC ONCOLOGY PATIENTS; HICKMAN-BROVIAC CATHETERS; RIGHT ATRIAL CATHETERS; PORT-A-CATH; EXTERNAL CATHETERS; COMPLICATIONS; EXPERIENCE	Objective: To evaluate infectious morbidity associated with long-term use of venous access devices. Design: Prospective, observational study. Setting: Comprehensive cancer center at a university hospital. Participants: 1431 consecutive patients with cancer requiring 1630 venous access devices for long-term use inserted between 1 June 1987 and 31 May 1989. Measurements: Quantitative microbiologic tests to identify device-related bacteremia and fungemia, catheter tunnel infection, pocket infection in implantable port devices, and site infections; number of days the device remained in situ and time until infectious morbidity; vessel or device thrombosis and device breakage. Results: At least one device-related infection occurred with 341 of 788 (43% [95% CI, 39% to 47%]) catheters compared with 57 of 680 (8% [CI, 6% to 10%]) completely implanted ports (P less-than-or-equal-to 0.001). Device-related bacteremia or fungemia is the predominant infection occurring with catheters, whereas ports have a more equal distribution of pocket, site, and device-related bacteremia. The predominant organisms isolated in catheter-related bacteremia were gram-negative bacilli (55%) compared with gram-positive cocci (65.5%) in port-related bacteremia. The number of infections per 1000 device days was 2.77 (95% CI, 2.48 to 3.06) for catheters compared with 0.21 (CI, 0.16 to 0.27) for ports (P less-than-or-equal-to 0.001). Based on a parametric model of time to first infection, devices lasted longer in patients with solid tumors than in those with hematopoietic tumors. Ports lasted longer than catheters across all patient groups. Conclusions: The incidence of infections per device-day was 12 times greater with catheters than with ports. Patients with solid tumors were the least likely to have device-related infectious morbidity compared with those with hematologic cancers. The reasons for the difference in infectious complications is uncertain but may be attributable to type of disease, intensity of therapy, frequency with which devices are accessed, or duration of neutropenia.	CORNELL UNIV, MED CTR, COLL MED, NEW YORK, NY 10021 USA	Cornell University	GROEGER, JS (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT ANESTHESIOL & CRIT CARE MED, SPECIAL CARE UNIT, 1275 YORK AVE, NEW YORK, NY 10021 USA.							ANDREMONT A, 1988, J CLIN MICROBIOL, V26, P2297, DOI 10.1128/JCM.26.11.2297-2299.1988; BENEZRA D, 1988, AM J MED, V85, P495; BRINCKER H, 1986, CANCER, V57, P1124, DOI 10.1002/1097-0142(19860315)57:6<1124::AID-CNCR2820570611>3.0.CO;2-D; BROTHERS TE, 1988, SURG GYNECOL OBSTET, V166, P295; BROVIAC JW, 1974, SURG GYNECOL OBSTET, V139, P24; BRUNBUISSON C, 1987, ARCH INTERN MED, V147, P873, DOI 10.1001/archinte.147.5.873; CARDE P, 1989, EUR J CANCER CLIN ON, V25, P939, DOI 10.1016/0277-5379(89)90151-X; COOPER GL, 1988, J CLIN MICROBIOL, V26, P8, DOI 10.1128/JCM.26.1.8-12.1988; COOPER GL, 1985, NEW ENGL J MED, V312, P1142, DOI 10.1056/NEJM198505023121802; DAWSON S, 1991, AM J PEDIAT HEMATOL, V13, P126; FLYNN PM, 1987, PEDIATR INFECT DIS J, V6, P729, DOI 10.1097/00006454-198708000-00007; GRANNAN KJ, 1990, J SURG ONCOL, V44, P52, DOI 10.1002/jso.2930440112; GROEGER JS, 1993, ANN SURG, V218, P206, DOI 10.1097/00000658-199308000-00014; HICKMAN RO, 1979, SURG GYNECOL OBSTET, V148, P871; HOCKENBERRY MJ, 1989, AM J PEDIAT HEMATOL, V11, P295; INGRAM J, 1991, AM J PEDIAT HEMATOL, V13, P130; JACOBS MB, 1984, ARCH INTERN MED, V144, P1597, DOI 10.1001/archinte.144.8.1597; JOHNSON PR, 1986, J INFECT DIS, V154, P570, DOI 10.1093/infdis/154.4.570; KIEHN TE, 1990, EUR J CLIN MICROBIOL, V9, P869, DOI 10.1007/BF01967501; KLUNNE MCK, 1989, CANCER, V64, P1747; LOKICH JJ, 1985, J CLIN ONCOL, V3, P710, DOI 10.1200/JCO.1985.3.5.710; MAKI DG, 1988, AM J MED, V85, P307, DOI 10.1016/0002-9343(88)90579-7; Maki DG, 1982, CURRENT TOPICS CLIN, P309; MIRRO J, 1989, J CLIN ONCOL, V7, P214, DOI 10.1200/JCO.1989.7.2.214; MIRRO J, 1990, J PEDIATR SURG, V25, P120, DOI 10.1016/S0022-3468(05)80176-9; MOOSA HH, 1991, SURG GYNECOL OBSTET, V172, P275; NIEDERHUBER JE, 1982, SURGERY, V92, P706; PRESS OW, 1984, MEDICINE, V63, P189, DOI 10.1097/00005792-198407000-00001; RIELLA MC, 1976, SURG GYNECOL OBSTET, V143, P205; ROSS MN, 1988, SURG GYNECOL OBSTET, V167, P141; SCHWARTZ C, 1990, J CLIN ONCOL, V8, P1591, DOI 10.1200/JCO.1990.8.9.1591; SHULMAN RJ, 1987, J CLIN ONCOL, V5, P137, DOI 10.1200/JCO.1987.5.1.137; STRUM S, 1986, J CLIN ONCOL, V4, P596, DOI 10.1200/JCO.1986.4.4.596; TANCREDE CH, 1985, J INFECT DIS, V152, P99, DOI 10.1093/infdis/152.1.99; TENNEY JH, 1986, ARCH INTERN MED, V146, P1949, DOI 10.1001/archinte.146.10.1949; VANHOFF J, 1990, J CLIN ONCOL, V8, P1255, DOI 10.1200/JCO.1990.8.7.1255; WESENBERG F, 1987, PEDIATR HEMAT ONCOL, V4, P137, DOI 10.3109/08880018709141260; WHIMBEY E, 1984, J CLIN MICROBIOL, V19, P766, DOI 10.1128/JCM.19.6.766-771.1984; WURZEL CL, 1988, AM J DIS CHILD, V142, P536, DOI 10.1001/archpedi.1988.02150050074036	39	317	329	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1168	1174		10.7326/0003-4819-119-12-199312150-00003	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239247				2022-12-01	WOS:A1993MM12100003
J	MYERS, JK; WIDLANSKI, TS				MYERS, JK; WIDLANSKI, TS			MECHANISM-BASED INACTIVATION OF PROSTATIC ACID-PHOSPHATASE	SCIENCE			English	Article							VIRULENCE DETERMINANT; TYROSINE KINASES; PROTEINS; YERSINIA	Protein phosphatases play important roles in the regulation of cell growth and metabolism, yet little is known about their enzymatic mechanism. By extrapolation from data on inhibitors of other types of hydrolases, an inhibitor of prostatic acid phosphatase was designed that is likely to function as a mechanism-based phosphotyrosine phosphatase inactivator. This molecule, 4-(fluoromethyl)phenyl phosphate, represents a useful paradigm for the design of potent and specific phosphatase inhibitors.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington					NIGMS NIH HHS [R01 GM47918-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047918] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER D R, 1990, New Biologist, V2, P1049; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; CHU TM, 1982, CLIN BIOCH ANAL, V11, P117; CLEMENS JC, 1991, MOL MICROBIOL, V5, P2617, DOI 10.1111/j.1365-2958.1991.tb01970.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HALAZY S, 1990, BIOORG CHEM, V18, P330, DOI 10.1016/0045-2068(90)90007-R; HELLER JE, 1987, J UROLOGY, V137, P1091, DOI 10.1016/S0022-5347(17)44414-4; LEGOFF JM, 1988, ENDOCRINOLOGY, V123, P1693, DOI 10.1210/endo-123-3-1693; LIN MF, 1987, ADV PROT PHOSPHATASE, V4, P199; NGUYEN L, 1990, CLIN CHEM, V36, P1450; SILVERMAN RB, 1988, MECHANISM BASED ENZY; VANETTEN RL, 1978, CLIN CHEM, V24, P1525; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; WAKSELMAN M, 1983, NOUV J CHIM, V7, P439; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	17	75	82	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1451	1453		10.1126/science.8248785	http://dx.doi.org/10.1126/science.8248785			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248785				2022-12-01	WOS:A1993MJ04600042
J	BABUL, R; ADAM, S; KREMER, B; DUFRASNE, S; WIGGINS, S; HUGGINS, M; THEILMANN, J; BLOCH, M; HAYDEN, MR				BABUL, R; ADAM, S; KREMER, B; DUFRASNE, S; WIGGINS, S; HUGGINS, M; THEILMANN, J; BLOCH, M; HAYDEN, MR			ATTITUDES TOWARD DIRECT PREDICTIVE TESTING FOR THE HUNTINGTON DISEASE GENE - RELEVANCE FOR OTHER ADULT-ONSET DISORDERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKED DNA MARKERS; RISK; DIAGNOSIS	Objective.-To assess attitudes toward, and projected utilization of, direct mutation testing by individuals at risk for Huntington disease (HD). Design.-Prior to the cloning of the gene for HD, a questionnaire concerning the use of a definitive test was constructed and mailed to 354 participants in the Canadian Collaborative Study for HD. Completed questionnaires were received from 250 participants (response rate, 71%). Persons were asked to indicate whether they would participate in a new predictive test that was either 100% accurate (the definitive test, requiring blood only from the proband) or only 99% accurate. Results.-Most (72%) of the persons who had previously received a result in a predictive testing program said they would request testing in either situation. Significantly more persons would request the definitive test than the 99% accurate test (72% vs 58%; P<.02). Respondents for whom testing was uninformative in the linkage test program or who had previously received an increased-risk result were more likely to indicate they would use the test than those who received a decreased-risk result or chose not to have the original test (P=.0003). Less than half (46%) of the participants who initially chose not to have the linkage test said they would return for the new direct test. The major factor that has limited acceptance of predictive testing for this group is the concern about receiving an increased-risk result in the absence of any therapy to alter progression of the disease. Conclusions.-A direct mutation test for HD will most readily be accepted by persons who wanted but could not previously receive a result in the linkage test program and those who previously received an increased-risk result. In the absence of therapy, the majority of persons who previously chose not to have predictive testing are unlikely to participate in a new test despite improved accuracy. This has implications for the expected demands for testing services for other adult-onset genetic disorders.	UNIV BRITISH COLUMBIA, DEPT MED GENET, 416-2125 E MALL, VANCOUVER V6T 1Z4, BC, CANADA; MCGILL UNIV CLIN, ROYAL VICTORIA HOSP, MONTREAL H3A 2B4, QUEBEC, CANADA	University of British Columbia; McGill University; Royal Victoria Hospital			Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; Adam, Shelin/0000-0002-4401-6157				ADAM S, 1993, J MED GENET, V30, P549, DOI 10.1136/jmg.30.7.549; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; BLOCH M, 1992, AM J MED GENET, V42, P499, DOI 10.1002/ajmg.1320420416; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; BREUNING MH, 1987, LANCET, V2, P1359; CRAUFURD D, 1989, LANCET, V2, P603; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; FLEISS JL, 1981, STAT METHODS RATES P, P119; FOX S, 1989, AM J MED GENET, V32, P211, DOI 10.1002/ajmg.1320320214; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARPER PS, IN PRESS J MED GENET; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; HUGGINS M, 1992, AM J MED GENET, V42, P508, DOI 10.1002/ajmg.1320420417; KAHNEMAN D, 1982, SCI AM, V246, P160, DOI 10.1038/scientificamerican0182-160; KESSLER S, 1987, AM J MED GENET, V26, P259, DOI 10.1002/ajmg.1320260204; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARKEL DS, 1987, AM J MED GENET, V26, P295, DOI 10.1002/ajmg.1320260207; MASTROMAURO C, 1987, AM J MED GENET, V26, P271, DOI 10.1002/ajmg.1320260205; MEISSEN GJ, 1987, AM J MED GENET, V26, P283, DOI 10.1002/ajmg.1320260206; QUAID KA, 1993, AM J MED GENET, V45, P41, DOI 10.1002/ajmg.1320450112; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SKRAASTAD MI, 1991, AM J MED GENET, V39, P217, DOI 10.1002/ajmg.1320390221; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; TYLER A, 1992, BRIT MED J, V304, P1593, DOI 10.1136/bmj.304.6842.1593; TYLER A, 1990, J MED GENET, V27, P488, DOI 10.1136/jmg.27.8.488; WASMUTH JJ, 1988, NATURE, V332, P734, DOI 10.1038/332734a0; WENT L, 1990, J MED GENET, V27, P34, DOI 10.1136/jmg.27.1.34; WEXLER NS, 1992, FASEB J, V6, P2820, DOI 10.1096/fasebj.6.10.1386047; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001	32	61	61	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2321	2325		10.1001/jama.270.19.2321	http://dx.doi.org/10.1001/jama.270.19.2321			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230594				2022-12-01	WOS:A1993MF99300026
J	BREO, DL				BREO, DL			HUNTING DINO DNA - SCHWEITZER,MARY PUTS T-REX BONES UNDER THE MICROSCOPE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2376	2377		10.1001/jama.270.19.2376	http://dx.doi.org/10.1001/jama.270.19.2376			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230604				2022-12-01	WOS:A1993MF99300036
J	ENGELHARDT, H; SCHUSTER, SC; BAEUERLEIN, E				ENGELHARDT, H; SCHUSTER, SC; BAEUERLEIN, E			AN ARCHIMEDEAN SPIRAL - THE BASAL DISK OF THE WOLINELLA FLAGELLAR MOTOR	SCIENCE			English	Article							CELL-ENVELOPE ASSOCIATIONS; SUCCINOGENES; APPARATUS; COMPLEXES	The motor that powers the rotation of the bacterial flagellum reaches through both membranes into the cytoplasm of Gram-negative bacteria. The flagellum is connected by a flexible link (hook) to the motor axis, which passes through the center of a structure called the basal disk. The basal disk functions with the L-P ring complex as a bushing, enabling the rotation of the motor in the cell wall. The protein subunits of the basal disk of Wolinella succinogenes form an Archimedian spiral. The polymerization of subunits from a nucleation point at the motor in the form of a spiral allows constant growth of the basal disk. The disk is thought to provide a reinforcement at the flagellar insertion at the cell pole and to disperse forces that are generated by the momentum of the flagellar rotation.	MAX PLANCK INST BIOCHEM,DEPT MEMBRANE BIOCHEM,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST BIOCHEM,DEPT STRUCT BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society; Max Planck Society								AKIBA T, 1991, SCIENCE, V252, P1544, DOI 10.1126/science.2047860; BERG HC, 1973, NATURE, V245, P380, DOI 10.1038/245380a0; BRACEWELL RN, 1990, J OPT SOC AM A, V7, P21, DOI 10.1364/JOSAA.7.000021; CIRAGGS S, 1965, EXP CELL RES, V40, P658; COULTON JW, 1978, J BACTERIOL, V136, P1037, DOI 10.1128/JB.136.3.1037-1049.1978; DEPAMPHILIS ML, 1971, J BACTERIOL, V105, P110; ENGELHARDT H, UNPUB; FERRIS FG, 1984, CAN J MICROBIOL, V30, P322, DOI 10.1139/m84-048; GIBSON J, 1988, ELECTRON MICROSC REV, V1, P39; Grell K.G., 1973, PROTOZOOLOGY; JONES CJ, 1991, ADV MICROB PHYSL, V32, P110; JONES DM, 1985, J GEN MICROBIOL, V131, P2335; KUPPER J, 1989, J BACTERIOL, V171, P2803, DOI 10.1128/jb.171.5.2803-2810.1989; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; MOROOKA T, 1983, MICROBIOL IMMUNOL, V27, P655, DOI 10.1111/j.1348-0421.1983.tb00628.x; PATEL GB, 1986, CAN J MICROBIOL, V32, P623, DOI 10.1139/m86-117; SCHUSTER SC, 1992, J BACTERIOL, V174, P263, DOI 10.1128/jb.174.1.263-268.1992; SCHUSTER SC, UNPUB; THOMASHOW LS, 1985, J BACTERIOL, V163, P1038, DOI 10.1128/JB.163.3.1038-1046.1985; TICHENOR D, 1973, J OPT SOC AM, V63, P1620, DOI 10.1364/JOSA.63.001620; WOLIN MJ, 1961, J BACTERIOL, V81, P911, DOI 10.1128/JB.81.6.911-917.1961	21	15	15	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1046	1048		10.1126/science.8235620	http://dx.doi.org/10.1126/science.8235620			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235620				2022-12-01	WOS:A1993MG18700032
J	HOWARD, M; GRIMALDI, JC; BAZAN, JF; LUND, FE; SANTOSARGUMEDO, L; PARKHOUSE, RME; WALSETH, TF; LEE, HC				HOWARD, M; GRIMALDI, JC; BAZAN, JF; LUND, FE; SANTOSARGUMEDO, L; PARKHOUSE, RME; WALSETH, TF; LEE, HC			FORMATION AND HYDROLYSIS OF CYCLIC ADP RIBOSE CATALYZED BY LYMPHOCYTE ANTIGEN-CD38	SCIENCE			English	Article							CD38; DIFFERENTIATION; METABOLITE; MOLECULE; CYCLASE; RELEASE; ENZYME; NAD+	CD38 is a 42-kilodalton glycoprotein expressed extensively on B and T lymphocytes. CD38 exhibits a structural homology to Aplysia adenosine diphosphate (ADP)-ribosyl cyclase. This enzyme catalyzes the synthesis of cyclic ADP-ribose (cADPR), a metabolite of nicotinamide adenine dinucleotide (NAD+) with calcium-mobilizing activity. A complementary DNA encoding the extracellular domain of murine CD38 was constructed and expressed, and the resultant recombinant soluble CD38 was purified to homogeneity. Soluble CD38 catalyzed the formation and hydrolysis of cADPR when added to NAD+. Purified cADPR augmented the proliferative response of activated murine B cells, potentially implicating the enzymatic activity of CD38 in lymphocyte function.	INST ANIM HLTH,SURREY GU24 0NF,ENGLAND; UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	HOWARD, M (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC,901 CALIFORNIA AVE,PALO ALTO,CA 94304, USA.		Lee, Hon Cheung/C-4329-2009; Bazan, J. Fernando/B-4562-2010; Walseth, Timothy F/F-9518-2010	Walseth, Timothy F/0000-0003-2558-7859; Parkhouse, Michael/0000-0001-5967-3291; Santos-Argumedo, Leopoldo/0000-0002-4772-0713	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA005695] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484] Funding Source: Medline; NIDA NIH HHS [DA05695] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BENHAM CD, 1992, NATURE, V359, P103, DOI 10.1038/359103a0; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GLICK DL, 1991, CELL REGUL, V2, P212; HARADA N, 1993, J IMMUNOL, V151, P3111; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HOWARD M, UNPUB; JACKSON DG, 1990, J IMMUNOL, V144, P2811; JOHNSON RL, 1992, J BIOL CHEM, V267, P4600; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1993, J BIOL CHEM, V268, P293; MALAVASI F, 1992, INT J CLIN LAB RES, V22, P73, DOI 10.1007/BF02591400; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; SANTOSARGUMEDO L, 1993, J IMMUNOL, V151, P3119; SERVENTI IM, 1992, CURR TOP MICROBIOL, V175, P43; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; STRYER L, 1988, BIOCHEMISTRY-US, P191; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; YAMADA H, 1993, J EXP MED, V177, P1614	28	679	710	3	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1056	1059		10.1126/science.8235624	http://dx.doi.org/10.1126/science.8235624			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235624				2022-12-01	WOS:A1993MG18700036
J	GREBER, UF; WILLETTS, M; WEBSTER, P; HELENIUS, A				GREBER, UF; WILLETTS, M; WEBSTER, P; HELENIUS, A			STEPWISE DISMANTLING OF ADENOVIRUS-2 DURING ENTRY INTO CELLS	CELL			English	Article							SEMLIKI FOREST VIRUS; INCOMING INFLUENZA-VIRUS; EPIDERMAL GROWTH-FACTOR; HELA-CELLS; STRUCTURAL PROTEINS; ELECTRON-MICROSCOPY; POLYPEPTIDE-IX; EARLY EVENTS; TYPE-2; INVIVO	Adenoviruses enter their host cells by receptor-mediated endocytosis and acid-activated penetration from endosomes into the cytosol and deliver their DNA genome into the nucleus. Our results show that incoming adenovirus type 2 particles undergo a stepwise disassembly program necessary to allow progress of the virus in the entry pathway and release of the genome into the nucleus. The fibers are released, the penton base structures dissociated, the proteins connecting the DNA to the inside surface of the capsid degraded or shed, and the capsid-stabilizing minor proteins eliminated. The uncoating process starts immediately upon endocytic uptake with the loss of fibers and ends with the uptake of dissociated hexon proteins and DNA into the nucleus.			GREBER, UF (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.		Greber, Urs F/G-9458-2015	Greber, Urs F/0000-0003-2278-120X; Webster, Paul/0000-0002-1980-6931	NIAID NIH HHS [AI 18599] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018599, R37AI018599] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKUSJARVI G, 1981, J VIROL, V38, P469; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BAUM SG, 1972, J VIROL, V10, P211, DOI 10.1128/JVI.10.2.211-219.1972; BLUMENTHAL R, 1986, BIOCHEMISTRY-US, V25, P2231, DOI 10.1021/bi00356a057; BOUDIN ML, 1980, VIROLOGY, V101, P144, DOI 10.1016/0042-6822(80)90491-2; BOUDIN ML, 1979, VIROLOGY, V92, P125, DOI 10.1016/0042-6822(79)90219-8; BURNETT RM, 1985, J MOL BIOL, V185, P125, DOI 10.1016/0022-2836(85)90187-1; CHARDONN.Y, 1970, VIROLOGY, V40, P462, DOI 10.1016/0042-6822(70)90189-3; CHARDONNET Y, 1972, VIROLOGY, V48, P342, DOI 10.1016/0042-6822(72)90045-1; COLBY WW, 1981, J VIROL, V39, P977, DOI 10.1128/JVI.39.3.977-980.1981; COTTEN M, 1993, J VIROL, V67, P3777, DOI 10.1128/JVI.67.7.3777-3785.1993; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; DEVAUX C, 1987, VIROLOGY, V161, P121, DOI 10.1016/0042-6822(87)90177-2; DEVAUX C, 1990, J MOL BIOL, V215, P567, DOI 10.1016/S0022-2836(05)80169-X; EVERITT E, 1975, VIROLOGY, V67, P197, DOI 10.1016/0042-6822(75)90417-1; EVERITT E, 1973, VIROLOGY, V52, P130, DOI 10.1016/0042-6822(73)90404-2; FITZGERALD DJP, 1983, CELL, V32, P607, DOI 10.1016/0092-8674(83)90480-4; FURCINITTI PS, 1989, EMBO J, V8, P3563, DOI 10.1002/j.1460-2075.1989.tb08528.x; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GRABLE M, 1992, J VIROL, V66, P723; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; GRUNHAUS A, 1992, SEMIN VIROL, V3, P237; GRUTTER M, 1974, J MOL BIOL, V89, P163, DOI 10.1016/0022-2836(74)90168-5; HARLOW E, 1988, ANTIBODIES LABORATOR; HELENIUS A, 1982, J GEN VIROL, V58, P47, DOI 10.1099/0022-1317-58-1-47; HELENIUS A, 1992, CELL, V69, P577, DOI 10.1016/0092-8674(92)90219-3; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; JORNVALL H, 1980, EUR J BIOCHEM, V104, P237, DOI 10.1111/j.1432-1033.1980.tb04421.x; KIELIAN M, 1990, MOL BIOL MED, V7, P17; KIELIAN M, 1986, J CELL BIOL, V98, P139; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVER WG, 1969, VIROLOGY, V39, P599, DOI 10.1016/0042-6822(69)90111-1; LAWRENCE WILLIAM C., 1967, J VIROL, V1, P851; LYON M, 1978, VIROLOGY, V87, P81, DOI 10.1016/0042-6822(78)90160-5; MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; MANGEL WF, 1993, NATURE, V361, P274, DOI 10.1038/361274a0; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MELLMAN I, 1992, J EXP BIOL, V172, P39; MILES BD, 1980, VIROLOGY, V105, P265, DOI 10.1016/0042-6822(80)90177-4; MORGAN C, 1969, J VIROL, V4, P777, DOI 10.1128/JVI.4.5.777-796.1969; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; Nevins J R, 1980, Methods Enzymol, V65, P768; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PASTAN I, 1986, CONCEPTS VIRAL PATHO, V2, P141; PAUZA CD, 1991, ADV EXP MED BIOL, V300, P111; PETTERSSON U, 1971, VIROLOGY, V43, P123, DOI 10.1016/0042-6822(71)90230-3; PHILIPSON L, 1983, CURR TOP MICROBIOL, V109, P1; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; PRAGE L, 1970, VIROLOGY, V42, P341, DOI 10.1016/0042-6822(70)90278-3; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; RIGAUT KD, 1991, J VIROL, V65, P2622, DOI 10.1128/JVI.65.5.2622-2628.1991; ROBERTS MM, 1986, SCIENCE, V232, P1148, DOI 10.1126/science.3704642; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; SETH P, 1984, J VIROL, V51, P650, DOI 10.1128/JVI.51.3.650-655.1984; SINGH I, 1992, J VIROL, V66, P7049, DOI 10.1128/JVI.66.12.7049-7058.1992; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; STEWART PL, 1993, EMBO J, V12, P2589, DOI 10.1002/j.1460-2075.1993.tb05919.x; SUSSENBACH JS, 1967, VIROLOGY, V33, P567, DOI 10.1016/0042-6822(67)90056-6; SVENSSON U, 1985, J VIROL, V55, P442, DOI 10.1128/JVI.55.2.442-449.1985; TIHANYI K, 1993, J BIOL CHEM, V268, P1780; VALENTINE RC, 1965, J MOL BIOL, V13, P13, DOI 10.1016/S0022-2836(65)80076-6; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; VARGA MJ, 1991, J VIROL, V65, P6061, DOI 10.1128/JVI.65.11.6061-6070.1991; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WILLIAMS JF, 1970, J GEN VIROL, V9, P251, DOI 10.1099/0022-1317-9-3-251; WITTELS M, 1991, VIRUS RES, V18, P271, DOI 10.1016/0168-1702(91)90024-P; [No title captured]	74	668	688	2	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 5	1993	75	3					477	486		10.1016/0092-8674(93)90382-Z	http://dx.doi.org/10.1016/0092-8674(93)90382-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8221887	Green Accepted			2022-12-01	WOS:A1993MF83000010
J	NISWANDER, L; TICKLE, C; VOGEL, A; BOOTH, I; MARTIN, GR				NISWANDER, L; TICKLE, C; VOGEL, A; BOOTH, I; MARTIN, GR			FGF-4 REPLACES THE APICAL ECTODERMAL RIDGE AND DIRECTS OUTGROWTH AND PATTERNING OF THE LIMB	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; CHICK WING BUD; RETINOIC ACID; QUANTITATIVE-ANALYSIS; POLARIZING ACTIVITY; LOCAL APPLICATION; MOUSE EMBRYO; EXPRESSION; CELLS; ZPA	The apical ectodermal ridge plays a key role in limb development. We show that recombinant FGF-4 can substitute for the ridge to provide all the signals necessary for virtually complete outgrowth and patterning of the chick limb. FGF-4 stimulates proliferation of cells in the distal mesenchyme and maintains a signal from the posterior to the distal mesenchyme that appears to be required for elaboration of skeletal elements in the normal proximodistal sequence. Moreover, retinoic acid, which is capable of providing polarizing activity, can supply this signal. This suggests that polarizing activity plays a role in patterning along the proximodistal axis, in addition to its well-established role in anteroposterior patterning. Taken together, the data suggest a simple mechanism whereby FGF-4 links growth and pattern formation during limb development.	UNIV CALIF SAN FRANCISCO, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA; UNIV COLL & MIDDLESEX SCH MED, DEPT ANAT & DEV BIOL, LONDON W1P 6DB, ENGLAND	University of California System; University of California San Francisco; University of London; University College London	NISWANDER, L (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT ANAT, SAN FRANCISCO, CA 94143 USA.		Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD025331, R01HD025331] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 43821] Funding Source: Medline; NICHD NIH HHS [HD-25331] Funding Source: Medline; Wellcome Trust Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R, 1993, DEVELOPMENT, V117, P1421; AONO H, 1988, DEV BIOL, V128, P136, DOI 10.1016/0012-1606(88)90275-8; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; GLOBUS M, 1976, DIFFERENTIATION, V6, P91, DOI 10.1111/j.1432-0436.1976.tb01474.x; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAN JK, 1993, DEV BIOL, V158, P549, DOI 10.1006/dbio.1993.1212; HAUB O, 1991, DEVELOPMENT, V112, P397; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; HINCHLIFFE JR, 1981, J EMBRYOL EXP MORPH, V62, P63; JOSEPHSILVERSTEIN J, 1989, J CELL BIOL, V108, P2459, DOI 10.1083/jcb.108.6.2459; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LYONS KM, 1990, DEVELOPMENT, V109, P833; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MACCABE JA, 1991, J EXP ZOOL, V257, P208, DOI 10.1002/jez.1402570209; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PETERS KG, 1992, DEVELOPMENT, V114, P233; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REITER RS, 1982, DEV BIOL, V93, P28, DOI 10.1016/0012-1606(82)90235-4; RILEY BB, 1993, DEVELOPMENT, V118, P95; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAVAGE MP, 1993, IN PRESS DEV DYN; SOLURSH M, 1984, CELL DIFFER DEV, V15, P17, DOI 10.1016/0045-6039(84)90025-3; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TODT WL, 1987, DEVELOPMENT, V101, P501; VOGEL A, 1993, DEVELOPMENT, V119, P199; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILSON DJ, 1987, DEVELOPMENT, V99, P99	40	573	584	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 5	1993	75	3					579	587		10.1016/0092-8674(93)90391-3	http://dx.doi.org/10.1016/0092-8674(93)90391-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8221896				2022-12-01	WOS:A1993MF83000019
J	MIMMS, LT; MOSLEY, JW; HOLLINGER, FB; AACH, RD; STEVENS, CE; CUNNINGHAM, M; VALLARI, DV; BARBOSA, LH; NEMO, GJ				MIMMS, LT; MOSLEY, JW; HOLLINGER, FB; AACH, RD; STEVENS, CE; CUNNINGHAM, M; VALLARI, DV; BARBOSA, LH; NEMO, GJ			EFFECT OF CONCURRENT ACUTE INFECTION WITH HEPATITIS-C VIRUS ON ACUTE HEPATITIS-B VIRUS-INFECTION	BRITISH MEDICAL JOURNAL			English	Article							TRANSFUSION-TRANSMITTED VIRUSES; NON-A-HEPATITIS; POSTTRANSFUSION HEPATITIS; RECIPIENTS; TRANSMISSION; ANTIBODY; DONORS; BLOOD; RISK	Objective-To investigate the possible interference with acute hepatitis B virus infection by coinfection with hepatitis C virus. Design-Analysis of stored sera collected for transfusion transmitted viruses study in 1970s. Setting-Four major medical centres in the United States. Patients-12 recipients of blood infected with hepatitis B virus. Main outcome measures-In 1970s, presence of antibodies in hepatitis B virus and raised serum alanine aminotransferase concentration; detection of antibodies to hepatitis C virus with new enzyme linked immunoassays. Results-Five of the 12 patients were coinfected with hepatitis C virus. Hepatitis B surface antigen was first detected at day 59 in patients infected with hepatitis B virus alone and at day 97 in those coinfected with hepatitis C virus (p=0.01); median durations of antigenaemia were 83 and 21 days respectively (p=0.05), and the antigen concentration was lower in the coinfected patients. Alanine aminotransferase patterns were uniphasic when hepatitis B virus infection occurred alone (range 479-2465 IU/l) and biphasic in patients with combined acute infection (no value >380 IU/l; p=0.0025). Four coinfected recipients developed chronic hepatitis C virus infection. The fifth patient was followed for only four months. Conclusions-Acute coinfection with hepatitis C virus and hepatitis B virus inhibits hepatitis B virus infection in humans, and onset of hepatitis B may reduce the severity of hepatitis C virus infection but not frequency of chronicity. Alanine aminotransferase concentration showed a biphasic pattern in dual infection.	UNIV SO CALIF,DEPT MED,LOS ANGELES,CA 90032; ABBOTT LABS,ABBOTT PK,IL; BAYLOR COLL MED,HOUSTON,TX 77030; MT SINAI MED CTR,CLEVELAND,OH 44106; NEW YORK BLOOD CTR,NEW YORK,NY 10021; NHLBI,TRANSFUS MED BRANCH,BETHESDA,MD 20892	University of Southern California; Abbott Laboratories; Baylor College of Medicine; New York Blood Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Hollinger, F Blaine/AAY-3323-2021		NHLBI NIH HHS [N01-HB-42972] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; BAGINSKI I, 1992, TRANSFUSION, V32, P215, DOI 10.1046/j.1537-2995.1992.32392213803.x; BAKH J, 1991, P NATL ACAD SCI USA, V89, P187; BROTMAN B, 1983, J MED VIROL, V11, P191, DOI 10.1002/jmv.1890110303; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P224; EBLE K, 1991, J MED VIROL, V33, P139, DOI 10.1002/jmv.1890330302; GILLES PN, 1992, J VIROL, V66, P3955, DOI 10.1128/JVI.66.6.3955-3960.1992; HOLLINGER FB, 1984, J INFECT DIS, V150, P250, DOI 10.1093/infdis/150.2.250; MIMMS L, 1990, LANCET, V336, P1590, DOI 10.1016/0140-6736(90)93377-2; MOSLEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77, DOI 10.1001/jama.263.1.77; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; TATEDA A, 1979, J INFECT DIS, V139, P511, DOI 10.1093/infdis/139.5.511; TSIQUAYE KN, 1983, J MED VIROL, V11, P179, DOI 10.1002/jmv.1890110302; VALLARI DS, 1992, J CLIN MICROBIOL, V30, P552, DOI 10.1128/JCM.30.3.552-556.1992	15	99	100	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1095	1097		10.1136/bmj.307.6912.1095	http://dx.doi.org/10.1136/bmj.307.6912.1095			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8251805	Bronze, Green Published			2022-12-01	WOS:A1993ME91800013
J	GRINDLEY, NDF				GRINDLEY, NDF			ANALYSIS OF A NUCLEOPROTEIN COMPLEX - THE SYNAPTOSOME OF GAMMA-DELTA RESOLVASE	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; MUTANTS; DOMAIN; TN3; RES	The gammadelta resolvase protein is one of a large family of transposon-encoded site-specific recombinases. It performs recombination in a DNA-protein complex that contains 12 resolvase protomers and two copies of the 120-base pair DNA substrate, res (each with three binding sites for a resolvase dimer). A derivative of resolvase with altered DNA binding specificity was used to show that the role of resolvase at site I, which contains the crossover point, differs from its role at the other two binding sites. The resolvase dimers that initially bind to site I are the only ones that require the residue Ser10, essential for catalysis of DNA breakage. In addition, these site I-bound dimers do not use a specific interaction between dimers that is required elsewhere in the complex for synapsis of the res sites.			GRINDLEY, NDF (corresponding author), YALE UNIV,BASS CTR MOLEC & STRUCT BIOL,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511, USA.							CRAIG NL, 1989, MOBILE DNA, P211; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ELLEDGE SJ, 1989, GENE DEV, V3, P185, DOI 10.1101/gad.3.2.185; GRINDLEY NDF, 1982, CELL, V30, P19, DOI 10.1016/0092-8674(82)90007-1; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HATFULL GF, 1986, P NATL ACAD SCI USA, V83, P5429, DOI 10.1073/pnas.83.15.5429; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HUGHES RE, 1993, EMBO J, V12, P1447, DOI 10.1002/j.1460-2075.1993.tb05788.x; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; HUGHES RK, UNPUB; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KLIPPEL A, 1988, EMBO J, V7, P3983, DOI 10.1002/j.1460-2075.1988.tb03286.x; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; MAZZARELLI JM, 1993, BIOCHEMISTRY-US, V32, P2979, DOI 10.1021/bi00063a008; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; RICE PR, UNPUB; RIMPHANITCHAYAKIT V, 1990, EMBO J, V9, P719, DOI 10.1002/j.1460-2075.1990.tb08165.x; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; STARK WM, 1989, TRENDS GENET, V5, P304, DOI 10.1016/0168-9525(89)90113-3; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045	22	36	36	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					738	740		10.1126/science.8235593	http://dx.doi.org/10.1126/science.8235593			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235593				2022-12-01	WOS:A1993MD95200041
J	TSAO, YH; EVANS, DF; WENNERSTROM, H				TSAO, YH; EVANS, DF; WENNERSTROM, H			LONG-RANGE ATTRACTIVE FORCE BETWEEN HYDROPHOBIC SURFACES OBSERVED BY ATOMIC-FORCE MICROSCOPY	SCIENCE			English	Article							SILICON-NITRIDE POWDERS	There is evidence from atomic force microscopy for a long-range attractive force between hydrophobic surfaces that is virtually identical to that observed with the surface forces apparatus. This force is present in the nonaqueous solvent ethylene glycol. A possible molecular mechanism involves in-plane polarized domains of solid-like monolayers adsorbed on mica, and a theoretical model has been developed that accounts for many of the observations.	LUND UNIV,CTR CHEM,DIV PHYS CHEM,S-22100 LUND,SWEDEN	Lund University	TSAO, YH (corresponding author), UNIV MINNESOTA,DEPT CHEM ENGN & MAT SCI,MINNEAPOLIS,MN 55455, USA.				NIGMS NIH HHS [GM34341] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034341] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARD P, 1989, J PHYS CHEM-US, V93, P6441, DOI 10.1021/j100354a032; BENNIG G, 1988, PHYS REV LETT, V56, P930; BERGSTROM L, 1990, COLLOID SURFACE, V49, P183, DOI 10.1016/0166-6622(90)80101-9; BERGSTROM L, 1989, J AM CERAM SOC, V72, P103, DOI 10.1111/j.1151-2916.1989.tb05961.x; BURNHAM NA, 1992, SCANNING TUNNELING M, pCH2; CHRISTENSON HK, 1990, J PHYS CHEM-US, V94, P8004, DOI 10.1021/j100384a002; Derjaguin B, 1934, KOLLOID Z, V69, P155, DOI 10.1007/BF01433225; ISRAELACHVILI J, 1982, NATURE, V300, P341, DOI 10.1038/300341a0; KURIHARA K, 1990, CHEM LETT, V9, P1553; LEE GU, 1992, THESIS U MINNESOTA; MCCONNELL HM, 1984, P NATL ACAD SCI USA, V81, P3249, DOI 10.1073/pnas.81.10.3249; MOHWALD H, 1990, ANNU REV PHYS CHEM, V41, P411; OKAHATA Y, 1981, BER BUNSEN PHYS CHEM, V85, P789, DOI 10.1002/bbpc.19810850811; PARKER JL, 1992, LANGMUIR, V8, P757, DOI 10.1021/la00039a003; PASHLEY RM, 1985, SCIENCE, V229, P1088, DOI 10.1126/science.4035349; PODGORNIK R, 1989, J CHEM PHYS, V91, P5840, DOI 10.1063/1.457535; SCALES PJ, 1992, THIN SOLID FILMS, V215, P223, DOI 10.1016/0040-6090(92)90442-E; TSAO YH, 1993, LANGMUIR, V9, P779, DOI 10.1021/la00027a029; TSAO YH, 1991, LANGMUIR, V7, P3154, DOI 10.1021/la00060a039	19	206	214	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 22	1993	262	5133					547	550		10.1126/science.8211182	http://dx.doi.org/10.1126/science.8211182			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC935	8211182				2022-12-01	WOS:A1993MC93500033
J	LAMBRIGHT, DG; NOEL, JP; HAMM, HE; SIGLER, PB				LAMBRIGHT, DG; NOEL, JP; HAMM, HE; SIGLER, PB			STRUCTURAL DETERMINANTS FOR ACTIVATION OF THE ALPHA-SUBUNIT OF A HETEROTRIMERIC G-PROTEIN	NATURE			English	Article							AMINO-ACID-SEQUENCE; ROD OUTER SEGMENTS; ELONGATION-FACTOR-TU; GTP-BINDING PROTEIN; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; GUANINE-NUCLEOTIDES; ESCHERICHIA-COLI	The 1.8 Angstrom crystal structure of transducin alpha-GDP, when compared to that of the activated complex with GTP-gamma S, reveals the nature of the conformational changes that occur on activation of a heterotrimeric G-protein alpha-subunit. Structural changes initiated by direct contacts with the terminal phosphate of GTP propagate to regions that have been implicated in effector activation. The changes are distinct from those observed in other members of the GTPase superfamily.	YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	Yale University; Howard Hughes Medical Institute; Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Noel, Joseph P/A-9459-2009; Hamm, Heidi E/G-2374-2014					BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1993, X PLOR VERSION 3 1 M; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CLARK KL, 1993, MOL CELL BIOL, V13, P1; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FUNG BKK, 1983, J BIOL CHEM, V258, P503; HARGRAVE PA, 1994, MOL PHARM CELL REGUL, V3, P25; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; JOHN J, 1988, J BIOL CHEM, V263, P11792; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; LAURSEN RA, 1981, J BIOL CHEM, V256, P8102; LEE E, 1992, J BIOL CHEM, V267, P1212; MAZZONI MR, 1993, J PROTEIN CHEM, V12, P215, DOI 10.1007/BF01026043; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; NAKAFUKU M, 1987, P NATL ACAD SCI USA, V84, P2140, DOI 10.1073/pnas.84.8.2140; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NUKADA T, 1986, FEBS LETT, V197, P305, DOI 10.1016/0014-5793(86)80347-7; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PFISTER C, 1993, CELL SIGNAL, V5, P235, DOI 10.1016/0898-6568(93)90015-E; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; ROBISHAW JD, 1986, P NATL ACAD SCI USA, V83, P1251, DOI 10.1073/pnas.83.5.1251; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRYER L, 1983, METHOD ENZYMOL, V96, P617; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; WHITEWAY M, IN PRESS MOL CELL BI; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316	44	520	536	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 23	1994	369	6482					621	628		10.1038/369621a0	http://dx.doi.org/10.1038/369621a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	8208289				2022-12-01	WOS:A1994NT45900047
J	SPOOR, F; WOOD, B; ZONNEVELD, F				SPOOR, F; WOOD, B; ZONNEVELD, F			IMPLICATIONS OF EARLY HOMINID LABYRINTHINE MORPHOLOGY FOR EVOLUTION OF HUMAN BIPEDAL LOCOMOTION	NATURE			English	Article							SEMICIRCULAR CANALS; ENDOLYMPH FLOW; AFARENSIS; NEURONS; MODEL; EAST	The upright posture and obligatory bipedalism of modern humans are unique among living primates, The evolutionary history of this behaviour has traditionally been pursued by functional analysis of the postcranial skeleton and the preserved footprint trails of fossil hominids. Here H e report a systematic attempt to reconstruct the locomotor behaviour of early hominids by looking at a major component of the mechanism for the unconscious perception of movement, namely by examining the vestibular system of living primates and early hominids. High-resolution computed tomography was used to generate cross-sectional images of the bony labyrinth. Among the fossil hominids the earliest species to demonstrate the modern human morphology is Home erectus. In contrast, the semicircular canal dimensions in crania from southern Africa attributed to Australopithecus and Paranthropus resemble those of the extant great apes. Among early Home specimens, the canal dimensions of Stw 53 are unlike those seen in any of the hominids or great apes, whereas those of SK 847 are modern-human-like.	UNIV LIVERPOOL,DEPT HUMAN ANAT & CELL BIOL,HOMINID PALAEONTOL RES GRP,LIVERPOOL L69 3BX,ENGLAND; UNIV UTRECHT HOSP,DEPT RADIOL,UTRECHT,NETHERLANDS	University of Liverpool; Utrecht University; Utrecht University Medical Center			Spoor, Fred/C-1718-2008					Berg W, 1903, Z MORPHOL ANTHROPOL, V5, P315; BLANKS RHI, 1985, BRAIN RES, V340, P315, DOI 10.1016/0006-8993(85)90928-X; BLANKS RHI, 1975, J NEUROPHYSIOL, V38, P1250, DOI 10.1152/jn.1975.38.5.1250; Clarke R.J., 1985, P171; CURTHOYS IS, 1977, J MORPHOL, V151, P1, DOI 10.1002/jmor.1051510102; DEAN MC, 1982, AM J PHYS ANTHROPOL, V59, P157, DOI 10.1002/ajpa.1330590206; Fleagle JG, 1988, PRIMATE ADAPTATION E; GOLDBERG JM, 1971, J NEUROPHYSIOL, V34, P635, DOI 10.1152/jn.1971.34.4.635; Gray A.A., 1907, LABYRINTH ANIMALS; GRINE FE, 1993, AM J PHYS ANTHROPOL, V92, P411, DOI 10.1002/ajpa.1330920402; HADZISELIMOVIC H, 1964, ACTA ANAT, V57, P306; HARTWIGSCHERER S, 1991, J HUM EVOL, V21, P439, DOI 10.1016/0047-2484(91)90094-C; HUNT KD, 1994, J HUM EVOL, V26, P183, DOI 10.1006/jhev.1994.1011; JOHANSON DC, 1987, NATURE, V327, P205, DOI 10.1038/327205a0; Kimbel William H., 1993, P461; LATIMER B, 1989, AM J PHYS ANTHROPOL, V78, P369, DOI 10.1002/ajpa.1330780306; MATONO S, 1986, CURRENT PERPSECTIVES, P122; MCHENRY HM, 1992, AM J PHYS ANTHROPOL, V87, P407, DOI 10.1002/ajpa.1330870404; MCHENRY HM, 1986, J HUM EVOL, V15, P177, DOI 10.1016/S0047-2484(86)80044-6; MULLER M, 1994, J THEOR BIOL, V167, P239, DOI 10.1006/jtbi.1994.1066; MULLER M, 1988, J THEOR BIOL, V134, P473, DOI 10.1016/S0022-5193(88)80053-5; OMAN CM, 1987, ACTA OTO-LARYNGOL, V103, P1, DOI 10.3109/00016488709134691; RAMPRASHAD F, 1984, AM J ANAT, V169, P295, DOI 10.1002/aja.1001690306; Robinson J.T., 1972, EARLY HOMINID POSTUR; ROSE MD, 1984, AM J PHYS ANTHROPOL, V63, P371, DOI 10.1002/ajpa.1330630404; SPOOR CF, 1994, COUR FORSCH SENCKENB, V171, P251; SPOOR CF, 1993, THESIS URECHT U; SUSMAN RL, 1984, FOLIA PRIMATOL, V43, P113, DOI 10.1159/000156176; SUSMAN RL, 1989, AM J PHYS ANTHROPOL, V79, P451, DOI 10.1002/ajpa.1330790403; TENKATE JH, 1970, J EXP BIOL, V53, P501; TURKEWITSCH B. G., 1934, ZEITSCHR ANAT U ENTWICKLUNGSGESCH, V103, P551, DOI 10.1007/BF02118934; Tuttle R.H., 1987, P503; VRBA ES, 1979, AM J PHYS ANTHROPOL, V51, P117, DOI 10.1002/ajpa.1330510114; Walker A., 1981, HOMO ERECTUS PAPERS, P193; Walker Alan, 1993, P411; WOOD B, 1993, NATURE, V363, P587, DOI 10.1038/363587a0; Zonneveld F.W., 1985, P427	37	202	214	0	88	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 23	1994	369	6482					645	648		10.1038/369645a0	http://dx.doi.org/10.1038/369645a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	8208290				2022-12-01	WOS:A1994NT45900054
J	ACHKAR, AA; LIE, JT; HUNDER, GG; OFALLON, WM; GABRIEL, SE				ACHKAR, AA; LIE, JT; HUNDER, GG; OFALLON, WM; GABRIEL, SE			HOW DOES PREVIOUS CORTICOSTEROID TREATMENT AFFECT THE BIOPSY FINDINGS IN GIANT-CELL (TEMPORAL) ARTERITIS	ANNALS OF INTERNAL MEDICINE			English	Article						TEMPORAL ARTERITIS; ADRENAL CORTEX HORMONES; BIOPSY; PREDNISONE	CLASSIFICATION; CRITERIA	Objective: To determine the effect of previous corticosteroid treatment on the results of temporal artery biopsy. Design: Consecutive case series. Setting: Tertiary care center. Patients: A consecutive cohort of 535 patients who had temporal artery biopsies at Mayo Clinic, Rochester, Minnesota, between 1 January 1988 and 31 December 1991. Measurements and Results: The dose and duration of corticosteroid treatment received before temporal artery biopsy and detailed clinical and laboratory data were obtained from the patients' medical records. All temporal artery biopsy slides were re-evaluated by a pathologist blinded to clinical data, previous corticosteroid treatment information, and the original pathologic diagnosis. Biopsy specimens were classified as negative for arteritis, positive for typical temporal arteritis, or positive for atypical temporal arteritis. Biopsy results were positive for 31% of patients (89 of 286) who did not receive corticosteroids before biopsy and for 35% of those (86 of 249) who did receive corticosteroids before biopsy (P = 0.4; 95% confidence interval for the difference, -4.7% to 11.5%). Patients who received corticosteroids before biopsy tended to have clinical features more suggestive of arteritis. A multiple logistic regression analysis model, controlling for these differences in clinical and laboratory features, showed that the biopsy positivity rate was unrelated to previous corticosteroid treatment. Conclusions: Although these results do not prove that histologic features are unaffected by corticosteroids, they show that, in this large, consecutive sample, the positivity rates of temporal artery biopsy were similar in untreated and corticosteroid-treated patients. Temporal artery biopsy may show arteritis even after more than 14 days of corticosteroid therapy in the presence of clinical indications of active disease.	MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA; UC DAVIS MED CTR, DEPT PATHOL, SACRAMENTO, CA 95817 USA	Mayo Clinic; University of California System; University of California Davis								AIELLO PD, 1993, OPHTHALMOLOGY, V100, P550; ALBERT DM, 1976, ARCH OPHTHALMOL-CHIC, V94, P2072; ALLISON MC, 1984, ANN RHEUM DIS, V43, P416, DOI 10.1136/ard.43.3.416; BLOCH DA, 1990, ARTHRITIS RHEUM, V33, P1137; CHMELEWSKI WL, 1992, ARCH INTERN MED, V152, P1690, DOI 10.1001/archinte.152.8.1690; COHEN DN, 1973, T AM ACAD OPHTHALMOL, V77, P74; CULLEN J F, 1976, Survey of Ophthalmology, V20, P247, DOI 10.1016/0039-6257(76)90224-1; FAUCHALD P, 1972, ANN INTERN MED, V77, P845, DOI 10.7326/0003-4819-77-6-845; HALL S, 1983, LANCET, V2, P1217; HUNDER GG, 1990, RHEUM DIS CLIN N AM, V16, P399; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; HUNDER GG, 1975, ANN INTERN MED, V82, P613, DOI 10.7326/0003-4819-82-5-613; HUNDER GG, 1993, TXB RHEUMATOLOGY, P1103; KLEIN RG, 1976, MAYO CLIN PROC, V51, P504; LIE JT, 1990, RHEUM DIS CLIN N AM, V16, P269; LIE JT, 1994, J RHEUMATOL, V21, P186; MACHADO EBV, 1988, ARTHRITIS RHEUM, V31, P745, DOI 10.1002/art.1780310607; MCDONNELL PJ, 1986, OPHTHALMOLOGY, V93, P518; PONGE T, 1988, J RHEUMATOL, V15, P997; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P456	20	235	239	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1994	120	12					987	992		10.7326/0003-4819-120-12-199406150-00003	http://dx.doi.org/10.7326/0003-4819-120-12-199406150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ964	8185147				2022-12-01	WOS:A1994NQ96400003
J	HARADA, A; OGUCHI, K; OKABE, S; KUNO, J; TERADA, S; OHSHIMA, T; SATOYOSHITAKE, R; TAKEI, Y; NODA, T; HIROKAWA, N				HARADA, A; OGUCHI, K; OKABE, S; KUNO, J; TERADA, S; OHSHIMA, T; SATOYOSHITAKE, R; TAKEI, Y; NODA, T; HIROKAWA, N			ALTERED MICROTUBULE ORGANIZATION IN SMALL-CALIBER AXONS OF MICE LACKING TAU-PROTEIN	NATURE			English	Article							PAIRED HELICAL FILAMENTS; MOLECULAR-STRUCTURE; NERVOUS-SYSTEM; ANTISENSE OLIGONUCLEOTIDES; CEREBELLAR NEURONS; TARGETED MUTATION; QUICK-FREEZE; GENE; LOCALIZATION; MOUSE	THE tau gene encodes a protein (Tau) that is a major neuronal microtubule-associated protein localized mostly in axons(1-4). It has microtubule-binding and tubulin-polymerizing activity in vitro(3,4) and is thought to make short crossbridges between axonal microtuhules(5,6). Further, tau-transfected non-neuronal cells extend long axon-like processes in which microtubule bundles resembling those in axons are formed(6-8). In contrast, tau antisense oligonucleotides selectively suppress axonal elongation in cultured neurons(9,10). Thus tau is thought to be essential for neuronal cell morphogenesis, especially axonal elongation and maintenance. To test this hypothesis, we used gene targeting to produce mice lacking the tau gene. We show that the nervous system of tau-deficient mice appears to be normal immunohistologically. Furthermore, axonal elongation is not affected in cultured neurons. But in some small-calibre axons, microtubule stability is decreased and microtubule organization is significantly changed. We observed an increase in microtubule-associated protein 1A which may compensate for the functions of tau in large-calibre axons. Our results argue against the suggested role of tau in axonal elongation but confirm that it is crucial in the stabilization and organization of axonal microtubules in a certain type of axon.	UNIV TOKYO,SCH MED,DEPT ANAT & CELL BIOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,SCH PHARMACEUT SCI,DEPT NEUROPATHOL & NEUROSCI,BUNKYO KU,TOKYO 113,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT CELL BIOL,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; University of Tokyo; Japanese Foundation for Cancer Research			Takei, Yosuke/I-1828-2015; Noda, Tetsuo/B-1667-2016	Takei, Yosuke/0000-0002-5026-8027; Okabe, Shigeo/0000-0003-1216-8890; Terada, Sumio/0000-0001-5689-0186				BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BLOOM GS, 1984, J CELL BIOL, V98, P320, DOI 10.1083/jcb.98.1.320; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CACERES A, 1991, J NEUROSCI, V11, P1515; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; DOTTI CG, 1988, J NEUROSCI, V8, P1454; GEORGIEFF IS, 1991, J CELL SCI, V100, P55; Goslin K., 1991, CULTURING NERVE CELL, P251; HARADA A, 1990, CELL STRUCT FUNCT, V15, P329, DOI 10.1247/csf.15.329; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; IHARA Y, 1990, GERONTOLOGY, V36, P15; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MATUS A, 1988, ANNU REV NEUROSCI, V11, P20; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; OKABE S, 1992, J CELL BIOL, V117, P105, DOI 10.1083/jcb.117.1.105; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; SATOYOSHITAKE R, 1989, NEURON, V3, P229, DOI 10.1016/0896-6273(89)90036-6; SHIOMURA Y, 1987, J NEUROSCI, V7, P1461; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; UMEYAMA T, 1993, J CELL BIOL, V120, P451, DOI 10.1083/jcb.120.2.451	30	572	591	2	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 9	1994	369	6480					488	491		10.1038/369488a0	http://dx.doi.org/10.1038/369488a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	8202139				2022-12-01	WOS:A1994NQ28600058
J	GATTINONI, L; BOMBINO, M; PELOSI, P; LISSONI, A; PESENTI, A; FUMAGALLI, R; TAGLIABUE, M				GATTINONI, L; BOMBINO, M; PELOSI, P; LISSONI, A; PESENTI, A; FUMAGALLI, R; TAGLIABUE, M			LUNG STRUCTURE AND FUNCTION IN DIFFERENT STAGES OF SEVERE ADULT-RESPIRATORY-DISTRESS-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXTRACORPOREAL MEMBRANE-OXYGENATION; END-EXPIRATORY PRESSURE; PULMONARY BAROTRAUMA; MECHANICAL VENTILATION; GAS-EXCHANGE; FAILURE; SYSTEM; EMPHYSEMA; CURVE	Objective.-To assess the clinical consequences of duration of adult respiratory distress syndrome (ARDS) on lung structure and function. Design.-Retrospective analysis. Setting.-A university hospital referral center for extracorporeal support. Patients.-A total of 84 patients with severe ARDS (Murray score > 2.5) recruited from 48 intensive care units (1979 to 1992), who suffered ARDS and underwent mechanical ventilation for up to 1 week (37 patients with early ARDS), between 1 and 2 weeks (24 patients with intermediate ARDS), or more than 2 weeks (23 patients with late ARDS) and subsequently underwent extracorporeal support. Main Outcome Measures.-Before beginning extracorporeal support, we measured gas exchange, pulmonary mechanics, hemodynamics, oxygen transport and delivery, incidence of barotrauma (presence of one or more thoracic tubes for pneumothorax drainage), and organ dysfunctions. In a subgroup of 16 patients, we studied lung structure by computed tomographic scan, scoring the densities and quantifying the emphysemalike lesions (bullae). Results.-Late ARDS showed lower respiratory compliance, higher dead space, higher Pace,, lower venous admixture, and lower positive end-expiratory pressure requirement compared with early ARDS (P<.01). The incidence of pneumothorax (48.8% of the entire population) was significantly (P<.01) higher in late ARDS (87%) vs intermediate ARDS (46%) and early ARDS (30%). The mortality of patients with pneumothorax (66%) was significantly (P<.01) higher compared with patients without pneumothorax (46%). The number of bullae per lung was significantly higher in late ARDS vs intermediate and early ARDS (mean [SD], 8 [4], 4.3 [5], and 1.9 [3.9], respectively; P<.01), and they were preferentially distributed in the dependent lung regions. The number of bullae per lung was significantly higher in patients with pneumothorax vs those without pneumothorax (mean [SD], 13.6 [9.8] vs 1.4 [2.1]; P=.007). The mean (SD) duration of ARDS in patients with pneumothorax was 15.3 (10.0) days vs 7.0 (6.6) days in those without pneumothorax (P=.0001). No differences within the three groups were found in computed tomographic scan densities, hemodynamics, and number of organ system dysfunctions. Conclusions.-The lung structure and function changes markedly with ARDS duration, and the late stages may be described as restrictive lung disease with superimposed emphysemalike lesions. Presence of pneumothorax affects survival and appears to be related to the lung structural changes occurring with time.	UNIV MILAN, IST RIC & CURA CARATTERE SCI, MILAN, ITALY; OSPED SAN GERARDO, MONZA, ITALY	University of Milan; San Gerardo Hospital	GATTINONI, L (corresponding author), UNIV MILAN, OSPED MAGGIORE POLICLIN, IST ANESTESIA & RIANIMAZ, VIA FRANCESCO SFORZA 35, I-20122 MILAN, ITALY.		Fumagalli, Roberto/AAB-9746-2019; Rocco, Patricia/I-7460-2012; Pesenti, Antonio/H-7483-2012	Fumagalli, Roberto/0000-0003-0398-1329; Rocco, Patricia/0000-0003-1412-7136; Pesenti, Antonio/0000-0003-2593-729X; Pelosi, Paolo/0000-0001-5055-3023; Gattinoni, Luciano/0000-0001-5380-2494				Artigas A., 1991, ADULT RESP DISTRESS, P37; BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589, DOI 10.1164/arrd.1977.116.4.589; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; Bohr C., 1891, SKAND ARCH PHYSL, V53, P236, DOI [10.1111/j.1748-1716.1891.tb00581.x, DOI 10.1111/J.1748-1716.1891.TB00581.X]; BONE RC, 1992, CHEST, V101, P320, DOI 10.1378/chest.101.2.320; BONE RC, 1976, AM REV RESPIR DIS, V113, pA188; CHURG A, 1983, AM REV RESPIR DIS, V127, P117, DOI 10.1164/arrd.1983.127.1.117; DANTZKER DR, 1979, AM REV RESPIR DIS, V120, P1039; GAMMON RB, 1992, CHEST, V102, P568, DOI 10.1378/chest.102.2.568; GATTINONI L, 1987, AM REV RESPIR DIS, V136, P730, DOI 10.1164/ajrccm/136.3.730; GATTINONI L, 1993, JAMA-J AM MED ASSOC, V269, P2122, DOI 10.1001/jama.269.16.2122; GATTINONI L, 1984, INTENS CARE MED, V10, P121, DOI 10.1007/BF00265800; GATTINONI L, 1987, INTENS CARE MED, V13, P19, DOI 10.1007/BF00263552; GATTINONI L, 1991, ANESTHESIOLOGY, V74, P15, DOI 10.1097/00000542-199101000-00004; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; Gattinoni L, 1988, J Thorac Imaging, V3, P59, DOI 10.1097/00005382-198807000-00013; GREENE R, 1981, AM REV RESPIR DIS, V124, P593; HOLZAPFEL L, 1983, CRIT CARE MED, V11, P591, DOI 10.1097/00003246-198308000-00002; JARDIN F, 1982, NOUV PRESSE MED, V11, P29; KLOSE R, 1981, INTENS CARE MED, V7, P165; Kumar A, 1973, Crit Care Med, V1, P181, DOI 10.1097/00003246-197307000-00001; LAMY M, 1976, AM REV RESPIR DIS, V114, P267; LATORRE FJD, 1977, CHEST, V72, P141, DOI 10.1378/chest.72.2.141; LEMAIRE F, 1982, CHEST, V81, P654, DOI 10.1378/chest.81.5.654; Lemaire F, 1985, ACUTE RESPIRATORY FA, P521; MATAMIS D, 1984, CHEST, V86, P58, DOI 10.1378/chest.86.1.58; MAUNDER RJ, 1986, JAMA-J AM MED ASSOC, V255, P2463, DOI 10.1001/jama.255.18.2463; MOREL DR, 1985, AM REV RESPIR DIS, V132, P479; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; PESENTI A, 1993, INTENSIVE CRIT CARE, V12, P15; PETERSEN GW, 1983, CRIT CARE MED, V11, P67, DOI 10.1097/00003246-198302000-00002; PONTOPPIDAN H, 1985, ACUTE RESPIRATORY FA, P1; PRATT PC, 1979, AM J PATHOL, V95, P191; REHDER K, 1972, ANESTHESIOLOGY, V37, P16, DOI 10.1097/00000542-197207000-00004; ROUBY JJ, 1993, INTENS CARE MED, V19, P383, DOI 10.1007/BF01724877; SANDERS C, 1991, RADIOL CLIN N AM, V29, P1019; SLAVIN G, 1982, BRIT MED J, V285, P931, DOI 10.1136/bmj.285.6346.931; Snedecor G.W., 1980, STAT METHODS, V7; SNOW RL, 1982, AM REV RESPIR DIS, V126, P887; SUTER PM, 1985, ACUTE RESPIRATORY FA, P507; TOMASHEFSKI JF, 1983, AM J PATHOL, V112, P112; WOODRING JH, 1985, CRIT CARE MED, V13, P786, DOI 10.1097/00003246-198510000-00003; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193; ZWILLICH CW, 1974, AM J MED, V57, P161, DOI 10.1016/0002-9343(74)90440-9; 1979, EXTRACORPOREAL SUPPO	45	269	285	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	1994	271	22					1772	1779		10.1001/jama.271.22.1772	http://dx.doi.org/10.1001/jama.271.22.1772			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN725	8196122				2022-12-01	WOS:A1994NN72500028
J	SMITH, JL; ZALUZEC, EJ; WERY, JP; NIU, LW; SWITZER, RL; ZALKIN, H; SATOW, Y				SMITH, JL; ZALUZEC, EJ; WERY, JP; NIU, LW; SWITZER, RL; ZALKIN, H; SATOW, Y			STRUCTURE OF THE ALLOSTERIC REGULATORY ENZYME OF PURINE BIOSYNTHESIS	SCIENCE			English	Article							GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; ESCHERICHIA-COLI-PURF; AMINO-ACID-SEQUENCE; NUCLEOTIDE-SEQUENCE; ENDONUCLEASE-III; SYNCHROTRON RADIATION; ANOMALOUS DISPERSION; MOLECULAR-CLONING; PROTEIN; AMIDOPHOSPHORIBOSYLTRANSFERASE	Multiwavelength anomalous diffraction (MAD) has been used to determine the structure of the regulatory enzyme of de novo synthesis of purine nucleotides, glutamine 5-phosphoribosyl-1-pyrophosphate (PRPP) amidotransferase, from Bacillus subtilis. This allosteric enzyme, a 200-kilodalton tetramer, is subject to end product regulation by purine nucleotides. The metalloenzyme from B. subtilis is a paradigm for the higher eukaryotic enzymes, which have been refractory to isolation in stable form. The two folding domains of the polypeptide are correlated with functional domains for glutamine binding and for transfer of ammonia to the substrate PRPP. Eight molecules of the feedback inhibitor adenosine monophosphate (AMP) are bound to the tetrameric enzyme in two types of binding sites: the PRPP catalytic site of each subunit and an unusual regulatory site that is immediately adjacent to each active site but is between subunits. An oxygen-sensitive [4Fe-4S] cluster in each subunit is proposed to regulate protein turnover in vivo and is distant from the catalytic site. Oxygen sensitivity of the cluster is diminished by AMP, which blocks a channel through the protein to the cluster. The structure is representative of both glutamine amidotransferases and phosphoribosyltransferases.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907; UNIV TOKYO,FAC PHARMACEUT SCI,TOKYO 113,JAPAN; UNIV SCI & TECHNOL CHINA,DEPT BIOL,ANHUI,PEOPLES R CHINA	University of Illinois System; University of Illinois Urbana-Champaign; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Tokyo; Chinese Academy of Sciences; University of Science & Technology of China, CAS	SMITH, JL (corresponding author), PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907, USA.				NIDDK NIH HHS [DK-42303, R37 DK042303] Funding Source: Medline; NIGMS NIH HHS [GM-24658] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042303, R37DK042303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024658, R37GM024658] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVERILL BA, 1980, J BIOL CHEM, V255, P6007; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BERNLOHR DA, 1981, BIOCHEMISTRY-US, V20, P5675, DOI 10.1021/bi00523a006; BOLIN JT, 1993, AM CRYST ASS, P51; BRAYTON KA, 1994, J BIOL CHEM, V269, P5313; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; GRANDONI JA, 1989, J BIOL CHEM, V264, P6058; Hendrickson W. A., 1985, T AM CRYSTALLOGR ASS, V21, P11; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HERSHEY HV, 1986, GENE, V43, P287, DOI 10.1016/0378-1119(86)90218-0; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; IWAHANA H, 1993, J BIOL CHEM, V268, P7225; IWAHANA H, 1993, BIOCHEM BIOPH RES CO, V190, P192, DOI 10.1006/bbrc.1993.1030; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KENNEDY MC, 1992, ADV INORG CHEM RAD, V38, P323, DOI 10.1016/S0898-8838(08)60067-7; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; MAKAROFF CA, 1983, J BIOL CHEM, V258, P586; MAKAROFF CA, 1986, J BIOL CHEM, V261, P1416; MANTSALA P, 1984, J BIOL CHEM, V259, P8478; MANTSALA P, 1984, J BIOL CHEM, V259, P4230; MERRITT EA, COMMUNICATION; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; MEYER E, 1979, J BIOL CHEM, V254, P5397; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MUSICK WDL, 1981, CRC CR REV BIOCH MOL, V11, P1, DOI 10.3109/10409238109108698; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; Perutz M, 1989, MECHANISMS COOPERATI; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SAMPEI G, 1988, NUCLEIC ACIDS RES, V16, P8717, DOI 10.1093/nar/16.17.8717; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Smith JL, 1991, CURR OPIN STRUC BIOL, V1, P1002, DOI 10.1016/0959-440X(91)90098-E; SMITH JL, 1991, ISOMORPHOUS REPLACEM, P96; SOUCIET JL, 1988, J BIOL CHEM, V263, P3323; SUCK D, 1984, EMBO J, V3, P2423, DOI 10.1002/j.1460-2075.1984.tb02149.x; SWITZER R L, 1989, Biofactors, V2, P77; SWITZER RL, 1989, ALLOSTERIC ENZYMES, P129; TSO JY, 1982, J BIOL CHEM, V257, P3525; TSO JY, 1982, J BIOL CHEM, V257, P3532; VOLLMER SJ, 1983, J BIOL CHEM, V258, P582; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WONG JY, 1981, BIOCHEMISTRY-US, V20, P5669, DOI 10.1021/bi00523a005; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; ZHOU GC, 1990, J BIOL CHEM, V265, P21152; ZHOU GC, 1993, J BIOL CHEM, V268, P10471	52	240	244	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 3	1994	264	5164					1427	1433		10.1126/science.8197456	http://dx.doi.org/10.1126/science.8197456			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	8197456				2022-12-01	WOS:A1994NP22100033
J	MOYER, JH; LEETISCHLER, MJ; KWON, HY; SCHRICK, JJ; AVNER, ED; SWEENEY, WE; GODFREY, VL; CACHEIRO, NLA; WILKINSON, JE; WOYCHIK, RP				MOYER, JH; LEETISCHLER, MJ; KWON, HY; SCHRICK, JJ; AVNER, ED; SWEENEY, WE; GODFREY, VL; CACHEIRO, NLA; WILKINSON, JE; WOYCHIK, RP			CANDIDATE GENE ASSOCIATED WITH A MUTATION CAUSING RECESSIVE POLYCYSTIC KIDNEY-DISEASE IN MICE	SCIENCE			English	Article							MOUSE CHROMOSOME-2; DNA; PROTEINS; MITOSIS; REGION; MODEL; MOTIF	A line of transgenic mice was generated that contains an insertional mutation causing a phenotype similar to human autosomal recessive polycystic kidney disease. Homozygotes displayed a complex phenotype that included bilateral polycystic kidneys and an unusual liver lesion. The mutant locus was cloned and characterized through use of the transgene as a molecular marker. Additionally, a candidate polycystic kidney disease (PKD) gene was identified whose structure and expression are directly associated with the mutant locus. A complementary DNA derived from this gene predicted a peptide containing a motif that was originally identified in several genes involved in cell cycle control.	OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; UNIV TENNESSEE,GRAD SCH BIOMED SCI,DIV BIOL,OAK RIDGE NATL LAB,OAK RIDGE,TN 37831; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98105; UNIV TENNESSEE,DEPT PATHOBIOL,KNOXVILLE,TN 37920	United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; University of Washington; University of Washington Seattle; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture			Woychik, Richard P/C-8345-2019	Woychik, Richard P/0000-0001-8196-1732	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R13ES010067] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD25323] Funding Source: Medline; NIDDK NIH HHS [R01 DK45633-01] Funding Source: Medline; NIEHS NIH HHS [IAG 222Y01-ES-10067] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ATALA A, 1993, KIDNEY INT, V43, P1081, DOI 10.1038/ki.1993.151; Ausubel FM., 1988, CURRENT PROTOCOLS MO; AVNER E D, 1992, Journal of the American Society of Nephrology, V3, P292; AVNER ED, 1987, PEDIATR NEPHROL, V1, P587, DOI 10.1007/BF00853593; AVNER ED, 1992, P NATL ACAD SCI USA, V89, P7447, DOI 10.1073/pnas.89.16.7447; BERNSTEIN J, 1986, CAMPBELLS UROLOGY, P1760; BERNSTEIN J, 1978, PEDIATRIC KIDNEY DIS, P557; BOHNLEIN E, 1985, NUCLEIC ACIDS RES, V13, P4789, DOI 10.1093/nar/13.13.4789; COLE BR, 1990, CYSTIC KIDNEY, pCH13; COWLEY BD, 1991, J AM SOC NEPHROL, V1, P1948; DALGAARD OZ, 1971, DISEASES KIDNEY, P1252; Daoust Martin C., 1993, Journal of the American Society of Nephrology, V4, P262; FARBER E, 1956, CANCER RES, V16, P142; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GERMINO GG, 1992, GENOMICS, V13, P144, DOI 10.1016/0888-7543(92)90214-D; GERMINO GG, 1993, KIDNEY INT       S39, V43, P20; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GORDON J, 1992, ILAR NEWS, V34, P45; GORDON JW, 1980, P NATL ACAD SCI USA, V77, P7389; Guay-Woodford L. M., 1993, Journal of the American Society of Nephrology, V4, P814; Hogan B., 1986, MANIPULATING MOUSE E; Kimberling W. J., 1993, Journal of the American Society of Nephrology, V4, P816; Kissane J. M., 1974, PATHOLOGY KIDNEY, P69; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LIEBERMAN E, 1971, MEDICINE, V50, P277, DOI 10.1097/00005792-197107000-00003; MCGINNIS W, 1984, CELL, V38, P675, DOI 10.1016/0092-8674(84)90262-9; MOYER JH, UNPUB; NAUTA J, 1993, PEDIATR NEPHROL, V7, P163, DOI 10.1007/BF00864387; NORBY S, 1990, LANCET, V336, P323; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; REEDERS ST, 1992, NAT GENET, V1, P235, DOI 10.1038/ng0792-235; RUSSELL ES, 1977, MOUSE NEWSLETT, V56, P49; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRICK JJ, UNPUB; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; STUBBS L, 1990, GENOMICS, V6, P645, DOI 10.1016/0888-7543(90)90499-K; TAKAHASHI H, 1991, J AM SOC NEPHROL, V1, P980; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WOYCHIK RP, 1990, P NATL ACAD SCI USA, V87, P2588, DOI 10.1073/pnas.87.7.2588; WRIGHT AF, 1993, HUMAN GENET, V90, P323	41	303	309	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 27	1994	264	5163					1329	1333		10.1126/science.8191288	http://dx.doi.org/10.1126/science.8191288			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN767	8191288	Green Submitted			2022-12-01	WOS:A1994NN76700046
J	LIN, VSY; DIMAGNO, SG; THERIEN, MJ				LIN, VSY; DIMAGNO, SG; THERIEN, MJ			HIGHLY CONJUGATED, ACETYLENYL BRIDGED PORPHYRINS - NEW MODELS FOR LIGHT-HARVESTING ANTENNA SYSTEMS	SCIENCE			English	Article							ELECTRON-TRANSFER; SPECTROSCOPIC CHARACTERIZATION; OPTICAL-PROPERTIES; DIMERS; POLYMERS; DERIVATIVES; PICOSECOND; ARRAYS	A new class of porphyrin-based chromophore systems has been prepared from ethyne-elaborated porphyrin synthons through the use of metal-mediated cross-coupling methodologies. These systems feature porphyrin chromophores wired together through single ethynyl linkages. This type of topological connectivity affords exceptional electronic interactions between the chromophores which are manifest in their room temperature photo-physics, optical spectroscopy, and electrochemistry; these spectroscopic signatures indicate that these species model many of the essential characteristics of biological light-harvesting antenna systems.	UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104	University of Pennsylvania			DiMagno, Stephen G/H-9459-2016	DiMagno, Stephen G/0000-0001-7861-4799	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048130] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48130-01A1.4] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON HL, 1992, TETRAHEDRON LETT, V33, P1101, DOI 10.1016/S0040-4039(00)91871-9; ANDERSON HL, 1990, ANGEW CHEM INT EDIT, V29, P1400, DOI 10.1002/anie.199014001; ANDERSON HL, 1994, INORG CHEM, V33, P972, DOI 10.1021/ic00083a022; ANDERSON S, 1993, ACCOUNTS CHEM RES, V26, P469, DOI 10.1021/ar00033a003; ARNOLD DP, 1978, J CHEM SOC PERK T 1, P366, DOI 10.1039/p19780000366; ARNOLD DP, 1992, TETRAHEDRON, V48, P8781, DOI 10.1016/S0040-4020(01)89451-5; ARNOLD DP, 1993, J AM CHEM SOC, V115, P12197, DOI 10.1021/ja00078a081; ARNOLD DP, 1993, TETRAHEDRON LETT, V34, P693, DOI 10.1016/S0040-4039(00)61655-6; BEROVA N, 1993, J AM CHEM SOC, V115, P4769, DOI 10.1021/ja00064a042; BILSEL O, 1992, J AM CHEM SOC, V114, P6528, DOI 10.1021/ja00042a037; CHANG CK, 1984, ANGEW CHEM INT EDIT, V23, P164, DOI 10.1002/anie.198401641; COLLMAN JP, 1983, J AM CHEM SOC, V105, P2694, DOI 10.1021/ja00347a029; DIMAGNO SG, 1993, J ORG CHEM, V58, P5983, DOI 10.1021/jo00074a027; DIMAGNO SG, 1993, J AM CHEM SOC, V115, P2513, DOI 10.1021/ja00059a060; Eglinton G., 1963, ADV ORG CHEM, V4, P225; ERIKSSONS, 1990, CHEM PHYS, V1146, P165; FOWLER GJS, 1993, PHOTOCHEM PHOTOBIOL, V57, P2, DOI 10.1111/j.1751-1097.1993.tb02245.x; FOX MA, 1993, CHEM ENG NEWS, V71, P38, DOI 10.1021/cen-v071n011.p038; Gouterman M., 1978, PORPHYRINS, P1, DOI DOI 10.1016/B978-0-12-220103-5.50008-8; GRACA M, 1991, J ORG CHEM, V56, P4407; GREGG BA, 1989, J AM CHEM SOC, V111, P3024, DOI 10.1021/ja00190a041; GUST D, 1990, SCIENCE, V248, P199, DOI 10.1126/science.248.4952.199; GUST D, 1993, J AM CHEM SOC, V115, P5684, DOI 10.1021/ja00066a038; HERMANT RM, 1993, J AM CHEM SOC, V115, P2080, DOI 10.1021/ja00058a088; HEVESI J, 1969, SPECTROCHIM ACTA A-M, VA 25, P1751, DOI 10.1016/0584-8539(69)80203-5; HUNTER CA, 1989, CHEM PHYS, V133, P395, DOI 10.1016/0301-0104(89)80221-6; JAEGERMANN P, 1993, MOL PHYS, V78, P1057, DOI 10.1080/00268979300100691; JOHNSON DG, 1993, J AM CHEM SOC, V115, P5692, DOI 10.1021/ja00066a039; KAGAN NE, 1977, J AM CHEM SOC, V99, P5484, DOI 10.1021/ja00458a045; Kasha M., 1965, PURE APPL CHEM, V11, P371, DOI DOI 10.1351/PAC196511030371; Kessel D, 1990, PHOTODYNAMIC THERAPY, V2; KESSEL D, 1990, PHOTODYNAMIC THERAPY, V1; Kim J.B., 1978, PORPHYRINS STRUCTURE, P85, DOI [10.1016/b978-0-12-220101-1.5, DOI 10.1016/B978-0-12-220101-1.5]; LECOURS SM, UNPUB; LEMEST Y, 1992, INORG CHEM, V31, P835, DOI 10.1021/ic00031a028; LIN VSY, UNPUB; LINDSEY JS, 1987, J ORG CHEM, V52, P827, DOI 10.1021/jo00381a022; LUTTRULL DK, 1992, LANGMUIR, V8, P765, DOI 10.1021/la00039a006; MATSUURA K, 1993, PHOTOCHEM PHOTOBIOL, V57, P92, DOI 10.1111/j.1751-1097.1993.tb02261.x; MCGHEE EM, 1991, INORG CHEM, V30, P803, DOI 10.1021/ic00004a036; MILGROM LR, 1992, Patent No. 15099; MILLER JS, 1992, ADV MATER, V4, P498, DOI 10.1002/adma.19920040710; NAGATA T, 1990, J AM CHEM SOC, V112, P3054, DOI 10.1021/ja00164a027; NARANG SC, 1992, Patent No. 5091502; NISHIDE H, 1991, MACROMOLECULES, V24, P6306, DOI 10.1021/ma00023a037; ONEIL MP, 1992, SCIENCE, V257, P63, DOI 10.1126/science.257.5066.63; OSUKA A, 1988, J AM CHEM SOC, V110, P4454, DOI 10.1021/ja00221a079; OSUKA A, 1993, J AM CHEM SOC, V115, P4577, DOI 10.1021/ja00064a021; OSUKA A, 1991, CHEM PHYS LETT, V1181, P413; Paine J.B., 1978, PORPHYRINS A, V1, P101; PANDEY RK, 1992, TETRAHEDRON LETT, V33, P5315, DOI 10.1016/S0040-4039(00)79081-2; PANDEY RK, 1990, TETRAHEDRON LETT, V31, P7399, DOI 10.1016/S0040-4039(00)88499-3; PRATHAPAN S, 1993, J AM CHEM SOC, V115, P7519, DOI 10.1021/ja00069a068; PROESS G, 1992, TETRAHEDRON LETT, V33, P269, DOI 10.1016/0040-4039(92)88068-G; RODRIGUEZ J, 1991, J AM CHEM SOC, V113, P1652, DOI 10.1021/ja00005a032; SAKODA K, 1991, Patent No. 5051337; SCAMPORRINO E, 1992, MACROMOLECULES, V25, P1625, DOI 10.1021/ma00032a001; SCHICK GA, 1989, J AM CHEM SOC, V111, P1344, DOI 10.1021/ja00186a030; SEGAWA H, 1992, J CHEM SOC CHEM COMM, P784, DOI 10.1039/c39920000784; SEGAWA H, 1992, J PHYS CHEM-US, V96, P503, DOI 10.1021/j100181a001; SELENSKY R, 1981, CHEM PHYS, V60, P33, DOI 10.1016/0301-0104(81)80105-X; SESSLER JL, 1993, J AM CHEM SOC, V115, P4618, DOI 10.1021/ja00064a025; Smith K.M., 1975, PORPHYRINS METALLOPO; SUSLICK KS, 1992, J AM CHEM SOC, V114, P6928, DOI 10.1021/ja00043a055; TERRELL DR, 1991, Patent No. 428214; TRONRUD DE, 1986, J MOL BIOL, V188, P443, DOI 10.1016/0022-2836(86)90167-1; TSUCHIDA E, 1991, Patent No. 464717; Turro NJ., 1991, MODERN MOL PHOTOCHEM; USHIZAWA N, 1990, Patent No. 4957615; VISSCHERS RW, 1992, BIOCHIM BIOPHYS ACTA, V1100, P259, DOI 10.1016/0167-4838(92)90480-2; VOET D, 1990, BIOCHEMISTRY-US, P591; WASIELEWSKI MR, 1990, J AM CHEM SOC, V112, P6482, DOI 10.1021/ja00174a005; WEBBER SE, 1990, CHEM REV, V90, P1469, DOI 10.1021/cr00106a005; WEISHAUPT KR, 1985, Patent No. 161606; YONEYAMA M, 1991, CHEM LETT, P929, DOI 10.1246/cl.1991.929	75	767	773	2	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 20	1994	264	5162					1105	1111		10.1126/science.8178169	http://dx.doi.org/10.1126/science.8178169			7	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM146	8178169				2022-12-01	WOS:A1994NM14600021
J	MIDDLEBROOKS, JC; CLOCK, AE; XU, L; GREEN, DM				MIDDLEBROOKS, JC; CLOCK, AE; XU, L; GREEN, DM			A PANORAMIC CODE FOR SOUND LOCATION BY CORTICAL-NEURONS	SCIENCE			English	Article							PRIMARY AUDITORY-CORTEX; SUPERIOR COLLICULUS; SINGLE UNITS; SPACE; SENSITIVITY; PATTERNS; CATS	By conventional spike count measures, auditory neurons in the cat's anterior ectosylvian sulcus cortical area are broadly tuned for the location of a sound source. Nevertheless, an artificial neural network was trained to classify the temporal spike patterns of single neurons according to sound location. The spike patterns of 73 percent of single neurons coded sound location with more than twice the chance level of accuracy, and spike patterns consistently carried more information than spike counts alone. In contrast to neurons that are sharply tuned for location, these neurons appear to encode sound locations throughout 360 degrees of azimuth.	UNIV FLORIDA,INST BRAIN,DEPT OTOLARYNGOL,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT PSYCHOL,PSYCHOACOUST LAB,GAINESVILLE,FL 32611	State University System of Florida; University of Florida; State University System of Florida; University of Florida	MIDDLEBROOKS, JC (corresponding author), UNIV FLORIDA,INST BRAIN,DEPT NEUROSCI,GAINESVILLE,FL 32610, USA.		Xu, Li/C-5908-2008	Xu, Li/0000-0002-0988-7934				BRITTEN KH, 1992, J NEUROSCI, V12, P4745; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; GREEN DM, 1974, SIGNAL DETECTION THE; IMIG TJ, 1990, J NEUROPHYSIOL, V63, P1448, DOI 10.1152/jn.1990.63.6.1448; JENKINS WM, 1982, J NEUROPHYSIOL, V47, P987, DOI 10.1152/jn.1982.47.6.987; KNUDSEN EI, 1982, J NEUROSCI, V2, P1177; MIDDLEBROOKS JC, 1981, J NEUROSCI, V1, P107, DOI 10.1523/JNEUROSCI.01-01-00107.1981; MIDDLEBROOKS JC, 1984, J NEUROSCI, V4, P2621; Neyman J, 1933, PHILOS T R SOC LOND, V231, P289, DOI 10.1098/rsta.1933.0009; OPTICAN LM, 1987, J NEUROPHYSIOL, V57, P162, DOI 10.1152/jn.1987.57.1.162; PALMER AR, 1982, NATURE, V299, P248, DOI 10.1038/299248a0; RAJAN R, 1990, J NEUROPHYSIOL, V64, P872, DOI 10.1152/jn.1990.64.3.872; RICHMOND BJ, 1990, J NEUROPHYSIOL, V64, P370, DOI 10.1152/jn.1990.64.2.370; WIDROW B, 1960, IRE WESCON CONVENTIO, V4, P96	14	266	273	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					842	844		10.1126/science.8171339	http://dx.doi.org/10.1126/science.8171339			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171339	Green Submitted			2022-12-01	WOS:A1994NJ94900033
J	DANZIGER, R				DANZIGER, R			DISCRIMINATION AGAINST PEOPLE WITH HIV AND AIDS IN POLAND	BRITISH MEDICAL JOURNAL			English	Article								The recent increase in HIV seroprevalence in Poland, particularly among injecting drug users, has been accompanied by widespread discrimination against people affected by HIV and AIDS. As in other countries,this discrimination may be attributed to a large extent to fear and ignorance about HIV and AIDS together with pre-existing prejudices against the people who are most commonly associated with the epidemic. In Poland extreme hostility towards drug users combined with the powerful influence of a traditional Catholic church have so far impeded effective education about HIV and AIDS and antidiscrimination strategies,	UNIV LONDON LONDON SCH HYG & TROP MED,HLTH POLICY UNIT,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine								CHOPIN K, 1992, BRIT MED J, V304, P1429, DOI 10.1136/bmj.304.6839.1429; EASTERBROOK P, 1992, NEW SCI, V135, P11; RICH V, 1994, LANCET, V343, P47, DOI 10.1016/S0140-6736(94)90889-3; 1993, SLOWO DZIENNIK  0721; 1993, ECONOMIST       0718, P42; 1992, COOPERATION CENTRAL; 1990, REPORT AIDS; 1991, BRIDGING PLAN PREVEN, P39; 1992, DISCRIMINATION OTHER, P82; 1993, ZYCIE WARSZAWY  0527, P5; 1993, CESCHR CDDH937 SWISS; 1993, GAZETA WYBORCZA 0216, P10; 1992, SPOLECZENSTWO WOBEC; 1991, WIEDZA POSTAURY WOBE; 1993, RZECZPOSPOLITA   JUN	15	22	22	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 30	1994	308	6937					1145	1147		10.1136/bmj.308.6937.1145	http://dx.doi.org/10.1136/bmj.308.6937.1145			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK182	8173458	Green Published			2022-12-01	WOS:A1994NK18200022
J	HUSSAIN, LM; REDMOND, AD				HUSSAIN, LM; REDMOND, AD			ARE PREHOSPITAL DEATHS FROM ACCIDENTAL INJURY PREVENTABLE	BRITISH MEDICAL JOURNAL			English	Article							SEVERITY SCORE; TRAUMA DEATHS; EMERGENCY; CARE	Objective-To determine what proportion of prehospital deaths from accidental injury-deaths at the scene of the accident and those that occur before the person has reached hospital-are preventable. Design-Retrospective study of all deaths from accidental injury that occurred between 1 January 1987 and 31 December 1990 and were reported to the coroner. Setting-North Staffordshire. Main outcome measures-Injury severity score, probability of survival (probit analysis), and airway obstruction. Results-There were 152 pre-hospital deaths from accidental injury (110 males and 42 females). In the same period there were 257 deaths in hospital from accidental injury (136 males and 121 females). The average age at death was 41.9 years for those who died before reaching hospital, and their average injury severity score was 29.3. In contrast, those who died in hospital were older and equally likely to be males or females. Important neurological injury occurred in 113 pre-hospital deaths, and evidence of airway obstruction in 59. Eighty six pre-hospital deaths were due to road traffic accidents, and 37 of these were occupants in cars. On the basis of the injury severity score and age, death was found to have been inevitable or highly likely in 92 cases. In the remaining 60 cases death had not been inevitable and airway obstruction was present in up to 51 patients with injuries that they might have survived. Conclusion-Death was potentially preventable in at least 39% of those who died from accidental injury before they reached hospital. Training in first aid should be available more widely, and particularly to motorists as many pre-hospital deaths that could be prevented are due to road accidents.	N STAFFORDSHIRE HOSP,STOKE ON TRENT ST4 4LN,ENGLAND	Keele University; University Hospital of North Staffordshire NHS Trust								ALLAN AN, 1992, J BRIT ASS IMMEDIATE, V15, P50; ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BAXT WG, 1987, JAMA-J AM MED ASSOC, V257, P3246, DOI 10.1001/jama.257.23.3246; BULL JP, 1975, ACCIDENT ANAL PREV, V7, P249, DOI 10.1016/0001-4575(75)90026-3; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; Finney DJ., 1947, PROBIT ANAL; FISCHER H, 1991, COLOUR ATLAS TRAUMA, P83; GORDON MWG, 1989, ARCH EMERG MED, V6, P107; LENWORTH MJ, 1984, J TRAUMA, V24, P8; Redmond A D, 1993, J R Coll Surg Edinb, V38, P248; TRUNKEY D, 1985, ARCH EMERG MED, V2, P181; UNDERHILL TJ, 1989, ARCH EMERG MED, V6, P90; YATES DW, 1977, BRIT MED J, V2, P1249, DOI 10.1136/bmj.2.6097.1249; 1988, MANAGEMENT PATIENT M; 1990, AIS 90 HDB ABBREVIAT	17	138	144	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1994	308	6936					1077	1080		10.1136/bmj.308.6936.1077	http://dx.doi.org/10.1136/bmj.308.6936.1077			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173428	Green Published			2022-12-01	WOS:A1994NH48900023
J	ROSS, M; GROSSMAN, AB; MURDOCH, S; BUNDEY, R; GOLDING, J; PURCHASE, S; MUNYARD, T; SCOTT, M; BRIDGER, A				ROSS, M; GROSSMAN, AB; MURDOCH, S; BUNDEY, R; GOLDING, J; PURCHASE, S; MUNYARD, T; SCOTT, M; BRIDGER, A			PRISON - SHIELD FROM THREAT, OR THREAT TO SURVIVAL	BRITISH MEDICAL JOURNAL			English	Article									ST BARTHOLOMEWS HOSP,LONDON EC1A 7BE,ENGLAND; LIVERPOOL PERSONAL SERV SOC,LIVERPOOL L1 6AN,ENGLAND	University of London; Queen Mary University London	ROSS, M (corresponding author), ASHWELL MED CTR,BRADFORD BD8 9DB,ENGLAND.							BIRD AG, 1993, BRIT MED J, V307, P228, DOI 10.1136/bmj.307.6898.228; CHRISTIE B, 1993, BRIT MED J, V307, P151; GOLDSTEIN A, 1989, MOL CELLULAR ASPECTS; GORE SM, 1993, BRIT MED J, V307, P147, DOI 10.1136/bmj.307.6897.147; GOSSOP M, 1987, ADDICT BEHAV, V12, P1, DOI 10.1016/0306-4603(87)90002-5; LIEBLING A, 1993, BRIT MED J, V307, P399, DOI 10.1136/bmj.307.6901.399; WOOL R, 1993, GUARDIAN        1123; 1993, STATISTICAL B, V15; 1988, RIGHTS RESPONSIBILIT, P64; 1992, STATISTICS DRUG ADDI; 1991, CARING DRUG USERS MU; 1991, DRUGS MISUSE DEPENDE, P21	12	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1994	308	6936					1092	1095		10.1136/bmj.308.6936.1092	http://dx.doi.org/10.1136/bmj.308.6936.1092			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173433	Green Published			2022-12-01	WOS:A1994NH48900033
J	STRANG, J; GRIFFITHS, P; ABBEY, J; GOSSOP, M				STRANG, J; GRIFFITHS, P; ABBEY, J; GOSSOP, M			SURVEY OF USE OF INJECTED BENZODIAZEPINES AMONG DRUG-USERS IN BRITAIN	BRITISH MEDICAL JOURNAL			English	Article							TEMAZEPAM				STRANG, J (corresponding author), MAUDSLEY INST PSYCHIAT,NATL ADDICT CTR,LONDON SE5 8AF,ENGLAND.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725				CARNWATH T, 1993, BRIT MED J, V307, P385, DOI 10.1136/bmj.307.6900.385-c; GREEN S, 1992, BRIT J ADDICT, V87, P941; LAUNCHBURY AP, 1989, MANUF CHEMIST, V60, P38; RUBEN SM, 1992, BRIT J ADDICT, V87, P1387; Strang J., 1993, BENZODIAZEPINE DEPEN, P128	5	45	45	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1994	308	6936					1082	1082		10.1136/bmj.308.6936.1082	http://dx.doi.org/10.1136/bmj.308.6936.1082			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173431	Green Published			2022-12-01	WOS:A1994NH48900026
J	BETZ, AG; MILSTEIN, C; GONZALEZFERNANDEZ, A; PANNELL, R; LARSON, T; NEUBERGER, MS				BETZ, AG; MILSTEIN, C; GONZALEZFERNANDEZ, A; PANNELL, R; LARSON, T; NEUBERGER, MS			ELEMENTS REGULATING SOMATIC HYPERMUTATION OF AN IMMUNOGLOBULIN-KAPPA GENE - CRITICAL ROLE FOR THE INTRON ENHANCER MATRIX ATTACHMENT REGION	CELL			English	Article							ANTIGEN-DRIVEN SELECTION; CELL-SPECIFIC ENHANCER; HEAVY-CHAIN LOCUS; GERMINAL-CENTERS; IMMUNE-RESPONSE; TRANSGENIC MICE; VARIABLE GENES; B-CELLS; MUTATION; MATURATION	Following encounter with antigen, the immunoglobulin genes in B lymphocytes undergo somatic hypermutation. Most nucleotide substitutions are introduced into a region flanked by the V gene promoter and intron enhancer. Experiments described here using transgenic mice revealed that the V kappa promoter does not contain specific signals since hypermutation was retained on substituting it by a beta-globin promoter. However, both the kappa intron and kappa 3' enhancer regions were found to be essential for full hypermutation. This dependence of hypermutation on both enhancers contrasts with transgene expression in hybridomas in which only the 3' enhancer (and not the intron enhancer) is necessary to achieve high mRNA levels. The results show that full hypermutation depends on multiple elements, removal of some of which may drastically impair but not totally abolish the process.			BETZ, AG (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		González-Fernández, África/E-2641-2012; Betz, Alexander/GQQ-2221-2022	González-Fernández, África/0000-0002-9226-4825; 				ADETUGBO K, 1977, NATURE, V265, P299, DOI 10.1038/265299a0; APEL M, 1990, INT IMMUNOL, V2, P813, DOI 10.1093/intimm/2.9.813; AZUMA T, 1993, INT IMMUNOL, V5, P121, DOI 10.1093/intimm/5.2.121; BEREK C, 1987, EUR J IMMUNOL, V17, P1121, DOI 10.1002/eji.1830170808; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; BOTH GW, 1990, MOL CELL BIOL, V10, P5187, DOI 10.1128/MCB.10.10.5187; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DREHER ML, 1991, J IMMUNOL METHODS, V139, P197, DOI 10.1016/0022-1759(91)90189-M; FULTON R, 1993, NUCLEIC ACIDS RES, V21, P4941, DOI 10.1093/nar/21.21.4941; Galfre G, 1981, Methods Enzymol, V73, P3; GEARHART PJ, 1983, P NATL ACAD SCI-BIOL, V80, P3439, DOI 10.1073/pnas.80.11.3439; GIUSTI AM, 1993, J EXP MED, V177, P797, DOI 10.1084/jem.177.3.797; GOLDING GB, 1987, GENETICS, V115, P169; GONZALEZFERNANDEZ A, 1993, P NATL ACAD SCI USA, V90, P9862, DOI 10.1073/pnas.90.21.9862; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; HACKETT J, 1992, J EXP MED, V176, P225, DOI 10.1084/jem.176.1.225; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; KAARTINEN M, 1991, EUR J IMMUNOL, V21, P2863, DOI 10.1002/eji.1830211131; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIEBERSON R, 1991, NUCLEIC ACIDS RES, V19, P933, DOI 10.1093/nar/19.4.933; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LOZANO F, 1993, NATURE, V363, P271, DOI 10.1038/363271a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MACLENNAN I, 1991, NATURE, V354, P352, DOI 10.1038/354352a0; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MATTHIAS P, 1993, MOL CELL BIOL, V13, P1547, DOI 10.1128/MCB.13.3.1547; MAX EE, 1981, J BIOL CHEM, V256, P5116; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MEYER KB, 1990, NUCLEIC ACIDS RES, V18, P3565; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; NOSSAL GJV, 1992, CELL, V68, P1, DOI 10.1016/0092-8674(92)90198-L; OBRIEN RL, 1987, NATURE, V326, P405, DOI 10.1038/326405a0; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RADA C, 1991, P NATL ACAD SCI USA, V88, P5508, DOI 10.1073/pnas.88.13.5508; REYNAUD CA, 1991, CELL, V64, P995, DOI 10.1016/0092-8674(91)90323-Q; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; ROTHENFLUH HS, 1993, EUR J IMMUNOL, V23, P2152, DOI 10.1002/eji.1830230916; SHARPE MJ, 1990, EUR J IMMUNOL, V20, P1379, DOI 10.1002/eji.1830200625; SHARPE MJ, 1991, EMBO J, V10, P2139, DOI 10.1002/j.1460-2075.1991.tb07748.x; SOHN J, 1993, J EXP MED, V177, P493, DOI 10.1084/jem.177.2.493; STEELE EJ, 1992, IMMUNOL CELL BIOL, V70, P129, DOI 10.1038/icb.1992.18; TAKEDA S, 1993, EMBO J, V12, P2329, DOI 10.1002/j.1460-2075.1993.tb05887.x; UMAR A, 1991, P NATL ACAD SCI USA, V88, P4902, DOI 10.1073/pnas.88.11.4902; WEBER JS, 1991, J IMMUNOL, V146, P3652; XU M, 1989, J BIOL CHEM, V264, P21190	58	353	372	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					239	248		10.1016/0092-8674(94)90316-6	http://dx.doi.org/10.1016/0092-8674(94)90316-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	8168132				2022-12-01	WOS:A1994NH63400009
J	POWELL, SM; PETERSEN, GM; KRUSH, AJ; BOOKER, S; JEN, J; GIARDIELLO, FM; HAMILTON, SR; VOGELSTEIN, B; KINZLER, KW				POWELL, SM; PETERSEN, GM; KRUSH, AJ; BOOKER, S; JEN, J; GIARDIELLO, FM; HAMILTON, SR; VOGELSTEIN, B; KINZLER, KW			MOLECULAR DIAGNOSIS OF FAMILIAL ADENOMATOUS POLYPOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GERM-LINE MUTATIONS; APC GENE; SULINDAC; COLI; IDENTIFICATION; DNA; CHROMOSOME-5Q21; DELETION; LINKAGE; TISSUE	Background. Familial adenomatous polyposis is an inherited disease characterized by multiple colorectal tumors. The diagnosis has classically been based on the detection of multiple colorectal adenomas. The recent identification of germline mutations of the APC gene in patients with familial adenomatous polyposis makes presymptomatic molecular diagnosis possible, but the widespread distribution of the many mutations within this very large gene have heretofore made the search for such mutations impractical. We describe a novel approach that allows molecular genetic diagnosis in the majority of patients with the disease. Methods. We screened 62 unrelated patients from the Johns Hopkins Familial Adenomatous Polyposis Registry for germline APC mutations. Primary screening was accomplished by analysis of protein synthesized in vitro from surrogate APC genes. In addition, the relative amount of transcript from each APC allele was determined with an allele-specific-expression assay. Results. The protein assay revealed truncated protein in 51 of the 62 patients (82 percent). In 3 of the 11 remaining patients, the allele-specific-expression assay revealed significantly reduced expression of one allele of the APC gene. The use of these two assays in combination successfully identified germline APC mutations in 87 percent of the 62 patients. Conclusions. The protein and allele-specific-expression assays provide a practical and sensitive method for molecular diagnosis of familial adenomatous polyposis. This approach will facilitate care, allowing routine testing of subjects at risk and genetic confirmation of spontaneous mutations.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL CANCER INSTITUTE [R37CA035494, R01CA057345, R37CA057345, R01CA035494, R01CA044688] Funding Source: NIH RePORTER; NCI NIH HHS [CA-57345, CA-44688, CA-35494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALM T, 1973, CLIN GASTROENTEROL, V2, P577; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BULOW S, 1986, DIS COLON RECTUM, V29, P102, DOI 10.1007/BF02555389; BUSSEY HJR, 1990, FAMILIAL ADENOMATOUS, P1; CACHONGONZALEZ MB, 1991, J MED GENET, V28, P681, DOI 10.1136/jmg.28.10.681; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Nagase Hiroki, 1992, Human Mutation, V1, P467, DOI 10.1002/humu.1380010603; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; PETERSEN GM, 1991, GASTROENTEROLOGY, V100, P1658, DOI 10.1016/0016-5085(91)90666-9; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RIGAU J, 1991, ANN INTERN MED, V115, P952, DOI 10.7326/0003-4819-115-12-952; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SPIRIO L, 1993, AM J HUM GENET, V52, P286; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VARESCO L, 1993, AM J HUM GENET, V52, P280; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; WALSH PS, 1991, BIOTECHNIQUES, V10, P507	38	590	619	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1993	329	27					1982	1987		10.1056/NEJM199312303292702	http://dx.doi.org/10.1056/NEJM199312303292702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN573	8247073				2022-12-01	WOS:A1993MN57300002
J	ANTO, JM; SUNYER, J; REED, CE; SABRIA, J; MARTINEZ, F; MORELL, F; CODINA, R; RODRIGUEZROISIN, R; RODRIGO, MJ; ROCA, J; SAEZ, M				ANTO, JM; SUNYER, J; REED, CE; SABRIA, J; MARTINEZ, F; MORELL, F; CODINA, R; RODRIGUEZROISIN, R; RODRIGO, MJ; ROCA, J; SAEZ, M			PREVENTING ASTHMA EPIDEMICS DUE TO SOYBEANS BY DUST-CONTROL MEASURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRIMELLITIC ANHYDRIDE; IDENTIFICATION; AEROALLERGEN; ANTIBODIES; ALLERGENS; AVOIDANCE; EXPOSURE; TIME	Background. The inhalation of soybean dust released during the unloading of soybeans into a silo caused outbreaks of asthma in Barcelona, Spain. This study was designed to determine morbidity due to asthma and serum IgE reactivity before and after the installation of filters in the silo. Methods. We measured soybean-allergen concentrations in 136 samples of air collected for 9 months before and 24 months after the installation of filters. We compared the number of days on which there was an unexpected increase in emergency room visits for asthma, the number of days on which the number of emergency room visits for asthma in one four-hour period was so high that it was unlikely to be due to chance, and the mean daily number of emergency room and intensive care unit admissions for asthma for a total of 60 months before and after filter installation. Serum IgE antibodies against soybean allergens were measured in 38 patients before and after filter installation. Results. The concentration of airborne soybean allergens on days when soybeans were unloaded decreased from 324 to 25 U per cubic meter after the installation of filters (P<0.001). The number of days on which there was an unusually large number of visits to the hospital for asthma and the number of days on which asthma was epidemic both decreased significantly (both P<0.001), from 29 to 6 and from 18 to 0, respectively. The mean daily number of emergency room and intensive care unit admissions for asthma on days when soybeans were unloaded decreased from 8.3 to 5.4 and from 0.26 to 0.01, respectively (both P<0.001). The mean serum IgE antibody concentrations in the 38 patients studied decreased from 2 Pharmacia reference units per milliliter to 1 (P<0.001). Conclusions. Installing filters on silos to prevent airborne dissemination of allergenic soybean dust eliminates outbreaks of asthma caused by inhalation of the dust, thus supporting the idea that the avoidance of allergens helps prevent asthma.	MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905; HOSP VALLE DE HEBRON,SERV BIOQUIM,BARCELONA,SPAIN; HOSP VALLE DE HEBRON,SERV PNEUMOL,BARCELONA,SPAIN; HOSP CLIN BARCELONA,SERV PNEUMOL & ALLERGIA RESP,BARCELONA 36,SPAIN	Mayo Clinic; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; University of Barcelona; Hospital Clinic de Barcelona	ANTO, JM (corresponding author), INST MUNICIPAL INVEST MED,DEPT EPIDEMIOL & SALUT PUBL,DOCTOR AIGUADER 80,E-08003 BARCELONA,SPAIN.		Anto, J M/H-2676-2014; Sunyer, Jordi/G-6909-2014	Anto, J M/0000-0002-4736-8529; Sunyer, Jordi/0000-0002-2602-4110; Morell Brotad, Ferran/0000-0002-7206-4543				AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; ANTO JM, 1986, LANCET, V1, P900, DOI 10.1016/S0140-6736(86)90999-2; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; ANTO JM, 1990, CHEST, V98, pS185, DOI 10.1378/chest.98.5_Supplement.185S; FERRER A, 1990, EUR RESPIR J, V3, P846; FERRER A, 1990, EUR RESPIR J, V3, P429; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GOLDSTEIN IF, 1978, ENVIRON RES, V17, P266, DOI 10.1016/0013-9351(78)90029-4; GONZALEZ R, 1991, INT ARCH ALLER A IMM, V95, P53, DOI 10.1159/000235454; HENDRICK DJ, 1989, THORAX, V44, P609, DOI 10.1136/thx.44.8.609; HERNANDO L, 1989, LANCET, V1, P502; Hosmer D, 2013, APPL LOGISTIC REGRES; Knox E G, 1982, Stat Med, V1, P183, DOI 10.1002/sim.4780010210; MARTINEZ F, 1993, EUR RESPIR J, V6, P337; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MCGRATH KG, 1984, J OCCUP ENVIRON MED, V26, P671; NAVARRO C, 1993, EPIDEMIOLOGY, V4, P76, DOI 10.1097/00001648-199301000-00014; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PLATTSMILLS TAE, 1982, LANCET, V2, P675; RODRIGO MJ, 1990, J ALLERGY CLIN IMMUN, V85, P778, DOI 10.1016/0091-6749(90)90198-D; SUNYER J, 1992, AM REV RESPIR DIS, V145, P1098, DOI 10.1164/ajrccm/145.5.1098; SUNYER J, 1989, LANCET, V1, P179; SWANSON MC, 1991, J ALLERGY CLIN IMMUN, V87, P783, DOI 10.1016/0091-6749(91)90123-6; VENABLES KM, 1987, J ALLERGY CLIN IMMUN, V80, P212, DOI 10.1016/0091-6749(87)90131-X; WALLENSTEIN S, 1980, AM J EPIDEMIOL, V111, P367, DOI 10.1093/oxfordjournals.aje.a112908; WASSERFALLEN JB, 1990, AM REV RESPIR DIS, V142, P108, DOI 10.1164/ajrccm/142.1.108; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; 1989, LANCET, V2, P538	28	90	90	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1993	329	24					1760	1763		10.1056/NEJM199312093292402	http://dx.doi.org/10.1056/NEJM199312093292402			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK096	8232484				2022-12-01	WOS:A1993MK09600002
J	KRUMHOLZ, HM; FORMAN, DE; KUNTZ, RE; BAIM, DS; WEI, JY				KRUMHOLZ, HM; FORMAN, DE; KUNTZ, RE; BAIM, DS; WEI, JY			CORONARY REVASCULARIZATION AFTER MYOCARDIAL-INFARCTION IN THE VERY ELDERLY - OUTCOMES AND LONG-TERM FOLLOW-UP	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; AGED, 80 AND OLDER; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUALITY OF LIFE	ARTERY BYPASS; OCTOGENARIAN PATIENTS; ANGIOPLASTY; SURGERY; MORBIDITY; SURVIVAL	Objective: To determine the outcome of very elderly patients who had coronary revascularization during hospitalization for an acute myocardial infarction. Design: Retrospective cohort study. Setting: Community-based tertiary-care teaching hospital. Patients: A total of 1215 consecutive patients 80 years and older were hospitalized with a myocardial infarction between 1985 and 1990. The study sample included all 93 patients (8%) who had cardiac catheterization before discharge and had not been excluded from study because of the following: severe valvular disease, absence of significant coronary disease, or death before a decision about revascularization could be made. Measurements: Survival, quality of life, and functional status at least 1 year after discharge. Results: After catheterization, 41 patients had angioplasty, 18 had coronary artery bypass surgery, and 34 did not have revascularization. Among the patients alive at discharge, those who had revascularization had a high likelihood of achieving a good or excellent quality of life (angioplasty, 86% [31 of 36]; surgery, 89% [16 of 18]; medical therapy, 44% [11 of 25]) and of being able to care for themselves (angioplasty, 89% [32 of 36], surgery, 89% [16 of 18], medical therapy, 52% [13 of 25]). Mortality rates at 1 year were 24% (95% CI, 15% to 47%) for the angioplasty group, 6% (CI, 0% to 27%) for the surgery group, and 44% (CI, 27% to 62%) for the medical therapy group. In a Cox proportional hazards model that adjusted for clinical, demographic, hemodynamic, and anatomic differences between the groups, the performance of coronary revascularization was associated with increased survival (hazard ratio, 0.42; CI, 0.18 to 0.98). Conclusions: A small percentage of very elderly patients with complicated acute myocardial infarctions, selected by their physicians for invasive cardiovascular procedures, can tolerate these procedures, avoid serious complications, return to independent living, and have excellent probability of survival. Although our results suggest that coronary revascularization may have benefited these patients, the study design did not permit definite conclusions, and future studies are needed to resolve this important question.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; CHARLES A DANA RES INST, BOSTON, MA USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, GRECC, BOSTON, MA USA	Harvard University; Harvard Medical School; Harvard University; Geriatric Research Education & Clinical Center; Harvard University			, Harlan/AAI-2875-2020		NHLBI NIH HHS [HL-07374] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COX DR, 1972, J R STAT SOC B, V34, P187; EDMUNDS LH, 1988, NEW ENGL J MED, V319, P131, DOI 10.1056/NEJM198807213190302; FORMAN DE, 1992, J AM GERIATR SOC, V40, P19, DOI 10.1111/j.1532-5415.1992.tb01823.x; GLOWER DD, 1992, AM J CARDIOL, V70, P567, DOI 10.1016/0002-9149(92)90192-2; HORVATH KA, 1990, J THORAC CARDIOV SUR, V99, P92; JEROUDI MO, 1990, ANN INTERN MED, V113, P423, DOI 10.7326/0003-4819-113-6-423; KERN MJ, 1988, AM J CARDIOL, V61, P457, DOI 10.1016/0002-9149(88)90304-9; KO W, 1991, J THORAC CARDIOV SUR, V102, P532; KO W, 1992, CIRCULATION, V86, P191; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RICH JJ, 1990, AM J CARDIOL, V65, P675, DOI 10.1016/0002-9149(90)91051-7; RIZOPATRON C, 1990, AM J CARDIOL, V66, P857, DOI 10.1016/0002-9149(90)90365-8; SAFRAN C, 1989, ANN INTERN MED, V111, P751, DOI 10.7326/0003-4819-111-9-751; SMITH SC, 1990, J AM COLL CARDIOL, V16, P784, DOI 10.1016/S0735-1097(10)80322-5; TSAI TP, 1991, ANN THORAC SURG, V51, P983, DOI 10.1016/0003-4975(91)91024-P; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; UTLEY JR, 1991, J THORAC CARDIOV SUR, V101, P866; WEINTRAUB WS, 1991, AM J CARDIOL, V68, P1530, DOI 10.1016/0002-9149(91)90291-R; WYMAN RM, 1988, J AM COLL CARDIOL, V12, P1400, DOI 10.1016/S0735-1097(88)80002-0; 1988, AGING AM, P109; 1992, HLTH US 1991, P121	24	33	34	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1084	1090		10.7326/0003-4819-119-11-199312010-00005	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239227				2022-12-01	WOS:A1993MJ33500005
J	HARBURY, PB; ZHANG, T; KIM, PS; ALBER, T				HARBURY, PB; ZHANG, T; KIM, PS; ALBER, T			A SWITCH BETWEEN 2-STRANDED, 3-STRANDED AND 4-STRANDED COILED COILS IN GCN4 LEUCINE-ZIPPER MUTANTS	SCIENCE			English	Article							HELIX-FORMING TENDENCIES; ALPHA-FIBROUS PROTEINS; FOS-JUN INTERACTION; HYDROPHOBIC CORE; AMINO-ACIDS; STAPHYLOCOCCAL NUCLEASE; INFLUENZA-VIRUS; SIDE-CHAIN; REFINEMENT; STABILITY	Coiled-coil sequences in proteins consist of heptad repeats containing two characteristic hydrophobic positions. The role of these buried hydrophobic residues in determining the structures of coiled coils was investigated by studying mutants of the GCN4 leucine zipper. When sets of buried residues were altered, two-, three-, and four-helix structures were formed. The x-ray crystal structure of the tetramer revealed a parallel, four-stranded coiled coil. In the tetramer conformation, the local packing geometry of the two hydrophobic positions in the heptad repeat is reversed relative to that in the dimer. These studies demonstrate that conserved, buried residues in the GCN4 leucine zipper direct dimer formation. In contrast to proposals that the pattern of hydrophobic and polar amino acids in a protein sequence is sufficient to determine three-dimensional structure, the shapes of buried side chains in coiled coils are essential determinants of the global fold.	MIT,DEPT BIOL,WHITEHEAD INST,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142; UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Utah System of Higher Education; University of Utah	HARBURY, PB (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.				NIGMS NIH HHS [GM44162, GM48958] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044162, R01GM048958] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS EDT, 1967, J MOL BIOL, V24, P139, DOI 10.1016/0022-2836(67)90099-X; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Carr M. J., UNPUB; CHAN HS, 1990, P NATL ACAD SCI USA, V87, P6388, DOI 10.1073/pnas.87.16.6388; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P14, DOI 10.1016/0141-8130(91)90004-E; Creighton T.E., 1993, PROTEINS; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P683; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DEGRADO WF, 1990, BIOPOLYMERS, V29, P205, DOI 10.1002/bip.360290125; DeGrado WF, 1991, CURR OPIN STRUC BIOL, V1, P984, DOI 10.1016/0959-440X(91)90095-B; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HU JC, 1992, PROGR NUCLEIC ACIDS, V6, P82; HURLEY JH, 1992, J MOL BIOL, V224, P1143, DOI 10.1016/0022-2836(92)90475-Y; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU KF, 1989, MACROMOLECULES, V22, P3986, DOI 10.1021/ma00200a030; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90, DOI DOI 10.1007/S00249-009-0425-1; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; LOCKHART DJ, 1992, SCIENCE, V257, P947, DOI 10.1126/science.1502559; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; LUMB KJ, UNPUB; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P1591, DOI 10.1021/bi00220a021; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OAS TG, 1990, BIOCHEMISTRY-US, V29, P289; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RALEIGH DP, 1992, J AM CHEM SOC, V114, P10079, DOI 10.1021/ja00051a061; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SIKORSKI A, 1989, BIOPOLYMERS, V28, P1097, DOI 10.1002/bip.360280605; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; STITES WE, 1991, J MOL BIOL, V221, P7, DOI 10.1016/0022-2836(91)80195-Z; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; ZHU BY, 1993, PROTEIN SCI, V2, P383; [No title captured]	58	1337	1473	3	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1401	1407		10.1126/science.8248779	http://dx.doi.org/10.1126/science.8248779			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248779				2022-12-01	WOS:A1993MJ04600028
J	REYNET, C; KAHN, CR				REYNET, C; KAHN, CR			RAD - A MEMBER OF THE RAS FAMILY OVEREXPRESSED IN MUSCLE OF TYPE-II DIABETIC HUMANS	SCIENCE			English	Article							INVIVO INSULIN ACTION; PIMA-INDIANS; SIGNAL TRANSDUCTION; XENOPUS-OOCYTES; GENE-EXPRESSION; BETA-CELL; MELLITUS; NIDDM; PROTEINS; P21	To identify the gene or genes associated with insulin resistance in Type II (non-insulin-dependent) diabetes mellitus, subtraction libraries were prepared from skeletal muscle of normal and diabetic humans and screened with subtracted probes. Only one clone out of 4000 was selectively overexpressed in Type II diabetic muscle as compared to muscle of non-diabetic or Type I diabetic individuals. This clone encoded a new 29-kilodalton member of the Ras-guanosine triphosphatase superfamily and was termed Rad (Ras associated with diabetes). Messenger ribonucleic acid of Rad was expressed primarily in skeletal and cardiac muscle and was increased an average of 8.6-fold in the muscle of Type II diabetics as compared to normal individuals.	HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BECKNIELSEN H, 1992, DIABETES CARE, V15, P418, DOI 10.2337/diacare.15.3.418; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BELL GI, 1991, DIABETES, V40, P413, DOI 10.2337/diabetes.40.4.413; BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CHUNG DL, 1991, BIOCHEM BIOPH RES CO, V181, P1378, DOI 10.1016/0006-291X(91)92091-W; CORMONT M, 1993, J BIOL CHEM, V268, P19491; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; COX NJ, 1989, DIABETES, V38, P653, DOI 10.2337/diabetes.38.5.653; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DRUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738; ELBEIN SC, 1988, DIABETES, V37, P377, DOI 10.2337/diabetes.37.4.377; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FLIER JS, 1992, DIABETES, V41, P416; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KLARLUND JK, 1993, J BIOL CHEM, V268, P7646; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; Krolewski A.S., 1985, JOSLINS DIABETES MEL, P12; LILLIOJA S, 1987, DIABETES, V36, P1329, DOI 10.2337/diabetes.36.11.1329; LU KH, 1992, P NATL ACAD SCI USA, V89, P3889, DOI 10.1073/pnas.89.9.3889; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MARTIN BC, 1992, DIABETES, V41, P850, DOI 10.2337/diabetes.41.7.850; MCCLAIN DA, 1988, DIABETES, V37, P1071, DOI 10.2337/diabetes.37.8.1071; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; NEWMAN B, 1987, DIABETOLOGIA, V30, P763; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PORRAS A, 1992, J BIOL CHEM, V267, P21124; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; SANDERS DA, 1990, CELL GROWTH DIFFER, V1, P251; SCHULMAN GI, 1990, NEW ENGL J MED, V322, P223; SCHUMACHER MC, 1992, DIABETES, V41, P416, DOI 10.2337/diabetes.41.4.416; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STEINER DF, 1990, DIABETES CARE, V13, P600, DOI 10.2337/diacare.13.6.600; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDEROUWELAND MW, 1992, NAT GENET, V1, P368; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909	59	285	291	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1441	1444		10.1126/science.8248782	http://dx.doi.org/10.1126/science.8248782			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248782				2022-12-01	WOS:A1993MJ04600039
J	DELWART, EL; SHPAER, EG; LOUWAGIE, J; MCCUTCHAN, FE; GREZ, M; RUBSAMENWAIGMANN, H; MULLINS, JI				DELWART, EL; SHPAER, EG; LOUWAGIE, J; MCCUTCHAN, FE; GREZ, M; RUBSAMENWAIGMANN, H; MULLINS, JI			GENETIC-RELATIONSHIPS DETERMINED BY A DNA HETERODUPLEX MOBILITY ASSAY - ANALYSIS OF HIV-1 ENV GENES	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEOTIDE-SEQUENCE; HTLV-III; INFECTION; TYPE-1; NEUTRALIZATION; DIVERSITY; GENERATION; EVOLUTION; EMERGENCE	The genetic diversity of human immunodeficiency virus (HIV) is a major concern thought to impact on immunologic escape and eventual vaccine efficacy. Here, simple and rapid methods are described for the detection and estimation of genetic divergence between HIV strains on the basis of the observation that DNA heteroduplexes formed between related sequences have a reduced mobility in polyacrylamide gels proportional to their degree of divergence. Reliable phylogenetic subtypes were assigned for HIV-1 strains from around the world. Relationships between viruses were closest when derived from the same or epidemiologically linked individuals. When derived from epidemiologically unlinked individuals, the relationships between viruses in a given geographic region correlated with the length of time HIV-1 had been detected in the population and the number of strains initiating widespread infection. Heteroduplex mobility analysis thus provides a tool to expedite epidemiological investigations by assisting in the classification of HIV and is readily applicable to the screening and characterization of other infectious agents and cellular genes.	STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; FDN ADVANCEMENT MIL MED,ROCKVILLE,MD 20850; GEORG SPEYER HAUS CHEMOTHERAPEUT FORSCHUNGSINST,D-700251 FRANKFURT,GERMANY	Stanford University				Delwart, Eric/0000-0002-6296-4484	NIAID NIH HHS [AI07328, AI32885, AI85007] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI085007, R01AI032885] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BROWN AL, 1988, AIDS RES HUM RETROV, V4, P399, DOI 10.1089/aid.1988.4.399; CHEINGSONGPOPOV R, 1992, J INFECT DIS, V165, P256, DOI 10.1093/infdis/165.2.256; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; CRANAGE MP, 1993, AIDS RES HUM RETROV, V9, P13, DOI 10.1089/aid.1993.9.13; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DELWART E, UNPUB; DIETRICH U, 1993, AIDS, V7, P23, DOI 10.1097/00002030-199301000-00003; Domingo E, 1992, CURR OPIN GENET DEV, V2, P61, DOI 10.1016/S0959-437X(05)80323-5; Feisenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GREZ M, UNPUB; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; HO DD, 1985, NEW ENGL J MED, V313, P1493, DOI 10.1056/NEJM198512123132401; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; HSIEH CH, 1989, P NATL ACAD SCI USA, V86, P4833, DOI 10.1073/pnas.86.13.4833; ISSEL CJ, 1992, J VIROL, V66, P3398, DOI 10.1128/JVI.66.6.3398-3408.1992; KUSUMI K, 1992, J VIROL, V66, P875, DOI 10.1128/JVI.66.2.875-885.1992; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; LOUWAGIE J, 1992, AIDS RES HUM RETROV, V8, P1467, DOI 10.1089/aid.1992.8.1467; MCCUTCHAN FE, 1992, AIDS RES HUM RETROV, V8, P1887, DOI 10.1089/aid.1992.8.1887; MCCUTCHAN FE, 1992, J ACQ IMMUN DEF SYND, V5, P441; MCCUTCHAN FE, UNPUB; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MYERS G, 1992, AIDS RES HUM RETROV, V8, P373, DOI 10.1089/aid.1992.8.373; MYERS G, 1992, HUMAN RETROVIRUSES A; PANG S, 1992, AIDS, V6, P453, DOI 10.1097/00002030-199205000-00003; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RUBSAMENWAIGMANN H, 1991, LANCET, V337, P550, DOI 10.1016/0140-6736(91)91333-P; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SIMMONDS P, 1990, J VIROL, V64, P5840, DOI 10.1128/JVI.64.12.5840-5850.1990; SINGAL R, UNPUB; SRINIVASAN A, 1989, AIDS RES HUM RETROV, V5, P121, DOI 10.1089/aid.1989.5.121; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	46	729	773	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1257	1261		10.1126/science.8235655	http://dx.doi.org/10.1126/science.8235655			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235655				2022-12-01	WOS:A1993MH32400037
J	ZOU, YR; GU, H; RAJEWSKY, K				ZOU, YR; GU, H; RAJEWSKY, K			GENERATION OF A MOUSE STRAIN THAT PRODUCES IMMUNOGLOBULIN-KAPPA CHAINS WITH HUMAN CONSTANT REGIONS	SCIENCE			English	Article							GERMINAL-CENTERS; HUMAN-ANTIBODY; TRANSGENIC MICE; LYMPHOID-TISSUE; IMMUNE-RESPONSE; B-CELLS; EXPRESSION; GENES; REPERTOIRE; MATURATION	Humanized antibodies are highly efficient as immunotherapeutic reagents and have many advantages over rodent antibodies. A mouse strain was generated by gene targeting to replace the mouse kappa light chain constant (C) region gene with the human C(kappa) gene. Mice homozygous for the replacement mutation (C(kappa)R) produced normal concentrations of serum antibodies, most of which carry chimeric kappa light chains, and mounted normal immune responses to hapten-protein conjugates. This technology provides a feasible option for the generation of high-affinity humanized antibodies by means of the powerful somatic hypermutation-selection mechanism.			ZOU, YR (corresponding author), UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY.							APEL M, 1990, INT IMMUNOL, V2, P813, DOI 10.1093/intimm/2.9.813; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BORREBAECK CAK, 1988, IMMUNOL TODAY, V9, P335; BRUGGEMANN M, 1991, EUR J IMMUNOL, V21, P1323, DOI 10.1002/eji.1830210535; BRUGGEMANN M, 1989, J EXP MED, V170, P2153, DOI 10.1084/jem.170.6.2153; BRUGGEMANN M, 1989, P NATL ACAD SCI USA, V86, P6709, DOI 10.1073/pnas.86.17.6709; BUTCHER EC, 1982, J IMMUNOL, V129, P2698; CHOI TK, 1993, NAT GENET, V4, P17; COICO RF, 1983, J IMMUNOL, V131, P2254; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GRIFFITHS AD, 1993, CURR OPIN IMMUNOL, V5, P263, DOI 10.1016/0952-7915(93)90015-K; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HIETER PA, 1980, CELL, V22, P197, DOI 10.1016/0092-8674(80)90168-3; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; JERNE N K, 1971, European Journal of Immunology, V1, P1, DOI 10.1002/eji.1830010102; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KAARTINEN M, 1988, EUR J IMMUNOL, V18, P1095, DOI 10.1002/eji.1830180719; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KLOBECK HG, 1984, NUCLEIC ACIDS RES, V12, P6995, DOI 10.1093/nar/12.18.6995; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LUBIN I, 1991, SCIENCE, V252, P427, DOI 10.1126/science.1826797; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; RAJEWSKY K, 1983, ANNU REV IMMUNOL, V1, P569, DOI 10.1146/annurev.iy.01.040183.003033; REICHMANN L, 1988, NATURE, V332, P323; RODER JC, 1986, METHOD ENZYMOL, V121, P140; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SODERLIND E, 1992, IMMUNOL REV, V130, P109, DOI 10.1111/j.1600-065X.1992.tb01523.x; TAYLOR LD, 1992, NUCLEIC ACIDS RES, V20, P6287, DOI 10.1093/nar/20.23.6287; VERHOEYEN M, 1988, SCIENCE, V239, P1534, DOI 10.1126/science.2451287; Zou Y., UNPUB; ZOU YR, 1993, EMBO J, V12, P811, DOI 10.1002/j.1460-2075.1993.tb05721.x	35	37	50	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1271	1274		10.1126/science.8235658	http://dx.doi.org/10.1126/science.8235658			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235658				2022-12-01	WOS:A1993MH32400041
J	KIM, KH; KWON, BM; MYERS, AG; REES, DC				KIM, KH; KWON, BM; MYERS, AG; REES, DC			CRYSTAL-STRUCTURE OF NEOCARZINOSTATIN, AN ANTITUMOR PROTEIN-CHROMOPHORE COMPLEX	SCIENCE			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; MACROMOLECULAR CRYSTALLOGRAPHY; ACETYLCHOLINE-BINDING; APO-NEOCARZINOSTATIN; 2.8-A RESOLUTION; REFINEMENT; SYSTEM; DOMAIN; STABILIZATION; APOPROTEIN	Structures of the protein-chromophore complex and the apoprotein form of neocarzinostatin were determined at 1.8 angstrom resolution. Neocarzinostatin is composed of a labile chromophore with DNA-cleaving activity and a stabilizing protein. The chromophore displays marked nonlinearity of the triple bonds and is bound noncovalently in a pocket formed by the two protein domains. The chromophore pi-face interacts with the phenyl ring edges of Phe52 and Phe78. The amino sugar and carbonate groups of the chromophore are solvent exposed, whereas the epoxide, acetylene groups, and carbon C-12, the site of nucleophilic thiol addition during chromophore activation, are unexposed. The position of the amino group of the chromophore carbohydrate relative to C-12 supports the idea that the amino group plays a role in thiol activation.	CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125	California Institute of Technology					NATIONAL CANCER INSTITUTE [R29CA047148, R01CA047148, R37CA047148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045162, R37GM045162] Funding Source: NIH RePORTER; NCI NIH HHS [CA47148] Funding Source: Medline; NIGMS NIH HHS [GM45162] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADJADJ E, 1992, EUR J BIOCHEM, V203, P505, DOI 10.1111/j.1432-1033.1992.tb16576.x; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CHIMURA H, 1968, J ANTIBIOT, V21, P44, DOI 10.7164/antibiotics.21.44; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; COX JM, 1967, J MOL BIOL, V28, P151, DOI 10.1016/S0022-2836(67)80083-4; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; EDO K, 1986, J ANTIBIOT, V39, P1615, DOI 10.7164/antibiotics.39.1615; EDO K, 1985, TETRAHEDRON LETT, V26, P331, DOI 10.1016/S0040-4039(01)80810-8; EVANS SV, IN PRESS J MOL GRAPH; FALKSON G, 1984, J CLIN ONCOL, V2, P581, DOI 10.1200/JCO.1984.2.6.581; GAO XL, 1992, J MOL BIOL, V225, P125, DOI 10.1016/0022-2836(92)91030-S; GIBSON BW, 1984, J BIOL CHEM, V259, P801; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; ISHIDA N, 1965, J ANTIBIOT, V18, P68; ISHIGURO M, 1991, J MED CHEM, V34, P2366, DOI 10.1021/jm00112a008; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAPPEN LS, 1980, P NATL ACAD SCI-BIOL, V77, P1970, DOI 10.1073/pnas.77.4.1970; KHOKHLOV AS, 1969, J ANTIBIOT, V22, P541, DOI 10.7164/antibiotics.22.541; KIMOTO A, 1992, CANCER RES, V52, P1013; KOIDE Y, 1980, J ANTIBIOT, V33, P342, DOI 10.7164/antibiotics.33.342; KONNO T, 1992, EUR J CANCER, V28A, P403, DOI 10.1016/S0959-8049(05)80063-2; KUROMIZU K, 1986, ARCH BIOCHEM BIOPHYS, V246, P199, DOI 10.1016/0003-9861(86)90464-9; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LYNDSAY M, 1990, BIOCHEMISTRY-US, V29, P8401; MAEDA H, 1974, ARCH BIOCHEM BIOPHYS, V164, P379, DOI 10.1016/0003-9861(74)90046-0; MAEDA H, 1981, ANTICANCER RES, V1, P175; MYERS AG, 1987, TETRAHEDRON LETT, V28, P4493, DOI 10.1016/S0040-4039(00)96545-6; MYERS AG, 1989, J AM CHEM SOC, V111, P1146, DOI 10.1021/ja00185a064; MYERS AG, 1988, J AM CHEM SOC, V110, P7212, DOI 10.1021/ja00229a045; MYERS AG, 1992, J AM CHEM SOC, V114, P1086, DOI 10.1021/ja00029a046; NAPIER MA, 1979, BIOCHEM BIOPH RES CO, V89, P635, DOI 10.1016/0006-291X(79)90677-6; PLETNEV VZ, 1982, BIOPOLYMERS, V21, P287, DOI 10.1002/bip.360210205; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; RODMAN DA, 1993, NATURE, V362, P735; Rossmann M. G., 1972, MOL REPLACEMENT METH; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAKATA N, 1993, BIOL PHARM BULL, V16, P26; SHOJI JI, 1961, J ANTIBIOT, V14, P27; SIEKER LC, 1976, BIOCHEM BIOPH RES CO, V68, P358, DOI 10.1016/0006-291X(76)91152-9; STILL WC, 1988, MACROMODEL V2 5; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TANAKA T, 1991, TETRAHEDRON LETT, V32, P3175, DOI 10.1016/S0040-4039(00)79715-2; TANAKA T, 1993, J CHEM SOC CHEM COMM, V15, P1205; TEPLYAKOV A, 1993, EUR J BIOCHEM, V213, P737, DOI 10.1111/j.1432-1033.1993.tb17814.x; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANROEY P, 1989, P NATL ACAD SCI USA, V86, P6587, DOI 10.1073/pnas.86.17.6587; VONHOFF DD, 1984, AM J CLIN ONCOL-CANC, V7, P135, DOI 10.1097/00000421-198404000-00006	57	82	83	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1042	1046		10.1126/science.8235619	http://dx.doi.org/10.1126/science.8235619			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235619				2022-12-01	WOS:A1993MG18700031
J	SOLLNER, T; BENNETT, MK; WHITEHEART, SW; SCHELLER, RH; ROTHMAN, JE				SOLLNER, T; BENNETT, MK; WHITEHEART, SW; SCHELLER, RH; ROTHMAN, JE			A PROTEIN ASSEMBLY-DISASSEMBLY PATHWAY IN-VITRO THAT MAY CORRESPOND TO SEQUENTIAL STEPS OF SYNAPTIC VESICLE DOCKING, ACTIVATION, AND FUSION	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; SYNAPTOSOMAL-ASSOCIATED PROTEIN; VESICULAR TRANSPORT; RAT-BRAIN; IDENTIFICATION; COMPLEX; YEAST; ER; GLYCOPROTEIN; SNAP-25	The SNARE hypothesis holds that a transport vesicle chooses its target for fusion when a soluble NSF attachment protein (SNAP) receptor on the vesicle (v-SNARE) pairs with its cognate t-SNARE at the target membrane. Three synaptosomal membrane proteins have previously been identified: syntaxin, SNAP-25 (t-SNAREs), and vesicle-associated membrane protein (VAMP) (v-SNARE); all assemble with SNAPs and NSF into 20S fusion particles. We now report that in the absence of SNAP and NSF, these three SNAREs form a stable complex that can also bind synaptotagmin. Synaptotagmin is displaced by alpha-SNAP, suggesting that these two proteins share binding sites on the SNARE complex and implying that synaptotagmin operates as a ''clamp'' to prevent fusion from proceeding in the absence of a signal. The alpha-SNAP-SNARE complex can bind NSF, and NSF-dependent hydrolysis of ATP dissociates the complex, separating syntaxin, SNAP-25, and VAMP. ATP hydrolysis by NSF may provide motion to initiate bilayer fusion.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University	SOLLNER, T (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM CELLULAR BIOCHEM & BIOPHYS,NEW YORK,NY 10021, USA.			Whiteheart, Sidney/0000-0001-5577-0473				BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENTZ J, 1990, FEBS LETT, V276, P1, DOI 10.1016/0014-5793(90)80492-2; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, IN PRESS EMBO J; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFRINK LA, 1993, CELL, V72, P153; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARLOW E, 1988, ANTIBODIES LABORATOR; HELM CA, 1989, SCIENCE, V246, P919, DOI 10.1126/science.2814514; HESS DT, 1992, J NEUROSCI, V12, P4634; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; HUTTNER WB, 1983, J CELL BIOL, V96, P1373; INOUE A, 1992, J BIOL CHEM, V267, P10613; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MONCK JR, 1992, J CELL BIOL, V119, P1395, DOI 10.1083/jcb.119.6.1395; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; OSTERMANN J, 1993, IN PRESS CELL, V75; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; POPOV SV, 1993, CELL, V73, P1247, DOI 10.1016/0092-8674(93)90352-Q; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; SCHIAVO G, 1992, NATURE, V359, P862; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WATERS MG, 1992, J CELL BIOL, V1186, P1015; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; WILSON DW, 1992, METHOD ENZYMOL, V219, P309; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	55	1592	1619	5	127	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 5	1993	75	3					409	418		10.1016/0092-8674(93)90376-2	http://dx.doi.org/10.1016/0092-8674(93)90376-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8221884				2022-12-01	WOS:A1993MF83000004
J	LIE, RT; WILCOX, AJ; SKJAERVEN, R				LIE, RT; WILCOX, AJ; SKJAERVEN, R			A POPULATION-BASED STUDY OF THE RISK OF RECURRENCE OF BIRTH-DEFECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLEFT-PALATE; MALFORMATIONS; LIP	Background. Certain birth defects are known to recur in families, but most estimates of the risk of recurrence have come from clinic-based studies. In this study we estimated the risk of recurrent birth defects using a population-based registry. Methods. The study was based on the records of the first and second infants delivered by 371,933 women from 1967 through 1989. The records are maintained by the Medical Birth Registry of Norway. For the 9192 women whose first infant had a birth defect, we determined the relative risk of similar and dissimilar defects in the second infant. The reference population was women whose first infant had no defect. Results. Among first infants, 2.5 percent had a birth defect. The mothers of affected first infants were 2.4 times as likely as other women to have second infants with any registered defect. This increased risk was due primarily to an increased (7.6 times higher) risk of the same defect in the second infant as in the first (95 percent confidence interval, 6.5 to 8.8) and secondarily to a slightly increased (1.5 times higher) risk of a different defect in the second infant (95 percent confidence interval, 1.3 to 1.7). Among the women who lived in the same municipality during both pregnancies, the relative risk of having a second infant with the same defect was 11.6, as compared with 5.1 among the women who moved to another municipality after the birth of their first infant (P<0.001). Conclusions. Among women whose first infant has a birth defect, the risk of the same defect in the second infant is substantially increased and the risk of a different. defect in the second infant is slightly increased. Environment plays a strong part in repeated defects.	UNIV BERGEN,MED INFORMAT & STAT SECT,BERGEN,NORWAY; NATL INST PUBL HLTH,OSLO,NORWAY; NIEHS,EPIDEMIOL BRANCH,RES TRIANGLE PK,NC 27709	University of Bergen; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	LIE, RT (corresponding author), HAUKELAND HOSP,MED BIRTH REGISTRY NORWAY,MFH BLDG,N-5021 BERGEN,NORWAY.		Wilcox, Allen J/C-7723-2019	Wilcox, Allen J/0000-0002-3376-1311				CZEIZEL AE, 1988, MULTIPLE CONGENITAL; ENGELMAN L, 1990, BMDP STATISTICAL SOF, V2, P721; FARRALL M, 1992, AM J HUM GENET, V50, P270; FRASER FC, 1982, LANCET, V2, P144; HARPER PS, 1988, PRACTICAL GENETIC CO; KALTER H, 1983, NEW ENGL J MED, V308, P491, DOI 10.1056/NEJM198303033080904; KHOURY MJ, 1987, AM J MED GENET, V28, P159, DOI 10.1002/ajmg.1320280123; KHOURY MJ, 1983, PEDIATRICS, V71, P815; KNOX EG, 1991, EPIDEMIOLOGY CONGENI; KURNIT DM, 1987, AM J HUM GENET, V41, P979; LIE RT, IN PRESS BIOMETRICS; MITCHELL LE, 1992, AM J HUM GENET, V51, P323; RASMUSSEN SA, 1990, AM J HUM GENET, V46, P478; ROSENDAHL K, 1992, ACTA PAEDIATR, V81, P177, DOI 10.1111/j.1651-2227.1992.tb12198.x; SKJAERVEN R, 1988, AM J EPIDEMIOL, V128, P1352, DOI 10.1093/oxfordjournals.aje.a115088; SMITH DW, 1976, MAJOR PROBLEMS CLIN, V7, P16; VOLLSET SE, 1991, J AM STAT ASSOC, V86, P404, DOI 10.2307/2290585; WARKANY J, 1978, TERATOLOGY, V17, P187; Wilson JG, 1973, ENV BIRTH DEFECTS	19	96	98	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	1994	331	1					1	4		10.1056/NEJM199407073310101	http://dx.doi.org/10.1056/NEJM199407073310101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU951	8202094	Bronze			2022-12-01	WOS:A1994NU95100001
J	NODA, K; GLOVER, BJ; LINSTEAD, P; MARTIN, C				NODA, K; GLOVER, BJ; LINSTEAD, P; MARTIN, C			FLOWER COLOR INTENSITY DEPENDS ON SPECIALIZED CELL-SHAPE CONTROLLED BY A MYB-RELATED TRANSCRIPTION FACTOR	NATURE			English	Article							ANTIRRHINUM-MAJUS; GENE; HOMOLOGY; ARABIDOPSIS; EXPRESSION; ACTIVATOR; PATTERNS; PROTEINS; PRODUCTS; LOCUS	Flower colour is determined primarily by the production of pigments, usually anthocyanins or carotenoids, but the shade and intensity of the colour are often changed by other factors such as vacuolar compounds, pH and metal ions(1,2). Pigmentation can also be affected by the shape of epidermal cells, especially those facing prospective pollinators(3,4). A conical shape is believed to increase the proportion of incident light that enters the epidermal cells, enhancing light absorption by the floral pigments, and thus the intensity of their colour. We have identified a gene (mixta) that affects the intensity of pigmentation of epidermal cells in Antirrhinum majus petals. The cells of the corolla lobes fail to differentiate into their normal conical form in mixta mutants. We have cloned the mixta gene by transposon tagging; its sequence reveals that it encodes a Myb-related protein that probably participates in the transcriptional control of epidermal cell shape.	JOHN INNES INST,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	NODA, K (corresponding author), NIPPON OIL CO LTD,766 HIGASHI TOYOI,KUDAMATSU,YAMAGUCHI 744,JAPAN.							AVILA J, 1993, PLANT J, V3, P553, DOI 10.1046/j.1365-313X.1993.03040553.x; Brouillard R., 1988, FLAVONOIDS ADV RES 1, P525, DOI DOI 10.1007/978-1-4899-2913-6_16; CHUCK G, 1993, PLANT CELL, V5, P371, DOI 10.1105/tpc.5.4.371; COEN ES, 1986, CELL, V47, P285, DOI 10.1016/0092-8674(86)90451-4; GOFF SA, 1991, GENE DEV, V5, P298, DOI 10.1101/gad.5.2.298; GROTEWOLD E, 1991, P NATL ACAD SCI USA, V88, P4587, DOI 10.1073/pnas.88.11.4587; HUISKAMP M, 1994, CELL, V76, P555; JACKSON D, 1991, PLANT CELL, V3, P115, DOI 10.1105/tpc.3.2.115; KAY QON, 1981, BOT J LINN SOC, V83, P57, DOI 10.1111/j.1095-8339.1981.tb00129.x; Kay QON, 1988, PLANTS TODAY     JUL, P109; KEVAN PG, 1985, P NATL ACAD SCI USA, V82, P4750, DOI 10.1073/pnas.82.14.4750; Lassner MW., 1989, PLANT MOL BIOL REP, V7, P116, DOI DOI 10.1007/BF02669627; LUO D, 1991, PLANT J, V1, P59, DOI 10.1111/j.1365-313X.1991.00059.x; MARKS MD, 1989, PLANT CELL, V1, P1043, DOI 10.1105/tpc.1.11.1043; MARTIN C, 1985, EMBO J, V4, P1625, DOI 10.1002/j.1460-2075.1985.tb03829.x; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; Plaskitt K. A., 1988, Molecular Plant-Microbe Interactions, V1, P10, DOI 10.1094/MPMI-1-010; SMITH AM, 1983, PLANTA, V159, P570, DOI 10.1007/BF00409147; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STUBBE H, 1966, GENETIK ZYTOLOGIE AN	21	334	365	8	113	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 23	1994	369	6482					661	664		10.1038/369661a0	http://dx.doi.org/10.1038/369661a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	8208293				2022-12-01	WOS:A1994NT45900059
J	TAKAYAMA, JI; BERGMAN, AB; CONNELL, FA				TAKAYAMA, JI; BERGMAN, AB; CONNELL, FA			CHILDREN IN FOSTER-CARE IN THE STATE OF WASHINGTON - HEALTH-CARE UTILIZATION AND EXPENDITURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUPERVISION; CALIFORNIA; SERVICES; SYSTEM; POLICY	Objective.-To determine and compare health care utilization and expenditures of children in foster care with those of other children and to identify and describe high-cost children in foster care. Design.-Analysis of the Medicaid program claims data in the state of Washington. Population.-A total of 1631 children in foster care and 5316 children in the Aid to Families With Dependent Children (AFDC) program in 1990. The children were ages O through 7 years and eligible for Medicaid continuously during the study year. Main Outcome Measures.-Health care utilization and expenditures classified by types of health service and health care provider; proportion of children with 1990 expenditures exceeding $10 000 and most prominent diagnoses associated with their health care utilization. Results.-Mental health services were used by 25% of children in foster care compared with 3% of AFDC children (P<.001), and supportive services of visiting nurses and physical therapists were used by 13% of children in foster care and 1% of AFDC children (P<.001). Twice as many children in foster care than AFDC children used medical equipment or specialist services or were hospitalized (P<.001). Mean health care expenditures in 1990 were $3075 for children in foster care and $543 for AFDC children (P<.001). High-cost children included 8% of children in foster care and 0.4% of AFDC children. Among the high-cost children in foster care (n=106), 59% had mental disorders and 31% had congenital conditions. Conclusions.-Results suggest a higher prevalence and greater complexity of illnesses, particularly mental disorders, among children in foster care. Despite the high utilization and cost of mental health services, previous research suggests there may be underutilization of these services compared with need. Appropriate allocation of resources is essential if foster care agencies are to adequately meet the diverse and compelling needs of children in foster care.	UNIV WASHINGTON,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SEATTLE,WA; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,SEATTLE,WA 98195; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT PEDIAT,SEATTLE,WA 98104	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle								BENEDICT MI, 1991, CHILD WELFARE, V70, P45; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V42, P937, DOI 10.1016/0895-4356(89)90158-3; BUTLER JA, 1985, PEDIATRICS, V76, P495; CURTIS PA, 1993, CHILD WELFARE, V72, P533; DUGGER CW, 1991, NY TIMES        0908, pA17; FAMULARO R, 1992, J AM ACAD CHILD PSY, V31, P863, DOI 10.1097/00004583-199209000-00013; HALFON N, 1987, PEDIATRICS, V80, P183; HALFON N, 1992, PEDIATRICS, V89, P1238; HALFON N, 1992, PEDIATRICS, V89, P1230; HOCHSTADT NJ, 1987, CHILD ABUSE NEGLECT, V11, P53, DOI 10.1016/0145-2134(87)90033-0; JACOBS J, 1988, J CLIN EPIDEMIOL, V41, P215, DOI 10.1016/0895-4356(88)90124-2; JENKINS S, 1985, AM J ORTHOPSYCHIAT, V55, P267, DOI 10.1111/j.1939-0025.1985.tb03441.x; LEFKOWITZ DC, 1991, 14 DEP HLTH HUM SERV; Lewis Neil A., 1991, NEW YORK TIMES  0714, pA1; LOWRY MA, 1989, CHILDRENS RIGHTS PRO; MARCUS FF, 1989, NY TIMES        0109, pA15; Moffatt M E, 1985, Health Soc Work, V10, P129; PELTON LH, 1987, J SOC SOC WELFARE, V16, P37; Rosner B., 1995, FUNDAMENTALS BIOSTAT; SAUNDERS EJ, 1993, CHILD WELFARE, V72, P341; Schor E L, 1989, Pediatr Rev, V10, P209, DOI 10.1542/pir.10-7-209; SCHOR EL, 1981, CHILD WELFARE, V60, P313; SCHOR EL, 1982, PEDIATRICS, V69, P521; SHAH CP, 1974, CAN J PUBLIC HEALTH, V65, P34; SWIRE MR, 1978, CHILD WELFARE, V57, P563; SWIRE MR, 1977, CHILD WELFARE, V56, P635; TATARA T, 1993, 9 AM PUBL WELF ASS; TRUPIN E, 1988, WASHINGTON STATE CHI; WEINSTEIN J, 1990, CALIFORNIA W LAW REV, V26, P319; WHITE RB, 1987, CHILD WELFARE, V66, P387; ZILL N, 1990, HLTH OUR NATIONS CHI, V190, P1; 1991, STATE AM CHILDREN 19; 1987, PEDIATRICS, V79, P644; 1992, PEDIATRICS, V89, P681; 1988, STANDARDS HLTH CARE; 1992, NY TIMES        1213, pA48; 1991, COSTS LENGTHS STAY C	37	99	99	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1850	1855		10.1001/jama.271.23.1850	http://dx.doi.org/10.1001/jama.271.23.1850			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NP959	8196142				2022-12-01	WOS:A1994NP95900029
J	LAKKA, TA; VENALAINEN, JM; RAURAMAA, R; SALONEN, R; TUOMILEHTO, J; SALONEN, JT				LAKKA, TA; VENALAINEN, JM; RAURAMAA, R; SALONEN, R; TUOMILEHTO, J; SALONEN, JT			RELATION OF LEISURE-TIME PHYSICAL-ACTIVITY AND CARDIORESPIRATORY FITNESS TO THE RISK OF ACUTE MYOCARDIAL-INFARCTION IN MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISCHEMIC-HEART-DISEASE; EASTERN FINNISH MEN; UNITED-STATES RAILROAD; ALL-CAUSE MORTALITY; PROSPECTIVE POPULATION; PLASMA-FIBRINOGEN; COLLEGE ALUMNI; FOLLOW-UP; ASSOCIATION; PREDICTOR	Background. Previous studies have suggested that higher levels of regular physical activity and cardiorespiratory fitness are associated with a reduced risk of coronary heart disease. We investigated the independent associations of physical activity during leisure time and maximal oxygen uptake (a measure of cardiorespiratory fitness) with the risk of acute myocardial infarction. Methods. During the period 1984 to 1989, we performed base-line examinations in 1453 men 42 to 60 years old who did not report having cardiovascular disease or cancer. Physical activity was assessed quantitatively with a detailed questionnaire, and maximal oxygen uptake was measured directly by exercise testing. During an average follow-up of 4.9 years, 42 of the 1166 men with normal electrocardiograms at base line had a first acute myocardial infarction. Results. After adjustment for age and the year of examination, the relative hazard (risk) of myocardial infarction in the third of subjects with the highest level of physical activity (> 2.2 hours per week) was 0.31 (95 percent confidence interval, 0.12 to 0.85; P = 0.02), as compared with the third with the lowest level (P = 0.04 for linear trend over all three groups). The relative hazard in the third with the highest maximal oxygen uptake (> 2.7 liters per minute) was 0.26 (95 percent confidence interval, 0.10 to 0.68; P = 0.006) (P = 0.006 for linear trend), after adjustment for age, the year and season when the examination was performed, weight, height, and the type of respiratory-gas analyzer used. After up to 17 confounding variables were controlled for, the relative hazards for the third of subjects with the highest level of physical activity (0.34; 95 percent confidence interval, 0.12 to 0.94; P = 0.04) and maximal oxygen uptake (0.35; 95 percent confidence interval, 0.13 to 0.92; P = 0.03), as compared with the values in the lowest third, were significantly (P < 0.05) less than 1.0. Conclusions. Higher levels of both leisure-time physical activity and cardiorespiratory fitness had a strong, graded, inverse association with the risk of acute myocardial infarction, supporting the idea that lower levels of physical activity-and cardiorespiratory fitness are independent risk factors for coronary heart disease in men.	UNIV KUOPIO, PUBL HLTH RES INST, SF-70211 KUOPIO, FINLAND; KUOPIO RES INST EXERCISE MED, KUOPIO, FINLAND; NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, HELSINKI, FINLAND	University of Eastern Finland; Finland National Institute for Health & Welfare				Lakka, Timo/0000-0002-9199-2871				BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; COX DR, 1972, J R STAT SOC B, V34, P187; DEBACKER G, 1981, CARDIOLOGY, V67, P110, DOI 10.1159/000173235; DIXON WJ, 1988, BMDP STATISTICAL SOF; Durnin J., 1967, ENERGY WORK LEISURE; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; FLETCHER GF, 1990, CIRCULATION, V82, P2286, DOI 10.1161/01.CIR.82.6.2286; Fox S M 3rd, 1972, Mod Concepts Cardiovasc Dis, V41, P25; GARCIAPALMIERI MR, 1982, AM J CARDIOL, V50, P749, DOI 10.1016/0002-9149(82)91229-2; HASKELL WL, 1992, MED SCI SPORT EXER, V24, pS201, DOI 10.1249/00005768-199206001-00004; HEIN HO, 1992, J INTERN MED, V232, P471, DOI 10.1111/j.1365-2796.1992.tb00619.x; JACOBS DR, 1993, MED SCI SPORT EXER, V25, P81, DOI 10.1249/00005768-199301000-00012; KARVONEN MJ, 1982, ANN CLIN RES, V14, P118; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; LAKKA TA, 1992, INT J EPIDEMIOL, V21, P467, DOI 10.1093/ije/21.3.467; LAKKA TA, 1992, AM J EPIDEMIOL, V136, P806, DOI 10.1093/aje/136.7.806; LAKKA TA, 1993, J CLIN EPIDEMIOL, V46, P1119, DOI 10.1016/0895-4356(93)90111-D; LAKKA TA, IN PRESS AM J EPIDEM; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; MALKIA E, 1988, SUOMALAISTEN AIKUIST; MORRIS JN, 1980, LANCET, V2, P1207; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PETERS RK, 1983, JAMA-J AM MED ASSOC, V249, P3052, DOI 10.1001/jama.249.22.3052; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SALONEN JT, 1991, AM J EPIDEMIOL, V134, P268, DOI 10.1093/oxfordjournals.aje.a116080; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1988, AM J EPIDEMIOL, V127, P87, DOI 10.1093/oxfordjournals.aje.a114794; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SHAPER AG, 1992, BRIT HEART J, V67, P209; SHAPER AG, 1991, BRIT HEART J, V66, P384; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; SOBOLSKI J, 1987, AM J EPIDEMIOL, V125, P601, DOI 10.1093/oxfordjournals.aje.a114573; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; TUOMILEHTO J, 1992, EUR HEART J, V13, P577, DOI 10.1093/oxfordjournals.eurheartj.a060219; TUOMILEHTO J, 1992, EUR HEART J, V13, P1153, DOI 10.1093/oxfordjournals.eurheartj.a060329; WILSON TW, 1993, AM J EPIDEMIOL, V137, P292, DOI 10.1093/oxfordjournals.aje.a116676; [No title captured]	42	611	619	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1549	1554		10.1056/NEJM199406023302201	http://dx.doi.org/10.1056/NEJM199406023302201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	8177243				2022-12-01	WOS:A1994NN21500001
J	RUSSELL, RM				RUSSELL, RM			NUTRITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE-SPECIFIC MORTALITY; VITAMIN-E CONSUMPTION; MYOCARDIAL-INFARCTION; INTERVENTION TRIALS; CANCER INCIDENCE; RISK; SUPPLEMENTATION; POPULATION; LINXIAN; WOMEN				RUSSELL, RM (corresponding author), TUFTS UNIV,BOSTON,MA 02111, USA.							BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; KARDINAAL AFM, 1993, LANCET, V342, P1379, DOI 10.1016/0140-6736(93)92751-E; LI JY, 1993, J NATL CANCER I, V85, P1492, DOI 10.1093/jnci/85.18.1492; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SENTI FR, 1984, ASSESSMENT FOLATE NU; STAMPFER MJ, 1993, JAMA-J AM MED ASSOC, V270, P2726, DOI 10.1001/jama.270.22.2726; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; 1993, FED REG         0106, V58, P632; 1993, FED REG         0106, V58, P2066; 1994, NEW ENGL J MED, V330, P1029	14	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	1994	271	21					1687	1689		10.1001/jama.271.21.1687	http://dx.doi.org/10.1001/jama.271.21.1687			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN117	8182853				2022-12-01	WOS:A1994NN11700032
J	POMERANTZ, LM; BENNETT, J				POMERANTZ, LM; BENNETT, J			FUNGI AS A CAUSE OF OTITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									NIAID,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								HALL PJ, 1993, OTOLARYNG HEAD NECK, V108, P167, DOI 10.1177/019459989310800210; PETRAK RM, 1985, J INFECT DIS, V151, P196, DOI 10.1093/infdis/151.1.196	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	1994	271	20					1628	1628						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL758	8182818				2022-12-01	WOS:A1994NL75800038
J	ALLAIRE, M; CHERNAIA, MM; MALCOLM, BA; JAMES, MNG				ALLAIRE, M; CHERNAIA, MM; MALCOLM, BA; JAMES, MNG			PICORNAVIRAL 3C CYSTEINE PROTEINASES HAVE A FOLD SIMILAR TO CHYMOTRYPSIN-LIKE SERINE PROTEINASES	NATURE			English	Article							HEPATITIS-A VIRUS; MACROMOLECULAR STRUCTURES; WEISSENBERG CAMERA; DIFFRACTION DATA; CRYSTALLOGRAPHY; MUTAGENESIS; REFINEMENT; PROTEASES; PROGRAM	THE picornavirus family includes several pathogens such as poliovirus, rhinovirus (the major cause of the common cold), hepatitis A virus and the foot-and-mouth disease virus. Picornaviral proteins are expressed by direct translation of the genomic RNA into a single, large polyprotein precursor(1,2). Proteolysis of the viral polyprotein into the mature proteins is assured by the viral 3C enzymes, which are cysteine proteinases(3-6). Here we report the Xray crystal structure at 2.3 Angstrom resolution of the 3C proteinase from hepatitis A virus (HAV-3C). The overall architecture of HAV-3C reveals a fold resembling that of the chymotrypsin family of serine proteinases, which is consistent with earlier predictions(7,8). Catalytic residues include Cys 172 as nucleophile and His 44 as general base. The 3C cleavage specificity for glutamine residues is defined primarily by His 191. The overall structure suggests that an intermolecular (trans) cleavage releases 3C and that there is an active proteinase in the polyprotein.	UNIV ALBERTA,DEPT BIOCHEM,MRC,PROT STRUCT & FUNCT GRP,EDMONTON T6G 2H7,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,AB,CANADA; UNIV ALBERTA,DEPT MED MICROBIOL & INFECT DIS,EDMONTON T6G 2H7,AB,CANADA	University of Alberta; University of Alberta; University of Alberta								ARGOS P, 1984, NUCLEIC ACIDS RES, V12, P7251, DOI 10.1093/nar/12.18.7251; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CHERNAIA MM, 1993, J MOL BIOL, V234, P890, DOI 10.1006/jmbi.1993.1636; CHOTHIA C, 1982, BIOCHEMISTRY-US, V21, P3955, DOI 10.1021/bi00260a009; COHEN JI, 1987, J VIROL, V61, P50, DOI 10.1128/JVI.61.1.50-59.1987; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUJINAGA M, 1987, J MOL BIOL, V195, P397, DOI 10.1016/0022-2836(87)90659-0; FUJINAGA M, 1985, J MOL BIOL, V183, P479; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; HAMMERLE T, 1991, J BIOL CHEM, V266, P5412; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; IVANOFF LA, 1986, P NATL ACAD SCI USA, V83, P5392, DOI 10.1073/pnas.83.15.5392; JEWELL DA, 1992, BIOCHEMISTRY-US, V31, P7862, DOI 10.1021/bi00149a017; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KEAN KM, 1991, VIROLOGY, V181, P609, DOI 10.1016/0042-6822(91)90894-H; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUT J, 1971, COLD SPRING HARB SYM, V36, P117, DOI 10.1101/SQB.1972.036.01.017; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124	30	258	275	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					72	76		10.1038/369072a0	http://dx.doi.org/10.1038/369072a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164744				2022-12-01	WOS:A1994NJ86000056
J	IP, YT; REACH, M; ENGSTROM, Y; KADALAYIL, L; CAI, H; GONZALEZCRESPO, S; TATEI, K; LEVINE, M				IP, YT; REACH, M; ENGSTROM, Y; KADALAYIL, L; CAI, H; GONZALEZCRESPO, S; TATEI, K; LEVINE, M			DIF, A DORSAL-RELATED GENE THAT MEDIATES AN IMMUNE-RESPONSE IN DROSOPHILA	CELL			English	Article							NF-KAPPA-B; EMBRYONIC DORSOVENTRAL POLARITY; VENTRAL PATTERN-FORMATION; DNA-BINDING PROTEINS; ACUTE-PHASE RESPONSE; NUCLEAR-FACTOR; TRANSCRIPTION FACTORS; EXPRESSION; REL; TOLL	There are striking parallels between the regulation of gene expression along the dorsoventral (DV) axis of Drosophila embryos and lymphoid-restricted expression in the mammalian immune system. Both depend on regulatory factors containing rel domains (dorsal and NF-kappaB) that are controlled at the level of nuclear transport. A novel Rel-containing gene in Drosophila, Dif (dorsal-related immunity factor), provides a potential link between these seemingly disparate processes. Although Dif maps close to dorsal, it does not appear to participate in DV patterning, but instead mediates an immune response in Drosophila larvae. Dif is normally localized in the cytoplasm of the larval fat body, but quickly accumulates in the nucleus upon bacterial infection or injury. Evidence is presented that once in the nucleus, Dif binds to kappaB-like sequence motifs present in promoter regions of immunity genes. These results suggest that mammalian and insect immunity share a common evolutionary origin.	UNIV STOCKHOLM,ARRHENIUS LAB,DEPT MOLEC BIOL,S-10691 STOCKHOLM,SWEDEN	Stockholm University	IP, YT (corresponding author), UNIV CALIF SAN FRANCISCO,CTR MOLEC GENET,DEPT BIOL,SAN FRANCISCO,CA 94143, USA.			Levine, Michael/0000-0001-7629-0081; Engstrom, Ylva/0000-0002-8731-4613; Kadalayil, Latha/0000-0002-3757-5487	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046638, R37GM046638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1991, NEW BIOL, V3, P511; ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P409; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOMAN HG, 1972, NATURE, V237, P232, DOI 10.1038/237232a0; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; EDBROOKE MR, 1991, CYTOKINE, V3, P380, DOI 10.1016/1043-4666(91)90041-B; ENGSTROM Y, 1993, J MOL BIOL, V232, P327, DOI 10.1006/jmbi.1993.1392; ENGSTROM Y, 1993, INSECT MOL SCI, P125; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; FREEDMAN AR, 1992, BIOCHEM J, V287, P645, DOI 10.1042/bj2870645; Gateff E., 1980, INVERTEBRATE SYSTEMS, P517; GAY NJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P290, DOI 10.1016/0167-4781(92)90163-T; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GERTTULA S, 1988, GENETICS, V119, P123; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; GONZALEZCRESPO S, 1993, GENE DEV, V7, P1703, DOI 10.1101/gad.7.9.1703; GORDON AH, 1985, RES MONOGRAPHS CELL, V10; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GRANT PA, 1992, NUCLEIC ACIDS RES, V20, P4401, DOI 10.1093/nar/20.17.4401; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENTSCH B, 1992, NUCLEIC ACIDS RES, V20, P2657, DOI 10.1093/nar/20.11.2657; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1991, CELL, V64, P439; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOBAYASHI A, 1993, MOL CELL BIOL, V13, P4049, DOI 10.1128/MCB.13.7.4049; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; RON D, 1990, MOL CELL ENDOCRINOL, V74, P97; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; SAMAKOVLIS C, 1990, EMBO J, V9, P2969, DOI 10.1002/j.1460-2075.1990.tb07489.x; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SUN SC, 1991, EUR J BIOCHEM, V196, P247, DOI 10.1111/j.1432-1033.1991.tb15811.x; SUN SC, 1992, EUR J BIOCHEM, V204, P885, DOI 10.1111/j.1432-1033.1992.tb16708.x; TRYSELIUS Y, 1992, EUR J BIOCHEM, V204, P395, DOI 10.1111/j.1432-1033.1992.tb16648.x	69	379	390	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					753	763		10.1016/0092-8674(93)90495-C	http://dx.doi.org/10.1016/0092-8674(93)90495-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242747				2022-12-01	WOS:A1993MH74900020
J	NEELY, A; WEI, XY; OLCESE, R; BIRNBAUMER, L; STEFANI, E				NEELY, A; WEI, XY; OLCESE, R; BIRNBAUMER, L; STEFANI, E			POTENTIATION BY THE BETA-SUBUNIT OF THE RATIO OF THE IONIC CURRENT TO THE CHARGE MOVEMENT IN THE CARDIAC CALCIUM-CHANNEL	SCIENCE			English	Article							SKELETAL-MUSCLE; BETA-SUBUNIT; VENTRICULAR MYOCYTES; GUINEA-PIG; EXPRESSION; RECEPTOR	The voltage-activated rabbit cardiac calcium channel alpha1 subunit was expressed in Xenopus oocytes. The charge movement of its voltage sensor was measured and related to the opening of the ion-conducting pore. The half-activation potential for charge movement was 35 millivolts more negative than that for pore opening. Coexpression of the cardiac calcium channel beta subunit reduced this difference without affecting charge movement. Thus, intramolecular coupling between the voltage sensor and the channel pore opening can be facilitated by a regulatory subunit.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED ENDOCRINOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT NEUROL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	NEELY, A (corresponding author), BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA.		Neely, Alan/A-8715-2009	Neely, Alan/0000-0002-6007-2159	NHLBI NIH HHS [HL37044] Funding Source: Medline; NIAMS NIH HHS [AR38970] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038970] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; ADAMS DJ, 1979, J PHYSIOL-LONDON, V291, P467, DOI 10.1113/jphysiol.1979.sp012826; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; BEAN BP, 1989, J GEN PHYSIOL, V94, P65, DOI 10.1085/jgp.94.1.65; BENZANILLA F, 1991, SCIENCE, V254, P679; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; HADLEY RW, 1989, J PHYSIOL-LONDON, V415, P601, DOI 10.1113/jphysiol.1989.sp017738; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PEROZO E, 1992, BIOPHYS J, V62, P160, DOI 10.1016/S0006-3495(92)81802-7; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; SHIROKOV R, 1992, J GEN PHYSIOL, V99, P863, DOI 10.1085/jgp.99.6.863; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1991, J BIOL CHEM, V266, P21943	19	222	225	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1993	262	5133					575	578		10.1126/science.8211185	http://dx.doi.org/10.1126/science.8211185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC935	8211185				2022-12-01	WOS:A1993MC93500043
J	UREN, NG; MELIN, JA; DEBRUYNE, B; WIJNS, W; BAUDHUIN, T; CAMICI, PG				UREN, NG; MELIN, JA; DEBRUYNE, B; WIJNS, W; BAUDHUIN, T; CAMICI, PG			RELATION BETWEEN MYOCARDIAL BLOOD-FLOW AND THE SEVERITY OF CORONARY-ARTERY STENOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITRON-EMISSION TOMOGRAPHY; N-13 AMMONIA; NONINVASIVE QUANTIFICATION; PHYSIOLOGIC SIGNIFICANCE; SUBSELECTIVE MEASUREMENT; GEOMETRIC DIMENSIONS; RESERVE; PERFUSION; ARTERIOGRAPHY; DISEASE	Background. We assessed the relation between the severity of stenosis in a coronary artery and the degree of impairment of myocardial blood flow. Studies in laboratory animals have shown that as the degree of coronary-artery stenosis increases, the maximal coronary flow measured after maximal vasodilatation progressively decreases, with a concomitant decrease in basal flow. However, this relation has not been carefully documented in humans through measurement of myocardial blood flow. Methods, We studied 35 patients with single-vessel coronary artery disease and normal left ventricular function and 21 age-matched controls. Regional myocardial blood flow in the area supplied by the stenosed artery was measured by positron-emission tomography with oxygen-15-labeled water while the subject was at rest (basal flow) and during hyperemia induced by the intravenous administration of the vasodilator adenosine (140 mu g per kilogram of body weight per minute) or dipyridamole (0.56 mg per kilogram). Results. The mean (+/-SD) basal myocardial blood flow was 1.14+/-0.42 ml per minute per gram of tissue in the patients and 1.13+/-0.26 ml per minute per gram in the controls; during hyperemia, myocardial flow was 2.10+/-1.16 and 3.37+/-1.25 ml per minute per gram (P<0.001), respectively. Basal flow was unchanged regardless of the severity of stenosis, expressed as a percentage of the diameter of the affected vessel (range of degrees of stenosis, 17 to 87 percent). In contrast, flow during hyperemia correlated inversely and significantly with the degree of stenosis and correlated directly with the minimal luminal diameter. The coronary vasodilator reserve (defined as the ratio of flow during hyperemia to flow at base line) began to decline when the deg ree of stenosis was about 40 percent and approached unity when stenosis was 80 percent or greater. Conclusions. In humans, basal myocardial blood flow remains constant regardless of the severity of coronary-artery stenosis. However, during hyperemia, flow progressively decreases when the degree of stenosis is about 40 percent or more and does not differ significantly from basal flow when stenosis is 80 percent or greater.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH,CTR CLIN SCI,MRC, CYCLOTRON UNIT, LONDON W12 0HS, ENGLAND; UNIV CATHOLIQUE LOUVAIN, SCH MED, BRUSSELS, BELGIUM; CARDIOVASC CTR, AALST, BELGIUM	Imperial College London; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Cardiovascular Center Aalst			Camici, Paolo/AAN-1959-2020	Camici, Paolo/0000-0001-5584-0750; Wijns, William/0000-0002-7267-4376				ARAUJO LI, 1991, CIRCULATION, V83, P875, DOI 10.1161/01.CIR.83.3.875; BERGMANN SR, 1989, J AM COLL CARDIOL, V14, P639, DOI 10.1016/0735-1097(89)90105-8; BERGMANN SR, 1984, CIRCULATION, V70, P724, DOI 10.1161/01.CIR.70.4.724; BOL A, 1993, CIRCULATION, V87, P512, DOI 10.1161/01.CIR.87.2.512; BROWN BG, 1977, CIRCULATION, V55, P329, DOI 10.1161/01.CIR.55.2.329; CHAN SY, 1992, J AM COLL CARDIOL, V20, P979, DOI 10.1016/0735-1097(92)90201-W; COLE JS, 1976, CATHETER CARDIO DIAG, V2, P185, DOI 10.1002/ccd.1810020212; CZERNIN J, 1993, CIRCULATION, V88, P62, DOI 10.1161/01.CIR.88.1.62; DEMER LL, 1989, CIRCULATION, V79, P825, DOI 10.1161/01.CIR.79.4.825; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; GOLDSTEIN RA, 1987, J CLIN INVEST, V79, P1473, DOI 10.1172/JCI112976; GOULD KL, 1990, J AM COLL CARDIOL, V16, P198, DOI 10.1016/0735-1097(90)90479-9; GOULD KL, 1982, CIRCULATION, V66, P930, DOI 10.1161/01.CIR.66.5.930; GOULD KL, 1986, J AM COLL CARDIOL, V7, P775, DOI 10.1016/S0735-1097(86)80336-9; GOULD KL, 1974, AM J CARDIOL, V34, P48, DOI 10.1016/0002-9149(74)90092-7; GOULD KL, 1990, J AM COLL CARDIOL, V15, P459, DOI 10.1016/S0735-1097(10)80078-6; GOULD KL, 1974, AM J CARDIOL, V33, P87, DOI 10.1016/0002-9149(74)90743-7; GOULD KL, 1988, CIRCULATION, V78, P237, DOI 10.1161/01.CIR.78.2.237; HARRISON DG, 1984, CIRCULATION, V69, P1111, DOI 10.1161/01.CIR.69.6.1111; HERRERO P, 1990, CIRCULATION, V82, P1377, DOI 10.1161/01.CIR.82.4.1377; HOFFMAN EJ, 1986, IEEE T NUCL SCI, V33, P452, DOI 10.1109/TNS.1986.4337141; HUTCHINS GD, 1990, J AM COLL CARDIOL, V15, P1032, DOI 10.1016/0735-1097(90)90237-J; KIRKEEIDE RL, 1986, J AM COLL CARDIOL, V7, P103, DOI 10.1016/S0735-1097(86)80266-2; KLOCKE FJ, 1987, CIRCULATION, V76, P1183, DOI 10.1161/01.CIR.76.6.1183; KLOCKE FJ, 1987, CIRCULATION, V75, P34; KRIVOKAPICH J, 1989, CIRCULATION, V80, P1328, DOI 10.1161/01.CIR.80.5.1328; MCGINN AL, 1990, CIRCULATION, V81, P1319, DOI 10.1161/01.CIR.81.4.1319; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; ROSSEN JD, 1989, CIRCULATION, V79, P566, DOI 10.1161/01.CIR.79.3.566; SCHELBERT HR, 1982, AM J CARDIOL, V49, P1197, DOI 10.1016/0002-9149(82)90045-5; SHAH A, 1985, J AM COLL CARDIOL, V5, P92, DOI 10.1016/S0735-1097(85)80089-9; SIBLEY DH, 1986, J AM COLL CARDIOL, V8, P1332, DOI 10.1016/S0735-1097(86)80305-9; SLAGER CJ, 1986, J AM COLL CARDIOL, V7, P317, DOI 10.1016/S0735-1097(86)80498-3; SPINKS TJ, 1988, IEEE T NUCL SCI, V35, P721, DOI 10.1109/23.12819; UREN NG, 1993, J AM COLL CARDIOL, V21, P612, DOI 10.1016/0735-1097(93)90092-F; UREN NG, 1993, J AM COLL CARDIOL, V22, P650, DOI 10.1016/0735-1097(93)90172-W; VANOVERSCHELDE JLJ, 1993, CIRCULATION, V87, P1513, DOI 10.1161/01.CIR.87.5.1513; WHITE CW, 1984, NEW ENGL J MED, V310, P819, DOI 10.1056/NEJM198403293101304; WILSON RF, 1987, CIRCULATION, V75, P723, DOI 10.1161/01.CIR.75.4.723; WILSON RF, 1985, CIRCULATION, V72, P82, DOI 10.1161/01.CIR.72.1.82; WILSON RF, 1986, CIRCULATION, V73, P444, DOI 10.1161/01.CIR.73.3.444	41	696	711	2	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 23	1994	330	25					1782	1788		10.1056/NEJM199406233302503	http://dx.doi.org/10.1056/NEJM199406233302503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR295	8190154				2022-12-01	WOS:A1994NR29500003
J	GURNEY, ME; PU, HF; CHIU, AY; DALCANTO, MC; POLCHOW, CY; ALEXANDER, DD; CALIENDO, J; HENTATI, A; KWON, YW; DENG, HX; CHEN, WJ; ZHAI, P; SUFIT, RL; SIDDIQUE, T				GURNEY, ME; PU, HF; CHIU, AY; DALCANTO, MC; POLCHOW, CY; ALEXANDER, DD; CALIENDO, J; HENTATI, A; KWON, YW; DENG, HX; CHEN, WJ; ZHAI, P; SUFIT, RL; SIDDIQUE, T			MOTOR-NEURON DEGENERATION IN MICE THAT EXPRESS A HUMAN CU,ZN SUPEROXIDE-DISMUTASE MUTATION	SCIENCE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MICE; DOWNS-SYNDROME; NEUROMUSCULAR-JUNCTION; GROWTH-FACTOR; ANIMAL-MODEL; NITRIC-OXIDE; PEROXYNITRITE; ASSAY; GENE	Mutations of human Cu,Zn superoxide dismutase (SOD) are found in about 20 percent of patients with familial amyotrophic lateral sclerosis (ALS). Expression of high levels of human SOD containing a substitution of glycine to alanine at position 93-a change that has little effect on enzyme activity-caused motor neuron disease in transgenic mice. The mice became paralyzed in one or more limbs as a result of motor neuron loss from the spinal cord and died by 5 to 6 months of age. The results show that dominant, gain-of-function mutations in SOD contribute to the pathogenesis of familial ALS.	NORTHWESTERN UNIV,SCH MED,INST NEUROSCI,CHICAGO,IL 60611; CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV NEUROSCI,DUARTE,CA 91010; NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT PHYSIOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT NEUROL,CHICAGO,IL 60611	Northwestern University; City of Hope; Beckman Research Institute of City of Hope; Northwestern University; Northwestern University; Northwestern University	GURNEY, ME (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT CELL & MOLEC BIOL,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.		Siddique, Teepu/AAT-8166-2021; Eishingdrelo, Haifeng/R-8426-2019	Eishingdrelo, Haifeng/0000-0001-7205-1008; Siddique, Teepu/0000-0001-7293-9146; Kwon, Young/0000-0003-2465-9945; Deng, Han-Xiang/0000-0002-0030-8465				ASADA K, 1974, AGR BIOL CHEM TOKYO, V38, P471, DOI 10.1080/00021369.1974.10861178; AVRAHAM KB, 1991, J NEUROCYTOL, V20, P208, DOI 10.1007/BF01186993; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1624; BORCHELT DR, IN PRESS P NATL ACAD; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; CEBALLOSPICOT I, 1991, BRAIN RES, V552, P198, DOI 10.1016/0006-8993(91)90084-9; CHIU AY, 1993, J COMP NEUROL, V328, P351, DOI 10.1002/cne.903280303; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; ENGEL WK, 1959, BRAIN, V82, P203, DOI 10.1093/brain/82.2.203; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HALLEWELL RA, 1985, NUCLEIC ACIDS RES, V13, P2017, DOI 10.1093/nar/13.6.2017; HALLEWELL RA, 1986, SUPEROXIDE DISMUTASE, P249; HIRANO A, 1967, ARCH NEUROL-CHICAGO, V16, P232, DOI 10.1001/archneur.1967.00470210008002; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MULDER DW, 1982, HUMAN MOTOR NEURON D, P15; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SIDDIQUE T, 1991, ADV NEUROL, V56, P227; SIDDIQUE T, UNPUB; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9	25	3318	3473	4	196	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 17	1994	264	5166					1772	1775		10.1126/science.8209258	http://dx.doi.org/10.1126/science.8209258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR600	8209258				2022-12-01	WOS:A1994NR60000046
J	MERMALL, V; MCNALLY, JG; MILLER, KG				MERMALL, V; MCNALLY, JG; MILLER, KG			TRANSPORT OF CYTOPLASMIC PARTICLES CATALYZED BY AN UNCONVENTIONAL MYOSIN IN LIVING DROSOPHILA EMBRYOS	NATURE			English	Article							ACTIN-FILAMENTS; ACANTHAMOEBA; LOCALIZATION; VESICLES; MOVEMENT; GENE	MYOSINS are actin-activated ATPases that are able to translocate along actin filaments using energy derived from ATP hydrolysis. Non-muscle cells contain conventional myosins, which are similar in sequence and structure to muscle myosin, and a number of unconventional myosins whose head sequences are similar but tail sequences are unrelated to conventional myosins(1). The myosin superfamily currently consists of nine classes(2); Duosophila 95F is an unconventional myosin(3) and the original member of class VI, which includes a homologue found in pig kidney(2). Some unconventional myosins have been suggested as mediators of some types of intracellular transport(4,5), but there is little direct evidence for this function (but see ref. 6). We have observed transport of cytoplasmic particles in live Drosophila embryos in three dimensions using computational optical sectioning microscopy. We present here evidence that this transport is actin-based, ATP-dependent and catalysed by one such unconventional myosin, the 95F myosin. This is, to our knowledge, the first direct observation of transport catalysed by an unconventional myosin in living cells.	WASHINGTON UNIV, INST BIOMED COMP, ST LOUIS, MO 63130 USA	Washington University (WUSTL)	MERMALL, V (corresponding author), WASHINGTON UNIV, DEPT BIOL, CAMPUS BOX 1137, ST LOUIS, MO 63130 USA.							ADAMS RJ, 1986, NATURE, V322, P754, DOI 10.1038/322754a0; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; ALBANESI JP, 1985, J BIOL CHEM, V260, P8649; Ashburner M, 1989, DROSOPHILA LAB HDB, P1; BAINES IC, 1992, J CELL BIOL, V119, P1193, DOI 10.1083/jcb.119.5.1193; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; DOBERSTEIN SK, 1993, NATURE, V365, P841, DOI 10.1038/365841a0; ELLGAARD EG, 1975, CELL DIFFER DEV, V3, P379, DOI 10.1016/0045-6039(75)90006-8; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GAIL MH, 1970, BIOPHYS J, V10, P980, DOI 10.1016/S0006-3495(70)86347-0; GREENWOOD JA, 1955, ANN MATH STAT, V26, P233, DOI 10.1214/aoms/1177728540; HARTMAN R, 1993, COMPUT METH PROG BIO, V39, P195, DOI 10.1016/0169-2607(93)90021-C; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KELLERMAN KA, 1992, J CELL BIOL, V119, P823, DOI 10.1083/jcb.119.4.823; MARDIA KV, 1972, STATISTICS DIRECTION; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; SHEETZ MP, 1983, NATURE, V303, P31, DOI 10.1038/303031a0; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406	21	114	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	1994	369	6481					560	562		10.1038/369560a0	http://dx.doi.org/10.1038/369560a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	8202156				2022-12-01	WOS:A1994NR29400049
J	CHAN, AC; KADLECEK, TA; ELDER, ME; FILIPOVICH, AH; KUO, WL; IWASHIMA, M; PARSLOW, TG; WEISS, A				CHAN, AC; KADLECEK, TA; ELDER, ME; FILIPOVICH, AH; KUO, WL; IWASHIMA, M; PARSLOW, TG; WEISS, A			ZAP-70 DEFICIENCY IN AN AUTOSOMAL RECESSIVE FORM OF SEVERE COMBINED IMMUNODEFICIENCY	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASE; ZETA-CHAIN; MICE LACKING; T-CELLS; STIMULATION; THYMOCYTES; ACTIVATION; P56(LCK); P56LCK	Protein tyrosine kinases (PTKs) play an integral role in T cell activation and differentiation. Defects in the Src-family PTKs in mice and in T cell lines have resulted in variable defects in thymic development and in T cell antigen receptor (TCR) signal transduction. Here, three siblings are described with an autosomal recessive form of severe combined immunodeficiency disease (SCID) in which ZAP-70, a non-Src PTK, is absent as a result of mutations in the ZAP-70 gene. This absence is associated with defects in TCR signal transduction, suggesting an important functional role for ZAP-70.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA; UNIV MINNESOTA, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA; UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Kadlecek, Theresa/0000-0002-1020-8169	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-20684] Funding Source: Medline; NIGMS NIH HHS [GM39553] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Chan A. H. Y., UNPUB; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; ELDER ME, UNPUB; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KALLIONIERNI A, IN PRESS GENOMICS; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MONAFO WJ, 1992, CLIN EXP IMMUNOL, V90, P390; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TRASK BJ, 1991, AM J HUM GENET, V48, P1; Veillette A, 1991, Semin Immunol, V3, P143; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WIEST DL, 1993, J EXP MED, V178, P1701, DOI 10.1084/jem.178.5.1701	27	425	434	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	1994	264	5165					1599	1601		10.1126/science.8202713	http://dx.doi.org/10.1126/science.8202713			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ285	8202713				2022-12-01	WOS:A1994NQ28500039
J	LOMBARDI, G; SIDHU, S; BATCHELOR, R; LECHLER, R				LOMBARDI, G; SIDHU, S; BATCHELOR, R; LECHLER, R			ANERGIC T-CELLS AS SUPPRESSOR CELLS IN-VITRO	SCIENCE			English	Article							GROWTH-FACTOR-BETA; ANTIGEN-PRESENTING CELLS; RECEPTOR EXPRESSION; CLONES; PROLIFERATION; TOLERANCE; INHIBITION; INDUCTION; PEPTIDES; IL-10	T cell-mediated suppression is an established phenomenon, but its underlying mechanisms are obscure. An in vitro system was used to test the possibility that anergic T cells can act as specific suppressor cells. Anergic human T cells caused inhibition of antigen-specific and allospecific T cell proliferation. In order for the inhibition to occur, the anergic T cells had to be specific for the same antigen-presenting cells (APCs) as the T cells that were suppressed. The mechanism of this suppression appears to be competition for the APC surface and for locally produced interleukin-2.	ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0NN,ENGLAND	Imperial College London								ARNOLD B, 1993, IMMUNOL TODAY, V14, P12, DOI 10.1016/0167-5699(93)90317-E; BATCHELOR JR, 1984, TRANSPLANTATION, V37, P43, DOI 10.1097/00007890-198401000-00013; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DIMUTHU R, 1991, J IMMUNOL, V147, P3261; DING L, 1993, J IMMUNOL, V151, P1224; DUBOIS CM, 1990, J EXP MED, V172, P737, DOI 10.1084/jem.172.3.737; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GO C, 1993, J IMMUNOL, V150, P367; HEATH WR, 1991, P NATL ACAD SCI USA, V88, P5101, DOI 10.1073/pnas.88.12.5101; JENKINS MK, 1990, J IMMUNOL, V144, P16; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KILSHAW PJ, 1975, NATURE, V255, P489, DOI 10.1038/255489a0; LAMB JR, 1987, EUR J IMMUNOL, V17, P1641, DOI 10.1002/eji.1830171118; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LECHLER RI, 1993, TRANSPLANT SCI, V3, P6; LOMBARDI G, 1989, J IMMUNOL, V142, P753; MALEFYT RD, 1991, J EXP MED, V174, P915; MALEFYT RD, 1993, J IMMUNOL, V150, P4754; MARTINEZ OM, 1990, J IMMUNOL, V144, P2211; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; QUILL H, 1987, J IMMUNOL, V138, P3704; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; SIDHU S, 1992, J EXP MED, V176, P875, DOI 10.1084/jem.176.3.875; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P5914, DOI 10.1073/pnas.90.13.5914; TILNEY NL, 1978, J IMMUNOL, V121, P1480; WALDMANN H, 1992, J AUTOIMMUN, V5, P93, DOI 10.1016/0896-8411(92)90024-K	30	361	375	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 10	1994	264	5165					1587	1589		10.1126/science.8202711	http://dx.doi.org/10.1126/science.8202711			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ285	8202711				2022-12-01	WOS:A1994NQ28500035
J	COPELAND, A; LENNON, G				COPELAND, A; LENNON, G			RAPID ARRAYED FILTER PRODUCTION USING THE ORCA ROBOT	NATURE			English	Article											COPELAND, A (corresponding author), LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,BIOL & BIOTECHNOL RES PROGRAM,L-452,LIVERMORE,CA 94550, USA.		Lennon, Greg/T-4717-2019					CARRANO AV, 1989, GENOMICS, V4, P129, DOI 10.1016/0888-7543(89)90291-7; CARRANO AV, 1989, GENOME, V31, P1059, DOI 10.1139/g89-182; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; LENNON G, 1994, HIGH DENSITY GRID TE, P126; LENNON GG, 1991, TRENDS GENET, V7, P314, DOI 10.1016/0168-9525(91)90420-U; OLSEN AS, 1993, BIOTECHNIQUES, V14, P116; SCHOENY DE, 1991, J AM LAB, P42; SHLZUKA H, 1992, P NATL ACAD SCI USA, V89, P8794	8	15	16	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					421	422		10.1038/369421a0	http://dx.doi.org/10.1038/369421a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	8196771				2022-12-01	WOS:A1994NP17400063
J	SURRIDGE, C				SURRIDGE, C			WATERSHED FOR THE STRUCTURE OF CYTOCHROME-C	NATURE			English	Editorial Material							CONFORMATION CHANGE							Surridge, Christopher/0000-0003-4264-5176				CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; JENG MF, 1994, NAT STRUCT BIOL, V1, P234, DOI 10.1038/nsb0494-234; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; OTTING G, 1989, J AM CHEM SOC, V111, P1871, DOI 10.1021/ja00187a050; QI PX, 1994, NAT STRUCT BIOL, V1, P379; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; XU RX, 1993, BIOCHEMISTRY-US, V32, P2473, DOI 10.1021/bi00061a004	8	2	2	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					426	426		10.1038/369426a0	http://dx.doi.org/10.1038/369426a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	8196772	Bronze			2022-12-01	WOS:A1994NP17400064
J	CARANDINI, M; HEEGER, DJ				CARANDINI, M; HEEGER, DJ			SUMMATION AND DIVISION BY NEURONS IN PRIMATE VISUAL-CORTEX	SCIENCE			English	Article							CAT STRIATE CORTEX; CONTRAST-RESPONSE FUNCTION; LAYER-V NEURONS; SIMPLE CELLS; DIRECTION SELECTIVITY; INHIBITION; INVITRO; MECHANISMS	Recordings from monkey primary visual cortex (V1) were used to test a model for the visually driven responses of simple cells. According to the model, simple cells compute a linear sum of the responses of lateral geniculate nucleus (LGN) neurons. In addition, each simple cell's linear response is divided by the pooled activity of a large number of other simple cells. The cell membrane performs both operations; synaptic currents are summed and then divided by the total membrane conductance. Current and conductance are decoupled (by a complementary arrangement of excitation and inhibition) so that current depends only on the LGN inputs and conductance depends only on the cortical inputs. Closed form expressions were derived for fitting and interpreting physiological data. The model accurately predicted responses to drifting grating stimuli of various contrasts, orientations, and spatiotemporal frequencies.	STANFORD UNIV,DEPT PSYCHOL,STANFORD,CA 94305	Stanford University	CARANDINI, M (corresponding author), NYU,CTR NEURAL SCI,NEW YORK,NY 10003, USA.		Carandini, Matteo/ABD-8296-2021; Carandini, Matteo/C-1922-2008	Carandini, Matteo/0000-0003-4880-7682; Carandini, Matteo/0000-0003-4880-7682	NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH050228] Funding Source: NIH RePORTER; NIMH NIH HHS [1-R29-MH50228-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBRECHT DG, 1982, J NEUROPHYSIOL, V48, P217, DOI 10.1152/jn.1982.48.1.217; ALBRECHT DG, 1991, VISUAL NEUROSCI, V7, P531, DOI 10.1017/S0952523800010336; BENARDETE EA, 1992, VISUAL NEUROSCI, V8, P483, DOI 10.1017/S0952523800004995; BERMAN NJ, 1991, J PHYSIOL-LONDON, V440, P697, DOI 10.1113/jphysiol.1991.sp018731; BERNANDER O, 1991, P NATL ACAD SCI USA, V88, P11569, DOI 10.1073/pnas.88.24.11569; BONDS AB, 1989, VISUAL NEUROSCI, V2, P41, DOI 10.1017/S0952523800004314; CAMPBELL FW, 1969, J PHYSIOL-LONDON, V203, P223, DOI 10.1113/jphysiol.1969.sp008861; COOMBS JS, 1955, J PHYSIOL-LONDON, V130, P396, DOI 10.1113/jphysiol.1955.sp005414; DEAN AF, 1986, EXP BRAIN RES, V62, P143; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; FERSTER D, 1988, J NEUROSCI, V8, P1172; GROSSBERG S, 1988, NEURAL NETWORKS, V1, P17, DOI 10.1016/0893-6080(88)90021-4; HEEGER DJ, 1993, J NEUROPHYSIOL, V70, P1885, DOI 10.1152/jn.1993.70.5.1885; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P427, DOI 10.1017/S095252380001124X; HEGGELUND P, 1981, EXP BRAIN RES, V42, P89; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAGADEESH B, 1993, SCIENCE, V262, P1901, DOI 10.1126/science.8266083; JAGADEESH B, 1992, J NEUROSCI, V12, P1262; KOCH C, 1987, SYNAPTIC FUNCTION, P637; LI CY, 1984, PFLUG ARCH EUR J PHY, V401, P304; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P53, DOI 10.1113/jphysiol.1978.sp012488; OGAWA T, 1981, BRAIN RES, V226, P315, DOI 10.1016/0006-8993(81)91105-7; PALMER LA, 1981, J NEUROPHYSIOL, V46, P260, DOI 10.1152/jn.1981.46.2.260; SHAPLEY R, 1990, ANNU REV PSYCHOL, V41, P635, DOI 10.1146/annurev.ps.41.020190.003223; SPERLING G, 1968, J OPT SOC AM, V58, P1133, DOI 10.1364/JOSA.58.001133; STAFSTROM CE, 1984, J NEUROPHYSIOL, V52, P278, DOI 10.1152/jn.1984.52.2.278; STAFSTROM CE, 1984, J NEUROPHYSIOL, V52, P264, DOI 10.1152/jn.1984.52.2.264; STRATFORD K, 1990, COMPUTING NEURON, P296	29	439	445	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 27	1994	264	5163					1333	1336		10.1126/science.8191289	http://dx.doi.org/10.1126/science.8191289			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN767	8191289				2022-12-01	WOS:A1994NN76700047
J	SUH, WK; COHENDOYLE, MF; FRUH, K; WANG, K; PETERSON, PA; WILLIAMS, DB				SUH, WK; COHENDOYLE, MF; FRUH, K; WANG, K; PETERSON, PA; WILLIAMS, DB			INTERACTION OF MHC CLASS-I MOLECULES WITH THE TRANSPORTER ASSOCIATED WITH ANTIGEN-PROCESSING	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MUTANT-CELL LINE; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; PRESENTATION PATHWAY; PEPTIDE BINDING; LYMPHOCYTES-T; HEAVY-CHAINS; RMA-S; PROTEIN	The transporter associated with antigen processing (TAP) delivers cytosolic peptides into the endoplasmic reticulum (ER) where they bind to nascent class I histocompatibility molecules. Class I-peptide complexes are then displayed at the cell surface for recognition by cytotoxic T lymphocytes. Immunoprecipitation of either TAP or class I molecules revealed an association between the transporter and diverse class I products. TAP bound preferentially to heterodimers of the class I heavy chain and beta(2)-microglobulin, and the complex subsequently dissociated in parallel with transport of class I molecules from the ER to the Golgi apparatus. The TAP-class I complexes could also be dissociated in vitro by the addition of class I-binding peptides. The association of class I molecules with TAP likely promotes efficient capture of peptides before their exposure to the lumen of the ER.	UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ON, CANADA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	University of Toronto; Scripps Research Institute				Suh, Woong-Kyung/0000-0002-6420-3283; Frueh, Klaus/0000-0001-8014-3877				ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BIJLMAKERS MJ, 1993, CURR OPIN IMMUNOL, V5, P21, DOI 10.1016/0952-7915(93)90076-5; BURSHTYN DB, 1993, J IMMUNOL, V151, P3982; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CERUNDOLO V, 1992, EUR J IMMUNOL, V22, P2243, DOI 10.1002/eji.1830220910; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P2085, DOI 10.1002/eji.1830220819; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P3121, DOI 10.1002/eji.1830221214; ENGELHARD VH, 1994, CURR OPIN IMMUNOL, V6, P13, DOI 10.1016/0952-7915(94)90028-0; GASKINS HR, 1992, SCIENCE, V256, P1826, DOI 10.1126/science.1352067; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P493; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; LAPHAM CK, 1993, J EXP MED, V177, P1633, DOI 10.1084/jem.177.6.1633; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; NEEFJES JJ, 1993, J EXP MED, V178, P1971, DOI 10.1084/jem.178.6.1971; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1980, J IMMUNOL, V125, P2473; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; SHEPHERD JC, 1993, SCIENCE, V74, P577; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1992, NATURE, V356, P386, DOI 10.1038/356386a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; YANG Y, 1992, J BIOL CHEM, V267, P11669; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	56	278	281	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 27	1994	264	5163					1322	1326		10.1126/science.8191286	http://dx.doi.org/10.1126/science.8191286			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN767	8191286				2022-12-01	WOS:A1994NN76700044
J	BRENNER, RA; SMITH, GS; OVERPECK, MD				BRENNER, RA; SMITH, GS; OVERPECK, MD			DIVERGENT TRENDS IN CHILDHOOD DROWNING RATES, 1971 THROUGH 1988	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							5-YEAR TOTAL POPULATION; UNITED-STATES; CHILDREN; COUNTY; PREVENTION; ACCIDENTS; BRISBANE	Objective.-To examine national age-, race-, and sex-specific trends in unintentional drowning rates among US children aged 0 through 19 years. Design.-National mortality data published by the National Center for Health Statistics and population data from the US Bureau of the Census were used in calculating age-, race-, and sex-specific drowning rates for 1971 through 1988. Time trends were analyzed using Poisson regression techniques. Setting.-United States, 1971 through 1988. Main Outcome Measure.-Rates of death due to unintentional, non-boat-related drowning. Results.-From 1971 through 1988, there were 45 680 unintentional, non-boat-related drowning deaths among 0- through 19-year-olds in the United States. Drowning rates declined sharply in older children (-5.8% per year in 10- through 14-year-olds and -5.4% per year in 15- through 19-year-olds), declined only slightly in toddlers (-1.6% per year in 1- and 2-year-olds), and actually increased in infants (+1.6% per year in those children younger than 1 year). Conclusion.-Drowning rates in toddlers have changed little over time despite the availability of effective prevention strategies such as pool fencing. In older children, drowning rates have declined dramatically despite the lack of clear preventive initiatives. Prevention interventions targeted specifically at the infant and toddler age groups should receive priority.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR INJURY PREVENT,BALTIMORE,MD	Johns Hopkins University	BRENNER, RA (corresponding author), NICHHD,DIV EPIDEMIOL STAT & PREVENT RES,6100 EXECUT BLVD,ROOM 7B03,BETHESDA,MD 20892, USA.			Smith, Gordon/0000-0002-2911-3071	NIAAA NIH HHS [R29AA07700] Funding Source: Medline; PHS HHS [R49/CCR302486-01] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA007700] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAKER SP, 1992, INJURY FACT BOOK, P174; BUDNICK LD, 1985, AM J PUBLIC HEALTH, V75, P630, DOI 10.2105/AJPH.75.6.630; CASS DT, 1991, MED J AUSTRALIA, V154, P163, DOI 10.5694/j.1326-5377.1991.tb121021.x; DIETZ PE, 1974, AM J PUBLIC HEALTH, V64, P303, DOI 10.2105/AJPH.64.4.303; FELDMAN KW, 1993, CHILD ABUSE NEGLECT, V17, P329, DOI 10.1016/0145-2134(93)90055-A; FLOOD TJ, 1990, MMWR-MORBID MORTAL W, V39, P441; GRIEST KJ, 1989, PEDIATRICS, V83, P41; Gulaid J A, 1988, MMWR CDC Surveill Summ, V37, P27; HOWLAND J, 1988, ACCIDENT ANAL PREV, V20, P19, DOI 10.1016/0001-4575(88)90011-5; JENSEN LR, 1992, WESTERN J MED, V157, P641; JUMBELIC MI, 1990, JAMA-J AM MED ASSOC, V263, P1952, DOI 10.1001/jama.263.14.1952; MANN NC, 1992, PEDIATRICS, V89, P1068; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; OCARROLL PW, 1988, JAMA-J AM MED ASSOC, V260, P380, DOI 10.1001/jama.260.3.380; PEARN J, 1976, MED J AUSTRALIA, V2, P942, DOI 10.5694/j.1326-5377.1976.tb115532.x; PEARN JH, 1977, MED J AUSTRALIA, V1, P432, DOI 10.5694/j.1326-5377.1977.tb130794.x; PEARN JH, 1979, AM J PUBLIC HEALTH, V69, P450, DOI 10.2105/AJPH.69.5.450; PEARN JH, 1979, PEDIATRICS, V64, P68; PITT WR, 1991, MED J AUSTRALIA, V154, P661, DOI 10.5694/j.1326-5377.1991.tb121253.x; QUAN L, 1989, PEDIATRICS, V83, P1035; SAUNDERS E, 1989, PUBLIC HEALTH REP, V104, P368; SHINABERGER CS, 1990, AM J PUBLIC HEALTH, V80, P613, DOI 10.2105/AJPH.80.5.613; WINTEMUTE GJ, 1987, AM J PUBLIC HEALTH, V77, P830, DOI 10.2105/AJPH.77.7.830; WINTEMUTE GJ, 1990, AM J DIS CHILD, V144, P663, DOI 10.1001/archpedi.1990.02150300061018; 1989, VITAL HLTH STAT 3, V26; 1989, CURRENT POPULATI P25, V917; 1967, MANUAL INT STATISTIC; 1975, VITAL STATISTICS US, V2; 1991, DHHS PHS9150213 US D; 1989, CURRENT POPULATI P25, V1045; 1990, VITAL STATISTICS US, V2; [No title captured]	32	36	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	1994	271	20					1606	1608		10.1001/jama.271.20.1606	http://dx.doi.org/10.1001/jama.271.20.1606			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NL758	8182814				2022-12-01	WOS:A1994NL75800030
J	CASSEDAY, JH; EHRLICH, D; COVEY, E				CASSEDAY, JH; EHRLICH, D; COVEY, E			NEURAL TUNING FOR SOUND DURATION - ROLE OF INHIBITORY MECHANISMS IN THE INFERIOR COLLICULUS	SCIENCE			English	Article							SUPERIOR OLIVARY COMPLEX; BAT; NEURONS; ECHOLOCATION; NUCLEI; BRAIN; GABA	Duration is a biologically important feature of sound. Some neurons in the inferior colliculus of the big brown bat, Eptesicus fuscus, are tuned to sound duration, but it is unclear at what level the tuning originates or what neural mechanisms are responsible for it. The application of antagonists of the inhibitory neurotransmitters gamma-aminobutyric acid or glycine to neurons in the inferior colliculus eliminated duration tuning. Whole-cell patch-clamp recordings of synaptic currents suggested that inhibition produces a temporal frame within which excitation can occur. A model is proposed in which duration tuning arises when an early, sustained inhibitory input interacts with a delayed, transient excitatory input.			CASSEDAY, JH (corresponding author), DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710, USA.				NIDCD NIH HHS [DC-00607, DC-00287] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000607] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Casseday J.H., 1987, P109; CASSEDAY JH, 1992, J COMP NEUROL, V319, P34, DOI 10.1002/cne.903190106; CASSEDAY JH, 1988, J COMP NEUROL, V278, P313, DOI 10.1002/cne.902780302; COVEY E, 1993, J NEUROPHYSIOL, V69, P842, DOI 10.1152/jn.1993.69.3.842; COVEY E, 1991, J NEUROPHYSIOL, V66, P1080, DOI 10.1152/jn.1991.66.3.1080; COVEY E, 1991, J NEUROSCI, V11, P3456; Covey E., 1993, Society for Neuroscience Abstracts, V19, P535; EDGAR PP, 1990, J NEUROSCI, V10, P603; FAINGOLD CL, 1991, HEARING RES, V52, P201, DOI 10.1016/0378-5955(91)90200-S; FENG AS, 1990, PROG NEUROBIOL, V34, P313, DOI 10.1016/0301-0082(90)90008-5; GOOLER DM, 1992, J NEUROPHYSIOL, V67, P1, DOI 10.1152/jn.1992.67.1.1; GOULD E, 1971, Communications in Behavioral Biology Part A Original Articles, V5, P263; Griffin D.R., 1958, LISTENING DARK; HAPLEA S, IN PRESS J COMP PH A; HAVEY DC, 1980, ELECTROEN CLIN NEURO, V48, P249, DOI 10.1016/0013-4694(80)90313-2; JAGADEESH B, 1992, SCIENCE, V257, P552, DOI 10.1126/science.1636094; KALKO EKV, 1993, J BEHAV ECOL SOCIOBI, V33, P415; KONISHI M, 1993, SCI AM, V268, P66, DOI 10.1038/scientificamerican0493-66; Kuwada S., 1987, P146; MASTERTON RB, 1992, TRENDS NEUROSCI, V15, P280, DOI 10.1016/0166-2236(92)90077-L; PARK TJ, 1993, J NEUROSCI, V13, P2050; PINHEIRO AD, 1991, J COMP PHYSIOL A, V169, P69; Pollak GD., 1989, NEURAL BASIS ECHOLOC; POTTER HD, 1965, J NEUROPHYSIOL, V28, P1155, DOI 10.1152/jn.1965.28.6.1155; REPP BH, 1978, J EXP PSYCHOL HUMAN, V4, P621, DOI 10.1037/0096-1523.4.4.621; ROBERTS RC, 1987, J COMP NEUROL, V258, P267, DOI 10.1002/cne.902580207; Schnitzler H., 1980, ANIMAL SONAR SYSTEMS, V28, P109, DOI [10.10007/978-1-4684-7254-7_6, DOI 10.1007/978-1-4684-7254-7_6]; SCHWARTZ IR, 1992, HDB AUDITARY RES, V1, P117; SIMMONS JA, 1989, COGNITION, V33, P155, DOI 10.1016/0010-0277(89)90009-7; SIMMONS JA, 1979, SCIENCE, V203, P16, DOI 10.1126/science.758674; SIMMONS JA, 1988, ANIMAL SONAR PROCESS, P353; SUGA N, 1990, NEURAL NETWORKS, V3, P3, DOI 10.1016/0893-6080(90)90043-K; VATER M, 1992, J COMP NEUROL, V325, P183, DOI 10.1002/cne.903250205; VATER M, 1992, J COMP PHYSIOL A, V171, P541; YANG LC, 1992, J NEUROPHYSIOL, V68, P1760, DOI 10.1152/jn.1992.68.5.1760	35	332	343	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					847	850		10.1126/science.8171341	http://dx.doi.org/10.1126/science.8171341			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	8171341				2022-12-01	WOS:A1994NJ94900035
J	LAW, MR; WALD, NJ				LAW, MR; WALD, NJ			DISAGREEMENTS ARE NOT SUBSTANTIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article									ST BARTHOLOMEWS HOSP, COLL MED, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6BQ, ENGLAND	University of London; Queen Mary University London			Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1	6	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	1994	308	6935					1027	1029		10.1136/bmj.308.6935.1027	http://dx.doi.org/10.1136/bmj.308.6935.1027			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8167518	Green Published			2022-12-01	WOS:A1994NH08900026
J	CHOUILLET, AM; BELL, CMJ; HISCOX, JG				CHOUILLET, AM; BELL, CMJ; HISCOX, JG			MANAGEMENT OF BREAST-CANCER IN SOUTHEAST ENGLAND	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the extent to which management of invasive breast cancer reflected consensus guidelines in the Thames regions in 1990. Design-Population based study of case notes. Setting-Thames Cancer Registry. Subjects-All women with breast cancer diagnosed in early 1990 (417 cases) resident in the four Thames regions. Hospital records were traced for 346 cases, of which 12 were ineligible because of misclassification in initial registration and were excluded from the analysis. 334 cases were analysed. Main outcome measures-Investigations and treatment in the six months after diagnosis, stage of disease. Results-Of the 334 women identified, 86 were aged under 50. Three years after diagnosis, 74 were dead, seven (8%) aged under 50 and 67 (27%) aged 50 or over. Axillary surgery was used to stage cancer in only 155 cases (46%), although this is recommended in the guidelines. Only 79 (24%) case notes had any information recorded on stage. Stage could be determined reliably for only half of the sample. Treatment varied widely within the same age group and stage of disease. In particular, chemotherapy was not routinely given to patients under 50 with stage 11 disease. Only 17 records showed evidence that the patient was participating in a clinical trial. Conclusions-There was a lack of consensus on the management of breast cancer among clinicians in 1990. More patients should be included in clinical trials.			CHOUILLET, AM (corresponding author), THAMES CANC REGISTRY,SUTTON SM2 5PY,SURREY,ENGLAND.							BASNETT I, 1992, EUR J CANCER, V28A, P1945, DOI 10.1016/0959-8049(92)90233-R; DAY NE, 1989, BRIT J CANCER, V59, P954, DOI 10.1038/bjc.1989.203; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; GULLIFORD MC, 1993, BRIT J CANCER, V67, P819, DOI 10.1038/bjc.1993.149; MCCARTHY M, 1991, EUR J CANCER, V27, P579, DOI 10.1016/0277-5379(91)90222-Y; 1993, LANCET, V341, P171; 1986, BMJ, V293, P946; 1986, BREAST CANCER SCREEN; 1987, TNM CLASSIFICATION M; 1992, LANCET, V339, P71; 1993, HLTH NATION KEY AREA; 1992, CANCER S W THAMES 19	12	77	77	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					168	171		10.1136/bmj.308.6922.168	http://dx.doi.org/10.1136/bmj.308.6922.168			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8204162	Green Published			2022-12-01	WOS:A1994MR97400017
J	DOMBROWICZ, D; FLAMAND, V; BRIGMAN, KK; KOLLER, BH; KINET, JP				DOMBROWICZ, D; FLAMAND, V; BRIGMAN, KK; KOLLER, BH; KINET, JP			ABOLITION OF ANAPHYLAXIS BY TARGETED DISRUPTION OF THE HIGH-AFFINITY IMMUNOGLOBULIN-E RECEPTOR ALPHA-CHAIN GENE	CELL			English	Article							FC-EPSILON-RI; MOUSE MAST-CELLS; IMMEDIATE HYPERSENSITIVITY REACTIONS; EPIDERMAL LANGERHANS CELLS; IGE RECEPTOR; SURFACE EXPRESSION; TRANSFECTED CELLS; BONE-MARROW; RESISTANCE; MICE	Mast cells and basophils, which are activated by immunoglobulin E (IgE) and allergen, play a prominent role in anaphylaxis. However, they express at least three types of IgE receptor, including the high affinity IgE receptor (FcepsilonRI). The relative contribution of these IgE receptors, and possibly other receptors such as FcepsilonRII/CD23 and Mac-2, to the genesis of in vivo anaphylaxis is still unclear. To address this question, we have generated FcepsilonRI-deficient mice. These mice appear normal and express a normal number of mast cells, but they are resistant to cutaneous and systemic anaphylaxis. These data demonstrate that FcepsilonRI is necessary for the initiation of IgE-dependent anaphylactic reactions. Therefore, interfering with its function should be an effective means of treating allergy, regardless of the allergen specificity.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	DOMBROWICZ, D (corresponding author), NIAID,MOLEC ALLERGY & IMMUNOL SECT,ROCKVILLE,MD 20852, USA.		Dombrowicz, David/F-7044-2013	Dombrowicz, David/0000-0002-0485-8923; Flamand, Veronique/0000-0002-8906-3758	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046003] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 46003-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDE A, 1993, J CLIN INVEST, V92, P1639; ASHMAN RI, 1991, J IMMUNOL, V146, P211; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BLANK U, 1991, J BIOL CHEM, V266, P2639; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CHEN SSA, 1991, J IMMUNOL, V147, P1581; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DUNNE DW, 1992, EUR J IMMUNOL, V22, P1483, DOI 10.1002/eji.1830220622; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; HABA S, 1985, J IMMUNOL, V134, P3291; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ISHIZAKA K, 1989, CURR OPIN IMMUNOL, V4, P625; KATZ HR, 1992, J IMMUNOL, V148, P868; KINET JP, 1992, CURR OPIN IMMUNOL, V4, P43, DOI 10.1016/0952-7915(92)90122-U; KINET JP, 1992, INFLAMMATION BASIC P, P701; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; MARTIN TR, 1993, J IMMUNOL, V151, P367; MAURER D, UNPUB HUMAN PERIPHER; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RA C, 1989, J BIOL CHEM, V264, P15323; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RIHET P, 1991, EUR J IMMUNOL, V21, P2679, DOI 10.1002/eji.1830211106; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; ROTTEM M, 1992, BLOOD, V79, P972; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; TAKIZAWA F, 1992, J EXP MED, V176, P469, DOI 10.1084/jem.176.2.469; TEPLER I, 1989, J BIOL CHEM, V264, P5912; THOMPSON HL, 1990, J CLIN INVEST, V85, P1227, DOI 10.1172/JCI114557; TRUONG MJ, 1993, J EXP MED, V177, P243, DOI 10.1084/jem.177.1.243; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WERSHIL BK, 1987, J IMMUNOL, V139, P2605; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; YE ZS, 1992, J IMMUNOL, V149, P897	43	319	327	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					969	976		10.1016/0092-8674(93)90540-7	http://dx.doi.org/10.1016/0092-8674(93)90540-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252632	Bronze			2022-12-01	WOS:A1993MK96600016
J	ROSS, W; GOSINK, KK; SALOMON, J; IGARASHI, K; ZOU, C; ISHIHAMA, A; SEVERINOV, K; GOURSE, RL				ROSS, W; GOSINK, KK; SALOMON, J; IGARASHI, K; ZOU, C; ISHIHAMA, A; SEVERINOV, K; GOURSE, RL			A 3RD RECOGNITION ELEMENT IN BACTERIAL PROMOTERS - DNA-BINDING BY THE ALPHA-SUBUNIT OF RNA-POLYMERASE	SCIENCE			English	Article							FACTOR-INDEPENDENT ACTIVATION; COLI GALACTOSE OPERON; RRNB P1 PROMOTER; ESCHERICHIA-COLI; RIBOSOMAL-RNA; TRANSCRIPTION ACTIVATION; UPSTREAM ACTIVATION; BACILLUS-SUBTILIS; INVITRO TRANSCRIPTION; FEEDBACK-REGULATION	A DNA sequence rich in (A + T), located upstream of the -10, -35 region of the Escherichia coli ribosomal RNA promoter rrnB P1 and called the UP element, stimulates transcription by a factor of 30 in vivo, as well as in vitro in the absence of protein factors other than RNA polymerase (RNAP). When fused to other promoters, such as lacUV5, the UP element also stimulates transcription, indicating that it is a separable promoter module. Mutations in the carboxyl-terminal region of the alpha subunit of RNAP prevent stimulation of these promoters by the UP element although the mutant enzymes are effective in transcribing the ''core'' promoters (those lacking the UP element). Protection of UP element DNA by the mutant RNAPs is severely reduced in footprinting experiments, suggesting that the selective decrease in transcription might result from defective interactions between alpha and the UP element. Purified alpha binds specifically to the UP element, confirming that alpha acts directly in promoter recognition. Transcription of three other promoters was also reduced by the COOH-terminal alpha mutations. These results suggest that UP elements comprise a third promoter recognition region (in addition to the -10, -35 recognition hexamers, which interact with the sigma subunit) and may account for the presence of (A + T)-rich DNA upstream of many prokaryotic promoters. Since the same alpha mutations also block activation by some transcription factors, mechanisms of promoter stimulation by upstream DNA elements and positive control by certain transcription factors may be related.	UNIV WISCONSIN,DEPT BACTERIOL,1550 LINDEN DR,MADISON,WI 53706; NATL INST GENET,DEPT MOLEC GENET,MISHIMA,SHIZUOKA 411,JAPAN; PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016	University of Wisconsin System; University of Wisconsin Madison; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan			Severinov, Konstantin/C-8545-2016	Igarashi, Kazuhiko/0000-0002-2470-2475	NIAID NIH HHS [AI90035] Funding Source: Medline; NIGMS NIH HHS [GM49242, R01 GM37048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037048, R01GM049242] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNER CDB, 1983, J MOL BIOL, V168, P351, DOI 10.1016/S0022-2836(83)80023-0; BARTLETT MS, UNPUB; BAUER BF, 1988, GENE, V63, P123, DOI 10.1016/0378-1119(88)90551-3; BERTRANDBURGGRAF E, 1990, EMBO J, V9, P2265, DOI 10.1002/j.1460-2075.1990.tb07397.x; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BUSBY S, 1987, GENE, V53, P145, DOI 10.1016/0378-1119(87)90002-3; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; FRISBY D, 1991, J BACTERIOL, V173, P7557, DOI 10.1128/jb.173.23.7557-7564.1991; GAAL T, UNPUB; GALAS DJ, 1985, J MOL BIOL, V186, P17; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GEIDUSCHEK EP, 1988, BACTERIOPHAGES, V1, P93; GILADI H, 1992, J MOL BIOL, V227, P985, DOI 10.1016/0022-2836(92)90514-K; GOSINK KK, 1993, J BACTERIOL, V175, P1580, DOI 10.1128/JB.175.6.1580-1589.1993; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GOURSE RL, 1985, P NATL ACAD SCI USA, V82, P1069, DOI 10.1073/pnas.82.4.1069; GRAVES MC, 1986, J BIOL CHEM, V261, P1409; GUSSIN GN, 1992, J BACTERIOL, V174, P5156, DOI 10.1128/JB.174.15.5156-5160.1992; HAYWARD RS, 1991, J MOL BIOL, V221, P23, DOI 10.1016/0022-2836(91)80197-3; HSU LM, 1991, BIOCHEMISTRY-US, V30, P813, DOI 10.1021/bi00217a035; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; IGARASHI K, 1992, J MOL BIOL, V218, P1; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; JINKSROBERTSON S, 1987, ESCHERICHIA COLI SAL, P1358; JOSAITIS CA, 1990, BIOCHIM BIOPHYS ACTA, V1050, P307, DOI 10.1016/0167-4781(90)90186-6; JOSAITIS CA, UNPUB; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; LAVIGNE M, 1992, J MOL BIOL, V224, P293, DOI 10.1016/0022-2836(92)90995-V; LEE HS, 1993, J BACTERIOL, V175, P2479, DOI 10.1128/JB.175.8.2479-2482.1993; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; LUKACSOVICH T, 1989, GENE, V78, P189, DOI 10.1016/0378-1119(89)90328-4; MCALLISTER CF, 1988, J BIOL CHEM, V263, P11743; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.biochem.54.1.171; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; Miller, 1972, EXPT MOL GENETICS; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; NACHALIEL N, 1989, NUCLEIC ACIDS RES, V17, P9811, DOI 10.1093/nar/17.23.9811; NEWLANDS JT, 1992, NUCLEIC ACIDS RES, V20, P719, DOI 10.1093/nar/20.4.719; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; NEWLANDS JT, 1993, J BACTERIOL, V175, P661, DOI 10.1128/JB.175.3.661-668.1993; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PEREZMARTIN J, 1991, EMBO J, V10, P1375, DOI 10.1002/j.1460-2075.1991.tb07657.x; PETHO A, 1986, BIOCHIM BIOPHYS ACTA, V866, P37, DOI 10.1016/0167-4781(86)90098-9; PLASKON RR, 1987, NUCLEIC ACIDS RES, V15, P785, DOI 10.1093/nar/15.2.785; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; RAO L, IN PRESS J MOL BIOL; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; ROSS W, UNPUB; RUSSO FD, 1992, J BIOL CHEM, V267, P14515; SAKUMI K, 1993, J BACTERIOL, V175, P2455, DOI 10.1128/JB.175.8.2455-2457.1993; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; TAO K, 1993, MOL MICROBIOL, V7, P859, DOI 10.1111/j.1365-2958.1993.tb01176.x; ZACHARIAS M, 1992, BIOCHEMISTRY-US, V31, P2621, DOI 10.1021/bi00124a024; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	66	638	663	2	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1407	1413		10.1126/science.8248780	http://dx.doi.org/10.1126/science.8248780			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248780				2022-12-01	WOS:A1993MJ04600029
J	CAMERON, DL; WILLIAMS, JT				CAMERON, DL; WILLIAMS, JT			DOPAMINE D1 RECEPTORS FACILITATE TRANSMITTER RELEASE	NATURE			English	Article							RAT SUBSTANTIA NIGRA; POTASSIUM CONDUCTANCE; SYNAPTIC INPUTS; D2 RECEPTORS; NEURONS; AGONIST; ACTIVATION; DEPRESSION; MECHANISM; RESPONSES	A PHYSIOLOGICAL role for the dopamine D1 receptor has been difficult to define, particularly because of its complex pre- and postsynaptic localization in brain areas such as the striatum1. In the midbrain, however, D1 receptors are selectively localized to the terminals of GABA (gamma-aminobutyric acid)-containing afferents2-4. We have studied the actions of these D1 receptors on evoked GABA synaptic potentials recorded intracellularly from dopamine neurons in the ventral tegmental area (VTA). We report here that dopamine augmented GABA(B) inhibitory postsynaptic potentials (i.p.s.ps) in the presence of D2 receptor antagonists. This effect was mimicked by the D1 agonists SKF38393 and SKF82958 and blocked by the D1 antagonists SCH23390 and cis-flupenthixol. No modulation of the GABA(A) synaptic potential was observed. The postsynaptic actions of the GABA(B) agonist, baclofen, were unaffected by SKF38393, SCH23390 or cis-flupenthixol, confirming a presynaptic locus of D1 action. Additionally, D1 antagonists reduced the amplitude of the GABA(B) i.p.s.p. in the absence of D1 agonists. We conclude that dopamine acts tonically at presynaptic D1 receptors on the terminals of afferent GABA neurons to facilitate selectively GABA(B)-mediated neurotransmission in the midbrain.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	Oregon Health & Science University								ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; BALMFORTH AJ, 1990, J NEUROCHEM, V55, P2111, DOI 10.1111/j.1471-4159.1990.tb05803.x; BRAUN AR, 1986, EUR J PHARMACOL, V131, P301, DOI 10.1016/0014-2999(86)90588-1; CARLSON JH, 1987, SYNAPSE, V1, P411, DOI 10.1002/syn.890010505; CHESSELET MF, 1984, NEUROSCIENCE, V12, P347, DOI 10.1016/0306-4522(84)90058-7; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; ELIOT LS, 1993, NATURE, V361, P634, DOI 10.1038/361634a0; FILOUX F, 1988, BRAIN RES B, V20, P447; FLORAN B, 1990, NEUROSCI LETT, V116, P136, DOI 10.1016/0304-3940(90)90399-T; GEFFEN LB, 1976, NATURE, V260, P258, DOI 10.1038/260258a0; GOLDSMITH BA, 1991, P NATL ACAD SCI USA, V88, P9021, DOI 10.1073/pnas.88.20.9021; HARRISON MB, 1990, BRAIN RES, V528, P317, DOI 10.1016/0006-8993(90)91674-6; JOHNSON SW, 1992, J NEUROSCI, V12, P2000; JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136; LACEY MG, 1988, J PHYSIOL-LONDON, V401, P437, DOI 10.1113/jphysiol.1988.sp017171; LACEY MG, 1987, J PHYSIOL-LONDON, V392, P397, DOI 10.1113/jphysiol.1987.sp016787; LLINAS R, 1984, BRAIN RES, V294, P127, DOI 10.1016/0006-8993(84)91316-7; MANSOUR A, 1991, NEUROSCIENCE, V42, P359; MEMO M, 1982, P NATL ACAD SCI-BIOL, V79, P4456, DOI 10.1073/pnas.79.14.4456; MINTZ I, 1991, J NEUROSCI, V11, P3359; MOTTOLA DM, 1992, J PHARMACOL EXP THER, V262, P383; REUBI JC, 1977, NATURE, V268, P652, DOI 10.1038/268652a0; ROBERTSON GS, 1987, TRENDS PHARMACOL SCI, V8, P295, DOI 10.1016/0165-6147(87)90121-0; SUGITA S, 1992, NEUROSCI LETT, V134, P207, DOI 10.1016/0304-3940(92)90518-C; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; WEICK BG, 1987, BRAIN RES, V405, P234, DOI 10.1016/0006-8993(87)90293-9; WILLIAMS JT, 1984, NEUROSCIENCE, V13, P137, DOI 10.1016/0306-4522(84)90265-3; ZIOGAS J, 1991, BRIT J PHARMACOL, V103, P1196, DOI 10.1111/j.1476-5381.1991.tb12323.x	29	247	251	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 25	1993	366	6453					344	347		10.1038/366344a0	http://dx.doi.org/10.1038/366344a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247128				2022-12-01	WOS:A1993MJ70500049
J	LOSICK, R; SHAPIRO, L				LOSICK, R; SHAPIRO, L			CHECKPOINTS THAT COUPLE GENE-EXPRESSION TO MORPHOGENESIS	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM; SIGMA-FACTOR; FLAGELLIN SYNTHESIS; SUBTILIS; REGULON		STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University	LOSICK, R (corresponding author), HARVARD UNIV,BIOL LABS,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							ARNOSTI DN, 1989, P NATL ACAD SCI USA, V86, P830, DOI 10.1073/pnas.86.3.830; CHATER KF, 1989, CELL, V59, P133, DOI 10.1016/0092-8674(89)90876-3; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DREYFUS G, 1993, J BACTERIOL, V175, P3131, DOI 10.1128/JB.175.10.3131-3138.1993; GILLEN KL, 1991, J BACTERIOL, V173, P2301, DOI 10.1128/JB.173.7.2301-2310.1991; GILLEN KL, 1991, J BACTERIOL, V173, P6453, DOI 10.1128/jb.173.20.6453-6459.1991; HUGHES KT, 1993, SCIENCE, V262, P1277, DOI 10.1126/science.8235660; KAISER D, 1993, CELL, V73, P873, DOI 10.1016/0092-8674(93)90268-U; KUTSUKAKE K, 1990, J BACTERIOL, V172, P741, DOI 10.1128/jb.172.2.741-747.1990; KUTSUKAKE K, 1992, 15TH ANN M JAP SOC M; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; OHNISHI K, 1990, MOL GEN GENET, V221, P139, DOI 10.1007/BF00261713; OHNISHI K, 1992, MOL MICROBIOL, V6, P3149, DOI 10.1111/j.1365-2958.1992.tb01771.x; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; SAGER B, 1993, P NATL ACAD SCI USA, V90, P3690, DOI 10.1073/pnas.90.8.3690; YOUNG VB, 1990, MOL MICROBIOL, V4, P1119, DOI 10.1111/j.1365-2958.1990.tb00686.x	16	26	26	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1227	1228		10.1126/science.8235653	http://dx.doi.org/10.1126/science.8235653			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235653				2022-12-01	WOS:A1993MH32400028
J	VONRUDEN, L; NEHER, E				VONRUDEN, L; NEHER, E			A CA-DEPENDENT EARLY STEP IN THE RELEASE OF CATECHOLAMINES FROM ADRENAL CHROMAFFIN CELLS	SCIENCE			English	Article							PATCH-CLAMP TECHNIQUES; CALCIUM; EXOCYTOSIS; SECRETION; PHOSPHORYLATION; RESOLUTION; ACTIVATION; CHANNELS; PROTEINS; CA-2+	Intense stimuli, such as trains of depolarizing pulses or the caffeine-induced release of calcium from intracellular stores, readily depress the secretory response in neuroendocrine cells. Secretory responses are restored by rest periods of minutes in duration. This recovery was accelerated when the concentration of cytosolic calcium was moderately increased and probably resulted from calcium-dependent replenishment of a pool of release-ready granules. Continuously increased concentrations of calcium led to the over-filling of such a pool. Subsequently, secretory responses to stronger calcium stimuli were augmented. Hormone-induced calcium transients with a plateau phase of increased concentration of calcium may enhance the secretory response in this way.	MAX PLANCK INST BIOPHYS CHEM,DEPT MEMBRANE BIOPHYS,AM FASSBERG,D-37077 GOTTINGEN,GERMANY	Max Planck Society			Neher, Erwin/A-2109-2013					ARTALEJO CR, 1991, J PHYSIOL-LONDON, V444, P213, DOI 10.1113/jphysiol.1991.sp018874; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BOOKMAN RJ, 1992, ANN NY ACAD SCI, V635, P352; BYERLY L, 1988, CALCIUM CHANNEL MODU; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; FIDLER N, 1990, NATURE, V344, P499; FIRESTONE JA, 1992, J NEUROCHEM, V58, P441, DOI 10.1111/j.1471-4159.1992.tb09741.x; GILLIS KD, 1992, PFLUG ARCH EUR J PHY, V420, P121, DOI 10.1007/BF00378654; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAYCOCK JW, 1988, J NEUROSCI, V8, P3233; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KELLY RB, 1993, NEURON S, V10, P43; LINDAU M, 1992, BIOPHYS J, V61, P19, DOI 10.1016/S0006-3495(92)81812-X; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; LIU PS, 1991, J NEUROCHEM, V56, P172, DOI 10.1111/j.1471-4159.1991.tb02577.x; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PENNER R, 1987, BIOSCIENCE REP, V7, P313, DOI 10.1007/BF01121453; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SAGE S O, 1992, Current Biology, V2, P312, DOI 10.1016/0960-9822(92)90885-E; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754	35	275	277	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1061	1065		10.1126/science.8235626	http://dx.doi.org/10.1126/science.8235626			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235626				2022-12-01	WOS:A1993MG18700038
J	JIANG, Y; ROSSI, G; FERRONOVICK, S				JIANG, Y; ROSSI, G; FERRONOVICK, S			BET2P AND MAD2P ARE COMPONENTS OF A PRENYLTRANSFERASE THAT ADDS GERANYLGERANYL ONTO YPT1P AND SEC4P	NATURE			English	Article							GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; GENE-PRODUCT; YEAST; FARNESYLTRANSFERASE; TRANSFERASE; CYS; DEPENDENCE; SECRETION	THREE different prenyltransferases have been identified in yeast and higher cells1-6, the farnesyltransferase and the type I and type II geranylgeranyltransferases (GGTase). The farnesyltransferase and GGTase-I modify peptides in vitro with the CAAX (C, Cys; A, aliphatic residue; X, terminal amino acid) consensus motif2,7. These enzymes are heterodimers that have different beta-subunits and a shared alpha-subunit8. In yeast, the RAM2 gene encodes this alpha-subunit9. RAM2 is also homologous to MAD2, a yeast gene whose product has been implicated in the feedback control of mitosis10,11. We have shown that Bet2p is a component of the yeast GGTase-II (refs 6, 12) that geranylgeranylates Ypt1p, a small GTP-binding protein that mediates transport from the endoplasmic reticulum to the Golgi complex13-15. Here we report that Mad2p is a component of this enzyme. Bet2p forms a complex with Mad2p that appears to bind geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate. The efficient transfer of geranylgeranyl onto small GTP-binding proteins requires the presence of an additional activity.	YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06510	Yale University								ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1990, J BIOL CHEM, V265, P13007; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BOGUSKI MS, 1992, NEW BIOL, V4, P1; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KOHL NE, 1991, J BIOL CHEM, V266, P18884; LI R, 1993, NATURE, V366, P82, DOI 10.1038/366082a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; MAYER ML, 1992, J BIOL CHEM, V267, P20589; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; WAGNER P, 1987, EMBO J, V6, P2373, DOI 10.1002/j.1460-2075.1987.tb02514.x; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017	27	55	61	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					84	86		10.1038/366084a0	http://dx.doi.org/10.1038/366084a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	8232542				2022-12-01	WOS:A1993MF00700061
J	LIU, B; WONG, ML; TINKER, RL; GEIDUSCHEK, EP; ALBERTS, BM				LIU, B; WONG, ML; TINKER, RL; GEIDUSCHEK, EP; ALBERTS, BM			THE DNA-REPLICATION FORK CAN PASS RNA-POLYMERASE WITHOUT DISPLACING THE NASCENT TRANSCRIPT	NATURE			English	Article							ESCHERICHIA-COLI; MAGNETIC-RESONANCE; TERNARY COMPLEXES; LATE PROMOTERS; BACTERIOPHAGE-T4; PROTEIN; INITIATION; ELONGATION; SITE; TERMINATION	Replication proteins encoded by bacteriophage T4 generate DNA replication forks that can pass a molecule of Escherichia coli RNA polymerase moving in the same direction as the fork in vitro. The RNA polymerase ternary transcription complex remains bound to the DNA and retains a transcription bubble after the fork passes. The by-passed ternary complex can resume faithful RNA synthesis, suggesting that the multisubunit RNA polymerase of E. coli has evolved to retain its transcript after DNA replication, allowing partially completed transcripts to be elongated into full-length RNA molecules.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Diego; University of California System; University of California San Francisco								ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BEAN BL, 1977, BIOCHEMISTRY-US, V16, P3322, DOI 10.1021/bi00634a007; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BREMER H, 1987, CELLULAR MOL BIOL, P1527; CHA TA, 1986, J BIOL CHEM, V261, P7001; Chamberlin M., 1976, RNA POLYMERASE BOOK, P17; CHRISTENSEN AC, 1983, BACTERIOPHAGE T, V4, P184; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; FISHER R, 1982, J BIOL CHEM, V257, P1702; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HINKLE DC, 1972, J MOL BIOL, V70, P197, DOI 10.1016/0022-2836(72)90533-5; HIROSE S, 1983, MOL GEN GENET, V189, P422, DOI 10.1007/BF00325904; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; JOE JH, 1985, J MOL BIOL, V184, P441; Johnston D. E., 1976, RNA POLYMERASE, P413; KASSAVETIS GA, 1982, EMBO J, V1, P107, DOI 10.1002/j.1460-2075.1982.tb01132.x; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; KASSAVETIS GA, 1984, P NATL ACAD SCI-BIOL, V81, P5101, DOI 10.1073/pnas.81.16.5101; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; Kleinschmidt A.K.=, 1968, METHODS ENZYMOL, V12, P361; KUMAR SA, 1981, PROG BIOPHYS MOL BIO, V38, P165, DOI 10.1016/0079-6107(81)90013-4; KUMAR SA, 1975, J BIOL CHEM, V250, P2879; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MEYER TF, 1979, NATURE, V278, P365, DOI 10.1038/278365a0; MI H, 1983, EUR J BIOCHEM, V131, P113; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; MORRIS CF, 1987, J BIOL CHEM, V254, P6796; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; SASSEDWIGHT S, 1988, J MOL BIOL, V202, P107, DOI 10.1016/0022-2836(88)90523-2; SENTENAC A, 1992, TRANSCRIPTIONAL REGU, P27; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; STEIN PJ, 1978, BIOCHEMISTRY-US, V17, P2675, DOI 10.1021/bi00606a034; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WILLIAMS KP, 1987, J BIOL CHEM, V262, P12365; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	47	86	87	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					33	39		10.1038/366033a0	http://dx.doi.org/10.1038/366033a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	8232535				2022-12-01	WOS:A1993MF00700045
J	HOWITT, AJ; CHEALES, NA				HOWITT, AJ; CHEALES, NA			DIABETES REGISTERS - A GRASS-ROOTS APPROACH	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; COMMUNITY; POPULATION; DISTRICT; CARE	Objectives-To compile a register of diabetic patients within the catchment area of a district general hospital and evaluate the characteristics of the population using aggregated data from a general practice audit. Design-Cross sectional study. Practices identified all known diabetics and completed a questionnaire from information in each patient's medical record. Setting-Practices affiliated to a district audit group in south east England. Main outcome measures-Number of participating practices; prevalence of diabetes and its complications; and sex distribution of patients, age at diagnosis and review, treatment, and metabolic control. Comparisons with similar data from other studies. Results-41 out of 43 practices participated, and 2574 diabetic patients were identified (prevalence 1.18%). 52.4% of patients were male. The mean age was 61.6 years. 32% of patients were treated with insulin, 51.5% with oral hypoglycaemic agents, 16.5% with diet alone. The mean random blood glucose concentration was 10.4 mmol/l and glycosylated haemoglobin 10.1%. 8% had proteinuria, 7% a history of myocardial infarction, 5% a history of stroke, and 2% a diabetes related amputation. These proportions were not significantly different from those found in studies performed by different methods in Poole, Islington, Powys, Trowbridge, and Southall. Conclusion-It is feasible to compile a register of diabetic patients in a district and evaluate their characteristics by using only general practice sources.	KENT & SUSSEX HOSP,KENT MED AUDIT ADVISORY GRP,TURNBRIDGE WELLS AUDIT GRP,TUNBRIDGE WELLS TN4 8AT,KENT,ENGLAND									BURNETT SD, 1992, BRIT MED J, V305, P627, DOI 10.1136/bmj.305.6854.627; DONALDSON L, 1992, BRIT MED J, V305, P597, DOI 10.1136/bmj.305.6854.597; GATLING W, 1985, J ROY COLL PHYS LOND, V19, P248; GATLING W, 1988, PRACTICAL DIABETES, V5, P104; GIBBINS RL, 1989, J ROY COLL GEN PRACT, V39, P206; HIGGS ER, 1992, DIABETIC MED, V9, P550, DOI 10.1111/j.1464-5491.1992.tb01837.x; HILL RD, 1976, BRIT MED J, V1, P1137, DOI 10.1136/bmj.1.6018.1137; HURWITZ B, 1993, BRIT MED J, V306, P624, DOI 10.1136/bmj.306.6878.624; JONES JN, 1992, DIABETIC MED, V9, P176, DOI 10.1111/j.1464-5491.1992.tb01755.x; MANT D, 1987, BRIT MED J, V294, P223, DOI 10.1136/bmj.294.6566.223; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; NEIL HAW, 1987, DIABETIC MED, V4, P539, DOI 10.1111/j.1464-5491.1987.tb00926.x; PARNELL SJ, 1993, BRIT J GEN PRACT, V43, P65; PRINGLE M, 1993, BRIT MED J, V306, P630, DOI 10.1136/bmj.306.6878.630; Ward J D, 1992, Qual Health Care, V1, P260, DOI 10.1136/qshc.1.4.260; WILSON AE, 1993, DIABETIC MED, V10, P378, DOI 10.1111/j.1464-5491.1993.tb00084.x; 1993, NEW HLTH PROMOTION P; 1990, EPI INFO VERSION 5 0	18	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1046	1048		10.1136/bmj.307.6911.1046	http://dx.doi.org/10.1136/bmj.307.6911.1046			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251780	Bronze, Green Published			2022-12-01	WOS:A1993MD55600021
J	BRAMBLE, DM; JENKINS, FA				BRAMBLE, DM; JENKINS, FA			MAMMALIAN LOCOMOTOR-RESPIRATORY INTEGRATION - IMPLICATIONS FOR DIAPHRAGMATIC AND PULMONARY DESIGN	SCIENCE			English	Article							HORSES EQUUS-CABALLUS; AIRWAY BIFURCATIONS; PERIODIC-FLOW; SYNCHRONIZATION; VENTILATION; PRESSURE	Diaphragmatic function and intrapulmonary respiratory flow in running mammals were found to differ substantially from the corresponding conditions known in resting mammals. In trotting dogs, orbital oscillations of the diaphragm were driven by inertial displacements of the viscera induced by locomotion. In turn, oscillations of the visceral mass drove pulmonary ventilation independent of diaphragmatic contractions, which primarily served to modulate visceral kinetics. Visceral displacements and loading of the anterior chest wall by the forelimbs are among the factors that contribute to an asynchronous ventilation of the lungs and interlobar gas recycling. Basic features of mammalian respiratory design, including the structure of the diaphragm and lobation of the lungs, appear to reflect the mechanical requirements of locomotor-respiratory integration.	HARVARD UNIV, DEPT ORGANISM & EVOLUT BIOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, MUSEUM COMPARAT ZOOL, CAMBRIDGE, MA 02138 USA	Harvard University; Harvard University	BRAMBLE, DM (corresponding author), UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA.				NCRR NIH HHS [S07 RR07092] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007092] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AINSWORTH DM, 1989, RESP PHYSIOL, V78, P145, DOI 10.1016/0034-5687(89)90048-0; ALEXANDER RM, 1989, J ZOOL, V218, P69, DOI 10.1111/j.1469-7998.1989.tb02526.x; ALLEN JL, 1987, J APPL PHYSIOL, V62, P223, DOI 10.1152/jappl.1987.62.1.223; ATTENBURROW DP, 1982, EQUINE VET J, V14, P69, DOI 10.1111/j.2042-3306.1982.tb02340.x; BANZETT RB, 1992, J APPL PHYSIOL, V72, P1922, DOI 10.1152/jappl.1992.72.5.1922; BAUDINETTE RV, 1987, J EXP BIOL, V129, P251; BRAMBLE DM, 1989, LIFE SCI R, V45, P133; BRAMBLE DM, 1983, SCIENCE, V219, P251, DOI 10.1126/science.6849136; BRAMBLE DM, 1989, AM ZOOL, V29, P171; BRAMBLE DM, 1986, NONLINEAR OSCIL, P130; CARRIER DR, 1987, PALEOBIOLOGY, V13, P326; CARRIER DR, 1987, EXP BIOL, V47, P33; DETROYER A, 1981, SCIENCE, V213, P237, DOI 10.1126/science.7244632; DETROYER A, 1986, HDB PHYSL RESPIRATOR, V3, pCH26; GOLDBERG MB, 1981, RESP PHYSIOL, V43, P327, DOI 10.1016/0034-5687(81)90113-4; GRIFFITHS RI, 1992, P ROY SOC B-BIOL SCI, V249, P199, DOI 10.1098/rspb.1992.0104; HORSFIELD K, 1985, GAS MIXING DISTRIBUT, P23; KOTERBA AM, 1988, J APPL PHYSIOL, V64, P337, DOI 10.1152/jappl.1988.64.1.337; Lancaster D., 1975, ACTIVE FILTER COOKBO; LAWS JW, 1965, BRIT J RADIOL, V38, P512, DOI 10.1259/0007-1285-38-451-512; LEITH D E, 1971, Federation Proceedings, V30, P556; OTIS AB, 1956, J APPL PHYSIOL, V8, P427, DOI 10.1152/jappl.1956.8.4.427; PAIVA M, 1989, RESP PHYSL ANAL APPR, V40, P245; PIIPER J, 1989, COMP PULMONARY PHYSL, P369; ROCHESTER DF, 1985, J CLIN INVEST, V75, P1397, DOI 10.1172/JCI111841; ROUSSOS C, 1986, HDB PHYSL RESPIRATOR, V3, pCH29; SILVERMAN NR, 1973, J APPL PHYSIOL, V34, P726, DOI 10.1152/jappl.1973.34.5.726; SLIJPER EJ, 1962, WHALES, P140; TSUDA A, 1990, J APPL PHYSIOL, V69, P546, DOI 10.1152/jappl.1990.69.2.546; TSUDA A, 1990, J APPL PHYSIOL, V69, P553, DOI 10.1152/jappl.1990.69.2.553; TYLER WS, 1991, COMP BIOL NORMAL LUN, V1, pCH4; WEBEL ER, 1984, PATHWAY OXYGEN; WELLS L. J., 1954, CONTR EMBRYOL CARNEGIE INST WASHINGTON, V35, P107; WEST JB, 1977, REGIONAL DIFFERENCES; YOUNG IS, 1992, J EXP BIOL, V166, P19; YOUNG IS, 1992, J EXP BIOL, V164, P283	36	105	107	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1993	262	5131					235	240		10.1126/science.8211141	http://dx.doi.org/10.1126/science.8211141			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA665	8211141				2022-12-01	WOS:A1993MA66500033
J	CHENG, S; CHANG, SY; GRAVITT, P; RESPESS, R				CHENG, S; CHANG, SY; GRAVITT, P; RESPESS, R			LONG PCR	NATURE			English	Article							POLYMERASE CHAIN-REACTION; NONPOLYPOSIS COLORECTAL-CANCER; HUMAN PAPILLOMAVIRUS INFECTION; DNA-POLYMERASE; AMPLIFICATION; HOMOLOG; TYPE-16; GENE		ROCHE MOLEC SYST INC, DEPT INFECT DIS, ALAMEDA, CA 94501 USA		CHENG, S (corresponding author), ROCHE MOLEC SYST INC, DEPT HUMAN GENET, ALAMEDA, CA 94501 USA.							BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bauer HM, 1992, DIAGNOSTIC MOL PATHO, P131; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CHENG S, 1994, NAT GENET, V7, P350, DOI 10.1038/ng0794-350; CHESTER N, 1993, ANAL BIOCHEM, V209, P284, DOI 10.1006/abio.1993.1121; CHOU Q, 1992, NUCLEIC ACIDS RES, V20, P1717, DOI 10.1093/nar/20.7.1717; DALING JR, 1992, EPIDEMIOLOGY CERVICA, P223; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; EDMONSON PF, 1992, NUCLEIC ACIDS RES, V20, P4933, DOI 10.1093/nar/20.18.4933; ERLICH HA, 1992, ANNU REV GENET, V26, P479, DOI 10.1146/annurev.ge.26.120192.002403; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Good N E, 1972, Methods Enzymol, V24, P53; HO L, 1993, J VIROL, V67, P6413, DOI 10.1128/JVI.67.11.6413-6423.1993; KONG HM, 1993, J BIOL CHEM, V268, P1965; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; Nelson DL, 1991, CURR OPIN GENET DEV, V1, P61; ROSE EA, 1991, FASEB J, V5, P46, DOI 10.1096/fasebj.5.1.1991584; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; WONG DM, 1991, NUCLEIC ACIDS RES, V19, P2251, DOI 10.1093/nar/19.9.2251	26	181	205	0	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 23	1994	369	6482					684	685		10.1038/369684a0	http://dx.doi.org/10.1038/369684a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	8208299				2022-12-01	WOS:A1994NT45900065
J	SUZUKI, N; CHEUNG, TT; CAI, XD; ODAKA, A; OTVOS, L; ECKMAN, C; GOLDE, TE; YOUNKIN, SG				SUZUKI, N; CHEUNG, TT; CAI, XD; ODAKA, A; OTVOS, L; ECKMAN, C; GOLDE, TE; YOUNKIN, SG			AN INCREASED PERCENTAGE OF LONG AMYLOID-BETA PROTEIN SECRETED BY FAMILIAL AMYLOID-BETA PROTEIN-PRECURSOR (BETA-APP(717)) MUTANTS	SCIENCE			English	Article							ONSET ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E GENOTYPE; GENETIC-LINKAGE; DOWNS-SYNDROME; MESSENGER-RNA; E TYPE-4; MUTATION; PEPTIDE; PLAQUES; ALLELE	Normal processing of the amyloid beta protein precursor (beta APP) results in secretion of a soluble 4-kilodalton protein essentially identical to the amyloid beta protein (A beta) that forms insoluble fibrillar deposits in Alzheimer's disease. Human neuroblastoma (M17) cells transfected with constructs expressing wild-type beta APP or the beta APP(717) mutants linked to familial Alzheimer's disease were compared by (i) isolation of metabolically labeled 4-kilodalton A beta from conditioned medium, digestion with cyanogen bromide, and analysis of the carboxyl-terminal peptides released, or (ii) analysis of the A beta in conditioned medium with sandwich enzyme-linked immunosorbent assays that discriminate Ap(1-40) from the longer AP(1-42). Both methods demonstrated that the 4-kilodalton Ap released from wild-type beta APP is primarily but not exclusively AP(1-40). The beta APP(717) mutations, which are located th ree residues carboxyl to A beta(43), consistently caused a 1.5- to 1.9-fold increase in the percentage of longer A beta generated. Long A beta (for example, A beta(1-42)) forms insoluble amyloid fibrils more rapidly than Ap(1-40). Thus, the beta APP(717) mutants may cause Alzheimer's disease because they secrete increased amounts of long A beta, thereby fostering amyloid deposition.	CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106; TAKEDA CHEM IND LTD,DIV DISCOVERY RES,TSUKUBA,IBARAKI 30042,JAPAN; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	Case Western Reserve University; Takeda Chemical Industries; The Wistar Institute					NIA NIH HHS [AG06656] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006656] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANWAR N, 1993, LANCET, V342, P1038; BORGAONKAR DS, 1993, LANCET, V342, P625, DOI 10.1016/0140-6736(93)91458-X; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHEUNG TTP, UNPUB; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CZECH C, 1993, LANCET, V342, P1309; CZECH C, 1993, LANCET, V342, P1310; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HARDY J, 1993, LANCET, V342, P737; HARDY J, 1991, LANCET, V337, P1342; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; MANN DMA, 1986, NEUROPATH APPL NEURO, V12, P447, DOI 10.1111/j.1365-2990.1986.tb00053.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLAN M, 1992, NAT GENET, V2, P340, DOI 10.1038/ng1292-340; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; OTVOS L, 1993, EUR J BIOCHEM, V211, P249, DOI 10.1111/j.1432-1033.1993.tb19893.x; PAYAMI H, 1993, LANCET, V342, P738; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; ROBAKIS NK, 1987, LANCET, V1, P384; ROPPER AH, 1980, NEUROLOGY, V30, P639, DOI 10.1212/WNL.30.6.639; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; St George Hyslop P, 1992, NAT GENET, V2, P330; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; SUZUKI N, 1989, J IMMUNOL METHODS, V118, P245, DOI 10.1016/0022-1759(89)90012-4; SUZUKI N, 1993, J BIOCHEM-TOKYO, V113, P549, DOI 10.1093/oxfordjournals.jbchem.a124081; SUZUKI N, IN PRESS AM J PATHOL; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; VAN BROECKHOVEN C, 1992, NAT GENET, V2, P335, DOI 10.1038/ng1292-335; YOSHIOKA K, 1991, BIOCHEM BIOPH RES CO, V178, P1141, DOI 10.1016/0006-291X(91)91011-Z	49	1364	1440	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 27	1994	264	5163					1336	1340		10.1126/science.8191290	http://dx.doi.org/10.1126/science.8191290			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN767	8191290				2022-12-01	WOS:A1994NN76700048
J	AGNEW, JR; SUTTER, RW				AGNEW, JR; SUTTER, RW			ADVERSE REACTIONS TO TETANUS TOXOID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									CTR DIS CONTROL & PREVENT,NATL IMMUNIZAT PROGRAM,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								WASSILAK SGF, IN PRESS VACCINES; 1991, MMWR MORB MORTAL WKL, V40, P1	2	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	1994	271	20					1629	1629		10.1001/jama.271.20.1629	http://dx.doi.org/10.1001/jama.271.20.1629			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL758	8182821				2022-12-01	WOS:A1994NL75800040
J	LUO, XR; IKEDA, YY; PARKER, KL				LUO, XR; IKEDA, YY; PARKER, KL			A CELL-SPECIFIC NUCLEAR RECEPTOR IS ESSENTIAL FOR ADRENAL AND GONADAL DEVELOPMENT AND SEXUAL-DIFFERENTIATION	CELL			English	Article							EXPRESSION; HORMONE; HOMOLOG; PROTEIN; FTZ-F1	Studies in adrenocortical cells have implicated the orphan nuclear receptor SF-1 in the gene regulation of the steroid hydroxylases. We used targeted disruption of the Ftz-F1 gene, which encodes SF-1, to examine its role in intact mice. Despite normal survival in utero, all Ftz-F1 null animals died by postnatal day 8; these animals lacked adrenal glands and gonads and were severely deficient in corticosterone, supporting adrenocortical insufficiency as the probable cause of death. Male and female Ftz-F1 null mice had female internal genitalia, despite complete gonadal agenesis. These studies establish that the Ftz-F1 gene is essential for sexual differentiation and formation of the primary steroidogenic tissues.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; Howard Hughes Medical Institute	LUO, XR (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048460] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48460] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; Ballard P L, 1986, Monogr Endocrinol, V28, P1; CONTI FA, 1988, ENDOCRINOLOGY, P1810; DONOHOUE PA, 1994, IN PRESS METABOLIC B; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GINSBURG M, 1990, DEVELOPMENT, V110, P521; HARLOW E, 1988, ANTIBODIES LABORATOR; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HONDA S, 1993, J BIOL CHEM, V268, P7494; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1994, IN PRESS MOL ENDOCRI; JOSSO N, 1991, TRENDS ENDOCRIN MET, V2, P227, DOI 10.1016/1043-2760(91)90029-M; JOSSO N, 1977, RECENT PROGR HORMONE, V33, P117; Kaufman M.H., 1992, ATLAS MOUSE DEV; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LI S, 1990, NATURE, V347, P829; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; PANG S, 1992, ENDOCRINOLOGY, V131, P181, DOI 10.1210/en.131.1.181; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SMITH C, 1991, J ANAT, V174, P171; THOMAS KR, 1987, CELL, V51, P502; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; Wylie C. C., 1993, SEMIN DEV BIOL, V4, P161, DOI DOI 10.1016/J.YDBIO.2007.05.004	35	1293	1323	2	42	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					481	490		10.1016/0092-8674(94)90211-9	http://dx.doi.org/10.1016/0092-8674(94)90211-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	8187173				2022-12-01	WOS:A1994NM83200004
J	PRIOLEAU, MN; HUET, J; SENTENAC, A; MECHALI, M				PRIOLEAU, MN; HUET, J; SENTENAC, A; MECHALI, M			COMPETITION BETWEEN CHROMATIN AND TRANSCRIPTION COMPLEX ASSEMBLY REGULATES GENE-EXPRESSION DURING EARLY DEVELOPMENT	CELL			English	Article							RNA POLYMERASE-II; EARLY DROSOPHILA DEVELOPMENT; FERTILIZED XENOPUS EGGS; MYC PROTO-ONCOGENE; MIDBLASTULA TRANSITION; DIFFERENTIAL EXPRESSION; HISTONE SYNTHESIS; REPLICATING DNA; BINDING PROTEIN; LAEVIS OOCYTES	Xenopus early development is characterized by a generalized absence of transcription, which resumes at the midblastula transition (MBT). We analyzed this regulation using a plasmid containing the c-myc promoter that is under the same developmental control when injected into fertilized eggs. We find that the repression of transcription can be relieved simply by preincubating the reporter plasmid with TATA binding protein (TBP). However, the repression of gene activity normally occurring before the MBT soon becomes dominant over this activation independent of cell cycle phases. This inactivation correlates with chromatin assembly, and titration of chromatin components not only relieves repression of TBP-dependent transcription but also permits the establishment of stable transcription during early development. Our data suggest that the large excess of histones represses gene activity during early development through a dynamic competition between chromatin assembly and transcription complex assembly.	CTR ETUD SACLAY, SERV BIOCHIM & GENET MOLEC, F-91191 GIF SUR YVETTE, FRANCE		PRIOLEAU, MN (corresponding author), INST JACQUES MONOD, MOLEC EMBRYOL UNIT, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE.		Prioleau, Marie-Noelle/G-9824-2014; , prioleau/S-6007-2019	, prioleau/0000-0003-2585-4005				ADAMSON ED, 1974, J MOL BIOL, V88, P263, DOI 10.1016/0022-2836(74)90481-1; ADAMSON ED, 1977, DEV BIOL, V57, P136, DOI 10.1016/0012-1606(77)90360-8; ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; ANDREWS MT, 1987, CELL, V51, P445, DOI 10.1016/0092-8674(87)90640-4; BACHHVAROVA R, 1986, DEV BIOL, P453; BENDIG MM, 1983, P NATL ACAD SCI-BIOL, V80, P6197, DOI 10.1073/pnas.80.20.6197; BENDIG MM, 1984, MOL CELL BIOL, V4, P2109, DOI 10.1128/MCB.4.10.2109; BROWN DD, 1985, CELL, V42, P759, DOI 10.1016/0092-8674(85)90272-7; Burton N, 1991, Protein Expr Purif, V2, P432, DOI 10.1016/1046-5928(91)90105-R; COLMAN A, 1986, J EMBRYOL EXP MORPH, V97, P197; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Davidson E. H., 1986, GENE ACTIVITY EARLY; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; ETKIN LD, 1985, DEV BIOL, V108, P173, DOI 10.1016/0012-1606(85)90019-3; ETKIN LD, 1984, DIFFERENTIATION, V26, P194, DOI 10.1111/j.1432-0436.1984.tb01395.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HARLAND R, 1988, DEVELOPMENT, V102, P837; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; HARTL P, 1993, J CELL BIOL, V120, P613, DOI 10.1083/jcb.120.3.613; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KAYE PL, 1981, J EXP ZOOL, V216, P453, DOI 10.1002/jez.1402160314; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KIRSCHNER M, 1985, TRENDS GENET, V1, P41, DOI 10.1016/0168-9525(85)90021-6; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KRIEG PA, 1985, EMBO J, V4, P3463, DOI 10.1002/j.1460-2075.1985.tb04105.x; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LUND E, 1992, GENE DEV, V6, P1097, DOI 10.1101/gad.6.6.1097; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MECHALI M, 1984, CELL, V38, P55, DOI 10.1016/0092-8674(84)90526-9; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MIAKELYE R, 1983, J CELL BIOL, V97, P81, DOI 10.1083/jcb.97.1.81; MODAK SP, 1993, ONCOGENE, V8, P645; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; NEWPORT J, 1985, COLD SPRING HARB SYM, V50, P651, DOI 10.1101/SQB.1985.050.01.079; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NISHIKURA K, 1985, MOL CELL BIOL, V5, P1434, DOI 10.1128/MCB.5.6.1434; NURSE P, 1983, NATURE, V302, P378, DOI 10.1038/302378a0; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; RUSCONI S, 1981, P NATL ACAD SCI-BIOL, V78, P5051, DOI 10.1073/pnas.78.8.5051; RYOJI M, 1984, CELL, V37, P21, DOI 10.1016/0092-8674(84)90297-6; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHIOKAWA K, 1990, ROUX ARCH DEV BIOL, V199, P174, DOI 10.1007/BF01681491; SHIOKAWA K, 1989, ROUX ARCH DEV BIOL, V198, P78, DOI 10.1007/BF02447742; SHIOKAWA K, 1991, DEV GROWTH DIFFER, V33, P1; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; van Holde K.E., 1989, CHROMATIN; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WASSARMAN PM, 1981, DEV BIOL, V84, P364, DOI 10.1016/0012-1606(81)90405-X; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILSON C, 1986, CELL, V47, P589, DOI 10.1016/0092-8674(86)90623-9; WOLFFE A P, 1990, New Biologist, V2, P211; WOLFFE AP, 1986, CELL, V47, P217, DOI 10.1016/0092-8674(86)90444-7; WOODLAND HR, 1977, DEV BIOL, V57, P118, DOI 10.1016/0012-1606(77)90359-1; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; WYLLIE AH, 1978, DEV BIOL, V64, P178, DOI 10.1016/0012-1606(78)90069-6; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	68	132	133	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 6	1994	77	3					439	449		10.1016/0092-8674(94)90158-9	http://dx.doi.org/10.1016/0092-8674(94)90158-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	8181062				2022-12-01	WOS:A1994NK97000014
J	SOLDATI, T; SHAPIRO, AD; SVEJSTRUP, ABD; PFEFFER, SR				SOLDATI, T; SHAPIRO, AD; SVEJSTRUP, ABD; PFEFFER, SR			MEMBRANE TARGETING OF THE SMALL GTPASE RAB9 IS ACCOMPANIED BY NUCLEOTIDE EXCHANGE	NATURE			English	Article							GDP DISSOCIATION INHIBITOR; BINDING PROTEIN; VESICULAR TRANSPORT; ACTIVATING PROTEIN; ENDOCYTIC PATHWAY; PURIFICATION; CYTOSOL	THE Rab GTPases are key regulators of vesicular transport(1-6). A fraction of Rab proteins is present in the cytosol, bound with GDP, complexed tb a protein termed GDI(7-10). Rab9 is localized primarily to late endosomes, where it aids the transport of mannose 6-phosphate receptors to the trans-Golgi network(11). It has been proposed that Rab proteins are delivered to specific membranes by GDI, and that this process is accompanied by the exchange of bound GDP for GTP(1-3). In addition, Rab localization requires carboxy-terminal prenylation and specific structural determinants(12-14). Here we describe the reconstitution of the selective targeting of prenylated Rab9 protein onto late endosome membranes and show that this process is accompanied by endosome-triggered nucleotide exchange.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University			SOLDATI, Thierry/U-6494-2019; SOLDATI, Thierry/A-2902-2009	SOLDATI, Thierry/0000-0002-2056-7931; SOLDATI, Thierry/0000-0002-2056-7931				ARAKI S, 1990, J BIOL CHEM, V265, P13007; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DUNN B, 1993, NATURE, V362, P533; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHAPIRO AD, 1993, J BIOL CHEM, V268, P6925; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; TABAS I, 1979, J BIOL CHEM, V254, P1655; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	26	166	168	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 5	1994	369	6475					76	78		10.1038/369076a0	http://dx.doi.org/10.1038/369076a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ860	8164745	Green Published			2022-12-01	WOS:A1994NJ86000057
J	CHAPUY, MC; ARLOT, ME; DELMAS, PD; MEUNIER, PJ				CHAPUY, MC; ARLOT, ME; DELMAS, PD; MEUNIER, PJ			EFFECT OF CALCIUM AND CHOLECALCIFEROL TREATMENT FOR 3 YEARS ON HIP-FRACTURES IN ELDERLY WOMEN	BRITISH MEDICAL JOURNAL			English	Article							VITAMIN-D		HOP EDOUARD HERRIOT,INSERM,U234,SERV RHUMATOL & PATHOL OSSEUSE,F-69437 LYON 3,FRANCE	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)								CHAPUY MC, 1987, AM J CLIN NUTR, V46, P324, DOI 10.1093/ajcn/46.2.324; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; HEIKINHEIMO RJ, 1992, CALCIFIED TISSUE INT, V51, P105, DOI 10.1007/BF00298497; KHAW KT, 1992, BRIT MED J, V305, P273, DOI 10.1136/bmj.305.6848.273; SHERMAN SS, 1990, J CLIN ENDOCR METAB, V71, P405, DOI 10.1210/jcem-71-2-405	5	504	521	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1994	308	6936					1081	1082		10.1136/bmj.308.6936.1081	http://dx.doi.org/10.1136/bmj.308.6936.1081			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	8173430	Green Published			2022-12-01	WOS:A1994NH48900025
J	ZENG, FG; SHANNON, RV				ZENG, FG; SHANNON, RV			LOUDNESS-CODING MECHANISMS INFERRED FROM ELECTRIC-STIMULATION OF THE HUMAN AUDITORY-SYSTEM	SCIENCE			English	Article							COCHLEAR NUCLEUS; NERVE-FIBERS; LEVEL	Two distinct physiological mechanisms underlying loudness sensation were inferred from electric stimulation of the human auditory nerve and brainstem. In contrast to a power function relating loudness and stimulus intensity in acoustic hearing, loudness in electric stimulation of the auditory nerve depends on stimulus frequency. Loudness is an exponential function of electric amplitude for high frequencies and is a power function for low frequencies. A frequency-dependent, two-stage model is suggested to explain the loudness function, in which the first stage of processing is performed by a mechanical mechanism in the cochlea for high-frequency stimuli and by a neural mechanism in the cochlear nucleus for low-frequency stimuli.			ZENG, FG (corresponding author), HOUSE EAR RES INST,LOS ANGELES,CA 90057, USA.		Zeng, Fan-Gang/G-4875-2012		NIDCD NIH HHS [R03-DC01464, R01-DC01526] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC001464, R01DC001526] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BRACKMANN DE, 1993, OTOLARYNG HEAD NECK, V108, P624, DOI 10.1177/019459989310800602; BURNS EM, 1976, J ACOUST SOC AM, V60, P963; CLARK GM, 1987, ADV OTORHINOLARYNGOL, V38, P1; DORMAN MF, 1993, EAR HEARING, V14, P290, DOI 10.1097/00003446-199308000-00008; ECCLES JC, 1966, TOUCH HEAT PAIN; EDDINGTON D K, 1978, Annals of Otology Rhinology and Laryngology, V87, P5; EGGERMONT JJ, 1991, HEARING RES, V56, P153, DOI 10.1016/0378-5955(91)90165-6; FRISINA RD, 1990, HEARING RES, V44, P99, DOI 10.1016/0378-5955(90)90074-Y; KIM DO, 1979, J NEUROPHYSIOL, V42, P16, DOI 10.1152/jn.1979.42.1.16; MACKAY DM, 1963, SCIENCE, V139, P1213, DOI 10.1126/science.139.3560.1213-a; MOLLER AR, 1973, BRAIN RES, V57, P443, DOI 10.1016/0006-8993(73)90148-0; ROSEN S, 1992, J ACOUST SOC AM, V92, P773, DOI 10.1121/1.403946; SACHS MB, 1974, J ACOUST SOC AM, V56, P1835, DOI 10.1121/1.1903521; SHANNON RV, 1983, HEARING RES, V11, P157, DOI 10.1016/0378-5955(83)90077-1; SHANNON RV, 1993, OTOLARYNG HEAD NECK, V108, P634, DOI 10.1177/019459989310800603; SHANNON RV, 1992, IEEE T BIO-MED ENG, V39, P424, DOI 10.1109/10.126616; STEVENS SS, 1955, J ACOUST SOC AM, V27, P815, DOI 10.1121/1.1908048; STEVENS SS, 1953, SCIENCE, V118, P576; STEVENS SS, 1970, SCIENCE, V170, P1043, DOI 10.1126/science.170.3962.1043; VUREK LS, 1981, ANN OTO RHINOL LARYN, V90, P21, DOI 10.1177/00034894810902S208; WILSON P, 1992, AUDITORY PHYSL PERCE; YATES GK, 1992, TRENDS NEUROSCI, V15, P57, DOI 10.1016/0166-2236(92)90027-6; ZENG FG, 1992, HEARING RES, V60, P231, DOI 10.1016/0378-5955(92)90024-H	23	88	89	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 22	1994	264	5158					564	566		10.1126/science.8160013	http://dx.doi.org/10.1126/science.8160013			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	8160013				2022-12-01	WOS:A1994NH01000035
J	KONFORTI, BB; KOZIOLKIEWICZ, MJ; KONARSKA, MM				KONFORTI, BB; KOZIOLKIEWICZ, MJ; KONARSKA, MM			DISRUPTION OF BASE-PAIRING BETWEEN THE 5' SPLICE-SITE AND THE 5' END OF U1 SNRNA IS REQUIRED FOR SPLICEOSOME ASSEMBLY	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; JUNCTION SEQUENCES; CLEAVAGE SITE; U6 SNRNA; YEAST; INVITRO; SELECTION; PARTICLES; MUTATIONS	A short RNA oligonucleotide comprising the 51 splice site consensus sequence (5'SS RNA) is sufficient to bind U1 small nuclear ribonucleoprotein particle (snRNP) or to induce the association of U2 snRNP and U4-U5-U6 triple snRNP. Analysis of the requirements of these interactions demonstrates that the 5'SS RNA is recognized independently by at least two different elements during spliceosome assembly: the 51 end of U1 snRNA and a component(s) of the U2-U4-U5-U6 snRNP complex. Since stable 5'SS RNA-U1 snRNA base pairing prevents interaction of the 5SS RNA with U2-U4-U5-U6 snRNP complex, we conclude that disruption of the initial base pairing between the 5'SS RNA and the 5' end of U1 snRNA is required for subsequent spliceosome assembly.			KONFORTI, BB (corresponding author), ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Konarska, Maria M./AAT-2572-2021; Konarska, Maria/ABG-6405-2020	Konarska, Maria M./0000-0001-9235-1702; Koziolkiewicz, Maria/0000-0003-4628-4566	NIGMS NIH HHS [GM49044] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049044] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGLAND TE, 1980, NUCLEIC ACIDS, P65; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FRADIN A, 1984, CELL, V37, P927, DOI 10.1016/0092-8674(84)90427-6; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HALL KB, 1992, P NATL ACAD SCI USA, V89, P10969, DOI 10.1073/pnas.89.22.10969; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KRAMER A, 1984, CELL, V38, P299, DOI 10.1016/0092-8674(84)90551-8; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NELSON KK, 1990, P NATL ACAD SCI USA, V87, P6253, DOI 10.1073/pnas.87.16.6253; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; ROSE JK, 1976, NATURE, V262, P32, DOI 10.1038/262032a0; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SEIWERT SD, 1993, MOL CELL BIOL, V13, P3135, DOI 10.1128/MCB.13.6.3135; SERAPHIN B, 1993, CELL, V73, P803, DOI 10.1016/0092-8674(93)90258-R; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; VANSANTEN VL, 1986, NUCLEIC ACIDS RES, V14, P9911, DOI 10.1093/nar/14.24.9911; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; YUAN ZA, 1987, MOL CELL BIOL, V7, P3018, DOI 10.1128/MCB.7.8.3018; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	46	82	82	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					863	873		10.1016/0092-8674(93)90531-T	http://dx.doi.org/10.1016/0092-8674(93)90531-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252623				2022-12-01	WOS:A1993MK96600007
J	ALLEN, MC; DONOHUE, PK; DUSMAN, AE				ALLEN, MC; DONOHUE, PK; DUSMAN, AE			THE LIMIT OF VIABILITY - NEONATAL OUTCOME OF INFANTS BORN AT 22-WEEKS TO 25-WEEKS GESTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BIRTH-WEIGHT INFANTS; RESPIRATORY-DISTRESS SYNDROME; INTRAVENTRICULAR HEMORRHAGE; BOVINE SURFACTANT; PRETERM INFANTS; CEREBRAL-PALSY; 800 GRAMS; LESS; MORTALITY; SURVIVAL	Background. With improved survival of preterm infants, questions have been raised about the limit of viability. To provide better information and counseling for parents of infants about to be delivered after 22 to 25 weeks' gestation, we evaluated the mortality and neonatal morbidity of preterm infants born at these gestational ages. Methods. We studied retrospectively all 142 infants born at 22 to 25 weeks' gestation (as judged by best obstetrical estimate) from May 1988 through September 1991 in a single hospital. Mortality in the first six months, including stillbirths, and neonatal morbidity (i.e., the presence of intracranial pathologic conditions, chronic lung disease, and retinopathy of prematurity) were analyzed. Results. Fifty-six infants (39 percent) survived for six months. Survival improved with increasing gestational age; none of 29 infants born at 22 weeks' gestation survived, as compared with 6 of 40 (15 percent) born at 23 weeks, 19 of 34 (56 percent) born at 24 weeks, and 31 of 39 (79 percent) born at 25 weeks. There were seven stillbirths at 22 weeks' gestation and four stillbirths at 23 weeks. The more immature the infant, the higher the incidence of neonatal complications as determined by the number of days of mechanical ventilation, the length of the hospital stay, and the presence of retinopathy of prematurity, periventricular or intraventricular hemorrhage, or periventricular leukomalacia. Only 2 percent of infants born at 23 weeks' gestation survived without severe abnormalities on cranial ultrasonography, as compared with 21 percent of those born at 24 weeks and 69 percent of those born at 25 weeks. Conclusions. We believe that aggressive resuscitation of infants born at 25 weeks' gestation is indicated, but not of those born at 22 weeks. Whether the occasional child who is born at 23 or 24 weeks' gestation and does well justifies the considerable mortality and morbidity of the majority is a question that should be discussed by parents, health care providers, and society.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University	ALLEN, MC (corresponding author), JOHNS HOPKINS UNIV HOSP,DEPT PEDIAT NURSING,CMSC 210,601 N WOLFE ST,BALTIMORE,MD 21287, USA.							BENNETT FC, 1983, PEDIATRICS, V71, P319; BRITTON SB, 1981, J PEDIATR-US, V99, P937; BUCKWALD S, 1984, AM J DIS CHILD, V138, P779, DOI 10.1001/archpedi.1984.02140460069023; DONOHUE PK, 1993, PEDIATR RES, V31, pA201; GRAHAM M, 1987, LANCET, V2, P593; GRAZIANI LJ, 1986, PEDIATRICS, V78, P88; GRAZIANI LJ, 1985, J PEDIATR-US, V106, P269, DOI 10.1016/S0022-3476(85)80304-8; HACK M, 1989, NEW ENGL J MED, V321, P1642, DOI 10.1056/NEJM198912143212405; HANSEN NB, 1989, J DEV BEHAV PEDIATR, V10, P129; HIRATA T, 1983, J PEDIATR-US, V102, P741, DOI 10.1016/S0022-3476(83)80250-9; HOEKSTRA RE, 1991, PEDIATRICS, V88, P10; HOFFMAN EL, 1990, PEDIATRICS, V86, P27; KENDIG JW, 1991, NEW ENGL J MED, V324, P865, DOI 10.1056/NEJM199103283241301; LIECHTY EA, 1991, PEDIATRICS, V88, P19; NWAESEI CG, 1987, AM J OBSTET GYNECOL, V157, P890, DOI 10.1016/S0002-9378(87)80080-7; PAPILE LA, 1983, J PEDIATR-US, V103, P273, DOI 10.1016/S0022-3476(83)80366-7; ROBERTSON CMT, 1992, PEDIATRICS, V90, P750; SAIGAL S, 1989, J PEDIATR-US, V114, P839, DOI 10.1016/S0022-3476(89)80150-7; SANDERS M, 1991, PEDIATRICS, V88, P542; SHANKARAN S, 1989, J PEDIATR-US, V114, P109, DOI 10.1016/S0022-3476(89)80616-X; SHORTLAND D, 1988, J PERINAT MED, V16, P241, DOI 10.1515/jpme.1988.16.3.241; SPINNATO JA, 1984, OBSTET GYNECOL, V63, P491; STEVENSON D, 1992, J PEDIATR-US, V120, pS3, DOI 10.1016/S0022-3476(05)81226-0; WALKER EM, 1987, BRIT J OBSTET GYNAEC, V94, P670, DOI 10.1111/j.1471-0528.1987.tb03172.x; WILLIAMSON WD, 1983, AM J DIS CHILD, V137, P1181, DOI 10.1001/archpedi.1983.02140380041014	25	321	326	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1993	329	22					1597	1601		10.1056/NEJM199311253292201	http://dx.doi.org/10.1056/NEJM199311253292201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ546	8179651				2022-12-01	WOS:A1993MJ54600001
J	GHADIRI, MR; GRANJA, JR; MILLIGAN, RA; MCREE, DE; KHAZANOVICH, N				GHADIRI, MR; GRANJA, JR; MILLIGAN, RA; MCREE, DE; KHAZANOVICH, N			SELF-ASSEMBLING ORGANIC NANOTUBES BASED ON A CYCLIC PEPTIDE ARCHITECTURE	NATURE			English	Article							MOLECULAR-SIEVE; GRAMICIDIN-A; NANOCHEMISTRY; MICROTUBULES; PROTEINS; CARBON; PORE	HOLLOW tubular structures of molecular dimensions may offer a variety of applications in chemistry, biochemistry and materials science. Concentric carbon nanotubes1,2 have attracted a great deal of attention, while the three-dimensional tubular pore structures of molecular sieves have long been exploited industrially3-8. Nanoscale tubes based on organic materials have also been reported previously9-13. Here we report the design, synthesis and characterization of a new class of organic nanotubes based on rationally designed cyclic polypeptides. When protonated, these compounds crystallize into tubular structures hundreds of nanometres long, with internal diameters of 7-8 angstrom. Support for the proposed tubular structures is provided by electron microscopy, electron diffraction, Fourier-transform infrared spectroscopy and molecular modelling. These tubes are open-ended, with uniform shape and internal diameter. We anticipate that they may have possible applications in inclusion chemistry, catalysis, molecular electronics and molecular separation technology.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92307 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92307 USA	Scripps Research Institute; Scripps Research Institute	GHADIRI, MR (corresponding author), SCRIPPS RES INST, DEPT CHEM, LA JOLLA, CA 92307 USA.		Granja, Juan R/P-7646-2014	Granja, Juan R/0000-0002-5842-7504				ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; BRUMLIK CJ, 1991, J AM CHEM SOC, V113, P3174, DOI 10.1021/ja00008a057; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DAVIS ME, 1988, NATURE, V331, P698, DOI 10.1038/331698a0; DESSAU RM, 1990, ZEOLITES, V10, P522, DOI 10.1016/S0144-2449(05)80306-9; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; ESTERMANN M, 1991, NATURE, V352, P320, DOI 10.1038/352320a0; FUHRHOP JH, 1993, J AM CHEM SOC, V115, P1600, DOI 10.1021/ja00057a069; GEORGER JH, 1987, J AM CHEM SOC, V109, P6169, DOI 10.1021/ja00254a042; HARADA A, 1993, NATURE, V364, P516, DOI 10.1038/364516a0; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LANGS DA, 1988, SCIENCE, V241, P188, DOI 10.1126/science.2455345; LOTZ B, 1976, J MOL BIOL, V106, P915, DOI 10.1016/0022-2836(76)90343-0; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEIER WM, 1988, ATLAS ZEOLITE STRUCT; MILLIGAN RA, 1984, ULTRAMICROSCOPY, V13, P1, DOI 10.1016/0304-3991(84)90051-2; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; NAIK VM, 1986, BIOPHYS J, V49, P1147, DOI 10.1016/S0006-3495(86)83743-2; OZIN GA, 1992, ADV MATER, V4, P612, DOI 10.1002/adma.19920041003; ROVERO P, 1991, TETRAHEDRON LETT, V32, P2639, DOI 10.1016/S0040-4039(00)78806-X; SALEMME FR, 1983, PROG BIOPHYS MOL BIO, V42, P95, DOI 10.1016/0079-6107(83)90005-6; SCHROETER JP, 1992, J STRUCT BIOL, V109, P235, DOI 10.1016/1047-8477(92)90036-A; STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W; WALLACE BA, 1988, SCIENCE, V241, P182, DOI 10.1126/science.2455344; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191	27	1431	1478	9	493	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 25	1993	366	6453					324	327		10.1038/366324a0	http://dx.doi.org/10.1038/366324a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	MJ705	8247126				2022-12-01	WOS:A1993MJ70500042
J	SIRMON, MD				SIRMON, MD			TOBACCO, TULIPS, AND TERMINAL CARE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											SIRMON, MD (corresponding author), UNIV SO ALABAMA, COLL MED, DIV NEPHROL HYPERTENS, 2451 FILLINGIM ST, MOBILE, AL 36617 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1993	119	10					1042	1043		10.7326/0003-4819-119-10-199311150-00012	http://dx.doi.org/10.7326/0003-4819-119-10-199311150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG672	8214982				2022-12-01	WOS:A1993MG67200012
J	EBNER, R; CHEN, RH; LAWLER, S; ZIONCHECK, T; DERYNCK, R				EBNER, R; CHEN, RH; LAWLER, S; ZIONCHECK, T; DERYNCK, R			DETERMINATION OF TYPE-I RECEPTOR SPECIFICITY BY THE TYPE-II RECEPTORS FOR TGF-BETA OR ACTIVIN	SCIENCE			English	Article							SERINE THREONINE KINASE; XENOPUS EMBRYOS; EXPRESSION; CLONING	Transforming growth factor-beta (TGF-beta) and activin signal primarily through interaction with type I and type II receptors, which are transmembrane serine-threonine kinases. Tsk 7L is a type I receptor for TGF-beta and requires coexpression of the type II TGF-beta receptor for ligand binding. Tsk 7L also specifically bound activin, when coexpressed with the type IIA activin receptor. Tsk 7L could associate with either type II receptor and the ligand binding specificity of Tsk 7L was conferred by the type II receptor. Tsk 7L can therefore act as type I receptor for both activin and TGF-beta, and possibly other ligands.	UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,SAN FRANCISCO,CA 94143; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM CELL BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Chen, Ruey-Hwa/G-6121-2019	Chen, Ruey-Hwa/0000-0001-8124-5832				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EBNER R, UNPUB; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAWLER S, UNPUB; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1992, CELL, V70, P1069; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATTHEWS LS, 1991, CELL, V65, P973; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P379; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; SHUM LI, UNPUB; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TSUCHIDA K, IN PRESS P NATL ACAD; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	28	220	229	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					900	902		10.1126/science.8235612	http://dx.doi.org/10.1126/science.8235612			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235612				2022-12-01	WOS:A1993MF43800035
